token,label,label_gpt
Our,O,O
data,O,O
suggest,O,O
that,O,O
lipoxygenase,B,B
metabolites,I,I
activate,O,O
ROI,O,B
formation,O,O
which,O,O
then,O,O
induce,O,O
IL,B,B
-,I,I
2,I,I
expression,O,O
via,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
.,O,O
Human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
2,O,O
(,O,O
HIV,O,B
-,O,I
2,O,I
),O,O
",",O,O
like,O,O
HIV,O,B
-,O,I
1,O,I
",",O,O
causes,O,O
AIDS,O,O
and,O,O
is,O,O
associated,O,O
with,O,O
AIDS,O,O
cases,O,O
primarily,O,O
in,O,O
West,O,O
Africa,O,O
.,O,O
This,O,O
is,O,O
the,O,O
first,O,O
description,O,O
of,O,O
an,O,O
HIV,B,B
-,I,I
2,I,I
enhancer,I,I
element,I,I
which,O,O
displays,O,O
such,O,O
monocyte,O,B
specificity,O,O
",",O,O
and,O,O
no,O,O
comparable,O,O
enhancer,B,O
element,I,O
has,O,O
been,O,O
clearly,O,O
defined,O,O
for,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
While,O,O
a,O,O
nuclear,B,O
factor,I,B
(,O,O
s,O,O
),O,O
from,O,O
both,O,O
peripheral,O,B
blood,O,I
monocytes,O,I
and,O,O
T,O,B
cells,O,I
binds,O,O
the,O,O
peri,B,O
-,I,O
kappa,I,O
B,I,O
site,I,O
",",O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
suggest,O,O
that,O,O
either,O,O
a,O,O
different,O,O
protein,O,B
binds,O,O
to,O,O
this,O,O
site,O,O
in,O,O
monocytes,O,B
versus,O,O
T,O,B
cells,O,I
or,O,O
that,O,O
the,O,O
protein,O,B
recognizing,O,O
this,O,O
enhancer,B,O
element,I,O
undergoes,O,O
differential,O,O
modification,O,O
in,O,O
monocytes,O,B
and,O,O
T,O,B
cells,O,I
",",O,O
thus,O,O
supporting,O,O
the,O,O
transfection,O,O
data,O,O
.,O,O
Understanding,O,O
the,O,O
monocyte,O,B
-,O,I
specific,O,I
function,O,O
of,O,O
the,O,O
peri,B,O
-,I,O
kappa,I,O
B,I,O
factor,I,O
may,O,O
ultimately,O,O
provide,O,O
insight,O,O
into,O,O
the,O,O
different,O,O
role,O,O
monocytes,O,B
and,O,O
T,O,B
cells,O,I
play,O,O
in,O,O
HIV,O,O
pathogenesis,O,O
.,O,O
Distinct,O,O
signaling,O,O
properties,O,O
identify,O,O
functionally,O,O
different,O,O
CD4,B,B
epitopes,I,I
.,O,O
Whereas,O,O
different,O,O
anti,B,O
-,I,O
CD4,I,B
mAb,I,I
or,O,O
HIV,B,O
-,I,O
1,I,O
gp120,I,O
could,O,O
all,O,O
trigger,O,O
activation,O,O
of,O,O
the,O,O
protein,B,B
tyrosine,I,I
kinases,I,I
p56lck,B,I
and,O,O
p59fyn,B,I
and,O,O
phosphorylation,O,O
of,O,O
the,O,O
Shc,B,B
adaptor,I,I
protein,I,I
",",O,O
which,O,O
mediates,O,O
signals,O,O
to,O,O
Ras,B,B
",",O,O
they,O,O
differed,O,O
significantly,O,O
in,O,O
their,O,O
ability,O,O
to,O,O
activate,O,O
NF,B,B
-,I,I
AT,I,I
.,O,O
To,O,O
address,O,O
potential,O,O
mechanisms,O,O
by,O,O
which,O,O
estrogens,O,O
suppress,O,O
erythropoiesis,O,O
",",O,O
we,O,O
have,O,O
examined,O,O
their,O,O
effects,O,O
on,O,O
GATA,B,B
-,I,I
1,I,I
",",O,O
an,O,O
erythroid,B,O
transcription,I,O
factor,I,O
that,O,O
participates,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
the,O,O
majority,O,O
of,O,O
erythroid,B,O
cell,I,O
-,I,O
specific,I,O
genes,I,O
and,O,O
is,O,O
necessary,O,O
for,O,O
full,O,O
maturation,O,O
of,O,O
erythrocytes,O,O
.,O,O
ER,B,O
-,O,O
mediated,O,O
repression,O,O
of,O,O
GATA,B,B
-,I,I
1,I,I
activity,O,O
occurs,O,O
on,O,O
an,O,O
artificial,B,O
promoter,I,O
containing,O,O
a,O,O
single,O,O
GATA,B,B
-,I,I
binding,I,I
site,I,I
",",O,O
as,O,O
well,O,O
as,O,O
in,O,O
the,O,O
context,O,O
of,O,O
an,O,O
intact,B,O
promoter,I,O
which,O,O
is,O,O
normally,O,O
regulated,O,O
by,O,O
GATA,B,B
-,I,I
1,I,I
.,O,O
In,O,O
coimmunoprecipitatio,O,O
experiments,O,O
using,O,O
transfected,O,O
COS,O,O
cells,O,O
",",O,O
GATA,B,B
-,I,I
1,I,I
and,O,O
ER,B,B
associate,O,O
in,O,O
a,O,O
ligand,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
The,O,O
transcriptional,O,O
response,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
gene,I,O
to,O,O
stimulation,O,O
by,O,O
IL,B,B
-,I,I
1,I,I
+,O,O
IL,B,B
-,I,I
2,I,I
is,O,O
biphasic,O,O
.,O,O
It,O,O
also,O,O
primes,O,O
cells,O,O
to,O,O
become,O,O
IL,B,B
-,I,I
2,I,I
responsive,O,O
and,O,O
thereby,O,O
prepares,O,O
the,O,O
second,O,O
phase,O,O
",",O,O
in,O,O
which,O,O
IL,B,B
-,I,I
2,I,I
induces,O,O
a,O,O
100,O,O
-,O,O
fold,O,O
further,O,O
increase,O,O
in,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
transcripts,I,O
.,O,O
Transient,O,O
transfection,O,O
experiments,O,O
show,O,O
that,O,O
several,O,O
elements,O,O
in,O,O
the,O,O
promoter,B,O
-,I,O
proximal,I,O
region,I,O
of,O,O
the,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
gene,I,O
contribute,O,O
to,O,O
IL,B,B
-,I,I
1,I,I
responsiveness,O,O
",",O,O
most,O,O
importantly,O,O
an,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
site,I,O
conserved,O,O
in,O,O
the,O,O
human,B,O
and,I,O
mouse,I,O
gene,I,O
.,O,O
IL,B,B
-,I,I
2,I,I
responsiveness,O,O
",",O,O
on,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
depends,O,O
on,O,O
a,O,O
78,B,O
-,I,O
nucleotide,I,O
segment,I,O
1,O,O
.,O,O
3,O,O
kilobases,O,O
upstream,O,O
of,O,O
the,O,O
major,B,O
transcription,I,O
start,I,O
site,I,O
.,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
(,O,O
EBV,O,O
),O,O
is,O,O
known,O,O
to,O,O
infect,O,O
B,O,O
cells,O,O
and,O,O
epithelial,O,B
cells,O,I
.,O,O
The,O,O
appearance,O,O
of,O,O
the,O,O
BamHI,B,O
ZLF,I,O
-,I,O
1,I,O
gene,I,O
product,I,O
",",O,O
ZEBRA,B,O
",",O,O
by,O,O
RT,O,O
-,O,O
PCR,O,O
",",O,O
was,O,O
observed,O,O
within,O,O
8,O,O
hr,O,O
of,O,O
infection,O,O
.,O,O
Transcripts,O,O
encoding,O,O
gp350,B,O
/,I,O
220,I,O
",",O,O
the,O,O
major,B,O
coat,I,O
protein,I,O
of,O,O
EBV,O,O
",",O,O
were,O,O
identified,O,O
",",O,O
but,O,O
we,O,O
did,O,O
not,O,O
find,O,O
any,O,O
evidence,O,O
of,O,O
transcription,O,O
from,O,O
the,O,O
LMP,B,O
-,I,O
2A,I,O
or,O,O
EBER,B,O
-,I,O
1,I,O
loci,I,O
in,O,O
infected,O,O
thymocytes,O,O
.,O,O
The,O,O
main,O,O
difference,O,O
is,O,O
that,O,O
with,O,O
thymocytes,O,O
",",O,O
no,O,O
evidence,O,O
could,O,O
be,O,O
found,O,O
that,O,O
the,O,O
virus,O,O
ever,O,O
circularizes,O,O
.,O,O
Rather,O,O
",",O,O
EBV,O,O
remains,O,O
in,O,O
a,O,O
linear,O,O
configuration,O,O
from,O,O
which,O,O
replicative,B,O
genes,I,O
are,O,O
transcribed,O,O
.,O,O
Several,O,O
recent,O,O
studies,O,O
have,O,O
implicated,O,O
Jak,O,O
kinases,O,O
in,O,O
the,O,O
signaling,O,O
pathway,O,O
induced,O,O
by,O,O
IL,B,B
-,I,I
2,I,I
.,O,O
We,O,O
demonstrate,O,O
",",O,O
through,O,O
the,O,O
deletion,O,O
of,O,O
the,O,O
human,B,O
UDG,I,O
promoter,I,O
sequences,I,O
",",O,O
that,O,O
expression,O,O
of,O,O
E2F,B,B
-,I,I
1,I,I
activates,O,O
the,O,O
UDG,B,O
promoter,I,O
through,O,O
several,O,O
E2F,B,B
sites,I,O
.,O,O
Overexpression,O,O
of,O,O
UDG,B,B
in,O,O
Saos,O,O
2,O,O
cells,O,O
was,O,O
observed,O,O
to,O,O
delay,O,O
growth,O,O
late,O,O
in,O,O
G1,O,O
phase,O,O
and,O,O
transiently,O,O
arrest,O,O
these,O,O
cells,O,O
from,O,O
progressing,O,O
into,O,O
the,O,O
S,O,O
phase,O,O
.,O,O
Cellular,O,O
and,O,O
molecular,O,O
mechanisms,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
production,O,O
induced,O,O
by,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IL,B,B
-,I,I
12,I,I
in,O,O
a,O,O
human,O,O
NK,O,O
cell,O,O
line,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
when,O,O
used,O,O
together,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IL,B,B
-,I,I
12,I,I
synergized,O,O
in,O,O
the,O,O
induction,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
and,O,O
GM,B,B
-,I,I
CSF,I,I
and,O,O
this,O,O
synergy,O,O
was,O,O
attributed,O,O
to,O,O
an,O,O
increased,O,O
accumulation,O,O
and,O,O
stability,O,O
of,O,O
the,O,O
IFN,B,B
-,I,I
gamma,I,I
and,I,O
GM,I,B
-,I,I
CSF,I,I
mRNAs,I,O
.,O,O
To,O,O
investigate,O,O
the,O,O
signaling,O,O
pathways,O,O
involved,O,O
in,O,O
the,O,O
gene,O,O
induction,O,O
",",O,O
five,O,O
inhibitors,O,O
",",O,O
cyclosporin,O,O
A,O,O
(,O,O
CsA,O,O
),O,O
",",O,O
transforming,B,O
growth,I,O
factor,I,O
-,I,O
beta,I,O
",",O,O
cycloheximide,O,O
",",O,O
genistein,O,O
",",O,O
and,O,O
staurosporine,O,O
A,O,O
",",O,O
were,O,O
used,O,O
in,O,O
analyzing,O,O
the,O,O
effects,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IL,B,B
-,I,I
12,I,I
on,O,O
NK3,O,O
.,O,O
cells,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
but,O,O
not,O,O
IL,B,B
-,I,I
12,I,I
induced,O,O
nuclear,B,O
factors,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
AP1,B,O
",",O,O
and,O,O
regulation,O,O
of,O,O
the,O,O
nuclear,O,O
levels,O,O
of,O,O
these,O,O
two,O,O
DNA,B,B
binding,I,I
protein,I,I
complexes,I,I
is,O,O
correlated,O,O
with,O,O
IFN,O,B
-,O,I
gamma,O,I
and,O,O
GM,O,B
-,O,I
CSF,O,I
gene,O,I
expression,O,O
.,O,O
One,O,O
substrate,O,O
is,O,O
p95vav,B,B
",",O,O
which,O,O
is,O,O
expressed,O,O
exclusively,O,O
in,O,O
hematopoietic,O,B
and,O,O
trophoblast,O,B
cells,O,O
.,O,O
Furthermore,O,O
",",O,O
p95vav,B,B
synergizes,O,O
with,O,O
TCR,B,O
stimulation,O,O
in,O,O
inducing,O,O
NFAT,O,B
-,O,I
and,O,O
interleukin,O,B
-,O,I
2,O,I
-,O,I
dependent,O,O
transcription,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
activating,O,O
function,O,O
of,O,O
p95vav,B,B
is,O,O
blocked,O,O
by,O,O
FK506,O,O
",",O,O
suggesting,O,O
that,O,O
its,O,O
activity,O,O
also,O,O
depends,O,O
on,O,O
calcineurin,B,O
.,O,O
alpha,B,B
B,I,I
is,O,O
the,O,O
mouse,B,O
homologue,I,O
of,O,O
human,B,O
AML1,I,B
gene,I,I
detected,O,O
at,O,O
the,O,O
breakpoints,O,O
of,O,O
t,O,O
(,O,O
8,O,O
;,O,O
21,O,O
),O,O
and,O,O
t,O,O
(,O,O
3,O,O
;,O,O
21,O,O
),O,O
myeloid,O,O
leukemias,O,O
.,O,O
We,O,O
examined,O,O
alpha,B,B
A1,I,I
(,O,O
an,O,O
alpha,B,B
A,I,I
-,I,I
gene,I,I
product,I,I
),O,O
and,O,O
alpha,B,B
B1,I,I
and,O,O
alpha,B,B
B2,I,I
(,O,O
two,O,O
alpha,B,B
B,I,I
-,I,I
encoded,I,I
isomers,I,I
),O,O
for,O,O
their,O,O
effects,O,O
on,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
promoter,I,O
.,O,O
Although,O,O
further,O,O
studies,O,O
are,O,O
required,O,O
to,O,O
determine,O,O
the,O,O
precise,O,O
role,O,O
of,O,O
PEBP2,B,O
in,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
promoter,O,O
activity,O,O
",",O,O
the,O,O
present,O,O
findings,O,O
suggested,O,O
the,O,O
importance,O,O
of,O,O
the,O,O
relative,O,O
ratio,O,O
of,O,O
different,O,O
PEBP2,B,O
isoforms,I,O
in,O,O
regulating,O,O
the,O,O
levels,O,O
of,O,O
the,O,O
promoter,O,O
activity,O,O
.,O,O
IFN,B,B
-,I,I
gamma,I,I
priming,O,O
of,O,O
monocytes,O,O
enhances,O,O
LPS,O,O
-,O,O
induced,O,O
TNF,B,B
production,O,O
by,O,O
augmenting,O,O
both,O,O
transcription,O,O
and,O,O
MRNA,O,O
stability,O,O
.,O,O
The,O,O
induction,O,O
of,O,O
cytokine,B,O
expression,O,O
in,O,O
monocytes,O,O
/,O,O
macrophages,O,O
by,O,O
bacterial,B,O
endotoxin,I,O
or,O,O
lipopolysaccharide,O,O
is,O,O
a,O,O
critical,O,O
",",O,O
highly,O,O
regulated,O,O
host,O,O
defence,O,O
response,O,O
.,O,O
The,O,O
increased,O,O
transcriptional,O,O
rate,O,O
correlated,O,O
with,O,O
a,O,O
marked,O,O
increase,O,O
in,O,O
nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
activity,O,O
in,O,O
these,O,O
cells,O,O
as,O,O
determined,O,O
by,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
using,O,O
a,O,O
consensus,B,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
oligonucleotide,I,I
.,O,O
Consistent,O,O
with,O,O
the,O,O
increased,O,O
mRNA,B,B
stability,O,O
",",O,O
the,O,O
duration,O,O
of,O,O
mRNA,B,B
accumulation,O,O
was,O,O
longer,O,O
following,O,O
LPS,O,O
stimulation,O,O
in,O,O
primed,O,O
monocytes,O,O
",",O,O
in,O,O
addition,O,O
to,O,O
being,O,O
of,O,O
greater,O,O
magnitude,O,O
.,O,O
H,O,O
-,O,O
89,O,O
substantially,O,O
suppressed,O,O
LPS,O,O
-,O,O
induced,O,O
TNF,B,B
mRNA,I,I
accumulation,O,O
in,O,O
unprimed,O,O
cells,O,O
",",O,O
but,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
primed,O,O
monocytes,O,O
following,O,O
LPS,O,O
stimulation,O,O
.,O,O
A,O,O
Myc,B,B
-,I,I
associated,I,I
zinc,I,I
finger,I,I
protein,I,I
binding,I,I
site,I,I
is,O,O
one,O,O
of,O,O
four,O,O
important,O,O
functional,B,O
regions,I,O
in,O,O
the,O,O
CD4,B,B
promoter,I,I
.,O,O
Since,O,O
the,O,O
terminal,O,O
events,O,O
of,O,O
erythropoiesis,O,O
are,O,O
controlled,O,O
by,O,O
the,O,O
glycoprotein,B,B
hormone,I,I
erythropoietin,I,I
(,O,O
Epo,B,O
),O,O
",",O,O
we,O,O
investigated,O,O
whether,O,O
the,O,O
expression,O,O
or,O,O
activity,O,O
of,O,O
the,O,O
TAL1,B,B
gene,I,I
and,O,O
its,O,O
protein,B,B
products,I,I
were,O,O
affected,O,O
by,O,O
Epo,B,O
in,O,O
splenic,O,B
erythroblasts,O,I
from,O,O
mice,O,O
infected,O,O
with,O,O
an,O,O
anemia,O,O
-,O,O
inducing,O,O
strain,O,O
of,O,O
Friend,O,B
virus,O,I
(,O,O
FVA,O,O
cells,O,O
),O,O
.,O,O
The,O,O
role,O,O
of,O,O
shared,B,O
receptor,I,O
motifs,I,O
and,O,O
common,B,O
Stat,I,O
proteins,I,O
in,O,O
the,O,O
generation,O,O
of,O,O
cytokine,B,O
pleiotropy,O,O
and,O,O
redundancy,O,O
by,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
IL,B,B
-,I,I
4,I,I
",",O,O
IL,B,B
-,I,I
7,I,I
",",O,O
IL,B,B
-,I,I
13,I,I
",",O,O
and,O,O
IL,B,B
-,I,I
15,I,I
.,O,O
IL,B,B
-,I,I
13,I,I
Induced,O,O
the,O,O
same,O,O
complexes,O,O
as,O,O
IL,B,B
-,I,I
4,I,I
",",O,O
a,O,O
finding,O,O
explained,O,O
by,O,O
our,O,O
studies,O,O
implicating,O,O
IL,B,B
-,I,I
4R,I,I
as,O,O
a,O,O
shared,O,O
component,O,O
of,O,O
the,O,O
receptors,B,O
.,O,O
Control,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
proteolysis,O,O
by,O,O
site,O,O
-,O,O
specific,O,O
",",O,O
signal,O,O
-,O,O
induced,O,O
phosphorylation,O,O
.,O,O
When,O,O
either,O,O
serine,O,B
-,O,I
32,O,I
or,O,O
serine,O,B
-,O,I
36,O,I
of,O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
was,O,O
mutated,O,O
",",O,O
the,O,O
protein,O,O
did,O,O
not,O,O
undergo,O,O
signal,O,O
-,O,O
induced,O,O
phosphorylation,O,O
or,O,O
degradation,O,O
",",O,O
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
could,O,O
not,O,O
be,O,O
activated,O,O
.,O,O
Regulation,O,O
of,O,O
transcription,O,O
of,O,O
the,O,O
human,B,B
erythropoietin,I,I
receptor,I,I
gene,I,O
by,O,O
proteins,O,O
binding,O,O
to,O,O
GATA,B,B
-,I,I
1,I,I
and,I,O
Sp1,I,B
motifs,I,O
.,O,O
Erythropoietin,B,B
(,O,O
Epo,B,O
),O,O
",",O,O
the,O,O
primary,O,O
regulator,O,O
of,O,O
the,O,O
production,O,O
of,O,O
erythroid,O,B
cells,O,I
",",O,O
acts,O,O
by,O,O
binding,O,O
to,O,O
a,O,O
cell,B,O
surface,I,O
receptor,I,O
(,O,O
EpoR,B,B
),O,O
on,O,O
erythroid,O,O
progenitors,O,O
.,O,O
Interestingly,O,O
",",O,O
when,O,O
we,O,O
mutated,O,O
the,O,O
Sp1,B,O
site,I,O
",",O,O
resulting,O,O
in,O,O
a,O,O
marked,O,O
decrease,O,O
in,O,O
hEpoR,B,B
promoter,I,O
activity,O,O
",",O,O
we,O,O
could,O,O
restore,O,O
transactivation,O,O
by,O,O
increasing,O,O
GATA,B,B
-,I,I
1,I,I
levels,O,O
in,O,O
OCIM1,O,O
cells,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
while,O,O
GATA,B,B
-,I,I
1,I,I
can,O,O
transactivate,O,O
the,O,O
EpoR,B,B
promoter,I,O
",",O,O
the,O,O
level,O,O
of,O,O
hEpoR,B,B
gene,I,I
expression,O,O
does,O,O
not,O,O
depend,O,O
on,O,O
GATA,B,O
-,I,O
1,I,O
alone,O,O
.,O,O
The,O,O
deduced,O,O
amino,O,O
acid,O,O
sequence,O,O
similarity,O,O
to,O,O
the,O,O
proteins,O,O
encoded,O,O
by,O,O
these,O,O
two,O,O
latter,O,O
genes,O,O
is,O,O
approximately,O,O
65,O,O
%,O,O
and,O,O
includes,O,O
domains,O,O
and,O,O
amino,O,O
acid,O,O
residues,O,O
(,O,O
the,O,O
leucine,B,O
zipper,I,O
-,I,O
like,I,O
and,O,O
the,O,O
RGD,B,O
domain,I,O
",",O,O
a,O,O
serine,O,O
and,O,O
a,O,O
histidine,O,O
residue,O,O
in,O,O
the,O,O
NH2,B,O
-,I,O
and,O,O
in,O,O
the,O,O
COOH,B,O
-,I,O
terminal,I,O
portion,I,O
of,O,O
the,O,O
protein,O,O
",",O,O
respectively,O,O
),O,O
postulated,O,O
to,O,O
be,O,O
important,O,O
for,O,O
nm23,B,O
function,O,O
.,O,O
Treatment,O,O
of,O,O
U937,O,O
with,O,O
IFN,B,B
-,I,I
gamma,I,I
for,O,O
9,O,O
hr,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
cycloheximide,O,O
led,O,O
to,O,O
super,O,O
-,O,O
induction,O,O
of,O,O
Fc,B,B
gamma,I,I
RI,I,I
expression,O,O
.,O,O
Genomic,O,O
sequence,O,O
upstream,O,O
of,O,O
the,O,O
Fc,B,B
gamma,I,I
RIC,I,I
gene,I,O
was,O,O
cloned,O,O
and,O,O
subjected,O,O
to,O,O
primer,O,O
extension,O,O
analysis,O,O
",",O,O
which,O,O
demonstrated,O,O
a,O,O
single,O,O
transcription,B,O
initiation,I,O
site,I,O
without,O,O
a,O,O
TATA,B,B
box,I,I
.,O,O
Double,B,O
-,I,O
stranded,I,O
GIRE,I,O
sequence,I,O
",",O,O
but,O,O
not,O,O
a,O,O
scrambled,B,O
sequence,I,O
",",O,O
was,O,O
specifically,O,O
bound,O,O
by,O,O
nuclear,B,B
proteins,I,I
from,O,O
IFN,O,B
-,O,I
gamma,O,I
treated,O,O
U937,O,O
cells,O,O
.,O,O
The,O,O
Fc,B,O
gamma,I,O
RIC,I,O
GIRE,I,O
is,O,O
homologous,O,O
to,O,O
the,O,O
IFN,B,B
-,I,I
gamma,I,I
activation,I,O
sequence,I,O
(,O,O
GAS,B,O
),O,O
of,O,O
the,O,O
guanylate,B,O
binding,I,O
protein,I,O
and,O,O
to,O,O
X,B,O
box,I,O
elements,I,O
of,O,O
class,B,O
II,I,O
MHC,I,O
genes,I,O
.,O,O
In,O,O
HTLV,O,B
-,O,I
I,O,I
-,O,I
infected,O,O
cord,O,O
blood,O,O
lymphocytes,O,O
",",O,O
the,O,O
transition,O,O
from,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
dependent,O,O
to,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
independent,O,O
growth,O,O
correlated,O,O
with,O,O
the,O,O
acquisition,O,O
of,O,O
a,O,O
constitutively,O,O
activated,O,O
Jak,B,B
-,B,I
STAT,I,I
pathway,O,I
",",O,O
which,O,O
suggests,O,O
that,O,O
this,O,O
pathway,O,O
participates,O,O
in,O,O
HTLV,O,B
-,O,I
I,O,I
-,O,I
mediated,O,O
T,O,O
cell,O,O
transformation,O,O
.,O,O
Nitric,O,O
oxide,O,O
selectively,O,O
reduces,O,O
endothelial,O,O
expression,O,O
of,O,O
adhesion,B,O
molecules,I,O
and,O,O
proinflammatory,B,O
cytokines,I,O
.,O,O
In,O,O
a,O,O
concentration,O,O
-,O,O
dependent,O,O
manner,O,O
",",O,O
NO,O,B
inhibited,O,O
interleukin,B,B
(,I,O
IL,I,O
),I,O
-,I,O
1,I,O
alpha,O,O
-,O,O
stimulated,O,O
VCAM,B,B
-,I,I
1,I,I
expression,O,O
by,O,O
35,O,O
-,O,O
55,O,O
%,O,O
as,O,O
determined,O,O
by,O,O
cell,O,O
surface,O,O
enzyme,O,O
immunoassays,O,O
and,O,O
flow,O,O
cytometry,O,O
.,O,O
Inhibition,O,O
of,O,O
endogenous,O,O
NO,O,B
production,O,O
by,O,O
L,O,O
-,O,O
N,O,O
-,O,O
monomethyl,O,O
-,O,O
arginine,O,O
also,O,O
induced,O,O
the,O,O
expression,O,O
of,O,O
VCAM,B,B
-,I,I
1,I,I
",",O,O
but,O,O
did,O,O
not,O,O
augment,O,O
cytokine,O,O
-,O,O
induced,O,O
VCAM,B,B
-,I,I
1,I,I
expression,O,O
.,O,O
Murine,B,O
macrophage,I,O
inflammatory,I,O
protein,I,B
1,I,I
alpha,I,I
(,O,O
MIP,B,O
-,I,O
1,I,O
alpha,I,O
),O,O
and,O,O
its,O,O
human,B,O
equivalent,I,O
(,O,O
GOS19,B,O
",",O,O
LD78,B,O
",",O,O
or,O,O
AT464,B,O
),O,O
are,O,O
members,O,O
of,O,O
the,O,O
-,B,O
C,I,O
-,I,O
C,I,O
family,I,O
of,O,O
low,B,O
-,I,O
molecular,I,O
-,I,O
weight,I,O
chemokines,I,O
.,O,O
It,O,O
also,O,O
induces,O,O
chemotaxis,O,O
and,O,O
inflammatory,O,O
responses,O,O
in,O,O
mature,O,O
cell,O,O
types,O,O
.,O,O
One,O,O
member,O,O
",",O,O
ICK,B,O
-,I,O
1A,I,O
",",O,O
behaves,O,O
as,O,O
a,O,O
strong,B,O
negative,I,O
regulator,I,O
.,O,O
We,O,O
provide,O,O
evidence,O,O
for,O,O
an,O,O
additional,O,O
binding,B,O
site,I,O
",",O,O
the,O,O
MIP,B,B
-,I,I
1,I,I
alpha,I,I
nuclear,I,O
protein,I,O
(,I,O
MNP,I,O
),I,O
site,I,O
",",O,O
which,O,O
overlaps,O,O
the,O,O
ICK,B,B
-,I,I
1,I,I
site,I,I
.,O,O
The,O,O
signal,O,O
is,O,O
subsequently,O,O
propagated,O,O
through,O,O
the,O,O
activation,O,O
of,O,O
Raf,B,B
-,I,I
1,I,I
",",O,O
MEK,B,B
",",O,O
and,O,O
MAP,B,B
kinases,I,I
as,O,O
shown,O,O
by,O,O
their,O,O
increased,O,O
autophosphorylation,O,O
in,O,O
vitro,O,O
and,O,O
phosphorylation,O,O
in,O,O
situ,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
IL,B,B
-,I,I
5,I,I
induced,O,O
signals,O,O
are,O,O
propagated,O,O
through,O,O
two,O,O
distinct,O,O
pathways,O,O
:,O,O
(,O,O
1,O,O
),O,O
Lyn,B,O
-,O,O
-,O,O
>,O,O
Ras,B,O
-,O,O
-,O,O
>,O,O
Raf,B,O
-,I,O
1,I,O
-,O,O
-,O,O
>,O,O
MEK,B,O
-,O,O
-,O,O
>,O,O
MAP,B,O
kinase,I,O
and,O,O
(,O,O
2,O,O
),O,O
Jak2,B,O
-,O,O
-,O,O
>,O,O
STAT1,B,O
.,O,O
The,O,O
retinoblastoma,B,O
gene,I,O
product,I,O
negatively,O,O
regulates,O,O
transcriptional,O,O
activation,O,O
mediated,O,O
by,O,O
the,O,O
human,B,O
cytomegalovirus,I,O
IE2,I,O
protein,I,O
.,O,O
We,O,O
found,O,O
that,O,O
the,O,O
retinoblastoma,B,B
susceptibility,I,I
gene,I,I
product,I,I
(,O,O
Rb,B,O
),O,O
dramatically,O,O
suppressed,O,O
this,O,O
IE2,B,O
transactivation,O,O
of,O,O
various,B,O
promoters,I,O
.,O,O
However,O,O
",",O,O
the,O,O
relationship,O,O
remains,O,O
controversial,O,O
according,O,O
to,O,O
the,O,O
tumor,O,B
cell,O,I
types,O,I
and,O,O
experimental,O,O
system,O,O
",",O,O
with,O,O
conflicting,O,O
results,O,O
from,O,O
different,O,O
research,O,O
groups,O,O
.,O,O
And,O,O
there,O,O
was,O,O
no,O,O
statistically,O,O
significant,O,O
difference,O,O
in,O,O
NDP,B,B
kinase,I,I
expression,O,O
between,O,O
SCC,O,O
with,O,O
metastasis,O,O
and,O,O
SCC,O,O
without,O,O
metastasis,O,O
.,O,O
Retinoblastoma,B,B
protein,I,I
(,O,I
RB,B,I
),O,I
is,O,O
a,O,O
tumor,O,O
suppressor,O,O
and,O,O
functions,O,O
as,O,O
a,O,O
transcriptional,B,O
repressor,I,O
by,O,O
binding,O,O
and,O,O
inactivating,O,O
the,O,O
transactivator,B,O
E2F,I,B
-,I,I
I,I,I
.,O,O
RB,O,B
-,O,I
defective,O,I
tumor,O,I
lines,O,I
are,O,O
non,O,O
-,O,O
inducible,O,O
for,O,O
MHC,B,B
class,I,I
II,I,I
by,O,O
IFN,B,B
-,I,I
gamma,I,I
",",O,O
or,O,O
very,O,O
weakly,O,O
inducible,O,O
",",O,O
but,O,O
transfection,O,O
of,O,O
2,O,O
different,O,O
lines,O,O
with,O,O
RB,B,B
expression,I,O
vectors,I,O
re,O,O
-,O,O
establishes,O,O
or,O,O
substantially,O,O
enhances,O,O
class,O,O
II,O,O
inducibility,O,O
.,O,O
We,O,O
also,O,O
examined,O,O
the,O,O
IFN,B,B
-,I,I
gamma,I,I
induction,O,O
of,O,O
CIITA,B,O
in,O,O
RB,B,O
-,O,O
defective,O,O
lines,O,O
.,O,O
We,O,O
have,O,O
recently,O,O
demonstrated,O,O
that,O,O
stimulation,O,O
of,O,O
human,O,O
T,O,O
and,O,O
natural,O,O
killer,O,O
cells,O,O
with,O,O
IL,B,B
-,I,I
12,I,I
induces,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
the,O,O
Janus,B,O
family,I,O
tyrosine,I,O
kinase,I,O
JAK2,B,O
and,O,O
Tyk2,B,O
",",O,O
implicating,O,O
these,O,O
kinases,B,O
in,O,O
the,O,O
immediate,O,O
biochemical,O,O
response,O,O
to,O,O
IL,B,B
-,I,I
12,I,I
.,O,O
Furthermore,O,O
",",O,O
we,O,O
show,O,O
that,O,O
IL,B,B
-,I,I
12,I,I
stimulates,O,O
formation,O,O
of,O,O
a,O,O
DNA,B,B
-,I,I
binding,I,I
complex,I,I
that,O,O
recognizes,O,O
a,O,O
DNA,O,B
sequence,O,O
previously,O,O
shown,O,O
to,O,O
bind,O,O
STAT,B,B
proteins,I,I
and,O,O
that,O,O
this,O,O
complex,O,O
contains,O,O
STAT4,B,B
.,O,O
DESIGN,O,O
:,O,O
The,O,O
effects,O,O
of,O,O
hypercortisolaemia,O,O
",",O,O
hyperthermia,O,O
and,O,O
cellular,O,O
composition,O,O
on,O,O
number,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
per,O,O
cell,O,O
and,O,O
their,O,O
affinity,O,O
were,O,O
evaluated,O,O
",",O,O
both,O,O
in,O,O
vitro,O,O
and,O,O
in,O,O
vivo,O,O
",",O,O
in,O,O
peripheral,O,O
blood,O,O
mononuclear,O,B
leucocytes,O,I
of,O,O
control,O,O
subjects,O,O
and,O,O
in,O,O
patients,O,O
with,O,O
sepsis,O,O
or,O,O
septic,O,O
shock,O,O
.,O,O
RESULTS,O,O
:,O,O
Hypercortisolaemia,O,O
",",O,O
in,O,O
vitro,O,O
",",O,O
resulted,O,O
in,O,O
a,O,O
decreased,O,O
affinity,O,O
and,O,O
a,O,O
decreased,O,O
binding,O,O
capacity,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
.,O,O
Integrin,O,B
-,O,I
mediated,O,I
tyrosine,O,I
phosphorylation,O,I
and,O,O
cytokine,B,O
message,O,O
induction,O,O
in,O,O
monocytic,O,B
cells,O,I
.,O,O
The,O,O
tyrosine,O,O
kinase,O,O
inhibitors,O,O
genistein,O,O
and,O,O
herbimycin,O,O
A,O,O
block,O,O
both,O,O
integrin,B,B
-,O,I
mediated,O,I
tyrosine,O,I
phosphorylation,O,I
and,O,O
increases,O,O
in,O,O
IL,B,B
-,I,I
1,I,I
beta,I,I
message,O,I
levels,O,O
",",O,O
indicating,O,O
a,O,O
causal,O,O
relationship,O,O
between,O,O
the,O,O
two,O,O
events,O,O
.,O,O
These,O,O
observations,O,O
indicate,O,O
that,O,O
the,O,O
Syk,B,B
tyrosine,O,I
kinase,O,I
may,O,O
be,O,O
an,O,O
important,O,O
component,O,O
of,O,O
an,O,O
integrin,B,O
signaling,O,O
pathway,O,O
in,O,O
monocytic,O,B
cells,O,I
",",O,O
leading,O,O
to,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
to,O,O
increased,O,O
levels,O,O
of,O,O
cytokine,B,O
messages,O,O
.,O,O
To,O,O
determine,O,O
if,O,O
New,O,O
World,O,O
primates,O,O
express,O,O
an,O,O
inhibitor,O,O
that,O,O
influences,O,O
glucocorticoid,B,B
receptor,I,I
(,O,I
GR,B,I
),O,I
binding,O,O
characteristics,O,O
",",O,O
we,O,O
examined,O,O
[,O,O
3H,O,O
],O,O
dexamethasone,O,O
binding,O,O
in,O,O
cytosol,O,O
prepared,O,O
from,O,O
B95,O,O
-,O,O
8,O,O
lymphoid,O,B
cells,O,I
",",O,O
derived,O,O
from,O,O
the,O,O
cotton,O,O
top,O,O
tamarin,O,O
(,O,O
Saguinus,O,O
oedipus,O,O
),O,O
",",O,O
in,O,O
combination,O,O
with,O,O
cytosol,O,O
prepared,O,O
from,O,O
human,O,B
or,O,O
rat,O,B
tissues,O,I
.,O,O
Kinetic,O,O
studies,O,O
using,O,O
mixed,O,O
cytosol,O,O
indicated,O,O
that,O,O
B95,O,O
-,O,O
8,O,O
cytosol,O,O
did,O,O
not,O,O
affect,O,O
the,O,O
apparent,O,O
dissociation,O,O
rate,O,O
of,O,O
[,O,O
3H,O,O
],O,O
dexamethasone,O,O
.,O,O
The,O,O
results,O,O
further,O,O
demonstrated,O,O
the,O,O
activation,O,O
of,O,O
S6,B,B
kinase,I,I
(,O,O
pp90rsk,B,O
),O,O
",",O,O
evidenced,O,O
by,O,O
phosphorylation,O,O
of,O,O
S6,B,B
and,O,O
serum,O,B
response,O,I
factor,O,I
(,O,O
SRF,O,O
),O,O
peptides,O,O
",",O,O
in,O,O
PWM,O,O
treated,O,O
B,O,O
cells,O,O
.,O,O
We,O,O
have,O,O
recently,O,O
found,O,O
a,O,O
novel,O,O
conserved,B,O
motif,I,O
in,O,O
the,O,O
promoters,B,O
of,O,O
several,O,O
T,B,O
-,I,O
cell,I,O
-,I,O
expressed,I,O
cytokines,I,O
[,O,O
human,B,O
interleukin,I,B
-,I,I
2,I,I
",",I,O
-,I,O
4,I,O
",",I,O
-,I,O
5,I,O
and,I,O
-,I,O
13,I,O
and,O,O
human,B,O
and,I,O
mouse,I,O
granulocyte,I,B
/,I,I
macrophage,I,I
-,I,I
colony,I,I
stimulating,I,I
factor,I,I
(,O,I
GM,B,I
-,I,I
CSF,I,I
),O,I
],O,O
.,O,O
In,O,O
transfection,O,O
assays,O,O
",",O,O
the,O,O
human,B,O
GM,I,B
-,I,I
CSF,I,I
element,I,O
has,O,O
a,O,O
strong,O,O
positive,O,O
effect,O,O
on,O,O
the,O,O
expression,O,O
of,O,O
a,O,O
reporter,B,O
gene,I,O
by,O,O
the,O,O
human,O,O
T,O,O
cell,O,O
line,O,O
Jurkat,O,O
J6,O,O
upon,O,O
stimulation,O,O
.,O,O
In,O,O
different,O,O
genes,B,O
",",O,O
the,O,O
core,B,O
sequences,I,O
are,O,O
separated,O,O
by,O,O
integer,O,O
numbers,O,O
of,O,O
helical,O,O
turns,O,O
.,O,O
Aspirin,O,O
inhibits,O,O
nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,B
mobilization,O,O
and,O,O
monocyte,O,O
adhesion,O,O
in,O,O
stimulated,O,O
human,O,B
endothelial,O,I
cells,O,O
.,O,O
These,O,O
effects,O,O
of,O,O
aspirin,O,O
were,O,O
not,O,O
related,O,O
to,O,O
the,O,O
inhibition,O,O
of,O,O
cyclooxygenase,B,O
activity,O,O
",",O,O
since,O,O
indomethacin,O,O
was,O,O
ineffective,O,O
.,O,O
Activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
by,O,O
various,O,O
cellular,O,O
stimuli,O,O
involves,O,O
the,O,O
phosphorylation,O,O
and,O,O
subsequent,O,O
degradation,O,O
of,O,O
its,O,O
inhibitor,O,O
",",O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
",",O,O
although,O,O
the,O,O
underlying,O,O
mechanism,O,O
remains,O,O
unclear,O,O
.,O,O
Together,O,O
",",O,O
these,O,O
results,O,O
suggest,O,O
that,O,O
phosphorylation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
",",O,O
mediated,O,O
through,O,O
both,O,O
the,O,O
TNF,B,O
-,I,O
alpha,I,O
-,O,O
inducible,O,O
and,O,O
the,O,O
PP,B,O
-,I,O
2A,I,O
-,I,O
opposing,I,O
kinases,I,O
",",O,O
may,O,O
serve,O,O
to,O,O
target,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
for,O,O
proteasome,B,O
-,O,O
mediated,O,O
degradation,O,O
.,O,O
The,O,O
5,B,O
flanking,I,O
region,I,O
of,O,O
the,O,O
human,B,O
alpha,I,B
-,I,I
globin,I,I
gene,I,I
is,O,O
highly,O,O
G,O,O
+,O,O
C,O,O
rich,O,O
and,O,O
contains,O,O
multiple,O,O
copies,O,O
of,O,O
the,O,O
consensus,B,O
sequence,I,O
for,O,O
the,O,O
Sp1,B,B
binding,I,O
site,I,O
.,O,O
Finally,O,O
",",O,O
we,O,O
show,O,O
by,O,O
both,O,O
footprint,O,O
analysis,O,O
and,O,O
functional,O,O
assays,O,O
that,O,O
the,O,O
ability,O,O
of,O,O
the,O,O
G,B,O
+,I,O
C,I,O
-,I,O
rich,I,O
region,I,O
to,O,O
increase,O,O
alpha,B,B
-,I,I
globin,I,I
promoter,I,O
activity,O,O
from,O,O
a,O,O
stably,O,O
integrated,O,O
alpha,B,B
-,I,I
globin,I,I
gene,I,I
is,O,O
mediated,O,O
by,O,O
its,O,O
multiple,B,O
binding,I,O
sites,I,O
for,O,O
the,O,O
transcription,B,O
factor,I,O
Sp1,B,B
.,O,O
LFA,B,B
-,I,I
3,I,I
induced,O,O
moderate,O,O
levels,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
",",O,O
but,O,O
did,O,O
not,O,O
influence,O,O
the,O,O
levels,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
while,O,O
B7,B,O
costimulation,O,O
strongly,O,O
induced,O,O
both,O,O
AP,B,B
-,I,I
1,I,I
and,O,O
substantially,O,O
enhanced,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
binding,I,I
proteins,I,I
.,O,O
The,O,O
Ah,B,O
receptor,I,O
recognizes,O,O
DNA,B,B
binding,I,I
sites,I,I
for,O,O
the,O,O
B,B,B
cell,I,I
transcription,I,I
factor,I,I
",",O,O
BSAP,B,O
:,O,O
a,O,O
possible,O,O
mechanism,O,O
for,O,O
dioxin,O,O
-,O,O
mediated,O,O
alteration,O,O
of,O,O
CD19,B,O
gene,I,O
expression,O,O
in,O,O
human,O,O
B,O,B
lymphocytes,O,I
.,O,O
In,O,O
addition,O,O
",",O,O
the,O,O
Ah,B,B
receptor,I,I
complex,I,I
recognized,O,O
a,O,O
DNA,B,B
binding,I,I
site,I,I
for,O,O
B,B,B
cell,I,I
lineage,I,I
-,I,I
specific,I,I
activator,I,I
protein,I,I
(,O,O
BSAP,B,O
),O,O
in,O,O
the,O,O
promoter,B,O
region,I,O
of,O,O
the,O,O
human,O,O
CD19,B,B
gene,I,I
which,O,O
is,O,O
similar,O,O
to,O,O
the,O,O
consensus,B,O
Ah,I,B
receptor,I,I
DNA,I,I
binding,I,I
site,I,I
.,O,O
We,O,O
recently,O,O
identified,O,O
a,O,O
differentiation,B,O
inhibitory,I,O
factor,I,O
(,O,O
I,B,O
-,I,O
factor,I,O
),O,O
in,O,O
mouse,O,O
myeloid,O,O
leukemia,O,O
M1,O,O
cells,O,O
as,O,O
a,O,O
murine,B,O
homolog,I,O
of,O,O
the,O,O
human,B,O
nm23,I,B
-,I,I
H2,I,I
gene,I,I
product,I,I
.,O,O
In,O,O
the,O,O
present,O,O
experiment,O,O
",",O,O
we,O,O
examined,O,O
the,O,O
effect,O,O
of,O,O
nm23,B,B
proteins,I,I
on,O,O
various,O,O
differentiation,O,O
induction,O,O
systems,O,O
of,O,O
human,O,B
leukemic,O,I
cells,O,I
including,O,O
HL,O,B
-,O,I
60,O,I
",",O,O
U937,O,B
",",O,O
HEL,O,B
/,O,I
S,O,I
",",O,O
KU812F,O,B
",",O,O
K562,O,B
",",O,O
and,O,O
HEL,O,B
cells,O,I
.,O,O
Delayed,O,O
administration,O,O
of,O,O
rBPI21,B,B
also,O,O
affected,O,O
LPS,O,B
-,O,I
mediated,O,I
activation,O,I
of,O,I
the,O,I
nuclear,B,I
factor,I,I
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Two,O,O
to,O,O
4,O,O
h,O,O
following,O,O
LPS,O,B
addition,O,O
to,O,O
endothelial,O,B
cells,O,I
",",O,O
when,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
was,O,O
already,O,O
activated,O,O
",",O,O
addition,O,O
of,O,O
rBPI21,B,O
resulted,O,O
in,O,O
marked,O,O
reduction,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
detectable,O,O
at,O,O
4,O,O
or,O,O
6,O,O
h,O,O
.,O,O
GM,B,O
-,I,O
CSF,I,O
and,O,O
IL,B,B
-,I,I
2,I,I
share,O,O
common,O,O
control,O,O
mechanisms,O,O
in,O,O
response,O,O
to,O,O
costimulatory,O,O
signals,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
Antigen,O,O
complexed,O,O
with,O,O
major,B,O
histocompatibility,I,O
complex,I,O
class,I,O
I,I,O
or,I,O
II,I,O
molecules,I,O
on,O,O
the,O,O
surface,O,O
of,O,O
antigen,O,O
presenting,O,O
cells,O,O
interacts,O,O
with,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
on,O,O
the,O,O
surface,O,O
of,O,O
T,O,O
cells,O,O
and,O,O
initiates,O,O
an,O,O
activation,O,O
cascade,O,O
.,O,O
Costimulatory,O,O
signals,O,O
",",O,O
such,O,O
as,O,O
activation,O,O
of,O,O
the,O,O
CD28,B,B
cell,I,I
surface,I,I
molecule,I,I
on,O,O
T,O,O
cells,O,O
",",O,O
lead,O,O
to,O,O
activation,O,O
through,O,O
a,O,O
distinct,O,O
region,O,O
of,O,O
the,O,O
granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,I,O
GM,I,B
-,I,I
CSF,I,I
),I,O
promoter,I,O
.,O,O
Human,O,O
T,O,O
leukemia,O,O
virus,O,O
type,O,O
1,O,O
(,O,O
HTLV,O,O
-,O,O
1,O,O
),O,O
infects,O,O
T,O,O
cells,O,O
and,O,O
can,O,O
lead,O,O
to,O,O
increase,O,O
GM,B,B
-,I,I
CSF,I,I
expression,O,O
.,O,O
This,O,O
observation,O,O
",",O,O
together,O,O
with,O,O
the,O,O
fact,O,O
that,O,O
both,O,O
GM,B,B
-,I,I
CSF,I,I
and,O,O
IL,B,B
-,I,I
2,I,I
respond,O,O
to,O,O
TCR,B,O
signals,O,O
via,O,O
NFAT,B,O
",",O,O
implies,O,O
a,O,O
high,O,O
degree,O,O
of,O,O
conservation,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
cytokine,B,O
gene,O,O
expression,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
3,O,O
.,O,O
Danazol,O,O
decreased,O,O
the,O,O
transcription,O,O
rate,O,O
of,O,O
ER,B,B
gene,I,I
to,O,O
approximately,O,O
50,O,O
%,O,O
in,O,O
monocytes,O,O
in,O,O
a,O,O
run,O,O
-,O,O
on,O,O
assay,O,O
.,O,O
Formation,O,O
of,O,O
the,O,O
NFAT,B,B
-,I,I
1,I,I
transcriptional,I,I
complex,I,I
on,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
is,O,O
essential,O,O
for,O,O
IL,B,B
-,I,I
2,I,I
transcription,O,I
.,O,O
WIN,O,O
53071,O,O
inhibited,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
induced,O,O
in,O,O
the,O,O
calcium,O,B
-,O,I
dependent,O,I
PMA,O,I
and,O,O
ionomycin,O,O
pathway,O,O
.,O,O
We,O,O
examined,O,O
mRNA,B,O
levels,O,O
of,O,O
various,O,O
V,B,B
-,I,I
ATPase,I,I
subunits,O,O
during,O,O
differentiation,O,O
of,O,O
both,O,O
native,O,O
monocytes,O,O
and,O,O
the,O,O
cell,O,O
line,O,O
THP,O,O
-,O,O
1,O,O
",",O,O
and,O,O
found,O,O
that,O,O
transcriptional,O,O
and,O,O
post,O,O
-,O,O
transcriptional,O,O
mechanisms,O,O
could,O,O
account,O,O
for,O,O
increases,O,O
in,O,O
cell,O,O
V,B,B
-,I,I
ATPase,I,I
content,O,O
.,O,O
From,O,O
nuclear,O,O
runoff,O,O
experiments,O,O
",",O,O
we,O,O
found,O,O
that,O,O
one,O,O
subunit,O,O
in,O,O
particular,O,O
",",O,O
the,O,O
B2,B,B
isoform,I,I
(,O,O
Mr,O,O
56,O,O
",",O,O
),O,O
",",O,O
was,O,O
amplified,O,O
primarily,O,O
by,O,O
transcriptional,O,O
means,O,O
.,O,O
Primer,O,O
extension,O,O
and,O,O
ribonuclease,B,O
protection,O,O
analyses,O,O
indicate,O,O
a,O,O
single,O,O
major,B,O
transcriptional,I,O
start,I,O
site,I,O
.,O,O
We,O,O
transfected,O,O
promoter,B,O
-,I,O
luciferase,I,O
reporter,I,O
plasmids,I,O
into,O,O
THP,O,O
-,O,O
1,O,O
cells,O,O
to,O,O
define,O,O
sequences,O,O
that,O,O
mediate,O,O
transcriptional,O,O
control,O,O
during,O,O
monocyte,O,O
differentiation,O,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
function,O,O
of,O,O
these,O,O
elements,O,O
in,O,O
Burkitt,O,O
s,O,O
lymphoma,O,O
cells,O,O
(,O,O
Ramos,O,O
and,O,O
Daudi,O,O
),O,O
as,O,O
well,O,O
as,O,O
a,O,O
T,O,O
lymphocytic,O,O
cell,O,O
line,O,O
(,O,O
Jurkat,O,O
),O,O
.,O,O
Okadaic,O,O
acid,O,O
augments,O,O
PMA,O,O
-,O,O
as,O,O
well,O,O
as,O,O
calcium,O,O
-,O,O
mediated,O,O
activation,O,O
of,O,O
c,B,O
-,I,O
fos,I,O
",",O,O
and,O,O
has,O,O
little,O,O
or,O,O
no,O,O
effect,O,O
when,O,O
combined,O,O
with,O,O
cAMP,O,O
.,O,O
The,O,O
main,O,O
difference,O,O
between,O,O
Ramos,O,O
(,O,O
B,O,O
cells,O,O
),O,O
and,O,O
Jurkat,O,O
(,O,O
T,O,O
cells,O,O
),O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
c,B,O
-,I,O
fos,I,O
is,O,O
that,O,O
cAMP,O,O
plus,O,O
calcium,O,O
is,O,O
strongly,O,O
synergistic,O,O
in,O,O
Jurkat,O,O
and,O,O
is,O,O
without,O,O
effect,O,O
in,O,O
Ramos,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
cell,O,O
-,O,O
specific,O,O
patterns,O,O
of,O,O
synergy,O,O
are,O,O
an,O,O
essential,O,O
feature,O,O
for,O,O
c,B,O
-,I,O
fos,I,O
induction,O,O
and,O,O
may,O,O
be,O,O
relevant,O,O
for,O,O
c,B,O
-,I,O
fos,I,O
control,O,O
through,O,O
B,B,B
and,I,O
T,I,B
cell,I,I
antigen,I,I
receptors,I,I
.,O,O
Multiple,O,O
signals,O,O
are,O,O
required,O,O
for,O,O
function,O,O
of,O,O
the,O,O
human,B,O
granulocyte,I,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
gene,I,I
promoter,I,I
in,O,O
T,O,B
cells,O,I
.,O,O
These,O,O
results,O,O
imply,O,O
that,O,O
at,O,O
least,O,O
three,O,O
signals,O,O
are,O,O
required,O,O
to,O,O
activate,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
proximal,I,O
promoter,I,O
",",O,O
and,O,O
that,O,O
the,O,O
signals,O,O
impinge,O,O
on,O,O
distinct,O,O
transcription,B,O
factors,I,O
that,O,O
bind,O,O
to,O,O
the,O,O
hCLEO,B,O
and,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
regions,I,O
of,O,O
the,O,O
promoter,B,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
show,O,O
that,O,O
in,O,O
monocytes,O,O
and,O,O
T,O,O
cells,O,O
IL,B,B
-,I,I
10,I,I
stimulates,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
the,O,O
signal,B,O
transducers,I,O
and,O,O
activators,B,O
of,I,O
transcription,I,O
",",O,O
STAT1,B,O
alpha,I,O
and,O,O
STAT3,B,O
",",O,O
in,O,O
a,O,O
differential,O,O
manner,O,O
such,O,O
that,O,O
the,O,O
relative,O,O
formation,O,O
of,O,O
homo,B,O
-,I,O
and,I,O
heterodimers,I,O
varies,O,O
between,O,O
the,O,O
two,O,O
cell,O,O
types,O,O
.,O,O
IL,B,B
-,I,I
10,I,I
treatment,O,O
of,O,O
both,O,O
T,O,O
cells,O,O
and,O,O
monocytes,O,O
results,O,O
in,O,O
the,O,O
ligand,O,O
-,O,O
induced,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
tyk2,B,B
and,O,O
Jak1,B,B
",",O,O
but,O,O
not,O,O
Jak2,B,B
or,O,O
Jak3,B,B
.,O,O
Selective,O,O
modulation,O,O
of,O,O
immune,O,O
responsiveness,O,O
by,O,O
IL,B,B
-,I,I
10,I,I
in,O,O
cells,O,O
such,O,O
as,O,O
monocytes,O,O
and,O,O
T,O,O
cells,O,O
may,O,O
result,O,O
in,O,O
part,O,O
from,O,O
the,O,O
differential,O,O
activation,O,O
of,O,O
STAT,B,B
protein,I,I
pairs,I,O
.,O,O
However,O,O
",",O,O
the,O,O
real,O,O
effect,O,O
of,O,O
hormones,O,O
involved,O,O
in,O,O
ovulation,O,O
is,O,O
expressed,O,O
by,O,O
biological,O,O
modifications,O,O
on,O,O
target,O,O
tissues,O,O
.,O,O
They,O,O
also,O,O
display,O,O
constitutively,O,O
high,O,O
levels,O,O
of,O,O
p59fyn,B,B
and,O,O
CD3,B,B
zeta,I,I
tyrosine,O,I
phosphorylation,O,I
.,O,O
The,O,O
generation,O,O
of,O,O
second,O,O
messengers,O,O
in,O,O
T,O,O
cells,O,O
normally,O,O
leads,O,O
to,O,O
downstream,O,O
signaling,O,O
that,O,O
results,O,O
in,O,O
transcriptional,O,O
activation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
.,O,O
Levels,O,O
of,O,O
the,O,O
octamer,O,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
(,O,O
p50,B,O
-,I,O
p65,I,O
heterodimer,I,O
),O,O
",",O,O
and,O,O
AP,B,B
-,I,I
1,I,I
transcriptional,I,I
factors,I,I
are,O,O
constitutively,O,O
elevated,O,O
in,O,O
freshly,O,O
isolated,O,O
Ipr,O,O
CD4,O,O
-,O,O
8,O,O
-,O,O
T,O,O
cells,O,O
",",O,O
consistent,O,O
with,O,O
the,O,O
activated,O,O
phenotype,O,O
of,O,O
these,O,O
cells,O,O
.,O,O
We,O,O
demonstrate,O,O
that,O,O
cross,O,O
-,O,O
linking,O,O
CD30,B,O
with,O,O
an,O,O
anti,O,O
-,O,O
CD30,B,O
-,O,O
specific,O,O
monoclonal,O,O
antibody,O,O
",",O,O
which,O,O
mimics,O,O
the,O,O
described,O,O
biological,O,O
activities,O,O
of,O,O
the,O,O
CD30,B,O
ligand,I,O
(,O,O
CD30L,B,O
),O,O
",",O,O
results,O,O
in,O,O
HIV,O,B
expression,O,O
.,O,O
Type,B,O
II,I,O
major,I,O
histocompatibility,I,O
complex,I,O
combined,O,O
immune,O,O
deficiency,O,O
(,O,O
type,O,O
II,O,O
MHC,B,B
CID,O,I
or,O,O
bare,O,O
lymphocyte,O,O
syndrome,O,O
),O,O
is,O,O
a,O,O
congenital,O,O
immunodeficiency,O,O
disease,O,O
characterized,O,O
by,O,O
absent,O,O
MHC,B,B
class,I,I
II,I,I
expression,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
CIITA,B,O
is,O,O
an,O,O
MHC,B,B
class,I,I
II,I,I
gene,I,O
-,I,O
specific,I,O
transcription,I,O
activator,I,O
.,O,O
The,O,O
transcription,O,O
activation,O,O
function,O,O
is,O,O
provided,O,O
by,O,O
the,O,O
N,B,O
-,I,O
terminal,I,O
acidic,I,O
domain,I,O
(,O,O
amino,B,O
acids,I,O
26,I,O
-,I,O
137,I,O
),O,O
",",O,O
which,O,O
is,O,O
experimentally,O,O
exchangeable,O,O
with,O,O
a,O,O
heterologous,B,O
viral,I,O
transcription,I,O
-,I,O
activating,I,O
domain,I,O
.,O,O
These,O,O
results,O,O
demonstrate,O,O
that,O,O
P,B,B
-,I,I
selectin,I,I
",",O,O
through,O,O
its,O,O
ligands,O,O
on,O,O
monocytes,O,O
",",O,O
may,O,O
locally,O,O
regulate,O,O
cytokine,B,O
secretion,O,O
in,O,O
inflamed,O,O
tissues,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
nitric,O,O
oxide,O,O
(,O,O
NO,O,O
),O,O
activates,O,O
p21ras,B,B
in,O,O
human,O,O
T,O,B
cells,O,O
as,O,O
evidenced,O,O
by,O,O
an,O,O
increase,O,O
in,O,O
GTP,B,O
-,I,O
bound,I,O
p21ras,I,O
.,O,O
In,O,O
vitro,O,O
studies,O,O
using,O,O
pure,B,O
recombinant,I,O
p21ras,I,O
demonstrate,O,O
that,O,O
the,O,O
activation,O,O
is,O,O
direct,O,O
and,O,O
reversible,O,O
.,O,O
Circular,O,O
dichroism,O,O
analysis,O,O
reveals,O,O
that,O,O
NO,O,B
induces,O,O
a,O,O
profound,O,O
conformational,O,O
change,O,O
in,O,O
p21ras,B,B
in,O,O
association,O,O
with,O,O
GDP,O,B
/,O,I
GTP,O,I
exchange,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
p21ras,B,B
is,O,O
essential,O,O
for,O,O
NO,O,B
-,O,O
induced,O,O
downstream,O,O
signaling,O,O
",",O,O
such,O,O
as,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
",",O,O
and,O,O
that,O,O
endogenous,O,O
NO,O,B
can,O,O
activate,O,O
p21ras,B,B
in,O,O
the,O,O
same,O,O
cell,O,O
.,O,O
These,O,O
studies,O,O
identify,O,O
p21ras,B,B
as,O,O
a,O,O
target,O,O
of,O,O
the,O,O
same,O,O
cell,O,O
.,O,O
These,O,O
studies,O,O
identify,O,O
p21ras,B,B
as,O,O
a,O,O
target,O,O
of,O,O
NO,O,B
in,O,O
T,O,O
cells,O,O
and,O,O
suggest,O,O
that,O,O
NO,O,B
activates,O,O
p21ras,B,B
by,O,O
an,O,O
action,O,O
which,O,O
mimics,O,O
that,O,O
of,O,O
guanine,B,B
nucleotide,I,I
exchange,I,I
factors,I,I
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
we,O,O
analyzed,O,O
the,O,O
control,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
activity,O,O
in,O,O
Epstein,O,B
-,O,I
Barr,O,I
virus,O,I
(,O,I
EBV,O,I
),O,I
-,O,I
transformed,O,I
B,O,I
cell,O,I
clones,O,I
which,O,O
are,O,O
capable,O,O
of,O,O
secreting,O,O
IL,B,B
-,I,I
2,I,I
at,O,O
a,O,O
low,O,O
level,O,O
after,O,O
stimulation,O,O
with,O,O
phorbol,O,O
12,O,O
-,O,O
myristate,O,O
13,O,O
-,O,O
acetate,O,O
and,O,O
the,O,O
Ca2,O,B
+,O,I
ionophore,O,I
ionomycin,O,I
.,O,O
Transient,O,O
transfections,O,O
using,O,O
reporter,B,O
constructs,I,O
with,O,O
multiples,O,O
of,O,O
transcription,B,O
factor,I,O
binding,I,O
sites,I,O
from,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
[,O,O
distal,B,O
nuclear,I,O
factor,I,O
(,I,O
NF,I,B
),I,O
-,I,O
AT,I,O
",",O,O
proximal,B,O
NF,I,B
-,I,O
AT,I,O
",",O,O
AP,B,B
-,I,O
1,I,I
/,I,I
Octamer,I,I
(,O,I
UPS,B,I
),O,I
or,O,O
NF,B,B
-,I,O
chi,I,O
B,I,O
(,O,O
TCEd,B,O
),O,O
sites,O,O
],O,O
were,O,O
performed,O,O
.,O,O
In,O,O
EBV,O,O
-,O,O
transformed,O,O
B,O,O
clones,O,O
",",O,O
the,O,O
chi,B,O
B,I,O
site,I,O
exerted,O,O
the,O,O
strongest,O,O
inducible,O,O
activity,O,O
;,O,O
the,O,O
NF,B,B
-,I,O
AT,I,O
binding,I,O
sites,I,O
showed,O,O
either,O,O
no,O,O
or,O,O
only,O,O
weak,O,O
activity,O,O
compared,O,O
to,O,O
Jurkat,O,O
T,O,O
cells,O,O
.,O,O
In,O,O
seven,O,O
EBV,O,B
-,O,I
B,O,I
cell,O,I
clones,O,O
or,O,O
lines,O,O
differing,O,O
in,O,O
their,O,O
capacity,O,O
to,O,O
secrete,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
the,O,O
activity,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
correlated,O,O
well,O,O
with,O,O
the,O,O
status,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
secretion,O,O
.,O,O
Latent,B,O
membrane,I,O
protein,I,O
-,I,O
1,I,O
induces,O,O
cyclin,B,O
D2,I,O
expression,O,O
",",O,O
pRb,B,O
hyperphosphorylation,O,O
",",O,O
and,O,O
loss,O,O
of,O,O
TGF,B,B
-,I,I
1,I,I
-,O,I
mediated,O,I
growth,O,I
inhibition,O,I
in,O,O
EBV,O,B
-,O,I
positive,O,I
B,O,I
cells,O,I
.,O,O
Here,O,O
",",O,O
we,O,O
show,O,O
that,O,O
the,O,O
presence,O,O
of,O,O
either,O,O
wild,O,O
-,O,O
type,O,O
EBV,O,O
or,O,O
its,O,O
transforming,B,O
latent,I,O
membrane,I,O
protein,I,O
-,I,O
1,I,O
(,O,O
LMP,B,O
-,I,O
1,I,O
),O,O
results,O,O
in,O,O
the,O,O
loss,O,O
of,O,O
TGF,B,B
-,I,I
beta,I,I
1,I,I
-,O,I
mediated,O,I
growth,O,I
inhibition,O,I
in,O,O
human,O,O
B,O,O
cells,O,O
.,O,O
Does,O,O
thyroidectomy,O,O
",",O,O
radioactive,O,O
iodine,O,O
therapy,O,O
",",O,O
or,O,O
antithyroid,O,O
drug,O,O
treatment,O,O
alter,O,O
reactivity,O,O
of,O,O
patients,O,O
T,O,O
cells,O,O
to,O,O
epitopes,O,O
of,O,O
thyrotropin,B,O
receptor,I,O
in,O,O
autoimmune,O,O
thyroid,O,O
diseases,O,O
?,O,O
A,O,O
further,O,O
decrease,O,O
in,O,O
the,O,O
T,O,O
cell,O,O
reactivity,O,O
to,O,O
TSHR,B,O
peptides,O,O
was,O,O
observed,O,O
3,O,O
-,O,O
6,O,O
months,O,O
after,O,O
surgery,O,O
.,O,O
Six,O,O
to,O,O
8,O,O
weeks,O,O
after,O,O
RAI,O,O
therapy,O,O
",",O,O
the,O,O
number,O,O
of,O,O
patients,O,O
responding,O,O
to,O,O
any,O,O
peptide,O,O
and,O,O
the,O,O
average,O,O
number,O,O
of,O,O
recognized,O,O
peptides,O,O
increased,O,O
.,O,O
The,O,O
reactivity,O,O
of,O,O
T,O,O
cell,O,O
lines,O,O
in,O,O
different,O,O
groups,O,O
reflected,O,O
a,O,O
pattern,O,O
similar,O,O
to,O,O
PBMC,O,O
after,O,O
treatment,O,O
.,O,O
TSHR,B,B
antibody,I,I
and,O,O
microsomal,B,B
antibody,I,I
levels,O,O
decreased,O,O
after,O,O
surgery,O,O
",",O,O
but,O,O
increased,O,O
after,O,O
RAI,O,O
therapy,O,O
.,O,O
We,O,O
have,O,O
identified,O,O
an,O,O
in,O,O
vivo,O,O
footprint,O,O
over,O,O
the,O,O
PuF,B,O
site,I,O
on,O,O
the,O,O
translocated,O,O
c,B,B
-,I,I
myc,I,I
allele,I,O
in,O,O
Burkitt,O,O
s,O,O
lymphoma,O,O
cells,O,O
.,O,O
Transfection,O,O
experiments,O,O
with,O,O
c,B,B
-,I,I
myc,I,I
promoter,I,O
constructs,I,O
in,O,O
both,O,O
DHL,O,O
-,O,O
9,O,O
and,O,O
Raji,O,O
cells,O,O
revealed,O,O
that,O,O
the,O,O
PuF,B,O
site,I,O
functioned,O,O
as,O,O
a,O,O
positive,B,O
regulatory,I,O
element,I,O
in,O,O
B,O,O
cells,O,O
with,O,O
a,O,O
drop,O,O
in,O,O
activity,O,O
with,O,O
mutation,O,O
of,O,O
this,O,O
site,O,O
.,O,O
Electromobility,O,O
shift,O,O
assays,O,O
utilizing,O,O
this,O,O
sequence,O,O
demonstrated,O,O
binding,O,O
of,O,O
a,O,O
fetal,B,B
and,I,O
erythroid,I,B
-,I,I
specific,I,I
protein,I,I
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
the,O,O
5,B,O
-,I,O
UTR,I,O
of,O,O
the,O,O
gamma,B,B
-,I,I
gene,I,I
contains,O,O
sequences,O,O
that,O,O
may,O,O
be,O,O
important,O,O
for,O,O
its,O,O
transcriptional,O,O
and,O,O
developmental,O,O
regulation,O,O
.,O,O
However,O,O
",",O,O
this,O,O
deletion,O,O
mutation,O,O
prevented,O,O
the,O,O
induced,O,O
phosphorylation,O,O
",",O,O
degradative,O,O
loss,O,O
",",O,O
and,O,O
functional,O,O
release,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
from,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
Tax,O,O
-,O,O
expressing,O,O
cells,O,O
.,O,O
Alanine,O,O
substitutions,O,O
introduced,O,O
at,O,O
two,O,O
serine,O,B
residues,O,I
positioned,O,O
within,O,O
this,O,O
N,B,O
-,I,O
terminal,I,O
regulatory,I,O
region,I,O
of,O,O
I,B,O
kappa,I,O
B,I,O
alpha,I,O
also,O,O
yielded,O,O
constitutive,O,O
repressors,O,O
that,O,O
escaped,O,O
from,O,O
Tax,B,O
-,O,O
induced,O,O
turnover,O,O
and,O,O
that,O,O
potently,O,O
inhibited,O,O
immune,O,O
activation,O,O
pathways,O,O
for,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
induction,O,O
",",O,O
including,O,O
those,O,O
initiated,O,O
from,O,O
antigen,B,O
and,I,O
cytokine,I,O
receptors,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
introduction,O,O
of,O,O
a,O,O
phosphoserine,O,O
mimetic,O,O
at,O,O
these,O,O
sites,O,O
rectified,O,O
this,O,O
functional,O,O
defect,O,O
",",O,O
a,O,O
finding,O,O
consistent,O,O
with,O,O
a,O,O
causal,O,O
linkage,O,O
between,O,O
the,O,O
phosphorylation,O,O
status,O,O
and,O,O
proteolytic,O,O
stability,O,O
of,O,O
this,O,O
cytoplasmic,B,O
inhibitor,I,O
.,O,O
Together,O,O
",",O,O
these,O,O
in,O,O
vivo,O,O
studies,O,O
define,O,O
a,O,O
critical,O,O
signal,O,O
response,O,O
domain,O,O
in,O,O
I,B,O
kappa,I,O
B,I,O
alpha,I,O
that,O,O
coordinately,O,O
controls,O,O
the,O,O
biologic,O,O
activities,O,O
of,O,O
I,B,O
kappa,I,O
B,I,O
alpha,I,O
and,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
in,O,O
response,O,O
to,O,O
viral,O,O
and,O,O
immune,O,O
stimuli,O,O
.,O,O
Human,O,O
prostatic,O,B
epithelial,O,I
cells,O,I
from,O,O
an,O,O
androgen,O,O
-,O,O
dependent,O,O
LNCaP,O,O
cell,O,O
line,O,O
were,O,O
examined,O,O
in,O,O
response,O,O
to,O,O
conditioned,O,O
medium,O,O
(,O,O
CM,O,O
),O,O
derived,O,O
from,O,O
phytohemagglutinin,O,O
(,O,O
PHA,O,O
),O,O
-,O,O
stimulated,O,O
lymphocytes,O,O
.,O,O
Cell,O,O
morphology,O,O
showed,O,O
dendritic,O,O
processes,O,O
extending,O,O
from,O,O
cytoplasm,O,O
and,O,O
other,O,O
neuroendocrine,O,O
cell,O,O
characteristics,O,O
.,O,O
These,O,O
included,O,O
vimentin,B,B
",",O,O
correlating,O,O
to,O,O
cell,O,O
shape,O,O
changes,O,O
",",O,O
cytokeratins,B,B
8,I,I
and,I,O
18,I,I
",",O,O
associated,O,O
with,O,O
differentiated,O,O
cell,O,O
types,O,O
of,O,O
prostate,O,O
epithelia,O,O
",",O,O
and,O,O
neuron,B,B
-,I,I
specific,I,I
enolase,I,I
and,O,O
serotonin,O,B
",",O,O
associated,O,O
with,O,O
neuroendocrine,O,O
cells,O,O
.,O,O
Human,O,O
peripheral,O,O
blood,O,O
monocytes,O,O
responded,O,O
to,O,O
stimulation,O,O
of,O,O
platelet,B,B
-,I,I
activating,I,I
factor,I,I
(,O,O
PAF,B,O
),O,O
with,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
the,O,O
transcript,O,O
for,O,O
heparin,B,B
-,I,I
binding,I,I
epidermal,I,I
growth,I,I
factor,I,I
-,I,I
like,I,I
growth,I,I
factor,I,I
(,O,O
HB,B,O
-,I,O
EGF,I,O
),O,O
",",O,O
a,O,O
potent,B,O
mitogen,I,O
for,O,O
vascular,O,O
smooth,O,O
muscle,O,O
cells,O,O
.,O,O
This,O,O
function,O,O
of,O,O
PAF,B,B
was,O,O
observed,O,O
at,O,O
nanomolar,O,O
concentrations,O,O
of,O,O
the,O,O
ligand,O,O
",",O,O
starting,O,O
at,O,O
30,O,O
min,O,O
after,O,O
stimulation,O,O
.,O,O
These,O,O
functions,O,O
of,O,O
PAF,B,B
appeared,O,O
to,O,O
be,O,O
mediated,O,O
through,O,O
the,O,O
cell,B,O
surface,I,O
PAF,I,B
receptors,I,O
",",O,O
as,O,O
two,O,O
PAF,B,B
receptor,O,I
antagonists,O,O
",",O,O
WEB,O,O
2086,O,O
and,O,O
L,O,O
-,O,O
659,O,O
",",O,O
989,O,O
",",O,O
blocked,O,O
both,O,O
the,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
HB,B,O
-,I,O
EGF,I,O
mRNA,I,O
and,O,O
kappa,O,O
B,O,O
binding,O,O
activity,O,O
induced,O,O
by,O,O
PAF,B,B
.,O,O
The,O,O
antagonists,O,O
",",O,O
however,O,O
",",O,O
had,O,O
no,O,O
effect,O,O
on,O,O
phorbol,O,O
ester,O,O
-,O,O
induced,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
HB,B,O
-,I,O
EGF,I,O
mRNA,I,O
and,O,O
kappa,O,O
B,O,O
binding,O,O
activity,O,O
.,O,O
Several,O,O
criteria,O,O
indicated,O,O
that,O,O
the,O,O
defect,O,O
in,O,O
this,O,O
cell,O,O
line,O,O
influences,O,O
the,O,O
activity,O,O
of,O,O
an,O,O
isotype,B,O
-,I,O
specific,I,O
transcription,I,O
factor,I,O
.,O,O
The,O,O
DQB,B,O
X2,I,O
-,I,O
box,I,O
was,O,O
able,O,O
to,O,O
restore,O,O
expression,O,O
to,O,O
the,O,O
silent,B,O
DRA,I,O
reporter,I,O
construct,I,O
.,O,O
Moreover,O,O
",",O,O
replacement,O,O
of,O,O
the,O,O
DQB,B,B
X2,I,I
-,I,I
box,I,I
with,O,O
the,O,O
DRA,B,B
X2,I,I
-,I,I
box,I,I
markedly,O,O
diminished,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
DQB,B,B
promoter,I,O
in,O,O
the,O,O
mutant,O,O
cell,O,O
.,O,O
ZEBRA,B,O
is,O,O
a,O,O
bZIP,B,O
transcriptional,I,O
activator,I,O
which,O,O
binds,O,O
as,O,O
a,O,O
dimer,O,O
to,O,O
7,B,O
-,I,O
bp,I,O
response,I,O
elements,I,O
within,O,O
EBV,B,O
promoters,I,O
and,O,O
is,O,O
directly,O,O
involved,O,O
in,O,O
the,O,O
stimulation,O,O
of,O,O
virus,O,O
replication,O,O
at,O,O
the,O,O
EBV,B,O
lytic,I,O
origin,I,O
.,O,O
Both,O,O
chimeras,O,O
were,O,O
found,O,O
to,O,O
transactivate,O,O
model,O,O
and,O,O
native,O,O
promoters,O,O
at,O,O
equivalent,O,O
or,O,O
better,O,O
levels,O,O
than,O,O
ZEBRA,B,O
itself,O,O
.,O,O
These,O,O
activation,O,O
domains,O,O
restored,O,O
ZEBRA,B,O
s,O,O
ability,O,O
to,O,O
induce,O,O
early,B,O
antigen,I,O
and,O,O
to,O,O
stimulate,O,O
origin,O,O
replication,O,O
to,O,O
levels,O,O
that,O,O
were,O,O
equal,O,O
to,O,O
or,O,O
greater,O,O
than,O,O
those,O,O
of,O,O
wild,O,O
type,O,O
.,O,O
Because,O,O
these,O,O
are,O,O
the,O,O
characteristics,O,O
of,O,O
a,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
(,I,O
Stat,I,O
),I,O
protein,I,O
",",O,O
we,O,O
determined,O,O
whether,O,O
antibodies,B,O
to,I,O
Stat,I,O
proteins,I,O
will,O,O
interfere,O,O
with,O,O
gel,O,O
mobility,O,O
shift,O,O
and,O,O
found,O,O
that,O,O
antibodies,B,O
to,I,O
IL,I,B
-,I,I
4,I,I
Stat,I,O
",",O,O
also,O,O
known,O,O
as,O,O
Stat6,B,O
",",O,O
but,O,O
not,O,O
antibodies,B,O
to,O,O
other,O,O
Stat,B,O
proteins,I,O
",",O,O
interfere,O,O
with,O,O
the,O,O
formation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
NAF,I,I
complex,I,I
.,O,O
Monoallelic,O,O
expression,O,O
of,O,O
TAL1,B,B
was,O,O
observed,O,O
in,O,O
the,O,O
leukemic,O,B
cells,O,I
of,O,O
all,O,O
patients,O,O
(,O,O
8,O,O
of,O,O
8,O,O
),O,O
bearing,O,O
a,O,O
TAL1,B,B
gene,I,I
rearrangement,O,I
.,O,O
In,O,O
the,O,O
leukemic,O,B
cells,O,I
of,O,O
patients,O,O
without,O,O
detectable,O,O
TAL1,B,B
rearrangements,O,I
",",O,O
TAL1,B,B
transcription,O,O
occurred,O,O
in,O,O
either,O,O
a,O,O
monoallelic,O,O
(,O,O
3,O,O
of,O,O
7,O,O
patients,O,O
),O,O
or,O,O
a,O,O
biallelic,O,O
(,O,O
4,O,O
of,O,O
7,O,O
patients,O,O
),O,O
fashion,O,O
.,O,O
Expression,O,O
of,O,O
erythroid,B,B
-,I,I
specific,I,I
genes,I,I
in,O,O
acute,O,O
megakaryoblastic,O,B
leukaemia,O,I
and,O,O
transient,O,O
myeloproliferative,O,B
disorder,O,I
in,O,O
Down,O,O
s,O,O
syndrome,O,O
.,O,O
Acute,O,O
megakaryoblastic,O,B
leukaemia,O,I
(,O,O
M7,O,O
),O,O
and,O,O
transient,O,O
myeloproliferative,O,B
disorder,O,I
in,O,O
Down,O,O
s,O,O
syndrome,O,O
(,O,O
TMD,O,O
),O,O
are,O,O
characterized,O,O
by,O,O
rapid,O,O
growth,O,O
of,O,O
abnormal,O,O
blast,O,O
cells,O,O
which,O,O
express,O,O
megakaryocytic,B,B
markers,I,I
.,O,O
Erythroid,B,B
-,I,I
specific,I,I
mRNAs,I,O
encoding,O,O
gamma,B,B
-,I,I
globin,I,I
and,O,O
erythroid,B,B
delta,I,B
-,I,I
aminolevulinate,I,I
synthase,I,I
were,O,O
found,O,O
to,O,O
be,O,O
expressed,O,O
in,O,O
blasts,O,O
from,O,O
most,O,O
of,O,O
these,O,O
cases,O,O
",",O,O
indicating,O,O
that,O,O
majorities,O,O
of,O,O
the,O,O
blasts,O,O
in,O,O
M7,O,O
and,O,O
TMD,O,O
cases,O,O
have,O,O
erythroid,O,B
and,O,O
megakaryocytic,O,B
phenotypes,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
M7,O,O
blasts,O,O
and,O,O
TMD,O,O
blasts,O,O
correspond,O,O
to,O,O
the,O,O
erythroid,O,B
/,O,I
megakaryocytic,O,I
bipotential,O,I
progenitor,O,I
cells,O,O
.,O,O
In,O,O
this,O,O
paper,O,O
",",O,O
the,O,O
expression,O,O
of,O,O
this,O,O
gene,O,B
in,O,O
blood,O,B
cells,O,I
was,O,O
first,O,O
investigated,O,O
in,O,O
fractions,O,O
of,O,O
nucleated,O,B
cells,O,I
",",O,O
revealing,O,O
predominant,O,O
expression,O,O
of,O,O
the,O,O
Ah,B,B
receptor,I,I
gene,I,I
in,O,O
the,O,O
monocyte,O,B
fraction,O,I
.,O,O
The,O,O
incubation,O,O
with,O,O
transforming,B,O
growth,I,O
factor,I,O
beta,I,B
1,I,I
and,O,O
1,O,B
alpha,O,I
",",O,O
25,O,B
-,O,I
dihydroxyvitamin,O,I
D3,O,I
resulted,O,O
in,O,O
a,O,O
5,O,O
-,O,O
to,O,O
7,O,O
-,O,O
fold,O,O
increase,O,O
of,O,O
AhR,B,B
mRNA,I,I
.,O,O
In,O,O
vitro,O,O
translated,O,O
Spi,B,B
-,I,I
B,I,I
protein,I,I
can,O,O
bind,O,O
to,O,O
PU,B,B
.,I,I
binding,I,I
sites,I,I
in,O,O
myeloid,B,B
promoters,I,I
and,O,O
transactivate,O,O
these,O,O
promoters,B,O
in,O,O
nonmyeloid,O,B
cells,O,I
.,O,O
In,O,O
contrast,O,O
",",O,O
PU,B,B
.,I,I
is,O,O
expressed,O,O
at,O,O
high,O,O
levels,O,O
not,O,O
only,O,O
in,O,O
monocytes,O,B
and,O,O
macrophages,O,B
but,O,O
also,O,O
in,O,O
neutrophils,O,B
",",O,O
indicating,O,O
that,O,O
PU,B,B
.,I,I
can,O,O
activate,O,O
gene,O,O
expression,O,O
in,O,O
both,O,O
major,O,O
myeloid,O,B
lineages,O,I
.,O,O
The,O,O
promoters,B,O
were,O,O
used,O,O
without,O,O
enhancers,B,O
",",O,O
or,O,O
with,O,O
enhancers,B,O
derived,O,O
from,O,O
the,O,O
beta,B,B
-,I,I
globin,I,I
locus,I,I
control,I,I
region,I,I
and,O,O
the,O,O
alpha,B,B
-,I,I
globin,I,I
HS,I,I
-,I,I
40,I,I
enhancer,I,I
.,O,O
When,O,O
transfected,O,O
into,O,O
K562,O,O
cells,O,O
",",O,O
which,O,O
express,O,O
zeta,B,B
-,I,I
globin,I,I
",",O,O
comparable,O,O
amounts,O,O
of,O,O
activity,O,O
were,O,O
obtained,O,O
from,O,O
the,O,O
-,B,O
557,I,O
and,I,O
-,I,O
417,I,O
zeta,I,O
-,I,O
luciferase,I,O
constructs,I,O
and,O,O
the,O,O
alpha,B,B
-,I,I
luciferase,I,I
constructs,I,I
when,O,O
no,O,O
enhancers,B,O
or,O,O
the,O,O
alpha,B,B
-,I,I
globin,I,I
locus,I,I
enhancers,I,I
were,O,O
used,O,O
.,O,O
This,O,O
element,O,O
requires,O,O
GATA,B,B
-,I,I
1,I,I
and,O,O
additional,B,O
unknown,I,O
factors,I,O
for,O,O
maximal,O,O
activity,O,O
.,O,O
To,O,O
address,O,O
this,O,O
issue,O,O
",",O,O
mutationally,O,O
active,O,O
PKC,B,B
-,I,I
alpha,I,I
",",I,O
-,I,O
epsilon,I,B
",",I,O
or,I,O
-,I,O
zeta,I,B
have,O,O
been,O,O
transfected,O,O
into,O,O
T,O,O
cells,O,O
and,O,O
the,O,O
consequences,O,O
for,O,O
T,O,O
cell,O,O
activation,O,O
determined,O,O
.,O,O
Accordingly,O,O
",",O,O
the,O,O
effects,O,O
of,O,O
the,O,O
constitutively,B,O
active,I,O
PKCs,I,B
were,O,O
compared,O,O
to,O,O
the,O,O
effects,O,O
of,O,O
mutationally,O,O
activated,O,O
p21ras,B,B
.,O,O
The,O,O
ability,O,O
of,O,O
PKC,B,B
-,I,I
epsilon,I,I
to,O,O
induce,O,O
transactivation,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
-,I,I
1,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
was,O,O
similar,O,O
to,O,O
the,O,O
stimulatory,O,O
effect,O,O
of,O,O
a,O,O
constitutively,B,O
activated,I,O
p21ras,I,O
.,O,O
These,O,O
results,O,O
indicate,O,O
selective,O,O
functions,O,O
for,O,O
different,O,O
PKC,B,B
isotypes,I,O
in,O,O
T,O,O
cells,O,O
.,O,O
Moreover,O,O
",",O,O
the,O,O
data,O,O
comparing,O,O
the,O,O
effects,O,O
of,O,O
activated,B,O
Ras,I,O
and,O,O
PKC,B,B
mutants,I,O
suggest,O,O
that,O,O
PKC,B,B
-,I,I
alpha,I,I
",",O,O
p21ras,B,O
",",O,O
and,O,O
PKC,B,B
-,I,I
epsilon,I,I
are,O,O
not,O,O
positioned,O,O
linearly,O,O
on,O,O
a,O,O
single,O,O
signal,O,O
transduction,O,O
pathway,O,O
.,O,O
Differences,O,O
in,O,O
binding,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
to,O,O
DNA,O,B
in,O,O
steroid,O,O
-,O,O
resistant,O,O
asthma,O,O
.,O,O
We,O,O
examined,O,O
the,O,O
ability,O,O
of,O,O
nuclear,O,O
translocated,O,O
glucocorticoid,B,B
receptors,I,I
to,O,O
bind,O,O
to,O,O
their,O,O
DNA,B,B
binding,I,O
sites,I,O
(,O,O
GRE,B,O
),O,O
using,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
in,O,O
PBMC,O,O
from,O,O
patients,O,O
with,O,O
steroid,O,O
-,O,O
sensitive,O,O
and,O,O
steroid,O,O
-,O,O
resistant,O,O
asthma,O,O
.,O,O
Scatchard,O,O
analysis,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
-,O,I
GRE,B,I
binding,O,O
showed,O,O
no,O,O
change,O,O
in,O,O
binding,O,O
affinity,O,O
but,O,O
did,O,O
show,O,O
a,O,O
reduced,O,O
number,O,O
of,O,O
receptors,B,O
available,O,O
for,O,O
DNA,O,B
binding,O,O
in,O,O
the,O,O
steroid,O,O
-,O,O
resistant,O,O
patients,O,O
.,O,O
Interleukin,B,B
-,I,O
5,I,I
signaling,O,O
in,O,O
human,O,O
eosinophils,O,O
involves,O,O
JAK2,B,B
tyrosine,I,I
kinase,I,O
and,O,O
Stat1,B,B
alpha,I,I
.,O,O
Signaling,O,O
by,O,O
a,O,O
wide,O,O
variety,O,O
of,O,O
cytokines,B,O
",",O,O
including,O,O
interferons,B,B
",",O,O
interleukins,B,B
",",O,O
and,O,O
growth,B,O
factors,I,O
",",O,O
involves,O,O
activation,O,O
of,O,O
JAK,B,B
kinases,I,O
and,O,O
Stat,B,B
(,I,I
Signal,I,I
transducers,I,I
and,I,I
activators,I,I
of,I,I
transcription,I,I
),I,I
proteins,I,O
.,O,O
From,O,O
supershift,O,O
experiments,O,O
it,O,O
was,O,O
concluded,O,O
that,O,O
one,O,O
DNA,B,B
-,I,I
binding,I,I
complex,I,I
contained,O,O
Stat1,B,B
alpha,I,I
",",O,O
probably,O,O
as,O,O
a,O,O
homodimer,O,O
.,O,O
It,O,O
was,O,O
found,O,O
that,O,O
the,O,O
propagation,O,O
of,O,O
the,O,O
Tat,B,O
mutants,I,O
containing,O,O
wild,B,O
-,I,O
type,I,O
LTRs,I,O
was,O,O
less,O,O
efficient,O,O
than,O,O
that,O,O
of,O,O
the,O,O
LTR,B,O
-,I,O
modified,I,O
Tat,I,O
mutants,I,O
.,O,O
Here,O,O
we,O,O
show,O,O
that,O,O
the,O,O
lymphoid,B,B
-,I,I
specific,I,I
transcription,I,I
factor,I,I
Oct,I,B
-,I,I
2A,I,I
plays,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
HLA,B,B
-,I,I
DRA,I,I
gene,I,I
expression,O,O
in,O,O
class,O,O
II,O,O
-,O,O
positive,O,O
B,O,O
cell,O,O
lines,O,O
",",O,O
and,O,O
that,O,O
the,O,O
high,B,O
mobility,I,O
group,I,O
protein,I,O
(,O,O
HMG,B,B
),O,O
I,B,O
/,I,O
Y,I,O
binds,O,O
to,O,O
multiple,O,O
sites,O,O
within,O,O
the,O,O
DRA,B,B
promoter,I,I
",",O,O
including,O,O
the,O,O
Oct,B,B
-,I,I
2A,I,I
binding,I,I
site,I,I
.,O,O
We,O,O
conclude,O,O
that,O,O
distinct,O,O
sets,O,O
of,O,O
transcription,B,O
factors,I,O
are,O,O
involved,O,O
in,O,O
the,O,O
two,O,O
modes,O,O
of,O,O
HLA,B,B
-,I,I
DRA,I,I
expression,O,O
",",O,O
and,O,O
that,O,O
HMG,B,B
I,I,I
/,I,I
Y,I,I
may,O,O
be,O,O
important,O,O
for,O,O
B,O,B
cell,O,I
-,O,I
specific,O,I
expression,O,O
",",O,O
and,O,O
is,O,O
essential,O,O
for,O,O
IFN,B,B
-,I,I
gamma,I,I
induction,O,O
.,O,O
In,O,O
lymphoblastoid,O,B
cell,O,I
lines,O,I
",",O,O
six,O,O
EBV,B,B
-,I,I
encoded,I,I
nuclear,I,I
antigens,I,I
(,O,O
EBNA1,B,O
",",I,O
2,I,O
",",I,O
3A,I,O
",",I,O
3B,I,O
",",I,O
3C,I,O
",",I,O
-,I,O
LP,I,O
),O,O
",",O,O
three,O,O
latent,B,B
membrane,I,I
proteins,I,I
(,O,O
LMP1,B,O
",",O,O
2A,B,O
",",O,O
2B,B,O
),O,O
",",O,O
and,O,O
two,O,O
nuclear,B,B
RNAs,I,I
(,O,O
EBERs,B,O
),O,O
are,O,O
expressed,O,O
.,O,O
In,O,O
EBV,O,B
-,O,I
positive,O,I
cases,O,O
of,O,O
Hodgkin,O,B
s,O,I
disease,O,I
",",O,O
the,O,O
EBERs,B,B
",",O,O
EBNA1,B,B
",",O,O
and,O,O
the,O,O
LMPs,B,B
are,O,O
expressed,O,O
(,O,O
latency,O,O
II,O,O
),O,O
",",O,O
whereas,O,O
in,O,O
Burkitt,O,B
s,O,I
lymphoma,O,I
(,O,O
BL,O,O
),O,O
only,O,O
the,O,O
EBERs,B,B
and,O,O
EBNA1,B,B
have,O,O
been,O,O
detected,O,O
(,O,O
latency,O,O
I,O,O
),O,O
.,O,O
Expression,O,O
of,O,O
LMP1,B,B
was,O,O
seen,O,O
in,O,O
variable,O,O
proportions,O,O
of,O,O
tumor,O,O
cells,O,O
in,O,O
two,O,O
cases,O,O
and,O,O
EBNA2,B,B
was,O,O
detected,O,O
in,O,O
some,O,O
tumor,O,O
cells,O,O
in,O,O
three,O,O
other,O,O
cases,O,O
.,O,O
Also,O,O
",",O,O
the,O,O
BZLF1,B,B
trans,I,I
-,I,I
activator,I,I
protein,I,I
was,O,O
expressed,O,O
in,O,O
a,O,O
few,O,O
tumor,O,O
cells,O,O
in,O,O
6,O,O
cases,O,O
",",O,O
indicating,O,O
entry,O,O
into,O,O
the,O,O
lytic,O,O
cycle,O,O
.,O,O
A,O,O
phenotypic,O,O
drift,O,O
from,O,O
latency,O,O
I,O,O
to,O,O
latency,O,O
III,O,O
has,O,O
been,O,O
observed,O,O
previously,O,O
in,O,O
some,O,O
BL,O,O
cell,O,O
lines,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
a,O,O
similar,O,O
phenomenon,O,O
may,O,O
occur,O,O
in,O,O
BL,O,O
in,O,O
vivo,O,O
and,O,O
indicate,O,O
that,O,O
the,O,O
operational,O,O
definition,O,O
of,O,O
EBV,O,B
latencies,O,O
is,O,O
not,O,O
easily,O,O
applied,O,O
to,O,O
human,O,O
tumors,O,O
.,O,O
Eosinophils,O,B
were,O,O
purified,O,O
from,O,O
peripheral,O,O
blood,O,O
by,O,O
discontinuous,O,O
Percoll,O,O
gradients,O,O
and,O,O
stimulated,O,O
with,O,O
IL,B,B
-,I,I
5,I,I
.,O,O
Immunosuppression,O,O
has,O,O
been,O,O
often,O,O
associated,O,O
with,O,O
the,O,O
course,O,O
of,O,O
malignant,O,O
diseases,O,O
.,O,O
Whereas,O,O
PHA,B,O
-,O,O
induced,O,O
proliferation,O,O
of,O,O
PBMCs,O,O
derived,O,O
from,O,O
patients,O,O
with,O,O
breast,O,O
cancer,O,O
preoperatively,O,O
was,O,O
significantly,O,O
decreased,O,O
when,O,O
compared,O,O
with,O,O
data,O,O
obtained,O,O
in,O,O
healthy,O,O
control,O,O
individuals,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
the,O,O
degree,O,O
of,O,O
the,O,O
defect,O,O
in,O,O
PHA,B,O
-,O,O
induced,O,O
proliferation,O,O
of,O,O
PBMCs,O,O
depended,O,O
upon,O,O
the,O,O
tumour,O,O
burden,O,O
as,O,O
manifested,O,O
by,O,O
tumour,O,O
size,O,O
and,O,O
axillary,O,O
lymph,O,O
node,O,O
involvement,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
in,O,O
each,O,O
case,O,O
),O,O
.,O,O
PHA,B,O
-,O,O
induced,O,O
proliferation,O,O
of,O,O
PBMCs,O,O
dropped,O,O
significantly,O,O
in,O,O
patients,O,O
who,O,O
received,O,O
adjuvant,O,O
chemotherapy,O,O
consisting,O,O
of,O,O
cyclophosphamide,O,B
",",O,O
methotrexate,O,B
and,O,O
fluorouracil,O,B
(,O,O
CMF,O,O
),O,O
after,O,O
an,O,O
observation,O,O
period,O,O
of,O,O
6,O,O
months,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
but,O,O
not,O,O
in,O,O
patients,O,O
under,O,O
adjuvant,O,O
treatment,O,O
with,O,O
tamoxifen,O,O
only,O,O
.,O,O
We,O,O
thus,O,O
conclude,O,O
that,O,O
PHA,B,O
-,O,O
induced,O,O
proliferation,O,O
of,O,O
PBMCs,O,O
derived,O,O
from,O,O
patients,O,O
with,O,O
breast,O,B
cancer,O,I
depends,O,O
upon,O,O
the,O,O
tumour,O,O
load,O,O
and,O,O
is,O,O
a,O,O
good,O,O
clinical,O,O
predictor,O,O
for,O,O
the,O,O
further,O,O
course,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
A,O,O
previously,O,O
unrecognized,O,O
element,O,O
",",O,O
located,O,O
downstream,O,O
of,O,O
the,O,O
start,B,O
site,I,O
of,I,O
transcription,I,O
in,O,O
the,O,O
first,O,O
exon,B,O
of,O,O
the,O,O
DR,B,B
alpha,I,I
gene,I,I
",",O,O
has,O,O
been,O,O
defined,O,O
that,O,O
enhances,O,O
promoter,O,O
activity,O,O
up,O,O
to,O,O
eightfold,O,O
in,O,O
a,O,O
position,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
The,O,O
nuclear,O,B
factor,O,I
binds,O,O
to,O,O
the,O,O
DR,B,O
alpha,I,B
and,I,O
DP,I,O
alpha,I,B
element,I,O
but,O,O
not,O,O
to,O,O
the,O,O
element,O,O
in,O,O
the,O,O
DQ,B,O
alpha,I,B
gene,I,O
.,O,O
One,O,O
of,O,O
the,O,O
genes,O,O
that,O,O
encodes,O,O
a,O,O
CBF,B,B
alpha,I,I
subunit,I,O
is,O,O
AML1,B,O
",",O,O
also,O,O
called,O,O
Cbf,B,O
alpha,I,B
2,I,O
.,O,O
Three,O,O
different,O,O
isoforms,O,O
of,O,O
CBF,B,B
beta,I,I
were,O,O
also,O,O
tested,O,O
for,O,O
transcriptional,O,O
activity,O,O
on,O,O
the,O,O
SL3,B,O
enhancer,I,O
.,O,O
These,O,O
results,O,O
indicated,O,O
that,O,O
at,O,O
least,O,O
in,O,O
certain,O,O
cell,O,O
types,O,O
",",O,O
the,O,O
maximum,O,O
activity,O,O
of,O,O
CBF,B,B
required,O,O
both,O,O
subunits,O,O
.,O,O
We,O,O
also,O,O
examined,O,O
whether,O,O
CBF,B,O
could,O,O
distinguish,O,O
a,O,O
1,O,O
-,O,O
bp,O,O
difference,O,O
between,O,O
the,O,O
enhancer,O,O
core,O,O
of,O,O
SL3,O,O
and,O,O
the,O,O
core,O,O
of,O,O
the,O,O
nonleukemogenic,O,O
virus,O,O
",",O,O
Akv,O,O
.,O,O
However,O,O
",",O,O
no,O,O
combination,O,O
of,O,O
CBF,B,O
alpha,I,O
and,O,O
CBF,B,O
beta,I,O
subunits,O,O
that,O,O
we,O,O
tested,O,O
was,O,O
able,O,O
to,O,O
distinguish,O,O
the,O,O
1,O,O
-,O,O
bp,O,O
difference,O,O
in,O,O
transcription,O,O
assays,O,O
.,O,O
Using,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
(,O,O
EMSA,O,O
),O,O
",",O,O
we,O,O
now,O,O
show,O,O
that,O,O
",",O,O
in,O,O
monocytes,O,O
stimulated,O,O
with,O,O
LPS,O,O
or,O,O
TNF,B,B
alpha,I,I
",",O,O
IL,B,B
-,I,I
10,I,I
inhibits,O,O
nuclear,O,O
stimulation,O,O
of,O,O
nuclear,B,O
factor,I,O
kappa,I,O
B,I,O
(,O,O
NF,B,B
kappa,I,I
B,I,I
),O,O
",",O,O
a,O,O
transcription,B,O
factor,I,O
involved,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
inflammatory,B,O
cytokine,I,O
genes,I,O
.,O,O
Several,O,O
other,O,O
transcription,B,O
factors,I,O
including,O,O
NF,O,B
-,O,I
IL,B,I
-,I,I
6,I,I
",",O,O
AP,B,B
-,I,I
1,I,I
",",O,O
AP,B,B
-,I,I
2,I,I
",",O,O
GR,B,B
",",O,O
CREB,B,B
",",O,O
Oct,B,B
-,I,I
1,I,I
",",O,O
and,O,O
Sp,B,B
-,I,I
1,I,I
are,O,O
not,O,O
affected,O,O
by,O,O
IL,B,B
-,I,I
10,I,I
.,O,O
Furthermore,O,O
",",O,O
compounds,O,O
such,O,O
as,O,O
tosylphenylalanyl,O,O
chloromethyl,O,O
ketone,O,O
and,O,O
pyrrolidinedithiocar,O,O
that,O,O
are,O,O
known,O,O
to,O,O
selectively,O,O
inhibit,O,O
NF,B,B
kappa,I,I
B,I,I
activation,O,O
block,O,O
cytokine,O,O
gene,O,O
transcription,O,O
in,O,O
LPS,O,O
-,O,O
stimulated,O,O
monocytes,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
results,O,O
suggest,O,O
that,O,O
inhibition,O,O
of,O,O
NF,B,B
kappa,I,I
B,I,I
activation,O,O
may,O,O
be,O,O
an,O,O
important,O,O
mechanism,O,O
for,O,O
IL,B,B
-,I,I
10,I,I
suppression,O,O
of,O,O
cytokine,O,O
gene,O,O
transcription,O,O
in,O,O
human,O,O
monocytes,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
this,O,O
TR2RE,B,O
-,I,O
SV40,I,O
can,O,O
function,O,O
as,O,O
a,O,O
repressor,O,O
to,O,O
suppress,O,O
the,O,O
transcriptional,O,O
activities,O,O
of,O,O
both,O,O
SV40,B,O
early,I,O
and,I,O
late,I,O
promoters,I,O
.,O,O
We,O,O
have,O,O
analyzed,O,O
CBF,B,B
beta,I,I
-,I,I
MYH11,I,I
fusion,I,I
transcripts,I,I
by,O,O
RT,O,O
-,O,O
PCR,O,O
in,O,O
myelomonocytic,O,O
leukemias,O,O
",",O,O
with,O,O
or,O,O
without,O,O
eosinophilia,O,O
",",O,O
to,O,O
determine,O,O
whether,O,O
their,O,O
presence,O,O
correlates,O,O
with,O,O
morphology,O,O
.,O,O
Fifty,O,O
-,O,O
three,O,O
cases,O,O
(,O,O
11,O,O
AML,O,O
M4Eo,O,O
;,O,O
1,O,O
AML,O,O
M4,O,O
with,O,O
atypical,O,O
abnormal,O,O
eosinophils,O,O
(,O,O
AML,O,O
M4,O,O
`,O,O
`,O,O
Eo,O,O
),O,O
;,O,O
29,O,O
AML,O,O
M4,O,O
;,O,O
8,O,O
AML,O,O
M5,O,O
;,O,O
3,O,O
CMML,O,O
;,O,O
and,O,O
1,O,O
AML,O,O
M2,O,O
with,O,O
eosinophilia,O,O
),O,O
were,O,O
analyzed,O,O
.,O,O
Both,O,O
cases,O,O
tested,O,O
also,O,O
showed,O,O
MYH11,B,B
genomic,O,I
rearrangement,O,I
.,O,O
Follow,O,O
-,O,O
up,O,O
of,O,O
three,O,O
patient,O,O
showed,O,O
residual,O,O
positivity,O,O
in,O,O
apparent,O,O
complete,O,O
remission,O,O
.,O,O
HIV,B,B
-,I,I
1,I,I
Tat,I,I
potentiates,O,O
TNF,B,B
-,O,I
induced,O,I
NF,B,I
-,I,I
kappa,I,I
B,I,I
activation,O,O
and,O,O
cytotoxicity,O,O
by,O,O
altering,O,O
the,O,O
cellular,O,O
redox,O,O
state,O,O
.,O,O
In,O,O
HeLa,O,B
cells,O,O
stably,O,O
transfected,O,O
with,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
tat,I,I
gene,I,O
(,O,O
HeLa,O,O
-,O,O
tat,O,O
cells,O,O
),O,O
",",O,O
expression,O,O
of,O,O
the,O,O
Tat,B,O
protein,I,O
enhanced,O,O
both,O,O
TNF,B,B
-,O,I
induced,O,I
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
TNF,B,B
-,O,I
mediated,O,I
cytotoxicity,O,O
.,O,O
Thus,O,O
",",O,O
Mn,B,O
-,I,O
SOD,I,B
RNA,O,B
protein,O,I
levels,O,O
and,O,O
activity,O,O
were,O,O
markedly,O,O
reduced,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
Tat,B,O
.,O,O
The,O,O
use,O,O
of,O,O
glucocorticoids,O,O
in,O,O
acute,O,O
lymphoblastic,O,O
leukemia,O,O
of,O,O
childhood,O,O
.,O,O
Glucocorticoids,O,O
have,O,O
been,O,O
included,O,O
in,O,O
almost,O,O
all,O,O
treatment,O,O
regimens,O,O
for,O,O
childhood,O,O
acute,O,O
lymphoblastic,O,O
leukemia,O,O
for,O,O
decades,O,O
.,O,O
New,O,O
data,O,O
on,O,O
the,O,O
pharmacokinetics,O,O
",",O,O
pharmacodynamics,O,O
",",O,O
and,O,O
molecular,O,O
mechanisms,O,O
of,O,O
action,O,O
of,O,O
glucocorticoids,O,O
have,O,O
suggested,O,O
alternative,O,O
approaches,O,O
in,O,O
ALL,O,O
.,O,O
Blast,O,O
sensitivity,O,O
to,O,O
glucocorticoids,O,O
correlates,O,O
closely,O,O
with,O,O
sensitivity,O,O
to,O,O
other,O,O
",",O,O
putatively,O,O
non,O,B
-,O,I
cross,O,I
-,O,I
resisting,O,I
agents,O,O
and,O,O
with,O,O
outcome,O,O
after,O,O
multi,O,O
-,O,O
agent,O,O
therapy,O,O
",",O,O
suggesting,O,O
overlapping,O,O
mechanisms,O,O
of,O,O
action,O,O
",",O,O
and,O,O
focusing,O,O
attention,O,O
on,O,O
the,O,O
determinants,O,O
of,O,O
the,O,O
threshold,O,O
for,O,O
apoptosis,O,O
.,O,O
Expression,O,O
of,O,O
the,O,O
Epstein,B,B
-,I,I
Barr,I,I
virus,I,I
(,I,O
EBV,I,O
),I,O
latent,I,O
membrane,I,O
protein,I,O
1,I,O
(,I,O
LMP,I,O
-,I,O
1,I,O
),I,O
oncogene,I,O
is,O,O
regulated,O,O
by,O,O
the,O,O
EBV,B,B
nuclear,I,I
protein,I,I
2,I,I
(,I,O
EBNA,I,O
-,I,O
2,I,O
),I,O
transactivator,I,O
.,O,O
EBNA,B,B
-,I,I
2,I,I
is,O,O
known,O,O
to,O,O
interact,O,O
with,O,O
the,O,O
cellular,B,O
DNA,I,B
-,I,I
binding,I,I
protein,I,I
J,B,B
kappa,I,I
and,O,O
is,O,O
recruited,O,O
to,O,O
promoters,B,O
containing,O,O
the,O,O
GTGGGAA,O,O
J,B,B
kappa,I,I
recognition,I,I
sequence,I,I
.,O,O
The,O,O
minimal,B,O
EBNA,I,B
-,I,I
2,I,I
-,I,I
responsive,I,I
LMP,I,O
-,I,O
1,I,O
promoter,I,O
includes,O,O
one,O,O
J,B,B
kappa,I,I
-,I,I
binding,I,I
site,I,I
",",O,O
and,O,O
we,O,O
now,O,O
show,O,O
that,O,O
mutation,O,O
of,O,O
that,O,O
site,O,O
",",O,O
such,O,O
that,O,O
J,B,B
kappa,I,I
can,O,O
not,O,O
bind,O,O
",",O,O
reduces,O,O
EBNA,B,B
-,I,I
2,I,I
responsiveness,O,I
by,O,O
60,O,O
%,O,O
.,O,O
To,O,O
identify,O,O
other,O,O
factors,O,O
which,O,O
interact,O,O
with,O,O
the,O,O
LMP,B,B
-,I,I
1,I,I
EBNA,I,B
-,I,I
2,I,I
response,I,O
element,I,O
(,O,O
E2RE,B,O
),O,O
",",O,O
a,O,O
-,B,O
236,I,O
/,I,O
-,I,O
145,I,O
minimal,I,O
E2RE,I,O
was,O,O
used,O,O
as,O,O
a,O,O
probe,O,O
in,O,O
an,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
.,O,O
LBF4,B,O
is,O,O
B,O,O
-,O,O
and,O,O
T,O,O
-,O,O
cell,O,O
specific,O,O
and,O,O
recognizes,O,O
the,O,O
PU,B,O
.,I,O
GGAA,I,O
core,I,O
sequence,I,O
as,O,O
shown,O,O
by,O,O
methylation,O,O
interference,O,O
.,O,O
The,O,O
efficacy,O,O
of,O,O
serotonin,O,B
reuptake,O,I
inhibitors,O,I
(,O,O
SRIs,O,O
),O,O
is,O,O
uncertain,O,O
",",O,O
and,O,O
response,O,O
predictors,O,O
are,O,O
unavailable,O,O
.,O,O
Abnormal,O,O
fast,O,O
feedback,O,O
and,O,O
negative,O,O
feedback,O,O
of,O,O
the,O,O
hypothalamic,O,B
-,O,I
pituitary,O,I
-,O,I
adrenal,O,I
axis,O,I
implicates,O,O
a,O,O
dampened,O,O
limbic,B,B
-,I,I
hippocampal,I,I
glucocorticoid,I,I
type,I,I
II,I,I
receptor,I,I
(,O,O
GCII,B,O
),O,O
.,O,O
We,O,O
hypothesized,O,O
that,O,O
lymphocyte,B,B
GCII,I,I
is,O,O
altered,O,O
in,O,O
adolescent,O,O
MDD,O,O
and,O,O
could,O,O
serve,O,O
as,O,O
a,O,O
marker,O,O
for,O,O
response,O,O
to,O,O
SRIs,O,O
.,O,O
The,O,O
role,O,O
of,O,O
NFATp,B,B
in,O,O
cyclosporin,B,O
A,I,O
-,I,O
sensitive,I,O
tumor,I,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
gene,I,O
transcription,O,O
.,O,O
Thus,O,O
",",O,O
although,O,O
the,O,O
kappa,B,O
3,I,O
element,I,O
has,O,O
little,O,O
sequence,O,O
similarity,O,O
to,O,O
other,O,O
NFATp,B,B
-,I,O
binding,I,O
sites,I,O
",",O,O
it,O,O
appears,O,O
to,O,O
function,O,O
as,O,O
a,O,O
cyclosporin,B,O
-,I,O
sensitive,I,O
promoter,I,O
element,I,O
in,O,O
T,O,O
cells,O,O
by,O,O
virtue,O,O
of,O,O
its,O,O
ability,O,O
to,O,O
bind,O,O
NFATp,B,B
.,O,O
By,O,O
contrast,O,O
",",O,O
three,O,O
lymphoblastoid,O,B
cell,O,I
lines,O,I
(,O,O
immortalized,O,O
in,O,O
vitro,O,O
with,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
),O,O
were,O,O
weakly,O,O
positive,O,O
and,O,O
MNDA,B,B
was,O,O
up,O,O
-,O,O
regulated,O,O
by,O,O
interferon,B,O
-,I,O
alpha,I,O
(,O,O
IFN,B,B
-,I,O
alpha,I,O
),O,O
treatment,O,O
.,O,O
The,O,O
results,O,O
varied,O,O
with,O,O
the,O,O
agent,O,O
",",O,O
cell,O,O
type,O,O
",",O,O
and,O,O
stage,O,O
of,O,O
differentiation,O,O
.,O,O
Changes,O,O
in,O,O
MNDA,B,B
expression,O,O
occurred,O,O
slowly,O,O
(,O,O
hours,O,O
to,O,O
days,O,O
),O,O
",",O,O
suggesting,O,O
that,O,O
MNDA,B,B
could,O,O
mediate,O,O
changes,O,O
realized,O,O
over,O,O
a,O,O
long,O,O
period,O,O
.,O,O
EBNA,B,B
-,I,I
2,I,I
is,O,O
able,O,O
to,O,O
trans,O,O
-,O,O
activate,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
LMP,B,O
gene,I,O
in,O,O
several,O,O
cell,O,O
lines,O,O
.,O,O
Various,O,O
reports,O,O
have,O,O
delineated,O,O
the,O,O
cis,B,O
-,I,O
acting,I,O
elements,I,O
of,O,O
the,O,O
LMP,B,O
promoter,I,O
through,O,O
which,O,O
EBNA,B,B
-,I,I
2,I,I
mediates,O,O
trans,O,O
-,O,O
activation,O,O
.,O,O
These,O,O
complexes,O,O
were,O,O
destroyed,O,O
by,O,O
detergent,O,O
.,O,O
Enhanced,O,O
Ig,B,O
synthesis,O,O
is,O,O
a,O,O
result,O,O
of,O,O
coordinated,O,O
transcriptional,O,O
activation,O,O
of,O,O
Ig,B,O
genes,I,O
without,O,O
promoter,O,O
or,O,O
isotype,O,O
specificity,O,O
",",O,O
and,O,O
differential,O,O
accumulation,O,O
of,O,O
the,O,O
mRNA,B,O
encoding,O,O
the,O,O
secreted,O,O
form,O,O
of,O,O
Ig,B,O
heavy,I,O
chain,I,O
.,O,O
It,O,O
is,O,O
saturable,O,O
and,O,O
subject,O,O
to,O,O
negative,O,O
control,O,O
when,O,O
IL,B,B
-,I,I
6,I,I
stimulation,O,O
is,O,O
prolonged,O,O
.,O,O
Thus,O,O
",",O,O
differentiation,O,O
of,O,O
B,O,O
cells,O,O
with,O,O
IL,B,B
-,I,I
6,I,I
in,O,O
vitro,O,O
recapitulates,O,O
the,O,O
hallmarks,O,O
of,O,O
terminal,O,O
B,O,O
differentiation,O,O
in,O,O
vivo,O,O
;,O,O
Oct,B,O
-,I,O
2,I,O
may,O,O
have,O,O
a,O,O
role,O,O
in,O,O
this,O,O
process,O,O
.,O,O
We,O,O
have,O,O
previously,O,O
shown,O,O
that,O,O
treatment,O,O
of,O,O
Jurkat,O,O
T,O,O
cells,O,O
with,O,O
phytohemaglutinin,B,O
(,O,O
PHA,B,O
),O,O
and,O,O
the,O,O
phorbol,O,O
ester,O,O
",",O,O
PMA,O,O
",",O,O
activated,O,O
transcription,O,O
initiation,O,O
from,O,O
the,O,O
IL,B,B
-,I,I
3,I,I
gene,I,I
.,O,O
We,O,O
also,O,O
examined,O,O
the,O,O
function,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
3,I,I
CK,I,I
-,I,I
1,I,I
/,I,I
CK,I,I
-,I,I
2,I,I
elements,I,O
that,O,O
are,O,O
present,O,O
in,O,O
many,O,O
cytokine,B,O
genes,I,O
and,O,O
found,O,O
that,O,O
they,O,O
acted,O,O
as,O,O
a,O,O
repressor,O,O
of,O,O
basal,O,O
level,O,O
expression,O,O
when,O,O
cloned,O,O
upstream,O,O
of,O,O
a,O,O
heterologous,B,O
promoter,I,O
but,O,O
were,O,O
also,O,O
inducible,O,O
by,O,O
PMA,O,O
/,B,O
PHA,I,O
.,O,O
Glucocorticoids,O,O
have,O,O
an,O,O
inhibitory,O,O
effect,O,O
on,O,O
inflammatory,O,O
and,O,O
immune,O,O
responses,O,O
",",O,O
and,O,O
this,O,O
may,O,O
be,O,O
through,O,O
the,O,O
modulation,O,O
of,O,O
transcription,B,O
factor,I,O
binding,O,O
to,O,O
DNA,O,B
.,O,O
TNF,O,B
-,O,I
alpha,O,I
",",O,O
IL,O,B
-,O,I
1,O,I
beta,O,I
and,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
treatment,O,O
increased,O,O
AP,B,O
-,I,O
1,I,O
and,O,O
NF,O,B
kappa,O,I
B,O,I
DNA,O,I
binding,O,O
by,O,O
up,O,O
to,O,O
200,O,O
%,O,O
but,O,O
decreased,O,O
CREB,B,B
binding,O,O
(,O,O
38,O,O
%,O,O
),O,O
over,O,O
a,O,O
60,O,O
-,O,O
min,O,O
time,O,O
course,O,O
.,O,O
This,O,O
may,O,O
be,O,O
an,O,O
important,O,O
molecular,O,O
site,O,O
of,O,O
steroid,O,B
action,O,O
.,O,O
During,O,O
the,O,O
induction,O,O
of,O,O
anergy,O,O
",",O,O
T,O,O
cells,O,O
are,O,O
phenotypically,O,O
similar,O,O
to,O,O
cells,O,O
responding,O,O
to,O,O
an,O,O
immunogenic,O,O
stimulus,O,O
.,O,O
When,O,O
restimulated,O,O
",",O,O
however,O,O
",",O,O
anergic,O,O
T,O,O
cells,O,O
fail,O,O
to,O,O
up,O,O
-,O,O
regulate,O,O
transcription,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,O
and,O,O
in,O,O
consequence,O,O
do,O,O
not,O,O
produce,O,O
IL,B,B
-,I,I
2,I,I
.,O,O
The,O,O
effect,O,O
of,O,O
BDP,O,O
was,O,O
greatly,O,O
dependent,O,O
on,O,O
the,O,O
presence,O,O
of,O,O
Zn,O,B
+,O,I
+,O,I
ions,O,O
in,O,O
the,O,O
preparation,O,O
",",O,O
since,O,O
the,O,O
augmenting,O,O
effect,O,O
was,O,O
abolished,O,O
if,O,O
BDP,O,O
did,O,O
not,O,O
contain,O,O
zinc,O,O
.,O,O
The,O,O
receptor,O,O
concentration,O,O
",",O,O
as,O,O
measured,O,O
by,O,O
staining,O,O
and,O,O
steroid,O,B
binding,O,I
test,O,O
",",O,O
varied,O,O
considerably,O,O
but,O,O
showed,O,O
no,O,O
clear,O,O
correlation,O,O
to,O,O
clinical,O,O
response,O,O
.,O,O
Using,O,O
a,O,O
highly,O,O
sensitive,O,O
mutation,O,O
screening,O,O
assay,O,O
of,O,O
the,O,O
DNA,B,B
-,I,I
and,I,O
the,I,O
steroid,I,B
-,I,I
binding,I,I
region,I,O
",",O,O
none,O,O
of,O,O
the,O,O
treated,O,O
patients,O,O
revealed,O,O
any,O,O
mutation,O,O
",",O,O
suggesting,O,O
that,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
in,O,O
the,O,O
CLL,O,O
patients,O,O
tested,O,O
is,O,O
not,O,O
altered,O,O
in,O,O
these,O,O
domains,O,O
.,O,O
Expression,O,O
of,O,O
the,O,O
kappa,O,B
immunoglobulin,O,I
light,O,I
chain,O,I
gene,O,I
requires,O,O
developmental,O,O
-,O,O
and,O,O
tissue,O,O
-,O,O
specific,O,O
regulation,O,O
by,O,O
trans,B,O
-,I,O
acting,I,O
factors,I,O
which,O,O
interact,O,O
with,O,O
two,O,O
distinct,O,O
enhancer,B,O
elements,I,O
.,O,O
Methylation,O,O
studies,O,O
indicated,O,O
that,O,O
the,O,O
tal,B,O
-,I,O
15,I,O
GC,I,O
-,I,O
rich,I,O
region,I,O
behaves,O,O
like,O,O
a,O,O
CpG,B,O
island,I,O
",",O,O
hypomethylated,O,O
in,O,O
normal,O,O
cells,O,O
",",O,O
and,O,O
methylated,O,O
de,O,O
novo,O,O
on,O,O
transcriptionally,B,O
inactive,I,O
alleles,I,O
in,O,O
established,O,O
cell,O,O
lines,O,O
.,O,O
M,O,O
-,O,O
TAT,O,O
is,O,O
a,O,O
cytokine,O,O
-,O,O
dependent,O,O
cell,O,O
line,O,O
with,O,O
the,O,O
potential,O,O
to,O,O
differentiate,O,O
along,O,O
the,O,O
erythroid,O,B
and,O,O
megakaryocytic,O,B
lineages,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
addition,O,O
of,O,O
GM,B,B
-,I,I
CSF,I,I
to,O,O
the,O,O
M,O,O
-,O,O
TAT,O,O
/,O,O
EPO,O,O
cell,O,O
culture,O,O
decreased,O,O
the,O,O
amount,O,O
of,O,O
hemoglobin,O,O
",",O,O
even,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
EPO,B,O
",",O,O
indicating,O,O
that,O,O
the,O,O
EPO,B,B
signal,O,O
for,O,O
erythroid,O,O
differentiation,O,O
is,O,O
suppressed,O,O
by,O,O
GM,B,B
-,I,I
CSF,I,I
.,O,O
Transient,O,O
chloramphenicol,B,O
acetyltransferase,I,O
assay,O,O
revealed,O,O
that,O,O
the,O,O
region,O,O
containing,O,O
E2F,B,B
binding,I,I
site,I,I
had,O,O
a,O,O
strong,O,O
promoter,O,O
activity,O,O
",",O,O
and,O,O
introduction,O,O
of,O,O
the,O,O
mutation,O,O
at,O,O
the,O,O
E2F,B,B
binding,I,I
site,I,I
resulted,O,O
in,O,O
a,O,O
significant,O,O
loss,O,O
of,O,O
the,O,O
activity,O,O
.,O,O
E2F,B,B
-,I,I
1,I,I
and,I,O
DP,I,B
-,I,I
1,I,I
mRNAs,I,O
were,O,O
not,O,O
detectable,O,O
in,O,O
granulocytes,O,O
",",O,O
monocytes,O,O
and,O,O
resting,O,O
T,O,B
-,O,I
lymphocytes,O,I
but,O,O
were,O,O
induced,O,O
after,O,O
the,O,O
mitogenic,O,O
stimulation,O,O
of,O,O
T,O,B
-,O,I
lymphocytes,O,I
.,O,O
Association,O,O
of,O,O
alterations,O,O
in,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
moieties,I,O
with,O,O
HIV,O,B
type,O,I
1,O,I
proviral,O,I
latency,O,I
in,O,O
certain,O,O
monocytic,O,O
cells,O,O
.,O,O
Human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
(,O,O
HIV,O,B
-,O,I
1,O,I
),O,O
replication,O,O
is,O,O
controlled,O,O
by,O,O
a,O,O
complex,O,O
array,O,O
of,O,O
virally,B,O
encoded,I,O
and,I,O
cellular,I,O
proteins,I,O
.,O,O
The,O,O
NFATd,B,O
element,I,O
",",O,O
which,O,O
binds,O,O
the,O,O
transcription,B,O
factor,I,O
NFAT,B,B
-,I,I
1,I,I
and,O,O
is,O,O
very,O,O
active,O,O
in,O,O
T,O,O
cells,O,O
",",O,O
is,O,O
only,O,O
weakly,O,O
active,O,O
in,O,O
one,O,O
B,O,O
clone,O,O
and,O,O
not,O,O
at,O,O
all,O,O
in,O,O
another,O,O
.,O,O
This,O,O
parallels,O,O
the,O,O
increased,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
synthesis,O,O
secondary,O,O
to,O,O
increased,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
gene,O,O
transcription,O,O
",",O,O
i,O,O
.,O,O
e,O,O
.,O,O
",",O,O
increased,O,O
RNA,O,B
and,O,O
transcriptional,O,O
activity,O,O
of,O,O
its,O,O
promoter,O,O
-,O,O
enhancer,O,O
.,O,O
Transcriptional,O,O
activity,O,O
of,O,O
p105,B,B
is,O,O
also,O,O
increased,O,O
in,O,O
infected,O,O
cells,O,O
and,O,O
is,O,O
also,O,O
mediated,O,O
by,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
through,O,O
a,O,O
specific,O,O
kappa,B,O
B,I,O
motif,I,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
show,O,O
that,O,O
an,O,O
activation,B,O
-,I,O
deficient,I,O
glucocorticoid,I,B
receptor,I,I
mutant,I,O
is,O,O
as,O,O
effective,O,O
as,O,O
the,O,O
wild,B,O
-,I,O
type,I,O
receptor,I,O
in,O,O
repression,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
activity,O,O
",",O,O
inhibition,O,O
of,O,O
interleukin,B,B
-,I,I
2,I,I
production,O,O
",",O,O
inhibition,O,O
of,O,O
c,B,O
-,I,O
myc,I,O
expression,O,O
and,O,O
induction,O,O
of,O,O
apoptosis,O,O
.,O,O
HIV,O,B
type,O,I
1,O,I
protease,B,I
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
within,O,O
T,O,O
lymphoid,O,O
cells,O,O
.,O,O
It,O,O
has,O,O
been,O,O
reported,O,O
that,O,O
HIV,B,B
-,I,I
1,I,I
protease,I,O
may,O,O
cleave,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
precursor,O,O
to,O,O
its,O,O
active,O,O
form,O,O
in,O,O
vitro,O,O
.,O,O
Insertion,O,O
of,O,O
this,O,O
chimeric,B,O
promoter,I,O
(,O,O
ISG15,B,O
LTR,I,O
),O,O
upstream,O,O
of,O,O
the,O,O
human,B,O
IFNA2,I,O
gene,I,O
directed,O,O
high,O,O
levels,O,O
of,O,O
IFN,B,B
synthesis,O,O
in,O,O
Tat,O,O
-,O,O
expressing,O,O
cells,O,O
",",O,O
while,O,O
this,O,O
promoter,O,O
was,O,O
not,O,O
responsive,O,O
to,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
-,O,O
mediated,O,O
activation,O,O
.,O,O
Selected,O,O
transfected,O,O
clones,O,O
produced,O,O
low,O,O
levels,O,O
of,O,O
IFN,B,B
A,I,I
(,O,I
IFNA,B,I
),O,I
constitutively,O,O
",",O,O
and,O,O
their,O,O
abilities,O,O
to,O,O
express,O,O
interleukin,B,B
-,I,I
2,I,I
and,O,O
interleukin,B,B
-,I,I
2,I,I
receptor,I,I
upon,O,O
stimulation,O,O
with,O,O
phytohemagglutinin,B,O
and,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
were,O,O
retained,O,O
.,O,O
Flow,O,O
cytometric,O,O
analysis,O,O
also,O,O
showed,O,O
that,O,O
at,O,O
72,O,O
h,O,O
of,O,O
virus,O,O
exposure,O,O
fewer,O,O
T,O,O
cells,O,O
from,O,O
the,O,O
elderly,O,O
produced,O,O
interferon,B,B
-,I,I
gamma,I,I
(,O,I
IFN,B,I
-,I,I
gamma,I,I
),O,I
",",O,O
suggesting,O,O
a,O,O
link,O,O
between,O,O
the,O,O
magnitude,O,O
of,O,O
the,O,O
Fos,B,O
and,O,O
Jun,B,O
and,O,O
IFN,B,B
-,I,I
gamma,I,I
responses,O,O
.,O,O
The,O,O
regulation,O,O
of,O,O
HIV,O,B
by,O,O
retinoic,O,B
acid,O,I
correlates,O,O
with,O,O
cellular,O,O
expression,O,O
of,O,O
the,O,O
retinoic,B,B
acid,I,I
receptors,I,I
.,O,O
Even,O,O
a,O,O
moderate,O,O
increase,O,O
in,O,O
the,O,O
cellular,O,O
cysteine,O,B
supply,O,O
elevates,O,O
the,O,O
intracellular,O,O
glutathione,O,B
(,O,O
GSH,O,O
),O,O
and,O,O
glutathione,O,B
disulfide,O,I
(,O,O
GSSG,O,O
),O,O
levels,O,O
and,O,O
potentiates,O,O
immunological,O,O
functions,O,O
of,O,O
lymphocytes,O,O
in,O,O
vitro,O,O
.,O,O
As,O,O
signal,O,O
transduction,O,O
is,O,O
facilitated,O,O
by,O,O
prooxidant,O,O
conditions,O,O
",",O,O
we,O,O
propose,O,O
that,O,O
the,O,O
well,O,O
-,O,O
known,O,O
immunological,O,O
consequences,O,O
of,O,O
GSH,O,B
depletion,O,O
ultimately,O,O
may,O,O
be,O,O
results,O,O
of,O,O
the,O,O
accompanying,O,O
GSSG,O,B
deficiency,O,O
.,O,O
The,O,O
second,O,O
abnormality,O,O
in,O,O
kappa,O,O
B,O,O
-,O,O
binding,O,O
activity,O,O
in,O,O
T,O,O
cells,O,O
from,O,O
these,O,O
patients,O,O
is,O,O
that,O,O
RelA,B,O
",",O,O
a,O,O
member,O,O
of,O,O
the,O,O
Rel,B,O
homology,I,O
family,I,O
which,O,O
is,O,O
part,O,O
of,O,O
the,O,O
normal,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
complex,I,I
",",O,O
was,O,O
not,O,O
induced,O,O
in,O,O
the,O,O
nucleus,O,O
following,O,O
activation,O,O
.,O,O
Cord,O,O
blood,O,O
cultures,O,O
showed,O,O
an,O,O
additive,O,O
combination,O,O
of,O,O
`,O,O
`,O,O
adult,O,B
and,O,O
`,O,O
`,O,O
fetal,O,B
patterns,O,O
.,O,O
Our,O,O
studies,O,O
also,O,O
demonstrate,O,O
that,O,O
under,O,O
anemic,O,O
stress,O,O
",",O,O
recruitment,O,O
of,O,O
fetal,O,B
progenitors,O,O
may,O,O
occur,O,O
in,O,O
adulthood,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
our,O,O
data,O,O
suggest,O,O
that,O,O
two,O,O
interactive,O,O
mechanisms,O,O
regulate,O,O
monocytic,B,B
I,I,I
kappa,I,I
B,I,I
alpha,I,I
/,I,O
MAD,I,B
-,I,I
3,I,I
mRNA,I,I
levels,O,O
.,O,O
In,O,O
extracts,O,O
from,O,O
nonstimulated,O,O
cells,O,O
the,O,O
receptor,O,B
is,O,O
recovered,O,O
in,O,O
an,O,O
inducible,O,O
cytoplasmic,O,O
form,O,O
associated,O,O
with,O,O
the,O,O
90,B,O
-,I,O
kDa,I,O
heat,I,B
shock,I,I
protein,I,I
(,O,O
hsp90,B,O
),O,O
",",O,O
a,O,O
molecular,B,O
chaperone,I,O
.,O,O
It,O,O
was,O,O
not,O,O
possible,O,O
to,O,O
reconstitute,O,O
dioxin,B,B
receptor,I,I
function,O,O
with,O,O
proteins,O,O
expressed,O,O
in,O,O
wheat,O,B
germ,O,I
lysate,O,I
.,O,O
In,O,O
line,O,O
with,O,O
these,O,O
observations,O,O
",",O,O
reticulocyte,O,B
lysate,O,I
but,O,O
not,O,O
wheat,O,B
germ,O,I
lysate,O,I
promoted,O,O
the,O,O
association,O,O
of,O,O
de,O,O
novo,O,O
synthesized,O,O
dioxin,B,B
receptor,I,I
with,O,O
hsp90,B,O
.,O,O
Induction,O,O
of,O,O
transcription,B,O
factors,I,O
in,O,O
human,O,O
T,O,O
lymphocytes,O,O
by,O,O
aspirin,O,O
-,O,O
like,O,O
drugs,O,O
.,O,O
Protein,B,B
kinase,I,I
C,I,I
is,O,O
not,O,O
a,O,O
downstream,O,O
effector,O,O
of,O,O
p21ras,B,O
in,O,O
activated,O,O
T,O,O
cells,O,O
.,O,O
Data,O,O
is,O,O
presented,O,O
",",O,O
using,O,O
the,O,O
potent,O,O
and,O,O
selective,O,O
PKC,B,B
inhibitor,O,O
Ro,O,O
31,O,O
-,O,O
8425,O,O
and,O,O
transient,O,O
expression,O,O
of,O,O
a,O,O
constitutively,O,O
active,O,O
ras,O,O
mutant,O,O
",",O,O
which,O,O
clearly,O,O
shows,O,O
that,O,O
PKC,B,B
is,O,O
not,O,O
downstream,O,O
of,O,O
p21ras,B,O
in,O,O
the,O,O
induction,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
transcriptional,O,I
activity,O,O
and,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
in,O,O
human,O,O
Jurkat,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
signaling,O,O
pathways,O,O
involving,O,O
PKC,B,B
activation,O,O
",",O,O
calcium,O,B
mobilization,O,I
and,O,O
ras,B,B
activation,O,O
combine,O,O
to,O,O
provide,O,O
the,O,O
necessary,O,O
components,O,O
for,O,O
production,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
during,O,O
T,O,O
cell,O,O
activation,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
stimulation,O,O
through,O,O
the,O,O
IL,B,B
-,I,I
2R,I,I
induced,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
subsequent,O,O
nuclear,O,O
translocation,O,O
of,O,O
stat3,B,B
",",O,O
a,O,O
newly,O,O
identified,O,O
member,O,O
of,O,O
the,O,O
signal,B,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
(,I,O
STAT,I,O
),I,O
family,I,O
of,O,O
proteins,O,O
.,O,O
Apart,O,O
from,O,O
stat3,B,B
",",O,O
another,O,O
cytoplasmic,B,O
protein,I,O
was,O,O
tyrosine,O,O
phosphorylated,O,O
and,O,O
subsequently,O,O
translocated,O,O
to,O,O
the,O,O
nucleus,O,O
in,O,O
response,O,O
to,O,O
IL,B,B
-,I,I
2,I,I
.,O,O
This,O,O
protein,O,O
had,O,O
an,O,O
apparent,O,O
molecular,O,O
mass,O,O
of,O,O
84,O,O
kDa,O,O
and,O,O
was,O,O
not,O,O
recognized,O,O
by,O,O
stat3,B,O
or,O,O
stat1,B,O
mAb,I,O
or,O,O
antisera,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
we,O,O
report,O,O
that,O,O
IL,B,B
-,I,I
2,I,I
induces,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
subsequent,O,O
nuclear,O,O
translocation,O,O
of,O,O
stat3,B,O
and,O,O
an,O,O
as,O,O
yet,O,O
undefined,O,O
84,B,O
-,I,O
kDa,I,O
protein,I,O
in,O,O
antigen,O,O
-,O,O
specific,O,O
human,O,O
T,O,O
cell,O,O
lines,O,O
.,O,O
Human,O,O
T,O,B
-,O,I
cell,O,I
leukemia,O,I
virus,O,I
type,O,I
I,O,I
Tax,B,I
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
involves,O,O
phosphorylation,O,O
and,O,O
degradation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
and,O,O
RelA,B,B
(,O,O
p65,B,O
),O,O
-,O,O
mediated,O,O
induction,O,O
of,O,O
the,O,O
c,B,O
-,I,O
rel,I,O
gene,I,O
.,O,O
The,O,O
tax,O,O
gene,O,O
product,O,O
of,O,O
human,O,O
T,O,B
-,O,I
cell,O,I
leukemia,O,I
virus,O,I
type,O,I
I,O,I
(,O,O
HTLV,O,O
-,O,O
I,O,O
),O,O
is,O,O
a,O,O
potent,O,O
transcriptional,B,O
activator,I,O
that,O,O
both,O,O
stimulates,O,O
viral,O,O
gene,O,O
expression,O,O
and,O,O
activates,O,O
an,O,O
array,O,O
of,O,O
cellular,B,O
genes,I,O
involved,O,O
in,O,O
T,O,B
-,O,I
cell,O,I
growth,O,O
.,O,O
In,O,O
contrast,O,O
to,O,O
prior,O,O
in,O,O
vitro,O,O
studies,O,O
",",O,O
at,O,O
least,O,O
a,O,O
fraction,O,O
of,O,O
the,O,O
phosphorylated,O,O
form,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
remains,O,O
physically,O,O
associated,O,O
with,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
complex,I,I
in,O,O
vivo,O,O
but,O,O
is,O,O
subject,O,O
to,O,O
rapid,O,O
degradation,O,O
",",O,O
thereby,O,O
promoting,O,O
the,O,O
nuclear,O,O
translocation,O,O
of,O,O
the,O,O
active,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
complex,I,I
.,O,O
Therefore,O,O
we,O,O
investigated,O,O
the,O,O
modifications,O,O
imposed,O,O
on,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,O
I,I,B
kappa,I,I
B,I,I
components,I,O
following,O,O
stimulation,O,O
and,O,O
show,O,O
that,O,O
the,O,O
final,O,O
step,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
induction,O,O
in,O,O
vivo,O,O
involves,O,O
phosphorylation,O,O
of,O,O
several,O,O
members,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,O
I,I,B
kappa,I,I
B,I,I
protein,I,I
families,I,O
.,O,O
Isolation,O,O
of,O,O
differentially,O,O
expressed,O,O
sequence,O,O
tags,O,O
from,O,O
steroid,O,B
-,O,I
responsive,O,I
cells,O,O
using,O,O
mRNA,B,O
differential,O,O
display,O,O
.,O,O
Although,O,O
much,O,O
is,O,O
known,O,O
about,O,O
the,O,O
structure,O,O
and,O,O
function,O,O
of,O,O
steroid,O,B
receptors,O,I
",",O,O
relatively,O,O
few,O,O
cell,O,O
-,O,O
specific,O,O
steroid,O,B
-,O,I
regulated,O,I
genes,O,O
have,O,O
been,O,O
isolated,O,O
and,O,O
characterized,O,O
.,O,O
In,O,O
this,O,O
paper,O,O
we,O,O
describe,O,O
results,O,O
using,O,O
mRNA,B,O
differential,O,O
display,O,O
reverse,B,O
transcriptase,I,O
PCR,O,O
(,O,O
DDPCR,O,O
),O,O
to,O,O
identify,O,O
and,O,O
isolate,O,O
short,O,O
cDNA,O,O
sequence,O,O
tags,O,O
from,O,O
thymocyte,O,O
and,O,O
prostate,O,O
cells,O,O
under,O,O
various,O,O
hormone,O,O
conditions,O,O
.,O,O
GIG10,B,O
is,O,O
a,O,O
novel,O,O
sequence,O,O
and,O,O
GIG18,B,O
is,O,O
the,O,O
mouse,O,O
homologue,O,O
of,O,O
a,O,O
human,B,O
expressed,I,O
sequence,I,O
tag,I,O
isolated,O,O
from,O,O
activated,O,O
B,O,B
lymphocytes,O,I
.,O,O
We,O,O
have,O,O
shown,O,O
that,O,O
",",O,O
within,O,O
the,O,O
thymus,O,O
",",O,O
a,O,O
population,O,O
of,O,O
large,O,O
",",O,O
immature,O,O
cells,O,O
expresses,O,O
CD21,B,B
.,O,O
EBV,O,O
altered,O,O
the,O,O
activation,O,O
responses,O,O
of,O,O
immature,O,O
thymocytes,O,O
in,O,O
vitro,O,O
.,O,O
This,O,O
function,O,O
was,O,O
a,O,O
result,O,O
of,O,O
the,O,O
interaction,O,O
of,O,O
EBV,O,O
with,O,O
its,O,O
receptor,O,O
",",O,O
CD21,B,B
",",O,O
but,O,O
was,O,O
caused,O,O
by,O,O
infection,O,O
rather,O,O
than,O,O
surface,O,O
signaling,O,O
",",O,O
because,O,O
neither,O,O
specific,B,O
mAb,I,O
nor,O,O
the,O,O
P3HR,O,O
-,O,O
1,O,O
strain,O,O
of,O,O
virus,O,O
mimicked,O,O
the,O,O
effect,O,O
of,O,O
B95,O,O
-,O,O
8,O,O
.,O,O
Consistent,O,O
with,O,O
the,O,O
activity,O,O
of,O,O
B95,B,O
-,I,O
8,I,O
",",O,O
EBNA,B,B
-,I,O
2,I,O
transcripts,I,O
were,O,O
identified,O,O
within,O,O
infected,O,O
thymocyte,O,O
populations,O,O
.,O,O
A,O,O
second,O,O
transcript,O,O
was,O,O
identified,O,O
as,O,O
encoding,O,O
the,O,O
recently,O,O
characterized,O,O
RAZ,B,O
",",O,O
which,O,O
also,O,O
is,O,O
associated,O,O
with,O,O
replicative,O,O
infection,O,O
.,O,O
The,O,O
regulation,O,O
of,O,O
nuclear,B,O
factor,I,O
(,I,O
NF,I,B
),I,O
-,I,O
kappa,I,O
B,I,O
activation,O,O
by,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
(,I,O
TcR,I,O
),I,O
/,I,O
CD3,I,O
complex,I,O
in,O,O
primary,O,O
human,O,O
T,O,O
cells,O,O
has,O,O
been,O,O
studied,O,O
at,O,O
various,O,O
times,O,O
after,O,O
activation,O,O
.,O,O
p50,B,B
.,I,O
c,I,O
-,I,O
rel,I,O
heterodimers,I,O
were,O,O
also,O,O
detected,O,O
bound,O,O
to,O,O
this,O,O
sequence,O,O
at,O,O
early,O,O
time,O,O
points,O,O
(,O,O
7,O,O
-,O,O
16,O,O
h,O,O
;,O,O
early,O,O
),O,O
",",O,O
and,O,O
both,O,O
remained,O,O
active,O,O
at,O,O
later,O,O
time,O,O
points,O,O
(,O,O
40,O,O
h,O,O
;,O,O
late,O,O
),O,O
after,O,O
activation,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
the,O,O
regulation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
during,O,O
T,O,O
cell,O,O
activation,O,O
by,O,O
TcR,B,O
/,I,O
CD3,I,O
signals,O,O
is,O,O
biphasic,O,O
:,O,O
TcR,B,O
/,I,O
CD3,I,O
triggers,O,O
its,O,O
immediate,O,O
translocation,O,O
",",O,O
which,O,O
is,O,O
transient,O,O
if,O,O
no,O,O
TNF,B,B
-,I,I
alpha,I,I
is,O,O
present,O,O
.,O,O
The,O,O
cis,B,O
-,I,O
acting,I,O
region,I,O
",",O,O
GM,B,O
-,I,O
kappa,I,O
B,I,O
/,I,O
GC,I,O
-,I,O
box,I,O
(,O,O
positions,B,O
-,I,O
95,I,O
and,O,O
-,B,O
73,I,O
),O,O
",",O,O
within,O,O
the,O,O
murine,B,O
GM,I,O
-,I,O
CSF,I,O
gene,I,O
promoter,I,O
is,O,O
required,O,O
for,O,O
maximal,O,O
induction,O,O
by,O,O
stimulation,O,O
with,O,O
phorbol,O,O
-,O,O
12,O,O
-,O,O
myristate,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
and,O,O
calcium,O,O
ionophore,O,O
(,O,O
A23187,O,O
),O,O
in,O,O
T,O,O
cells,O,O
.,O,O
We,O,O
report,O,O
here,O,O
that,O,O
three,O,O
copies,O,O
of,O,O
the,O,O
GC,B,O
-,I,O
box,I,O
can,O,O
functionally,O,O
compensate,O,O
for,O,O
the,O,O
GM,B,O
-,I,O
kappa,I,O
B,I,O
/,I,O
GC,I,O
-,I,O
box,I,O
region,I,O
",",O,O
suggesting,O,O
that,O,O
the,O,O
GC,O,O
-,O,O
motif,O,O
can,O,O
function,O,O
independently,O,O
of,O,O
the,O,O
GM,B,O
-,I,O
kappa,I,O
B,I,O
motif,I,O
.,O,O
A,O,O
factor,O,O
that,O,O
regulates,O,O
the,O,O
class,B,O
II,I,O
major,I,O
histocompatibility,I,O
complex,I,O
gene,I,O
DPA,B,B
is,O,O
a,O,O
member,O,O
of,O,O
a,O,O
subfamily,O,O
of,O,O
zinc,B,B
finger,I,I
proteins,I,O
that,O,O
includes,O,O
a,O,O
Drosophila,B,B
developmental,I,I
control,I,I
protein,I,I
.,O,O
It,O,O
encodes,O,O
a,O,O
protein,O,O
predicted,O,O
to,O,O
contain,O,O
688,O,O
amino,O,O
acid,O,O
residues,O,O
",",O,O
including,O,O
11,O,O
zinc,B,B
finger,I,I
motifs,I,I
of,O,O
the,O,O
C2H2,B,O
type,I,O
in,O,O
the,O,O
C,B,O
-,I,O
terminal,I,O
region,I,O
",",O,O
that,O,O
are,O,O
Kruppel,O,B
-,O,I
like,O,I
in,O,O
the,O,O
conservation,O,O
of,O,O
the,O,O
H,B,O
/,I,O
C,I,O
link,I,O
sequence,I,O
connecting,O,O
them,O,O
.,O,O
One,O,O
of,O,O
the,O,O
Drosophila,B,O
sequences,I,O
",",O,O
ttk,B,B
",",O,O
is,O,O
a,O,O
developmental,B,O
control,I,O
gene,I,O
",",O,O
while,O,O
a,O,O
second,O,O
does,O,O
not,O,O
contain,O,O
a,O,O
zinc,B,O
finger,I,O
region,I,O
but,O,O
encodes,O,O
a,O,O
structure,O,O
important,O,O
in,O,O
oocyte,O,O
development,O,O
.,O,O
This,O,O
protein,O,B
appears,O,O
to,O,O
require,O,O
both,O,O
the,O,O
S,B,O
and,I,O
J,I,O
elements,I,O
",",O,O
which,O,O
are,O,O
separated,O,O
by,O,O
10,O,O
bp,O,O
for,O,O
optimal,O,O
binding,O,O
.,O,O
These,O,O
initial,O,O
pathways,O,O
culminate,O,O
in,O,O
a,O,O
common,O,O
pathway,O,O
through,O,O
which,O,O
all,O,O
of,O,O
the,O,O
stimulating,O,O
agents,O,O
ultimately,O,O
signal,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
.,O,O
This,O,O
Oct,B,B
-,I,I
2,I,I
-,O,I
dependent,O,O
transactivation,O,O
is,O,O
inhibited,O,O
by,O,O
RA,O,B
.,O,O
We,O,O
also,O,O
show,O,O
that,O,O
both,O,O
Fos,B,B
and,O,O
Jun,B,B
components,O,O
of,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
factors,O,O
participate,O,O
in,O,O
the,O,O
OAP40,B,O
complex,I,O
.,O,O
OAP,B,O
confers,O,O
to,O,O
Oct,B,B
-,I,I
2,I,I
responsivity,O,O
to,O,O
both,O,O
TPA,O,O
/,O,O
Ca2,O,B
+,O,I
and,O,O
RA,O,B
",",O,O
since,O,O
specific,O,O
mutations,O,O
of,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
/,I,I
OAP,I,I
-,I,I
binding,I,I
site,I,I
significantly,O,O
reduce,O,O
the,O,O
transactivation,O,O
by,O,O
Oct,B,B
-,I,I
2,I,I
in,O,O
response,O,O
to,O,O
TPA,O,O
and,O,O
Ca2,O,B
+,O,I
and,O,O
abolish,O,O
the,O,O
inhibition,O,O
by,O,O
RA,O,B
.,O,O
Therefore,O,O
",",O,O
we,O,O
propose,O,O
that,O,O
the,O,O
TPA,O,O
/,O,O
calcium,O,O
-,O,O
activated,O,O
AP,B,O
-,I,O
1,I,O
/,B,O
OAP,I,O
element,O,O
is,O,O
the,O,O
main,O,O
target,O,O
of,O,O
positive,O,O
or,O,O
negative,O,O
regulatory,O,O
signals,O,O
influencing,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
octamer,I,O
motif,I,O
",",O,O
through,O,O
synergism,O,O
with,O,O
Oct,B,O
-,I,O
2,I,O
and,O,O
antagonism,O,O
by,O,O
RAR,B,O
.,O,O
As,O,O
in,O,O
XSCID,O,O
",",O,O
X,O,O
-,O,O
chromosome,O,O
inactivation,O,O
in,O,O
obligate,O,O
carriers,O,O
of,O,O
XCID,O,O
was,O,O
nonrandom,O,O
in,O,O
T,O,O
and,O,O
B,O,O
lymphocytes,O,O
.,O,O
Both,O,O
pyrrolidine,O,O
dithiocarbamate,O,O
",",O,O
an,O,O
oxidant,O,O
scavenger,O,O
",",O,O
and,O,O
N,O,O
-,O,O
acetyl,O,O
-,O,O
cysteine,O,O
",",O,O
a,O,O
precursor,O,O
of,O,O
the,O,O
endogenous,O,O
antioxidant,O,O
glutathione,O,O
",",O,O
inhibited,O,O
stimulation,O,O
of,O,O
macrophage,O,O
procoagulant,O,O
activity,O,O
by,O,O
LPS,O,O
.,O,O
An,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
binding,O,O
site,O,O
is,O,O
an,O,O
essential,O,O
component,O,O
of,O,O
the,O,O
element,O,O
but,O,O
alone,O,O
is,O,O
not,O,O
sufficient,O,O
to,O,O
account,O,O
for,O,O
the,O,O
activity,O,O
or,O,O
the,O,O
specificity,O,O
of,O,O
the,O,O
element,O,O
.,O,O
Thapsigargin,O,B
(,O,O
TG,O,O
),O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
Ca,B,B
(,I,I
2,I,I
+,I,I
),I,I
-,I,O
ATPase,I,O
",",O,O
depletes,O,O
intracellular,O,O
Ca2,O,B
+,O,I
stores,O,O
and,O,O
induces,O,O
a,O,O
sustained,O,O
Ca2,O,B
+,O,I
influx,O,O
without,O,O
altering,O,O
phosphatidyl,O,O
inositol,O,O
levels,O,O
.,O,O
A,O,O
similar,O,O
increase,O,O
in,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
by,O,O
TG,O,O
was,O,O
also,O,O
observed,O,O
in,O,O
human,O,O
peripheral,O,O
T,O,O
cells,O,O
.,O,O
However,O,O
",",O,O
TG,O,O
and,O,O
PMA,O,O
exhibited,O,O
a,O,O
synergistic,O,O
action,O,O
on,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
expression,O,O
",",O,O
suggesting,O,O
that,O,O
TG,O,O
and,O,O
PMA,O,O
induce,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
through,O,O
distinct,O,O
pathways,O,O
.,O,O
PMA,B,B
-,I,I
but,I,O
not,I,O
TG,I,B
-,I,I
induced,I,O
IL,I,B
-,I,I
2R,I,I
alpha,I,I
is,O,O
inhibited,O,O
by,O,O
the,O,O
PKC,B,O
inhibitor,O,O
H7,O,O
",",O,O
whereas,O,O
TG,B,B
-,I,I
but,I,O
not,I,O
PMA,I,B
-,I,I
induced,I,O
IL,I,B
-,I,I
2R,I,I
alpha,I,I
was,O,O
inhibited,O,O
by,O,O
cholera,O,O
toxin,O,O
",",O,O
forskolin,O,O
and,O,O
1,O,O
",",O,O
9,O,O
-,O,O
dideoxy,O,O
forskolin,O,O
.,O,O
The,O,O
agent,O,O
",",O,O
17,O,O
beta,O,O
-,O,O
estradiol,O,O
",",O,O
but,O,O
not,O,O
17,O,O
alpha,O,O
-,O,O
estradiol,O,O
",",O,O
significantly,O,O
reduced,O,O
PMNs,O,O
chemotaxis,O,O
to,O,O
FMLP,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
(,O,O
control,O,O
vs,O,O
estrogen,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
-,O,O
(,O,O
-,O,O
6,O,O
),O,O
M,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Physiological,O,O
concentrations,O,O
of,O,O
estradiol,O,B
significantly,O,O
reduced,O,O
the,O,O
chemotaxis,O,O
of,O,O
PMNs,O,O
(,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
mol,O,O
),O,O
.,O,O
Pre,O,O
-,O,O
incubation,O,O
with,O,O
clomiphene,O,O
or,O,O
tamoxifen,O,O
which,O,O
are,O,O
estrogen,O,B
receptor,O,I
antagonists,O,I
",",O,O
eliminated,O,O
the,O,O
inhibitory,O,O
effect,O,O
of,O,O
17,O,O
beta,O,O
-,O,O
estradiol,O,O
on,O,O
the,O,O
chemotaxis,O,O
of,O,O
PMNs,O,O
",",O,O
restoring,O,O
it,O,O
to,O,O
the,O,O
control,O,O
level,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
the,O,O
level,O,O
of,O,O
estradiol,O,B
in,O,O
human,O,B
plasma,O,I
",",O,O
which,O,O
PMNs,O,O
were,O,O
drawn,O,O
",",O,O
showed,O,O
a,O,O
close,O,O
",",O,O
inverse,O,O
correlation,O,O
with,O,O
the,O,O
PMNs,O,O
chemotaxis,O,O
to,O,O
FMLP,O,O
(,O,O
r,O,O
-,O,O
0,O,O
.,O,O
821,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Two,O,O
gel,B,O
shift,I,O
complexes,I,O
(,O,O
Mono,B,O
A,I,O
and,O,O
Mono,B,O
B,I,O
),O,O
were,O,O
formed,O,O
with,O,O
separate,O,O
sequence,O,O
elements,O,O
within,O,O
this,O,O
region,O,O
.,O,O
Furthermore,O,O
",",O,O
multimerized,B,O
region,I,O
II,I,O
sequence,I,O
elements,I,O
enhanced,O,O
the,O,O
activity,O,O
of,O,O
a,O,O
heterologous,O,O
thymidine,O,B
kinase,O,I
promoter,O,I
in,O,O
monocytic,O,O
cells,O,O
but,O,O
not,O,O
other,O,O
cell,O,O
types,O,O
tested,O,O
.,O,O
Pyrrolidine,O,B
dithiocarbamate,O,I
",",O,O
a,O,O
potent,O,O
inhibitor,O,O
of,O,O
nuclear,B,B
factor,I,I
kappa,I,I
B,I,I
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
activation,O,O
",",O,O
prevents,O,O
apoptosis,O,O
in,O,O
human,O,O
promyelocytic,O,O
leukemia,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
and,O,O
thymocytes,O,O
.,O,O
However,O,O
",",O,O
PDTC,O,O
failed,O,O
to,O,O
inhibit,O,O
the,O,O
endonuclease,B,O
activity,O,O
contained,O,O
in,O,O
the,O,O
whole,O,O
cell,O,O
lysates,O,O
.,O,O
Since,O,O
PDTC,O,O
has,O,O
both,O,O
antioxidant,O,O
and,O,O
metal,O,O
-,O,O
ion,O,O
chelating,O,O
activities,O,O
",",O,O
we,O,O
tested,O,O
the,O,O
effects,O,O
of,O,O
N,O,O
-,O,O
acetyl,O,O
-,O,O
L,O,O
-,O,O
cysteine,O,O
(,O,O
NAC,O,O
),O,O
(,O,O
antioxidant,O,O
),O,O
or,O,O
o,O,O
-,O,O
phenanthroline,O,O
(,O,O
OP,O,O
),O,O
(,O,O
metal,O,O
-,O,O
ion,O,O
chelator,O,O
),O,O
on,O,O
the,O,O
induction,O,O
of,O,O
apoptosis,O,O
.,O,O
PKC,O,B
-,O,I
zeta,O,I
cells,O,O
expressed,O,O
a,O,O
more,O,O
differentiated,O,O
phenotype,O,O
as,O,O
assessed,O,O
by,O,O
changes,O,O
in,O,O
morphology,O,O
",",O,O
surface,O,O
antigen,O,O
expression,O,O
",",O,O
and,O,O
lysosomal,B,O
enzyme,I,O
activities,O,O
and,O,O
were,O,O
distinct,O,O
from,O,O
parental,O,O
U937,O,O
cells,O,O
stimulated,O,O
to,O,O
differentiate,O,O
by,O,O
exposure,O,O
to,O,O
phorbol,O,O
esters,O,O
.,O,O
Increased,O,O
expression,O,O
of,O,O
the,O,O
c,B,B
-,I,I
jun,I,I
protooncogene,O,I
and,O,O
an,O,O
increase,O,O
in,O,O
AP,B,B
-,I,I
1,I,I
binding,O,I
activity,O,I
in,O,O
PKC,O,B
-,O,I
zeta,O,I
cells,O,O
provides,O,O
a,O,O
potential,O,O
mechanism,O,O
for,O,O
explaining,O,O
the,O,O
altered,O,O
differentiation,O,O
status,O,O
of,O,O
this,O,O
cell,O,O
.,O,O
It,O,O
is,O,O
surprising,O,O
that,O,O
the,O,O
faster,B,O
-,I,O
migrating,I,O
complex,I,O
was,O,O
composed,O,O
also,O,O
of,O,O
p50,B,B
and,O,O
p65,B,B
.,O,O
OBF,B,O
-,I,O
1,I,O
",",O,O
a,O,O
novel,B,O
B,I,O
cell,I,O
-,I,O
specific,I,O
coactivator,I,O
that,O,O
stimulates,O,O
immunoglobulin,B,O
promoter,I,O
activity,O,O
through,O,O
association,O,O
with,O,O
octamer,B,O
-,I,O
binding,I,O
proteins,I,O
.,O,O
The,O,O
OBF,B,O
-,I,O
1,I,O
mRNA,I,O
is,O,O
expressed,O,O
in,O,O
a,O,O
highly,O,O
cell,O,O
-,O,O
specific,O,O
manner,O,O
",",O,O
being,O,O
most,O,O
abundant,O,O
in,O,O
B,O,O
cells,O,O
and,O,O
essentially,O,O
absent,O,O
in,O,O
most,O,O
of,O,O
the,O,O
other,O,O
cells,O,O
or,O,O
tissues,O,O
tested,O,O
.,O,O
The,O,O
first,O,O
early,O,O
-,O,O
induced,O,O
peak,O,O
was,O,O
transient,O,O
and,O,O
likely,O,O
corresponds,O,O
to,O,O
the,O,O
well,O,O
documented,O,O
typical,O,O
junB,B,B
mRNA,I,I
",",O,O
stimulated,O,O
in,O,O
response,O,O
to,O,O
numerous,O,O
growth,B,O
factors,I,O
",",O,O
including,O,O
IL,B,B
-,I,I
6,I,I
.,O,O
Second,O,O
",",O,O
tyrphostin,O,O
",",O,O
a,O,O
tyrosine,O,O
kinase,O,O
inhibitor,O,O
",",O,O
impaired,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
first,O,O
but,O,O
not,O,O
the,O,O
second,O,O
junB,B,B
mRNA,I,I
peak,O,I
.,O,O
Erythropoietin,B,B
(,O,O
Epo,B,O
),O,O
",",O,O
granulocyte,B,B
/,I,I
macrophage,I,I
colony,I,I
stimulating,I,I
factor,I,I
(,O,O
GM,B,O
-,I,O
CSF,I,O
),O,O
",",O,O
and,O,O
interleukin,B,B
3,I,I
(,O,O
IL,B,O
-,I,O
3,I,O
),O,O
promoted,O,O
the,O,O
growth,O,O
of,O,O
NS,O,B
-,O,I
Meg,O,I
cells,O,O
.,O,O
Ten,O,O
-,O,O
day,O,O
exposure,O,O
to,O,O
Epo,B,O
induced,O,O
mature,O,O
erythroblasts,O,O
and,O,O
red,O,O
cells,O,O
.,O,O
These,O,O
benzidine,O,O
-,O,O
positive,O,O
cells,O,O
were,O,O
positive,O,O
for,O,O
hemoglobin,B,B
F,O,I
staining,O,O
.,O,O
The,O,O
T,B,B
cell,I,I
surface,I,I
molecule,I,I
CD28,B,I
binds,O,O
to,O,O
ligands,O,O
on,O,O
accessory,O,B
cells,O,I
and,O,O
APCs,O,B
",",O,O
playing,O,O
an,O,O
important,O,O
costimulatory,O,O
role,O,O
in,O,O
the,O,O
response,O,O
of,O,O
T,O,B
cells,O,I
to,O,O
Ags,B,O
.,O,O
Our,O,O
knowledge,O,O
of,O,O
the,O,O
intracellular,O,O
signaling,O,O
pathways,O,O
coupled,O,O
to,O,O
this,O,O
receptor,O,O
is,O,O
incomplete,O,O
.,O,O
Enhanced,O,O
responsiveness,O,O
to,O,O
nuclear,B,B
factor,I,I
kappa,I,I
B,I,I
contributes,O,O
to,O,O
the,O,O
unique,O,O
phenotype,O,O
of,O,O
simian,O,O
immunodeficiency,O,O
virus,O,O
variant,O,O
SIVsmmPBj14,O,O
.,O,O
In,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
cell,O,O
types,O,O
",",O,O
the,O,O
basal,O,O
transcriptional,O,O
activity,O,O
of,O,O
the,O,O
LTR,B,O
from,O,O
SIVsmmPBj14,O,O
was,O,O
found,O,O
to,O,O
be,O,O
2,O,O
-,O,O
to,O,O
4,O,O
.,O,O
5,O,O
-,O,O
fold,O,O
higher,O,O
than,O,O
that,O,O
of,O,O
an,O,O
LTR,B,O
from,O,O
a,O,O
non,O,B
-,O,I
acutely,O,I
pathogenic,O,I
strain,O,I
.,O,O
Mutagenesis,O,O
studies,O,O
",",O,O
and,O,O
the,O,O
use,O,O
of,O,O
a,O,O
reporter,O,O
construct,O,O
containing,O,O
an,O,O
enhancerless,O,O
promoter,O,O
",",O,O
indicate,O,O
that,O,O
these,O,O
transcriptional,O,O
effects,O,O
are,O,O
due,O,O
principally,O,O
to,O,O
the,O,O
22,B,O
-,I,O
bp,I,O
sequence,I,O
duplication,I,O
and,O,O
the,O,O
NF,B,B
kappa,I,I
B,I,I
site,I,I
contained,O,O
within,O,O
it,O,O
.,O,O
In,O,O
such,O,O
cells,O,O
",",O,O
DNA,O,B
binding,O,I
activity,O,I
of,O,I
NF,B,I
-,I,I
kappa,I,I
B,I,I
can,O,O
be,O,O
detected,O,O
without,O,O
intentional,O,O
stimulation,O,O
.,O,O
This,O,O
nuclear,B,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
was,O,O
still,O,O
present,O,O
when,O,O
contaminant,O,O
LPS,O,O
was,O,O
removed,O,O
by,O,O
ultrafiltration,O,O
and,O,O
when,O,O
serum,O,O
was,O,O
omitted,O,O
.,O,O
Using,O,O
LPS,O,O
-,O,O
free,O,O
and,O,O
serum,O,O
-,O,O
free,O,O
conditions,O,O
",",O,O
constitutive,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
can,O,O
be,O,O
detected,O,O
in,O,O
different,O,O
cell,O,O
lines,O,O
of,O,O
the,O,O
monocytic,O,B
lineage,O,I
(,O,O
HL60,O,O
",",O,O
U937,O,O
",",O,O
THP,O,O
-,O,O
1,O,O
",",O,O
Mono,O,O
Mac,O,O
1,O,O
and,O,O
Mono,O,O
Mac,O,O
6,O,O
),O,O
",",O,O
but,O,O
not,O,O
in,O,O
Molt,O,O
4,O,O
T,O,O
cells,O,O
or,O,O
K562,O,O
stem,O,O
cells,O,O
.,O,O
The,O,O
constitutive,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
appears,O,O
to,O,O
be,O,O
functionally,O,O
active,O,O
",",O,O
since,O,O
a,O,O
low,O,O
level,O,O
of,O,O
tumour,B,O
necrosis,I,O
factor,I,O
(,I,O
TNF,I,B
),I,O
transcript,I,O
is,O,O
detectable,O,O
in,O,O
monocytes,O,O
",",O,O
and,O,O
this,O,O
level,O,O
can,O,O
be,O,O
increased,O,O
by,O,O
blocking,O,O
transcript,O,O
degradation,O,O
using,O,O
cycloheximide,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
SCL,B,O
mRNA,I,O
levels,O,O
did,O,O
not,O,O
decrease,O,O
significantly,O,O
between,O,O
day,O,O
7,O,O
and,O,O
day,O,O
14,O,O
cells,O,O
",",O,O
suggesting,O,O
that,O,O
posttranscriptional,O,O
mechanisms,O,O
are,O,O
largely,O,O
responsible,O,O
for,O,O
the,O,O
decrease,O,O
in,O,O
SCL,B,O
protein,I,O
observed,O,O
.,O,O
In,O,O
BFU,O,O
-,O,O
E,O,O
-,O,O
derived,O,O
colonies,O,O
cultured,O,O
with,O,O
Steel,B,O
factor,I,O
",",O,O
colony,O,O
size,O,O
was,O,O
significantly,O,O
increased,O,O
compared,O,O
to,O,O
control,O,O
.,O,O
Activated,O,O
macrophages,O,O
contribute,O,O
to,O,O
chronic,O,O
inflammation,O,O
by,O,O
the,O,O
secretion,O,O
of,O,O
cytokines,B,O
and,O,O
proteinases,B,O
.,O,O
Tumor,B,B
necrosis,I,I
factor,I,I
alpha,I,I
(,O,O
TNF,B,B
alpha,I,I
),O,O
is,O,O
particularly,O,O
important,O,O
in,O,O
this,O,O
process,O,O
because,O,O
of,O,O
its,O,O
ability,O,O
to,O,O
regulate,O,O
other,O,O
inflammatory,O,O
mediators,O,O
in,O,O
an,O,O
autocrine,O,O
and,O,O
paracrine,O,O
fashion,O,O
.,O,O
We,O,O
present,O,O
data,O,O
to,O,O
show,O,O
that,O,O
the,O,O
expression,O,O
of,O,O
TNF,B,B
alpha,I,I
is,O,O
regulated,O,O
by,O,O
the,O,O
transcription,B,O
factor,I,O
C,B,B
/,I,I
EBP,I,I
beta,I,I
(,O,O
NF,B,O
-,I,O
IL6,I,O
),O,O
.,O,O
Calcium,B,B
/,I,I
calmodulin,I,I
-,I,I
dependent,I,I
protein,I,B
kinase,I,I
II,I,I
downregulates,O,O
both,O,O
calcineurin,O,B
and,O,O
protein,O,B
kinase,O,I
C,O,I
-,O,I
mediated,O,I
pathways,O,O
for,O,O
cytokine,B,O
gene,I,O
transcription,O,O
in,O,O
human,O,O
T,O,B
cells,O,O
.,O,O
However,O,O
",",O,O
the,O,O
role,O,O
of,O,O
CaM,B,B
-,I,I
K,I,I
II,I,I
remains,O,O
unknown,O,O
.,O,O
We,O,O
have,O,O
used,O,O
mutants,O,O
of,O,O
these,O,O
kinases,B,B
and,O,O
phosphatases,B,O
(,O,O
gamma,B,B
B,I,I
*,I,I
CaM,I,I
-,I,I
K,I,I
and,O,O
delta,B,B
CaM,I,I
-,I,I
AI,I,I
",",O,O
respectively,O,O
),O,O
to,O,O
explore,O,O
their,O,O
relative,O,O
role,O,O
in,O,O
cytokine,B,O
gene,I,O
transcription,O,O
and,O,O
their,O,O
interactions,O,O
with,O,O
PKC,B,O
-,O,O
dependent,O,O
signaling,O,O
systems,O,O
.,O,O
When,O,O
both,O,O
mutants,O,O
were,O,O
used,O,O
in,O,O
combination,O,O
",",O,O
gamma,B,B
B,I,I
*,I,I
CaM,I,I
-,I,I
K,I,I
inhibited,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
by,O,O
delta,B,B
CaM,I,I
-,I,I
AI,I,I
.,O,O
Similar,O,O
results,O,O
were,O,O
obtained,O,O
when,O,O
a,O,O
construct,O,O
containing,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
promoter,I,I
also,O,O
was,O,O
used,O,O
.,O,O
Induction,O,O
of,O,O
TaxI,B,O
in,O,O
a,O,O
human,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
Jurkat,O,O
carrying,O,O
the,O,O
TaxI,B,O
gene,I,O
under,O,O
the,O,O
metallothionein,B,O
promoter,I,O
led,O,O
to,O,O
increases,O,O
in,O,O
mRNA,B,O
and,O,O
surface,O,O
expression,O,O
of,O,O
ICAM,B,B
-,I,I
I,I,I
.,O,O
Three,O,O
other,O,O
ATL,O,O
cell,O,O
lines,O,O
(,O,O
TL,O,O
-,O,O
OmI,O,O
",",O,O
H582,O,O
",",O,O
HuT102,O,O
),O,O
were,O,O
found,O,O
to,O,O
have,O,O
little,O,O
mRNA,B,O
for,O,O
the,O,O
LFA,B,B
-,I,I
I,I,I
beta,I,I
chain,I,I
(,O,I
CD18,B,I
),O,I
.,O,O
H582,O,O
and,O,O
HuT102,O,O
were,O,O
also,O,O
negative,O,O
for,O,O
the,O,O
LFA,B,B
-,I,I
I,I,I
alpha,I,I
chain,I,I
(,I,O
CDIIa,I,O
),I,O
mRNA,I,O
.,O,O
Infection,O,O
with,O,O
Theileria,O,O
annulata,O,O
induces,O,O
expression,O,O
of,O,O
matrix,B,B
metalloproteinase,I,I
9,I,I
and,O,O
transcription,B,O
factor,I,O
AP,B,O
-,I,O
1,I,O
in,O,O
bovine,O,O
leucocytes,O,O
.,O,O
T,O,O
.,O,O
annulata,O,O
-,O,O
infected,O,O
leucocytes,O,O
produce,O,O
a,O,O
number,O,O
of,O,O
novel,O,O
metalloproteinase,B,B
activities,O,O
.,O,O
One,O,O
of,O,O
these,O,O
",",O,O
previously,O,O
called,O,O
B1,B,B
",",O,O
is,O,O
a,O,O
97,B,O
-,I,O
kDa,I,O
protein,I,O
which,O,O
is,O,O
secreted,O,O
in,O,O
large,O,O
amounts,O,O
and,O,O
has,O,O
been,O,O
purified,O,O
from,O,O
protein,O,O
-,O,O
free,O,O
",",O,O
conditioned,O,O
medium,O,O
.,O,O
In,O,O
addition,O,O
we,O,O
assayed,O,O
the,O,O
level,O,O
of,O,O
mRNA,B,B
encoding,O,O
c,B,B
-,I,I
Fos,I,I
",",O,O
a,O,O
common,O,O
component,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
and,O,O
observed,O,O
that,O,O
it,O,O
was,O,O
indeed,O,O
up,O,O
-,O,O
regulated,O,O
in,O,O
infected,O,O
cells,O,O
.,O,O
We,O,O
generated,O,O
conditional,O,O
EBV,O,B
mutants,O,O
by,O,O
expressing,O,O
EBNA2,B,B
as,O,O
chimeric,B,O
fusion,I,O
protein,I,O
with,O,O
the,O,O
hormone,O,B
binding,O,I
domain,O,I
of,O,O
the,O,O
estrogen,B,B
receptor,I,I
on,O,O
the,O,O
genetic,O,O
background,O,O
of,O,O
the,O,O
virus,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
EBV,O,B
is,O,O
using,O,O
a,O,O
common,O,O
pathway,O,O
for,O,O
B,O,B
-,O,I
cell,O,I
activation,O,I
bypassing,O,O
the,O,O
requirement,O,O
for,O,O
antigen,O,O
",",O,O
T,O,B
-,O,I
cell,O,I
signals,O,I
and,O,O
growth,B,O
factors,I,O
.,O,O
The,O,O
synergistic,O,O
antigen,B,O
receptor,I,O
initiated,O,O
signals,O,O
are,O,O
mediated,O,O
through,O,O
protein,B,B
kinase,I,I
C,I,I
because,O,O
they,O,O
can,O,O
be,O,O
mimicked,O,O
by,O,O
the,O,O
phorbol,O,O
ester,O,O
",",O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
",",O,O
but,O,O
not,O,O
with,O,O
calcium,O,B
ionophores,O,I
;,O,O
and,O,O
are,O,O
staurosporine,O,O
sensitive,O,O
but,O,O
cyclosporine,O,O
resistant,O,O
.,O,O
The,O,O
IL,B,B
-,I,I
1,I,I
-,O,I
induced,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
DNA,O,O
nuclear,O,O
localization,O,O
is,O,O
transient,O,O
and,O,O
can,O,O
be,O,O
prolonged,O,O
either,O,O
by,O,O
an,O,O
antigen,O,O
receptor,O,O
-,O,O
initiated,O,O
signal,O,O
or,O,O
by,O,O
inhibiting,O,O
protein,O,B
synthesis,O,O
.,O,O
A,O,O
synthetic,O,O
oligodeoxyribonucleo,O,B
containing,O,O
an,O,O
SP1,B,B
-,I,I
box,I,I
(,O,O
5,O,O
-,O,O
GGGCGG,O,O
),O,O
could,O,O
compete,O,O
with,O,O
factors,O,O
binding,O,O
to,O,O
the,O,O
12,B,O
-,I,O
bp,I,O
insert,I,O
.,O,O
Functional,O,O
Myc,B,B
-,I,I
Max,I,I
heterodimer,I,O
is,O,O
required,O,O
for,O,O
activation,O,O
-,O,O
induced,O,O
apoptosis,O,O
in,O,O
T,O,O
cell,O,O
hybridomas,O,O
.,O,O
T,O,O
cell,O,O
hybridomas,O,O
respond,O,O
to,O,O
activation,O,O
signals,O,O
by,O,O
undergoing,O,O
apoptotic,O,O
cell,O,O
death,O,O
",",O,O
and,O,O
this,O,O
is,O,O
likely,O,O
to,O,O
represent,O,O
comparable,O,O
events,O,O
related,O,O
to,O,O
tolerance,O,O
induction,O,O
in,O,O
immature,O,O
and,O,O
mature,O,O
T,O,O
cells,O,O
in,O,O
vivo,O,O
.,O,O
Computer,O,O
analysis,O,O
of,O,O
the,O,O
SM,B,B
protein,I,I
sequence,O,O
showed,O,O
a,O,O
C,B,O
terminal,I,O
section,I,O
of,O,O
SM,B,B
to,O,O
be,O,O
related,O,O
to,O,O
genome,B,O
positional,I,O
homologues,I,O
of,O,O
four,O,O
other,O,O
herpesviruses,O,O
and,O,O
revealed,O,O
consensus,B,O
CKII,I,B
sites,I,O
near,O,O
the,O,O
N,B,B
termini,I,O
of,O,O
the,O,O
EBV,B,O
SM,I,O
protein,I,O
",",O,O
the,O,O
herpes,B,O
simplex,I,O
virus,I,O
(,I,O
HSV,I,O
),I,O
ICP27,I,O
protein,I,O
and,O,O
the,O,O
herpesvirus,B,O
saimiri,I,O
(,I,O
HVS,I,O
),I,O
open,I,O
reading,I,O
frame,I,O
57,I,O
protein,I,O
.,O,O
Mutagenesis,O,O
of,O,O
the,O,O
CKII,B,B
site,O,I
in,O,O
SM,B,O
made,O,O
no,O,O
difference,O,O
to,O,O
the,O,O
transactivation,O,O
in,O,O
this,O,O
transient,O,O
transfection,O,O
assay,O,O
.,O,O
The,O,O
proto,B,O
-,I,O
oncogene,I,O
c,I,O
-,I,O
fos,I,O
is,O,O
an,O,O
immediate,B,O
-,I,O
early,I,O
gene,I,O
",",O,O
and,O,O
one,O,O
of,O,O
the,O,O
first,O,O
genes,O,O
transcribed,O,O
after,O,O
stimulation,O,O
of,O,O
most,O,O
cells,O,O
with,O,O
a,O,O
variety,O,O
of,O,O
ligands,O,O
.,O,O
The,O,O
serum,B,O
response,I,O
element,I,O
(,O,O
SRE,B,O
),O,O
in,O,O
the,O,O
c,B,O
-,I,O
fos,I,O
regulatory,I,O
region,I,O
participates,O,O
in,O,O
induction,O,O
of,O,O
transcription,O,O
by,O,O
various,O,O
growth,B,O
factors,I,O
and,O,O
by,O,O
phorbol,O,O
esters,O,O
and,O,O
subsequent,O,O
squelching,O,O
of,O,O
transcription,O,O
.,O,O
Band,B,O
A,I,O
contains,O,O
the,O,O
serum,B,B
response,I,I
factor,I,I
plus,O,O
additional,O,O
factor,O,O
(,O,O
s,O,O
),O,O
.,O,O
The,O,O
phosphorylated,O,O
tyrosine,O,O
residue,O,O
itself,O,O
is,O,O
important,O,O
for,O,O
the,O,O
protein,O,B
-,O,I
protein,O,I
interaction,O,I
.,O,O
RJ,O,O
2,O,O
.,O,O
2,O,O
.,O,O
5,O,O
is,O,O
a,O,O
human,O,O
B,O,B
cell,O,I
mutant,O,I
derived,O,O
from,O,O
the,O,O
Burkitt,O,O
lymphoma,O,O
Raji,O,O
cell,O,O
which,O,O
is,O,O
defective,O,O
in,O,O
the,O,O
AIR,O,B
-,O,I
1,O,I
locus,O,I
function,O,I
.,O,O
Thus,O,O
",",O,O
the,O,O
use,O,O
of,O,O
DNase,B,B
I,I,I
allowed,O,O
us,O,O
",",O,O
for,O,O
the,O,O
first,O,O
time,O,O
",",O,O
to,O,O
correlate,O,O
the,O,O
AIR,B,B
-,I,I
1,I,I
locus,I,I
defect,I,I
with,O,O
class,B,O
II,I,O
promoter,I,O
occupancy,O,O
alterations,O,O
and,O,O
distinguish,O,O
these,O,O
alterations,O,O
from,O,O
the,O,O
ones,O,O
observed,O,O
in,O,O
phenotypically,O,O
similar,O,O
but,O,O
genetically,O,O
distinct,O,O
MHC,O,B
class,O,I
II,O,I
-,O,I
negative,O,I
cells,O,I
.,O,O
The,O,O
interleukin,B,B
2,I,I
receptor,I,I
alpha,I,I
-,I,I
chain,I,I
(,I,O
IL,I,B
-,I,I
2R,I,I
alpha,I,I
),I,O
gene,I,O
is,O,O
rapidly,O,O
and,O,O
potently,O,O
induced,O,O
in,O,O
T,O,O
cells,O,O
in,O,O
response,O,O
to,O,O
mitogenic,O,O
stimuli,O,O
.,O,O
This,O,O
element,O,O
had,O,O
maximal,O,O
activity,O,O
in,O,O
lymphoid,O,B
cells,O,I
",",O,O
paralleling,O,O
the,O,O
cell,O,O
type,O,O
specificity,O,O
of,O,O
Elf,B,B
-,I,I
1,I,I
expression,O,O
.,O,O
Elf,B,B
-,I,I
1,I,I
physically,O,O
associated,O,O
with,O,O
HMG,B,B
-,I,I
I,I,I
and,O,O
with,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
p50,B,I
and,O,O
c,B,O
-,I,O
Rel,I,O
in,O,O
vitro,O,O
",",O,O
suggesting,O,O
that,O,O
protein,O,O
-,O,O
protein,O,O
interactions,O,O
might,O,O
functionally,O,O
coordinate,O,O
the,O,O
actions,O,O
of,O,O
the,O,O
upstream,B,O
and,I,O
downstream,I,O
positive,I,O
regulatory,I,O
elements,I,O
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
showed,O,O
that,O,O
a,O,O
majority,O,O
of,O,O
these,O,O
genes,O,O
were,O,O
expressed,O,O
at,O,O
comparable,O,O
levels,O,O
in,O,O
U,O,O
-,O,O
937,O,O
and,O,O
HeLa,O,O
cells,O,O
.,O,O
Among,O,O
258,O,O
X,O,O
chromosome,O,O
-,O,O
containing,O,O
sperm,O,O
",",O,O
19,O,O
%,O,O
had,O,O
a,O,O
repeat,O,O
number,O,O
equal,O,O
to,O,O
the,O,O
donor,B,O
s,I,O
somatic,I,O
DNA,I,B
(,O,O
47,O,O
repeats,O,O
),O,O
",",O,O
66,O,O
%,O,O
were,O,O
expansions,O,O
and,O,O
15,O,O
%,O,O
were,O,O
contractions,O,O
.,O,O
Aspirin,O,O
-,O,O
like,O,O
drugs,O,O
can,O,O
protect,O,O
human,O,O
T,O,O
lymphocytes,O,O
against,O,O
benzoquinone,O,O
cytotoxicity,O,O
:,O,O
evidence,O,O
for,O,O
a,O,O
NAD,B,B
(,I,O
P,I,I
),I,O
H,I,O
:,I,O
quinone,I,O
reductase,I,O
-,O,O
dependent,O,O
mechanism,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
the,O,O
QR,B,B
gene,I,I
is,O,O
regulated,O,O
by,O,O
the,O,O
transcription,B,O
factor,I,O
AP,B,B
-,I,I
1,I,I
.,O,O
Both,O,O
drugs,O,O
protected,O,O
the,O,O
cells,O,O
against,O,O
BQ,O,O
cytotoxicity,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
",",O,O
e,O,O
.,O,O
g,O,O
.,O,O
",",O,O
sodium,O,O
diclofenac,O,O
at,O,O
15,O,O
microM,O,O
reduced,O,O
the,O,O
fraction,O,O
of,O,O
BQ,O,O
-,O,O
treated,O,O
dead,O,O
cells,O,O
by,O,O
70,O,O
%,O,O
.,O,O
ALDs,O,O
induced,O,O
QR,B,B
activity,O,O
in,O,O
the,O,O
M4,O,O
cells,O,O
in,O,O
the,O,O
same,O,O
range,O,O
of,O,O
concentrations,O,O
that,O,O
protected,O,O
the,O,O
cells,O,O
against,O,O
BQ,O,O
toxicity,O,O
.,O,O
A,O,O
good,O,O
linear,O,O
correlation,O,O
",",O,O
with,O,O
an,O,O
r,O,O
value,O,O
of,O,O
0,O,O
.,O,O
91,O,O
",",O,O
between,O,O
the,O,O
ED50,O,O
values,O,O
for,O,O
the,O,O
differentiation,O,O
-,O,O
inducing,O,O
activity,O,O
towards,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
and,O,O
that,O,O
towards,O,O
NB4,O,O
cells,O,O
was,O,O
found,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
a,O,O
molecular,O,O
mechanism,O,O
of,O,O
positive,O,O
regulation,O,O
of,O,O
PAFR,B,O
gene,O,O
expression,O,O
by,O,O
PAF,B,O
through,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
",",O,O
possibly,O,O
by,O,O
a,O,O
phosphorylation,O,O
reaction,O,O
involving,O,O
protein,B,B
kinase,I,I
C,I,I
by,O,O
PAF,B,O
.,O,O
One,O,O
gene,O,O
",",O,O
two,O,O
transcripts,B,O
:,O,O
isolation,O,O
of,O,O
an,O,O
alternative,O,O
transcript,O,O
encoding,O,O
for,O,O
the,O,O
autoantigen,B,O
La,I,B
/,I,I
SS,I,I
-,I,I
B,I,I
from,O,O
a,O,O
cDNA,B,O
library,I,O
of,O,O
a,O,O
patient,O,O
with,O,O
primary,O,O
Sjogrens,O,O
syndrome,O,O
.,O,O
The,O,O
B,B,O
cell,I,O
-,I,O
associated,I,O
surface,I,O
molecule,I,O
CD40,I,O
functions,O,O
to,O,O
regulate,O,O
B,O,O
cell,O,O
responses,O,O
.,O,O
The,O,O
activation,O,O
is,O,O
rapid,O,O
and,O,O
is,O,O
mediated,O,O
through,O,O
a,O,O
tyrosine,O,O
kinase,O,O
-,O,O
dependent,O,O
pathway,O,O
.,O,O
These,O,O
inhibitors,O,O
specifically,O,O
prevented,O,O
degradation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
and,O,O
nuclear,O,O
translocation,O,O
of,O,O
c,B,O
-,I,O
Rel,I,O
/,I,O
p65,I,O
heterodimers,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
TPCK,O,O
and,O,O
TLCK,O,O
did,O,O
not,O,O
block,O,O
induction,O,O
of,O,O
an,O,O
immediate,B,O
-,I,O
early,I,O
gene,I,O
encoding,O,O
the,O,O
transcription,B,O
factor,I,O
",",O,O
Egr,B,O
-,I,O
1,I,O
.,O,O
The,O,O
median,O,O
dissociation,O,O
constant,O,O
(,O,O
Kd,O,O
),O,O
was,O,O
similar,O,O
in,O,O
all,O,O
three,O,O
groups,O,O
of,O,O
patients,O,O
and,O,O
in,O,O
healthy,O,O
women,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
S,O,O
.,O,O
D,O,O
(,O,O
range,O,O
),O,O
:,O,O
PHP,O,O
",",O,O
1,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
0,O,O
(,O,O
0,O,O
.,O,O
2,O,O
-,O,O
4,O,O
),O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
;,O,O
SH,O,O
",",O,O
0,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
4,O,O
(,O,O
0,O,O
.,O,O
2,O,O
-,O,O
1,O,O
.,O,O
2,O,O
),O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
;,O,O
RT,O,O
",",O,O
1,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
(,O,O
0,O,O
.,O,O
4,O,O
-,O,O
1,O,O
.,O,O
9,O,O
),O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
;,O,O
controls,O,O
",",O,O
1,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
6,O,O
(,O,O
0,O,O
.,O,O
3,O,O
-,O,O
2,O,O
.,O,O
6,O,O
),O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
),O,O
.,O,O
However,O,O
",",O,O
the,O,O
maximal,O,O
binding,O,O
capacity,O,O
(,O,O
Nmax,O,O
),O,O
was,O,O
significantly,O,O
enhanced,O,O
in,O,O
PHP,O,O
(,O,O
3,O,O
9,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
9,O,O
(,O,O
1,O,O
.,O,O
3,O,O
-,O,O
7,O,O
.,O,O
6,O,O
),O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
cells,O,O
vs,O,O
.,O,O
2,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
(,O,O
1,O,O
.,O,O
1,O,O
-,O,O
4,O,O
.,O,O
),O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
cells,O,O
in,O,O
controls,O,O
;,O,O
P,O,O
0,O,O
.,O,O
),O,O
and,O,O
decreased,O,O
in,O,O
SH,O,O
(,O,O
0,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
(,O,O
0,O,O
.,O,O
2,O,O
-,O,O
1,O,O
.,O,O
6,O,O
),O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
cells,O,O
vs,O,O
.,O,O
2,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
(,O,O
1,O,O
.,O,O
1,O,O
-,O,O
4,O,O
.,O,O
),O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
cells,O,O
in,O,O
controls,O,O
;,O,O
P,O,O
0,O,O
.,O,O
),O,O
",",O,O
whereas,O,O
no,O,O
changes,O,O
were,O,O
seen,O,O
in,O,O
RT,O,O
(,O,O
2,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
7,O,O
(,O,O
1,O,O
.,O,O
2,O,O
-,O,O
3,O,O
.,O,O
3,O,O
),O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
cells,O,O
vs,O,O
.,O,O
2,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
(,O,O
1,O,O
.,O,O
1,O,O
-,O,O
4,O,O
.,O,O
4,O,O
),O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
cells,O,O
in,O,O
controls,O,O
),O,O
.,O,O
Changes,O,O
of,O,O
calcitriol,B,B
receptors,I,I
in,O,O
primary,O,O
and,O,O
secondary,O,O
hyperparathyroidism,O,O
could,O,O
magnify,O,O
the,O,O
consequences,O,O
of,O,O
disturbances,O,O
in,O,O
serum,O,O
concentration,O,O
of,O,O
calcitriol,O,B
itself,O,O
and,O,O
might,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
development,O,O
of,O,O
secondary,O,O
hyperparathyroidism,O,O
in,O,O
uremia,O,O
.,O,O
Studies,O,O
of,O,O
these,O,O
females,O,O
show,O,O
that,O,O
the,O,O
XIST,B,B
locus,I,O
on,O,O
their,O,O
tiny,B,O
ring,I,O
X,I,B
chromosomes,I,O
is,O,O
either,O,O
not,O,O
present,O,O
or,O,O
not,O,O
expressed,O,O
.,O,O
As,O,O
XIST,B,B
transcription,O,O
is,O,O
well,O,O
correlated,O,O
with,O,O
inactivation,O,O
of,O,O
the,O,O
X,B,B
chromosome,I,O
in,O,O
female,O,O
somatic,O,B
cells,O,O
and,O,O
spermatogonia,O,O
",",O,O
nonexpression,O,O
of,O,O
the,O,O
locus,O,O
even,O,O
when,O,O
it,O,O
is,O,O
present,O,O
suggests,O,O
that,O,O
these,O,O
chromosomes,B,O
are,O,O
transcriptionally,O,O
active,O,O
.,O,O
We,O,O
examined,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
ring,O,O
X,B,B
chromosomes,I,I
lacking,O,O
XIST,B,B
expression,O,O
(,O,O
XISTE,O,O
-,O,O
),O,O
",",O,O
from,O,O
three,O,O
females,O,O
with,O,O
severe,O,O
phenotypes,O,O
.,O,O
The,O,O
increase,O,O
in,O,O
IL,B,B
-,I,I
2,I,I
gene,O,O
expression,O,O
triggered,O,O
by,O,O
CD28,B,O
involves,O,O
a,O,O
kappa,B,B
B,I,I
-,I,I
like,I,I
sequence,I,I
in,O,O
the,O,O
5,B,O
-,I,O
regulatory,I,O
region,I,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
",",O,O
called,O,O
CD28,B,O
-,I,O
responsive,I,O
element,I,O
.,O,O
Here,O,O
we,O,O
report,O,O
that,O,O
CD28,B,O
engagement,O,O
",",O,O
however,O,O
",",O,O
exerts,O,O
opposite,O,O
effects,O,O
on,O,O
the,O,O
transcription,B,O
factor,I,O
AP,I,B
-,I,I
1,I,I
.,O,O
The,O,O
activity,O,O
of,O,O
constructs,O,O
containing,O,O
5,B,O
deletion,I,O
mutants,I,O
of,O,O
the,O,O
alpha,B,B
4,I,I
gene,I,I
promoter,I,I
was,O,O
compared,O,O
in,O,O
transfection,O,O
assays,O,O
into,O,O
cell,O,O
lines,O,O
that,O,O
express,O,O
alpha,B,B
4,I,I
and,O,O
cell,O,O
lines,O,O
that,O,O
do,O,O
not,O,O
.,O,O
The,O,O
sequence,O,O
between,O,O
position,O,O
-,B,O
42,I,O
and,I,O
-,I,O
76,I,O
base,I,O
pairs,I,O
(,O,O
bp,O,O
),O,O
was,O,O
required,O,O
for,O,O
efficient,O,O
transcription,O,O
in,O,O
cells,O,O
that,O,O
express,O,O
alpha,B,B
4,I,I
",",O,O
but,O,O
it,O,O
showed,O,O
no,O,O
activity,O,O
in,O,O
HeLa,O,O
cells,O,O
",",O,O
which,O,O
do,O,O
not,O,O
express,O,O
alpha,B,O
4,I,O
.,O,O
When,O,O
all,O,O
three,O,O
sites,O,O
were,O,O
present,O,O
",",O,O
a,O,O
second,O,O
complex,O,O
`,O,O
a,O,O
was,O,O
detected,O,O
",",O,O
which,O,O
contains,O,O
an,O,O
unknown,O,O
member,O,O
of,O,O
the,O,O
Ets,B,B
family,I,I
.,O,O
Formation,O,O
of,O,O
complex,O,O
a,O,O
was,O,O
cell,O,B
-,O,I
type,O,I
specific,O,O
and,O,O
correlated,O,O
with,O,O
a,O,O
high,O,O
level,O,O
of,O,O
transcription,O,O
.,O,O
This,O,O
arrangement,O,O
of,O,O
Ets,B,B
sites,I,I
",",O,O
coupled,O,O
with,O,O
the,O,O
tissue,O,B
-,O,I
and,O,I
developmental,O,I
-,O,I
specific,O,I
expression,O,O
of,O,O
Ets,B,B
members,I,I
",",O,O
likely,O,O
play,O,O
a,O,O
key,O,O
role,O,O
in,O,O
defining,O,O
the,O,O
pattern,O,O
of,O,O
alpha,B,O
4,I,O
integrin,I,O
.,O,O
Antiandrogens,O,O
result,O,O
in,O,O
protection,O,O
of,O,O
both,O,O
the,O,O
hinge,B,O
region,I,O
and,O,O
C,B,B
-,I,I
terminus,I,I
of,O,O
the,O,O
androgen,B,O
receptor,I,O
agonist,O,O
proteolytic,O,O
attack,O,O
",",O,O
whereas,O,O
other,O,O
studies,O,O
showed,O,O
that,O,O
antiestrogens,O,O
and,O,O
antiprogestagens,O,O
expose,O,O
the,O,O
C,B,B
-,I,I
terminal,I,I
end,I,I
of,O,O
the,O,O
ligand,B,O
binding,I,O
domain,I,O
of,O,O
their,O,O
respective,O,O
receptors,O,O
to,O,O
protease,B,O
.,O,O
However,O,O
",",O,O
reagents,O,O
such,O,O
as,O,O
nerve,B,B
growth,I,I
factor,I,I
(,O,O
NGF,B,O
),O,O
and,O,O
the,O,O
phorbol,O,B
ester,O,I
phorbol,O,I
12,O,I
-,O,I
myristate,O,I
13,O,I
-,O,I
acetate,O,I
(,O,O
PMA,O,O
),O,O
",",O,O
which,O,O
induce,O,O
phenotypical,O,O
differentiation,O,O
of,O,O
the,O,O
SH,O,O
-,O,O
SY5Y,O,O
neuroblastoma,O,O
cell,O,O
line,O,O
",",O,O
activated,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
but,O,O
only,O,O
in,O,O
that,O,O
particular,O,O
cell,O,O
line,O,O
.,O,O
To,O,O
identify,O,O
ets,B,O
-,I,O
related,I,O
transcriptional,I,O
regulators,I,O
expressed,O,O
in,O,O
pre,O,O
-,O,O
B,O,O
lymphocytes,O,O
that,O,O
may,O,O
interact,O,O
with,O,O
either,O,O
the,O,O
pi,B,O
or,O,O
the,O,O
microB,B,O
site,I,O
",",O,O
we,O,O
have,O,O
used,O,O
a,O,O
PCR,O,O
approach,O,O
with,O,O
degenerate,O,O
oligonucleotides,O,O
encoding,O,O
conserved,O,O
sequences,O,O
in,O,O
all,O,O
members,O,O
of,O,O
the,O,O
ets,B,O
family,I,O
.,O,O
We,O,O
have,O,O
cloned,O,O
the,O,O
gene,O,O
for,O,O
a,O,O
new,O,O
ets,B,B
-,I,I
related,I,I
transcription,I,I
factor,I,I
",",O,O
ERP,B,B
(,O,O
ets,B,B
-,I,I
related,I,I
protein,I,I
),O,O
",",O,O
from,O,O
the,O,O
murine,O,O
pre,O,O
-,O,O
B,O,O
cell,O,O
line,O,O
BASC,O,O
6C2,O,O
and,O,O
from,O,O
mouse,O,O
lung,O,O
tissue,O,O
.,O,O
Full,O,O
-,O,O
length,O,O
ERP,B,B
expresses,O,O
only,O,O
negligible,O,O
DNA,O,B
-,O,I
binding,O,I
activity,O,I
by,O,O
itself,O,O
.,O,O
Two,O,O
cis,B,O
-,I,O
acting,I,O
elements,I,O
GM,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
GC,I,I
-,I,I
box,I,I
and,O,O
",",O,O
of,O,O
the,O,O
granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,I,O
GM,I,B
-,I,I
CSF,I,I
),I,O
gene,I,O
are,O,O
required,O,O
for,O,O
maximal,O,O
induction,O,O
in,O,O
Jurkat,O,B
T,O,I
cells,O,I
by,O,O
costimulation,O,O
with,O,O
phorbol,O,O
-,O,O
12,O,O
-,O,O
myristate,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
and,O,O
Ca2,O,B
+,O,I
ionophore,O,I
(,O,O
A23187,O,O
),O,O
.,O,O
Nonpituitary,B,O
human,I,O
prolactin,I,B
gene,I,I
transcription,O,O
is,O,O
independent,O,O
of,O,O
Pit,B,O
-,I,O
1,I,O
and,O,O
differentially,O,O
controlled,O,O
in,O,O
lymphocytes,O,O
and,O,O
in,O,O
endometrial,O,B
stroma,O,I
.,O,O
Our,O,O
experiments,O,O
also,O,O
show,O,O
that,O,O
activated,O,O
PR,B,O
does,O,O
not,O,O
confer,O,O
direct,O,O
transcriptional,O,O
control,O,O
on,O,O
the,O,O
dPRL,B,O
promoter,I,O
.,O,O
One,O,O
of,O,O
the,O,O
nuclear,B,O
factors,I,O
(,O,O
NFs,B,O
),O,O
that,O,O
regulates,O,O
the,O,O
response,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
5,I,I
promoter,I,O
to,O,O
cAMP,O,O
and,O,O
PMA,O,O
has,O,O
properties,O,O
similar,O,O
to,O,O
NF,B,O
for,O,O
activated,O,O
t,O,O
cell,O,O
.,O,O
JNK,B,B
is,O,O
involved,O,O
in,O,O
signal,O,O
integration,O,O
during,O,O
costimulation,O,O
of,O,O
T,O,O
lymphocytes,O,O
.,O,O
T,O,B
lymphocyte,O,I
activation,O,O
and,O,O
interleukin,B,B
-,I,I
2,I,I
(,O,I
IL,B,I
-,I,I
2,I,I
),O,I
production,O,O
require,O,O
at,O,O
least,O,O
two,O,O
signals,O,O
",",O,O
generated,O,O
by,O,O
phorbol,O,O
ester,O,O
(,O,O
TPA,O,O
),O,O
and,O,O
Ca2,O,B
+,O,I
ionophore,O,I
or,O,O
costimulation,O,O
of,O,O
the,O,O
T,B,B
cell,I,I
receptor,I,I
(,O,I
TCR,B,I
),O,I
and,O,O
the,O,O
CD28,B,B
auxiliary,I,I
receptor,I,I
.,O,O
Full,O,O
activation,O,O
of,O,O
the,O,O
MAP,B,B
kinases,I,I
that,O,O
phosphorylate,O,O
the,O,O
Jun,B,B
activation,I,I
domain,I,I
",",O,O
JNK1,B,B
and,O,O
JNK2,B,B
",",O,O
required,O,O
costimulation,O,O
of,O,O
T,O,O
cells,O,O
with,O,O
either,O,O
TPA,O,O
and,O,O
Ca2,O,B
+,O,I
ionophore,O,I
or,O,O
antibodies,O,O
to,O,O
TCR,B,O
and,O,O
CD28,B,O
.,O,O
The,O,O
effect,O,O
of,O,O
a,O,O
liposomal,O,O
formulation,O,O
of,O,O
methylprednisolone,O,O
(,O,O
MPL,O,O
),O,O
on,O,O
the,O,O
inhibition,O,O
of,O,O
lymphocyte,O,O
proliferation,O,O
in,O,O
spleen,O,O
cells,O,O
was,O,O
investigated,O,O
following,O,O
IV,O,O
dosing,O,O
in,O,O
rats,O,O
.,O,O
Liposomes,O,O
do,O,O
not,O,O
alter,O,O
the,O,O
suppressive,O,O
action,O,O
of,O,O
MPL,O,O
when,O,O
placed,O,O
in,O,O
lymphocyte,O,O
culture,O,O
.,O,O
Inhibition,O,O
effects,O,O
versus,O,O
time,O,O
were,O,O
described,O,O
by,O,O
a,O,O
pharmacodynamic,O,O
model,O,O
using,O,O
MPL,O,O
concentrations,O,O
in,O,O
plasma,O,O
as,O,O
an,O,O
input,O,O
function,O,O
.,O,O
In,O,O
vivo,O,O
protein,O,B
-,O,I
DNA,O,I
contacts,O,O
are,O,O
detectable,O,O
at,O,O
Ii,B,O
kappa,I,O
B,I,O
-,I,O
1,I,O
in,O,O
cell,O,B
lines,O,I
in,O,O
which,O,O
this,O,O
site,O,O
is,O,O
functional,O,O
as,O,O
either,O,O
a,O,O
positive,B,O
or,I,O
negative,I,O
regulator,I,O
.,O,O
Ii,B,O
kappa,I,B
B,I,I
-,I,I
2,I,I
is,O,O
a,O,O
site,O,O
of,O,O
positive,O,O
regulation,O,O
in,O,O
B,O,B
-,O,I
cell,O,I
lines,O,I
and,O,O
a,O,O
site,O,O
of,O,O
negative,O,O
regulation,O,O
in,O,O
H9,O,O
T,O,O
cells,O,O
",",O,O
myelomonocytic,O,O
",",O,O
and,O,O
glial,O,O
cell,O,O
lines,O,O
.,O,O
Again,O,O
",",O,O
in,O,O
vitro,O,O
supershift,O,O
studies,O,O
indicate,O,O
that,O,O
the,O,O
presence,O,O
of,O,O
p50,B,O
",",O,O
p52,B,O
",",O,O
p65,B,O
",",O,O
and,O,O
cRel,B,O
correlates,O,O
with,O,O
positive,O,O
function,O,O
whereas,O,O
the,O,O
presence,O,O
of,O,O
only,O,O
p50,B,O
and,O,O
p52,B,O
correlates,O,O
with,O,O
negative,O,O
function,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
determine,O,O
whether,O,O
activation,O,O
of,O,O
Epstein,O,B
-,O,I
Barr,O,I
virus,O,I
(,O,I
EBV,O,I
),O,O
replication,O,O
in,O,O
tumour,O,O
cells,O,O
of,O,O
AIDS,O,O
-,O,O
related,O,O
non,O,O
-,O,O
Hodgkin,O,O
s,O,O
lymphoma,O,O
(,O,O
ARNHL,O,O
),O,O
is,O,O
correlated,O,O
with,O,O
CD4,B,B
+,I,I
cell,O,I
counts,O,I
and,O,O
influences,O,O
antibody,O,O
response,O,O
to,O,O
EBV,O,B
[,O,O
anti,B,O
-,I,O
Z,I,O
Epstein,I,O
-,I,O
Barr,I,O
replicative,I,O
activator,I,O
(,O,O
ZEBRA,B,O
),O,O
",",O,O
anti,B,O
-,I,O
early,I,O
antigen,I,O
(,O,O
EA,B,O
),O,O
",",O,O
anti,B,O
-,I,O
viral,I,O
capsid,I,O
antigen,I,O
(,O,O
VCA,B,O
),O,O
],O,O
.,O,O
DESIGN,O,O
:,O,O
Retrospective,O,O
study,O,O
based,O,O
on,O,O
immunohistochemistry,O,O
and,O,O
in,O,O
situ,O,O
hybridization,O,O
to,O,O
detect,O,O
EBV,O,B
replicative,O,O
gene,O,O
products,O,O
in,O,O
tissue,O,O
samples,O,O
from,O,O
patients,O,O
affected,O,O
by,O,O
ARNHL,O,O
and,O,O
correlation,O,O
with,O,O
CD4,B,B
+,I,I
cell,O,I
counts,O,I
and,O,O
results,O,O
of,O,O
EBV,O,B
serology,O,O
(,O,O
including,O,O
anti,O,O
-,O,O
ZEBRA,B,O
activity,O,O
),O,O
in,O,O
sera,O,O
from,O,O
the,O,O
same,O,O
patients,O,O
.,O,O
In,O,O
cells,O,O
stimulated,O,O
with,O,O
anti,B,O
-,I,O
CD3,I,O
mAb,I,O
",",O,O
PGE2,B,O
inhibited,O,O
cell,O,O
proliferation,O,O
and,O,O
the,O,O
production,O,O
of,O,O
all,O,O
the,O,O
cytokines,B,O
examined,O,O
.,O,O
Addition,O,O
of,O,O
rIL,B,B
-,I,I
2,I,I
fully,O,O
restored,O,O
the,O,O
proliferative,O,O
response,O,O
and,O,O
partially,O,O
restored,O,O
the,O,O
production,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
5,I,I
",",O,O
but,O,O
not,O,O
that,O,O
of,O,O
other,O,O
cytokines,B,O
.,O,O
It,O,O
seems,O,O
therefore,O,O
that,O,O
PGE2,B,O
",",O,O
by,O,O
elevating,O,O
cAMP,O,O
levels,O,O
",",O,O
interferes,O,O
with,O,O
the,O,O
activation,O,O
pathway,O,O
for,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
but,O,O
not,O,O
for,O,O
NF,B,B
-,I,I
AT,I,I
",",O,O
AP,B,B
-,I,I
1,I,I
or,O,O
binding,I,O
protein,I,O
.,O,O
Moreover,O,O
",",O,O
rapamycin,O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
pp70S6K,B,B
activation,O,O
",",O,O
had,O,O
no,O,O
effect,O,O
on,O,O
induction,O,O
of,O,O
EGR,B,O
-,I,O
1,I,O
expression,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
analysis,O,O
of,O,O
pp90rsk,B,B
activity,O,O
by,O,O
phosphorylation,O,O
of,O,O
a,O,O
peptide,O,O
derived,O,O
from,O,O
S6,B,B
protein,I,I
demonstrated,O,O
stimulation,O,O
of,O,O
this,O,O
kinase,B,O
in,O,O
TPA,O,O
-,O,O
treated,O,O
U,O,B
-,O,O
937,O,O
",",O,O
and,O,O
not,O,O
TUR,O,O
",",O,O
cells,O,O
.,O,O
PDTC,O,O
or,O,O
N,O,B
-,O,O
acetylcysteine,O,O
dose,O,O
dependently,O,O
reduced,O,O
TNF,B,B
-,I,O
induced,I,O
VCAM,I,B
-,I,I
1,I,I
but,O,O
not,O,O
ICAM,B,B
-,I,I
1,I,I
surface,I,O
protein,I,O
(,O,O
also,O,O
in,O,O
human,O,B
umbilical,O,I
arterial,O,I
endothelial,O,I
cells,O,O
),O,O
and,O,O
mRNA,O,O
expression,O,O
(,O,O
by,O,O
70,O,O
%,O,O
at,O,O
100,O,O
mumol,O,O
/,O,O
L,O,O
PDTC,O,O
),O,O
in,O,O
HUVECs,O,O
as,O,O
assessed,O,O
by,O,O
flow,O,O
cytometry,O,O
and,O,O
polymerase,O,O
chain,O,O
reaction,O,O
.,O,O
We,O,O
have,O,O
identified,O,O
a,O,O
`,B,O
`,I,O
two,I,O
-,I,O
handed,I,O
zinc,I,B
finger,I,I
protein,I,I
",",O,O
denoted,O,O
ZEB,B,O
",",O,O
the,O,O
DNA,O,B
-,O,I
binding,O,I
specificity,O,O
of,O,O
which,O,O
mimics,O,O
that,O,O
of,O,O
the,O,O
cellular,B,O
repressor,I,O
.,O,O
By,O,O
employing,O,O
a,O,O
derivative,O,O
E,B,O
box,I,O
that,O,O
binds,O,O
ZEB,B,O
but,O,O
not,O,O
E2A,B,O
",",O,O
we,O,O
have,O,O
shown,O,O
that,O,O
the,O,O
repressor,B,O
is,O,O
active,O,O
in,O,O
B,O,O
cells,O,O
and,O,O
the,O,O
IgH,B,O
enhancer,I,O
is,O,O
silenced,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
binding,O,O
competition,O,O
by,O,O
bHLH,B,O
proteins,I,O
.,O,O
Effects,O,O
of,O,O
the,O,O
antisense,O,O
myb,O,B
expression,O,O
on,O,O
hemin,O,O
-,O,O
and,O,O
erythropoietin,O,O
-,O,O
induced,O,O
erythroid,O,O
differentiation,O,O
of,O,O
K562,O,O
cells,O,O
.,O,O
In,O,O
order,O,O
to,O,O
elucidate,O,O
the,O,O
role,O,O
of,O,O
c,B,O
-,I,O
myb,I,O
gene,I,O
in,O,O
erythroid,O,O
differentiation,O,O
of,O,O
K562,O,O
cell,O,O
induced,O,O
by,O,O
hemin,B,O
(,O,O
Hm,B,O
),O,O
and,O,O
erythropoietin,B,O
(,O,O
Epo,B,O
),O,O
",",O,O
we,O,O
constructed,O,O
recombinant,B,O
plasmid,I,O
that,O,O
could,O,O
produce,O,O
antisense,B,O
myb,I,O
RNA,I,O
after,O,O
induction,O,O
with,O,O
dexamethasone,O,O
.,O,O
During,O,O
treatment,O,O
with,O,O
Hm,B,O
",",O,O
K562,O,O
cells,O,O
constitutively,O,O
expressed,O,O
c,B,O
-,I,O
myb,I,O
mRNA,I,O
",",O,O
and,O,O
50,O,O
%,O,O
of,O,O
them,O,O
began,O,O
to,O,O
synthesize,O,O
hemoglobin,B,B
(,O,O
Hb,B,O
),O,O
.,O,O
We,O,O
investigated,O,O
whether,O,O
non,O,O
-,O,O
abortive,O,O
maternal,O,O
infections,O,O
would,O,O
compromise,O,O
fetal,O,O
brain,O,O
development,O,O
and,O,O
alter,O,O
hypothalamic,O,O
-,O,O
pituitary,O,O
-,O,O
adrenocortical,O,O
(,O,O
HPA,O,O
),O,O
axis,O,O
functioning,O,O
when,O,O
adult,O,O
.,O,O
The,O,O
adult,O,O
male,O,O
progeny,O,O
(,O,O
3,O,O
mo,O,O
old,O,O
),O,O
of,O,O
both,O,O
experimental,O,O
groups,O,O
showed,O,O
increased,O,O
basal,O,O
plasma,O,O
corticosterone,O,B
levels,O,O
.,O,O
Both,O,O
groups,O,O
showed,O,O
substantial,O,O
decreases,O,O
in,O,O
mineralocorticoid,O,B
(,O,O
MR,O,O
),O,O
and,O,O
glucocorticoid,O,B
receptor,O,I
(,O,O
GR,O,O
),O,O
levels,O,O
in,O,O
the,O,O
hippocampus,O,B
",",O,O
a,O,O
limbic,O,O
brain,O,O
structure,O,O
critical,O,O
for,O,O
HPA,O,O
axis,O,O
regulation,O,O
",",O,O
whereas,O,O
GR,B,O
concentrations,O,O
in,O,O
the,O,O
hypothalamus,O,B
were,O,O
unchanged,O,O
and,O,O
in,O,O
anterior,O,O
pituitary,O,B
were,O,O
slightly,O,O
increased,O,O
.,O,O
HRBC,O,B
and,O,O
LPS,O,O
indeed,O,O
stimulated,O,O
the,O,O
maternal,O,O
immune,O,O
system,O,O
as,O,O
revealed,O,O
by,O,O
specific,O,O
anti,B,O
-,I,O
HRBC,I,B
antibody,I,O
production,O,O
and,O,O
enhanced,O,O
IL,O,B
-,O,I
1,O,I
beta,O,I
mRNA,O,I
expression,O,O
in,O,O
splenocytes,O,O
",",O,O
respectively,O,O
.,O,O
NM23,B,B
was,O,O
identified,O,O
in,O,O
a,O,O
system,O,O
of,O,O
murine,O,O
melanoma,O,O
cell,O,O
lines,O,O
",",O,O
in,O,O
which,O,O
an,O,O
inverse,O,O
relationship,O,O
was,O,O
found,O,O
between,O,O
NM23,B,B
expression,O,O
and,O,O
metastatic,O,O
ability,O,O
.,O,O
The,O,O
transmission,O,O
of,O,O
signals,O,O
from,O,O
the,O,O
membrane,O,O
to,O,O
the,O,O
nucleus,O,O
is,O,O
mediated,O,O
principally,O,O
through,O,O
the,O,O
action,O,O
of,O,O
protein,B,B
tyrosine,I,I
and,I,O
serine,I,B
/,I,I
threonine,I,I
kinases,I,O
.,O,O
Fos,B,O
kinase,I,O
may,O,O
play,O,O
a,O,O
role,O,O
in,O,O
transcriptional,O,O
regulation,O,O
through,O,O
its,O,O
capacity,O,O
to,O,O
phosphorylate,O,O
c,B,O
-,I,O
Fos,I,O
at,O,O
a,O,O
site,O,O
required,O,O
for,O,O
expression,O,O
of,O,O
the,O,O
transcriptional,O,O
transrepressive,O,O
activity,O,O
of,O,O
this,O,O
molecule,O,O
.,O,O
Each,O,O
of,O,O
the,O,O
remaining,O,O
four,O,O
patients,O,O
also,O,O
yielded,O,O
at,O,O
least,O,O
one,O,O
type,O,O
-,O,O
specific,O,O
T,O,O
-,O,O
cell,O,O
clone,O,O
reactive,O,O
with,O,O
an,O,O
HSV,O,B
-,O,I
2,O,I
epitope,O,O
mapping,O,O
to,O,O
approximately,O,O
0,O,O
.,O,O
67,O,O
to,O,O
0,O,O
.,O,O
73,O,O
map,O,O
units,O,O
.,O,O
Human,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
reactive,O,O
with,O,O
gC,B,B
and,O,O
VP16,B,B
are,O,O
reported,O,O
here,O,O
for,O,O
the,O,O
first,O,O
time,O,O
.,O,O
We,O,O
studied,O,O
genomic,B,O
DNA,I,B
and,O,O
RNA,O,B
extracted,O,O
from,O,O
the,O,O
patient,O,O
s,O,O
peripheral,O,O
leucocytes,O,O
in,O,O
order,O,O
to,O,O
determine,O,O
the,O,O
origin,O,O
of,O,O
the,O,O
basophils,O,O
.,O,O
The,O,O
RAR,B,B
alpha,I,I
rearranged,O,O
band,O,O
in,O,O
the,O,O
Southern,O,O
blot,O,O
analysis,O,O
and,O,O
a,O,O
chimaeric,B,O
product,I,O
of,O,O
PML,B,O
-,I,O
RAR,I,B
alpha,I,I
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
were,O,O
strongly,O,O
visible,O,O
before,O,O
ATRA,O,O
treatment,O,O
",",O,O
but,O,O
at,O,O
the,O,O
time,O,O
of,O,O
maximal,O,O
basophilia,O,O
both,O,O
of,O,O
them,O,O
were,O,O
markedly,O,O
diminished,O,O
.,O,O
Activation,O,O
of,O,O
the,O,O
interleukin,B,B
6,I,I
gene,I,O
by,O,O
Mycobacterium,O,O
tuberculosis,O,O
or,O,O
lipopolysaccharide,O,O
is,O,O
mediated,O,O
by,O,O
nuclear,B,O
factors,I,O
NF,I,B
-,I,I
IL6,I,I
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
Proc,O,O
Natl,O,O
Acad,O,O
Sci,O,O
U,O,O
S,O,O
A,O,O
1995,O,O
Apr,O,O
11,O,O
;,O,O
92,O,O
(,O,O
8,O,O
),O,O
:,O,O
3632,O,O
],O,O
In,O,O
this,O,O
regard,O,O
",",O,O
the,O,O
cytokine,B,O
interleukin,B,B
6,I,I
(,O,O
IL,B,O
-,I,O
6,I,O
),O,O
may,O,O
play,O,O
a,O,O
role,O,O
in,O,O
the,O,O
clinical,O,O
manifestations,O,O
and,O,O
pathological,O,O
events,O,O
of,O,O
tuberculosis,O,O
infection,O,O
.,O,O
LAM,B,B
and,O,O
LPS,O,B
were,O,O
potent,O,O
inducers,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
gene,I,I
expression,O,O
in,O,O
peripheral,O,O
blood,O,O
monocytes,O,O
.,O,O
Two,O,O
nuclear,B,O
factor,I,O
NF,I,O
-,I,O
IL6,I,O
(,O,O
positions,O,O
-,B,O
153,I,O
to,I,O
-,I,O
145,I,O
and,O,O
-,O,O
83,O,O
to,O,O
-,O,O
75,O,O
),O,O
and,O,O
one,O,O
nuclear,B,O
factor,I,O
NF,I,O
-,I,O
kappa,I,O
B,I,O
(,I,O
positions,I,O
-,I,O
72,I,O
to,I,O
-,I,O
63,I,O
),I,O
motifs,I,O
are,O,O
present,O,O
within,O,O
this,O,O
fragment,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
NF,B,O
-,I,O
IL6,I,O
and,I,O
NF,I,O
-,I,O
kappa,I,O
B,I,O
sites,I,O
mediate,O,O
IL,B,B
-,I,I
6,I,I
induction,O,O
in,O,O
response,O,O
to,O,O
both,O,O
LPS,O,B
and,O,O
LAM,B,B
",",O,O
acting,O,O
as,O,O
bacterial,B,O
or,I,O
mycobacterial,I,O
response,I,O
elements,I,O
.,O,O
Using,O,O
FACS,O,O
",",O,O
Northern,O,O
blotting,O,O
",",O,O
and,O,O
nuclear,O,O
run,O,O
-,O,O
on,O,O
analyses,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
the,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
CD14,B,B
expression,O,O
during,O,O
monocytic,O,B
cell,O,I
maturation,O,O
is,O,O
regulated,O,O
mainly,O,O
at,O,O
the,O,O
level,O,O
of,O,O
gene,O,O
transcription,O,O
",",O,O
and,O,O
that,O,O
new,O,O
protein,O,B
synthesis,O,I
is,O,O
required,O,O
for,O,O
CD14,B,B
induction,O,O
.,O,O
This,O,O
region,O,O
contains,O,O
two,O,O
binding,B,O
sites,I,O
for,O,O
the,O,O
Sp1,B,B
transcription,I,I
factor,I,I
.,O,O
UV,O,O
irradiation,O,O
and,O,O
H2O2,O,O
treatment,O,O
of,O,O
T,O,O
lymphocytes,O,O
induce,O,O
protein,O,B
tyrosine,O,I
phosphorylation,O,I
and,O,O
Ca2,O,B
+,O,I
signals,O,O
similar,O,O
to,O,O
those,O,O
observed,O,O
following,O,O
biological,O,O
stimulation,O,O
.,O,O
Similarly,O,O
",",O,O
Jurkat,O,O
T,O,O
cell,O,O
lines,O,O
deficient,O,O
in,O,O
CD3,O,O
or,O,O
CD45,O,O
expression,O,O
also,O,O
gave,O,O
impaired,O,O
UV,O,O
responses,O,O
.,O,O
Inhibition,O,O
of,O,O
the,O,O
differentiation,O,O
of,O,O
human,O,O
myeloid,O,O
cell,O,O
lines,O,O
by,O,O
redox,O,O
changes,O,O
induced,O,O
through,O,O
glutathione,O,O
depletion,O,O
.,O,O
The,O,O
glutathione,O,B
-,O,I
depleting,O,I
agent,O,I
diethyl,O,O
maleate,O,O
(,O,O
DEM,O,O
),O,O
prevented,O,O
the,O,O
development,O,O
of,O,O
differentiated,O,O
features,O,O
in,O,O
response,O,O
to,O,O
phorbol,O,O
esters,O,O
",",O,O
including,O,O
adherence,O,O
of,O,O
the,O,O
cells,O,O
to,O,O
plastic,O,O
surfaces,O,O
and,O,O
repression,O,O
of,O,O
the,O,O
myeloperoxidase,B,O
and,I,O
CD34,I,O
genes,I,O
.,O,O
This,O,O
nuclear,B,O
complex,I,O
was,O,O
activated,O,O
by,O,O
LPS,O,O
with,O,O
kinetics,O,O
that,O,O
preceded,O,O
induction,O,O
of,O,O
the,O,O
TF,B,O
gene,I,O
.,O,O
Human,O,B
immunodeficiency,O,I
virus,O,I
type,O,I
1,O,I
Nef,O,B
protein,O,I
down,O,O
-,O,O
regulates,O,O
transcription,B,O
factors,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
in,O,O
human,O,O
T,O,B
cells,O,I
in,O,O
vitro,O,O
after,O,O
T,O,B
-,O,I
cell,O,I
receptor,O,I
stimulation,O,O
.,O,O
To,O,O
define,O,O
the,O,O
mechanism,O,O
of,O,O
action,O,O
of,O,O
the,O,O
Nef,B,B
protein,O,I
",",O,O
the,O,O
signal,O,O
transduction,O,O
pathways,O,O
which,O,O
may,O,O
be,O,O
affected,O,O
in,O,O
T,O,B
cells,O,I
by,O,O
constitutive,O,O
expression,O,O
of,O,O
the,O,O
nef,O,O
gene,O,O
were,O,O
examined,O,O
.,O,O
Stimulation,O,O
of,O,O
T,O,O
cells,O,O
with,O,O
tumor,O,O
necrosis,O,O
factor,O,O
",",O,O
interleukin,O,B
-,O,I
1,O,I
",",O,O
or,O,O
lipopolysaccharide,O,O
resulted,O,O
in,O,O
the,O,O
recruitment,O,O
of,O,O
transcriptional,O,O
factors,O,O
to,O,O
a,O,O
similar,O,O
level,O,O
whether,O,O
or,O,O
not,O,O
the,O,O
cells,O,O
expressed,O,O
the,O,O
nef,O,O
gene,O,O
.,O,O
When,O,O
cells,O,O
were,O,O
preincubated,O,O
with,O,O
dihydrolipoic,O,O
acid,O,O
(,O,O
0,O,O
.,O,O
2,O,O
mM,O,O
),O,O
the,O,O
expression,O,O
of,O,O
c,B,O
-,I,O
fos,I,O
mRNA,I,O
was,O,O
suppressed,O,O
at,O,O
30,O,O
min,O,O
after,O,O
stimulation,O,O
of,O,O
TPA,O,O
(,O,O
0,O,O
.,O,O
5,O,O
microM,O,O
),O,O
whereas,O,O
in,O,O
the,O,O
case,O,O
of,O,O
preincubation,O,O
of,O,O
alpha,O,O
-,O,O
lipoic,O,O
acid,O,O
(,O,O
0,O,O
.,O,O
2,O,O
microM,O,O
),O,O
",",O,O
the,O,O
expression,O,O
was,O,O
enhanced,O,O
at,O,O
30,O,O
min,O,O
.,O,O
This,O,O
resulted,O,O
in,O,O
only,O,O
a,O,O
partial,O,O
inhibition,O,O
of,O,O
TNF,B,B
-,O,I
or,O,I
PMA,O,I
-,O,I
induced,O,I
HIV,O,B
replication,O,O
in,O,O
U1,O,O
cells,O,O
",",O,O
and,O,O
no,O,O
detectable,O,O
effect,O,O
on,O,O
HIV,O,B
replication,O,O
in,O,O
chronically,O,O
infected,O,O
U937,O,O
cells,O,O
.,O,O
Another,O,O
limitation,O,O
is,O,O
that,O,O
antioxidant,O,O
concentrations,O,O
high,O,O
enough,O,O
to,O,O
block,O,O
NK,B,O
-,I,O
kappa,I,O
B,I,O
activation,O,O
were,O,O
shown,O,O
to,O,O
have,O,O
a,O,O
suppressive,O,O
effect,O,O
on,O,O
immune,O,O
functions,O,O
in,O,O
vitro,O,O
",",O,O
because,O,O
NAC,O,O
and,O,O
BHA,O,O
blocked,O,O
IL,O,B
-,O,I
2,O,I
-,O,I
induced,O,I
PBMC,O,O
proliferation,O,O
.,O,O
We,O,O
have,O,O
developed,O,O
a,O,O
three,O,O
-,O,O
layer,O,O
Percoll,O,O
density,O,O
gradient,O,O
that,O,O
allows,O,O
separation,O,O
of,O,O
the,O,O
different,O,O
granules,O,O
and,O,O
vesicles,O,O
from,O,O
human,O,O
neutrophils,O,O
;,O,O
in,O,O
particular,O,O
",",O,O
it,O,O
allows,O,O
separation,O,O
of,O,O
specific,O,O
and,O,O
gelatinase,O,O
granules,O,O
.,O,O
This,O,O
allows,O,O
us,O,O
to,O,O
characterize,O,O
these,O,O
two,O,O
granule,O,O
populations,O,O
with,O,O
regard,O,O
to,O,O
their,O,O
content,O,O
of,O,O
membrane,B,B
proteins,I,I
",",O,O
which,O,O
become,O,O
incorporated,O,O
into,O,O
the,O,O
plasma,O,B
membrane,O,I
during,O,O
exocytosis,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
found,O,O
that,O,O
20,O,O
%,O,O
to,O,O
25,O,O
%,O,O
of,O,O
both,O,O
the,O,O
adhesion,B,B
protein,I,I
Mac,I,I
-,I,I
1,I,I
and,O,O
the,O,O
NADPH,B,B
-,I,I
oxidase,I,I
component,I,I
cytochrome,I,I
b558,B,I
is,O,O
localized,O,O
in,O,O
gelatinase,B,B
granules,O,I
.,O,O
This,O,O
shows,O,O
that,O,O
gelatinase,B,B
granules,O,I
are,O,O
functionally,O,O
important,O,O
relative,O,O
to,O,O
specific,O,O
granules,O,O
in,O,O
mediating,O,O
early,O,O
inflammatory,O,O
responses,O,O
.,O,O
Treatment,O,O
of,O,O
human,O,O
resting,O,O
T,O,O
cells,O,O
with,O,O
phorbol,O,O
esters,O,O
strongly,O,O
induced,O,O
the,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
and,O,O
the,O,O
activation,O,O
of,O,O
NF,B,B
.,I,O
kappa,I,O
B,I,O
.,O,O
Rather,O,O
",",O,O
the,O,O
data,O,O
indicate,O,O
that,O,O
mitogen,O,O
increases,O,O
the,O,O
levels,O,O
of,O,O
a,O,O
nuclear,O,O
factor,O,O
(,O,O
s,O,O
),O,O
that,O,O
dimerizes,O,O
with,O,O
CREB,B,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
effect,O,O
of,O,O
alpha,O,B
-,O,I
tocopherol,O,I
(,O,O
alpha,O,B
-,O,I
tcp,O,I
),O,O
on,O,O
one,O,O
cellular,O,O
event,O,O
in,O,O
atherosclerotic,O,O
plaque,O,O
development,O,O
",",O,O
monocyte,O,B
adhesion,O,O
to,O,O
stimulated,O,O
endothelial,O,B
cells,O,I
(,O,O
ECs,O,O
),O,O
.,O,O
Agonist,O,O
-,O,O
induced,O,O
monocytic,O,B
cell,O,I
adhesion,O,O
",",O,O
but,O,O
not,O,O
basal,O,O
adhesion,O,O
",",O,O
was,O,O
inhibited,O,O
in,O,O
a,O,O
time,O,O
-,O,O
and,O,O
concentration,O,O
-,O,O
dependent,O,O
manner,O,O
by,O,O
alpha,O,B
-,O,I
tcp,O,I
.,O,O
Central,O,O
nervous,O,O
system,O,O
-,O,O
derived,O,O
cells,O,O
express,O,O
a,O,O
kappa,O,B
B,O,I
-,O,I
binding,O,I
activity,O,I
that,O,O
enhances,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
transcription,O,O
in,O,O
vitro,O,O
and,O,O
facilitates,O,O
TAR,B,O
-,O,O
independent,O,O
transactivation,O,O
by,O,O
Tat,B,O
.,O,O
Tat,B,O
transactivation,O,O
mediated,O,O
by,O,O
the,O,O
kappa,B,B
B,I,I
domain,I,I
is,O,O
sufficient,O,O
to,O,O
allow,O,O
replication,O,O
of,O,O
TAR,B,O
-,O,O
deleted,O,O
mutant,O,O
HIV,O,O
-,O,O
1,O,O
in,O,O
astrocytes,O,O
.,O,O
For,O,O
one,O,O
of,O,O
these,O,O
proteins,O,B
",",O,O
p57,B,B
",",O,O
binding,O,O
to,O,O
the,O,O
IRES,B,O
correlates,O,O
with,O,O
translation,O,O
.,O,O
Retinoid,B,B
-,I,I
like,I,I
receptors,I,I
play,O,O
a,O,O
central,O,O
role,O,O
in,O,O
hormonal,O,O
responses,O,O
by,O,O
forming,O,O
heterodimers,B,O
with,O,O
other,O,O
nuclear,B,B
hormone,I,I
receptors,I,I
.,O,O
Hence,O,O
",",O,O
PPAR,B,B
can,O,O
positively,O,O
or,O,O
negatively,O,O
influence,O,O
TH,O,B
action,O,O
depending,O,O
on,O,O
TRE,B,B
structure,O,O
and,O,O
THR,B,B
isotype,I,O
.,O,O
Comparison,O,O
of,O,O
retinoic,O,B
acid,O,I
and,O,O
phorbol,O,B
myristate,O,I
acetate,O,I
as,O,O
inducers,O,O
of,O,O
monocytic,O,O
differentiation,O,O
.,O,O
Several,O,O
human,O,O
myeloid,O,O
leukemia,O,O
cell,O,O
lines,O,O
growing,O,O
in,O,O
vitro,O,O
can,O,O
be,O,O
induced,O,O
to,O,O
differentiate,O,O
to,O,O
more,O,O
mature,O,O
monocyte,O,O
/,O,O
macrophage,O,O
-,O,O
like,O,O
cells,O,O
by,O,O
treatment,O,O
with,O,O
protein,B,B
kinase,I,I
C,I,I
-,O,I
activating,O,I
phorbol,O,B
esters,O,I
",",O,O
such,O,O
as,O,O
PMA,O,O
.,O,O
Lymphoid,O,B
cells,O,I
transformed,O,O
by,O,O
Abelson,O,O
murine,O,O
leukemia,O,O
virus,O,O
have,O,O
provided,O,O
one,O,O
of,O,O
the,O,O
classic,O,O
models,O,O
for,O,O
study,O,O
of,O,O
early,O,O
B,O,B
-,O,I
cell,O,I
development,O,I
and,O,O
immunoglobulin,B,O
rearrangement,O,O
.,O,O
To,O,O
test,O,O
this,O,O
hypothesis,O,O
",",O,O
light,B,O
-,I,O
chain,I,O
gene,I,O
structure,I,O
was,O,O
examined,O,O
in,O,O
pre,O,B
-,O,I
B,O,I
cells,O,I
transformed,O,O
by,O,O
temperature,O,O
-,O,O
sensitive,O,O
mutants,O,O
of,O,O
the,O,O
Abelson,O,O
virus,O,O
and,O,O
in,O,O
derivatives,O,O
that,O,O
survive,O,O
at,O,O
the,O,O
nonpermissive,O,O
temperature,O,O
because,O,O
they,O,O
express,O,O
a,O,O
human,B,B
BCL,I,I
-,I,I
2,I,I
gene,I,I
.,O,O
Our,O,O
studies,O,O
reveal,O,O
that,O,O
inactivation,O,O
of,O,O
the,O,O
v,B,O
-,I,O
abl,I,B
protein,I,I
tyrosine,I,I
kinase,I,I
triggers,O,O
high,O,O
-,O,O
frequency,O,O
rearrangement,O,O
of,O,O
kappa,B,B
and,I,O
lambda,I,B
light,I,I
-,I,I
chain,I,I
genes,I,O
.,O,O
Expression,O,O
and,O,O
genomic,O,O
configuration,O,O
of,O,O
GM,B,O
-,I,O
CSF,I,O
",",O,O
IL,B,O
-,I,O
3,I,O
",",O,O
M,B,O
-,I,O
CSF,I,O
receptor,I,O
(,O,O
C,B,O
-,I,O
FMS,I,O
),O,O
",",O,O
early,B,O
growth,I,O
response,I,O
gene,I,O
-,I,O
1,I,O
(,O,O
EGR,B,O
-,I,O
1,I,O
),O,O
and,O,O
M,B,O
-,I,O
CSF,I,O
genes,I,O
in,O,O
primary,O,O
myelodysplastic,O,O
syndromes,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
the,O,O
M,B,B
-,I,I
CSF,I,I
gene,I,O
",",O,O
that,O,O
has,O,O
been,O,O
recently,O,O
reassigned,O,O
to,O,O
the,O,O
short,B,O
arm,I,O
of,I,O
chromosome,I,O
1,I,O
(,O,O
lp,B,O
),O,O
",",O,O
was,O,O
also,O,O
investigated,O,O
.,O,O
Similar,O,O
analysis,O,O
of,O,O
poly,B,O
(,I,O
A,I,O
),I,O
RNA,I,B
from,O,O
a,O,O
variety,O,O
of,O,O
adult,O,O
tissues,O,O
demonstrated,O,O
HB9,B,O
transcripts,O,O
in,O,O
pancreas,O,O
",",O,O
small,O,O
intestine,O,O
",",O,O
and,O,O
colon,O,O
.,O,O
The,O,O
observed,O,O
increase,O,O
in,O,O
IL,B,B
-,I,I
2,I,I
levels,O,O
might,O,O
facilitate,O,O
virus,O,O
spread,O,O
from,O,O
or,O,O
to,O,O
T,O,O
cells,O,O
.,O,O
Recent,O,O
reports,O,O
demonstrated,O,O
that,O,O
ionizing,O,O
radiation,O,O
in,O,O
the,O,O
dose,O,O
range,O,O
of,O,O
2,O,O
-,O,O
50,O,O
Gy,O,O
results,O,O
in,O,O
expression,O,O
of,O,O
NF,B,B
-,I,O
kappa,I,O
B,I,O
in,O,O
human,O,O
KG,O,B
-,O,O
1,O,O
myeloid,O,O
leukemia,O,O
cells,O,O
and,O,O
human,O,O
B,O,O
-,O,O
lymphocyte,O,O
precursor,O,O
cells,O,O
;,O,O
the,O,O
precise,O,O
mechanism,O,O
involved,O,O
and,O,O
the,O,O
significance,O,O
are,O,O
not,O,O
yet,O,O
known,O,O
.,O,O
The,O,O
present,O,O
report,O,O
demonstrates,O,O
that,O,O
even,O,O
lower,O,O
doses,O,O
of,O,O
ionizing,O,O
radiation,O,O
",",O,O
0,O,O
.,O,O
25,O,O
-,O,O
2,O,O
.,O,O
0,O,O
Gy,O,O
",",O,O
are,O,O
capable,O,O
of,O,O
inducing,O,O
expression,O,O
of,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
in,O,O
EBV,O,O
-,O,O
transformed,O,O
244B,O,O
human,O,O
lymphoblastoid,O,O
cells,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
the,O,O
p50,B,B
and,I,O
p65,I,B
NF,I,B
-,I,I
kappa,I,I
B,I,I
subunits,I,O
was,O,O
also,O,O
shown,O,O
to,O,O
be,O,O
regulated,O,O
differentially,O,O
after,O,O
exposures,O,O
to,O,O
1,O,O
.,O,O
0,O,O
and,O,O
2,O,O
.,O,O
0,O,O
Gy,O,O
.,O,O
The,O,O
two,O,O
human,B,O
GATA3,I,O
zinc,I,O
fingers,I,O
are,O,O
encoded,O,O
by,O,O
two,O,O
separate,O,O
exons,B,O
highly,O,O
conserved,O,O
with,O,O
those,O,O
of,O,O
GATA1,B,O
",",O,O
but,O,O
no,O,O
other,O,O
structural,O,O
homologies,O,O
between,O,O
these,O,O
two,O,O
genes,O,O
can,O,O
be,O,O
found,O,O
.,O,O
The,O,O
human,B,O
and,I,O
mouse,I,O
GATA3,I,B
transcription,I,O
units,I,O
start,O,O
at,O,O
a,O,O
major,B,O
initiation,I,O
site,I,O
.,O,O
Retinoic,O,O
acid,O,O
-,O,O
induced,O,O
expression,O,O
of,O,O
CD38,B,B
antigen,I,O
in,O,O
myeloid,O,O
cells,O,O
is,O,O
mediated,O,O
through,O,O
retinoic,B,O
acid,I,O
receptor,I,O
-,I,O
alpha,I,O
.,O,O
CD38,B,B
is,O,O
a,O,O
leukocyte,B,O
differentiation,I,O
antigen,I,O
that,O,O
has,O,O
been,O,O
thought,O,O
to,O,O
be,O,O
a,O,O
phenotypic,O,O
marker,O,O
of,O,O
different,O,O
subpopulations,O,O
of,O,O
T,O,O
-,O,O
and,O,O
B,O,O
-,O,O
lymphocytes,O,O
.,O,O
In,O,O
myeloid,O,B
cells,O,I
",",O,O
CD38,B,B
is,O,O
expressed,O,O
during,O,O
early,O,O
stages,O,O
of,O,O
differentiation,O,O
.,O,O
Some,O,O
antioxidants,O,O
inhibit,O,O
",",O,O
in,O,O
a,O,O
co,O,O
-,O,O
ordinate,O,O
fashion,O,O
",",O,O
the,O,O
production,O,O
of,O,O
tumor,B,B
necrosis,I,I
factor,I,I
-,I,I
alpha,I,I
",",O,O
IL,B,B
-,I,I
beta,I,I
",",O,O
and,O,O
IL,B,B
-,I,I
6,I,I
by,O,O
human,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
.,O,O
Inhibition,O,O
of,O,O
cytokine,B,O
production,O,O
was,O,O
gene,O,O
selective,O,O
and,O,O
not,O,O
due,O,O
to,O,O
general,O,O
effects,O,O
on,O,O
protein,O,B
synthesis,O,I
.,O,O
Much,O,O
higher,O,O
concentrations,O,O
of,O,O
other,O,O
antioxidants,O,O
-,O,O
-,O,O
including,O,O
ascorbic,O,O
acid,O,O
",",O,O
trolox,O,O
",",O,O
alpha,O,B
-,O,I
tocopherol,O,I
",",O,O
butylated,O,O
hydroxytoluene,O,O
",",O,O
and,O,O
the,O,O
5,O,O
-,O,O
lipoxygenase,O,O
inhibitor,O,O
zileuton,O,O
-,O,O
-,O,O
did,O,O
not,O,O
affect,O,O
the,O,O
production,O,O
of,O,O
these,O,O
cytokines,B,O
.,O,O
Thus,O,O
antioxidants,O,O
vary,O,O
widely,O,O
in,O,O
potency,O,O
as,O,O
inhibitors,O,O
of,O,O
the,O,O
activation,O,O
of,O,O
transcription,B,O
factors,I,O
and,O,O
of,O,O
the,O,O
transcription,O,O
of,O,O
genes,B,O
for,O,O
pro,B,O
-,I,O
inflammatory,I,O
cytokines,I,O
.,O,O
This,O,O
protein,O,B
has,O,O
now,O,O
been,O,O
purified,O,O
and,O,O
its,O,O
encoding,O,O
gene,O,O
cloned,O,O
.,O,O
Examination,O,O
of,O,O
the,O,O
primary,O,O
amino,O,O
acid,O,O
sequence,O,O
of,O,O
this,O,O
protein,O,O
indicates,O,O
that,O,O
it,O,O
is,O,O
a,O,O
member,O,O
of,O,O
the,O,O
signal,B,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
(,I,O
Stat,I,O
),I,O
family,I,O
of,O,O
DNA,B,B
binding,I,I
proteins,I,O
",",O,O
hereby,O,O
designated,O,O
IL,B,B
-,I,I
4,I,I
Stat,I,I
.,O,O
Such,O,O
observations,O,O
indicate,O,O
that,O,O
IL,B,B
-,I,I
4,I,I
Stat,I,I
has,O,O
the,O,O
same,O,O
functional,B,O
domain,I,O
for,O,O
both,O,O
receptor,O,O
coupling,O,O
and,O,O
dimerization,O,O
.,O,O
Lung,O,B
disease,O,I
associated,O,O
with,O,O
disorders,O,O
such,O,O
as,O,O
cystic,O,B
fibrosis,O,I
(,O,O
CF,O,O
),O,O
may,O,O
be,O,O
amenable,O,O
to,O,O
somatic,O,O
gene,O,O
therapy,O,O
in,O,O
which,O,O
there,O,O
is,O,O
delivery,O,O
of,O,O
the,O,O
normal,B,O
gene,I,O
directly,O,O
to,O,O
the,O,O
respiratory,O,B
epithelium,O,I
using,O,O
E1a,O,B
-,O,I
adenovirus,O,I
(,O,O
Ad,O,O
),O,O
type,O,O
2,O,O
-,O,O
or,O,O
5,O,O
-,O,O
based,O,O
vectors,O,O
.,O,O
In,O,O
the,O,O
E1a,O,B
-,O,I
positive,O,I
samples,O,O
",",O,O
the,O,O
average,O,O
of,O,O
E1a,O,B
copy,O,I
number,O,I
was,O,O
55,O,O
+,O,O
/,O,O
-,O,O
18,O,O
/,O,O
10,O,O
(,O,O
3,O,O
),O,O
recovered,O,O
cells,O,O
.,O,O
Tumor,O,O
cells,O,O
showed,O,O
an,O,O
overexpression,O,O
of,O,O
p53,B,B
protein,I,I
and,O,O
were,O,O
estrogen,B,B
receptor,I,I
-,O,I
positive,O,I
.,O,O
The,O,O
magnitude,O,O
and,O,O
time,O,O
kinetics,O,O
of,O,O
the,O,O
LIF,B,O
effects,O,O
were,O,O
similar,O,O
to,O,O
interleukin,B,O
1,I,O
(,O,O
IL,B,B
-,I,I
1,I,I
),O,O
",",O,O
IL,B,O
-,I,O
6,I,O
",",O,O
and,O,O
tumor,B,O
necrosis,I,O
factor,I,O
(,O,O
TNF,B,B
),O,O
",",O,O
other,O,O
cytokines,O,O
known,O,O
to,O,O
induce,O,O
HIV,O,O
replication,O,O
in,O,O
this,O,O
cell,O,O
line,O,O
.,O,O
To,O,O
characterize,O,O
mechanisms,O,O
responsible,O,O
for,O,O
these,O,O
LIF,B,O
effects,O,O
",",O,O
levels,O,O
of,O,O
HIV,B,O
mRNA,I,O
",",O,O
activation,O,O
of,O,O
the,O,O
DNA,B,B
binding,I,I
protein,I,I
nuclear,I,I
factor,I,I
(,B,I
NF,I,I
),I,I
-,I,I
kB,I,I
",",O,O
signal,O,O
transduction,O,O
pathways,O,O
",",O,O
and,O,O
potential,O,O
interactions,O,O
with,O,O
other,O,O
cytokines,B,O
were,O,O
analyzed,O,O
.,O,O
In,O,O
both,O,O
cell,O,O
lines,O,O
LIF,B,O
increased,O,O
NF,B,B
-,I,I
kB,I,I
activity,O,O
.,O,O
Induction,O,O
of,O,O
NF,B,B
-,I,I
kB,I,I
and,O,O
HIV,O,O
replication,O,O
by,O,O
cytokines,B,O
are,O,O
at,O,O
least,O,O
in,O,O
part,O,O
dependent,O,O
on,O,O
reactive,O,O
oxygen,O,O
intermediates,O,O
.,O,O
The,O,O
mechanisms,O,O
involved,O,O
in,O,O
the,O,O
inhibition,O,O
of,O,O
growth,O,O
of,O,O
a,O,O
human,O,O
B,O,O
lymphoma,O,O
cell,O,O
line,O,O
",",O,O
B104,O,O
",",O,O
by,O,O
anti,B,O
-,I,O
MHC,I,O
class,I,O
II,I,O
antibodies,I,O
(,O,O
Ab,B,O
),O,O
were,O,O
compared,O,O
with,O,O
those,O,O
in,O,O
anti,B,O
-,I,O
IgM,I,O
Ab,I,O
-,O,O
induced,O,O
B104,O,O
growth,O,O
inhibition,O,O
.,O,O
In,O,O
order,O,O
to,O,O
study,O,O
CD14,B,B
gene,I,I
regulation,O,O
",",O,O
the,O,O
human,B,O
CD14,I,B
gene,I,I
was,O,O
cloned,O,O
from,O,O
a,O,O
partial,O,O
EcoRI,B,O
digested,I,O
chromosome,I,O
5,I,O
library,I,O
.,O,O
Four,O,O
regions,O,O
in,O,O
this,O,O
DNA,B,B
fragment,I,I
interact,O,O
with,O,O
nuclear,B,O
proteins,I,O
isolated,O,O
from,O,O
monocytic,O,B
cells,O,I
.,O,O
The,O,O
Sp1,B,B
transcription,B,I
factor,I,I
bound,O,O
to,O,O
three,O,O
different,O,O
regions,O,O
in,O,O
the,O,O
CD14,B,B
promoter,I,I
.,O,O
Binding,O,O
data,O,O
were,O,O
derived,O,O
from,O,O
Scatchard,O,O
analysis,O,O
.,O,O
In,O,O
fertile,O,O
women,O,O
remarkable,O,O
changes,O,O
in,O,O
androgen,B,B
binding,I,I
sites,I,I
were,O,O
seen,O,O
in,O,O
the,O,O
course,O,O
of,O,O
the,O,O
menstrual,O,O
cycle,O,O
",",O,O
with,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
the,O,O
immediate,O,O
preovulatory,O,O
period,O,O
.,O,O
The,O,O
immunological,O,O
implications,O,O
of,O,O
these,O,O
results,O,O
are,O,O
discussed,O,O
.,O,O
Stimulation,O,O
of,O,O
the,O,O
CD28,B,B
cell,I,I
surface,I,I
molecule,I,I
delivers,O,O
costimulatory,O,O
signals,O,O
essential,O,O
for,O,O
lymphokine,B,O
production,O,O
in,O,O
activated,O,O
T,O,B
cells,O,I
via,O,O
a,O,O
conserved,B,O
sequence,I,O
element,I,O
found,O,O
in,O,O
the,O,O
promoter,B,O
of,O,O
several,O,O
lymphokine,B,O
genes,I,O
.,O,O
Diminished,O,O
glucocorticoid,B,B
receptors,I,I
do,O,O
not,O,O
result,O,O
in,O,O
glucocorticoid,O,O
resistance,O,O
.,O,O
Corticosteroid,B,B
Type,I,I
I,I,I
and,I,O
Type,I,B
II,I,I
receptors,I,I
are,O,O
inversely,O,O
correlated,O,O
with,O,O
age,O,O
.,O,O
All,O,O
-,O,O
trans,O,O
retinoic,O,O
acid,O,O
and,O,O
1,O,O
alpha,O,O
",",O,O
25,O,O
-,O,O
dihydroxyvitamin,O,O
D3,O,O
co,O,O
-,O,O
operate,O,O
to,O,O
promote,O,O
differentiation,O,O
of,O,O
the,O,O
human,O,O
promyeloid,O,B
leukemia,O,I
cell,O,I
line,O,I
HL60,O,I
to,O,O
monocytes,O,O
.,O,O
A,O,O
basis,O,O
for,O,O
differentiation,O,O
therapy,O,O
of,O,O
leukemias,O,O
is,O,O
provided,O,O
by,O,O
knowledge,O,O
of,O,O
agents,O,O
which,O,O
induce,O,O
specific,O,O
lineage,O,O
maturation,O,O
.,O,O
That,O,O
RA,O,B
promotes,O,O
both,O,O
neutrophil,O,B
and,O,O
monocyte,O,B
differentiation,O,O
has,O,O
implications,O,O
for,O,O
the,O,O
use,O,O
of,O,O
RA,O,B
and,O,O
D3,O,B
in,O,O
treatment,O,O
of,O,O
leukemias,O,O
and,O,O
provides,O,O
insight,O,O
into,O,O
mechanisms,O,O
whereby,O,O
RAR,O,B
",",O,O
VDR,B,B
and,O,O
RXR,B,B
facilitate,O,O
monocyte,O,B
differentiation,O,O
.,O,O
Thrombin,B,B
and,O,O
thrombin,B,B
receptor,I,I
agonist,O,I
peptide,O,I
induce,O,O
early,O,O
events,O,O
of,O,O
T,O,B
cell,O,I
activation,O,I
and,O,O
synergize,O,O
with,O,O
TCR,B,B
cross,O,I
-,O,I
linking,O,I
for,O,O
CD69,B,B
expression,O,I
and,O,O
interleukin,O,B
2,O,I
production,O,I
.,O,O
There,O,O
was,O,O
a,O,O
good,O,O
correlation,O,O
between,O,O
thrombin,B,B
-,O,I
induced,O,I
tyrosine,O,I
phosphorylation,O,I
of,O,O
the,O,O
latter,O,O
three,O,O
proteins,O,O
and,O,O
Ca2,O,B
+,O,I
mobilization,O,I
.,O,O
Stress,O,O
response,O,O
of,O,O
senescent,O,O
T,O,O
lymphocytes,O,O
:,O,O
reduced,O,O
hsp70,B,B
is,O,O
independent,O,O
of,O,O
the,O,O
proliferative,O,O
block,O,O
.,O,O
Senescent,O,O
human,O,O
T,O,O
lymphocyte,O,O
cultures,O,O
are,O,O
unable,O,O
to,O,O
undergo,O,O
proliferation,O,O
",",O,O
but,O,O
show,O,O
no,O,O
difference,O,O
from,O,O
early,O,O
passage,O,O
cells,O,O
in,O,O
cytotoxic,O,O
function,O,O
or,O,O
surface,O,O
antigenic,O,O
profile,O,O
.,O,O
Interestingly,O,O
",",O,O
the,O,O
progressive,O,O
decline,O,O
in,O,O
the,O,O
heat,O,O
shock,O,O
response,O,O
of,O,O
cultured,O,O
T,O,O
cells,O,O
correlates,O,O
with,O,O
the,O,O
percent,O,O
proliferative,O,O
life,O,O
span,O,O
completed,O,O
rather,O,O
than,O,O
with,O,O
the,O,O
actual,O,O
proliferative,O,O
activity,O,O
at,O,O
the,O,O
time,O,O
of,O,O
heat,O,O
shock,O,O
.,O,O
Wortmannin,O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
receptor,O,B
-,O,I
coupled,O,I
PLD,B,I
activation,O,O
",",O,O
blocked,O,O
the,O,O
anti,B,O
-,I,O
CD3,I,O
-,O,O
induced,O,O
increases,O,O
in,O,O
both,O,O
PLD,B,B
activity,O,O
and,O,O
AP,B,B
-,I,I
1,I,I
enhancer,I,I
activity,O,O
.,O,O
We,O,O
found,O,O
a,O,O
good,O,O
correlation,O,O
in,O,O
the,O,O
transfected,O,O
cells,O,O
between,O,O
PLD,B,B
activation,O,O
and,O,O
induction,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
enhancer,I,I
activity,O,O
under,O,O
different,O,O
experimental,O,O
conditions,O,O
.,O,O
We,O,O
therefore,O,O
reexamined,O,O
this,O,O
issue,O,O
by,O,O
using,O,O
two,O,O
different,O,O
experimental,O,O
approaches,O,O
that,O,O
allowed,O,O
LMP1,B,B
-,O,O
induced,O,O
effects,O,O
to,O,O
be,O,O
monitored,O,O
immediately,O,O
following,O,O
expression,O,O
of,O,O
the,O,O
viral,O,O
protein,O,O
and,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
selective,O,O
pressures,O,O
;,O,O
activation,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
transcription,B,O
factor,I,O
and,O,O
upregulation,O,O
of,O,O
the,O,O
cell,B,O
adhesion,I,O
molecule,I,O
ICAM,B,B
-,I,I
1,I,I
were,O,O
used,O,O
as,O,O
early,O,O
indices,O,O
of,O,O
LMP1,B,O
function,O,O
.,O,O
In,O,O
the,O,O
second,O,O
approach,O,O
",",O,O
we,O,O
tested,O,O
the,O,O
generality,O,O
of,O,O
this,O,O
phenomenon,O,O
by,O,O
transiently,O,O
expressing,O,O
LMP1,B,B
from,O,O
a,O,O
strong,O,O
constitutively,O,O
active,O,O
promoter,O,O
in,O,O
a,O,O
range,O,O
of,O,O
different,O,O
cell,O,B
types,O,I
.,O,O
In,O,O
the,O,O
same,O,O
experiments,O,O
",",O,O
all,O,O
three,O,O
non,O,B
-,O,I
B,O,I
-,O,I
cell,O,I
lines,O,I
showed,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
activation,O,O
and,O,O
ICAM,B,O
-,I,O
1,I,O
upregulation,O,O
but,O,O
never,O,O
any,O,O
effect,O,O
upon,O,O
Bcl,B,B
-,I,I
2,I,I
.,O,O
We,O,O
found,O,O
that,O,O
tyrosine,B,B
kinase,I,I
activity,O,O
was,O,O
similar,O,O
for,O,O
both,O,O
mAbs,B,O
over,O,O
a,O,O
period,O,O
of,O,O
hours,O,O
.,O,O
However,O,O
",",O,O
the,O,O
inositol,O,B
phosphate,O,I
response,O,O
was,O,O
stronger,O,O
for,O,O
64,B,O
.,I,O
1,I,O
than,O,O
for,O,O
OKT3,B,O
.,O,O
To,O,O
tie,O,O
these,O,O
events,O,O
to,O,O
gene,O,O
activation,O,O
",",O,O
we,O,O
measured,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
NF,B,B
-,I,I
AT,I,I
activity,O,O
in,O,O
the,O,O
nucleus,O,O
after,O,O
anti,B,O
-,I,O
CD3,I,O
stimulation,O,O
.,O,O
Both,O,O
stimuli,O,O
induced,O,O
the,O,O
appearance,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
components,I,I
(,O,O
c,B,O
-,I,O
Rel,I,O
",",O,O
p65,B,O
(,O,O
RelA,B,O
),O,O
",",O,O
and,O,O
p50,B,O
(,O,O
NF,B,O
-,I,O
kappa,I,O
B1,I,O
),O,O
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
DNA,O,I
binding,O,I
activity,O,I
in,O,O
the,O,O
nucleus,O,O
.,O,O
From,O,O
a,O,O
consecutive,O,O
series,O,O
of,O,O
350,O,O
cases,O,O
of,O,O
adult,O,O
de,O,O
novo,O,O
acute,O,O
myeloid,O,O
leukemia,O,O
(,O,O
AML,O,O
),O,O
",",O,O
we,O,O
identified,O,O
20,O,O
cases,O,O
(,O,O
6,O,O
%,O,O
),O,O
with,O,O
a,O,O
unique,O,O
immunophenotype,O,O
:,O,O
CD33,O,O
+,O,O
",",O,O
CD56,O,O
+,O,O
",",O,O
CD11a,O,O
+,O,O
",",O,O
CD13lo,O,O
",",O,O
CD15lo,O,O
",",O,O
CD34,O,O
+,O,O
/,O,O
-,O,O
",",O,O
HLA,B,O
-,I,O
DR,I,O
-,O,O
",",O,O
CD16,B,O
-,O,O
.,O,O
This,O,O
was,O,O
supported,O,O
by,O,O
the,O,O
observation,O,O
that,O,O
the,O,O
down,O,O
-,O,O
regulatory,O,O
capacity,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
appeared,O,O
to,O,O
be,O,O
dependent,O,O
on,O,O
de,O,O
novo,O,O
protein,O,B
synthesis,O,O
.,O,O
Although,O,O
these,O,O
data,O,O
suggest,O,O
AP,B,O
-,I,O
1,I,O
regulated,O,O
cytokine,B,O
mRNA,O,O
expression,O,O
",",O,O
results,O,O
from,O,O
PBMo,O,O
are,O,O
not,O,O
in,O,O
accordance,O,O
with,O,O
this,O,O
notion,O,O
.,O,O
These,O,O
differences,O,O
may,O,O
represent,O,O
different,O,O
regulatory,O,O
pathways,O,O
of,O,O
the,O,O
two,O,O
cell,O,O
systems,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
present,O,O
results,O,O
demonstrate,O,O
clearly,O,O
that,O,O
mycoplasma,B,O
products,I,O
can,O,O
have,O,O
a,O,O
profound,O,O
impact,O,O
on,O,O
the,O,O
activation,O,O
status,O,O
of,O,O
eukaryotic,O,O
cells,O,O
.,O,O
Novel,B,O
membrane,I,O
receptors,I,O
for,O,O
aldosterone,O,B
in,O,O
human,O,B
lymphocytes,O,I
:,O,O
a,O,O
50,B,O
kDa,I,O
protein,I,O
on,O,O
SDS,O,O
-,O,O
PAGE,O,O
.,O,O
The,O,O
novel,O,O
aldosterone,O,B
membrane,O,O
receptor,O,O
was,O,O
analyzed,O,O
on,O,O
SDS,O,O
-,O,O
PAGE,O,O
after,O,O
labeling,O,O
of,O,O
microsomal,O,O
membranes,O,O
from,O,O
human,O,B
mononuclear,O,I
leukocytes,O,I
with,O,O
a,O,O
[,O,O
125I,O,O
],O,O
-,O,O
derivative,O,O
by,O,O
use,O,O
of,O,O
BASED,O,O
as,O,O
a,O,O
photoactivatable,O,O
crosslinker,O,O
.,O,O
Binding,O,O
of,O,O
1,O,O
nM,O,O
[,O,O
125I,O,B
],O,I
-,O,I
aldosterone,O,I
was,O,O
found,O,O
at,O,O
a,O,O
molecular,O,O
weight,O,O
of,O,O
approximately,O,O
50,O,O
kDa,O,O
which,O,O
was,O,O
absent,O,O
with,O,O
1,O,O
microM,O,O
cold,O,O
aldosterone,O,O
",",O,O
but,O,O
not,O,O
cortisol,O,O
in,O,O
the,O,O
binding,O,O
media,O,O
.,O,O
It,O,O
",",O,O
thus,O,O
",",O,O
appears,O,O
as,O,O
an,O,O
integral,B,O
membrane,I,O
protein,I,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
chromatin,O,O
organization,O,O
of,O,O
the,O,O
integrated,O,O
human,B,B
immunodeficiency,I,I
virus,I,I
type,I,I
1,I,I
(,I,I
HIV,I,I
-,I,I
1,I,I
),I,I
genome,I,O
has,O,O
previously,O,O
revealed,O,O
a,O,O
major,B,O
constitutive,I,O
DNase,I,B
I,I,I
-,I,I
hypersensitive,I,I
site,I,I
associated,O,O
with,O,O
the,O,O
pol,B,O
gene,I,O
(,O,O
E,O,O
.,O,O
Verdin,O,O
",",O,O
J,O,O
.,O,O
Virol,O,O
.,O,O
65,O,O
:,O,O
6790,O,O
-,O,O
6799,O,O
",",O,O
1991,O,O
.,O,O
Site,B,O
D,I,O
(,O,O
nt,B,O
4816,I,O
to,I,O
4851,I,O
),O,O
specifically,O,O
bound,O,O
a,O,O
ubiquitously,B,O
expressed,I,O
factor,I,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
a,O,O
rapidly,O,O
inducible,O,O
transcriptional,B,O
activator,I,O
that,O,O
responds,O,O
to,O,O
a,O,O
variety,O,O
of,O,O
signals,O,O
and,O,O
influences,O,O
the,O,O
expression,O,O
of,O,O
many,O,O
genes,O,O
involved,O,O
in,O,O
the,O,O
immune,O,O
response,O,O
.,O,O
Human,O,B
herpesvirus,O,I
6,O,I
(,O,O
HHV,O,B
-,O,I
6,O,I
),O,O
is,O,O
a,O,O
lymphotropic,O,O
herpesvirus,O,O
",",O,O
and,O,O
in,O,O
vitro,O,O
",",O,O
it,O,O
can,O,O
productively,O,O
infect,O,O
human,O,O
CD4,O,B
+,O,I
T,O,I
cells,O,I
as,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
Sequence,O,O
analyses,O,O
show,O,O
that,O,O
this,O,O
protein,O,O
has,O,O
significant,O,O
homology,O,O
with,O,O
the,O,O
human,B,O
cytomegalovirus,I,B
UL44,I,I
gene,I,I
coding,O,O
for,O,O
the,O,O
ICP36,B,B
family,I,I
of,O,I
early,B,I
-,I,I
late,I,I
-,I,I
class,I,I
phosphoprotein,I,I
.,O,O
Sequence,O,O
analyses,O,O
of,O,O
pCD41,B,O
indicate,O,O
that,O,O
there,O,O
are,O,O
two,O,O
potential,O,O
open,B,O
reading,I,O
frames,I,O
(,O,O
ORFs,B,O
),O,O
",",O,O
A,B,O
and,O,O
B,B,O
",",O,O
which,O,O
are,O,O
homologous,O,O
to,O,O
the,O,O
ORFs,B,O
found,O,O
in,O,O
the,O,O
genomic,O,O
clone,O,O
pGD41,B,O
.,O,O
CD14,B,O
-,O,O
mediated,O,O
translocation,O,O
of,O,O
nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
induced,O,O
by,O,O
lipopolysaccharide,O,O
does,O,O
not,O,O
require,O,O
tyrosine,B,O
kinase,I,O
activity,O,O
.,O,O
Nuclear,O,O
translocation,O,O
of,O,O
cytosolic,O,O
NF,O,B
-,O,I
kappa,O,I
B,O,I
is,O,O
correlated,O,O
with,O,O
a,O,O
number,O,O
of,O,O
LPS,O,O
-,O,O
inducible,O,O
responses,O,O
.,O,O
LPS,O,B
-,O,O
stimulated,O,O
translocation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
CHO,O,O
/,O,O
CD14,O,O
cells,O,O
resembled,O,O
the,O,O
same,O,O
response,O,O
in,O,O
the,O,O
murine,O,O
macrophage,O,O
-,O,O
like,O,O
cell,O,O
line,O,O
RAW,O,O
264,O,O
.,O,O
7,O,O
.,O,O
The,O,O
stimulatory,O,O
effects,O,O
of,O,O
gp160,O,O
are,O,O
mediated,O,O
through,O,O
the,O,O
CD4,B,O
molecule,I,O
",",O,O
since,O,O
pretreatment,O,O
with,O,O
soluble,O,O
CD4,B,O
abrogates,O,O
its,O,O
activity,O,O
.,O,O
The,O,O
stimulatory,O,O
effect,O,O
of,O,O
gp160,O,B
on,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
is,O,O
protein,O,O
synthesis,O,O
independent,O,O
",",O,O
is,O,O
dependent,O,O
upon,O,O
protein,O,O
tyrosine,O,O
phosphorylation,O,O
",",O,O
and,O,O
abrogated,O,O
by,O,O
inhibitors,O,O
of,O,O
protein,B,O
kinase,I,O
C,I,O
.,O,O
No,O,O
evidence,O,O
for,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
progesterone,B,O
receptor,I,O
on,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
during,O,O
pregnancy,O,O
[,O,O
see,O,O
comments,O,O
],O,O
A,O,O
role,O,O
for,O,O
the,O,O
progesterone,B,O
receptor,I,O
in,O,O
the,O,O
mechanism,O,O
of,O,O
the,O,O
known,O,O
effect,O,O
of,O,O
progesterone,O,O
on,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
is,O,O
also,O,O
excluded,O,O
.,O,O
In,O,O
nuclear,O,B
run,O,I
-,O,I
on,O,I
analysis,O,O
",",O,O
such,O,O
tolerant,O,O
cells,O,O
show,O,O
only,O,O
a,O,O
low,O,O
degree,O,O
of,O,O
transcription,O,O
",",O,O
indicating,O,O
that,O,O
tolerance,O,O
operates,O,O
at,O,O
or,O,O
upstream,O,O
of,O,O
the,O,O
transcription,O,O
level,O,O
.,O,O
The,O,O
CD14,B,B
LPS,O,I
receptor,O,I
is,O,O
",",O,O
however,O,O
",",O,O
up,O,O
-,O,O
regulated,O,O
(,O,O
not,O,O
down,O,O
-,O,O
regulated,O,O
),O,O
in,O,O
tolerant,O,O
cells,O,O
",",O,O
and,O,O
LPS,O,B
can,O,O
",",O,O
in,O,O
fact,O,O
",",O,O
still,O,O
lead,O,O
to,O,O
activation,O,O
of,O,O
tolerant,O,O
cells,O,O
as,O,O
evidenced,O,O
by,O,O
mobilization,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
nuclear,B,B
factor,I,I
kappa,I,I
B,I,I
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
.,O,O
Resolution,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
complex,I,O
in,O,O
gel,O,O
shift,O,O
analysis,O,O
shows,O,O
that,O,O
the,O,O
binding,B,O
protein,I,O
",",O,O
mobilized,O,O
in,O,O
naive,O,O
Mono,O,B
Mac,O,I
6,O,I
cells,O,O
",",O,O
consists,O,O
mainly,O,O
of,O,O
p50,B,B
-,I,I
p65,I,I
heterodimers,I,O
",",O,O
while,O,O
in,O,O
tolerant,O,O
cells,O,O
",",O,O
the,O,O
p50,B,B
homodimer,I,I
is,O,O
predominant,O,O
.,O,O
This,O,O
increase,O,O
in,O,O
p50,B,B
homodimers,I,I
coincides,O,O
with,O,O
an,O,O
increase,O,O
in,O,O
p105,B,B
mRNA,I,I
",",O,O
suggestive,O,O
of,O,O
a,O,O
transcriptional,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
p50,B,B
.,O,O
Analysis,O,O
of,O,O
Oct2,B,B
-,I,I
isoform,I,I
expression,O,O
in,O,O
lipopolysaccharide,O,O
-,O,O
stimulated,O,O
B,O,O
lymphocytes,O,O
.,O,O
Oct2,B,B
-,I,I
isoform,I,I
expression,O,O
in,O,O
splenic,O,O
B,O,O
cells,O,O
stimulated,O,O
with,O,O
lipopolysaccharide,O,O
or,O,O
lipopolysaccharide,O,O
plus,O,O
phorbol,O,O
-,O,O
di,O,O
-,O,O
butyrate,O,O
was,O,O
analysed,O,O
by,O,O
cDNA,O,O
cloning,O,O
.,O,O
A,O,O
new,O,O
exon,B,O
containing,O,O
a,O,O
highly,O,O
basic,O,O
region,O,O
(,O,O
4c,O,O
),O,O
was,O,O
characterized,O,O
",",O,O
between,B,O
exons,I,O
4,I,O
and,I,O
5,I,O
.,O,O
In,O,O
addition,O,O
",",O,O
a,O,O
new,O,O
combination,O,O
isoform,O,O
containing,O,O
Oct2a,B,B
s,I,O
amino,I,O
terminal,I,O
insert,I,O
(,O,O
exon,B,O
7a,I,O
),O,O
and,O,O
Oct2b,B,B
s,I,O
carboxy,I,O
terminal,I,O
insert,I,O
(,O,O
exon,B,O
13,I,O
),O,O
was,O,O
found,O,O
that,O,O
created,O,O
a,O,O
novel,O,O
large,O,O
isoform,O,O
",",O,O
Oct2ab,B,B
.,O,O
Positive,O,O
regulators,O,O
of,O,O
the,O,O
lineage,O,O
-,O,O
specific,O,O
transcription,B,O
factor,I,O
GATA,B,B
-,I,I
1,I,I
in,O,O
differentiating,O,O
erythroid,O,B
cells,O,O
.,O,O
Analyses,O,O
with,O,O
cultured,O,O
cells,O,O
and,O,O
cell,O,O
-,O,O
free,O,O
systems,O,O
have,O,O
provided,O,O
strong,O,O
evidence,O,O
that,O,O
GATA,B,B
-,I,I
1,I,I
is,O,O
involved,O,O
in,O,O
control,O,O
of,O,O
globin,B,B
gene,I,I
expression,O,O
during,O,O
erythroid,O,B
differentiation,O,O
.,O,O
The,O,O
role,O,O
of,O,O
the,O,O
human,B,O
immunodeficiency,I,O
virus,I,O
(,I,O
HIV,I,B
-,I,I
1,I,I
),I,O
Nef,I,B
protein,I,O
in,O,O
T,O,O
cell,O,O
activation,O,O
pathways,O,O
was,O,O
investigated,O,O
using,O,O
a,O,O
Jurkat,O,B
CD4,O,I
+,O,I
cell,O,I
line,O,I
stably,O,O
transfected,O,O
with,O,O
a,O,O
Nef,O,B
expression,O,O
vector,O,O
.,O,O
The,O,O
response,O,O
of,O,O
mammalian,O,B
cells,O,I
to,O,O
stress,O,O
is,O,O
controlled,O,O
by,O,O
transcriptional,B,O
regulatory,I,O
proteins,I,O
such,O,O
as,O,O
nuclear,B,B
factor,I,I
kappa,I,I
B,I,I
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
to,O,O
induce,O,O
a,O,O
wide,O,O
variety,O,O
of,O,O
early,B,O
response,I,O
genes,I,O
.,O,O
In,O,O
comparison,O,O
to,O,O
other,O,O
activators,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
such,O,O
as,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
or,O,O
tumor,B,O
necrosis,I,O
factor,I,O
",",O,O
we,O,O
did,O,O
not,O,O
detect,O,O
changes,O,O
in,O,O
the,O,O
tyrosine,O,O
phosphorylation,O,O
status,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
following,O,O
treatment,O,O
with,O,O
either,O,O
of,O,O
these,O,O
agents,O,O
.,O,O
Molecular,O,O
",",O,O
biochemical,O,O
and,O,O
epidemiological,O,O
evidence,O,O
implicate,O,O
HTLV,O,B
-,O,I
I,O,I
as,O,O
an,O,O
etiologic,O,O
agent,O,O
of,O,O
adult,O,O
T,O,B
cell,O,I
leukemia,O,I
(,O,O
ATL,O,O
),O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
NFKB2,B,B
precursor,O,I
is,O,O
physically,O,O
associated,O,O
with,O,O
c,B,O
-,I,O
Rel,I,O
and,O,O
with,O,O
Tax,B,O
in,O,O
HTLV,O,B
-,O,I
I,O,I
infected,O,O
cells,O,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
effects,O,O
of,O,O
RA,O,O
on,O,O
normal,O,O
hematopoiesis,O,O
by,O,O
using,O,O
early,O,O
hematopoietic,O,O
progenitor,O,O
cells,O,O
(,O,O
HPC,O,O
),O,O
stringently,O,O
purified,O,O
from,O,O
adult,O,O
peripheral,O,O
blood,O,O
.,O,O
This,O,O
phenomenon,O,O
is,O,O
correlated,O,O
with,O,O
inhibition,O,O
of,O,O
GATA1,B,B
induction,O,O
in,O,O
the,O,O
early,O,O
stages,O,O
of,O,O
erythropoietic,O,O
differentiation,O,O
.,O,O
We,O,O
have,O,O
previously,O,O
shown,O,O
that,O,O
a,O,O
human,O,O
B,O,B
lymphoma,O,I
cell,O,I
line,O,I
",",O,O
B104,O,O
",",O,O
expressed,O,O
surface,B,O
IgM,I,B
(,O,O
sIgM,B,O
),O,O
and,O,O
surface,B,O
IgD,I,B
(,O,O
sIgD,B,O
),O,O
",",O,O
and,O,O
that,O,O
crosslinking,O,O
of,O,O
sIgM,B,O
and,O,O
sIgD,B,O
by,O,O
anti,B,O
-,I,O
IgM,I,O
antibody,I,O
(,I,O
Ab,I,O
),I,O
and,O,O
anti,B,O
-,I,O
IgD,I,O
Ab,I,O
",",O,O
respectively,O,O
",",O,O
induced,O,O
Ca2,O,O
+,O,O
influx,O,O
to,O,O
almost,O,O
the,O,O
same,O,O
degree,O,O
",",O,O
whereas,O,O
only,O,O
sIgM,B,O
-,O,O
crosslinking,O,O
caused,O,O
B104,O,O
cell,O,O
death,O,O
.,O,O
Phorbol,O,B
myristate,O,I
acetate,O,I
induced,O,O
Egr,B,B
-,I,I
1,I,I
mRNA,I,I
expression,O,O
but,O,O
forskolin,O,O
and,O,O
dibutyryl,O,O
cyclic,O,O
AMP,O,O
did,O,O
not,O,O
.,O,O
Treatment,O,O
of,O,O
human,O,O
erythrocytes,O,O
with,O,O
10,O,O
microM,O,O
sodium,O,O
orthovanadate,O,O
(,O,O
NaOV,O,O
),O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
plasma,B,O
membrane,I,O
Ca,I,B
-,I,I
ATPase,I,I
and,O,O
phosphotyrosine,B,O
phosphatase,I,O
",",O,O
decreased,O,O
parasitemia,O,O
by,O,O
30,O,O
%,O,O
.,O,O
Because,O,O
erythrocytes,O,O
are,O,O
anucleated,O,O
",",O,O
these,O,O
results,O,O
are,O,O
discussed,O,O
as,O,O
evidence,O,O
for,O,O
biochemical,O,O
changes,O,O
by,O,O
TCDD,O,O
without,O,O
requiring,O,O
the,O,O
activation,O,O
of,O,O
gene,B,O
products,I,O
.,O,O
Irrespective,O,O
of,O,O
the,O,O
human,O,B
cell,O,I
partner,O,I
used,O,O
for,O,O
fusion,O,O
",",O,O
a,O,O
certain,O,O
number,O,O
of,O,O
hybrids,O,O
lost,O,O
CD5,B,B
surface,O,I
expression,O,I
over,O,O
a,O,O
period,O,O
of,O,O
time,O,O
in,O,O
culture,O,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
indicate,O,O
that,O,O
MS,B,B
-,I,I
2beta,I,I
and,O,O
MS,B,B
-,I,I
2gamma,I,I
interact,O,O
with,O,O
nuclear,B,O
factors,I,O
that,O,O
are,O,O
induced,O,O
during,O,O
U937,O,B
differentiation,O,I
.,O,O
These,O,O
factors,O,O
are,O,O
detected,O,O
at,O,O
the,O,O
time,O,O
CD11b,B,B
promoter,I,O
is,O,O
activated,O,O
.,O,O
The,O,O
presence,O,O
of,O,O
multiple,O,O
potential,O,O
binding,O,O
sites,O,O
for,O,O
MS,B,O
-,I,O
2,I,O
in,O,O
the,O,O
promoter,O,O
regions,O,O
of,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
genes,O,O
expressed,O,O
in,O,O
mature,O,O
myeloid,O,B
cells,O,O
suggests,O,O
this,O,O
factor,O,O
plays,O,O
a,O,O
general,O,O
role,O,O
in,O,O
myeloid,O,B
differentiation,O,O
.,O,O
Acetylsalicylic,O,O
acid,O,O
and,O,O
sodium,O,O
salicylate,O,O
inhibit,O,O
LPS,O,O
-,O,O
induced,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
c,I,I
-,I,I
Rel,I,I
nuclear,O,I
translocation,O,I
",",O,O
and,O,O
synthesis,O,O
of,O,O
tissue,B,O
factor,I,O
(,O,O
TF,B,O
),O,O
and,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alfa,I,O
(,O,O
TNF,B,O
-,I,O
alpha,I,O
),O,O
in,O,O
human,O,B
monocytes,O,O
.,O,O
Interferon,O,B
augments,O,O
PML,B,B
and,O,O
PML,B,B
/,I,I
RAR,I,I
alpha,I,I
expression,O,O
in,O,O
normal,O,O
myeloid,O,O
and,O,O
acute,O,O
promyelocytic,O,O
cells,O,O
and,O,O
cooperates,O,O
with,O,O
all,O,O
-,O,O
trans,O,O
retinoic,O,O
acid,O,O
to,O,O
induce,O,O
maturation,O,O
of,O,O
a,O,O
retinoid,O,O
-,O,O
resistant,O,O
promyelocytic,O,O
cell,O,O
line,O,O
.,O,O
PML,B,B
is,O,O
expressed,O,O
in,O,O
diverse,O,O
tissues,O,O
and,O,O
cell,O,O
lines,O,O
and,O,O
localized,O,O
in,O,O
the,O,O
nucleus,O,O
with,O,O
a,O,O
typical,O,O
speckled,O,O
pattern,O,O
.,O,O
Neutral,B,O
sphingomyelinase,I,B
(,O,O
SMase,B,O
),O,O
can,O,O
be,O,O
activated,O,O
by,O,O
extracellular,O,O
signals,O,O
to,O,O
produce,O,O
ceramide,O,O
",",O,O
which,O,O
may,O,O
affect,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,B
kinase,I,I
(,O,I
MAPK,B,I
),O,O
activities,O,O
.,O,O
PMA,O,O
acted,O,O
synergistically,O,O
with,O,O
ionomycin,O,O
to,O,O
activate,O,O
JNK,B,B
MAPKs,I,I
in,O,O
Jurkat,O,O
and,O,O
EL4,O,O
within,O,O
10,O,O
minutes,O,O
.,O,O
Ara,O,O
-,O,O
C,O,O
activated,O,O
JNKs,B,B
only,O,O
after,O,O
prolonged,O,O
incubation,O,O
(,O,O
90,O,O
-,O,O
120,O,O
minutes,O,O
),O,O
.,O,O
The,O,O
transmembrane,O,O
domains,O,O
are,O,O
well,O,O
conserved,O,O
",",O,O
but,O,O
there,O,O
is,O,O
striking,O,O
sequence,O,O
divergence,O,O
of,O,O
the,O,O
carboxy,B,O
-,I,O
terminal,I,O
cytoplasmic,I,O
domain,I,O
essential,O,O
for,O,O
B,O,B
-,O,I
cell,O,I
immortalization,O,I
and,O,O
interaction,O,O
with,O,O
the,O,O
tumor,B,O
necrosis,I,O
factor,I,O
receptor,I,O
signaling,O,O
pathway,O,O
.,O,O
Distinct,O,O
patterns,O,O
of,O,O
chromosome,B,O
1,I,O
abnormalities,O,O
were,O,O
found,O,O
among,O,O
the,O,O
histologic,O,O
types,O,O
of,O,O
breast,O,O
carcinoma,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
the,O,O
utility,O,O
of,O,O
this,O,O
FISH,O,O
technique,O,O
for,O,O
a,O,O
better,O,O
definition,O,O
of,O,O
the,O,O
biological,O,O
characteristics,O,O
of,O,O
ductal,O,O
carcinomas,O,O
.,O,O
Increased,O,O
proliferation,O,O
",",O,O
cytotoxicity,O,O
",",O,O
and,O,O
gene,O,O
expression,O,O
after,O,O
stimulation,O,O
of,O,O
human,O,O
peripheral,O,O
blood,O,O
T,O,O
lymphocytes,O,O
through,O,O
a,O,O
surface,O,O
ganglioside,O,O
(,O,O
GD3,O,O
),O,O
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
J,O,O
Immunol,O,O
1994,O,O
Jul,O,O
15,O,O
;,O,O
153,O,O
(,O,O
2,O,O
),O,O
:,O,O
910,O,O
],O,O
However,O,O
",",O,O
their,O,O
specific,O,O
function,O,O
in,O,O
these,O,O
processes,O,O
has,O,O
not,O,O
been,O,O
clearly,O,O
defined,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
have,O,O
investigated,O,O
the,O,O
mechanisms,O,O
by,O,O
which,O,O
the,O,O
R24,B,O
mAb,I,O
affects,O,O
T,O,O
cell,O,O
functions,O,O
.,O,O
We,O,O
have,O,O
observed,O,O
that,O,O
the,O,O
R24,B,O
mAb,I,O
stimulates,O,O
GD3,O,O
+,O,O
T,O,O
cell,O,O
proliferation,O,O
",",O,O
cytotoxicity,O,O
",",O,O
and,O,O
surface,O,O
marker,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
-,I,I
chain,I,I
",",O,O
IL,B,B
-,I,I
2R,I,I
beta,I,I
-,I,I
chain,I,I
",",O,O
HLA,B,B
-,I,I
DR,I,I
",",O,O
CD11a,B,B
",",O,O
and,O,O
CD11c,B,B
.,O,O
R24,B,O
-,O,O
stimulated,O,O
increases,O,O
in,O,O
proliferation,O,O
",",O,O
cytotoxicity,O,O
",",O,O
and,O,O
cell,O,O
surface,O,O
protein,O,O
expression,O,O
could,O,O
be,O,O
blocked,O,O
by,O,O
cyclosporin,O,O
and,O,O
staurosporin,O,O
",",O,O
indicating,O,O
that,O,O
cyclophilin,B,O
/,I,O
calcineurin,I,O
and,O,O
protein,B,O
kinase,I,O
C,I,O
may,O,O
be,O,O
involved,O,O
in,O,O
the,O,O
R24,B,O
signaling,O,O
pathway,O,O
.,O,O
Additionally,O,O
",",O,O
herbimycin,O,O
A,O,O
",",O,O
a,O,O
tyrosine,B,B
kinase,I,I
inhibitor,O,O
",",O,O
blocked,O,O
the,O,O
R24,B,O
-,O,O
stimulated,O,O
increase,O,O
in,O,O
proliferation,O,O
but,O,O
not,O,O
cytotoxicity,O,O
at,O,O
concentrations,O,O
consistent,O,O
with,O,O
specificity,O,O
for,O,O
tyrosine,B,B
kinases,I,I
.,O,O
Using,O,O
fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
(,O,O
FISH,O,O
),O,O
",",O,O
we,O,O
show,O,O
here,O,O
that,O,O
the,O,O
genes,B,O
encoding,O,O
the,O,O
TATA,B,B
-,I,I
box,I,I
binding,I,I
protein,I,I
(,O,O
TBP,B,O
),O,O
",",O,O
TFIIB,B,O
",",O,O
TFIIE,B,O
alpha,I,O
",",O,O
TFIIE,B,O
beta,I,O
",",O,O
RAP30,B,O
",",O,O
RAP74,B,O
and,O,O
the,O,O
62,B,O
kDa,I,O
subunit,I,O
",",O,O
of,O,O
TFIIH,B,O
are,O,O
located,O,O
at,O,O
the,O,O
human,B,O
chromosomal,I,O
bands,I,O
6q26,I,O
-,I,O
27,I,O
",",I,O
1p21,I,O
-,I,O
22,I,O
",",I,O
3q21,I,O
-,I,O
24,I,O
",",I,O
8p12,I,O
",",I,O
13q14,I,O
",",I,O
19p13,I,O
.,I,O
3,I,O
and,I,O
11p14,I,O
-,I,O
15,I,O
.,I,O
1,I,O
",",O,O
respectively,O,O
.,O,O
Although,O,O
no,O,O
proof,O,O
yet,O,O
exists,O,O
of,O,O
a,O,O
role,O,O
for,O,O
these,O,O
lesions,O,O
in,O,O
DLCL,O,O
pathogenesis,O,O
",",O,O
the,O,O
feature,O,O
of,O,O
the,O,O
BCL,B,B
-,I,I
6,I,I
gene,I,I
product,I,I
",",O,O
its,O,O
specific,O,O
pattern,O,O
of,O,O
expression,O,O
in,O,O
B,O,B
cells,O,I
",",O,O
and,O,O
the,O,O
clustering,O,O
of,O,O
lesions,O,O
disrupting,O,O
its,O,O
regulatory,O,O
domain,O,O
strongly,O,O
suggest,O,O
that,O,O
deregulation,O,O
of,O,O
BCL,B,B
-,I,I
6,I,I
expression,O,O
may,O,O
contribute,O,O
to,O,O
DLCL,O,O
development,O,O
.,O,O
DLCL,O,O
represent,O,O
a,O,O
heterogeneous,O,O
group,O,O
of,O,O
neoplasms,O,O
which,O,O
are,O,O
treated,O,O
homogeneously,O,O
despite,O,O
the,O,O
fact,O,O
that,O,O
only,O,O
50,O,O
%,O,O
of,O,O
patients,O,O
experience,O,O
long,O,O
-,O,O
term,O,O
disease,O,O
-,O,O
free,O,O
survival,O,O
(,O,O
Schneider,O,O
et,O,O
al,O,O
.,O,O
1990,O,O
),O,O
.,O,O
It,O,O
is,O,O
thus,O,O
generally,O,O
believed,O,O
that,O,O
the,O,O
pancreatic,O,B
endocrine,O,I
-,O,I
lineage,O,I
possesses,O,O
the,O,O
ability,O,O
to,O,O
mature,O,O
along,O,O
a,O,O
differentiation,O,O
pathway,O,O
that,O,O
shares,O,O
many,O,O
characteristics,O,O
with,O,O
those,O,O
of,O,O
neuronal,O,B
differentiation,O,I
.,O,O
Octamer,O,B
independent,O,I
activation,O,I
of,O,I
transcription,O,I
from,O,I
the,O,I
kappa,B,I
immunoglobulin,I,I
germline,I,I
promoter,I,I
.,O,O
To,O,O
further,O,O
elucidate,O,O
the,O,O
role,O,O
of,O,O
this,O,O
variant,O,O
octamer,B,B
motif,I,I
in,O,O
the,O,O
regulation,O,O
of,O,O
germline,B,O
transcription,O,O
from,O,O
the,O,O
unrearranged,O,O
kappa,B,O
locus,I,O
",",O,O
we,O,O
have,O,O
quantitated,O,O
the,O,O
relative,O,O
binding,O,O
affinity,O,O
of,O,O
Oct,B,B
-,I,I
1,I,I
and,O,O
Oct,B,B
-,I,I
2,I,I
for,O,O
the,O,O
variant,O,O
octamer,B,B
motif,I,I
and,O,O
determined,O,O
the,O,O
functional,O,O
role,O,O
of,O,O
this,O,O
octamer,B,B
motif,I,I
in,O,O
transcriptional,O,O
activation,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
we,O,O
showed,O,O
that,O,O
CD14,O,B
+,O,I
adherent,O,O
human,O,O
monocytes,O,O
can,O,O
differentiate,O,O
into,O,O
CD1,O,B
+,O,I
relB,O,B
+,O,I
dendritic,O,O
cells,O,O
(,O,O
DC,O,O
),O,O
by,O,O
the,O,O
combination,O,O
of,O,O
GM,B,O
-,I,O
CSF,I,O
plus,O,O
interleukin,B,O
-,I,O
4,I,O
(,O,O
IL,B,B
-,I,I
4,I,I
),O,O
and,O,O
that,O,O
they,O,O
differentiate,O,O
into,O,O
tartrate,O,B
-,O,I
resistant,O,I
acid,O,I
phosphatase,O,I
(,O,I
TRAP,O,I
),O,O
-,O,O
positive,O,O
osteoclast,O,O
-,O,O
like,O,O
multinucleated,O,O
giant,O,O
cells,O,O
(,O,O
MGC,O,O
),O,O
by,O,O
the,O,O
combination,O,O
of,O,O
M,B,O
-,I,O
CSF,I,O
plus,O,O
IL,B,B
-,I,I
4,I,I
.,O,O
The,O,O
mechanism,O,O
of,O,O
inhibition,O,O
is,O,O
related,O,O
to,O,O
the,O,O
surface,O,O
expression,O,O
of,O,O
several,O,O
cell,O,O
adhesion,B,O
molecules,I,O
.,O,O
Flow,O,O
cytometry,O,O
analyses,O,O
on,O,O
cultured,O,O
cells,O,O
that,O,O
were,O,O
treated,O,O
with,O,O
tepoxalin,O,O
or,O,O
antisense,O,O
oligonucleotides,O,O
to,O,O
the,O,O
P65,B,B
/,I,I
p50,I,I
subunit,I,I
of,O,I
NF,B,I
-,I,I
kappa,I,I
B,I,I
",",O,O
and,O,O
then,O,O
stimulated,O,O
with,O,O
PMA,O,O
",",O,O
revealed,O,O
a,O,O
reduced,O,O
expression,O,O
of,O,O
CD11b,B,B
/,I,I
CD18,I,I
on,O,O
monocytic,O,O
HL60,O,O
cells,O,O
",",O,O
and,O,O
endothelial,B,B
adhesion,I,I
molecule,I,I
-,I,I
1,I,I
(,O,I
CD62E,B,I
),O,I
and,O,O
vascular,B,B
adhesion,I,I
molecule,I,I
-,I,I
1,I,I
(,O,I
CD106,B,I
),O,I
on,O,O
human,O,O
umbilical,O,O
vein,O,O
endothelial,O,O
cells,O,O
.,O,O
Tepoxalin,O,O
also,O,O
inhibited,O,O
the,O,O
secretion,O,O
of,O,O
a,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
regulated,I,O
chemokine,I,O
",",O,O
IL,B,B
-,I,I
8,I,I
",",O,O
a,O,O
known,O,O
inducer,O,O
of,O,O
CD11b,B,O
/,I,O
CD18,I,O
expression,O,O
.,O,O
Thus,O,O
the,O,O
suppression,O,O
of,O,O
CD11b,B,O
/,I,O
CD18,I,O
expression,O,O
by,O,O
tepoxalin,O,O
may,O,O
involve,O,O
IL,B,O
-,I,O
8,I,O
.,O,O
Characterization,O,O
of,O,O
a,O,O
CD43,B,O
/,I,O
leukosialin,I,O
-,O,O
mediated,O,O
pathway,O,O
for,O,O
inducing,O,O
apoptosis,O,O
in,O,O
human,O,O
T,O,O
-,O,O
lymphoblastoid,O,O
cells,O,O
.,O,O
The,O,O
monoclonal,B,O
antibody,I,O
(,O,O
mAb,B,O
),O,O
J393,B,O
induces,O,O
apoptosis,O,O
in,O,O
Jurkat,O,O
T,O,O
-,O,O
cells,O,O
.,O,O
NH2,B,O
-,O,O
terminal,O,O
amino,O,O
acid,O,O
sequence,O,O
analysis,O,O
identified,O,O
the,O,O
140,B,O
-,I,O
kDa,I,O
surface,I,O
antigen,I,O
for,O,O
mAb,B,O
J393,I,O
as,O,O
CD43,B,B
/,I,O
leukosialin,I,O
",",O,O
the,O,O
major,O,O
sialoglycoprotein,B,O
of,O,O
leukocytes,O,O
.,O,O
While,O,O
Jurkat,O,O
cells,O,O
co,O,O
-,O,O
expressed,O,O
two,O,O
discrete,O,O
cell,B,O
-,I,O
surface,I,O
isoforms,I,O
of,O,O
CD43,B,B
",",O,O
recognized,O,O
by,O,O
mAb,B,O
J393,I,O
and,O,O
mAb,B,O
G10,I,O
-,I,O
2,I,O
",",O,O
respectively,O,O
",",O,O
only,O,O
J393,B,O
/,I,O
CD43,I,B
signaled,O,O
apoptosis,O,O
.,O,O
Tyrosine,B,B
kinase,I,I
inhibition,O,O
by,O,O
herbimycin,O,O
A,O,O
diminished,O,O
J393,B,O
/,I,O
CD43,I,O
-,O,O
mediated,O,O
apoptosis,O,O
",",O,O
whereas,O,O
inhibition,O,O
of,O,O
phosphotyrosine,B,B
phosphatase,I,I
activity,O,I
by,O,O
bis,O,O
(,O,O
maltolato,O,O
),O,O
oxovanadium,O,O
-,O,O
IV,O,O
enhanced,O,O
cell,O,O
death,O,O
.,O,O
Consequently,O,O
",",O,O
the,O,O
present,O,O
study,O,O
was,O,O
addressed,O,O
to,O,O
understand,O,O
this,O,O
phenomenon,O,O
and,O,O
revealed,O,O
the,O,O
existence,O,O
of,O,O
a,O,O
unique,B,O
47,I,O
kDa,I,O
protein,I,B
factor,I,I
having,O,O
affinity,O,O
for,O,O
this,O,O
SRE,B,O
sequence,I,O
in,O,O
lymphocytes,O,O
from,O,O
normal,O,O
subjects,O,O
as,O,O
well,O,O
as,O,O
its,O,O
absence,O,O
in,O,O
lymphocytes,O,O
from,O,O
untreated,O,O
CML,O,O
patients,O,O
.,O,O
To,O,O
understand,O,O
the,O,O
mechanism,O,O
by,O,O
which,O,O
PRL,B,B
regulates,O,O
the,O,O
biphasic,O,O
expression,O,O
of,O,O
IRF,B,B
-,I,I
1,I,I
",",O,O
we,O,O
cloned,O,O
the,O,O
rat,B,O
IRF,I,B
-,I,I
1,I,I
gene,I,O
and,O,O
functionally,O,O
characterized,O,O
the,O,O
IRF,B,B
-,I,I
1,I,I
promoter,I,O
.,O,O
Hence,O,O
",",O,O
the,O,O
PRL,B,B
-,O,O
induced,O,O
biphasic,O,O
expression,O,O
of,O,O
the,O,O
IRF,B,B
-,I,I
1,I,I
gene,I,O
appears,O,O
to,O,O
be,O,O
controlled,O,O
by,O,O
separate,O,O
PRL,B,B
-,I,O
responsive,I,O
elements,I,O
:,O,O
elements,O,O
in,O,O
the,O,O
first,O,O
0,O,O
.,O,O
2,O,O
kb,O,O
of,O,O
the,O,O
IRF,B,B
-,I,I
1,I,I
promoter,I,I
region,I,I
act,O,O
during,O,O
early,O,O
activation,O,O
",",O,O
and,O,O
elements,O,O
between,O,O
0,O,O
.,O,O
2,O,O
and,O,O
1,O,O
.,O,O
7,O,O
kb,O,O
act,O,O
in,O,O
concert,O,O
with,O,O
the,O,O
proximal,O,O
0,O,O
.,O,O
2,O,O
-,O,O
kb,O,O
region,O,O
during,O,O
S,O,B
phase,O,I
progression,O,I
.,O,O
The,O,O
SCL,B,B
protein,I,I
displays,O,O
cell,O,O
-,O,O
specific,O,O
heterogeneity,O,O
in,O,O
size,O,O
.,O,O
In,O,O
most,O,O
cell,O,O
lines,O,O
",",O,O
proteins,O,O
of,O,O
molecular,O,O
weight,O,O
49,O,B
and,O,O
44,O,B
kDa,O,I
were,O,O
found,O,O
",",O,O
however,O,O
two,O,O
myeloid,O,B
cell,O,I
lines,O,I
expressed,O,O
only,O,O
lower,O,O
molecular,B,O
weight,I,O
species,I,O
of,I,O
24,I,B
and,I,O
22,I,B
kDa,I,I
.,O,O
The,O,O
restricted,O,O
pattern,O,O
of,O,O
SCL,B,B
protein,I,O
synthesis,O,O
is,O,O
consistent,O,O
with,O,O
the,O,O
restricted,O,O
expression,O,O
of,O,O
SCL,B,B
mRNA,I,O
documented,O,O
previously,O,O
.,O,O
This,O,O
effect,O,O
required,O,O
surface,O,O
expression,O,O
of,O,O
the,O,O
CD45,B,B
PTPase,I,I
and,O,O
was,O,O
not,O,O
observed,O,O
in,O,O
CD45,O,B
-,O,I
deficient,O,I
variants,O,I
of,O,O
Jurkat,O,B
cells,O,O
.,O,O
Pervanadate,B,O
activated,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
",",O,O
as,O,O
shown,O,O
by,O,O
an,O,O
increase,O,O
in,O,O
DNA,O,B
-,O,I
binding,O,I
activity,O,I
of,O,O
this,O,O
transcription,B,O
factor,I,O
.,O,O
Signals,O,O
transduced,O,O
via,O,O
the,O,O
TCR,B,B
activate,O,O
the,O,O
transcription,B,O
factor,I,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,B
(,O,O
NF,B,B
-,I,I
kappaB,I,I
),O,O
",",O,O
which,O,O
",",O,O
in,O,O
turn,O,O
",",O,O
is,O,O
critical,O,O
to,O,O
the,O,O
transcriptional,O,O
induction,O,O
of,O,O
many,O,O
genes,O,O
important,O,O
for,O,O
the,O,O
proliferation,O,O
and,O,O
expression,O,O
of,O,O
a,O,O
differentiated,O,O
phenotype,O,O
.,O,O
Here,O,O
we,O,O
identify,O,O
intracellular,O,O
signaling,O,O
components,O,O
involved,O,O
in,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
following,O,O
TCR,B,B
stimulation,O,O
.,O,O
We,O,O
have,O,O
shown,O,O
elsewhere,O,O
that,O,O
both,O,O
the,O,O
major,B,O
immediate,I,O
-,I,O
early,I,O
gene,I,O
(,O,O
MIE,B,O
),O,O
and,O,O
lytic,O,O
cycle,O,O
infectious,O,O
progeny,O,O
virus,O,O
expression,O,O
can,O,O
be,O,O
induced,O,O
in,O,O
otherwise,O,O
nonpermissive,O,O
monocyte,O,O
-,O,O
like,O,O
U,O,O
-,O,O
937,O,O
cell,O,O
cultures,O,O
infected,O,O
with,O,O
either,O,O
human,O,O
CMV,O,O
(,O,O
HCMV,O,O
),O,O
or,O,O
simian,O,O
CMV,O,O
(,O,O
SCMV,O,O
),O,O
by,O,O
treatment,O,O
with,O,O
the,O,O
phorbol,O,O
ester,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
TPA,O,O
),O,O
.,O,O
Therefore,O,O
",",O,O
to,O,O
evaluate,O,O
the,O,O
mechanism,O,O
of,O,O
TPA,O,O
responsiveness,O,O
of,O,O
the,O,O
SNE,B,B
motifs,I,O
and,O,O
of,O,O
a,O,O
related,O,O
16,O,O
-,O,O
bp,O,O
SEE,B,B
(,O,O
SRF,B,O
/,I,O
ETS,I,O
element,I,O
),O,O
motif,O,O
found,O,O
in,O,O
the,O,O
HCMV,B,O
and,I,O
chimpanzee,I,O
CMV,I,O
MIE,I,O
enhancers,I,O
",",O,O
we,O,O
have,O,O
examined,O,O
the,O,O
functional,O,O
responses,O,O
and,O,O
protein,O,B
binding,O,O
properties,O,O
of,O,O
multimerized,B,O
wild,I,O
-,I,O
type,I,O
and,I,O
mutant,I,O
elements,I,O
added,O,O
upstream,O,O
to,O,O
the,O,O
SCMV,B,O
MIE,I,O
or,O,O
simian,B,O
virus,I,O
40,I,O
minimal,I,O
promoter,I,O
regions,I,O
in,O,O
the,O,O
U,O,O
-,O,O
937,O,O
",",O,O
K,O,O
-,O,O
562,O,O
",",O,O
HL,O,O
-,O,O
60,O,O
",",O,O
THP,O,O
-,O,O
1,O,O
",",O,O
and,O,O
Jurkat,O,O
cell,O,O
lines,O,O
.,O,O
T,O,B
-,O,I
cell,O,I
-,O,I
directed,O,O
TAL,B,O
-,I,O
1,I,O
expression,O,O
induces,O,O
T,O,B
-,O,I
cell,O,I
malignancies,O,O
in,O,O
transgenic,O,O
mice,O,O
.,O,O
The,O,O
survival,O,O
rate,O,O
of,O,O
tal,B,O
-,I,O
1,I,O
transgenic,O,O
animals,O,O
was,O,O
much,O,O
lower,O,O
as,O,O
compared,O,O
with,O,O
control,O,O
mice,O,O
.,O,O
To,O,O
further,O,O
unravel,O,O
the,O,O
tal,B,O
-,I,O
1,I,O
oncogenic,O,O
potential,O,O
",",O,O
a,O,O
strain,O,O
of,O,O
tal,B,O
-,I,O
1,I,O
transgenic,O,O
mice,O,O
was,O,O
crossbred,O,O
with,O,O
p53,O,B
-,O,I
/,O,I
-,O,I
mice,O,I
;,O,O
the,O,O
survival,O,O
rate,O,O
in,O,O
these,O,O
animals,O,O
was,O,O
reduced,O,O
by,O,O
more,O,O
than,O,O
one,O,O
-,O,O
half,O,O
when,O,O
compared,O,O
with,O,O
that,O,O
of,O,O
tal,B,O
-,I,O
1,I,O
mice,O,O
",",O,O
and,O,O
histopathological,O,O
analysis,O,O
revealed,O,O
exclusively,O,O
T,O,B
-,O,I
cell,O,I
lymphomas,O,O
.,O,O
TSC2,B,B
is,O,O
a,O,O
gene,O,O
on,O,O
chromosome,B,O
16p13,I,O
.,I,O
3,I,O
associated,O,O
with,O,O
the,O,O
autosomal,O,O
dominant,O,O
neurocutaneous,O,O
disorder,O,O
",",O,O
tuberous,O,O
sclerosis,O,O
complex,O,O
(,O,O
TSC,O,O
),O,O
.,O,O
TSC2,B,O
messenger,I,O
RNA,I,O
was,O,O
widely,O,O
expressed,O,O
in,O,O
various,O,O
cell,O,O
types,O,O
throughout,O,O
the,O,O
body,O,O
",",O,O
including,O,O
epithelia,O,B
",",O,O
lymphocytes,O,B
",",O,O
and,O,O
cells,O,O
with,O,O
endocrine,O,B
functions,O,O
",",O,O
e,O,O
.,O,O
g,O,O
.,O,O
",",O,O
adrenal,O,B
cortex,O,I
and,O,O
anterior,O,B
pituitary,O,I
.,O,O
Fas,B,B
-,O,I
mediated,O,I
apoptosis,O,I
plays,O,O
an,O,O
important,O,O
role,O,O
in,O,O
regulating,O,O
the,O,O
immune,O,O
response,O,O
in,O,O
peripheral,O,O
T,O,O
cells,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
interleukin,O,B
-,O,I
1beta,O,I
-,O,I
converting,O,I
enzyme,O,I
family,O,I
protease,O,I
inhibitors,O,I
Ac,O,O
-,O,O
DEVD,O,O
-,O,O
CHO,O,O
and,O,O
CrmA,O,O
blocked,O,O
Fas,B,B
-,O,I
mediated,O,I
apoptosis,O,I
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
peripheral,O,O
T,O,O
cells,O,O
use,O,O
distinct,O,O
apoptosis,O,O
signaling,O,O
pathways,O,O
with,O,O
differential,O,O
sensitivity,O,O
to,O,O
Bcl,B,B
-,I,I
2,I,I
and,O,O
interleukin,O,B
-,O,I
1beta,O,I
-,O,I
converting,O,I
enzyme,O,I
family,O,I
protease,O,I
inhibitors,O,I
.,O,O
However,O,O
",",O,O
in,O,O
contrast,O,O
to,O,O
human,O,B
lymphocytes,O,I
",",O,O
IFN,B,B
-,I,I
gamma,I,I
production,O,O
was,O,O
inhibited,O,O
and,O,O
IFN,B,B
-,I,I
gamma,I,I
mRNA,I,O
levels,O,O
were,O,O
unaffected,O,O
at,O,O
24,O,O
h,O,O
and,O,O
only,O,O
slightly,O,O
upregulated,O,O
at,O,O
48,O,O
and,O,O
72,O,O
h,O,O
of,O,O
culture,O,O
in,O,O
murine,O,B
splenocytes,O,I
incubated,O,O
with,O,O
cipro,O,O
(,O,O
20,O,O
micrograms,O,O
/,O,O
ml,O,O
),O,O
.,O,O
Cipro,O,O
did,O,O
not,O,O
affect,O,O
the,O,O
nuclear,B,O
transcription,I,O
factors,I,O
AP,B,O
-,I,O
1,I,O
or,O,O
NFIL,B,O
-,I,O
2A,I,O
.,O,O
An,O,O
additional,O,O
distinguishing,O,O
characteristic,O,O
of,O,O
HTLV,O,B
-,O,I
I,O,I
infection,O,O
is,O,O
the,O,O
profound,O,O
state,O,O
of,O,O
viral,O,O
latency,O,O
that,O,O
is,O,O
present,O,O
in,O,O
circulating,O,O
primary,O,O
leukemic,O,O
T,O,O
cells,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
physical,O,O
interaction,O,O
of,O,O
Tax,B,B
with,O,O
p100,B,B
leads,O,O
to,O,O
the,O,O
inhibition,O,O
of,O,O
Tax,B,B
-,O,O
induced,O,O
activation,O,O
of,O,O
the,O,O
HTLV,O,B
-,O,I
I,O,I
and,O,O
human,B,O
immunodeficiency,I,O
virus,I,O
type,I,O
1,I,O
long,I,O
terminal,I,O
repeats,I,O
",",O,O
reflecting,O,O
p100,B,B
-,O,O
mediated,O,O
cytoplasmic,O,O
sequestration,O,O
of,O,O
the,O,O
normally,O,O
nuclearly,O,O
expressed,O,O
Tax,B,B
protein,I,O
.,O,O
Selection,O,O
against,O,O
such,O,O
mutations,O,O
may,O,O
be,O,O
the,O,O
result,O,O
of,O,O
functional,O,O
redundancy,O,O
of,O,O
these,O,O
myogenic,B,O
transcription,I,O
factors,I,O
.,O,O
In,O,O
vertebrates,O,O
",",O,O
five,O,O
distinct,O,O
DNA,B,B
binding,I,I
subunits,I,I
are,O,O
currently,O,O
known,O,O
which,O,O
might,O,O
extensively,O,O
heterodimerize,O,O
",",O,O
thereby,O,O
forming,O,O
complexes,O,O
with,O,O
distinct,O,O
transcriptional,O,O
activity,O,O
",",O,O
DNA,O,B
sequence,O,I
specificity,O,I
",",O,O
and,O,O
cell,O,B
type,O,I
-,O,I
and,O,I
cell,O,I
stage,O,I
-,O,I
specific,O,I
distribution,O,I
.,O,O
Other,O,O
I,B,O
kappa,I,B
B,I,I
proteins,I,O
are,O,O
rather,O,O
involved,O,O
in,O,O
terminating,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
s,O,O
activity,O,O
in,O,O
the,O,O
nucleus,O,O
.,O,O
The,O,O
intracellular,O,O
events,O,O
that,O,O
lead,O,O
to,O,O
the,O,O
inactivation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
",",O,O
i,O,O
.,O,O
e,O,O
.,O,O
the,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
are,O,O
complex,O,O
.,O,O
In,O,O
previous,O,O
studies,O,O
",",O,O
it,O,O
was,O,O
shown,O,O
that,O,O
the,O,O
fusion,O,O
region,O,O
of,O,O
the,O,O
pml,B,O
/,I,O
RAR,I,O
-,I,O
alpha,I,O
protein,I,O
",",O,O
expressed,O,O
by,O,O
acute,O,O
promyelocytic,O,O
leukemia,O,O
(,O,O
APL,O,O
),O,O
cells,O,O
",",O,O
can,O,O
be,O,O
specifically,O,O
recognized,O,O
in,O,O
vitro,O,O
by,O,O
donor,O,O
(,O,O
D,O,O
.,O,O
E,O,O
.,O,O
CD4,O,B
T,O,I
cells,O,I
in,O,O
a,O,O
HLA,B,B
class,I,I
II,I,I
DR11,O,I
-,O,I
restricted,O,I
fashion,O,O
.,O,O
We,O,O
present,O,O
here,O,O
the,O,O
results,O,O
on,O,O
the,O,O
recognition,O,O
of,O,O
several,O,O
pml,O,O
/,O,O
RAR,O,O
-,O,O
alpha,O,O
peptides,O,O
by,O,O
APL,O,O
patients,O,O
expressing,O,O
HLA,B,B
DR11,I,I
.,O,O
These,O,O
clones,O,O
were,O,O
tested,O,O
for,O,O
their,O,O
recognition,O,O
of,O,O
BCR1,O,O
/,O,O
25,O,O
.,O,O
APL,O,O
blasts,O,O
",",O,O
available,O,O
only,O,O
from,O,O
patients,O,O
F,O,O
.,O,O
R,O,O
.,O,O
and,O,O
P,O,O
.,O,O
G,O,O
",",O,O
were,O,O
not,O,O
lysed,O,O
by,O,O
C3,O,O
/,O,O
5,O,O
and,O,O
were,O,O
unable,O,O
to,O,O
present,O,O
peptide,O,O
BCR1,O,O
/,O,O
25,O,O
.,O,O
No,O,O
peptide,O,O
-,O,O
specific,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
or,O,O
clone,O,O
could,O,O
be,O,O
generated,O,O
from,O,O
both,O,O
donors,O,O
and,O,O
patients,O,O
.,O,O
Interferon,B,B
-,I,I
gamma,I,I
(,O,O
IFN,B,B
-,I,I
gamma,I,I
),O,O
is,O,O
produced,O,O
by,O,O
natural,O,B
killer,O,I
cells,O,O
and,O,O
certain,O,O
subsets,O,O
of,O,O
T,O,O
cells,O,O
",",O,O
but,O,O
the,O,O
basis,O,O
for,O,O
its,O,O
selective,O,O
expression,O,O
is,O,O
unknown,O,O
.,O,O
The,O,O
proximal,O,O
element,O,O
is,O,O
a,O,O
composite,O,O
site,O,O
that,O,O
binds,O,O
members,O,O
of,O,O
the,O,O
CREB,B,B
/,I,I
ATF,I,I
",",O,O
AP,B,B
-,I,I
1,I,I
",",O,O
and,O,O
octamer,B,B
families,I,I
of,O,I
transcription,B,I
factors,I,I
.,O,O
S107,O,O
plasmacytoma,O,O
cells,O,O
",",O,O
which,O,O
express,O,O
CD40,B,B
but,O,O
are,O,O
defective,O,O
for,O,O
the,O,O
nuclear,O,O
appearance,O,O
of,O,O
p50,B,B
/,I,I
p65,I,I
-,I,I
NF,I,I
-,I,I
kappaB,I,I
",",O,O
do,O,O
not,O,O
express,O,O
RelB,B,B
after,O,O
CD40,B,B
stimulation,O,O
.,O,O
The,O,O
nuclear,O,O
body,O,O
(,O,O
NB,O,O
),O,O
is,O,O
a,O,O
cellular,O,O
organelle,O,O
that,O,O
is,O,O
involved,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
acute,O,O
promyelocytic,O,O
leukemia,O,O
and,O,O
viral,O,O
infection,O,O
.,O,O
The,O,O
predicted,O,O
amino,O,B
acid,O,I
sequence,O,I
of,O,I
the,O,I
amino,B,I
-,I,I
terminal,I,I
portion,I,I
of,O,I
Sp140,B,O
was,O,O
similar,O,O
to,O,O
Sp100,B,O
",",O,O
a,O,O
previously,O,O
identified,O,O
NB,B,O
protein,I,O
.,O,O
B,O,B
lymphocyte,O,I
stimulation,O,O
via,O,O
both,O,O
CD40,B,O
and,O,O
surface,B,O
Ig,I,B
(,I,I
sIg,I,I
),I,I
receptors,I,O
substantially,O,O
induced,O,O
fra,B,O
-,I,O
1,I,O
expression,O,O
",",O,O
and,O,O
for,O,O
both,O,O
receptors,O,O
",",O,O
induction,O,O
was,O,O
protein,B,B
kinase,I,I
C,I,I
(,O,I
PKC,B,I
),O,I
dependent,O,O
.,O,O
Induction,O,O
of,O,O
fra,B,B
-,I,I
1,I,I
following,O,O
engagement,O,O
of,O,O
CD40,B,O
did,O,O
not,O,O
require,O,O
protein,O,O
synthesis,O,O
",",O,O
suggesting,O,O
that,O,O
the,O,O
PKC,B,O
-,O,O
dependent,O,O
linkage,O,O
between,O,O
CD40,B,O
and,O,O
fra,B,O
-,I,O
1,I,O
is,O,O
direct,O,O
.,O,O
Pentoxifylline,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
infection,O,O
with,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
.,O,O
Cytokine,O,O
dysregulation,O,O
in,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
(,O,O
HIV,O,B
-,O,I
1,O,I
),O,O
infection,O,O
has,O,O
been,O,O
documented,O,O
in,O,O
numerous,O,O
studies,O,O
and,O,O
has,O,O
been,O,O
cited,O,O
as,O,O
an,O,O
important,O,O
component,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
this,O,O
retroviral,O,O
infection,O,O
.,O,O
Pentoxifylline,O,O
",",O,O
a,O,O
trisubstituted,O,O
xanthine,O,O
derivative,O,O
",",O,O
has,O,O
been,O,O
used,O,O
to,O,O
decrease,O,O
blood,O,O
viscosity,O,O
and,O,O
is,O,O
reasonably,O,O
well,O,O
tolerated,O,O
by,O,O
most,O,O
recipients,O,O
of,O,O
the,O,O
drug,O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
The,O,O
other,O,O
two,O,O
SR,O,O
patients,O,O
had,O,O
an,O,O
abnormally,O,O
low,O,O
GR,B,O
number,O,O
with,O,O
normal,O,O
binding,O,O
affinity,O,O
that,O,O
was,O,O
not,O,O
limited,O,O
to,O,O
T,O,O
cells,O,O
.,O,O
This,O,O
may,O,O
be,O,O
due,O,O
to,O,O
the,O,O
low,O,O
prevalence,O,O
of,O,O
overexpressed,O,O
ER,B,B
and,O,O
the,O,O
small,O,O
number,O,O
of,O,O
controls,O,O
.,O,O
A,O,O
large,O,O
prospective,O,O
trial,O,O
is,O,O
needed,O,O
to,O,O
determine,O,O
if,O,O
one,O,O
or,O,O
more,O,O
of,O,O
these,O,O
biomarkers,O,O
",",O,O
is,O,O
predictive,O,O
of,O,O
breast,O,B
cancer,O,I
development,O,O
.,O,O
Inhibition,O,O
of,O,O
RANTES,B,B
expression,O,O
did,O,O
not,O,O
appear,O,O
to,O,O
be,O,O
secondary,O,O
to,O,O
IL,B,B
-,I,I
2,I,I
inhibition,O,O
and,O,O
required,O,O
binding,O,O
to,O,O
the,O,O
intracellular,O,O
glucocorticoid,B,B
receptor,I,I
.,O,O
Association,O,O
of,O,O
TRAF1,B,B
",",O,O
TRAF2,B,B
",",O,O
and,O,O
TRAF3,B,B
with,O,O
an,O,O
Epstein,B,O
-,I,O
Barr,I,O
virus,I,O
LMP1,I,O
domain,I,O
important,O,O
for,O,O
B,O,O
-,O,O
lymphocyte,O,O
transformation,O,O
:,O,O
role,O,O
in,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
.,O,O
The,O,O
Epstein,B,O
-,I,O
Barr,I,O
virus,I,O
(,I,O
EBV,I,O
),I,O
transforming,I,O
protein,I,O
LMP1,I,O
appears,O,O
to,O,O
be,O,O
a,O,O
constitutively,B,O
activated,I,O
tumor,I,O
necrosis,I,O
factor,I,O
receptor,I,O
(,O,O
TNFR,B,O
),O,O
on,O,O
the,O,O
basis,O,O
of,O,O
an,O,O
intrinsic,O,O
ability,O,O
to,O,O
aggregate,O,O
in,O,O
the,O,O
plasma,O,O
membrane,O,O
and,O,O
an,O,O
association,O,O
of,O,O
its,O,O
cytoplasmic,B,O
carboxyl,I,O
terminus,I,O
(,O,O
CT,B,O
),O,O
with,O,O
TNFR,B,O
-,I,O
associated,I,O
factors,I,O
(,O,O
TRAFs,B,O
),O,O
.,O,O
TRAF1,B,B
",",O,O
TRAF2,B,B
",",O,O
and,O,O
TRAF3,B,B
bind,O,O
to,O,O
a,O,O
single,O,O
site,O,O
in,O,O
the,O,O
LMP1,B,O
CT,I,O
corresponding,O,O
to,O,O
amino,O,O
acids,O,O
(,O,O
aa,O,O
),O,O
199,O,O
to,O,O
214,O,O
",",O,O
within,O,O
a,O,O
domain,O,O
which,O,O
is,O,O
important,O,O
for,O,O
B,O,B
-,O,I
lymphocyte,O,I
growth,O,I
transformation,O,I
(,O,O
aa,O,O
to,O,O
231,O,O
.,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
by,O,O
LMP1,B,O
(,O,O
1,O,O
-,O,O
231,O,O
),O,O
is,O,O
likely,O,O
to,O,O
be,O,O
mediated,O,O
by,O,O
TRAF1,B,B
/,B,O
TRAF2,I,B
heteroaggregates,O,O
since,O,O
TRAF1,B,B
is,O,O
unique,O,O
among,O,O
the,O,O
TRAFs,B,O
in,O,O
coactivating,O,O
NF,B,O
-,I,O
kappaB,I,O
with,O,O
LMP1,B,O
(,O,O
1,O,O
-,O,O
231,O,O
),O,O
",",O,O
a,O,O
TRAF2,B,B
dominant,O,O
-,O,O
negative,O,O
mutant,O,O
can,O,O
block,O,O
LMP1,B,O
(,O,O
1,O,O
-,O,O
231,O,O
),O,O
-,O,O
mediated,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
as,O,O
well,O,O
as,O,O
TRAF1,B,B
coactivation,O,O
",",O,O
and,O,O
30,O,O
%,O,O
of,O,O
TRAF2,B,B
is,O,O
associated,O,O
with,O,O
TRAF1,B,B
in,O,O
EBV,O,O
-,O,O
transformed,O,O
B,O,O
cells,O,O
.,O,O
The,O,O
gene,O,O
encoding,O,O
the,O,O
Epstein,B,B
-,I,I
Barr,I,I
virus,I,I
(,I,O
EBV,I,O
),I,O
-,I,O
specific,I,O
dUTPase,I,B
was,O,O
amplified,O,O
from,O,O
virus,B,O
DNA,I,B
by,O,O
PCR,O,O
.,O,O
Preliminary,O,O
experiments,O,O
yielded,O,O
a,O,O
Km,O,O
value,O,O
of,O,O
about,O,O
0,O,O
.,O,O
8,O,O
microM,O,O
for,O,O
dUTP,O,B
.,O,O
This,O,O
indicated,O,O
that,O,O
the,O,O
dUTPase,O,O
is,O,O
expressed,O,O
during,O,O
EBV,O,O
replication,O,O
and,O,O
reactivation,O,O
.,O,O
Two,O,O
pp56,B,O
(,I,O
lck,I,O
),I,O
mutants,I,O
lacking,O,O
either,O,O
the,O,O
entire,O,O
catalytic,B,O
domain,I,O
or,O,O
the,O,O
entire,O,O
NH2,B,O
regulatory,B,O
domain,I,O
were,O,O
generated,O,O
",",O,O
and,O,O
their,O,O
abilities,O,O
to,O,O
trigger,O,O
transactivation,O,O
of,O,O
the,O,O
TCR,B,O
-,I,O
regulated,I,O
nuclear,I,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
(,I,O
NF,I,O
-,I,O
AT,I,O
),I,O
region,I,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
were,O,O
compared,O,O
.,O,O
The,O,O
results,O,O
showed,O,O
that,O,O
the,O,O
average,O,O
number,O,O
of,O,O
GCR,B,B
in,O,O
asthmatics,O,O
was,O,O
significantly,O,O
lower,O,O
than,O,O
that,O,O
in,O,O
healthy,O,O
subjects,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
and,O,O
there,O,O
was,O,O
a,O,O
linear,O,O
correlation,O,O
between,O,O
the,O,O
number,O,O
of,O,O
GCR,B,B
and,O,O
the,O,O
course,O,O
of,O,O
asthma,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
there,O,O
is,O,O
no,O,O
primary,O,O
and,O,O
general,O,O
impairment,O,O
of,O,O
glucocorticoid,O,B
metabolism,O,O
in,O,O
the,O,O
asthmatics,O,O
",",O,O
but,O,O
the,O,O
number,O,O
of,O,O
GCR,B,B
in,O,O
the,O,O
asthmatics,O,O
is,O,O
lower,O,O
than,O,O
that,O,O
in,O,O
healthy,O,O
controls,O,O
.,O,O
Subsequently,O,O
binding,O,O
sites,O,O
have,O,O
been,O,O
demonstrated,O,O
in,O,O
the,O,O
plasma,O,O
membrane,O,O
of,O,O
human,O,O
lymphocytes,O,O
which,O,O
show,O,O
pharmacological,O,O
(,O,O
aldosterone,O,B
specificity,O,O
),O,O
and,O,O
kinetic,O,O
(,O,O
high,O,O
turnover,O,O
),O,O
properties,O,O
identical,O,O
with,O,O
those,O,O
of,O,O
the,O,O
rapid,O,O
aldosterone,O,O
effects,O,O
in,O,O
the,O,O
same,O,O
cells,O,O
.,O,O
The,O,O
macrophage,B,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,I,O
M,I,O
-,I,O
CSF,I,O
),I,O
receptor,I,O
is,O,O
expressed,O,O
in,O,O
a,O,O
tissue,O,O
-,O,O
specific,O,O
fashion,O,O
from,O,O
two,O,O
distinct,O,O
promoters,B,O
in,O,O
monocytes,O,O
/,O,O
macrophages,O,O
and,O,O
the,O,O
placenta,O,O
.,O,O
CONCLUSION,O,O
.,O,O
The,O,O
number,O,O
of,O,O
GCR,B,O
may,O,O
be,O,O
improved,O,O
by,O,O
inhalation,O,O
of,O,O
oxygen,O,O
.,O,O
Signaling,O,O
via,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IL,B,B
-,I,I
4,I,I
in,O,O
JAK3,O,O
-,O,O
deficient,O,O
severe,O,O
combined,O,O
immunodeficiency,O,O
lymphocytes,O,O
:,O,O
JAK3,B,O
-,O,O
dependent,O,O
and,O,O
independent,O,O
pathways,O,O
.,O,O
However,O,O
",",O,O
IL,B,B
-,I,I
4,I,I
-,O,O
induced,O,O
effects,O,O
were,O,O
clearly,O,O
improved,O,O
following,O,O
JAK3,B,O
expression,O,O
.,O,O
Interleukin,B,O
2,I,B
(,O,O
IL,B,B
-,I,I
2,I,I
),O,O
stimulates,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
.,O,O
We,O,O
identified,O,O
an,O,O
86,O,O
-,O,O
nucleotide,O,O
fragment,O,O
that,O,O
is,O,O
90,O,O
%,O,O
identical,O,O
to,O,O
the,O,O
recently,O,O
characterized,O,O
murine,B,O
IL,I,B
-,I,I
2,I,I
-,I,I
responsive,I,I
element,I,I
(,O,O
mIL,B,O
-,I,O
2rE,I,O
),O,O
.,O,O
Tumor,B,O
necrosis,I,O
factor,I,O
receptor,I,O
-,I,O
1,I,O
(,O,O
TNFR,B,O
-,I,O
1,I,O
),O,O
and,O,O
CD95,B,O
(,O,O
also,O,O
called,O,O
Fas,B,O
or,O,O
APO,B,O
-,I,O
1,I,O
),O,O
are,O,O
cytokine,B,O
receptors,I,O
that,O,O
engage,O,O
the,O,O
apoptosis,O,O
pathway,O,O
through,O,O
a,O,O
region,O,O
of,O,O
intracellular,O,O
homology,O,O
",",O,O
designated,O,O
the,O,O
`,O,O
death,B,O
domain,I,O
.,O,O
Another,O,O
death,B,O
domain,I,O
-,I,O
containing,I,O
member,I,O
of,O,O
the,O,O
TNFR,B,B
family,I,I
",",O,O
death,B,O
receptor,I,O
3,I,O
(,O,O
DR3,B,B
),O,O
",",O,O
was,O,O
identified,O,O
and,O,O
was,O,O
shown,O,O
to,O,O
induce,O,O
both,O,O
apoptosis,O,O
and,O,O
activation,O,O
of,O,O
nuclear,B,O
factor,I,O
kappaB,I,O
.,O,O
Differential,O,O
nuclear,O,O
localization,O,O
of,O,O
p50,B,B
",",O,O
p52,B,B
",",O,O
and,O,O
RelB,B,B
proteins,O,O
in,O,O
human,O,O
accessory,O,O
cells,O,O
of,O,O
the,O,O
immune,O,O
response,O,O
in,O,O
situ,O,O
.,O,O
The,O,O
different,O,O
patterns,O,O
of,O,O
p50,B,B
",",O,O
p52,B,B
and,O,O
RelB,B,B
protein,O,O
nuclear,O,O
localization,O,O
may,O,O
provide,O,O
insight,O,O
into,O,O
their,O,O
different,O,O
roles,O,O
during,O,O
the,O,O
immune,O,B
response,O,I
in,O,O
vivo,O,O
.,O,O
Although,O,O
mutation,O,O
of,O,O
either,O,O
Y113,O,O
and,O,O
Y128,O,O
has,O,O
a,O,O
minimal,O,O
effect,O,O
on,O,O
SLP,B,O
-,I,O
76,I,O
function,O,O
",",O,O
mutation,O,O
of,O,O
both,O,O
residues,O,O
decreases,O,O
significantly,O,O
the,O,O
ability,O,O
of,O,O
SLP,B,O
-,I,O
76,I,O
to,O,O
promote,O,O
T,O,O
cell,O,O
activation,O,O
.,O,O
The,O,O
IRF,B,B
-,I,I
2,I,I
promoter,B,O
region,I,O
contains,O,O
a,O,O
CpG,O,O
island,O,O
",",O,O
with,O,O
several,O,O
GC,B,O
boxes,I,O
",",O,O
a,O,O
putative,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,I,I
binding,I,I
site,I,I
",",O,O
and,O,O
a,O,O
CAAT,B,O
box,I,O
",",O,O
but,O,O
no,O,O
TATA,B,O
box,I,O
.,O,O
When,O,O
the,O,O
promoter,B,O
region,I,O
was,O,O
linked,O,O
with,O,O
a,O,O
heterologous,B,O
reporter,I,O
gene,I,O
",",O,O
we,O,O
found,O,O
that,O,O
the,O,O
promoter,B,O
region,I,O
is,O,O
inducible,O,O
by,O,O
both,O,O
interferons,B,O
(,O,O
interferon,B,B
-,I,I
alpha,I,I
and,I,O
-,I,O
gamma,I,I
),O,O
and,O,O
interferon,B,B
regulatory,I,I
factor,I,I
1,I,I
.,O,O
Interferon,B,B
alpha,I,I
selectively,O,O
affects,O,O
expression,O,O
of,O,O
the,O,O
human,B,O
myeloid,I,B
cell,I,I
nuclear,I,I
differentiation,I,I
antigen,I,I
in,O,O
late,O,O
stage,O,O
cells,O,O
in,O,O
the,O,O
monocytic,O,B
but,O,O
not,O,O
the,O,O
granulocytic,O,B
lineage,O,I
.,O,O
Although,O,O
",",O,O
the,O,O
level,O,O
of,O,O
MNDA,B,B
mRNA,I,I
in,O,O
primary,O,O
monocytes,O,B
is,O,O
very,O,O
low,O,O
it,O,O
was,O,O
up,O,O
-,O,O
regulated,O,O
at,O,O
6,O,O
h,O,O
following,O,O
the,O,O
addition,O,O
of,O,O
interferon,B,B
alpha,I,I
.,O,O
This,O,O
reduced,O,O
level,O,O
of,O,O
mRNA,B,B
could,O,O
then,O,O
be,O,O
elevated,O,O
with,O,O
subsequent,O,O
interferon,B,B
alpha,I,I
treatment,O,O
.,O,O
We,O,O
identified,O,O
a,O,O
protein,O,B
",",O,O
p37,O,O
",",O,O
which,O,O
specifically,O,O
bound,O,O
to,O,O
DRE,B,B
1,I,I
.,O,O
Binding,O,O
of,O,O
the,O,O
cDNA,B,B
fusion,I,I
protein,I,I
",",O,O
similarly,O,O
to,O,O
the,O,O
results,O,O
obtained,O,O
with,O,O
purified,O,O
Jurkat,O,O
protein,O,O
",",O,O
was,O,O
decreased,O,O
by,O,O
introduction,O,O
of,O,O
site,O,O
-,O,O
specific,O,O
mutations,O,O
in,O,O
the,O,O
DRE,B,B
1,I,I
regulatory,I,I
sequence,I,I
.,O,O
Cotransfection,O,O
of,O,O
a,O,O
YB,B,B
-,I,I
1,I,I
expression,I,O
plasmid,I,O
increases,O,O
HTLV,O,B
-,O,I
I,O,I
basal,O,O
transcription,O,O
approximately,O,O
14,O,O
-,O,O
fold,O,O
in,O,O
Jurkat,O,B
T,O,I
lymphocytes,O,I
.,O,O
The,O,O
subjects,O,O
were,O,O
exposed,O,O
to,O,O
cold,O,O
air,O,O
(,O,O
4,O,O
degrees,O,O
C,O,O
),O,O
twice,O,O
/,O,O
d,O,O
",",O,O
30,O,O
min,O,O
/,O,O
exposure,O,O
",",O,O
for,O,O
a,O,O
total,O,O
of,O,O
80,O,O
exposures,O,O
.,O,O
These,O,O
results,O,O
describe,O,O
for,O,O
the,O,O
first,O,O
time,O,O
the,O,O
rapid,O,O
modulation,O,O
of,O,O
the,O,O
NT3R,B,B
in,O,O
response,O,O
to,O,O
the,O,O
combined,O,O
influence,O,O
of,O,O
cold,O,O
exposure,O,O
and,O,O
reduced,O,O
circulating,O,O
T4,O,B
and,O,O
TSH,O,B
.,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
activity,O,O
in,O,O
human,O,O
CD40,O,B
-,O,I
activated,O,I
B,O,I
lymphocytes,O,I
is,O,O
dependent,O,O
on,O,O
NF,B,B
-,I,I
kappaB,I,I
.,O,O
In,O,O
these,O,O
cells,O,O
",",O,O
nuclear,B,O
factors,I,O
involved,O,O
in,O,O
activation,O,O
of,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
",",O,O
which,O,O
contains,O,O
the,O,O
transcriptional,B,O
control,I,O
elements,I,O
of,O,O
the,O,O
virus,O,O
",",O,O
are,O,O
unknown,O,O
.,O,O
In,O,O
preincubated,O,O
cells,O,O
",",O,O
the,O,O
cycloheximide,O,O
response,O,O
is,O,O
decreased,O,O
",",O,O
especially,O,O
in,O,O
the,O,O
case,O,O
of,O,O
FOSB,B,B
.,O,O
Regions,O,O
of,O,O
low,O,O
base,O,O
order,O,O
-,O,O
dependent,O,O
stem,O,O
-,O,O
loop,O,O
potential,O,O
in,O,O
the,O,O
region,O,O
of,O,O
the,O,O
gene,O,O
are,O,O
defined,O,O
.,O,O
Susceptibility,O,O
of,O,O
these,O,O
transformed,O,O
cell,O,O
lines,O,O
to,O,O
NK,O,O
cells,O,O
was,O,O
determined,O,O
by,O,O
cytolytic,O,O
assays,O,O
.,O,O
Cell,O,O
specific,O,O
expression,O,O
of,O,O
human,B,O
Bruton,I,O
s,I,O
agammaglobulinemia,I,O
tyrosine,I,O
kinase,I,O
gene,I,O
(,O,O
Btk,B,O
),O,O
is,O,O
regulated,O,O
by,O,O
Sp1,B,O
-,I,O
and,O,O
Spi,B,O
-,I,O
1,I,O
/,I,O
PU,I,O
.,I,O
1,I,O
family,I,O
members,I,O
.,O,O
In,O,O
vitro,O,O
footprinting,O,O
analysis,O,O
within,O,O
this,O,O
part,O,O
of,O,O
the,O,O
promoter,B,O
revealed,O,O
two,O,O
Sp1,B,B
binding,I,O
sites,I,O
as,O,O
well,O,O
as,O,O
a,O,O
PU,B,B
-,I,I
box,I,I
.,O,O
In,O,O
addition,O,O
Spi,B,O
-,I,O
B,I,O
as,O,O
well,O,O
as,O,O
PU,B,O
.,I,O
1,I,O
were,O,O
able,O,O
to,O,O
transactivate,O,O
Btk,B,O
expression,O,O
.,O,O
They,O,O
also,O,O
demonstrate,O,O
for,O,O
the,O,O
first,O,O
time,O,O
the,O,O
occurrence,O,O
of,O,O
T,O,O
cell,O,O
responses,O,O
against,O,O
EBV,B,O
transactivating,I,O
factors,I,O
",",O,O
which,O,O
might,O,O
be,O,O
central,O,O
in,O,O
the,O,O
control,O,O
of,O,O
virus,O,O
reactivation,O,O
.,O,O
CD14,B,B
-,O,I
mediated,O,I
signal,O,I
pathway,O,I
of,O,I
Porphyromonas,O,O
gingivalis,O,O
lipopolysaccharide,O,O
in,O,O
human,O,O
gingival,O,O
fibroblasts,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
observed,O,O
unexpectedly,O,O
by,O,O
immunohistochemical,O,O
",",O,O
Western,O,O
blotting,O,O
(,O,O
immunoblotting,O,O
),O,O
",",O,O
and,O,O
Northern,O,O
(,O,O
RNA,O,O
),O,O
blotting,O,O
assays,O,O
that,O,O
CD14,B,B
is,O,O
expressed,O,O
at,O,O
high,O,O
density,O,O
in,O,O
human,O,O
gingival,O,O
fibroblasts,O,O
.,O,O
The,O,O
inhibitor,O,O
also,O,O
dramatically,O,O
inhibited,O,O
monocyte,O,B
chemotactic,O,I
activity,O,O
of,O,O
and,O,O
MCP,B,B
-,I,I
1,I,I
production,O,O
by,O,O
the,O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
tyrosine,B,B
kinase,I,I
activated,O,O
by,O,O
G,B,O
-,I,O
CSF,I,O
appears,O,O
to,O,O
directly,O,O
transduce,O,O
a,O,O
signal,O,O
to,O,O
a,O,O
protein,O,B
which,O,O
functions,O,O
as,O,O
a,O,O
transcriptional,B,O
regulator,I,O
.,O,O
Thus,O,O
",",O,O
we,O,O
focused,O,O
our,O,O
study,O,O
on,O,O
isolated,O,O
FDC,O,B
clusters,O,I
from,O,O
normal,O,O
tonsils,O,O
.,O,O
As,O,O
showed,O,O
on,O,O
tissue,O,O
sections,O,O
",",O,O
we,O,O
detected,O,O
the,O,O
p50,B,B
in,O,O
both,O,O
cytoplasm,O,O
and,O,O
nucleus,O,O
of,O,O
FDC,O,O
.,O,O
Now,O,O
that,O,O
these,O,O
proteins,O,O
are,O,O
purified,O,O
and,O,O
cloned,O,O
",",O,O
the,O,O
major,O,O
goals,O,O
will,O,O
be,O,O
to,O,O
understand,O,O
their,O,O
role,O,O
and,O,O
the,O,O
roles,O,O
of,O,O
other,O,O
family,O,O
members,O,O
in,O,O
thymic,O,O
development,O,O
.,O,O
This,O,O
effect,O,O
is,O,O
blocked,O,O
by,O,O
anti,B,O
-,I,O
VCAM,I,B
antibodies,I,O
.,O,O
This,O,O
activity,O,O
seems,O,O
to,O,O
be,O,O
due,O,O
to,O,O
increased,O,O
cAMP,O,B
levels,O,O
because,O,O
forskolin,O,O
and,O,O
IBMX,O,O
mimic,O,O
the,O,O
effects,O,O
of,O,O
PGE2,O,O
.,O,O
These,O,O
data,O,O
support,O,O
the,O,O
positive,O,O
role,O,O
for,O,O
PGE2,O,B
on,O,O
some,O,O
immune,O,O
functions,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
analysis,O,O
of,O,O
EBV,O,B
protein,O,O
expression,O,O
by,O,O
IH,O,O
revealed,O,O
a,O,O
heterogeneous,O,O
pattern,O,O
of,O,O
EBV,B,B
gene,I,O
expression,O,O
at,O,O
the,O,O
single,O,O
-,O,O
cell,O,O
level,O,O
consisting,O,O
of,O,O
both,O,O
LMP1,O,B
+,O,O
and,O,O
LMP1,O,B
-,O,O
tumour,O,O
cells,O,O
",",O,O
suggesting,O,O
a,O,O
mixture,O,O
of,O,O
latency,O,O
I,O,O
and,O,O
II,O,O
.,O,O
This,O,O
made,O,O
the,O,O
need,O,O
for,O,O
VD,O,B
analogues,O,O
with,O,O
selectively,O,O
increased,O,O
cell,O,O
regulatory,O,O
properties,O,O
.,O,O
Studies,O,O
with,O,O
20,O,O
-,O,O
epi,O,O
analogues,O,O
pointed,O,O
out,O,O
the,O,O
importance,O,O
of,O,O
the,O,O
carbon,O,O
-,O,O
20,O,O
position,O,O
and,O,O
led,O,O
to,O,O
the,O,O
development,O,O
of,O,O
20,O,O
-,O,O
methyl,O,O
derivatives,O,O
of,O,O
VD,O,B
.,O,O
Moreover,O,O
",",O,O
ZK161422,O,O
",",O,O
but,O,O
not,O,O
ZK157202,O,O
",",O,O
showed,O,O
preference,O,O
for,O,O
gene,O,O
activation,O,O
from,O,O
a,O,O
promoter,B,O
carrying,O,O
a,O,O
VD,B,B
response,I,O
element,I,O
with,O,O
a,O,O
palindromic,O,O
arrangement,O,O
of,O,O
two,O,O
hexameric,B,O
receptor,I,O
binding,I,O
sites,I,O
spaced,O,O
by,O,O
9,O,O
nucleotides,O,O
(,O,O
IP9,O,O
),O,O
rather,O,O
than,O,O
for,O,O
activation,O,O
from,O,O
a,O,O
response,B,O
element,I,O
formed,O,O
by,O,O
a,O,O
direct,O,O
repeat,O,O
spaced,O,O
by,O,O
3,O,O
nucleotides,O,O
(,O,O
DR3,O,O
),O,O
.,O,O
This,O,O
observation,O,O
supports,O,O
a,O,O
model,O,O
",",O,O
in,O,O
which,O,O
promoter,O,O
selectivity,O,O
reflects,O,O
the,O,O
selectively,O,O
increased,O,O
antiproliferative,O,O
effect,O,O
of,O,O
VD,O,B
analogues,O,O
.,O,O
The,O,O
process,O,O
of,O,O
activation,O,O
involves,O,O
calcium,O,B
mobilization,O,O
",",O,O
activation,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
(,O,O
PKC,B,O
),O,O
",",O,O
and,O,O
phosphorylation,O,O
of,O,O
tyrosine,B,B
kinases,I,I
.,O,O
The,O,O
involvement,O,O
of,O,O
p21,B,O
(,I,O
ras,I,O
),I,O
in,O,O
the,O,O
regulation,O,O
of,O,O
calcium,O,B
-,O,I
dependent,O,I
signals,O,O
has,O,O
been,O,O
suggested,O,O
through,O,O
analysis,O,O
of,O,O
its,O,O
role,O,O
in,O,O
the,O,O
activation,O,O
of,O,O
NF,B,O
-,I,O
AT,I,O
.,O,O
The,O,O
expression,O,O
of,O,O
activated,O,O
p21,B,B
(,I,O
ras,I,I
),I,O
negatively,O,O
regulated,O,O
the,O,O
induction,O,O
of,O,O
IE,B,O
genes,I,O
by,O,O
calcium,O,O
ionophore,O,O
.,O,O
A,O,O
later,O,O
result,O,O
of,O,O
inhibition,O,O
of,O,O
this,O,O
activation,O,O
pathway,O,O
by,O,O
p21,B,B
(,I,O
ras,I,I
),I,O
was,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
AP,B,B
-,I,I
1,I,I
and,O,O
subsequent,O,O
coordinate,O,O
reductions,O,O
in,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
expression,O,O
and,O,O
protein,O,O
production,O,O
.,O,O
Calcineurin,B,B
acts,O,O
in,O,O
synergy,O,O
with,O,O
PMA,O,O
to,O,O
inactivate,O,O
I,B,B
kappa,I,I
B,I,I
/,I,I
",",O,O
an,O,O
inhibitor,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Calcineurin,B,B
stimulates,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
element,I,O
by,O,O
enhancing,O,O
inactivation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
/,I,I
",",O,O
an,O,O
inhibitor,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
thereby,O,O
increasing,O,O
the,O,O
amount,O,O
of,O,O
nuclear,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
DNA,O,I
binding,O,O
activity,O,O
.,O,O
Inhibition,O,O
of,O,O
membrane,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
and,O,O
IL,B,B
-,I,I
2R,I,I
beta,I,I
expression,O,O
by,O,O
10,O,O
(,O,O
-,O,O
6,O,O
),O,O
M,O,O
DM,O,O
was,O,O
partially,O,O
reversible,O,O
by,O,O
recombinant,B,O
human,I,O
IL,I,B
-,I,I
2,I,I
(,O,O
rhIL,B,O
-,I,O
2,I,O
),O,O
.,O,O
The,O,O
mechanism,O,O
of,O,O
action,O,O
of,O,O
DM,O,O
on,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
transcription,O,O
was,O,O
examined,O,O
by,O,O
determining,O,O
the,O,O
mRNA,O,O
levels,O,O
of,O,O
the,O,O
p50,O,O
subunit,O,O
of,O,O
nuclear,O,O
factor,O,O
kappa,O,O
B,O,O
(,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
),O,O
",",O,O
a,O,O
transcription,B,O
factor,I,O
that,O,O
stimulates,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
gene,O,O
expression,O,O
.,O,O
However,O,O
",",O,O
simultaneous,O,O
incubation,O,O
of,O,O
RU,O,B
486,O,I
with,O,O
dexamethasone,O,B
caused,O,O
a,O,O
distinct,O,O
interference,O,O
of,O,O
RU,O,B
486,O,I
with,O,O
dexamethasone,O,B
.,O,O
The,O,O
protein,B,B
-,I,I
tyrosine,I,I
kinase,I,I
ZAP,B,B
-,I,I
70,I,I
is,O,O
implicated,O,O
",",O,O
together,O,O
with,O,O
the,O,O
Src,B,B
kinase,I,I
p56,B,I
(,I,I
lck,I,I
),I,I
",",O,O
in,O,O
controlling,O,O
the,O,O
early,O,O
steps,O,O
of,O,O
the,O,O
T,O,B
-,O,I
cell,O,I
antigen,O,I
receptor,O,I
(,O,I
TCR,B,I
),O,I
signaling,O,O
cascade,O,O
.,O,O
To,O,O
help,O,O
elucidate,O,O
further,O,O
the,O,O
mechanism,O,O
by,O,O
which,O,O
ZAP,B,B
-,I,I
70,I,I
regulates,O,O
these,O,O
initial,O,O
events,O,O
",",O,O
we,O,O
used,O,O
a,O,O
dominant,O,O
-,O,O
negative,O,O
mutant,O,O
approach,O,O
.,O,O
ZAP,B,B
-,I,I
70,I,I
will,O,O
then,O,O
be,O,O
able,O,O
to,O,O
effectively,O,O
control,O,O
phosphorylation,O,O
of,O,O
its,O,O
substrates,O,O
and,O,O
lead,O,O
to,O,O
gene,O,O
activation,O,O
.,O,O
Peripheral,O,O
blood,O,O
mononuclear,O,O
cell,O,O
GCR,B,O
binding,O,O
affinities,O,O
for,O,O
dexamethasone,O,O
and,O,O
budesonide,O,O
were,O,O
also,O,O
determined,O,O
for,O,O
both,O,O
patient,O,O
groups,O,O
by,O,O
using,O,O
a,O,O
radioligand,O,O
binding,O,O
assay,O,O
and,O,O
Scatchard,O,O
analysis,O,O
.,O,O
The,O,O
GCR,B,B
binding,O,O
affinity,O,O
for,O,O
budesonide,O,O
was,O,O
significantly,O,O
higher,O,O
in,O,O
both,O,O
groups,O,O
(,O,O
i,O,O
.,O,O
e,O,O
.,O,O
",",O,O
lower,O,O
dissociation,O,O
constant,O,O
),O,O
than,O,O
that,O,O
obtained,O,O
for,O,O
dexamethasone,O,O
.,O,O
Characterization,O,O
of,O,O
the,O,O
murine,B,O
cyclin,I,O
-,I,O
dependent,I,O
kinase,I,O
inhibitor,I,O
gene,I,O
p27Kip1,B,O
.,O,O
The,O,O
gene,O,O
consists,O,O
of,O,O
at,O,O
least,O,O
three,O,O
exons,O,O
and,O,O
spans,O,O
more,O,O
than,O,O
5,B,O
.,I,O
6,I,O
kb,I,O
of,I,O
DNA,I,B
.,O,O
Primer,O,O
extension,O,O
and,O,O
nuclease,O,O
S1,O,O
protection,O,O
analysis,O,O
revealed,O,O
two,O,O
major,O,O
transcription,B,O
initiation,I,O
sites,I,O
.,O,O
The,O,O
-,B,O
326,I,O
to,I,O
-,I,O
615,I,O
region,I,O
contained,O,O
positive,B,O
regulatory,I,O
elements,I,O
.,O,O
Constitutive,O,O
nuclear,O,O
appearance,O,O
was,O,O
also,O,O
observed,O,O
for,O,O
NF,O,B
-,O,I
kB2,O,I
/,O,I
p52,O,I
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
T,O,O
cells,O,O
representing,O,O
different,O,O
activation,O,O
and,O,O
/,O,O
or,O,O
differentiation,O,O
stages,O,O
can,O,O
be,O,O
differentially,O,O
responsive,O,O
to,O,O
ROI,O,O
-,O,O
mediated,O,O
signals,O,O
.,O,O
Furthermore,O,O
",",O,O
overexpression,O,O
and,O,O
constitutive,O,O
nuclear,O,O
localization,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
",",O,O
but,O,O
not,O,O
Jun,B,O
",",I,O
Fos,I,O
",",I,O
NF,I,B
-,I,I
kappaB,I,I
",",I,O
Oct,I,O
or,I,O
Ets,I,O
family,I,O
members,I,O
",",O,O
renders,O,O
the,O,O
interleukin,B,O
-,I,O
2,I,O
enhancer,I,O
in,O,O
Jurkat,O,O
T,O,O
lymphocytes,O,O
resistant,O,O
to,O,O
FK506,O,O
and,O,O
cyclosporin,O,O
A,O,O
.,O,O
These,O,O
findings,O,O
thus,O,O
reveal,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
second,O,O
inducible,O,O
autoregulated,O,O
inhibitory,O,O
pathway,O,O
that,O,O
helps,O,O
ensure,O,O
the,O,O
rapid,O,O
but,O,O
transient,O,O
action,O,O
of,O,O
nuclear,B,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Implications,O,O
for,O,O
replication,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
First,O,O
",",O,O
anti,B,O
-,I,O
CD45,I,B
antibodies,I,I
did,O,O
not,O,O
affect,O,O
basal,O,O
but,O,O
decreased,O,O
activated,O,O
levels,O,O
of,O,O
expression,O,O
from,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
.,O,O
The,O,O
expression,O,O
of,O,O
GM,B,B
-,I,I
CSF,I,I
and,O,O
IL,B,B
-,I,I
2,I,I
is,O,O
inhibited,O,O
by,O,O
immunosuppressive,O,O
drugs,O,O
such,O,O
as,O,O
cyclosporin,O,O
A,O,O
(,O,O
CsA,O,O
),O,O
and,O,O
FK506,O,O
.,O,O
The,O,O
constitutively,O,O
active,O,O
type,O,O
of,O,O
the,O,O
CN,B,O
A,I,O
subunit,I,O
",",O,O
which,O,O
lacks,O,O
the,O,O
auto,B,O
-,I,O
inhibitory,I,O
and,O,O
calmodulin,B,O
-,I,O
binding,I,O
domains,I,O
",",O,O
acts,O,O
in,O,O
synergy,O,O
with,O,O
PMA,O,O
to,O,O
activate,O,O
transcription,O,O
from,O,O
the,O,O
GM,B,B
-,I,I
CSF,I,I
promoter,I,I
.,O,O
Alternate,O,O
immune,O,O
system,O,O
targets,O,O
for,O,O
TCDD,O,O
:,O,O
lymphocyte,O,B
stem,O,I
cells,O,I
and,O,O
extrathymic,O,B
T,O,I
-,O,I
cell,O,I
development,O,I
.,O,O
TCDD,O,O
mediates,O,O
atrophy,O,O
induction,O,O
through,O,O
its,O,O
specific,O,O
receptor,O,O
(,O,O
the,O,O
AhR,B,O
),O,O
and,O,O
not,O,O
through,O,O
effects,O,O
on,O,O
the,O,O
estrogen,O,B
receptor,O,I
.,O,O
Both,O,O
TCDD,O,O
and,O,O
estradiol,O,O
induce,O,O
extrathymic,O,B
T,O,I
-,O,I
cell,O,I
differentiation,O,I
in,O,O
the,O,O
liver,O,O
.,O,O
It,O,O
predicts,O,O
for,O,O
two,O,O
open,B,O
reading,I,O
frames,I,O
(,O,O
ORFs,B,O
),O,O
.,O,O
ORF1,B,O
consists,O,O
of,O,O
240,O,O
bp,O,O
that,O,O
would,O,O
encode,O,O
80,O,O
amino,O,B
acids,O,I
",",O,O
while,O,O
the,O,O
major,B,O
ORF2,I,O
consists,O,O
of,O,O
648,O,O
bp,O,O
capable,O,O
of,O,O
coding,O,O
for,O,O
216,O,O
amino,O,B
acids,O,I
.,O,O
To,O,O
investigate,O,O
the,O,O
mechanisms,O,O
of,O,O
transcriptional,O,O
activation,O,O
of,O,O
interleukin,B,O
-,I,O
1beta,I,O
(,O,O
IL,B,B
-,I,I
1beta,I,I
),O,O
in,O,O
non,O,O
-,O,O
monocytic,O,O
cells,O,O
",",O,O
we,O,O
constructed,O,O
a,O,O
series,O,O
of,O,O
reporter,O,O
plasmids,O,O
with,O,O
the,O,O
bacterial,O,B
chloramphenicol,O,I
acetyltransferase,O,I
gene,O,I
linked,O,O
to,O,O
various,O,O
parts,O,O
of,O,O
the,O,O
human,B,O
IL,I,B
-,I,I
1beta,I,I
promoter,I,I
and,O,O
performed,O,O
transient,O,O
transfection,O,O
experiments,O,O
.,O,O
Egr,B,B
-,I,I
1,I,I
expression,O,O
correlates,O,O
with,O,O
the,O,O
cellular,O,B
phenotype,O,I
and,O,O
the,O,O
specific,O,O
pattern,O,O
of,O,O
viral,O,O
latency,O,O
established,O,O
within,O,O
the,O,O
individual,O,O
cell,O,B
lines,O,I
.,O,O
Several,O,O
forms,O,O
of,O,O
EGR,B,B
-,I,I
1,I,I
protein,I,O
are,O,O
found,O,O
within,O,O
the,O,O
different,O,O
groups,O,O
of,O,O
cell,O,B
lines,O,I
",",O,O
and,O,O
the,O,O
binding,O,O
activity,O,O
to,O,O
DNA,B,B
consensus,I,I
sequences,I,I
was,O,O
investigated,O,O
.,O,O
In,O,O
all,O,O
cells,O,O
tested,O,O
",",O,O
IL,B,B
-,I,I
10,I,I
activated,O,O
Stat1,B,B
and,O,O
Stat3,B,B
and,O,O
induced,O,O
the,O,O
formation,O,O
of,O,O
three,O,O
distinct,O,O
DNA,B,B
binding,I,I
complexes,I,I
that,O,O
contained,O,O
different,O,O
combinations,O,O
of,O,O
these,O,O
two,O,O
transcription,B,O
factors,I,O
.,O,O
Using,O,O
a,O,O
structure,O,O
-,O,O
function,O,O
mutagenesis,O,O
approach,O,O
",",O,O
two,O,O
tyrosine,O,B
residues,O,I
(,O,O
Tyr427,O,B
and,O,O
Tyr477,O,B
),O,O
in,O,O
the,O,O
intracellular,B,O
domain,I,O
of,O,O
the,O,O
murine,O,O
IL,B,B
-,I,I
10,I,I
receptor,O,I
were,O,O
found,O,O
to,O,O
be,O,O
redundantly,O,O
required,O,O
for,O,O
receptor,O,O
function,O,O
and,O,O
for,O,O
activation,O,O
of,O,O
Stat3,B,B
but,O,O
not,O,O
for,O,O
Stat1,B,B
or,O,O
Stat5,B,B
.,O,O
This,O,O
study,O,O
thus,O,O
supports,O,O
the,O,O
concept,O,O
that,O,O
utilization,O,O
of,O,O
distinct,O,O
STAT,B,B
proteins,I,I
by,O,O
different,O,O
cytokine,B,O
receptors,I,O
is,O,O
dependent,O,O
on,O,O
the,O,O
expression,O,O
of,O,O
particular,O,O
ligand,O,O
-,O,O
activatable,O,O
",",O,O
tyrosine,B,O
-,I,O
containing,I,O
STAT,I,O
docking,I,O
sites,I,O
in,O,O
receptor,B,O
intracellular,I,O
domains,I,O
.,O,O
Silencing,O,O
of,O,O
human,O,O
fetal,O,O
globin,B,B
expression,O,O
is,O,O
impaired,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
the,O,O
adult,B,O
beta,I,B
-,I,I
globin,I,I
gene,I,I
activator,I,I
protein,I,I
EKLF,B,O
.,O,O
Globin,B,B
genes,I,I
are,O,O
subject,O,O
to,O,O
tissue,O,O
-,O,O
specific,O,O
and,O,O
developmental,O,O
stage,O,O
-,O,O
specific,O,O
regulation,O,O
.,O,O
Stimulation,O,O
of,O,O
human,O,B
peripheral,O,I
blood,O,I
mononuclear,O,I
cells,O,I
by,O,O
zinc,O,B
and,O,O
related,O,O
cations,O,O
.,O,O
Therefore,O,O
",",O,O
monokine,O,O
induction,O,O
is,O,O
a,O,O
zinc,O,B
-,O,I
specific,O,I
effect,O,I
influenced,O,O
by,O,O
the,O,O
physicochemical,O,O
properties,O,O
of,O,O
the,O,O
ion,O,O
.,O,O
Confirmation,O,O
of,O,O
the,O,O
unique,O,O
significance,O,O
of,O,O
zinc,O,B
for,O,O
immune,O,O
function,O,O
provides,O,O
a,O,O
better,O,O
understanding,O,O
of,O,O
the,O,O
mechanisms,O,O
of,O,O
specific,O,O
zinc,O,B
-,O,I
mediated,O,I
immune,O,I
modulation,O,I
.,O,O
E3,B,B
",",O,O
a,O,O
hematopoietic,B,B
-,I,I
specific,I,I
transcript,I,O
directly,O,O
regulated,O,O
by,O,O
the,O,O
retinoic,B,B
acid,I,I
receptor,I,I
alpha,I,I
.,O,O
E3,B,B
",",O,O
one,O,O
of,O,O
nine,O,O
sequences,O,O
identified,O,O
",",O,O
was,O,O
upregulated,O,O
in,O,O
an,O,O
immediate,O,O
-,O,O
early,O,O
manner,O,O
",",O,O
with,O,O
transcript,O,O
levels,O,O
peaking,O,O
after,O,O
60,O,O
minutes,O,O
exposure,O,O
to,O,O
RA,O,B
.,O,O
E3,B,B
transcripts,I,O
were,O,O
RA,O,B
-,O,I
inducible,O,I
in,O,O
HL60,O,O
cells,O,O
",",O,O
but,O,O
not,O,O
in,O,O
an,O,O
RA,O,B
-,O,I
resistant,O,I
subclone,O,I
",",O,O
HL60R,O,O
",",O,O
that,O,O
harbors,O,O
a,O,O
mutated,O,O
RAR,B,B
alpha,I,I
gene,I,I
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
E3,B,B
is,O,O
a,O,O
hematopoietic,B,B
-,I,I
specific,I,I
gene,I,O
that,O,O
is,O,O
an,O,O
immediate,O,O
target,O,O
for,O,O
the,O,O
activated,O,O
RAR,B,O
alpha,I,O
during,O,O
myelopoiesis,O,O
.,O,O
The,O,O
molecular,O,O
mechanism,O,O
underlying,O,O
IL,B,B
-,I,I
2,I,I
transcriptional,O,O
blockade,O,O
in,O,O
anergic,O,O
T,O,O
cell,O,O
clones,O,O
is,O,O
not,O,O
fully,O,O
understood,O,O
.,O,O
To,O,O
examine,O,O
whether,O,O
an,O,O
active,O,O
negative,O,O
regulatory,O,O
process,O,O
occurs,O,O
",",O,O
we,O,O
created,O,O
a,O,O
reporter,B,O
construct,I,O
containing,O,O
as,O,O
an,O,O
enhancer,B,O
four,O,O
copies,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
AT,I,I
site,I,I
and,O,O
one,O,O
copy,O,O
of,O,O
the,O,O
octamer,B,B
site,I,I
(,O,I
4X,B,I
NF,I,I
-,I,I
AT,I,I
-,I,I
Oct,I,I
),O,I
.,O,O
The,O,O
simplest,O,O
model,O,O
to,O,O
explain,O,O
these,O,O
results,O,O
is,O,O
that,O,O
anergy,O,O
is,O,O
mediated,O,O
by,O,O
a,O,O
complex,O,O
of,O,O
multiple,O,O
transcription,B,O
factors,I,O
that,O,O
exert,O,O
a,O,O
cis,O,O
-,O,O
acting,O,O
dominant,O,O
negative,O,O
regulatory,O,O
effect,O,O
on,O,O
the,O,O
trans,O,O
-,O,O
activation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
expression,O,O
of,O,O
the,O,O
activation,B,O
-,I,O
dependent,I,O
cell,I,O
surface,I,O
markers,I,O
CD25,B,B
and,O,O
CD69,B,B
was,O,O
within,O,O
normal,O,O
limits,O,O
.,O,O
Whereas,O,O
AP,B,O
-,I,O
1,I,O
",",O,O
NF,O,B
-,O,I
kappa,O,I
B,O,I
",",O,O
Oct,B,O
",",O,O
CREB,B,O
and,O,O
SP1,B,O
displayed,O,O
normal,O,O
binding,O,O
activities,O,O
in,O,O
nuclear,O,O
extracts,O,O
",",O,O
the,O,O
binding,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
to,O,O
its,O,O
IL,B,O
-,I,O
2,I,O
promoter,O,O
response,O,O
element,O,O
was,O,O
barely,O,O
detectable,O,O
both,O,O
before,O,O
and,O,O
after,O,O
T,O,O
cell,O,O
stimulation,O,O
.,O,O
Our,O,O
results,O,O
strongly,O,O
suggest,O,O
that,O,O
this,O,O
NF,B,B
-,I,I
AT,I,I
/,O,I
DNA,O,I
binding,O,I
defect,O,O
is,O,O
responsible,O,O
for,O,O
the,O,O
multiple,O,O
cytokine,B,O
deficiency,O,O
and,O,O
the,O,O
SCID,O,O
phenotype,O,O
observed,O,O
in,O,O
the,O,O
two,O,O
infant,O,O
brothers,O,O
.,O,O
During,O,O
Epstein,O,B
-,O,I
Barr,O,I
virus,O,I
latent,O,O
infection,O,O
of,O,O
B,O,B
lymphocytes,O,I
in,O,O
vitro,O,O
",",O,O
six,O,O
viral,B,O
nuclear,I,O
antigens,I,O
(,O,O
EBNAs,B,O
),O,O
are,O,O
expressed,O,O
from,O,O
one,O,O
of,O,O
two,O,O
promoters,B,O
",",O,O
Cp,B,O
or,O,O
Wp,B,O
",",O,O
whose,O,O
activities,O,O
are,O,O
mutually,O,O
exclusive,O,O
.,O,O
Deletion,O,O
of,O,O
the,O,O
EBNA2,B,O
-,I,O
dependent,I,O
enhancer,I,O
located,O,O
upstream,O,O
of,O,O
Cp,B,O
resulted,O,O
in,O,O
a,O,O
ca,O,O
.,O,O
two,O,O
-,O,O
to,O,O
fivefold,O,O
reduction,O,O
in,O,O
Cp,B,O
activity,O,O
in,O,O
the,O,O
LCLs,O,O
assayed,O,O
.,O,O
Deletion,O,O
of,O,O
the,O,O
glucocorticoid,O,B
response,O,I
elements,O,I
located,O,O
at,O,O
ca,B,O
.,I,O
bp,I,O
-,I,O
850,I,O
upstream,O,O
of,O,O
Cp,B,O
did,O,O
not,O,O
result,O,O
in,O,O
a,O,O
significant,O,O
loss,O,O
in,O,O
activity,O,O
.,O,O
The,O,O
identification,O,O
of,O,O
oriP,B,O
and,O,O
the,O,O
EBNA2,B,O
-,I,O
dependent,I,O
enhancer,I,O
as,O,O
the,O,O
major,O,O
positive,O,O
cis,B,O
elements,I,O
involved,O,O
in,O,O
regulating,O,O
Cp,B,O
activity,O,O
in,O,O
LCL,O,O
suggests,O,O
that,O,O
EBNA,B,O
gene,I,O
transcription,O,O
is,O,O
largely,O,O
autoregulated,O,O
by,O,O
EBNA,B,O
1,I,O
and,O,O
EBNA,B,O
2,I,O
.,O,O
Expression,O,O
of,O,O
interleukin,B,B
1beta,I,I
and,O,O
other,O,O
cytokines,B,O
",",O,O
such,O,O
as,O,O
interleukin,B,B
6,I,I
and,O,O
tumor,B,B
necrosis,I,I
factor,I,I
alpha,I,I
",",O,O
has,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
dependent,O,O
on,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
",",O,O
NFkappaB,B,O
.,O,O
HIV,O,O
-,O,O
1,O,O
infection,O,O
resulted,O,O
in,O,O
constitutive,O,O
",",O,O
low,O,O
-,O,O
level,O,O
expression,O,O
of,O,O
type,B,O
1,I,O
interferon,I,B
(,O,O
IFN,B,O
),O,O
at,O,O
the,O,O
mRNA,O,O
level,O,O
.,O,O
We,O,O
suggest,O,O
that,O,O
HIV,O,B
-,O,I
1,O,I
infection,O,O
of,O,O
myeloid,O,B
cells,O,I
induces,O,O
IFN,B,B
production,O,O
and,O,O
PKR,B,B
activity,O,O
",",O,O
which,O,O
in,O,O
turn,O,O
contribute,O,O
to,O,O
enhanced,O,O
IkappaBalpha,B,B
phosphorylation,O,O
and,O,O
subsequent,O,O
degradation,O,O
.,O,O
Nuclear,O,O
translocation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
subunits,I,O
may,O,O
ultimately,O,O
increase,O,O
the,O,O
intracellular,O,O
pool,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
/,I,I
IkappaBalpha,I,I
by,O,O
an,O,O
autoregulatory,O,O
mechanism,O,O
.,O,O
The,O,O
transcription,O,O
and,O,O
transformation,O,O
activity,O,O
of,O,O
c,B,O
-,I,O
Jun,I,B
is,O,O
governed,O,O
by,O,O
a,O,O
27,B,O
-,I,O
amino,I,O
acid,I,O
regulatory,I,O
motif,I,O
",",O,O
labeled,O,O
the,O,O
delta,B,O
-,I,O
domain,I,O
",",O,O
which,O,O
is,O,O
deleted,O,O
in,O,O
v,B,O
-,I,O
Jun,I,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
differentiated,O,O
B,O,O
cells,O,O
contain,O,O
a,O,O
novel,O,O
substoichiometric,O,O
TAF,B,O
of,O,O
105,O,O
kDa,O,O
not,O,O
found,O,O
associated,O,O
with,O,O
TFIID,B,O
isolated,O,O
from,O,O
other,O,O
cell,O,O
types,O,O
.,O,O
All,O,O
cells,O,O
tested,O,O
express,O,O
TAFII105,B,B
mRNA,I,O
",",O,O
but,O,O
only,O,O
B,O,B
cells,O,O
contain,O,O
significant,O,O
levels,O,O
of,O,O
protein,O,B
associated,O,O
with,O,O
TFIID,B,B
.,O,O
The,O,O
association,O,O
of,O,O
20q,B,O
deletions,I,O
with,O,O
myeloid,O,B
`,O,O
`,O,O
stem,O,B
cell,O,I
disorders,O,O
suggests,O,O
that,O,O
the,O,O
deletions,O,O
mark,O,O
the,O,O
site,O,O
of,O,O
one,O,O
or,O,O
more,O,O
genes,O,O
",",O,O
loss,O,O
or,O,O
inactivation,O,O
of,O,O
which,O,O
plays,O,O
a,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
normal,O,O
hematopoietic,O,B
progenitors,O,I
.,O,O
Seventeen,O,O
microsatellite,B,O
markers,I,O
that,O,O
span,O,O
the,O,O
common,O,O
deleted,O,O
region,O,O
were,O,O
used,O,O
to,O,O
search,O,O
for,O,O
loss,O,O
of,O,O
heterozygosity,O,O
in,O,O
granulocyte,B,B
DNA,I,I
.,O,O
Therefore,O,O
",",O,O
the,O,O
human,B,B
androgen,I,I
receptor,I,I
assay,O,I
(,O,O
HUMARA,O,O
),O,O
was,O,O
used,O,O
to,O,O
determine,O,O
granulocyte,O,B
clonality,O,O
.,O,O
These,O,O
results,O,O
show,O,O
that,O,O
",",O,O
in,O,O
the,O,O
vast,O,O
majority,O,O
of,O,O
patients,O,O
presented,O,O
here,O,O
",",O,O
the,O,O
failure,O,O
to,O,O
detect,O,O
loss,O,O
of,O,O
heterozygosity,O,O
can,O,O
not,O,O
be,O,O
attributed,O,O
to,O,O
the,O,O
presence,O,O
of,O,O
normal,O,O
polyclonal,O,O
granulocytes,O,B
.,O,O
In,O,O
contrast,O,O
to,O,O
MM,O,O
cells,O,O
",",O,O
normal,O,O
splenic,O,B
B,O,I
cells,O,O
express,O,O
dephosphorylated,B,O
pRB,I,O
.,O,O
Although,O,O
CD40,B,O
ligand,I,O
(,O,O
CD40L,B,O
),O,O
triggers,O,O
a,O,O
shift,O,O
from,O,O
dephosphorylated,O,O
to,O,O
phosphorylated,O,O
pRB,B,O
and,O,O
proliferation,O,O
of,O,O
B,O,B
cells,O,O
",",O,O
the,O,O
addition,O,O
of,O,O
exogenous,O,O
IL,B,B
-,I,I
6,I,I
to,O,O
CD40L,B,O
-,O,O
treated,O,O
B,O,B
cells,O,O
does,O,O
not,O,O
alter,O,O
either,O,O
pRB,B,O
or,O,O
proliferation,O,O
",",O,O
as,O,O
observed,O,O
in,O,O
MM,O,O
cells,O,O
.,O,O
Soluble,B,O
factors,I,O
secreted,O,O
by,O,O
activated,O,O
T,O,O
-,O,O
lymphocytes,O,O
modulate,O,O
the,O,O
transcription,O,O
of,O,O
the,O,O
immunosuppressive,B,O
cytokine,I,O
TGF,B,B
-,I,I
beta,I,I
2,I,I
in,O,O
glial,O,O
cells,O,O
.,O,O
These,O,O
data,O,O
along,O,O
with,O,O
previous,O,O
observations,O,O
demonstrating,O,O
the,O,O
potent,O,O
immunosuppressive,O,O
activity,O,O
of,O,O
TGF,B,B
-,I,I
beta,I,I
2,I,I
",",O,O
support,O,O
a,O,O
model,O,O
for,O,O
a,O,O
feedback,O,O
mechanism,O,O
between,O,O
the,O,O
activated,O,O
T,O,O
-,O,O
lymphocytes,O,O
and,O,O
astrocytes,O,O
via,O,O
TGF,B,B
-,I,I
beta,I,I
2,I,I
to,O,O
regulate,O,O
the,O,O
immune,O,O
response,O,O
.,O,O
The,O,O
transcriptionally,B,O
regulatory,I,O
regions,I,O
of,O,O
the,O,O
lymphomagenic,O,O
Akv,O,O
and,O,O
SL3,O,O
-,O,O
3,O,O
murine,O,O
leukemia,O,O
retroviruses,O,O
(,O,O
MLVs,O,O
),O,O
contain,O,O
two,O,O
types,O,O
of,O,O
E,B,B
-,I,I
box,I,I
consensus,I,O
motifs,I,O
",",O,O
CAGATG,O,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
requirements,O,O
of,O,O
the,O,O
individual,O,O
E,B,B
-,I,I
boxes,I,I
in,O,O
MLV,O,O
transcriptional,O,O
regulation,O,O
.,O,O
In,O,O
lymphoid,O,O
cell,O,O
lines,O,O
only,O,O
",",O,O
the,O,O
E,B,B
(,I,O
gre,I,O
),I,O
-,I,O
binding,I,O
protein,I,O
complexes,I,O
included,O,O
ALF1,B,O
or,O,O
HEB,B,O
and,O,O
E2A,B,O
basic,I,O
helix,I,O
-,I,O
loop,I,O
-,I,O
helix,I,O
proteins,I,O
.,O,O
ALF1,B,B
transactivated,O,O
transcription,O,O
of,O,O
Akv,O,B
MLV,O,I
through,O,O
the,O,O
two,O,O
E,B,B
(,I,I
gre,I,I
),I,I
motifs,I,O
equally,O,O
",",O,O
whereas,O,O
E2A,B,B
protein,I,I
required,O,O
the,O,O
promoter,O,O
-,O,O
proximal,O,O
E,B,B
(,I,I
gre,I,I
),I,I
motif,O,O
.,O,O
Moreover,O,O
",",O,O
ectopic,B,O
Id1,I,B
repressed,O,O
E,B,B
(,I,I
gre,I,I
),I,I
-,O,O
directed,O,O
but,O,O
not,O,O
EA,B,B
/,I,I
S,I,I
-,O,I
directed,O,I
MLV,O,I
transcription,O,O
in,O,O
lymphoid,O,B
cell,O,I
lines,O,I
.,O,O
In,O,O
conclusion,O,O
",",O,O
E,B,B
(,I,I
gre,I,I
),I,I
motifs,O,O
and,O,O
interacting,O,O
basic,B,O
helix,I,O
-,I,O
loop,I,O
-,I,O
helix,I,O
proteins,I,O
are,O,O
important,O,O
determinants,O,O
for,O,O
MLV,O,B
transcriptional,O,I
activity,O,I
in,O,O
lymphocytic,O,B
cell,O,I
lines,O,I
.,O,O
Reversal,O,O
of,O,O
apoptosis,O,O
by,O,O
the,O,O
leukaemia,O,B
-,O,I
associated,O,I
E2A,B,I
-,I,I
HLF,I,I
chimaeric,I,I
transcription,I,I
factor,I,I
.,O,O
We,O,O
cloned,O,O
human,O,O
nur77,B,B
beta,I,I
cDNA,I,I
",",O,O
called,O,O
TINUR,B,O
.,O,O
Although,O,O
NGFI,B,O
-,I,O
B,I,O
/,I,O
nur77,I,O
is,O,O
essential,O,O
for,O,O
TCR,O,O
-,O,O
mediated,O,O
apoptosis,O,O
in,O,O
T,B,O
-,I,O
cell,I,O
hybridomas,I,O
",",O,O
the,O,O
reports,O,O
on,O,O
nur77,O,B
knock,O,I
-,O,I
out,O,I
mice,O,I
and,O,O
nur77,O,B
dominant,O,I
negative,O,I
transgenic,O,I
mice,O,I
suggest,O,O
that,O,O
there,O,O
is,O,O
a,O,O
functional,O,O
redundancy,O,O
among,O,O
NGFI,B,O
-,I,O
B,I,O
/,I,O
nur77,I,O
family,I,O
.,O,O
Correlations,O,O
were,O,O
found,O,O
between,O,O
plasma,B,O
IFN,I,B
alpha,I,I
and,O,O
receptor,O,O
Kd,O,O
on,O,O
monocytes,O,O
of,O,O
AIDS,O,O
-,O,O
GR,O,O
(,O,O
r,O,O
0,O,O
.,O,O
77,O,O
),O,O
and,O,O
between,O,O
IFN,B,B
alpha,I,I
and,O,O
plasma,O,O
cortisol,O,O
in,O,O
the,O,O
same,O,O
group,O,O
(,O,O
r,O,O
0,O,O
.,O,O
74,O,O
),O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
glucocorticoids,O,O
failed,O,O
to,O,O
inhibit,O,O
IFNalpha,B,B
production,O,O
from,O,O
AIDS,O,O
-,O,O
GR,O,O
monocytes,O,O
(,O,O
approximately,O,O
20,O,O
%,O,O
inhibition,O,O
),O,O
.,O,O
This,O,O
activation,O,O
differed,O,O
substantially,O,O
from,O,O
that,O,O
mediated,O,O
by,O,O
phorbol,O,O
12,O,O
-,O,O
myristate,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
and,O,O
Ca2,O,B
+,O,I
ionophore,O,I
or,O,O
produced,O,O
by,O,O
costimulation,O,O
with,O,O
antibodies,B,O
against,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
-,I,O
CD3,I,O
complex,I,O
and,O,O
to,O,O
CD28,B,O
.,O,O
The,O,O
age,O,O
-,O,O
associated,O,O
immune,O,O
dysfunction,O,O
may,O,O
be,O,O
implicated,O,O
to,O,O
some,O,O
degree,O,O
in,O,O
the,O,O
extreme,O,O
susceptibility,O,O
of,O,O
the,O,O
elderly,O,O
to,O,O
infection,O,O
and,O,O
neoplasia,O,O
and,O,O
may,O,O
even,O,O
participate,O,O
in,O,O
various,O,O
aspects,O,O
of,O,O
senescence,O,O
.,O,O
The,O,O
biochemical,O,O
modifications,O,O
responsible,O,O
for,O,O
the,O,O
defect,O,O
in,O,O
transduction,O,O
and,O,O
execution,O,O
of,O,O
the,O,O
proliferative,O,O
signal,O,O
are,O,O
analyzed,O,O
as,O,O
a,O,O
function,O,O
of,O,O
age,O,O
.,O,O
The,O,O
multiple,O,O
alterations,O,O
observed,O,O
on,O,O
the,O,O
various,O,O
biochemical,O,O
pathways,O,O
may,O,O
appear,O,O
as,O,O
a,O,O
consequence,O,O
of,O,O
a,O,O
unique,O,O
deleterious,O,O
mechanism,O,O
more,O,O
fundamentally,O,O
related,O,O
to,O,O
the,O,O
process,O,O
of,O,O
senescence,O,O
such,O,O
as,O,O
the,O,O
inability,O,O
to,O,O
cope,O,O
with,O,O
oxidative,O,O
stress,O,O
.,O,O
Induction,O,O
of,O,O
bcl,B,B
-,I,I
expression,O,O
by,O,O
phosphorylated,O,O
CREB,O,B
proteins,O,O
during,O,O
B,O,B
-,O,I
cell,O,I
activation,O,O
and,O,O
rescue,O,O
from,O,O
apoptosis,O,O
.,O,O
Engagement,O,O
of,O,O
surface,O,O
immunoglobulin,O,O
on,O,O
mature,O,O
B,O,B
cells,O,I
leads,O,O
to,O,O
rescue,O,O
from,O,O
apoptosis,O,O
and,O,O
to,O,O
proliferation,O,O
.,O,O
These,O,O
stimuli,O,O
result,O,O
in,O,O
phosphorylation,O,O
of,O,O
CREB,B,B
at,O,O
serine,O,O
133,O,O
.,O,O
It,O,O
is,O,O
possible,O,O
that,O,O
the,O,O
CRE,B,B
site,I,I
is,O,O
responsible,O,O
for,O,O
induction,O,O
of,O,O
bcl,B,B
-,I,I
expression,O,I
in,O,O
other,O,O
cell,O,O
types,O,O
",",O,O
particularly,O,O
those,O,O
in,O,O
which,O,O
protein,B,B
kinase,I,I
C,I,I
is,O,O
involved,O,O
.,O,O
MNDA,B,B
(,O,O
myeloid,B,O
cell,I,O
nuclear,I,O
differentiation,I,O
antigen,I,O
),O,O
is,O,O
an,O,O
interferon,B,O
alpha,I,O
regulated,I,O
nuclear,I,O
protein,I,O
expressed,O,O
only,O,O
in,O,O
cells,O,O
of,O,O
the,O,O
human,O,O
myelomonocytic,O,O
lineage,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
DNA,O,B
methylation,O,I
was,O,O
revealed,O,O
as,O,O
one,O,O
of,O,O
the,O,O
possible,O,O
factors,O,O
in,O,O
establishing,O,O
MNDA,B,B
expression,O,O
.,O,O
This,O,O
abnormality,O,O
was,O,O
not,O,O
seen,O,O
in,O,O
resting,O,O
T,O,O
cells,O,O
nor,O,O
T,O,O
cells,O,O
from,O,O
patients,O,O
with,O,O
systemic,O,O
lupus,O,O
erythematosus,O,O
",",O,O
rheumatoid,O,O
arthritis,O,O
(,O,O
RA,O,O
),O,O
",",O,O
or,O,O
SS,O,O
accompanied,O,O
by,O,O
RA,O,O
.,O,O
Characterization,O,O
of,O,O
a,O,O
new,O,O
isoform,O,O
of,O,O
the,O,O
NFAT,B,B
(,O,O
nuclear,B,I
factor,I,I
of,I,I
activated,I,I
T,I,I
cells,I,I
),O,O
gene,O,O
family,O,O
member,O,O
NFATc,B,B
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
J,O,O
Biol,O,O
Chem,O,O
1996,O,O
Dec,O,O
27,O,O
;,O,O
271,O,O
(,O,O
52,O,O
),O,O
:,O,O
33705,O,O
],O,O
The,O,O
amino,B,O
acid,I,O
sequence,I,O
of,O,O
NFATc,B,B
.,I,O
beta,I,O
differs,O,O
from,O,O
that,O,O
of,O,O
NFATc,B,B
.,O,O
Transient,O,O
expression,O,O
of,O,O
NFATc,B,B
.,I,O
beta,I,O
was,O,O
capable,O,O
of,O,O
activating,O,O
an,O,O
interleukin,B,O
-,I,O
2,I,O
NFAT,I,B
-,I,O
driven,I,O
reporter,I,O
gene,I,O
in,O,O
stimulated,O,O
Jurkat,O,O
cells,O,O
in,O,O
a,O,O
CsA,O,O
-,O,O
sensitive,O,O
manner,O,O
.,O,O
However,O,O
",",O,O
NFATc,B,B
.,I,O
beta,I,O
neither,O,O
bound,O,O
to,O,O
the,O,O
kappa3,B,O
element,I,O
(,O,O
an,O,O
NFAT,B,B
-,I,I
binding,I,I
site,I,I
),O,O
in,O,O
the,O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
promoter,I,O
nor,O,O
activated,O,O
the,O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
promoter,I,O
in,O,O
cotransfection,O,O
assays,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
examined,O,O
seven,O,O
EBV,O,O
-,O,O
positive,O,O
gastric,O,O
carcinoma,O,O
tissues,O,O
for,O,O
viral,O,O
gene,O,O
expression,O,O
at,O,O
the,O,O
mRNA,O,O
level,O,O
",",O,O
from,O,O
which,O,O
studies,O,O
on,O,O
the,O,O
EBV,O,O
oncogenicity,O,O
in,O,O
human,O,O
epithelial,O,O
cells,O,O
will,O,O
benefit,O,O
.,O,O
Both,O,O
are,O,O
located,O,O
in,O,O
the,O,O
particulate,O,O
fraction,O,O
following,O,O
platelet,O,B
activation,O,O
and,O,O
are,O,O
also,O,O
able,O,O
to,O,O
bind,O,O
to,O,O
a,O,O
GST,B,O
-,I,O
construct,I,O
containing,O,O
the,O,O
SH2,B,B
and,I,O
SH3,I,B
domains,I,I
of,O,I
phospholipase,B,I
C,I,I
gamma,I,I
1,I,I
.,O,O
Constitutive,O,O
expression,O,O
of,O,O
specific,O,O
interferon,B,B
isotypes,I,I
in,O,O
peripheral,O,B
blood,O,I
leukocytes,O,I
from,O,O
normal,O,O
individuals,O,O
and,O,O
in,O,O
promonocytic,O,B
U937,O,I
cells,O,O
.,O,O
Constitutive,O,O
expression,O,O
of,O,O
IFN,B,B
-,I,I
alpha5,I,I
and,O,O
IFN,B,B
-,I,I
beta,I,I
was,O,O
detected,O,O
in,O,O
different,O,O
lymphoid,O,O
cells,O,O
including,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
from,O,O
normal,O,O
individuals,O,O
following,O,O
amplification,O,O
of,O,O
IFN,B,B
mRNA,I,I
by,O,O
reverse,B,O
transcriptase,I,O
-,O,O
polymerase,O,O
chain,O,O
reaction,O,O
and,O,O
direct,O,O
sequencing,O,O
of,O,O
the,O,O
amplified,B,O
product,I,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
IFN,B,B
-,I,I
alpha5,I,I
and,O,O
IFN,B,B
-,I,I
beta,I,I
are,O,O
produced,O,O
at,O,O
low,O,O
levels,O,O
in,O,O
normal,O,O
tissues,O,O
and,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
cell,O,O
function,O,O
and,O,O
in,O,O
the,O,O
maintenance,O,O
of,O,O
homeostasis,O,O
.,O,O
Thus,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
-,O,I
induced,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
promoter,I,O
activity,O,O
requires,O,O
a,O,O
complex,B,O
upstream,I,O
element,I,O
",",O,O
which,O,O
appears,O,O
to,O,O
contain,O,O
binding,B,O
sites,I,O
for,O,O
both,O,O
positive,B,O
and,I,O
negative,I,O
regulatory,I,O
factors,I,O
.,O,O
Lymphocytes,O,O
from,O,O
CML,O,O
patients,O,O
lack,O,O
a,O,O
47,B,O
kDa,I,O
factor,I,O
having,O,O
affinity,O,O
for,O,O
a,O,O
genomic,B,O
sterol,I,O
regulatory,I,O
sequence,I,O
.,O,O
The,O,O
proximal,B,O
sequence,I,O
element,I,O
(,I,O
PSE,I,O
),I,O
-,I,O
binding,I,O
transcription,I,O
factor,I,O
(,O,O
PTF,B,O
),O,O
",",O,O
which,O,O
binds,O,O
the,O,O
PSE,B,O
of,O,O
both,O,O
RNA,B,B
polymerase,I,I
II,I,I
-,I,I
and,I,O
RNA,I,B
polymerase,I,I
III,I,I
-,I,I
transcribed,I,O
mammalian,I,O
small,I,O
nuclear,I,O
RNA,I,B
(,I,I
snRNA,I,I
),I,I
genes,I,O
",",O,O
is,O,O
essential,O,O
for,O,O
their,O,O
transcription,O,O
.,O,O
Here,O,O
we,O,O
describe,O,O
the,O,O
isolation,O,O
and,O,O
expression,O,O
of,O,O
a,O,O
cDNA,B,B
encoding,O,O
PTF,B,B
beta,I,I
",",O,O
as,O,O
well,O,O
as,O,O
functional,O,O
studies,O,O
using,O,O
anti,B,O
-,I,O
PTF,I,B
beta,I,I
antibodies,I,I
.,O,O
We,O,O
report,O,O
here,O,O
on,O,O
the,O,O
identification,O,O
of,O,O
a,O,O
17,B,O
kDa,I,O
variant,I,O
of,O,O
the,O,O
14,B,O
kDa,I,O
Id,I,B
-,I,I
3,I,I
protein,O,I
termed,O,O
Id,B,B
-,I,I
3L,I,I
(,O,O
long,O,O
version,O,O
),O,O
which,O,O
possesses,O,O
a,O,O
unique,O,O
60,B,O
amino,I,O
acid,I,O
carboxy,I,O
-,I,O
terminus,I,O
generated,O,O
by,O,O
read,O,O
through,O,O
of,O,O
a,O,O
coding,B,O
intron,I,O
and,O,O
alternative,O,O
splicing,O,O
.,O,O
Tyloxapol,O,O
inhibits,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
cytokine,B,O
release,O,O
",",O,O
scavenges,O,O
HOCI,B,O
",",O,O
and,O,O
reduces,O,O
viscosity,O,O
of,O,O
cystic,O,O
fibrosis,O,O
sputum,O,O
.,O,O
In,O,O
the,O,O
search,O,O
for,O,O
a,O,O
potential,O,O
treatment,O,O
",",O,O
we,O,O
have,O,O
tested,O,O
tyloxapol,O,O
",",O,O
an,O,O
alkylaryl,O,O
polyether,O,O
alcohol,O,O
polymer,O,O
detergent,O,O
previously,O,O
used,O,O
as,O,O
a,O,O
mucolytic,O,O
agent,O,O
in,O,O
adult,O,O
chronic,O,O
bronchitis,O,O
.,O,O
Tyloxapol,O,O
inhibits,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
nuclear,I,O
factor,I,B
-,I,I
kappa,I,I
B,I,I
(,O,O
NK,B,O
-,I,O
kappa,I,O
B,I,O
),O,O
",",O,O
reduces,O,O
resting,O,O
secretion,O,O
of,O,O
the,O,O
cytokine,B,O
interleukin,B,B
-,I,I
8,I,I
(,O,O
IL,B,O
-,I,O
8,I,O
),O,O
in,O,O
cultured,O,O
human,O,B
monocytes,O,I
",",O,O
and,O,O
inhibits,O,O
lipopolysaccharide,O,B
(,O,O
LPS,O,O
),O,O
-,O,O
stimulated,O,O
release,O,O
of,O,O
tumor,B,B
necrosis,I,I
factor,I,I
-,I,I
alpha,I,I
(,O,O
TNF,B,O
-,I,O
alpha,I,O
),O,O
",",O,O
IL,B,O
-,I,O
1,I,O
beta,I,O
",",O,O
IL,B,O
-,I,O
6,I,O
",",O,O
IL,B,O
-,I,O
8,I,O
",",O,O
granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,O,O
GM,B,O
-,I,O
CSF,I,O
),O,O
",",O,O
and,O,O
the,O,O
eiconsanoids,O,O
thromboxane,O,B
A2,O,I
and,O,O
leukotriene,O,B
B4,O,I
(,O,O
LTB4,O,O
),O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
examined,O,O
the,O,O
molecular,O,O
mechanism,O,O
by,O,O
which,O,O
agents,O,O
that,O,O
elevate,O,O
intracellular,O,O
cAMP,O,O
inhibit,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
(,O,O
TNFalpha,B,B
),O,O
",",O,O
tissue,B,O
factor,I,O
",",O,O
endothelial,B,O
leukocyte,I,O
adhesion,I,O
molecule,I,O
-,I,O
1,I,O
",",O,O
and,O,O
vascular,B,O
cell,I,O
adhesion,I,O
molecule,I,O
-,I,O
1,I,O
genes,I,O
.,O,O
We,O,O
propose,O,O
that,O,O
direct,O,O
interaction,O,O
between,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
and,O,O
nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
factors,I,O
is,O,O
at,O,O
least,O,O
a,O,O
partial,O,O
explanation,O,O
for,O,O
the,O,O
effects,O,O
of,O,O
this,O,O
hormone,O,O
in,O,O
inflammatory,O,O
diseases,O,O
.,O,O
Abnormalities,O,O
in,O,O
the,O,O
p16,B,B
",",I,O
p15,I,B
and,I,O
CDK4,I,B
genes,I,O
that,O,O
regulate,O,O
transition,O,O
through,O,O
the,O,O
G1,O,O
phase,O,O
of,O,O
the,O,O
cell,O,O
cycle,O,O
have,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
malignant,O,O
progression,O,O
of,O,O
astrocytomas,O,O
.,O,O
The,O,O
primary,O,O
and,O,O
recurrent,O,O
tumors,O,O
in,O,O
Group,O,O
A,O,O
did,O,O
not,O,O
show,O,O
structural,O,O
alterations,O,O
in,O,O
the,O,O
p16,B,B
",",I,O
p15,I,B
or,I,O
CDK4,I,B
genes,I,O
",",O,O
whereas,O,O
homozygous,O,O
codeletion,O,O
of,O,O
p16,B,B
and,O,O
p15,B,B
was,O,O
observed,O,O
in,O,O
both,O,O
primary,O,O
and,O,O
recurrent,O,O
tumors,O,O
in,O,O
Group,O,O
B,O,O
.,O,O
The,O,O
primary,O,O
tumors,O,O
in,O,O
Group,O,O
C,O,O
had,O,O
a,O,O
normal,O,O
profile,O,O
of,O,O
p16,B,B
",",O,O
p15,B,B
and,O,O
CDK4,B,B
at,O,O
presentation,O,O
.,O,O
Approximately,O,O
40,O,O
%,O,O
of,O,O
diffuse,O,O
large,O,O
cell,O,O
lymphoma,O,O
are,O,O
associated,O,O
with,O,O
chromosomal,O,O
translocations,O,O
that,O,O
deregulate,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
BCL6,B,B
gene,I,O
by,O,O
juxtaposing,O,O
heterologous,B,O
promoters,I,O
to,O,O
the,O,O
BCL,B,B
-,I,I
6,I,I
coding,I,I
domain,I,I
.,O,O
In,O,O
transient,O,O
transfectin,O,O
experiments,O,O
",",O,O
BCL6,B,B
can,O,O
repress,O,O
transcription,O,O
from,O,O
promoters,B,O
linked,O,O
to,O,O
its,O,O
DNA,B,B
target,I,I
sequence,I,I
and,O,O
this,O,O
activity,O,O
is,O,O
dependent,O,O
upon,O,O
specific,O,O
DNA,O,B
-,O,I
binding,O,I
and,O,O
the,O,O
presence,O,O
of,O,O
an,O,O
intact,O,O
N,B,B
-,I,I
terminal,I,I
half,I,I
of,O,O
the,O,O
protein,O,O
.,O,O
As,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
transcription,I,I
factor,I,I
has,O,O
a,O,O
central,O,O
role,O,O
in,O,O
the,O,O
control,O,O
of,O,O
transcription,O,O
of,O,O
several,O,O
genes,B,O
involved,O,O
in,O,O
immune,O,O
and,O,O
inflammatory,O,O
responses,O,O
",",O,O
the,O,O
authors,O,O
have,O,O
analysed,O,O
the,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
human,O,O
umbilical,O,O
cord,O,O
T,O,O
lymphocytes,O,O
.,O,O
The,O,O
key,O,O
role,O,O
of,O,O
erythropoietin,B,B
(,O,O
Epo,B,O
),O,O
for,O,O
colony,O,O
formation,O,O
by,O,O
early,O,O
erythroid,O,O
progenitors,O,O
(,O,O
burst,O,O
-,O,O
forming,O,O
units,O,O
-,O,O
erythroid,O,O
[,O,O
BFU,O,O
-,O,O
E,O,O
],O,O
),O,O
has,O,O
been,O,O
confirmed,O,O
.,O,O
High,O,O
concentrations,O,O
of,O,O
either,O,O
compound,O,O
(,O,O
1,O,O
),O,O
drastically,O,O
reduced,O,O
the,O,O
number,O,O
of,O,O
primary,O,O
HPP,O,O
-,O,O
CFC,O,O
colonies,O,O
and,O,O
totally,O,O
abolished,O,O
their,O,O
recloning,O,O
capacity,O,O
and,O,O
(,O,O
2,O,O
),O,O
inhibited,O,O
HSC,O,O
proliferation,O,O
.,O,O
Altogether,O,O
",",O,O
these,O,O
results,O,O
suggest,O,O
that,O,O
ATRA,O,B
/,O,I
9,O,I
-,O,I
cis,O,I
RA,O,I
may,O,O
play,O,O
a,O,O
key,O,O
role,O,O
in,O,O
FL,O,O
hematopoiesis,O,O
via,O,O
a,O,O
dual,O,O
effect,O,O
hypothetically,O,O
mediated,O,O
by,O,O
interaction,O,O
with,O,O
the,O,O
RAR,B,B
/,I,I
RXR,I,I
heterodimer,I,O
",",O,O
ie,O,O
",",O,O
inhibition,O,O
of,O,O
HSC,O,O
/,O,O
primitive,O,O
HPC,O,O
proliferation,O,O
and,O,O
induction,O,O
of,O,O
CFU,O,B
-,O,I
GEMM,O,I
/,O,I
BFU,O,I
-,O,I
E,O,I
/,O,I
CFU,O,I
-,O,I
M,O,I
shift,O,O
from,O,O
the,O,O
multipotent,O,O
/,O,O
erythroid,O,O
/,O,O
monocytic,O,O
to,O,O
the,O,O
granulocytic,O,O
-,O,O
neutrophilic,O,O
differentiation,O,O
program,O,O
.,O,O
We,O,O
previously,O,O
suggested,O,O
that,O,O
the,O,O
measurement,O,O
of,O,O
corticosteroid,B,B
receptors,I,I
in,O,O
lymphocytes,O,O
is,O,O
an,O,O
index,O,O
of,O,O
an,O,O
analogous,O,O
pattern,O,O
in,O,O
brain,O,O
.,O,O
Receptors,O,O
were,O,O
measured,O,O
by,O,O
radioreceptor,O,O
assay,O,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
ligand,B,O
-,I,O
binding,I,O
domain,I,O
of,O,O
human,B,O
retinoic,I,B
acid,I,I
receptor,I,I
alpha,I,I
by,O,O
site,O,O
-,O,O
directed,O,O
mutagenesis,O,O
.,O,O
Three,O,O
subtypes,O,O
of,O,O
retinoic,B,B
acid,I,I
receptors,I,I
(,O,O
RAR,B,O
),O,O
",",O,O
termed,O,O
RAR,B,O
alpha,I,O
",",O,O
RAR,B,O
beta,I,O
",",O,O
and,O,O
RAR,B,O
gamma,I,O
",",O,O
have,O,O
been,O,O
described,O,O
.,O,O
RARs,B,B
specifically,O,O
bind,O,O
all,O,O
-,O,O
trans,O,O
-,O,O
retinoic,O,B
acid,O,I
(,O,O
RA,O,B
),O,O
",",O,O
9,O,B
-,O,I
cis,O,I
-,O,I
RA,O,I
",",O,O
and,O,O
retinoid,O,B
analogs,O,I
.,O,O
Interestingly,O,O
",",O,O
residue,O,O
C,O,B
-,O,I
235,O,I
is,O,O
specifically,O,O
important,O,O
in,O,O
antagonist,O,O
binding,O,O
.,O,O
With,O,O
respect,O,O
to,O,O
arginine,O,B
residues,O,I
",",O,O
only,O,O
the,O,O
two,O,O
single,O,O
mutations,O,O
of,O,O
R,O,B
-,O,I
276,O,I
and,O,O
R,O,B
-,O,I
394,O,I
to,O,O
alanine,O,O
showed,O,O
a,O,O
dramatic,O,O
decrease,O,O
of,O,O
agonist,O,O
and,O,O
antagonist,O,O
binding,O,O
whereas,O,O
the,O,O
R272A,O,O
mutation,O,O
showed,O,O
only,O,O
a,O,O
slight,O,O
effect,O,O
.,O,O
For,O,O
all,O,O
other,O,O
arginine,O,B
mutations,O,O
",",O,O
no,O,O
differences,O,O
in,O,O
affinity,O,O
were,O,O
detectable,O,O
.,O,O
The,O,O
two,O,O
mutations,O,O
R217A,O,B
and,O,O
R294A,O,B
caused,O,O
an,O,O
increased,O,O
binding,O,O
efficiency,O,O
for,O,O
antagonists,O,O
but,O,O
no,O,O
change,O,O
in,O,O
agonist,O,O
binding,O,O
.,O,O
From,O,O
these,O,O
results,O,O
",",O,O
we,O,O
can,O,O
conclude,O,O
that,O,O
electrostatic,O,O
interactions,O,O
of,O,O
retinoids,O,O
with,O,O
the,O,O
RAR,B,B
alpha,I,I
-,I,I
LBD,I,I
play,O,O
a,O,O
significant,O,O
role,O,O
in,O,O
ligand,O,O
binding,O,O
.,O,O
In,O,O
spite,O,O
of,O,O
this,O,O
similar,O,O
downstream,O,O
signalling,O,O
",",O,O
IL4,B,B
and,O,O
IL13,B,B
used,O,O
a,O,O
different,O,O
set,O,O
of,O,O
Janus,B,O
kinases,I,O
:,O,O
IL13,B,B
is,O,O
unable,O,O
to,O,O
activate,O,O
JAK1,B,B
and,O,O
JAK3,B,B
.,O,O
Our,O,O
findings,O,O
support,O,O
the,O,O
recently,O,O
determined,O,O
calcineurin,B,B
X,O,I
-,O,I
ray,O,I
crystal,O,I
structure,O,I
",",O,O
provide,O,O
evidence,O,O
that,O,O
calcineurin,B,B
is,O,O
the,O,O
only,O,O
CsA,B,B
-,I,I
sensitive,I,I
component,I,I
limiting,O,O
signaling,O,O
from,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
to,O,O
the,O,O
nucleus,O,O
",",O,O
and,O,O
suggest,O,O
a,O,O
means,O,O
to,O,O
render,O,O
cells,O,O
and,O,O
tissues,O,O
resistant,O,O
to,O,O
the,O,O
toxic,O,O
side,O,O
effects,O,O
of,O,O
CsA,O,B
and,O,O
FK506,O,B
.,O,O
Epstein,O,B
-,O,I
Barr,O,I
viral,O,O
latency,O,O
is,O,O
disrupted,O,O
by,O,O
the,O,O
immediate,B,O
-,I,O
early,I,O
BRLF1,I,B
protein,I,O
through,O,O
a,O,O
cell,O,O
-,O,O
specific,O,O
mechanism,O,O
.,O,O
Epithelial,O,B
cells,O,O
are,O,O
the,O,O
major,O,O
site,O,O
of,O,O
lytic,O,O
EBV,O,B
replication,O,O
within,O,O
the,O,O
human,O,O
host,O,O
",",O,O
and,O,O
viral,O,O
reactivation,O,O
occurs,O,O
in,O,O
EBV,O,B
-,O,I
associated,O,I
nasopharyngeal,O,I
carcinomas,O,I
.,O,O
Eosinophils,O,B
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
effector,O,O
phase,O,O
of,O,O
allergic,O,O
inflammation,O,O
.,O,O
The,O,O
extent,O,O
to,O,O
which,O,O
peptides,O,O
containing,O,O
chemically,O,O
and,O,O
post,O,O
-,O,O
translationally,O,O
modified,O,O
amino,B,O
acid,I,O
side,I,O
chains,I,O
are,O,O
recognized,O,O
by,O,O
primed,O,O
CTL,O,O
has,O,O
not,O,O
been,O,O
clearly,O,O
defined,O,O
.,O,O
The,O,O
CTL,O,O
specifically,O,O
recognized,O,O
the,O,O
succinimide,O,O
-,O,O
containing,O,O
peptide,O,O
showing,O,O
only,O,O
weak,O,O
cross,O,O
-,O,O
reactivity,O,O
at,O,O
high,O,O
concentrations,O,O
of,O,O
the,O,O
parent,O,O
peptide,O,O
containing,O,O
unmodified,O,O
asparagine,O,O
.,O,O
Moreover,O,O
",",O,O
since,O,O
succinimide,O,O
intermediates,O,O
of,O,O
deamidated,O,O
peptides,O,O
can,O,O
occasionally,O,O
be,O,O
very,O,O
stable,O,O
",",O,O
these,O,O
peptides,O,O
have,O,O
the,O,O
potential,O,O
to,O,O
act,O,O
as,O,O
altered,O,O
self,O,O
-,O,O
Ags,O,O
with,O,O
significant,O,O
implications,O,O
for,O,O
autoimmunity,O,O
.,O,O
A,O,O
3,O,O
-,O,O
>,O,O
5,O,O
XPB,B,O
helicase,I,O
defect,O,O
in,O,O
repair,B,O
/,I,O
transcription,I,O
factor,I,O
TFIIH,B,O
of,O,O
xeroderma,O,O
pigmentosum,O,O
group,O,O
B,O,O
affects,O,O
both,O,O
DNA,O,B
repair,O,O
and,O,O
transcription,O,O
.,O,O
Although,O,O
identical,O,O
in,O,O
composition,O,O
and,O,O
stoichiometry,O,O
to,O,O
TFIIHwt,B,O
",",O,O
TFIIHmut,B,O
shows,O,O
a,O,O
reduced,O,O
3,O,O
-,O,O
>,O,O
5,O,O
XPB,B,B
helicase,O,O
activity,O,O
.,O,O
The,O,O
XPB,B,B
mutation,O,O
causes,O,O
a,O,O
severe,O,O
NER,O,O
defect,O,O
.,O,O
The,O,O
latter,O,O
defect,O,O
may,O,O
provide,O,O
an,O,O
explanation,O,O
for,O,O
many,O,O
of,O,O
the,O,O
XP,O,O
and,O,O
CS,O,O
symptoms,O,O
that,O,O
are,O,O
difficult,O,O
to,O,O
rationalize,O,O
based,O,O
solely,O,O
on,O,O
an,O,O
NER,O,O
defect,O,O
.,O,O
PU,B,B
.,I,O
1,I,O
is,O,O
completely,O,O
absent,O,O
from,O,O
peripheral,O,B
T,O,I
cells,O,I
and,O,O
most,O,O
T,O,B
cell,O,I
lines,O,I
based,O,O
on,O,O
sensitive,O,O
RT,O,O
-,O,O
PCR,O,O
assays,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
Spi,B,B
-,I,O
B,I,I
is,O,O
expressed,O,O
exclusively,O,O
in,O,O
lymphoid,O,B
cells,O,I
and,O,O
can,O,O
be,O,O
detected,O,O
in,O,O
early,O,O
fetal,O,O
thymus,O,O
and,O,O
spleen,O,O
.,O,O
In,O,O
situ,O,O
hybridization,O,O
and,O,O
Northern,O,O
blot,O,O
analysis,O,O
suggest,O,O
that,O,O
Spi,B,B
-,I,O
B,I,I
gene,O,O
expression,O,O
increases,O,O
during,O,O
B,O,B
cell,O,I
maturation,O,I
and,O,O
decreases,O,O
during,O,O
T,O,B
cell,O,I
maturation,O,I
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
data,O,O
suggest,O,O
that,O,O
differences,O,O
in,O,O
patterns,O,O
of,O,O
expression,O,O
between,O,O
Spi,B,B
-,I,I
B,I,I
and,O,O
PU,B,B
.,I,I
distinguish,O,O
the,O,O
function,O,O
of,O,O
each,O,O
protein,O,O
during,O,O
development,O,O
of,O,O
the,O,O
immune,O,B
system,O,I
.,O,O
DNase,B,B
I,I,I
hypersensitive,I,I
site,I,I
(,O,O
DHS,B,O
),O,O
mapping,O,O
revealed,O,O
that,O,O
the,O,O
perforin,B,B
locus,I,I
contained,O,O
six,O,O
DHS,B,O
within,O,O
7,O,O
.,O,O
0,O,O
kb,O,O
of,O,O
the,O,O
5,B,O
upstream,I,O
sequence,I,O
(,O,O
-,O,O
7,O,O
0,O,O
kb,O,O
),O,O
and,O,O
two,O,O
DHS,B,O
in,O,O
intron,B,O
2,I,O
.,O,O
Chloramphenicol,B,O
acetyltransferase,I,O
(,O,O
CAT,B,B
),O,O
activities,O,O
directed,O,O
by,O,O
5,B,O
upstream,I,O
promoter,I,O
were,O,O
detected,O,O
preferentially,O,O
in,O,O
perforin,O,O
-,O,O
expressing,O,O
cell,O,O
lines,O,O
.,O,O
When,O,O
single,O,O
-,O,O
point,O,O
mutation,O,O
was,O,O
introduced,O,O
to,O,O
each,O,O
GC,B,O
box,I,O
",",O,O
EBS,B,O
",",O,O
and,O,O
GT,B,O
box,I,O
in,O,O
PFP9a20,B,O
",",O,O
at,O,O
least,O,O
3,O,O
-,O,O
fold,O,O
less,O,O
CAT,B,O
activity,O,O
was,O,O
observed,O,O
in,O,O
CTLL,O,O
-,O,O
R8,O,O
cells,O,O
.,O,O
The,O,O
results,O,O
suggest,O,O
that,O,O
a,O,O
combination,O,O
of,O,O
the,O,O
three,O,O
proximal,O,O
cis,B,O
-,I,O
acting,I,O
elements,I,O
may,O,O
constitute,O,O
a,O,O
minimal,O,O
region,O,O
responsible,O,O
for,O,O
CTL,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
perforin,B,B
.,O,O
Thus,O,O
Oct,B,O
-,I,O
2,I,O
plays,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
cellular,O,O
gene,O,O
expression,O,O
in,O,O
both,O,O
B,O,O
cells,O,O
and,O,O
neuronal,O,O
cells,O,O
as,O,O
well,O,O
as,O,O
in,O,O
the,O,O
control,O,O
of,O,O
viral,O,O
latency,O,O
.,O,O
Instead,O,O
",",O,O
ATF,B,B
-,I,I
2,I,I
and,O,O
Jun,B,B
proteins,I,I
bind,O,O
to,O,O
the,O,O
composite,B,O
kappa,I,B
3,I,I
/,I,I
CRE,I,I
site,I,I
and,O,O
NFATp,B,B
binds,O,O
to,O,O
a,O,O
newly,O,O
identified,O,O
second,O,O
NFAT,B,B
site,I,I
centered,O,O
at,O,O
-,B,O
76,I,O
nucleotides,I,O
relative,O,O
to,O,O
the,O,O
TNF,B,B
-,I,I
alpha,I,I
transcription,I,O
start,I,O
site,I,O
.,O,O
Consistent,O,O
with,O,O
these,O,O
results,O,O
",",O,O
quantitative,O,O
DNase,B,B
footprinting,O,I
of,O,O
the,O,O
TNF,B,B
-,I,I
alpha,I,I
promoter,I,O
using,O,O
increasing,O,O
amounts,O,O
of,O,O
recombinant,O,O
NFATp,B,B
demonstrated,O,O
that,O,O
the,O,O
-,B,O
76,I,O
site,I,O
binds,O,O
to,O,O
NFATp,B,B
with,O,O
a,O,O
higher,O,O
affinity,O,O
than,O,O
the,O,O
kappa,B,B
3,I,I
site,I,I
.,O,O
Thus,O,O
",",O,O
through,O,O
the,O,O
differential,O,O
use,O,O
of,O,O
the,O,O
same,O,O
promoter,B,O
element,I,O
",",O,O
the,O,O
composite,B,O
kappa,I,B
3,I,I
/,I,I
CRE,I,I
site,I,I
",",O,O
the,O,O
TNF,B,B
-,I,I
alpha,I,I
gene,I,O
is,O,O
regulated,O,O
in,O,O
a,O,O
cell,O,B
-,O,I
type,O,I
-,O,I
specific,O,I
manner,O,O
in,O,O
response,O,O
to,O,O
the,O,O
same,O,O
extracellular,O,O
signal,O,O
.,O,O
To,O,O
address,O,O
possible,O,O
mechanisms,O,O
that,O,O
could,O,O
explain,O,O
this,O,O
selective,O,O
activity,O,O
of,O,O
c,B,O
-,I,O
ErbB,I,O
",",O,O
we,O,O
analyzed,O,O
the,O,O
ability,O,O
of,O,O
these,O,O
receptors,O,O
to,O,O
activate,O,O
the,O,O
different,O,O
members,O,O
of,O,O
the,O,O
Stat,B,B
transcription,I,I
factor,I,I
family,I,O
.,O,O
Ligand,O,O
activation,O,O
of,O,O
c,B,O
-,I,O
ErbB,I,B
induced,O,O
the,O,O
tyrosine,O,O
phosphorylation,O,O
",",O,O
DNA,O,B
-,O,I
binding,O,I
",",O,O
and,O,O
reporter,B,O
gene,I,O
transcription,O,O
of,O,O
Stat,B,B
5b,I,I
in,O,O
erythroblasts,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
ligand,O,O
activation,O,O
of,O,O
c,B,O
-,I,O
Kit,I,B
was,O,O
unable,O,O
to,O,O
induce,O,O
any,O,O
of,O,O
these,O,O
effects,O,O
in,O,O
the,O,O
same,O,O
cells,O,O
.,O,O
Sequence,O,O
-,O,O
specific,O,O
DNA,O,B
binding,O,I
of,O,O
the,O,O
B,B,B
-,I,I
cell,I,I
-,I,I
specific,I,I
coactivator,I,I
OCA,B,I
-,I,I
B,I,I
.,O,O
While,O,O
one,O,O
of,O,O
the,O,O
twins,O,O
was,O,O
clinically,O,O
affected,O,O
",",O,O
the,O,O
other,O,O
was,O,O
asymptomatic,O,O
.,O,O
This,O,O
is,O,O
the,O,O
first,O,O
documented,O,O
case,O,O
of,O,O
female,O,O
twins,O,O
discordant,O,O
for,O,O
Fabry,O,O
disease,O,O
.,O,O
Precise,O,O
alignment,B,O
of,I,O
sites,I,O
required,O,O
for,O,O
mu,B,B
enhancer,I,O
activation,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
The,O,O
lymphocyte,B,O
-,I,O
specific,I,O
immunoglobulin,I,O
mu,I,B
heavy,I,I
-,I,I
chain,I,I
gene,I,O
intronic,I,O
enhancer,I,O
is,O,O
regulated,O,O
by,O,O
multiple,O,O
nuclear,B,O
factors,I,O
.,O,O
The,O,O
previously,O,O
defined,O,O
minimal,B,O
enhancer,I,O
containing,O,O
the,O,O
muA,B,B
",",I,O
muE3,I,B
",",I,O
and,I,O
muB,I,B
sites,I,O
is,O,O
transactivated,O,O
by,O,O
a,O,O
combination,O,O
of,O,O
the,O,O
ETS,B,B
-,I,I
domain,I,I
proteins,I,O
PU,B,B
.,I,I
Ets,B,B
-,I,I
1,I,I
in,O,O
nonlymphoid,O,O
cells,O,O
.,O,O
The,O,O
core,O,O
GGAAs,O,O
of,O,O
the,O,O
muA,B,B
and,I,O
muB,I,B
sites,I,O
are,O,O
separated,O,O
by,O,O
30,O,O
nucleotides,O,O
",",O,O
suggesting,O,O
that,O,O
ETS,B,B
proteins,I,O
bind,O,O
to,O,O
these,O,O
sites,O,O
from,O,O
these,O,O
same,O,O
side,O,O
of,O,O
the,O,O
DNA,O,B
helix,O,O
.,O,O
In,O,O
allergic,O,O
bronchial,O,O
asthma,O,O
",",O,O
inflammation,O,O
seems,O,O
to,O,O
be,O,O
orchestrated,O,O
predominantly,O,O
by,O,O
a,O,O
subset,O,O
of,O,O
T,O,O
lymphocytes,O,O
",",O,O
with,O,O
a,O,O
phenotype,O,O
similar,O,O
to,O,O
the,O,O
Th2,O,O
subset,O,O
able,O,O
to,O,O
produce,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
5,I,I
.,O,O
Some,O,O
criteria,O,O
which,O,O
can,O,O
be,O,O
used,O,O
to,O,O
define,O,O
steroid,O,B
-,O,I
resistant,O,I
bronchial,O,I
asthma,O,I
are,O,O
listed,O,O
here,O,O
.,O,O
Mechanisms,O,O
of,O,O
transactivation,O,O
by,O,O
nuclear,B,B
factor,I,I
of,I,I
activated,I,I
T,I,I
cells,I,I
-,I,I
1,I,I
.,O,O
Nuclear,B,B
factor,I,I
of,I,I
activated,I,I
T,I,I
cells,I,I
-,I,I
family,I,I
proteins,I,I
(,O,O
NFAT1,B,B
/,I,I
NFATp,I,I
",",O,O
NFATc,B,B
",",O,O
NFAT3,B,B
",",O,O
and,O,O
NFAT4,B,B
/,I,I
NFATx,I,I
/,I,I
NFATc3,I,I
),O,O
play,O,O
a,O,O
key,O,O
role,O,O
in,O,O
the,O,O
transcription,O,O
of,O,O
cytokine,B,O
genes,I,O
and,O,O
other,O,O
genes,O,O
during,O,O
the,O,O
immune,O,O
response,O,O
.,O,O
Our,O,O
results,O,O
emphasize,O,O
the,O,O
multiple,O,O
levels,O,O
at,O,O
which,O,O
NFAT,O,B
-,O,I
dependent,O,I
transactivation,O,I
is,O,O
regulated,O,O
",",O,O
and,O,O
predict,O,O
significant,O,O
differences,O,O
in,O,O
the,O,O
architecture,O,O
of,O,O
cooperative,O,O
transcription,B,O
complexes,I,O
containing,O,O
different,O,O
NFAT,B,B
-,I,I
family,I,I
proteins,I,I
.,O,O
A,O,O
major,O,O
obstacle,O,O
in,O,O
understanding,O,O
the,O,O
signaling,O,O
events,O,O
that,O,O
follow,O,O
CD28,B,B
receptor,O,I
ligation,O,O
arises,O,O
from,O,O
the,O,O
fact,O,O
that,O,O
CD28,B,B
acts,O,O
as,O,O
a,O,O
costimulus,O,O
to,O,O
TCR,B,B
engagement,O,O
",",O,O
making,O,O
it,O,O
difficult,O,O
to,O,O
assess,O,O
the,O,O
relative,O,O
contribution,O,O
of,O,O
CD28,B,B
signals,O,O
as,O,O
distinct,O,O
from,O,O
those,O,O
of,O,O
the,O,O
TCR,B,B
.,O,O
This,O,O
revealed,O,O
that,O,O
NF,B,B
-,I,I
kappaB,I,I
generation,O,O
was,O,O
sensitive,O,O
to,O,O
chloroquine,O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
acidic,B,O
sphingomyelinase,I,O
",",O,O
but,O,O
not,O,O
to,O,O
the,O,O
phosphatidylinositol,B,O
3,I,O
-,I,O
kinase,I,O
inhibitor,O,O
",",O,O
wortmannin,O,O
.,O,O
To,O,O
investigate,O,O
the,O,O
presence,O,O
of,O,O
various,O,O
isoforms,O,O
of,O,O
the,O,O
estrogen,B,B
receptor,I,I
(,O,O
ER,B,O
),O,O
in,O,O
SLE,O,O
we,O,O
isolated,O,O
RNA,O,B
from,O,O
mononuclear,O,B
cells,O,I
of,O,O
lupus,O,O
patients,O,O
and,O,O
normal,O,O
controls,O,O
.,O,O
It,O,O
is,O,O
expressed,O,O
on,O,O
a,O,O
subpopulation,O,O
of,O,O
macrophages,O,B
in,O,O
lymphoid,O,B
tissues,O,I
and,O,O
in,O,O
chronic,O,O
inflammation,O,O
(,O,O
e,O,O
.,O,O
g,O,O
.,O,O
",",O,O
during,O,O
autoimmune,O,O
diseases,O,O
),O,O
.,O,O
Sialoadhesin,B,B
expression,O,O
was,O,O
functional,O,O
as,O,O
shown,O,O
by,O,O
cell,O,O
adhesion,O,O
assays,O,O
with,O,O
human,O,B
RBCs,O,I
.,O,O
Northern,O,O
blotting,O,O
experiments,O,O
indicated,O,O
that,O,O
regulation,O,O
predominantly,O,O
occurred,O,O
at,O,O
the,O,O
mRNA,O,B
level,O,I
.,O,O
The,O,O
results,O,O
suggest,O,O
a,O,O
new,O,O
option,O,O
for,O,O
HIV,O,B
gene,O,I
therapy,O,I
;,O,O
bcl,B,O
-,I,O
2,I,O
muteins,I,O
that,O,O
have,O,O
noncleavable,B,O
alterations,I,O
surrounding,O,O
the,O,O
HIV,B,B
protease,I,I
cleavage,I,I
site,I,I
.,O,O
In,O,O
contrast,O,O
to,O,O
freshly,O,O
isolated,O,O
T,O,O
cells,O,O
",",O,O
in,O,O
vitro,O,O
-,O,O
cultured,O,O
T,O,O
cells,O,O
did,O,O
not,O,O
require,O,O
costimulation,O,O
for,O,O
cytokine,B,O
secretion,O,O
in,O,O
response,O,O
to,O,O
anti,B,O
-,I,O
CD3,I,O
alone,O,O
.,O,O
The,O,O
induction,O,O
of,O,O
T,O,O
cell,O,O
proliferation,O,O
requires,O,O
signals,O,O
from,O,O
the,O,O
TCR,B,O
and,O,O
a,O,O
co,B,O
-,I,O
receptor,I,O
molecule,I,O
",",O,O
such,O,O
as,O,O
CD28,B,O
",",O,O
that,O,O
activate,O,O
parallel,O,O
and,O,O
partially,O,O
cross,O,O
-,O,O
reactive,O,O
signaling,O,O
pathways,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
PKA,B,B
inhibits,O,O
T,O,O
cell,O,O
activation,O,O
by,O,O
interfering,O,O
with,O,O
multiple,O,O
events,O,O
along,O,O
the,O,O
two,O,O
signaling,O,O
pathways,O,O
operating,O,O
downstream,O,O
of,O,O
the,O,O
TCR,B,O
and,O,O
the,O,O
CD28,B,O
co,I,O
-,I,O
receptor,I,O
molecules,I,O
.,O,O
This,O,O
pattern,O,O
of,O,O
STAT,B,B
activation,O,O
was,O,O
seen,O,O
in,O,O
all,O,O
BCP,O,O
-,O,O
ALL,O,O
cases,O,O
that,O,O
respond,O,O
to,O,O
IL,B,B
-,I,I
7,I,I
in,O,O
proliferation,O,O
assays,O,O
.,O,O
To,O,O
determine,O,O
the,O,O
contribution,O,O
of,O,O
the,O,O
cytoplasmic,B,O
domain,I,O
of,O,O
the,O,O
IL,B,B
-,I,I
7,I,I
receptor,I,I
alpha,I,I
chain,I,I
(,O,O
IL,B,B
-,I,I
7R,I,I
alpha,I,I
),O,O
to,O,O
activation,O,O
of,O,O
STAT,B,B
proteins,I,I
",",O,O
transfectants,O,O
of,O,O
the,O,O
murine,O,O
pro,O,O
-,O,O
B,O,O
cell,O,O
line,O,O
BAF3,O,O
were,O,O
made,O,O
that,O,O
express,O,O
chimeric,B,O
receptors,I,O
consisting,O,O
of,O,O
the,O,O
extracellular,B,O
domain,I,O
of,O,O
human,B,O
granulocyte,I,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
receptor,I,I
(,O,O
G,B,B
-,I,I
CSF,I,I
-,I,I
R,I,I
),O,O
and,O,O
the,O,O
transmembrane,B,O
and,I,O
intracellular,I,O
domains,I,O
of,O,O
human,B,O
IL,I,B
-,I,I
7R,I,I
alpha,I,I
.,O,O
The,O,O
oligo,O,O
sequence,O,O
I,O,O
stimulated,O,O
proliferation,O,O
of,O,O
both,O,O
T,O,O
and,O,O
",",O,O
to,O,O
a,O,O
lesser,O,O
extent,O,O
",",O,O
B,O,O
cells,O,O
.,O,O
The,O,O
percentage,O,O
of,O,O
cells,O,O
expressing,O,O
CD40,B,O
in,O,O
T,O,O
and,O,O
B,O,O
cell,O,O
co,O,O
-,O,O
cultures,O,O
increased,O,O
from,O,O
4,O,O
.,O,O
2,O,O
%,O,O
to,O,O
13,O,O
.,O,O
8,O,O
%,O,O
after,O,O
oligo,O,O
stimulation,O,O
in,O,O
patients,O,O
",",O,O
while,O,O
it,O,O
increased,O,O
form,O,O
4,O,O
.,O,O
7,O,O
%,O,O
to,O,O
48,O,O
.,O,O
6,O,O
%,O,O
in,O,O
healthy,O,O
controls,O,O
.,O,O
We,O,O
demonstrate,O,O
that,O,O
CaMKIV,B,O
/,I,O
Gr,I,O
reconstitutes,O,O
the,O,O
capacity,O,O
of,O,O
the,O,O
cytosolic,O,O
component,O,O
of,O,O
NFAT,B,O
to,O,O
direct,O,O
transcription,O,O
from,O,O
NFAT,B,O
sites,I,O
in,O,O
non,O,O
-,O,O
T,O,O
cells,O,O
.,O,O
This,O,O
was,O,O
identified,O,O
as,O,O
the,O,O
mRNA,B,B
encoding,O,O
the,O,O
transcription,B,O
factor,I,O
egr,B,B
-,I,I
1,I,I
",",O,O
which,O,O
is,O,O
expressed,O,O
with,O,O
fast,O,O
kinetics,O,O
in,O,O
T,O,O
and,O,O
NK,O,B
cells,O,O
upon,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
but,O,O
not,O,O
IL,B,B
-,I,I
12,I,I
",",O,O
stimulation,O,O
.,O,O
Increasing,O,O
the,O,O
levels,O,O
of,O,O
BCL,B,B
-,I,I
2,I,I
retarded,O,O
the,O,O
G0,O,O
-,O,O
-,O,O
S,O,O
transition,O,O
",",O,O
sustained,O,O
the,O,O
levels,O,O
of,O,O
cyclin,B,B
-,I,I
dependent,I,I
kinase,I,I
inhibitor,O,I
p27Kip1,O,O
",",O,O
and,O,O
repressed,O,O
postactivation,O,O
death,O,O
.,O,O
However,O,O
",",O,O
the,O,O
transcription,O,O
and,O,O
synthesis,O,O
of,O,O
interleukin,B,B
2,I,I
and,O,O
other,O,O
delayed,O,O
early,O,O
cytokines,B,O
were,O,O
markedly,O,O
attenuated,O,O
by,O,O
BCL,B,O
-,I,O
2,I,O
.,O,O
On,O,O
the,O,O
basis,O,O
of,O,O
several,O,O
independent,O,O
assays,O,O
",",O,O
we,O,O
now,O,O
report,O,O
a,O,O
physical,O,O
and,O,O
functional,O,O
interaction,O,O
between,O,O
Tax,B,O
and,O,O
the,O,O
transcription,B,O
factor,I,O
",",O,O
TFIIA,B,O
.,O,O
Finally,O,O
",",O,O
TFIIA,B,O
facilitates,O,O
Tax,B,O
transactivation,O,O
in,O,O
vitro,O,O
and,O,O
in,O,O
vivo,O,O
.,O,O
Inhibition,O,O
of,O,O
transcription,B,O
factor,I,O
Stat1,B,B
activity,O,O
in,O,O
mononuclear,O,B
cell,O,I
cultures,O,O
and,O,O
T,O,O
cells,O,O
by,O,O
the,O,O
cyclic,O,O
AMP,O,B
signaling,O,I
pathway,O,I
.,O,O
Suppression,O,O
of,O,O
c,B,O
-,I,O
jun,I,B
by,O,O
antisense,O,O
oligonucleotides,O,O
inhibits,O,O
cell,O,O
adhesion,O,O
but,O,O
not,O,O
respiratory,O,O
burst,O,O
during,O,O
phorbol,O,O
ester,O,O
-,O,O
induced,O,O
differentiation,O,O
of,O,O
U937,O,B
human,O,I
monoblastic,O,I
cells,O,I
.,O,O
GM,B,B
-,I,I
CSF,I,I
gene,I,O
activation,O,O
in,O,O
T,O,O
cells,O,O
is,O,O
known,O,O
to,O,O
involve,O,O
the,O,O
transcription,B,O
factors,I,O
nuclear,B,B
factor,I,I
-,I,I
kappa,I,I
B,I,I
",",O,O
AP,B,B
-,I,I
1,I,I
",",O,O
NFAT,B,B
",",O,O
and,O,O
Sp1,O,B
.,O,O
A,O,O
2,B,O
-,I,O
bp,I,O
mutation,I,O
within,O,O
the,O,O
CBF,B,O
site,O,O
resulted,O,O
in,O,O
a,O,O
2,O,O
-,O,O
3,O,O
-,O,O
fold,O,O
decrease,O,O
in,O,O
the,O,O
activities,O,O
of,O,O
both,O,O
a,O,O
69,B,O
-,I,O
bp,I,O
proximal,I,O
promoter,I,O
fragment,I,O
and,O,O
a,O,O
627,B,O
-,I,O
bp,I,O
full,I,O
-,I,O
length,I,O
promoter,I,O
fragment,I,O
.,O,O
The,O,O
AML1,B,B
and,I,O
CBF,I,B
beta,I,I
genes,I,O
that,O,O
encode,O,O
CBF,B,B
each,O,O
have,O,O
the,O,O
ability,O,O
to,O,O
influence,O,O
cell,O,O
growth,O,O
and,O,O
differentiation,O,O
and,O,O
have,O,O
been,O,O
implicated,O,O
as,O,O
proto,B,O
-,I,O
oncogenes,I,O
in,O,O
acute,O,O
myeloid,O,O
leukemia,O,O
.,O,O
The,O,O
GM,B,O
-,I,O
CSF,I,O
locus,I,O
may,O,O
represent,O,O
one,O,O
of,O,O
several,O,O
target,O,O
genes,B,O
that,O,O
are,O,O
dysregulated,O,O
in,O,O
acute,O,O
myeloid,O,O
leukemia,O,O
.,O,O
The,O,O
preferential,O,O
induction,O,O
of,O,O
c,B,B
-,I,I
jun,I,I
by,O,O
H2O2,O,O
did,O,O
not,O,O
represent,O,O
redox,O,O
stabilization,O,O
of,O,O
mRNA,B,O
transcripts,I,O
",",O,O
and,O,O
oxidative,O,O
signals,O,O
closely,O,O
resembled,O,O
PHA,O,O
/,O,O
PMA,O,O
stimulation,O,O
by,O,O
effectively,O,O
transactivating,O,O
the,O,O
full,O,O
length,O,O
c,B,B
-,I,I
jun,I,I
promoter,O,O
via,O,O
the,O,O
proximal,B,O
tumor,I,O
promoter,I,O
-,I,O
responsive,I,O
element,I,O
(,I,O
TRE,I,O
),I,O
-,I,O
like,I,O
promoter,I,O
element,I,O
.,O,O
Furthermore,O,O
",",O,O
sublethal,O,O
levels,O,O
of,O,O
H2O2,O,B
actively,O,O
suppressed,O,O
the,O,O
transcriptional,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
and,O,O
IL,B,B
-,I,I
2,I,I
reporters,I,O
as,O,O
well,O,O
as,O,O
the,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
mRNA,I,O
in,O,O
cells,O,O
stimulated,O,O
with,O,O
PHA,O,O
/,O,O
PMA,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
oxidative,O,O
signals,O,O
can,O,O
positively,O,O
and,O,O
negatively,O,O
regulate,O,O
T,O,O
cell,O,O
transcriptional,O,O
events,O,O
and,O,O
that,O,O
changes,O,O
in,O,O
cellular,O,O
redox,O,O
can,O,O
uncouple,O,O
AP,B,O
-,I,O
1,I,O
regulation,O,O
of,O,O
c,B,O
-,I,O
jun,I,O
from,O,O
transcriptional,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
via,O,O
NF,B,B
-,I,I
AT,I,I
.,O,O
Many,O,O
of,O,O
Pb,O,O
s,O,O
effects,O,O
on,O,O
the,O,O
immune,O,O
system,O,O
could,O,O
be,O,O
explained,O,O
through,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Tyrosine,B,O
kinase,I,O
and,O,O
cAMP,B,O
-,I,O
dependent,I,O
protein,I,O
kinase,I,O
activities,O,O
in,O,O
CD40,O,O
-,O,O
activated,O,O
human,O,O
B,O,O
lymphocytes,O,O
.,O,O
In,O,O
vitro,O,O
",",O,O
human,O,O
B,O,O
lymphocytes,O,O
undergo,O,O
long,O,O
-,O,O
term,O,O
proliferation,O,O
when,O,O
activated,O,O
through,O,O
CD40,B,O
",",O,O
a,O,O
protein,O,O
expressed,O,O
on,O,O
their,O,O
cell,O,O
surface,O,O
.,O,O
Rather,O,O
",",O,O
tyrosine,O,B
phosphorylation,O,I
was,O,O
shown,O,O
to,O,O
be,O,O
directly,O,O
involved,O,O
in,O,O
mediating,O,O
CD40,B,O
-,O,O
dependent,O,O
signals,O,O
.,O,O
To,O,O
examine,O,O
the,O,O
potential,O,O
effects,O,O
of,O,O
stress,O,O
on,O,O
TH1,O,O
/,O,O
TH2,O,O
balance,O,O
",",O,O
we,O,O
studied,O,O
the,O,O
ability,O,O
of,O,O
three,O,O
prototype,O,O
stress,O,O
hormones,O,O
-,O,O
dexamethasone,O,O
(,O,O
a,O,O
synthetic,O,O
glucocorticoid,O,O
),O,O
and,O,O
the,O,O
catecholamines,O,O
norepinephrine,O,O
and,O,O
epinephrine,O,O
-,O,O
to,O,O
alter,O,O
the,O,O
production,O,O
of,O,O
IL,B,B
-,I,I
12,I,I
(,O,O
p70,B,O
),O,O
and,O,O
IL,B,B
-,I,I
10,I,I
induced,O,O
by,O,O
bacterial,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
in,O,O
human,O,O
whole,O,O
blood,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
either,O,O
catecholamine,O,O
on,O,O
IL,B,B
-,I,I
12,I,I
or,O,O
IL,B,B
-,I,I
secretion,O,O
were,O,O
blocked,O,O
completely,O,O
by,O,O
propranolol,O,O
",",O,O
a,O,O
beta,O,B
-,O,I
adrenoreceptor,O,I
antagonist,O,O
",",O,O
indicating,O,O
that,O,O
they,O,O
were,O,O
mediated,O,O
by,O,O
the,O,O
beta,B,B
-,I,I
adrenergic,I,I
receptor,I,I
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
may,O,O
regulate,O,O
IL,O,B
-,O,I
12,O,I
and,O,O
IL,O,B
-,O,I
10,O,I
secretion,O,O
and,O,O
",",O,O
hence,O,O
",",O,O
TH1,O,O
/,O,O
TH2,O,O
balance,O,O
via,O,O
the,O,O
peripheral,O,O
end,O,O
-,O,O
effectors,O,O
of,O,O
the,O,O
stress,O,O
system,O,O
.,O,O
There,O,O
is,O,O
increasing,O,O
evidence,O,O
that,O,O
lipoproteins,B,B
of,O,O
Treponema,O,O
pallidum,O,O
and,O,O
Borrelia,O,O
burgdorferi,O,O
are,O,O
key,O,O
inflammatory,O,O
mediators,O,O
during,O,O
syphilis,O,O
and,O,O
Lyme,O,O
disease,O,O
.,O,O
Acylation,O,O
of,O,O
OspA,B,B
and,O,O
the,O,O
synthetic,O,O
peptides,O,O
was,O,O
requisite,O,O
for,O,O
cell,O,O
activation,O,O
.,O,O
Polymyxin,O,B
B,O,I
abrogated,O,O
only,O,O
the,O,O
response,O,O
to,O,O
LPS,O,B
.,O,O
Finally,O,O
",",O,O
the,O,O
biological,O,O
relevance,O,O
of,O,O
the,O,O
observation,O,O
that,O,O
T,B,O
pallidum,I,O
lipoproteins,I,O
-,O,O
lipopeptides,O,O
induce,O,O
both,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
cytokine,B,O
production,O,O
in,O,O
monocytes,O,O
was,O,O
supported,O,O
by,O,O
the,O,O
ability,O,O
of,O,O
the,O,O
synthetic,O,O
analogs,O,O
to,O,O
promote,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
replication,O,O
in,O,O
chronically,O,O
infected,O,O
U1,O,O
monocytoid,O,O
cells,O,O
;,O,O
these,O,O
observations,O,O
also,O,O
suggest,O,O
a,O,O
potential,O,O
mechanism,O,O
whereby,O,O
a,O,O
syphilitic,O,O
chancre,O,O
can,O,O
serve,O,O
as,O,O
a,O,O
cofactor,O,O
for,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
transmission,O,O
.,O,O
The,O,O
present,O,O
study,O,O
describes,O,O
the,O,O
cloning,O,O
of,O,O
a,O,O
lymphoid,B,B
-,I,I
restricted,I,I
gene,I,O
",",O,O
LYSP100,B,O
",",O,O
that,O,O
is,O,O
homologous,O,O
to,O,O
another,O,O
protein,O,O
that,O,O
localizes,O,O
to,O,O
PML,O,B
NBs,O,I
",",O,O
SP100,B,O
.,O,O
We,O,O
term,O,O
the,O,O
LYSP100,B,O
structures,O,O
`,O,O
`,O,O
LANDs,O,O
",",O,O
for,O,O
LYSP100,B,O
-,O,O
associated,O,O
nuclear,O,O
domains,O,O
.,O,O
Immunoelectron,O,O
microscopy,O,O
revealed,O,O
LANDs,O,O
to,O,O
be,O,O
globular,O,O
",",O,O
electron,O,O
-,O,O
dense,O,O
structures,O,O
morphologically,O,O
distinct,O,O
from,O,O
the,O,O
annular,O,O
structures,O,O
characteristic,O,O
of,O,O
PML,O,B
NBs,O,I
.,O,O
Transcriptional,O,O
control,O,O
of,O,O
steroid,O,B
-,O,I
regulated,O,I
apoptosis,O,I
in,O,O
murine,O,O
thymoma,O,B
cells,O,O
.,O,O
Early,O,O
studies,O,O
in,O,O
murine,O,O
T,O,O
cell,O,O
lines,O,O
indicated,O,O
that,O,O
transcriptional,O,O
transactivation,O,O
functions,O,O
encoded,O,O
in,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
(,I,O
GR,I,O
),I,O
N,I,O
-,I,O
terminal,I,O
domain,I,O
are,O,O
required,O,O
for,O,O
glucocorticoid,O,B
-,O,I
mediated,O,I
apoptosis,O,I
.,O,O
To,O,O
better,O,O
understand,O,O
the,O,O
contribution,O,O
of,O,O
the,O,O
GR,B,O
N,I,O
-,I,O
terminal,I,O
transactivation,I,O
domain,I,O
in,O,O
mediating,O,O
murine,O,O
thymocyte,O,B
apoptosis,O,I
",",O,O
we,O,O
stably,O,O
transfected,O,O
GR,B,O
",",O,O
GR,B,O
variants,I,O
",",O,O
and,O,O
the,O,O
androgen,B,B
receptor,I,I
(,O,O
AR,B,O
),O,O
into,O,O
receptor,O,O
-,O,O
negative,O,O
S49,O,O
murine,O,O
thymoma,O,B
cells,O,O
.,O,O
One,O,O
p21ras,B,B
effector,O,I
pathway,O,I
involves,O,O
the,O,O
MAP,B,B
kinase,I,I
ERK,B,I
-,I,I
2,I,I
",",O,O
and,O,O
we,O,O
have,O,O
examined,O,O
its,O,O
role,O,O
in,O,O
NFAT,B,B
regulation,O,O
.,O,O
In,O,O
vivo,O,O
differentiation,O,O
therapy,O,O
with,O,O
retinoids,O,O
in,O,O
APL,O,O
patients,O,O
follows,O,O
strict,O,O
guidelines,O,O
related,O,O
both,O,O
to,O,O
the,O,O
APL,O,O
cell,O,O
and,O,O
the,O,O
biodisposal,O,O
of,O,O
all,O,O
-,O,O
trans,O,O
retinoic,O,O
acid,O,O
.,O,O
IL,O,B
-,O,I
2,O,I
-,O,I
",",O,O
IL,O,B
-,O,I
12,O,I
-,O,I
",",O,O
and,O,O
IFN,O,B
-,O,I
alpha,O,I
-,O,I
mediated,O,O
signaling,O,O
pathways,O,O
were,O,O
analyzed,O,O
in,O,O
primary,O,O
NK,O,B
cells,O,O
and,O,O
in,O,O
the,O,O
NK3,O,O
.,O,O
3,O,O
cell,O,B
line,O,I
.,O,O
Gel,O,O
mobility,O,O
shift,O,O
and,O,O
immunoprecipitation,O,O
analyses,O,O
revealed,O,O
that,O,O
in,O,O
addition,O,O
to,O,O
activating,O,O
STAT3,B,B
(,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
-,I,O
3,I,I
),O,O
and,O,O
STAT5,B,B
",",O,O
IL,B,B
-,I,I
2,I,I
induced,O,O
tyrosine,O,O
and,O,O
serine,O,O
phosphorylation,O,O
of,O,O
STAT1,B,B
alpha,I,I
",",O,O
which,O,O
formed,O,O
IFN,B,B
-,I,I
gamma,I,I
-,I,I
activated,I,I
sequence,I,I
-,I,I
binding,I,I
complexes,I,I
by,O,O
itself,O,O
and,O,O
with,O,O
STAT3,B,B
.,O,O
Although,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IFN,B,B
-,I,I
alpha,I,I
activated,O,O
STAT1,B,B
alpha,I,I
and,O,O
STAT5,B,B
",",O,O
IL,B,B
-,I,I
2,I,I
predominantly,O,O
activated,O,O
STAT5,B,B
",",O,O
while,O,O
IFN,B,B
-,I,I
alpha,I,I
predominantly,O,O
activated,O,O
STAT1,B,B
alpha,I,I
.,O,O
STAT1,B,B
alpha,I,I
activation,O,O
by,O,O
IL,B,B
-,I,I
12,I,I
correlated,O,O
with,O,O
increased,O,O
phosphorylation,O,O
of,O,O
serine,O,O
",",O,O
but,O,O
not,O,O
tyrosine,O,O
.,O,O
Direct,O,O
evidence,O,O
that,O,O
N,O,O
-,O,O
acetylcysteine,O,O
(,O,O
NAC,O,O
),O,O
enhances,O,O
the,O,O
immune,O,O
response,O,O
of,O,O
peripheral,O,O
blood,O,O
T,O,O
cells,O,O
at,O,O
the,O,O
level,O,O
of,O,O
NF,B,B
(,I,I
kappa,I,I
),I,I
B,I,I
is,O,O
presented,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
NAC,O,O
blocks,O,O
the,O,O
suppression,O,O
of,O,O
T,O,O
cell,O,O
mitogenesis,O,O
and,O,O
cytokine,B,O
production,O,O
by,O,O
protease,O,O
inhibitors,O,O
such,O,O
as,O,O
N,O,O
-,O,O
tosylphenylalanine,O,O
chloromethyl,O,O
ketone,O,O
(,O,O
TPCK,O,O
),O,O
.,O,O
Strikingly,O,O
",",O,O
the,O,O
immunosuppressive,O,O
effects,O,O
of,O,O
TPCK,O,O
are,O,O
blocked,O,O
when,O,O
T,O,O
cells,O,O
are,O,O
pretreated,O,O
for,O,O
15,O,O
min,O,O
with,O,O
5,O,O
mM,O,O
NAC,O,O
.,O,O
Our,O,O
data,O,O
support,O,O
the,O,O
notion,O,O
that,O,O
NF,B,B
(,I,O
kappa,I,I
),I,O
B,I,O
and,O,O
I,B,B
(,I,O
kappa,I,I
),I,O
B,I,O
proteases,I,O
play,O,O
obligate,O,O
roles,O,O
in,O,O
T,O,O
cell,O,O
activation,O,O
and,O,O
mitogenesis,O,O
",",O,O
roles,O,O
that,O,O
are,O,O
enhanced,O,O
significantly,O,O
by,O,O
NAC,O,O
.,O,O
Recently,O,O
it,O,O
has,O,O
become,O,O
clear,O,O
that,O,O
these,O,O
cytokines,B,O
activate,O,O
a,O,O
number,O,O
of,O,O
important,O,O
intracellular,B,O
signaling,I,O
molecules,I,O
",",O,O
including,O,O
the,O,O
Janus,B,B
kinases,I,I
JAK1,B,O
and,O,O
JAK3,B,O
and,O,O
members,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
family,I,O
of,O,O
signal,B,O
transducers,I,O
and,O,O
activators,B,O
of,I,O
transcription,I,O
(,O,O
STATs,B,O
),O,O
.,O,O
In,O,O
this,O,O
review,O,O
we,O,O
examine,O,O
the,O,O
structure,O,O
and,O,O
function,O,O
of,O,O
cytokine,B,O
receptors,I,O
and,O,O
the,O,O
signaling,O,O
pathways,O,O
involved,O,O
in,O,O
their,O,O
regulation,O,O
of,O,O
gene,O,O
expression,O,O
.,O,O
Retinoic,O,B
acid,O,I
(,O,O
RA,O,B
),O,O
and,O,O
1,O,O
",",O,O
25,O,O
alpha,O,O
-,O,O
dihydroxycholecalcif,O,O
(,O,O
VitD3,O,B
),O,O
are,O,O
potent,O,O
regulators,O,O
of,O,O
hematopoletic,O,O
differentiation,O,O
.,O,O
Yet,O,O
",",O,O
little,O,O
is,O,O
known,O,O
as,O,O
to,O,O
how,O,O
the,O,O
RA,B,B
and,I,O
VitD3,I,B
receptor,I,O
network,I,O
operates,O,O
in,O,O
hematopoietic,O,O
cells,O,O
",",O,O
and,O,O
whether,O,O
receptor,O,O
interactions,O,O
can,O,O
explain,O,O
the,O,O
interplay,O,O
between,O,O
the,O,O
RA,O,B
-,O,O
and,O,O
VitD3,O,B
-,O,O
signaling,O,O
pathways,O,O
during,O,O
differentiation,O,O
.,O,O
Therefore,O,O
",",O,O
we,O,O
analyzed,O,O
the,O,O
expression,O,O
",",O,O
DNA,O,B
binding,O,O
",",O,O
and,O,O
transcriptional,O,O
activity,O,O
of,O,O
the,O,O
endogenous,B,O
RA,I,B
and,I,O
VitD3,I,B
receptors,I,O
[,O,O
retinoic,B,B
acid,I,I
receptors,I,I
(,O,O
RARs,B,O
),O,O
",",O,O
retinoid,B,B
X,I,I
receptors,I,I
(,O,O
RXRs,B,O
),O,O
",",O,O
and,O,O
VitD3,B,B
receptor,I,I
(,O,O
VDR,B,O
),O,O
],O,O
in,O,O
the,O,O
U,O,O
-,O,O
937,O,O
cell,O,O
line,O,O
",",O,O
in,O,O
which,O,O
RA,O,B
and,O,O
VitD3,O,B
induce,O,O
distinct,O,O
monocytic,O,O
differentiation,O,O
pathways,O,O
.,O,O
However,O,O
",",O,O
transcriptional,O,O
activation,O,O
was,O,O
only,O,O
observed,O,O
from,O,O
a,O,O
VitD3,B,B
response,I,I
element,I,I
-,I,I
driven,I,I
reporter,I,I
construct,I,I
.,O,O
Also,O,O
",",O,O
VitD3,O,B
inhibited,O,O
the,O,O
expression,O,O
of,O,O
CD23,B,O
and,O,O
CD49f,B,O
",",O,O
characteristic,O,O
markers,O,O
of,O,O
retinoid,O,O
-,O,O
induced,O,O
U,O,B
-,O,I
937,O,I
cell,O,I
differentiation,O,I
.,O,O
Freshly,O,O
isolated,O,O
monocytes,O,O
expressed,O,O
94,B,O
-,I,O
kD,I,O
STAT5A,I,B
",",O,O
92,O,O
-,O,O
kD,O,O
STAT5B,B,B
",",O,O
and,O,O
an,O,O
80,B,O
-,I,O
kD,I,O
STAT5A,I,B
molecule,I,O
.,O,O
STAT5A,B,B
-,I,I
STAT5A,I,I
homodimers,I,O
and,O,O
STAT5A,B,B
-,I,I
STAT5B,I,I
heterodimers,I,O
formed,O,O
in,O,O
response,O,O
to,O,O
GM,B,O
-,I,O
CSF,I,O
.,O,O
Translocation,B,O
(,I,O
3,I,O
;,I,O
14,I,O
),I,O
(,I,O
q27,I,O
;,I,O
q11,I,O
),I,O
:,O,O
a,O,O
new,O,O
variant,O,O
translocation,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
non,O,B
-,O,I
Hodgkin,O,I
s,O,I
lymphoma,O,I
of,O,I
B,O,I
-,O,I
cell,O,I
type,O,I
with,O,O
BCL6,B,B
rearrangement,O,O
.,O,O
Southern,O,O
blot,O,O
analysis,O,O
showed,O,O
rearrangement,O,O
of,O,O
BCL6,B,B
",",O,O
JH,B,B
",",O,O
and,O,O
TCR,B,B
beta,I,I
but,O,O
not,O,O
of,O,O
TCR,B,B
delta,I,I
.,O,O
Basal,O,O
total,O,O
white,O,B
blood,O,I
cell,O,I
and,O,O
granulocyte,O,B
counts,O,I
did,O,O
not,O,O
appreciably,O,O
differ,O,O
between,O,O
PML,B,O
/,I,O
RARalpha,I,O
transgenic,O,O
and,O,O
control,O,O
mice,O,O
.,O,O
As,O,O
expected,O,O
",",O,O
nearly,O,O
all,O,O
control,O,O
mice,O,O
(,O,O
94,O,O
.,O,O
4,O,O
%,O,O
),O,O
survived,O,O
irradiation,O,O
",",O,O
yet,O,O
this,O,O
irradiation,O,O
was,O,O
lethal,O,O
to,O,O
45,O,O
.,O,O
8,O,O
%,O,O
of,O,O
PML,B,O
/,I,O
RARalpha,I,O
transgenic,O,O
mice,O,O
.,O,O
B,O,B
-,O,I
cell,O,I
immortalization,O,I
by,O,O
Epstein,O,B
-,O,I
Barr,O,I
virus,O,I
(,O,O
EBV,O,O
),O,O
is,O,O
dependent,O,O
on,O,O
permanent,O,O
control,O,O
of,O,O
the,O,O
cellular,O,B
processes,O,I
which,O,O
normally,O,O
regulate,O,O
cell,O,B
division,O,I
and,O,O
apoptosis,O,I
",",O,O
functions,O,O
possessed,O,O
by,O,O
p53,B,O
in,O,O
a,O,O
number,O,O
of,O,O
normal,O,O
cell,O,B
types,O,I
.,O,O
Latent,B,B
membrane,I,I
protein,I,I
1,I,I
and,O,O
",",O,O
to,O,O
a,O,O
lesser,O,O
extent,O,O
",",O,O
EBV,B,B
nuclear,I,I
antigen,I,I
2,I,I
mediated,O,O
the,O,O
increase,O,O
in,O,O
p53,B,B
levels,O,O
via,O,O
activation,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
transcription,B,I
factor,I,I
.,O,O
Tissue,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
interleukin,B,B
-,I,I
3,I,I
(,O,I
IL,B,I
-,I,I
3,I,I
),O,I
is,O,O
mediated,O,O
via,O,O
cis,B,O
-,I,O
acting,I,O
elements,I,O
located,O,O
within,O,O
315,O,O
base,O,O
pairs,O,O
of,O,O
the,O,O
transcription,B,O
start,I,O
.,O,O
In,O,O
addition,O,O
to,O,O
the,O,O
already,O,O
identified,O,O
NIP,B,O
repressor,I,O
site,I,O
",",O,O
evidence,O,O
is,O,O
presented,O,O
for,O,O
a,O,O
second,B,O
repressor,I,O
region,I,O
that,O,O
restricts,O,O
promoter,O,O
activity,O,O
in,O,O
fibroblasts,O,O
.,O,O
In,O,O
the,O,O
current,O,O
studies,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
production,O,O
by,O,O
T,O,O
cells,O,O
from,O,O
elderly,O,O
(,O,O
mean,O,O
78,O,O
years,O,O
),O,O
and,O,O
young,O,O
(,O,O
mean,O,O
37,O,O
years,O,O
),O,O
humans,O,O
was,O,O
measured,O,O
in,O,O
cultures,O,O
stimulated,O,O
with,O,O
PHA,B,O
",",O,O
PHA,B,O
plus,O,O
PMA,O,O
",",O,O
crosslinked,O,O
anti,O,O
-,O,O
CD3,O,O
mAB,O,O
OKT3,O,O
plus,O,O
PMA,O,O
",",O,O
or,O,O
PMA,O,O
plus,O,O
ionomycin,O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
T,O,O
cells,O,O
from,O,O
elderly,O,O
subjects,O,O
with,O,O
normal,O,O
levels,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
exhibited,O,O
normal,O,O
activation,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
and,O,O
NF,B,B
-,I,I
AT,I,I
.,O,O
IL,B,B
-,I,I
13,I,I
caused,O,O
rapid,O,O
phosphorylation,O,O
of,O,O
the,O,O
three,O,O
out,O,O
of,O,O
four,O,O
members,O,O
of,O,O
the,O,O
known,O,O
Janus,B,B
family,I,I
of,I,I
kinases,I,I
(,O,O
JAKs,B,O
),O,O
.,O,O
IL,B,B
-,I,I
4,I,I
also,O,O
stimulated,O,O
all,O,O
three,O,O
kinases,B,O
and,O,O
substrates,O,O
",",O,O
but,O,O
unlike,O,O
in,O,O
immune,O,B
cells,O,I
",",O,O
IL,B,B
-,I,I
4,I,I
did,O,O
not,O,O
involve,O,O
JAK3,B,O
activation,O,O
for,O,O
its,O,O
signaling,O,O
in,O,O
colon,O,B
cancer,O,I
cell,O,I
lines,O,I
.,O,O
Furthermore,O,O
",",O,O
JAK2,B,B
associated,O,O
with,O,O
the,O,O
IL,B,B
-,I,I
4R,I,I
p140,I,I
before,O,O
and,O,O
after,O,O
stimulation,O,O
with,O,O
IL,B,B
-,I,I
13,I,I
.,O,O
Differential,O,O
regulation,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
gene,I,I
transcription,O,O
and,O,O
expression,O,O
by,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
10,I,I
in,O,O
human,O,O
monocytic,O,B
cell,O,I
lines,O,I
.,O,O
To,O,O
investigate,O,O
the,O,O
molecular,O,O
mechanism,O,O
of,O,O
the,O,O
inhibitory,O,O
effect,O,O
on,O,O
transcriptional,O,O
or,O,O
post,O,O
-,O,O
transcriptional,O,O
regulation,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
gene,I,I
expression,O,O
by,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
10,I,I
",",O,O
we,O,O
studied,O,O
IL,B,B
-,I,I
6,I,I
production,O,O
",",O,O
expression,O,O
level,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
mRNA,I,I
",",O,O
IL,B,B
-,I,I
6,I,I
promoter,O,I
activity,O,O
",",O,O
transcriptional,O,O
activity,O,O
of,O,O
NF,B,O
-,I,O
kappaB,I,O
and,O,O
NF,B,O
-,I,O
IL,I,O
-,I,O
6,I,O
",",O,O
and,O,O
IL,B,B
-,I,I
6,I,I
mRNA,I,I
stability,O,O
in,O,O
human,O,O
monocytic,O,B
cell,O,I
lines,O,I
",",O,O
THP,O,B
-,O,I
1,O,I
and,O,O
U937,O,B
",",O,O
stimulated,O,O
by,O,O
PMA,O,O
and,O,O
LPS,O,O
in,O,O
the,O,O
absence,O,O
or,O,O
the,O,O
presence,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
or,O,O
IL,B,B
-,I,I
10,I,I
.,O,O
In,O,O
chloramphenicol,B,B
acetyltransferase,I,I
assays,O,O
",",O,O
utilizing,O,O
the,O,O
transient,O,O
transfection,O,O
of,O,O
a,O,O
chloramphenicol,B,B
acetyltransferase,I,I
reporter,I,I
plasmid,I,I
containing,O,O
the,O,O
IL,B,B
-,I,I
6,I,I
gene,I,I
promoter,I,I
",",O,O
IL,B,B
-,I,I
4,I,I
",",O,O
but,O,O
not,O,O
IL,B,B
-,I,I
10,I,I
",",O,O
suppressed,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
the,O,O
IL,O,B
-,O,I
6,O,I
gene,O,I
promoter,O,I
stimulated,O,O
by,O,O
PMA,O,O
and,O,O
LPS,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
IL,B,B
-,I,I
10,I,I
enhanced,O,O
the,O,O
degradation,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
mRNA,I,I
in,O,O
a,O,O
mRNA,O,B
stability,O,I
assay,O,I
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
IL,B,B
-,I,I
4,I,I
may,O,O
inhibit,O,O
the,O,O
transcription,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
6,I,I
gene,I,O
by,O,O
affecting,O,O
NF,B,B
-,I,I
kappaB,I,I
binding,O,I
activity,O,O
",",O,O
while,O,O
IL,B,B
-,I,I
10,I,I
may,O,O
inhibit,O,O
the,O,O
IL,B,B
-,I,I
6,I,I
mRNA,I,I
levels,O,O
post,O,O
-,O,O
transcriptionally,O,O
",",O,O
without,O,O
suppressing,O,O
promoter,O,O
activity,O,O
.,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
by,O,O
CsA,O,O
-,O,O
treated,O,O
cells,O,O
is,O,O
therefore,O,O
dramatically,O,O
reduced,O,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
showed,O,O
the,O,O
induction,O,O
of,O,O
a,O,O
CsA,B,O
-,I,O
resistant,I,O
NFAT,I,B
complex,I,O
in,O,O
the,O,O
nuclear,O,O
extracts,O,O
of,O,O
peripheral,O,O
blood,O,O
T,O,O
cells,O,O
stimulated,O,O
with,O,O
PMA,O,O
plus,O,O
alphaCD28,B,O
.,O,O
Deactivation,O,O
of,O,O
mononuclear,O,O
phagocytes,O,O
is,O,O
critical,O,O
to,O,O
limit,O,O
the,O,O
inflammatory,O,O
response,O,O
but,O,O
can,O,O
be,O,O
detrimental,O,O
in,O,O
the,O,O
face,O,O
of,O,O
progressive,O,O
infection,O,O
.,O,O
We,O,O
compared,O,O
the,O,O
effects,O,O
of,O,O
the,O,O
deactivating,B,O
cytokine,I,O
interleukin,B,B
10,I,I
(,O,O
IL,B,B
-,I,I
10,I,I
),O,O
on,O,O
human,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cell,O,O
(,O,O
PBMC,O,O
),O,O
responses,O,O
to,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
",",O,O
Cryptococcus,O,O
neoformans,O,O
",",O,O
and,O,O
Candida,O,O
albicans,O,O
.,O,O
Characterization,O,O
and,O,O
purification,O,O
of,O,O
a,O,O
protein,B,B
kinase,I,I
C,I,I
substrate,I,I
in,O,O
human,O,O
B,O,O
cells,O,O
.,O,O
These,O,O
findings,O,O
",",O,O
therefore,O,O
",",O,O
could,O,O
have,O,O
clinical,O,O
significance,O,O
to,O,O
AIDS,O,O
patients,O,O
with,O,O
malignancies,O,O
who,O,O
are,O,O
undergoing,O,O
radiotherapy,O,O
and,O,O
chemotherapy,O,O
.,O,O
To,O,O
determine,O,O
whether,O,O
the,O,O
IL,B,B
-,I,I
10R,I,I
has,O,O
signaling,O,O
functions,O,O
similar,O,O
to,O,O
IL,B,B
-,I,I
6R,I,I
in,O,O
cells,O,O
normally,O,O
expressing,O,O
these,O,O
receptors,O,O
",",O,O
leukocytes,O,O
of,O,O
the,O,O
B,O,O
-,O,O
",",O,O
T,O,O
-,O,O
",",O,O
and,O,O
NK,O,O
-,O,O
cell,O,O
lineages,O,O
were,O,O
treated,O,O
with,O,O
either,O,O
cytokine,O,O
.,O,O
The,O,O
IL,B,B
-,I,I
10R,I,I
",",O,O
together,O,O
with,O,O
reporter,O,O
gene,O,O
constructs,O,O
containing,O,O
different,O,O
IL,B,B
-,I,I
6,I,I
-,I,I
responsive,I,I
gene,I,I
elements,I,I
",",O,O
reconstituted,O,O
in,O,O
hepatoma,O,B
cells,O,I
an,O,O
induction,O,O
of,O,O
transcription,O,O
by,O,O
IL,B,B
-,I,I
10,I,I
that,O,O
was,O,O
comparable,O,O
to,O,O
that,O,O
by,O,O
IL,B,B
-,I,I
6,I,I
.,O,O
These,O,O
receptor,O,O
functions,O,O
required,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
box,B,O
3,I,O
motifs,I,O
",",O,O
as,O,O
shown,O,O
by,O,O
the,O,O
analysis,O,O
of,O,O
the,O,O
mouse,O,B
IL,B,I
-,I,I
10R,I,I
constructs,O,O
containing,O,O
progressively,B,O
truncated,I,O
cytoplasmic,I,O
domains,I,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
both,O,O
common,O,O
mechanisms,O,O
",",O,O
such,O,O
as,O,O
the,O,O
one,O,O
mediated,O,O
by,O,O
the,O,O
CIITA,B,O
trans,I,O
-,I,O
activator,I,O
",",O,O
and,O,O
distinct,O,O
tissue,O,O
-,O,O
specific,O,O
constraints,O,O
contribute,O,O
to,O,O
the,O,O
transcriptional,O,O
control,O,O
of,O,O
constitutive,O,O
and,O,O
IFN,B,B
-,I,I
gamma,I,I
-,O,I
induced,O,I
MHC,B,B
class,I,I
II,I,I
gene,I,I
expression,O,O
.,O,O
E3330,O,O
inhibited,O,O
this,O,O
induced,O,O
promoter,O,O
activity,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
There,O,O
are,O,O
four,O,O
putative,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
binding,I,O
sites,I,O
(,O,O
kappa,B,B
B,I,I
-,I,I
1,I,I
",",O,O
kappa,B,B
B,I,I
-,I,I
2,I,I
",",O,O
kappa,B,B
B,I,I
-,I,I
3,I,I
",",O,O
kappa,B,B
B,I,I
-,I,I
4,I,I
),O,O
in,O,O
human,B,O
TNF,I,B
-,I,I
alpha,I,I
promoter,I,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
have,O,O
analysed,O,O
the,O,O
structural,O,O
requirements,O,O
for,O,O
transcriptional,O,O
activation,O,O
by,O,O
BSAP,B,O
.,O,O
We,O,O
have,O,O
demonstrated,O,O
that,O,O
the,O,O
level,O,O
of,O,O
CRE,B,B
binding,I,O
protein,I,O
(,O,O
CREB,B,O
),O,O
was,O,O
the,O,O
same,O,O
in,O,O
all,O,O
cell,O,O
lines,O,O
and,O,O
that,O,O
the,O,O
putative,O,O
AR,B,O
-,I,O
CRE,I,O
forms,O,O
specific,O,O
and,O,O
compatible,O,O
protein,O,O
interactions,O,O
with,O,O
CREB,B,O
.,O,O
Structural,O,O
and,O,O
functional,O,O
characterization,O,O
of,O,O
the,O,O
human,B,O
CD36,I,B
gene,I,I
promoter,I,I
:,O,O
identification,O,O
of,O,O
a,O,O
proximal,O,O
PEBP2,B,O
/,I,O
CBF,I,O
site,I,O
.,O,O
In,O,O
these,O,O
cells,O,O
",",O,O
CD36,B,B
is,O,O
involved,O,O
in,O,O
phagocytosis,O,O
of,O,O
apoptotic,O,O
cells,O,O
",",O,O
and,O,O
foam,O,O
cell,O,O
formation,O,O
by,O,O
uptake,O,O
of,O,O
oxidized,B,O
low,I,O
density,I,O
lipoprotein,I,O
.,O,O
Biochemical,O,O
analysis,O,O
of,O,O
the,O,O
region,O,O
-,B,O
158,I,O
/,I,O
-,I,O
90,I,O
revealed,O,O
a,O,O
binding,O,O
site,O,O
for,O,O
transcription,B,O
factors,I,O
of,O,O
the,O,O
polyomavirus,B,O
enhancer,I,O
-,I,O
binding,I,O
protein,I,O
2,I,O
/,I,O
core,I,O
-,I,O
binding,I,O
factor,I,O
(,I,O
PEBP2,I,O
/,I,O
CBF,I,O
),I,O
family,I,O
at,O,O
position,B,O
-,I,O
103,I,O
.,O,O
Disruption,O,O
of,O,O
the,O,O
PEBP2,B,B
/,I,I
CBF,I,I
site,I,O
markedly,O,O
diminished,O,O
the,O,O
role,O,O
of,O,O
the,O,O
PEBP2,B,B
/,I,I
CBF,I,I
factors,I,O
in,O,O
the,O,O
constitutive,O,O
transcription,O,O
of,O,O
the,O,O
CD36,B,O
gene,I,O
.,O,O
The,O,O
association,O,O
of,O,O
specific,O,O
HLA,B,B
-,I,I
DQ,I,I
alleles,I,O
with,O,O
autoimmunity,O,O
is,O,O
correlated,O,O
with,O,O
discrete,O,O
polymorphisms,O,O
in,O,O
the,O,O
HLA,B,B
-,I,I
DQ,I,I
sequence,I,O
that,O,O
are,O,O
localized,O,O
within,O,O
sites,O,O
suitable,O,O
for,O,O
peptide,O,O
recognition,O,O
.,O,O
Appearance,O,O
of,O,O
the,O,O
STAT1,B,B
factor,O,I
is,O,O
significantly,O,O
reduced,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
cyclosporin,O,O
A,O,O
",",O,O
and,O,O
blocked,O,O
by,O,O
cycloheximide,O,O
",",O,O
indicating,O,O
that,O,O
its,O,O
activation,O,O
is,O,O
dependent,O,O
upon,O,O
a,O,O
protein,O,B
(,O,O
s,O,O
),O,O
synthesized,O,O
in,O,O
response,O,O
to,O,O
initial,O,O
signaling,O,O
events,O,O
.,O,O
Neutralizing,O,O
antiserum,O,O
against,O,O
IFN,B,B
-,I,I
gamma,I,I
",",O,O
but,O,O
not,O,O
other,O,O
cytokines,B,O
tested,O,O
",",O,O
blocked,O,O
activation,O,O
of,O,O
the,O,O
factor,O,O
almost,O,O
completely,O,O
",",O,O
and,O,O
IFN,B,B
-,I,I
gamma,I,I
was,O,O
found,O,O
in,O,O
the,O,O
culture,O,O
supernatants,O,O
of,O,O
stimulated,O,O
cells,O,O
at,O,O
levels,O,O
at,O,O
which,O,O
recombinant,O,O
IFN,B,B
-,I,I
gamma,I,I
could,O,O
activate,O,O
the,O,O
factor,O,O
in,O,O
naive,O,O
cells,O,O
.,O,O
Therefore,O,O
",",O,O
a,O,O
STAT1,B,B
transcription,B,O
factor,I,O
is,O,O
activated,O,O
by,O,O
IFN,B,B
-,I,I
gamma,I,I
synthesized,O,O
and,O,O
released,O,O
upon,O,O
stimulation,O,O
of,O,O
T,O,O
lymphocyte,O,O
populations,O,O
.,O,O
While,O,O
Jurkat,O,O
cells,O,O
both,O,O
secrete,O,O
and,O,O
respond,O,O
to,O,O
IFN,B,B
-,I,I
gamma,I,I
in,O,O
an,O,O
autocrine,O,O
loop,O,O
",",O,O
it,O,O
seems,O,O
likely,O,O
that,O,O
the,O,O
responding,O,O
cells,O,O
may,O,O
differ,O,O
from,O,O
those,O,O
synthesizing,O,O
this,O,O
cytokine,B,O
in,O,O
the,O,O
mononuclear,O,O
cell,O,O
cultures,O,O
in,O,O
the,O,O
light,O,O
of,O,O
the,O,O
recent,O,O
report,O,O
that,O,O
Th1,O,O
cells,O,O
lack,O,O
the,O,O
IFN,B,B
-,I,I
gamma,I,I
receptor,O,I
chain,O,I
necessary,O,O
for,O,O
activation,O,O
of,O,O
STAT1,B,B
(,O,O
Pernis,O,O
",",O,O
A,O,O
.,O,O
",",O,O
S,O,O
.,O,O
",",O,O
Gollob,O,O
",",O,O
K,O,O
.,O,O
J,O,O
.,O,O
",",O,O
Garfein,O,O
",",O,O
E,O,O
.,O,O
",",O,O
Coffman,O,O
",",O,O
R,O,O
.,O,O
L,O,O
.,O,O
",",O,O
Schindler,O,O
",",O,O
C,O,O
.,O,O
",",O,O
and,O,O
Rothman,O,O
",",O,O
P,O,O
.,O,O
",",O,O
Science,O,O
1995,O,O
.,O,O
269,O,O
:,O,O
245,O,O
.,O,O
Based,O,O
on,O,O
the,O,O
presence,O,O
of,O,O
T,B,O
cell,I,O
receptor,I,O
-,I,O
beta,I,O
(,I,O
TcR,I,B
-,I,O
beta,I,I
),I,O
gene,I,O
rearrangements,I,O
in,O,O
L428,O,O
and,O,O
HDLM,O,O
-,O,O
1,O,O
cells,O,O
",",O,O
the,O,O
expression,O,O
of,O,O
CD2,B,O
in,O,O
HDLM,O,O
-,O,O
1,O,O
cells,O,O
",",O,O
and,O,O
the,O,O
presence,O,O
of,O,O
immunoglobulin,B,B
heavy,I,I
-,I,I
chain,I,I
(,I,I
IgH,I,I
),I,I
gene,I,O
rearrangement,I,O
in,O,O
KM,O,O
-,O,O
H2,O,O
cells,O,O
",",O,O
some,O,O
researchers,O,O
have,O,O
concluded,O,O
that,O,O
these,O,O
long,O,O
-,O,O
term,O,O
cell,O,O
lines,O,O
derived,O,O
from,O,O
patients,O,O
with,O,O
Hodgkin,O,O
s,O,O
disease,O,O
are,O,O
lymphoid,O,O
in,O,O
nature,O,O
.,O,O
Expression,O,O
of,O,O
the,O,O
MAP,B,O
kinase,I,O
-,I,O
specific,I,O
phosphatase,I,O
",",O,O
MKP,B,B
-,I,I
1,I,I
",",O,O
which,O,O
blocks,O,O
ERK,B,B
activation,O,O
",",O,O
inhibited,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
and,O,O
NF,B,B
-,I,I
AT,I,I
-,O,I
driven,O,O
transcription,O,O
stimulated,O,O
by,O,O
a,O,O
calcium,O,O
ionophore,O,O
and,O,O
PMA,O,O
",",O,O
and,O,O
in,O,O
addition,O,O
",",O,O
MKP,B,B
-,I,I
1,I,I
neutralized,O,O
the,O,O
transcriptional,O,O
enhancement,O,O
caused,O,O
by,O,O
active,O,O
Raf,O,B
-,O,I
1,O,I
and,O,O
MEK1,O,O
expression,O,O
.,O,O
Although,O,O
GM,B,B
-,I,I
CSF,I,I
does,O,O
not,O,O
appear,O,O
to,O,O
be,O,O
essential,O,O
for,O,O
normal,O,O
hemopoiesis,O,O
",",O,O
overexpression,O,O
of,O,O
GM,O,B
-,O,I
CSF,O,I
has,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
some,O,O
diseases,O,O
such,O,O
as,O,O
myeloid,O,B
leukemia,O,I
and,O,O
chronic,O,B
inflammation,O,I
.,O,O
We,O,O
investigated,O,O
oligonucleotide,O,O
-,O,O
directed,O,O
triple,O,O
helix,O,O
formation,O,O
across,O,O
this,O,O
regulatory,B,O
sequence,I,O
as,O,O
a,O,O
potential,O,O
tool,O,O
to,O,O
inhibit,O,O
GM,B,B
-,I,I
CSF,I,I
gene,O,O
transcription,O,O
.,O,O
Triplex,O,O
formation,O,O
by,O,O
GM3,O,B
blocked,O,O
recombinant,B,O
and,I,O
nuclear,I,O
NF,I,B
-,I,I
kappaB,I,I
proteins,I,O
binding,O,O
to,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
element,I,O
.,O,O
Finally,O,O
",",O,O
GM3,O,B
greatly,O,O
reduced,O,O
the,O,O
concentration,O,O
of,O,O
endogenous,O,O
GM,B,O
-,I,O
CSF,I,O
mRNA,I,O
induced,O,O
by,O,O
different,O,O
stimuli,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
but,O,O
did,O,O
not,O,O
affect,O,O
interleukin,B,O
3,I,O
mRNA,I,O
levels,O,O
in,O,O
the,O,O
same,O,O
cells,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
kappaB,B,B
element,I,O
in,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
promoter,I,O
plays,O,O
a,O,O
central,O,O
role,O,O
in,O,O
the,O,O
transcriptional,O,O
activation,O,O
of,O,O
the,O,O
endogenous,O,O
GM,B,O
-,I,O
CSF,I,O
gene,I,O
.,O,O
Colinear,O,O
triplex,O,O
formation,O,O
acts,O,O
as,O,O
a,O,O
selective,O,O
transcriptional,O,O
repressor,O,O
of,O,O
the,O,O
GM,B,B
-,I,I
CSF,I,I
gene,I,O
and,O,O
may,O,O
have,O,O
potential,O,O
therapeutic,O,O
application,O,O
in,O,O
cases,O,O
of,O,O
undesirable,O,O
overexpression,O,O
of,O,O
this,O,O
protein,O,O
.,O,O
ML,O,O
-,O,O
9,O,O
induced,O,O
nitroblue,O,O
tetrazolium,O,O
(,O,O
NBT,O,O
),O,O
-,O,O
reducing,O,O
activity,O,O
of,O,O
U937,O,O
cell,O,O
more,O,O
rapidly,O,O
than,O,O
VD3,O,O
:,O,O
This,O,O
differentiation,O,O
marker,O,O
was,O,O
induced,O,O
significantly,O,O
after,O,O
incubation,O,O
with,O,O
ML,O,O
-,O,O
9,O,O
and,O,O
VD3,O,O
for,O,O
4,O,O
hours,O,O
and,O,O
1,O,O
day,O,O
",",O,O
respectively,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
ML,O,O
-,O,O
9,O,O
should,O,O
be,O,O
useful,O,O
for,O,O
studying,O,O
the,O,O
mechanisms,O,O
of,O,O
monocytic,O,B
differentiation,O,O
.,O,O
Modulation,O,O
of,O,O
endogenous,O,O
IL,B,B
-,I,I
1,I,I
beta,I,I
and,O,O
IL,B,B
-,I,I
1,I,I
receptor,I,I
antagonist,O,O
results,O,O
in,O,O
opposing,O,O
effects,O,O
on,O,O
HIV,O,B
expression,O,O
in,O,O
chronically,O,O
infected,O,O
monocytic,O,B
cells,O,O
.,O,O
The,O,O
present,O,O
study,O,O
examines,O,O
the,O,O
mechanisms,O,O
involved,O,O
in,O,O
LPS,O,B
-,O,I
mediated,O,I
induction,O,O
of,O,O
HIV,O,B
expression,O,O
in,O,O
U1,O,O
cells,O,O
",",O,O
a,O,O
promonocytic,O,B
cell,O,O
line,O,O
chronically,O,O
infected,O,O
with,O,O
HIV,O,O
.,O,O
Costimulation,O,O
of,O,O
U1,O,O
cells,O,O
with,O,O
LPS,O,O
plus,O,O
GM,B,O
-,I,O
CSF,I,O
resulted,O,O
in,O,O
the,O,O
accumulation,O,O
of,O,O
steady,O,O
-,O,O
state,O,O
levels,O,O
of,O,O
HIV,B,B
RNA,I,I
;,O,O
however,O,O
",",O,O
only,O,O
a,O,O
weak,O,O
induction,O,O
of,O,O
HIV,B,B
long,I,I
terminal,I,I
repeat,I,I
-,O,I
driven,O,I
transcription,O,I
",",O,O
which,O,O
was,O,O
not,O,O
associated,O,O
with,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
cellular,B,O
transcription,I,O
factor,I,O
nuclear,B,B
factor,I,I
-,I,I
kappa,I,I
B,I,I
",",O,O
was,O,O
noted,O,O
.,O,O
IL,B,B
-,I,I
12,I,I
is,O,O
a,O,O
novel,O,O
heterodimeric,B,O
cytokine,I,O
important,O,O
for,O,O
the,O,O
regulation,O,O
and,O,O
differentiation,O,O
of,O,O
lymphocytes,O,O
and,O,O
NK,O,B
cells,O,O
.,O,O
Using,O,O
these,O,O
T,O,O
cells,O,O
as,O,O
a,O,O
model,O,O
of,O,O
IL,B,B
-,I,I
12,I,I
signal,O,O
transduction,O,O
",",O,O
we,O,O
confirmed,O,O
that,O,O
these,O,O
events,O,O
involve,O,O
members,O,O
of,O,O
the,O,O
Janus,B,O
kinase,I,O
family,I,O
of,O,O
nonreceptor,B,O
tyrosine,I,O
kinases,I,O
JAK2,B,O
",",O,O
TYK2,B,O
",",O,O
and,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
4,I,O
.,O,O
These,O,O
mechanisms,O,O
include,O,O
the,O,O
assembly,O,O
of,O,O
higher,B,O
order,I,O
nucleoprotein,I,B
complexes,I,I
and,O,O
other,O,O
protein,O,B
-,O,I
protein,O,I
interactions,O,O
that,O,O
enhance,O,O
the,O,O
functional,O,O
specificity,O,O
of,O,O
transcriptional,B,O
regulators,I,O
in,O,O
lymphocytes,O,O
.,O,O
Patients,O,O
with,O,O
HIV,O,O
infections,O,O
often,O,O
show,O,O
elevated,O,O
circulating,O,O
levels,O,O
of,O,O
cortisol,O,B
",",O,O
suggesting,O,O
some,O,O
misfunction,O,O
in,O,O
the,O,O
regulatory,O,O
systems,O,O
that,O,O
maintain,O,O
the,O,O
levels,O,O
of,O,O
this,O,O
critical,O,O
hormone,O,O
.,O,O
At,O,O
the,O,O
cellular,O,O
level,O,O
",",O,O
it,O,O
is,O,O
known,O,O
that,O,O
both,O,O
acute,O,O
HIV,O,B
infection,O,O
and,O,O
glucocorticoids,O,O
can,O,O
cause,O,O
apoptotic,O,O
cell,O,O
death,O,O
in,O,O
thymic,O,O
lymphocytes,O,O
.,O,O
In,O,O
vitro,O,O
",",O,O
chronically,O,O
HIV,O,B
-,O,I
infected,O,I
cells,O,O
of,O,O
the,O,O
lymphoid,O,O
CEM,O,O
line,O,O
displayed,O,O
resistance,O,O
to,O,O
glucocorticoid,O,O
-,O,O
induced,O,O
apoptosis,O,O
.,O,O
Thus,O,O
it,O,O
appears,O,O
that,O,O
there,O,O
may,O,O
often,O,O
be,O,O
malfunction,O,O
of,O,O
the,O,O
normal,O,O
glucocorticoid,O,O
response,O,O
in,O,O
HIV,O,B
-,O,I
infected,O,I
cells,O,O
probably,O,O
due,O,O
to,O,O
altered,O,O
interactions,O,O
between,O,O
the,O,O
glucocorticoid,B,O
receptor,I,O
and,O,O
its,O,O
hormone,O,O
.,O,O
Nuclei,O,O
of,O,O
unstimulated,O,O
PBL,O,O
from,O,O
different,O,O
donors,O,O
expressed,O,O
p62c,B,B
-,I,I
fos,I,I
and,O,O
p39c,B,B
-,I,I
jun,I,I
",",O,O
but,O,O
AP,B,B
-,I,I
1,I,I
was,O,O
not,O,O
detected,O,O
in,O,O
the,O,O
majority,O,O
of,O,O
samples,O,O
.,O,O
Following,O,O
PHA,B,O
stimulation,O,O
of,O,O
PBL,O,O
",",O,O
the,O,O
increase,O,O
in,O,O
AP,B,B
-,I,I
1,I,I
activity,O,O
was,O,O
delayed,O,O
with,O,O
respect,O,O
to,O,O
the,O,O
augmentation,O,O
of,O,O
p39c,B,B
-,I,I
jun,I,I
expression,O,O
.,O,O
However,O,O
",",O,O
no,O,O
cytoplasmic,B,O
p62c,I,B
-,I,I
fos,I,I
was,O,O
detected,O,O
in,O,O
unstimulated,O,O
PBL,O,O
",",O,O
although,O,O
in,O,O
some,O,O
cases,O,O
cytoplasmic,B,O
p39c,I,B
-,I,I
jun,I,I
was,O,O
detected,O,O
",",O,O
suggesting,O,O
that,O,O
subcellular,O,O
compartmentalization,O,O
of,O,O
these,O,O
proteins,B,O
may,O,O
occur,O,O
under,O,O
certain,O,O
circumstances,O,O
.,O,O
However,O,O
",",O,O
the,O,O
inducible,O,O
degradation,O,O
of,O,O
p105,B,B
is,O,O
not,O,O
coupled,O,O
with,O,O
the,O,O
generation,O,O
of,O,O
p50,B,B
.,O,O
Together,O,O
",",O,O
these,O,O
studies,O,O
demonstrate,O,O
that,O,O
the,O,O
processing,O,O
and,O,O
inducible,O,O
degradation,O,O
of,O,O
p105,B,B
are,O,O
differentially,O,O
regulated,O,O
.,O,O
However,O,O
",",O,O
synthesis,O,O
of,O,O
the,O,O
26,B,O
-,I,O
kDa,I,O
membrane,I,O
form,I,O
of,O,O
TNF,B,B
was,O,O
effectively,O,O
blocked,O,O
by,O,O
CNI,O,O
-,O,O
1493,O,O
.,O,O
r,B,O
-,I,O
hTBP,I,B
-,I,I
1,I,I
and,O,O
rhu,B,O
TNFR,I,B
:,I,O
Fc,I,O
also,O,O
decreased,O,O
p24,B,O
antigen,I,O
synthesized,O,O
by,O,O
U1,O,O
cells,O,O
in,O,O
response,O,O
to,O,O
other,O,O
stimuli,O,O
",",O,O
including,O,O
phytohemagglutinin,B,O
(,I,O
PHA,I,O
),I,O
-,I,O
induced,I,O
supernatant,I,O
",",O,O
granulocyte,B,O
-,I,O
macrophage,I,O
colony,I,O
-,I,O
stimulating,I,O
factor,I,O
",",O,O
interleukin,B,O
-,I,O
6,I,O
",",O,O
and,O,O
TNF,B,B
.,O,O
Addition,O,O
of,O,O
r,B,O
-,I,O
hTBP,I,B
-,I,I
1,I,I
to,O,O
U1,O,O
cells,O,O
during,O,O
the,O,O
last,O,O
4,O,O
h,O,O
of,O,O
a,O,O
24,O,O
h,O,O
incubation,O,O
with,O,O
PMA,O,O
still,O,O
inhibited,O,O
p24,B,O
antigen,I,O
production,O,O
by,O,O
15,O,O
%,O,O
.,O,O
r,B,O
-,I,O
hTBP,I,B
-,I,I
1,I,I
also,O,O
partially,O,O
reversed,O,O
inhibition,O,O
of,O,O
U1,O,B
cellular,O,I
proliferation,O,I
caused,O,O
by,O,O
PMA,O,O
.,O,O
Transcriptional,O,O
activation,O,O
of,O,O
RNA,B,B
polymerase,I,I
III,I,I
-,I,I
dependent,I,I
genes,I,I
by,O,O
the,O,O
human,B,O
T,I,B
-,I,I
cell,I,I
leukemia,I,I
virus,I,I
type,I,I
1,I,I
tax,I,I
protein,I,I
.,O,O
The,O,O
viral,B,O
protein,I,O
Tax,I,O
was,O,O
likely,O,O
responsible,O,O
for,O,O
this,O,O
higher,O,O
level,O,O
of,O,O
class,B,O
II,I,O
gene,I,O
transcription,O,O
",",O,O
as,O,O
purified,B,O
Tax,I,O
was,O,O
found,O,O
to,O,O
stimulate,O,O
both,O,O
genes,O,O
when,O,O
added,O,O
to,O,O
the,O,O
uninfected,O,O
cell,O,O
extract,O,O
or,O,O
in,O,O
reconstituted,O,O
systems,O,O
.,O,O
Expression,O,O
of,O,O
Retinoid,B,B
X,I,I
Receptor,I,I
alpha,I,I
is,O,O
increased,O,O
upon,O,O
monocytic,O,B
cell,O,I
differentiation,O,I
.,O,O
Efficient,O,O
gene,O,O
activation,O,O
requires,O,O
the,O,O
heterodimerization,O,O
of,O,O
VDR,B,B
with,O,O
Retinoid,B,B
X,I,I
Receptors,I,I
(,O,O
RXR,B,B
),O,O
.,O,O
Combinations,O,O
of,O,O
all,O,O
-,O,O
trans,O,O
retinoic,O,O
acid,O,O
(,O,O
RA,O,B
),O,O
and,O,O
VD,O,B
",",O,O
in,O,O
some,O,O
cases,O,O
",",O,O
increased,O,O
this,O,O
effect,O,O
.,O,O
We,O,O
have,O,O
generated,O,O
rabbit,O,B
antisera,O,I
against,O,O
this,O,O
putative,O,O
p13MTCP1,B,B
protein,I,I
and,O,O
screened,O,O
for,O,O
expression,O,O
of,O,O
p13MTCP1,B,B
normal,O,O
lymphoid,O,B
tissues,O,I
and,O,O
33,O,O
cases,O,O
of,O,O
immature,O,B
and,O,O
mature,O,B
lymphoid,O,I
T,O,I
-,O,I
cell,O,I
proliferations,O,I
using,O,O
a,O,O
sensitive,O,O
Western,O,B
blot,O,I
assay,O,I
.,O,O
The,O,O
p13MTCP1,B,B
protein,I,I
was,O,O
detected,O,O
in,O,O
the,O,O
three,O,O
T,O,B
-,O,I
cell,O,I
proliferations,O,I
with,O,O
MTCP1,B,O
rearrangements,I,O
because,O,O
of,O,O
t,O,O
(,O,O
X,O,O
;,O,O
14,O,O
),O,O
translocations,O,O
",",O,O
but,O,O
neither,O,O
in,O,O
normal,O,O
resting,O,O
and,O,O
activated,O,O
lymphocytes,O,O
nor,O,O
in,O,O
the,O,O
other,O,O
T,O,B
-,O,I
cell,O,I
leukemias,O,I
.,O,O
A,O,O
variety,O,O
of,O,O
cytokines,B,O
and,O,O
growth,B,O
factors,I,O
act,O,O
through,O,O
an,O,O
induction,O,O
of,O,O
gene,O,O
expression,O,O
mediated,O,O
by,O,O
a,O,O
family,O,O
of,O,O
latent,B,O
transcription,I,O
factors,I,O
called,O,O
STAT,B,B
(,I,O
signal,I,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
),I,O
proteins,I,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
(,O,O
EMSAs,O,O
),O,O
demonstrated,O,O
that,O,O
unstimulated,O,O
monocytes,O,O
predominantly,O,O
expressed,O,O
p50,B,B
NF,B,O
-,I,O
kappa,I,O
B,I,O
.,O,O
However,O,O
",",O,O
the,O,O
combined,O,O
stimulation,O,O
did,O,O
not,O,O
result,O,O
in,O,O
enhanced,O,O
p50,B,O
and,O,O
p65,B,O
protein,I,O
expression,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
on,O,O
the,O,O
transcription,B,O
factors,I,O
were,O,O
specific,O,O
",",O,O
since,O,O
no,O,O
change,O,O
was,O,O
observed,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
NF,B,B
-,I,I
IL,I,I
-,I,I
6,I,I
or,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
",",O,O
the,O,O
inhibitor,O,O
of,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
effects,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
on,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
transcription,B,O
factors,I,O
AP,B,B
-,I,I
1,I,I
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
may,O,O
be,O,O
important,O,O
for,O,O
the,O,O
modulatory,O,O
effects,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
on,O,O
the,O,O
cytokine,B,O
expression,O,O
in,O,O
activated,O,O
human,O,O
monocytes,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
MIP,B,B
-,I,I
1,I,I
alpha,I,I
is,O,O
induced,O,O
during,O,O
cellular,O,O
activation,O,O
of,O,O
CD4,O,B
+,O,I
T,O,I
-,O,I
cells,O,I
and,O,O
monocytes,O,O
.,O,O
It,O,O
is,O,O
also,O,O
expressed,O,O
in,O,O
transformed,O,O
B,O,O
-,O,O
cells,O,O
.,O,O
We,O,O
have,O,O
previously,O,O
identified,O,O
a,O,O
new,O,O
transcription,B,O
factor,I,O
family,I,O
(,O,O
the,O,O
MNP,B,O
family,I,O
),O,O
whose,O,O
expression,O,O
is,O,O
crucial,O,O
for,O,O
the,O,O
induction,O,O
of,O,O
MIP,B,O
-,I,O
1,I,O
alpha,I,O
transcription,O,O
during,O,O
cellular,O,O
activation,O,O
and,O,O
in,O,O
transformed,O,O
B,O,O
cells,O,O
.,O,O
In,O,O
this,O,O
report,O,O
we,O,O
show,O,O
induction,O,O
of,O,O
MNP,B,O
-,I,O
1,I,O
in,O,O
Jurkat,O,O
T,O,O
-,O,O
cells,O,O
expressing,O,O
HIV,B,B
-,I,I
1,I,I
tat,I,I
.,O,O
Differentiation,O,O
of,O,O
T,O,B
-,O,I
helper,O,I
lymphocytes,O,I
:,O,O
selective,O,O
regulation,O,O
by,O,O
members,O,O
of,O,O
the,O,O
STAT,B,B
family,I,I
of,O,I
transcription,B,I
factors,I,I
.,O,O
Specific,O,O
docking,B,O
sites,I,O
within,O,O
individual,O,O
cytokine,B,O
receptors,I,O
have,O,O
been,O,O
identified,O,O
for,O,O
almost,O,O
all,O,O
Stat,B,O
proteins,I,O
.,O,O
The,O,O
direct,O,O
coupling,O,O
between,O,O
cytokine,B,O
receptor,I,O
and,O,O
transcription,B,O
factor,I,O
helps,O,O
to,O,O
explain,O,O
how,O,O
different,O,O
cytokines,B,O
elicit,O,O
distinct,O,O
patterns,O,O
of,O,O
gene,O,O
expression,O,O
.,O,O
Here,O,O
we,O,O
identify,O,O
the,O,O
gene,O,B
encoding,O,O
the,O,O
lymphocyte,B,B
homing,I,I
and,I,O
migration,I,O
protein,I,O
CD44,B,B
as,O,O
a,O,O
target,O,O
of,O,O
EGR1,B,O
regulation,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
The,O,O
EGR1,B,O
binding,I,O
motif,I,O
was,O,O
shown,O,O
to,O,O
be,O,O
necessary,O,O
for,O,O
stimulus,O,O
-,O,O
induced,O,O
expression,O,O
of,O,O
a,O,O
CD44,B,B
promoter,B,O
-,I,O
chloramphenicol,I,O
acetyltransferase,I,O
reporter,I,O
construct,I,O
in,O,O
nontransformed,O,O
B,O,O
lymphocytes,O,O
and,O,O
was,O,O
required,O,O
for,O,O
transactivation,O,O
by,O,O
an,O,O
EGR1,B,O
expression,I,O
vector,I,O
in,O,O
a,O,O
B,O,O
-,O,O
cell,O,O
line,O,O
.,O,O
These,O,O
studies,O,O
identify,O,O
EGR1,B,B
as,O,O
an,O,O
intermediary,O,O
linking,O,O
BCR,B,O
-,O,O
derived,O,O
signals,O,O
to,O,O
the,O,O
induction,O,O
of,O,O
CD44,B,B
.,O,O
In,O,O
Jurkat,O,O
cells,O,O
that,O,O
are,O,O
not,O,O
sensitive,O,O
to,O,O
H2O2,O,O
-,O,O
induced,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
",",O,O
H2O2,O,O
potentiated,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
sustained,O,O
high,O,O
[,O,O
Ca2,O,B
+,O,I
],O,O
i,O,O
following,O,O
thapsigargin,O,O
treatment,O,O
.,O,O
A,O,O
mutant,O,O
Tax,B,B
protein,I,O
deficient,O,O
in,O,O
transactivation,O,O
of,O,O
genes,O,O
by,O,O
the,O,O
nuclear,B,O
factor,I,O
(,I,O
NF,I,B
),I,O
-,I,O
kappaB,I,O
pathway,O,O
was,O,O
unable,O,O
to,O,O
induce,O,O
transcriptional,O,O
activity,O,O
of,O,O
IL,B,B
-,I,I
1alpha,I,I
promoter,I,O
-,I,O
CAT,I,O
constructs,I,O
",",O,O
but,O,O
was,O,O
rescued,O,O
by,O,O
exogenous,O,O
provision,O,O
of,O,O
p65,B,O
/,I,O
p50,I,O
NF,B,B
-,I,I
kappaB,I,I
.,O,O
mRNA,O,O
for,O,O
c,O,O
-,O,O
fes,O,O
has,O,O
been,O,O
detected,O,O
exclusively,O,O
in,O,O
myeloid,O,B
cells,O,O
and,O,O
vascular,O,B
endothelial,O,I
cells,O,O
in,O,O
adult,O,O
mammals,O,O
.,O,O
Although,O,O
a,O,O
13,B,O
-,I,O
kilobase,I,O
-,I,O
pair,I,O
(,I,O
kb,I,O
),I,O
human,I,O
c,I,B
-,I,I
fes,I,I
transgene,I,O
exhibits,O,O
high,O,O
levels,O,O
of,O,O
expression,O,O
in,O,O
mice,O,O
",",O,O
the,O,O
sequences,O,O
that,O,O
confer,O,O
myeloid,O,B
-,O,I
cell,O,I
-,O,I
specific,O,I
expression,O,O
of,O,O
the,O,O
human,B,O
c,I,B
-,I,I
fes,I,I
gene,I,O
have,O,O
not,O,O
been,O,O
defined,O,O
.,O,O
However,O,O
",",O,O
the,O,O
first,O,O
two,O,O
footprints,O,O
resided,O,O
in,O,O
sequences,O,O
that,O,O
were,O,O
largely,O,O
dispensable,O,O
for,O,O
transient,O,O
activity,O,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
analyses,O,O
demonstrated,O,O
that,O,O
the,O,O
151,B,O
-,I,O
bp,I,O
region,I,O
contains,O,O
nuclear,B,B
protein,I,I
binding,I,I
sites,I,I
for,O,O
Sp1,B,B
",",O,O
PU,B,B
.,I,O
1,I,O
",",O,O
and,O,O
/,O,O
or,O,O
Elf,B,B
-,I,O
1,I,O
",",O,O
and,O,O
a,O,O
novel,B,O
factor,I,O
.,O,O
IL,B,B
-,I,O
10,I,O
markedly,O,O
reduces,O,O
nuclear,O,B
factor,O,I
(,B,I
NF,I,I
),I,I
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
nuclear,O,I
activity,O,I
induced,O,O
in,O,O
PBMC,O,O
by,O,O
stimulation,O,O
with,O,O
the,O,O
anti,B,O
-,I,O
CD3,I,O
mAb,I,O
OKT3,B,O
.,O,O
As,O,O
judged,O,O
by,O,O
supershifting,O,O
the,O,O
DNA,B,B
-,I,I
protein,I,I
complexes,I,O
with,O,O
Abs,B,O
recognizing,O,O
specific,O,O
components,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
protein,I,I
family,I,O
",",O,O
the,O,O
p50,B,O
/,I,O
p65,I,O
(,O,O
Rel,B,O
A,I,O
),O,O
heterodimeric,O,O
form,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
primarily,O,O
affected,O,O
.,O,O
The,O,O
maximal,O,O
effect,O,O
is,O,O
observed,O,O
at,O,O
the,O,O
IL,B,B
-,I,I
10,I,I
concentration,O,O
of,O,O
20,O,O
U,O,O
/,O,O
ml,O,O
.,O,O
Our,O,O
results,O,O
demonstrate,O,O
that,O,O
IL,B,B
-,I,I
10,I,I
can,O,O
inhibit,O,O
the,O,O
induction,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
nuclear,O,O
activity,O,O
in,O,O
CD3,O,O
-,O,O
stimulated,O,O
T,O,O
lymphocytes,O,O
.,O,O
In,O,O
a,O,O
panel,O,O
of,O,O
32,O,O
B,O,B
-,O,I
cell,O,I
lines,O,I
",",O,O
A,B,O
-,I,O
myb,I,B
was,O,O
very,O,O
strongly,O,O
expressed,O,O
in,O,O
most,O,O
Burkitt,O,O
s,O,O
lymphoma,O,O
(,O,O
BL,O,O
),O,O
cell,O,O
lines,O,O
",",O,O
but,O,O
weak,O,O
or,O,O
negative,O,O
in,O,O
2,O,O
pre,O,O
-,O,O
B,O,B
acute,O,I
lymphoblastic,O,I
leukemia,O,I
(,O,I
ALL,O,I
),O,I
",",O,O
4,O,O
non,O,O
-,O,O
Hodgkin,O,O
s,O,O
lymphoma,O,O
(,O,O
NHL,O,O
),O,O
",",O,O
6,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
-,O,O
immortalized,O,O
lymphoblastoid,O,O
cell,O,O
lines,O,O
",",O,O
and,O,O
6,O,O
myeloma,O,O
lines,O,O
.,O,O
C,O,B
-,O,I
myb,O,I
and,O,O
B,B,B
-,I,I
myb,I,I
were,O,O
expressed,O,O
in,O,O
all,O,O
neoplastic,O,O
groups,O,O
",",O,O
except,O,O
in,O,O
CLL,O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
A,B,B
-,I,I
myb,I,I
expression,O,O
",",O,O
unlike,O,O
that,O,O
of,O,O
c,B,B
-,I,I
myb,I,I
and,O,O
B,B,B
-,I,I
myb,I,I
",",O,O
is,O,O
restricted,O,O
to,O,O
a,O,O
subset,O,O
of,O,O
B,O,B
-,O,I
cell,O,I
neoplasias,O,I
(,O,O
in,O,O
particular,O,O
BL,O,O
and,O,O
slg,O,O
+,O,O
B,O,B
-,O,I
ALL,O,I
),O,O
representative,O,O
of,O,O
a,O,O
specific,O,O
stage,O,O
of,O,O
B,O,B
-,O,I
cell,O,I
differentiation,O,I
.,O,O
Here,O,O
we,O,O
provide,O,O
evidence,O,O
that,O,O
this,O,O
transformation,O,O
is,O,O
the,O,O
result,O,O
of,O,O
double,O,O
infection,O,O
of,O,O
a,O,O
cell,O,O
with,O,O
two,O,O
virions,O,O
",",O,O
the,O,O
P3HR1,B,O
virus,I,O
genome,I,O
and,O,O
a,O,O
mini,B,O
-,I,O
EBV,I,O
plasmid,I,O
carrying,O,O
the,O,O
chimeric,O,O
EBNA2,B,O
gene,I,O
.,O,O
It,O,O
remains,O,O
open,O,O
whether,O,O
the,O,O
growth,O,O
retarding,O,O
property,O,O
of,O,O
the,O,O
EBNA2,B,O
-,I,O
oestrogen,I,O
receptor,I,O
fusion,I,O
protein,I,O
in,O,O
B,O,O
cell,O,O
lymphoma,O,O
lines,O,O
is,O,O
due,O,O
to,O,O
unphysiologically,O,O
high,O,O
expression,O,O
of,O,O
the,O,O
chimeric,B,O
protein,I,O
or,O,O
to,O,O
interference,O,O
with,O,O
a,O,O
cellular,O,O
programme,O,O
driving,O,O
proliferation,O,O
in,O,O
these,O,O
cell,O,O
lines,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
",",O,O
as,O,O
already,O,O
reported,O,O
for,O,O
the,O,O
IL2Rbeta,B,O
promoter,I,O
",",O,O
GA,B,O
-,I,O
binding,I,O
protein,I,O
is,O,O
an,O,O
essential,O,O
component,O,O
of,O,O
gammac,O,O
basal,O,O
promoter,O,O
activity,O,O
.,O,O
Detection,O,O
of,O,O
intracellular,B,O
signal,I,O
transduction,I,O
molecules,I,O
in,O,O
PBMC,O,O
from,O,O
rhesus,O,O
macaques,O,O
and,O,O
sooty,O,O
mangabeys,O,O
.,O,O
The,O,O
molecular,O,O
mechanisms,O,O
associated,O,O
with,O,O
the,O,O
T,O,O
-,O,O
cell,O,O
dysfunction,O,O
remain,O,O
to,O,O
be,O,O
elucidated,O,O
.,O,O
Because,O,O
relatively,O,O
little,O,O
is,O,O
known,O,O
about,O,O
these,O,O
events,O,O
in,O,O
nonhuman,O,O
primates,O,O
",",O,O
our,O,O
laboratory,O,O
defined,O,O
optimal,O,O
conditions,O,O
",",O,O
reagents,O,O
",",O,O
and,O,O
assays,O,O
for,O,O
the,O,O
study,O,O
of,O,O
signal,O,O
transduction,O,O
events,O,O
in,O,O
cells,O,O
from,O,O
nonhuman,O,O
primates,O,O
.,O,O
The,O,O
protein,O,B
phosphorylation,O,I
patterns,O,O
in,O,O
the,O,O
two,O,O
monkeys,O,O
exhibited,O,O
quantitative,O,O
",",O,O
qualitative,O,O
",",O,O
and,O,O
kinetic,O,O
differences,O,O
.,O,O
Expression,O,O
of,O,O
ATF,B,B
-,I,I
2,I,I
in,O,O
S,O,B
.,O,I
did,O,O
not,O,O
activate,O,O
TRE,B,B
-,I,I
1,I,I
in,O,O
the,O,O
presence,O,O
of,O,O
Tax,B,O
.,O,O
This,O,O
shows,O,O
that,O,O
in,O,O
a,O,O
eukaryotic,O,O
nucleus,O,O
",",O,O
Tax,B,O
specifically,O,O
interacts,O,O
with,O,O
the,O,O
basic,B,O
domain,I,O
-,I,O
leucine,I,O
zipper,I,O
region,I,O
of,O,O
ATF,B,B
-,I,I
1,I,I
",",O,O
CREB,B,B
",",O,O
and,O,O
CREM,B,B
.,O,O
Trapoxin,O,O
is,O,O
a,O,O
microbially,O,O
derived,O,O
cyclotetrapeptide,O,O
that,O,O
inhibits,O,O
histone,B,B
deacetylation,O,I
in,O,O
vivo,O,O
and,O,O
causes,O,O
mammalian,O,B
cells,O,I
to,O,O
arrest,O,O
in,O,O
the,O,O
cell,O,O
cycle,O,O
.,O,O
The,O,O
mechanisms,O,O
by,O,O
which,O,O
these,O,O
promoters,O,O
of,O,O
cell,O,O
growth,O,O
exert,O,O
their,O,O
inhibitory,O,O
effects,O,O
vary,O,O
",",O,O
but,O,O
in,O,O
most,O,O
instances,O,O
they,O,O
involve,O,O
a,O,O
disruption,O,O
of,O,O
the,O,O
IFN,O,B
-,O,I
alpha,O,I
/,O,I
beta,O,I
-,O,I
induced,O,O
transcription,O,O
complex,O,O
ISGF3,O,O
such,O,O
that,O,O
the,O,O
DNA,O,B
-,O,I
binding,O,I
component,O,I
of,O,I
this,O,I
complex,O,I
(,O,O
the,O,O
48,O,B
-,O,I
kDa,O,I
ISGF3gamma,O,I
protein,O,I
),O,O
does,O,O
not,O,O
bind,O,O
to,O,O
the,O,O
interferon,O,B
-,O,I
stimulated,O,I
response,O,I
element,O,I
(,O,O
ISRE,O,O
),O,O
.,O,O
Phorbol,O,O
ester,O,O
treatment,O,O
of,O,O
monocytes,O,O
inhibited,O,O
IFN,O,B
alpha,O,I
-,O,I
stimulated,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
the,O,O
transcription,B,O
factors,I,O
Stat1alpha,B,B
",",O,O
Stat2,B,B
",",O,O
and,O,O
Stat3,B,B
and,O,O
of,O,O
the,O,O
tyrosine,B,O
kinase,I,O
Tyk2,B,B
but,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
IFN,B,B
-,I,I
gamma,I,I
activation,O,O
of,O,O
Stat1alpha,B,B
.,O,O
Pretreatment,O,O
of,O,O
cells,O,O
with,O,O
vanadate,O,O
prevented,O,O
the,O,O
effects,O,O
of,O,O
PMA,O,O
with,O,O
regard,O,O
to,O,O
PMA,O,O
-,O,O
induced,O,O
Tyk2,B,O
dephosphorylation,O,O
.,O,O
Interleukin,B,B
-,I,I
2,I,I
(,I,O
IL,I,B
-,I,I
2,I,I
),I,O
promoter,I,O
-,B,O
reporter,I,O
gene,I,O
behavior,O,O
closely,O,O
parallels,O,O
the,O,O
endogenous,B,O
gene,I,O
in,O,O
response,O,O
to,O,O
T,B,O
cell,I,O
receptor,I,O
and,O,O
costimulatory,O,O
signals,O,O
.,O,O
The,O,O
RAR,B,O
-,I,O
RXR,I,O
as,O,O
well,O,O
as,O,O
the,O,O
RXR,B,O
-,I,O
RXR,I,O
pathway,O,O
is,O,O
involved,O,O
in,O,O
signaling,O,O
growth,O,O
inhibition,O,O
of,O,O
human,O,B
CD34,O,I
+,O,I
erythroid,O,I
progenitor,O,I
cells,O,O
.,O,O
Previous,O,O
studies,O,O
have,O,O
shown,O,O
that,O,O
retinoic,O,O
acid,O,O
(,O,O
RA,O,B
),O,O
",",O,O
similar,O,O
to,O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
(,O,O
TNF,B,B
-,I,I
alpha,I,I
),O,O
",",O,O
can,O,O
act,O,O
as,O,O
a,O,O
bifunctional,O,O
regulator,O,O
of,O,O
the,O,O
growth,O,O
of,O,O
bone,O,O
marrow,O,O
progenitors,O,O
",",O,O
in,O,O
that,O,O
it,O,O
can,O,O
stimulate,O,O
granulocyte,O,O
-,O,O
macrophage,O,O
colony,O,O
-,O,O
stimulating,O,O
factor,O,O
(,O,O
GM,O,O
-,O,O
CSF,O,O
),O,O
-,O,O
or,O,O
interleukin,O,B
-,O,I
3,O,I
(,O,O
IL,O,B
-,O,I
3,O,I
),O,O
-,O,O
induced,O,O
GM,O,O
colony,O,O
formation,O,O
",",O,O
but,O,O
potently,O,O
inhibit,O,O
G,B,O
-,I,O
CSF,I,O
-,O,O
induced,O,O
growth,O,O
.,O,O
Erythroid,O,B
colony,O,I
growth,O,I
was,O,O
also,O,O
inhibited,O,O
when,O,O
CD34,O,B
+,O,I
progenitors,O,I
were,O,O
seeded,O,O
at,O,O
one,O,O
cell,O,O
per,O,O
well,O,O
",",O,O
suggesting,O,O
a,O,O
direct,O,O
action,O,O
of,O,O
RA,O,O
.,O,O
At,O,O
this,O,O
concentration,O,O
",",O,O
Ro,O,O
13,O,O
-,O,O
7410,O,O
potently,O,O
inhibited,O,O
G,B,B
-,I,I
CSF,I,I
-,O,I
stimulated,O,I
myeloid,O,I
as,O,O
well,O,O
as,O,O
SCF,B,B
+,O,I
Epo,B,I
-,O,I
induced,O,I
erythroid,O,I
colony,O,I
growth,O,I
.,O,O
At,O,O
the,O,O
same,O,O
concentration,O,O
",",O,O
Ro,O,O
25,O,O
-,O,O
6603,O,O
and,O,O
Ro,O,O
25,O,O
-,O,O
7386,O,O
had,O,O
little,O,O
or,O,O
no,O,O
effect,O,O
on,O,O
G,B,B
-,I,I
CSF,I,I
-,O,I
induced,O,I
colony,O,I
formation,O,I
",",O,O
whereas,O,O
they,O,O
inhibited,O,O
75,O,O
%,O,O
and,O,O
53,O,O
%,O,O
",",O,O
respectively,O,O
",",O,O
of,O,O
SCF,B,B
+,O,I
Epo,B,I
-,O,I
stimulated,O,I
BFU,O,I
-,O,I
E,O,I
colony,O,I
growth,O,I
.,O,O
Thus,O,O
",",O,O
the,O,O
RAR,B,B
-,I,I
RXR,I,I
response,O,O
pathway,O,O
can,O,O
signal,O,O
growth,O,O
inhibition,O,O
of,O,O
normal,O,O
bone,O,O
marrow,O,O
myeloid,O,B
and,O,O
erythroid,O,B
progenitor,O,I
cells,O,O
.,O,O
After,O,O
treatment,O,O
of,O,O
APL,O,O
cells,O,O
with,O,O
AM580,O,O
either,O,O
alone,O,O
or,O,O
in,O,O
combination,O,O
with,O,O
granulocyte,B,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,O,O
G,B,B
-,I,I
CSF,I,I
),O,O
",",O,O
the,O,O
compound,O,O
induces,O,O
granulocytic,O,B
maturation,O,O
",",O,O
as,O,O
assessed,O,O
by,O,O
determination,O,O
of,O,O
the,O,O
levels,O,O
of,O,O
leukocyte,B,B
alkaline,I,I
phosphatase,I,I
",",I,O
CD11b,I,B
",",I,O
CD33,I,B
",",I,O
and,I,O
G,I,B
-,I,I
CSF,I,I
receptor,I,I
mRNA,I,I
",",O,O
at,O,O
concentrations,O,O
that,O,O
are,O,O
10,O,O
-,O,O
to,O,O
100,O,O
-,O,O
fold,O,O
lower,O,O
than,O,O
those,O,O
of,O,O
ATRA,O,O
necessary,O,O
to,O,O
produce,O,O
similar,O,O
effects,O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
AM580,O,B
is,O,O
not,O,O
effective,O,O
as,O,O
ATRA,O,O
in,O,O
modulating,O,O
the,O,O
expression,O,O
of,O,O
these,O,O
differentiation,B,O
markers,I,O
in,O,O
the,O,O
HL,O,O
-,O,O
60,O,O
cell,O,O
line,O,O
and,O,O
in,O,O
freshly,O,O
isolated,O,O
granulocytes,O,O
obtained,O,O
from,O,O
the,O,O
peripheral,O,O
blood,O,O
of,O,O
chronic,O,O
myelogenous,O,O
leukemia,O,O
patients,O,O
during,O,O
the,O,O
stable,O,O
phase,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
In,O,O
NB4,O,O
cells,O,O
",",O,O
two,O,O
other,O,O
synthetic,O,O
nonselective,O,O
RAR,O,B
ligands,O,O
are,O,O
capable,O,O
of,O,O
inducing,O,O
LAP,B,O
as,O,O
much,O,O
as,O,O
AM580,O,O
",",O,O
whereas,O,O
RAR,O,B
beta,O,I
-,O,I
or,O,O
RAR,O,B
gamma,O,I
-,O,I
specific,O,I
ligands,O,O
are,O,O
totally,O,O
ineffective,O,O
.,O,O
These,O,O
results,O,O
show,O,O
that,O,O
AM580,O,B
is,O,O
more,O,O
powerful,O,O
than,O,O
ATRA,O,B
in,O,O
modulating,O,O
the,O,O
expression,O,O
of,O,O
differentiation,O,O
antigens,O,O
only,O,O
in,O,O
cells,O,O
in,O,O
which,O,O
PML,B,B
-,I,I
RAR,I,I
is,O,O
present,O,O
.,O,O
Binding,O,O
experiments,O,O
",",O,O
using,O,O
COS,O,B
-,O,I
7,O,I
cells,O,O
transiently,O,O
transfected,O,O
with,O,O
PML,B,B
-,I,I
RAR,I,I
and,O,O
the,O,O
normal,O,O
RAR,B,B
alpha,I,I
",",O,O
show,O,O
that,O,O
AM580,O,B
has,O,O
a,O,O
lower,O,O
affinity,O,O
than,O,O
ATRA,O,B
for,O,O
both,O,O
receptors,O,O
.,O,O
Inhibition,O,O
of,O,O
vitamin,B,B
D,I,I
receptor,I,I
-,I,I
retinoid,I,I
X,I,I
receptor,I,I
-,I,I
vitamin,I,I
D,I,I
response,I,I
element,I,I
complex,I,I
formation,O,O
by,O,O
nuclear,O,O
extracts,O,O
of,O,O
vitamin,O,B
D,O,I
-,O,I
resistant,O,I
New,O,I
World,O,I
primate,O,I
cells,O,O
.,O,O
Nuclear,O,O
and,O,O
post,O,O
-,O,O
nuclear,O,O
extracts,O,O
were,O,O
prepared,O,O
from,O,O
two,O,O
B,O,O
-,O,O
lymphoblastoid,O,O
cell,O,O
lines,O,O
known,O,O
to,O,O
be,O,O
representative,O,O
of,O,O
the,O,O
vitamin,O,B
D,O,I
-,O,I
resistant,O,I
and,O,O
wild,O,O
type,O,O
phenotypes,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
vitamin,O,B
D,O,I
-,O,I
resistant,O,I
cell,O,I
nuclear,O,I
extract,O,I
contained,O,O
a,O,O
protein,O,B
(,O,O
s,O,O
),O,O
which,O,O
was,O,O
bound,O,O
specifically,O,O
to,O,O
the,O,O
VDRE,B,O
and,O,O
was,O,O
capable,O,O
of,O,O
completely,O,O
inhibiting,O,O
VDR,B,B
-,I,I
RXR,I,I
-,I,I
VDRE,I,I
complex,I,I
formation,O,O
;,O,O
these,O,O
effects,O,O
were,O,O
not,O,O
demonstrated,O,O
with,O,O
nuclear,O,O
extract,O,O
from,O,O
the,O,O
wild,O,O
type,O,O
cell,O,O
line,O,O
or,O,O
with,O,O
the,O,O
post,O,O
-,O,O
nuclear,O,O
extract,O,O
of,O,O
the,O,O
vitamin,O,B
D,O,I
-,O,I
resistant,O,I
cell,O,I
line,O,I
.,O,O
We,O,O
conclude,O,O
that,O,O
a,O,O
VDRE,B,B
-,I,I
binding,I,I
protein,I,I
(,O,O
s,O,O
),O,O
",",O,O
distinct,O,O
from,O,O
IDBP,B,O
and,O,O
present,O,O
in,O,O
nuclear,O,O
extract,O,O
of,O,O
cells,O,O
from,O,O
a,O,O
prototypical,O,O
vitamin,O,B
D,O,I
-,O,I
resistant,O,I
NWP,O,O
",",O,O
is,O,O
capable,O,O
of,O,O
inhibiting,O,O
normal,O,O
VDR,B,B
-,I,I
RXR,I,I
heterodimer,O,I
binding,O,I
to,O,O
the,O,O
VDRE,B,B
.,O,O
Finally,O,O
",",O,O
the,O,O
activation,O,O
-,O,O
induced,O,O
changes,O,O
in,O,O
one,O,O
set,O,O
of,O,O
phosphoproteins,B,O
were,O,O
dramatically,O,O
inhibited,O,O
by,O,O
cyclosporin,O,B
A,O,I
.,O,O
Like,O,O
IkappaBalpha,B,B
",",O,O
Tax,B,O
-,O,O
mediated,O,O
breakdown,O,O
of,O,O
IkappaBbeta,B,B
in,O,O
transfected,O,O
T,O,O
lymphocytes,O,O
is,O,O
blocked,O,O
either,O,O
by,O,O
cell,O,O
-,O,O
permeable,O,O
proteasome,O,O
inhibitors,O,O
or,O,O
by,O,O
mutation,O,O
Of,O,O
IkappaBbeta,B,B
at,O,O
two,O,O
serine,O,O
residues,O,O
present,O,O
within,O,O
its,O,O
N,B,O
-,I,O
terminal,I,O
region,I,O
.,O,O
Although,O,O
a,O,O
role,O,O
of,O,O
p16,B,O
in,O,O
this,O,O
regulation,O,O
has,O,O
been,O,O
presumed,O,O
",",O,O
there,O,O
is,O,O
no,O,O
proof,O,O
so,O,O
far,O,O
that,O,O
loss,O,O
of,O,O
this,O,O
tumor,B,O
suppressor,I,O
gene,I,O
really,O,O
affects,O,O
E2F,B,O
-,O,O
mediated,O,O
regulations,O,O
.,O,O
Nuclear,B,B
factors,I,I
from,O,I
unstimulated,O,I
",",O,O
but,O,O
not,O,O
from,O,O
activated,O,O
cells,O,O
",",O,O
bound,O,O
a,O,O
site,O,O
",",O,O
META,B,B
(,I,I
D,I,I
-,I,I
),I,I
",",O,O
adjacent,O,O
to,O,O
META,B,B
(,I,I
D,I,I
+,I,I
),I,I
.,O,O
We,O,O
have,O,O
isolated,O,O
a,O,O
novel,B,O
cDNA,I,B
clone,I,I
encoding,O,O
interferon,B,B
(,I,I
IFN,I,I
),I,I
consensus,I,I
sequence,I,I
-,I,I
binding,I,I
protein,I,I
in,O,O
adult,O,O
T,O,B
-,O,I
cell,O,I
leukemia,O,I
cell,O,I
line,O,I
or,O,O
activated,O,O
T,O,B
cells,O,I
(,O,I
ICSAT,B,I
),O,I
;,O,O
this,O,O
protein,O,O
is,O,O
the,O,O
human,O,O
homolog,O,O
of,O,O
the,O,O
recently,O,O
cloned,O,O
Pip,B,B
/,I,I
LSIRF,I,I
.,O,O
Here,O,O
",",O,O
we,O,O
describe,O,O
the,O,O
effect,O,O
of,O,O
383,B,O
-,I,O
bp,I,O
(,I,O
delta383,I,O
),I,O
and,I,O
99,I,O
-,I,O
bp,I,O
(,I,O
delta99,I,O
),I,O
sequences,I,O
containing,O,O
the,O,O
PYBF,B,B
-,I,I
binding,I,I
site,I,I
on,O,O
transcription,O,O
from,O,O
various,O,O
globin,O,O
and,O,O
non,O,O
-,O,O
globin,O,O
promoters,O,O
",",O,O
using,O,O
a,O,O
transient,O,O
assay,O,O
with,O,O
the,O,O
cat,B,O
reporter,I,O
gene,I,O
in,O,O
murine,O,B
erythroleukemia,O,I
(,O,I
MEL,O,I
),O,I
cells,O,O
",",O,O
a,O,O
cell,O,O
line,O,O
with,O,O
abundant,O,O
PYBF,B,O
activity,O,O
.,O,O
Translocation,B,O
breakpoints,I,O
in,O,O
three,O,O
patients,O,O
with,O,O
campomelic,O,O
and,O,O
autosomal,O,O
sex,O,O
reversal,O,O
map,O,O
more,O,O
than,O,O
130,O,O
kb,O,O
from,O,O
SOX9,B,B
.,O,O
Campomelic,O,O
(,O,O
CMPD1,O,O
),O,O
and,O,O
autosomal,O,O
XY,O,O
sex,O,O
reversal,O,O
(,O,O
SRA1,O,O
),O,O
are,O,O
caused,O,O
by,O,O
mutations,O,O
in,O,O
the,O,O
SRY,B,O
-,I,O
related,I,O
gene,I,O
SOX9,B,B
on,O,O
17q,B,O
.,O,O
Unexpectedly,O,O
",",O,O
the,O,O
17q,B,O
breakpoints,I,O
in,O,O
four,O,O
CMPD1,O,O
translocation,O,O
cases,O,O
previously,O,O
analyzed,O,O
by,O,O
us,O,O
and,O,O
others,O,O
map,O,O
50,O,O
kb,O,O
or,O,O
more,O,O
from,O,O
SOX9,B,B
.,O,O
DeltaSpi,B,B
-,I,I
B,I,I
product,O,O
was,O,O
not,O,O
able,O,O
to,O,O
bind,O,O
DNA,O,B
and,O,O
was,O,O
recovered,O,O
in,O,O
cytoplasmic,O,B
cellular,O,I
extracts,O,O
.,O,O
Both,O,O
CIITA,B,O
and,O,O
Bob1,B,O
increase,O,O
the,O,O
expression,O,O
from,O,O
the,O,O
DRA,B,O
promoter,I,O
",",O,O
which,O,O
is,O,O
a,O,O
prototypic,O,O
class,B,O
II,I,O
promoter,I,O
.,O,O
However,O,O
",",O,O
the,O,O
growth,O,O
of,O,O
most,O,O
mutated,O,O
viruses,O,O
was,O,O
suppressed,O,O
in,O,O
primary,O,O
rhesus,O,O
monkey,O,O
alveolar,O,O
macrophages,O,O
(,O,O
SIVmacMER,O,O
approximately,O,O
2xNFkappaB,B,O
approximately,O,O
substNFkappaB,B,O
>,O,O
deltaNFkappaB,B,O
>,O,O
deltaNFkappaB,B,O
deltaSpl234,B,O
approximately,O,O
deltaNFkappaBdeltaSp,B,O
>,O,O
deltaSpl234,B,O
approximately,O,O
substSpl2,B,O
>,O,O
substSp23,B,O
approximately,O,O
substSp34,B,O
approximately,O,O
substSpl234,B,O
>,O,O
or,O,O
SIVmac239,O,O
.,O,O
The,O,O
ability,O,O
of,O,O
T,O,B
cells,O,I
to,O,O
form,O,O
high,O,O
intracellular,O,O
levels,O,O
of,O,O
cAMP,O,B
is,O,O
acquired,O,O
during,O,O
development,O,O
in,O,O
the,O,O
human,O,B
thymus,O,I
and,O,O
is,O,O
retained,O,O
by,O,O
the,O,O
majority,O,O
of,O,O
mature,O,O
peripheral,O,B
T,O,I
lymphocytes,O,I
.,O,O
A,O,O
hydrophobic,O,O
domain,O,O
of,O,O
Ca2,B,B
+,I,I
-,I,I
modulating,I,O
cyclophilin,I,B
ligand,I,I
modulates,O,O
calcium,O,B
influx,O,I
signaling,O,O
in,O,O
T,O,B
lymphocytes,O,I
.,O,O
Ca2,B,B
+,I,I
-,I,I
modulating,I,O
cyclophilin,I,B
ligand,I,I
(,O,O
CAML,B,B
),O,O
was,O,O
originally,O,O
described,O,O
as,O,O
a,O,O
cyclophilin,B,B
B,I,I
-,I,I
binding,I,I
protein,I,I
whose,O,O
overexpression,O,O
in,O,O
T,O,B
cells,O,I
causes,O,O
a,O,O
rise,O,O
in,O,O
intracellular,O,O
calcium,O,B
",",O,O
thus,O,O
activating,O,O
transcription,B,O
factors,I,O
responsible,O,O
for,O,O
the,O,O
early,O,O
immune,O,O
response,O,O
.,O,O
The,O,O
Epstein,B,B
-,I,I
Barr,I,I
virus,I,I
-,I,I
encoded,I,O
nuclear,I,O
antigen,I,O
EBNA,I,B
-,I,I
5,I,I
accumulates,O,O
in,O,O
PML,O,B
-,O,I
containing,O,I
bodies,O,I
.,O,O
The,O,O
chromosome,B,O
17,I,O
breakpoint,I,O
was,O,O
localized,O,O
to,O,O
intron,B,O
2,I,O
of,O,O
RARA,B,B
by,O,O
Southern,O,O
blotting,O,O
",",O,O
and,O,O
there,O,O
was,O,O
no,O,O
evidence,O,O
at,O,O
the,O,O
molecular,O,O
level,O,O
for,O,O
rearrangement,O,O
at,O,O
PML,B,B
locus,I,I
.,O,O
Immunocytochemistry,O,O
identified,O,O
the,O,O
cells,O,O
in,O,O
the,O,O
infiltrate,O,O
as,O,O
cytotoxic,O,B
T,O,I
cells,O,I
.,O,O
In,O,O
these,O,O
same,O,O
animals,O,O
",",O,O
E1A,B,B
protein,I,I
was,O,O
detected,O,O
20,O,O
days,O,O
after,O,O
infection,O,O
in,O,O
two,O,O
and,O,O
47,O,O
days,O,O
after,O,O
infection,O,O
in,O,O
one,O,O
while,O,O
persistent,O,O
bronchiolitis,O,O
was,O,O
observed,O,O
in,O,O
four,O,O
and,O,O
three,O,O
animals,O,O
20,O,O
and,O,O
47,O,O
days,O,O
after,O,O
infection,O,O
",",O,O
respectively,O,O
.,O,O
of,O,O
-,O,O
1,I,O
/,I,O
CRE,I,O
site,I,O
within,O,O
ZII,B,O
abolished,O,O
the,O,O
inducibility,O,O
of,O,O
Zp,B,O
by,O,O
HHV,O,O
-,O,O
6,O,O
",",O,O
whereas,O,O
positioning,O,O
of,O,O
the,O,O
ZII,B,O
domain,I,O
upstream,O,O
of,O,O
the,O,O
beta,B,O
-,I,O
globin,I,O
minimal,I,O
promoter,I,O
conferred,O,O
responsiveness,O,O
following,O,O
HHV,O,O
-,O,O
6,O,O
infection,O,O
.,O,O
Antibodies,O,O
against,O,O
CRE,B,O
-,I,O
binding,I,O
(,I,O
CREB,I,B
),I,O
protein,I,O
but,O,O
not,O,O
against,O,O
c,B,O
-,I,O
Fos,I,O
or,O,O
c,B,O
-,I,O
Jun,I,O
were,O,O
able,O,O
to,O,O
supershift,O,O
the,O,O
DNA,B,B
-,I,I
protein,I,I
complex,I,I
",",O,O
identifying,O,O
the,O,O
nature,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
which,O,O
binds,O,O
to,O,O
ZII,B,O
as,O,O
a,O,O
member,O,O
of,O,O
the,O,O
CREB,B,B
family,I,I
of,I,I
proteins,I,I
.,O,O
Regulation,O,O
of,O,O
the,O,O
nuclear,B,B
factor,I,I
of,I,I
activated,I,I
T,I,I
cells,I,I
in,O,O
stably,O,O
transfected,O,O
Jurkat,O,O
cell,O,O
clones,O,O
.,O,O
Glucocorticoids,O,O
induced,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
mRNA,O,I
expression,O,O
in,O,O
asthma,O,O
.,O,O
The,O,O
lymphoid,B,B
-,I,I
specific,I,I
transcription,I,I
factor,I,I
Oct,B,B
-,I,I
2a,I,I
is,O,O
implicated,O,O
in,O,O
B,O,B
cell,O,I
-,O,I
specific,O,I
transcriptional,O,I
activity,O,O
via,O,O
the,O,O
octamer,O,O
motif,O,O
.,O,O
Structure,O,O
/,O,O
function,O,O
analysis,O,O
of,O,O
various,O,O
Oct,B,B
-,I,I
2a,I,I
effector,I,O
regions,I,O
in,O,O
the,O,O
context,O,O
of,O,O
the,O,O
GAL4,B,B
DNA,I,I
-,I,I
binding,I,I
domain,I,I
revealed,O,O
that,O,O
Oct,B,B
-,I,I
2a,I,I
contains,O,O
two,O,O
functionally,O,O
different,O,O
activation,B,O
domains,I,O
at,O,O
the,O,O
N,B,B
and,I,O
the,I,O
C,I,B
termini,I,O
.,O,O
When,O,O
this,O,O
domain,O,O
was,O,O
transferred,O,O
to,O,O
a,O,O
potent,O,O
activator,O,O
",",O,O
transcription,O,O
was,O,O
strongly,O,O
inhibited,O,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
present,O,O
a,O,O
deletion,O,O
analysis,O,O
of,O,O
the,O,O
N,B,B
-,I,I
terminal,I,I
region,I,I
of,O,O
Oct,B,B
-,I,I
2a,I,I
to,O,O
determine,O,O
the,O,O
minimal,B,O
repression,I,O
domain,I,O
.,O,O
The,O,O
possibility,O,O
that,O,O
Oct,B,B
-,I,I
2a,I,I
can,O,O
act,O,O
as,O,O
an,O,O
activator,O,O
and,O,O
/,O,O
or,O,O
a,O,O
repressor,O,O
may,O,O
have,O,O
important,O,O
consequences,O,O
for,O,O
the,O,O
function,O,O
of,O,O
Oct,B,B
-,I,I
2a,I,I
in,O,O
B,O,B
cell,O,I
differentiation,O,I
and,O,O
other,O,O
developmental,O,O
processes,O,O
.,O,O
Although,O,O
there,O,O
have,O,O
been,O,O
a,O,O
number,O,O
of,O,O
reports,O,O
demonstrating,O,O
that,O,O
glucocorticoids,O,B
(,O,O
in,O,O
particular,O,O
dexamethasone,O,O
),O,O
antagonize,O,O
the,O,O
eosinophil,O,B
life,O,I
-,O,I
prolonging,O,I
effects,O,O
of,O,O
hemopoietins,B,O
",",O,O
direct,O,O
effects,O,O
of,O,O
dexamethasone,O,O
on,O,O
eosinophil,O,B
apoptosis,O,O
have,O,O
not,O,O
been,O,O
documented,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
dexamethasone,O,O
was,O,O
a,O,O
potent,O,O
inhibitor,O,O
of,O,O
neutrophil,O,B
apoptosis,O,O
.,O,O
For,O,O
this,O,O
purpose,O,O
",",O,O
we,O,O
used,O,O
three,O,O
main,O,O
approaches,O,O
.,O,O
The,O,O
first,O,O
was,O,O
to,O,O
abruptly,O,O
terminate,O,O
tumor,O,B
necrosis,O,I
factor,O,I
-,O,I
induced,O,I
NF,B,B
-,I,I
kappaB,I,I
binding,O,O
to,O,O
the,O,O
enhancer,O,O
sequences,O,O
in,O,O
U1,O,O
monocytic,O,O
cells,O,O
",",O,O
using,O,O
a,O,O
short,O,O
pulse,O,O
of,O,O
exogenous,B,O
tumor,I,B
necrosis,I,I
factor,I,I
.,O,O
Together,O,O
",",O,O
our,O,O
results,O,O
indicate,O,O
that,O,O
occupancy,O,O
of,O,O
the,O,O
viral,B,O
enhancer,I,O
by,O,O
NF,B,B
-,I,I
kappaB,I,I
(,I,O
p50,I,O
/,I,O
p65,I,O
),I,O
heterodimers,I,O
is,O,O
required,O,O
for,O,O
ongoing,O,O
transcription,O,O
of,O,O
integrated,O,O
HIV,O,B
provirus,O,I
in,O,O
monocytes,O,O
",",O,O
even,O,O
in,O,O
cells,O,O
chronically,O,O
infected,O,O
and,O,O
permanently,O,O
producing,O,O
functional,O,O
HIV,B,B
Tat,I,I
protein,I,I
.,O,O
In,O,O
an,O,O
attempt,O,O
to,O,O
identify,O,O
changes,O,O
in,O,O
gene,O,B
expression,O,I
that,O,O
accompany,O,O
the,O,O
T,O,B
-,O,I
cell,O,I
stimulation,O,I
defects,O,O
associated,O,O
with,O,O
the,O,O
loss,O,O
of,O,O
Rel,B,B
",",O,O
we,O,O
have,O,O
examined,O,O
the,O,O
expression,O,O
of,O,O
cell,B,B
surface,I,I
activation,I,I
markers,I,I
and,O,O
cytokine,O,B
production,O,I
in,O,O
mitogen,O,O
-,O,O
stimulated,O,O
Rel,O,B
-,O,I
/,O,I
-,O,I
T,O,I
cells,O,I
.,O,O
Exogenous,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
which,O,O
restitutes,O,O
the,O,O
proliferative,O,O
response,O,O
of,O,O
the,O,O
anti,O,O
-,O,O
CD3,O,O
-,O,O
and,O,O
anti,O,O
-,O,O
CD28,O,O
-,O,O
treated,O,O
Rel,O,B
-,O,I
/,O,I
-,O,I
T,O,I
cells,O,I
",",O,O
restores,O,O
production,O,O
of,O,O
IL,O,B
-,O,I
5,O,I
",",O,O
TNF,B,B
-,I,I
alpha,I,I
",",O,O
and,O,O
IFN,B,B
-,I,I
gamma,I,I
",",O,O
but,O,O
not,O,O
IL,B,B
-,I,I
3,I,I
and,O,O
GM,B,B
-,I,I
CSF,I,I
expression,O,I
to,O,O
approximately,O,O
normal,O,O
levels,O,O
.,O,O
These,O,O
findings,O,O
establish,O,O
that,O,O
Rel,B,B
can,O,O
function,O,O
as,O,O
an,O,O
activator,O,O
or,O,O
repressor,O,O
of,O,O
gene,O,O
expression,O,O
and,O,O
is,O,O
required,O,O
by,O,O
T,O,O
lymphocytes,O,O
for,O,O
production,O,O
of,O,O
IL,B,B
-,I,I
3,I,I
and,O,O
GM,B,B
-,I,I
CSF,I,I
.,O,O
Nuclear,O,O
appearance,O,O
of,O,O
a,O,O
factor,O,O
that,O,O
binds,O,O
the,O,O
CD28,B,O
response,I,O
element,I,O
within,O,O
the,O,O
interleukin,B,O
-,I,O
2,I,O
enhancer,I,O
correlates,O,O
with,O,O
interleukin,B,O
-,I,O
2,I,O
production,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
mitogenic,O,O
combinations,O,O
of,O,O
T,O,O
cell,O,O
activation,O,O
signals,O,O
are,O,O
integrated,O,O
at,O,O
the,O,O
level,O,O
of,O,O
NF,B,O
-,I,O
MATp35,I,O
induction,O,O
.,O,O
Transcriptional,O,O
basis,O,O
for,O,O
hyporesponsiveness,O,O
of,O,O
the,O,O
human,B,O
inducible,I,O
nitric,I,B
oxide,I,I
synthase,I,I
gene,I,I
to,O,O
lipopolysaccharide,O,O
/,O,O
interferon,O,O
-,O,O
gamma,O,O
.,O,O
Two,O,O
explanations,O,O
for,O,O
hyporesponsiveness,O,O
of,O,O
the,O,O
human,B,O
iNOS,I,O
promoter,I,O
to,O,O
LPS,O,O
+,O,O
/,O,O
-,O,O
IFN,B,O
-,I,O
gamma,I,O
were,O,O
found,O,O
:,O,O
(,O,O
1,O,O
),O,O
multiple,O,O
inactivating,O,O
nucleotide,O,O
substitutions,O,O
in,O,O
the,O,O
human,O,O
counterpart,O,O
of,O,O
the,O,O
enhancer,B,O
element,I,O
that,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
regulate,O,O
LPS,O,O
/,O,O
IFN,B,O
-,I,O
gamma,I,O
induced,O,O
expression,O,O
of,O,O
the,O,O
mouse,B,O
iNOS,I,O
gene,I,O
;,O,O
and,O,O
(,O,O
2,O,O
),O,O
and,O,O
absence,O,O
of,O,O
one,O,O
or,O,O
more,O,O
nuclear,B,O
factors,I,O
in,O,O
human,O,O
macrophages,O,O
(,O,O
e,O,O
.,O,O
g,O,O
.,O,O
",",O,O
an,O,O
LPS,B,O
-,I,O
inducible,I,O
nuclear,I,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
/,I,O
Rel,I,O
complex,I,O
),O,O
",",O,O
that,O,O
is,O,O
(,O,O
are,O,O
),O,O
required,O,O
for,O,O
maximal,O,O
expression,O,O
of,O,O
the,O,O
gene,O,O
.,O,O
Severe,O,O
skewing,O,O
of,O,O
X,O,O
inactivation,O,O
resulting,O,O
in,O,O
inactivity,O,O
of,O,O
the,O,O
intact,O,O
X,B,O
was,O,O
found,O,O
in,O,O
blood,O,O
and,O,O
cultures,O,O
of,O,O
both,O,O
types,O,O
of,O,O
skin,O,O
",",O,O
but,O,O
analysis,O,O
of,O,O
DNA,O,B
prepared,O,O
directly,O,O
from,O,O
hypopigmented,O,O
skin,O,O
showed,O,O
significant,O,O
inactivation,O,O
of,O,O
the,O,O
translocated,O,O
X,B,O
",",O,O
inconsistent,O,O
with,O,O
the,O,O
usual,O,O
mechanism,O,O
of,O,O
phenotypic,O,O
expression,O,O
in,O,O
X,B,O
;,I,O
autosome,I,O
translocations,I,O
.,O,O
While,O,O
partial,O,O
variable,O,O
monosomy,O,O
of,O,O
loci,O,O
on,O,O
chromosome,B,O
17p,I,O
can,O,O
not,O,O
be,O,O
excluded,O,O
as,O,O
contributing,O,O
to,O,O
the,O,O
phenotype,O,O
in,O,O
this,O,O
patient,O,O
",",O,O
it,O,O
is,O,O
argued,O,O
that,O,O
the,O,O
major,O,O
likely,O,O
factor,O,O
is,O,O
partial,O,O
functional,O,O
disomy,O,O
of,O,O
sequences,O,O
on,O,O
Xp,B,O
in,O,O
cell,O,O
lineages,O,O
that,O,O
have,O,O
failed,O,O
to,O,O
inactivate,O,O
the,O,O
intact,O,O
X,B,O
chromosome,I,O
.,O,O
After,O,O
several,O,O
round,O,O
of,O,O
subcloning,O,O
followed,O,O
by,O,O
transfection,O,O
",",O,O
oriP,B,O
was,O,O
mapped,O,O
to,O,O
a,O,O
1,B,O
.,I,O
955,I,O
-,I,O
kb,I,O
viral,I,O
segment,I,O
.,O,O
Large,O,O
amounts,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
significant,O,O
quantities,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
were,O,O
induced,O,O
in,O,O
SEA,O,O
-,O,O
activated,O,O
CD4,O,O
+,O,O
spleen,O,O
T,O,O
cells,O,O
",",O,O
whereas,O,O
Oct,O,B
-,O,I
1,O,I
and,O,O
Oct,O,B
-,O,I
2,O,I
DNA,O,I
binding,O,I
activity,O,I
was,O,O
similar,O,O
in,O,O
both,O,O
resting,O,O
and,O,O
activated,O,O
T,O,O
cells,O,O
.,O,O
Fas,B,B
ligation,O,I
induces,O,O
apoptosis,O,O
and,O,O
Jun,B,B
kinase,I,I
activation,O,I
independently,O,O
of,O,O
CD45,B,O
and,O,O
Lck,B,O
in,O,O
human,O,O
T,O,O
cells,O,O
.,O,O
More,O,O
is,O,O
known,O,O
regarding,O,O
signal,O,O
transduction,O,O
events,O,O
that,O,O
occur,O,O
after,O,O
ligation,O,O
of,O,O
the,O,O
T,B,O
-,I,O
cell,I,O
antigen,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
.,O,O
Although,O,O
prior,O,O
studies,O,O
suggest,O,O
a,O,O
role,O,O
for,O,O
protein,B,B
tyrosine,I,I
kinases,I,I
and,O,O
phosphatases,O,O
in,O,O
Fas,B,O
signaling,O,O
",",O,O
we,O,O
report,O,O
here,O,O
that,O,O
Fas,O,O
ligation,O,O
induces,O,O
apoptosis,O,O
in,O,O
T,O,O
cells,O,O
deficient,O,O
in,O,O
either,O,O
CD45,B,B
or,O,O
Lck,B,B
.,O,O
Globin,O,B
gene,O,I
switching,O,I
.,O,O
In,O,O
contrast,O,O
",",O,O
in,O,O
vivo,O,O
footprints,O,O
on,O,O
GT,B,O
(,I,O
CACCC,I,O
),I,O
motifs,I,O
differed,O,O
between,O,O
the,O,O
cells,O,O
expressing,O,O
the,O,O
fetal,O,O
or,O,O
the,O,O
adult,O,O
globin,O,O
program,O,O
.,O,O
The,O,O
active,O,O
vitamin,O,O
D3,O,O
metabolite,O,O
1,O,O
",",O,O
25,O,O
-,O,O
dihydroxycholecalcif,O,O
(,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
),O,O
acts,O,O
as,O,O
an,O,O
antiproliferative,O,O
and,O,O
differentiating,O,O
agent,O,O
for,O,O
the,O,O
monoblastoid,O,O
cell,O,O
line,O,O
U937,O,O
and,O,O
as,O,O
an,O,O
important,O,O
immunologic,O,O
mediator,O,O
implicated,O,O
particularly,O,O
in,O,O
the,O,O
function,O,O
of,O,O
cells,O,O
belonging,O,O
to,O,O
the,O,O
monocyte,O,O
/,O,O
macrophage,O,O
lineage,O,O
.,O,O
Cell,O,B
cycle,O,I
analysis,O,I
showed,O,O
shifts,O,O
in,O,O
the,O,O
distribution,O,O
of,O,O
cells,O,B
from,O,O
G1,O,B
to,O,O
S,O,B
phase,O,I
",",O,O
which,O,O
were,O,O
more,O,O
pronounced,O,O
after,O,O
cadmium,O,B
treatment,O,I
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
",",O,O
in,O,O
contrast,O,O
to,O,O
most,O,O
LPS,O,B
effects,O,I
",",O,O
AP,B,B
-,I,I
1,I,I
",",O,O
but,O,O
not,O,O
nuclear,B,B
factor,I,I
-,I,I
kappaB,I,I
",",O,O
mediates,O,O
LPS,O,B
induction,O,I
of,O,I
collagenase,B,I
transcription,O,I
in,O,O
macrophagelike,O,B
cells,O,I
.,O,O
Activation,O,O
of,O,O
macrophages,O,O
by,O,O
bacterial,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
induces,O,O
transcription,O,O
of,O,O
genes,O,O
that,O,O
encode,O,O
for,O,O
proinflammatory,B,O
regulators,I,O
of,O,O
the,O,O
immune,O,O
response,O,O
.,O,O
LPS,O,O
treatment,O,O
of,O,O
RAW,O,O
264,O,O
.,O,O
7,O,O
cells,O,O
",",O,O
murine,O,O
bone,O,O
marrow,O,O
-,O,O
derived,O,O
macrophages,O,O
",",O,O
and,O,O
the,O,O
human,O,O
monocyte,O,O
cell,O,O
line,O,O
THP,O,O
-,O,O
1,O,O
resulted,O,O
in,O,O
rapid,O,O
activation,O,O
of,O,O
the,O,O
p46,B,O
and,I,O
p54,I,O
isoforms,I,O
of,O,O
JNK,B,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
LPS,O,O
activation,O,O
of,O,O
JNK,B,B
in,O,O
monocyte,O,B
/,O,I
macrophage,O,I
cells,O,O
is,O,O
a,O,O
CD14,O,B
-,O,I
and,O,O
protein,O,B
tyrosine,O,I
phosphorylation,O,I
-,O,I
dependent,O,I
event,O,O
that,O,O
may,O,O
mediate,O,O
the,O,O
early,O,O
activation,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
in,O,O
regulating,O,O
LPS,O,O
-,O,O
triggered,O,O
gene,O,O
induction,O,O
.,O,O
A,O,O
cell,B,O
type,I,O
-,I,O
specific,I,O
enhancer,I,O
in,O,O
the,O,O
human,B,O
B7,I,O
.,I,O
gene,I,O
regulated,O,O
by,O,O
NF,B,B
-,I,I
kappaB,I,I
.,O,O
This,O,O
183,B,O
-,I,O
bp,I,O
region,I,O
was,O,O
both,O,O
cell,O,B
type,O,I
specific,O,O
and,O,O
responsive,O,O
to,O,O
two,O,O
distinct,O,O
stimuli,O,O
",",O,O
lipopolysaccharide,O,O
and,O,O
dibutyryl,O,O
cAMP,O,O
",",O,O
known,O,O
to,O,O
regulate,O,O
B7,B,O
.,I,O
1,I,O
expression,O,O
.,O,O
Deletional,O,O
and,O,O
site,O,O
-,O,O
directed,O,O
mutagenesis,O,O
revealed,O,O
the,O,O
presence,O,O
of,O,O
multiple,O,O
functionally,O,O
critical,O,O
cis,B,O
elements,I,O
within,O,O
this,O,O
region,O,O
",",O,O
one,O,O
of,O,O
which,O,O
was,O,O
a,O,O
nuclear,B,O
factor,I,O
(,I,O
NF,I,B
),I,O
-,I,O
kappaB,I,O
consensus,I,O
sequence,I,O
.,O,O
This,O,O
is,O,O
the,O,O
first,O,O
description,O,O
",",O,O
to,O,O
our,O,O
knowledge,O,O
",",O,O
of,O,O
regulatory,B,O
elements,I,O
that,O,O
control,O,O
expression,O,O
of,O,O
a,O,O
gene,O,O
encoding,O,O
a,O,O
B7,B,B
costimulatory,I,I
molecule,I,I
.,O,O
Recombinant,O,O
c,B,O
-,I,O
Jun,I,O
and,O,O
c,B,O
-,I,O
Fos,I,O
were,O,O
ubiquitinylated,O,O
by,O,O
the,O,O
ubiquitin,B,O
carrier,I,O
enzymes,I,O
E214K,B,O
",",O,O
E220K,B,O
",",O,O
or,O,O
E232K,B,O
in,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
ubiquitin,B,O
-,I,O
activating,I,O
enzyme,I,O
",",O,O
E1,B,O
.,O,O
We,O,O
have,O,O
also,O,O
characterized,O,O
the,O,O
genomic,B,O
mBob1,I,B
clone,I,O
.,O,O
Analysis,O,O
of,O,O
its,O,O
intron,O,O
-,O,O
exon,O,O
structure,O,O
has,O,O
allowed,O,O
identification,O,O
of,O,O
a,O,O
C,B,B
-,I,I
terminal,I,I
splice,I,I
variant,I,I
.,O,O
mBob1,B,B
interacts,O,O
with,O,O
the,O,O
octamer,B,O
transcription,I,O
factors,I,O
Oct,B,B
-,I,I
1,I,I
and,O,O
Oct,B,B
-,I,I
2,I,I
and,O,O
stimulates,O,O
transcription,O,O
mediated,O,O
by,O,O
these,O,O
factors,O,O
.,O,O
It,O,O
is,O,O
well,O,O
established,O,O
that,O,O
the,O,O
two,O,O
major,O,O
glial,O,B
cells,O,I
in,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
(,O,O
CNS,O,O
),O,O
",",O,O
astrocytes,O,B
and,O,O
microglia,O,B
",",O,O
are,O,O
key,O,O
participants,O,O
in,O,O
mediating,O,O
the,O,O
neurologic,O,O
dysfunction,O,O
associated,O,O
with,O,O
HIV,O,O
infection,O,O
of,O,O
the,O,O
CNS,O,O
.,O,O
Moreover,O,O
",",O,O
gp120,B,B
induces,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
(,O,O
STAT,B,O
-,I,O
1,I,O
alpha,I,O
),O,O
as,O,O
well,O,O
as,O,O
the,O,O
Janus,B,B
kinase,I,I
(,O,O
JAK2,B,O
),O,O
in,O,O
glial,O,B
cells,O,O
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
as,O,O
well,O,O
as,O,O
Ab,O,O
blocking,O,O
and,O,O
cytokine,B,O
secretion,O,O
studies,O,O
indicated,O,O
that,O,O
the,O,O
induction,O,O
of,O,O
either,O,O
endogenous,B,O
TNF,I,B
-,I,I
alpha,I,I
or,O,O
IL,B,B
-,I,I
10,I,I
was,O,O
not,O,O
involved,O,O
in,O,O
the,O,O
cooperativity,O,O
",",O,O
nor,O,O
was,O,O
an,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
receptors,I,O
.,O,O
Interaction,O,O
of,O,O
HTLV,B,O
-,I,O
I,I,O
Tax,I,O
with,O,O
the,O,O
human,B,O
proteasome,I,B
:,O,O
implications,O,O
for,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
induction,O,O
.,O,O
We,O,O
identified,O,O
a,O,O
physical,O,O
interaction,O,O
between,O,O
Tax,B,O
and,O,O
the,O,O
HsN3,B,O
subunit,I,O
of,O,O
the,O,O
human,B,O
proteasome,I,B
.,O,O
This,O,O
raises,O,O
the,O,O
intriguing,O,O
possibility,O,O
that,O,O
physical,O,O
association,O,O
of,O,O
the,O,O
HsN3,B,O
proteasome,I,B
subunit,I,O
with,O,O
HTLV,B,O
-,I,O
I,I,O
Tax,I,O
coupled,O,O
with,O,O
the,O,O
independent,O,O
interaction,O,O
of,O,O
Tax,B,O
with,O,O
either,O,O
p100,O,O
or,O,O
p65,O,O
-,O,O
I,B,O
kappa,I,O
B,I,O
alpha,I,O
targets,O,O
these,O,O
cytoplasmic,B,O
NF,I,O
-,I,O
kappa,I,O
B,I,O
/,I,O
Rel,I,O
complexes,I,O
to,O,O
the,O,O
proteasome,B,B
for,O,O
processing,O,O
.,O,O
Basement,O,O
membrane,O,O
immunoreactivity,O,O
for,O,O
type,B,O
IV,I,B
collagen,I,I
and,O,O
laminin,B,B
was,O,O
discontinuous,O,O
in,O,O
most,O,O
examples,O,O
of,O,O
IDC,O,O
regardless,O,O
of,O,O
type,O,O
",",O,O
with,O,O
a,O,O
trend,O,O
toward,O,O
more,O,O
intense,O,O
staining,O,O
in,O,O
comedo,O,O
than,O,O
in,O,O
noncomedo,O,O
carcinomas,O,O
.,O,O
Periductal,O,O
angiogenesis,O,O
was,O,O
not,O,O
significantly,O,O
related,O,O
to,O,O
the,O,O
type,O,O
of,O,O
IDC,O,O
but,O,O
was,O,O
more,O,O
pronounced,O,O
with,O,O
comedo,O,O
carcinomas,O,O
.,O,O
They,O,O
correlated,O,O
with,O,O
markers,O,O
of,O,O
tumor,O,O
aggressivity,O,O
(,O,O
axillary,O,O
node,O,O
involvement,O,O
and,O,O
especially,O,O
with,O,O
markers,O,O
of,O,O
high,O,O
mitotic,O,O
rate,O,O
as,O,O
Ki,O,B
-,O,I
67,O,I
staining,O,O
",",O,O
histological,O,O
grade,O,O
),O,O
.,O,O
OBJECTIVE,O,O
:,O,O
We,O,O
sought,O,O
to,O,O
investigate,O,O
the,O,O
molecular,O,O
mechanisms,O,O
regulating,O,O
this,O,O
early,O,O
inflammatory,O,O
response,O,O
.,O,O
We,O,O
have,O,O
focused,O,O
on,O,O
the,O,O
study,O,O
of,O,O
the,O,O
signal,O,O
transduction,O,O
pathways,O,O
triggered,O,O
by,O,O
CD23,B,O
in,O,O
human,O,O
monocytes,O,O
and,O,O
the,O,O
promonocytic,O,O
cell,O,O
line,O,O
U937,O,O
.,O,O
IkappaBalpha,B,B
phosphorylation,O,O
and,O,O
degradation,O,O
was,O,O
analyzed,O,O
by,O,O
Western,O,O
blot,O,O
.,O,O
Paclitaxel,O,O
and,O,O
other,O,O
drugs,O,O
that,O,O
disturb,O,O
microtubule,B,O
dynamics,O,O
kill,O,O
cells,O,O
in,O,O
a,O,O
Fas,B,B
/,B,I
Fas,I,I
ligand,I,I
(,O,O
FasL,B,O
),O,O
-,O,O
dependent,O,O
manner,O,O
;,O,O
antibody,O,O
to,O,O
FasL,B,O
inhibits,O,O
paclitaxel,O,O
-,O,O
induced,O,O
apoptosis,O,O
.,O,O
Without,O,O
NFAT,B,O
nuclear,O,O
translocation,O,O
",",O,O
the,O,O
FasL,B,O
gene,O,O
is,O,O
not,O,O
transcribed,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
Bcl,B,B
-,I,I
2,I,I
can,O,O
be,O,O
overcome,O,O
",",O,O
at,O,O
least,O,O
partially,O,O
",",O,O
through,O,O
phosphorylation,O,O
of,O,O
Bcl,B,B
-,I,I
2,I,I
.,O,O
MHC,O,B
-,O,I
peptide,O,I
ligand,O,I
interactions,O,O
establish,O,O
a,O,O
functional,O,O
threshold,O,O
for,O,O
antigen,O,O
-,O,O
specific,O,O
T,O,O
cell,O,O
recognition,O,O
.,O,O
Regulatory,O,O
effects,O,O
of,O,O
interleukin,B,B
-,I,I
11,I,I
during,O,O
acute,O,O
lung,O,O
inflammatory,O,O
injury,O,O
.,O,O
IL,B,B
-,I,I
11,I,I
mRNA,I,O
and,O,O
protein,O,O
were,O,O
both,O,O
up,O,O
-,O,O
regulated,O,O
during,O,O
the,O,O
course,O,O
of,O,O
this,O,O
inflammatory,O,O
response,O,O
.,O,O
Recently,O,O
",",O,O
we,O,O
and,O,O
others,O,O
have,O,O
shown,O,O
that,O,O
thrombopoietin,B,B
induces,O,O
rapid,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
Jak2,B,B
and,O,O
other,O,O
proteins,O,O
in,O,O
human,O,O
platelets,O,O
and,O,O
BaF3,O,O
cells,O,O
",",O,O
genetically,O,O
engineered,O,O
to,O,O
express,O,O
c,B,B
-,I,I
Mpl,I,I
",",O,O
a,O,O
receptor,O,O
for,O,O
thrombopoietin,B,O
.,O,O
Thus,O,O
",",O,O
our,O,O
data,O,O
indicate,O,O
that,O,O
Stat3,B,B
and,O,O
Stat5,B,B
may,O,O
be,O,O
involved,O,O
in,O,O
signal,O,O
transduction,O,O
after,O,O
ligand,O,O
binding,O,O
to,O,O
c,B,O
-,I,O
Mpl,I,O
and,O,O
that,O,O
this,O,O
event,O,O
may,O,O
have,O,O
a,O,O
role,O,O
in,O,O
megakaryopoiesis,O,O
/,O,O
thrombopoiesis,O,O
or,O,O
possibly,O,O
a,O,O
mature,O,O
platelet,O,O
function,O,O
such,O,O
as,O,O
aggregation,O,O
.,O,O
Damage,O,O
to,O,O
the,O,O
genes,O,O
encoding,O,O
proteins,O,B
that,O,O
function,O,O
in,O,O
intracellular,O,O
signaling,O,O
",",O,O
transcription,O,O
",",O,O
or,O,O
regulation,O,O
of,O,O
the,O,O
cell,O,B
cycle,O,I
has,O,O
been,O,O
identified,O,O
and,O,O
linked,O,O
at,O,O
varying,O,O
degrees,O,O
to,O,O
the,O,O
progression,O,O
of,O,O
certain,O,O
lymphoid,O,B
malignancies,O,O
.,O,O
One,O,O
such,O,O
example,O,O
is,O,O
the,O,O
excessive,O,O
expression,O,O
of,O,O
`,B,O
`,I,O
normal,I,O
lymphokines,I,O
of,O,O
cytokines,B,O
which,O,O
accompanies,O,O
many,O,O
lymphoproliferative,O,O
diseases,O,O
.,O,O
The,O,O
dysregulated,O,O
expression,O,O
of,O,O
cytokines,B,O
during,O,O
malignancy,O,O
can,O,O
result,O,O
in,O,O
the,O,O
augmentation,O,O
of,O,O
growth,O,O
of,O,O
transformed,O,O
lymphocytes,O,O
",",O,O
as,O,O
well,O,O
as,O,O
an,O,O
alteration,O,O
of,O,O
the,O,O
anti,O,O
-,O,O
tumor,O,O
immune,O,O
response,O,O
.,O,O
In,O,O
addition,O,O
to,O,O
its,O,O
role,O,O
as,O,O
a,O,O
precursor,O,O
for,O,O
other,O,O
steroid,O,B
hormones,O,I
",",O,O
DHEA,O,O
has,O,O
been,O,O
proposed,O,O
to,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
immunity,O,O
.,O,O
Monocytes,O,B
stimulated,O,O
with,O,O
LPS,O,B
concentrations,O,O
of,O,O
1,O,O
.,O,O
0,O,O
micrograms,O,O
/,O,O
ml,O,O
displayed,O,O
the,O,O
above,O,O
cytotoxic,O,O
markers,O,O
",",O,O
whereas,O,O
monocytes,O,O
stimulated,O,O
with,O,O
DHEA,O,B
alone,O,O
or,O,O
with,O,O
LPS,O,O
at,O,O
a,O,O
lower,O,O
concentration,O,O
of,O,O
0,O,O
.,O,O
2,O,O
ng,O,O
/,O,O
ml,O,O
did,O,O
not,O,O
.,O,O
Finally,O,O
",",O,O
Scatchard,O,B
plot,O,I
analysis,O,O
demonstrated,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
DHEA,O,B
receptor,O,I
in,O,O
monocytes,O,O
",",O,O
suggesting,O,O
that,O,O
DHEA,O,B
effects,O,O
on,O,O
LPS,O,O
-,O,O
stimulated,O,O
monocytes,O,O
are,O,O
mediated,O,O
through,O,O
a,O,O
receptor,O,O
-,O,O
dependent,O,O
process,O,O
.,O,O
IL,B,B
-,I,I
4,I,I
activates,O,O
gene,O,O
expression,O,O
by,O,O
inducing,O,O
tyrosine,O,O
phosphorylation,O,O
",",O,O
homodimerization,O,O
",",O,O
and,O,O
nuclear,O,O
translocation,O,O
of,O,O
the,O,O
latent,B,O
transcription,I,O
factor,I,O
",",O,O
STAT6,B,B
(,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
-,I,O
6,I,O
),O,O
.,O,O
Because,O,O
STAT6,B,B
activation,O,O
is,O,O
essential,O,O
for,O,O
IL,B,B
-,I,I
4,I,I
-,O,I
induced,O,O
gene,O,O
expression,O,O
",",O,O
we,O,O
examined,O,O
the,O,O
ability,O,O
of,O,O
type,O,O
I,O,O
and,O,O
type,O,O
II,O,O
IFNs,B,O
to,O,O
regulate,O,O
activation,O,O
of,O,O
STAT6,B,B
by,O,O
IL,B,B
-,I,I
4,I,I
in,O,O
primary,O,O
human,O,O
monocytes,O,O
.,O,O
The,O,O
shift,O,O
from,O,O
complex,B,O
I,I,O
to,O,O
complex,B,O
II,I,O
seen,O,O
only,O,O
in,O,O
SCM,O,B
-,O,I
1,O,I
-,O,I
producer,O,O
T,O,O
cell,O,O
lines,O,O
upon,O,O
activation,O,O
was,O,O
completely,O,O
suppressed,O,O
by,O,O
cyclosporin,O,O
A,O,O
.,O,O
One,O,O
-,O,O
hybrid,O,O
assays,O,O
in,O,O
yeast,B,O
isolated,I,O
NF,I,B
-,I,I
ATp,I,I
as,O,O
an,O,O
E1,B,O
binding,I,O
protein,I,O
",",O,O
and,O,O
transfection,O,O
of,O,O
NF,B,B
-,I,I
ATp,I,I
into,O,O
T,O,O
and,O,O
B,O,O
cell,O,O
lines,O,O
strongly,O,O
enhanced,O,O
the,O,O
activation,B,O
-,I,O
dependent,I,O
SCM,I,B
-,I,I
1,I,I
promoter,O,O
activity,O,O
.,O,O
Recent,O,O
studies,O,O
have,O,O
reported,O,O
that,O,O
lymphocytes,O,O
produce,O,O
",",O,O
transport,O,O
and,O,O
bind,O,O
dopamine,O,B
present,O,O
in,O,O
plasma,O,O
.,O,O
The,O,O
importance,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
sites,I,O
was,O,O
confirmed,O,O
by,O,O
using,O,O
vectors,O,O
containing,O,O
wild,B,O
-,I,O
type,I,O
or,I,O
mutant,I,O
kappaB,I,O
sites,I,O
in,O,O
a,O,O
heterologous,B,O
promoter,I,O
.,O,O
Consistent,O,O
with,O,O
the,O,O
role,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
mediating,O,O
dopamine,O,O
responsiveness,O,O
",",O,O
the,O,O
proteasome,O,O
inhibitor,O,O
MG132,O,O
abolished,O,O
dopamine,O,O
-,O,O
induced,O,O
transcriptional,O,O
activation,O,O
.,O,O
A,O,O
significant,O,O
correlation,O,O
between,O,O
high,O,O
lymphocytic,O,B
infiltration,O,I
(,O,O
2,O,O
.,O,O
5,O,O
points,O,O
),O,O
",",O,O
low,O,O
body,O,B
mass,O,I
and,O,O
fat,O,O
was,O,O
identified,O,O
.,O,O
Moderate,O,O
body,O,B
mass,O,I
",",O,O
relatively,O,O
low,O,O
fat,O,O
level,O,O
and,O,O
positive,O,O
receptor,O,B
status,O,I
are,O,O
among,O,O
factors,O,O
of,O,O
good,O,O
prognosis,O,O
in,O,O
breast,O,B
cancer,O,I
of,O,I
early,O,I
stages,O,I
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
analyzed,O,O
the,O,O
binding,O,O
activity,O,O
of,O,O
IL,B,B
-,I,I
10,I,I
-,I,I
and,I,O
IFN,I,B
-,I,I
gamma,I,I
-,I,I
activated,I,O
STAT,I,B
molecules,I,I
to,O,O
two,O,O
kinds,O,O
of,O,O
GAS,B,O
-,O,O
motif,O,O
sequences,O,O
.,O,O
This,O,O
may,O,O
explain,O,O
the,O,O
difference,O,O
between,O,O
IL,B,B
-,I,I
10,I,I
and,O,O
IFN,B,B
-,I,I
gamma,I,I
in,O,O
biological,O,O
activity,O,O
",",O,O
and,O,O
the,O,O
inhibitory,O,O
effect,O,O
of,O,O
IL,B,B
-,I,I
10,I,I
on,O,O
IFN,B,B
-,I,I
gamma,I,I
activities,O,O
.,O,O
Peptides,O,O
derived,O,O
from,O,O
the,O,O
HSV,B,O
-,I,O
2,I,O
VP16,I,O
protein,I,O
were,O,O
utilized,O,O
for,O,O
studies,O,O
of,O,O
peptide,O,O
binding,O,O
to,O,O
DQ0302,O,O
molecules,O,O
and,O,O
T,O,O
cell,O,O
activation,O,O
at,O,O
both,O,O
neutral,O,O
and,O,O
acidic,O,O
pH,O,O
.,O,O
The,O,O
short,O,O
truncated,O,O
analog,O,O
433,O,O
-,O,O
442A,O,O
binds,O,O
very,O,O
poorly,O,O
at,O,O
both,O,O
acidic,O,O
and,O,O
neutral,O,O
pH,O,O
.,O,O
Much,O,O
higher,O,O
concentrations,O,O
of,O,O
wild,O,O
type,O,O
peptides,O,O
were,O,O
needed,O,O
to,O,O
activate,O,O
T,O,O
cells,O,O
at,O,O
neutral,O,O
pH,O,O
.,O,O
To,O,O
investigate,O,O
a,O,O
potential,O,O
role,O,O
of,O,O
E2F,B,B
-,I,I
1,I,I
in,O,O
differentiation,O,O
",",O,O
we,O,O
assayed,O,O
the,O,O
ability,O,O
of,O,O
megakaryocytes,O,O
to,O,O
form,O,O
platelets,O,O
in,O,O
an,O,O
in,O,O
vivo,O,O
transgenic,O,O
model,O,O
.,O,O
Administration,O,O
of,O,O
megakaryocyte,B,B
growth,I,I
and,I,I
development,I,I
factor,I,I
or,O,O
interleukin,B,B
6,I,I
could,O,O
not,O,O
overcome,O,O
the,O,O
differentiation,O,O
block,O,O
.,O,O
A,O,O
recent,O,O
sib,O,O
-,O,O
pair,O,O
analysis,O,O
revealed,O,O
a,O,O
tight,O,O
linkage,O,O
between,O,O
markers,O,O
on,O,O
5q31,B,O
.,I,O
1,I,O
and,O,O
a,O,O
major,B,O
susceptibility,I,O
gene,I,O
controlling,O,O
total,O,O
serum,O,O
IgE,B,O
levels,O,O
.,O,O
Evidence,O,O
for,O,O
lowered,O,O
induction,O,O
of,O,O
nuclear,B,B
factor,I,I
kappa,I,I
B,I,I
in,O,O
activated,O,O
human,O,O
T,O,O
lymphocytes,O,O
during,O,O
aging,O,O
.,O,O
Inhibition,O,O
of,O,O
lipopolysaccharide,O,O
-,O,O
induced,O,O
monocyte,B,O
interleukin,I,B
-,I,I
1,I,I
receptor,I,I
antagonist,O,I
synthesis,O,O
by,O,O
cortisol,O,O
:,O,O
involvement,O,O
of,O,O
the,O,O
mineralocorticoid,B,B
receptor,I,I
.,O,O
The,O,O
mineralocorticoid,O,B
aldosterone,O,I
exerted,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
LPS,O,O
-,O,O
induced,O,O
monocyte,O,O
IL,B,B
-,I,I
1ra,I,I
secretion,O,O
in,O,O
vitro,O,O
",",O,O
which,O,O
was,O,O
blocked,O,O
by,O,O
coincubation,O,O
with,O,O
spironolactone,O,O
.,O,O
Moreover,O,O
",",O,O
we,O,O
provide,O,O
evidence,O,O
that,O,O
",",O,O
in,O,O
addition,O,O
to,O,O
a,O,O
glucocorticoid,B,B
receptor,I,I
-,O,I
mediated,O,I
effect,O,O
",",O,O
the,O,O
mineralocorticoid,B,B
receptor,I,I
is,O,O
involved,O,O
in,O,O
the,O,O
inhibition,O,O
of,O,O
monocyte,O,B
IL,B,B
-,I,I
1ra,I,I
secretion,O,O
by,O,O
cortisol,O,O
.,O,O
Cell,O,B
-,O,I
mediated,O,I
immunity,O,O
plays,O,O
an,O,O
essential,O,O
role,O,O
in,O,O
the,O,O
control,O,O
of,O,O
infection,O,O
with,O,O
the,O,O
human,O,O
cytomegalovirus,O,B
(,O,I
HCMV,O,I
),O,I
.,O,O
Here,O,O
",",O,O
we,O,O
have,O,O
readdressed,O,O
the,O,O
issue,O,O
of,O,O
CD8,O,B
(,O,O
+,O,O
),O,O
T,O,O
cells,O,O
specific,O,O
for,O,O
the,O,O
72,B,O
-,I,O
kDa,I,O
major,I,O
immediate,I,O
-,I,O
early,I,O
protein,I,B
(,O,O
IE,B,B
-,I,I
1,I,I
),O,O
",",O,O
which,O,O
is,O,O
nonstructural,O,O
but,O,O
is,O,O
found,O,O
very,O,O
early,O,O
and,O,O
throughout,O,O
the,O,O
replicative,O,O
cycle,O,O
.,O,O
In,O,O
summary,O,O
",",O,O
our,O,O
results,O,O
suggest,O,O
that,O,O
IE,B,B
-,I,I
1,I,I
is,O,O
far,O,O
more,O,O
important,O,O
as,O,O
a,O,O
CD8,O,B
(,O,O
+,O,O
),O,O
-,O,O
T,O,O
-,O,O
cell,O,O
target,O,O
than,O,O
current,O,O
opinion,O,O
suggests,O,O
.,O,O
E1A,B,B
oncogene,I,I
induction,O,O
of,O,O
cellular,O,O
susceptibility,O,O
to,O,O
killing,O,O
by,O,O
cytolytic,O,O
lymphocytes,O,O
through,O,O
target,O,O
cell,O,O
sensitization,O,O
to,O,O
apoptotic,O,O
injury,O,O
.,O,O
Since,O,O
CLs,O,O
can,O,O
induce,O,O
either,O,O
apoptotic,O,O
or,O,O
necrotic,O,O
cell,O,O
death,O,O
",",O,O
we,O,O
asked,O,O
whether,O,O
E1A,B,B
sensitization,O,O
to,O,O
injury,O,O
-,O,O
induced,O,O
apoptosis,O,O
is,O,O
sufficient,O,O
to,O,O
explain,O,O
E1A,B,B
-,O,O
induced,O,O
cytolytic,O,O
susceptibility,O,O
.,O,O
Copyright,O,O
1999,O,O
Academic,O,O
Press,O,O
.,O,O
TCL1,B,B
oncogene,I,I
expression,O,O
in,O,O
AIDS,O,O
-,O,O
related,O,O
lymphomas,O,O
and,O,O
lymphoid,O,O
tissues,O,O
.,O,O
We,O,O
find,O,O
that,O,O
TCL1,B,B
is,O,O
expressed,O,O
in,O,O
the,O,O
majority,O,O
of,O,O
AIDS,O,O
IBLP,O,O
tumors,O,O
examined,O,O
.,O,O
They,O,O
also,O,O
indicate,O,O
that,O,O
abundant,O,O
TCL1,B,B
expression,O,O
in,O,O
quiescent,O,O
mantle,O,O
zone,O,O
B,O,O
cells,O,O
is,O,O
down,O,O
-,O,O
regulated,O,O
in,O,O
activated,O,O
germinal,O,O
center,O,O
follicular,O,O
B,O,O
cells,O,O
in,O,O
parallel,O,O
to,O,O
the,O,O
known,O,O
expression,O,O
pattern,O,O
of,O,O
BCL,B,B
-,I,I
2,I,I
.,O,O
High,O,O
-,O,O
level,O,O
expression,O,O
in,O,O
nonproliferating,O,O
B,O,O
cells,O,O
suggests,O,O
that,O,O
TCL1,B,O
may,O,O
function,O,O
in,O,O
protecting,O,O
naive,O,O
preactivated,O,O
B,O,O
cells,O,O
from,O,O
apoptosis,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
a,O,O
model,O,O
of,O,O
CD28,B,O
costimulation,O,O
using,O,O
PMA,O,O
plus,O,O
the,O,O
natural,B,O
ligand,I,O
CD80,I,O
that,O,O
resulted,O,O
in,O,O
very,O,O
limited,O,O
stimulation,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
as,O,O
evidenced,O,O
by,O,O
both,O,O
cytokine,B,O
production,O,O
and,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
stimulation,O,O
.,O,O
We,O,O
have,O,O
determined,O,O
that,O,O
the,O,O
JAK,B,B
/,B,I
STAT,I,I
pathway,O,O
positively,O,O
regulates,O,O
Qp,B,O
activity,O,O
.,O,O
In,O,O
transient,O,O
-,O,O
transfection,O,O
assays,O,O
",",O,O
a,O,O
Qp,B,O
-,I,O
CAT,I,O
reporter,I,O
was,O,O
activated,O,O
by,O,O
cotransfected,O,O
JAK,B,B
-,I,O
1,I,O
and,O,O
by,O,O
treatment,O,O
of,O,O
cells,O,O
with,O,O
the,O,O
cytokine,B,O
IL,B,B
-,I,I
6,I,I
.,O,O
Consistent,O,O
with,O,O
a,O,O
role,O,O
for,O,O
STATs,B,B
in,O,O
Qp,B,O
function,O,O
",",O,O
Qp,B,O
using,O,O
Burkitt,O,O
s,O,O
lymphoma,O,O
Rael,O,O
cells,O,O
and,O,O
cultured,O,O
nasopharyngeal,O,O
carcinoma,O,O
(,O,O
NPC,O,O
),O,O
cells,O,O
contained,O,O
nuclear,O,O
STAT,B,B
protein,I,O
.,O,O
This,O,O
negative,O,O
regulation,O,O
required,O,O
Zta,B,B
DNA,O,I
-,O,I
binding,O,I
activity,O,I
.,O,O
We,O,O
provide,O,O
evidence,O,O
that,O,O
Zta,B,B
up,O,O
-,O,O
regulation,O,O
of,O,O
p53,B,B
leads,O,O
to,O,O
p53,B,B
-,O,O
mediated,O,O
interference,O,O
with,O,O
JAK,B,B
/,B,I
STAT,I,I
activation,O,O
of,O,O
Qp,B,O
.,O,O
Reactive,O,O
oxygen,O,B
intermediate,O,I
-,O,I
release,O,I
of,O,O
fibre,O,O
-,O,O
exposed,O,O
monocytes,O,O
increases,O,O
inflammatory,O,O
cytokine,B,O
-,I,O
mRNA,I,O
level,O,O
",",O,O
protein,B,B
tyrosine,I,I
kinase,I,I
and,O,O
NF,B,B
-,I,I
kappaB,I,I
activity,O,I
in,O,O
co,O,O
-,O,O
cultured,O,O
bronchial,O,O
epithelial,O,O
cells,O,O
(,O,O
BEAS,O,O
-,O,O
2B,O,O
),O,O
.,O,O
We,O,O
show,O,O
here,O,O
that,O,O
the,O,O
response,O,O
of,O,O
the,O,O
HIV,O,B
-,O,I
1,O,I
long,O,I
terminal,O,I
repeat,O,I
(,O,O
LTR,B,O
),O,O
to,O,O
mitogenic,O,O
or,O,O
Tat,B,O
-,O,O
mediated,O,O
activation,O,O
is,O,O
sensitive,O,O
to,O,O
the,O,O
suppressive,O,O
action,O,O
of,O,O
a,O,O
Herpesvirus,O,O
saimiri,O,O
(,O,O
HVS,O,O
),O,O
-,O,O
transformed,O,O
CD8,O,B
+,O,I
T,O,I
cell,O,I
clone,O,I
from,O,O
an,O,O
HIV,O,B
-,O,I
infected,O,I
individual,O,I
and,O,O
supernatants,O,O
from,O,O
CD8,O,B
+,O,I
T,O,I
cells,O,I
of,O,O
HIV,O,B
-,O,I
1,O,I
-,O,I
infected,O,I
asymptomatic,O,I
subjects,O,I
(,O,O
CD4,B,B
+,I,I
>,O,I
350,O,I
/,O,I
microliters,O,I
),O,O
.,O,O
Mutagenesis,O,O
of,O,O
NF,B,B
kappa,I,I
B,I,I
or,I,O
Sp,I,O
-,I,O
1,I,O
elements,I,O
within,O,O
the,O,O
LTR,B,O
resulted,O,O
in,O,O
no,O,O
change,O,O
in,O,O
the,O,O
ability,O,O
of,O,O
CD8,O,O
+,O,O
T,O,O
cell,O,O
supernatants,O,O
to,O,O
inhibit,O,O
Tat,O,O
-,O,O
or,O,O
mitogen,O,O
-,O,O
mediated,O,O
LTR,O,O
transcription,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
observations,O,O
suggest,O,O
that,O,O
mitogenic,O,O
activation,O,O
",",O,O
mediated,O,O
primarily,O,O
through,O,O
the,O,O
NF,B,B
kappa,I,I
B,I,I
enhancer,I,O
",",O,O
is,O,O
susceptible,O,O
to,O,O
CD8,B,O
-,O,O
mediated,O,O
inhibition,O,O
",",O,O
however,O,O
",",O,O
inhibition,O,O
of,O,O
Tat,B,O
-,O,O
mediated,O,O
activation,O,O
may,O,O
rely,O,O
upon,O,O
a,O,O
different,O,O
pathway,O,O
that,O,O
is,O,O
NFAT,B,B
-,I,I
1,I,I
dependent,O,O
.,O,O
Nuclear,B,B
factor,I,I
(,I,O
NF,I,B
),I,O
-,I,O
kappa,I,O
B,I,O
is,O,O
a,O,O
redox,B,O
sensitive,I,O
cytosolic,I,O
transcription,I,O
factor,I,O
.,O,O
Induction,O,O
of,O,O
endothelial,B,B
adhesion,I,I
molecules,I,I
by,O,O
the,O,O
cytokine,B,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
(,O,O
TNF,B,B
),O,O
can,O,O
occur,O,O
independently,O,O
of,O,O
protein,B,O
kinase,I,O
C,I,O
and,O,O
activation,O,O
of,O,O
a,O,O
protein,B,O
tyrosine,I,O
kinase,I,O
(,O,O
PTK,B,O
),O,O
has,O,O
recently,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
upregulation,O,O
of,O,O
vascular,B,B
cell,I,I
adhesion,I,I
molecule,I,I
1,I,I
(,O,O
VCAM,B,B
-,I,I
1,I,I
),O,O
by,O,O
interleukin,B,B
-,I,I
4,I,I
(,O,O
IL,B,O
-,I,O
4,I,O
),O,O
on,O,O
endothelial,O,B
cells,O,I
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
constitutive,O,O
expression,O,O
of,O,O
bcl,B,B
-,I,I
xl,I,I
but,O,O
not,O,O
bcl,B,B
-,I,I
2,I,I
",",O,O
bcl,B,B
-,I,I
xs,I,I
",",O,O
bak,B,B
",",O,O
bad,B,B
",",O,O
or,O,O
bax,B,B
was,O,O
associated,O,O
with,O,O
apoptosis,O,O
resistance,O,O
after,O,O
IL,B,B
-,I,I
2,I,I
deprivation,O,O
in,O,O
CTLL,O,O
-,O,O
2,O,O
cells,O,O
that,O,O
expressed,O,O
Tax,B,O
.,O,O
Transient,O,O
-,O,O
transfection,O,O
assays,O,O
showed,O,O
that,O,O
bcl,B,B
-,I,I
x,I,I
promoter,I,O
was,O,O
transactivated,O,O
by,O,O
wild,B,O
-,I,O
type,I,O
Tax,I,O
.,O,O
We,O,O
find,O,O
that,O,O
recruitment,O,O
of,O,O
EKLF,B,B
to,O,O
5,B,O
HS2,I,O
requires,O,O
the,O,O
TATA,B,B
box,I,O
",",O,O
but,O,O
recruitment,O,O
to,O,O
5,B,O
HS3,I,O
depends,O,O
on,O,O
the,O,O
CACCC,O,B
and,O,O
TATA,B,B
boxes,I,O
of,O,O
the,O,O
beta,B,O
-,I,O
globin,I,O
promoter,I,O
.,O,O
We,O,O
have,O,O
found,O,O
that,O,O
the,O,O
recruitment,O,O
of,O,O
EKLF,B,B
to,O,O
5,B,O
HS3,I,O
depends,O,O
on,O,O
the,O,O
presence,O,O
of,O,O
5,B,O
HS2,I,O
in,O,O
cis,O,O
",",O,O
but,O,O
the,O,O
recruitment,O,O
to,O,O
5,B,O
HS2,I,O
does,O,O
not,O,O
depend,O,O
on,O,O
5,B,O
HS3,I,O
.,O,O
Based,O,O
on,O,O
these,O,O
results,O,O
",",O,O
we,O,O
present,O,O
a,O,O
model,O,O
that,O,O
illustrates,O,O
how,O,O
EKLF,B,O
may,O,O
be,O,O
recruited,O,O
to,O,O
the,O,O
beta,B,B
-,I,I
globin,I,I
locus,I,O
.,O,O
We,O,O
also,O,O
report,O,O
that,O,O
in,O,O
RAW,O,O
264,O,O
.,O,O
cells,O,O
",",O,O
an,O,O
E,O,B
(,O,O
2,O,I
),O,O
receptor,O,O
-,O,O
positive,O,O
murine,O,O
monocytic,O,O
line,O,O
",",O,O
E,O,B
(,O,O
2,O,I
),O,O
downregulates,O,O
cytokine,O,O
-,O,O
induced,O,O
TNF,B,B
gene,O,I
expression,O,O
by,O,O
decreasing,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
Jun,B,O
NH,I,O
(,I,O
2,I,O
),I,O
-,I,O
terminal,I,O
kinase,I,O
(,O,O
JNK,B,O
),O,O
.,O,O
The,O,O
resulting,O,O
diminished,O,O
phosphorylation,O,O
of,O,O
c,B,O
-,I,O
Jun,I,B
and,O,O
JunD,B,B
at,O,O
their,O,O
NH,B,O
(,I,O
2,I,O
),I,O
-,I,O
termini,I,O
decreases,O,O
the,O,O
ability,O,O
of,O,O
these,O,O
nuclear,O,O
proteins,O,O
to,O,O
autostimulate,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
c,B,O
-,I,O
Jun,I,B
and,I,O
JunD,I,B
genes,I,O
",",O,O
thus,O,O
leading,O,O
to,O,O
lower,O,O
production,O,O
of,O,O
c,B,O
-,I,O
Jun,I,B
and,O,O
JunD,B,B
.,O,O
Recent,O,O
data,O,O
show,O,O
that,O,O
TCR,B,O
/,I,O
CD3,I,O
stimulation,O,O
induces,O,O
activation,O,O
of,O,O
Stat5,B,O
in,O,O
murine,O,O
T,O,O
cells,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
we,O,O
show,O,O
that,O,O
CD3,B,O
ligation,O,O
by,O,O
mAb,B,O
and,O,O
SE,O,O
triggers,O,O
a,O,O
rapid,O,O
",",O,O
PP1,B,O
-,O,O
sensitive,O,O
tyrosine,O,O
and,O,O
serine,O,O
phosphorylation,O,O
of,O,O
Stat3,B,O
in,O,O
human,O,O
CD4,O,O
+,O,O
T,O,O
cells,O,O
.,O,O
Clusters,O,O
of,O,O
genes,B,O
expressed,O,O
by,O,O
stromal,O,O
cells,O,O
and,O,O
lymphocytes,O,O
in,O,O
the,O,O
breast,O,O
tumors,O,O
also,O,O
were,O,O
identified,O,O
in,O,O
this,O,O
analysis,O,O
.,O,O
Stimulation,O,O
of,O,O
T,O,O
cells,O,O
with,O,O
calcium,O,O
ionophore,O,O
induced,O,O
a,O,O
shift,O,O
in,O,O
the,O,O
molecular,O,O
weight,O,O
of,O,O
NFATp,B,O
that,O,O
is,O,O
due,O,O
to,O,O
its,O,O
dephosphorylation,O,O
.,O,O
This,O,O
dephosphorylation,O,O
was,O,O
inhibited,O,O
by,O,O
treatment,O,O
of,O,O
T,O,O
cells,O,O
with,O,O
cyclosporin,O,O
A,O,O
or,O,O
FK506,O,O
prior,O,O
to,O,O
stimulation,O,O
.,O,O
The,O,O
B,B,O
cell,I,O
-,I,O
associated,I,O
surface,I,O
molecule,I,O
CD40,B,O
plays,O,O
a,O,O
key,O,O
role,O,O
in,O,O
T,O,O
cell,O,O
-,O,O
dependent,O,O
B,O,O
cell,O,O
maturation,O,O
",",O,O
as,O,O
individuals,O,O
with,O,O
defects,O,O
in,O,O
either,O,O
CD40,B,O
or,O,O
its,O,O
ligand,O,O
are,O,O
impaired,O,O
in,O,O
immunoglobulin,B,O
isotype,O,O
class,O,O
switching,O,O
and,O,O
germinal,O,O
center,O,O
formation,O,O
.,O,O
CD40,B,B
signaling,O,O
activates,O,O
downstream,B,O
effectors,I,O
",",O,O
including,O,O
the,O,O
tyrosine,B,B
protein,I,I
kinase,I,I
",",O,O
Lyn,B,B
",",O,O
the,O,O
phosphatidylinositol,B,B
-,I,I
3,I,I
-,I,I
kinase,I,I
(,O,O
PI,B,B
-,I,I
3,I,I
kinase,I,I
),O,O
",",O,O
and,O,O
the,O,O
transcription,O,O
factor,O,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
stress,B,B
-,I,I
activated,I,I
protein,I,I
kinases,I,I
(,O,O
SAPK,B,O
),O,O
are,O,O
activated,O,O
after,O,O
CD40,B,B
cross,O,I
-,O,I
linking,O,I
on,O,O
various,O,O
B,O,O
cell,O,O
lines,O,O
or,O,O
human,O,O
tonsillar,O,B
B,O,I
cells,O,I
.,O,O
In,O,O
summary,O,O
",",O,O
CD40,B,B
signaling,O,O
preferentially,O,O
induces,O,O
SAPK,B,B
but,O,O
not,O,O
MAPK,B,B
.,O,O
Using,O,O
CD45,O,B
-,O,I
or,O,O
CD3,O,B
-,O,I
negative,O,O
variants,O,O
of,O,O
the,O,O
Jurkat,O,O
leukemic,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
we,O,O
show,O,O
that,O,O
the,O,O
different,O,O
biochemical,O,O
events,O,O
induced,O,O
by,O,O
pervanadate,O,O
appeared,O,O
to,O,O
be,O,O
dependent,O,O
on,O,O
the,O,O
presence,O,O
at,O,O
the,O,O
cell,O,O
surface,O,O
of,O,O
either,O,O
CD45,B,B
or,O,O
CD3,B,B
.,O,O
CD45,B,B
-,O,I
dependent,O,I
events,O,O
such,O,O
as,O,O
tyrosine,B,O
phosphorylation,I,O
of,O,O
Shc,B,O
",",O,O
activation,O,O
of,O,O
nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
",",O,O
activator,B,O
protein,I,O
-,I,O
1,I,O
(,O,O
AP,B,B
-,I,I
1,I,I
),O,O
",",O,O
transcription,B,O
factors,I,O
",",O,O
and,O,O
stimulation,O,O
of,O,O
interleukin,B,O
-,I,O
2,I,O
(,I,O
IL,I,B
-,I,I
2,I,I
),I,O
promoter,I,O
and,O,O
of,O,O
CD69,B,B
and,O,O
CD25,B,B
surface,O,O
expression,O,O
paralleled,O,O
activation,O,O
of,O,O
the,O,O
tyrosine,B,O
kinases,I,O
lck,B,O
and,O,O
fyn,B,O
.,O,O
Previously,O,O
",",O,O
the,O,O
action,O,O
of,O,O
MC903,O,O
and,O,O
KH1060,O,O
was,O,O
presumed,O,O
to,O,O
be,O,O
mediated,O,O
by,O,O
the,O,O
nuclear,B,O
vitamin,I,B
D,I,I
receptor,I,I
(,O,I
VDRnuc,B,I
),O,I
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
although,O,O
MC903,O,O
and,O,O
KH1060,O,O
may,O,O
bind,O,O
the,O,O
VDRnuc,B,O
",",O,O
that,O,O
the,O,O
differentiative,O,O
activities,O,O
of,O,O
these,O,O
agents,O,O
requires,O,O
nongenomic,O,O
signaling,O,O
pathways,O,O
.,O,O
Here,O,O
we,O,O
show,O,O
that,O,O
1alpha,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2,O,O
-,O,O
d5,O,O
-,O,O
previtamin,O,O
D3,O,O
(,O,O
HF,O,O
),O,O
",",O,O
JN,O,O
",",O,O
KH1060,O,O
",",O,O
and,O,O
MC903,O,O
induce,O,O
expression,O,O
of,O,O
PKC,B,B
alpha,I,I
and,O,O
PKC,B,B
delta,I,I
and,O,O
translocation,O,O
of,O,O
both,O,O
isoforms,O,O
to,O,O
the,O,O
particulate,O,O
fraction,O,O
",",O,O
and,O,O
PKC,B,B
alpha,I,I
to,O,O
the,O,O
nuclear,O,O
fraction,O,O
.,O,O
Retinoic,O,O
acid,O,O
can,O,O
directly,O,O
modulate,O,O
gene,O,O
expression,O,O
via,O,O
binding,O,O
to,O,O
its,O,O
nuclear,B,B
receptors,I,I
",",O,O
which,O,O
can,O,O
",",O,O
in,O,O
turn,O,O
",",O,O
activate,O,O
transcription,O,O
of,O,O
target,B,O
genes,I,O
.,O,O
Tax,B,O
has,O,O
been,O,O
shown,O,O
to,O,O
transactivate,O,O
several,O,O
cellular,B,O
genes,I,O
.,O,O
Induced,O,O
MIP,B,B
-,I,I
1alpha,I,I
expression,O,O
and,O,O
secretion,O,O
in,O,O
PMA,O,O
/,O,O
PHA,O,O
stimulated,O,O
tax,O,O
transfected,O,O
cells,O,O
correlate,O,O
with,O,O
the,O,O
noninduction,O,O
of,O,O
MNP,B,B
-,I,I
1,I,I
transcription,B,O
factor,I,O
",",O,O
which,O,O
is,O,O
intimately,O,O
involved,O,O
in,O,O
downmodulating,O,O
the,O,O
MIP,B,B
-,I,I
1alpha,I,I
gene,I,O
.,O,O
Copyright,O,O
1999,O,O
Academic,O,O
Press,O,O
.,O,O
Like,O,O
a,O,O
delayed,O,O
-,O,O
type,O,O
hypersensitivity,O,O
response,O,O
",",O,O
the,O,O
rheumatoid,O,O
synovium,O,O
represents,O,O
an,O,O
effector,O,O
site,O,O
.,O,O
The,O,O
other,O,O
major,O,O
subpopulation,O,O
expressing,O,O
the,O,O
CD4,B,B
receptor,I,I
",",O,O
namely,O,O
",",O,O
the,O,O
double,O,O
-,O,O
positive,O,O
(,O,O
DP,O,O
),O,O
CD4,O,B
(,O,O
+,O,O
),O,O
CD8,O,B
(,O,O
+,O,O
),O,O
CD3,O,B
(,O,O
+,O,O
/,O,O
-,O,O
),O,O
thymocytes,O,O
",",O,O
despite,O,O
the,O,O
entry,O,O
of,O,O
the,O,O
virus,O,O
",",O,O
do,O,O
not,O,O
produce,O,O
a,O,O
significant,O,O
level,O,O
of,O,O
virus,O,O
",",O,O
presumably,O,O
because,O,O
they,O,O
are,O,O
unresponsive,O,O
to,O,O
TNF,B,B
and,O,O
IL,B,B
-,I,I
7,I,I
.,O,O
Activation,O,O
of,O,O
CD40,B,B
is,O,O
essential,O,O
for,O,O
thymus,O,B
-,O,I
dependent,O,I
humoral,O,I
immune,O,I
responses,O,I
and,O,O
rescuing,O,O
B,O,B
cells,O,I
from,O,O
apoptosis,O,O
.,O,O
MBP,B,O
over,O,O
the,O,O
concentration,O,O
range,O,O
of,O,O
0,O,O
.,O,O
1,O,O
to,O,O
10,O,O
microM,O,O
stimulated,O,O
the,O,O
release,O,O
of,O,O
up,O,O
to,O,O
approximately,O,O
8,O,O
ng,O,O
/,O,O
ml,O,O
IL,B,B
-,I,I
8,I,I
.,O,O
MBP,B,O
also,O,O
induced,O,O
transient,O,O
increases,O,O
in,O,O
mRNA,B,O
for,O,O
macrophage,B,B
inflammatory,I,I
protein,I,I
(,I,I
MIP,I,I
),I,I
-,I,I
1alpha,I,I
and,O,O
MIP,B,B
-,I,I
1beta,I,I
",",O,O
but,O,O
did,O,O
not,O,O
stimulate,O,O
the,O,O
release,O,O
of,O,O
either,O,O
chemokine,B,O
.,O,O
Patients,O,O
with,O,O
the,O,O
recessively,O,O
inherited,O,O
disorder,O,O
ataxia,O,O
telangiectasia,O,O
(,O,O
A,O,O
-,O,O
T,O,O
),O,O
have,O,O
a,O,O
high,O,O
level,O,O
of,O,O
specific,O,O
chromosome,B,O
translocations,I,O
which,O,O
can,O,O
be,O,O
easily,O,O
observed,O,O
in,O,O
peripheral,O,O
T,O,O
cells,O,O
and,O,O
show,O,O
a,O,O
greatly,O,O
increased,O,O
predisposition,O,O
to,O,O
leukaemia,O,O
/,O,O
lymphoma,O,O
",",O,O
mainly,O,O
of,O,O
T,O,O
cell,O,O
origin,O,O
.,O,O
On,O,O
the,O,O
average,O,O
",",O,O
no,O,O
correlation,O,O
was,O,O
established,O,O
between,O,O
degree,O,O
of,O,O
lymphocyte,O,O
infiltration,O,O
in,O,O
breast,O,O
tumor,O,O
and,O,O
age,O,O
and,O,O
menopause,O,O
onset,O,O
.,O,O
A,O,O
high,O,O
-,O,O
affinity,O,O
calcineurin,B,B
-,O,I
binding,O,I
peptide,O,I
was,O,O
selected,O,O
from,O,O
combinatorial,O,O
peptide,O,O
libraries,O,O
based,O,O
on,O,O
the,O,O
calcineurin,B,B
docking,I,I
motif,I,I
of,O,O
NFAT,B,O
.,O,O
Substitution,O,O
of,O,O
the,O,O
optimized,O,O
peptide,O,O
sequence,O,O
into,O,O
the,O,O
natural,O,O
calcineurin,B,B
docking,I,I
site,I,I
increased,O,O
the,O,O
calcineurin,B,B
responsiveness,O,I
of,O,O
NFAT,B,O
.,O,O
Compounds,O,O
that,O,O
interfere,O,O
selectively,O,O
with,O,O
the,O,O
calcineurin,B,B
-,B,I
NFAT,I,I
interaction,O,I
without,O,O
affecting,O,O
calcineurin,B,B
phosphatase,B,I
activity,O,I
may,O,O
be,O,O
useful,O,O
as,O,O
therapeutic,O,O
agents,O,O
that,O,O
are,O,O
less,O,O
toxic,O,O
than,O,O
current,O,O
drugs,O,O
.,O,O
9,O,O
-,O,O
cis,O,O
retinoic,O,O
acid,O,O
induces,O,O
monocyte,B,B
chemoattractant,I,I
protein,I,I
-,I,I
1,I,I
secretion,O,O
in,O,O
human,O,O
monocytic,O,B
THP,O,I
-,O,I
1,O,I
cells,O,O
.,O,O
Thus,O,O
",",O,O
both,O,O
copies,O,O
of,O,O
BRCA1,B,O
were,O,O
retained,O,O
in,O,O
tumor,O,O
.,O,O
The,O,O
DNA,O,B
variation,O,O
",",O,O
233G,O,O
-,O,O
-,O,O
>,O,O
A,O,O
",",O,O
does,O,O
not,O,O
result,O,O
in,O,O
an,O,O
amino,O,O
acid,O,O
change,O,O
",",O,O
and,O,O
is,O,O
considered,O,O
a,O,O
benign,O,O
polymorphism,O,O
.,O,O
Therefore,O,O
",",O,O
we,O,O
investigated,O,O
whether,O,O
IVS1,O,O
-,O,O
10T,O,O
-,O,O
-,O,O
>,O,O
C,O,O
deleteriously,O,O
affected,O,O
BRCA1,B,O
splicing,O,O
or,O,O
expression,O,O
",",O,O
and,O,O
thereby,O,O
inactivated,O,O
the,O,O
other,O,O
BRCA1,B,O
allele,I,O
.,O,O
For,O,O
example,O,O
dendritic,O,B
cells,O,I
(,O,O
DC,O,O
),O,O
can,O,O
be,O,O
found,O,O
in,O,O
colonies,O,O
of,O,O
GM,O,B
-,O,I
CSF,O,I
-,O,I
responsive,O,I
bone,O,B
marrow,O,I
cells,O,I
",",O,O
and,O,O
under,O,O
experimental,O,O
conditions,O,O
are,O,O
routinely,O,O
expanded,O,O
as,O,O
a,O,O
population,O,O
in,O,O
vitro,O,O
from,O,O
GM,O,B
-,O,I
CSF,O,I
-,O,I
responsive,O,I
progenitor,O,B
cells,O,I
.,O,O
We,O,O
have,O,O
used,O,O
this,O,O
MTHC,O,O
system,O,O
to,O,O
analyze,O,O
differences,O,O
in,O,O
gene,O,O
expression,O,O
as,O,O
the,O,O
cells,O,O
mature,O,O
along,O,O
the,O,O
DC,O,B
and,O,O
macrophage,O,B
pathways,O,I
.,O,O
We,O,O
have,O,O
investigated,O,O
mechanisms,O,O
and,O,O
consequences,O,O
of,O,O
STAT5,B,B
activation,O,O
through,O,O
the,O,O
human,B,O
IL,I,B
-,I,I
4,I,I
receptor,I,O
(,O,O
IL,B,O
-,I,O
4R,I,O
),O,O
.,O,O
By,O,O
functionally,O,O
expressing,O,O
receptor,B,O
mutants,I,O
in,O,O
the,O,O
murine,O,O
pro,O,O
-,O,O
B,O,O
cell,O,O
line,O,O
Ba,O,O
/,O,O
F3,O,O
",",O,O
we,O,O
could,O,O
show,O,O
that,O,O
phosphorylated,O,O
tyrosine,O,O
residues,O,O
within,O,O
the,O,O
IL,B,B
-,I,I
4R,I,I
alpha,I,I
chain,I,I
are,O,O
dispensable,O,O
for,O,O
IL,B,B
-,I,I
4,I,I
-,O,I
induced,O,I
STAT5,B,O
activity,O,O
.,O,O
An,O,O
inhibitory,O,O
",",O,O
`,O,O
`,O,O
dominant,O,O
-,O,O
negative,O,O
",",O,O
form,O,O
of,O,O
the,O,O
calcineurin,B,O
catalytic,I,O
(,I,O
A,I,O
),I,O
subunit,I,O
was,O,O
prepared,O,O
",",O,O
which,O,O
lacks,O,O
the,O,O
calmodulin,B,O
-,I,O
binding,I,O
domain,I,O
",",O,O
autoinhibitory,B,O
domain,I,O
and,O,O
most,O,O
of,O,O
its,O,O
catalytic,O,O
core,O,O
but,O,O
possesses,O,O
the,O,O
regulatory,B,O
(,I,O
B,I,O
),I,O
subunit,I,O
binding,O,O
domain,O,O
.,O,O
Immunoprecipitation,O,O
of,O,O
epitope,B,O
-,I,O
labeled,I,O
BKO,I,O
demonstrated,O,O
for,O,O
the,O,O
formation,O,O
of,O,O
a,O,O
tight,O,O
complex,O,O
with,O,O
endogenous,B,O
B,I,O
subunit,I,O
in,O,O
Jurkat,O,O
cells,O,O
",",O,O
consistent,O,O
with,O,O
an,O,O
inhibitory,O,O
mechanism,O,O
that,O,O
involves,O,O
the,O,O
sequestration,O,O
of,O,O
the,O,O
B,B,O
subunit,I,O
.,O,O
Monoclonal,B,B
anti,I,I
-,I,I
D,I,I
antibodies,I,O
submitted,O,O
to,O,O
the,O,O
Third,O,O
Monoclonal,O,O
International,O,O
Workshop,O,O
were,O,O
evaluated,O,O
against,O,O
a,O,O
number,O,O
of,O,O
D,O,B
variant,O,O
cells,O,O
using,O,O
standard,O,O
serological,O,O
techniques,O,O
.,O,O
Cells,O,O
within,O,O
each,O,O
category,O,O
did,O,O
not,O,O
give,O,O
any,O,O
aberrant,O,O
results,O,O
.,O,O
B,O,B
cells,O,O
were,O,O
purified,O,O
from,O,O
buffy,O,O
coat,O,O
preparations,O,O
of,O,O
healthy,O,O
blood,O,O
donors,O,O
by,O,O
positive,O,O
selection,O,O
using,O,O
an,O,O
anti,B,B
CD20,I,I
monoclonal,I,I
antibody,I,I
and,O,O
a,O,O
MiniMACS,O,O
separation,O,O
unit,O,O
.,O,O
RNA,B,B
was,O,O
extracted,O,O
by,O,O
phenol,O,O
/,O,O
chloroform,O,O
and,O,O
c,B,O
-,I,O
fos,I,B
expression,O,O
was,O,O
analyzed,O,O
by,O,O
PCR,O,O
assisted,O,O
mRNA,O,O
assay,O,O
.,O,O
A,O,O
significant,O,O
2,O,O
-,O,O
4,O,O
fold,O,O
increase,O,O
of,O,O
c,B,O
-,I,O
fos,I,B
expression,O,O
was,O,O
observed,O,O
within,O,O
30,O,O
min,O,O
of,O,O
stimulation,O,O
with,O,O
IL,B,B
-,I,I
10,I,I
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Since,O,O
this,O,O
is,O,O
the,O,O
first,O,O
report,O,O
on,O,O
IL,B,B
-,I,I
10,I,I
induced,O,O
signal,O,O
transduction,O,O
",",O,O
these,O,O
data,O,O
may,O,O
help,O,O
to,O,O
identify,O,O
the,O,O
intracellular,O,O
mechanisms,O,O
by,O,O
which,O,O
IL,B,B
-,I,I
10,I,I
stimulates,O,O
human,O,O
B,O,O
-,O,O
cells,O,O
.,O,O
MNDA,B,B
was,O,O
not,O,O
detected,O,O
in,O,O
normal,O,O
tissue,O,O
histiocytes,O,O
but,O,O
was,O,O
found,O,O
in,O,O
activated,O,O
macrophages,O,O
and,O,O
foreign,O,O
body,O,O
giant,O,O
cells,O,O
associated,O,O
with,O,O
inflammation,O,O
.,O,O
Flow,O,O
cytometric,O,O
cell,O,O
sorting,O,O
of,O,O
normal,O,O
bone,O,O
marrow,O,O
established,O,O
that,O,O
MNDA,B,B
is,O,O
initially,O,O
expressed,O,O
in,O,O
myeloid,O,O
blast,O,O
cells,O,O
.,O,O
Peroxisome,B,B
proliferator,I,I
-,I,I
activated,I,I
receptors,I,I
(,O,O
PPARs,B,O
),O,O
",",O,O
members,O,O
of,O,O
the,O,O
nuclear,B,O
receptor,I,O
superfamily,I,O
of,O,O
transcription,B,O
factors,I,O
",",O,O
are,O,O
activated,O,O
by,O,O
fatty,O,O
acid,O,O
metabolites,O,O
",",O,O
peroxisome,O,O
proliferators,O,O
",",O,O
and,O,O
thiazolidinediones,O,O
and,O,O
are,O,O
now,O,O
recognized,O,O
as,O,O
important,O,O
mediators,O,O
in,O,O
the,O,O
inflammatory,O,O
response,O,O
.,O,O
Expression,O,O
of,O,O
wild,B,O
-,I,O
type,I,O
had,O,O
a,O,O
very,O,O
small,O,O
effect,O,O
on,O,O
the,O,O
TCR,O,B
-,O,I
induced,O,I
tyrosine,O,O
phosphorylation,O,O
of,O,O
ZAP,B,B
-,I,I
70,I,I
and,O,O
Syk,B,B
",",O,O
even,O,O
when,O,O
was,O,O
overexpressed,O,O
20,O,O
-,O,O
100,O,O
-,O,O
fold,O,O
over,O,O
endogenous,B,O
.,O,O
However,O,O
",",O,O
the,O,O
two,O,O
SH2,B,B
domains,I,I
of,O,O
did,O,O
not,O,O
facilitate,O,O
its,O,O
recognition,O,O
of,O,O
ZAP,B,B
-,I,I
70,I,I
and,O,O
Syk,B,B
as,O,O
substrates,O,O
in,O,O
intact,O,O
cells,O,O
.,O,O
Eosinophil,B,B
granule,I,I
major,I,I
basic,I,I
protein,I,I
(,O,O
MBP,B,O
),O,O
is,O,O
expressed,O,O
exclusively,O,O
in,O,O
eosinophils,O,B
and,O,O
basophils,O,B
in,O,O
hematopoietic,O,O
cells,O,O
.,O,O
In,O,O
the,O,O
cell,O,O
line,O,O
HT93A,O,O
",",O,O
which,O,O
is,O,O
capable,O,O
of,O,O
differentiating,O,O
towards,O,O
both,O,O
the,O,O
eosinophil,O,B
and,O,O
neutrophil,O,B
lineages,O,O
in,O,O
response,O,O
to,O,O
retinoic,O,O
acid,O,O
(,O,O
RA,O,O
),O,O
",",O,O
C,B,O
/,I,O
EBPalpha,I,O
mRNA,I,O
expression,O,O
decreased,O,O
significantly,O,O
concomitant,O,O
with,O,O
eosinophilic,O,B
and,O,O
neutrophilic,O,B
differentiation,O,O
",",O,O
whereas,O,O
C,B,O
/,I,O
EBPbeta,I,O
expression,O,O
was,O,O
markedly,O,O
increased,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
have,O,O
demonstrated,O,O
that,O,O
both,O,O
C,B,B
/,I,I
EBPbeta,I,I
and,O,O
GATA,B,B
-,I,I
1,I,I
can,O,O
bind,O,O
simultaneously,O,O
to,O,O
the,O,O
C,O,B
/,O,I
EBP,O,I
-,O,I
and,O,O
GATA,B,B
-,I,I
binding,I,I
sites,I,I
in,O,O
the,O,O
MBP,B,O
promoter,I,O
.,O,O
Role,O,O
of,O,O
the,O,O
camp,B,O
response,I,O
element,I,O
site,I,O
in,O,O
mediating,O,O
repression,O,O
by,O,O
the,O,O
upstream,B,O
regulatory,I,O
region,I,O
.,O,O
DNase,B,O
I,I,O
footprinting,O,O
identified,O,O
several,O,O
protected,O,O
areas,O,O
including,O,O
Sp1,B,B
",",I,O
Sp1,I,B
/,I,I
AP,I,I
-,I,I
2,I,I
",",I,O
and,I,O
cAMP,I,B
response,I,I
element,I,I
(,I,I
CRE,I,I
),I,I
binding,I,I
sites,I,I
within,O,O
the,O,O
201,O,O
-,O,O
bp,O,O
core,O,O
promoter,O,O
region,O,O
and,O,O
Sp1,B,B
",",I,O
NRE,I,B
-,I,I
2a,I,I
",",I,O
TCF,I,B
-,I,I
1,I,I
/,I,I
LEF,I,I
-,I,I
1,I,I
",",I,O
and,I,O
Sp1,I,B
/,I,I
NF,I,I
-,I,I
AT,I,I
binding,I,I
sites,I,I
in,O,O
the,O,O
upstream,B,O
regulatory,I,O
region,I,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
analysis,O,O
of,O,O
proteins,O,B
binding,O,O
to,O,O
the,O,O
CRE,B,B
site,I,I
identified,O,O
both,O,O
ATF,B,B
-,I,I
1,I,I
and,O,O
ATF,B,B
-,I,I
2,I,I
in,O,O
Jurkat,O,O
cells,O,O
.,O,O
In,O,O
summary,O,O
",",O,O
we,O,O
have,O,O
identified,O,O
a,O,O
tissue,B,B
-,I,I
specific,I,I
regulatory,I,I
region,I,I
5,O,I
of,O,I
the,O,I
ecto,B,I
-,I,I
5,I,I
-,I,I
NT,I,I
core,I,I
promoter,I,I
that,O,O
requires,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
functional,O,O
CRE,B,B
site,I,I
within,O,O
the,O,O
basal,B,O
promoter,I,O
for,O,O
its,O,O
suppressive,O,O
activity,O,O
.,O,O
Extracellular,O,O
signal,O,O
-,O,O
regulated,O,O
protein,O,B
kinase,O,I
(,O,O
ERK,O,O
),O,O
-,O,O
dependent,O,O
and,O,O
ERK,O,O
-,O,O
independent,O,O
pathways,O,O
target,O,O
STAT3,B,O
on,O,O
serine,O,O
-,O,O
727,O,O
in,O,O
human,O,B
neutrophils,O,O
stimulated,O,O
by,O,O
chemotactic,B,O
factors,I,O
and,O,O
cytokines,B,O
.,O,O
(,O,O
2,O,O
-,O,O
Amino,O,O
-,O,O
3,O,O
-,O,O
methoxyphenyl,O,O
),O,O
oxanaphthalen,O,O
-,O,O
4,O,O
-,O,O
one,O,O
(,O,O
PD,O,O
98059,O,O
),O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
extracellular,O,O
signal,B,O
-,I,O
regulated,I,O
protein,I,B
kinase,I,I
(,O,O
ERK,B,O
),O,O
activation,O,O
",",O,O
blocked,O,O
the,O,O
serine,O,O
phosphorylation,O,O
of,O,O
STAT3,B,O
induced,O,O
by,O,O
chemotactic,B,O
factors,I,O
or,O,O
PMA,O,O
.,O,O
These,O,O
foci,O,O
",",O,O
which,O,O
were,O,O
preferentially,O,O
found,O,O
adjacent,O,O
to,O,O
nucleoli,O,O
or,O,O
at,O,O
the,O,O
nuclear,O,O
periphery,O,O
",",O,O
did,O,O
not,O,O
represent,O,O
sites,O,O
of,O,O
active,O,O
transcription,O,O
or,O,O
binding,O,O
of,O,O
GATA,B,O
-,I,O
1,I,O
to,O,O
consensus,B,O
sites,I,O
in,O,O
the,O,O
beta,B,O
-,I,O
globin,I,O
loci,I,O
.,O,O
After,O,O
exercise,O,O
following,O,O
placebo,O,O
administration,O,O
we,O,O
observed,O,O
increases,O,O
in,O,O
concentrations,O,O
of,O,O
blood,O,O
substrates,O,O
",",O,O
plasma,B,O
adrenocorticotropin,I,O
(,O,O
ACTH,B,O
),O,O
",",O,O
growth,O,O
hormone,O,O
and,O,O
cortisol,O,O
and,O,O
in,O,O
the,O,O
number,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
in,O,O
lymphocytes,O,O
without,O,O
changes,O,O
in,O,O
the,O,O
dissociation,O,O
constant,O,O
.,O,O
Intravenous,O,O
PCr,O,O
injection,O,O
led,O,O
to,O,O
smaller,O,O
changes,O,O
in,O,O
ACTH,B,B
and,O,O
cortisol,O,B
concentrations,O,O
as,O,O
well,O,O
as,O,O
to,O,O
a,O,O
lower,O,O
activation,O,O
of,O,O
glucocorticoid,O,B
binding,O,O
in,O,O
lymphocytes,O,O
.,O,O
Putative,B,O
steroid,I,B
binding,I,O
domain,I,O
of,O,O
the,O,O
human,B,O
mineralocorticoid,I,B
receptor,I,I
",",O,O
expressed,O,O
in,O,O
E,O,O
.,O,O
coli,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
heat,B,O
shock,I,O
proteins,I,O
shows,O,O
typical,O,O
native,O,O
receptor,O,O
characteristics,O,O
.,O,O
These,O,O
bacterially,B,O
-,I,O
produced,I,O
MR,I,O
constructs,I,O
had,O,O
no,O,O
steroid,O,B
binding,O,I
activity,O,I
per,O,O
se,O,O
.,O,O
The,O,O
Kd,O,O
value,O,O
for,O,O
aldosterone,O,B
was,O,O
0,O,O
.,O,O
3,O,O
nM,O,O
and,O,O
the,O,O
Bmax,O,O
32,O,O
pmol,O,O
/,O,O
mg,O,O
.,O,O
Renal,O,O
cell,O,O
carcinoma,O,O
-,O,O
derived,O,O
gangliosides,O,O
suppress,O,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
activation,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
Indeed,O,O
",",O,O
we,O,O
detected,O,O
gangliosides,O,O
in,O,O
supernatants,O,O
from,O,O
RCC,O,O
explants,O,O
and,O,O
not,O,O
from,O,O
adjacent,O,O
normal,O,O
kidney,O,O
tissue,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
TNFalpha,B,B
-,O,O
inducible,O,O
reactive,O,O
oxygen,O,O
species,O,O
(,O,O
ROS,O,O
),O,O
in,O,O
IL,B,B
-,I,I
8,I,I
expression,O,O
by,O,O
`,O,O
`,O,O
monocyte,O,O
-,O,O
like,O,O
U937,O,O
histiocytic,O,O
lymphoma,O,O
cells,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
TNFalpha,B,B
induces,O,O
a,O,O
delayed,O,O
ROS,O,O
-,O,O
dependent,O,O
signalling,O,O
pathway,O,O
that,O,O
is,O,O
required,O,O
for,O,O
NF,B,B
-,I,I
kappaB,I,I
transcriptional,O,I
activation,O,O
and,O,O
is,O,O
separable,O,O
from,O,O
that,O,O
required,O,O
for,O,O
its,O,O
nuclear,O,O
translocation,O,O
.,O,O
Estrogen,B,B
receptors,I,I
influence,O,O
non,O,O
-,O,O
genomic,O,O
events,O,O
",",O,O
which,O,O
are,O,O
rapid,O,O
in,O,O
onset,O,O
and,O,O
genomic,O,O
events,O,O
",",O,O
which,O,O
are,O,O
longer,O,O
acting,O,O
responses,O,O
.,O,O
Estrogens,O,B
also,O,O
influence,O,O
production,O,O
of,O,O
mitogens,O,O
which,O,O
",",O,O
when,O,O
released,O,O
at,O,O
sites,O,O
of,O,O
vascular,O,O
injury,O,O
",",O,O
affect,O,O
vascular,O,O
remodeling,O,O
.,O,O
Protein,B,B
kinase,I,I
C,I,I
and,O,O
calcineurin,B,B
synergize,O,O
to,O,O
activate,O,O
IkappaB,B,B
kinase,I,I
and,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
T,O,O
lymphocytes,O,O
.,O,O
We,O,O
also,O,O
demonstrate,O,O
that,O,O
the,O,O
IKK,B,B
complex,I,I
",",O,O
but,O,O
not,O,O
p90,B,O
(,I,O
rsk,I,O
),I,O
",",O,O
is,O,O
responsible,O,O
for,O,O
the,O,O
in,O,O
vivo,O,O
phosphorylation,O,O
of,O,O
IkappaBalpha,B,B
mediated,O,O
by,O,O
the,O,O
co,O,O
-,O,O
activation,O,O
of,O,O
PKC,B,B
and,O,O
calcineurin,B,B
.,O,O
The,O,O
p53,B,O
paradox,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
tumor,O,O
progression,O,O
.,O,O
Additional,O,O
upstream,O,O
gene,O,O
segments,O,O
dramatically,O,O
affected,O,O
B29,B,O
minimal,B,O
promoter,I,O
activity,O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
B29,B,B
gene,I,I
expression,O,O
is,O,O
controlled,O,O
by,O,O
the,O,O
complex,O,O
interplay,O,O
of,O,O
positive,O,O
and,O,O
negative,B,O
regulatory,I,O
elements,I,O
.,O,O
A,O,O
novel,O,O
immunosuppressive,B,O
factor,I,O
in,O,O
bovine,O,O
colostrum,O,O
blocks,O,O
activation,O,O
of,O,O
the,O,O
interleukin,B,B
2,I,I
gene,I,I
enhancer,I,O
at,O,O
the,O,O
NFAT,B,B
site,I,O
.,O,O
A,O,O
factor,O,O
in,O,O
bovine,O,O
colostrum,O,O
(,O,O
colostrum,B,O
inhibitory,I,O
factor,I,O
",",O,O
CIF,B,O
),O,O
inhibits,O,O
interleukin,B,B
2,I,I
(,O,I
IL2,B,I
),O,I
production,O,O
in,O,O
activated,O,O
T,O,O
helper,O,O
cells,O,O
by,O,O
blocking,O,O
the,O,O
accumulation,O,O
of,O,O
IL2,B,B
mRNA,I,I
.,O,O
To,O,O
determine,O,O
whether,O,O
CIF,B,O
blocks,O,O
at,O,O
the,O,O
level,O,O
of,O,O
IL2,B,B
transcription,O,O
",",O,O
we,O,O
introduced,O,O
reporter,O,O
plasmids,O,O
into,O,O
the,O,O
human,O,B
T,O,I
leukemia,O,I
cell,O,I
line,O,I
Jurkat,O,I
by,O,O
transient,O,O
transfection,O,O
.,O,O
The,O,O
NFAT,B,B
-,I,I
controlled,I,I
luciferase,I,I
gene,I,I
system,I,I
distinguishes,O,O
CIF,B,O
from,O,O
other,O,O
T,O,B
cell,O,I
inhibitory,O,I
activities,O,I
present,O,O
in,O,O
colostrum,O,O
",",O,O
in,O,O
particular,O,O
",",O,O
TGF,B,B
beta,I,I
1,I,I
and,O,O
TGF,B,B
beta,I,I
2,I,I
and,O,O
the,O,O
glucocorticoids,O,O
.,O,O
The,O,O
NFAT,B,B
-,O,I
luc,O,I
assay,O,O
is,O,O
a,O,O
useful,O,O
technique,O,O
for,O,O
the,O,O
rapid,O,O
",",O,O
sensitive,O,O
measurement,O,O
of,O,O
CIF,B,O
or,O,O
other,O,O
immunosuppressants,O,O
with,O,O
a,O,O
similar,O,O
mode,O,O
of,O,O
action,O,O
.,O,O
To,O,O
propel,O,O
itself,O,O
in,O,O
infected,O,O
cells,O,O
",",O,O
the,O,O
pathogen,O,O
Shigella,O,O
flexneri,O,O
subverts,O,O
the,O,O
Cdc42,B,B
-,O,I
controlled,O,I
machinery,O,O
responsible,O,O
for,O,O
actin,B,O
assembly,O,O
during,O,O
filopodia,O,O
formation,O,O
.,O,O
Using,O,O
a,O,O
combination,O,O
of,O,O
bacterial,O,B
motility,O,I
assays,O,I
in,O,O
platelet,O,B
extracts,O,I
with,O,O
Escherichia,O,B
coli,O,I
expressing,O,O
the,O,O
Shigella,B,B
IcsA,I,I
protein,I,I
and,O,O
in,O,O
vitro,O,O
analysis,O,O
of,O,O
reconstituted,O,O
systems,O,O
from,O,O
purified,B,O
proteins,I,O
",",O,O
we,O,O
show,O,O
here,O,O
that,O,O
the,O,O
bacterial,B,B
protein,I,I
IcsA,I,I
binds,O,O
N,B,B
-,I,I
WASP,I,I
and,O,O
activates,O,O
it,O,O
in,O,O
a,O,O
Cdc42,B,B
-,O,I
like,O,I
fashion,O,I
.,O,O
VASP,O,B
is,O,O
not,O,O
involved,O,O
in,O,O
Shigella,O,B
movement,O,O
",",O,O
and,O,O
the,O,O
function,O,O
of,O,O
profilin,B,B
does,O,O
not,O,O
require,O,O
its,O,O
binding,O,O
to,O,O
proline,B,B
-,I,I
rich,I,I
regions,I,O
.,O,O
c,B,O
-,I,O
Maf,I,B
induces,O,O
monocytic,O,O
differentiation,O,O
and,O,O
apoptosis,O,O
in,O,O
bipotent,O,O
myeloid,O,O
progenitors,O,O
.,O,O
We,O,O
have,O,O
shown,O,O
that,O,O
the,O,O
c,B,O
-,I,O
Maf,I,O
and,O,O
c,B,O
-,I,O
Myb,I,B
transcription,I,O
factors,I,O
physically,O,O
interact,O,O
in,O,O
myeloid,O,O
cells,O,O
to,O,O
form,O,O
inhibitory,O,O
complexes,O,O
that,O,O
hinder,O,O
transactivation,O,O
of,O,O
c,B,O
-,I,O
Myb,I,O
target,I,O
genes,I,O
through,O,O
direct,O,O
binding,O,O
to,O,O
Myb,B,O
consensus,I,O
sites,I,O
.,O,O
Elevated,O,O
levels,O,O
of,O,O
c,B,O
-,I,O
Maf,I,B
protein,I,O
led,O,O
to,O,O
marked,O,O
increases,O,O
in,O,O
Myb,B,B
:,I,O
Maf,I,B
complexes,I,O
and,O,O
the,O,O
accumulation,O,O
of,O,O
monocyte,O,B
/,O,I
macrophage,O,I
cells,O,O
",",O,O
followed,O,O
by,O,O
eventual,O,O
programmed,O,O
cell,O,O
death,O,O
.,O,O
Analysis,O,O
of,O,O
targets,O,O
that,O,O
could,O,O
mediate,O,O
these,O,O
phenotypic,O,O
changes,O,O
indicated,O,O
that,O,O
c,B,O
-,I,O
Maf,I,B
likely,O,O
plays,O,O
a,O,O
key,O,O
role,O,O
in,O,O
myeloid,O,B
cell,O,I
development,O,O
through,O,O
dual,O,O
mechanisms,O,O
;,O,O
inhibition,O,O
of,O,O
a,O,O
select,O,O
set,O,O
of,O,O
c,B,O
-,I,O
Myb,I,B
regulated,O,O
targets,O,O
",",O,O
such,O,O
as,O,O
Bcl,B,B
-,I,I
2,I,I
and,O,O
CD13,B,B
/,I,I
APN,I,I
",",O,O
coupled,O,O
with,O,O
the,O,O
activation,O,O
of,O,O
as,O,O
yet,O,O
undefined,O,O
differentiation,B,O
-,I,O
promoting,I,O
genes,I,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
effect,O,O
of,O,O
Rb,B,B
expression,O,O
on,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
promoter,O,O
for,O,O
HLA,B,B
-,I,I
DRA,I,I
",",O,O
the,O,O
prototype,B,O
class,I,O
II,I,O
gene,I,O
.,O,O
Different,O,O
glucocorticoid,O,B
hormones,O,I
(,O,I
GCH,O,I
),O,I
show,O,O
differences,O,O
in,O,O
the,O,O
intensity,O,O
and,O,O
in,O,O
the,O,O
kinetics,O,O
of,O,O
their,O,O
immunomodulating,O,O
activity,O,O
.,O,O
The,O,O
mechanism,O,O
(,O,O
s,O,O
),O,O
of,O,O
action,O,O
of,O,O
GCH,O,B
is,O,O
under,O,O
investigation,O,O
",",O,O
but,O,O
is,O,O
has,O,O
been,O,O
noted,O,O
that,O,O
they,O,O
exert,O,O
immune,O,O
activity,O,O
via,O,O
the,O,O
genomic,O,O
pathway,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
BCL,B,B
-,I,I
6,I,I
may,O,O
play,O,O
a,O,O
role,O,O
in,O,O
regulating,O,O
differentiation,O,O
of,O,O
normal,O,O
germinal,O,O
center,O,O
B,O,O
cells,O,O
and,O,O
that,O,O
its,O,O
deregulated,O,O
expression,O,O
caused,O,O
by,O,O
rearrangements,O,O
may,O,O
contribute,O,O
to,O,O
lymphomagenesis,O,O
.,O,O
Activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
induced,O,O
by,O,O
prooxidants,O,O
and,O,O
several,O,O
stimuli,O,O
eliciting,O,O
oxidative,O,O
stress,O,O
",",O,O
such,O,O
as,O,O
cytokines,B,O
",",O,O
lipopolysaccharide,O,O
",",O,O
UV,O,O
irradiation,O,O
and,O,O
other,O,O
mediators,O,O
.,O,O
To,O,O
better,O,O
understand,O,O
the,O,O
assembly,O,O
mechanism,O,O
for,O,O
the,O,O
progesterone,B,B
receptor,I,I
(,O,O
PR,B,O
),O,O
",",O,O
we,O,O
have,O,O
developed,O,O
cell,O,B
-,O,I
free,O,I
systems,O,I
for,O,O
studying,O,O
interactions,O,O
of,O,O
PR,B,O
",",O,O
hsp90,B,B
",",O,O
and,O,O
other,O,O
associated,B,O
proteins,I,O
.,O,O
These,O,O
interactions,O,O
require,O,O
ATP,O,B
/,O,I
Mg2,O,I
+,O,I
and,O,O
when,O,O
ATP,O,B
is,O,O
limiting,O,O
the,O,O
PR,B,O
complex,O,O
is,O,O
altered,O,O
to,O,O
one,O,O
containing,O,O
the,O,O
proteins,O,O
p60,B,B
and,O,O
p48,B,B
",",O,O
but,O,O
lacking,O,O
immunophilins,B,B
and,O,O
p23,B,B
.,O,O
One,O,O
contains,O,O
hsp90,B,B
bound,O,O
to,O,O
hsp70,B,B
and,O,O
p60,B,B
and,O,O
this,O,O
complex,O,O
forms,O,O
spontaneously,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
ATP,O,B
.,O,O
This,O,O
explains,O,O
",",O,O
in,O,O
part,O,O
",",O,O
the,O,O
known,O,O
effects,O,O
of,O,O
ATP,O,B
and,O,O
molybdate,O,O
on,O,O
assembly,O,O
of,O,O
PR,B,O
complexes,I,O
.,O,O
We,O,O
have,O,O
recently,O,O
demonstrated,O,O
that,O,O
hydrocortisone,O,O
and,O,O
other,O,O
glucocorticoids,O,O
inhibit,O,O
reactive,O,O
oxygen,O,B
species,O,I
(,O,O
ROS,O,O
),O,O
generation,O,O
by,O,O
mononuclear,O,B
(,O,O
MNC,O,O
),O,O
and,O,O
polymorphonuclear,O,B
leucocytes,O,I
(,O,O
PMNL,O,O
),O,O
.,O,O
Since,O,O
NF,O,B
-,O,I
kappaB,O,I
/,O,I
IkappaB,B,I
system,O,O
regulates,O,O
the,O,O
transcription,O,O
of,O,O
proinflammatory,B,O
genes,I,O
",",O,O
including,O,O
those,O,O
responsible,O,O
for,O,O
ROS,O,O
generation,O,O
",",O,O
we,O,O
tested,O,O
the,O,O
hypothesis,O,O
that,O,O
hydrocortisone,O,O
may,O,O
stimulate,O,O
IkappaB,B,O
production,O,O
thus,O,O
inhibiting,O,O
NF,B,B
-,I,I
kappaB,I,I
translocation,O,O
from,O,O
the,O,O
cytosol,O,O
into,O,O
the,O,O
nucleus,O,O
in,O,O
MNC,O,O
",",O,O
in,O,O
vivo,O,O
.,O,O
Blood,O,O
samples,O,O
were,O,O
obtained,O,O
prior,O,O
to,O,O
the,O,O
injection,O,O
and,O,O
at,O,O
1,O,O
",",O,O
2,O,O
",",O,O
4,O,O
",",O,O
8,O,O
and,O,O
24,O,O
hr,O,O
after,O,O
the,O,O
injection,O,O
.,O,O
The,O,O
total,O,O
protein,O,B
content,O,I
of,O,O
NF,B,O
-,I,O
kappaB,I,O
subunit,I,O
(,O,O
P65,B,O
),O,O
in,O,O
MNC,O,O
lysates,O,O
also,O,O
showed,O,O
a,O,O
decrease,O,O
following,O,O
hydrocortisone,O,O
injection,O,O
.,O,O
This,O,O
decrease,O,O
was,O,O
observed,O,O
at,O,O
2,O,O
hr,O,O
",",O,O
reached,O,O
a,O,O
nadir,O,O
at,O,O
4,O,O
hr,O,O
",",O,O
and,O,O
returned,O,O
to,O,O
baseline,O,O
levels,O,O
at,O,O
24,O,O
hr,O,O
.,O,O
Monocyte,O,O
apoptosis,O,O
was,O,O
determined,O,O
by,O,O
four,O,O
independent,O,O
methods,O,O
",",O,O
including,O,O
annexin,O,O
-,O,O
V,O,O
staining,O,O
",",O,O
TUNEL,O,O
",",O,O
DNA,O,B
-,O,I
laddering,O,I
",",O,O
and,O,O
typical,O,O
morphology,O,O
by,O,O
means,O,O
of,O,O
transmission,O,O
electron,O,O
microscopy,O,O
.,O,O
Necrosis,O,O
was,O,O
excluded,O,O
by,O,O
propidium,O,O
iodide,O,O
staining,O,O
.,O,O
Proinflammatory,B,O
cytokines,I,O
such,O,O
as,O,O
IL,B,B
-,I,I
1beta,I,I
and,O,O
TNF,B,B
-,I,I
alpha,I,I
were,O,O
down,O,O
-,O,O
regulated,O,O
by,O,O
GC,O,O
treatment,O,O
.,O,O
Continuous,O,O
treatment,O,O
of,O,O
monocytes,O,O
with,O,O
IL,B,B
-,I,I
1beta,I,I
",",O,O
but,O,O
not,O,O
with,O,O
TNF,B,B
-,I,I
alpha,I,I
",",O,O
could,O,O
almost,O,O
completely,O,O
prevent,O,O
GC,O,O
-,O,O
induced,O,O
cell,O,O
death,O,O
.,O,O
The,O,O
addition,O,O
of,O,O
mifepristone,O,O
or,O,O
caspase,O,O
-,O,O
3,O,O
inhibitor,O,O
could,O,O
partially,O,O
abrogate,O,O
GC,O,O
-,O,O
induced,O,O
apoptosis,O,O
as,O,O
well,O,O
as,O,O
GC,O,O
-,O,O
induced,O,O
inhibition,O,O
of,O,O
IL,B,B
-,I,I
1beta,I,I
.,O,O
The,O,O
inflammatory,O,O
mediators,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
and,O,O
tumor,B,O
necrosis,I,O
factor,I,O
(,O,O
TNF,B,B
),O,O
are,O,O
potent,O,O
activators,O,O
of,O,O
NF,B,O
-,I,O
kappaB,I,O
.,O,O
Kinase,O,O
assays,O,O
showed,O,O
that,O,O
TNF,B,B
elicited,O,O
a,O,O
rapid,O,O
but,O,O
short,O,O
-,O,O
lived,O,O
induction,O,O
of,O,O
IKK,B,B
activity,O,O
with,O,O
a,O,O
3,O,O
-,O,O
fold,O,O
greater,O,O
effect,O,O
on,O,O
IKK,B,B
-,I,O
alpha,I,O
than,O,O
on,O,O
IKK,B,B
-,I,O
beta,I,O
",",O,O
peaking,O,O
at,O,O
5,O,O
min,O,O
.,O,O
Furthermore,O,O
",",O,O
our,O,O
studies,O,O
showed,O,O
association,O,O
of,O,O
the,O,O
IKK,B,B
-,I,O
alpha,I,O
/,I,O
beta,I,O
heterodimer,I,O
with,O,O
NIK,B,O
",",O,O
IkappaB,B,B
-,I,O
alpha,I,O
and,O,O
-,B,O
epsilon,I,O
in,O,O
unstimulated,O,O
cells,O,O
.,O,O
The,O,O
understanding,O,O
of,O,O
LPS,O,B
-,O,I
and,O,O
TNF,O,B
-,O,I
induced,O,I
signaling,O,O
may,O,O
allow,O,O
the,O,O
development,O,O
of,O,O
specific,O,O
strategies,O,O
to,O,O
treat,O,O
sepsis,O,O
-,O,O
associated,O,O
disease,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
examine,O,O
the,O,O
ability,O,O
of,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
(,O,O
TNFalpha,B,B
",",O,O
a,O,O
proinflammatory,B,O
cytokine,I,O
),O,O
and,O,O
interleukin,B,B
(,I,O
IL,I,B
),I,O
-,I,O
10,I,O
(,O,O
an,O,O
anti,B,O
-,I,O
inflammatory,I,O
cytokine,I,O
),O,O
to,O,O
differentially,O,O
regulate,O,O
the,O,O
sensitivity,O,O
of,O,O
human,O,O
monocytes,O,O
/,O,O
macrophages,O,O
to,O,O
glucocorticoids,O,O
.,O,O
Finally,O,O
",",O,O
we,O,O
investigated,O,O
whether,O,O
the,O,O
modulation,O,O
of,O,O
corticosensitivity,O,O
in,O,O
TNFalpha,O,B
-,O,O
and,O,O
IL,O,B
-,O,O
10,O,I
-,O,O
pretreated,O,O
U937,O,O
cells,O,O
was,O,O
related,O,O
to,O,O
a,O,O
change,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
concentration,O,O
and,O,O
affinity,O,O
.,O,O
TNFalpha,B,B
decreased,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
while,O,O
IL,B,B
-,I,O
10,I,I
increased,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
the,O,O
concentration,O,O
of,O,O
dexamethasone,O,B
binding,O,O
sites,O,O
in,O,O
these,O,O
cells,O,O
",",O,O
with,O,O
no,O,O
discernible,O,O
effect,O,O
on,O,O
their,O,O
binding,O,O
affinity,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
glucocorticoids,O,B
differentially,O,O
modulate,O,O
TNFalpha,B,B
and,O,O
IL,B,B
-,I,I
10,I,I
secretion,O,O
by,O,O
human,O,O
monocytes,O,O
in,O,O
a,O,O
LPS,O,O
dose,O,O
-,O,O
dependent,O,O
fashion,O,O
and,O,O
that,O,O
the,O,O
sensitivity,O,O
of,O,O
these,O,O
cells,O,O
to,O,O
glucocorticoids,O,B
is,O,O
altered,O,O
by,O,O
TNFalpha,B,B
or,O,O
IL,B,B
-,I,I
10,I,I
pretreatment,O,O
;,O,O
TNFalpha,B,B
blocks,O,O
their,O,O
effects,O,O
",",O,O
whereas,O,O
IL,B,B
-,I,I
10,I,I
acts,O,O
synergistically,O,O
with,O,O
glucocorticoids,O,B
.,O,O
Because,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
contributes,O,O
to,O,O
the,O,O
transcription,O,O
of,O,O
numerous,O,O
inflammatory,B,O
genes,I,O
and,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
a,O,O
molecular,O,O
target,O,O
of,O,O
antiinflammatory,O,O
drugs,O,O
",",O,O
we,O,O
sought,O,O
to,O,O
characterize,O,O
the,O,O
functional,O,O
role,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
protein,I,O
complex,I,O
in,O,O
lupus,O,O
T,O,O
cells,O,O
.,O,O
Also,O,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activity,O,O
remained,O,O
absent,O,O
in,O,O
follow,O,O
-,O,O
up,O,O
studies,O,O
.,O,O
As,O,O
p65,B,B
complexes,I,I
are,O,O
transcriptionally,O,O
active,O,O
in,O,O
comparison,O,O
to,O,O
the,O,O
p50,O,B
homodimer,O,I
",",O,O
this,O,O
novel,O,O
finding,O,O
may,O,O
provide,O,O
insight,O,O
on,O,O
the,O,O
origin,O,O
of,O,O
abnormal,B,O
cytokine,I,O
or,O,O
other,O,O
gene,O,O
transcription,O,O
in,O,O
SLE,O,O
patients,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
investigate,O,O
further,O,O
the,O,O
events,O,O
triggered,O,O
by,O,O
TLR2,B,O
in,O,O
response,O,O
to,O,O
LPS,O,O
.,O,O
Intracellular,O,O
deletion,O,O
variants,O,O
of,O,O
TLR2,B,O
lacking,O,O
C,O,B
-,O,I
terminal,O,I
13,O,I
or,O,O
141,O,O
aa,O,O
fail,O,O
to,O,O
recruit,O,O
IRAK,B,O
",",O,O
which,O,O
is,O,O
consistent,O,O
with,O,O
the,O,O
inability,O,O
of,O,O
these,O,O
mutants,O,O
to,O,O
transmit,O,O
LPS,O,O
cellular,O,O
signaling,O,O
.,O,O
Here,O,O
we,O,O
provide,O,O
novel,O,O
evidence,O,O
that,O,O
AG,O,O
-,O,O
490,O,O
potently,O,O
inhibits,O,O
the,O,O
autokinase,O,O
activity,O,O
of,O,O
JAK3,B,B
and,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
DNA,O,B
binding,O,O
of,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
5a,I,O
and,I,O
5b,I,O
(,I,O
STAT5a,I,O
/,I,O
b,I,O
),I,O
.,O,O
AG,O,O
-,O,O
490,O,O
also,O,O
inhibited,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
mediated,O,I
proliferative,O,I
growth,O,I
in,O,O
human,O,O
T,O,O
cells,O,O
with,O,O
an,O,O
IC50,O,O
),O,O
25,O,O
microM,O,O
that,O,O
was,O,O
partially,O,O
recoverable,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
findings,O,O
suggest,O,O
that,O,O
AG,O,O
-,O,O
490,O,O
inhibits,O,O
the,O,O
JAK3,B,O
-,O,O
mediated,O,O
Type,O,O
II,O,O
signaling,O,O
pathway,O,O
but,O,O
not,O,O
the,O,O
T,O,O
cell,O,O
receptor,O,O
-,O,O
derived,O,O
Type,O,O
I,O,O
pathway,O,O
and,O,O
possesses,O,O
therapeutic,O,O
potential,O,O
for,O,O
T,O,O
cell,O,O
-,O,O
derived,O,O
pathologies,O,O
such,O,O
as,O,O
graft,O,O
-,O,O
versus,O,O
-,O,O
host,O,O
disease,O,O
",",O,O
allergy,O,O
",",O,O
and,O,O
autoimmune,O,O
disorders,O,O
.,O,O
Two,O,O
-,O,O
color,O,O
immunohistochemistry,O,O
demonstrated,O,O
that,O,O
both,O,O
macrophages,O,B
and,O,O
fibroblast,O,B
-,O,I
like,O,I
synoviocytes,O,I
were,O,O
positive,O,O
for,O,O
nuclear,O,O
C,B,B
/,I,I
EBP,I,I
beta,I,I
.,O,O
PU,B,O
.,I,O
1,I,O
is,O,O
a,O,O
hematopoietic,B,O
-,I,O
specific,I,O
Ets,I,B
family,I,I
transcription,I,I
factor,I,I
that,O,O
is,O,O
required,O,O
for,O,O
development,O,O
of,O,O
some,O,O
lymphoid,O,B
and,O,O
myeloid,O,B
lineages,O,I
.,O,O
We,O,O
find,O,O
that,O,O
PU,B,O
.,I,O
1,I,O
interacts,O,O
directly,O,O
with,O,O
GATA,B,B
-,I,I
1,I,I
",",O,O
a,O,O
zinc,B,B
finger,I,I
transcription,I,I
factor,I,I
required,O,O
for,O,O
erythroid,O,B
differentiation,O,I
.,O,O
Both,O,O
the,O,O
DNA,B,B
binding,I,I
and,O,O
transactivation,B,I
domains,I,O
of,O,O
PU,B,O
.,I,O
1,I,O
are,O,O
required,O,O
for,O,O
repression,O,O
and,O,O
both,O,O
domains,O,O
are,O,O
also,O,O
needed,O,O
to,O,O
block,O,O
terminal,O,O
differentiation,O,O
in,O,O
MEL,O,B
cells,O,O
.,O,O
To,O,O
better,O,O
clarify,O,O
the,O,O
molecular,O,O
basis,O,O
of,O,O
IL,B,B
-,I,I
12,I,I
action,O,O
",",O,O
we,O,O
set,O,O
out,O,O
to,O,O
characterize,O,O
genes,O,O
up,O,O
-,O,O
regulated,O,O
by,O,O
IL,B,B
-,I,I
12,I,I
",",O,O
first,O,O
by,O,O
contrasting,O,O
IL,B,B
-,I,I
12,I,I
-,O,I
and,O,O
IFN,B,B
-,I,I
alpha,I,I
-,I,I
inducible,I,I
genes,I,O
.,O,O
We,O,O
identified,O,O
several,O,O
genes,O,O
up,O,O
-,O,O
regulated,O,O
by,O,O
IL,B,B
-,I,I
12,I,I
",",O,O
namely,O,O
",",O,O
MIP,B,B
-,I,I
1alpha,I,I
",",O,O
MIP,B,B
-,I,I
1beta,I,I
",",O,O
IL,B,B
-,I,I
1RA,I,I
",",O,O
and,O,O
IFN,B,B
regulatory,I,I
factor,I,I
-,I,I
1,I,I
(,I,O
IRF,I,B
-,I,I
1,I,I
),I,O
.,O,O
Therefore,O,O
",",O,O
IRF,B,B
-,I,I
1,I,I
may,O,O
be,O,O
an,O,O
important,O,O
contributor,O,O
to,O,O
IL,B,B
-,I,I
12,I,I
signaling,O,O
",",O,O
and,O,O
we,O,O
speculate,O,O
that,O,O
the,O,O
defective,O,O
IL,B,B
-,I,I
12,I,I
responses,O,O
seen,O,O
in,O,O
IRF,B,B
-,O,I
1,O,I
-,O,I
/,O,I
-,O,I
mice,O,O
might,O,O
be,O,O
attributable,O,O
",",O,O
in,O,O
part,O,O
",",O,O
to,O,O
the,O,O
absence,O,O
of,O,O
this,O,O
transcription,B,O
factor,I,O
.,O,O
To,O,O
determine,O,O
whether,O,O
it,O,O
is,O,O
possible,O,O
to,O,O
artificially,O,O
enhance,O,O
the,O,O
opening,O,O
of,O,O
the,O,O
chromatin,O,O
structure,O,O
of,O,O
a,O,O
minimal,B,O
beta,I,B
-,I,I
globin,I,I
promoter,I,I
",",O,O
we,O,O
placed,O,O
a,O,O
101bp,O,O
",",O,O
erythroid,B,B
-,I,I
specific,I,I
DNase,I,I
1,I,I
hypersensitive,I,I
site,I,I
-,I,I
forming,I,I
element,I,I
(,O,O
HSFE,B,O
),O,O
immediately,O,O
upstream,O,O
of,O,O
the,O,O
beta,B,B
-,I,I
globin,I,I
promoter,I,I
and,I,O
gene,I,O
.,O,O
This,O,O
remodeling,O,O
of,O,O
promoter,O,O
chromatin,O,O
structure,O,O
resulted,O,O
in,O,O
3,O,O
-,O,O
fold,O,O
increases,O,O
in,O,O
beta,B,B
-,I,I
globin,I,I
gene,I,I
transcription,O,O
and,O,O
induction,O,O
",",O,O
and,O,O
inhibited,O,O
long,O,O
-,O,O
term,O,O
beta,B,B
-,I,I
globin,I,I
gene,I,I
silencing,O,O
.,O,O
Regulation,O,O
of,O,O
low,O,O
shear,O,O
flow,O,O
-,O,O
induced,O,O
HAEC,O,O
VCAM,B,B
-,I,I
1,I,I
expression,O,O
and,O,O
monocyte,O,O
adhesion,O,O
.,O,O
Here,O,O
we,O,O
investigate,O,O
the,O,O
hypothesis,O,O
that,O,O
low,O,O
shear,O,O
-,O,O
induced,O,O
activation,O,O
of,O,O
NF,B,O
-,I,O
kappaB,I,O
is,O,O
responsible,O,O
for,O,O
enhanced,O,O
expression,O,O
of,O,O
vascular,B,O
cell,I,O
adhesion,I,O
molecule,I,O
(,O,O
VCAM,B,B
-,I,I
1,I,I
),O,O
resulting,O,O
in,O,O
augmented,O,O
endothelial,O,O
cell,O,O
-,O,O
monocyte,O,O
(,O,O
EC,O,O
-,O,O
Mn,O,O
),O,O
adhesion,O,O
and,O,O
that,O,O
this,O,O
activation,O,O
is,O,O
dependent,O,O
on,O,O
intracellular,O,O
oxidant,O,O
activity,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
NF,B,B
-,I,I
kappaB,I,I
plays,O,O
a,O,O
key,O,O
role,O,O
in,O,O
low,O,O
shear,O,O
-,O,O
induced,O,O
VCAM,B,B
-,I,I
1,I,I
expression,O,O
and,O,O
that,O,O
pathways,O,O
mediating,O,O
low,O,O
shear,O,O
-,O,O
and,O,O
cytokine,O,O
-,O,O
induced,O,O
EC,O,B
-,O,I
Mn,O,I
adhesion,O,O
may,O,O
be,O,O
differentially,O,O
regulated,O,O
.,O,O
Nuclear,B,O
factor,I,O
-,I,O
90,I,O
of,O,O
activated,O,O
T,O,O
-,O,O
cells,O,O
:,O,O
A,O,O
double,B,O
-,I,O
stranded,I,O
RNA,I,B
-,O,I
binding,O,I
protein,O,I
and,O,O
substrate,O,O
for,O,O
the,O,O
double,B,O
-,I,O
stranded,I,O
RNA,I,B
-,I,I
dependent,I,I
protein,I,I
kinase,I,I
",",O,O
PKR,B,O
.,O,O
Using,O,O
in,O,O
vitro,O,O
translated,O,O
polypeptides,O,O
",",O,O
we,O,O
have,O,O
demonstrated,O,O
that,O,O
NF90,B,B
specifically,O,O
binds,O,O
to,O,O
double,B,O
-,I,O
stranded,I,O
RNA,I,B
.,O,O
C5a,O,O
-,O,O
induced,O,O
reporter,B,O
gene,I,O
expression,O,O
was,O,O
abolished,O,O
by,O,O
introducing,O,O
mutations,O,O
into,O,O
the,O,O
kappaB,B,O
sites,I,O
and,O,O
by,O,O
coexpression,O,O
of,O,O
a,O,O
dominant,B,O
negative,I,O
IkappaBalpha,I,O
construct,I,O
resistant,O,O
to,O,O
agonist,O,O
-,O,O
induced,O,O
phosphorylation,O,O
.,O,O
Pertussis,O,B
toxin,O,I
",",O,O
which,O,O
ADP,O,O
-,O,O
ribosylates,O,O
the,O,O
Gi,B,B
proteins,I,I
known,O,O
to,O,O
couple,O,O
to,O,O
the,O,O
C5a,B,B
receptor,I,I
",",O,O
produced,O,O
minimal,O,O
inhibition,O,O
of,O,O
C5a,O,O
-,O,O
induced,O,O
IL,B,B
-,I,I
8,I,I
expression,O,O
and,O,O
had,O,O
little,O,O
effect,O,O
on,O,O
C5a,O,O
-,O,O
induced,O,O
calcium,O,B
mobilization,O,I
in,O,O
RAW264,O,O
.,O,O
cells,O,O
.,O,O
Patients,O,O
with,O,O
GC,O,B
-,O,I
insensitive,O,I
asthma,O,I
expressed,O,O
a,O,O
significantly,O,O
higher,O,O
number,O,O
of,O,O
GCRbeta,O,B
-,O,I
immunoreactive,O,I
cells,O,I
in,O,O
their,O,O
BAL,O,O
and,O,O
peripheral,O,O
blood,O,O
than,O,O
GC,O,O
-,O,O
sensitive,O,O
asthmatics,O,O
or,O,O
normal,O,O
control,O,O
subjects,O,O
.,O,O
CD40,B,B
/,B,I
CD40,I,I
ligand,O,I
interactions,O,O
play,O,O
a,O,O
key,O,O
role,O,O
in,O,O
the,O,O
immune,O,O
responses,O,O
of,O,O
B,O,O
lymphocytes,O,O
",",O,O
monocytes,O,O
",",O,O
and,O,O
dendritic,O,O
cells,O,O
.,O,O
However,O,O
",",O,O
the,O,O
components,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
complexes,I,O
were,O,O
different,O,O
in,O,O
monocytes,O,O
and,O,O
B,O,O
cells,O,O
",",O,O
because,O,O
p50,B,O
is,O,O
part,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
complex,I,I
induced,O,O
by,O,O
CD40,B,B
triggering,O,O
in,O,O
both,O,O
monocytes,O,O
and,O,O
B,O,O
cells,O,O
",",O,O
whereas,O,O
p65,B,O
was,O,O
only,O,O
induced,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
although,O,O
the,O,O
Janus,B,B
kinase,I,I
3,I,I
tyrosine,I,I
kinase,I,I
was,O,O
associated,O,O
with,O,O
CD40,B,B
molecules,O,I
in,O,O
both,O,O
monocytes,O,B
and,O,O
resting,O,O
B,O,B
cells,O,I
",",O,O
Janus,B,B
kinase,I,I
3,I,I
phosphorylation,O,O
induction,O,O
was,O,O
observed,O,O
only,O,O
in,O,O
CD40,O,B
-,O,I
activated,O,I
monocytes,O,I
",",O,O
with,O,O
subsequent,O,O
induction,O,O
of,O,O
STAT5a,B,B
DNA,O,I
binding,O,I
activity,O,I
in,O,O
the,O,O
nucleus,O,O
.,O,O
Interestingly,O,O
",",O,O
when,O,O
we,O,O
fused,O,O
HT,O,B
-,O,I
2,O,I
cells,O,I
expressing,O,O
the,O,O
EPOR,B,B
with,O,O
Ba,O,B
/,O,I
F3,O,I
cells,O,I
in,O,O
a,O,O
complementation,O,O
assay,O,O
",",O,O
the,O,O
resulting,O,O
hybridomas,O,O
proliferated,O,O
and,O,O
potently,O,O
activated,O,O
STAT,B,B
-,I,I
5,I,I
and,O,O
MAPK,B,B
in,O,O
response,O,O
to,O,O
EPO,B,B
.,O,O
Moreover,O,O
",",O,O
Ba,O,O
/,O,O
F3,O,O
cells,O,O
apparently,O,O
express,O,O
this,O,O
factor,O,O
(,O,O
s,O,O
),O,O
and,O,O
somatic,O,O
fusions,O,O
can,O,O
",",O,O
therefore,O,O
",",O,O
confer,O,O
EPO,B,B
-,O,I
responsiveness,O,I
to,O,O
HT,O,O
-,O,O
2,O,O
cells,O,O
that,O,O
lack,O,O
this,O,O
factor,O,O
.,O,O
When,O,O
a,O,O
drug,O,O
appears,O,O
to,O,O
be,O,O
less,O,O
effective,O,O
than,O,O
preclinical,O,O
models,O,O
suggest,O,O
",",O,O
can,O,O
failures,O,O
in,O,O
effectiveness,O,O
from,O,O
delivery,O,O
or,O,O
dosing,O,O
be,O,O
differentiated,O,O
?,O,O
The,O,O
disappointing,O,O
results,O,O
of,O,O
clinical,O,O
trials,O,O
with,O,O
IL,B,B
-,I,I
10,I,I
-,O,I
-,O,I
so,O,O
at,O,O
odds,O,O
with,O,O
the,O,O
prediction,O,O
of,O,O
benefit,O,O
from,O,O
animal,O,O
models,O,O
-,O,O
-,O,O
bring,O,O
into,O,O
question,O,O
the,O,O
validity,O,O
of,O,O
those,O,O
models,O,O
as,O,O
well,O,O
as,O,O
the,O,O
soundness,O,O
of,O,O
design,O,O
of,O,O
the,O,O
clinical,O,O
trials,O,O
on,O,O
which,O,O
efficacy,O,O
of,O,O
IL,B,B
-,I,I
10,I,I
is,O,O
judged,O,O
.,O,O
The,O,O
variability,O,O
of,O,O
response,O,O
even,O,O
to,O,O
the,O,O
most,O,O
narrowly,O,O
targeted,O,O
agents,O,O
suggests,O,O
that,O,O
these,O,O
diseases,O,O
are,O,O
far,O,O
more,O,O
heterogeneous,O,O
in,O,O
humans,O,O
than,O,O
in,O,O
their,O,O
murine,O,O
counterparts,O,O
.,O,O
Potent,O,O
and,O,O
stable,O,O
attenuation,O,O
of,O,O
live,O,O
-,O,O
HIV,O,B
-,O,I
1,O,I
by,O,O
gain,O,O
of,O,O
a,O,O
proteolysis,B,O
-,I,O
resistant,I,O
inhibitor,I,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
(,O,O
IkappaB,B,O
-,I,O
alphaS32,I,O
/,I,O
36A,I,O
),O,O
and,O,O
the,O,O
implications,O,O
for,O,O
vaccine,O,O
development,O,O
.,O,O
These,O,O
findings,O,O
illustrate,O,O
gain,O,O
-,O,O
of,O,O
-,O,O
function,O,O
as,O,O
a,O,O
feasible,O,O
strategy,O,O
for,O,O
developing,O,O
safer,O,O
live,O,O
-,O,O
attenuated,O,O
HIVs,O,O
to,O,O
be,O,O
tested,O,O
as,O,O
candidates,O,O
for,O,O
AIDS,O,O
vaccine,O,O
.,O,O
Multiple,O,O
NF,B,B
-,I,O
ATc,I,O
isoforms,I,O
with,O,O
individual,O,O
transcriptional,O,O
properties,O,O
are,O,O
synthesized,O,O
in,O,O
T,O,O
lymphocytes,O,O
.,O,O
The,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,O
ATc,I,O
that,O,O
controls,O,O
gene,O,O
expression,O,O
in,O,O
T,O,O
lymphocytes,O,O
and,O,O
embryonic,O,O
cardiac,O,O
cells,O,O
is,O,O
expressed,O,O
in,O,O
three,O,O
prominent,O,O
isoforms,O,O
.,O,O
Various,O,O
stimuli,O,O
of,O,O
T,O,O
cells,O,O
that,O,O
induce,O,O
the,O,O
activity,O,O
of,O,O
TAD,B,B
-,I,I
A,I,I
also,O,O
enhance,O,O
the,O,O
activity,O,O
of,O,O
TAD,B,B
-,I,I
B,I,I
",",O,O
but,O,O
",",O,O
unlike,O,O
TAD,B,B
-,I,I
A,I,I
",",O,O
TAD,B,B
-,I,I
B,I,I
remains,O,O
unphosphorylated,O,O
by,O,O
protein,O,B
from,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoyl,O,O
12,O,O
-,O,O
phorbol,O,O
13,O,O
-,O,O
acetate,O,O
-,O,O
stimulated,O,O
T,O,O
cells,O,O
.,O,O
Selection,O,O
and,O,O
long,O,O
-,O,O
term,O,O
persistence,O,O
of,O,O
reactive,O,O
CTL,O,B
clones,O,O
during,O,O
an,O,O
EBV,O,B
chronic,O,I
response,O,I
are,O,O
determined,O,O
by,O,O
avidity,O,O
",",O,O
CD8,B,B
variable,O,I
contribution,O,O
compensating,O,O
for,O,O
differences,O,O
in,O,O
TCR,B,B
affinities,O,O
.,O,O
We,O,O
found,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
TCR,B,O
affinities,O,O
among,O,O
the,O,O
different,O,O
clonotypes,O,O
that,O,O
segregated,O,O
with,O,O
Vbeta,O,O
usage,O,O
.,O,O
Nuclear,O,O
localization,O,O
and,O,O
formation,O,O
of,O,O
beta,B,B
-,I,I
catenin,I,I
-,I,I
lymphoid,I,I
enhancer,I,I
factor,I,I
1,I,I
complexes,I,O
are,O,O
not,O,O
sufficient,O,O
for,O,O
activation,O,O
of,O,O
gene,O,O
expression,O,O
.,O,O
Lymphoid,O,O
cell,O,O
differentiation,O,O
relies,O,O
on,O,O
precisely,O,O
orchestrated,O,O
gene,O,O
activation,O,O
and,O,O
repression,O,O
events,O,O
.,O,O
Packaging,O,O
of,O,O
viral,O,O
particles,O,O
",",O,O
integration,O,O
into,O,O
the,O,O
target,O,O
genome,O,O
",",O,O
and,O,O
stability,O,O
of,O,O
the,O,O
integrated,O,O
provirus,O,O
are,O,O
not,O,O
affected,O,O
by,O,O
the,O,O
LTR,B,O
modification,O,O
.,O,O
Enhancer,O,O
replacement,O,O
is,O,O
therefore,O,O
an,O,O
effective,O,O
strategy,O,O
to,O,O
target,O,O
expression,O,O
of,O,O
a,O,O
retroviral,B,O
transgene,I,O
to,O,O
a,O,O
specific,O,O
progeny,O,O
of,O,O
transduced,O,O
hematopoietic,O,B
stem,O,I
cells,O,I
.,O,O
Regulation,O,O
of,O,O
Fas,B,B
ligand,I,I
expression,O,O
and,O,O
cell,O,O
death,O,O
by,O,O
apoptosis,B,O
-,I,O
linked,I,O
gene,I,O
4,I,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
ALG,B,O
-,I,O
4,I,O
is,O,O
necessary,O,O
and,O,O
sufficient,O,O
for,O,O
FasL,B,B
expression,O,O
.,O,O
We,O,O
now,O,O
find,O,O
that,O,O
LMP1,B,O
signaling,O,O
through,O,O
TRADD,B,O
differs,O,O
from,O,O
TNFR1,B,O
signaling,O,O
through,O,O
TRADD,B,O
.,O,O
Inhibition,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
resulted,O,O
in,O,O
the,O,O
externalization,O,O
of,O,O
phosphatidylserine,O,O
",",O,O
induction,O,O
of,O,O
DNA,O,B
breaks,O,O
",",O,O
and,O,O
morphological,O,O
changes,O,O
consistent,O,O
with,O,O
apoptosis,O,O
.,O,O
Among,O,O
upstream,B,O
signaling,I,O
molecules,I,O
of,O,O
ERK,B,B
",",O,O
Shc,B,B
was,O,O
constitutively,O,O
associated,O,O
with,O,O
Grb2,O,B
and,O,O
was,O,O
not,O,O
tyrosine,O,O
-,O,O
phosphorylated,O,O
by,O,O
GM,B,O
-,I,O
CSF,I,O
and,O,O
FMLP,O,O
",",O,O
and,O,O
Sos1,B,B
and,O,O
c,B,B
-,I,I
Raf,I,I
-,I,I
1,I,I
were,O,O
not,O,O
phosphorylated,O,O
by,O,O
GM,B,O
-,I,O
CSF,I,O
",",O,O
IL,O,O
-,O,O
3,O,O
",",O,O
TNF,O,O
",",O,O
and,O,O
FMLP,O,O
in,O,O
monocytes,O,O
",",O,O
whereas,O,O
all,O,O
these,O,O
signaling,O,O
molecules,O,O
were,O,O
affected,O,O
and,O,O
/,O,O
or,O,O
utilized,O,O
by,O,O
GM,B,O
-,I,O
CSF,I,O
in,O,O
MO7e,O,O
cells,O,O
.,O,O
In,O,O
contrast,O,O
to,O,O
neutrophils,O,O
",",O,O
p38,B,B
was,O,O
constitutively,O,O
phosphorylated,O,O
and,O,O
agonist,O,O
-,O,O
dependent,O,O
phosphorylation,O,O
and,O,O
activation,O,O
was,O,O
not,O,O
detected,O,O
in,O,O
human,O,O
monocytes,O,O
.,O,O
Functional,O,O
analysis,O,O
indicates,O,O
that,O,O
the,O,O
BRs,B,O
are,O,O
involved,O,O
in,O,O
control,O,O
of,O,O
hIL,B,O
-,I,O
5,I,O
promoter,I,O
activity,O,O
.,O,O
PNU156804,O,O
action,O,O
is,O,O
restricted,O,O
to,O,O
some,O,O
signaling,O,O
pathways,O,O
;,O,O
it,O,O
does,O,O
not,O,O
affect,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
by,O,O
PMA,O,O
in,O,O
T,O,O
cells,O,O
but,O,O
blocks,O,O
that,O,O
induced,O,O
by,O,O
CD40,B,O
cross,O,O
-,O,O
linking,O,O
in,O,O
B,O,O
lymphocytes,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
STAT1,B,B
and,O,O
STAT5,B,B
in,O,O
a,O,O
human,O,O
T,O,B
-,O,I
cell,O,I
line,O,I
was,O,O
induced,O,O
by,O,O
Tax,B,O
.,O,O
Transcriptional,O,O
control,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
5,I,I
gene,O,I
by,O,O
human,O,O
helper,O,O
T,O,B
cells,O,I
:,O,O
IL,B,B
-,I,I
5,I,I
synthesis,O,O
is,O,O
regulated,O,O
independently,O,O
from,O,O
IL,B,B
-,I,I
2,I,I
or,O,O
IL,B,B
-,I,I
4,I,I
synthesis,O,O
.,O,O
METHODS,O,O
:,O,O
Allergen,O,O
-,O,O
specific,O,O
T,O,B
-,O,I
cell,O,I
clones,O,I
and,O,O
T,O,B
-,O,I
cell,O,I
hybridomas,O,I
were,O,O
established,O,O
from,O,O
the,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
of,O,O
patients,O,O
with,O,O
asthma,O,O
",",O,O
and,O,O
the,O,O
transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
5,I,I
gene,I,I
was,O,O
investigated,O,O
with,O,O
transient,O,O
transfection,O,O
and,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
analysis,O,O
.,O,O
RESULTS,O,O
:,O,O
A,O,O
human,O,O
IL,B,B
-,I,I
5,I,I
promoter,I,O
/,I,O
enhancer,I,O
-,I,O
luciferase,I,O
gene,I,O
construct,I,O
",",O,O
pIL,B,O
-,I,O
5,I,O
(,I,O
-,I,O
511,I,O
),I,O
Luc,I,O
",",O,O
was,O,O
transcribed,O,O
on,O,O
activation,O,O
of,O,O
IL,O,B
-,O,I
5,O,I
-,O,I
producing,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
",",O,O
but,O,O
not,O,O
IL,O,B
-,O,I
5,O,I
-,O,I
nonproducing,O,O
clones,O,O
.,O,O
pIL,B,O
-,I,O
5,I,O
(,I,O
-,I,O
511,I,O
),I,O
Luc,I,O
was,O,O
transcribed,O,O
by,O,O
T,O,O
-,O,O
cell,O,O
hybridomas,O,O
derived,O,O
from,O,O
fusion,O,O
between,O,O
IL,O,B
-,O,I
5,O,I
-,O,I
producing,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
and,O,O
an,O,O
IL,O,B
-,O,I
5,O,I
gene,O,O
-,O,O
nonexpressing,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
",",O,O
but,O,O
not,O,O
by,O,O
hybridomas,O,O
derived,O,O
from,O,O
IL,O,B
-,O,I
5,O,I
-,O,I
nonproducing,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
.,O,O
CONCLUSION,O,O
:,O,O
IL,B,B
-,I,I
5,I,I
synthesis,O,O
by,O,O
human,O,O
helper,O,O
T,O,O
cells,O,O
is,O,O
regulated,O,O
at,O,O
the,O,O
transcriptional,O,O
level,O,O
.,O,O
We,O,O
used,O,O
an,O,O
adenoviral,O,O
technique,O,O
of,O,O
blocking,O,O
NF,B,B
-,I,I
kappaB,I,I
through,O,O
overexpression,O,O
of,O,O
the,O,O
inhibitory,B,O
subunit,I,O
IkappaBalpha,B,O
",",O,O
which,O,O
has,O,O
the,O,O
advantage,O,O
that,O,O
it,O,O
can,O,O
be,O,O
used,O,O
in,O,O
the,O,O
diseased,O,O
tissue,O,O
itself,O,O
",",O,O
with,O,O
>,O,O
90,O,O
%,O,O
of,O,O
the,O,O
synovial,O,O
macrophages,O,O
",",O,O
fibroblasts,O,O
",",O,O
and,O,O
T,O,O
cells,O,O
infected,O,O
.,O,O
Of,O,O
even,O,O
more,O,O
interest,O,O
",",O,O
IkappaBalpha,B,O
overexpression,O,O
inhibited,O,O
the,O,O
production,O,O
of,O,O
matrix,B,O
metalloproteinases,I,B
1,I,I
and,I,O
3,I,I
while,O,O
not,O,O
affecting,O,O
their,O,O
tissue,O,O
inhibitor,O,O
.,O,O
This,O,O
finding,O,O
may,O,O
provide,O,O
a,O,O
tool,O,O
to,O,O
improve,O,O
current,O,O
protocols,O,O
of,O,O
immunotherapy,O,O
and,O,O
insights,O,O
to,O,O
how,O,O
tumor,O,O
cells,O,O
are,O,O
or,O,O
are,O,O
not,O,O
killed,O,O
by,O,O
LAK,O,O
cells,O,O
.,O,O
Clonality,O,O
analysis,O,O
utilizing,O,O
X,B,B
-,I,I
chromosome,I,I
inactivation,O,I
has,O,O
been,O,O
used,O,O
in,O,O
the,O,O
study,O,O
of,O,O
various,O,O
diseases,O,O
",",O,O
including,O,O
hematological,O,O
malignancies,O,O
.,O,O
One,O,O
problem,O,O
in,O,O
using,O,O
these,O,O
clonality,O,O
methods,O,O
",",O,O
however,O,O
",",O,O
is,O,O
that,O,O
there,O,O
may,O,O
be,O,O
significant,O,O
variation,O,O
in,O,O
Lyonization,O,O
in,O,O
blood,O,O
cells,O,O
in,O,O
normal,O,O
individuals,O,O
.,O,O
We,O,O
also,O,O
found,O,O
that,O,O
the,O,O
deviation,O,O
of,O,O
methylation,O,O
in,O,O
granulocytes,O,B
and,O,O
T,O,B
cells,O,I
was,O,O
well,O,O
correlated,O,O
.,O,O
Thus,O,O
",",O,O
we,O,O
conclude,O,O
that,O,O
appropriate,O,O
controls,O,O
from,O,O
the,O,O
same,O,O
individuals,O,O
",",O,O
such,O,O
as,O,O
T,O,B
cells,O,I
in,O,O
the,O,O
case,O,O
of,O,O
stem,O,O
cell,O,O
disorders,O,O
",",O,O
should,O,O
always,O,O
be,O,O
employed,O,O
to,O,O
conclusively,O,O
determine,O,O
whether,O,O
certain,O,O
cells,O,O
of,O,O
hematopoietic,O,O
origin,O,O
are,O,O
clonal,O,O
.,O,O
A,O,O
high,O,O
expression,O,O
of,O,O
WT1,B,B
has,O,O
been,O,O
detected,O,O
in,O,O
a,O,O
range,O,O
of,O,O
acute,O,O
leukemias,O,O
",",O,O
and,O,O
WT1,B,B
is,O,O
downregulated,O,O
during,O,O
induced,O,O
differentiation,O,O
of,O,O
some,O,O
leukemic,O,O
cell,O,O
lines,O,O
.,O,O
K562,O,O
cells,O,O
express,O,O
endogenous,O,O
WT1,B,B
",",O,O
which,O,O
is,O,O
downregulated,O,O
as,O,O
a,O,O
response,O,O
to,O,O
induced,O,O
differentiation,O,O
along,O,O
the,O,O
erythroid,O,B
and,O,O
megakaryocytic,O,B
pathways,O,O
.,O,O
However,O,O
",",O,O
activation,O,O
of,O,O
STAT6,B,O
",",O,O
CD23,B,B
expression,O,O
",",O,O
and,O,O
IgE,B,B
synthesis,O,O
induced,O,O
by,O,O
IL,B,B
-,I,I
4,I,I
were,O,O
not,O,O
affected,O,O
in,O,O
p47phox,O,O
-,O,O
deficient,O,O
patients,O,O
",",O,O
which,O,O
raises,O,O
the,O,O
possibility,O,O
that,O,O
p47phox,O,O
may,O,O
be,O,O
important,O,O
in,O,O
other,O,O
signaling,O,O
activities,O,O
as,O,O
well,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
METHODS,O,O
:,O,O
Protein,O,B
production,O,O
in,O,O
supernatants,O,O
was,O,O
assessed,O,O
by,O,O
ELISA,O,O
",",O,O
and,O,O
mRNA,B,B
expression,O,O
was,O,O
evaluated,O,O
by,O,O
semiquantitative,O,O
RT,O,B
-,O,I
PCR,O,I
.,O,O
On,O,O
the,O,O
contrary,O,O
",",O,O
the,O,O
release,O,O
of,O,O
MCP,B,B
-,I,I
1,I,I
was,O,O
significantly,O,O
inhibited,O,O
",",O,O
also,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
Messenger,B,O
RNA,I,B
production,O,O
coding,O,O
for,O,O
IL,B,B
-,I,I
8,I,I
",",O,O
RANTES,B,B
",",O,O
and,O,O
MCP,B,B
-,I,I
1,I,I
showed,O,O
parallel,O,O
variations,O,O
to,O,O
the,O,O
production,O,O
of,O,O
the,O,O
correspondent,B,O
proteins,I,O
.,O,O
Furthermore,O,O
",",O,O
SLP,B,B
-,I,I
76,I,I
and,O,O
Vav,B,B
have,O,O
a,O,O
synergistic,O,O
effect,O,O
on,O,O
interleukin,B,B
(,I,I
IL,I,I
),I,I
-,I,I
2,I,I
promoter,I,O
activity,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
Surprisingly,O,O
",",O,O
we,O,O
find,O,O
also,O,O
that,O,O
the,O,O
interaction,O,O
between,O,O
SLP,B,O
-,I,O
76,I,O
and,O,O
Vav,B,O
is,O,O
not,O,O
required,O,O
for,O,O
their,O,O
cooperation,O,O
in,O,O
augmenting,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
activity,O,O
",",O,O
as,O,O
the,O,O
two,O,O
molecules,O,O
appear,O,O
to,O,O
function,O,O
in,O,O
different,O,O
signaling,O,O
pathways,O,O
upstream,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
expression,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
overexpression,O,O
of,O,O
Vav,B,O
leads,O,O
to,O,O
enhanced,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
activity,O,O
without,O,O
affecting,O,O
AP,B,B
-,I,I
1,I,I
.,O,O
Additionally,O,O
",",O,O
overexpression,O,O
of,O,O
Vav,B,O
",",O,O
but,O,O
not,O,O
SLP,B,O
-,I,O
76,I,O
",",O,O
augments,O,O
CD28,O,O
-,O,O
induced,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
activity,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
show,O,O
that,O,O
Jagged1,B,O
is,O,O
a,O,O
Rel,B,O
/,I,O
NF,I,O
-,I,O
kappaB,I,O
-,I,O
responsive,I,O
gene,I,O
.,O,O
This,O,O
correlated,O,O
with,O,O
the,O,O
initiation,O,O
of,O,O
signaling,O,O
downstream,O,O
of,O,O
Notch,O,O
",",O,O
as,O,O
evidenced,O,O
by,O,O
increased,O,O
levels,O,O
of,O,O
HES,B,O
-,I,O
1,I,O
transcripts,I,O
in,O,O
co,O,O
-,O,O
cultivated,O,O
T,O,O
cells,O,O
and,O,O
of,O,O
CD23,B,O
transcripts,I,O
in,O,O
co,O,O
-,O,O
cultivated,O,O
B,O,O
cells,O,O
.,O,O
Our,O,O
results,O,O
demonstrated,O,O
that,O,O
:,O,O
(,O,O
i,O,O
),O,O
PGN,O,O
induced,O,O
phosphorylation,O,O
of,O,O
the,O,O
transcription,B,O
factors,I,O
ATF,B,B
-,I,I
1,I,I
and,O,O
CREB,B,B
;,O,O
(,O,O
ii,O,O
),O,O
ATF,B,B
-,I,I
1,I,I
and,O,O
CREB,B,B
bound,O,O
DNA,O,B
as,O,O
a,O,O
dimer,O,O
and,O,O
induced,O,O
transcriptional,O,O
activation,O,O
of,O,O
a,O,O
CRE,B,O
reporter,I,O
plasmid,I,O
",",O,O
which,O,O
was,O,O
inhibited,O,O
by,O,O
dominant,O,O
negative,O,O
CREB,B,B
and,O,O
ATF,B,B
-,I,I
1,I,I
;,O,O
(,O,O
iii,O,O
),O,O
PGN,O,O
induced,O,O
phosphorylation,O,O
of,O,O
c,B,O
-,I,O
Jun,I,B
",",O,O
protein,O,O
synthesis,O,O
of,O,O
JunB,B,B
and,O,O
c,B,O
-,I,O
Fos,I,B
",",O,O
and,O,O
transcriptional,O,O
activation,O,O
of,O,O
the,O,O
AP,B,O
-,I,O
1,I,O
reporter,I,O
plasmid,I,O
",",O,O
which,O,O
was,O,O
inhibited,O,O
by,O,O
dominant,O,O
negative,O,O
c,B,O
-,I,O
Fos,I,B
;,O,O
and,O,O
(,O,O
iv,O,O
),O,O
PGN,O,O
-,O,O
induced,O,O
activation,O,O
of,O,O
CREB,B,B
/,I,O
ATF,I,B
and,O,O
AP,B,O
-,I,O
1,I,O
was,O,O
mediated,O,O
through,O,O
CD14,B,O
.,O,O
In,O,O
contrast,O,O
to,O,O
these,O,O
findings,O,O
",",O,O
mucosal,O,O
hGR,B,B
levels,O,O
were,O,O
significantly,O,O
decreased,O,O
in,O,O
both,O,O
steroid,O,B
-,O,I
treated,O,I
(,O,O
18,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
15,O,O
.,O,O
5,O,O
),O,O
and,O,O
not,O,O
steroid,O,B
-,O,I
treated,O,I
(,O,O
37,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
30,O,O
.,O,O
5,O,O
),O,O
patients,O,O
compared,O,O
with,O,O
control,O,O
subjects,O,O
(,O,O
125,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
97,O,O
.,O,O
1,O,O
;,O,O
P,O,O
0,O,O
.,O,O
and,O,O
P,O,O
0,O,O
.,O,O
respectively,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
created,O,O
transgenic,O,O
mice,O,O
overexpressing,O,O
ICSAT,B,O
in,O,O
lymphocytes,O,O
.,O,O
Altered,O,O
memory,O,O
T,O,B
cell,O,I
differentiation,O,O
in,O,O
patients,O,O
with,O,O
early,O,O
rheumatoid,O,O
arthritis,O,O
.,O,O
A,O,O
cell,O,O
culture,O,O
system,O,O
was,O,O
then,O,O
employed,O,O
that,O,O
permitted,O,O
the,O,O
differentiation,O,O
of,O,O
Th,B,B
effectors,I,I
from,O,O
resting,O,O
memory,O,O
T,O,B
cells,O,I
by,O,O
short,O,O
term,O,O
priming,O,O
.,O,O
Our,O,O
findings,O,O
offer,O,O
important,O,O
insights,O,O
into,O,O
parasite,O,O
survival,O,O
strategies,O,O
and,O,O
demonstrate,O,O
that,O,O
parasite,O,O
-,O,O
induced,O,O
constitutive,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
is,O,O
an,O,O
essential,O,O
step,O,O
in,O,O
maintaining,O,O
the,O,O
transformed,O,O
phenotype,O,O
of,O,O
the,O,O
infected,O,O
cells,O,O
.,O,O
A,O,O
polymorphism,O,O
that,O,O
affects,O,O
OCT,B,O
-,I,O
1,I,O
binding,O,O
to,O,O
the,O,O
TNF,B,B
promoter,I,I
region,I,I
is,O,O
associated,O,O
with,O,O
severe,O,O
malaria,O,O
[,O,O
see,O,O
comments,O,O
],O,O
The,O,O
results,O,O
show,O,O
that,O,O
the,O,O
CYP1A1,B,B
mRNA,I,I
level,O,I
induced,O,O
by,O,O
UV,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
tryptophan,O,O
was,O,O
higher,O,O
than,O,O
that,O,O
induced,O,O
by,O,O
UV,O,O
alone,O,O
in,O,O
both,O,O
HaCaT,O,O
cells,O,O
and,O,O
lymphocytes,O,O
after,O,O
3,O,O
h,O,O
of,O,O
incubation,O,O
post,O,O
-,O,O
UV,O,O
irradiation,O,O
.,O,O
Wild,O,O
-,O,O
type,O,O
(,O,O
wt,O,O
),O,O
cells,O,O
were,O,O
inducible,O,O
either,O,O
by,O,O
the,O,O
tryptophan,O,B
photoproduct,O,I
6,O,I
-,O,I
formylindolo,O,I
[,O,I
3,O,I
",",O,I
2,O,I
-,O,I
b,O,I
],O,I
carbazole,O,I
(,O,O
FICZ,O,O
),O,O
or,O,O
by,O,O
UV,O,B
-,O,I
irradiation,O,I
but,O,O
very,O,O
low,O,O
or,O,O
undetectable,O,O
levels,O,O
were,O,O
observed,O,O
in,O,O
the,O,O
c12,O,O
cells,O,O
.,O,O
This,O,O
shows,O,O
that,O,O
the,O,O
induction,O,O
of,O,O
gene,O,O
expression,O,O
by,O,O
FICZ,O,O
and,O,O
UV,O,B
is,O,O
Ah,B,B
receptor,I,I
dependent,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
photoproducts,O,O
of,O,O
tryptophan,O,B
are,O,O
suggested,O,O
to,O,O
be,O,O
mediators,O,O
of,O,O
light,O,O
via,O,O
binding,O,O
to,O,O
the,O,O
Ah,B,B
receptor,I,I
and,O,O
as,O,O
such,O,O
also,O,O
could,O,O
have,O,O
a,O,O
role,O,O
in,O,O
light,O,O
-,O,O
regulated,O,O
biological,O,O
rhythms,O,O
.,O,O
Repression,O,O
by,O,O
Ikaros,B,O
and,O,O
Aiolos,B,O
is,O,O
mediated,O,O
through,O,O
histone,B,B
deacetylase,I,I
complexes,I,I
.,O,O
To,O,O
better,O,O
understand,O,O
signals,O,O
controlling,O,O
proliferation,O,O
and,O,O
viability,O,O
",",O,O
erythroid,O,B
cells,O,I
that,O,O
resist,O,O
apoptosis,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
EPO,B,O
were,O,O
subcloned,O,O
and,O,O
characterized,O,O
(,O,O
HCD57,O,O
-,O,O
SREI,O,O
cells,O,O
),O,O
.,O,O
Enforced,O,O
expression,O,O
of,O,O
Id3,B,B
",",O,O
which,O,O
has,O,O
the,O,O
capacity,O,O
to,O,O
inhibit,O,O
many,O,O
basic,B,O
helix,I,O
-,I,O
loop,I,O
-,I,O
helix,I,O
(,I,O
bHLH,I,O
),I,O
transcription,I,O
factors,I,O
",",O,O
in,O,O
human,O,O
CD34,O,O
(,O,O
+,O,O
),O,O
hematopoietic,O,O
progenitor,O,O
cells,O,O
that,O,O
have,O,O
not,O,O
undergone,O,O
T,B,O
cell,I,O
receptor,I,O
(,I,O
TCR,I,O
),I,O
gene,I,O
rearrangements,I,O
inhibits,O,O
development,O,O
of,O,O
the,O,O
transduced,O,O
cells,O,O
into,O,O
TCRalpha,O,O
beta,O,O
and,O,O
gamma,O,O
delta,O,O
cells,O,O
in,O,O
a,O,O
fetal,O,O
thymic,O,O
organ,O,O
culture,O,O
(,O,O
FTOC,O,O
),O,O
.,O,O
These,O,O
cells,O,O
had,O,O
properties,O,O
of,O,O
both,O,O
natural,O,B
killer,O,I
(,O,O
NK,O,O
),O,O
and,O,O
pre,O,B
-,O,I
T,O,I
cells,O,O
.,O,O
HIV,O,B
-,O,I
1,O,I
reactivation,O,O
in,O,O
resting,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
of,O,O
infected,O,O
adults,O,O
upon,O,O
in,O,O
vitro,O,O
CD4,B,B
cross,O,O
-,O,O
linking,O,O
by,O,O
ligands,O,O
of,O,O
the,O,O
CDR2,B,O
-,I,O
loop,I,O
in,O,O
extracellular,B,O
domain,I,O
1,I,O
.,O,O
Additionally,O,O
",",O,O
virus,O,O
reactivation,O,O
in,O,O
resting,O,O
PBMCs,O,O
infected,O,O
in,O,O
vitro,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
was,O,O
found,O,O
to,O,O
be,O,O
specifically,O,O
induced,O,O
by,O,O
ligands,O,O
of,O,O
the,O,O
CDR2,B,O
-,I,O
loop,I,O
in,O,O
domain,B,O
1,I,O
(,O,O
D1,B,O
),O,O
of,O,O
CD4,B,B
(,O,O
virus,B,O
envelope,I,O
and,I,O
anti,I,O
-,I,O
CD4,I,O
monoclonal,I,O
antibodies,I,O
),O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
virus,O,O
reactivation,O,O
was,O,O
not,O,O
observed,O,O
following,O,O
CD4,B,B
oligomerization,O,O
by,O,O
antibodies,B,O
that,O,O
bind,O,O
other,O,O
epitopes,O,O
in,O,O
D1,B,O
",",O,O
including,O,O
the,O,O
D1,B,O
/,I,O
CDR3,I,O
-,I,O
loop,I,O
.,O,O
Our,O,O
results,O,O
indicate,O,O
that,O,O
the,O,O
signaling,O,O
events,O,O
initiated,O,O
in,O,O
PBMCs,O,O
by,O,O
oligomerization,O,O
of,O,O
CD4,B,B
at,O,O
the,O,O
D1,B,O
/,I,O
CDR2,I,O
-,I,O
loop,I,O
can,O,O
trigger,O,O
HIV,O,B
-,O,I
1,O,I
upregulation,O,O
in,O,O
infected,O,O
individuals,O,O
.,O,O
Signaling,O,O
through,O,O
the,O,O
lymphotoxin,B,B
-,I,I
beta,I,I
receptor,I,I
stimulates,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
alone,O,O
and,O,O
in,O,O
cooperation,O,O
with,O,O
soluble,O,O
or,O,O
membrane,B,O
-,I,O
bound,I,O
TNF,I,B
-,I,I
alpha,I,I
.,O,O
The,O,O
level,O,O
of,O,O
ongoing,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
within,O,O
an,O,O
individual,O,O
is,O,O
critical,O,O
to,O,O
HIV,O,B
-,O,I
1,O,I
pathogenesis,O,O
.,O,O
Given,O,O
the,O,O
critical,O,O
role,O,O
that,O,O
LT,B,B
-,I,I
alpha1beta2,I,I
plays,O,O
in,O,O
lymphoid,O,O
architecture,O,O
",",O,O
we,O,O
speculate,O,O
that,O,O
LT,B,B
-,I,I
alpha1beta2,I,I
may,O,O
be,O,O
involved,O,O
in,O,O
HIV,O,B
-,O,I
associated,O,I
abnormalities,O,I
of,O,O
the,O,O
lymphoid,O,O
organs,O,O
.,O,O
The,O,O
secretion,O,O
levels,O,O
of,O,O
interleukin,B,B
-,I,I
6,I,I
(,O,O
IL,B,O
-,I,O
6,I,O
),O,O
and,O,O
von,O,B
Willebrand,O,I
factor,O,I
(,O,O
vWF,O,O
),O,O
were,O,O
determined,O,O
",",O,O
to,O,O
serve,O,O
as,O,O
markers,O,O
for,O,O
EC,O,O
activation,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
nuclear,O,O
extracts,O,O
of,O,O
the,O,O
mAECA,O,O
-,O,O
treated,O,O
EC,O,O
were,O,O
analyzed,O,O
for,O,O
the,O,O
induction,O,O
of,O,O
translocation,O,O
of,O,O
nuclear,B,O
factor,I,O
kappaB,I,O
(,O,O
NF,B,B
-,I,I
kappaB,I,I
),O,O
",",O,O
using,O,O
a,O,O
specific,O,O
NF,B,O
-,I,O
kappaB,I,O
oligoprobe,O,O
in,O,O
an,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
.,O,O
The,O,O
mAECA,B,B
",",O,O
but,O,O
not,O,O
normal,B,O
human,I,B
IgG,I,I
",",O,O
had,O,O
anti,O,O
-,O,O
human,O,B
aortic,O,I
EC,O,I
activity,O,O
.,O,O
Four,O,O
of,O,O
the,O,O
6,O,O
mAECA,B,B
activated,O,O
EC,O,B
",",O,O
manifested,O,O
by,O,O
increased,O,O
IL,B,B
-,I,I
6,I,I
and,O,O
vWF,O,B
secretion,O,O
.,O,O
However,O,O
NF,B,B
-,I,I
ATs,I,I
appear,O,O
in,O,O
the,O,O
nuclei,O,O
of,O,O
IL,O,B
-,O,I
4,O,I
-,O,I
",",O,O
IL,O,B
-,O,I
5,O,I
-,O,I
",",O,O
or,O,O
ionomycin,O,B
-,O,I
stimulated,O,O
eosinophils,O,O
.,O,O
Both,O,O
PPARalpha,B,B
activators,O,O
decreased,O,O
cytokine,O,O
-,O,O
induced,O,O
VCAM,B,B
-,I,I
1,I,I
mRNA,O,I
expression,O,O
without,O,O
altering,O,O
its,O,O
mRNA,O,O
half,O,O
-,O,O
life,O,O
.,O,O
Such,O,O
findings,O,O
also,O,O
have,O,O
implications,O,O
regarding,O,O
the,O,O
clinical,O,O
use,O,O
of,O,O
lipid,O,O
-,O,O
lowering,O,O
agents,O,O
",",O,O
like,O,O
fibric,O,O
acids,O,O
",",O,O
which,O,O
can,O,O
activate,O,O
PPARalpha,B,B
.,O,O
CBP,B,O
/,I,O
p300,I,O
integrates,O,O
Raf,B,O
/,O,O
Rac,B,O
-,O,O
signaling,O,O
pathways,O,O
in,O,O
the,O,O
transcriptional,O,O
induction,O,O
of,O,O
NF,B,B
-,I,I
ATc,I,I
during,O,O
T,O,O
cell,O,O
activation,O,O
.,O,O
We,O,O
have,O,O
carried,O,O
out,O,O
a,O,O
detailed,O,O
analysis,O,O
of,O,O
the,O,O
cellular,O,O
immune,O,O
functions,O,O
of,O,O
breast,O,B
cancer,O,I
patients,O,O
in,O,O
comparison,O,O
with,O,O
healthy,O,O
controls,O,O
.,O,O
Inhibition,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
has,O,O
been,O,O
achieved,O,O
by,O,O
pharmacological,O,O
and,O,O
genetic,O,O
approaches,O,O
;,O,O
however,O,O
",",O,O
monocyte,O,O
interactions,O,O
with,O,O
activated,O,O
endothelium,O,O
in,O,O
shear,O,O
flow,O,O
following,O,O
gene,O,O
transfer,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
inhibitor,O,O
IkappaB,B,O
-,I,O
alpha,I,O
have,O,O
not,O,O
been,O,O
studied,O,O
.,O,O
This,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
reduction,O,O
in,O,O
endothelial,O,O
MCP,B,B
-,I,I
1,I,I
secretion,O,O
and,O,O
GRO,B,B
-,I,I
alpha,I,I
immobilization,O,O
.,O,O
Adhesion,O,O
assays,O,O
under,O,O
physiological,O,O
shear,O,O
flow,O,O
conditions,O,O
showed,O,O
that,O,O
firm,O,O
arrest,O,O
",",O,O
spreading,O,O
",",O,O
and,O,O
transmigration,O,O
of,O,O
monocytes,O,O
on,O,O
TNF,B,B
-,I,I
alpha,I,I
-,O,I
activated,O,I
endothelium,O,O
was,O,O
markedly,O,O
inhibited,O,O
by,O,O
IkappaB,B,B
-,I,I
alpha,I,I
overexpression,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
rolling,O,O
of,O,O
monocytes,O,O
was,O,O
increased,O,O
by,O,O
IkappaB,B,B
-,I,I
alpha,I,I
transfer,O,O
and,O,O
was,O,O
partly,O,O
mediated,O,O
by,O,O
P,B,B
-,I,I
selectin,I,I
;,O,O
however,O,O
",",O,O
it,O,O
appeared,O,O
to,O,O
be,O,O
unaffected,O,O
by,O,O
the,O,O
inhibition,O,O
of,O,O
E,B,B
-,I,I
selectin,I,I
induction,O,O
.,O,O
Copyright,O,O
1999,O,O
Academic,O,O
Press,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
oestrogens,O,B
on,O,O
oestrogen,O,O
-,O,O
receptive,O,O
organs,O,O
and,O,O
cells,O,O
is,O,O
mediated,O,O
via,O,O
intracellular,B,O
receptors,I,O
(,O,O
ERalpha,B,B
and,O,O
ERbeta,B,B
),O,O
.,O,O
All,O,O
tissues,O,O
and,O,O
cells,O,O
studied,O,O
were,O,O
homozygous,O,O
for,O,O
the,O,O
wild,B,O
-,I,O
type,I,O
gene,I,O
",",O,O
and,O,O
were,O,O
heterozygous,O,O
as,O,O
well,O,O
as,O,O
homozygous,O,O
for,O,O
the,O,O
codon,B,O
-,I,O
10,I,O
-,I,O
variant,I,O
type,I,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
codon,B,O
-,I,O
10,I,O
-,I,O
variant,I,O
type,I,O
is,O,O
not,O,O
a,O,O
characteristic,O,O
of,O,O
breast,O,B
cancer,O,I
.,O,O
USF,B,O
/,I,O
c,I,O
-,I,O
Myc,I,O
enhances,O,O
",",O,O
while,O,O
Yin,B,O
-,I,O
Yang,I,O
1,I,O
suppresses,O,O
",",O,O
the,O,O
promoter,O,O
activity,O,O
of,O,O
CXCR4,B,B
",",O,O
a,O,O
coreceptor,B,O
for,O,O
HIV,O,B
-,O,I
1,O,I
entry,O,O
.,O,O
We,O,O
have,O,O
identified,O,O
an,O,O
E,B,B
box,I,I
around,O,O
-,B,O
260,I,O
and,O,O
a,O,O
YY1,B,B
binding,I,I
site,I,I
around,O,O
-,B,O
300,I,O
relative,O,O
to,O,O
the,O,O
transcription,B,O
start,I,O
site,I,O
.,O,O
RCC,O,O
-,O,O
S,O,O
did,O,O
not,O,O
alter,O,O
the,O,O
cytoplasmic,O,O
levels,O,O
of,O,O
RelA,B,B
and,O,O
NF,B,B
-,I,I
kappaB1,I,I
but,O,O
did,O,O
suppress,O,O
their,O,O
nuclear,O,O
localization,O,O
and,O,O
inhibited,O,O
the,O,O
activation,O,O
of,O,O
RelA,B,B
/,I,O
NF,I,B
-,I,I
kappaB1,I,I
binding,I,O
complexes,I,O
.,O,O
These,O,O
results,O,O
show,O,O
that,O,O
RCC,O,O
-,O,O
S,O,O
can,O,O
induce,O,O
in,O,O
normal,O,O
T,O,O
cells,O,O
the,O,O
same,O,O
phenotype,O,O
of,O,O
impaired,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
that,O,O
is,O,O
detected,O,O
in,O,O
T,O,O
cells,O,O
of,O,O
RCC,O,O
patient,O,O
.,O,O
Human,O,B
monocytes,O,O
isolated,O,O
from,O,O
peripheral,O,O
blood,O,O
of,O,O
healthy,O,O
donors,O,O
show,O,O
a,O,O
time,O,O
-,O,O
dependent,O,O
differentiation,O,O
into,O,O
macrophages,O,O
upon,O,O
in,O,O
vitro,O,O
cultivation,O,O
",",O,O
closely,O,O
mimicking,O,O
their,O,O
in,O,O
vivo,O,O
migration,O,O
and,O,O
maturation,O,O
into,O,O
extravascular,O,O
tissues,O,O
.,O,O
The,O,O
mediator,O,O
(,O,O
s,O,O
),O,O
of,O,O
this,O,O
maturation,O,O
process,O,O
has,O,O
not,O,O
been,O,O
yet,O,O
defined,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
involvement,O,O
of,O,O
signal,B,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
(,I,O
STAT,I,B
),I,O
factors,I,O
in,O,O
this,O,O
phenomenon,O,O
and,O,O
reported,O,O
the,O,O
specific,O,O
",",O,O
time,O,O
-,O,O
dependent,O,O
",",O,O
activation,O,O
of,O,O
STAT1,B,B
protein,O,O
starting,O,O
at,O,O
day,O,O
0,O,O
/,O,O
1,O,O
of,O,O
cultivation,O,O
and,O,O
maximally,O,O
expressed,O,O
at,O,O
day,O,O
5,O,O
.,O,O
STAT1,B,B
activity,O,O
was,O,O
evident,O,O
on,O,O
the,O,O
STAT,B,B
binding,I,O
sequences,I,O
(,O,O
SBE,B,O
),O,O
present,O,O
in,O,O
the,O,O
promoters,B,O
of,O,O
genes,O,O
which,O,O
are,O,O
up,O,O
-,O,O
regulated,O,O
during,O,O
monocyte,O,O
to,O,O
macrophage,O,O
maturation,O,O
such,O,O
as,O,O
FcgammaRI,B,O
and,O,O
ICAM,B,O
-,I,O
1,I,O
",",O,O
and,O,O
in,O,O
the,O,O
promoter,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
IFN,I,B
regulatory,I,I
factor,I,I
-,I,I
1,I,I
.,O,O
Compared,O,O
with,O,O
monocytes,O,O
adherent,O,O
on,O,O
plastic,O,O
surfaces,O,O
",",O,O
freshly,O,O
isolated,O,O
cells,O,O
allowed,O,O
to,O,O
adhere,O,O
either,O,O
to,O,O
fibronectin,O,O
-,O,O
or,O,O
laminin,O,O
-,O,O
coated,O,O
flasks,O,O
exhibited,O,O
an,O,O
increased,O,O
STAT1,B,B
binding,O,O
activity,O,O
both,O,O
in,O,O
control,O,O
and,O,O
in,O,O
IFN,O,B
-,O,I
gamma,O,I
-,O,I
treated,O,O
cells,O,O
.,O,O
Thereafter,O,O
",",O,O
PML,B,O
is,O,O
downmodulated,O,O
in,O,O
late,O,O
granulocytic,O,O
maturation,O,O
",",O,O
whereas,O,O
it,O,O
is,O,O
sustainably,O,O
expressed,O,O
through,O,O
the,O,O
erythroid,O,O
pathway,O,O
.,O,O
Furthermore,O,O
",",O,O
PML,B,B
and,O,O
pRb,B,B
105,I,O
were,O,O
co,O,O
-,O,O
immunoprecipitated,O,O
in,O,O
cellular,O,O
lysates,O,O
derived,O,O
from,O,O
erythroid,O,B
precursors,O,O
indicating,O,O
that,O,O
this,O,O
functional,O,O
interaction,O,O
may,O,O
have,O,O
a,O,O
biochemical,O,O
basis,O,O
.,O,O
Endogenous,O,O
and,O,O
therapeutic,O,O
steroid,O,B
hormones,O,I
affect,O,O
the,O,O
immune,O,O
system,O,O
",",O,O
and,O,O
inflammatory,O,O
diseases,O,O
are,O,O
associated,O,O
with,O,O
activation,O,O
of,O,O
the,O,O
hypothalamic,O,O
-,O,O
pituitary,O,O
-,O,O
adrenal,O,O
axis,O,O
",",O,O
providing,O,O
evidence,O,O
of,O,O
an,O,O
immune,O,O
-,O,O
endocrine,O,O
interplay,O,O
.,O,O
No,O,O
effect,O,O
of,O,O
age,O,O
",",O,O
sex,O,O
",",O,O
course,O,O
",",O,O
duration,O,O
or,O,O
severity,O,O
of,O,O
disease,O,O
",",O,O
or,O,O
prior,O,O
steroid,O,B
treatments,O,I
was,O,O
detected,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
the,O,O
physiological,O,O
relationship,O,O
between,O,O
binding,O,O
and,O,O
function,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
is,O,O
disturbed,O,O
in,O,O
MS,O,O
.,O,O
Treatment,O,O
of,O,O
cells,O,O
with,O,O
PD98059,O,O
",",O,O
a,O,O
specific,O,O
inhibitor,O,O
of,O,O
mitogen,B,B
-,I,I
activated,I,I
protein,I,I
kinase,I,I
kinase,I,I
(,O,O
MEK,B,O
),O,O
",",O,O
inhibited,O,O
TPA,O,O
-,O,O
induced,O,O
ERK2,B,O
activity,O,O
.,O,O
METHODS,O,O
:,O,O
Twenty,O,O
-,O,O
two,O,O
patients,O,O
with,O,O
severe,O,O
restrictive,O,O
anorexia,O,O
nervosa,O,O
",",O,O
10,O,O
patients,O,O
with,O,O
active,O,O
Cushing,O,O
s,O,O
disease,O,O
",",O,O
and,O,O
24,O,O
healthy,O,O
volunteers,O,O
without,O,O
psychiatric,O,O
disorders,O,O
or,O,O
mood,O,O
alterations,O,O
were,O,O
investigated,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
number,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
on,O,O
mononuclear,O,O
leukocytes,O,O
(,O,O
MNL,O,O
),O,O
was,O,O
comparable,O,O
in,O,O
patients,O,O
with,O,O
anorexia,O,O
nervosa,O,O
",",O,O
patients,O,O
with,O,O
active,O,O
Cushing,O,O
s,O,O
disease,O,O
",",O,O
and,O,O
normal,O,O
subjects,O,O
(,O,O
binding,O,O
capacity,O,O
3,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
23,O,O
vs,O,O
.,O,O
3,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
30,O,O
and,O,O
3,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
20,O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
6,O,O
),O,O
cells,O,O
),O,O
In,O,O
patients,O,O
with,O,O
anorexia,O,O
nervosa,O,O
",",O,O
the,O,O
incorporation,O,O
of,O,O
[,O,O
3H,O,B
],O,I
thymidine,O,I
into,O,O
the,O,O
MNL,O,O
was,O,O
inversely,O,O
correlated,O,O
with,O,O
urinary,O,O
free,O,O
cortisol,O,O
levels,O,O
.,O,O
Different,O,O
sequence,O,O
requirements,O,O
for,O,O
expression,O,O
in,O,O
erythroid,O,B
and,O,O
megakaryocytic,O,B
cells,O,O
within,O,O
a,O,O
regulatory,B,O
element,I,O
upstream,O,O
of,O,O
the,O,O
GATA,B,O
-,I,O
1,I,O
gene,I,O
.,O,O
We,O,O
have,O,O
localized,O,O
a,O,O
317,O,O
base,O,O
pair,O,O
cis,B,O
-,I,O
acting,I,O
regulatory,I,O
element,I,O
",",O,O
HS,B,O
I,I,O
",",O,O
associated,O,O
with,O,O
a,O,O
hematopoietic,B,O
-,I,O
specific,I,O
DNase,I,B
I,I,I
hypersensitive,I,I
site,I,I
",",O,O
which,O,O
lies,O,O
approx,O,O
.,O,O
This,O,O
core,O,O
contains,O,O
a,O,O
GATA,B,B
site,I,I
separated,O,O
by,O,O
10,O,O
base,O,O
pairs,O,O
from,O,O
an,O,O
E,B,B
-,I,I
box,I,I
motif,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
sodium,O,O
salicylate,O,O
and,O,O
additional,O,O
NSAIDs,O,O
used,O,O
at,O,O
concentrations,O,O
that,O,O
activate,O,O
HSF1,B,O
also,O,O
inhibited,O,O
the,O,O
expression,O,O
of,O,O
other,O,O
monocytic,B,O
genes,I,O
(,O,O
TNF,B,B
-,I,I
alpha,I,I
",",O,O
IL,B,B
-,I,I
1beta,I,I
",",O,O
IL,B,B
-,I,I
6,I,I
",",O,O
IL,B,B
-,I,I
8,I,I
",",O,O
IL,B,B
-,I,I
10,I,I
",",O,O
ICAM,B,B
-,I,I
1,I,I
),O,O
activated,O,O
by,O,O
exposure,O,O
to,O,O
a,O,O
pro,O,O
-,O,O
inflammatory,O,O
stimulus,O,O
(,O,O
lipopolysaccharide,O,O
",",O,O
LPS,O,O
),O,O
.,O,O
Copyright,O,O
1999,O,O
Academic,O,O
Press,O,O
.,O,O
Fibroblast,B,B
growth,I,I
factors,I,I
(,O,O
FGFs,B,O
),O,O
are,O,O
heparin,B,O
-,I,O
binding,I,O
proteins,I,O
crucial,O,O
to,O,O
embryogenesis,O,O
",",O,O
angiogenesis,O,O
",",O,O
and,O,O
wound,O,O
healing,O,O
.,O,O
FGF,B,B
-,I,I
1,I,I
is,O,O
abundantly,O,O
expressed,O,O
in,O,O
the,O,O
synovium,O,O
in,O,O
rheumatoid,O,O
arthritis,O,O
and,O,O
in,O,O
rejecting,O,O
allografts,O,O
",",O,O
sites,O,O
of,O,O
chronic,O,O
immune,O,O
-,O,O
mediated,O,O
inflammation,O,O
.,O,O
In,O,O
this,O,O
paper,O,O
",",O,O
we,O,O
show,O,O
that,O,O
HCMV,O,O
down,O,O
regulates,O,O
gamma,O,B
interferon,O,I
(,O,I
IFN,B,I
-,I,I
gamma,I,I
),O,I
-,O,O
induced,O,O
HLA,B,B
-,I,I
DR,I,I
expression,O,O
in,O,O
U373,O,O
MG,O,O
astrocytoma,O,O
cells,O,O
due,O,O
to,O,O
a,O,O
defect,O,O
downstream,O,O
of,O,O
STAT1,B,O
phosphorylation,O,O
and,O,O
nuclear,O,O
translocation,O,O
.,O,O
Inhibition,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
transcriptional,O,I
activity,O,O
and,O,O
promotion,O,O
of,O,O
IkappaBalpha,B,O
degradation,O,O
.,O,O
DZA,O,O
inhibits,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
NF,B,B
-,I,O
kappaB,I,I
through,O,O
the,O,O
hindrance,O,O
of,O,O
p65,B,B
(,O,O
Rel,B,I
-,I,I
A,I,I
),O,O
phosphorylation,O,O
without,O,O
reduction,O,O
of,O,O
its,O,O
nuclear,O,O
translocation,O,O
and,O,O
DNA,O,B
binding,O,I
activity,O,O
.,O,O
The,O,O
inhibitory,O,O
effect,O,O
of,O,O
DZA,O,O
on,O,O
NF,B,B
-,I,O
kappaB,I,I
transcriptional,O,I
activity,O,O
is,O,O
potentiated,O,O
by,O,O
the,O,O
addition,O,O
of,O,O
homocysteine,O,O
.,O,O
Decidual,O,O
gammadelta,O,B
T,O,I
cells,O,I
",",O,O
which,O,O
significantly,O,O
increase,O,O
in,O,O
number,O,O
during,O,O
pregnancy,O,O
",",O,O
might,O,O
play,O,O
a,O,O
role,O,O
in,O,O
recognition,O,O
of,O,O
fetal,B,O
antigens,I,O
and,O,O
also,O,O
in,O,O
determining,O,O
the,O,O
quality,O,O
of,O,O
the,O,O
response,O,O
to,O,O
these,O,O
antigens,B,O
.,O,O
Here,O,O
",",O,O
we,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
Rho,B,B
in,O,O
regulating,O,O
the,O,O
distribution,O,O
of,O,O
the,O,O
monocyte,B,B
-,I,I
binding,I,I
receptors,I,I
E,B,B
-,I,I
selectin,I,I
",",O,O
ICAM,B,B
-,I,I
1,I,I
",",O,O
and,O,O
VCAM,B,B
-,I,I
1,I,I
in,O,O
human,O,B
endothelial,O,I
cells,O,I
.,O,O
C3,O,B
transferase,O,I
and,O,O
cytochalasin,O,B
D,O,I
did,O,O
not,O,O
alter,O,O
the,O,O
expression,O,O
levels,O,O
of,O,O
monocyte,B,O
-,I,O
binding,I,O
receptors,I,O
on,O,O
endothelial,O,B
cells,O,I
",",O,O
but,O,O
did,O,O
inhibit,O,O
clustering,O,O
of,O,O
E,B,B
-,I,I
selectin,I,I
",",O,O
ICAM,B,B
-,I,I
1,I,I
",",O,O
and,O,O
VCAM,B,B
-,I,I
1,I,I
on,O,O
the,O,O
cell,O,O
surface,O,O
induced,O,O
by,O,O
monocyte,O,O
adhesion,O,O
or,O,O
cross,B,O
-,I,O
linking,I,O
antibodies,I,O
.,O,O
Similarly,O,O
",",O,O
N19RhoA,B,O
inhibited,O,O
receptor,O,O
clustering,O,O
.,O,O
Finally,O,O
",",O,O
receptor,O,B
clusters,O,O
colocalized,O,O
with,O,O
ezrin,B,B
/,I,I
moesin,I,I
/,I,I
radixin,I,I
proteins,I,O
.,O,O
Although,O,O
recognized,O,O
as,O,O
fundamental,O,O
aspects,O,O
of,O,O
T,O,O
lymphocyte,O,O
development,O,O
",",O,O
only,O,O
recently,O,O
have,O,O
the,O,O
mechanisms,O,O
governing,O,O
positive,O,O
and,O,O
negative,O,O
selection,O,O
been,O,O
examined,O,O
at,O,O
a,O,O
molecular,O,O
level,O,O
.,O,O
Negative,O,O
selection,O,O
refers,O,O
to,O,O
the,O,O
deletion,O,O
or,O,O
inactivation,O,O
of,O,O
potentially,O,O
autoreactive,O,O
thymocytes,O,O
.,O,O
CD28,B,B
costimulation,O,O
augments,O,O
IL,B,B
-,I,I
2,I,I
secretion,O,O
of,O,O
activated,O,O
lamina,O,O
propria,O,O
T,O,O
cells,O,O
by,O,O
increasing,O,O
mRNA,O,B
stability,O,O
without,O,O
enhancing,O,O
IL,B,B
-,I,I
2,I,I
gene,O,O
transactivation,O,O
.,O,O
Previous,O,O
studies,O,O
have,O,O
characterized,O,O
the,O,O
CD28,B,B
augmentation,O,O
of,O,O
TCR,B,O
-,O,O
mediated,O,O
signaling,O,O
in,O,O
peripheral,O,O
blood,O,O
T,O,O
cells,O,O
through,O,O
transcriptional,O,O
activation,O,O
of,O,O
an,O,O
IL,B,B
-,I,I
2,I,I
promoter,O,O
CD28,B,B
response,I,O
element,I,O
(,O,O
CD28RE,B,O
),O,O
",",O,O
along,O,O
with,O,O
enhanced,O,O
mRNA,O,B
stability,O,O
.,O,O
LPMC,O,O
exhibited,O,O
increased,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
in,O,O
response,O,O
to,O,O
CD28,B,O
costimulation,O,O
",",O,O
compared,O,O
with,O,O
cells,O,O
activated,O,O
through,O,O
CD2,B,O
alone,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
production,O,O
of,O,O
a,O,O
Th1,B,O
cytokine,I,O
",",O,O
IFN,B,B
-,I,I
gamma,I,I
",",O,O
by,O,O
HBsAg,B,O
-,O,O
reactive,O,O
cells,O,O
was,O,O
associated,O,O
with,O,O
hepatocyte,O,O
damage,O,O
in,O,O
chronic,O,O
hepatitis,O,O
B,O,O
",",O,O
while,O,O
no,O,O
counteracting,O,O
effect,O,O
of,O,O
Th2,B,O
cytokines,I,O
produced,O,O
by,O,O
those,O,O
cells,O,O
was,O,O
observed,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Arsenic,O,B
trioxide,O,I
(,O,O
As2O3,O,O
),O,O
can,O,O
induce,O,O
clinical,O,O
remission,O,O
in,O,O
patients,O,O
with,O,O
acute,O,O
promyelocytic,O,O
leukemia,O,O
via,O,O
induction,O,O
of,O,O
differentiation,O,O
and,O,O
programmed,O,O
cell,O,O
death,O,O
(,O,O
apoptosis,O,O
),O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
As2O3,O,O
on,O,O
a,O,O
panel,O,O
of,O,O
malignant,O,O
lymphocytes,O,O
to,O,O
determine,O,O
whether,O,O
growth,O,O
-,O,O
inhibitory,O,O
and,O,O
apoptotic,O,O
effects,O,O
of,O,O
As2O3,O,O
can,O,O
be,O,O
observed,O,O
in,O,O
these,O,O
cells,O,O
at,O,O
clinically,O,O
achievable,O,O
concentrations,O,O
.,O,O
Caspase,B,B
-,I,I
3,I,I
activation,O,O
",",O,O
usually,O,O
resulting,O,O
from,O,O
delta,O,O
psi,O,O
(,O,O
m,O,O
),O,O
collapse,O,O
",",O,O
was,O,O
not,O,O
always,O,O
associated,O,O
with,O,O
As2O3,O,O
-,O,O
induced,O,O
apoptosis,O,O
.,O,O
As2O3,O,O
induced,O,O
PML,O,B
(,O,I
promyelocytic,O,I
leukemia,O,I
),O,I
protein,O,I
degradation,O,O
but,O,O
did,O,O
not,O,O
modulate,O,O
expression,O,O
of,O,O
cell,B,B
cycle,I,I
-,I,I
related,I,I
proteins,I,I
",",O,O
including,O,O
c,B,B
-,I,I
myc,I,I
",",O,O
retinoblastoma,B,B
protein,I,I
",",O,O
cyclin,B,B
-,I,I
dependent,I,I
kinase,I,I
4,I,I
",",O,O
cyclin,B,B
D1,I,I
",",O,O
and,O,O
p53,B,B
",",O,O
or,O,O
expression,O,O
of,O,O
differentiation,B,O
-,I,O
related,I,O
antigens,I,O
.,O,O
A20,O,O
can,O,O
be,O,O
regulated,O,O
by,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
transcription,B,O
factor,I,O
",",O,O
which,O,O
is,O,O
known,O,O
to,O,O
be,O,O
activated,O,O
by,O,O
the,O,O
EBV,B,O
LMP,I,O
-,I,O
1,I,O
protein,I,O
.,O,O
CTLA,B,O
-,I,O
4,I,O
ligation,O,O
inhibited,O,O
CD3,O,O
/,O,O
CD28,B,O
-,O,O
induced,O,O
IL,B,B
-,I,I
2,I,I
mRNA,I,O
accumulation,O,O
by,O,O
inhibiting,O,O
IL,B,B
-,I,I
2,I,I
transcription,O,O
",",O,O
which,O,O
appears,O,O
to,O,O
be,O,O
mediated,O,O
in,O,O
part,O,O
through,O,O
decreasing,O,O
NF,B,B
-,I,I
AT,I,I
accumulation,O,O
in,O,O
the,O,O
nuclei,O,O
.,O,O
Further,O,O
",",O,O
CTLA,B,B
-,I,I
4,I,I
engagement,O,O
inhibited,O,O
progression,O,O
through,O,O
the,O,O
cell,O,O
cycle,O,O
by,O,O
inhibiting,O,O
the,O,O
production,O,O
of,O,O
cyclin,B,B
D3,I,I
",",O,O
cyclin,B,B
-,I,I
dependent,I,I
kinase,I,I
(,B,I
cdk,I,I
),I,I
4,I,I
",",O,O
and,O,O
cdk6,B,B
when,O,O
the,O,O
T,O,O
cells,O,O
were,O,O
stimulated,O,O
with,O,O
anti,B,O
-,I,O
CD3,I,O
/,I,O
CD28,I,O
and,O,O
with,O,O
anti,B,O
-,I,O
CD3,I,O
alone,O,O
.,O,O
Dexamethasone,O,B
(,O,I
Dex,O,I
),O,I
",",O,O
a,O,O
synthetic,O,O
glucocorticoid,O,O
hormone,O,O
",",O,O
cooperated,O,O
with,O,O
Epo,B,O
and,O,O
stem,B,O
cell,I,O
factor,I,O
to,O,O
induce,O,O
erythroid,O,O
progenitors,O,O
to,O,O
undergo,O,O
15,O,O
to,O,O
22,O,O
cell,O,O
divisions,O,O
",",O,O
corresponding,O,O
to,O,O
a,O,O
10,O,O
(,O,O
5,O,O
),O,O
-,O,O
to,O,O
10,O,O
(,O,O
6,O,O
),O,O
-,O,O
fold,O,O
amplification,O,O
of,O,O
erythroid,O,O
cells,O,O
.,O,O
Sustained,O,O
proliferation,O,O
of,O,O
erythroid,O,B
progenitors,O,I
could,O,O
be,O,O
induced,O,O
equally,O,O
well,O,O
from,O,O
purified,O,O
erythroid,O,B
burst,O,I
-,O,I
forming,O,I
units,O,I
(,O,O
BFU,O,B
-,O,I
E,O,I
),O,O
",",O,O
from,O,O
CD34,O,B
(,O,O
+,O,O
),O,O
blast,O,B
cells,O,I
",",O,O
and,O,O
from,O,O
bone,O,B
marrow,O,I
depleted,O,O
from,O,O
CD34,O,B
(,O,O
+,O,O
),O,O
cells,O,I
.,O,O
We,O,O
conclude,O,O
that,O,O
NF,B,B
-,I,I
kappaB,I,I
is,O,O
a,O,O
context,O,O
-,O,O
dependent,O,O
apoptosis,O,O
regulator,O,O
.,O,O
SOCS,B,B
-,I,I
3,I,I
protein,O,I
was,O,O
detectable,O,O
as,O,O
early,O,O
as,O,O
30,O,O
min,O,O
following,O,O
IL,B,B
-,I,I
2,I,I
stimulation,O,O
",",O,O
while,O,O
CIS,B,B
was,O,O
seen,O,O
only,O,O
at,O,O
low,O,O
levels,O,O
after,O,O
2,O,O
h,O,O
.,O,O
Tyrosine,O,B
phosphorylation,O,I
of,O,I
SOCS,B,B
-,I,I
3,I,I
was,O,O
observed,O,O
upon,O,O
coexpression,O,O
with,O,O
Jak1,B,O
and,O,O
Jak2,B,O
but,O,O
only,O,O
weakly,O,O
with,O,O
Jak3,B,O
.,O,O
Finally,O,O
",",O,O
proliferation,O,O
induced,O,O
by,O,O
both,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
and,O,O
IL,B,B
-,I,I
3,I,I
was,O,O
significantly,O,O
inhibited,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
SOCS,B,B
-,I,I
3,I,I
.,O,O
There,O,O
was,O,O
",",O,O
however,O,O
",",O,O
a,O,O
significant,O,O
difference,O,O
in,O,O
the,O,O
amounts,O,O
of,O,O
the,O,O
nuclear,B,O
protein,I,O
",",O,O
REF,B,O
-,I,O
1,I,O
(,O,O
which,O,O
regulates,O,O
AP,B,B
-,I,I
1,I,I
DNA,O,I
binding,O,I
by,O,O
altering,O,O
the,O,O
redox,O,O
status,O,O
of,O,O
FOS,B,B
and,O,O
JUN,B,B
proteins,I,O
),O,O
",",O,O
in,O,O
alveolar,O,O
macrophages,O,O
compared,O,O
with,O,O
monocytes,O,O
.,O,O
Finally,O,O
",",O,O
addition,O,O
of,O,O
REF,B,B
-,I,I
1,I,I
from,O,O
activated,O,O
monocytes,O,O
to,O,O
alveolar,O,B
macrophage,O,I
nuclear,O,I
proteins,O,I
resulted,O,O
in,O,O
a,O,O
marked,O,O
increase,O,O
in,O,O
AP,B,B
-,I,I
1,I,I
DNA,O,I
binding,O,I
.,O,O
Studies,O,O
over,O,O
the,O,O
past,O,O
few,O,O
years,O,O
have,O,O
identified,O,O
lymphotoxin,O,B
as,O,O
a,O,O
critical,O,O
signaling,O,O
molecule,O,O
not,O,O
only,O,O
for,O,O
the,O,O
organogenesis,O,O
of,O,O
secondary,O,O
lymphoid,O,O
tissues,O,O
but,O,O
for,O,O
the,O,O
maintenance,O,O
of,O,O
aspects,O,O
of,O,O
their,O,O
microarchitecture,O,O
as,O,O
well,O,O
.,O,O
This,O,O
review,O,O
focuses,O,O
on,O,O
studies,O,O
defining,O,O
recently,O,O
identified,O,O
crucial,O,O
signals,O,O
for,O,O
the,O,O
biogenesis,O,O
of,O,O
secondary,O,O
lymphoid,O,B
organs,O,I
and,O,O
for,O,O
the,O,O
maintenance,O,O
of,O,O
their,O,O
proper,O,O
microarchitecture,O,O
.,O,O
The,O,O
costimulatory,B,O
molecule,I,O
CD28,B,B
has,O,O
a,O,O
restricted,O,O
tissue,O,O
distribution,O,O
and,O,O
is,O,O
expressed,O,O
on,O,O
T,O,B
cells,O,I
and,O,O
some,O,O
plasmacytoma,O,B
cells,O,I
.,O,O
In,O,O
vivo,O,O
",",O,O
CD8,O,B
+,O,I
T,O,I
cells,O,I
and,O,O
",",O,O
less,O,O
frequently,O,O
",",O,O
CD4,O,B
+,O,I
T,O,I
cells,O,I
may,O,O
completely,O,O
lose,O,O
CD28,B,B
surface,O,I
expression,O,I
during,O,O
chronic,O,O
infections,O,O
and,O,O
with,O,O
aging,O,O
.,O,O
Both,O,O
alpha,O,B
-,O,I
and,O,I
beta,O,I
-,O,I
bound,O,I
complexes,O,I
are,O,O
found,O,O
only,O,O
in,O,O
lymphoid,O,O
tissues,O,O
",",O,O
in,O,O
CD28,O,B
+,O,I
T,O,I
cells,O,I
",",O,O
and,O,O
in,O,O
some,O,O
transformed,O,O
B,O,B
cells,O,I
.,O,O
A,O,O
role,O,O
for,O,O
RanBP1,B,O
in,O,O
the,O,O
release,O,O
of,O,O
CRM1,B,O
from,O,O
the,O,O
nuclear,B,O
pore,I,O
complex,I,O
in,O,O
a,O,O
terminal,O,O
step,O,O
of,O,O
nuclear,O,O
export,O,O
.,O,O
It,O,O
also,O,O
stimulates,O,O
nuclear,O,O
export,O,O
in,O,O
cells,O,O
that,O,O
have,O,O
not,O,O
been,O,O
preincubated,O,O
with,O,O
RanQ69L,B,O
.,O,O
In,O,O
a,O,O
model,O,O
where,O,O
foreign,O,O
cells,O,O
(,O,O
rat,O,B
fibroblasts,O,I
),O,O
were,O,O
cocultured,O,O
with,O,O
human,O,O
IL,O,B
-,O,I
2,O,I
activated,O,O
NK,O,B
cells,O,I
",",O,O
we,O,O
observed,O,O
that,O,O
NK,O,B
cells,O,I
were,O,O
capable,O,O
of,O,O
efficiently,O,O
killing,O,O
their,O,O
targets,O,O
only,O,O
if,O,O
the,O,O
cells,O,O
overexpressed,O,O
the,O,O
oncogene,O,O
c,B,B
-,I,I
Myc,I,I
or,O,O
E1A,B,B
.,O,O
These,O,O
results,O,O
provided,O,O
evidence,O,O
that,O,O
c,B,O
-,I,O
Myc,I,B
and,O,O
E1A,B,B
activated,O,O
the,O,O
NK,O,B
cell,O,I
induced,O,O
cytolysis,O,O
at,O,O
a,O,O
post,O,O
-,O,O
triggering,O,O
stage,O,O
of,O,O
NK,O,B
cell,O,I
-,O,I
target,O,I
cell,O,I
interaction,O,O
.,O,O
Unicellular,O,O
-,O,O
unilineage,O,O
erythropoietic,O,O
cultures,O,O
:,O,O
molecular,O,O
analysis,O,O
of,O,O
regulatory,O,O
gene,O,O
expression,O,O
at,O,O
sibling,O,O
cell,O,O
level,O,O
.,O,O
In,O,O
the,O,O
culture,O,O
system,O,O
reported,O,O
here,O,O
",",O,O
(,O,O
1,O,O
),O,O
the,O,O
growth,B,O
factor,I,O
(,O,O
GF,B,O
),O,O
stimulus,O,O
induces,O,O
cord,O,O
blood,O,O
(,O,O
CB,O,O
),O,O
progenitor,O,O
cells,O,O
to,O,O
proliferate,O,O
and,O,O
differentiate,O,O
/,O,O
mature,O,O
exclusively,O,O
along,O,O
the,O,O
erythroid,O,O
lineage,O,O
;,O,O
(,O,O
2,O,O
),O,O
this,O,O
erythropoietic,O,O
wave,O,O
is,O,O
characterized,O,O
by,O,O
less,O,O
than,O,O
4,O,O
%,O,O
apoptotic,O,O
cells,O,O
;,O,O
(,O,O
3,O,O
),O,O
asymmetric,O,O
divisions,O,O
are,O,O
virtually,O,O
absent,O,O
",",O,O
ie,O,O
",",O,O
nonresponsive,O,O
hematopoietic,O,O
progenitors,O,O
with,O,O
no,O,O
erythropoietic,O,O
potential,O,O
are,O,O
forced,O,O
into,O,O
apoptosis,O,O
;,O,O
(,O,O
4,O,O
),O,O
the,O,O
system,O,O
is,O,O
cell,O,O
division,O,O
controlled,O,O
(,O,O
cdc,O,O
),O,O
",",O,O
ie,O,O
",",O,O
the,O,O
number,O,O
of,O,O
divisions,O,O
performed,O,O
by,O,O
each,O,O
cell,O,O
is,O,O
monitored,O,O
.,O,O
Single,O,O
-,O,O
cell,O,O
reverse,B,O
transcriptase,I,O
-,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
RT,O,O
-,O,O
PCR,O,O
),O,O
analysis,O,O
was,O,O
applied,O,O
to,O,O
this,O,O
culture,O,O
system,O,O
to,O,O
investigate,O,O
gene,O,O
expression,O,O
of,O,O
diverse,O,O
receptors,B,O
",",O,O
markers,B,O
of,I,O
differentiation,I,O
",",O,O
and,O,O
transcription,B,O
factors,I,O
(,O,O
EKLF,B,B
",",O,O
GATA,B,B
-,I,I
1,I,I
",",O,O
GATA,B,B
-,I,I
2,I,I
",",O,O
p45,B,B
NF,I,I
-,I,I
E2,I,I
",",O,O
PU,B,B
.,I,I
",",O,O
and,O,O
SCL,B,B
/,I,I
Tal1,I,I
),O,O
at,O,O
discrete,O,O
stages,O,O
of,O,O
erythropoietic,O,O
development,O,O
.,O,O
However,O,O
",",O,O
stimulation,O,O
with,O,O
IL,B,B
-,I,I
2,I,I
resulted,O,O
in,O,O
Jak3,B,B
and,O,O
STAT5,B,B
phosphorylation,O,O
in,O,O
both,O,O
leukemic,O,B
ATLL,O,I
cells,O,O
and,O,O
IL,O,B
-,O,I
2,O,I
-,O,I
dependent,O,I
lines,O,O
.,O,O
A,O,O
skewed,O,O
XCI,O,O
pattern,O,O
with,O,O
greater,O,O
than,O,O
75,O,O
%,O,O
amplification,O,O
of,O,O
1,O,O
allele,B,O
(,O,O
allele,B,O
ratio,O,O
>,O,O
3,O,O
:,O,O
1,O,O
),O,O
was,O,O
found,O,O
in,O,O
22,O,O
(,O,O
9,O,O
.,O,O
1,O,O
%,O,O
),O,O
of,O,O
242,O,O
control,O,O
subjects,O,O
.,O,O
Although,O,O
statistical,O,O
evaluation,O,O
of,O,O
the,O,O
data,O,O
showed,O,O
a,O,O
significant,O,O
difference,O,O
between,O,O
patients,O,O
with,O,O
a,O,O
chronic,O,O
MPD,O,O
and,O,O
control,O,O
subjects,O,O
",",O,O
proof,O,O
of,O,O
clonality,O,O
in,O,O
individual,O,O
",",O,O
especially,O,O
elderly,O,O
",",O,O
patients,O,O
is,O,O
difficult,O,O
.,O,O
Here,O,O
we,O,O
report,O,O
that,O,O
in,O,O
erythroid,O,B
cells,O,O
",",O,O
GATA,B,B
-,I,O
1,I,I
strongly,O,O
induces,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
anti,B,B
-,I,I
apoptotic,I,I
protein,I,O
bcl,B,B
-,I,I
xL,I,I
",",O,O
but,O,O
not,O,O
the,O,O
related,O,O
proteins,O,O
bcl,B,B
-,I,I
2,I,I
and,O,O
mcl,B,B
-,I,I
1,I,I
.,O,O
In,O,O
T,O,O
lymphocytes,O,O
",",O,O
the,O,O
hematopoietic,B,O
cytokine,I,O
interleukin,B,B
-,I,I
2,I,I
(,O,I
IL,B,I
-,I,I
2,I,I
),O,I
uses,O,O
phosphatidylinositol,B,B
3,I,I
-,I,I
kinase,I,I
(,O,I
PI,B,I
3,I,I
-,I,I
kinase,I,I
),O,I
-,O,I
induced,O,O
signaling,O,O
pathways,O,O
to,O,O
regulate,O,O
E2F,B,B
transcriptional,O,I
activity,O,O
",",O,O
a,O,O
critical,O,O
cell,O,O
cycle,O,O
checkpoint,O,O
.,O,O
PI,B,B
3,I,I
-,I,I
kinase,I,I
also,O,O
regulates,O,O
the,O,O
activity,O,O
of,O,O
p70,B,B
(,I,O
s6k,I,O
),I,O
",",O,O
the,O,O
40S,B,O
ribosomal,I,O
protein,I,O
S6,I,O
kinase,I,O
",",O,O
a,O,O
response,O,O
that,O,O
is,O,O
abrogated,O,O
by,O,O
the,O,O
macrolide,O,O
rapamycin,O,O
.,O,O
Moreover,O,O
",",O,O
the,O,O
effects,O,O
of,O,O
rapamycin,O,O
on,O,O
",",O,O
and,O,O
the,O,O
role,O,O
of,O,O
p70,B,B
(,I,O
s6k,I,O
),I,O
in,O,O
",",O,O
IL,B,O
-,I,O
2,I,O
and,O,O
PI,B,B
3,I,I
-,I,I
kinase,I,I
activation,O,O
of,O,O
E2Fs,B,O
have,O,O
not,O,O
been,O,O
characterized,O,O
.,O,O
Our,O,O
present,O,O
results,O,O
show,O,O
that,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
and,O,O
PI,B,O
3,I,O
-,I,O
kinase,I,O
-,O,O
induced,O,O
pathways,O,O
for,O,O
the,O,O
regulation,O,O
of,O,O
E2F,B,O
transcriptional,O,O
activity,O,O
include,O,O
both,O,O
rapamycin,O,O
-,O,O
resistant,O,O
and,O,O
rapamycin,O,O
-,O,O
sensitive,O,O
components,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
rapamycin,O,O
-,O,O
controlled,O,O
processes,O,O
involved,O,O
in,O,O
E2F,B,O
regulation,O,O
appear,O,O
to,O,O
be,O,O
mediated,O,O
by,O,O
p70,B,O
(,I,O
s6k,I,O
),I,O
.,O,O
Since,O,O
1988,O,O
",",O,O
several,O,O
families,O,O
of,O,O
functionally,O,O
important,O,O
T,B,O
cell,I,O
transcription,I,O
factors,I,O
have,O,O
been,O,O
identified,O,O
.,O,O
These,O,O
include,O,O
the,O,O
Ikaros,B,B
",",O,O
LKLF,B,B
",",O,O
and,O,O
GATA3,B,B
zinc,I,O
-,I,O
finger,I,O
proteins,I,O
;,O,O
the,O,O
Ets,B,B
",",O,O
CREB,B,B
/,I,I
ATF,I,I
",",O,O
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
/,I,I
NFAT,I,I
transcription,I,O
factors,I,O
;,O,O
the,O,O
Stat,B,B
proteins,I,O
;,O,O
and,O,O
HMG,B,B
box,I,I
transcription,I,I
factors,I,I
such,O,O
as,O,O
LEF1,B,B
",",O,O
TCF1,B,B
",",O,O
and,O,O
Sox4,B,B
.,O,O
The,O,O
proliferative,O,O
deficiency,O,O
of,O,O
the,O,O
transgenic,O,O
T,O,O
cells,O,O
was,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
apoptosis,O,O
.,O,O
Paradoxical,O,O
priming,O,O
effects,O,O
of,O,O
IL,B,B
-,I,I
10,I,I
on,O,O
cytokine,B,O
production,O,O
.,O,O
Interestingly,O,O
",",O,O
an,O,O
enhanced,O,O
frequency,O,O
of,O,O
CD16,B,B
and,O,O
CD68,O,B
(,O,O
+,O,O
),O,O
cells,O,O
among,O,O
the,O,O
CD14,O,B
(,O,O
+,O,O
),O,O
cells,O,O
was,O,O
observed,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
IL,B,B
-,I,I
10,I,I
",",O,O
independently,O,O
of,O,O
the,O,O
pre,O,O
-,O,O
culture,O,O
conditions,O,O
of,O,O
the,O,O
PBMC,O,O
.,O,O
Transcription,B,O
factors,I,O
Sp1,B,B
and,O,O
AP,B,B
-,I,I
2,I,I
mediate,O,O
induction,O,O
of,O,O
acid,B,O
sphingomyelinase,I,O
during,O,O
monocytic,O,B
differentiation,O,O
.,O,O
Cells,O,O
from,O,O
the,O,O
human,O,O
monocytic,O,B
leukemia,O,I
cell,O,I
line,O,I
THP,O,O
-,O,O
1,O,O
differentiate,O,O
towards,O,O
a,O,O
macrophage,O,B
-,O,I
like,O,I
phenotype,O,I
when,O,O
stimulated,O,O
with,O,O
phorbol,O,O
12,O,O
-,O,O
myristate,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
",",O,O
1,O,O
",",O,O
25,O,O
-,O,O
dihydroxy,O,O
-,O,O
vitamin,O,O
D3,O,O
",",O,O
and,O,O
various,O,O
other,O,O
agents,O,O
.,O,O
A,O,O
PMA,B,B
responsive,I,O
element,I,O
was,O,O
localized,O,O
to,O,O
a,O,O
region,O,O
between,O,O
-,B,O
319,I,O
and,I,O
-,I,O
219,I,O
bp,I,O
upstream,I,O
of,O,O
the,O,O
initiation,O,O
codon,O,O
and,O,O
co,O,O
-,O,O
transfections,O,O
with,O,O
transcription,B,O
factor,I,O
expression,I,O
plasmids,I,O
for,O,O
AP,B,B
-,I,I
2,I,I
and,O,O
Sp1,B,B
resulted,O,O
in,O,O
augmented,O,O
ASM,O,O
promoter,O,O
activity,O,O
",",O,O
which,O,O
was,O,O
abolished,O,O
when,O,O
the,O,O
binding,B,O
sites,I,O
for,O,O
these,O,O
two,O,O
factors,O,O
were,O,O
deleted,O,O
.,O,O
However,O,O
",",O,O
the,O,O
intensity,O,O
of,O,O
the,O,O
complex,O,O
formed,O,O
appeared,O,O
to,O,O
increase,O,O
when,O,O
nuclear,O,O
extracts,O,O
from,O,O
PMA,O,O
-,O,O
treated,O,O
cells,O,O
were,O,O
used,O,O
.,O,O
NF,B,B
-,I,I
kappaB,I,I
DNA,O,I
binding,O,I
was,O,O
evaluated,O,O
by,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
.,O,O
Direct,O,O
activation,O,O
of,O,O
PKC,B,O
with,O,O
PMA,O,O
induced,O,O
both,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,I
and,O,O
TNF,B,B
-,I,I
alpha,I,I
production,O,O
by,O,O
human,O,O
monocytes,O,O
.,O,O
Furthermore,O,O
",",O,O
our,O,O
results,O,O
provide,O,O
evidence,O,O
that,O,O
PTK,B,B
plays,O,O
a,O,O
role,O,O
in,O,O
LPS,O,O
-,O,O
induced,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
and,O,O
TNF,B,B
-,I,I
alpha,I,I
release,O,O
in,O,O
human,O,O
monocytes,O,O
and,O,O
thus,O,O
could,O,O
be,O,O
a,O,O
potential,O,O
therapeutic,O,O
target,O,O
in,O,O
inflammatory,O,O
states,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
GDSP,O,O
on,O,O
pancreatic,O,O
weight,O,O
",",O,O
serum,B,O
amylase,I,O
and,I,O
lipase,I,O
",",O,O
morphologic,O,O
changes,O,O
in,O,O
the,O,O
pancreas,O,O
",",O,O
neutrophil,O,O
infiltration,O,O
",",O,O
and,O,O
nuclear,B,O
factor,I,O
KB,I,B
(,O,I
NF,B,I
-,I,I
KB,I,I
),O,I
activation,O,O
were,O,O
measured,O,O
in,O,O
rats,O,O
infused,O,O
with,O,O
supramaximal,O,O
dose,O,O
of,O,O
cerulein,O,O
(,O,O
5,O,O
(,O,O
g,O,O
/,O,O
kg,O,O
/,O,O
h,O,O
),O,O
for,O,O
6,O,O
h,O,O
.,O,O
Elastatinal,O,O
had,O,O
some,O,O
of,O,O
the,O,O
same,O,O
effects,O,O
as,O,O
GDSP,O,O
but,O,O
was,O,O
less,O,O
potent,O,O
and,O,O
effective,O,O
.,O,O
The,O,O
nature,O,O
of,O,O
the,O,O
nuclear,B,O
factor,I,O
(,O,O
s,O,O
),O,O
that,O,O
control,O,O
TNF,B,B
-,I,I
alpha,I,I
gene,O,O
transcription,O,O
in,O,O
humans,O,O
remains,O,O
obscure,O,O
",",O,O
although,O,O
NF,B,B
-,I,I
kappaB,I,I
has,O,O
been,O,O
suggested,O,O
.,O,O
Our,O,O
previous,O,O
studies,O,O
pertaining,O,O
to,O,O
macrophage,O,O
response,O,O
to,O,O
LPS,O,O
identified,O,O
a,O,O
novel,O,O
DNA,B,B
-,I,I
binding,I,I
domain,I,I
located,O,O
from,O,O
-,O,O
550,O,O
to,O,O
-,O,O
487,O,O
in,O,O
the,O,O
human,B,O
TNF,I,B
-,I,I
alpha,I,I
promoter,I,O
that,O,O
contains,O,O
transcriptional,O,O
activity,O,O
",",O,O
but,O,O
lacks,O,O
any,O,O
known,O,O
NF,B,B
-,I,I
kappaB,I,I
-,B,I
binding,I,I
sites,I,O
.,O,O
Inhibition,O,O
of,O,O
LITAF,B,B
mRNA,I,I
expression,O,O
in,O,O
THP,O,B
-,O,I
1,O,I
cells,O,O
resulted,O,O
in,O,O
a,O,O
reduction,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
transcripts,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
high,O,O
level,O,O
of,O,O
expression,O,O
of,O,O
LITAF,B,B
mRNA,I,I
was,O,O
observed,O,O
predominantly,O,O
in,O,O
the,O,O
placenta,O,O
",",O,O
peripheral,O,O
blood,O,O
leukocytes,O,O
",",O,O
lymph,O,O
nodes,O,O
",",O,O
and,O,O
the,O,O
spleen,O,O
.,O,O
A,O,O
human,B,O
IFNGR1,I,O
small,I,O
deletion,I,O
hotspot,I,O
associated,O,O
with,O,O
dominant,O,O
susceptibility,O,O
to,O,O
mycobacterial,O,O
infection,O,O
[,O,O
see,O,O
comments,O,O
],O,O
Characterization,O,O
of,O,O
expression,O,O
of,O,O
the,O,O
gene,O,O
for,O,O
human,B,O
pterin,I,O
carbinolamine,I,O
dehydratase,I,O
/,I,O
dimerization,I,O
cofactor,I,O
of,O,O
HNF1,B,O
.,O,O
In,O,O
the,O,O
nucleus,O,O
",",O,O
it,O,O
functions,O,O
as,O,O
a,O,O
dimerization,B,O
cofactor,I,O
of,O,O
HNF1,B,B
and,O,O
increases,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
HNF1,B,B
.,O,O
Transfection,O,O
of,O,O
Jurkat,O,O
cells,O,O
with,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
subunits,I,O
p50,B,O
and,O,O
p65,B,O
confers,O,O
resistance,O,O
against,O,O
Fas,O,O
-,O,O
mediated,O,O
apoptosis,O,O
.,O,O
Capacitance,O,O
would,O,O
simply,O,O
involve,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
12R,I,I
beta,I,I
1,I,I
and,I,O
beta,I,B
2,I,I
subunits,I,O
",",O,O
regulated,O,O
by,O,O
TCR,O,O
",",O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IFNs,B,O
.,O,O
The,O,O
activation,O,O
of,O,O
STAT3,B,B
was,O,O
not,O,O
found,O,O
in,O,O
human,O,O
eosinophils,O,O
",",O,O
monocytes,O,O
",",O,O
and,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
",",O,O
although,O,O
the,O,O
STAT3,B,B
protein,I,O
was,O,O
expressed,O,O
in,O,O
these,O,O
cells,O,O
.,O,O
The,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
ATc,I,I
is,O,O
synthesized,O,O
in,O,O
three,O,O
prominent,O,O
isoforms,B,O
.,O,O
These,O,O
differ,O,O
in,O,O
the,O,O
length,O,O
of,O,O
their,O,O
C,O,O
terminal,O,O
peptides,O,O
and,O,O
mode,O,O
of,O,O
synthesis,O,O
.,O,O
Together,O,O
",",O,O
these,O,O
results,O,O
demonstrate,O,O
that,O,O
ER,B,B
and,O,O
PR,B,B
can,O,O
be,O,O
activated,O,O
by,O,O
endogenous,O,O
or,O,O
exogenous,O,O
ligands,O,O
to,O,O
induce,O,O
a,O,O
genetic,O,O
response,O,O
that,O,O
impairs,O,O
TNF,B,B
-,I,I
alpha,I,I
-,O,I
induced,O,I
apoptosis,O,I
in,O,O
U937,O,O
cells,O,O
.,O,O
Retinoidal,O,O
antagonists,O,O
and,O,O
potential,O,O
agonists,O,O
.,O,O
Inhibition,O,O
of,O,O
T,O,O
cell,O,O
signaling,O,O
by,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,O
kinase,I,O
-,I,O
targeted,I,O
hematopoietic,I,O
tyrosine,I,O
phosphatase,I,O
(,O,O
HePTP,B,O
),O,O
.,O,O
Activation,O,O
of,O,O
T,O,B
lymphocytes,O,I
to,O,O
produce,O,O
cytokines,B,O
is,O,O
regulated,O,O
by,O,O
the,O,O
counterbalance,O,O
of,O,O
protein,B,B
-,I,I
tyrosine,I,I
kinases,I,I
and,O,O
protein,O,B
-,O,I
tyrosine,O,I
phosphatases,O,I
",",O,O
many,O,O
of,O,O
which,O,O
have,O,O
a,O,O
high,O,O
degree,O,O
of,O,O
substrate,O,O
specificity,O,O
because,O,O
of,O,O
physical,O,O
association,O,O
with,O,O
their,O,O
targets,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
HePTP,B,O
had,O,O
no,O,O
effects,O,O
on,O,O
N,B,B
-,I,I
terminal,I,I
c,I,I
-,I,I
Jun,I,I
kinase,I,I
or,O,O
on,O,O
events,O,O
upstream,O,O
of,O,O
the,O,O
MAP,O,B
kinases,O,I
.,O,O
However,O,O
",",O,O
p38,B,B
MAPK,I,I
is,O,O
activated,O,O
strongly,O,O
and,O,O
synergistically,O,O
by,O,O
either,O,O
CD3,B,B
/,I,I
CD28,I,I
coligation,O,I
or,O,O
PMA,O,O
/,O,O
Ca2,O,B
+,O,I
ionophore,O,I
stimulation,O,O
",",O,O
which,O,O
mimics,O,O
TCR,B,B
-,O,I
CD3,B,I
/,I,I
CD28,I,I
-,O,I
mediated,O,I
signaling,O,O
.,O,O
We,O,O
have,O,O
compared,O,O
the,O,O
effects,O,O
of,O,O
Epo,B,O
and,O,O
the,O,O
chemical,O,O
inducers,O,O
",",O,O
delta,O,B
-,O,I
aminolaevulinic,O,I
acid,O,I
(,O,I
delta,O,I
-,O,I
ALA,O,I
),O,I
and,O,O
haemin,O,O
on,O,O
the,O,O
differentiation,O,O
capacity,O,O
of,O,O
UT,O,O
-,O,O
7,O,O
cells,O,O
.,O,O
Epo,B,B
alone,O,O
promoted,O,O
relatively,O,O
early,O,O
events,O,O
in,O,O
erythroid,O,B
maturation,O,O
",",O,O
without,O,O
significant,O,O
changes,O,O
in,O,O
haemoglobin,O,B
production,O,O
or,O,O
morphology,O,O
.,O,O
Epo,B,B
caused,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
proportion,O,O
of,O,O
cells,O,O
expressing,O,O
cell,O,O
surface,O,O
glycophorin,B,B
A,I,I
(,O,O
GPA,B,O
),O,O
and,O,O
up,O,O
-,O,O
regulated,O,O
beta,B,B
-,I,I
and,I,I
gamma,I,I
-,I,I
globin,I,I
by,O,O
several,O,O
fold,O,O
.,O,O
There,O,O
is,O,O
little,O,O
direct,O,O
evidence,O,O
regarding,O,O
the,O,O
role,O,O
of,O,O
alveolar,O,B
macrophages,O,I
in,O,O
these,O,O
activation,O,O
events,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
",",O,O
in,O,O
this,O,O
inflammatory,O,O
model,O,O
",",O,O
initial,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
occurs,O,O
in,O,O
alveolar,O,B
macrophages,O,I
and,O,O
the,O,O
ensuing,O,O
production,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
may,O,O
propagate,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
to,O,O
other,O,O
cell,O,O
types,O,O
in,O,O
the,O,O
lung,O,O
.,O,O
Interferon,B,B
-,I,I
beta,I,I
mediates,O,O
stromal,O,B
cell,O,I
rescue,O,O
of,O,O
T,O,O
cells,O,O
from,O,O
apoptosis,O,O
.,O,O
Interferon,B,B
-,I,I
alpha,I,I
and,I,O
-,I,O
beta,I,O
promote,O,O
the,O,O
reversion,O,O
of,O,O
blast,O,O
Tcells,O,O
to,O,O
a,O,O
resting,O,O
G0,O,O
/,O,O
G1,O,O
configuration,O,O
with,O,O
all,O,O
the,O,O
characteristic,O,O
features,O,O
of,O,O
stromal,O,O
cell,O,O
rescue,O,O
;,O,O
such,O,O
as,O,O
high,O,O
Bcl,B,B
-,I,I
XL,I,I
expression,O,O
and,O,O
low,O,O
Bcl,B,B
-,I,I
2,I,I
.,O,O
We,O,O
also,O,O
show,O,O
that,O,O
DFX,O,O
treatment,O,O
limits,O,O
the,O,O
in,O,O
vivo,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
",",O,O
a,O,O
transcription,B,O
factor,I,O
involved,O,O
in,O,O
both,O,O
TNF,B,B
-,I,I
alpha,I,I
gene,O,O
transcription,O,O
and,O,O
TNF,B,B
-,I,I
alpha,I,I
signalling,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
the,O,O
influence,O,O
of,O,O
the,O,O
sequences,O,O
located,O,O
between,B,O
-,I,O
3134,I,O
and,I,O
-,I,O
2987,I,O
on,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
the,O,O
proIL,B,O
-,I,O
1beta,I,O
gene,I,O
in,O,O
LPS,O,O
-,O,O
stimulated,O,O
Raw,O,O
264,O,O
.,O,O
7,O,O
cells,O,O
was,O,O
examined,O,O
in,O,O
detail,O,O
.,O,O
These,O,O
specific,O,O
bindings,O,O
were,O,O
time,O,O
and,O,O
LPS,O,O
dose,O,O
dependent,O,O
.,O,O
These,O,O
data,O,O
indicated,O,O
that,O,O
two,O,O
NF,B,B
-,I,I
kappaB,I,I
-,I,I
binding,I,I
sites,I,I
",",O,O
which,O,O
are,O,O
located,O,O
between,O,O
-,B,O
3134,I,O
and,I,O
-,I,O
3059,I,O
",",O,O
are,O,O
critical,O,O
for,O,O
the,O,O
activation,O,O
of,O,O
proIL,B,O
-,I,O
1beta,I,O
gene,I,O
transcription,O,O
.,O,O
N,O,O
-,O,O
acetyl,O,O
-,O,O
L,O,O
-,O,O
cysteine,O,O
inhibits,O,O
primary,O,O
human,O,O
T,O,O
cell,O,O
responses,O,O
at,O,O
the,O,O
dendritic,O,B
cell,O,I
level,O,O
:,O,O
association,O,O
with,O,O
NF,B,B
-,I,I
kappaB,I,I
inhibition,O,O
.,O,O
Altogether,O,O
",",O,O
our,O,O
results,O,O
suggest,O,O
that,O,O
NAC,O,O
might,O,O
impair,O,O
the,O,O
generation,O,O
of,O,O
primary,O,O
immune,O,O
responses,O,O
in,O,O
humans,O,O
through,O,O
its,O,O
inhibitory,O,O
action,O,O
on,O,O
DC,O,O
.,O,O
Gel,O,O
supershift,O,O
assays,O,O
demonstrated,O,O
that,O,O
thrombin,B,O
induced,O,O
binding,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
Bp65,I,I
(,O,O
Rel,B,O
A,I,O
),O,O
to,O,O
downstream,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
site,I,O
of,O,O
the,O,O
ICAM,B,O
-,I,O
1,I,O
promoter,I,O
.,O,O
Thrombin,B,B
receptor,O,I
activation,O,I
peptide,O,I
",",O,O
a,O,O
14,O,O
-,O,O
amino,O,O
-,O,O
acid,O,O
peptide,O,O
representing,O,O
the,O,O
new,O,O
NH2,B,O
terminus,I,O
of,O,O
proteolytically,O,O
activated,O,O
receptor,B,O
-,I,O
1,I,O
",",O,O
mimicked,O,O
thrombin,B,O
s,O,O
action,O,O
in,O,O
inducing,O,O
ICAM,B,B
-,I,I
1,I,I
expression,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
thrombin,B,O
activates,O,O
endothelial,O,O
ICAM,B,B
-,I,I
1,I,I
expression,O,O
and,O,O
polymorphonuclear,O,O
leukocyte,O,O
adhesion,O,O
by,O,O
NF,B,B
-,I,I
kappa,I,I
Bp65,I,I
binding,O,O
to,O,O
the,O,O
downstream,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
site,I,O
of,O,O
ICAM,B,B
-,I,I
1,I,I
promoter,I,O
after,O,O
proteolytically,O,O
activated,O,O
receptor,O,O
-,O,O
1,O,O
activation,O,O
.,O,O
Here,O,O
we,O,O
demonstrate,O,O
that,O,O
both,O,O
Smad6,B,B
and,O,O
Smad7,B,B
are,O,O
human,B,O
bone,I,O
morphogenetic,I,O
protein,I,O
-,I,O
2,I,O
(,O,O
hBMP,B,O
-,I,O
2,I,O
),O,O
-,O,O
inducible,O,O
antagonists,O,O
of,O,O
hBMP,B,O
-,I,O
2,I,O
-,O,O
induced,O,O
growth,O,O
arrest,O,O
and,O,O
apoptosis,O,O
in,O,O
mouse,O,O
B,O,O
cell,O,O
hybridoma,O,O
HS,O,O
-,O,O
72,O,O
cells,O,O
.,O,O
The,O,O
effect,O,O
was,O,O
dose,O,O
dependent,O,O
and,O,O
appeared,O,O
relatively,O,O
late,O,O
.,O,O
Significant,O,O
differences,O,O
were,O,O
observed,O,O
from,O,O
day,O,O
4,O,O
onward,O,O
.,O,O
RA,O,B
previously,O,O
was,O,O
found,O,O
to,O,O
inhibit,O,O
granulocyte,B,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
-,O,I
-,O,I
and,O,O
not,O,O
granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
-,O,I
-,O,I
stimulated,O,O
proliferation,O,O
of,O,O
CD34,O,B
+,O,I
cells,O,O
.,O,O
Interestingly,O,O
",",O,O
CyA,O,O
and,O,O
indomethacin,O,O
did,O,O
not,O,O
suppress,O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
(,O,O
TNF,B,B
-,I,I
alpha,I,I
),O,O
-,O,O
induced,O,O
adhesion,O,O
molecule,O,O
expression,O,O
on,O,O
HUVECs,O,O
",",O,O
whereas,O,O
aspirin,O,O
had,O,O
an,O,O
inhibitory,O,O
effect,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Our,O,O
results,O,O
show,O,O
that,O,O
the,O,O
tested,O,O
agents,O,O
(,O,O
except,O,O
indomethacin,O,O
),O,O
are,O,O
inhibitors,O,O
of,O,O
the,O,O
T,O,O
cell,O,O
-,O,O
mediated,O,O
immune,O,O
response,O,O
",",O,O
as,O,O
expected,O,O
",",O,O
that,O,O
aspirin,O,O
is,O,O
an,O,O
effective,O,O
suppressor,O,O
of,O,O
adhesion,B,O
molecule,I,O
expression,O,O
",",O,O
and,O,O
that,O,O
all,O,O
three,O,O
agents,O,O
can,O,O
induce,O,O
Hsp60,B,B
in,O,O
HUVECs,O,O
.,O,O
METHODS,O,O
:,O,O
Ten,O,O
atopic,O,O
asthmatic,O,O
subjects,O,O
were,O,O
treated,O,O
with,O,O
FP,O,O
250,O,O
microg,O,O
twice,O,O
daily,O,O
for,O,O
4,O,O
weeks,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
a,O,O
24,O,O
-,O,O
hour,O,O
urinary,O,O
cortisol,O,B
excretion,O,O
and,O,O
an,O,O
adrenocorticotropic,O,B
hormone,O,I
test,O,O
before,O,O
and,O,O
after,O,O
treatment,O,O
with,O,O
FP,O,O
were,O,O
performed,O,O
.,O,O
However,O,O
",",O,O
we,O,O
detected,O,O
a,O,O
significant,O,O
reduction,O,O
of,O,O
the,O,O
GR,B,B
mRNA,I,I
levels,O,O
in,O,O
the,O,O
endobronchial,O,B
biopsy,O,I
specimens,O,O
after,O,O
FP,O,O
treatment,O,O
(,O,O
36,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
23,O,O
.,O,O
1,O,O
and,O,O
25,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
10,O,O
.,O,O
9,O,O
amol,O,O
GR,B,B
mRNA,I,I
/,O,O
microg,O,O
RNA,O,B
",",O,O
respectively,O,O
;,O,O
P,O,O
<,O,O
.,O,O
.,O,O
In,O,O
the,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
an,O,O
even,O,O
more,O,O
striking,O,O
downregulation,O,O
of,O,O
the,O,O
GR,O,B
by,O,O
its,O,O
cognate,O,O
ligand,O,O
was,O,O
documented,O,O
(,O,O
30,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
26,O,O
.,O,O
5,O,O
and,O,O
8,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
5,O,O
amol,O,O
GR,B,B
mRNA,I,I
/,O,O
microg,O,O
RNA,O,B
",",O,O
respectively,O,O
;,O,O
P,O,O
<,O,O
.,O,O
),O,O
",",O,O
possibly,O,O
reflecting,O,O
differences,O,O
in,O,O
glucocorticoid,O,O
sensitivity,O,O
between,O,O
tissues,O,O
.,O,O
Inflammation,O,O
is,O,O
constantly,O,O
observed,O,O
in,O,O
allergic,O,O
reactions,O,O
.,O,O
The,O,O
action,O,O
of,O,O
glucocorticosteroids,O,O
is,O,O
mediated,O,O
through,O,O
glucocorticoid,B,B
receptors,I,I
present,O,O
in,O,O
the,O,O
cellular,O,B
cytoplasm,O,I
.,O,O
Interaction,O,O
to,O,O
DNA,O,B
induces,O,O
changes,O,O
in,O,O
the,O,O
transcription,O,O
rate,O,O
",",O,O
leading,O,O
to,O,O
either,O,O
gene,O,O
induction,O,O
or,O,O
gene,O,O
repression,O,O
.,O,O
RESULTS,O,O
:,O,O
Phorbol,O,O
-,O,O
myristate,O,O
-,O,O
acetate,O,O
and,O,O
ionomycine,O,O
strongly,O,O
increase,O,O
the,O,O
percent,O,O
-,O,O
age,O,O
of,O,O
IL,O,B
-,O,I
2,O,I
+,O,I
cells,O,O
;,O,O
an,O,O
additional,O,O
50,O,O
%,O,O
HCSs,O,O
significantly,O,O
suppresses,O,O
the,O,O
percentage,O,O
to,O,O
",",O,O
or,O,O
below,O,O
the,O,O
level,O,O
of,O,O
unstimulated,O,O
cells,O,O
.,O,O
50,O,O
%,O,O
HCS,O,O
downregulates,O,O
the,O,O
alpha,B,B
-,I,I
chain,I,I
and,O,O
slightly,O,O
upregulates,O,O
the,O,O
beta,B,B
-,I,I
chain,I,I
.,O,O
Inhibition,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
-,O,I
inducible,O,I
gene,O,I
expression,O,I
in,O,O
human,O,O
monocytes,O,O
by,O,O
type,B,O
I,I,B
and,I,O
type,I,O
II,I,B
interferons,I,I
.,O,O
However,O,O
",",O,O
the,O,O
mechanism,O,O
by,O,O
which,O,O
IFNs,B,O
mediate,O,O
this,O,O
inhibition,O,O
has,O,O
not,O,O
been,O,O
defined,O,O
.,O,O
Because,O,O
STAT6,B,O
activation,O,O
plays,O,O
an,O,O
essential,O,O
role,O,O
in,O,O
IL,B,B
-,I,I
4,I,I
/,O,I
IL,B,I
-,I,I
13,I,I
-,O,I
induced,O,I
gene,O,I
expression,O,I
",",O,O
the,O,O
ability,O,O
of,O,O
IFN,B,B
-,I,I
beta,I,I
and,O,O
IFN,B,B
-,I,I
gamma,I,I
to,O,O
inhibit,O,O
STAT6,B,O
activity,O,O
provides,O,O
an,O,O
explanation,O,O
for,O,O
how,O,O
IFNs,B,O
can,O,O
suppress,O,O
IL,B,B
-,I,I
4,I,I
/,O,I
IL,B,I
-,I,I
13,I,I
-,O,I
inducible,O,I
gene,O,I
expression,O,I
.,O,O
HLA,B,B
class,I,I
I,I,I
Ags,I,I
have,O,O
been,O,O
implicated,O,O
to,O,O
play,O,O
a,O,O
major,O,O
role,O,O
in,O,O
this,O,O
process,O,O
",",O,O
since,O,O
signaling,O,O
via,O,O
HLA,B,B
class,I,I
I,I,I
molecules,I,I
can,O,O
induce,O,O
the,O,O
proliferation,O,O
of,O,O
aortic,O,O
endothelial,O,B
as,O,O
well,O,O
as,O,O
smooth,O,B
muscle,O,I
cells,O,I
.,O,O
A,O,O
cdk2,O,B
inhibitor,O,I
",",O,O
Olomoucine,O,B
",",O,O
as,O,O
well,O,O
as,O,O
a,O,O
dominant,B,B
-,I,I
negative,I,I
cdk2,I,I
construct,I,I
prevented,O,O
HLA,B,B
class,I,I
I,I,I
-,O,I
mediated,O,I
inactivation,O,I
of,O,I
Rb,B,I
;,O,O
in,O,O
contrast,O,O
",",O,O
dominant,B,B
-,I,I
negative,I,I
cdk4,I,I
and,I,O
cdk6,I,B
constructs,I,I
had,O,O
no,O,O
effect,O,O
.,O,O
PG490,O,B
inhibits,O,O
interleukin,B,B
expression,O,O
by,O,O
normal,O,O
human,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
stimulated,O,O
with,O,O
phorbol,O,O
12,O,O
-,O,O
myristate,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
and,O,O
antibody,O,O
to,O,O
CD3,B,O
(,O,O
IC50,O,O
of,O,O
10,O,O
ng,O,O
/,O,O
ml,O,O
),O,O
",",O,O
and,O,O
with,O,O
PMA,O,O
and,O,O
ionomycin,O,O
(,O,O
Iono,O,O
",",O,O
IC50,O,O
of,O,O
40,O,O
ng,O,O
/,O,O
ml,O,O
),O,O
.,O,O
In,O,O
Jurkat,O,O
T,O,O
-,O,O
cells,O,O
",",O,O
PG490,O,B
inhibits,O,O
PMA,O,O
/,O,O
Iono,O,O
-,O,O
stimulated,O,O
IL,B,B
-,I,I
2,I,I
transcription,O,O
.,O,O
PG490,O,B
can,O,O
completely,O,O
inhibit,O,O
transcriptional,O,O
activation,O,O
at,O,O
the,O,O
purine,B,B
-,I,I
box,I,I
/,I,I
ARRE,I,I
/,I,I
NF,I,I
-,I,I
AT,I,I
and,I,O
NF,I,B
-,I,I
kappaB,I,I
target,I,O
DNA,I,B
sequences,I,O
triggered,O,O
by,O,O
all,O,O
stimuli,O,O
examined,O,O
(,O,O
PMA,O,O
",",O,O
PMA,O,O
/,O,O
Iono,O,O
",",O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
),O,O
.,O,O
PG490,O,B
also,O,O
inhibits,O,O
PMA,O,O
-,O,O
stimulated,O,O
activation,O,O
of,O,O
a,O,O
chimeric,B,O
transcription,I,O
factor,I,O
in,O,O
which,O,O
the,O,O
C,B,O
-,I,O
terminal,I,O
TA1,I,O
transactivation,I,O
domain,I,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
p65,I,I
is,O,O
fused,O,O
to,O,O
the,O,O
DNA,B,B
binding,I,O
domain,I,O
of,O,O
GAL4,B,O
.,O,O
Unexpected,O,O
and,O,O
coordinated,O,O
expression,O,O
of,O,O
Spi,B,B
-,I,I
1,I,I
",",O,O
Fli,B,B
-,I,I
1,I,I
",",O,O
and,O,O
megakaryocytic,B,O
genes,I,O
in,O,O
four,O,O
Epo,O,O
-,O,O
dependent,O,O
cell,O,O
lines,O,O
established,O,O
from,O,O
transgenic,O,O
mice,O,O
displaying,O,O
erythroid,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
a,O,O
thermosensitive,B,O
SV40,I,O
T,I,O
antigen,I,O
.,O,O
Most,O,O
erythroleukemic,O,O
cell,O,O
lines,O,O
established,O,O
in,O,O
vitro,O,O
coexpress,O,O
erythrocytic,B,O
and,I,O
megakaryocytic,I,O
markers,I,O
that,O,O
often,O,O
are,O,O
associated,O,O
with,O,O
expression,O,O
of,O,O
Spi,B,B
-,I,I
1,I,I
and,O,O
/,O,O
or,O,O
Fli,B,B
-,I,I
1,I,I
transcription,I,O
factors,I,O
known,O,O
as,O,O
transactivators,B,O
of,I,O
megakaryocyte,I,O
-,I,O
specific,I,O
promoters,I,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
we,O,O
examined,O,O
the,O,O
possibility,O,O
of,O,O
establishing,O,O
new,O,O
cell,O,O
lines,O,O
keeping,O,O
strictly,O,O
erythroid,O,B
-,O,I
specific,O,I
properties,O,O
in,O,O
vitro,O,O
through,O,O
the,O,O
targeted,O,O
and,O,O
conditional,O,O
immortalization,O,O
of,O,O
erythrocytic,O,B
progenitors,O,I
.,O,O
However,O,O
",",O,O
like,O,O
normal,O,O
Ter,O,B
119,O,I
erythroid,O,I
cells,O,O
",",O,O
these,O,O
Ter,O,B
119,O,I
positive,O,I
cells,O,O
from,O,O
transgenic,O,O
mice,O,O
still,O,O
expressed,O,O
high,O,O
levels,O,O
of,O,O
beta,B,B
-,I,I
globin,I,I
and,O,O
very,O,O
low,O,O
or,O,O
undetectable,O,O
glycoprotein,B,O
IIb,I,O
and,O,O
platelet,B,B
factor,I,I
4,I,I
megakaryocytic,I,I
transcripts,I,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
data,O,O
indicate,O,O
that,O,O
the,O,O
unexpected,O,O
expression,O,O
of,O,O
megakaryocytic,B,B
genes,I,I
is,O,O
a,O,O
specific,O,O
property,O,O
of,O,O
immortalized,O,O
cells,O,O
that,O,O
can,O,O
not,O,O
be,O,O
explained,O,O
only,O,O
by,O,O
enhanced,O,O
expression,O,O
of,O,O
Spi,B,O
-,I,O
1,I,O
and,I,O
/,I,O
or,I,O
Fli,I,O
-,I,O
1,I,O
genes,I,O
.,O,O
Fludarabine,O,O
-,O,O
induced,O,O
immunosuppression,O,O
is,O,O
associated,O,O
with,O,O
inhibition,O,O
of,O,O
STAT1,B,B
signaling,O,O
.,O,O
Fludarabine,O,B
is,O,O
a,O,O
nucleoside,O,B
analog,O,I
used,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
hematologic,O,O
malignancies,O,O
that,O,O
can,O,O
induce,O,O
severe,O,O
and,O,O
prolonged,O,O
immunosuppression,O,O
.,O,O
STAT1,B,B
",",O,O
which,O,O
is,O,O
activated,O,O
in,O,O
response,O,O
to,O,O
many,O,O
lymphocyte,B,B
-,I,I
activating,I,I
cytokines,I,I
including,O,O
the,O,O
interferons,B,B
",",O,O
is,O,O
essential,O,O
for,O,O
cell,O,B
-,O,I
mediated,O,I
immunity,O,I
",",O,O
as,O,O
the,O,O
absence,O,O
of,O,O
this,O,O
protein,O,O
is,O,O
associated,O,O
with,O,O
prominent,O,O
defects,O,O
in,O,O
the,O,O
ability,O,O
to,O,O
control,O,O
viral,O,O
infections,O,O
.,O,O
Here,O,O
we,O,O
show,O,O
that,O,O
fludarabine,O,O
",",O,O
but,O,O
not,O,O
the,O,O
immunosuppressant,O,O
cyclosporine,O,O
A,O,O
",",O,O
inhibits,O,O
the,O,O
cytokine,B,O
-,O,O
induced,O,O
activation,O,O
of,O,O
STAT1,B,B
and,O,O
STAT1,B,B
-,O,O
dependent,O,O
gene,O,O
transcription,O,O
in,O,O
normal,O,O
resting,O,O
or,O,O
activated,O,O
lymphocytes,O,O
.,O,O
Fludarabine,O,O
caused,O,O
a,O,O
specific,O,O
depletion,O,O
of,O,O
STAT1,B,B
protein,I,O
(,O,O
and,O,O
mRNA,O,O
),O,O
but,O,O
not,O,O
of,O,O
other,O,O
STATs,B,O
.,O,O
This,O,O
loss,O,O
of,O,O
STAT1,B,B
was,O,O
also,O,O
seen,O,O
in,O,O
cells,O,O
from,O,O
patients,O,O
treated,O,O
with,O,O
fludarabine,O,O
in,O,O
vivo,O,O
.,O,O
Thus,O,O
",",O,O
STAT1,B,B
may,O,O
be,O,O
a,O,O
useful,O,O
target,O,O
in,O,O
the,O,O
development,O,O
of,O,O
new,O,O
immunosuppressive,O,O
and,O,O
antineoplastic,O,O
agents,O,O
.,O,O
Furthermore,O,O
",",O,O
it,O,O
demonstrates,O,O
that,O,O
aging,O,O
does,O,O
not,O,O
influence,O,O
the,O,O
sensitivity,O,O
of,O,O
this,O,O
phosphatase,B,O
.,O,O
Spi,B,O
-,I,O
C,I,O
",",O,O
a,O,O
novel,O,O
Ets,B,B
protein,I,O
that,O,O
is,O,O
temporally,O,O
regulated,O,O
during,O,O
B,O,O
lymphocyte,O,O
development,O,O
.,O,O
Spi,B,B
-,I,I
C,I,I
interacted,O,O
with,O,O
DNA,O,B
similarly,O,O
to,O,O
PU,B,B
.,I,O
1,I,O
as,O,O
judged,O,O
by,O,O
methylation,O,O
interference,O,O
",",O,O
band,O,O
-,O,O
shift,O,O
and,O,O
site,O,O
selection,O,O
analysis,O,O
",",O,O
and,O,O
activated,O,O
transcription,O,O
of,O,O
a,O,O
kappaY,B,O
element,I,O
reporter,I,O
gene,I,O
upon,O,O
co,O,O
-,O,O
transfection,O,O
of,O,O
HeLa,O,O
cells,O,O
.,O,O
Spi,B,B
-,I,I
C,I,I
RNA,I,B
was,O,O
expressed,O,O
in,O,O
mature,O,O
B,O,B
lymphocytes,O,I
and,O,O
at,O,O
lower,O,O
levels,O,O
in,O,O
macrophages,O,O
.,O,O
Under,O,O
these,O,O
conditions,O,O
",",O,O
dexamethasone,O,O
had,O,O
a,O,O
minimal,O,O
effect,O,O
on,O,O
cell,O,O
growth,O,O
",",O,O
elicited,O,O
little,O,O
internucleosomal,O,O
DNA,O,B
fragmentation,O,O
",",O,O
and,O,O
induced,O,O
no,O,O
cell,O,O
cycle,O,O
perturbation,O,O
.,O,O
Human,O,O
T,O,O
-,O,O
cell,O,O
leukemia,O,O
virus,O,O
type,O,O
I,O,O
(,O,O
HTLV,O,O
-,O,O
I,O,O
),O,O
is,O,O
an,O,O
etiologic,O,O
agent,O,O
of,O,O
adult,O,O
T,O,O
-,O,O
cell,O,O
leukemia,O,O
(,O,O
ATL,O,O
),O,O
.,O,O
The,O,O
viral,B,O
protein,I,O
Tax,B,O
induces,O,O
the,O,O
activation,O,O
and,O,O
nuclear,O,O
translocalization,O,O
of,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappaB,I,I
",",O,O
which,O,O
is,O,O
proposed,O,O
to,O,O
play,O,O
a,O,O
crucial,O,O
role,O,O
in,O,O
the,O,O
transformation,O,O
of,O,O
T,O,O
cells,O,O
by,O,O
HTLV,O,O
-,O,O
I,O,O
.,O,O
However,O,O
",",O,O
the,O,O
HTLV,B,B
-,I,I
I,I,I
genes,I,O
including,O,O
Tax,B,O
are,O,O
not,O,O
expressed,O,O
significantly,O,O
in,O,O
primary,O,O
leukemic,O,B
cells,O,I
from,O,O
ATL,O,O
patients,O,O
.,O,O
We,O,O
found,O,O
that,O,O
leukemic,O,B
cells,O,I
from,O,O
ATL,O,O
patients,O,O
",",O,O
like,O,O
HTLV,O,B
-,O,I
I,O,I
-,O,I
infected,O,O
T,O,O
-,O,O
cell,O,O
lines,O,O
",",O,O
display,O,O
constitutive,O,O
NF,B,B
-,I,I
kappaB,I,I
DNA,O,I
binding,O,I
activity,O,I
and,O,O
increased,O,O
degradation,O,O
of,O,O
IkappaBalpha,B,O
(,O,O
an,O,O
inhibitor,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
),O,O
.,O,O
One,O,O
T,O,B
-,O,I
cell,O,I
line,O,I
derived,O,O
from,O,O
ATL,O,O
leukemic,O,O
cells,O,O
",",O,O
TL,O,B
-,O,I
Om1,O,I
",",O,O
displayed,O,O
constitutive,O,O
NF,B,B
-,I,I
kappaB,I,I
activity,O,O
",",O,O
as,O,O
well,O,O
as,O,O
enhanced,O,O
degradation,O,O
of,O,O
IkappaBalpha,B,O
",",O,O
despite,O,O
the,O,O
lack,O,O
of,O,O
detectable,O,O
Tax,B,O
expression,O,O
.,O,O
Interestingly,O,O
",",O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
TL,O,B
-,O,I
Om1,O,I
consists,O,O
of,O,O
p50,B,O
/,I,O
p50,I,O
and,O,O
p50,B,O
/,I,O
p65,I,O
like,O,O
that,O,O
in,O,O
fresh,O,O
primary,O,O
leukemic,O,O
cells,O,O
.,O,O
The,O,O
most,O,O
characterized,O,O
pathway,O,O
is,O,O
via,O,O
JAK,B,B
-,B,I
STAT,I,I
signaling,O,O
.,O,O
Therefore,O,O
",",O,O
this,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
analyze,O,O
the,O,O
role,O,O
of,O,O
Lck,B,B
in,O,O
IFN,B,B
-,I,I
alpha,I,I
signaling,O,O
by,O,O
using,O,O
the,O,O
Jurkat,O,O
",",O,O
JCam,O,O
(,O,O
an,O,O
Lck,O,B
-,O,I
defective,O,I
cell,O,I
line,O,I
derived,O,O
from,O,O
Jurkat,O,O
),O,O
",",O,O
and,O,O
JCam,O,O
/,O,O
Lck,O,O
(,O,O
JCam,O,O
cells,O,O
with,O,O
Lck,B,B
restored,O,O
),O,O
.,O,O
Finally,O,O
",",O,O
the,O,O
results,O,O
demonstrate,O,O
that,O,O
IFN,B,B
-,I,I
alpha,I,I
exerts,O,O
an,O,O
antiproliferative,O,O
effect,O,O
in,O,O
all,O,O
three,O,O
cell,O,O
lines,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
MAPk,B,B
kinase,I,I
(,O,O
MKK,B,B
),O,O
that,O,O
activates,O,O
p38,B,B
MAPk,I,I
in,O,O
response,O,O
to,O,O
LPS,O,O
",",O,O
the,O,O
p38,B,B
MAPk,I,I
isoforms,I,O
that,O,O
are,O,O
activated,O,O
as,O,O
part,O,O
of,O,O
this,O,O
pathway,O,O
",",O,O
and,O,O
the,O,O
functional,O,O
responses,O,O
affected,O,O
by,O,O
p38,B,B
MAPk,I,I
activation,O,O
.,O,O
Although,O,O
MKK3,B,B
",",O,O
MKK4,B,B
",",O,O
and,O,O
MKK6,B,B
all,O,O
activated,O,O
p38,B,B
MAPk,I,I
in,O,O
experimental,O,O
models,O,O
",",O,O
only,O,O
MKK3,B,B
was,O,O
found,O,O
to,O,O
activate,O,O
recombinant,O,O
p38,B,B
MAPk,I,I
in,O,O
LPS,O,O
-,O,O
treated,O,O
neutrophils,O,O
.,O,O
The,O,O
I,B,O
gamma,I,B
3,I,I
ECS,B,O
lies,O,O
upstream,O,O
of,O,O
the,O,O
major,B,O
I,I,O
gamma,I,B
3,I,I
transcription,I,O
initiation,I,O
site,I,O
and,O,O
displays,O,O
more,O,O
than,O,O
90,O,O
%,O,O
identity,O,O
with,O,O
the,O,O
corresponding,O,O
human,B,O
I,I,O
gamma,I,B
1,I,I
",",O,O
I,B,O
gamma,I,B
2,I,I
",",O,O
and,O,O
I,B,O
gamma,I,B
4,I,I
regions,O,O
.,O,O
In,O,O
these,O,O
transfected,O,O
CL,O,O
-,O,O
cells,O,O
",",O,O
CD40,O,O
:,O,O
CD40L,B,O
engagement,O,O
and,O,O
exposure,O,O
to,O,O
IL,B,B
-,I,O
4,I,I
synergistically,O,O
induced,O,O
gamma,O,B
3,O,I
ECS,O,O
-,O,O
dependent,O,O
luciferase,B,O
reporter,I,O
gene,I,O
activation,O,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
showed,O,O
that,O,O
p50,B,B
/,I,I
p65,I,I
/,I,I
c,I,I
-,I,I
Rel,I,I
and,O,O
STAT,B,B
-,I,I
6,I,I
are,O,O
effectively,O,O
induced,O,O
by,O,O
CD40L,B,O
and,O,O
IL,B,B
-,I,I
4,I,I
",",O,O
respectively,O,O
",",O,O
and,O,O
bind,O,O
to,O,O
specific,O,O
DNA,B,B
motifs,I,O
within,O,O
the,O,O
ECS,B,O
.,O,O
CIITA,B,O
-,O,O
induced,O,O
occupation,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
promoters,I,O
is,O,O
independent,O,O
of,O,O
the,O,O
cooperative,O,O
stabilization,O,O
of,O,O
the,O,O
promoter,B,O
-,I,O
bound,I,O
multi,I,O
-,I,O
protein,I,O
complexes,I,O
.,O,O
Activation,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
promoters,I,O
requires,O,O
binding,O,O
of,O,O
at,O,O
least,O,O
three,O,O
distinct,O,O
multi,B,O
-,I,O
protein,I,O
complexes,I,O
(,O,O
RFX,B,B
",",O,O
X2BP,B,B
and,O,O
NF,B,B
-,I,I
Y,I,I
),O,O
.,O,O
We,O,O
show,O,O
",",O,O
however,O,O
",",O,O
that,O,O
the,O,O
presence,O,O
of,O,O
CIITA,B,O
does,O,O
not,O,O
affect,O,O
the,O,O
stability,O,O
of,O,O
the,O,O
higher,O,O
-,O,O
order,O,O
protein,O,O
complex,O,O
formed,O,O
on,O,O
DNA,O,B
by,O,O
RFX,B,B
",",O,O
X2BP,B,B
and,O,O
NF,B,B
-,I,I
Y,I,I
.,O,O
Finally,O,O
",",O,O
we,O,O
conclude,O,O
that,O,O
this,O,O
effect,O,O
of,O,O
CIITA,B,O
is,O,O
cell,O,O
-,O,O
type,O,O
specific,O,O
",",O,O
since,O,O
expression,O,O
of,O,O
CIITA,B,O
is,O,O
not,O,O
required,O,O
for,O,O
normal,O,O
occupation,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
promoters,I,O
in,O,O
B,O,O
lymphocytes,O,O
.,O,O
SH2,B,B
domain,I,I
-,I,I
containing,I,I
protein,I,I
76,I,I
(,O,I
SLP,B,I
-,I,I
76,I,I
),O,I
interacts,O,O
with,O,O
the,O,O
guanine,B,B
nucleotide,I,I
exchange,I,I
factor,I,I
Vav,B,O
to,O,O
activate,O,O
the,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
cells,I,O
(,O,O
NF,B,B
-,I,I
AT,I,I
),O,I
",",O,O
and,O,O
its,O,O
expression,O,O
is,O,O
required,O,O
for,O,O
normal,O,O
T,O,O
cell,O,O
development,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
another,O,O
inducible,O,O
gene,O,O
expression,O,O
of,O,O
monocyte,B,B
chemotactic,I,I
protein,I,I
-,I,I
1,I,I
(,O,I
a,O,I
CC,B,I
chemokine,I,I
),O,I
and,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
transcriptional,B,O
factor,I,O
(,O,O
FcRFgamma,B,O
),O,O
bound,O,O
to,O,O
the,O,O
gamma,B,O
response,I,O
region,I,O
were,O,O
similarly,O,O
or,O,O
less,O,O
abundantly,O,O
induced,O,O
by,O,O
IFNgamma,B,O
treatment,O,O
in,O,O
PMA,O,O
-,O,O
or,O,O
RA,O,O
-,O,O
differentiated,O,O
U937,O,O
cells,O,O
",",O,O
indicating,O,O
that,O,O
increased,O,O
IP,B,O
-,I,O
10,I,O
mRNA,I,O
induction,O,O
was,O,O
not,O,O
due,O,O
to,O,O
the,O,O
augmented,O,O
ability,O,O
of,O,O
the,O,O
cells,O,O
to,O,O
respond,O,O
to,O,O
the,O,O
presence,O,O
of,O,O
IFNgamma,B,O
.,O,O
Role,O,O
of,O,O
cellular,B,O
tumor,I,O
necrosis,I,O
factor,I,O
receptor,I,O
-,I,O
associated,I,O
factors,I,O
in,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
and,O,O
lymphocyte,O,O
transformation,O,O
by,O,O
herpesvirus,O,O
Saimiri,O,O
STP,B,O
.,O,O
In,O,O
addition,O,O
",",O,O
a,O,O
somewhat,O,O
divergent,O,O
region,O,O
of,O,O
STP,B,O
-,I,O
C488,I,O
is,O,O
critical,O,O
for,O,O
TRAF,B,O
association,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
caspase,O,O
1,O,O
(,O,O
ICE,O,O
),O,O
did,O,O
not,O,O
cleave,O,O
SP1,B,O
in,O,O
vitro,O,O
.,O,O
Comparison,O,O
of,O,O
tumor,O,O
specimen,O,O
from,O,O
MM,O,O
precursor,O,O
lesions,O,O
",",O,O
primary,O,O
tumors,O,O
",",O,O
and,O,O
metastases,O,O
revealed,O,O
that,O,O
CD40,B,B
surface,O,I
expression,O,I
is,O,O
down,O,O
-,O,O
regulated,O,O
during,O,O
tumor,O,O
progression,O,O
.,O,O
CD40,B,B
expression,O,I
was,O,O
confirmed,O,O
in,O,O
7,O,O
human,O,O
MM,O,O
cell,O,O
lines,O,O
established,O,O
from,O,O
immunogenic,O,O
primary,O,O
tumors,O,O
or,O,O
metastases,O,O
",",O,O
whereas,O,O
11,O,O
cell,O,O
lines,O,O
established,O,O
from,O,O
advanced,O,O
stages,O,O
were,O,O
CD40,B,B
negative,O,I
.,O,O
Furthermore,O,O
",",O,O
CD40,B,B
ligation,O,O
of,O,O
a,O,O
HLA,O,B
-,O,I
A2,O,I
+,O,O
",",O,O
MelanA,O,B
/,O,I
MART1,O,I
+,O,O
MM,O,O
cell,O,O
line,O,O
enhanced,O,O
its,O,O
susceptibility,O,O
to,O,O
specific,O,O
lysis,O,O
by,O,O
a,O,O
HLA,O,B
-,O,I
A2,O,I
-,O,O
restricted,O,O
",",O,O
MelanA,O,B
/,O,I
MART,O,I
-,O,I
1,O,I
-,O,O
specific,O,O
CTL,O,O
clone,O,O
.,O,O
Human,O,O
immunodeficiency,O,O
virus,O,O
-,O,O
associated,O,O
Hodgkin,O,O
s,O,O
disease,O,O
derives,O,O
from,O,O
post,O,O
-,O,O
germinal,O,O
center,O,O
B,O,O
cells,O,O
.,O,O
Human,O,O
immunodeficiency,O,O
virus,O,O
-,O,O
associated,O,O
Hodgkin,O,O
s,O,O
disease,O,O
(,O,O
HIV,O,B
-,O,I
HD,O,I
),O,O
displays,O,O
several,O,O
peculiarities,O,O
when,O,O
compared,O,O
with,O,O
HD,O,O
of,O,O
the,O,O
general,O,O
population,O,O
.,O,O
MDS1,B,B
/,I,I
EVI1,I,I
is,O,O
inappropriately,O,O
activated,O,O
in,O,O
myeloid,O,B
leukemias,O,I
following,O,O
chromosomal,O,O
rearrangements,O,O
involving,O,O
band,B,O
3q26,I,O
.,O,O
This,O,O
fusion,O,O
protein,O,O
contains,O,O
the,O,O
DNA,B,B
-,I,I
binding,I,I
domain,I,I
of,O,O
the,O,O
transcription,B,O
factor,I,O
AML1,B,B
fused,O,O
in,O,O
-,O,O
frame,O,O
to,O,O
the,O,O
entire,O,O
MDS1,B,B
/,I,I
EVI1,I,I
with,O,O
the,O,O
exclusion,O,O
of,O,O
its,O,O
first,O,O
12,O,O
amino,O,B
acids,O,I
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
have,O,O
analyzed,O,O
the,O,O
response,O,O
of,O,O
the,O,O
hematopoietic,O,B
precursor,O,I
cell,O,I
line,O,I
32Dcl3,O,O
",",O,O
expressing,O,O
either,O,O
the,O,O
normal,B,O
protein,I,O
MDS1,I,B
/,I,I
EVI1,I,I
or,O,O
the,O,O
fusion,B,O
protein,I,O
AML1,I,B
/,I,I
MDS1,I,I
/,I,I
EVI1,I,I
",",O,O
to,O,O
factors,O,O
that,O,O
control,O,O
cell,O,O
differentiation,O,O
or,O,O
cell,O,O
replication,O,O
.,O,O
This,O,O
effect,O,O
is,O,O
similar,O,O
to,O,O
that,O,O
previously,O,O
described,O,O
by,O,O
others,O,O
for,O,O
32Dcl3,O,O
cells,O,O
that,O,O
express,O,O
transgenic,B,O
Evil,I,O
.,O,O
By,O,O
using,O,O
the,O,O
yeast,O,O
two,O,O
-,O,O
hybrid,O,O
system,O,O
",",O,O
we,O,O
also,O,O
show,O,O
that,O,O
EVI1,B,O
(,O,O
contained,O,O
in,O,O
its,O,O
entirety,O,O
in,O,O
MDS1,B,O
/,I,O
EVI1,I,O
and,O,O
AML1,B,O
/,I,O
MDS1,I,O
/,I,O
EVI1,I,O
),O,O
physically,O,O
interacts,O,O
with,O,O
SMAD3,B,O
",",O,O
which,O,O
is,O,O
an,O,O
intracellular,O,O
mediator,O,O
of,O,O
TGF,B,O
-,I,O
beta1,I,O
signaling,O,O
.,O,O
The,O,O
levels,O,O
of,O,O
cAMP,B,B
-,I,I
dependent,I,I
protein,I,I
kinase,I,I
and,O,O
Rap1,B,B
were,O,O
assessed,O,O
by,O,O
Western,O,O
blot,O,O
analysis,O,O
",",O,O
immunostaining,O,O
",",O,O
and,O,O
computer,O,O
-,O,O
assisted,O,O
imaging,O,O
.,O,O
In,O,O
many,O,O
pathological,O,O
situations,O,O
",",O,O
the,O,O
balance,O,O
between,O,O
Th1,O,B
and,O,O
Th2,O,B
immune,O,I
responses,O,I
determines,O,O
the,O,O
outcome,O,O
of,O,O
diverse,O,O
immunologically,O,O
mediated,O,O
clinical,O,O
syndromes,O,O
including,O,O
infectious,O,O
",",O,O
autoimmune,O,O
",",O,O
and,O,O
allergic,O,O
diseases,O,O
.,O,O
Tcf,B,B
-,I,I
1,I,I
-,O,I
mediated,O,O
transcription,O,O
in,O,O
T,O,O
lymphocytes,O,O
:,O,O
differential,O,O
role,O,O
for,O,O
glycogen,B,B
synthase,I,I
kinase,I,I
-,I,I
3,I,I
in,O,O
fibroblasts,O,O
and,O,O
T,O,O
cells,O,O
.,O,O
Beta,O,B
-,O,I
catenin,O,I
is,O,O
the,O,O
vertebrate,O,O
homolog,O,O
of,O,O
the,O,O
Drosophila,B,B
segment,I,I
polarity,I,I
gene,I,I
Armadillo,B,I
and,O,O
plays,O,O
roles,O,O
in,O,O
both,O,O
cell,O,O
-,O,O
cell,O,O
adhesion,O,O
and,O,O
transduction,O,O
of,O,O
the,O,O
Wnt,O,B
signaling,O,I
cascade,O,I
.,O,O
Recently,O,O
",",O,O
members,O,O
of,O,O
the,O,O
Lef,B,O
/,I,O
Tcf,I,O
transcription,I,O
factor,I,O
family,I,O
have,O,O
been,O,O
identified,O,O
as,O,O
protein,O,B
partners,O,O
of,O,O
beta,B,O
-,I,O
catenin,I,O
",",O,O
explaining,O,O
how,O,O
beta,B,O
-,I,O
catenin,I,O
alters,O,O
gene,O,O
expression,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
in,O,O
C57MG,O,O
fibroblast,O,O
cells,O,O
",",O,O
lithium,O,O
inactivates,O,O
GSK,B,B
-,I,I
3beta,I,I
and,O,O
induces,O,O
Tcf,O,B
-,O,I
controlled,O,I
transcription,O,I
.,O,O
Overexpression,O,O
of,O,O
SIT,B,O
in,O,O
Jurkat,O,O
cells,O,O
downmodulates,O,O
T,O,O
cell,O,O
receptor,O,O
-,O,O
and,O,O
phytohemagglutinin,O,O
-,O,O
mediated,O,O
activation,O,O
of,O,O
the,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
(,O,O
NF,B,B
-,I,I
AT,I,I
),O,O
by,O,O
interfering,O,O
with,O,O
signaling,O,O
processes,O,O
that,O,O
are,O,O
probably,O,O
located,O,O
upstream,O,O
of,O,O
activation,O,O
of,O,O
phospholipase,B,O
C,I,O
.,O,O
However,O,O
",",O,O
binding,O,O
of,O,O
to,O,O
SIT,B,B
is,O,O
not,O,O
required,O,O
for,O,O
inhibition,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
induction,O,O
",",O,O
suggesting,O,O
that,O,O
SIT,B,B
not,O,O
only,O,O
regulates,O,O
NF,B,B
-,I,I
AT,I,I
activity,O,O
but,O,O
also,O,O
controls,O,O
NF,B,B
-,I,I
AT,I,I
unrelated,O,O
pathways,O,O
of,O,O
T,O,O
cell,O,O
activation,O,O
involving,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
function,O,O
of,O,O
conditionally,O,O
expressed,O,O
EBNA2,B,O
in,O,O
the,O,O
context,O,O
of,O,O
the,O,O
IFN,B,B
response,O,O
in,O,O
Burkitt,O,O
s,O,O
lymphoma,O,O
cell,O,O
lines,O,O
.,O,O
Expression,O,O
of,O,O
EBNA2,B,B
led,O,O
to,O,O
the,O,O
transcriptional,O,O
activation,O,O
of,O,O
both,O,O
endogenous,O,O
or,O,O
transfected,O,O
IFN,B,B
-,I,I
stimulated,I,I
genes,I,I
(,O,O
ISGs,B,O
),O,O
",",O,O
genes,O,O
which,O,O
contain,O,O
within,O,O
their,O,O
promoters,B,O
either,O,O
the,O,O
interferon,B,B
-,I,I
stimulated,I,I
response,I,I
element,I,I
(,O,O
ISRE,B,O
),O,O
or,O,O
the,O,O
gamma,B,B
interferon,I,I
activation,I,I
site,I,I
(,O,O
GAS,B,O
),O,O
.,O,O
PGG,O,O
-,O,O
Glucan,O,O
",",O,O
a,O,O
soluble,O,O
beta,O,B
-,O,I
(,O,I
1,O,I
",",O,I
6,O,I
),O,I
-,O,I
branched,O,I
beta,O,I
-,O,I
(,O,I
1,O,I
",",O,I
3,O,I
),O,I
-,O,I
linked,O,I
glucose,O,I
homopolymer,O,I
derived,O,O
from,O,O
the,O,O
cell,O,O
wall,O,O
of,O,O
the,O,O
yeast,O,O
Saccharomyces,O,O
cerevisiae,O,O
",",O,O
is,O,O
an,O,O
immunomodulator,O,O
which,O,O
enhances,O,O
leukocyte,O,O
anti,O,O
-,O,O
infective,O,O
activity,O,O
and,O,O
enhances,O,O
myeloid,O,O
and,O,O
megakaryocyte,O,O
progenitor,O,O
proliferation,O,O
.,O,O
The,O,O
binding,O,O
of,O,O
3H,O,O
-,O,O
PGG,O,O
-,O,O
Glucan,O,O
to,O,O
human,O,B
leukocyte,O,I
membranes,O,O
was,O,O
specific,O,O
",",O,O
concentration,O,O
-,O,O
dependent,O,O
",",O,O
saturable,O,O
",",O,O
and,O,O
high,O,O
affinity,O,O
(,O,O
Kd,O,O
approximately,O,O
6,O,O
nM,O,O
),O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
potentiation,O,O
of,O,O
nonphlogistic,O,O
clearance,O,O
of,O,O
apoptotic,O,O
leukocytes,O,O
by,O,O
phagocytes,O,O
is,O,O
a,O,O
hitherto,O,O
unrecognized,O,O
property,O,O
of,O,O
glucocorticoids,O,B
that,O,O
has,O,O
potential,O,O
implications,O,O
for,O,O
therapies,O,O
aimed,O,O
at,O,O
promoting,O,O
the,O,O
resolution,O,O
of,O,O
inflammatory,O,O
diseases,O,O
.,O,O
However,O,O
",",O,O
the,O,O
mechanisms,O,O
and,O,O
strategies,O,O
to,O,O
overcome,O,O
RA,O,B
resistance,O,O
by,O,O
APL,O,O
cells,O,O
are,O,O
still,O,O
unclear,O,O
.,O,O
Also,O,O
",",O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
(,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
to,O,O
10,O,O
(,O,O
-,O,O
7,O,O
),O,O
mol,O,O
/,O,O
L,O,O
),O,O
in,O,O
combination,O,O
with,O,O
RA,O,B
markedly,O,O
inhibits,O,O
cellular,O,O
proliferation,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
and,O,O
time,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
Interestingly,O,O
",",O,O
the,O,O
combination,O,O
of,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
and,O,O
RA,O,B
markedly,O,O
enhanced,O,O
the,O,O
levels,O,O
of,O,O
p27,B,B
(,I,I
KIP1,I,I
),I,I
transcript,O,O
and,O,O
protein,O,O
as,O,O
compared,O,O
with,O,O
levels,O,O
induced,O,O
by,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
alone,O,O
.,O,O
Molecular,O,O
mechanisms,O,O
of,O,O
neutrophil,O,B
-,O,I
endothelial,O,B
cell,O,I
adhesion,O,I
induced,O,O
by,O,O
redox,O,O
imbalance,O,O
.,O,O
Previous,O,O
studies,O,O
have,O,O
implicated,O,O
a,O,O
role,O,O
for,O,O
intracellular,O,O
thiols,O,O
in,O,O
the,O,O
activation,O,O
of,O,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
and,O,O
transcriptional,O,O
regulation,O,O
of,O,O
endothelial,B,B
cell,I,I
adhesion,I,I
molecules,I,I
.,O,O
This,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
determine,O,O
whether,O,O
changes,O,O
in,O,O
endothelial,O,B
cell,O,I
glutathione,O,I
(,O,O
GSH,O,O
),O,O
or,O,O
oxidized,O,O
glutathione,O,B
(,O,O
GSSG,O,O
),O,O
can,O,O
alter,O,O
neutrophil,O,B
adhesivity,O,I
and,O,O
to,O,O
define,O,O
the,O,O
molecular,O,O
mechanism,O,O
that,O,O
underlies,O,O
this,O,O
GSSG,O,O
/,O,O
GSH,O,O
-,O,O
induced,O,O
adhesion,O,O
response,O,O
.,O,O
Diamide,O,O
plus,O,O
BSO,O,O
-,O,O
induced,O,O
thiol,O,O
/,O,O
disulfide,O,O
imbalance,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
biphasic,O,O
increase,O,O
in,O,O
neutrophil,O,O
adhesion,O,O
to,O,O
HUVECs,O,O
with,O,O
peak,O,O
responses,O,O
observed,O,O
at,O,O
15,O,O
minutes,O,O
(,O,O
phase,O,O
1,O,O
),O,O
and,O,O
240,O,O
minutes,O,O
(,O,O
phase,O,O
2,O,O
),O,O
.,O,O
This,O,O
study,O,O
demonstrates,O,O
that,O,O
changes,O,O
in,O,O
endothelial,O,B
cell,O,I
GSSG,O,O
/,O,O
GSH,O,O
cause,O,O
transcription,O,O
-,O,O
independent,O,O
and,O,O
transcription,O,O
-,O,O
dependent,O,O
surface,O,O
expression,O,O
of,O,O
different,O,O
endothelial,B,B
cell,I,I
adhesion,I,I
molecules,I,I
",",O,O
which,O,O
leads,O,O
to,O,O
a,O,O
2,O,O
-,O,O
phase,O,O
neutrophil,O,O
-,O,O
endothelial,O,O
adhesion,O,O
response,O,O
.,O,O
In,O,O
-,O,O
situ,O,O
detection,O,O
of,O,O
fragmented,O,O
DNA,O,B
was,O,O
performed,O,O
to,O,O
identify,O,O
apoptotic,O,O
cells,O,O
.,O,O
Angiotensin,B,O
II,I,O
activates,O,O
the,O,O
proinflammatory,B,O
transcription,I,O
factor,I,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
in,O,O
human,O,O
monocytes,O,O
.,O,O
ANG,B,O
II,I,O
",",O,O
like,O,O
TNFalpha,B,B
",",O,O
caused,O,O
rapid,O,O
activation,O,O
of,O,O
NF,B,O
-,I,O
kappaB,I,O
in,O,O
human,O,O
mononuclear,O,O
cells,O,O
isolated,O,O
from,O,O
peripheral,O,O
blood,O,O
by,O,O
Ficoll,O,O
density,O,O
gradient,O,O
.,O,O
Recently,O,O
",",O,O
its,O,O
presence,O,O
has,O,O
been,O,O
demonstrated,O,O
in,O,O
atherosclerotic,O,O
lesions,O,O
.,O,O
Increased,O,O
mRNA,B,B
and,O,O
surface,O,O
expression,O,O
of,O,O
E,B,B
-,I,I
selectin,I,I
",",O,O
ICAM,B,B
-,I,I
1,I,I
",",O,O
and,O,O
VCAM,B,B
-,I,I
1,I,I
were,O,O
noted,O,O
within,O,O
hours,O,O
.,O,O
Transient,O,O
pseudo,O,O
-,O,O
hypoaldosteronism,O,O
following,O,O
resection,O,O
of,O,O
the,O,O
ileum,O,O
:,O,O
normal,O,O
level,O,O
of,O,O
lymphocytic,B,O
aldosterone,I,B
receptors,I,I
outside,O,O
the,O,O
acute,O,O
phase,O,O
.,O,O
A,O,O
urinary,O,O
steroidogram,O,O
resulted,O,O
in,O,O
highly,O,O
elevated,O,O
tetrahydrocortisol,O,B
(,O,O
THF,O,O
:,O,O
13,O,O
.,O,O
3,O,O
mg,O,O
/,O,O
24h,O,O
;,O,O
N,O,O
:,O,O
1,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
0,O,O
),O,O
with,O,O
no,O,O
increase,O,O
in,O,O
tetrahydrocortisone,O,B
(,O,O
THE,O,O
:,O,O
3,O,O
.,O,O
16,O,O
mg,O,O
/,O,O
24h,O,O
;,O,O
N,O,O
:,O,O
2,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
2,O,O
0,O,O
),O,O
excretion,O,O
",",O,O
and,O,O
with,O,O
low,O,O
THE,O,B
/,O,O
THF,O,O
(,O,O
0,O,O
.,O,O
24,O,O
;,O,O
N,O,O
:,O,O
1,O,O
.,O,O
87,O,O
+,O,O
/,O,O
-,O,O
0,O,O
36,O,O
),O,O
and,O,O
alpha,O,B
THF,O,O
/,O,O
THF,O,O
(,O,O
0,O,O
.,O,O
35,O,O
;,O,O
N,O,O
:,O,O
0,O,O
92,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
42,O,O
),O,O
ratios,O,O
.,O,O
Small,O,O
-,O,O
bowel,O,O
resection,O,O
in,O,O
ileostomized,O,O
patients,O,O
causes,O,O
excessive,O,O
fecal,O,O
sodium,O,B
losses,O,O
and,O,O
results,O,O
in,O,O
chronic,O,O
sodium,O,B
depletion,O,O
with,O,O
contraction,O,O
of,O,O
the,O,O
plasma,O,O
volume,O,O
and,O,O
severe,O,O
secondary,O,O
hyperaldosteronism,O,O
.,O,O
A,O,O
decrease,O,O
in,O,O
the,O,O
translation,O,O
rate,O,O
is,O,O
observed,O,O
when,O,O
the,O,O
cells,O,O
are,O,O
induced,O,O
to,O,O
differentiate,O,O
along,O,O
the,O,O
monocytic,O,O
/,O,O
macrophage,O,O
pathway,O,O
or,O,O
along,O,O
the,O,O
granulocytic,O,O
pathway,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
treatment,O,O
of,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
with,O,O
retinoic,O,O
acid,O,O
or,O,O
DMSO,O,O
",",O,O
which,O,O
results,O,O
in,O,O
a,O,O
granulocytic,O,O
differentiation,O,O
of,O,O
these,O,O
cells,O,O
",",O,O
decreases,O,O
4E,B,B
-,I,I
BP1,I,I
amount,O,O
without,O,O
affecting,O,O
its,O,O
phosphorylation,O,O
and,O,O
strongly,O,O
increases,O,O
4E,B,B
-,I,I
BP2,I,I
amount,O,O
.,O,O
We,O,O
found,O,O
frequent,O,O
hypermutation,O,O
in,O,O
follicular,O,O
lymphoma,O,O
(,O,O
25,O,O
of,O,O
59,O,O
42,O,O
%,O,O
),O,O
(,O,O
germinal,O,O
center,O,O
cell,O,O
origin,O,O
),O,O
and,O,O
mucosa,O,O
-,O,O
associated,O,O
lymphoid,O,O
tissue,O,O
(,O,O
MALT,O,O
),O,O
lymphoma,O,O
(,O,O
19,O,O
of,O,O
45,O,O
42,O,O
%,O,O
),O,O
(,O,O
postgerminal,O,O
center,O,O
),O,O
",",O,O
but,O,O
only,O,O
occasionally,O,O
in,O,O
mantle,O,O
cell,O,O
lymphoma,O,O
(,O,O
1,O,O
of,O,O
21,O,O
4,O,O
.,O,O
8,O,O
%,O,O
),O,O
(,O,O
pregerminal,O,O
center,O,O
),O,O
Most,O,O
mutations,O,O
were,O,O
outside,O,O
the,O,O
motifs,O,O
potentially,O,O
important,O,O
for,O,O
transcription,O,O
",",O,O
suggesting,O,O
they,O,O
were,O,O
not,O,O
important,O,O
in,O,O
lymphomagenesis,O,O
but,O,O
may,O,O
",",O,O
like,O,O
Ig,O,B
mutation,O,O
",",O,O
represent,O,O
an,O,O
inherent,O,O
feature,O,O
of,O,O
the,O,O
lymphoma,O,O
precursor,O,O
cells,O,O
.,O,O
Markedly,O,O
impaired,O,O
binding,O,O
was,O,O
observed,O,O
",",O,O
consistent,O,O
with,O,O
both,O,O
the,O,O
use,O,O
of,O,O
different,O,O
anchor,O,O
residues,O,O
and,O,O
with,O,O
changes,O,O
in,O,O
levels,O,O
of,O,O
DQ,O,O
cis,O,O
-,O,O
dimer,B,O
availability,O,O
for,O,O
peptide,O,O
binding,O,O
interactions,O,O
.,O,O
Detection,O,O
of,O,O
intracellular,B,O
phosphorylated,I,O
STAT,I,B
-,I,I
1,I,I
by,O,O
flow,O,O
cytometry,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
this,O,O
technique,O,O
should,O,O
permit,O,O
dissection,O,O
of,O,O
a,O,O
full,O,O
range,O,O
of,O,O
cellular,O,O
signaling,O,O
pathways,O,O
at,O,O
the,O,O
protein,O,O
level,O,O
.,O,O
Consequently,O,O
",",O,O
cytosolic,O,O
activation,O,O
",",O,O
nuclear,O,O
translocation,O,O
and,O,O
DNA,O,B
-,O,I
binding,O,I
of,O,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
were,O,O
decreased,O,O
.,O,O
5,O,O
Neutrophil,O,B
apoptosis,O,O
and,O,O
inhibition,O,O
of,O,O
neutrophil,O,B
function,O,O
were,O,O
induced,O,O
at,O,O
lower,O,O
concentrations,O,O
of,O,O
SMX,O,O
-,O,O
NHOH,O,O
and,O,O
SMX,O,O
-,O,O
NO,O,O
than,O,O
those,O,O
inducing,O,O
loss,O,O
of,O,O
membrane,O,O
viability,O,O
",",O,O
with,O,O
SMX,O,O
having,O,O
no,O,O
effect,O,O
.,O,O
7,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
balance,O,O
between,O,O
oxidation,O,O
of,O,O
SMX,O,O
to,O,O
its,O,O
toxic,O,O
metabolites,O,O
and,O,O
their,O,O
reduction,O,O
is,O,O
an,O,O
important,O,O
protective,O,O
cellular,O,O
mechanism,O,O
.,O,O
Recently,O,O
",",O,O
we,O,O
reported,O,O
cases,O,O
of,O,O
angioimmunoblastic,O,O
T,O,O
-,O,O
cell,O,O
lymphoma,O,O
(,O,O
AITL,O,O
),O,O
with,O,O
hyperplastic,O,O
GCs,O,O
(,O,O
AITL,O,O
/,O,O
GC,O,O
),O,O
",",O,O
and,O,O
observed,O,O
that,O,O
borders,O,O
of,O,O
enlarged,O,O
GCs,O,O
were,O,O
ill,O,O
defined,O,O
",",O,O
with,O,O
features,O,O
suggestive,O,O
of,O,O
an,O,O
outward,O,O
migration,O,O
of,O,O
GC,O,O
cells,O,O
to,O,O
surrounding,O,O
interfollicular,O,O
zones,O,O
.,O,O
In,O,O
FL,O,O
",",O,O
follicles,O,O
were,O,O
densely,O,O
populated,O,O
",",O,O
and,O,O
their,O,O
borders,O,O
were,O,O
irregular,O,O
",",O,O
with,O,O
some,O,O
Bcl,O,B
-,O,I
6,O,I
+,O,I
cells,O,O
in,O,O
the,O,O
interfollicular,O,O
zones,O,O
.,O,O
Double,O,O
staining,O,O
revealed,O,O
that,O,O
these,O,O
interfollicular,O,O
Bcl,O,B
+,O,I
cells,O,I
in,O,O
AITL,O,O
/,O,O
GC,O,O
were,O,O
Bcl6,O,B
+,O,I
/,O,O
CD3,O,B
+,O,I
/,O,O
CD20,O,B
-,O,I
/,O,O
CD57,O,B
-,O,I
T,O,O
cells,O,O
.,O,O
In,O,O
typical,O,O
AITL,O,O
",",O,O
some,O,O
neoplastic,O,O
cells,O,O
were,O,O
positive,O,O
for,O,O
Bcl,B,B
-,I,I
6,I,I
",",O,O
showing,O,O
variable,O,O
degrees,O,O
of,O,O
staining,O,O
.,O,O
(,O,O
2,O,O
),O,O
Intrafollicular,O,O
CD3,O,B
+,O,I
T,O,O
cells,O,O
",",O,O
many,O,O
of,O,O
which,O,O
were,O,O
also,O,O
positive,O,O
for,O,O
Bcl,B,B
-,I,I
6,I,I
",",O,O
were,O,O
markedly,O,O
depleted,O,O
in,O,O
AITL,O,O
/,O,O
GC,O,O
",",O,O
with,O,O
increased,O,O
interfollicular,O,O
Bcl,O,B
-,O,I
6,O,I
+,O,I
/,O,O
CD3,O,B
+,O,I
cells,O,I
",",O,O
suggesting,O,O
an,O,O
outward,O,O
migration,O,O
of,O,O
intrafollicular,O,O
T,O,O
cells,O,O
in,O,O
this,O,O
condition,O,O
.,O,O
(,O,O
5,O,O
),O,O
Some,O,O
neoplastic,O,O
cells,O,O
in,O,O
AITL,O,O
stained,O,O
for,O,O
Bcl,B,B
-,I,I
6,I,I
",",O,O
suggesting,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
Bcl,B,B
-,I,I
6,I,I
expression,O,O
in,O,O
this,O,O
tumor,O,O
.,O,O
To,O,O
continue,O,O
our,O,O
investigation,O,O
of,O,O
the,O,O
cellular,O,O
events,O,O
that,O,O
occur,O,O
following,O,O
human,O,O
CMV,O,O
(,O,O
HCMV,O,O
),O,O
infection,O,O
",",O,O
we,O,O
focused,O,O
on,O,O
the,O,O
regulation,O,O
of,O,O
cellular,O,O
activation,O,O
following,O,O
viral,O,O
binding,O,O
to,O,O
human,O,O
monocytes,O,O
.,O,O
Because,O,O
these,O,O
induced,O,O
gene,O,O
products,O,O
have,O,O
NF,B,B
-,I,I
kappaB,I,I
sites,I,O
in,O,O
their,O,O
promoter,B,O
regions,I,O
",",O,O
we,O,O
next,O,O
examined,O,O
whether,O,O
there,O,O
was,O,O
an,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
nuclear,O,O
NF,B,B
-,I,I
kappaB,I,I
levels,O,O
.,O,O
These,O,O
results,O,O
support,O,O
our,O,O
hypothesis,O,O
that,O,O
HCMV,O,O
initiates,O,O
a,O,O
signal,O,O
transduction,O,O
pathway,O,O
that,O,O
leads,O,O
to,O,O
monocyte,O,O
activation,O,O
and,O,O
pinpoints,O,O
a,O,O
potential,O,O
mechanism,O,O
whereby,O,O
HCMV,O,O
infection,O,O
of,O,O
monocytes,O,O
can,O,O
result,O,O
in,O,O
profound,O,O
pathogenesis,O,O
",",O,O
especially,O,O
in,O,O
chronic,O,O
inflammatory,O,O
-,O,O
type,O,O
conditions,O,O
.,O,O
Glycoprotein,B,B
(,I,O
GP,I,O
),I,O
IX,I,O
is,O,O
a,O,O
subunit,O,O
of,O,O
the,O,O
von,B,O
Willebrand,I,O
receptor,I,O
",",O,O
GPIb,B,O
-,I,O
V,I,O
-,I,O
IX,I,O
",",O,O
which,O,O
mediates,O,O
adhesion,O,O
of,O,O
platelets,O,O
to,O,O
the,O,O
subendothelium,O,O
of,O,O
damaged,O,O
blood,O,O
vessels,O,O
.,O,O
Previous,O,O
characterization,O,O
of,O,O
the,O,O
GPIX,B,B
promoter,I,O
identified,O,O
a,O,O
functional,O,O
Ets,O,B
site,O,O
that,O,O
",",O,O
when,O,O
disrupted,O,O
",",O,O
reduced,O,O
promoter,O,O
activity,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
Fli,B,B
-,I,I
1,I,I
is,O,O
likely,O,O
to,O,O
regulate,O,O
lineage,B,O
-,I,O
specific,I,O
genes,I,O
during,O,O
megakaryocytopoiesis,O,O
.,O,O
However,O,O
",",O,O
I,B,O
(,I,O
kappa,I,O
),I,O
B,I,O
(,I,O
alpha,I,O
),I,O
has,O,O
also,O,O
been,O,O
detected,O,O
in,O,O
the,O,O
nucleus,O,O
of,O,O
cell,O,O
lines,O,O
and,O,O
when,O,O
overexpressed,O,O
by,O,O
transient,O,O
transfection,O,O
.,O,O
Immunoprecipitation,O,O
experiments,O,O
failed,O,O
to,O,O
demonstrate,O,O
an,O,O
association,O,O
between,O,O
nuclear,O,O
I,B,O
(,I,O
kappa,I,O
),I,O
B,I,O
(,I,O
alpha,I,O
),I,O
and,O,O
NF,B,B
-,I,I
kappaB,I,I
proteins,O,O
.,O,O
SERCA,B,B
activity,O,O
was,O,O
measured,O,O
as,O,O
the,O,O
thapsigargin,O,O
sensitive,O,O
",",O,O
Ca2,O,B
+,O,I
dependent,O,O
and,O,O
ouabain,O,B
resistant,O,O
",",O,O
ATP,O,B
in,O,O
platelet,O,B
membranes,O,I
.,O,O
Cobalt,O,O
chloride,O,O
-,O,O
induced,O,O
signaling,O,O
in,O,O
endothelium,O,B
leading,O,O
to,O,O
the,O,O
augmented,O,O
adherence,O,O
of,O,O
sickle,O,B
red,O,I
blood,O,I
cells,O,I
and,O,O
transendothelial,O,O
migration,O,O
of,O,O
monocyte,O,B
-,O,I
like,O,I
HL,O,I
-,O,I
60,O,I
cells,O,I
is,O,O
blocked,O,O
by,O,O
PAF,O,B
-,O,I
receptor,O,I
antagonist,O,O
.,O,O
In,O,O
response,O,O
to,O,O
hypoxia,O,O
",",O,O
sickle,O,B
red,O,I
blood,O,I
cells,O,I
(,O,O
SS,O,O
RBC,O,O
),O,O
and,O,O
leukocytes,O,O
exhibit,O,O
increased,O,O
adherence,O,O
to,O,O
the,O,O
vascular,O,O
endothelium,O,O
",",O,O
while,O,O
diapedesis,O,O
of,O,O
leukocytes,O,O
through,O,O
the,O,O
blood,O,O
vessel,O,O
increases,O,O
.,O,O
We,O,O
utilized,O,O
CoCl2,O,O
as,O,O
a,O,O
mimetic,O,O
molecule,O,O
for,O,O
hypoxia,O,O
to,O,O
study,O,O
cellular,O,O
signaling,O,O
pathways,O,O
.,O,O
Additionally,O,O
",",O,O
CoCl2,O,O
caused,O,O
a,O,O
two,O,O
-,O,O
to,O,O
threefold,O,O
increase,O,O
in,O,O
the,O,O
rate,O,O
of,O,O
transendothelial,O,O
migration,O,O
of,O,O
monocyte,O,B
-,O,I
like,O,I
HL,O,I
-,O,I
60,O,I
cells,O,I
and,O,O
a,O,O
twentyfold,O,O
increase,O,O
in,O,O
phosphorylation,O,O
of,O,O
platelet,B,B
endothelial,I,I
cell,I,I
adhesion,I,I
molecules,I,I
(,O,O
PECAM,B,O
-,I,O
1,I,O
),O,O
.,O,O
Activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
is,O,O
thought,O,O
to,O,O
be,O,O
required,O,O
for,O,O
cytokine,O,O
release,O,O
from,O,O
LPS,O,O
-,O,O
responsive,O,O
cells,O,O
",",O,O
a,O,O
critical,O,O
step,O,O
for,O,O
endotoxic,O,O
effects,O,O
.,O,O
LPS,O,O
-,O,O
induced,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
was,O,O
not,O,O
inhibited,O,O
by,O,O
a,O,O
dominant,O,O
negative,O,O
mutant,O,O
of,O,O
TRAF2,B,O
that,O,O
is,O,O
involved,O,O
in,O,O
TNF,B,O
signaling,O,O
.,O,O
Tyrosine,O,O
phosphorylation,O,O
of,O,O
IFN,B,B
-,I,I
gammaR,I,I
",",O,O
Jak1,B,O
",",O,O
Jak2,B,O
",",O,O
and,O,O
Stat1alpha,B,O
was,O,O
examined,O,O
by,O,O
immunoblotting,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
IFN,B,B
-,I,I
gamma,I,I
enhanced,O,O
the,O,O
DNA,O,B
-,O,I
binding,O,I
activity,O,O
of,O,O
Stat1alpha,B,O
.,O,O
Moreover,O,O
",",O,O
several,O,O
transgenic,O,O
mice,O,O
developed,O,O
acute,O,O
leukemia,O,O
",",O,O
classified,O,O
as,O,O
T,O,O
-,O,O
ALL,O,O
based,O,O
on,O,O
the,O,O
surface,O,O
marker,O,O
analysis,O,O
and,O,O
DNA,O,B
rearrangements,O,O
",",O,O
suggesting,O,O
that,O,O
an,O,O
additional,O,O
event,O,O
is,O,O
required,O,O
for,O,O
malignant,O,O
transformation,O,O
of,O,O
lymphoid,O,O
cells,O,O
expressing,O,O
E2A,B,O
-,I,O
HLF,I,O
.,O,O
Our,O,O
findings,O,O
provide,O,O
insight,O,O
into,O,O
the,O,O
biological,O,O
function,O,O
of,O,O
E2A,B,B
-,I,I
HLF,I,I
in,O,O
lymphoid,O,B
development,O,I
and,O,O
also,O,O
its,O,O
role,O,O
in,O,O
leukemogenesis,O,O
.,O,O
This,O,O
RXR,B,B
agonist,O,I
activity,O,I
is,O,O
blocked,O,O
by,O,O
RAR,B,B
-,O,I
specific,O,I
antagonists,O,I
",",O,O
suggesting,O,O
extensive,O,O
cross,O,O
-,O,O
talk,O,O
between,O,O
the,O,O
partners,O,O
of,O,O
the,O,O
RXR,B,B
-,I,I
RARalpha403,I,I
heterodimer,I,I
.,O,O
We,O,O
found,O,O
IL,B,B
-,I,I
2Ralpha,I,I
expression,O,O
to,O,O
be,O,O
increased,O,O
in,O,O
BAL,O,O
cells,O,O
from,O,O
involved,O,O
sites,O,O
of,O,O
active,O,O
pulmonary,O,B
tuberculosis,O,I
.,O,O
Expression,O,O
of,O,O
the,O,O
alpha,B,B
-,I,I
chain,I,I
of,O,O
IL,B,B
-,I,I
2Ralpha,I,I
on,O,O
peripheral,O,O
blood,O,O
monocytes,O,O
(,O,O
PBM,O,O
),O,O
was,O,O
induced,O,O
by,O,O
M,O,O
.,O,O
by,O,O
flow,O,O
cytometry,O,O
evaluation,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
two,O,O
VDR,B,O
3,I,O
-,I,O
UTR,I,O
haplotypes,O,O
conferred,O,O
an,O,O
identical,O,O
half,O,O
-,O,O
life,O,O
on,O,O
a,O,O
heterologous,B,O
beta,I,B
-,I,I
globin,I,I
reporter,I,I
gene,I,I
",",O,O
in,O,O
an,O,O
in,O,O
vitro,O,O
assay,O,O
.,O,O
The,O,O
IL,B,B
-,I,I
2,I,I
growth,O,I
hormone,O,I
is,O,O
the,O,O
major,O,O
growth,O,O
factor,O,O
of,O,O
activated,O,O
T,O,O
lymphocytes,O,O
during,O,O
a,O,O
developing,O,O
immune,O,O
response,O,O
.,O,O
In,O,O
several,O,O
cell,O,O
types,O,O
",",O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
/,O,O
or,O,O
activating,B,O
protein,I,B
-,I,I
1,I,I
(,O,I
AP,B,I
-,I,I
1,I,I
),O,I
has,O,O
been,O,O
demonstrated,O,O
to,O,O
be,O,O
extremely,O,O
important,O,O
in,O,O
blocking,O,O
apoptosis,O,O
.,O,O
Similarly,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
neither,O,O
activates,O,O
JNK,B,O
nor,O,O
increases,O,O
AP,B,B
-,I,I
1,I,I
binding,O,O
activity,O,O
to,O,O
a,O,O
consensus,O,O
o,B,O
-,I,O
tetradecanoylphorbol,I,O
13,I,O
-,I,O
acetate,I,O
(,I,O
TPA,I,O
),I,O
response,I,O
element,I,O
.,O,O
In,O,O
particular,O,O
",",O,O
our,O,O
findings,O,O
suggest,O,O
that,O,O
local,O,O
metabolism,O,O
of,O,O
steroids,O,B
by,O,O
normal,O,O
as,O,O
well,O,O
as,O,O
leukemic,O,O
myeloid,O,O
cells,O,O
influences,O,O
their,O,O
responsiveness,O,O
to,O,O
D3,O,B
and,O,O
retinoids,O,B
.,O,O
The,O,O
phosphorylation,O,O
appears,O,O
to,O,O
be,O,O
related,O,O
to,O,O
the,O,O
signaling,O,O
events,O,O
that,O,O
are,O,O
activated,O,O
by,O,O
TRAF2,B,O
under,O,O
these,O,O
circumstances,O,O
",",O,O
since,O,O
two,O,O
nonfunctional,O,O
mutants,O,O
were,O,O
found,O,O
to,O,O
be,O,O
phosphorylated,O,O
significantly,O,O
less,O,O
than,O,O
the,O,O
wild,B,O
-,I,O
type,I,O
protein,I,O
.,O,O
We,O,O
conclude,O,O
from,O,O
these,O,O
studies,O,O
that,O,O
the,O,O
phosphorylation,O,O
of,O,O
TRAF2,B,B
is,O,O
likely,O,O
to,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
regulating,O,O
signaling,O,O
by,O,O
virtue,O,O
of,O,O
its,O,O
ability,O,O
to,O,O
influence,O,O
the,O,O
CD40,B,O
-,B,O
TRAF2,I,O
interaction,O,O
.,O,O
Unlike,O,O
the,O,O
proposed,O,O
role,O,O
of,O,O
Cbl,B,O
as,O,O
a,O,O
negative,O,O
regulator,O,O
",",O,O
our,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
Cbl,B,O
homologue,O,O
Cbl,B,O
-,I,O
b,I,O
has,O,O
a,O,O
positive,O,O
role,O,O
in,O,O
T,O,O
-,O,O
cell,O,O
signaling,O,O
",",O,O
most,O,O
likely,O,O
via,O,O
a,O,O
direct,O,O
interaction,O,O
with,O,O
the,O,O
upstream,B,O
kinase,I,O
Zap,B,O
-,I,O
70,I,O
.,O,O
Grf40,B,O
",",O,O
A,O,O
novel,O,O
Grb2,B,O
family,I,O
member,I,O
",",O,O
is,O,O
involved,O,O
in,O,O
T,O,O
cell,O,O
signaling,O,O
through,O,O
interaction,O,O
with,O,O
SLP,B,O
-,I,O
76,I,O
and,O,O
LAT,B,O
.,O,O
As,O,O
a,O,O
result,O,O
of,O,O
its,O,O
transforming,O,O
abilities,O,O
",",O,O
activated,B,O
Ras,I,B
is,O,O
expressed,O,O
in,O,O
a,O,O
great,O,O
number,O,O
of,O,O
cancers,O,O
.,O,O
This,O,O
review,O,O
will,O,O
discuss,O,O
the,O,O
mechanisms,O,O
by,O,O
which,O,O
Ras,B,B
expressing,O,O
tumors,O,O
are,O,O
able,O,O
to,O,O
evade,O,O
destruction,O,O
by,O,O
the,O,O
immune,O,O
system,O,O
and,O,O
enhance,O,O
their,O,O
growth,O,O
and,O,O
metastatic,O,O
potential,O,O
.,O,O
Though,O,O
the,O,O
levels,O,O
of,O,O
DP1,B,B
and,I,O
-,I,O
2,I,O
increase,O,O
when,O,O
cells,O,O
progress,O,O
from,O,O
G0,O,O
to,O,O
S,O,O
",",O,O
the,O,O
proportion,O,O
of,O,O
DP1,B,B
to,O,O
DP2,B,B
remains,O,O
relatively,O,O
constant,O,O
during,O,O
the,O,O
cell,O,O
cycle,O,O
.,O,O
We,O,O
also,O,O
observed,O,O
an,O,O
increase,O,O
in,O,O
electrophoretic,O,O
mobility,O,O
of,O,O
the,O,O
predominant,O,O
E2F,B,B
components,I,O
",",O,O
DP1,B,B
and,O,O
E2F4,B,B
",",O,O
as,O,O
B,O,O
-,O,O
lymphocytes,O,O
progressed,O,O
from,O,O
G0,O,O
into,O,O
early,O,O
G1,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
DNA,O,B
-,O,I
binding,O,I
activities,O,I
of,O,O
Jun,B,O
-,I,O
Fos,I,O
heterodimers,I,O
were,O,O
observed,O,O
by,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
during,O,O
the,O,O
course,O,O
of,O,O
natural,O,O
cytotoxicity,O,O
.,O,O
The,O,O
therapeutic,O,O
potential,O,O
of,O,O
drugs,O,O
that,O,O
block,O,O
the,O,O
induction,O,O
of,O,O
cyclooxygenase,B,B
-,I,I
2,I,I
has,O,O
been,O,O
emphasized,O,O
.,O,O
When,O,O
two,O,O
4,O,O
-,O,O
trifluoromethyl,O,O
salicylate,O,O
derivatives,O,O
[,O,O
2,O,O
-,O,O
acetoxy,O,O
-,O,O
4,O,O
-,O,O
trifluoromethyl,O,O
-,O,O
benzoic,O,O
acid,O,O
(,O,O
triflusal,O,O
),O,O
and,O,O
its,O,O
deacetylated,O,O
metabolite,O,O
2,O,O
-,O,O
hydroxy,O,O
-,O,O
4,O,O
-,O,O
trifluoromethylbenzo,O,O
acid,O,O
(,O,O
HTB,O,O
),O,O
],O,O
were,O,O
compared,O,O
with,O,O
aspirin,O,O
and,O,O
sodium,O,O
salicylate,O,O
as,O,O
cyclooxygenase,B,B
-,I,I
2,I,I
(,O,I
COX,O,I
-,O,I
2,O,I
),O,I
inhibitors,O,O
",",O,O
we,O,O
observed,O,O
that,O,O
in,O,O
bacterial,O,O
lipopolysaccharide,O,O
-,O,O
activated,O,O
human,O,O
blood,O,O
",",O,O
triflusal,O,O
",",O,O
aspirin,O,O
",",O,O
and,O,O
HTB,O,O
",",O,O
but,O,O
not,O,O
sodium,O,O
salicylate,O,O
",",O,O
inhibited,O,O
COX,O,B
-,O,I
2,O,I
-,O,I
mediated,O,I
prostaglandin,O,I
E2,O,I
(,O,I
PGE2,O,I
),O,I
production,O,O
(,O,O
IC50,O,O
0,O,O
.,O,O
16,O,O
",",O,O
0,O,O
.,O,O
18,O,O
",",O,O
0,O,O
.,O,O
39,O,O
",",O,O
and,O,O
>,O,O
10,O,O
mM,O,O
",",O,O
respectively,O,O
Intracellular,O,O
signals,O,O
that,O,O
mediate,O,O
differentiation,O,O
of,O,O
pluripotent,O,O
hemopoietic,O,O
progenitors,O,O
to,O,O
dendritic,O,B
cells,O,I
(,O,O
DC,O,O
),O,O
are,O,O
largely,O,O
undefined,O,O
.,O,O
The,O,O
CD34,O,B
+,O,I
myelomonocytic,O,I
cell,O,I
line,O,I
KG1,O,I
differentiates,O,O
into,O,O
dendritic,O,B
-,O,I
like,O,I
cells,O,I
in,O,O
response,O,O
to,O,O
granulocyte,B,O
-,I,O
macrophage,I,O
CSF,I,O
plus,O,O
TNF,B,B
-,I,I
alpha,I,I
",",O,O
or,O,O
PMA,O,O
(,O,O
with,O,O
or,O,O
without,O,O
the,O,O
calcium,O,O
ionophore,O,O
ionomycin,O,O
",",O,O
or,O,O
TNF,B,B
-,I,I
alpha,I,I
),O,O
",",O,O
with,O,O
different,O,O
stimuli,O,O
mediating,O,O
different,O,O
aspects,O,O
of,O,O
the,O,O
process,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
examined,O,O
whether,O,O
gp41,B,O
-,O,O
induced,O,O
IL,B,B
-,I,I
10,I,I
up,O,O
-,O,O
regulation,O,O
is,O,O
mediated,O,O
by,O,O
the,O,O
previously,O,O
described,O,O
synergistic,O,O
activation,O,O
of,O,O
cAMP,O,O
and,O,O
NF,B,B
-,I,I
kappaB,I,I
pathways,O,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
modulation,O,O
of,O,O
transcriptional,O,O
activity,O,O
in,O,O
myelopoiesis,O,O
and,O,O
leukemogenesis,O,O
.,O,O
The,O,O
transcription,B,O
factors,I,O
PU,B,O
.,I,O
1,I,O
and,O,O
C,B,O
/,I,O
EBPalpha,I,O
are,O,O
responsible,O,O
for,O,O
normal,O,O
myeloid,O,O
differentiation,O,O
from,O,O
stem,O,O
cells,O,O
to,O,O
monocytes,O,O
or,O,O
granulocytes,O,O
.,O,O
However,O,O
",",O,O
the,O,O
phenotypic,O,O
analysis,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
-,O,I
deficient,O,O
mice,O,O
supports,O,O
the,O,O
idea,O,O
that,O,O
there,O,O
are,O,O
tissue,O,O
-,O,O
and,O,O
gene,O,O
-,O,O
specific,O,O
functions,O,O
as,O,O
well,O,O
.,O,O
Despite,O,O
minimal,O,O
discrepancies,O,O
in,O,O
the,O,O
coding,B,O
region,I,O
",",O,O
there,O,O
are,O,O
striking,O,O
tissue,O,O
-,O,O
and,O,O
cell,O,O
type,O,O
-,O,O
specific,O,O
differences,O,O
in,O,O
isoform,O,O
expression,O,O
patterns,O,O
.,O,O
Thus,O,O
CTL,O,O
clones,O,O
that,O,O
recognized,O,O
the,O,O
viral,O,O
",",O,O
self,O,O
",",O,O
and,O,O
bacterial,O,O
peptides,O,O
expressed,O,O
a,O,O
highly,O,O
restricted,O,O
alphabeta,O,O
TCR,B,O
phenotype,O,O
.,O,O
RFLAT,B,B
-,I,I
1,I,I
:,O,O
a,O,O
new,O,O
zinc,B,O
finger,I,O
transcription,I,O
factor,I,O
that,O,O
activates,O,O
RANTES,B,B
gene,I,I
expression,O,O
in,O,O
T,O,O
lymphocytes,O,O
.,O,O
Furthermore,O,O
",",O,O
these,O,O
oxidative,O,O
stresses,O,O
inhibited,O,O
activity,O,O
of,O,O
calcineurin,O,O
",",O,O
a,O,O
serine,O,O
/,O,O
threonine,B,O
phosphatase,I,O
that,O,O
regulates,O,O
NFAT,B,B
activation,O,O
.,O,O
Several,O,O
intracellular,O,O
signaling,B,O
proteins,I,O
",",O,O
such,O,O
as,O,O
CBL,B,B
and,O,O
VAV,B,B
",",O,O
were,O,O
phosphorylated,O,O
on,O,O
tyrosine,O,O
in,O,O
response,O,O
to,O,O
CD80,B,O
",",O,O
CD86,B,O
",",O,O
and,O,O
anti,B,O
-,I,O
CD28,I,O
mAb,I,O
.,O,O
In,O,O
addition,O,O
",",O,O
the,O,O
association,O,O
of,O,O
phosphoinositide,B,B
3,I,I
-,I,I
kinase,I,I
with,O,O
CD28,B,O
and,O,O
enhanced,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
phospholipase,O,B
Cgamma,O,I
were,O,O
seen,O,O
after,O,O
anti,O,O
-,O,O
CD28,O,O
mAb,O,O
and,O,O
CHO,O,B
-,O,I
CD80,O,I
stimulation,O,O
but,O,O
to,O,O
a,O,O
much,O,O
lesser,O,O
extent,O,O
after,O,O
CHO,B,B
-,I,I
CD86,I,I
stimulation,O,O
.,O,O
However,O,O
",",O,O
CD80,B,O
and,O,O
CD86,B,O
also,O,O
induce,O,O
distinct,O,O
signal,O,O
transduction,O,O
pathways,O,O
including,O,O
the,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
CD28,B,O
and,O,O
phospholipase,B,B
Cgamma1,I,I
and,O,O
the,O,O
SH2,B,O
-,O,O
dependent,O,O
association,O,O
of,O,O
phosphoinositide,B,B
3,I,I
-,I,I
kinase,I,I
with,O,O
CD28,B,O
.,O,O
Binding,O,O
of,O,O
HMG,B,B
-,I,I
I,I,I
(,I,I
Y,I,I
),I,I
elicits,O,O
structural,O,O
changes,O,O
in,O,O
a,O,O
silencer,O,O
of,O,O
the,O,O
human,B,O
beta,I,B
-,I,I
globin,I,I
gene,I,I
.,O,O
If,O,O
there,O,O
is,O,O
a,O,O
reciprocal,O,O
elevation,O,O
of,O,O
gamma,B,B
-,I,I
globin,I,I
expression,O,O
upon,O,O
repression,O,O
",",O,O
this,O,O
approach,O,O
could,O,O
be,O,O
useful,O,O
in,O,O
additional,O,O
hemoglobinopathies,O,O
.,O,O
We,O,O
demonstrate,O,O
that,O,O
binding,O,O
of,O,O
HMG,B,B
-,I,I
I,I,I
(,I,I
Y,I,I
),I,I
to,O,O
this,O,O
oligonucleotide,O,O
causes,O,O
bending,O,O
/,O,O
flexure,O,O
of,O,O
the,O,O
DNA,O,B
.,O,O
The,O,O
master,O,O
switch,O,O
for,O,O
the,O,O
expression,O,O
of,O,O
these,O,O
genes,O,O
is,O,O
the,O,O
class,B,O
II,I,B
transactivator,I,I
(,O,O
CIITA,B,O
),O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
overexpression,O,O
of,O,O
CREB,B,O
inhibited,O,O
GAL4,B,O
-,O,O
p65,O,O
(,O,O
286,O,O
-,O,O
551,O,O
),O,O
-,O,O
mediated,O,O
transcription,O,O
.,O,O
Glucocorticoid,B,B
receptors,I,I
in,O,O
cord,O,O
blood,O,O
lymphocytes,O,O
of,O,O
healthy,O,O
neonates,O,O
and,O,O
of,O,O
preterms,O,O
suffering,O,O
from,O,O
respiratory,O,O
distress,O,O
syndrome,O,O
.,O,O
We,O,O
measured,O,O
the,O,O
number,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
(,O,O
GR,B,O
),O,O
in,O,O
cord,O,B
blood,O,I
lymphocytes,O,I
and,O,O
the,O,O
binding,O,O
affinity,O,O
(,O,O
Kd,O,O
),O,O
in,O,O
15,O,O
term,O,O
and,O,O
in,O,O
20,O,O
preterm,O,O
babies,O,O
.,O,O
Thirteen,O,O
preterms,O,O
of,O,O
the,O,O
latter,O,O
group,O,O
received,O,O
prenatal,O,O
steroid,O,B
treatment,O,I
.,O,O
The,O,O
number,O,O
of,O,O
GR,B,O
and,O,O
the,O,O
Kd,O,O
were,O,O
similar,O,O
in,O,O
the,O,O
term,O,O
and,O,O
preterm,O,O
(,O,O
with,O,O
and,O,O
without,O,O
NRDS,O,O
),O,O
babies,O,O
.,O,O
In,O,O
order,O,O
to,O,O
elucidate,O,O
the,O,O
role,O,O
of,O,O
NF,B,B
-,I,I
ATp,I,I
",",O,O
one,O,O
of,O,O
the,O,O
most,O,O
prominent,O,O
members,O,O
of,O,O
family,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
transcription,I,I
factors,I,I
in,O,O
peripheral,O,O
T,O,O
lymphocytes,O,O
",",O,O
in,O,O
T,O,O
cell,O,O
activation,O,O
and,O,O
differentiation,O,O
we,O,O
created,O,O
NF,B,B
-,I,I
ATp,I,I
-,O,I
deficient,O,I
mice,O,I
by,O,O
gene,O,O
targeting,O,O
.,O,O
Apart,O,O
from,O,O
clear,O,O
-,O,O
cut,O,O
defects,O,O
in,O,O
the,O,O
synthesis,O,O
of,O,O
mRNAs,B,O
for,O,O
Th2,B,B
-,I,I
type,I,I
lymphokines,I,I
",",O,O
such,O,O
as,O,O
IL,B,B
-,I,I
4,I,I
",",O,O
IL,B,B
-,I,I
5,I,I
",",O,O
IL,B,B
-,I,I
10,I,I
and,O,O
IL,B,B
-,I,I
13,I,I
",",O,O
in,O,O
primary,O,O
and,O,O
secondary,O,O
stimulations,O,O
of,O,O
spleen,O,O
cells,O,O
in,O,O
vitro,O,O
",",O,O
of,O,O
a,O,O
distinct,O,O
impaired,O,O
deletion,O,O
of,O,O
V,O,O
beta,O,O
11,O,O
+,O,O
/,O,O
CD4,O,O
+,O,O
T,O,O
lymphocytes,O,O
from,O,O
these,O,O
mice,O,O
was,O,O
detected,O,O
after,O,O
superantigen,O,O
injection,O,O
.,O,O
Moreover,O,O
",",O,O
NF,B,B
-,I,I
ATp,I,I
-,O,I
-,O,I
mice,O,O
older,O,O
than,O,O
6,O,O
weeks,O,O
show,O,O
an,O,O
2,O,O
-,O,O
5,O,O
fold,O,O
increase,O,O
in,O,O
number,O,O
of,O,O
lymphocytes,O,O
.,O,O
Our,O,O
data,O,O
constitute,O,O
a,O,O
starting,O,O
point,O,O
for,O,O
studies,O,O
to,O,O
elucidate,O,O
the,O,O
molecular,O,O
mechanism,O,O
by,O,O
which,O,O
TGF,B,B
-,I,I
beta,I,I
regulates,O,O
IgA,B,B
production,O,O
.,O,O
Daidzein,O,O
and,O,O
genistein,O,O
glucuronides,O,O
in,O,O
vitro,O,O
are,O,O
weakly,O,O
estrogenic,O,O
and,O,O
activate,O,O
human,O,B
natural,O,I
killer,O,I
cells,O,O
at,O,O
nutritionally,O,O
relevant,O,O
concentrations,O,O
.,O,O
Daidzein,O,B
and,O,O
genistein,O,B
glucuronides,O,I
(,O,O
DG,O,B
and,O,O
GG,O,B
),O,O
",",O,O
major,O,O
isoflavone,O,O
metabolites,O,O
",",O,O
may,O,O
be,O,O
partly,O,O
responsible,O,O
for,O,O
biological,O,O
effects,O,O
of,O,O
isoflavones,O,O
",",O,O
such,O,O
as,O,O
estrogen,O,B
receptor,O,I
binding,O,O
and,O,O
natural,O,O
killer,O,B
cell,O,I
(,O,I
NK,O,I
),O,O
activation,O,O
or,O,O
inhibition,O,O
.,O,O
DG,O,B
and,O,O
GG,O,B
were,O,O
synthesized,O,O
using,O,O
3,O,O
-,O,O
methylcholanthrene,O,O
-,O,O
induced,O,O
rat,O,O
liver,O,O
microsomes,O,O
.,O,O
DG,O,O
and,O,O
GG,O,O
were,O,O
further,O,O
purified,O,O
by,O,O
a,O,O
Sephadex,O,O
LH,O,O
-,O,O
20,O,O
column,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
propose,O,O
a,O,O
novel,O,O
function,O,O
for,O,O
CD44,O,B
.,O,O
Using,O,O
synovial,O,B
cells,O,O
from,O,O
rheumatoid,O,B
arthritis,O,I
(,O,I
RA,O,I
),O,I
patients,O,O
",",O,O
we,O,O
demonstrated,O,O
that,O,O
CD44,O,B
cross,O,O
-,O,O
linking,O,O
and,O,O
binding,O,O
to,O,O
hyaluronan,O,O
augmented,O,O
VCAM,B,B
-,I,I
1,I,I
expression,O,O
and,O,O
subsequently,O,O
VCAM,B,B
-,I,I
1,I,I
-,O,I
mediated,O,I
cell,O,O
adhesion,O,O
.,O,O
In,O,O
neutrophils,O,O
",",O,O
TNF,B,B
-,I,I
alpha,I,I
caused,O,O
a,O,O
gliotoxin,O,O
-,O,O
inhibitable,O,O
activation,O,O
of,O,O
an,O,O
inducible,O,O
form,O,O
of,O,O
NF,B,O
-,I,O
kappaB,I,O
",",O,O
a,O,O
response,O,O
that,O,O
may,O,O
underlie,O,O
the,O,O
ability,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
to,O,O
delay,O,O
apoptosis,O,O
at,O,O
later,O,O
times,O,O
(,O,O
12,O,O
-,O,O
24,O,O
h,O,O
),O,O
and,O,O
limit,O,O
its,O,O
early,O,O
killing,O,O
effect,O,O
.,O,O
We,O,O
previously,O,O
identified,O,O
a,O,O
Fas,B,B
ligand,I,I
regulatory,I,I
element,I,I
(,O,O
FLRE,B,O
),O,O
in,O,O
the,O,O
Fas,B,B
ligand,I,I
(,I,O
fasL,I,O
),I,O
promoter,I,O
that,O,O
binds,O,O
Egr,B,B
family,I,I
proteins,I,I
and,O,O
demonstrated,O,O
that,O,O
Egr,B,B
-,I,I
3,I,I
(,O,O
PILOT,B,O
),O,O
but,O,O
not,O,O
Egr,B,B
-,I,I
1,I,I
(,O,O
NGFI,B,O
-,I,O
A,I,O
",",O,O
Krox,B,O
-,I,O
24,I,O
",",O,O
Tis,B,O
-,I,O
8,I,O
",",O,O
and,O,O
Zif,B,O
-,I,O
268,I,O
),O,O
induces,O,O
transcription,O,O
of,O,O
fasL,B,O
.,O,O
The,O,O
aberrant,O,O
CD4,O,B
(,O,O
-,O,O
),O,O
CD8,O,B
(,O,O
-,O,O
),O,O
T,O,O
cells,O,O
from,O,O
lpr,O,O
/,O,O
lpr,O,O
and,O,O
gld,O,O
/,O,O
gld,O,O
mice,O,O
",",O,O
which,O,O
have,O,O
mutations,O,O
in,O,O
the,O,O
genes,O,O
encoding,O,O
Fas,B,B
and,O,O
FasL,B,B
",",O,O
respectively,O,O
",",O,O
have,O,O
an,O,O
activated,O,O
phenotype,O,O
and,O,O
constitutively,O,O
express,O,O
high,O,O
levels,O,O
of,O,O
fasL,B,B
mRNA,I,O
",",O,O
prompting,O,O
us,O,O
to,O,O
ask,O,O
what,O,O
role,O,O
if,O,O
any,O,O
the,O,O
FLRE,B,B
and,O,O
Egr,B,B
family,I,I
proteins,I,I
have,O,O
in,O,O
this,O,O
aberrant,O,O
expression,O,O
of,O,O
fasL,B,O
.,O,O
Although,O,O
overexpressed,O,O
Egr,B,B
-,I,I
1,I,I
was,O,O
ineffective,O,O
",",O,O
overexpressed,O,O
Egr,B,B
-,I,I
2,I,I
was,O,O
as,O,O
potent,O,O
as,O,O
Egr,B,B
-,I,I
3,I,I
in,O,O
inducing,O,O
fasL,B,B
promoter,I,I
-,I,I
dependent,I,I
reporter,I,I
constructs,I,I
in,O,O
T,O,O
cell,O,O
hybridomas,O,O
and,O,O
HeLa,O,O
cells,O,O
",",O,O
and,O,O
both,O,O
up,O,O
-,O,O
regulated,O,O
endogenous,O,O
fasL,B,B
mRNA,I,I
in,O,O
HeLa,O,O
cells,O,O
.,O,O
FasL,B,B
-,I,I
dependent,I,I
reporter,I,I
constructs,I,I
in,O,O
MRL,O,O
-,O,O
lpr,O,O
/,O,O
lpr,O,O
and,O,O
C3H,O,O
-,O,O
gld,O,O
/,O,O
gld,O,O
CD4,O,O
(,O,O
-,O,O
),O,O
CD8,O,O
(,O,O
-,O,O
),O,O
T,O,O
cells,O,O
were,O,O
constitutively,O,O
active,O,O
",",O,O
and,O,O
this,O,O
activity,O,O
was,O,O
largely,O,O
prevented,O,O
by,O,O
mutation,O,O
of,O,O
the,O,O
critical,O,O
Egr,B,B
family,I,I
binding,I,I
element,I,I
.,O,O
The,O,O
activity,O,O
of,O,O
the,O,O
CCAAT,B,O
-,I,O
box,I,O
binding,I,O
factor,I,O
NF,I,O
-,I,O
Y,I,O
is,O,O
modulated,O,O
through,O,O
the,O,O
regulated,O,O
expression,O,O
of,O,O
its,O,O
A,B,O
subunit,I,O
during,O,O
monocyte,O,O
to,O,O
macrophage,O,O
differentiation,O,O
:,O,O
regulation,O,O
of,O,O
tissue,B,O
-,I,O
specific,I,O
genes,I,O
through,O,O
a,O,O
ubiquitous,O,O
transcription,B,O
factor,I,O
.,O,O
Recent,O,O
studies,O,O
have,O,O
suggested,O,O
that,O,O
Y319,O,O
also,O,O
positively,O,O
regulate,O,O
ZAP,B,O
-,I,O
70,I,O
function,O,O
.,O,O
Deletion,O,O
of,O,O
interdomain,B,O
B,I,B
did,O,O
not,O,O
affect,O,O
the,O,O
ability,O,O
of,O,O
ZAP,B,O
-,I,O
70,I,O
to,O,O
bind,O,O
to,O,O
the,O,O
receptor,O,O
.,O,O
Differential,O,O
induction,O,O
of,O,O
DNA,B,B
-,I,I
binding,I,I
activities,I,O
following,O,O
CD19,B,O
cross,O,O
-,O,O
linking,O,O
in,O,O
human,O,O
B,O,B
lineage,O,I
cells,O,O
.,O,O
The,O,O
B,B,B
cell,I,I
-,I,I
specific,I,I
cell,I,I
surface,I,I
molecule,I,I
CD19,B,I
is,O,O
expressed,O,O
at,O,O
all,O,O
stages,O,O
of,O,O
B,O,B
cell,O,I
development,O,I
",",O,O
including,O,O
normal,O,O
plasma,O,O
cells,O,O
",",O,O
and,O,O
mediates,O,O
signal,O,O
transduction,O,O
via,O,O
interaction,O,O
with,O,O
cytoplasmic,B,O
effector,I,O
proteins,I,O
.,O,O
Oxidants,O,O
",",O,O
transcription,B,O
factors,I,O
",",O,O
and,O,O
intestinal,O,B
inflammation,O,I
.,O,O
It,O,O
is,O,O
now,O,O
well,O,O
appreciated,O,O
that,O,O
chronic,O,O
gut,O,O
inflammation,O,O
is,O,O
characterized,O,O
by,O,O
enhanced,O,O
production,O,O
of,O,O
reactive,O,O
metabolites,O,O
of,O,O
oxygen,O,B
and,O,O
nitrogen,O,B
.,O,O
Finally,O,O
",",O,O
oxidants,O,O
are,O,O
believed,O,O
to,O,O
promote,O,O
intestinal,O,B
epithelial,O,I
cell,O,I
apoptosis,O,O
",",O,O
and,O,O
the,O,O
B,B,B
-,I,I
cell,I,I
lymphoma,I,I
/,I,I
leukemia,I,I
-,I,I
2,I,I
gene,I,I
product,I,I
is,O,O
believed,O,O
to,O,O
inhibit,O,O
this,O,O
phenomenon,O,O
in,O,O
an,O,O
antioxidant,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
The,O,O
regulatory,B,O
regions,I,O
of,O,O
several,O,O
genes,O,O
specifically,O,O
expressed,O,O
in,O,O
B,O,B
cells,O,I
contain,O,O
functional,B,O
binding,I,O
sites,I,O
for,O,O
Oct2,B,O
.,O,O
These,O,O
target,B,O
genes,I,O
show,O,O
quite,O,O
distinct,O,O
expression,O,O
patterns,O,O
demonstrating,O,O
that,O,O
transcription,B,O
factors,I,O
in,O,O
addition,O,O
to,O,O
Oct2,B,O
are,O,O
involved,O,O
in,O,O
their,O,O
regulation,O,O
.,O,O
The,O,O
protein,O,B
has,O,O
no,O,O
known,O,O
DNA,B,B
-,I,I
binding,I,I
domain,I,I
but,O,O
does,O,O
contain,O,O
three,O,O
ankyrin,O,B
repeats,O,I
that,O,O
are,O,O
likely,O,O
to,O,O
be,O,O
important,O,O
in,O,O
protein,O,O
-,O,O
protein,O,O
interactions,O,O
.,O,O
Binding,O,O
of,O,O
c,B,O
Rel,I,O
to,O,O
STAT5,B,B
target,I,O
sequences,I,O
in,O,O
HTLV,O,O
-,O,O
transformed,O,O
T,O,O
cells,O,O
.,O,O
Fas,B,B
(,O,O
CD95,B,I
),O,O
and,O,O
Fas,B,B
ligand,I,O
(,O,O
CD95L,B,I
),O,O
are,O,O
an,O,O
interacting,O,O
receptor,O,O
-,O,O
ligand,O,O
pair,O,O
required,O,O
for,O,O
immune,O,O
homeostasis,O,O
.,O,O
Although,O,O
resting,O,O
Jurkat,O,O
cells,O,O
express,O,O
Fas,B,B
",",O,O
Fas,B,B
mRNA,I,O
was,O,O
induced,O,O
approximately,O,O
10,O,O
fold,O,O
in,O,O
2,O,O
h,O,O
upon,O,O
P,O,O
/,O,O
I,O,O
stimulation,O,O
.,O,O
The,O,O
functional,O,O
contribution,O,O
of,O,O
the,O,O
kappaB,B,B
-,I,I
Sp1,I,I
composite,I,I
site,I,I
in,O,O
P,B,O
/,I,O
I,I,O
-,I,O
inducible,I,O
fas,I,O
promoter,I,O
activation,O,O
was,O,O
verified,O,O
by,O,O
using,O,O
kappaB,O,B
-,O,I
Sp1,B,I
concatamers,O,I
(,O,O
-,B,O
295,I,O
to,I,O
-,I,O
286,I,O
),O,O
in,O,O
a,O,O
thymidine,B,O
kinase,I,O
promoter,I,O
-,I,O
driven,I,O
reporter,I,O
construct,I,O
and,O,O
native,B,O
promoter,I,O
constructs,I,O
in,O,O
Jurkat,O,O
cells,O,O
overexpressing,O,O
IkappaB,B,O
-,I,O
alpha,I,O
.,O,O
The,O,O
induction,O,O
of,O,O
clonal,O,O
anergy,O,O
in,O,O
a,O,O
T,O,O
cell,O,O
inhibits,O,O
IL,B,B
-,I,I
2,I,I
secretion,O,O
because,O,O
of,O,O
the,O,O
development,O,O
of,O,O
a,O,O
proximal,O,O
signal,O,O
transduction,O,O
defect,O,O
.,O,O
Members,O,O
of,O,O
the,O,O
cyclic,B,O
adenosine,I,O
monophosphate,I,O
(,I,O
cAMP,I,O
),I,O
response,I,O
element,I,O
binding,I,O
(,I,O
CREB,I,O
),I,O
/,I,O
activating,I,O
transcription,I,O
factor,I,O
1,I,O
(,I,O
ATF,I,O
-,I,O
1,I,O
),I,O
family,I,O
of,O,O
transcription,B,O
factors,I,O
bind,O,O
three,O,O
21,B,O
-,I,O
bp,I,O
repeats,I,O
(,O,O
Tax,B,O
-,I,O
responsive,I,O
element,I,O
-,I,O
1,I,O
",",O,O
or,O,O
TRE,B,O
-,I,O
1,I,O
),O,O
within,O,O
the,O,O
viral,B,O
promoter,I,O
and,O,O
are,O,O
important,O,O
for,O,O
basal,O,O
and,O,O
Tax,O,O
-,O,O
mediated,O,O
transcription,O,O
.,O,O
Exposing,O,O
human,O,O
umbilical,O,O
vein,O,O
endothelial,O,B
cells,O,I
(,O,O
HUVECs,O,O
),O,O
to,O,O
anoxia,O,O
/,O,O
reoxygenation,O,O
(,O,O
A,O,O
/,O,O
R,O,O
),O,O
results,O,O
in,O,O
an,O,O
increase,O,O
in,O,O
polymorphonuclear,O,B
leukocyte,O,I
(,O,O
PMN,O,O
),O,O
adhesion,O,O
to,O,O
HUVECs,O,O
.,O,O
NO,O,B
production,O,O
by,O,O
HUVECs,O,O
is,O,O
increased,O,O
after,O,O
the,O,O
second,O,O
A,O,O
/,O,O
R,O,O
challenge,O,O
",",O,O
but,O,O
not,O,O
after,O,O
the,O,O
first,O,O
A,O,O
/,O,O
R,O,O
challenge,O,O
.,O,O
However,O,O
",",O,O
while,O,O
HUVECs,O,O
contained,O,O
endothelial,O,B
NOS,B,I
protein,I,I
",",O,O
no,O,O
inducible,O,O
NOS,B,O
was,O,O
detected,O,O
in,O,O
either,O,O
tolerant,O,O
or,O,O
nontolerant,O,O
cells,O,O
.,O,O
The,O,O
inhibition,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
was,O,O
observed,O,O
in,O,O
the,O,O
CD3,B,O
(,O,O
+,O,O
),O,O
T,O,O
-,O,O
lymphocyte,O,O
cytoplasm,O,B
as,O,O
early,O,O
as,O,O
4,O,O
h,O,O
after,O,O
activation,O,O
by,O,O
PMA,O,O
+,O,O
ionomycin,O,O
.,O,O
Delta,O,O
-,O,O
opioid,O,B
receptors,O,I
expressed,O,O
by,O,O
Jurkat,O,O
T,O,O
cells,O,O
enhance,O,O
IL,B,B
-,I,I
2,I,I
secretion,O,O
by,O,O
increasing,O,O
AP,B,O
-,I,O
1,I,O
complexes,I,O
and,O,O
activity,O,O
of,O,O
the,O,O
NF,B,O
-,I,O
AT,I,O
/,I,O
AP,I,O
-,I,O
1,I,O
-,I,O
binding,I,O
promoter,I,O
element,I,O
.,O,O
Reporter,O,O
gene,O,O
constructs,O,O
were,O,O
used,O,O
to,O,O
map,O,O
this,O,O
effect,O,O
of,O,O
deltorphin,O,O
to,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
-,I,I
and,I,O
NF,I,B
-,I,I
AT,I,I
/,I,I
AP,I,I
-,I,I
binding,I,I
sites,I,I
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
.,O,O
These,O,O
cells,O,O
",",O,O
stimulated,O,O
by,O,O
an,O,O
agonistic,O,O
monoclonal,O,O
antibody,O,O
against,O,O
CD40,B,O
or,O,O
by,O,O
transfection,O,O
with,O,O
a,O,O
CD40L,B,O
expression,I,O
vector,I,O
",",O,O
secreted,O,O
p40,B,O
and,O,O
showed,O,O
enhanced,O,O
p40,B,O
mRNA,I,O
expression,O,O
.,O,O
No,O,O
mutation,O,O
was,O,O
identified,O,O
in,O,O
either,O,O
of,O,O
the,O,O
genes,O,O
in,O,O
the,O,O
gynecomastias,O,O
.,O,O
We,O,O
have,O,O
mapped,O,O
the,O,O
DNase,B,B
-,I,I
I,I,I
-,I,I
hypersensitive,I,I
(,I,I
HS,I,I
),I,I
regions,I,O
of,O,O
the,O,O
human,B,O
GATA,I,B
-,I,I
3,I,I
gene,I,O
in,O,O
T,O,O
-,O,O
cells,O,O
and,O,O
non,O,B
-,O,I
T,O,I
-,O,I
cells,O,I
and,O,O
studied,O,O
their,O,O
transcriptional,O,O
activities,O,O
.,O,O
HS,B,O
I,I,O
-,I,O
III,I,O
",",O,O
located,O,O
5,O,O
from,O,O
the,O,O
transcriptional,B,O
initiation,I,O
site,I,O
",",O,O
were,O,O
found,O,O
in,O,O
hematopoietic,O,O
and,O,O
non,O,B
-,O,I
hematopoietic,O,I
cells,O,I
",",O,O
whereas,O,O
HS,B,O
IV,I,O
-,I,O
VII,I,O
",",O,O
located,O,O
3,O,O
from,O,O
the,O,O
transcriptional,B,O
start,I,O
site,I,O
",",O,O
were,O,O
exclusively,O,O
observed,O,O
in,O,O
T,O,O
-,O,O
cells,O,O
.,O,O
Among,O,O
these,O,O
hypersensitive,B,O
sites,I,O
",",O,O
two,O,O
transcriptional,B,O
control,I,O
elements,I,O
were,O,O
found,O,O
",",O,O
one,O,O
in,O,O
the,O,O
first,B,O
intron,I,O
of,O,O
the,O,O
GATA,B,B
-,I,I
3,I,I
gene,I,I
and,O,O
the,O,O
other,O,O
between,B,O
8,I,O
.,I,O
3,I,O
and,I,O
5,I,O
.,I,O
9,I,O
kilobases,I,O
5,O,O
from,O,O
the,O,O
GATA,B,B
-,I,I
3,I,I
transcriptional,I,I
initiation,I,I
site,I,I
.,O,O
Two,O,O
CAGGTG,O,O
E,O,O
-,O,O
boxes,O,O
",",O,O
located,O,O
at,O,O
the,O,O
5,B,O
-,I,O
and,I,O
3,I,O
-,I,O
ends,I,O
of,O,O
the,O,O
silencer,O,O
",",O,O
were,O,O
necessary,O,O
for,O,O
this,O,O
silencer,O,O
activity,O,O
.,O,O
The,O,O
3,B,O
-,I,O
CAGGTG,I,O
E,I,O
-,I,O
box,I,O
could,O,O
bind,O,O
USF,B,B
proteins,I,O
",",O,O
the,O,O
ubiquitous,B,O
repressor,I,O
ZEB,B,B
",",O,O
or,O,O
the,O,O
basic,B,O
helix,I,O
-,I,O
loop,I,O
-,I,O
helix,I,O
proteins,I,O
E2A,B,B
and,O,O
HEB,B,B
",",O,O
and,O,O
we,O,O
showed,O,O
that,O,O
a,O,O
competition,O,O
between,O,O
ZEB,B,B
and,O,O
E2A,B,B
/,I,I
HEB,I,I
proteins,I,O
is,O,O
involved,O,O
in,O,O
the,O,O
silencer,O,O
activity,O,O
.,O,O
Reactive,O,O
oxygen,O,O
intermediate,O,O
-,O,O
dependent,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
by,O,O
interleukin,B,O
-,I,O
1beta,I,O
requires,O,O
5,B,O
-,I,O
lipoxygenase,I,B
or,O,O
NADPH,O,B
oxidase,O,I
activity,O,O
.,O,O
However,O,O
",",O,O
the,O,O
sources,O,O
for,O,O
ROIs,O,O
in,O,O
various,O,O
cell,O,O
types,O,O
are,O,O
yet,O,O
to,O,O
be,O,O
determined,O,O
and,O,O
might,O,O
include,O,O
5,B,B
-,I,I
lipoxygenase,I,I
(,O,O
5,B,B
-,I,I
LOX,I,I
),O,O
and,O,O
NADPH,O,O
oxidase,O,O
.,O,O
Stimulation,O,O
of,O,O
lymphoid,O,B
cells,O,I
with,O,O
interleukin,B,B
-,I,I
1beta,I,I
(,O,O
IL,B,B
-,I,I
1beta,I,I
),O,O
led,O,O
to,O,O
ROI,O,O
production,O,O
and,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
",",O,O
which,O,O
could,O,O
both,O,O
be,O,O
blocked,O,O
by,O,O
antioxidants,O,O
or,O,O
FLAP,B,O
inhibitors,O,O
",",O,O
confirming,O,O
that,O,O
5,B,B
-,I,I
LOX,I,I
was,O,O
the,O,O
source,O,O
of,O,O
ROIs,O,O
and,O,O
was,O,O
required,O,O
for,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
in,O,O
these,O,O
cells,O,O
.,O,O
Cutting,O,O
edge,O,O
:,O,O
dominant,O,O
effect,O,O
of,O,O
Ile50Val,B,O
variant,I,O
of,O,O
the,O,O
human,B,O
IL,I,B
-,I,I
4,I,I
receptor,I,I
alpha,I,I
-,I,I
chain,I,I
in,O,O
IgE,B,O
synthesis,O,O
.,O,O
Constitutive,O,O
expression,O,O
of,O,O
human,B,O
colony,I,B
-,I,I
stimulating,I,I
factor,I,I
-,I,I
1,I,I
receptor,I,I
(,O,O
CSF,B,O
-,I,O
1R,I,O
),O,O
confers,O,O
long,O,O
-,O,O
lasting,O,O
CSF,B,O
-,I,O
1,I,O
-,O,O
dependent,O,O
proliferation,O,O
to,O,O
mouse,O,O
myeloid,O,O
cell,O,O
lines,O,O
.,O,O
Morphologic,O,O
and,O,O
cytofluorometry,O,O
analysis,O,O
established,O,O
that,O,O
most,O,O
47,O,O
.,O,O
10,O,O
cells,O,O
are,O,O
immature,O,O
myelomonocytic,O,O
cells,O,O
.,O,O
In,O,O
agar,O,O
cultures,O,O
",",O,O
47,O,O
.,O,O
10,O,O
cells,O,O
form,O,O
7,O,O
-,O,O
and,O,O
14,O,O
-,O,O
day,O,O
colonies,O,O
in,O,O
response,O,O
to,O,O
a,O,O
cocktail,O,O
of,O,O
granulocyte,B,B
/,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,O,O
2,O,O
.,O,O
5,O,O
ng,O,O
/,O,O
mL,O,O
),O,O
",",O,O
interleukin,B,B
-,I,I
3,I,I
(,O,O
1,O,O
ng,O,O
/,O,O
mL,O,O
),O,O
",",O,O
and,O,O
mouse,O,B
CSF,B,I
-,I,I
1,I,I
(,O,O
10,O,O
ng,O,O
/,O,O
mL,O,O
),O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
we,O,O
have,O,O
characterized,O,O
a,O,O
novel,O,O
continuous,O,O
myeloid,O,O
cell,O,O
line,O,O
presenting,O,O
a,O,O
hierarchical,O,O
structure,O,O
similar,O,O
to,O,O
that,O,O
of,O,O
the,O,O
bone,O,O
marrow,O,O
progenitor,O,O
cell,O,O
compartment,O,O
.,O,O
Regulation,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
expression,O,O
by,O,O
the,O,O
transcription,B,O
factor,I,O
JunB,B,O
during,O,O
T,O,O
helper,O,O
cell,O,O
differentiation,O,O
.,O,O
Here,O,O
we,O,O
show,O,O
that,O,O
JunB,B,O
",",O,O
but,O,O
not,O,O
the,O,O
other,O,O
Jun,B,O
family,I,O
members,I,O
",",O,O
was,O,O
selectively,O,O
induced,O,O
in,O,O
Th2,O,O
cells,O,O
and,O,O
not,O,O
in,O,O
Th1,O,O
cells,O,O
during,O,O
differentiation,O,O
.,O,O
The,O,O
finding,O,O
of,O,O
Tax,B,O
mutants,O,O
segregating,O,O
these,O,O
two,O,O
pathways,O,O
suggested,O,O
that,O,O
the,O,O
NF,B,O
-,I,O
kappaB,I,O
pathway,O,O
was,O,O
essential,O,O
for,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
independent,O,I
growth,O,O
of,O,O
CTLL,O,O
-,O,O
2,O,O
cells,O,O
while,O,O
the,O,O
CRE,B,O
pathway,O,O
was,O,O
unnecessary,O,O
.,O,O
However,O,O
",",O,O
both,O,O
pathways,O,O
were,O,O
necessary,O,O
for,O,O
another,O,O
transformation,O,O
-,O,O
related,O,O
activity,O,O
(,O,O
colony,O,O
formation,O,O
in,O,O
soft,O,O
agar,O,O
),O,O
of,O,O
CTLL,B,O
-,I,O
2,I,O
/,I,O
Tax,I,O
.,O,O
Our,O,O
results,O,O
show,O,O
that,O,O
Tax,B,O
has,O,O
at,O,O
least,O,O
two,O,O
distinct,O,O
activities,O,O
on,O,O
T,O,O
cells,O,O
",",O,O
and,O,O
suggest,O,O
that,O,O
Tax,B,O
plays,O,O
a,O,O
crucial,O,O
role,O,O
in,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
independent,O,I
T,O,I
-,O,I
cell,O,I
transformation,O,I
induced,O,O
by,O,O
HTLV,O,O
-,O,O
1,O,O
",",O,O
in,O,O
addition,O,O
to,O,O
its,O,O
well,O,O
-,O,O
known,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
dependent,O,I
cell,O,I
transformation,O,I
.,O,O
First,O,O
",",O,O
it,O,O
gives,O,O
no,O,O
information,O,O
on,O,O
memory,O,O
to,O,O
lytic,B,O
cycle,I,O
antigens,I,O
;,O,O
second,O,O
",",O,O
it,O,O
preferentially,O,O
amplifies,O,O
the,O,O
dominant,O,O
components,O,O
of,O,O
latent,O,O
antigen,O,O
-,O,O
specific,O,O
memory,O,O
at,O,O
the,O,O
expense,O,O
of,O,O
key,O,O
subdominant,O,O
reactivities,O,O
.,O,O
Here,O,O
we,O,O
describe,O,O
an,O,O
alternative,O,O
approach,O,O
",",O,O
based,O,O
on,O,O
in,O,O
vitro,O,O
stimulation,O,O
with,O,O
epitope,O,O
peptide,O,O
-,O,O
loaded,O,O
dendritic,O,B
cells,O,I
(,O,O
DCs,O,O
),O,O
",",O,O
which,O,O
allows,O,O
one,O,O
to,O,O
probe,O,O
the,O,O
CTL,O,B
repertoire,O,O
for,O,O
any,O,O
individual,O,O
reactivity,O,O
of,O,O
choice,O,O
;,O,O
this,O,O
method,O,O
proved,O,O
significantly,O,O
more,O,O
efficient,O,O
than,O,O
stimulation,O,O
with,O,O
peptide,O,O
alone,O,O
.,O,O
The,O,O
present,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
analyze,O,O
the,O,O
roles,O,O
of,O,O
the,O,O
two,O,O
GR,B,B
isoforms,I,I
on,O,O
glucocorticoid,O,O
-,O,O
mediated,O,O
transrepression,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
.,O,O
Furthermore,O,O
",",O,O
GRbeta,B,B
did,O,O
not,O,O
antagonize,O,O
the,O,O
repressive,O,O
effects,O,O
of,O,O
GRalpha,B,B
on,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
activity,O,I
.,O,O
Surprisingly,O,O
",",O,O
overexpression,O,O
of,O,O
GRbeta,B,B
in,O,O
Jurkat,O,O
cells,O,O
did,O,O
not,O,O
cause,O,O
significant,O,O
inhibition,O,O
of,O,O
GRalpha,B,B
-,O,O
induced,O,O
transactivation,O,O
of,O,O
a,O,O
GRE,B,B
-,I,I
dependent,I,I
luciferase,I,I
reporter,I,I
gene,I,I
either,O,O
.,O,O
Extinction,O,O
of,O,O
immunoglobulin,B,B
gene,I,I
expression,O,I
in,O,O
B,O,O
cells,O,O
upon,O,O
fusion,O,O
with,O,O
HeLa,O,O
cells,O,O
is,O,O
preceded,O,O
by,O,O
rapid,O,O
nuclear,O,O
depletion,O,O
of,O,O
essential,B,O
transcription,I,O
factors,I,O
and,O,O
is,O,O
accompanied,O,O
by,O,O
widespread,O,O
inactivation,O,O
of,O,O
genes,O,O
expressed,O,O
in,O,O
a,O,O
B,O,O
cell,O,O
-,O,O
specific,O,O
manner,O,O
.,O,O
Evidence,O,O
for,O,O
suppressed,O,O
activity,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
NFAT1,B,O
at,O,O
its,O,O
proximal,B,O
binding,I,O
element,I,O
P0,B,O
in,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
promoter,I,O
associated,O,O
with,O,O
enhanced,O,O
IL,B,B
-,I,I
4,I,I
gene,I,I
transcription,O,O
in,O,O
T,O,O
cells,O,O
of,O,O
atopic,O,O
patients,O,O
.,O,O
In,O,O
a,O,O
series,O,O
of,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
with,O,O
protein,O,B
extracts,O,O
of,O,O
highly,O,O
polarized,O,O
Th2,O,B
clones,O,O
from,O,O
atopics,O,O
and,O,O
Th1,O,B
clones,O,O
from,O,O
controls,O,O
we,O,O
compared,O,O
DNA,O,B
-,O,I
binding,O,I
activities,O,O
at,O,O
the,O,O
two,O,O
NFAT,B,B
-,I,I
binding,I,I
elements,I,O
P0,B,O
and,O,O
P1,B,O
of,O,O
the,O,O
crucial,O,O
proximal,O,O
human,O,O
IL,B,B
-,I,I
4,I,I
promoter,I,O
.,O,O
At,O,O
the,O,O
most,O,O
proximal,O,O
P0,B,O
site,O,O
",",O,O
NFAT,O,B
-,O,I
containing,O,I
complexes,O,O
devoid,O,O
of,O,O
NFAT2,B,B
were,O,O
readily,O,O
inducible,O,O
in,O,O
the,O,O
Th1,O,B
clones,O,O
",",O,O
but,O,O
hardly,O,O
or,O,O
not,O,O
in,O,O
the,O,O
Th2,O,B
clones,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
high,O,O
-,O,O
level,O,O
IL,B,B
-,I,I
4,I,I
production,O,O
in,O,O
atopic,O,O
Th2,O,O
cells,O,O
is,O,O
associated,O,O
with,O,O
selective,O,O
reduction,O,O
of,O,O
suppressive,O,O
NFAT1,B,O
activity,O,O
at,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
P0,I,I
element,I,O
and,O,O
that,O,O
some,O,O
patients,O,O
with,O,O
this,O,O
multifactorial,O,O
disease,O,O
may,O,O
have,O,O
a,O,O
putative,O,O
systemic,O,O
disorder,O,O
at,O,O
this,O,O
level,O,O
.,O,O
Rather,O,O
",",O,O
squirrel,O,O
monkeys,O,O
express,O,O
a,O,O
soluble,O,O
factor,O,O
that,O,O
",",O,O
in,O,O
mixing,O,O
studies,O,O
of,O,O
cytosol,O,O
from,O,O
squirrel,O,O
monkey,O,O
lymphocytes,O,O
(,O,O
SML,O,O
),O,O
and,O,O
mouse,O,O
L929,O,O
cells,O,O
",",O,O
reduced,O,O
GR,O,O
binding,O,O
affinity,O,O
by,O,O
11,O,O
-,O,O
fold,O,O
.,O,O
A,O,O
role,O,O
for,O,O
changes,O,O
in,O,O
immunophilins,B,O
",",O,O
causing,O,O
glucocorticoid,O,B
resistance,O,O
in,O,O
neotropical,O,O
primates,O,O
",",O,O
is,O,O
supported,O,O
by,O,O
the,O,O
following,O,O
:,O,O
the,O,O
changes,O,O
in,O,O
FKBP51,B,B
and,O,O
FKBP52,B,B
were,O,O
observed,O,O
in,O,O
cells,O,O
from,O,O
other,O,O
neotropical,O,O
primates,O,O
with,O,O
glucocorticoid,O,O
resistance,O,O
;,O,O
the,O,O
elevated,O,O
level,O,O
of,O,O
FKBP51,B,B
was,O,O
reflected,O,O
in,O,O
an,O,O
abundance,O,O
of,O,O
FKBP51,B,B
in,O,O
heat,B,O
shock,I,O
protein,I,O
90,I,O
complexes,I,O
in,O,O
SML,O,O
;,O,O
when,O,O
cytosols,O,O
of,O,O
SML,O,O
and,O,O
L929,O,O
cells,O,O
were,O,O
mixed,O,O
",",O,O
the,O,O
decrease,O,O
in,O,O
GR,O,B
binding,O,O
was,O,O
associated,O,O
with,O,O
incorporation,O,O
of,O,O
FKBP51,B,B
into,O,O
GR,B,B
heterocomplexes,I,O
;,O,O
the,O,O
effect,O,O
of,O,O
SML,O,O
cytosol,O,O
on,O,O
GR,O,B
binding,O,O
was,O,O
reproduced,O,O
with,O,O
cytosol,O,O
from,O,O
COS,O,O
cells,O,O
expressing,O,O
squirrel,O,O
monkey,O,O
FKBP51,B,B
;,O,O
and,O,O
both,O,O
the,O,O
effect,O,O
of,O,O
SML,O,O
cytosol,O,O
on,O,O
GR,O,B
binding,O,O
and,O,O
the,O,O
incorporation,O,O
of,O,O
FKBP51,B,B
into,O,O
GR,B,B
heterocomplexes,I,O
were,O,O
blocked,O,O
by,O,O
FK506,O,O
.,O,O
The,O,O
prevalent,O,O
complex,O,O
is,O,O
the,O,O
heterodimer,B,O
p50,I,B
-,I,I
p65,I,I
.,O,O
NF,B,B
-,I,I
kappaB,I,I
activity,O,O
is,O,O
tightly,O,O
correlated,O,O
with,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
a,O,O
long,B,O
terminal,I,O
repeat,I,O
(,O,O
LTR,B,O
),O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
transfected,O,O
in,O,O
thymocytes,O,O
.,O,O
GCs,O,O
induce,O,O
apoptosis,O,O
in,O,O
neoplastic,O,O
lymphoid,O,O
cells,O,O
;,O,O
and,O,O
",",O,O
defective,O,O
apoptosis,O,O
is,O,O
implicated,O,O
in,O,O
the,O,O
genesis,O,O
of,O,O
chronic,O,O
lymphocytic,O,O
leukemia,O,O
(,O,O
CLL,O,O
),O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
imbalanced,O,O
expression,O,O
of,O,O
the,O,O
GR,B,B
isoforms,I,I
may,O,O
be,O,O
a,O,O
mechanism,O,O
of,O,O
GC,O,B
resistance,O,O
",",O,O
and,O,O
may,O,O
have,O,O
implications,O,O
for,O,O
tumorigenesis,O,O
by,O,O
enhancing,O,O
cell,O,O
survival,O,O
.,O,O
A,O,O
second,O,O
hypersensitive,O,O
site,O,O
(,O,O
HS,O,B
2,O,I
),O,O
was,O,O
identified,O,O
within,O,O
the,O,O
first,O,O
intron,O,O
in,O,O
pre,O,O
-,O,O
monocytic,O,B
cells,O,O
",",O,O
which,O,O
express,O,O
Elk,O,B
-,O,O
1,O,I
only,O,O
when,O,O
differentiating,O,O
to,O,O
monocytes,O,O
.,O,O
Twenty,O,O
-,O,O
seven,O,O
patients,O,O
with,O,O
tumors,O,O
of,O,O
the,O,O
oral,O,B
cavity,O,I
",",O,O
oropharynx,O,B
",",O,O
and,O,O
maxillary,O,B
sinus,O,I
were,O,O
examined,O,O
",",O,O
all,O,O
of,O,O
which,O,O
were,O,O
confirmed,O,O
as,O,O
squamous,O,B
cell,O,I
carcinomas,O,I
.,O,O
Serial,O,O
sectioning,O,O
of,O,O
6,O,O
micrometer,O,O
was,O,O
performed,O,O
using,O,O
a,O,O
cryostat,O,O
",",O,O
and,O,O
samples,O,O
were,O,O
immunohistochemicall,O,O
stained,O,O
using,O,O
the,O,O
streptoavidin,B,O
-,B,O
biotin,I,O
peroxidase,I,O
method,O,O
and,O,O
a,O,O
monoclonal,O,O
antibody,O,O
against,O,O
c,O,B
-,O,I
fos,O,I
.,O,O
Three,O,O
of,O,O
the,O,O
27,O,O
patients,O,O
with,O,O
squamous,O,O
cell,O,O
carcinoma,O,O
showed,O,O
slight,O,O
expression,O,O
of,O,O
c,O,B
-,O,I
fos,O,I
in,O,O
their,O,O
tumor,O,O
cells,O,O
before,O,O
and,O,O
/,O,O
or,O,O
at,O,O
4,O,O
or,O,O
10,O,O
Gy,O,O
of,O,O
radiotherapy,O,O
.,O,O
In,O,O
patients,O,O
whose,O,O
infiltration,O,O
of,O,O
c,B,B
-,I,I
fos,I,I
-,I,I
positive,I,I
lymphocytes,I,O
into,O,O
tumor,O,O
tissues,O,O
were,O,O
moderate,O,O
or,O,O
remarkable,O,O
at,O,O
4,O,O
Gy,O,O
of,O,O
radiotherapy,O,O
",",O,O
the,O,O
tumors,O,O
responded,O,O
significantly,O,O
well,O,O
to,O,O
radiation,O,O
therapy,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
",",O,O
chi2,O,O
test,O,O
),O,O
",",O,O
and,O,O
the,O,O
patients,O,O
took,O,O
a,O,O
significantly,O,O
favorable,O,O
clinical,O,O
course,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
",",O,O
chi2,O,O
test,O,O
),O,O
.,O,O
The,O,O
allele,O,O
-,O,O
specific,O,O
expression,O,O
profiles,O,O
of,O,O
other,O,O
imprinted,B,O
genes,I,O
",",O,O
IGF2,B,B
and,O,O
H19,B,B
",",O,O
on,O,O
human,B,O
chromosome,I,O
11,I,O
were,O,O
constant,O,O
and,O,O
consistent,O,O
with,O,O
those,O,O
in,O,O
other,O,O
tissues,O,O
.,O,O
Our,O,O
unexpected,O,O
observations,O,O
of,O,O
paternal,O,O
or,O,O
biallelic,O,O
expression,O,O
of,O,O
WT1,B,B
in,O,O
fibroblasts,O,O
and,O,O
lymphocytes,O,O
",",O,O
together,O,O
with,O,O
the,O,O
previous,O,O
findings,O,O
of,O,O
maternal,O,O
or,O,O
biallelic,O,O
expression,O,O
in,O,O
placentae,O,O
and,O,O
brains,O,O
",",O,O
suggest,O,O
that,O,O
the,O,O
allele,O,O
-,O,O
specific,O,O
regulatory,O,O
system,O,O
of,O,O
WT1,B,B
is,O,O
unique,O,O
and,O,O
may,O,O
be,O,O
controlled,O,O
by,O,O
a,O,O
putative,O,O
tissue,O,O
-,O,O
and,O,O
individual,O,O
-,O,O
specific,O,O
modifier,O,O
.,O,O
T,O,B
cell,O,I
responses,O,O
to,O,O
some,O,O
nuclear,O,B
antigens,O,I
",",O,O
particularly,O,O
U1RNP,B,B
",",O,O
have,O,O
been,O,O
detected,O,O
in,O,O
patients,O,O
with,O,O
systemic,O,O
lupus,O,O
erythematosus,O,O
(,O,O
SLE,O,O
),O,O
and,O,O
in,O,O
healthy,O,O
subjects,O,O
.,O,O
METHODS,O,O
.,O,O
HLA,O,B
-,O,I
DR,O,I
typing,O,O
was,O,O
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
and,O,O
sequence,O,O
specific,O,O
oligonucleotide,O,O
typing,O,O
.,O,O
RESULTS,O,O
.,O,O
Six,O,O
of,O,O
20,O,O
patients,O,O
with,O,O
SS,O,O
and,O,O
10,O,O
/,O,O
19,O,O
controls,O,O
proliferated,O,O
to,O,O
La,O,B
(,O,O
rSSB,B,I
),O,O
.,O,O
Tumor,B,B
necrosis,I,I
factor,I,I
(,I,O
TNF,I,B
),I,O
-,I,O
alpha,I,O
-,O,O
induced,O,O
HIV,O,O
-,O,O
1,O,O
replication,O,O
in,O,O
OM10,O,O
.,O,O
or,O,O
Ach2,O,O
cells,O,O
was,O,O
significantly,O,O
inhibited,O,O
by,O,O
non,O,B
-,O,I
cytotoxic,O,I
doses,O,O
of,O,O
AuTG,O,O
(,O,O
>,O,O
10,O,O
microM,O,O
in,O,O
OM10,O,O
.,O,O
cells,O,O
and,O,O
>,O,O
25,O,O
F,O,O
.,O,O
M,O,O
in,O,O
Ach2,O,O
cells,O,O
),O,O
",",O,O
while,O,O
25,O,O
microM,O,O
of,O,O
the,O,O
counter,B,O
-,I,O
anion,I,O
thioglucose,I,O
(,O,O
TG,B,O
),O,O
or,O,O
gold,O,O
compound,O,O
containing,O,O
divalent,O,O
gold,O,O
ion,O,O
",",O,O
HAuCl3,O,O
",",O,O
had,O,O
no,O,O
effect,O,O
.,O,O
Specific,O,O
staining,O,O
as,O,O
well,O,O
as,O,O
electron,O,O
microscopic,O,O
examinations,O,O
revealed,O,O
the,O,O
accumulation,O,O
of,O,O
metal,O,O
gold,O,O
in,O,O
the,O,O
cells,O,O
",",O,O
supporting,O,O
our,O,O
previous,O,O
hypothesis,O,O
that,O,O
gold,O,O
ions,O,O
could,O,O
block,O,O
NF,B,B
-,I,I
kappaB,I,I
-,O,I
DNA,O,I
binding,O,I
by,O,O
a,O,O
redox,O,O
mechanism,O,O
.,O,O
In,O,O
the,O,O
absence,O,O
of,O,O
karyotypic,O,O
abnormalities,O,O
",",O,O
there,O,O
is,O,O
no,O,O
specific,O,O
test,O,O
to,O,O
detect,O,O
clonal,O,O
eosinophilia,O,O
in,O,O
IHES,O,O
.,O,O
Peripheral,O,O
blood,O,O
eosinophils,O,B
were,O,O
isolated,O,O
by,O,O
their,O,O
autofluoresence,O,O
using,O,O
flow,O,O
cytometric,O,O
sorting,O,O
.,O,O
After,O,O
corticosteroid,O,O
suppression,O,O
of,O,O
her,O,O
blood,O,O
eosinophilia,O,O
",",O,O
a,O,O
clonal,O,O
population,O,O
of,O,O
eosinophils,O,B
could,O,O
no,O,O
longer,O,O
be,O,O
detected,O,O
in,O,O
purified,O,O
eosinophils,O,B
.,O,O
This,O,O
pro,B,O
-,I,O
IL,I,B
-,I,I
16,I,I
is,O,O
subsequently,O,O
processed,O,O
to,O,O
the,O,O
mature,O,O
cytokine,O,O
of,O,O
13,B,O
kDa,I,O
.,O,O
The,O,O
5,B,O
sequences,I,O
up,O,O
to,O,O
nucleotide,O,O
-,O,O
120,O,O
of,O,O
the,O,O
human,O,B
and,O,O
murine,O,B
IL,B,B
-,I,I
16,I,I
genes,O,O
share,O,O
>,O,O
84,O,O
%,O,O
sequence,O,O
homology,O,O
and,O,O
harbor,B,O
promoter,I,O
elements,I,O
for,O,O
constitutive,O,O
and,O,O
inducible,O,O
transcription,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
Therefore,O,O
",",O,O
this,O,O
genetic,O,O
variant,O,O
",",O,O
which,O,O
predisposes,O,O
to,O,O
low,O,O
bone,O,B
mineral,O,I
density,O,I
in,O,O
many,O,O
populations,O,O
",",O,O
may,O,O
confer,O,O
resistance,O,O
to,O,O
certain,O,O
infectious,O,O
diseases,O,O
.,O,O
Indeed,O,O
",",O,O
the,O,O
availability,O,O
of,O,O
selective,O,O
and,O,O
orally,O,O
active,O,O
proteasome,O,B
inhibitors,O,O
should,O,O
prove,O,O
useful,O,O
in,O,O
delineating,O,O
the,O,O
roles,O,O
of,O,O
the,O,O
proteasome,O,B
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
other,O,O
pathophysiological,O,O
conditions,O,O
such,O,O
as,O,O
cancer,O,O
and,O,O
heart,O,O
disease,O,O
.,O,O
Lysophosphatidyletha,O,O
(,O,O
lysoPE,O,O
),O,O
and,O,O
other,O,O
lysophospholipids,O,O
did,O,O
not,O,O
affect,O,O
LPS,O,O
-,O,O
induced,O,O
TF,O,O
activity,O,O
of,O,O
human,O,O
monocytes,O,O
.,O,O
TF,O,B
antigen,O,I
expression,O,O
as,O,O
elicited,O,O
by,O,O
LPS,O,O
was,O,O
also,O,O
lowered,O,O
by,O,O
lysoPC,O,O
.,O,O
LysoPC,O,B
inhibited,O,O
the,O,O
TF,O,B
activity,O,O
of,O,O
Mono,O,O
Mac,O,O
-,O,O
6,O,O
cells,O,O
to,O,O
a,O,O
similar,O,O
extent,O,O
as,O,O
in,O,O
the,O,O
monocytes,O,O
.,O,O
A,O,O
Taq,B,O
I,I,O
polymorphism,I,O
was,O,O
identified,O,O
which,O,O
enabled,O,O
chicken,O,O
IL2,B,O
to,O,O
be,O,O
mapped,O,O
to,O,O
chromosome,B,O
4,I,O
",",O,O
linked,O,O
to,O,O
ANX5,B,O
",",O,O
with,O,O
synteny,O,O
with,O,O
mouse,B,O
chromosome,I,O
3,I,O
and,O,O
human,B,O
chromosome,I,O
4,I,O
.,O,O
There,O,O
is,O,O
increasing,O,O
evidence,O,O
that,O,O
IFN,B,B
-,I,I
alpha,I,I
has,O,O
an,O,O
important,O,O
role,O,O
in,O,O
T,O,B
-,O,I
cell,O,I
biology,O,O
.,O,O
The,O,O
induction,O,O
of,O,O
these,O,O
genes,O,O
is,O,O
associated,O,O
with,O,O
interleukin,B,B
-,I,I
2,I,I
(,O,O
IL,B,O
-,I,O
2,I,O
),O,O
-,O,O
induced,O,O
T,O,B
-,O,I
cell,O,I
proliferation,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
our,O,O
results,O,O
suggest,O,O
that,O,O
IFN,B,B
-,I,I
alpha,I,I
",",O,O
IL,B,B
-,I,I
2,I,I
",",O,O
IL,B,B
-,I,I
12,I,I
",",O,O
and,O,O
IL,B,B
-,I,I
15,I,I
have,O,O
overlapping,O,O
activities,O,O
on,O,O
human,O,O
T,O,B
cells,O,I
.,O,O
The,O,O
Megakaryocyte,B,B
/,I,I
Platelet,I,I
-,I,I
specific,I,I
enhancer,I,I
of,O,O
the,O,O
alpha2beta1,B,B
integrin,I,I
gene,I,I
:,O,O
two,O,O
tandem,O,O
AP1,B,B
sites,I,I
and,O,O
the,O,O
mitogen,B,B
-,I,I
activated,I,I
protein,I,I
kinase,I,I
signaling,O,I
cascade,O,I
.,O,O
Transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
alpha2,B,B
integrin,I,I
gene,I,I
in,O,O
cells,O,O
undergoing,O,O
megakaryocytic,O,B
differentiation,O,I
requires,O,O
a,O,O
core,B,O
promoter,I,O
between,O,O
bp,O,O
-,O,O
30,O,O
and,O,O
-,O,O
92,O,O
",",O,O
a,O,O
silencer,B,O
between,O,O
bp,O,O
-,O,O
92,O,O
and,O,O
-,O,O
351,O,O
",",O,O
and,O,O
megakaryocytic,B,B
enhancers,I,I
in,O,O
the,O,O
distal,B,O
5,I,O
flank,I,O
.,O,O
Therefore,O,O
",",O,O
our,O,O
data,O,O
not,O,O
only,O,O
reveal,O,O
that,O,O
Nmi,B,O
can,O,O
potentiate,O,O
STAT,B,B
-,O,I
dependent,O,I
transcription,O,I
",",O,O
but,O,O
also,O,O
suggest,O,O
that,O,O
it,O,O
can,O,O
augment,O,O
coactivator,O,O
protein,O,B
recruitment,O,O
to,O,O
at,O,O
least,O,O
some,O,O
members,O,O
of,O,O
a,O,O
group,O,O
of,O,O
sequence,B,O
-,I,O
specific,I,O
transcription,I,O
factors,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
activation,O,O
in,O,O
THP,B,O
-,I,O
1,I,O
cells,I,O
occurred,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
vanadate,O,O
and,O,O
was,O,O
unaffected,O,O
by,O,O
catalase,B,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
the,O,O
presence,O,O
in,O,O
vaginal,O,B
fluid,O,I
of,O,O
agent,O,O
(,O,O
s,O,O
),O,O
derived,O,O
from,O,O
indigenous,O,O
bacteria,O,O
that,O,O
can,O,O
activate,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
",",O,O
cytokine,B,O
production,O,O
",",O,O
and,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
cells,O,O
of,O,O
macrophage,O,B
lineage,O,I
",",O,O
with,O,O
possible,O,O
influence,O,O
on,O,O
vaginal,O,O
physiology,O,O
and,O,O
host,O,O
defense,O,O
.,O,O
Activated,O,O
primed,O,O
CD4,O,B
T,O,I
cells,O,O
contain,O,O
more,O,O
NFAT1,B,B
and,O,O
support,O,O
greater,O,O
NFAT,B,B
-,O,I
directed,O,I
transcription,O,I
than,O,O
unprimed,O,O
CD4,O,B
T,O,I
cells,O,O
",",O,O
while,O,O
activator,B,O
protein,I,O
1,I,B
binding,O,I
and,O,O
activator,B,O
protein,I,O
1,I,I
-,O,I
mediated,O,I
transcription,O,I
by,O,O
both,O,O
cell,O,O
types,O,O
is,O,O
similar,O,O
.,O,O
These,O,O
agents,O,O
also,O,O
significantly,O,O
decreased,O,O
TNF,B,B
-,O,I
and,O,O
LPS,O,B
-,O,I
stimulated,O,O
increases,O,O
in,O,O
HUVEC,B,B
surface,I,O
VCAM,I,B
-,I,I
1,I,I
.,O,O
TNF,B,B
stimulated,O,O
expression,O,O
of,O,O
both,O,O
intercellular,B,B
adhesion,I,I
molecule,I,I
-,I,I
1,I,I
and,O,O
E,B,B
-,I,I
selectin,I,I
in,O,O
HUVECs,O,B
",",O,O
but,O,O
in,O,O
HUAECs,O,B
",",O,O
only,O,O
intercellular,B,B
adhesion,I,I
molecule,I,I
-,I,I
1,I,I
was,O,O
increased,O,O
.,O,O
Functional,O,O
testosterone,B,B
receptors,I,I
in,O,O
plasma,O,O
membranes,O,O
of,O,O
T,O,O
cells,O,O
.,O,O
AR,B,B
can,O,O
be,O,O
visualized,O,O
with,O,O
the,O,O
anti,B,O
-,I,O
AR,I,B
antibodies,I,I
in,O,O
the,O,O
cytoplasm,O,O
of,O,O
permeabilized,O,O
T,O,O
cells,O,O
by,O,O
using,O,O
CLSM,O,O
",",O,O
though,O,O
AR,B,B
are,O,O
not,O,O
detectable,O,O
in,O,O
cytosol,O,O
fractions,O,O
when,O,O
using,O,O
the,O,O
charcoal,O,O
binding,O,O
assay,O,O
with,O,O
3H,O,O
-,O,O
R1881,O,O
as,O,O
ligand,O,O
.,O,O
Cytoplasmic,B,O
AR,I,B
do,O,O
not,O,O
translocate,O,O
to,O,O
the,O,O
nucleus,O,O
of,O,O
T,O,O
cells,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
testosterone,O,O
",",O,O
in,O,O
contrast,O,O
to,O,O
cytoplasmic,B,O
AR,I,B
in,O,O
human,O,O
cancer,O,O
LNCaP,O,O
cells,O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
the,O,O
cell,B,O
surface,I,O
receptors,I,O
for,O,O
testosterone,O,B
are,O,O
in,O,O
a,O,O
functionally,O,O
active,O,O
state,O,O
",",O,O
enabling,O,O
T,O,O
cells,O,O
a,O,O
nongenomic,O,O
response,O,O
to,O,O
testosterone,O,B
.,O,O
Limited,O,O
proteolysis,O,O
for,O,O
assaying,O,O
ligand,O,O
binding,O,O
affinities,O,O
of,O,O
nuclear,B,B
receptors,I,I
.,O,O
Using,O,O
the,O,O
wild,B,O
-,I,O
type,I,O
or,I,O
mutated,I,O
human,I,O
retinoic,I,B
acid,I,I
receptor,I,I
alpha,I,I
as,O,O
a,O,O
model,O,O
",",O,O
kDa,O,O
values,O,O
determined,O,O
by,O,O
classical,O,O
competition,O,O
binding,O,O
assays,O,O
using,O,O
tritiated,O,O
ligands,O,O
are,O,O
in,O,O
agreement,O,O
with,O,O
those,O,O
measured,O,O
by,O,O
the,O,O
proteolytic,O,O
assay,O,O
.,O,O
B,O,B
lymphocytes,O,O
from,O,O
patients,O,O
with,O,O
chronic,O,O
lymphocytic,O,O
leukemia,O,O
contain,O,O
signal,B,B
transducer,I,I
and,I,I
activator,I,I
of,I,I
transcription,I,I
(,I,O
STAT,I,B
),I,O
1,I,O
and,O,O
STAT3,B,B
constitutively,O,O
phosphorylated,O,O
on,O,O
serine,O,O
residues,O,O
.,O,O
In,O,O
summary,O,O
",",O,O
the,O,O
constitutive,O,O
serine,O,O
phosphorylation,O,O
of,O,O
STAT1,B,B
and,O,O
STAT3,B,B
is,O,O
present,O,O
in,O,O
all,O,O
CLL,O,O
samples,O,O
tested,O,O
to,O,O
date,O,O
",",O,O
although,O,O
the,O,O
physiologic,O,O
significance,O,O
of,O,O
this,O,O
modification,O,O
remains,O,O
to,O,O
be,O,O
determined,O,O
.,O,O
G,O,O
vaginalis,O,O
lysates,O,O
also,O,O
activated,O,O
HIV,O,B
expression,O,O
in,O,O
certain,O,O
T,O,O
cell,O,O
lines,O,O
.,O,O
Highly,O,O
purified,O,O
monocytes,O,O
were,O,O
incubated,O,O
with,O,O
IL,B,B
-,I,I
10,I,I
for,O,O
60,O,O
to,O,O
90,O,O
minutes,O,O
before,O,O
the,O,O
addition,O,O
of,O,O
IFNgamma,B,B
or,O,O
IFNalpha,B,B
.,O,O
IL,B,B
-,I,I
10,I,I
preincubation,O,O
resulted,O,O
in,O,O
the,O,O
inhibition,O,O
of,O,O
gene,O,O
expression,O,O
for,O,O
several,O,O
IFN,B,B
-,I,I
induced,I,I
genes,I,O
",",O,O
such,O,O
as,O,O
IP,B,B
-,I,I
10,I,I
",",O,O
ISG54,B,O
",",O,O
and,O,O
intercellular,B,O
adhesion,I,O
molecule,I,O
-,I,O
1,I,O
.,O,O
The,O,O
development,O,O
of,O,O
ringed,O,O
sideroblasts,O,O
in,O,O
erythroid,O,B
colonies,O,I
by,O,O
iron,O,B
staining,O,O
and,O,O
their,O,O
X,O,B
-,O,I
inactivation,O,I
pattern,O,O
were,O,O
also,O,O
examined,O,O
.,O,O
Granulosa,O,B
cell,O,I
tumor,O,I
of,O,O
the,O,O
ovary,O,O
.,O,O
All,O,O
of,O,O
the,O,O
tumors,O,O
exhibited,O,O
typical,O,O
morphology,O,O
",",O,O
were,O,O
limited,O,O
to,O,O
the,O,O
ovary,O,O
(,O,O
stage,O,O
I,O,O
),O,O
",",O,O
and,O,O
7,O,O
cases,O,O
followed,O,O
a,O,O
benign,O,O
clinical,O,O
course,O,O
.,O,O
Comparison,O,O
of,O,O
primary,O,O
sensitization,O,O
of,O,O
naive,O,O
human,O,B
T,O,I
cells,O,I
to,O,O
varicella,O,O
-,O,O
zoster,O,O
virus,O,O
peptides,O,O
by,O,O
dendritic,O,B
cells,O,I
in,O,O
vitro,O,O
with,O,O
responses,O,O
elicited,O,O
in,O,O
vivo,O,O
by,O,O
varicella,O,O
vaccination,O,O
.,O,O
Dendritic,O,B
cells,O,I
(,O,O
DC,O,O
),O,O
are,O,O
potent,O,O
APC,O,O
during,O,O
primary,O,O
and,O,O
secondary,O,O
immune,O,O
responses,O,O
.,O,O
Monocytes,O,B
were,O,O
effective,O,O
APC,O,O
for,O,O
VZV,O,O
peptides,O,O
only,O,O
after,O,O
immunization,O,O
.,O,O
IL,B,B
-,I,I
10,I,I
treatment,O,O
prevented,O,O
the,O,O
downregulation,O,O
of,O,O
p27,B,B
(,I,O
Kip1,I,I
),O,O
",",O,O
an,O,O
inhibitory,B,O
protein,I,O
that,O,O
controls,O,O
progression,O,O
out,O,O
of,O,O
the,O,O
G0,O,O
phase,O,O
of,O,O
the,O,O
cell,O,O
cycle,O,O
.,O,O
Associated,O,O
with,O,O
the,O,O
inhibition,O,O
of,O,O
the,O,O
cell,O,O
cycle,O,O
",",O,O
IL,B,B
-,I,I
10,I,I
suppressed,O,O
SEB,B,O
induction,O,O
of,O,O
interleukin,B,O
-,I,O
2,I,O
(,O,O
IL,B,O
-,I,O
2,I,O
),O,O
.,O,O
Although,O,O
this,O,O
reversal,O,O
by,O,O
IL,B,O
-,I,O
2,I,O
was,O,O
pronounced,O,O
",",O,O
it,O,O
was,O,O
not,O,O
complete,O,O
",",O,O
suggesting,O,O
that,O,O
IL,B,B
-,I,I
10,I,I
may,O,O
have,O,O
some,O,O
effects,O,O
not,O,O
directly,O,O
related,O,O
to,O,O
the,O,O
suppression,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
.,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
13,I,I
induced,O,O
dose,O,O
-,O,O
and,O,O
time,O,O
-,O,O
dependent,O,O
increases,O,O
in,O,O
IL,O,B
-,O,I
1RI,O,I
and,O,O
IL,O,B
-,O,I
1RII,O,I
mRNA,O,O
levels,O,O
.,O,O
IFN,B,B
-,I,I
gamma,I,I
decreased,O,O
basal,O,O
expression,O,O
as,O,O
well,O,O
as,O,O
the,O,O
induction,O,O
of,O,O
these,O,O
genes,O,O
by,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
13,I,I
.,O,O
Inhibition,O,O
of,O,O
IL,B,B
-,I,I
1RI,I,I
and,O,O
IL,O,B
-,O,I
1RII,O,I
mRNA,O,O
levels,O,O
by,O,O
IFN,B,B
-,I,I
gamma,I,I
was,O,O
transcriptionally,O,O
mediated,O,O
",",O,O
and,O,O
correlated,O,O
directly,O,O
with,O,O
decreased,O,O
production,O,O
of,O,O
soluble,O,O
IL,B,B
-,I,I
1RII,I,I
.,O,O
In,O,O
both,O,O
cell,O,O
types,O,O
",",O,O
the,O,O
cytokine,B,O
that,O,O
inhibits,O,O
the,O,O
induction,O,O
of,O,O
IkappaBalpha,B,O
by,O,O
DEX,O,O
",",O,O
also,O,O
rescues,O,O
these,O,O
cells,O,O
from,O,O
DEX,O,O
-,O,O
induced,O,O
apoptosis,O,O
",",O,O
although,O,O
the,O,O
rescue,O,O
cytokine,O,O
is,O,O
different,O,O
in,O,O
Th1,O,O
and,O,O
Th2,O,O
cells,O,O
.,O,O
Infection,O,O
of,O,O
human,O,O
monocytes,O,O
with,O,O
influenza,O,O
A,O,O
virus,O,O
induces,O,O
a,O,O
broad,O,O
range,O,O
of,O,O
proinflammatory,B,O
cytokines,I,O
and,O,O
mononuclear,O,O
cell,O,O
attracting,O,O
chemokines,B,O
before,O,O
the,O,O
infected,O,O
cells,O,O
undergo,O,O
apoptosis,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
the,O,O
long,O,O
-,O,O
term,O,O
regulation,O,O
of,O,O
transcription,B,O
factor,I,O
gene,O,O
expression,O,O
in,O,O
non,O,O
-,O,O
proliferating,O,O
cells,O,O
seems,O,O
to,O,O
be,O,O
of,O,O
minor,O,O
importance,O,O
after,O,O
influenza,O,O
infection,O,O
since,O,O
in,O,O
apoptosisprone,O,O
cells,O,O
an,O,O
immediate,O,O
availability,O,O
of,O,O
transcription,B,O
factor,I,O
proteins,I,O
is,O,O
required,O,O
.,O,O
Patients,O,O
with,O,O
diabetic,O,O
nephropathy,O,O
showed,O,O
higher,O,O
NF,B,B
-,I,I
kappaB,I,I
binding,O,I
activity,O,I
in,O,O
Electrophoretic,O,O
Mobility,O,O
Shift,O,O
Assays,O,O
and,O,O
stronger,O,O
immunohistological,O,O
staining,O,O
for,O,O
activated,O,O
NF,B,B
-,I,I
kappaBp65,I,I
than,O,O
patients,O,O
without,O,O
renal,O,O
complications,O,O
.,O,O
Resorption,O,O
lacunae,O,O
can,O,O
be,O,O
observed,O,O
by,O,O
day,O,O
22,O,O
.,O,O
We,O,O
incubated,O,O
sodium,O,B
oleate,O,I
with,O,O
human,O,B
umbilical,O,I
vein,O,I
endothelial,O,I
cells,O,I
for,O,O
0,O,O
to,O,O
72,O,O
hours,O,O
",",O,O
followed,O,O
by,O,O
coincubation,O,O
of,O,O
oleate,O,B
with,O,O
human,B,B
recombinant,I,I
tumor,I,I
necrosis,I,I
factor,I,I
",",O,O
interleukin,B,B
(,I,O
IL,I,B
),I,O
-,I,O
1alpha,I,I
",",O,O
IL,B,B
-,I,O
1beta,I,I
",",O,O
IL,B,B
-,I,O
4,I,I
",",O,O
Escherichia,O,B
coli,O,I
lipopolysaccharide,O,I
(,O,O
LPS,O,O
),O,O
",",O,O
or,O,O
phorbol,O,B
12,O,I
-,O,I
myristate,O,I
13,O,I
-,O,I
acetate,O,I
for,O,O
a,O,O
further,O,O
6,O,O
to,O,O
24,O,O
hours,O,O
.,O,O
The,O,O
endothelial,O,B
expression,O,O
of,O,O
vascular,B,B
cell,I,I
adhesion,I,I
molecule,I,I
-,I,I
1,I,I
(,O,O
VCAM,B,B
-,I,I
1,I,I
),O,O
",",O,O
E,B,B
-,I,I
selectin,I,I
",",O,O
and,O,O
intercellular,B,B
adhesion,I,I
molecule,I,I
-,I,I
1,I,I
was,O,O
monitored,O,O
by,O,O
cell,O,B
surface,O,I
enzyme,O,I
immunoassays,O,I
or,O,O
flow,O,B
cytometry,O,I
",",O,O
and,O,O
steady,O,O
-,O,O
state,O,O
levels,O,O
of,O,O
VCAM,B,B
-,I,I
1,I,I
mRNA,I,I
were,O,O
assessed,O,O
by,O,O
Northern,O,B
blot,O,I
analysis,O,I
.,O,O
Incubation,O,O
of,O,O
endothelial,O,B
cells,O,I
with,O,O
oleate,O,O
for,O,O
72,O,O
hours,O,O
decreased,O,O
the,O,O
relative,O,O
proportions,O,O
of,O,O
saturated,O,O
(,O,O
palmitic,O,B
and,O,O
stearic,O,B
),O,O
acids,O,O
in,O,O
total,O,O
cell,O,B
lipids,O,I
and,O,O
increased,O,O
the,O,O
proportions,O,O
of,O,O
oleate,O,O
in,O,O
total,O,O
cell,O,B
lipids,O,I
without,O,O
significantly,O,O
changing,O,O
the,O,O
relative,O,O
proportions,O,O
of,O,O
polyunsaturated,O,B
fatty,O,I
acids,O,I
.,O,O
The,O,O
importance,O,O
of,O,O
BCL2,B,B
and,O,O
Stat3,B,B
on,O,O
IL,B,B
-,I,I
6,I,I
-,O,I
induced,O,O
macrophage,O,O
-,O,O
differentiation,O,O
and,O,O
apoptosis,O,O
was,O,O
studied,O,O
with,O,O
1A9,O,O
-,O,O
M,O,O
cells,O,O
expressing,O,O
human,B,O
BCL2,I,O
or,O,O
a,O,O
dominant,O,O
-,O,O
negative,O,O
form,O,O
of,O,O
Stat3,B,O
",",O,O
respectively,O,O
.,O,O
IL,B,B
-,I,I
6,I,I
-,O,I
induced,O,O
apoptosis,O,O
",",O,O
but,O,O
not,O,O
macrophage,O,O
-,O,O
differentiation,O,O
",",O,O
was,O,O
blocked,O,O
by,O,O
continuously,O,O
expressed,O,O
BCL2,B,O
.,O,O
Interleukin,B,B
-,I,I
8,I,I
(,O,O
IL,B,B
-,I,I
8,I,I
),O,O
is,O,O
a,O,O
chemokine,B,O
that,O,O
belongs,O,O
to,O,O
the,O,O
alpha,B,O
-,I,O
chemokine,I,O
or,O,O
CXC,B,O
subfamily,I,O
and,O,O
is,O,O
produced,O,O
by,O,O
a,O,O
wide,O,O
variety,O,O
of,O,O
human,O,O
cells,O,O
",",O,O
including,O,O
monocytes,O,O
and,O,O
polymorphonuclear,O,O
cells,O,O
(,O,O
PMN,O,O
),O,O
.,O,O
IL,B,B
-,I,I
8,I,I
is,O,O
secreted,O,O
in,O,O
response,O,O
to,O,O
inflammatory,O,O
stimuli,O,O
",",O,O
notably,O,O
bacterial,O,O
products,O,O
such,O,O
as,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
",",O,O
but,O,O
little,O,O
is,O,O
known,O,O
about,O,O
the,O,O
mechanisms,O,O
by,O,O
which,O,O
these,O,O
agents,O,O
mediate,O,O
IL,B,B
-,I,I
8,I,I
induction,O,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
show,O,O
that,O,O
Mycoplasma,B,O
fermentans,I,O
lipid,I,B
-,I,I
associated,I,I
membrane,I,I
proteins,I,I
(,O,O
LAMPf,B,O
),O,O
induce,O,O
the,O,O
production,O,O
of,O,O
high,O,O
levels,O,O
of,O,O
IL,B,B
-,I,I
8,I,I
by,O,O
THP,O,O
-,O,O
1,O,O
(,O,O
human,O,O
monocyte,O,O
),O,O
cells,O,O
and,O,O
PMN,O,O
at,O,O
the,O,O
same,O,O
extent,O,O
as,O,O
LPS,O,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
C3a,B,O
and,O,O
C3a,B,O
(,I,O
desArg,I,O
),I,O
on,O,O
gene,O,O
expression,O,O
and,O,O
protein,O,B
secretion,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
in,O,O
human,O,O
PBMCs,O,O
",",O,O
either,O,O
alone,O,O
or,O,O
in,O,O
combination,O,O
with,O,O
LPS,O,O
or,O,O
IL,B,B
-,I,I
1beta,I,I
.,O,O
Furthermore,O,O
",",O,O
we,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
C3a,B,B
and,O,O
C3a,B,B
(,I,O
desArg,I,O
),I,O
on,O,O
induction,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
and,O,O
activating,B,O
protein,I,O
-,I,O
1,I,O
binding,O,O
.,O,O
These,O,O
results,O,O
demonstrate,O,O
the,O,O
capacity,O,O
of,O,O
intact,O,O
C3a,B,B
and,O,O
its,O,O
circulating,O,O
des,B,O
-,I,O
Arg,I,O
form,I,O
to,O,O
exert,O,O
immunmodulatory,O,O
effects,O,O
in,O,O
vitro,O,O
.,O,O
Phenylarsine,O,O
oxide,O,O
inhibits,O,O
ex,O,O
vivo,O,O
HIV,O,B
-,O,I
1,O,I
expression,O,O
.,O,O
Pharmacological,O,O
control,O,O
of,O,O
antigen,O,O
responsiveness,O,O
in,O,O
genetically,O,O
modified,O,O
T,O,O
lymphocytes,O,O
.,O,O
Recently,O,O
",",O,O
fibromyalgia,O,O
(,O,O
FMS,O,O
),O,O
was,O,O
shown,O,O
to,O,O
be,O,O
a,O,O
disorder,O,O
associated,O,O
with,O,O
an,O,O
altered,O,O
functioning,O,O
of,O,O
the,O,O
stress,O,O
response,O,O
system,O,O
.,O,O
FMS,O,O
patients,O,O
display,O,O
a,O,O
hyperreactive,O,O
pituitary,O,O
adrenocorticotropic,O,O
hormone,O,O
(,O,O
ACTH,O,O
),O,O
release,O,O
in,O,O
response,O,O
to,O,O
corticotropin,O,O
-,O,O
releasing,O,O
hormone,O,O
(,O,O
CRH,O,O
),O,O
and,O,O
to,O,O
insulin,O,O
-,O,O
induced,O,O
hypoglycemia,O,O
.,O,O
Therefore,O,O
we,O,O
investigated,O,O
the,O,O
properties,O,O
and,O,O
function,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptors,I,I
(,O,O
GR,B,O
),O,O
in,O,O
FMS,O,O
patients,O,O
and,O,O
compared,O,O
the,O,O
results,O,O
with,O,O
those,O,O
of,O,O
healthy,O,O
persons,O,O
and,O,O
patients,O,O
with,O,O
chronic,O,O
low,O,O
back,O,O
pain,O,O
(,O,O
LBP,O,O
a,O,O
localized,O,O
pain,O,O
condition,O,O
),O,O
.,O,O
Forty,O,O
primary,O,O
FMS,O,O
patients,O,O
(,O,O
F,O,O
:,O,O
M,O,O
36,O,O
:,O,O
4,O,O
),O,O
",",O,O
28,O,O
LBP,O,O
patients,O,O
(,O,O
25,O,O
:,O,O
3,O,O
),O,O
and,O,O
14,O,O
(,O,O
12,O,O
:,O,O
2,O,O
),O,O
healthy,O,O
",",O,O
sedentary,O,O
control,O,O
persons,O,O
were,O,O
recruited,O,O
for,O,O
the,O,O
study,O,O
.,O,O
Urinary,O,O
free,O,O
cortisol,O,B
excretion,O,O
in,O,O
FMS,O,O
and,O,O
LBP,O,O
patients,O,O
was,O,O
lower,O,O
compared,O,O
to,O,O
controls,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
FMS,O,O
patients,O,O
have,O,O
a,O,O
mild,O,O
hypocortisolemia,O,O
",",O,O
increased,O,O
cortisol,O,B
feedback,O,O
resistance,O,O
in,O,O
combination,O,O
probably,O,O
with,O,O
a,O,O
reduced,O,O
CRH,O,O
synthesis,O,O
or,O,O
release,O,O
in,O,O
the,O,O
hypothalamus,O,O
.,O,O
The,O,O
suggested,O,O
roles,O,O
of,O,O
the,O,O
downstream,B,O
3,I,O
regions,I,O
acting,O,O
as,O,O
a,O,O
Locus,B,O
Control,I,O
Region,I,O
(,O,O
LCR,B,O
),O,O
",",O,O
have,O,O
allowed,O,O
comparisons,O,O
to,O,O
be,O,O
made,O,O
between,O,O
the,O,O
regulation,O,O
of,O,O
the,O,O
IgH,B,O
locus,I,O
with,O,O
other,O,O
model,O,O
systems,O,O
whose,O,O
gene,O,O
expression,O,O
is,O,O
governed,O,O
by,O,O
LCR,B,O
activity,O,O
.,O,O
T,O,B
lymphocytes,O,O
recognize,O,O
antigens,O,O
in,O,O
the,O,O
form,O,O
of,O,O
peptides,O,O
bound,O,O
to,O,O
HLA,B,B
-,I,I
molecules,I,I
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
Peptides,O,O
derived,O,O
from,O,O
oncogenic,B,B
proteins,I,I
were,O,O
screened,O,O
for,O,O
the,O,O
presence,O,O
of,O,O
HLA,B,B
binding,I,O
motifs,I,O
;,O,O
actual,O,O
binding,O,O
were,O,O
evaluated,O,O
by,O,O
HLA,O,B
stabilization,O,O
experiments,O,O
using,O,O
transfectants,O,O
and,O,O
specific,O,O
anti,B,O
-,I,O
HLA,I,B
antibodies,I,I
.,O,O
Specific,O,O
lymphocytes,O,O
were,O,O
induced,O,O
by,O,O
in,O,O
vitro,O,O
peptide,O,O
sensitization,O,O
and,O,O
screened,O,O
by,O,O
thymidine,O,O
uptake,O,O
or,O,O
cellular,O,O
cytotoxic,O,O
assays,O,O
.,O,O
RESULTS,O,O
:,O,O
We,O,O
identified,O,O
peptides,O,O
derived,O,O
from,O,O
EWS,B,B
/,I,I
FLI,I,I
-,I,I
1,I,I
fusion,I,I
protein,I,I
and,O,O
from,O,O
mutated,B,O
K,I,B
-,I,I
RAS,I,I
protein,I,I
(,O,O
encompassing,O,O
respectively,O,O
the,O,O
fusion,B,O
point,I,O
and,O,O
the,O,O
mutation,O,O
at,O,O
position,B,O
12,I,O
),O,O
that,O,O
showed,O,O
binding,B,O
motif,I,O
for,O,O
HLA,B,B
-,I,I
Cw,I,I
*,I,I
and,O,O
HLA,B,B
-,I,I
A3,I,I
respectively,O,O
.,O,O
OCA,B,B
-,I,I
is,O,O
a,O,O
functional,O,O
analog,O,O
of,O,O
VP16,B,O
but,O,O
targets,O,O
a,O,O
separate,O,O
surface,O,O
of,O,O
the,O,O
Oct,B,B
-,I,I
1,I,I
POU,I,I
domain,I,I
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
Mol,O,O
Cell,O,O
Biol,O,O
1998,O,O
Apr,O,O
;,O,O
18,O,O
(,O,O
4,O,O
),O,O
:,O,O
2430,O,O
],O,O
Here,O,O
",",O,O
we,O,O
show,O,O
that,O,O
OCA,B,B
-,I,I
B,I,I
alters,O,O
the,O,O
activity,O,O
of,O,O
Oct,B,B
-,I,I
1,I,I
in,O,O
two,O,O
ways,O,O
.,O,O
These,O,O
results,O,O
emphasize,O,O
the,O,O
structural,O,O
versatility,O,O
of,O,O
the,O,O
Oct,B,B
-,I,I
1,I,I
POU,I,I
domain,I,I
in,O,O
its,O,O
interaction,O,O
with,O,O
coregulators,O,O
.,O,O
Phosphatidylinositol,B,B
3,I,I
-,I,I
kinase,I,I
couples,O,O
the,O,O
interleukin,B,B
-,I,I
2,I,I
receptor,I,I
to,O,O
the,O,O
cell,B,B
cycle,I,I
regulator,I,I
E2F,B,I
.,O,O
We,O,O
eliminate,O,O
both,O,O
Stat5,B,B
and,O,O
Raf,B,B
/,B,I
MEK,I,I
pathways,O,I
from,O,O
E2F,B,B
regulation,O,I
.,O,O
TRADD,B,B
was,O,O
the,O,O
only,O,O
protein,O,B
that,O,O
interacted,O,O
with,O,O
wild,B,O
-,I,O
type,I,O
TES2,I,B
and,O,O
not,O,O
with,O,O
isoleucine,B,B
-,I,I
mutated,I,I
TES2,I,I
.,O,O
In,O,O
transfection,O,O
assays,O,O
",",O,O
TRADD,B,B
and,O,O
TES2,B,B
synergistically,O,O
mediated,O,O
high,O,O
-,O,O
level,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,I
.,O,O
Bipotential,O,O
T,O,B
/,O,I
natural,O,B
killer,O,I
(,O,I
NK,O,I
),O,I
progenitor,O,O
cells,O,O
are,O,O
present,O,O
in,O,O
the,O,O
human,O,O
thymus,O,O
.,O,O
Although,O,O
experimental,O,O
evidence,O,O
is,O,O
lacking,O,O
",",O,O
lytic,O,O
viral,O,B
DNA,O,I
replication,O,O
is,O,O
believed,O,O
to,O,O
remove,O,O
modifications,O,O
or,O,O
binding,B,O
factors,I,O
from,O,O
the,O,O
genome,O,O
which,O,O
serve,O,O
to,O,O
repress,O,O
late,O,O
gene,O,O
expression,O,O
during,O,O
latency,O,O
or,O,O
the,O,O
early,O,O
lytic,O,O
cycle,O,O
.,O,O
Thus,O,O
",",O,O
replication,O,O
of,O,O
the,O,O
transcriptional,B,O
template,I,O
is,O,O
not,O,O
a,O,O
prerequisite,O,O
for,O,O
expression,O,O
with,O,O
late,O,O
kinetics,O,O
",",O,O
a,O,O
finding,O,O
inconsistent,O,O
with,O,O
the,O,O
current,O,O
models,O,O
which,O,O
posit,O,O
a,O,O
cis,O,O
-,O,O
active,O,O
relationship,O,O
between,O,O
lytic,O,O
EBV,O,B
DNA,O,I
replication,O,I
and,O,O
late,O,O
gene,O,O
expression,O,O
.,O,O
This,O,O
induction,O,O
of,O,O
C,B,O
/,I,O
EBP,I,B
epsilon,I,I
mRNA,I,I
expression,O,O
is,O,O
transcriptionally,O,O
mediated,O,O
and,O,O
occurs,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
synthesis,O,O
of,O,O
additional,O,O
protein,B,B
factors,I,I
.,O,O
We,O,O
suspect,O,O
that,O,O
the,O,O
C,B,B
/,I,I
EBP,I,I
epsilon,I,I
promoter,I,O
/,I,O
enhancer,I,O
contains,O,O
a,O,O
retinoic,B,B
acid,I,I
-,I,I
response,I,I
element,I,O
that,O,O
is,O,O
directly,O,O
stimulated,O,O
by,O,O
retinoids,O,O
.,O,O
Core,B,O
-,I,O
specific,I,O
mAb,I,O
inhibited,O,O
mCD14,B,B
-,O,I
mediated,O,I
uptake,O,O
of,O,O
homologous,O,O
and,O,O
heterologous,O,O
LPS,O,O
",",O,O
while,O,O
producing,O,O
less,O,O
concurrent,O,O
enhancement,O,O
of,O,O
non,O,B
-,O,I
mCD14,B,I
-,O,I
mediated,O,I
LPS,O,I
uptake,O,O
.,O,O
Transfection,O,O
of,O,O
EL,O,O
-,O,O
4,O,O
cells,O,O
with,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
promoter,I,I
-,I,I
reporter,I,I
constructs,I,O
carrying,O,O
mutated,B,O
P,I,B
-,I,I
like,I,I
elements,I,I
showed,O,O
that,O,O
four,O,O
P,B,B
-,I,I
like,I,I
elements,I,I
",",O,O
",",O,O
P,B,B
",",O,O
P2,B,B
and,O,O
P4,B,B
",",O,O
but,O,O
not,O,O
P3,B,B
",",O,O
were,O,O
required,O,O
for,O,O
optimal,O,O
activation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
promoter,I,I
.,O,O
The,O,O
initiating,O,O
event,O,O
is,O,O
still,O,O
uncertain,O,O
",",O,O
but,O,O
activation,O,O
of,O,O
a,O,O
recently,O,O
described,O,O
receptor,B,O
-,I,O
associated,I,O
protein,I,O
kinase,I,O
is,O,O
one,O,O
of,O,O
the,O,O
earliest,O,O
events,O,O
detectable,O,O
(,O,O
Martin,O,O
et,O,O
al,O,O
.,O,O
",",O,O
Eur,O,O
.,O,O
J,O,O
.,O,O
Immunol,O,O
.,O,O
1994,O,O
.,O,O
24,O,O
:,O,O
1566,O,O
.,O,O
From,O,O
these,O,O
observations,O,O
we,O,O
conclude,O,O
that,O,O
free,O,O
thiols,O,O
in,O,O
the,O,O
IL,B,B
-,I,I
1RI,I,I
complex,I,I
are,O,O
essential,O,O
for,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
1RI,I,I
-,I,I
associated,I,I
protein,I,I
kinase,I,I
and,O,O
that,O,O
this,O,O
process,O,O
is,O,O
mandatory,O,O
for,O,O
IL,B,B
-,I,I
1,I,I
signaling,O,O
leading,O,O
to,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
.,O,O
Strikingly,O,O
",",O,O
Western,O,O
blotting,O,O
and,O,O
immunocytochemical,O,O
experiments,O,O
indicated,O,O
that,O,O
PDTC,O,O
promoted,O,O
a,O,O
transient,O,O
and,O,O
rapid,O,O
shuttling,O,O
of,O,O
NFATp,B,O
and,O,O
NFATc,B,O
",",O,O
leading,O,O
to,O,O
their,O,O
accelerated,O,O
export,O,O
from,O,O
the,O,O
nucleus,O,O
of,O,O
activated,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
A,B,O
-,I,O
myb,I,B
transcription,I,I
factor,I,I
in,O,O
neoplastic,O,O
and,O,O
normal,O,O
B,O,O
cells,O,O
.,O,O
Its,O,O
normal,O,O
cellular,O,O
equivalent,O,O
c,B,B
-,I,I
myb,I,I
",",O,O
has,O,O
been,O,O
shown,O,O
to,O,O
promote,O,O
the,O,O
proliferation,O,O
and,O,O
block,O,O
the,O,O
differentiation,O,O
of,O,O
haematopoietic,O,O
cells,O,O
in,O,O
several,O,O
experimental,O,O
models,O,O
and,O,O
is,O,O
required,O,O
for,O,O
fetal,O,O
haematopoiesis,O,O
.,O,O
Both,O,O
have,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
transcription,B,O
factors,I,O
.,O,O
These,O,O
studies,O,O
indicate,O,O
that,O,O
A,B,B
-,I,I
myb,I,I
plays,O,O
a,O,O
role,O,O
during,O,O
a,O,O
narrow,O,O
window,O,O
of,O,O
normal,O,O
B,O,B
cell,O,I
differentiation,O,I
.,O,O
Expression,O,O
of,O,O
bcl,B,B
-,I,I
6,I,I
protein,I,O
in,O,O
normal,O,O
skin,O,B
and,O,O
epidermal,O,B
neoplasms,O,I
.,O,O
It,O,O
was,O,O
recently,O,O
shown,O,O
by,O,O
us,O,O
that,O,O
the,O,O
protein,O,O
is,O,O
located,O,O
in,O,O
germinal,O,B
center,O,I
B,O,I
cells,O,I
and,O,O
their,O,O
neoplastic,O,O
counterparts,O,O
.,O,O
Squamous,O,B
cell,O,I
carcinomas,O,I
showed,O,O
a,O,O
variety,O,O
of,O,O
expression,O,O
levels,O,O
",",O,O
while,O,O
two,O,O
undifferentiated,O,O
spindle,O,B
-,O,I
shaped,O,I
carcinomas,O,I
and,O,O
one,O,O
undifferentiated,O,O
SCC,O,B
cell,O,I
line,O,I
remained,O,O
unstained,O,O
.,O,O
We,O,O
recently,O,O
identified,O,O
the,O,O
winged,B,O
-,I,O
helix,I,O
transcription,I,O
factor,I,O
Trident,B,O
and,O,O
described,O,O
its,O,O
expression,O,O
pattern,O,O
in,O,O
synchronized,O,O
fibroblasts,O,O
.,O,O
During,O,O
T,O,O
cell,O,O
differentiation,O,O
",",O,O
expression,O,O
peaked,O,O
in,O,O
the,O,O
actively,O,O
dividing,O,O
immature,O,O
single,O,O
positive,O,O
cells,O,O
.,O,O
The,O,O
estrogen,B,B
receptor,I,I
(,O,O
ER,B,O
),O,O
repressed,O,O
erythroid,O,O
differentiation,O,O
and,O,O
erythroid,B,O
-,I,O
specific,I,O
gene,I,O
expression,O,O
.,O,O
These,O,O
bHLH,B,B
antagonists,I,O
are,O,O
induced,O,O
during,O,O
a,O,O
mitogenic,O,O
signalling,O,O
response,O,O
",",O,O
and,O,O
they,O,O
function,O,O
by,O,O
sequestering,O,O
their,O,O
bHLH,B,B
targets,I,O
in,O,O
inactive,B,O
heterodimers,I,O
that,O,O
are,O,O
unable,O,O
to,O,O
bind,O,O
to,O,O
specific,O,O
gene,B,O
regulatory,I,O
(,I,O
E,I,B
box,I,I
),I,O
sequences,I,O
.,O,O
Recently,O,O
",",O,O
cyclin,O,O
E,O,B
-,O,I
Cdk2,O,I
-,O,I
and,O,O
cyclin,O,O
A,O,B
-,O,I
Cdk2,O,I
-,O,I
dependent,O,O
phosphorylation,O,O
of,O,O
a,O,O
single,O,O
conserved,O,O
serine,O,O
residue,O,O
(,O,O
Ser5,O,O
),O,O
in,O,O
Id2,B,O
has,O,O
been,O,O
shown,O,O
to,O,O
occur,O,O
during,O,O
late,O,O
G1,O,O
-,O,O
to,O,O
-,O,O
S,O,O
phase,O,O
transition,O,O
of,O,O
the,O,O
cell,O,O
cycle,O,O
",",O,O
and,O,O
this,O,O
neutralizes,O,O
the,O,O
function,O,O
of,O,O
Id2,B,O
in,O,O
abrogating,O,O
E,B,B
-,I,I
box,I,I
-,I,I
dependent,I,O
bHLH,I,B
homo,O,I
-,O,I
or,O,I
heterodimer,O,I
complex,O,I
formation,O,O
in,O,O
vitro,O,O
(,O,O
E,O,O
.,O,O
Hara,O,O
",",O,O
M,O,O
.,O,O
Hall,O,O
",",O,O
and,O,O
G,O,O
.,O,O
Peters,O,O
",",O,O
EMBO,O,O
J,O,O
.,O,O
16,O,O
:,O,O
332,O,O
-,O,O
342,O,O
",",O,O
1997,O,O
.,O,O
Furthermore,O,O
",",O,O
compared,O,O
with,O,O
wild,B,O
-,I,O
type,I,O
Id3,I,B
",",O,O
an,O,O
Id3,B,O
Asp5,I,O
mutant,I,O
(,O,O
mimicking,O,O
phosphorylation,O,O
),O,O
is,O,O
unable,O,O
to,O,O
promote,O,O
cell,O,O
cycle,O,O
S,O,O
phase,O,O
entry,O,O
in,O,O
transfected,O,O
fibroblasts,O,O
",",O,O
whereas,O,O
an,O,O
Id3,B,B
Ala5,I,O
mutant,I,O
(,O,O
ablating,O,O
phosphorylation,O,O
),O,O
displays,O,O
an,O,O
activity,O,O
significantly,O,O
greater,O,O
than,O,O
that,O,O
of,O,O
wild,B,O
-,I,O
type,I,O
Id3,I,O
protein,I,O
.,O,O
Here,O,O
we,O,O
describe,O,O
cloning,O,O
and,O,O
characterization,O,O
of,O,O
full,O,O
-,O,O
length,O,O
cDNA,B,B
encoding,I,O
murine,I,O
(,I,O
m,I,O
),I,O
NFATc,I,B
which,O,O
predicts,O,O
that,O,O
the,O,O
protein,O,O
has,O,O
all,O,O
the,O,O
conserved,B,O
structural,I,O
motifs,I,O
of,O,O
NFAT,B,B
family,I,I
members,I,I
",",O,O
including,O,O
the,O,O
rel,O,O
homology,O,O
domain,O,O
",",O,O
the,O,O
NFAT,B,B
homology,I,I
domain,I,I
and,O,O
the,O,O
nuclear,O,O
translocation,O,O
signals,O,O
.,O,O
In,O,O
the,O,O
mouse,O,O
embryo,O,O
",",O,O
mNFATc,B,B
transcript,I,O
was,O,O
strongly,O,O
expressed,O,O
in,O,O
thymus,O,O
",",O,O
lung,O,O
and,O,O
submandibular,O,O
gland,O,O
and,O,O
weakly,O,O
in,O,O
skeletal,O,O
muscle,O,O
and,O,O
heart,O,O
suggesting,O,O
that,O,O
mNFATc,B,B
may,O,O
have,O,O
a,O,O
role,O,O
both,O,O
in,O,O
embryogenesis,O,O
and,O,O
in,O,O
mature,O,O
T,O,O
cells,O,O
.,O,O
a,O,
Furthermore,O,O
",",O,O
we,O,O
show,O,O
that,O,O
patients,O,O
with,O,O
GC,O,B
-,O,I
insensitive,O,I
asthma,O,I
have,O,O
cytokine,O,O
-,O,O
induced,O,O
abnormalities,O,O
in,O,O
the,O,O
DNA,O,B
binding,O,I
capability,O,I
of,O,O
the,O,O
GCR,B,B
.,O,O
Mutation,O,O
of,O,O
the,O,O
CBF1,B,B
/,I,I
RBP,I,I
-,I,I
Jkappa,I,I
binding,I,I
site,I,I
in,O,O
EBNA3C,B,O
abrogated,O,O
repression,O,O
",",O,O
strongly,O,O
suggesting,O,O
that,O,O
CBF1,B,B
/,I,I
RBP,I,I
-,I,I
Jkappa,I,I
is,O,O
necessary,O,O
for,O,O
targeting,O,O
the,O,O
viral,O,O
protein,O,O
to,O,O
Cp,B,O
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
clarify,O,O
the,O,O
relationship,O,O
between,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
and,O,O
the,O,O
effectiveness,O,O
of,O,O
glucocorticoid,O,B
therapy,O,O
in,O,O
patients,O,O
with,O,O
ulcerative,O,O
colitis,O,O
",",O,O
we,O,O
investigated,O,O
the,O,O
number,O,O
and,O,O
apparent,O,O
dissociation,O,O
constant,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
in,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
leukocytes,O,O
of,O,O
patients,O,O
with,O,O
ulcerative,O,O
colitis,O,O
.,O,O
The,O,O
apparent,O,O
dissociation,O,O
constant,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptors,I,I
from,O,O
the,O,O
nonresponders,O,O
",",O,O
responders,O,O
",",O,O
and,O,O
healthy,O,O
controls,O,O
were,O,O
7,O,O
.,O,O
(,O,O
range,O,O
",",O,O
5,O,O
.,O,O
66,O,O
-,O,O
10,O,O
),O,O
",",O,O
4,O,O
.,O,O
27,O,O
(,O,O
range,O,O
",",O,O
4,O,O
-,O,O
5,O,O
.,O,O
13,O,O
),O,O
",",O,O
and,O,O
6,O,O
.,O,O
18,O,O
(,O,O
range,O,O
",",O,O
5,O,O
.,O,O
86,O,O
-,O,O
6,O,O
.,O,O
74,O,O
),O,O
nM,O,O
",",O,O
respectively,O,O
.,O,O
Nonresponders,O,O
had,O,O
a,O,O
significant,O,O
increase,O,O
both,O,O
in,O,O
the,O,O
number,O,O
of,O,O
binding,B,O
sites,I,O
and,O,O
in,O,O
the,O,O
apparent,O,O
dissociation,O,O
constant,O,O
compared,O,O
with,O,O
responders,O,O
(,O,O
P,O,O
0,O,O
.,O,O
;,O,O
P,O,O
0,O,O
.,O,O
),O,O
.,O,O
Cooperation,O,O
of,O,O
binding,B,O
sites,I,O
for,O,O
STAT6,B,O
and,O,O
NF,B,O
kappa,I,O
B,I,O
/,I,O
rel,I,O
in,O,O
the,O,O
IL,B,B
-,I,O
4,I,O
-,O,O
induced,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
the,O,O
human,B,O
IgE,I,O
germline,I,O
promoter,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
lipopolysaccharide,O,O
stimulation,O,O
primarily,O,O
induced,O,O
the,O,O
p65,B,O
/,I,O
p50,I,O
heterodimer,I,O
that,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
result,O,O
in,O,O
gene,O,O
activation,O,O
.,O,O
Cyclosporin,O,O
A,O,O
inhibits,O,O
early,O,O
mRNA,O,O
expression,O,O
of,O,O
G0,B,O
/,I,O
G1,I,O
switch,I,O
gene,I,O
2,I,O
(,O,O
G0S2,B,O
),O,O
in,O,O
cultured,O,O
human,O,O
blood,O,O
mononuclear,O,O
cells,O,O
.,O,O
In,O,O
cells,O,O
that,O,O
have,O,O
been,O,O
preincubated,O,O
to,O,O
lower,O,O
mRNA,O,B
levels,O,O
",",O,O
there,O,O
is,O,O
a,O,O
transient,O,O
increase,O,O
in,O,O
G0S2,B,B
mRNA,I,I
",",O,O
peaking,O,O
between,O,O
1,O,O
-,O,O
2,O,O
h,O,O
",",O,O
in,O,O
response,O,O
to,O,O
Concanavalin,O,B
-,O,I
A,O,I
(,O,O
ConA,O,O
),O,O
",",O,O
or,O,O
to,O,O
the,O,O
combination,O,O
of,O,O
phorbol,O,B
ester,O,I
(,O,O
TPA,O,O
),O,O
",",O,O
and,O,O
the,O,O
calcium,O,B
ionophore,O,I
",",O,O
ionomycin,O,O
.,O,O
YY1,B,O
",",O,O
a,O,O
widely,O,O
distributed,O,O
human,B,O
transcription,I,O
factor,I,O
",",O,O
is,O,O
known,O,O
to,O,O
inhibit,O,O
HIV,B,B
-,I,I
1,I,I
long,I,I
terminal,I,I
repeat,I,I
(,O,I
LTR,B,I
),O,I
transcription,O,O
and,O,O
virus,O,O
production,O,O
.,O,O
LSF,B,B
(,O,O
also,O,O
known,O,O
as,O,O
LBP,B,B
-,I,I
1,I,I
",",O,O
UBP,B,B
",",O,O
and,O,O
CP,B,B
-,I,I
2,I,I
),O,O
has,O,O
been,O,O
shown,O,O
to,O,O
repress,O,O
LTR,O,B
transcription,O,O
in,O,O
vitro,O,O
",",O,O
but,O,O
transient,O,O
expression,O,O
of,O,O
LSF,B,B
has,O,O
no,O,O
effect,O,O
on,O,O
LTR,B,B
activity,O,O
in,O,O
vivo,O,O
.,O,O
Relative,O,O
affinities,O,O
of,O,O
transcriptional,B,O
regulatory,I,O
elements,I,O
for,O,O
their,O,O
respective,O,O
factor,O,O
have,O,O
been,O,O
essentially,O,O
studied,O,O
by,O,O
bandshift,O,O
analysis,O,O
.,O,O
Here,O,O
we,O,O
report,O,O
a,O,O
real,O,O
-,O,O
time,O,O
study,O,O
of,O,O
factor,O,B
/,O,O
DNA,O,B
interactions,O,O
using,O,O
a,O,O
surface,O,O
plasmon,O,O
resonance,O,O
approach,O,O
and,O,O
further,O,O
characterization,O,O
of,O,O
recovered,B,O
proteins,I,B
involved,O,O
in,O,O
this,O,O
interaction,O,O
.,O,O
This,O,O
result,O,O
",",O,O
confirmed,O,O
by,O,O
competitions,O,O
with,O,O
each,O,O
GATA,B,O
site,I,O
",",O,O
demonstrated,O,O
the,O,O
higher,O,O
relative,O,O
affinity,O,O
(,O,O
at,O,O
least,O,O
sevenfold,O,O
),O,O
of,O,O
site,O,O
3,O,O
.,O,O
Stable,O,O
transfection,O,O
of,O,O
U937,O,O
cells,O,O
with,O,O
sense,O,O
or,O,O
antisense,B,O
RXR,I,B
-,I,I
alpha,I,I
cDNA,I,O
suggests,O,O
a,O,O
role,O,O
for,O,O
RXR,B,B
-,I,I
alpha,I,I
in,O,O
the,O,O
control,O,O
of,O,O
monoblastic,O,O
differentiation,O,O
induced,O,O
by,O,O
retinoic,O,O
acid,O,O
and,O,O
vitamin,O,O
D,O,O
.,O,O
The,O,O
role,O,O
of,O,O
the,O,O
viral,B,O
trans,I,O
-,I,O
activator,I,O
Tax,I,B
protein,I,O
in,O,O
the,O,O
induction,O,O
of,O,O
VCAM,B,B
-,I,I
1,I,I
was,O,O
first,O,O
indicated,O,O
by,O,O
the,O,O
detection,O,O
of,O,O
this,O,O
adhesion,B,O
molecule,I,O
on,O,O
Jurkat,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
stably,O,O
expressing,O,O
the,O,O
tax,O,O
gene,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
Tax,B,B
on,O,O
VCAM,B,B
-,I,I
1,I,I
gene,O,O
transcription,O,O
was,O,O
next,O,O
confirmed,O,O
in,O,O
JPX,O,O
-,O,O
9,O,O
cells,O,O
",",O,O
a,O,O
subclone,O,O
of,O,O
Jurkat,O,O
cells,O,O
",",O,O
carrying,O,O
the,O,O
tax,B,O
sequences,I,O
under,O,O
the,O,O
control,O,O
of,O,O
an,O,O
inducible,B,O
promoter,I,O
.,O,O
Furthermore,O,O
",",O,O
deletion,O,O
and,O,O
mutation,O,O
analyses,O,O
of,O,O
the,O,O
VCAM,B,B
-,I,I
1,I,I
promoter,I,O
performed,O,O
with,O,O
chloramphenicol,B,O
acetyltransferase,I,O
constructs,I,O
revealed,O,O
that,O,O
Tax,B,B
was,O,O
trans,O,O
activating,O,O
the,O,O
VCAM,B,B
-,I,I
1,I,I
promoter,I,O
via,O,O
two,O,O
NF,B,O
-,I,O
kappaB,I,O
sites,I,O
present,O,O
at,O,O
bp,O,O
-,O,O
72,O,O
and,O,O
-,O,O
57,O,O
in,O,O
the,O,O
VCAM,B,B
-,I,I
1,I,I
gene,I,O
promoter,I,O
",",O,O
with,O,O
both,O,O
of,O,O
them,O,O
being,O,O
required,O,O
for,O,O
the,O,O
Tax,B,B
-,O,O
induced,O,O
expression,O,O
of,O,O
this,O,O
adhesion,B,O
molecule,I,O
.,O,O
We,O,O
have,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
Vpr,B,O
on,O,O
host,O,O
cell,O,O
activation,O,O
and,O,O
confirm,O,O
that,O,O
it,O,O
influences,O,O
cellular,O,O
proliferation,O,O
.,O,O
In,O,O
the,O,O
absence,O,O
of,O,O
TCR,B,O
-,O,O
mediated,O,O
activation,O,O
",",O,O
Vpr,B,O
induces,O,O
apoptosis,O,O
whereas,O,O
in,O,O
its,O,O
presence,O,O
",",O,O
Vpr,B,O
interrupts,O,O
the,O,O
expected,O,O
induction,O,O
of,O,O
apoptosis,O,O
.,O,O
Our,O,O
finding,O,O
that,O,O
Vpr,B,O
can,O,O
regulate,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
supports,O,O
the,O,O
hypothesis,O,O
that,O,O
some,O,O
aspects,O,O
of,O,O
viral,O,O
pathogenesis,O,O
are,O,O
the,O,O
consequence,O,O
of,O,O
cell,O,O
dysregulation,O,O
by,O,O
Vpr,B,O
.,O,O
In,O,O
fact,O,O
",",O,O
by,O,O
employing,O,O
a,O,O
novel,O,O
haptenized,O,O
lysis,O,O
synthetic,O,O
substrate,O,O
which,O,O
allows,O,O
the,O,O
isolation,O,O
of,O,O
glutaminyl,O,O
-,O,O
tTG,O,O
substrates,O,O
in,O,O
vivo,O,O
",",O,O
we,O,O
identified,O,O
pRB,B,O
as,O,O
a,O,O
potential,O,O
tTG,O,O
substrate,O,O
in,O,O
U937,O,O
cells,O,O
undergoing,O,O
apoptosis,O,O
.,O,O
Interleukin,B,B
2,I,I
(,O,O
IL,B,B
-,I,I
2,I,I
),O,O
induces,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
STATs,B,O
3,I,O
and,I,O
5,I,O
(,O,O
signal,O,O
transducer,O,O
and,O,O
activator,O,O
of,O,O
transcription,O,O
),O,O
.,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
T,B,O
cell,I,O
antigen,I,O
receptor,I,O
complex,I,O
induction,O,O
of,O,O
STAT3alpha,B,B
serine,O,O
727,O,O
phosphorylation,O,O
is,O,O
dependent,O,O
on,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
MEK,B,O
/,B,O
ERK,I,O
pathway,O,O
.,O,O
These,O,O
results,O,O
thus,O,O
show,O,O
that,O,O
STAT3,B,B
proteins,I,O
are,O,O
targets,O,O
for,O,O
multiple,O,O
kinase,O,O
pathways,O,O
in,O,O
T,O,O
cells,O,O
and,O,O
can,O,O
integrate,O,O
signals,O,O
from,O,O
both,O,O
cytokine,B,O
receptors,I,O
and,O,O
antigen,B,O
receptors,I,O
.,O,O
In,O,O
addition,O,O
",",O,O
both,O,O
RelA,B,B
and,O,O
c,B,O
-,I,O
Rel,I,O
",",O,O
but,O,O
not,O,O
NF,B,O
-,I,O
kappa,I,O
B1,I,O
",",O,O
were,O,O
shown,O,O
to,O,O
transactivate,O,O
an,O,O
ICAM,B,O
-,I,O
1,I,O
kappa,I,O
B,I,O
-,I,O
reporter,I,O
construct,I,O
.,O,O
Competent,O,O
transcription,O,O
initiation,O,O
by,O,O
RNA,B,B
polymerase,I,I
II,I,I
in,O,O
cell,O,O
-,O,O
free,O,O
extracts,O,O
from,O,O
xeroderma,O,B
pigmentosum,O,I
groups,O,I
B,O,I
and,O,O
D,O,O
in,O,O
an,O,O
optimized,O,O
RNA,O,B
transcription,O,I
assay,O,I
.,O,O
We,O,O
have,O,O
employed,O,O
an,O,O
optimized,O,O
cell,O,O
-,O,O
free,O,O
RNA,O,B
transcription,O,I
assay,O,I
to,O,O
analyze,O,O
transcription,O,O
activity,O,O
of,O,O
XP,O,B
-,O,I
B,O,I
and,O,O
XP,O,B
-,O,I
D,O,I
.,O,O
Binding,O,O
capacity,O,O
(,O,O
4978,O,O
+,O,O
/,O,O
-,O,O
391,O,O
versus,O,O
4131,O,O
+,O,O
/,O,O
-,O,O
321,O,O
sites,O,O
/,O,O
cell,O,O
),O,O
",",O,O
Kd,O,O
values,O,O
for,O,O
dexamethasone,O,B
(,O,O
6,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
versus,O,O
5,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
3,O,O
nmol,O,O
/,O,O
L,O,O
),O,O
",",O,O
and,O,O
IC50,O,O
values,O,O
for,O,O
dexamethasone,O,B
(,O,O
3,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
3,O,O
versus,O,O
3,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
nmol,O,O
/,O,O
L,O,O
and,O,O
cortisol,O,B
(,O,O
12,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
6,O,O
versus,O,O
9,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
3,O,O
nmol,O,O
/,O,O
L,O,O
),O,O
were,O,O
not,O,O
significantly,O,O
different,O,O
.,O,O
Patients,O,O
with,O,O
renin,B,B
values,O,O
less,O,O
than,O,O
0,O,O
.,O,O
13,O,O
ng,O,O
angiotensin,O,O
I,O,O
/,O,O
L,O,O
per,O,O
second,O,O
were,O,O
markedly,O,O
less,O,O
sensitive,O,O
to,O,O
cortisol,O,O
than,O,O
those,O,O
with,O,O
higher,O,O
values,O,O
.,O,O
The,O,O
composite,B,O
PU,I,O
.,I,O
1,I,O
and,I,O
Pip,I,O
site,I,O
likely,O,O
accounts,O,O
for,O,O
both,O,O
lineage,O,O
and,O,O
stage,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
CD20,B,B
whereas,O,O
the,O,O
CD20,B,B
E,I,I
box,I,I
binding,I,I
proteins,I,I
enhance,O,O
overall,O,O
promoter,O,O
activity,O,O
and,O,O
may,O,O
link,O,O
the,O,O
promoter,O,O
to,O,O
a,O,O
distant,B,O
enhancer,I,O
.,O,O
HIV,O,B
infection,O,I
is,O,O
also,O,O
associated,O,O
with,O,O
activation,O,O
of,O,O
the,O,O
hypothalamo,O,O
-,O,O
pituitary,O,O
-,O,O
adrenal,O,O
axis,O,O
function,O,O
and,O,O
increased,O,O
plasma,O,O
and,O,O
urinary,O,O
cortisol,O,B
concentrations,O,I
.,O,O
After,O,O
DMSO,O,O
treatment,O,O
",",O,O
HL,O,B
-,O,I
60,O,I
cells,O,O
eventually,O,O
died,O,O
via,O,O
apoptosis,O,O
",",O,O
whereas,O,O
the,O,O
viability,O,O
of,O,O
PDBu,O,O
-,O,O
treated,O,O
cells,O,O
was,O,O
not,O,O
affected,O,O
during,O,O
the,O,O
same,O,O
interval,O,O
.,O,O
The,O,O
generality,O,O
of,O,O
this,O,O
finding,O,O
was,O,O
confirmed,O,O
by,O,O
the,O,O
induction,O,O
of,O,O
Bcl,B,B
-,I,I
xL,I,I
in,O,O
human,O,B
myeloid,O,I
U,O,I
-,O,I
937,O,I
cells,O,O
",",O,O
human,O,B
peripheral,O,I
blood,O,I
monocytes,O,I
exposed,O,O
to,O,O
phorbol,O,B
ester,O,I
",",O,O
and,O,O
mouse,O,B
thioglycollate,O,I
-,O,I
activated,O,I
and,O,I
resident,O,I
peritoneal,O,I
macrophages,O,I
.,O,O
Monochloramine,O,O
derivatives,O,O
are,O,O
long,O,O
lived,O,O
physiological,O,O
oxidants,O,O
produced,O,O
by,O,O
neutrophils,O,B
during,O,O
the,O,O
respiratory,O,O
burst,O,O
.,O,O
Cyclosporine,O,B
(,O,O
CsA,O,O
),O,O
is,O,O
both,O,O
a,O,O
clinical,O,O
immunosuppressive,O,O
drug,O,O
and,O,O
a,O,O
probe,O,O
to,O,O
dissect,O,O
intracellular,O,O
signaling,O,O
pathways,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
degree,O,O
of,O,O
CN,B,O
inhibition,O,O
was,O,O
reflected,O,O
by,O,O
a,O,O
similar,O,O
degree,O,O
of,O,O
reduction,O,O
in,O,O
lymphocyte,O,B
proliferation,O,O
and,O,O
IFN,B,B
-,I,I
gamma,I,I
production,O,O
in,O,O
the,O,O
allogeneic,O,O
mixed,O,O
lymphocyte,O,O
cultures,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
reduction,O,O
of,O,O
CN,B,O
activity,O,O
observed,O,O
in,O,O
CsA,O,O
-,O,O
treated,O,O
patients,O,O
is,O,O
accompanied,O,O
by,O,O
a,O,O
similar,O,O
degree,O,O
of,O,O
reduction,O,O
in,O,O
lymphocyte,B,O
gene,I,O
activation,O,O
",",O,O
and,O,O
accounts,O,O
for,O,O
the,O,O
immunosuppression,O,O
observed,O,O
.,O,O
Control,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activity,O,O
by,O,O
the,O,O
I,B,B
kappa,I,I
B,I,I
beta,I,I
inhibitor,I,I
.,O,O
The,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
maintained,O,O
in,O,O
an,O,O
inactive,O,O
cytoplasmic,O,O
state,O,O
by,O,O
I,B,B
kappa,I,I
B,I,I
inhibitors,I,I
.,O,O
G28,B,O
-,I,O
5,I,O
sFv,I,O
was,O,O
a,O,O
more,O,O
potent,O,O
agonist,O,O
than,O,O
G28,B,O
-,I,O
5,I,O
IgG,I,O
and,O,O
was,O,O
able,O,O
to,O,O
stimulate,O,O
CD40,B,O
responses,O,O
by,O,O
B,O,O
cells,O,O
and,O,O
monocytes,O,O
.,O,O
Increased,O,O
CRH,B,O
promoter,O,O
activity,O,O
following,O,O
phorbol,O,O
ester,O,O
treatment,O,O
was,O,O
inhibited,O,O
by,O,O
a,O,O
dominant,O,O
negative,O,O
NF,B,O
-,I,O
IL6,I,O
mutant,I,O
",",O,O
showing,O,O
that,O,O
the,O,O
effects,O,O
of,O,O
phorbol,O,O
ester,O,O
were,O,O
principally,O,O
mediated,O,O
by,O,O
C,B,O
/,I,O
EBP,I,O
.,O,O
We,O,O
screened,O,O
TSG101,B,B
for,O,O
somatic,O,O
mutations,O,O
in,O,O
DNA,O,B
and,O,O
RNA,O,B
samples,O,O
isolated,O,O
from,O,O
a,O,O
variety,O,O
of,O,O
common,O,O
human,O,O
malignancies,O,O
",",O,O
EBV,O,O
-,O,O
immortalised,O,O
B,O,O
-,O,O
cells,O,O
",",O,O
and,O,O
normal,O,O
lung,O,O
parenchyma,O,O
.,O,O
Intragenic,O,O
TSG101,B,B
deletions,O,O
in,O,O
RNA,B,B
transcripts,I,O
were,O,O
frequently,O,O
found,O,O
in,O,O
all,O,O
types,O,O
of,O,O
samples,O,O
.,O,O
A,O,O
similar,O,O
spectrum,O,O
of,O,O
transcript,O,O
deletions,O,O
has,O,O
previously,O,O
been,O,O
described,O,O
in,O,O
the,O,O
putative,B,O
tumour,I,O
suppressor,I,O
gene,I,O
FHIT,B,O
.,O,O
Interleukin,B,B
-,I,I
7,I,I
upregulates,O,O
the,O,O
interleukin,B,B
-,I,I
2,I,I
-,I,I
gene,I,I
expression,O,O
in,O,O
activated,O,O
human,O,B
T,O,I
lymphocytes,O,I
at,O,O
the,O,O
transcriptional,O,O
level,O,O
by,O,O
enhancing,O,O
the,O,O
DNA,O,B
binding,O,I
activities,O,O
of,O,O
both,O,O
nuclear,O,B
factor,O,I
of,O,I
activated,O,I
T,O,I
cells,O,I
and,O,O
activator,B,O
protein,I,O
-,I,O
1,I,O
.,O,O
Production,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
requires,O,O
the,O,O
formation,O,O
of,O,O
transcription,B,O
factors,I,O
involved,O,O
in,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
-,I,I
gene,I,I
regulation,O,O
.,O,O
The,O,O
three,O,O
-,O,O
dimensional,O,O
positioning,O,O
of,O,O
immunoglobulin,B,B
(,I,O
Ig,I,I
),I,O
genes,I,O
within,O,O
the,O,O
nucleus,O,O
of,O,O
human,O,B
cells,O,O
was,O,O
investigated,O,O
using,O,O
in,O,O
situ,O,O
hybridization,O,O
and,O,O
confocal,O,O
microscopy,O,O
.,O,O
The,O,O
visualization,O,O
of,O,O
heavy,B,B
and,I,O
light,I,B
chain,I,I
genes,I,O
in,O,O
B,O,B
-,O,I
lymphoid,O,I
cells,O,O
showed,O,O
that,O,O
the,O,O
three,O,O
Ig,B,I
genes,I,O
are,O,O
differentially,O,O
and,O,O
nonrandomly,O,O
distributed,O,O
in,O,O
different,O,O
nuclear,O,O
subvolumes,O,O
:,O,O
the,O,O
kappa,B,B
genes,I,O
were,O,O
found,O,O
to,O,O
be,O,O
preferentially,O,O
confined,O,O
to,O,O
an,O,O
outer,O,O
nuclear,O,O
volume,O,O
",",O,O
whereas,O,O
the,O,O
gamma,B,B
and,I,O
lambda,I,B
genes,I,O
consistently,O,O
occupied,O,O
more,O,O
central,O,O
positions,O,O
within,O,O
the,O,O
nucleus,O,O
",",O,O
the,O,O
lambda,B,B
genes,I,O
being,O,O
more,O,O
interior,O,O
when,O,O
compared,O,O
with,O,O
the,O,O
gamma,B,B
genes,I,O
.,O,O
These,O,O
findings,O,O
show,O,O
that,O,O
healthy,O,O
virus,O,O
carriers,O,O
maintain,O,O
a,O,O
high,O,O
frequency,O,O
of,O,O
BZLF1,O,O
-,O,O
specific,O,O
memory,O,O
T,O,O
cells,O,O
",",O,O
potentially,O,O
to,O,O
control,O,O
virus,O,O
spread,O,O
from,O,O
lytically,O,O
infected,O,O
cells,O,O
.,O,O
We,O,O
have,O,O
therefore,O,O
investigated,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
A,B,O
-,I,O
MYB,I,O
and,O,O
its,O,O
regulation,O,O
in,O,O
several,O,O
human,O,O
lymphoid,O,O
cell,O,O
lines,O,O
using,O,O
co,O,O
-,O,O
transfection,O,O
assays,O,O
and,O,O
show,O,O
that,O,O
A,B,O
-,I,O
MYB,I,O
is,O,O
transcriptionally,O,O
active,O,O
in,O,O
all,O,O
the,O,O
B,O,O
cell,O,O
lines,O,O
studied,O,O
",",O,O
but,O,O
not,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
Transcription,O,O
factor,O,O
Egr,B,B
-,I,I
1,I,I
activity,O,O
down,O,O
-,O,O
regulates,O,O
Fas,O,B
and,O,O
CD23,O,B
expression,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
Transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
must,O,O
be,O,O
released,O,O
from,O,O
cytoplasmic,B,O
inhibitory,I,O
molecules,I,O
(,O,O
I,B,O
kappa,I,O
Bs,I,O
),O,O
in,O,O
order,O,O
to,O,O
move,O,O
to,O,O
the,O,O
nucleus,O,O
and,O,O
to,O,O
activate,O,O
its,O,O
target,B,O
genes,I,O
.,O,O
The,O,O
half,O,O
-,O,O
life,O,O
of,O,O
both,O,O
inhibitors,O,O
is,O,O
increased,O,O
in,O,O
HeLa,O,B
cells,O,O
.,O,O
PCR,O,O
analysis,O,O
of,O,O
spontaneous,O,O
EBV,O,B
-,O,I
transformed,O,I
lymphoblastoid,O,I
cell,O,I
lines,O,I
(,O,O
LCL,O,O
),O,O
from,O,O
three,O,O
individuals,O,O
with,O,O
primary,O,O
infection,O,O
showed,O,O
that,O,O
two,O,O
were,O,O
infected,O,O
with,O,O
type,O,O
A,O,O
and,O,O
one,O,O
B,O,O
EBV,O,B
.,O,O
TCR,B,O
beta,I,O
analysis,O,O
showed,O,O
that,O,O
while,O,O
there,O,O
was,O,O
loop,O,O
length,O,O
restriction,O,O
in,O,O
the,O,O
putative,O,O
peptide,O,O
contact,O,O
site,O,O
of,O,O
all,O,O
responding,O,O
beta,B,O
chains,I,O
",",O,O
diverse,O,O
and,O,O
unique,O,O
(,O,O
non,O,O
-,O,O
recurrent,O,O
),O,O
TCR,O,O
beta,O,O
clonotypes,O,O
were,O,O
selected,O,O
in,O,O
individuals,O,O
during,O,O
primary,O,O
infection,O,O
and,O,O
continued,O,O
to,O,O
emerge,O,O
after,O,O
long,O,O
-,O,O
term,O,O
virus,O,O
exposure,O,O
.,O,O
CD40,B,B
ligation,O,O
leads,O,O
to,O,O
B,O,O
cell,O,O
activation,O,O
events,O,O
such,O,O
as,O,O
proliferation,O,O
",",O,O
Ig,O,B
secretion,O,O
",",O,O
isotype,O,O
switching,O,O
",",O,O
and,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
cell,B,O
surface,I,O
molecules,I,O
",",O,O
as,O,O
well,O,O
as,O,O
the,O,O
generation,O,O
of,O,O
memory,O,O
B,O,O
cells,O,O
.,O,O
Many,O,O
of,O,O
these,O,O
events,O,O
are,O,O
dependent,O,O
upon,O,O
the,O,O
ability,O,O
of,O,O
CD40,B,B
to,O,O
activate,O,O
the,O,O
transcription,O,O
factor,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
.,O,O
To,O,O
define,O,O
the,O,O
CD40,B,B
signaling,O,O
components,O,O
upstream,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
and,O,O
the,O,O
functional,O,O
consequences,O,O
downstream,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
",",O,O
we,O,O
examined,O,O
mouse,O,O
B,O,B
cell,O,I
transfectants,O,I
expressing,O,O
wild,B,O
-,I,O
type,I,O
or,I,O
mutant,I,O
human,I,O
CD40,I,B
.,O,O
A,O,O
threonine,O,O
residue,O,O
at,O,O
position,B,O
234,I,O
",",O,O
previously,O,O
shown,O,O
to,O,O
be,O,O
important,O,O
for,O,O
CD40,B,B
association,O,O
with,O,O
TNF,B,B
receptor,I,I
-,I,I
associated,I,I
factor,I,I
2,I,I
(,O,O
TRAF2,B,O
),O,O
",",O,O
TRAF3,B,O
",",O,O
and,O,O
TRAF5,B,O
",",O,O
was,O,O
not,O,O
required,O,O
for,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
was,O,O
independent,O,O
of,O,O
the,O,O
transmembrane,B,O
domain,I,O
of,O,O
CD40,B,B
",",O,O
suggesting,O,O
that,O,O
it,O,O
is,O,O
independent,O,O
of,O,O
p23,B,O
",",O,O
a,O,O
molecule,O,O
that,O,O
associates,O,O
with,O,O
CD40,B,O
in,O,O
a,O,O
region,O,O
other,O,O
than,O,O
the,O,O
cytoplasmic,B,O
domain,I,O
.,O,O
CD40,O,B
-,O,I
or,O,O
pervanadate,O,O
-,O,O
mediated,O,O
I,O,B
kappa,O,I
B,O,I
tyrosine,O,O
phosphorylation,O,O
was,O,O
not,O,O
detected,O,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
correlated,O,O
with,O,O
the,O,O
ability,O,O
of,O,O
CD40,B,O
to,O,O
induce,O,O
Ab,O,O
secretion,O,O
and,O,O
the,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
ICAM,B,B
-,I,I
1,I,I
and,O,O
LFA,B,B
-,I,I
1,I,I
.,O,O
The,O,O
M,B,B
-,I,I
CSF,I,I
receptor,I,I
was,O,O
first,O,O
detectable,O,O
in,O,O
the,O,O
myeloid,O,B
-,O,I
committed,O,I
CD34,O,I
+,O,I
Thy,O,I
-,O,I
l,O,I
-,O,I
CD45RA,O,I
+,O,I
subset,O,O
.,O,O
All,O,O
other,O,O
molecules,O,O
studied,O,O
were,O,O
found,O,O
to,O,O
be,O,O
expressed,O,O
at,O,O
this,O,O
stage,O,O
of,O,O
differentiation,O,O
.,O,O
Addition,O,O
of,O,O
GM,B,B
-,I,I
CSF,I,I
to,O,O
this,O,O
basic,O,O
cocktail,O,O
consistently,O,O
increased,O,O
the,O,O
clonogenic,O,O
capacity,O,O
of,O,O
single,O,O
CD34,O,B
+,O,I
Thy,O,I
-,O,I
1,O,I
+,O,I
cells,O,O
",",O,O
and,O,O
this,O,O
effect,O,O
was,O,O
further,O,O
enhanced,O,O
(,O,O
up,O,O
to,O,O
72,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
3,O,O
%,O,O
on,O,O
day,O,O
7,O,O
),O,O
by,O,O
the,O,O
inclusion,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
.,O,O
Induction,O,O
of,O,O
endothelial,B,B
cell,I,I
surface,I,I
adhesion,I,I
molecules,I,I
by,O,O
tumor,B,O
necrosis,I,O
factor,I,O
is,O,O
blocked,O,O
by,O,O
protein,O,B
tyrosine,O,I
phosphatase,O,I
inhibitors,O,I
:,O,O
role,O,O
of,O,O
the,O,O
nuclear,B,O
transcription,I,O
factor,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
.,O,O
The,O,O
induction,O,O
of,O,O
ICAM,B,B
-,I,I
1,I,I
",",O,O
VCAM,B,B
-,I,I
1,I,I
",",O,O
and,O,O
ELAM,B,B
-,I,I
1,I,I
by,O,O
TNF,B,B
in,O,O
MVEC,O,O
occurred,O,O
within,O,O
6,O,O
h,O,O
and,O,O
was,O,O
also,O,O
completely,O,O
down,O,O
-,O,O
regulated,O,O
by,O,O
PAO,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
Further,O,O
",",O,O
monocytes,O,O
from,O,O
patients,O,O
demonstrate,O,O
an,O,O
augmented,O,O
susceptibility,O,O
to,O,O
a,O,O
productive,O,O
infection,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
in,O,O
vitro,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
I,B,O
kappa,I,O
B,I,O
-,I,O
alpha,I,O
levels,O,O
in,O,O
PBMC,O,O
and,O,O
monocytes,O,O
from,O,O
healthy,O,O
subjects,O,O
or,O,O
from,O,O
patients,O,O
with,O,O
nontuberculous,O,O
pulmonary,O,O
conditions,O,O
were,O,O
intact,O,O
.,O,O
Further,O,O
",",O,O
M,O,O
.,O,O
tuberculosis,O,O
and,O,O
its,O,O
tuberculin,B,O
",",O,O
purified,B,O
protein,I,B
derivative,I,I
",",O,O
induced,O,O
the,O,O
degradation,O,O
of,O,O
I,B,O
kappa,I,O
B,I,O
-,I,O
alpha,I,O
and,O,O
the,O,O
expression,O,O
of,O,O
I,B,O
kappa,I,O
B,I,O
-,I,O
alpha,I,O
mRNA,I,O
",",O,O
and,O,O
purified,O,O
protein,O,B
derivative,O,I
induced,O,O
the,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
monocytes,O,O
.,O,O
Spi,B,B
-,I,I
1,I,I
/,I,I
PU,I,I
.,I,I
1,I,I
is,O,O
a,O,O
myeloid,B,B
-,I,I
and,I,O
B,I,B
-,I,I
cell,I,I
specific,I,I
transcription,I,I
factor,I,I
which,O,O
is,O,O
also,O,O
involved,O,O
in,O,O
Friend,O,O
virus,O,O
-,O,O
induced,O,O
murine,O,O
erythroleukemia,O,O
.,O,O
We,O,O
developed,O,O
a,O,O
heterologous,O,O
system,O,O
to,O,O
analyze,O,O
the,O,O
contribution,O,O
of,O,O
these,O,O
alterations,O,O
to,O,O
the,O,O
induction,O,O
of,O,O
primary,O,O
erythroblast,O,O
transformation,O,O
.,O,O
These,O,O
results,O,O
show,O,O
that,O,O
Spi,O,B
-,O,I
1,O,I
/,O,I
PU,B,I
.,I,I
1,I,O
requires,O,O
signals,O,O
emanating,O,O
from,O,O
specific,O,O
cytokine,O,B
and,O,O
growth,O,B
factor,O,I
receptors,O,I
to,O,O
affect,O,O
the,O,O
survival,O,O
",",O,O
proliferation,O,O
and,O,O
differentiation,O,O
control,O,O
of,O,O
primary,O,O
erythroblasts,O,O
.,O,O
They,O,O
also,O,O
suggest,O,O
that,O,O
the,O,O
function,O,O
of,O,O
Spi,B,O
-,I,O
1,I,O
/,I,O
PU,I,O
.,I,O
1,I,O
in,O,O
the,O,O
late,O,O
phase,O,O
of,O,O
Friend,O,O
leukemia,O,O
requires,O,O
specific,O,O
signaling,O,O
from,O,O
the,O,O
gp55,B,O
-,I,O
modified,I,O
EpoR,I,O
generated,O,O
during,O,O
the,O,O
early,O,O
phase,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
METHODS,O,O
:,O,O
Allergen,O,O
-,O,O
specific,O,O
T,O,O
cell,O,O
clones,O,O
and,O,O
T,O,O
cell,O,O
hybridomas,O,O
were,O,O
established,O,O
from,O,O
the,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
of,O,O
patients,O,O
with,O,O
asthma,O,O
",",O,O
and,O,O
the,O,O
responses,O,O
to,O,O
various,O,O
stimuli,O,O
were,O,O
determined,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Fibrin,O,B
deposition,O,I
and,O,O
thrombosis,O,O
have,O,O
been,O,O
implicated,O,O
in,O,O
both,O,O
allograft,O,O
rejection,O,O
and,O,O
vasculopathy,O,O
after,O,O
cardiac,O,O
transplantation,O,O
.,O,O
Inhibition,O,O
of,O,O
TF,B,B
induction,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
high,O,O
CsA,O,O
blood,O,O
concentrations,O,O
was,O,O
also,O,O
observed,O,O
when,O,O
stimulation,O,O
of,O,O
cells,O,O
was,O,O
performed,O,O
with,O,O
interferon,B,O
-,I,O
gamma,I,O
or,O,O
interleukin,B,O
-,I,O
1beta,I,O
.,O,O
As,O,O
shown,O,O
by,O,O
reverse,O,O
transcription,O,O
-,O,O
polymerase,O,O
chain,O,O
reaction,O,O
and,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
",",O,O
respectively,O,O
",",O,O
treatment,O,O
with,O,O
CsA,O,O
leads,O,O
to,O,O
decreased,O,O
TF,B,B
mRNA,I,I
expression,O,O
and,O,O
reduced,O,O
activation,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
transcription,I,O
factor,I,O
",",O,O
which,O,O
is,O,O
known,O,O
to,O,O
contribute,O,O
to,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
TF,B,B
promotor,I,O
in,O,O
human,O,O
monocytes,O,O
.,O,O
Inhibition,O,O
of,O,O
monocyte,O,O
TF,B,B
induction,O,O
by,O,O
CsA,O,O
may,O,O
contribute,O,O
to,O,O
its,O,O
successful,O,O
use,O,O
in,O,O
cardiac,O,O
transplant,O,O
medicine,O,O
and,O,O
might,O,O
be,O,O
useful,O,O
in,O,O
managing,O,O
further,O,O
settings,O,O
of,O,O
vascular,O,O
pathology,O,O
also,O,O
known,O,O
to,O,O
involve,O,O
TF,B,B
expression,O,O
and,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
.,O,O
Both,O,O
cytokines,B,O
induced,O,O
assembly,O,O
of,O,O
STAT5A,B,O
and,O,O
STAT5B,B,O
containing,O,O
complexes,O,O
capable,O,O
of,O,O
binding,O,O
to,O,O
the,O,O
interferon,B,O
-,I,O
gamma,I,O
activation,I,O
sequence,I,O
(,O,O
GAS,B,O
),O,O
",",O,O
and,O,O
these,O,O
complexes,O,O
rapidly,O,O
translocated,O,O
(,O,O
within,O,O
1,O,O
min,O,O
),O,O
into,O,O
the,O,O
nucleus,O,O
of,O,O
IL,O,B
-,O,I
2,O,I
-,O,I
or,O,I
IL,O,B
-,O,I
7,O,I
-,O,I
treated,O,O
cells,O,O
.,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IL,B,B
-,I,I
7,I,I
were,O,O
equivalent,O,O
in,O,O
their,O,O
ability,O,O
to,O,O
induce,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
STAT5A,B,B
and,O,O
STAT5B,B,B
and,O,O
to,O,O
facilitate,O,O
binding,O,O
of,O,O
these,O,O
STATs,B,O
to,O,O
an,O,O
immobilized,B,O
GAS,I,O
element,I,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IL,B,B
-,I,I
7,I,I
induce,O,O
assembly,O,O
of,O,O
STAT,B,O
heterodimers,I,O
in,O,O
a,O,O
similar,O,O
manner,O,O
and,O,O
that,O,O
subsequent,O,O
cellular,O,O
responses,O,O
may,O,O
be,O,O
driven,O,O
by,O,O
induction,O,O
of,O,O
similar,O,O
sets,O,O
of,O,O
genes,B,O
.,O,O
The,O,O
POU,B,B
transcription,I,I
factors,I,I
Oct,B,B
-,I,I
1,I,I
and,O,O
Oct,B,B
-,I,I
2,I,I
regulate,O,O
the,O,O
activity,O,O
of,O,O
octamer,B,O
-,I,O
dependent,I,O
promoters,I,O
",",O,O
including,O,O
those,O,O
that,O,O
direct,O,O
transcription,O,O
from,O,O
rearranged,O,O
immunoglobulin,B,B
genes,I,I
.,O,O
The,O,O
class,B,O
II,I,O
trans,I,O
-,I,O
activator,I,O
(,O,O
CIITA,B,O
),O,O
is,O,O
a,O,O
bi,B,B
-,I,I
or,I,O
multi,I,B
-,I,I
functional,I,I
domain,I,I
protein,I,I
which,O,O
plays,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
genes,I,I
.,O,O
Transient,O,O
transfection,O,O
of,O,O
a,O,O
B,O,B
lymphoma,O,I
line,O,O
resulted,O,O
in,O,O
up,O,O
to,O,O
89,O,O
%,O,O
reduction,O,O
of,O,O
constitutive,O,O
MHC,B,B
class,I,I
II,I,I
expression,O,O
within,O,O
5,O,O
days,O,O
and,O,O
suppression,O,O
of,O,O
HLA,B,B
-,I,I
DRA,I,I
mRNA,I,I
synthesis,O,O
.,O,O
The,O,O
active,O,O
ingredients,O,O
mediating,O,O
the,O,O
pharmacological,O,O
effect,O,O
are,O,O
mainly,O,O
sesquiterpene,O,O
lactones,O,O
",",O,O
such,O,O
as,O,O
helenalin,O,O
",",O,O
11alpha,O,O
",",O,O
13,O,O
-,O,O
dihydrohelenalin,O,O
",",O,O
chamissonolid,O,O
and,O,O
their,O,O
ester,O,O
derivatives,O,O
.,O,O
We,O,O
show,O,O
here,O,O
that,O,O
helenalin,O,B
",",O,O
and,O,O
",",O,O
to,O,O
a,O,O
much,O,O
lesser,O,O
degree,O,O
",",O,O
11alpha,O,B
",",O,O
13,O,O
-,O,O
dihydrohelenalin,O,B
and,O,O
chamissonolid,O,B
",",O,O
inhibit,O,O
activation,O,O
of,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappaB,I,I
.,O,O
Rather,O,O
",",O,O
helenalin,O,B
modifies,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
/,I,O
IkappaB,I,O
complex,I,O
",",O,O
preventing,O,O
the,O,O
release,O,O
of,O,O
IkappaB,B,O
.,O,O
The,O,O
tax,B,O
protein,I,O
of,O,O
human,O,O
T,O,O
-,O,O
cell,O,O
leukemia,O,O
virus,O,O
type,O,O
1,O,O
mediates,O,O
the,O,O
transactivation,O,O
of,O,O
the,O,O
c,B,O
-,I,O
sis,I,O
/,I,O
platelet,I,O
-,I,O
derived,I,O
growth,I,O
factor,I,O
-,I,O
B,I,O
promoter,I,O
through,O,O
interactions,O,O
with,O,O
the,O,O
zinc,B,O
finger,I,O
transcription,I,O
factors,I,O
Sp1,B,O
and,O,O
NGFI,B,O
-,I,O
A,I,O
/,I,O
Egr,I,O
-,I,O
1,I,O
.,O,O
In,O,O
the,O,O
present,O,O
work,O,O
",",O,O
we,O,O
have,O,O
investigated,O,O
the,O,O
mechanism,O,O
(,O,O
s,O,O
),O,O
whereby,O,O
Tax,B,O
transactivates,O,O
the,O,O
c,B,O
-,I,O
sis,I,O
/,I,O
PDGF,I,B
-,I,I
B,I,I
proto,I,I
-,I,I
oncogene,I,I
.,O,O
Interestingly,O,O
",",O,O
co,O,O
-,O,O
immunoprecipitation,O,O
analysis,O,O
also,O,O
revealed,O,O
that,O,O
Tax,B,O
mutant,O,O
IEXC29S,B,O
is,O,O
unable,O,O
to,O,O
interact,O,O
with,O,O
NGFI,B,B
-,I,I
A,I,I
/,I,I
Egr,I,I
-,I,I
1,I,I
",",O,O
whereas,O,O
Tax,B,O
mutant,O,O
IEXL320G,B,O
is,O,O
able,O,O
to,O,O
interact,O,O
with,O,O
NGFI,B,B
-,I,I
A,I,I
/,I,I
Egr,I,I
-,I,I
1,I,I
.,O,O
Dendritic,O,B
cells,O,I
(,O,O
DC,O,O
),O,O
are,O,O
potent,O,O
APCs,O,O
that,O,O
enter,O,O
resting,O,O
tissues,O,O
as,O,O
precursors,O,O
and,O,O
",",O,O
after,O,O
Ag,O,O
exposure,O,O
",",O,O
differentiate,O,O
and,O,O
migrate,O,O
to,O,O
draining,O,O
lymph,O,O
nodes,O,O
.,O,O
Immunohistochemical,O,O
staining,O,O
demonstrated,O,O
RelB,B,O
within,O,O
the,O,O
differentiated,O,O
lymph,O,O
node,O,O
interdigitating,O,O
DC,O,O
and,O,O
follicular,O,O
DC,O,O
",",O,O
but,O,O
not,O,O
undifferentiated,O,O
DC,O,O
in,O,O
normal,O,O
skin,O,O
.,O,O
NF,B,B
-,I,I
AT,I,I
activation,O,I
induced,O,O
by,O,O
a,O,O
CAML,B,B
-,O,I
interacting,O,O
member,O,O
of,O,O
the,O,O
tumor,B,O
necrosis,I,O
factor,I,O
receptor,I,O
superfamily,I,O
.,O,O
The,O,O
CAML,B,B
(,I,O
calcium,I,O
-,I,O
modulator,I,O
and,I,O
cyclophilin,I,O
ligand,I,O
),I,O
protein,I,O
is,O,O
a,O,O
coinducer,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
activation,O,I
when,O,O
overexpressed,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
.,O,O
In,O,O
most,O,O
cells,O,O
",",O,O
Rel,B,O
/,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
transcription,B,O
factors,I,O
appear,O,O
to,O,O
mediate,O,O
survival,O,O
signals,O,O
that,O,O
protect,O,O
cells,O,O
from,O,O
apoptosis,O,O
;,O,O
however,O,O
",",O,O
under,O,O
some,O,O
circumstances,O,O
",",O,O
activation,O,O
of,O,O
these,O,O
factors,O,O
may,O,O
also,O,O
promote,O,O
apoptosis,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
coordination,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
and,O,O
STAT6,B,B
may,O,O
be,O,O
required,O,O
for,O,O
induction,O,O
of,O,O
germline,B,O
Cepsilon,O,O
transcription,O,O
by,O,O
IL,B,B
-,I,I
4,I,I
",",O,O
and,O,O
that,O,O
CD40,B,O
-,O,O
mediated,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
may,O,O
be,O,O
important,O,O
in,O,O
regulating,O,O
both,O,O
enhancement,O,O
of,O,O
germline,B,O
Cepsilon,O,O
transcription,O,O
and,O,O
class,O,O
switching,O,O
to,O,O
IgE,B,O
.,O,O
There,O,O
are,O,O
many,O,O
hypotheses,O,O
concerning,O,O
the,O,O
pathogenesis,O,O
of,O,O
endometriosis,O,O
",",O,O
though,O,O
no,O,O
single,O,O
theory,O,O
can,O,O
explain,O,O
all,O,O
cases,O,O
.,O,O
This,O,O
review,O,O
considers,O,O
the,O,O
evidence,O,O
for,O,O
different,O,O
theories,O,O
of,O,O
the,O,O
histogenesis,O,O
of,O,O
endometriosis,O,O
and,O,O
discusses,O,O
possible,O,O
immune,O,B
factors,O,O
that,O,O
may,O,O
be,O,O
involved,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
Proteins,O,B
of,O,O
the,O,O
ATF,O,B
/,O,I
CREB,B,I
class,O,O
of,O,O
transcription,B,O
factors,I,O
stimulate,O,O
gene,O,O
expression,O,O
of,O,O
several,O,O
cell,B,O
growth,I,O
-,I,O
related,I,O
genes,I,O
through,O,O
protein,B,O
kinase,I,O
A,I,O
-,I,O
related,I,O
cAMP,I,O
response,I,O
elements,I,O
.,O,O
One,O,O
ATF,B,B
/,I,I
CRE,I,I
motif,I,O
is,O,O
located,O,O
in,O,O
the,O,O
distal,B,O
promoter,I,O
at,O,O
the,O,O
nuclear,B,B
matrix,I,I
-,I,I
associated,I,I
Site,I,I
IV,I,I
",",O,O
and,O,O
the,O,O
second,O,O
motif,O,O
is,O,O
present,O,O
in,O,O
the,O,O
proximal,B,O
promoter,I,O
at,O,O
Site,B,O
I,I,O
.,O,O
Site,O,B
-,O,I
directed,O,I
mutational,O,I
studies,O,I
demonstrate,O,O
that,O,O
Site,B,B
I,I,I
and,O,O
Site,B,B
IV,I,I
together,O,O
support,O,O
ATF1,O,O
-,O,O
and,O,O
CREB,O,O
-,O,O
induced,O,O
trans,O,O
-,O,O
activation,O,O
of,O,O
the,O,O
H4,B,B
promoter,I,I
.,O,O
Thus,O,O
",",O,O
our,O,O
data,O,O
establish,O,O
that,O,O
ATF,B,O
/,I,O
CREB,I,O
factors,I,O
functionally,O,O
modulate,O,O
histone,B,O
H4,I,B
gene,I,I
transcription,O,I
at,O,O
distal,B,O
and,I,O
proximal,I,O
promoter,I,O
elements,I,O
.,O,O
Abnormal,O,O
apoptosis,O,O
and,O,O
cell,O,O
cycle,O,O
progression,O,O
in,O,O
humans,O,O
exposed,O,O
to,O,O
methyl,O,O
tertiary,O,O
-,O,O
butyl,O,O
ether,O,O
and,O,O
benzene,O,O
contaminating,O,O
water,O,O
.,O,O
Because,O,O
cell,O,O
cycle,O,O
analysis,O,O
showed,O,O
that,O,O
in,O,O
PBL,O,O
from,O,O
chemically,O,O
-,O,O
exposed,O,O
individuals,O,O
",",O,O
between,O,O
20,O,O
-,O,O
50,O,O
%,O,O
of,O,O
cells,O,O
were,O,O
accumulated,O,O
at,O,O
the,O,O
S,O,O
-,O,O
G2,O,O
/,O,O
M,O,O
boundaries,O,O
.,O,O
Indeed,O,O
",",O,O
addition,O,O
of,O,O
inhibitors,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
pyrrolidine,O,O
dithiocarbamate,O,O
(,O,O
PDTC,O,O
),O,O
",",O,O
to,O,O
the,O,O
lymphocytes,O,O
of,O,O
the,O,O
chemically,O,O
-,O,O
exposed,O,O
group,O,O
was,O,O
capable,O,O
of,O,O
inhibiting,O,O
programmed,O,O
cell,O,O
death,O,O
by,O,O
40,O,O
%,O,O
.,O,O
This,O,O
reversal,O,O
of,O,O
apoptosis,O,O
almost,O,O
to,O,O
the,O,O
control,O,O
level,O,O
by,O,O
inhibitor,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
may,O,O
indicate,O,O
involvement,O,O
of,O,O
this,O,O
signaling,B,O
molecule,I,O
in,O,O
MTBE,O,O
and,O,O
benzene,O,O
induction,O,O
of,O,O
programmed,O,O
cell,O,O
death,O,O
.,O,O
Purification,O,O
and,O,O
characterization,O,O
of,O,O
the,O,O
human,B,O
SR,I,O
31747A,I,O
-,I,O
binding,I,O
protein,I,O
.,O,O
A,O,O
nuclear,B,O
membrane,I,O
protein,I,O
related,O,O
to,O,O
yeast,B,O
sterol,I,O
isomerase,I,O
.,O,O
SR,O,B
31747A,O,I
",",O,O
defined,O,O
as,O,O
a,O,O
sigma,O,O
ligand,O,O
",",O,O
is,O,O
a,O,O
novel,O,O
immunosuppressive,O,O
agent,O,O
that,O,O
blocks,O,O
proliferation,O,O
of,O,O
human,O,B
and,O,O
mouse,O,B
lymphocytes,O,O
.,O,O
Using,O,O
a,O,O
radiolabeled,O,O
chemical,O,O
probe,O,O
",",O,O
we,O,O
here,O,O
purified,O,O
a,O,O
target,O,O
of,O,O
SR,O,B
31747A,O,I
and,O,O
called,O,O
it,O,O
SR,B,B
-,I,I
SR,I,B
-,I,I
BP,I,I
retained,O,O
its,O,O
binding,O,O
properties,O,O
and,O,O
migrated,O,O
on,O,O
SDS,O,B
-,O,I
polyacrylamide,O,I
gel,O,I
as,O,O
a,O,O
Mr,B,B
28,I,I
",",I,I
protein,I,I
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
of,O,O
SR,B,B
-,I,I
BP,I,I
gene,O,O
expression,O,O
revealed,O,O
a,O,O
single,O,O
transcript,O,O
of,O,O
2,B,O
kilobases,I,O
which,O,O
was,O,O
widely,O,O
expressed,O,O
among,O,O
organs,O,O
",",O,O
with,O,O
the,O,O
highest,O,O
abundance,O,O
in,O,O
liver,O,B
and,O,O
the,O,O
lowest,O,O
abundance,O,O
in,O,O
brain,O,B
.,O,O
Here,O,O
we,O,O
report,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
synthesis,O,O
and,O,O
of,O,O
the,O,O
hydrolytic,O,O
activity,O,O
of,O,O
phospholipase,B,B
C,I,I
gamma,I,I
1,I,I
(,O,O
PLC,B,B
gamma,I,I
1,I,I
),O,O
in,O,O
human,O,B
T,O,I
lymphocytes,O,I
by,O,O
IFN,B,B
-,I,I
beta,I,I
.,O,O
The,O,O
increased,O,O
level,O,O
of,O,O
PLC,B,B
gamma,I,I
1,I,I
becomes,O,O
evident,O,O
after,O,O
90,O,O
min,O,O
of,O,O
IFN,B,B
-,I,I
beta,I,I
treatment,O,O
and,O,O
is,O,O
still,O,O
detectable,O,O
after,O,O
24,O,O
h,O,O
.,O,O
Neither,O,O
the,O,O
PLC,B,B
gamma,I,I
1,I,I
overexpression,O,O
induced,O,O
by,O,O
IFN,B,B
nor,O,O
the,O,O
increased,O,O
hydrolytic,O,O
activity,O,O
of,O,O
the,O,O
enzyme,B,O
appear,O,O
to,O,O
be,O,O
affected,O,O
by,O,O
pretreatment,O,O
of,O,O
the,O,O
cells,O,O
with,O,O
the,O,O
protein,O,B
tyrosine,B,I
kinase,I,I
inhibitor,O,I
genistein,O,O
",",O,O
which,O,O
is,O,O
known,O,O
to,O,O
prevent,O,O
the,O,O
association,O,O
of,O,O
ISGF3,B,O
components,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
in,O,O
human,O,B
T,O,I
lymphocytes,O,I
IFN,B,B
-,I,I
beta,I,I
can,O,O
activate,O,O
other,O,O
transcription,B,O
factor,I,O
(,O,O
s,O,O
),O,O
distinct,O,O
from,O,O
ISGF3,B,O
to,O,O
regulate,O,O
PLC,B,O
gamma,I,O
1,I,O
expression,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
used,O,O
a,O,O
RT,O,O
-,O,O
PCR,O,O
based,O,O
approach,O,O
to,O,O
compare,O,O
the,O,O
stability,O,O
of,O,O
the,O,O
big,B,O
T,I,O
and,I,O
small,I,O
t,I,O
allele,I,O
in,O,O
normal,O,O
heterozygous,O,O
lymphocytes,O,O
and,O,O
the,O,O
heterozygous,O,O
cell,O,O
lines,O,O
NB4,O,O
(,O,O
myeloid,O,B
leukemia,O,I
),O,O
and,O,O
PC,O,O
-,O,O
3,O,O
and,O,O
DU,O,O
145,O,O
(,O,O
prostate,O,B
cancers,O,I
),O,O
.,O,O
Interestingly,O,O
",",O,O
we,O,O
consistently,O,O
observed,O,O
30,O,O
%,O,O
less,O,O
RT,B,B
-,I,I
PCR,I,I
product,I,I
derived,O,O
from,O,O
the,O,O
small,B,O
t,I,O
allele,I,O
mRNA,I,O
in,O,O
steady,O,O
state,O,O
",",O,O
a,O,O
finding,O,O
which,O,O
also,O,O
speaks,O,O
against,O,O
a,O,O
higher,O,O
stability,O,O
of,O,O
the,O,O
small,B,O
t,I,O
allele,I,O
mRNA,I,O
.,O,O
Moreover,O,O
",",O,O
anti,B,O
-,I,O
TNF,I,B
-,I,I
alpha,I,I
inhibited,O,O
HIV,B,B
-,I,I
1,I,I
long,I,I
terminal,I,I
repeat,I,I
(,O,I
LTR,B,I
),O,I
-,O,I
driven,O,I
transcription,O,I
of,O,O
a,O,O
reporter,B,O
gene,I,O
in,O,O
primary,O,O
T,O,O
cells,O,O
in,O,O
response,O,O
to,O,O
activation,O,O
",",O,O
either,O,O
in,O,O
the,O,O
presence,O,O
or,O,O
the,O,O
absence,O,O
of,O,O
HIV,B,B
-,I,I
1,I,I
Tat,I,I
.,O,O
Our,O,O
results,O,O
support,O,O
an,O,O
important,O,O
role,O,O
for,O,O
autocrine,O,O
TNF,B,B
-,I,I
alpha,I,I
secretion,O,O
in,O,O
controlling,O,O
HIV,O,O
replication,O,O
in,O,O
primary,O,O
T,O,B
cells,O,O
because,O,O
of,O,O
its,O,O
ability,O,O
to,O,O
maintain,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
elevated,O,O
in,O,O
the,O,O
nucleus,O,O
of,O,O
T,O,B
cells,O,O
.,O,O
Intercellular,B,O
adhesion,I,O
molecule,I,O
1,I,O
(,O,O
ICAM,B,B
-,I,I
1,I,I
),O,O
is,O,O
an,O,O
important,O,O
molecule,O,O
in,O,O
promotion,O,O
of,O,O
polymorphonuclear,O,O
neutrophil,O,O
transendothelial,O,O
migration,O,O
during,O,O
inflammation,O,O
.,O,O
The,O,O
compound,O,O
induced,O,O
G1,O,O
arrest,O,O
and,O,O
granulocytic,O,O
differentiation,O,O
of,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
",",O,O
although,O,O
the,O,O
differentiation,O,O
-,O,O
inducing,O,O
effect,O,O
was,O,O
modest,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
JAK2,B,O
/,B,O
STAT5,I,O
activation,O,O
is,O,O
a,O,O
common,O,O
JAK,B,O
/,B,O
STAT,I,O
pathway,O,O
for,O,O
hIL,B,O
-,I,O
5,I,O
-,O,O
mediated,O,O
signal,O,O
in,O,O
these,O,O
cells,O,O
.,O,O
Nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
(,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
),I,O
/,I,O
Rel,I,O
transcription,I,O
factors,I,O
may,O,O
be,O,O
involved,O,O
in,O,O
atherosclerosis,O,O
",",O,O
as,O,O
is,O,O
suggested,O,O
by,O,O
the,O,O
presence,O,O
of,O,O
activated,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
human,O,O
atherosclerotic,O,O
lesions,O,O
.,O,O
Our,O,O
results,O,O
demonstrate,O,O
that,O,O
short,O,O
-,O,O
term,O,O
incubation,O,O
of,O,O
these,O,O
cells,O,O
with,O,O
oxLDL,B,O
activated,I,O
p50,I,B
/,I,I
p65,I,I
containing,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
dimers,I,O
and,O,O
induced,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
target,B,O
gene,I,O
IL,I,B
-,I,I
8,I,I
.,O,O
This,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
was,O,O
inhibited,O,O
by,O,O
the,O,O
antioxidant,O,O
and,O,O
H2O2,O,O
scavenger,O,O
pyrrolidine,O,O
dithiocarbamate,O,O
and,O,O
the,O,O
proteasome,B,O
inhibitor,O,O
PSI,O,O
.,O,O
The,O,O
oxLDL,B,O
-,O,O
induced,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
activation,O,O
was,O,O
accompanied,O,O
by,O,O
an,O,O
initial,O,O
depletion,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
followed,O,O
by,O,O
a,O,O
slight,O,O
transient,O,O
increase,O,O
in,O,O
the,O,O
level,O,O
of,O,O
this,O,O
inhibitor,O,O
protein,O,O
.,O,O
These,O,O
observations,O,O
provide,O,O
additional,O,O
evidence,O,O
that,O,O
oxLDL,B,O
is,O,O
a,O,O
potent,O,O
modulator,O,O
of,O,O
gene,O,O
expression,O,O
and,O,O
suggest,O,O
that,O,O
(,O,O
dys,O,O
),O,O
regulation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
is,O,O
likely,O,O
to,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
atherogenesis,O,O
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
demonstrate,O,O
that,O,O
leukocyte,O,B
adhesion,O,O
to,O,O
cultured,O,O
corneal,O,B
endothelial,O,I
cells,O,O
is,O,O
mediated,O,O
by,O,O
the,O,O
CD18,B,B
antigen,I,O
",",O,O
and,O,O
to,O,O
determine,O,O
whether,O,O
dexamethasone,O,O
directly,O,O
suppresses,O,O
adhesion,O,O
by,O,O
inhibiting,O,O
activation,O,O
of,O,O
nuclear,B,O
factor,I,O
kappa,I,O
B,I,O
(,O,O
NFkappaB,B,O
),O,O
.,O,O
Nonadherent,O,O
neutrophils,O,B
were,O,O
removed,O,O
by,O,O
sealing,O,O
and,O,O
inverting,O,O
the,O,O
culture,O,O
well,O,O
.,O,O
RESULTS,O,O
:,O,O
Neutrophil,O,O
adhesion,O,O
to,O,O
cultured,O,O
corneal,O,B
endothelial,O,I
cells,O,I
increased,O,O
significantly,O,O
on,O,O
exposure,O,O
to,O,O
TNFalpha,B,B
(,O,O
451,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
45,O,O
.,O,O
4,O,O
cells,O,O
/,O,O
mm2,O,O
",",O,O
n,O,O
16,O,O
compared,O,O
to,O,O
control,O,O
(,O,O
156,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
27,O,O
.,O,O
3,O,O
cells,O,O
/,O,O
mm2,O,O
",",O,O
n,O,O
16,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
.,O,O
The,O,O
transcriptional,B,O
start,I,O
sites,I,O
were,O,O
identified,O,O
by,O,O
an,O,O
RNase,B,B
protection,O,I
assay,O,I
.,O,O
Since,O,O
GH,B,B
stimulates,O,O
the,O,O
development,O,O
and,O,O
function,O,O
of,O,O
granulocytes,O,O
",",O,O
we,O,O
investigated,O,O
the,O,O
expression,O,O
of,O,O
GH,B,B
in,O,O
granulocyte,O,O
subsets,O,O
.,O,O
Restriction,O,O
analysis,O,O
revealed,O,O
that,O,O
neutrophils,O,O
express,O,O
the,O,O
GH,B,B
-,I,O
N,I,O
gene,I,O
but,O,O
not,O,O
the,O,O
GH,B,B
-,I,O
V,I,O
gene,I,O
.,O,O
In,O,O
addition,O,O
",",O,O
BHRF1,B,O
protected,O,O
these,O,O
cells,O,O
from,O,O
monocyte,O,O
-,O,O
mediated,O,O
killing,O,O
but,O,O
failed,O,O
to,O,O
protect,O,O
them,O,O
from,O,O
killing,O,O
mediated,O,O
by,O,O
lymphokine,O,O
-,O,O
activated,O,O
killer,O,O
cells,O,O
.,O,O
Genomic,O,O
organization,O,O
",",O,O
sequence,O,O
",",O,O
and,O,O
transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
human,B,O
eotaxin,I,B
gene,I,O
.,O,O
Eotaxin,B,B
is,O,O
an,O,O
eosinophil,B,B
specific,I,O
beta,I,O
-,I,O
chemokine,I,O
assumed,O,O
to,O,O
be,O,O
involved,O,O
in,O,O
eosinophilic,O,B
inflammatory,O,O
diseases,O,O
such,O,O
as,O,O
atopic,O,O
dermatitis,O,O
",",O,O
allergic,O,O
rhinitis,O,O
",",O,O
asthma,O,O
and,O,O
parasitic,O,O
infections,O,O
.,O,O
Here,O,O
we,O,O
describe,O,O
the,O,O
functional,O,O
characterization,O,O
of,O,O
this,O,O
promoter,O,O
and,O,O
identification,O,O
of,O,O
the,O,O
factors,O,O
in,O,O
B,O,B
and,O,O
T,O,B
cells,O,O
that,O,O
regulate,O,O
its,O,O
activity,O,O
.,O,O
The,O,O
pp52,B,B
promoter,I,O
contains,O,O
an,O,O
initiator,O,O
specifying,O,O
the,O,O
unique,O,O
5,B,O
terminus,I,O
of,O,O
pp52,B,O
mRNA,I,O
",",O,O
tandem,O,O
pairs,O,O
of,O,O
Ets,B,B
and,I,O
SP1,I,B
motifs,I,O
",",O,O
and,O,O
a,O,O
lone,B,O
C,I,B
/,I,I
EBP,I,I
motif,I,O
.,O,O
BACKGROUND,O,O
:,O,O
Recent,O,O
studies,O,O
have,O,O
raised,O,O
the,O,O
hypothesis,O,O
that,O,O
glucocorticoids,O,O
could,O,O
diminish,O,O
the,O,O
ability,O,O
of,O,O
endothelial,O,B
cells,O,I
to,O,O
direct,O,O
leukocyte,O,B
traffic,O,O
into,O,O
inflamed,O,O
tissues,O,O
by,O,O
inhibiting,O,O
expression,O,O
of,O,O
the,O,O
adhesion,B,O
molecules,I,O
endothelial,B,O
-,I,O
leukocyte,I,O
adhesion,I,O
molecule,I,O
-,I,O
1,I,O
and,O,O
intercellular,B,O
adhesion,I,O
molecule,I,O
-,I,O
1,I,O
.,O,O
The,O,O
immediate,O,O
-,O,O
early,O,O
gene,O,O
product,O,O
Egr,B,B
-,I,I
1,I,I
regulates,O,O
the,O,O
human,B,O
interleukin,I,B
-,I,I
2,I,I
receptor,I,I
beta,I,I
-,I,I
chain,I,I
promoter,I,O
through,O,O
noncanonical,B,O
Egr,I,B
and,I,O
Sp1,I,O
binding,I,O
sites,I,O
.,O,O
In,O,O
Jurkat,O,O
cells,O,O
",",O,O
both,O,O
sites,O,O
were,O,O
required,O,O
for,O,O
maximal,O,O
IL,B,B
-,I,I
2Rbeta,I,I
promoter,O,O
activity,O,O
",",O,O
and,O,O
in,O,O
HeLaS3,O,O
cells,O,O
",",O,O
transfection,O,O
of,O,O
Egr,B,B
-,I,I
1,I,I
could,O,O
drive,O,O
activity,O,O
of,O,O
a,O,O
reporter,O,O
construct,O,O
containing,O,O
both,O,O
sites,O,O
.,O,O
Acquisition,O,O
of,O,O
heat,O,B
shock,O,I
factor,O,I
2,O,I
(,O,O
HSF2,O,O
),O,O
DNA,O,B
binding,O,I
activity,O,I
is,O,O
accompanied,O,O
by,O,O
induced,O,O
transcription,O,O
of,O,O
heat,B,B
shock,I,I
genes,I,I
in,O,O
hemin,O,O
-,O,O
treated,O,O
K562,O,O
cells,O,O
undergoing,O,O
erythroid,O,O
differentiation,O,O
.,O,O
Sequential,O,O
development,O,O
of,O,O
structural,O,O
and,O,O
functional,O,O
alterations,O,O
in,O,O
T,O,O
cells,O,O
from,O,O
tumor,O,O
-,O,O
bearing,O,O
mice,O,O
.,O,O
These,O,O
defects,O,O
are,O,O
paralleled,O,O
by,O,O
an,O,O
impaired,O,O
ability,O,O
to,O,O
produce,O,O
Th1,B,O
cytokines,I,O
(,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
IFN,B,B
-,I,I
gamma,I,I
),O,O
.,O,O
Like,O,O
the,O,O
class,B,B
II,I,I
genes,I,I
",",O,O
the,O,O
HLA,B,B
-,I,I
DM,I,I
genes,I,I
contain,O,O
upstream,O,O
regulatory,O,O
sequences,O,O
similar,O,O
to,O,O
the,O,O
S,B,O
-,I,O
X,I,O
-,I,O
Y,I,O
regulatory,I,O
region,I,O
as,O,O
well,O,O
as,O,O
additional,O,O
putative,O,O
regulatory,O,O
sites,O,O
.,O,O
The,O,O
class,B,B
II,I,I
-,I,I
specific,I,I
transcription,I,I
factors,I,I
RFX,B,O
and,O,O
CIITA,B,O
are,O,O
also,O,O
required,O,O
for,O,O
expression,O,O
",",O,O
as,O,O
cell,O,B
lines,O,I
deficient,O,O
in,O,O
these,O,O
factors,O,O
failed,O,O
to,O,O
allow,O,O
transcription,O,O
from,O,O
the,O,O
DM,B,B
promoters,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
in,O,O
vivo,O,O
footprint,O,O
analysis,O,O
showed,O,O
the,O,O
putative,O,O
X,B,B
and,I,O
Y,I,B
boxes,I,O
to,O,O
be,O,O
occupied,O,O
by,O,O
transcription,B,O
factors,I,O
in,O,O
wild,O,O
-,O,O
type,O,O
B,O,O
cells,O,O
",",O,O
but,O,O
not,O,O
in,O,O
RFX,O,O
-,O,O
deficient,O,O
B,O,O
cells,O,O
.,O,O
None,O,O
of,O,O
the,O,O
other,O,O
putative,O,O
regulatory,O,O
sites,O,O
was,O,O
occupied,O,O
in,O,O
vivo,O,O
",",O,O
indicating,O,O
that,O,O
they,O,O
may,O,O
not,O,O
be,O,O
functional,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
Ad2,O,O
was,O,O
internalized,O,O
by,O,O
macrophages,O,O
.,O,O
Critical,O,O
cytoplasmic,B,O
domains,I,O
of,O,O
human,B,O
interleukin,I,B
-,I,I
9,I,I
receptor,I,I
alpha,I,I
chain,I,I
in,O,O
interleukin,B,B
-,O,I
9,O,I
-,O,I
mediated,O,I
cell,O,I
proliferation,O,I
and,O,O
signal,O,O
transduction,O,O
.,O,O
In,O,O
a,O,O
previous,O,O
study,O,O
",",O,O
we,O,O
demonstrated,O,O
that,O,O
bufalin,O,O
",",O,O
which,O,O
is,O,O
an,O,O
active,O,O
principle,O,O
of,O,O
Chinese,O,O
medicine,O,O
",",O,O
chan,O,O
su,O,O
",",O,O
caused,O,O
apoptosis,O,O
in,O,O
human,O,O
leukemia,O,O
U937,O,O
cells,O,O
by,O,O
anomalous,O,O
activation,O,O
of,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,O
kinase,I,O
(,O,O
MAPK,B,O
),O,O
via,O,O
the,O,O
signaling,O,O
pathway,O,O
of,O,O
Ras,B,O
",",O,O
Raf,B,O
-,I,O
1,I,O
",",O,O
and,O,O
MAPK,B,O
kinase,I,O
-,I,O
1,I,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
the,O,O
effect,O,O
of,O,O
overexpression,O,O
of,O,O
bcl,B,B
-,I,I
2,I,I
in,O,O
U937,O,O
cells,O,O
on,O,O
the,O,O
signaling,O,O
pathway,O,O
of,O,O
apoptosis,O,O
that,O,O
is,O,O
induced,O,O
by,O,O
bufalin,O,O
.,O,O
The,O,O
genes,O,O
encoding,O,O
the,O,O
functionally,O,O
related,O,O
hepatocyte,B,B
nuclear,I,I
factors,I,I
HNF,B,B
-,I,I
1alpha,I,I
and,O,O
HNF,B,B
-,I,I
4alpha,I,I
play,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
normal,O,O
pancreatic,O,O
beta,O,O
-,O,O
cell,O,O
function,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
show,O,O
that,O,O
HNF,B,B
-,I,I
3alpha,I,I
",",I,O
-,I,O
3beta,I,O
",",I,O
-,I,O
3gamma,I,O
",",I,O
-,I,O
4gamma,I,O
",",I,O
and,I,O
-,I,O
6,I,O
are,O,O
expressed,O,O
in,O,O
pancreatic,O,B
beta,O,I
-,O,I
cells,O,I
.,O,O
We,O,O
report,O,O
the,O,O
identification,O,O
and,O,O
characterization,O,O
of,O,O
simple,B,O
tandem,I,O
repeat,I,O
DNA,I,B
polymorphisms,I,O
in,O,O
the,O,O
genes,O,O
encoding,O,O
HNF,B,B
-,I,I
3alpha,I,I
",",O,O
-,B,O
3beta,I,O
",",O,O
-,B,O
3gamma,I,O
",",O,O
-,B,O
4gamma,I,O
",",O,O
and,O,O
-,B,O
6,I,O
and,O,O
the,O,O
mapping,O,O
of,O,O
HNF,B,B
-,I,I
6,I,I
to,O,O
chromosome,B,O
bands,I,O
15q21,B,O
.,I,O
1,I,O
-,I,O
21,I,O
.,I,O
2,I,O
by,O,O
fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
.,O,O
Anti,B,O
-,I,O
E,I,B
.,I,I
chaffeensis,I,I
antibody,I,O
complexed,O,O
with,O,O
E,O,B
.,O,I
chaffeensis,O,I
significantly,O,O
enhanced,O,O
mRNA,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
1beta,I,I
in,O,O
THP,O,O
-,O,O
1,O,O
cells,O,O
.,O,O
Decreased,O,O
transcriptional,O,O
activation,O,O
by,O,O
N,B,B
-,I,I
terminal,I,I
deletions,I,I
of,O,O
CIITA,B,O
is,O,O
correlated,O,O
directly,O,O
with,O,O
their,O,O
reduced,O,O
binding,O,O
to,O,O
TAFII32,B,O
.,O,O
Ligand,O,O
binding,O,O
and,O,O
activation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
10,I,I
receptor,I,I
expressed,O,O
on,O,O
B,O,O
-,O,O
CLL,O,O
cells,O,O
results,O,O
in,O,O
the,O,O
phosphorylation,O,O
of,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
1,I,O
(,O,O
STAT1,B,B
),O,O
and,O,O
STAT3,B,B
proteins,O,O
.,O,O
When,O,O
18C7,B,O
was,O,O
incubated,O,O
with,O,O
MR,B,O
before,O,O
aldosterone,O,O
or,O,O
progesterone,O,O
",",O,O
the,O,O
antibody,O,O
inhibited,O,O
75,O,O
-,O,O
80,O,O
%,O,O
of,O,O
the,O,O
binding,O,O
.,O,O
Molecular,O,O
cloning,O,O
of,O,O
SLAP,B,B
-,I,I
130,I,I
",",O,O
an,O,O
SLP,B,B
-,I,I
76,I,I
-,I,I
associated,I,O
substrate,I,O
of,O,O
the,O,O
T,B,B
cell,I,I
antigen,I,I
receptor,I,I
-,I,I
stimulated,I,O
protein,I,O
tyrosine,I,O
kinases,I,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
SLP,B,B
-,I,I
76,I,I
recruits,O,O
a,O,O
negative,O,O
regulator,O,O
",",O,O
SLAP,B,B
-,I,I
130,I,I
",",O,O
as,O,O
well,O,O
as,O,O
positive,O,O
regulators,O,O
of,O,O
signal,O,O
transduction,O,O
in,O,O
T,O,B
cells,O,I
.,O,O
This,O,O
review,O,O
focuses,O,O
on,O,O
the,O,O
molecular,O,O
actions,O,O
of,O,O
prolactin,O,O
in,O,O
the,O,O
immune,O,O
system,O,O
.,O,O
From,O,O
analyses,O,O
of,O,O
mice,O,O
deficient,O,O
in,O,O
transcription,B,B
factor,I,I
genes,I,I
and,O,O
from,O,O
the,O,O
characterizations,O,O
of,O,O
chromosome,B,O
breakpoints,I,O
in,O,O
human,O,O
leukemias,O,O
",",O,O
it,O,O
has,O,O
become,O,O
evident,O,O
that,O,O
transcription,B,B
factors,I,I
are,O,O
important,O,O
regulators,O,O
of,O,O
hematopoiesis,O,O
.,O,O
Induction,O,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
expression,O,O
in,O,O
monocytic,O,B
cells,O,O
by,O,O
Cryptococcus,O,O
neoformans,O,O
and,O,O
Candida,O,O
albicans,O,O
.,O,O
Because,O,O
candidiasis,O,O
and,O,O
cryptococcosis,O,O
are,O,O
common,O,O
in,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
(,O,O
HIV,O,B
),O,O
-,O,O
infected,O,O
persons,O,O
",",O,O
the,O,O
effect,O,O
of,O,O
Cryptococcus,O,B
neoformans,O,I
and,O,O
Candida,O,B
albicans,O,I
on,O,O
HIV,O,B
expression,O,O
in,O,O
monocytic,O,O
cells,O,O
was,O,O
examined,O,O
.,O,O
Stimulation,O,O
of,O,O
the,O,O
latently,O,O
HIV,O,B
-,O,O
infected,O,O
myelomonocytic,O,O
cell,O,O
line,O,O
OM,O,O
-,O,O
10,O,O
.,O,O
1,O,O
with,O,O
C,O,O
.,O,O
neoformans,O,O
and,O,O
C,O,O
.,O,O
albicans,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
pooled,O,O
human,O,O
serum,O,O
caused,O,O
a,O,O
ratio,O,O
-,O,O
dependent,O,O
increase,O,O
in,O,O
HIV,O,B
production,O,O
.,O,O
In,O,O
THP,O,O
-,O,O
1,O,O
cells,O,O
transfected,O,O
with,O,O
HIV,B,B
plasmid,I,I
constructs,I,I
",",O,O
both,O,O
organisms,O,O
induced,O,O
transcription,O,O
from,O,O
the,O,O
HIV,B,B
long,I,I
terminal,I,I
repeat,I,I
that,O,O
was,O,O
dependent,O,O
on,O,O
intact,O,O
NF,B,B
-,I,I
kappaB,I,I
binding,I,I
sequences,I,I
.,O,O
Thus,O,O
",",O,O
C,O,O
.,O,O
neoformans,O,O
and,O,O
C,O,O
.,O,O
albicans,O,O
enhance,O,O
HIV,O,B
expression,O,O
in,O,O
monocytic,O,O
cells,O,O
through,O,O
a,O,O
TNF,O,B
-,O,I
alpha,O,I
-,O,I
and,O,O
NF,O,B
-,O,I
kappaB,O,I
-,O,I
dependent,O,O
mechanism,O,O
.,O,O
In,O,O
this,O,O
report,O,O
we,O,O
present,O,O
the,O,O
characterisation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
subunits,I,O
engaged,O,O
in,O,O
complexes,O,O
binding,O,O
to,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
NF,I,B
-,I,I
kappaB,I,I
site,I,O
in,O,O
human,O,O
T,O,O
-,O,O
cells,O,O
",",O,O
that,O,O
harbour,O,O
a,O,O
defective,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
With,O,O
the,O,O
use,O,O
of,O,O
specific,B,O
antibodies,I,O
we,O,O
have,O,O
determined,O,O
the,O,O
composition,O,O
of,O,O
each,O,O
complex,O,O
using,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
.,O,O
c,B,O
-,I,O
Myb,I,B
and,O,O
Ets,B,B
proteins,I,O
synergize,O,O
to,O,O
overcome,O,O
transcriptional,O,O
repression,O,O
by,O,O
ZEB,B,O
.,O,O
IL,B,B
-,I,I
4,I,I
-,O,I
dependent,O,O
activation,O,O
of,O,O
Stat6,B,O
was,O,O
also,O,O
observed,O,O
in,O,O
HC11,O,O
mammary,O,O
epithelial,O,O
cells,O,O
.,O,O
In,O,O
these,O,O
cells,O,O
",",O,O
Stat6,B,O
activation,O,O
led,O,O
to,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
beta,B,B
-,I,I
casein,I,I
gene,I,I
promoter,I,I
.,O,O
In,O,O
pre,O,O
-,O,O
B,O,O
cells,O,O
(,O,O
Ba,O,B
/,O,I
F3,O,I
),O,O
",",O,O
the,O,O
transactivation,O,O
domain,O,O
of,O,O
Stat6,B,O
was,O,O
IL,B,B
-,I,I
4,I,I
regulated,O,O
",",O,O
independently,O,O
from,O,O
its,O,O
DNA,O,B
binding,O,I
function,O,I
.,O,O
Activation,O,O
of,O,O
helper,O,O
T,O,O
cells,O,O
results,O,O
in,O,O
coordinate,O,O
expression,O,O
of,O,O
a,O,O
number,O,O
of,O,O
cytokines,B,O
involved,O,O
in,O,O
differentiation,O,O
",",O,O
proliferation,O,O
and,O,O
activation,O,O
of,O,O
the,O,O
haematopoietic,O,O
system,O,O
.,O,O
Granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
stimulating,I,I
factor,I,I
(,O,O
GM,B,B
-,I,I
CSF,I,I
),O,O
is,O,O
one,O,O
such,O,O
cytokine,B,O
",",O,O
whose,O,O
increased,O,O
expression,O,O
results,O,O
mostly,O,O
from,O,O
increases,O,O
in,O,O
transcription,O,O
.,O,O
ETS1,B,B
is,O,O
a,O,O
transcription,B,O
factor,I,O
of,O,O
the,O,O
ETS,B,B
family,I,I
that,O,O
is,O,O
expressed,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
We,O,O
have,O,O
previously,O,O
shown,O,O
that,O,O
ETS1,B,B
can,O,O
transactivate,O,O
GM,B,B
-,I,I
CSF,I,I
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
",",O,O
but,O,O
only,O,O
after,O,O
the,O,O
cells,O,O
have,O,O
been,O,O
stimulated,O,O
by,O,O
treatment,O,O
with,O,O
PMA,O,O
and,O,O
ionomycin,O,O
",",O,O
agents,O,O
that,O,O
mimic,O,O
T,O,O
cell,O,O
activation,O,O
.,O,O
This,O,O
defect,O,O
in,O,O
maturation,O,O
resulted,O,O
in,O,O
a,O,O
transgene,O,O
dose,O,O
-,O,O
dependent,O,O
reduction,O,O
in,O,O
peripheral,O,O
T,O,B
lymphocytes,O,I
",",O,O
with,O,O
the,O,O
CD8,O,B
lineage,O,I
being,O,O
more,O,O
severely,O,O
affected,O,O
.,O,O
CD40,B,B
is,O,O
an,O,O
important,O,O
signaling,O,O
and,O,O
activation,O,O
Ag,O,O
found,O,O
on,O,O
certain,O,O
bone,O,O
marrow,O,O
-,O,O
derived,O,O
cells,O,O
.,O,O
Recently,O,O
",",O,O
CD40,B,B
also,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
expressed,O,O
by,O,O
mesenchymal,O,B
cells,O,I
",",O,O
including,O,O
human,O,O
fibroblasts,O,O
.,O,O
Little,O,O
is,O,O
known,O,O
about,O,O
the,O,O
role,O,O
of,O,O
CD40,B,B
in,O,O
fibroblasts,O,O
.,O,O
The,O,O
current,O,O
study,O,O
investigates,O,O
the,O,O
hypothesis,O,O
that,O,O
CD40,B,B
expressed,O,O
on,O,O
lung,O,O
fibroblasts,O,O
is,O,O
an,O,O
activation,O,O
structure,O,O
and,O,O
mechanism,O,O
for,O,O
interaction,O,O
with,O,O
hemopoietic,O,O
cells,O,O
.,O,O
Signaling,O,O
through,O,O
CD40,B,B
with,O,O
soluble,O,O
CD40,B,O
ligand,O,O
stimulated,O,O
fibroblast,O,O
activation,O,O
",",O,O
as,O,O
evidenced,O,O
by,O,O
mobilization,O,O
of,O,O
nuclear,O,O
factor,O,O
-,O,O
kappaB,O,O
and,O,O
by,O,O
induction,O,O
of,O,O
the,O,O
proinflammatory,O,O
and,O,O
chemoattractant,O,O
cytokines,B,O
IL,B,B
-,I,I
6,I,I
and,O,O
IL,B,B
-,I,I
8,I,I
.,O,O
In,O,O
contrast,O,O
",",O,O
it,O,O
was,O,O
found,O,O
to,O,O
be,O,O
TNF,B,B
-,I,I
alpha,I,I
independent,O,O
in,O,O
the,O,O
early,O,O
time,O,O
point,O,O
.,O,O
In,O,O
fact,O,O
",",O,O
mAb,B,O
L243,I,O
but,O,O
not,O,O
the,O,O
staphylococcal,B,O
superantigens,I,O
",",O,O
staphylococcal,B,O
exotoxin,I,O
toxic,I,O
shock,I,O
syndrome,I,O
toxin,I,O
-,I,O
I,I,O
or,O,O
staphylococcal,B,O
enterotoxin,I,O
B,I,O
",",O,O
regulate,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
binding,O,I
activity,O,I
.,O,O
Regulation,O,O
of,O,O
inosine,B,O
-,I,O
5,I,O
-,I,O
monophosphate,I,O
dehydrogenase,I,O
type,I,O
II,I,O
gene,O,O
expression,O,O
in,O,O
human,O,O
T,O,O
cells,O,O
.,O,O
Additional,O,O
major,O,O
protein,O,B
-,O,I
DNA,O,I
interactions,O,O
do,O,O
not,O,O
occur,O,O
within,O,O
the,O,O
promoter,O,O
region,O,O
after,O,O
T,O,O
lymphocyte,O,B
activation,O,O
",",O,O
indicating,O,O
a,O,O
requirement,O,O
for,O,O
additional,O,O
protein,O,B
-,O,I
protein,O,I
interactions,O,O
and,O,O
/,O,O
or,O,O
post,O,O
-,O,O
translational,O,O
modifications,O,O
of,O,O
pre,B,O
-,I,O
bound,I,O
transcription,I,O
factors,I,O
to,O,O
account,O,O
for,O,O
the,O,O
observed,O,O
increase,O,O
in,O,O
IMPDH,O,B
type,O,I
II,O,I
gene,O,I
expression,O,O
.,O,O
NAC,O,B
had,O,O
no,O,O
effect,O,O
on,O,O
the,O,O
half,O,O
-,O,O
life,O,O
of,O,O
E,B,B
-,I,I
selectin,I,I
or,I,O
VCAM,I,B
-,I,I
1,I,I
mRNA,I,O
.,O,O
Fusion,O,O
proteins,O,O
involving,O,O
the,O,O
retinoic,O,B
acid,O,I
receptor,B,I
alpha,I,I
(,O,O
RAR,B,O
alpha,I,O
),O,O
and,O,O
the,O,O
PML,B,O
or,O,O
PLZF,B,O
nuclear,I,O
protein,I,O
are,O,O
the,O,O
genetic,O,O
markers,O,O
of,O,O
acute,O,O
promyelocytic,O,O
leukemias,O,O
(,O,O
APLs,O,O
),O,O
.,O,O
Cytomegalovirus,O,O
(,O,O
CMV,O,O
),O,O
infection,O,O
induced,O,O
interleukin,B,B
-,I,I
8,I,I
(,O,O
IL,B,O
-,I,O
8,I,O
),O,O
gene,O,O
transcription,O,O
in,O,O
a,O,O
human,O,B
monocytic,O,I
cell,O,I
line,O,I
",",O,O
THP,O,O
-,O,O
1,O,O
cells,O,O
",",O,O
leading,O,O
to,O,O
IL,B,B
-,I,I
8,I,I
secretion,O,O
.,O,O
Moreover,O,O
",",O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
demonstrated,O,O
that,O,O
CMV,O,O
induced,O,O
the,O,O
formation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
complexes,I,O
.,O,O
Interleukin,B,B
-,I,I
12,I,I
(,O,O
IL,B,B
-,I,I
12,I,I
),O,O
is,O,O
a,O,O
cytokine,B,O
that,O,O
exhibits,O,O
pleiotropic,O,O
effects,O,O
on,O,O
lymphocytes,O,O
and,O,O
natural,O,O
killer,O,O
cells,O,O
and,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
have,O,O
promise,O,O
for,O,O
the,O,O
immunotherapy,O,O
of,O,O
cancer,O,O
.,O,O
This,O,O
presents,O,O
several,O,O
problems,O,O
in,O,O
vectors,O,O
",",O,O
particularly,O,O
those,O,O
in,O,O
which,O,O
additional,O,O
genes,O,B
",",O,O
either,O,O
a,O,O
co,B,O
-,I,O
stimulatory,I,O
gene,I,O
or,O,O
a,O,O
selectable,O,O
marker,O,O
",",O,O
are,O,O
inserted,O,O
.,O,O
Direct,O,O
analysis,O,O
of,O,O
these,O,O
modified,O,O
cells,O,O
acting,O,O
as,O,O
tumor,O,O
vaccines,O,O
is,O,O
underway,O,O
.,O,O
Plasma,O,O
sialyltransferase,B,O
levels,O,O
in,O,O
psychiatric,O,O
disorders,O,O
as,O,O
a,O,O
possible,O,O
indicator,O,O
of,O,O
HPA,O,O
axis,O,O
function,O,O
.,O,O
While,O,O
there,O,O
was,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
plasma,O,O
cortisol,O,B
levels,O,O
in,O,O
the,O,O
depressed,O,O
group,O,O
",",O,O
there,O,O
were,O,O
no,O,O
changes,O,O
in,O,O
the,O,O
lymphocyte,O,O
GR,B,B
binding,O,O
parameters,O,O
(,O,O
K,O,O
(,O,O
m,O,O
),O,O
and,O,O
Bmax,O,O
),O,O
.,O,O
There,O,O
was,O,O
",",O,O
however,O,O
",",O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
the,O,O
plasma,B,O
sialyltransferase,I,O
:,I,O
cortisol,O,O
ratio,O,O
in,O,O
the,O,O
depressed,O,O
group,O,O
suggesting,O,O
an,O,O
inability,O,O
of,O,O
the,O,O
raised,O,O
cortisol,O,O
levels,O,O
to,O,O
induce,O,O
enzyme,O,O
expression,O,O
and,O,O
this,O,O
ratio,O,O
may,O,O
provide,O,O
a,O,O
useful,O,O
biochemical,O,O
marker,O,O
of,O,O
cortisol,O,O
receptor,O,O
function,O,O
.,O,O
Therefore,O,O
",",O,O
while,O,O
the,O,O
total,O,O
plasma,B,O
sialyltransferase,I,O
:,O,O
cortisol,O,O
ratio,O,O
reflects,O,O
HPA,O,O
axis,O,O
function,O,O
",",O,O
alterations,O,O
in,O,O
specific,O,O
isozyme,O,O
activity,O,O
may,O,O
also,O,O
be,O,O
associated,O,O
with,O,O
other,O,O
CNS,O,O
disease,O,O
states,O,O
.,O,O
Using,O,O
a,O,O
previously,O,O
described,O,O
mutant,O,O
of,O,O
the,O,O
Jurkat,O,O
T,O,O
cell,O,O
line,O,O
",",O,O
we,O,O
show,O,O
that,O,O
proximal,O,O
signaling,O,O
events,O,O
dependent,O,O
on,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
CD45,B,O
tyrosine,I,O
phosphatase,I,O
are,O,O
required,O,O
for,O,O
TCR,B,O
-,O,O
stimulated,O,O
CD95,B,O
ligand,I,O
expression,O,O
.,O,O
Together,O,O
",",O,O
these,O,O
studies,O,O
begin,O,O
a,O,O
dissection,O,O
of,O,O
the,O,O
biochemical,O,O
events,O,O
that,O,O
lead,O,O
to,O,O
expression,O,O
of,O,O
CD95,B,B
ligand,I,I
",",O,O
a,O,O
required,O,O
step,O,O
for,O,O
TCR,B,O
-,O,O
induced,O,O
apoptosis,O,O
.,O,O
This,O,O
paper,O,O
aims,O,O
to,O,O
review,O,O
the,O,O
role,O,O
of,O,O
free,O,O
radical,O,O
-,O,O
induced,O,O
tissue,O,O
damage,O,O
and,O,O
antioxidant,O,O
defence,O,O
mechanisms,O,O
in,O,O
inflammatory,O,O
diseases,O,O
that,O,O
involve,O,O
pathogenic,O,O
processes,O,O
similar,O,O
to,O,O
the,O,O
periodontal,O,O
diseases,O,O
.,O,O
There,O,O
is,O,O
a,O,O
clearly,O,O
defined,O,O
and,O,O
substantial,O,O
role,O,O
for,O,O
free,O,O
radicals,O,O
or,O,O
reactive,O,O
oxygen,O,O
species,O,O
(,O,O
ROS,O,O
),O,O
in,O,O
periodontitis,O,O
",",O,O
but,O,O
little,O,O
research,O,O
has,O,O
been,O,O
performed,O,O
in,O,O
this,O,O
area,O,O
.,O,O
Large,O,O
germline,O,O
deletions,O,O
of,O,O
TSC2,B,O
occur,O,O
in,O,O
<,O,O
5,O,O
%,O,O
of,O,O
cases,O,O
",",O,O
and,O,O
a,O,O
number,O,O
of,O,O
small,O,O
intragenic,O,O
mutations,O,O
have,O,O
been,O,O
described,O,O
.,O,O
TCP,O,O
succinate,O,O
(,O,O
200,O,O
microM,O,O
",",O,O
24,O,O
h,O,O
),O,O
reduced,O,O
TNF,B,B
-,I,O
induced,I,O
VCAM,I,B
-,I,I
1,I,I
and,O,O
E,B,B
-,I,I
selectin,I,I
expression,O,O
from,O,O
a,O,O
specific,O,O
mean,O,O
fluorescence,O,O
intensity,O,O
of,O,O
151,O,O
+,O,O
/,O,O
-,O,O
28,O,O
to,O,O
12,O,O
+,O,O
/,O,O
-,O,O
4,O,O
channels,O,O
and,O,O
from,O,O
225,O,O
+,O,O
/,O,O
-,O,O
38,O,O
to,O,O
79,O,O
+,O,O
/,O,O
-,O,O
21,O,O
channels,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
Eed,B,B
-,O,I
mediated,O,I
transcriptional,O,I
effects,O,I
are,O,O
likely,O,O
to,O,O
reflect,O,O
the,O,O
interaction,O,O
of,O,O
Eed,B,B
with,O,O
multiple,O,O
molecular,O,O
partners,O,O
",",O,O
including,O,O
K,B,B
protein,I,I
.,O,O
When,O,O
macrophages,O,O
were,O,O
pretreated,O,O
with,O,O
low,O,O
doses,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
and,O,O
then,O,O
stimulated,O,O
with,O,O
IFN,B,B
-,I,I
alpha,I,I
",",O,O
clearly,O,O
enhanced,O,O
formation,O,O
of,O,O
specific,O,O
transcription,B,O
factor,I,O
complexes,O,O
was,O,O
detected,O,O
.,O,O
Activation,O,O
and,O,O
regulation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
are,O,O
tightly,O,O
controlled,O,O
by,O,O
a,O,O
group,O,O
of,O,O
inhibitory,B,O
proteins,I,O
(,O,O
I,B,B
kappa,I,I
B,I,I
),O,O
that,O,O
sequester,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
the,O,O
cytoplasm,O,O
of,O,O
immune,O,O
/,O,O
inflammatory,O,O
effector,O,O
cells,O,O
.,O,O
Liberated,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
migrates,O,O
to,O,O
the,O,O
nucleus,O,O
",",O,O
where,O,O
it,O,O
binds,O,O
to,O,O
specific,B,O
promoter,I,O
sites,I,O
and,O,O
activates,O,O
gene,O,O
transcription,O,O
.,O,O
Constitutive,O,O
expression,O,O
of,O,O
E2a,B,B
-,I,I
Pbx1,I,I
did,O,O
not,O,O
induce,O,O
apoptosis,O,O
or,O,O
continued,O,O
cycling,O,O
of,O,O
Rat,O,B
-,O,I
1,O,I
fibroblasts,O,I
in,O,O
low,O,O
serum,O,O
conditions,O,O
.,O,O
The,O,O
human,B,B
C,I,I
/,I,I
gene,I,O
is,O,O
transcribed,O,O
by,O,O
two,O,O
alternative,O,O
promoters,B,O
",",O,O
Palpha,B,B
and,O,O
Pbeta,B,B
.,O,O
A,O,O
combination,O,O
of,O,O
differential,O,O
splicing,O,O
and,O,O
alternative,O,O
use,O,O
of,O,O
promoters,B,O
generates,O,O
four,O,O
mRNA,B,O
isoforms,I,O
",",O,O
of,O,O
2,O,O
.,O,O
6,O,O
kb,O,O
and,O,O
1,O,O
.,O,O
3,O,O
-,O,O
1,O,O
.,O,O
5,O,O
kb,O,O
in,O,O
size,O,O
.,O,O
C,B,O
/,I,O
EBPepsilon,I,B
mRNA,I,O
was,O,O
greatly,O,O
induced,O,O
during,O,O
in,O,O
vitro,O,O
granulocytic,O,O
differentiation,O,O
of,O,O
human,O,O
primary,O,O
CD34,O,O
(,O,O
+,O,O
),O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
C,B,O
/,I,O
EBPepsilon,I,B
is,O,O
regulated,O,O
in,O,O
a,O,O
complex,O,O
fashion,O,O
and,O,O
may,O,O
play,O,O
a,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
genes,O,O
involved,O,O
in,O,O
myeloid,O,O
differentiation,O,O
.,O,O
We,O,O
now,O,O
report,O,O
that,O,O
PO,B,O
-,I,O
B,I,O
DNA,O,B
-,O,O
binding,O,O
in,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
is,O,O
similarly,O,O
induced,O,O
during,O,O
differentiation,O,O
to,O,O
the,O,O
granulocytic,O,O
lineage,O,O
(,O,O
with,O,O
either,O,O
retinoic,O,O
acid,O,O
or,O,O
dimethylsulfoxide,O,O
),O,O
.,O,O
Recent,O,O
studies,O,O
have,O,O
revealed,O,O
that,O,O
interactions,O,O
between,O,O
transcription,B,B
factors,I,I
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
regulation,O,O
of,O,O
gene,O,O
expression,O,O
in,O,O
eukaryotic,O,B
cells,O,I
.,O,O
Oct,B,O
-,I,O
2,I,O
expressed,O,O
in,O,O
this,O,O
tester,O,O
strain,O,O
represses,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
reporter,O,O
gene,O,O
and,O,O
changes,O,O
the,O,O
phenotype,O,O
of,O,O
the,O,O
cell,O,O
from,O,O
Lac,O,O
+,O,O
to,O,O
Lac,O,O
-,O,O
.,O,O
One,O,O
of,O,O
them,O,O
",",O,O
hT86,O,O
",",O,O
encoding,O,O
a,O,O
putative,B,O
zinc,I,B
finger,I,I
protein,I,I
was,O,O
found,O,O
to,O,O
derepress,O,O
beta,B,O
-,I,O
galactosidase,I,O
activity,O,O
in,O,O
the,O,O
Oct,B,O
-,I,O
2,I,O
-,O,O
harboring,O,O
tester,O,O
strain,O,O
at,O,O
the,O,O
transcriptional,O,O
level,O,O
.,O,O
Thus,O,O
",",O,O
Tap,B,O
is,O,O
likely,O,O
to,O,O
be,O,O
an,O,O
important,O,O
cellular,O,O
mediator,O,O
of,O,O
Tip,B,O
function,O,O
in,O,O
T,O,O
cell,O,O
transformation,O,O
by,O,O
herpesvirus,O,O
saimiri,O,O
.,O,O
Triggering,O,O
of,O,O
the,O,O
T,B,O
-,I,O
cell,I,O
receptor,I,O
-,I,O
CD3,I,O
complex,I,O
activates,O,O
two,O,O
major,O,O
signal,O,O
cascades,O,O
in,O,O
T,O,O
lymphocytes,O,O
",",O,O
(,O,O
i,O,O
),O,O
Ca2,O,B
+,O,I
-,O,I
dependent,O,I
signal,O,I
cascades,O,I
and,O,O
(,O,O
ii,O,O
),O,O
protein,B,B
kinase,I,I
cascades,O,I
.,O,O
Both,O,O
signal,O,O
cascades,O,O
contribute,O,O
to,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
interleukin,B,B
2,I,I
(,I,I
IL,I,I
-,I,I
2,I,I
),I,I
gene,I,O
during,O,O
T,O,O
-,O,O
cell,O,O
activation,O,O
.,O,O
Functional,O,O
analysis,O,O
of,O,O
monocytic,O,B
THP,O,I
-,O,I
1,O,I
cells,O,O
transfected,O,O
with,O,O
plasmids,B,O
containing,O,O
various,O,O
lengths,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
promoter,I,O
localized,O,O
enhancer,B,O
elements,I,O
in,O,O
a,O,O
region,O,O
(,O,O
-,B,O
182,I,O
to,I,O
-,I,O
37,I,O
base,I,O
pairs,I,O
(,O,O
bp,O,O
),O,O
that,O,O
were,O,O
required,O,O
for,O,O
optimal,O,O
transcription,O,O
of,O,O
the,O,O
TNF,B,B
-,I,I
alpha,I,I
gene,I,O
in,O,O
response,O,O
to,O,O
LPS,O,O
.,O,O
In,O,O
unstimulated,O,O
THP,O,O
-,O,O
1,O,O
",",O,O
CRE,B,B
-,I,I
binding,I,I
protein,I,I
and,O,O
",",O,O
to,O,O
a,O,O
lesser,O,O
extent,O,O
",",O,O
c,B,O
-,I,O
Jun,I,O
complexes,I,O
were,O,O
found,O,O
to,O,O
bind,O,O
to,O,O
the,O,O
CRE,B,B
site,I,I
.,O,O
The,O,O
CRE,B,B
and,I,O
kappaB3,I,B
sites,I,O
in,O,O
region,B,O
II,I,O
together,O,O
conferred,O,O
strong,O,O
LPS,O,O
responsiveness,O,O
to,O,O
a,O,O
heterologous,B,O
promoter,I,O
",",O,O
whereas,O,O
individually,O,O
they,O,O
failed,O,O
to,O,O
provide,O,O
transcriptional,O,O
activation,O,O
.,O,O
Furthermore,O,O
",",O,O
increasing,O,O
the,O,O
spacing,O,O
between,O,O
the,O,O
CRE,B,O
and,I,O
the,I,O
kappaB3,I,O
sites,I,O
completely,O,O
abolished,O,O
LPS,O,O
induction,O,O
",",O,O
suggesting,O,O
a,O,O
cooperative,O,O
interaction,O,O
between,O,O
c,B,O
-,I,O
Jun,I,O
complexes,I,O
and,O,O
p50,B,O
/,I,O
p65,I,O
.,O,O
IFN,B,B
-,I,I
alpha,I,I
/,I,I
beta,I,I
specifically,O,O
induced,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
translocation,O,O
into,O,O
nucleus,O,O
of,O,O
signal,B,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
(,I,O
STAT,I,O
),I,O
2,I,O
protein,I,O
in,O,O
the,O,O
T,O,O
cell,O,O
clones,O,O
.,O,O
IL,B,B
-,I,I
10,I,I
inhibition,O,O
of,O,O
IFN,B,B
-,I,I
gamma,I,I
-,O,I
induced,O,O
ICAM,B,B
-,I,I
1,I,I
expression,O,O
was,O,O
apparent,O,O
as,O,O
early,O,O
as,O,O
3,O,O
hours,O,O
and,O,O
was,O,O
blocked,O,O
by,O,O
an,O,O
anti,B,O
-,I,O
IL,I,B
-,I,I
10,I,I
antibody,I,O
but,O,O
not,O,O
by,O,O
an,O,O
isotype,B,O
-,I,O
matched,I,O
control,I,O
antibody,I,O
.,O,O
The,O,O
other,O,O
",",O,O
CIITA,B,O
",",O,O
encodes,O,O
a,O,O
large,O,O
protein,O,O
with,O,O
a,O,O
defined,O,O
acidic,B,O
transcriptional,I,O
activation,I,O
domain,I,O
;,O,O
this,O,O
protein,O,O
does,O,O
not,O,O
interact,O,O
with,O,O
DNA,O,B
.,O,O
However,O,O
",",O,O
these,O,O
plasmids,B,O
produced,O,O
transcriptional,O,O
activity,O,O
in,O,O
HeLa,O,O
cells,O,O
only,O,O
in,O,O
conjunction,O,O
with,O,O
interferon,B,B
gamma,I,I
stimulation,O,O
",",O,O
a,O,O
condition,O,O
in,O,O
which,O,O
expression,O,O
of,O,O
both,O,O
CIITA,B,B
and,O,O
class,B,B
II,I,I
major,I,I
histocompatibility,I,I
complex,I,I
surface,I,I
proteins,I,I
are,O,O
induced,O,O
.,O,O
Thus,O,O
",",O,O
RFX5,B,O
can,O,O
activate,O,O
transcription,O,O
only,O,O
in,O,O
cooperation,O,O
with,O,O
CIITA,B,B
.,O,O
Phosphatidylinositol,B,B
3,I,I
-,I,I
kinase,I,I
(,O,O
PI3,B,B
-,I,I
K,I,I
),O,O
has,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
cell,O,O
proliferation,O,O
in,O,O
many,O,O
cell,O,O
types,O,O
.,O,O
Acute,O,O
promyelocytic,O,O
leukemia,O,O
(,O,O
APL,O,O
),O,O
is,O,O
associated,O,O
with,O,O
reciprocal,O,O
chromosomal,O,O
translocations,O,O
involving,O,O
the,O,O
retinoic,B,B
acid,I,I
receptor,I,I
alpha,I,I
(,I,O
RARalpha,I,O
),I,O
locus,I,O
on,O,O
chromosome,B,O
17,I,O
.,O,O
The,O,O
resulting,O,O
fusion,B,O
genes,I,O
encode,O,O
the,O,O
two,O,O
structurally,O,O
unique,O,O
PML,B,B
/,I,I
RARalpha,I,I
and,O,O
RARalpha,B,B
/,I,I
PML,I,I
fusion,I,O
proteins,I,O
as,O,O
well,O,O
as,O,O
aberrant,B,O
PML,I,B
gene,I,I
products,I,O
",",O,O
the,O,O
respective,O,O
pathogenetic,O,O
roles,O,O
of,O,O
which,O,O
have,O,O
not,O,O
been,O,O
elucidated,O,O
.,O,O
Interferon,O,B
-,O,I
gamma,O,I
(,O,O
IFN,B,B
-,I,I
gamma,I,I
),O,O
is,O,O
a,O,O
key,O,O
cytokine,O,O
of,O,O
T,O,O
lymphocytes,O,O
with,O,O
major,O,O
regulatory,O,O
functions,O,O
in,O,O
the,O,O
immune,O,O
system,O,O
.,O,O
This,O,O
novel,B,O
target,I,O
site,I,O
",",O,O
denoted,O,O
the,O,O
C,B,O
-,I,O
site,I,O
",",O,O
was,O,O
shown,O,O
by,O,O
several,O,O
criteria,O,O
",",O,O
including,O,O
cell,O,O
distribution,O,O
studies,O,O
",",O,O
stimulation,O,O
experiments,O,O
",",O,O
supershift,O,O
assays,O,O
",",O,O
and,O,O
cross,O,O
-,O,O
competition,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
to,O,O
bind,O,O
the,O,O
transcription,B,O
factor,I,O
AP,I,O
-,I,O
1,I,O
.,O,O
Mutation,O,O
of,O,O
the,O,O
C,B,B
-,I,I
site,I,I
that,O,O
prevented,O,O
AP,B,O
-,I,O
1,I,O
binding,O,O
to,O,O
this,O,O
site,O,O
was,O,O
sufficient,O,O
strikingly,O,O
to,O,O
reduce,O,O
inducible,O,O
promoter,O,O
activity,O,O
in,O,O
primary,O,O
CD45R0,O,O
T,O,O
cells,O,O
.,O,O
Latent,O,O
infection,O,O
of,O,O
B,O,O
lymphocytes,O,O
by,O,O
Epstein,O,B
-,O,I
Barr,O,I
virus,O,I
(,O,O
EBV,O,O
),O,O
can,O,O
be,O,O
disrupted,O,O
by,O,O
expression,O,O
of,O,O
the,O,O
EBV,B,O
ZEBRA,I,O
protein,I,O
.,O,O
The,O,O
studies,O,O
described,O,O
herein,O,O
demonstrate,O,O
that,O,O
the,O,O
activation,O,O
domain,O,O
.,O,O
The,O,O
involvement,O,O
of,O,O
the,O,O
CCK,B,B
(,I,O
B,I,O
),I,O
receptor,I,O
in,O,O
such,O,O
a,O,O
stimulation,O,O
was,O,O
demonstrated,O,O
by,O,O
the,O,O
inhibiting,O,O
effect,O,O
of,O,O
the,O,O
selective,O,O
CCK,B,B
(,I,O
B,I,O
),I,O
receptor,I,O
antagonist,O,O
PD,O,O
-,O,O
135,O,O
",",O,O
158,O,O
.,O,O
To,O,O
better,O,O
understand,O,O
the,O,O
AP,B,O
-,I,O
1,I,O
-,O,O
dependent,O,O
luciferase,B,O
expression,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
",",O,O
we,O,O
tested,O,O
two,O,O
specific,O,O
inhibitors,O,O
of,O,O
serine,B,O
/,I,O
threonine,I,O
phosphatases,I,O
-,I,O
1,I,O
and,I,O
-,I,O
2A,I,O
:,O,O
okadaic,O,O
acid,O,O
and,O,O
calyculin,O,O
A,O,O
.,O,O
In,O,O
Jurkat,O,B
T,O,I
cells,O,I
activated,O,O
by,O,O
phorbol,O,O
-,O,O
12,O,O
-,O,O
myristate,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
and,O,O
phytohemagglutinin,B,O
",",O,O
CCK,O,B
-,O,I
8,O,I
induced,O,O
IL,O,B
-,O,I
2,O,I
expression,O,O
.,O,O
Our,O,O
results,O,O
indicate,O,O
that,O,O
CCK,O,B
-,O,I
8,O,I
exerts,O,O
a,O,O
trophic,O,O
effect,O,O
in,O,O
Jurkat,O,B
T,O,I
cells,O,I
through,O,O
stimulation,O,O
of,O,O
CCK,B,B
(,I,O
B,I,I
),I,O
receptors,I,O
by,O,O
modulation,O,O
of,O,O
expression,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
-,I,O
regulated,I,O
genes,I,O
.,O,O
Binding,B,O
sites,I,O
at,O,O
the,O,O
core,O,O
region,O,O
show,O,O
little,O,O
conservation,O,O
with,O,O
consensus,B,O
sites,I,O
.,O,O
While,O,O
the,O,O
activation,O,O
of,O,O
JAK2,B,B
",",O,O
Shc,B,B
",",O,O
Erk,B,B
",",O,O
and,O,O
STAT5,B,B
proteins,I,O
correlated,O,O
with,O,O
hGM,B,O
-,I,O
CSF,I,O
-,O,O
mediated,O,O
cell,O,O
growth,O,O
",",O,O
cellular,O,O
differentiation,O,O
occurred,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
activation,O,O
of,O,O
these,O,O
signal,O,O
transduction,O,O
pathways,O,O
.,O,O
We,O,O
utilized,O,O
THP,O,B
-,O,I
1,O,I
cells,O,O
to,O,O
examine,O,O
the,O,O
response,O,O
to,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
with,O,O
macrophage,O,B
activation,O,O
.,O,O
Molecular,O,O
cloning,O,O
and,O,O
characterization,O,O
of,O,O
a,O,O
cDNA,B,B
",",O,O
CHEMR1,B,O
",",O,O
encoding,O,O
a,O,O
chemokine,B,O
receptor,I,O
with,O,O
a,O,O
homology,O,O
to,O,O
the,O,O
human,B,O
C,I,B
-,I,I
C,I,I
chemokine,I,I
receptor,I,I
",",O,O
CCR,B,B
-,I,I
4,I,I
.,O,O
Chemokines,B,O
refer,O,O
to,O,O
a,O,O
rapidly,O,O
expanding,O,O
family,O,O
of,O,O
small,O,O
cytokines,B,O
whose,O,O
primary,O,O
function,O,O
is,O,O
recruitment,O,O
of,O,O
leukocytes,O,O
to,O,O
inflammatory,O,O
sites,O,O
.,O,O
These,O,O
are,O,O
known,O,O
to,O,O
bind,O,O
to,O,O
seven,B,O
-,I,O
transmembrane,I,O
-,I,O
domain,I,O
containing,I,O
receptors,I,O
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
in,O,O
mouse,O,O
cell,O,B
lines,O,I
suggests,O,O
that,O,O
its,O,O
expression,O,O
is,O,O
found,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
cells,O,O
",",O,O
including,O,O
T,O,B
cells,O,I
",",O,O
B,O,B
cells,O,I
",",O,O
and,O,O
macrophages,O,B
.,O,O
This,O,O
suggests,O,O
that,O,O
CHEMR1,B,O
may,O,O
be,O,O
a,O,O
receptor,O,O
for,O,O
unidentified,O,O
C,B,O
-,I,O
C,I,O
chemokine,I,O
or,O,O
a,O,O
low,O,O
-,O,O
affinity,O,O
receptor,O,O
for,O,O
MIP,B,O
-,I,O
1alpha,I,O
.,O,O
Its,O,O
N,B,B
-,I,I
terminal,I,I
region,I,I
is,O,O
capable,O,O
of,O,O
activating,O,O
transcription,O,O
from,O,O
a,O,O
reporter,O,O
gene,O,O
when,O,O
fused,O,O
to,O,O
a,O,O
DNA,B,B
binding,I,I
domain,I,I
.,O,O
To,O,O
understand,O,O
the,O,O
mechanisms,O,O
underlined,O,O
in,O,O
this,O,O
regulation,O,O
in,O,O
normal,O,O
human,O,O
cells,O,O
",",O,O
we,O,O
have,O,O
analysed,O,O
in,O,O
vivo,O,O
protein,O,B
-,O,I
DNA,O,I
interactions,O,O
at,O,O
the,O,O
Cyclin,B,O
A,I,O
locus,O,O
in,O,O
primary,O,O
T,O,O
lymphocytes,O,O
.,O,O
The,O,O
third,O,O
site,O,O
was,O,O
occupied,O,O
in,O,O
quiescent,O,O
cells,O,O
or,O,O
in,O,O
cells,O,O
stimulated,O,O
by,O,O
anti,B,O
CD2,I,O
or,O,O
anti,B,O
CD28,I,O
alone,O,O
.,O,O
We,O,O
have,O,O
recently,O,O
reported,O,O
a,O,O
series,O,O
(,O,O
A,O,O
),O,O
of,O,O
1,O,O
",",O,O
25D3,O,O
-,O,O
resistant,O,O
variants,O,O
of,O,O
HL60,O,O
cells,O,O
which,O,O
proliferate,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
1,O,O
",",O,O
25D3,O,O
and,O,O
do,O,O
not,O,O
express,O,O
differentiation,O,O
markers,O,O
(,O,O
Exp,O,O
.,O,O
Cell,O,B
Res,O,I
.,O,O
224,O,O
",",O,O
312,O,O
",",O,O
1996,O,O
.,O,O
Human,B,O
immunodeficiency,I,O
virus,I,O
type,I,O
1,I,O
(,I,O
HIV,I,B
-,I,I
1,I,I
),I,O
Tat,I,O
",",O,O
an,O,O
early,O,O
regulatory,B,O
protein,I,O
that,O,O
is,O,O
critical,O,O
for,O,O
viral,O,O
gene,O,O
expression,O,O
and,O,O
replication,O,O
",",O,O
transactivates,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
long,I,O
terminal,I,O
repeat,I,O
(,O,O
LTR,B,O
),O,O
via,O,O
its,O,O
binding,O,O
to,O,O
the,O,O
transactivation,B,O
response,I,O
element,I,O
(,O,O
TAR,B,O
),O,O
and,O,O
",",O,O
along,O,O
with,O,O
other,O,O
cellular,O,B
factors,O,O
",",O,O
increases,O,O
viral,O,O
transcription,O,O
initiation,O,O
and,O,O
elongation,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
a,O,O
combined,O,O
pharmacologic,O,O
and,O,O
genetic,O,O
strategy,O,O
using,O,O
two,O,O
PKC,B,B
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
inhibitors,O,O
",",O,O
pentoxifylline,O,O
(,O,O
PTX,O,O
),O,O
and,O,O
a,O,O
stably,O,O
expressed,O,O
anti,B,O
-,I,O
Tat,I,O
single,I,O
-,I,O
chain,I,O
intracellular,I,O
antibody,I,O
(,O,O
sFv,B,O
intrabody,I,O
),O,O
was,O,O
employed,O,O
to,O,O
obtain,O,O
cooperative,O,O
inhibition,O,O
of,O,O
both,O,O
HIV,O,B
-,O,I
1,O,I
LTR,B,I
-,O,I
driven,O,I
gene,O,I
expression,O,O
and,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
.,O,O
Treatment,O,O
of,O,O
cells,O,O
with,O,O
PTX,O,O
and,O,O
Go,O,O
-,O,O
6976,O,O
resulted,O,O
in,O,O
cooperative,O,O
inhibition,O,O
of,O,O
both,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
-,O,I
driven,O,I
gene,O,I
expression,O,I
and,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,I
.,O,O
The,O,O
combined,O,O
treatment,O,O
resulted,O,O
in,O,O
more,O,O
durable,O,O
inhibition,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,I
than,O,O
was,O,O
seen,O,O
with,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
inhibitors,O,I
alone,O,O
or,O,O
the,O,O
anti,O,O
-,O,O
Tat,B,O
sFv,I,O
intrabodies,I,O
alone,O,O
.,O,O
CD28,B,B
is,O,O
an,O,O
important,O,O
costimulatory,B,O
molecule,I,O
in,O,O
the,O,O
activation,O,O
of,O,O
human,O,B
T,O,I
cells,O,O
.,O,O
Also,O,O
in,O,O
the,O,O
current,O,O
study,O,O
",",O,O
binding,O,O
activity,O,O
to,O,O
the,O,O
CD28RE,B,B
/,I,I
AP,I,I
-,I,I
1,I,I
sequence,I,I
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
is,O,O
evaluated,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
functional,O,O
complexes,O,O
encompassing,O,O
both,O,O
the,O,O
CD28RE,B,B
and,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
-,I,I
binding,I,I
sites,I,I
influence,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
activity,O,O
in,O,O
CD28,B,B
-,O,I
costimulated,O,I
T,O,I
cells,O,O
.,O,O
Inducible,O,O
expression,O,O
and,O,O
phosphorylation,O,O
of,O,O
coactivator,B,O
BOB,I,B
.,I,O
1,I,I
/,I,I
OBF,I,I
.,I,I
1,I,I
in,O,O
T,O,O
cells,O,O
[,O,O
see,O,O
comments,O,O
],O,O
Upon,O,O
activation,O,O
of,O,O
Jurkat,O,O
T,O,O
cells,O,O
and,O,O
primary,O,O
murine,O,O
thymocytes,O,O
with,O,O
phorbol,O,O
esters,O,O
and,O,O
ionomycin,O,O
",",O,O
BOB,B,B
.,I,I
1,I,I
/,I,I
OBF,I,I
.,I,I
1,I,I
expression,O,O
and,O,O
transactivation,O,O
function,O,O
were,O,O
induced,O,O
.,O,O
Mutation,O,O
of,O,O
Ser184,O,O
also,O,O
diminished,O,O
transactivation,O,O
function,O,O
in,O,O
B,O,O
cells,O,O
",",O,O
suggesting,O,O
that,O,O
the,O,O
activating,O,O
phosphorylation,O,O
that,O,O
is,O,O
inducible,O,O
in,O,O
T,O,O
cells,O,O
is,O,O
constitutively,O,O
present,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
In,O,O
fact,O,O
",",O,O
the,O,O
offspring,O,O
of,O,O
alcoholics,O,O
have,O,O
higher,O,O
levels,O,O
of,O,O
G,B,B
(,I,I
S,I,I
),I,I
alpha,I,I
expression,O,O
in,O,O
certain,O,O
tissues,O,O
compared,O,O
with,O,O
the,O,O
offspring,O,O
of,O,O
nonalcoholics,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
research,O,O
was,O,O
to,O,O
test,O,O
the,O,O
hypothesis,O,O
that,O,O
a,O,O
causal,O,O
relationship,O,O
exists,O,O
between,O,O
the,O,O
level,O,O
of,O,O
expression,O,O
of,O,O
G,B,B
(,I,I
S,I,I
),I,I
alpha,I,I
and,O,O
induction,O,O
of,O,O
the,O,O
adenylyl,B,B
cyclase,I,I
(,O,I
AC,O,I
),O,I
cascade,O,I
.,O,O
The,O,O
methodology,O,O
employed,O,O
transient,O,O
transfection,O,O
of,O,O
HEK,O,B
293,O,I
cells,O,O
with,O,O
a,O,O
cDNA,O,B
for,O,O
the,O,O
52,O,O
-,O,O
kDa,O,O
form,O,O
of,O,O
G,B,B
(,I,O
S,I,I
),I,O
alpha,I,O
under,O,O
regulation,O,O
by,O,O
inducible,B,O
metallothionein,I,O
promoters,I,O
.,O,O
VSMCs,O,O
derived,O,O
from,O,O
human,O,O
coronary,O,O
atherosclerotic,O,O
plaques,O,O
that,O,O
apoptose,O,O
even,O,O
in,O,O
serum,O,O
also,O,O
generated,O,O
thrombin,B,O
(,O,O
AUC,O,O
of,O,O
260,O,O
+,O,O
/,O,O
-,O,O
2,O,O
nmol,O,O
x,O,O
min,O,O
/,O,O
L,O,O
;,O,O
PT,O,O
of,O,O
128,O,O
+,O,O
/,O,O
-,O,O
4,O,O
nmol,O,O
/,O,O
L,O,O
.,O,O
Patients,O,O
with,O,O
one,O,O
type,O,O
of,O,O
major,B,O
histocompatibility,I,O
complex,I,O
class,I,O
II,I,O
combined,O,O
immunodeficiency,O,O
have,O,O
mutations,O,O
in,O,O
a,O,O
gene,O,O
termed,O,O
class,B,O
II,I,O
transactivator,I,O
(,O,O
CIITA,B,B
),O,O
",",O,O
which,O,O
coordinately,O,O
controls,O,O
the,O,O
transcription,O,O
of,O,O
the,O,O
three,O,O
major,O,O
human,B,O
class,I,O
II,I,O
genes,I,O
",",O,O
HLA,B,B
-,I,I
DR,I,I
",",I,O
-,I,O
DQ,I,B
",",I,O
and,I,O
-,I,O
DP,I,B
.,O,O
We,O,O
report,O,O
here,O,O
that,O,O
ectopic,O,O
expression,O,O
of,O,O
CIITA,B,B
cDNAs,I,O
derived,O,O
by,O,O
reverse,O,O
transcriptase,O,O
polymerase,O,O
chain,O,O
reaction,O,O
from,O,O
clone,O,O
13,O,O
do,O,O
not,O,O
restore,O,O
expression,O,O
of,O,O
HLA,B,B
-,I,I
DQ,I,I
in,O,O
another,O,O
CIITA,O,O
-,O,O
deficient,O,O
cell,O,O
line,O,O
",",O,O
RJ2,O,O
.,O,O
2,O,O
.,O,O
5,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
somatic,O,O
cell,O,O
fusion,O,O
between,O,O
clone,O,O
13,O,O
and,O,O
RJ2,O,O
.,O,O
2,O,O
.,O,O
5,O,O
restored,O,O
expression,O,O
of,O,O
the,O,O
HLA,B,B
-,I,I
DQ,I,I
haplotype,O,I
encoded,O,O
by,O,O
the,O,O
RJ2,B,O
.,I,O
2,I,O
.,I,O
5,I,O
DQB,I,B
gene,I,O
.,O,O
The,O,O
cytokines,B,O
interleukin,B,B
(,I,O
IL,I,I
),I,O
-,I,O
4,I,O
and,O,O
IL,B,B
-,I,O
13,I,O
play,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
inducing,O,O
Cepsilon,B,O
germline,I,O
transcripts,I,O
and,O,O
IgE,B,O
isotype,I,O
switching,O,O
in,O,O
human,O,B
B,O,I
cells,O,O
.,O,O
We,O,O
show,O,O
that,O,O
ligand,O,O
-,O,O
induced,O,O
homodimerization,O,O
of,O,O
chimeric,B,O
surface,I,O
receptors,I,O
consisting,O,O
of,O,O
the,O,O
extracellular,B,O
and,I,O
transmembrane,I,O
domains,I,O
of,O,O
the,O,O
erythropoietin,B,B
receptor,I,I
and,O,O
of,O,O
the,O,O
intracellular,B,O
domain,I,O
of,O,O
IL,B,B
-,I,I
4Ralpha,I,I
induces,O,O
Janus,B,O
kinase,I,O
1,I,O
(,O,O
Jak1,B,O
),O,O
activation,O,O
",",O,O
STAT6,B,O
activation,O,O
",",O,O
and,O,O
Cepsilon,B,O
germline,I,O
transcripts,I,O
in,O,O
human,O,O
B,O,O
cell,O,O
line,O,O
BJAB,O,O
.,O,O
Characterization,O,O
of,O,O
peripheral,O,O
blood,O,O
T,O,O
-,O,O
lymphocytes,O,O
transduced,O,O
with,O,O
HTLV,B,O
-,I,O
I,I,O
Tax,I,O
mutants,I,O
with,O,O
different,O,O
trans,O,O
-,O,O
activating,O,O
phenotypes,O,O
.,O,O
Analysis,O,O
of,O,O
these,O,O
PBLs,O,O
revealed,O,O
that,O,O
activation,O,O
of,O,O
the,O,O
NF,B,O
-,I,O
kappaB,I,O
pathway,O,O
is,O,O
sufficient,O,O
to,O,O
promote,O,O
the,O,O
growth,O,O
response,O,O
to,O,O
IL,B,B
-,I,I
2,I,I
.,O,O
Some,O,O
of,O,O
the,O,O
most,O,O
potent,O,O
antiinflammatory,O,O
and,O,O
immunosuppressive,O,O
agents,O,O
are,O,O
synthetic,O,O
glucocorticoids,O,O
.,O,O
The,O,O
development,O,O
of,O,O
improved,O,O
glucocorticoid,O,B
-,O,I
based,O,I
drugs,O,O
will,O,O
require,O,O
the,O,O
separation,O,O
of,O,O
beneficial,O,O
from,O,O
deleterious,O,O
effects,O,O
.,O,O
One,O,O
possibility,O,O
toward,O,O
this,O,O
goal,O,O
is,O,O
to,O,O
try,O,O
to,O,O
dissociate,O,O
two,O,O
main,O,O
activities,O,O
of,O,O
glucocorticoids,O,B
",",O,O
i,O,O
.,O,O
e,O,O
.,O,O
transactivation,O,O
and,O,O
transrepression,O,O
.,O,O
To,O,O
understand,O,O
the,O,O
molecular,O,O
mechanisms,O,O
controlling,O,O
CD19,B,B
gene,O,I
expression,O,O
",",O,O
we,O,O
isolated,O,O
and,O,O
functionally,O,O
characterized,O,O
the,O,O
CD19,B,B
promoter,I,O
using,O,O
in,O,O
vivo,O,O
footprinting,O,O
",",O,O
gel,O,O
shift,O,O
assays,O,O
",",O,O
and,O,O
transfection,O,O
studies,O,O
.,O,O
EBF,B,B
and,O,O
E47,B,B
collaborate,O,O
to,O,O
induce,O,O
expression,O,O
of,O,O
the,O,O
endogenous,B,O
immunoglobulin,I,O
surrogate,I,O
light,I,O
chain,I,O
genes,I,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
data,O,O
suggest,O,O
that,O,O
EBF,B,B
and,O,O
E47,B,B
synergize,O,O
to,O,O
activate,O,O
expression,O,O
of,O,O
a,O,O
subset,O,O
of,O,O
genes,O,O
that,O,O
define,O,O
an,O,O
early,O,O
stage,O,O
of,O,O
the,O,O
B,O,B
cell,O,I
lineage,O,O
.,O,O
Treatment,O,O
of,O,O
cells,O,O
expressing,O,O
the,O,O
chimeric,B,O
receptor,I,O
kit,B,O
/,I,O
IL,I,B
-,I,I
4R,I,I
alpha,I,I
with,O,O
SCF,B,O
induces,O,O
activation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
4R,I,I
alpha,I,I
-,I,I
associated,I,I
kinase,I,I
JAK,B,I
-,I,I
1,I,I
and,O,O
the,O,O
transcription,B,O
factor,I,O
STAT6,B,B
.,O,O
Dose,O,O
-,O,O
dependence,O,O
studies,O,O
using,O,O
histamine,O,B
and,O,O
dimaprit,O,O
showed,O,O
that,O,O
the,O,O
EC50,O,O
values,O,O
for,O,O
cAMP,O,B
production,O,O
and,O,O
c,B,O
-,I,O
fos,I,O
increase,O,O
were,O,O
similar,O,O
",",O,O
suggesting,O,O
that,O,O
cAMP,O,B
might,O,O
be,O,O
involved,O,O
in,O,O
c,B,O
-,I,O
fos,I,O
induction,O,O
via,O,O
H2,B,O
receptors,I,O
.,O,O
BACKGROUND,O,O
:,O,O
Activated,O,O
platelets,O,O
tether,O,O
and,O,O
activate,O,O
myeloid,O,B
leukocytes,O,I
.,O,O
Throughout,O,O
the,O,O
study,O,O
period,O,O
",",O,O
CD41,O,B
immunofluorescence,O,O
of,O,O
leukocytes,O,O
(,O,O
flow,O,O
cytometry,O,O
),O,O
revealed,O,O
increased,O,O
leukocyte,O,O
-,O,O
platelet,O,O
adhesion,O,O
in,O,O
patients,O,O
with,O,O
AMI,O,O
compared,O,O
with,O,O
control,O,O
patients,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SE,O,O
of,O,O
fluorescence,O,O
[,O,O
channels,O,O
],O,O
before,O,O
PTCA,O,O
:,O,O
77,O,O
+,O,O
/,O,O
-,O,O
16,O,O
versus,O,O
35,O,O
+,O,O
/,O,O
-,O,O
9,O,O
;,O,O
P,O,O
.,O,O
),O,O
.,O,O
After,O,O
4,O,O
hours,O,O
",",O,O
IL,B,B
-,I,I
1,I,I
beta,I,I
and,O,O
IL,B,B
-,I,I
8,I,I
concentration,O,O
of,O,O
the,O,O
cell,O,O
-,O,O
free,O,O
supernatant,O,O
had,O,O
increased,O,O
by,O,O
268,O,O
+,O,O
/,O,O
-,O,O
36,O,O
%,O,O
and,O,O
210,O,O
+,O,O
/,O,O
-,O,O
7,O,O
%,O,O
",",O,O
respectively,O,O
and,O,O
cellular,O,O
MCP,B,B
-,I,I
1,I,I
content,O,O
had,O,O
increased,O,O
by,O,O
170,O,O
+,O,O
/,O,O
-,O,O
8,O,O
%,O,O
.,O,O
The,O,O
present,O,O
work,O,O
shows,O,O
that,O,O
the,O,O
primary,O,O
CD8,O,B
+,O,I
CTL,O,I
response,O,O
to,O,O
EBV,O,O
in,O,O
infectious,O,O
mononucleosis,O,O
patients,O,O
contains,O,O
multiple,O,O
lytic,O,O
antigen,O,O
-,O,O
specific,O,O
reactivities,O,O
at,O,O
levels,O,O
at,O,O
least,O,O
as,O,O
high,O,O
as,O,O
those,O,O
seen,O,O
against,O,O
latent,B,O
antigens,I,O
;,O,O
similar,O,O
reactivities,O,O
are,O,O
also,O,O
detectable,O,O
in,O,O
CTL,O,O
memory,O,O
.,O,O
Clonal,O,O
analysis,O,O
revealed,O,O
individual,O,O
responses,O,O
to,O,O
the,O,O
two,O,O
immediate,B,O
early,I,O
proteins,I,O
BZLF1,B,B
and,O,O
BRLF1,B,B
",",O,O
and,O,O
to,O,O
three,O,O
(,O,O
BMLF1,B,B
",",O,O
BMRF1,B,B
",",O,O
and,O,O
BALF2,B,B
),O,O
of,O,O
the,O,O
six,O,O
early,B,O
proteins,I,O
tested,O,O
.,O,O
The,O,O
unique,O,O
capacity,O,O
of,O,O
gamma,O,O
-,O,O
herpesvirus,O,O
to,O,O
amplify,O,O
the,O,O
viral,O,O
load,O,O
in,O,O
vivo,O,O
through,O,O
a,O,O
latent,O,O
growth,O,O
-,O,O
transforming,O,O
infection,O,O
may,O,O
have,O,O
rendered,O,O
these,O,O
agents,O,O
less,O,O
dependent,O,O
upon,O,O
viral,O,O
replication,O,O
as,O,O
a,O,O
means,O,O
of,O,O
successfully,O,O
colonizing,O,O
their,O,O
hosts,O,O
.,O,O
Triggering,O,O
of,O,O
HLA,B,B
class,I,I
II,I,I
antigens,I,I
by,O,O
the,O,O
anti,B,O
-,I,O
HLA,I,B
-,I,I
DR,I,I
monoclonal,I,O
antibody,I,O
(,I,O
mAb,I,O
),I,O
L243,I,O
significantly,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
differentially,O,O
enhanced,O,O
the,O,O
release,O,O
of,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
(,O,O
TNF,B,B
-,I,I
alpha,I,I
),O,O
by,O,O
the,O,O
non,O,O
-,O,O
Hodgkin,O,O
s,O,O
lymphoma,O,O
cells,O,O
Ri,O,O
-,O,O
I,O,O
",",O,O
Ci,O,O
-,O,O
I,O,O
",",O,O
and,O,O
Sc,O,O
-,O,O
I,O,O
",",O,O
which,O,O
are,O,O
at,O,O
a,O,O
distinct,O,O
stage,O,O
of,O,O
B,O,B
-,O,I
cell,O,I
differentiation,O,I
",",O,O
and,O,O
by,O,O
the,O,O
more,O,O
mature,O,O
Burkitt,O,O
lymphoma,O,O
cell,O,O
Raji,O,O
;,O,O
in,O,O
contrast,O,O
",",O,O
it,O,O
did,O,O
not,O,O
induce,O,O
TNF,B,B
-,I,I
alpha,I,I
release,O,O
by,O,O
the,O,O
pre,O,O
-,O,O
B,O,B
leukemia,O,I
cells,O,I
Nalm,O,I
-,O,I
6,O,I
and,O,O
BV173,O,O
.,O,O
Altogether,O,O
",",O,O
our,O,O
data,O,O
demonstrate,O,O
that,O,O
:,O,O
(,O,O
a,O,O
),O,O
the,O,O
ability,O,O
of,O,O
B,O,B
cells,O,I
to,O,O
release,O,O
TNF,B,B
-,I,I
alpha,I,I
after,O,O
triggering,O,O
of,O,O
HLA,B,B
-,I,I
DR,I,I
antigens,I,I
depends,O,O
on,O,O
their,O,O
stage,O,O
of,O,O
differentiation,O,O
;,O,O
(,O,O
b,O,O
),O,O
levels,O,O
of,O,O
released,O,O
TNF,B,B
-,I,I
alpha,I,I
seem,O,O
to,O,O
correlate,O,O
with,O,O
the,O,O
stage,O,O
of,O,O
B,O,B
-,O,I
cell,O,I
maturation,O,I
but,O,O
do,O,O
not,O,O
correlate,O,O
with,O,O
the,O,O
amounts,O,O
of,O,O
cell,B,O
surface,I,O
HLA,I,B
-,I,I
DR,I,I
antigens,I,I
;,O,O
(,O,O
c,O,O
),O,O
secreted,O,O
TNF,B,B
-,I,I
alpha,I,I
regulates,O,O
the,O,O
levels,O,O
of,O,O
expression,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
by,O,O
an,O,O
autocrine,O,O
loop,O,O
;,O,O
and,O,O
(,O,O
d,O,O
),O,O
intracellular,O,O
signals,O,O
mediating,O,O
TNF,B,B
-,I,I
alpha,I,I
release,O,O
by,O,O
B,O,B
cells,O,I
are,O,O
distinct,O,O
from,O,O
those,O,O
regulating,O,O
homotypic,O,O
aggregation,O,O
and,O,O
proliferation,O,O
.,O,O
To,O,O
identify,O,O
genes,O,O
that,O,O
are,O,O
expressed,O,O
in,O,O
T,O,B
cells,O,I
after,O,O
stimulation,O,O
",",O,O
mRNA,O,O
from,O,O
T,O,B
lymphocytes,O,I
that,O,O
had,O,O
been,O,O
activated,O,O
by,O,O
the,O,O
simultaneous,O,O
stimulation,O,O
of,O,O
the,O,O
CD3,B,B
and,O,O
CD28,B,B
trigger,O,O
molecules,O,O
was,O,O
transcribed,O,O
for,O,O
a,O,O
differential,O,O
mRNA,O,O
display,O,O
analysis,O,O
into,O,O
cDNA,O,O
and,O,O
was,O,O
compared,O,O
with,O,O
cDNA,O,O
from,O,O
CD28,B,B
-,O,O
or,O,O
CD3,B,B
-,O,O
activated,O,O
or,O,O
resting,O,O
lymphocytes,O,O
.,O,O
The,O,O
predictive,B,O
protein,I,B
-,I,I
coding,I,I
region,I,I
of,O,O
RP1,B,O
had,O,O
a,O,O
significant,O,O
homology,O,O
to,O,O
members,O,O
of,O,O
the,O,O
recently,O,O
found,O,O
adenomatous,B,O
polyposis,I,O
coli,I,O
(,I,O
APC,I,O
),I,O
protein,I,B
-,I,I
binding,I,I
EB1,I,O
gene,I,O
family,I,O
",",O,O
which,O,O
codes,O,O
for,O,O
yet,O,O
unknown,O,O
protein,O,B
(,O,O
s,O,O
),O,O
.,O,O
Bacterially,O,O
expressed,O,O
RP1,B,O
protein,I,B
revealed,O,O
specific,O,O
binding,O,O
to,O,O
wild,B,O
-,I,O
type,I,O
but,O,O
not,O,O
to,O,O
mutated,B,O
APC,I,O
protein,I,B
.,O,O
Cyclosporin,O,B
A,O,I
interferes,O,O
with,O,O
the,O,O
inducible,O,O
degradation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
inhibitors,O,O
",",O,O
but,O,O
not,O,O
with,O,O
the,O,O
processing,O,O
of,O,O
p105,O,B
/,O,I
NF,B,B
-,I,I
kappa,I,I
B1,I,I
in,O,O
T,O,O
cells,O,O
.,O,O
We,O,O
show,O,O
for,O,O
human,O,O
Jurkat,O,O
T,O,O
leukemia,O,O
cells,O,O
",",O,O
as,O,O
well,O,O
as,O,O
human,O,O
and,O,O
mouse,O,O
primary,O,O
T,O,O
lymphocytes,O,O
",",O,O
that,O,O
this,O,O
inhibitory,O,O
effect,O,O
is,O,O
accompanied,O,O
by,O,O
an,O,O
impaired,O,O
nuclear,O,O
translocation,O,O
of,O,O
the,O,O
Rel,B,B
proteins,I,O
c,B,O
-,I,O
Rel,I,O
",",O,O
RelA,B,O
/,I,O
p65,I,O
and,O,O
NF,B,B
-,I,I
kappa,I,I
B1,I,I
/,I,I
p50,I,I
",",O,O
whereas,O,O
the,O,O
nuclear,O,O
appearance,O,O
of,O,O
RelB,B,B
remains,O,O
unaffected,O,O
.,O,O
Accordingly,O,O
",",O,O
immunoblot,O,O
experiments,O,O
showed,O,O
that,O,O
amongst,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,B,I
Rel,I,I
proteins,I,I
",",O,O
RelA,B,B
and,O,O
p50,B,B
are,O,O
mobilized,O,O
to,O,O
the,O,O
nucleus,O,O
following,O,O
microglial,O,B
cell,O,I
stimulation,O,O
with,O,O
A,O,O
beta,O,O
(,O,O
25,O,O
-,O,O
35,O,O
),O,O
plus,O,O
IFN,B,B
gamma,I,I
.,O,O
Higher,O,O
concentrations,O,O
of,O,O
A,O,O
beta,O,O
(,O,O
25,O,O
-,O,O
35,O,O
),O,O
were,O,O
effective,O,O
by,O,O
themselves,O,O
in,O,O
inducing,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
",",O,O
both,O,O
in,O,O
the,O,O
N9,O,B
microglial,O,I
cell,O,I
line,O,I
and,O,O
in,O,O
rat,O,O
primary,O,O
microglia,O,B
",",O,O
as,O,O
well,O,O
as,O,O
in,O,O
human,O,O
monocytes,O,B
.,O,O
For,O,O
purposes,O,O
of,O,O
comparison,O,O
",",O,O
microglia,O,O
were,O,O
also,O,O
stimulated,O,O
with,O,O
bacterial,O,O
LPS,O,O
",",O,O
a,O,O
known,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
inducer,O,O
.,O,O
As,O,O
expected,O,O
",",O,O
LPS,O,O
strongly,O,O
induced,O,O
the,O,O
formation,O,O
of,O,O
two,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
DNA,O,B
-,O,I
binding,O,I
activities,O,I
",",O,O
one,O,O
of,O,O
which,O,O
was,O,O
identified,O,O
as,O,O
RelA,B,B
/,I,I
p50,I,I
.,O,O
Collectively,O,O
",",O,O
these,O,O
findings,O,O
indicate,O,O
that,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
might,O,O
constitute,O,O
one,O,O
of,O,O
the,O,O
mechanisms,O,O
underlying,O,O
the,O,O
inducible,O,O
expression,O,O
of,O,O
kappa,B,B
B,I,I
-,I,I
dependent,I,I
genes,I,I
in,O,O
microglia,O,O
stimulated,O,O
by,O,O
A,O,O
beta,O,O
peptides,O,O
and,O,O
IFN,B,O
gamma,I,O
",",O,O
or,O,O
by,O,O
LPS,O,O
.,O,O
The,O,O
persistence,O,O
of,O,O
TGF,O,B
-,O,I
beta1,O,I
-,O,I
transcribing,O,O
macrophages,O,O
",",O,O
despite,O,O
paralysis,O,O
of,O,O
T,O,O
cell,O,O
function,O,O
",",O,O
may,O,O
provide,O,O
an,O,O
explanation,O,O
for,O,O
the,O,O
chronicity,O,O
of,O,O
the,O,O
disease,O,O
",",O,O
and,O,O
may,O,O
identify,O,O
a,O,O
novel,O,O
therapeutic,O,O
target,O,O
in,O,O
this,O,O
inflammatory,O,O
vasculopathy,O,O
.,O,O
We,O,O
have,O,O
generated,O,O
transgenic,O,O
mice,O,O
that,O,O
express,O,O
a,O,O
catalytically,B,O
inactive,I,O
form,I,O
of,O,O
Ca2,B,B
+,I,I
/,I,I
calmodulin,I,I
-,I,I
dependent,I,I
protein,I,I
kinase,I,I
IV,I,I
(,O,O
CaMKIV,B,O
),O,O
specifically,O,O
in,O,O
thymic,O,O
T,O,O
cells,O,O
.,O,O
We,O,O
isolated,O,O
a,O,O
new,O,O
mouse,B,B
gene,I,I
that,O,O
is,O,O
highly,O,O
expressed,O,O
in,O,O
thymocytes,O,O
",",O,O
testis,O,O
",",O,O
and,O,O
brain,O,O
.,O,O
Rabbit,O,O
antiserum,O,O
raised,O,O
against,O,O
a,O,O
COOH,O,O
-,O,O
terminal,O,O
polypeptide,O,O
of,O,O
the,O,O
recognized,O,O
a,O,O
protein,O,O
with,O,O
an,O,O
apparent,O,O
molecular,O,O
mass,O,O
of,O,O
155,O,O
kD,O,O
.,O,O
The,O,O
serum,O,O
also,O,O
detected,O,O
a,O,O
170,B,O
-,I,O
kD,I,O
protein,I,O
that,O,O
seems,O,O
to,O,O
be,O,O
a,O,O
mouse,O,B
homologue,O,O
of,O,O
human,B,O
BAF170,I,O
.,O,O
Transcriptional,O,O
induction,O,O
of,O,O
collagenase,B,B
-,I,I
1,I,I
in,O,O
differentiated,O,O
monocyte,O,B
-,O,I
like,O,I
(,O,O
U937,O,O
),O,O
cells,O,O
is,O,O
regulated,O,O
by,O,O
AP,B,O
-,I,O
1,I,O
and,O,O
an,O,O
upstream,B,O
C,I,B
/,I,I
EBP,I,I
-,I,I
beta,I,I
site,I,O
.,O,O
Chloramphenicol,B,O
acetyltransferase,I,O
expression,I,O
constructs,I,O
containing,O,O
regions,O,O
of,O,O
the,O,O
human,B,O
collagenase,I,B
-,I,I
1,I,I
promoter,I,O
were,O,O
stably,O,O
or,O,O
transiently,O,O
transfected,O,O
into,O,O
U937,O,O
cells,O,O
",",O,O
and,O,O
reporter,O,O
activity,O,O
was,O,O
assessed,O,O
at,O,O
various,O,O
times,O,O
after,O,O
the,O,O
onset,O,O
of,O,O
phorbol,O,O
12,O,O
-,O,O
myristate,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
-,O,O
mediated,O,O
differentiation,O,O
.,O,O
In,O,O
particular,O,O
",",O,O
Western,O,O
",",O,O
supershift,O,O
",",O,O
and,O,O
promoter,O,O
deletion,O,O
analyses,O,O
suggested,O,O
a,O,O
role,O,O
for,O,O
CCAAT,B,O
/,I,O
enhancer,I,O
-,I,O
binding,I,O
protein,I,B
-,I,I
beta,I,I
(,I,O
C,I,O
/,I,O
EBP,I,O
-,I,O
beta,I,O
),I,O
binding,I,O
site,I,O
between,O,O
-,B,O
2010,I,O
and,I,O
-,I,O
1954,I,O
in,O,O
regulating,O,O
transcription,O,O
of,O,O
collagenase,B,O
-,I,O
1,I,O
in,O,O
monocytic,O,O
cells,O,O
.,O,O
It,O,O
has,O,O
been,O,O
recently,O,O
claimed,O,O
that,O,O
polymorphism,O,O
for,O,O
the,O,O
vitamin,B,B
D,I,I
receptor,I,I
(,O,O
VDR,B,O
),O,O
influences,O,O
several,O,O
aspects,O,O
of,O,O
calcium,O,O
and,O,O
bone,O,O
metabolism,O,O
.,O,O
To,O,O
evaluate,O,O
the,O,O
physiologic,O,O
plausibility,O,O
of,O,O
these,O,O
claims,O,O
",",O,O
we,O,O
compared,O,O
the,O,O
abundance,O,O
of,O,O
the,O,O
VDR,B,B
mRNA,I,I
in,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
(,O,O
PBMCs,O,O
),O,O
between,O,O
different,O,O
VDR,B,B
genotypes,I,O
using,O,O
a,O,O
quantitative,O,O
reverse,O,O
transcribed,O,O
polymerase,O,O
chain,O,O
reaction,O,O
-,O,O
based,O,O
method,O,O
.,O,O
The,O,O
concentration,O,O
of,O,O
the,O,O
VDR,B,B
mRNA,I,I
",",O,O
corrected,O,O
for,O,O
the,O,O
number,O,O
of,O,O
monocytes,O,O
",",O,O
was,O,O
similar,O,O
among,O,O
the,O,O
three,O,O
genotype,O,O
groups,O,O
",",O,O
as,O,O
were,O,O
the,O,O
other,O,O
variables,O,O
examined,O,O
:,O,O
serum,B,O
calcitriol,I,O
",",O,O
serum,B,O
osteocalcin,I,O
",",O,O
and,O,O
vertebral,O,O
and,O,O
hip,O,O
bone,O,O
density,O,O
.,O,O
Both,O,O
truncated,O,O
forms,O,O
also,O,O
bound,O,O
to,O,O
the,O,O
transcription,B,O
factor,I,O
RBP,I,B
-,I,I
Jkappa,I,I
in,O,O
extracts,O,O
prepared,O,O
from,O,O
human,O,O
and,O,O
murine,O,O
T,O,B
-,O,I
ALL,O,I
cell,O,O
lines,O,O
.,O,O
Unexpectedly,O,O
",",O,O
a,O,O
second,O,O
",",O,O
stronger,O,O
RBP,B,B
-,I,I
Jkappa,I,I
-,I,I
binding,I,I
site,I,I
",",O,O
which,O,O
lies,O,O
within,O,O
the,O,O
intracellular,B,O
domain,I,O
close,O,O
to,O,O
the,O,O
transmembrane,O,O
region,O,O
and,O,O
significantly,O,O
augments,O,O
association,O,O
with,O,O
RBP,B,B
-,I,I
Jkappa,I,I
",",O,O
was,O,O
not,O,O
needed,O,O
for,O,O
oncogenesis,O,O
or,O,O
for,O,O
transcriptional,O,O
activation,O,O
.,O,O
In,O,O
support,O,O
of,O,O
this,O,O
interpretation,O,O
",",O,O
mutation,O,O
of,O,O
putative,O,O
nuclear,B,B
localization,I,I
sequences,I,I
decreased,O,O
nuclear,O,B
localization,O,I
and,O,O
increased,O,O
transcriptional,O,O
activation,O,O
by,O,O
membrane,B,O
-,I,O
bound,I,O
DeltaE,I,O
.,O,O
These,O,O
studies,O,O
have,O,O
indicated,O,O
that,O,O
the,O,O
individual,O,O
repeats,O,O
are,O,O
not,O,O
identical,O,O
with,O,O
respect,O,O
to,O,O
the,O,O
cellular,B,O
factors,I,O
with,O,O
which,O,O
they,O,O
interact,O,O
.,O,O
EMS,O,O
analyses,O,O
utilizing,O,O
a,O,O
series,O,O
of,O,O
mutated,B,O
pp,I,B
repeat,I,I
elements,I,I
demonstrate,O,O
that,O,O
the,O,O
nucleotide,O,O
sequence,O,O
requirements,O,O
for,O,O
U1,B,B
(,O,O
U1A,B,I
/,I,I
U1B,I,I
),O,O
and,O,O
U2,B,B
formation,O,O
are,O,O
separable,O,O
from,O,O
those,O,O
required,O,O
for,O,O
C1,B,B
-,I,I
C3,I,I
formation,O,O
.,O,O
EMS,O,O
supershift,O,O
analyses,O,O
have,O,O
demonstrated,O,O
that,O,O
Sp1,B,B
is,O,O
involved,O,O
in,O,O
U1A,O,I
formation,O,O
while,O,O
Sp3,B,B
is,O,O
involved,O,O
in,O,O
U1B,O,I
and,O,O
U2,O,B
formation,O,O
.,O,O
In,O,O
the,O,O
adult,O,O
bone,O,O
marrow,O,O
",",O,O
we,O,O
found,O,O
expression,O,O
of,O,O
runt,O,B
polypeptides,O,I
in,O,O
differentiating,O,O
myeloid,O,B
cells,O,I
and,O,O
in,O,O
B,O,B
lymphocytes,O,I
.,O,O
Signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
-,I,O
3,I,B
(,O,O
STAT3,B,O
),O,O
is,O,O
constitutively,O,O
activated,O,O
in,O,O
normal,O,O
",",O,O
self,O,O
-,O,O
renewing,O,O
B,O,B
-,O,I
1,O,I
cells,O,I
but,O,O
only,O,O
inducibly,O,O
expressed,O,O
in,O,O
conventional,O,O
B,O,B
lymphocytes,O,I
[,O,O
see,O,O
comments,O,O
],O,O
Cytokine,B,O
and,O,O
growth,B,O
factor,I,O
receptor,I,O
engagement,O,O
leads,O,O
to,O,O
the,O,O
rapid,O,O
phosphorylation,O,O
and,O,O
activation,O,O
of,O,O
latent,O,O
",",O,O
cytosolic,B,O
signal,I,O
transducers,I,O
activators,I,O
of,I,O
transcription,I,O
(,I,O
STAT,I,B
),I,O
proteins,I,O
",",O,O
which,O,O
then,O,O
translocate,O,O
to,O,O
the,O,O
nucleus,O,O
where,O,O
they,O,O
regulate,O,O
transcriptional,O,O
events,O,O
from,O,O
specific,B,O
promoter,I,O
sequences,I,O
.,O,O
B,O,B
-,O,O
lymphocytes,O,O
are,O,O
self,O,O
-,O,O
renewing,O,O
",",O,O
CD5,O,B
+,O,I
B,O,I
cells,O,I
that,O,O
display,O,O
a,O,O
propensity,O,O
for,O,O
malignant,O,O
transformation,O,O
and,O,O
are,O,O
the,O,O
normal,O,O
counterpart,O,O
to,O,O
human,O,O
chronic,O,O
lymphocytic,O,O
leukemias,O,O
.,O,O
Further,O,O
",",O,O
B,O,B
-,O,I
1,O,I
cells,O,I
are,O,O
characterized,O,O
by,O,O
aberrant,O,O
intracellular,O,O
signaling,O,O
",",O,O
including,O,O
hyperresponsiveness,O,O
to,O,O
phorbol,O,O
ester,O,O
PKC,O,B
agonists,O,O
.,O,O
Induction,O,O
of,O,O
STAT3,B,B
is,O,O
inhibited,O,O
by,O,O
both,O,O
the,O,O
serine,O,B
/,O,I
threonine,O,I
protein,O,I
kinase,O,I
inhibitor,O,I
H,O,O
-,O,O
7,O,O
and,O,O
the,O,O
immunosuppressive,O,O
drug,O,O
rapamycin,O,O
and,O,O
requires,O,O
de,O,O
novo,O,O
protein,O,B
synthesis,O,I
",",O,O
demonstrating,O,O
novel,O,O
coupling,O,O
between,O,O
sIg,B,O
and,O,O
STAT,B,B
proteins,I,I
that,O,O
differs,O,O
from,O,O
the,O,O
classical,O,O
paradigm,O,O
for,O,O
STAT,B,B
induction,O,O
by,O,O
cytokine,B,O
receptors,I,O
.,O,O
One,O,O
of,O,O
the,O,O
potential,O,O
advantages,O,O
of,O,O
autologous,O,O
PBSCT,O,O
is,O,O
the,O,O
possibility,O,O
that,O,O
peripheral,O,B
blood,O,I
stem,O,I
cells,O,I
(,O,O
PBSC,O,O
),O,O
are,O,O
less,O,O
likely,O,O
to,O,O
be,O,O
contaminated,O,O
by,O,O
leukemic,O,O
cells,O,O
than,O,O
bone,O,B
marrow,O,I
grafts,O,I
.,O,O
This,O,O
effect,O,O
was,O,O
specifically,O,O
due,O,O
to,O,O
Tat,B,B
",",O,O
since,O,O
Jurkat,O,O
and,O,O
U937,O,O
cells,O,O
cotransfected,O,O
either,O,O
with,O,O
tat,B,O
cDNA,I,O
in,O,O
antisense,O,O
orientation,O,O
(,O,O
tat,B,O
/,I,O
AS,I,O
),O,O
",",O,O
tat,B,O
carrying,O,O
a,O,O
mutation,O,O
in,O,O
the,O,O
aminoacid,B,O
cys22,I,O
-,I,O
gly22,I,O
(,O,O
tat,B,O
22,I,O
/,I,O
S,I,O
),O,O
or,O,O
with,O,O
the,O,O
backbone,B,O
vector,I,O
alone,I,O
(,O,O
pRPneo,B,O
-,I,O
SL3,I,O
),O,O
did,O,O
not,O,O
show,O,O
any,O,O
significant,O,O
difference,O,O
in,O,O
c,B,O
-,I,O
fos,I,O
promoter,I,O
activity,O,O
as,O,O
compared,O,O
to,O,O
cells,O,O
transfected,O,O
with,O,O
FC3,B,O
plasmid,I,O
alone,O,O
.,O,O
c,B,O
-,I,O
Fos,I,B
protein,O,O
was,O,O
shown,O,O
essential,O,O
for,O,O
an,O,O
optimal,O,O
transactivation,O,O
of,O,O
the,O,O
HIV,O,B
-,O,I
1,O,I
long,B,I
terminal,I,I
repeat,I,I
(,O,O
LTR,B,O
),O,O
by,O,O
Tat,B,O
:,O,O
incubation,O,O
of,O,O
Jurkat,O,O
cells,O,O
with,O,O
antisense,O,O
",",O,O
but,O,O
not,O,O
sense,O,O
",",O,O
c,O,B
-,O,I
fos,O,I
oligonucleotides,O,O
significantly,O,O
reduced,O,O
either,O,O
the,O,O
Tat,B,O
-,O,O
enhanced,O,O
expression,O,O
of,O,O
an,O,O
LTR,B,O
-,I,O
CAT,I,O
reporter,I,O
construct,I,O
or,O,O
the,O,O
levels,O,O
of,O,O
gag,B,B
p24,I,I
in,O,O
the,O,O
culture,O,O
supernatants,O,O
of,O,O
Jurkat,O,O
cells,O,O
and,O,O
PBMC,O,O
acutely,O,O
infected,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
Regulation,O,O
of,O,O
the,O,O
tissue,B,O
factor,I,B
gene,I,I
in,O,O
human,O,O
monocytic,O,B
cells,O,I
.,O,O
Role,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
",",O,O
and,O,O
Sp1,B,B
proteins,O,I
in,O,O
uninduced,O,O
and,O,O
lipopolysaccharide,O,O
-,O,O
induced,O,O
expression,O,O
.,O,O
The,O,O
human,B,O
TF,I,B
promoter,I,I
contains,O,O
binding,O,O
sites,O,O
for,O,O
the,O,O
transcription,O,O
factors,O,O
AP,B,B
-,I,I
1,I,I
",",O,O
c,B,B
-,I,I
Rel,I,I
/,I,I
p65,I,I
",",O,O
Egr,B,B
-,I,I
1,I,I
",",O,O
and,O,O
Sp1,B,B
.,O,O
The,O,O
two,O,O
AP,B,B
-,I,I
1,I,I
sites,I,I
bound,O,O
c,B,B
-,I,I
Fos,I,I
/,I,I
c,I,I
-,I,I
Jun,I,I
heterodimers,I,O
in,O,O
both,O,O
unstimulated,O,O
and,O,O
LPS,O,B
-,O,I
stimulated,O,I
cells,O,I
.,O,O
Inhibitory,O,O
effect,O,O
of,O,O
growth,O,B
hormone,O,I
on,O,O
TNF,B,B
-,I,I
alpha,I,I
secretion,O,O
and,O,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
translocation,O,O
in,O,O
lipopolysaccharide,O,O
-,O,O
stimulated,O,O
human,O,O
monocytes,O,O
.,O,O
The,O,O
present,O,O
study,O,O
demonstrates,O,O
that,O,O
human,O,O
THP,O,O
-,O,O
1,O,O
promonocytic,O,O
cells,O,O
",",O,O
engineered,O,O
by,O,O
gene,O,O
transfer,O,O
to,O,O
constitutively,O,O
produce,O,O
human,O,O
growth,O,B
hormone,O,I
(,O,O
hGH,O,O
),O,O
",",O,O
secreted,O,O
depressed,O,O
amounts,O,O
of,O,O
TNF,B,B
-,I,I
alpha,I,I
in,O,O
response,O,O
to,O,O
challenge,O,O
by,O,O
LPS,O,O
.,O,O
Previously,O,O
",",O,O
we,O,O
showed,O,O
that,O,O
fibroblast,O,B
conditioned,O,I
medium,O,I
(,O,O
FCM,O,O
),O,O
is,O,O
able,O,O
to,O,O
inhibit,O,O
both,O,O
TNF,B,B
mRNA,I,I
accumulation,O,I
and,O,O
protein,O,B
release,O,O
in,O,O
peripheral,O,O
blood,O,O
-,O,O
derived,O,O
human,O,O
monocytes,O,O
(,O,O
PBM,O,O
),O,O
stimulated,O,O
with,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
show,O,O
that,O,O
exogenous,O,O
PGE2,O,O
mimics,O,O
the,O,O
NF,B,O
-,I,O
kappaB,I,O
inhibitory,O,O
effect,O,O
of,O,O
FCM,O,O
.,O,O
Two,O,O
main,O,O
pieces,O,O
of,O,O
data,O,O
prompted,O,O
us,O,O
to,O,O
focus,O,O
on,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
platelet,B,B
fibrinogen,I,I
receptor,I,I
",",O,O
the,O,O
alphaIIbbeta3,B,B
integrin,I,I
.,O,O
Immunoblot,O,O
and,O,O
flow,O,O
cytometry,O,O
analysis,O,O
revealed,O,O
a,O,O
limited,O,O
proteolysis,O,O
of,O,O
the,O,O
carboxyl,B,O
terminus,I,O
of,O,O
the,O,O
alphaIIb,B,B
subunit,I,I
heavy,I,I
chain,I,I
(,O,O
alphaIIbH,B,B
),O,O
",",O,O
as,O,O
judged,O,O
by,O,O
the,O,O
disappearance,O,O
of,O,O
the,O,O
epitope,O,O
for,O,O
the,O,O
monoclonal,B,O
antibody,I,O
PMI,I,O
-,I,O
1,I,O
.,O,O
Treatment,O,O
by,O,O
NE,B,O
of,O,O
ATP,O,B
-,O,I
depleted,O,I
platelets,O,I
or,O,O
Chinese,O,B
hamster,O,I
ovary,O,I
cells,O,I
expressing,O,O
human,B,O
recombinant,I,O
alphaIIbbeta3,I,B
clearly,O,O
established,O,O
that,O,O
activation,O,O
of,O,O
the,O,O
integrin,B,O
was,O,O
independent,O,O
of,O,O
signal,O,O
transduction,O,O
events,O,O
and,O,O
was,O,O
concomitant,O,O
with,O,O
the,O,O
proteolysis,O,O
of,O,O
alphaIIbH,B,B
.,O,O
In,O,O
contrast,O,O
",",O,O
LAI,O,O
replicates,O,O
well,O,O
in,O,O
memory,O,B
CD4,O,I
T,O,I
cells,O,I
stimulated,O,O
in,O,O
the,O,O
same,O,O
way,O,O
.,O,O
These,O,O
studies,O,O
were,O,O
conducted,O,O
with,O,O
highly,O,O
purified,O,O
(,O,O
FACS,O,O
-,O,O
isolated,O,O
),O,O
subsets,O,O
of,O,O
CD4,O,B
T,O,I
cells,O,O
identified,O,O
by,O,O
expression,O,O
of,O,O
both,O,O
CD45RA,B,B
and,O,O
CD62L,B,B
.,O,O
The,O,O
suppression,O,O
of,O,O
productive,O,O
LAI,O,O
replication,O,O
in,O,O
naive,O,O
T,O,B
cells,O,O
is,O,O
not,O,O
due,O,O
to,O,O
differential,O,O
expression,O,O
of,O,O
viral,B,O
coreceptors,I,O
",",O,O
nor,O,O
is,O,O
it,O,O
due,O,O
to,O,O
inhibition,O,O
of,O,O
activation,O,O
of,O,O
the,O,O
important,O,O
HIV,O,O
transcription,B,O
factors,I,O
",",O,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
and,O,O
activator,B,O
protein,I,O
-,I,O
1,I,O
.,O,O
To,O,O
test,O,O
the,O,O
hypothesis,O,O
that,O,O
the,O,O
chimera,B,O
PMLRAR,I,B
alpha,I,I
plays,O,O
a,O,O
role,O,O
in,O,O
leukemogenesis,O,O
",",O,O
we,O,O
expressed,O,O
a,O,O
PMLRAR,B,B
alpha,I,I
cDNA,I,O
in,O,O
myeloid,O,B
cells,O,O
of,O,O
transgenic,O,O
mice,O,O
.,O,O
Retinoic,O,O
acid,O,O
caused,O,O
the,O,O
leukemic,O,O
cells,O,O
to,O,O
differentiate,O,O
in,O,O
vitro,O,O
and,O,O
in,O,O
vivo,O,O
",",O,O
eliciting,O,O
remissions,O,O
of,O,O
both,O,O
the,O,O
preleukemic,O,O
state,O,O
and,O,O
APL,O,O
in,O,O
mice,O,O
.,O,O
Our,O,O
results,O,O
demonstrate,O,O
that,O,O
PMLRAR,B,B
alpha,I,I
impairs,O,O
neutrophil,O,B
differentiation,O,O
and,O,O
initiates,O,O
the,O,O
development,O,O
of,O,O
APL,O,O
.,O,O
The,O,O
transgenic,O,O
mice,O,O
described,O,O
here,O,O
provide,O,O
an,O,O
apparently,O,O
accurate,O,O
model,O,O
for,O,O
human,O,O
APL,O,O
that,O,O
includes,O,O
clear,O,O
evidence,O,O
of,O,O
tumor,O,O
progression,O,O
.,O,O
Such,O,O
hypermethylation,O,O
-,O,O
associated,O,O
silencing,O,O
of,O,O
gene,O,O
expression,O,O
has,O,O
been,O,O
shown,O,O
for,O,O
several,O,O
genes,O,O
regulating,O,O
the,O,O
growth,O,O
and,O,O
differentiation,O,O
of,O,O
hematopoietic,O,B
cells,O,I
",",O,O
including,O,O
the,O,O
estrogen,B,B
receptor,I,I
(,I,O
ER,I,O
),I,O
gene,I,O
",",O,O
P15,O,B
",",O,O
P16,O,B
and,O,O
others,O,O
.,O,O
The,O,O
high,O,O
prevalence,O,O
of,O,O
promoter,O,O
methylation,O,B
suggests,O,O
that,O,O
this,O,O
molecular,O,O
abnormality,O,O
can,O,O
be,O,O
used,O,O
to,O,O
monitor,O,O
disease,O,O
activity,O,O
during,O,O
therapy,O,O
.,O,O
Finally,O,O
",",O,O
reactivation,O,O
of,O,O
tumor,O,O
-,O,O
suppressor,O,O
gene,O,O
expression,O,O
through,O,O
pharmacologic,O,O
inhibition,O,O
of,O,O
DNA,B,B
methyltransferase,I,I
and,O,O
resultant,O,O
DNA,O,B
demethylation,O,I
appears,O,O
to,O,O
be,O,O
a,O,O
promising,O,O
new,O,O
avenue,O,O
of,O,O
therapy,O,O
in,O,O
acute,O,O
leukemia,O,O
.,O,O
Redox,O,O
regulation,O,O
of,O,O
the,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,B
kinase,I,I
pathway,O,I
during,O,O
lymphocyte,O,B
activation,O,O
.,O,O
In,O,O
earlier,O,O
studies,O,O
",",O,O
we,O,O
have,O,O
identified,O,O
the,O,O
transcription,B,O
factors,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
as,O,O
molecular,O,O
targets,O,O
for,O,O
oxidative,O,O
signalling,O,O
processes,O,O
during,O,O
cell,O,O
cycle,O,O
entry,O,O
",",O,O
and,O,O
have,O,O
shown,O,O
that,O,O
oxidative,O,O
signalling,O,O
is,O,O
involved,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
early,O,O
changes,O,O
in,O,O
gene,O,O
expression,O,O
during,O,O
the,O,O
G0,O,O
to,O,O
G1,O,O
phase,O,O
transition,O,O
.,O,O
Using,O,O
the,O,O
yeast,O,O
two,O,O
-,O,O
hybrid,O,O
system,O,O
to,O,O
screen,O,O
for,O,O
proteins,O,B
which,O,O
interact,O,O
with,O,O
Tax1,B,O
",",O,O
we,O,O
isolated,O,O
the,O,O
B,B,O
subunit,I,O
of,O,O
the,O,O
CCAAT,B,O
binding,I,O
protein,I,O
NF,B,O
-,I,O
Y,I,O
from,O,O
a,O,O
HeLa,B,O
cDNA,I,O
library,I,O
.,O,O
The,O,O
interaction,O,O
of,O,O
Tax1,B,O
with,O,O
NF,B,O
-,I,O
YB,I,O
was,O,O
specific,O,O
in,O,O
that,O,O
NF,B,O
-,I,O
YB,I,O
did,O,O
not,O,O
interact,O,O
with,O,O
a,O,O
variety,O,O
of,O,O
other,O,O
transcription,B,O
factors,I,O
",",O,O
including,O,O
human,B,O
immunodeficiency,I,O
virus,I,O
Tat,I,O
",",O,O
human,B,O
papillomavirus,I,O
E6,I,O
",",O,O
and,O,O
Bicoid,B,O
",",O,O
or,O,O
with,O,O
the,O,O
M7,B,O
(,I,O
amino,I,O
acids,I,O
29CP,I,O
-,I,O
AS,I,O
),I,O
Tax1,I,O
mutant,I,O
.,O,O
However,O,O
",",O,O
NF,B,B
-,I,I
YB,I,I
did,O,O
interact,O,O
with,O,O
the,O,O
C,B,B
-,I,I
terminal,I,I
Tax1,I,I
mutants,I,O
M22,B,O
(,O,O
130TL,B,O
-,I,O
AS,I,O
),O,O
and,O,O
M47,B,O
(,O,O
319LL,B,O
-,I,O
RS,I,O
),O,O
.,O,O
Through,O,O
activation,O,O
of,O,O
this,O,O
and,O,O
other,O,O
NF,B,B
-,I,I
Y,I,I
driven,O,O
promoters,B,O
",",O,O
the,O,O
Tax1,B,O
-,B,O
NF,I,O
-,I,O
Y,I,O
interaction,O,O
may,O,O
play,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
causing,O,O
cellular,O,O
transformation,O,O
and,O,O
HTLV,O,O
-,O,O
1,O,O
pathogenesis,O,O
.,O,O
In,O,O
murine,O,O
Ba,O,O
/,O,O
F3,O,O
cells,O,O
transfected,O,O
with,O,O
the,O,O
human,B,O
G,I,B
-,I,I
CSFR,I,I
and,O,O
NFS,O,O
-,O,O
60,O,O
cells,O,O
constitutively,O,O
expressing,O,O
the,O,O
murine,B,O
G,I,B
-,I,I
CSFR,I,I
",",O,O
G,B,B
-,I,I
CSF,I,I
induced,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
activation,O,O
of,O,O
Jak1,B,B
",",O,O
Jak2,B,B
",",O,O
and,O,O
Tyk2,B,B
.,O,O
Using,O,O
a,O,O
mitogenically,B,O
incompetent,I,O
human,I,B
G,I,I
-,I,I
CSFR,I,I
mutant,I,O
in,O,O
which,O,O
Pro639,O,B
and,O,O
Pro641,O,B
were,O,O
substituted,O,O
by,O,O
alanine,O,O
",",O,O
the,O,O
box,B,O
1,I,O
PDP,I,O
motif,I,O
was,O,O
found,O,O
to,O,O
be,O,O
required,O,O
for,O,O
activation,O,O
of,O,O
Jak,B,B
kinases,I,O
",",O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
the,O,O
G,B,B
-,I,I
CSFR,I,I
",",O,O
and,O,O
recruitment,O,O
of,O,O
Stat,B,B
proteins,I,O
.,O,O
Activation,O,O
of,O,O
the,O,O
Jak,B,B
-,B,I
Stat,I,I
pathway,O,O
correlates,O,O
with,O,O
proliferative,O,O
signaling,O,O
by,O,O
the,O,O
G,B,B
-,I,I
CSFR,I,I
and,O,O
requires,O,O
the,O,O
membrane,B,O
-,I,O
proximal,I,O
box,I,O
1,I,O
PXP,I,O
motif,I,O
",",O,O
which,O,O
is,O,O
conserved,O,O
in,O,O
members,O,O
of,O,O
the,O,O
cytokine,B,B
receptor,I,I
superfamily,I,I
.,O,O
Impaired,O,O
induction,O,O
of,O,O
c,B,B
-,I,I
fos,I,I
/,I,I
c,I,B
-,I,I
jun,I,I
genes,I,O
and,O,O
of,O,O
transcriptional,B,O
regulatory,I,O
proteins,I,O
binding,O,O
distinct,O,O
c,B,B
-,I,I
fos,I,I
/,I,I
c,I,B
-,I,I
jun,I,I
promoter,I,O
elements,I,O
in,O,O
activated,O,O
human,O,O
T,O,O
cells,O,O
during,O,O
aging,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
RNase,B,O
protection,O,O
assays,O,O
revealed,O,O
that,O,O
anti,O,O
-,O,O
CD3,O,O
/,O,O
PMA,O,O
-,O,O
stimulated,O,O
T,O,O
cells,O,O
from,O,O
a,O,O
substantial,O,O
proportion,O,O
of,O,O
elderly,O,O
subjects,O,O
exhibited,O,O
decreased,O,O
levels,O,O
of,O,O
c,B,B
-,I,I
fos,I,I
and,I,O
/,I,O
or,I,O
c,I,B
-,I,I
jun,I,I
mRNA,I,O
compared,O,O
to,O,O
T,O,O
cells,O,O
from,O,O
young,O,O
subjects,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Retinoic,O,B
acid,O,I
(,O,O
RA,O,O
),O,O
has,O,O
important,O,O
immune,O,O
-,O,O
modulating,O,O
effects,O,O
on,O,O
both,O,O
T,O,O
and,O,O
B,O,O
cell,O,O
function,O,O
.,O,O
CONCLUSION,O,O
:,O,O
These,O,O
studies,O,O
suggest,O,O
that,O,O
RA,O,O
can,O,O
augment,O,O
IL,B,B
-,I,I
2,I,I
mRNA,I,I
production,O,O
by,O,O
T,O,O
cells,O,O
with,O,O
a,O,O
possible,O,O
paracrine,O,O
effect,O,O
on,O,O
IL,B,B
-,I,I
2R,I,I
-,I,I
alpha,I,I
expression,O,O
.,O,O
Interleukin,B,B
-,I,I
6,I,I
levels,O,O
are,O,O
increased,O,O
in,O,O
lung,O,O
transplant,O,O
patients,O,O
clinically,O,O
diagnosed,O,O
with,O,O
CMV,O,O
pneumonitis,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
RelA,B,B
(,I,O
p65,I,I
),I,O
subunit,I,O
was,O,O
barely,O,O
detectable,O,O
in,O,O
monocytes,O,O
",",O,O
but,O,O
its,O,O
level,O,O
increased,O,O
markedly,O,O
in,O,O
MDMs,O,O
.,O,O
In,O,O
MDMs,O,O
",",O,O
an,O,O
upregulation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
synthesis,O,O
as,O,O
well,O,O
as,O,O
the,O,O
appearance,O,O
of,O,O
a,O,O
novel,O,O
M,O,B
(,O,O
r,O,I
),O,O
40,O,I
",",O,I
form,O,I
of,O,I
I,B,I
kappa,I,I
B,I,I
alpha,I,I
were,O,O
also,O,O
observed,O,O
.,O,O
However,O,O
",",O,O
the,O,O
intensity,O,O
of,O,O
p65,B,B
labeling,O,O
was,O,O
much,O,O
higher,O,O
in,O,O
several,O,O
thymocytes,O,O
from,O,O
the,O,O
medulla,O,O
.,O,O
p65,O,B
",",O,O
p50,O,B
",",O,O
and,O,O
c,O,B
-,O,I
Rel,O,I
activities,O,O
were,O,O
found,O,O
in,O,O
both,O,O
CD4,O,O
-,O,O
and,O,O
CD8,O,O
-,O,O
positive,O,O
thymocytes,O,O
.,O,O
These,O,O
observations,O,O
suggest,O,O
that,O,O
p65,B,B
and,I,O
c,I,B
-,I,I
Rel,I,I
complexes,I,O
play,O,O
distinct,O,O
roles,O,O
in,O,O
gene,O,O
expression,O,O
and,O,O
that,O,O
both,O,O
forms,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
play,O,O
critical,O,O
roles,O,O
during,O,O
late,O,O
stages,O,O
of,O,O
the,O,O
intrathymic,O,O
maturation,O,O
of,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
function,O,O
of,O,O
LEF,B,B
-,I,I
1,I,I
is,O,O
dependent,O,O
",",O,O
in,O,O
part,O,O
",",O,O
on,O,O
the,O,O
HMG,B,B
domain,I,I
that,O,O
induces,O,O
a,O,O
sharp,O,O
bend,O,O
in,O,O
the,O,O
DNA,O,B
helix,O,I
",",O,O
and,O,O
on,O,O
an,O,O
activation,B,O
domain,I,O
that,O,O
stimulates,O,O
transcription,O,O
only,O,O
in,O,O
a,O,O
specific,O,O
context,O,O
of,O,O
other,O,O
enhancer,B,O
-,I,O
binding,I,O
proteins,I,O
.,O,O
Overexpression,O,O
of,O,O
ALY,B,B
stimulates,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
TCR,B,B
alpha,I,I
enhancer,I,I
complex,I,I
reconstituted,O,O
in,O,O
transfected,O,O
nonlymphoid,O,O
HeLa,O,O
cells,O,O
",",O,O
whereas,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
ALY,B,B
by,O,O
anti,O,O
-,O,O
sense,O,O
oligonucleotides,O,O
virtually,O,O
eliminates,O,O
TCR,B,B
alpha,I,I
enhancer,I,I
activity,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
AML1,B,B
may,O,O
play,O,O
a,O,O
role,O,O
in,O,O
growth,O,O
and,O,O
differentiation,O,O
of,O,O
cells,O,O
along,O,O
erythroid,O,B
and,O,O
/,O,O
or,O,O
megakaryocytic,O,B
lineages,O,O
",",O,O
because,O,O
a,O,O
significant,O,O
level,O,O
of,O,O
the,O,O
AML1,B,B
gene,O,O
is,O,O
expressed,O,O
in,O,O
these,O,O
cells,O,O
.,O,O
We,O,O
overexpressed,O,O
AML1a,B,B
(,O,O
without,O,O
the,O,O
transcription,B,O
-,I,O
activating,I,O
domain,I,O
),O,O
and,O,O
AML1b,B,B
(,O,O
with,O,O
the,O,O
domain,O,O
),O,O
proteins,O,O
in,O,O
K562,O,O
leukemia,O,O
cells,O,O
",",O,O
which,O,O
can,O,O
be,O,O
induced,O,O
to,O,O
differentiate,O,O
into,O,O
hemoglobin,O,B
-,O,I
producing,O,I
cells,O,O
and,O,O
megakaryocytes,O,B
.,O,O
The,O,O
AML1a,O,B
-,O,I
transfected,O,O
K562,O,O
cells,O,O
had,O,O
a,O,O
reduced,O,O
capacity,O,O
to,O,O
differentiate,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
sodium,O,O
n,O,O
-,O,O
butyrate,O,O
but,O,O
not,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
other,O,O
inducers,O,O
",",O,O
such,O,O
as,O,O
hemin,O,O
",",O,O
1,O,O
-,O,O
beta,O,O
-,O,O
D,O,O
-,O,O
arabinofuranosylcyto,O,O
",",O,O
and,O,O
herbimycin,O,O
A,O,O
.,O,O
We,O,O
have,O,O
cloned,O,O
and,O,O
sequenced,O,O
a,O,O
portion,O,O
of,O,O
the,O,O
ER,B,B
upstream,B,I
regulatory,I,I
region,I,I
from,O,O
the,O,O
ER,O,B
-,O,I
positive,O,I
MCF,O,I
-,O,I
7,O,I
and,O,O
the,O,O
ER,O,B
-,O,I
negative,O,I
MDA,O,I
-,O,I
MB,O,I
-,O,I
231,O,I
breast,O,I
cancer,O,I
cell,O,I
lines,O,I
to,O,O
determine,O,O
if,O,O
sequence,O,O
alterations,O,O
in,O,O
this,O,O
region,O,O
account,O,O
for,O,O
the,O,O
ER,B,B
-,O,I
negative,O,I
phenotype,O,I
of,O,O
some,O,O
tumors,O,O
.,O,O
The,O,O
influence,O,O
of,O,O
the,O,O
anti,O,O
-,O,O
allergy,O,O
agent,O,O
azelastine,O,O
hydrochloride,O,O
(,O,O
Azeptin,O,O
),O,O
on,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
activation,O,O
associated,O,O
with,O,O
the,O,O
generation,O,O
of,O,O
cytokines,B,O
and,O,O
nitric,O,O
oxide,O,O
(,O,O
NO,O,O
),O,O
was,O,O
investigated,O,O
in,O,O
various,O,O
kinds,O,O
of,O,O
human,O,O
and,O,O
mouse,O,O
cells,O,O
.,O,O
In,O,O
parallel,O,O
with,O,O
the,O,O
decreased,O,O
cytokine,B,O
generation,O,O
",",O,O
each,O,O
cytokine,B,O
mRNA,I,O
was,O,O
less,O,O
expressed,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
10,O,O
(,O,O
-,O,O
5,O,O
),O,O
M,O,O
Azeptin,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
both,O,O
inducible,O,O
nitric,B,B
oxide,I,I
synthase,I,I
-,O,I
mRNA,O,I
level,O,I
and,O,O
NO,O,B
generation,O,O
in,O,O
mouse,O,O
peritoneal,O,O
macrophages,O,O
were,O,O
suppressed,O,O
by,O,O
10,O,O
(,O,O
-,O,O
5,O,O
),O,O
M,O,O
Azeptin,O,O
.,O,O
Using,O,O
anti,B,O
-,I,O
C,I,O
/,I,O
EBPbeta,I,O
(,O,O
NF,B,O
-,I,O
IL6,I,O
),O,O
",",O,O
anti,B,O
-,I,O
C,I,O
/,I,O
EBPdelta,I,O
(,O,O
NF,B,O
-,I,O
IL6beta,I,O
),O,O
",",O,O
anti,B,O
-,I,O
NF,I,O
-,I,O
ATc,I,O
",",O,O
anti,B,O
-,I,O
NF,I,O
-,I,O
ATp,I,O
",",O,O
anti,B,O
-,I,O
Fos,I,O
",",O,O
and,O,O
anti,B,O
-,I,O
Jun,I,O
Abs,I,O
we,O,O
demonstrate,O,O
that,O,O
the,O,O
previously,O,O
identified,O,O
PRE,B,O
-,I,O
I,I,O
binding,I,O
factor,I,O
POS,B,O
-,I,O
1,I,O
is,O,O
composed,O,O
of,O,O
different,O,O
transcription,B,O
factors,I,O
in,O,O
different,O,O
Th,O,O
cell,O,O
subsets,O,O
.,O,O
Different,O,O
cytokines,B,O
activate,O,O
transcription,O,O
at,O,O
the,O,O
appropriate,O,O
germline,B,O
promoter,I,O
.,O,O
Experimental,O,O
expression,O,O
in,O,O
mice,O,O
and,O,O
spontaneous,O,O
expression,O,O
in,O,O
human,O,O
SLE,O,O
of,O,O
polyomavirus,B,B
T,I,I
-,I,I
antigen,I,I
.,O,O
A,O,O
molecular,O,O
basis,O,O
for,O,O
induction,O,O
of,O,O
antibodies,B,O
to,O,O
DNA,O,B
and,O,O
eukaryotic,B,B
transcription,I,I
factors,I,I
.,O,O
We,O,O
have,O,O
previously,O,O
demonstrated,O,O
that,O,O
experimental,O,O
expression,O,O
of,O,O
the,O,O
polyomavirus,B,B
transcription,I,I
factor,I,I
T,I,I
-,I,I
antigen,I,I
has,O,O
the,O,O
potential,O,O
to,O,O
induce,O,O
anti,B,O
-,I,O
DNA,I,O
antibodies,I,O
in,O,O
mice,O,O
.,O,O
Two,O,O
sets,O,O
of,O,O
independent,O,O
evidences,O,O
are,O,O
presented,O,O
here,O,O
that,O,O
demonstrate,O,O
a,O,O
biological,O,O
relevance,O,O
for,O,O
this,O,O
model,O,O
.,O,O
Secondly,O,O
",",O,O
we,O,O
investigated,O,O
whether,O,O
polyomavirus,O,B
reactivation,O,O
occurs,O,O
in,O,O
SLE,O,O
patients,O,O
",",O,O
and,O,O
whether,O,O
antibodies,B,O
to,O,O
T,B,B
-,I,I
antigen,I,I
",",O,O
DNA,O,B
",",O,O
and,O,O
to,O,O
TBP,B,B
and,O,O
CREB,B,B
are,O,O
linked,O,O
to,O,O
such,O,O
events,O,O
.,O,O
Both,O,O
within,O,O
and,O,O
among,O,O
these,O,O
SLE,O,O
patients,O,O
",",O,O
frequent,O,O
polyomavirus,O,B
reactivations,O,O
were,O,O
observed,O,O
that,O,O
could,O,O
not,O,O
be,O,O
explained,O,O
by,O,O
certain,O,O
rearrangements,O,O
of,O,O
the,O,O
noncoding,O,O
control,O,O
regions,O,O
",",O,O
nor,O,O
by,O,O
corticosteroid,O,O
treatment,O,O
.,O,O
Antibodies,O,O
recognizing,O,O
double,O,O
-,O,O
stranded,O,O
DNA,O,B
were,O,O
confined,O,O
to,O,O
patients,O,O
with,O,O
frequent,O,O
polyomavirus,O,O
reactivations,O,O
.,O,O
The,O,O
results,O,O
described,O,O
here,O,O
indicate,O,O
that,O,O
cognate,O,O
interaction,O,O
of,O,O
B,O,O
cells,O,O
recognizing,O,O
DNA,O,B
or,O,O
DNA,B,B
-,I,I
associated,I,I
proteins,I,I
and,O,O
T,O,O
cells,O,O
recognizing,O,O
T,B,O
antigen,I,O
had,O,O
taken,O,O
place,O,O
as,O,O
a,O,O
consequence,O,O
of,O,O
complex,O,O
formation,O,O
between,O,O
T,B,O
ag,I,O
and,O,O
DNA,O,B
in,O,O
vivo,O,O
in,O,O
the,O,O
context,O,O
of,O,O
polyomavirus,O,O
reactivations,O,O
.,O,O
Intimate,O,O
interactions,O,O
between,O,O
multipotential,O,O
hemopoietic,O,O
stem,O,O
cells,O,O
and,O,O
their,O,O
microenvironment,O,O
work,O,O
towards,O,O
redefining,O,O
the,O,O
identity,O,O
and,O,O
the,O,O
differentiative,O,O
fate,O,O
of,O,O
these,O,O
primitive,O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
gammac,B,O
is,O,O
not,O,O
necessary,O,O
to,O,O
trigger,O,O
IL,B,B
-,I,I
4,I,I
-,O,I
mediated,O,I
responses,O,I
in,O,O
B,O,O
cells,O,O
",",O,O
but,O,O
its,O,O
presence,O,O
is,O,O
important,O,O
for,O,O
optimal,O,O
IL,B,B
-,I,I
4,I,I
-,O,I
signaling,O,I
.,O,O
Cell,O,B
-,O,I
to,O,I
-,O,I
cell,O,I
contact,O,I
activates,O,O
the,O,O
long,B,O
terminal,I,O
repeat,I,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
1,O,O
through,O,O
its,O,O
kappaB,B,B
motif,I,O
.,O,O
Cell,O,B
-,O,I
to,O,I
-,O,I
cell,O,I
contact,O,I
between,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
and,O,O
transfected,O,O
human,O,O
colonic,O,B
carcinoma,O,I
cell,O,I
line,O,I
HT29,O,O
activates,O,O
transcription,O,O
of,O,O
the,O,O
long,B,O
terminal,I,O
repeats,I,O
(,O,O
LTR,B,O
),O,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
.,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
transcription,O,O
is,O,O
controlled,O,O
by,O,O
a,O,O
complex,O,O
array,O,O
of,O,O
virus,B,B
-,I,I
encoded,I,I
and,I,O
cellular,I,O
proteins,I,O
.,O,O
Identification,O,O
of,O,O
nucleotide,B,O
sequences,I,O
that,O,O
regulate,O,O
transcription,O,O
of,O,O
the,O,O
murine,O,O
leukemia,O,O
virus,O,O
long,B,O
terminal,I,O
repeat,I,O
in,O,O
activated,O,O
T,O,O
cells,O,O
.,O,O
Differentiation,O,O
of,O,O
U,O,O
-,O,O
937,O,O
promonocytic,O,O
cells,O,O
by,O,O
etoposide,O,O
and,O,O
ICRF,O,O
-,O,O
193,O,O
",",O,O
two,O,O
antitumour,O,O
DNA,B,B
topoisomerase,I,I
II,I,I
inhibitors,O,O
with,O,O
different,O,O
mechanisms,O,O
of,O,O
action,O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
these,O,O
effects,O,O
were,O,O
not,O,O
observed,O,O
upon,O,O
pulse,O,O
-,O,O
treatment,O,O
with,O,O
6,O,O
microM,O,O
ICRF,O,B
-,O,I
193,O,I
.,O,O
By,O,O
contrast,O,O
",",O,O
ICRF,O,B
-,O,I
193,O,I
only,O,O
provoked,O,O
a,O,O
late,O,O
activation,O,O
(,O,O
from,O,O
hours,O,O
72,O,O
to,O,O
96,O,O
),O,O
of,O,O
the,O,O
total,O,O
enzyme,O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
the,O,O
binding,O,O
activity,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
(,I,I
B,I,I
),I,I
and,O,O
EGR,B,B
-,I,I
1,I,I
transcription,B,I
factors,I,I
was,O,O
little,O,O
affected,O,O
.,O,O
GATA,B,B
-,I,I
1,I,I
DNA,O,B
binding,O,I
activity,O,I
is,O,O
down,O,O
-,O,O
regulated,O,O
in,O,O
late,O,O
S,O,O
phase,O,O
in,O,O
erythroid,O,B
cells,O,I
.,O,O
These,O,O
results,O,O
may,O,O
also,O,O
relate,O,O
to,O,O
recent,O,O
data,O,O
implicating,O,O
GATA,B,B
-,I,I
1,I,I
function,O,O
in,O,O
apoptosis,O,O
and,O,O
cell,O,O
cycle,O,O
progression,O,O
Activated,O,O
neutrophils,O,B
have,O,O
the,O,O
ability,O,O
to,O,O
upregulate,O,O
the,O,O
expression,O,O
of,O,O
many,O,O
genes,O,O
",",O,O
in,O,O
particular,O,O
those,O,O
encoding,O,O
cytokines,B,B
and,O,O
chemokines,B,B
",",O,O
and,O,O
to,O,O
subsequently,O,O
release,O,O
the,O,O
corresponding,O,O
proteins,O,O
.,O,O
Following,O,O
neutrophil,O,B
stimulation,O,O
with,O,O
proinflammatory,O,O
agonists,O,O
(,O,O
such,O,O
as,O,O
lipopolysaccharide,O,O
[,O,O
LPS,O,O
],O,O
",",O,O
tumor,B,O
necrosis,I,B
factor,I,I
-,I,I
alpha,I,I
[,O,O
TNF,B,B
-,I,I
alpha,I,I
],O,O
",",O,O
and,O,O
fMet,O,O
-,O,O
Leu,O,O
-,O,O
Phe,O,O
),O,O
that,O,O
induce,O,O
the,O,O
production,O,O
of,O,O
cytokines,B,O
and,O,O
chemokines,B,O
in,O,O
these,O,O
cells,O,O
",",O,O
NF,B,O
-,I,O
kappaB,I,O
/,I,O
Rel,I,O
proteins,I,O
translocated,O,O
to,O,O
nuclear,O,O
fractions,O,O
",",O,O
resulting,O,O
in,O,O
a,O,O
transient,O,O
induction,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
DNA,O,I
binding,O,I
activity,O,I
",",O,O
as,O,O
determined,O,O
in,O,O
gel,O,O
mobility,O,O
shift,O,O
assays,O,O
.,O,O
The,O,O
onset,O,O
of,O,O
both,O,O
processes,O,O
was,O,O
found,O,O
to,O,O
be,O,O
closely,O,O
paralleled,O,O
by,O,O
",",O,O
and,O,O
dependent,O,O
on,O,O
",",O,O
IkappaB,B,B
-,I,I
alpha,I,I
degradation,O,O
.,O,O
Two,O,O
distinct,O,O
pathways,O,O
of,O,O
interleukin,B,B
-,I,I
5,I,I
synthesis,O,O
in,O,O
allergen,O,O
-,O,O
specific,O,O
human,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
are,O,O
suppressed,O,O
by,O,O
glucocorticoids,O,O
.,O,O
Glucocorticoids,O,O
(,O,O
GC,O,O
),O,O
have,O,O
long,O,O
been,O,O
used,O,O
as,O,O
the,O,O
most,O,O
effective,O,O
agents,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
allergic,O,O
diseases,O,O
accompanied,O,O
by,O,O
eosinophilia,O,O
such,O,O
as,O,O
chronic,O,O
asthma,O,O
and,O,O
atopic,O,O
dermatitis,O,O
.,O,O
GC,O,O
efficiently,O,O
suppressed,O,O
IL,B,B
-,I,I
5,I,I
synthesis,O,O
of,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
activated,O,O
via,O,O
either,O,O
T,B,O
-,I,O
cell,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
or,O,O
IL,B,B
-,I,I
2,I,I
receptor,I,I
(,O,O
IL,B,O
-,I,O
2R,I,O
),O,O
.,O,O
Stimulation,O,O
of,O,O
CD2,B,O
or,O,O
TCR,B,O
/,I,O
CD3,I,O
induced,O,O
activation,O,O
of,O,O
the,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
(,O,O
NFAT,B,O
),O,O
",",O,O
the,O,O
binding,B,O
site,I,O
of,O,O
which,O,O
is,O,O
included,O,O
in,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
promoter,I,I
.,O,O
The,O,O
LAZ3,B,B
/,I,I
BCL6,I,I
transcript,I,O
was,O,O
found,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
tissues,O,O
",",O,O
including,O,O
skeletal,O,B
muscle,O,I
",",O,O
peripheral,O,B
blood,O,I
leukocytes,O,I
",",O,O
and,O,O
weakly,O,O
in,O,O
normal,O,O
lymph,O,B
nodes,O,I
.,O,O
IL,O,B
-,O,I
4,O,I
treatment,O,O
rapidly,O,O
induced,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
insulin,B,B
receptor,I,I
substrate,I,I
(,I,O
IRS,I,B
),I,O
-,I,O
1,I,O
and,O,O
IRS,B,B
-,I,O
2,I,O
in,O,O
1D4,O,O
but,O,O
not,O,O
in,O,O
E1C3,O,O
cells,O,O
.,O,O
Nuclear,B,B
transcription,I,I
factor,I,I
kB,I,I
(,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
),O,O
is,O,O
a,O,O
ubiquitous,B,O
transcription,I,O
factor,I,O
and,O,O
pleiotropic,B,O
regulator,I,O
of,O,O
numerous,O,O
genes,O,O
involved,O,O
in,O,O
the,O,O
immune,O,B
and,O,O
inflammatory,O,I
responses,O,I
.,O,O
This,O,O
transcription,B,O
factor,I,O
is,O,O
activated,O,O
via,O,O
the,O,O
selective,O,O
phosphorylation,O,O
",",O,O
ubiquination,O,O
and,O,O
degradation,O,O
of,O,O
its,O,O
inhibitor,B,O
protein,I,B
I,I,I
-,I,I
kB,I,I
thereby,O,O
allowing,O,O
translocation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
into,O,O
the,O,O
nucleus,O,O
where,O,O
it,O,O
upregulates,O,O
the,O,O
transcription,O,O
of,O,O
a,O,O
variety,O,O
of,O,O
adhesion,B,O
molecules,I,O
(,O,O
e,O,O
.,O,O
g,O,O
.,O,O
ICAM,B,O
-,I,O
1,I,O
",",O,O
VCAM,B,O
-,I,O
1,I,O
),O,O
",",O,O
cytokines,B,O
(,O,O
TNF,B,O
",",O,O
IL,B,B
-,I,I
1,I,I
",",O,O
IL,B,B
-,I,I
6,I,I
),O,O
and,O,O
enzymes,B,O
(,O,O
iNOS,B,O
),O,O
.,O,O
Based,O,O
upon,O,O
work,O,O
from,O,O
our,O,O
laboratory,O,O
",",O,O
we,O,O
propose,O,O
that,O,O
inhibition,O,O
of,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
activation,O,O
produces,O,O
significant,O,O
anti,O,O
inflammatory,O,O
activity,O,O
which,O,O
may,O,O
be,O,O
mediated,O,O
by,O,O
the,O,O
inhibition,O,O
of,O,O
transcription,O,O
of,O,O
certain,O,O
pro,B,O
-,I,O
inflammatory,I,O
mediators,I,O
and,O,O
adhesion,B,O
molecules,I,O
.,O,O
Generation,O,O
of,O,O
cytotoxic,O,O
T,O,O
lymphocytes,O,O
against,O,O
immunorecessive,B,O
epitopes,I,O
after,O,O
multiple,O,O
immunizations,O,O
with,O,O
adenovirus,O,O
vectors,O,O
is,O,O
dependent,O,O
on,O,O
haplotype,O,O
.,O,O
However,O,O
",",O,O
the,O,O
cytotoxic,O,B
T,O,I
lymphocyte,O,I
(,O,O
CTL,O,O
),O,O
response,O,O
to,O,O
Ad,O,O
could,O,O
limit,O,O
the,O,O
effectiveness,O,O
of,O,O
such,O,O
approaches,O,O
.,O,O
The,O,O
immune,O,O
response,O,O
to,O,O
Ad,O,O
in,O,O
BALB,O,O
/,O,O
c,O,O
mice,O,O
was,O,O
more,O,O
complex,O,O
.,O,O
Understanding,O,O
the,O,O
cis,B,O
-,I,O
and,I,O
transacting,I,O
factors,I,O
that,O,O
regulate,O,O
the,O,O
tissue,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
PECAM,B,O
-,I,O
1,I,O
should,O,O
increase,O,O
our,O,O
understanding,O,O
of,O,O
the,O,O
mechanisms,O,O
by,O,O
which,O,O
vascular,O,B
-,O,I
specific,O,I
gene,O,I
expression,O,I
is,O,O
achieved,O,O
.,O,O
However,O,O
",",O,O
little,O,O
is,O,O
known,O,O
about,O,O
negative,O,O
regulation,O,O
of,O,O
IL,B,B
-,I,I
1beta,I,I
expression,O,O
at,O,O
the,O,O
transcriptional,O,O
level,O,O
",",O,O
which,O,O
may,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
anti,O,O
-,O,O
inflammatory,O,O
and,O,O
immunosuppressive,O,O
effects,O,O
.,O,O
Interaction,O,O
of,O,O
transcription,B,O
factors,I,O
RFX1,B,O
and,O,O
MIBP1,B,O
with,O,O
the,O,O
gamma,B,O
motif,I,O
of,O,O
the,O,O
negative,B,O
regulatory,I,O
element,I,O
of,O,O
the,O,O
hepatitis,B,B
B,I,I
virus,I,I
core,I,I
promoter,I,I
.,O,O
The,O,O
negative,B,O
regulatory,I,O
element,I,O
(,O,O
NRE,B,B
),O,O
of,O,O
the,O,O
hepatitis,B,B
B,I,I
virus,I,I
(,I,O
HBV,I,B
),I,O
core,I,O
promoter,I,O
contains,O,O
three,O,O
subregions,O,O
which,O,O
act,O,O
synergistically,O,O
to,O,O
suppress,O,O
core,O,O
promoter,O,O
activity,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
RFX1,B,O
can,O,O
bind,O,O
simultaneously,O,O
",",O,O
most,O,O
likely,O,O
as,O,O
a,O,O
heterodimer,B,O
",",O,O
with,O,O
the,O,O
transcription,B,O
factor,I,O
MIBP1,B,O
to,O,O
NRE,B,B
gamma,I,I
.,O,O
Use,O,O
of,O,O
arsenic,O,B
trioxide,O,I
(,O,O
As2O3,O,O
),O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
acute,O,O
promyelocytic,O,O
leukemia,O,O
(,O,O
APL,O,O
),O,O
:,O,O
II,O,O
.,O,O
Pharmacokinetic,O,O
studies,O,O
",",O,O
which,O,O
were,O,O
performed,O,O
in,O,O
eight,O,O
patients,O,O
",",O,O
showed,O,O
that,O,O
after,O,O
a,O,O
peak,O,O
level,O,O
of,O,O
5,O,O
.,O,O
54,O,O
micromol,O,O
/,O,O
L,O,O
to,O,O
7,O,O
.,O,O
30,O,O
micromol,O,O
/,O,O
L,O,O
",",O,O
plasma,O,O
arsenic,O,B
was,O,O
rapidly,O,O
eliminated,O,O
",",O,O
and,O,O
the,O,O
continuous,O,O
administration,O,O
of,O,O
As2O3,O,O
did,O,O
not,O,O
alter,O,O
its,O,O
pharmacokinetic,O,O
behaviors,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
As2O3,O,B
treatment,O,O
is,O,O
an,O,O
effective,O,O
and,O,O
relatively,O,O
safe,O,O
drug,O,O
in,O,O
APL,O,O
patients,O,O
refractory,O,O
to,O,O
ATRA,O,O
and,O,O
conventional,O,O
chemotherapy,O,O
.,O,O
LR1,B,O
also,O,O
binds,O,O
Ig,B,B
heavy,I,I
chain,I,I
switch,O,I
region,O,I
sequences,O,O
and,O,O
may,O,O
function,O,O
in,O,O
class,O,O
switch,O,O
recombination,O,O
.,O,O
Both,O,O
of,O,O
these,O,O
parameters,O,O
",",O,O
however,O,O
",",O,O
did,O,O
not,O,O
change,O,O
significantly,O,O
after,O,O
mitogen,B,O
stimulation,O,O
.,O,O
There,O,O
was,O,O
a,O,O
significant,O,O
negative,O,O
correlation,O,O
between,O,O
IC50S,O,O
of,O,O
prednisolone,O,B
and,O,O
increase,O,O
-,O,O
ratios,O,O
(,O,O
post,O,O
/,O,O
pre,O,O
ratio,O,O
),O,O
of,O,O
Bmax,O,B
after,O,O
mitogen,B,O
stimulation,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
Bmax,O,B
and,O,O
Kd,O,B
were,O,O
not,O,O
significantly,O,O
changed,O,O
after,O,O
mitogen,B,O
stimulation,O,O
in,O,O
both,O,O
subgroups,O,O
of,O,O
CRF,O,O
.,O,O
The,O,O
ZEBRA,B,B
protein,I,O
from,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
(,O,O
EBV,O,O
),O,O
activates,O,O
a,O,O
switch,O,O
from,O,O
the,O,O
latent,O,O
to,O,O
the,O,O
lytic,O,O
expression,O,O
program,O,O
of,O,O
the,O,O
virus,O,O
.,O,O
The,O,O
additional,O,O
function,O,O
that,O,O
is,O,O
required,O,O
for,O,O
initiation,O,O
of,O,O
the,O,O
lytic,O,O
viral,O,O
life,O,O
cycle,O,O
is,O,O
likely,O,O
to,O,O
require,O,O
phosphorylation,O,O
of,O,O
serine,O,B
186,O,O
of,O,O
the,O,O
ZEBRA,B,B
protein,I,I
",",O,O
which,O,O
may,O,O
influence,O,O
either,O,O
DNA,O,B
recognition,O,O
or,O,O
transcriptional,O,O
activation,O,O
of,O,O
lytic,B,O
viral,I,O
promoters,I,O
in,O,O
a,O,O
chromatinized,B,O
viral,I,O
episome,I,O
.,O,O
Immune,O,O
hyperactivation,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
-,O,I
infected,O,O
T,O,O
cells,O,O
mediated,O,O
by,O,O
Tat,B,O
and,O,O
the,O,O
CD28,B,B
pathway,O,I
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
reduction,O,O
of,O,O
symptoms,O,O
due,O,O
to,O,O
topical,O,O
fluticasone,O,O
propionate,O,O
in,O,O
patients,O,O
with,O,O
rhinitis,O,O
and,O,O
allergy,O,O
to,O,O
house,O,O
dust,O,O
mite,O,O
is,O,O
not,O,O
correlated,O,O
with,O,O
the,O,O
characteristics,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
.,O,O
Human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
(,O,O
HIV,O,O
-,O,O
1,O,O
),O,O
replicates,O,O
more,O,O
efficiently,O,O
in,O,O
vitro,O,O
in,O,O
differentiated,O,O
macrophages,O,O
than,O,O
in,O,O
freshly,O,O
isolated,O,O
monocytes,O,O
.,O,O
We,O,O
demonstrated,O,O
that,O,O
constitutive,O,O
expression,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
primary,O,O
human,O,O
monocytes,O,O
changed,O,O
significantly,O,O
with,O,O
differentiation,O,O
in,O,O
vitro,O,O
to,O,O
monocyte,O,O
-,O,O
derived,O,O
macrophages,O,O
(,O,O
MDMs,O,O
),O,O
and,O,O
differentiation,O,O
in,O,O
vivo,O,O
to,O,O
alveolar,O,O
macrophages,O,O
(,O,O
AMs,O,O
),O,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,O,I
independent,O,O
suppression,O,O
of,O,O
HIV,O,O
expression,O,O
by,O,O
ascorbic,O,O
acid,O,O
.,O,O
Pretreatment,O,O
of,O,O
ACH,O,O
-,O,O
2,O,O
T,O,O
cells,O,O
by,O,O
NAC,O,O
followed,O,O
by,O,O
stimulation,O,O
with,O,O
PMA,O,O
",",O,O
TNF,B,B
-,I,I
alpha,I,I
",",O,O
or,O,O
hydrogen,O,O
peroxide,O,O
(,O,O
H2O2,O,O
),O,O
resulted,O,O
in,O,O
strong,O,O
suppression,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
molecular,O,O
mechanism,O,O
of,O,O
HIV,O,O
inhibition,O,O
by,O,O
ascorbate,O,O
is,O,O
not,O,O
mediated,O,O
via,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
inhibition,O,O
",",O,O
unlike,O,O
that,O,O
seen,O,O
with,O,O
other,O,O
antioxidants,O,O
.,O,O
A,O,O
T,B,B
cell,I,I
-,I,I
specific,I,I
enhancer,I,I
in,O,O
the,O,O
interleukin,B,B
-,I,I
3,I,I
locus,I,O
is,O,O
activated,O,O
cooperatively,O,O
by,O,O
Oct,B,B
and,I,O
NFAT,I,B
elements,I,O
within,O,O
a,O,O
DNase,B,B
I,I,I
-,I,I
hypersensitive,I,I
site,I,I
.,O,O
Interleukin,B,B
-,I,I
3,I,I
(,O,O
IL,B,B
-,I,I
3,I,I
),O,O
is,O,O
a,O,O
cytokine,B,O
that,O,O
is,O,O
expressed,O,O
primarily,O,O
in,O,O
activated,O,O
T,O,B
cells,O,I
.,O,O
We,O,O
suggest,O,O
that,O,O
the,O,O
T,O,B
cell,O,I
-,O,I
specific,O,I
expression,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
3,I,I
gene,I,O
is,O,O
partly,O,O
controlled,O,O
through,O,O
the,O,O
enhancer,O,O
by,O,O
cooperation,O,O
between,O,O
Oct,B,B
and,I,O
NFAT,I,B
family,I,O
proteins,I,O
.,O,O
The,O,O
adenovirus,B,B
E1B,I,B
19K,I,I
gene,I,I
plays,O,O
an,O,O
essential,O,O
role,O,O
in,O,O
transformation,O,O
of,O,O
primary,O,O
rodent,O,O
cells,O,O
in,O,O
cooperation,O,O
with,O,O
E1A,B,B
and,O,O
in,O,O
the,O,O
inhibition,O,O
of,O,O
apoptosis,O,O
during,O,O
lytic,O,O
infection,O,O
.,O,O
It,O,O
has,O,O
been,O,O
shown,O,O
that,O,O
this,O,O
E1B,B,B
19K,I,I
protein,I,I
is,O,O
not,O,O
necessary,O,O
for,O,O
viral,O,O
DNA,O,B
replication,O,O
in,O,O
human,O,O
cell,O,O
lines,O,O
",",O,O
such,O,O
as,O,O
HeLa,O,B
and,O,O
KB,O,B
.,O,O
Activation,O,O
of,O,O
Ras,O,B
and,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,O
kinase,I,O
pathway,O,O
by,O,O
terminal,B,O
complement,I,O
complexes,I,O
is,O,O
G,B,B
protein,I,I
dependent,O,O
.,O,O
Spontaneous,O,O
occurrence,O,O
of,O,O
early,O,O
region,O,O
1A,O,O
reiteration,O,O
mutants,O,O
of,O,O
type,O,O
5,O,O
adenovirus,O,B
in,O,O
persistently,O,O
infected,O,O
human,O,B
T,O,I
-,O,I
lymphocytes,O,I
.,O,O
Mutants,O,O
of,O,O
type,O,O
5,O,O
adenovirus,O,B
(,O,O
Ad5,O,O
),O,O
with,O,O
reiterated,B,O
DNA,I,B
sequences,I,O
in,O,O
the,O,O
E1a,B,B
region,I,O
appeared,O,O
in,O,O
a,O,O
human,O,B
T,O,I
-,O,I
lymphocyte,O,I
cell,O,I
line,O,I
",",O,O
Molt,O,B
-,O,I
4,O,I
",",O,O
persistently,O,O
infected,O,O
with,O,O
H5sub304,O,O
",",O,O
a,O,O
deletion,O,O
/,O,O
substitution,O,O
mutant,O,O
that,O,O
has,O,O
a,O,O
wild,O,O
-,O,O
type,O,O
phenotype,O,O
in,O,O
viral,O,O
replication,O,O
.,O,O
There,O,O
was,O,O
not,O,O
any,O,O
DNA,O,B
homology,O,O
between,O,O
the,O,O
breakpoints,O,O
in,O,O
the,O,O
second,O,O
exon,B,O
and,O,O
the,O,O
inserting,B,O
sequences,I,O
(,O,O
starting,O,O
at,O,O
nt,O,O
532,O,O
",",O,O
710,O,O
",",O,O
or,O,O
792,O,O
),O,O
.,O,O
The,O,O
observed,O,O
E1a,B,O
reiterations,I,O
provide,O,O
a,O,O
model,O,O
to,O,O
gain,O,O
insight,O,O
into,O,O
understanding,O,O
the,O,O
evolutionary,O,O
events,O,O
of,O,O
some,O,O
",",O,O
if,O,O
not,O,O
all,O,O
",",O,O
adenovirus,O,O
types,O,O
during,O,O
many,O,O
years,O,O
of,O,O
symbiotic,O,O
",",O,O
persistent,O,O
relationship,O,O
in,O,O
human,O,O
tonsils,O,O
and,O,O
adenoids,O,O
and,O,O
possibly,O,O
other,O,O
lymphoid,O,O
organs,O,O
.,O,O
Residues,O,O
432,O,O
",",O,O
435,O,O
",",O,O
437,O,O
",",O,O
438,O,O
",",O,O
and,O,O
440,O,O
(,O,O
position,B,O
P1,I,O
",",I,O
P4,I,O
",",I,O
P6,I,O
",",I,O
P7,I,O
",",I,O
and,I,O
P9,I,O
),O,O
contributed,O,O
to,O,O
DQ2,B,B
binding,O,O
",",O,O
whereas,O,O
residues,O,O
431,O,O
",",O,O
433,O,O
",",O,O
434,O,O
",",O,O
and,O,O
436,O,O
(,O,O
positions,B,O
P,I,O
1,I,O
",",I,O
P2,I,O
",",I,O
P3,I,O
",",I,O
and,I,O
P5,I,O
),O,O
contributed,O,O
to,O,O
TCR,B,B
contact,O,O
.,O,O
The,O,O
hypothesis,O,O
that,O,O
the,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
(,O,O
NF,B,B
-,I,I
AT,I,I
),O,O
may,O,O
influence,O,O
HIV,O,O
-,O,O
1,O,O
replication,O,O
is,O,O
therefore,O,O
compelling,O,O
given,O,O
the,O,O
tight,O,O
correlation,O,O
of,O,O
HIV,O,O
-,O,O
1,O,O
transcriptional,O,O
induction,O,O
to,O,O
T,O,O
cell,O,O
activation,O,O
.,O,O
These,O,O
results,O,O
link,O,O
regulatory,B,O
factors,I,O
critical,O,O
to,O,O
T,O,O
cell,O,O
commitment,O,O
directly,O,O
to,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
.,O,O
eTh2,O,O
cells,O,O
are,O,O
the,O,O
major,O,O
source,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
",",O,O
while,O,O
gamma,B,B
interferon,I,I
is,O,O
produced,O,O
by,O,O
eTh1,O,O
cells,O,O
.,O,O
However,O,O
",",O,O
although,O,O
NFAT,B,B
DNA,O,I
binding,O,I
is,O,O
similarly,O,O
induced,O,O
in,O,O
both,O,O
eTh1,O,O
and,O,O
eTh2,O,O
cells,O,O
upon,O,O
antigen,O,O
stimulation,O,O
",",O,O
only,O,O
the,O,O
NFAT,B,B
complexes,I,I
present,O,O
in,O,O
eTh2,O,O
cells,O,O
are,O,O
able,O,O
to,O,O
mediate,O,O
high,O,O
-,O,O
level,O,O
transcription,O,O
",",O,O
and,O,O
relatively,O,O
little,O,O
NFAT,B,B
transcriptional,O,I
activity,O,I
was,O,O
induced,O,O
in,O,O
eTh1,O,O
cells,O,O
.,O,O
The,O,O
greater,O,O
selectivity,O,O
of,O,O
PF,O,O
",",O,O
compared,O,O
with,O,O
FK506,O,O
",",O,O
at,O,O
both,O,O
the,O,O
molecular,O,O
and,O,O
cellular,O,O
levels,O,O
may,O,O
prove,O,O
advantageous,O,O
in,O,O
manipulating,O,O
T,O,O
cell,O,O
responses,O,O
in,O,O
vivo,O,O
.,O,O
V3,B,O
loop,I,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
suppresses,O,O
interleukin,B,B
2,I,I
-,O,I
induced,O,I
T,O,I
cell,O,I
growth,O,I
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
AIDS,O,O
Res,O,O
Hum,O,O
Retroviruses,O,O
1997,O,O
May,O,O
1,O,O
;,O,O
13,O,O
(,O,O
7,O,O
),O,O
633,O,O
],O,O
V3,B,O
-,I,O
BH10,I,O
neither,O,O
blocked,O,O
radiolabeled,O,O
IL,B,B
-,I,I
2,I,I
binding,O,O
to,O,O
IL,B,B
-,I,I
2,I,I
receptors,I,I
nor,O,O
affected,O,O
tyrosyl,O,O
phosphorylation,O,O
of,O,O
several,O,O
cellular,B,O
proteins,I,O
(,O,O
p120,B,O
",",O,O
p98,B,O
",",O,O
p96,B,O
",",O,O
p54,B,O
",",O,O
and,O,O
p38,B,O
),O,O
",",O,O
which,O,O
is,O,O
immediately,O,O
induced,O,O
by,O,O
IL,B,B
-,I,I
2,I,I
stimulation,O,O
.,O,O
However,O,O
",",O,O
V3,B,O
-,I,O
BH10,I,O
enhanced,O,O
IL,B,B
-,I,I
2,I,I
-,B,O
induced,I,O
mRNA,I,O
expression,O,O
of,O,O
c,B,O
-,I,O
fos,I,O
but,O,O
not,O,O
c,B,O
-,I,O
myc,I,O
or,O,O
junB,B,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Our,O,O
results,O,O
establish,O,O
that,O,O
PI,B,B
-,I,I
kinase,I,I
can,O,O
both,O,O
positively,O,O
and,O,O
negatively,O,O
regulate,O,O
T,O,O
-,O,O
cell,O,O
function,O,O
",",O,O
and,O,O
uncover,O,O
a,O,O
previously,O,O
unrecognized,O,O
function,O,O
for,O,O
PI,B,B
-,I,I
kinase,I,I
in,O,O
T,O,O
cells,O,O
as,O,O
a,O,O
selective,O,O
negative,O,O
regulator,O,O
of,O,O
TCR,B,O
-,O,O
signalling,O,O
events,O,O
and,O,O
therefore,O,O
as,O,O
a,O,O
determinant,O,O
of,O,O
T,O,O
-,O,O
cell,O,O
homeostasis,O,O
.,O,O
Pax,B,B
-,I,I
5a,I,I
was,O,O
detectable,O,O
in,O,O
pro,O,O
-,O,O
",",O,O
pre,O,O
-,O,O
",",O,O
and,O,O
mature,O,O
B,O,O
-,O,O
cell,O,O
lines,O,O
",",O,O
but,O,O
not,O,O
in,O,O
two,O,O
plasmacytomas,O,O
;,O,O
Pax,B,B
-,I,I
5b,I,I
was,O,O
shown,O,O
to,O,O
be,O,O
present,O,O
at,O,O
low,O,O
levels,O,O
in,O,O
mature,O,O
B,O,O
-,O,O
cell,O,O
lines,O,O
and,O,O
",",O,O
unexpectedly,O,O
",",O,O
in,O,O
one,O,O
plasma,O,O
cell,O,O
line,O,O
",",O,O
but,O,O
not,O,O
in,O,O
pro,O,O
-,O,O
B,O,O
-,O,O
cell,O,O
or,O,O
T,O,O
-,O,O
cell,O,O
lines,O,O
.,O,O
The,O,O
two,O,O
related,O,O
protein,B,B
-,I,I
tyrosine,I,I
kinases,I,I
Syk,B,O
and,O,O
Zap,B,O
are,O,O
rapidly,O,O
phosphorylated,O,O
on,O,O
tyrosine,O,O
residues,O,O
and,O,O
enzymatically,O,O
activated,O,O
upon,O,O
crosslinking,O,O
of,O,O
the,O,O
T,B,O
cell,I,O
antigen,I,O
receptor,I,O
.,O,O
One,O,O
means,O,O
of,O,O
understanding,O,O
the,O,O
role,O,O
of,O,O
p38,B,B
in,O,O
these,O,O
responses,O,O
is,O,O
to,O,O
identify,O,O
proteins,O,O
with,O,O
functions,O,O
regulated,O,O
by,O,O
p38,B,O
-,O,O
catalysed,O,O
phosphorylation,O,O
.,O,O
Altogether,O,O
",",O,O
these,O,O
results,O,O
support,O,O
the,O,O
hypothesis,O,O
that,O,O
the,O,O
activation,O,O
of,O,O
NK,O,B
cells,O,O
involved,O,O
transcriptional,O,O
and,O,O
post,O,O
-,O,O
transcriptional,O,O
events,O,O
",",O,O
and,O,O
that,O,O
reactive,O,O
intermediates,O,O
may,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
molecular,O,O
processes,O,O
related,O,O
with,O,O
the,O,O
generation,O,O
of,O,O
a,O,O
cytotoxic,O,O
response,O,O
by,O,O
NK,O,B
cells,O,O
.,O,O
The,O,O
predominant,O,O
E2F,B,B
complex,I,I
in,O,O
human,O,O
primary,O,O
haemopoietic,O,O
cells,O,O
and,O,O
in,O,O
AML,O,B
blasts,O,O
contains,O,O
E2F,B,B
-,I,I
4,I,I
",",O,O
DP,B,B
-,I,I
1,I,I
and,O,O
p130,B,B
.,O,O
We,O,O
also,O,O
studied,O,O
blasts,O,O
from,O,O
18,O,O
patients,O,O
with,O,O
acute,O,O
myeloid,O,O
leukaemia,O,O
(,O,O
AML,O,B
),O,O
.,O,O
An,O,O
E2F,B,B
-,I,I
4,I,I
/,I,I
p130,I,I
complex,I,O
was,O,O
detected,O,O
in,O,O
representative,O,O
samples,O,O
of,O,O
all,O,O
FAB,B,O
types,O,O
analysed,O,O
.,O,O
Associated,O,O
with,O,O
its,O,O
inhibitor,O,O
",",O,O
I,B,O
kappaB,I,B
",",O,O
NF,B,B
-,I,I
kappaB,I,I
resides,O,O
as,O,O
an,O,O
inactive,O,O
form,O,O
in,O,O
the,O,O
cytoplasm,O,O
.,O,O
The,O,O
transduction,O,O
pathways,O,O
that,O,O
lead,O,O
to,O,O
I,B,B
kappaB,I,I
inactivation,O,O
remain,O,O
poorly,O,O
understood,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
have,O,O
characterized,O,O
a,O,O
cellular,O,O
mutant,O,O
",",O,O
the,O,O
70,O,O
/,O,O
Z3,O,O
-,O,O
derived,O,O
1,O,O
.,O,O
murine,O,O
pre,O,O
-,O,O
B,O,O
cell,O,O
line,O,O
",",O,O
that,O,O
does,O,O
not,O,O
activate,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
response,O,O
to,O,O
several,O,O
stimuli,O,O
.,O,O
Our,O,O
results,O,O
demonstrate,O,O
that,O,O
1,O,O
.,O,O
is,O,O
a,O,O
cellular,B,O
transduction,I,O
mutant,I,O
exhibiting,O,O
a,O,O
defect,O,O
in,O,O
a,O,O
step,O,O
that,O,O
is,O,O
required,O,O
by,O,O
several,O,O
different,O,O
stimuli,O,O
to,O,O
activate,O,O
NF,B,B
-,I,I
kappaB,I,I
.,O,O
In,O,O
order,O,O
to,O,O
evaluate,O,O
the,O,O
conditions,O,O
for,O,O
optimal,O,O
expression,O,O
and,O,O
immunogenicity,O,O
of,O,O
varicella,B,O
-,I,O
zoster,I,O
virus,I,O
(,I,O
VZV,I,O
),I,O
proteins,I,O
in,O,O
a,O,O
herpes,O,B
simplex,O,I
virus,O,I
-,O,I
1,O,I
(,O,O
HSV,O,O
-,O,O
1,O,O
),O,O
vector,O,O
",",O,O
we,O,O
selected,O,O
the,O,O
VZV,B,O
glycoprotein,I,O
E,I,O
(,O,O
gE,B,O
),O,O
",",O,O
encoded,O,O
by,O,O
ORF,B,O
68,I,O
and,O,O
the,O,O
VZV,B,O
product,I,O
of,O,O
ORF,B,O
62,I,O
",",O,O
an,O,O
immediate,B,O
-,I,O
early,I,O
major,I,O
tegument,I,O
protein,I,O
(,O,O
IE62,B,O
),O,O
.,O,O
Immunoblot,O,O
analysis,O,O
and,O,O
immunoperoxidase,O,O
staining,O,O
of,O,O
infected,O,O
cell,O,O
monolayers,O,O
demonstrated,O,O
vector,O,O
expression,O,O
of,O,O
VZV,B,B
proteins,I,O
.,O,O
When,O,O
tested,O,O
in,O,O
cytotoxicity,O,O
assays,O,O
using,O,O
T,O,O
-,O,O
lymphocytes,O,O
from,O,O
VZV,O,O
immune,O,O
human,O,O
donors,O,O
",",O,O
the,O,O
range,O,O
of,O,O
precursor,O,O
frequencies,O,O
for,O,O
T,O,O
-,O,O
lymphocytes,O,O
that,O,O
recognized,O,O
VZV,B,B
gE,I,O
or,O,O
VZV,B,B
IE62,I,O
was,O,O
similar,O,O
whether,O,O
these,O,O
proteins,O,O
were,O,O
expressed,O,O
by,O,O
HSV,O,O
-,O,O
1,O,O
or,O,O
a,O,O
vaccinia,O,O
vector,O,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
the,O,O
active,O,O
form,O,O
of,O,O
NF,B,B
-,I,I
AT1,I,I
is,O,O
also,O,O
present,O,O
in,O,O
the,O,O
nuclei,O,O
of,O,O
HTLV,O,O
-,O,O
I,O,O
-,O,O
transformed,O,O
T,O,O
cells,O,O
that,O,O
express,O,O
the,O,O
Tax,B,O
protein,I,B
.,O,O
Interestingly,O,O
",",O,O
the,O,O
constitutive,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
AT1,I,I
in,O,O
these,O,O
T,O,O
cells,O,O
is,O,O
associated,O,O
with,O,O
its,O,O
dephosphorylation,O,O
.,O,O
Expression,O,O
of,O,O
NFAT,B,B
-,I,I
family,I,I
proteins,I,I
in,O,O
normal,O,O
human,O,O
T,O,O
cells,O,O
.,O,O
Higher,B,O
-,I,O
molecular,I,O
-,I,O
weight,I,O
species,I,O
of,O,O
NFATc,B,B
(,O,O
of,O,O
110,O,O
and,O,O
140,O,O
kDa,O,O
),O,O
were,O,O
also,O,O
detected,O,O
.,O,O
In,O,O
contrast,O,O
to,O,O
ionomycin,O,O
treatment,O,O
",",O,O
exposure,O,O
of,O,O
cells,O,O
to,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
plus,O,O
anti,B,O
-,I,O
CD28,I,O
did,O,O
not,O,O
induce,O,O
NFATc,B,O
",",O,O
indicating,O,O
that,O,O
under,O,O
these,O,O
conditions,O,O
",",O,O
interleukin,B,O
-,I,O
2,I,O
synthesis,O,O
by,O,O
these,O,O
cells,O,O
is,O,O
apparently,O,O
independent,O,O
of,O,O
NFATc,B,O
.,O,O
Cotransfection,O,O
experiments,O,O
revealed,O,O
that,O,O
both,O,O
hGATA,B,B
-,I,I
4,I,I
and,O,O
PMA,O,O
/,O,O
A23187,O,O
stimulation,O,O
are,O,O
necessary,O,O
for,O,O
the,O,O
IL,B,B
-,I,I
5,I,I
promoter,I,O
activation,O,O
.,O,O
The,O,O
requirement,O,O
of,O,O
another,O,O
regulatory,B,O
element,I,O
called,O,O
",",O,O
which,O,O
lies,O,O
downstream,O,O
of,O,O
the,O,O
-,B,O
70,I,O
GATA,I,O
site,I,O
",",O,O
was,O,O
also,O,O
demonstrated,O,O
.,O,O
The,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
with,O,O
extracts,O,O
of,O,O
COS,O,O
cells,O,O
expressing,O,O
GATA,B,B
-,I,I
binding,I,I
proteins,I,I
showed,O,O
that,O,O
GATA,B,B
-,I,I
4,I,I
has,O,O
the,O,O
highest,O,O
binding,O,O
affinity,O,O
to,O,O
the,O,O
-,B,O
70,I,O
GATA,I,O
site,I,O
among,O,O
the,O,O
three,O,O
GATA,B,O
-,I,O
binding,I,O
proteins,I,O
.,O,O
These,O,O
results,O,O
demonstrate,O,O
the,O,O
selective,O,O
role,O,O
of,O,O
GATA,B,B
-,I,I
4,I,I
in,O,O
the,O,O
transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
5,I,I
gene,I,O
in,O,O
a,O,O
circumstance,O,O
where,O,O
multiple,O,O
members,O,O
of,O,O
the,O,O
GATA,B,B
-,I,I
binding,I,I
proteins,I,I
are,O,O
expressed,O,O
.,O,O
We,O,O
found,O,O
that,O,O
NFATx1,B,B
DNA,O,I
binding,O,I
activity,O,O
and,O,O
interaction,O,O
with,O,O
AP,O,B
-,O,I
1,O,I
polypeptides,O,I
were,O,O
dependent,O,O
on,O,O
its,O,O
central,B,O
Rel,I,B
similarity,I,I
region,I,O
and,O,O
that,O,O
transcriptional,O,O
activation,O,O
was,O,O
reduced,O,O
by,O,O
deletions,O,O
of,O,O
either,O,O
its,O,O
N,B,B
-,I,I
terminal,I,I
domain,I,I
or,O,O
its,O,O
C,B,B
-,I,I
terminal,I,I
domain,I,I
",",O,O
suggesting,O,O
the,O,O
presence,O,O
of,O,O
intrinsic,B,O
transcriptional,I,O
activation,I,O
motifs,I,O
in,O,O
both,O,O
regions,O,O
.,O,O
NO,O,B
is,O,O
produced,O,O
from,O,O
at,O,O
least,O,O
three,O,O
different,O,O
NO,B,B
synthase,I,I
(,I,O
NOS,I,O
),I,O
isoforms,I,O
:,O,O
neuronal,B,B
NOS,I,O
(,O,O
nNOS,B,O
),O,O
",",O,O
endothelial,B,B
NOS,I,O
",",O,O
and,O,O
immunologic,B,B
NOS,I,O
(,O,O
iNOS,B,O
),O,O
.,O,O
Pyrrolidine,O,O
dithiocarbamate,O,O
(,O,O
PDTC,O,O
),O,O
is,O,O
an,O,O
inhibitor,O,O
of,O,O
NF,B,O
kappaB,I,O
in,O,O
most,O,O
cells,O,O
;,O,O
however,O,O
",",O,O
we,O,O
show,O,O
that,O,O
PDTC,O,O
is,O,O
also,O,O
a,O,O
potent,O,O
scavenger,O,O
of,O,O
NO,O,B
through,O,O
formation,O,O
of,O,O
mononitrosyl,O,O
iron,O,O
complexes,O,O
with,O,O
PDTC,O,O
.,O,O
Contrary,O,O
to,O,O
the,O,O
results,O,O
in,O,O
Jurkat,O,O
cells,O,O
",",O,O
PDTC,O,O
did,O,O
not,O,O
inhibit,O,O
tumor,B,O
necrosis,I,O
factor,I,B
-,I,I
alpha,I,I
-,O,I
induced,O,O
NF,B,O
kappaB,I,O
activation,O,O
in,O,O
astrocytes,O,O
;,O,O
instead,O,O
PDTC,O,O
itself,O,O
induces,O,O
NF,B,O
kappaB,I,O
activation,O,O
in,O,O
astrocytes,O,O
",",O,O
and,O,O
this,O,O
may,O,O
be,O,O
related,O,O
to,O,O
scavenging,O,O
of,O,O
endogenously,O,O
produced,O,O
NO,O,B
by,O,O
the,O,O
PDTC,O,O
iron,O,O
complex,O,O
.,O,O
In,O,O
astrocytes,O,O
PDTC,O,O
also,O,O
dramatically,O,O
induces,O,O
the,O,O
NF,B,O
kappaB,I,O
-,I,O
dependent,I,O
enzyme,I,O
",",O,O
iNOS,B,B
",",O,O
supporting,O,O
the,O,O
physiologic,O,O
relevance,O,O
of,O,O
endogenous,O,O
NO,O,B
regulation,O,O
of,O,O
NF,B,O
kappaB,I,O
.,O,O
Involvement,O,O
of,O,O
Stat3,B,B
in,O,O
interleukin,B,O
-,I,O
6,I,O
-,O,O
induced,O,O
IgM,B,O
production,O,O
in,O,O
a,O,O
human,O,O
B,O,O
-,O,O
cell,O,O
line,O,O
.,O,O
EGF,O,O
treatment,O,O
induced,O,O
IgM,B,O
production,O,O
in,O,O
cells,O,O
transfected,O,O
with,O,O
an,O,O
intact,O,O
gp130,B,O
cytoplasmic,I,B
tail,I,I
",",O,O
but,O,O
not,O,O
in,O,O
untransfected,O,O
cells,O,O
or,O,O
cells,O,O
transfected,O,O
with,O,O
a,O,O
cytoplasmic,B,B
tail,I,I
lacking,O,O
all,O,O
four,O,O
signal,B,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
(,I,O
Stat,I,O
),I,O
binding,I,O
sites,I,O
.,O,O
Moreover,O,O
",",O,O
EGF,O,B
treatment,O,O
induced,O,O
Stat3,B,B
phosphorylation,O,O
in,O,O
cells,O,O
transfected,O,O
with,O,O
the,O,O
intact,O,O
chimeric,B,O
EGF,I,B
-,I,I
gp130,I,I
receptor,I,I
along,O,O
with,O,O
induction,O,O
of,O,O
DNA,O,B
-,O,I
mobility,O,I
shift,O,I
of,O,O
a,O,O
classical,B,O
interferon,I,B
-,I,I
gamma,I,I
-,I,I
activated,I,I
site,I,I
.,O,O
The,O,O
in,O,O
vitro,O,O
transendothelial,O,O
migration,O,O
of,O,O
circulating,O,O
filarial,O,O
antigen,O,O
-,O,O
specific,O,O
T,O,O
-,O,O
cells,O,O
was,O,O
examined,O,O
in,O,O
Wuchereria,O,O
banerofti,O,O
infection,O,O
.,O,O
This,O,O
cis,B,O
element,I,O
binds,O,O
a,O,O
protein,O,B
complex,O,O
referred,O,O
to,O,O
as,O,O
HRF,B,O
(,O,O
heme,B,O
-,I,O
responsive,I,O
factor,I,O
),O,O
",",O,O
which,O,O
is,O,O
greatly,O,O
enhanced,O,O
both,O,O
in,O,O
heme,O,O
-,O,O
treated,O,O
FLCs,O,O
and,O,O
during,O,O
monocyte,O,O
-,O,O
to,O,O
-,O,O
macrophage,O,O
differentiation,O,O
.,O,O
One,O,O
of,O,O
the,O,O
latter,O,O
elements,O,O
",",O,O
the,O,O
IgH,B,O
3,I,O
enhancer,I,O
",",O,O
is,O,O
of,O,O
particular,O,O
interest,O,O
:,O,O
(,O,O
1,O,O
),O,O
it,O,O
is,O,O
B,O,O
cell,O,O
-,O,O
specific,O,O
and,O,O
active,O,O
only,O,O
in,O,O
late,O,O
B,O,O
cell,O,O
development,O,O
;,O,O
(,O,O
2,O,O
),O,O
in,O,O
rodent,O,O
plasmacytomas,O,O
and,O,O
in,O,O
some,O,O
human,O,O
Burkitt,O,O
s,O,O
lymphomas,O,O
it,O,O
is,O,O
part,O,O
of,O,O
a,O,O
locus,B,O
control,I,O
region,I,O
(,O,O
LCR,B,O
),O,O
that,O,O
is,O,O
involved,O,O
in,O,O
deregulation,O,O
of,O,O
the,O,O
c,B,O
-,I,O
myc,I,O
oncogene,I,O
as,O,O
a,O,O
result,O,O
of,O,O
translocation,O,O
into,O,O
the,O,O
IgH,B,O
locus,I,O
;,O,O
and,O,O
(,O,O
3,O,O
),O,O
it,O,O
has,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
mechanisms,O,O
that,O,O
control,O,O
Ig,B,B
gene,I,I
class,I,I
switch,O,I
recombination,O,I
.,O,O
Reactive,O,O
oxygen,O,B
species,O,I
(,O,O
ROS,O,B
),O,O
such,O,O
as,O,O
hydrogen,O,B
peroxide,O,I
serve,O,O
as,O,O
second,O,O
messengers,O,O
in,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappaB,I,I
",",O,O
and,O,O
hence,O,O
in,O,O
the,O,O
activation,O,O
and,O,O
replication,O,O
of,O,O
human,O,B
immunodeficiency,O,I
virus,O,I
type,O,I
1,O,I
(,O,O
HIV,O,B
-,O,I
1,O,I
),O,O
in,O,O
human,O,B
cells,O,O
.,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
was,O,O
very,O,O
effective,O,O
when,O,O
cells,O,O
were,O,O
subjected,O,O
to,O,O
hyperthermia,O,O
before,O,O
being,O,O
treated,O,O
with,O,O
HOCl,O,O
.,O,O
Collectively,O,O
",",O,O
these,O,O
results,O,O
suggest,O,O
that,O,O
HOCl,O,O
should,O,O
be,O,O
considered,O,O
as,O,O
an,O,O
oxidative,O,O
species,O,O
capable,O,O
of,O,O
inducing,O,O
NF,B,O
-,I,O
kappaB,I,O
in,O,O
a,O,O
T,O,O
-,O,O
lymphocytic,O,O
cell,O,O
line,O,O
through,O,O
a,O,O
transduction,O,O
mechanism,O,O
involving,O,O
ROS,O,O
",",O,O
and,O,O
having,O,O
a,O,O
long,O,O
-,O,O
distance,O,O
effect,O,O
through,O,O
subsequent,O,O
TNF,B,O
-,I,O
alpha,I,O
release,O,O
.,O,O
Rap1,B,O
is,O,O
a,O,O
small,O,O
",",O,O
Ras,B,O
-,I,O
like,I,O
GTPase,I,O
whose,O,O
function,O,O
and,O,O
regulation,O,O
are,O,O
still,O,O
largely,O,O
unknown,O,O
.,O,O
Stimulation,O,O
of,O,O
blood,O,O
platelets,O,O
with,O,O
alpha,B,B
-,I,I
thrombin,I,I
or,O,O
other,O,O
platelet,O,O
activators,O,O
caused,O,O
a,O,O
rapid,O,O
and,O,O
strong,O,O
induction,O,O
of,O,O
Rap1,B,B
that,O,O
associated,O,O
with,O,O
RBD,B,O
in,O,O
vitro,O,O
.,O,O
From,O,O
our,O,O
results,O,O
",",O,O
we,O,O
conclude,O,O
that,O,O
Rap1,B,B
activation,O,O
in,O,O
platelets,O,O
is,O,O
an,O,O
important,O,O
common,O,O
event,O,O
in,O,O
early,O,O
agonist,O,O
-,O,O
induced,O,O
signalling,O,O
",",O,O
and,O,O
that,O,O
this,O,O
activation,O,O
is,O,O
mediated,O,O
by,O,O
an,O,O
increased,O,O
intracellular,O,O
Ca2,O,B
+,O,I
concentration,O,I
The,O,O
transcriptional,B,O
regulatory,I,O
elements,I,O
of,O,O
many,O,O
inducible,B,O
T,I,O
-,I,O
cell,I,O
genes,I,O
contain,O,O
adjacent,O,O
or,O,O
overlapping,B,O
binding,I,O
sites,I,O
for,O,O
the,O,O
Ets,B,B
and,I,O
NF,I,B
-,I,I
kappaB,I,I
/,I,I
NFAT,I,I
families,I,O
of,O,O
transcription,B,O
factors,I,O
.,O,O
From,O,O
AML1,B,B
gene,I,I
",",O,O
two,O,O
representative,O,O
forms,O,O
of,O,O
proteins,O,O
",",O,O
AML1a,B,B
and,O,O
AML1b,B,B
",",O,O
are,O,O
produced,O,O
by,O,O
an,O,O
alternative,O,O
splicing,O,O
.,O,O
These,O,O
data,O,O
strongly,O,O
suggest,O,O
that,O,O
a,O,O
transcriptionally,O,O
active,O,O
form,O,O
of,O,O
AML1,B,B
is,O,O
essential,O,O
for,O,O
the,O,O
myeloid,O,B
cell,O,I
differentiation,O,I
.,O,O
When,O,O
introduced,O,O
into,O,O
interleukin,B,B
3,I,I
(,O,I
IL,B,I
-,I,I
3,I,I
),O,I
-,O,O
dependent,O,O
mouse,O,O
pro,O,O
-,O,O
B,O,O
lymphocytes,O,O
",",O,O
E2A,B,O
-,I,O
HLF,I,O
prevents,O,O
apoptosis,O,O
induced,O,O
by,O,O
growth,B,O
factor,I,O
deprivation,O,O
",",O,O
suggesting,O,O
that,O,O
IL,B,B
-,I,I
3,I,I
mediates,O,O
cell,O,O
survival,O,O
through,O,O
activation,O,O
of,O,O
a,O,O
transcription,B,O
factor,I,O
whose,O,O
activity,O,O
can,O,O
be,O,O
constitutively,O,O
replaced,O,O
by,O,O
the,O,O
chimeric,B,O
oncoprotein,I,O
.,O,O
The,O,O
expression,O,O
and,O,O
binding,O,O
activity,O,O
of,O,O
the,O,O
Nfil3,B,B
protein,I,O
(,O,O
also,O,O
called,O,O
E4bp4,B,O
),O,O
",",O,O
but,O,O
not,O,O
of,O,O
Hlf,B,O
",",O,O
Dbp,B,O
",",O,O
or,O,O
Tef,B,O
",",O,O
was,O,O
found,O,O
to,O,O
be,O,O
regulated,O,O
by,O,O
IL,B,B
-,I,I
3,I,I
in,O,O
mouse,O,O
pro,O,O
-,O,O
B,O,O
cell,O,O
lines,O,O
(,O,O
Baf,O,O
-,O,O
3,O,O
and,O,O
FL5,O,O
.,O,O
12,O,O
),O,O
.,O,O
Detection,O,O
of,O,O
adenovirus,O,B
DNA,O,I
in,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
assay,O,O
.,O,O
The,O,O
E1A,B,B
and,I,O
hexon,I,B
primers,I,O
amplified,O,O
DNA,O,B
from,O,O
representative,O,O
adenoviral,O,O
serotypes,O,O
in,O,O
all,O,O
six,O,O
adenoviral,O,O
groups,O,O
(,O,O
A,O,O
-,O,O
F,O,O
),O,O
.,O,O
In,O,O
addition,O,O
",",O,O
assay,O,O
of,O,O
PBMC,O,O
by,O,O
the,O,O
adenovirus,O,O
-,O,O
specific,O,O
PCR,O,O
may,O,O
help,O,O
detect,O,O
early,O,O
invasive,O,O
disease,O,O
and,O,O
warrants,O,O
further,O,O
evaluation,O,O
.,O,O
Common,O,O
and,O,O
distinct,O,O
intracellular,O,O
signaling,O,O
pathways,O,O
in,O,O
human,O,O
neutrophils,O,O
utilized,O,O
by,O,O
platelet,B,B
activating,I,I
factor,I,I
and,O,O
FMLP,B,O
.,O,O
Stimulation,O,O
of,O,O
human,O,B
neutrophils,O,I
with,O,O
chemoattractants,B,O
FMLP,B,B
or,O,O
platelet,B,B
activating,I,I
factor,I,I
(,O,O
PAF,B,B
),O,O
results,O,O
in,O,O
different,O,O
but,O,O
overlapping,O,O
functional,O,O
responses,O,O
.,O,O
We,O,O
questioned,O,O
whether,O,O
these,O,O
differences,O,O
might,O,O
reflect,O,O
patterns,O,O
of,O,O
intracellular,O,O
signal,O,O
transduction,O,O
.,O,O
Stimulation,O,O
with,O,O
either,O,O
PAF,B,B
or,O,O
FMLP,B,B
resulted,O,O
in,O,O
equivalent,O,O
phosphorylation,O,O
and,O,O
activation,O,O
of,O,O
the,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,O
kinase,I,O
(,I,O
MAPk,I,O
),I,O
homologue,I,O
38,B,O
-,I,O
kD,I,O
murine,I,O
MAP,I,O
kinase,I,O
homologous,O,O
to,O,O
HOG,B,O
-,I,O
1,I,O
(,I,O
p38,I,O
),I,O
MAPk,I,O
.,O,O
A,O,O
specific,O,O
p38,B,B
MAPk,I,I
inhibitor,O,O
(,O,O
SK,O,O
&,O,O
F,O,O
86002,O,O
),O,O
blocked,O,O
superoxide,O,O
anion,O,O
production,O,O
in,O,O
response,O,O
to,O,O
FMLP,B,O
and,O,O
reduced,O,O
adhesion,O,O
and,O,O
chemotaxis,O,O
in,O,O
response,O,O
to,O,O
PAF,B,O
or,O,O
FMLP,B,O
.,O,O
Chicken,B,O
NF,I,O
-,I,O
M,I,O
transcription,I,O
factor,I,O
",",O,O
in,O,O
cooperation,O,O
with,O,O
either,O,O
c,B,O
-,I,O
Myb,I,O
or,O,O
v,B,O
-,I,O
Myb,I,O
",",O,O
is,O,O
active,O,O
in,O,O
the,O,O
combinatorial,O,O
activation,O,O
of,O,O
myeloid,B,O
-,I,O
cell,I,O
-,I,O
specific,I,O
genes,I,O
in,O,O
heterologous,O,O
cell,O,O
types,O,O
",",O,O
such,O,O
as,O,O
embryonic,O,O
fibroblasts,O,O
.,O,O
In,O,O
the,O,O
present,O,O
report,O,O
",",O,O
we,O,O
show,O,O
that,O,O
A6H,B,O
costimulated,O,O
cell,O,O
proliferation,O,O
and,O,O
cytokine,B,O
production,O,O
in,O,O
purified,O,O
CD4,O,B
+,O,I
T,O,I
cells,O,O
.,O,O
Co,O,O
-,O,O
ligation,O,O
of,O,O
the,O,O
A6H,B,O
antigen,O,O
and,O,O
the,O,O
CD3,B,B
complex,I,I
induced,O,O
expression,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
AP,B,B
-,I,I
1,I,I
in,O,O
CD4,O,B
+,O,I
T,O,I
cells,O,O
",",O,O
whereas,O,O
no,O,O
increase,O,O
in,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
octamer,B,B
-,I,I
binding,I,I
(,I,I
Oct,I,I
),I,I
proteins,I,I
was,O,O
seen,O,O
compared,O,O
to,O,O
T,O,O
cells,O,O
stimulated,O,O
with,O,O
anti,B,O
-,I,O
CD3,I,B
alone,O,O
.,O,O
Molecular,O,O
differences,O,O
of,O,O
the,O,O
A6H,B,B
molecule,I,O
or,O,O
distinct,O,O
regulation,O,O
of,O,O
the,O,O
A6H,B,B
transduced,O,O
AP,B,O
-,I,O
1,I,O
activation,O,O
pathway,O,O
may,O,O
exist,O,O
in,O,O
CD4,O,O
+,O,O
and,O,O
CD8,O,O
+,O,O
T,O,O
cell,O,O
subpopulations,O,O
.,O,O
The,O,O
DNA,B,B
-,I,I
binding,I,I
domain,I,I
(,O,O
amino,B,O
acids,I,O
421,I,O
-,I,O
486,I,O
),O,O
is,O,O
completely,O,O
conserved,O,O
among,O,O
human,B,O
",",I,O
squirrel,I,O
monkey,I,O
",",I,O
owl,I,O
monkey,I,O
",",I,O
and,I,O
cotton,I,O
-,I,O
top,I,O
tamarin,I,O
receptors,I,O
.,O,O
Expressions,O,O
of,O,O
human,O,O
and,O,O
squirrel,O,B
monkey,O,I
glucocorticoid,B,B
receptors,I,I
and,O,O
a,O,O
squirrel,B,B
monkey,I,I
receptor,I,I
in,O,O
which,O,O
Phe774,O,O
was,O,O
mutated,O,O
to,O,O
Leu,O,O
(,O,O
F774L,O,O
),O,O
were,O,O
similar,O,O
.,O,O
Shared,O,O
gamma,B,B
(,I,O
c,I,I
),I,O
subunit,I,O
within,O,O
the,O,O
human,B,O
interleukin,I,O
-,I,O
7,I,O
receptor,I,O
complex,I,O
.,O,O
The,O,O
gamma,B,B
(,I,O
c,I,I
),I,O
subunit,I,O
can,O,O
be,O,O
employed,O,O
in,O,O
receptor,B,O
complexes,I,O
for,O,O
IL,B,B
-,I,I
2,I,I
",",I,O
-,I,O
4,I,O
",",I,O
-,I,O
7,I,O
",",I,O
-,I,O
9,I,O
",",I,O
and,I,O
-,I,O
15,I,O
",",O,O
and,O,O
the,O,O
multiple,O,O
signaling,O,O
defects,O,O
that,O,O
would,O,O
result,O,O
from,O,O
a,O,O
defective,O,O
gamma,B,B
(,I,O
c,I,I
),I,O
chain,I,O
in,O,O
these,O,O
receptors,O,O
are,O,O
proposed,O,O
to,O,O
cause,O,O
the,O,O
severe,O,O
phenotype,O,O
of,O,O
X,O,O
-,O,O
SCID,O,O
patients,O,O
.,O,O
These,O,O
observations,O,O
suggest,O,O
the,O,O
functional,O,O
importance,O,O
of,O,O
gamma,B,B
(,I,O
c,I,O
),I,O
in,O,O
the,O,O
IL,B,B
-,I,I
7R,I,I
complex,I,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
determined,O,O
the,O,O
effects,O,O
of,O,O
SAC,O,O
on,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
activation,O,O
in,O,O
human,O,B
T,O,I
lymphocytes,O,I
(,O,O
Jurkat,O,B
cells,O,I
),O,O
induced,O,O
by,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
(,O,O
TNF,B,B
-,I,I
alpha,I,I
),O,O
and,O,O
H2O2,O,O
.,O,O
Elf,B,O
-,I,O
2,I,O
",",O,O
a,O,O
rhombotin,B,O
-,I,O
2,I,O
binding,I,O
ets,I,O
transcription,I,O
factor,I,O
:,O,O
discovery,O,O
and,O,O
potential,O,O
role,O,O
in,O,O
T,O,B
cell,O,I
leukemia,O,I
.,O,O
By,O,O
screening,O,O
a,O,O
T,O,B
cell,O,I
cDNA,B,I
library,I,I
",",O,O
we,O,O
identified,O,O
a,O,O
novel,B,O
ets,I,B
transcription,I,I
factor,I,I
that,O,O
binds,O,O
RBTN,B,O
-,I,O
2,I,O
.,O,O
Thymocytes,O,O
expressed,O,O
four,O,O
-,O,O
to,O,O
10,O,O
-,O,O
fold,O,O
greater,O,O
amounts,O,O
of,O,O
the,O,O
3,B,O
.,I,O
5,I,O
kb,I,O
transcript,I,O
than,O,O
other,O,O
tissues,O,O
.,O,O
The,O,O
expression,O,O
patterns,O,O
suggest,O,O
that,O,O
RBTN,B,O
-,I,O
2,I,O
normally,O,O
interacts,O,O
equally,O,O
with,O,O
elf,B,O
-,I,O
2a,I,O
and,O,O
elf,B,O
-,I,O
2b,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
when,O,O
RBTN,B,B
-,I,I
2,I,I
is,O,O
inappropriately,O,O
expressed,O,O
in,O,O
T,O,O
cells,O,O
",",O,O
RBTN,B,B
-,I,I
2,I,I
would,O,O
interact,O,O
predominantly,O,O
with,O,O
elf,B,O
-,I,O
2b,I,O
;,O,O
this,O,O
interaction,O,O
may,O,O
lead,O,O
to,O,O
T,O,O
cell,O,O
proliferation,O,O
.,O,O
When,O,O
immunoglobulin,O,B
(,O,O
Ig,O,I
),O,O
-,O,O
secreting,O,O
plasmacytomas,O,O
are,O,O
fused,O,O
to,O,O
a,O,O
T,O,O
-,O,O
cell,O,O
lymphoma,O,O
",",O,O
Ig,B,B
gene,I,I
expression,O,I
ceases,O,O
in,O,O
greater,O,O
than,O,O
95,O,O
%,O,O
of,O,O
the,O,O
resulting,O,O
hybrids,O,O
.,O,O
In,O,O
the,O,O
rare,O,O
hybrids,O,O
that,O,O
continue,O,O
to,O,O
express,O,O
Ig,O,B
",",O,O
all,O,O
other,O,O
tested,O,O
B,B,B
lymphocyte,I,I
-,I,I
specific,I,I
genes,I,I
also,O,O
remain,O,O
active,O,O
.,O,O
The,O,O
low,O,O
frequency,O,O
with,O,O
which,O,O
these,O,O
Ig,O,B
-,O,I
expressing,O,I
hybrids,O,I
are,O,O
recovered,O,O
",",O,O
along,O,O
with,O,O
the,O,O
fact,O,O
that,O,O
cell,O,O
fusions,O,O
can,O,O
lead,O,O
to,O,O
chromosome,O,O
loss,O,O
",",O,O
led,O,O
us,O,O
to,O,O
propose,O,O
that,O,O
this,O,O
rare,O,O
phenotype,O,O
was,O,O
due,O,O
to,O,O
loss,O,O
of,O,O
a,O,O
T,B,B
-,I,I
cell,I,I
-,I,I
derived,I,I
chromosome,I,I
encoding,I,O
a,I,O
factor,I,O
or,O,O
factors,O,O
with,O,O
gene,O,O
silencing,O,O
activity,O,O
.,O,O
To,O,O
identify,O,O
the,O,O
relevant,O,O
chromosome,O,O
",",O,O
we,O,O
have,O,O
used,O,O
a,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
PCR,O,O
),O,O
-,O,O
assisted,O,O
method,O,O
of,O,O
chromosome,O,O
mapping,O,O
to,O,O
analyze,O,O
both,O,O
Ig,O,B
-,O,I
silenced,O,I
(,O,O
common,O,O
),O,O
and,O,O
Ig,O,B
-,O,I
expressing,O,I
(,O,O
rare,O,O
),O,O
hybrids,O,O
.,O,O
Kaposi,O,O
s,O,O
sarcoma,O,O
(,O,O
KS,O,O
),O,O
-,O,O
associated,O,O
herpesvirus,O,O
(,O,O
KSHV,O,O
),O,O
",",O,O
or,O,O
human,O,O
herpesvirus,O,O
8,O,O
",",O,O
is,O,O
a,O,O
lymphotropic,O,O
virus,O,O
strongly,O,O
linked,O,O
to,O,O
several,O,O
AIDS,O,O
-,O,O
related,O,O
neoplasms,O,O
.,O,O
Nuclear,B,B
factor,I,I
of,I,I
activated,I,I
T,I,I
cells,I,I
and,O,O
AP,B,O
-,I,O
1,I,O
are,O,O
insufficient,O,O
for,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
activation,O,O
:,O,O
requirement,O,O
for,O,O
CD28,B,B
up,O,I
-,O,I
regulation,O,I
of,O,O
RE,B,O
/,I,O
AP,I,O
.,O,O
Uncontrolled,O,O
replication,O,O
of,O,O
a,O,O
virus,O,O
",",O,O
which,O,O
is,O,O
harmful,O,O
to,O,O
the,O,O
host,O,O
is,O,O
also,O,O
disadvantageous,O,O
to,O,O
the,O,O
virus,O,O
.,O,O
Therefore,O,O
",",O,O
only,O,O
the,O,O
time,O,O
between,O,O
infection,O,O
and,O,O
eradication,O,O
remains,O,O
for,O,O
these,O,O
viruses,O,O
to,O,O
proliferate,O,O
.,O,O
Both,O,O
are,O,O
for,O,O
the,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
(,O,O
EBV,O,B
),O,O
.,O,O
Disturbance,O,O
of,O,O
both,O,O
the,O,O
immune,O,O
surveillance,O,O
as,O,O
well,O,O
as,O,O
viral,B,O
gene,I,O
regulation,O,O
may,O,O
result,O,O
in,O,O
EBV,O,O
-,O,O
associated,O,O
disease,O,O
.,O,O
3BP2,B,O
was,O,O
selectively,O,O
expressed,O,O
in,O,O
hematopoietic,O,O
/,O,O
lymphoid,O,O
tissues,O,O
and,O,O
bound,O,O
via,O,O
its,O,O
SH2,B,O
domain,I,O
activated,I,O
Syk,I,O
-,I,O
family,I,O
kinases,I,O
in,O,O
mammalian,O,O
cells,O,O
",",O,O
including,O,O
in,O,O
antigen,O,O
receptor,O,O
-,O,O
stimulated,O,O
T,O,O
cells,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
a,O,O
series,O,O
of,O,O
Burkitt,O,O
s,O,O
lymphoma,O,O
(,O,O
BL,O,O
),O,O
cell,O,O
lines,O,O
were,O,O
assayed,O,O
for,O,O
their,O,O
expression,O,O
of,O,O
tissue,B,O
inhibitor,I,O
of,I,O
metalloproteinases,I,O
(,I,O
TIMP,I,B
),I,O
-,I,O
1,I,O
.,O,O
Results,O,O
indicate,O,O
that,O,O
TIMP,O,B
-,O,O
1,O,O
-,O,O
positive,O,O
BL,O,O
lines,O,O
show,O,O
resistance,O,O
to,O,O
cold,O,O
-,O,O
shock,O,O
-,O,O
induced,O,O
apoptosis,O,O
.,O,O
Furthermore,O,O
",",O,O
recombinant,O,O
TIMP,B,B
-,I,O
1,I,O
",",O,O
but,O,O
not,O,O
TIMP,B,B
-,I,O
2,I,O
or,O,O
a,O,O
synthetic,O,O
metalloproteinase,O,O
inhibitor,O,O
(,O,O
BB,O,O
-,O,O
94,O,O
),O,O
",",O,O
confers,O,O
resistance,O,O
to,O,O
apoptosis,O,O
induced,O,O
by,O,O
both,O,O
CD95,O,O
-,O,O
dependent,O,O
and,O,O
-,O,O
independent,O,O
(,O,O
cold,O,O
shock,O,O
",",O,O
serum,O,O
deprivation,O,O
",",O,O
and,O,O
gamma,O,O
-,O,O
radiation,O,O
),O,O
pathways,O,O
in,O,O
TIMP,O,B
-,O,O
1,O,O
-,O,O
negative,O,O
BL,O,O
lines,O,O
.,O,O
The,O,O
spi,O,O
-,O,O
1,O,O
transfected,O,O
cells,O,O
showed,O,O
reduced,O,O
growth,O,O
rates,O,O
and,O,O
reduced,O,O
clonogenic,O,O
cell,O,O
growth,O,O
.,O,O
To,O,O
investigate,O,O
in,O,O
vivo,O,O
regulatory,O,O
mechanisms,O,O
that,O,O
control,O,O
the,O,O
population,O,O
of,O,O
type,O,O
2,O,O
T,O,O
cells,O,O
and,O,O
disease,O,O
susceptibility,O,O
",",O,O
we,O,O
have,O,O
created,O,O
lines,O,O
of,O,O
transgenic,O,O
mice,O,O
in,O,O
which,O,O
expression,O,O
of,O,O
a,O,O
chimeric,B,O
cytokine,I,O
receptor,I,O
(,O,O
the,O,O
mouse,B,O
interleukin,I,B
2,I,I
receptor,I,I
beta,I,I
chain,I,I
[,I,I
IL,I,I
-,I,I
2Rbeta,I,I
],I,I
extracellular,I,I
domain,I,I
fused,O,I
to,O,I
the,O,I
cytoplasmic,B,I
tail,I,I
of,O,I
IL,B,I
-,I,I
4Ralpha,I,I
),O,I
is,O,O
targeted,O,O
to,O,O
the,O,O
T,O,O
lymphoid,O,O
lineage,O,O
using,O,O
the,O,O
proximal,B,O
lck,I,O
promoter,I,O
.,O,O
We,O,O
have,O,O
recently,O,O
cloned,O,O
the,O,O
carboxylesterase,B,O
upstream,I,O
sequence,I,O
and,O,O
showed,O,O
its,O,O
basal,B,O
promoter,I,O
activity,O,O
in,O,O
CHO,O,O
cells,O,O
.,O,O
The,O,O
role,O,O
of,O,O
the,O,O
Ikaros,B,O
gene,I,O
in,O,O
lymphocyte,O,O
development,O,O
and,O,O
homeostasis,O,O
.,O,O
In,O,O
the,O,O
adult,O,O
",",O,O
however,O,O
",",O,O
lymphoid,O,O
lineages,O,O
rely,O,O
on,O,O
Ikaros,B,O
at,O,O
distinct,O,O
phases,O,O
of,O,O
their,O,O
development,O,O
.,O,O
Its,O,O
activity,O,O
is,O,O
essential,O,O
for,O,O
the,O,O
generation,O,O
of,O,O
B,O,O
cell,O,O
but,O,O
not,O,O
of,O,O
T,O,O
cell,O,O
precursors,O,O
",",O,O
although,O,O
the,O,O
differentiation,O,O
of,O,O
the,O,O
latter,O,O
is,O,O
not,O,O
normal,O,O
.,O,O
A,O,O
significant,O,O
increase,O,O
in,O,O
CD4,O,B
thymocytes,O,I
and,O,O
their,O,O
immediate,O,O
precursors,O,O
is,O,O
detected,O,O
",",O,O
and,O,O
because,O,O
these,O,O
cells,O,O
lack,O,O
markers,O,O
that,O,O
correlate,O,O
with,O,O
positive,O,O
selection,O,O
",",O,O
a,O,O
deregulation,O,O
in,O,O
their,O,O
maturation,O,O
process,O,O
is,O,O
suggested,O,O
.,O,O
Furthermore,O,O
",",O,O
Ikaros,O,O
-,O,O
thymocytes,O,O
hyperproliferate,O,O
in,O,O
response,O,O
to,O,O
T,B,O
cell,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
signaling,O,O
;,O,O
within,O,O
days,O,O
after,O,O
their,O,O
appearance,O,O
in,O,O
the,O,O
thymus,O,O
",",O,O
clonally,O,O
expanding,O,O
populations,O,O
are,O,O
detected,O,O
.,O,O
Deregulated,O,O
TCR,B,B
-,O,I
mediated,O,I
responses,O,I
and,O,O
the,O,O
fast,O,O
kinetics,O,O
of,O,O
tumor,O,O
development,O,O
in,O,O
these,O,O
mutant,O,O
thymocytes,O,O
implicate,O,O
Ikaros,O,B
as,O,O
a,O,O
central,B,O
tumor,I,O
suppressor,I,O
gene,I,O
for,O,O
the,O,O
T,O,O
cell,O,O
lineage,O,O
.,O,O
The,O,O
role,O,O
of,O,O
Aiolos,B,B
",",O,O
a,O,O
lymphoid,B,O
-,I,O
restricted,I,O
and,I,O
structurally,I,O
related,I,O
gene,I,O
",",O,O
in,O,O
lymphoid,O,O
differentiation,O,O
is,O,O
discussed,O,O
.,O,O
Changes,O,O
in,O,O
this,O,O
regulatory,O,O
network,O,O
may,O,O
reflect,O,O
differentiation,O,O
and,O,O
proliferation,O,O
adjustments,O,O
made,O,O
in,O,O
hemo,O,O
-,O,O
lymphoid,O,O
progenitors,O,O
and,O,O
precursors,O,O
as,O,O
they,O,O
give,O,O
rise,O,O
to,O,O
the,O,O
cells,O,O
of,O,O
our,O,O
immune,O,O
system,O,O
.,O,O
STAT1,B,B
pathway,O,O
is,O,O
involved,O,O
in,O,O
activation,O,O
of,O,O
caprine,O,O
arthritis,B,O
-,I,O
encephalitis,I,O
virus,I,O
long,I,O
terminal,I,O
repeat,I,O
in,O,O
monocytes,O,O
.,O,O
Substitution,O,O
mutations,O,O
in,O,O
this,O,O
consensus,B,O
sequence,I,O
eliminate,O,O
binding,O,O
of,O,O
the,O,O
inducible,B,O
factor,I,O
.,O,O
1,B,O
",",I,O
25,I,O
-,I,O
Dihydroxyvitamin,I,B
D3,I,I
receptors,I,I
in,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
from,O,O
patients,O,O
with,O,O
renal,O,B
insufficiency,O,I
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
we,O,O
have,O,O
investigated,O,O
the,O,O
specific,O,O
uptake,O,O
of,O,O
[,O,O
3H,O,O
],O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
by,O,O
PBMC,O,O
of,O,O
11,O,O
women,O,O
with,O,O
advanced,O,O
chronic,O,O
renal,O,B
failure,O,I
(,O,O
A,O,O
-,O,O
CRF,O,O
),O,O
",",O,O
6,O,O
women,O,O
with,O,O
mild,O,O
-,O,O
moderate,O,O
renal,O,B
insufficiency,O,I
(,O,O
M,O,O
-,O,O
CRF,O,O
),O,O
",",O,O
and,O,O
23,O,O
healthy,O,O
women,O,O
.,O,O
The,O,O
mean,O,O
dissociation,O,O
constant,O,O
(,O,O
KD,O,B
),O,O
was,O,O
similar,O,O
in,O,O
both,O,O
groups,O,O
of,O,O
patients,O,O
and,O,O
in,O,O
healthy,O,O
women,O,O
(,O,O
A,O,O
-,O,O
CRF,O,O
:,O,O
0,O,O
.,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
;,O,O
M,O,O
-,O,O
CRF,O,O
:,O,O
1,O,O
.,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
;,O,O
controls,O,O
:,O,O
1,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
6,O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
),O,O
.,O,O
No,O,O
correlation,O,O
was,O,O
seen,O,O
between,O,O
VDR,B,O
and,O,O
serum,O,O
calcitriol,O,O
or,O,O
PTH,O,O
levels,O,O
",",O,O
when,O,O
considering,O,O
both,O,O
groups,O,O
of,O,O
patients,O,O
together,O,O
or,O,O
separately,O,O
.,O,O
Conversely,O,O
",",O,O
a,O,O
significant,O,O
negative,O,O
correlation,O,O
was,O,O
found,O,O
between,O,O
VDR,B,B
and,O,O
serum,O,O
creatinine,O,B
values,O,O
when,O,O
A,O,O
-,O,O
CRF,O,O
and,O,O
M,O,O
-,O,O
CRF,O,O
were,O,O
considered,O,O
altogether,O,O
(,O,O
r,O,O
-,O,O
0,O,O
.,O,O
63,O,O
;,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
These,O,O
data,O,O
are,O,O
well,O,O
in,O,O
line,O,O
with,O,O
the,O,O
long,O,O
-,O,O
standing,O,O
notion,O,O
that,O,O
interindividual,O,O
differences,O,O
in,O,O
platelet,B,B
monoamine,I,I
oxidase,I,I
may,O,O
represent,O,O
differences,O,O
in,O,O
expression,O,O
of,O,O
the,O,O
enzyme,O,O
rather,O,O
than,O,O
genotypic,O,O
variation,O,O
.,O,O
Ciprofibrate,O,O
",",O,O
an,O,O
hypolipidaemic,O,O
peroxisome,O,O
proliferator,O,O
",",O,O
induced,O,O
differentiation,O,O
of,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
.,O,O
In,O,O
particular,O,O
",",O,O
TRAF6,B,O
interacted,O,O
with,O,O
membrane,B,O
-,I,O
proximal,I,O
determinants,I,O
distinct,O,O
from,O,O
those,O,O
binding,O,O
TRAFs,B,O
1,I,O
",",I,O
2,I,O
",",I,O
3,I,O
",",I,O
and,I,O
5,I,O
.,O,O
The,O,O
molecular,O,O
mechanisms,O,O
by,O,O
which,O,O
IL,B,B
-,I,I
4,I,I
induces,O,O
expression,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
gene,I,O
are,O,O
not,O,O
known,O,O
",",O,O
although,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
-,I,I
activated,I,O
transcription,I,O
factor,I,O
signal,I,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
6,I,O
(,O,O
Stat6,B,O
),O,O
is,O,O
required,O,O
for,O,O
this,O,O
effect,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Intestinal,O,B
epithelial,O,I
cells,O,I
initiate,O,O
an,O,O
inflammatory,O,O
response,O,O
with,O,O
resulting,O,O
neutrophil,O,B
-,O,I
mediated,O,I
tissue,O,O
damage,O,O
in,O,O
response,O,O
to,O,O
E,O,O
.,O,O
infection,O,O
;,O,O
this,O,O
inflammatory,O,O
cascade,O,O
can,O,O
be,O,O
blocked,O,O
by,O,O
inhibiting,O,O
the,O,O
transcription,O,O
of,O,O
genes,O,O
regulated,O,O
by,O,O
nuclear,B,O
factor,I,O
kappaB,I,O
.,O,O
The,O,O
triptolide,O,O
-,O,O
induced,O,O
apoptosis,O,O
is,O,O
accompanied,O,O
by,O,O
increase,O,O
of,O,O
DEVD,O,O
-,O,O
cleavable,O,O
caspases,B,B
activity,O,O
and,O,O
degradation,O,O
of,O,O
caspase,B,B
substrate,I,I
poly,I,I
(,I,I
ADP,I,I
-,I,I
ribose,I,I
),I,I
polymerase,I,I
(,O,I
PARP,B,I
),O,I
.,O,O
A,O,O
specific,O,O
inhibitor,O,O
of,O,O
caspases,B,B
",",O,O
zVAD,O,O
-,O,O
FMK,O,O
",",O,O
prevents,O,O
triptolide,O,O
-,O,O
induced,O,O
PARP,B,B
degradation,O,O
and,O,O
DNA,O,B
fragmentation,O,O
but,O,O
not,O,O
growth,O,O
arrest,O,O
.,O,O
A,O,O
novel,O,O
transcription,B,O
factor,I,O
regulates,O,O
expression,O,O
of,O,O
the,O,O
vacuolar,B,B
H,I,I
+,I,I
-,I,I
ATPase,I,I
B2,I,I
subunit,I,O
through,O,O
AP,B,B
-,I,I
2,I,I
sites,I,O
during,O,O
monocytic,O,O
differentiation,O,O
.,O,O
In,O,O
mobility,O,O
shift,O,O
assays,O,O
",",O,O
a,O,O
nuclear,B,O
factor,I,O
from,O,O
THP,O,O
-,O,O
1,O,O
and,O,O
U,O,O
-,O,O
937,O,O
cells,O,O
was,O,O
identified,O,O
that,O,O
binds,O,O
to,O,O
several,O,O
AP,B,B
-,I,I
2,I,I
response,I,I
elements,I,O
within,O,O
the,O,O
B2,B,B
promoter,I,O
",",O,O
but,O,O
does,O,O
not,O,O
react,O,O
with,O,O
AP,B,O
-,I,O
2,I,O
antibodies,I,O
",",O,O
and,O,O
has,O,O
a,O,O
DNA,B,B
sequence,I,I
binding,O,I
affinity,O,I
profile,O,O
that,O,O
differs,O,O
from,O,O
AP,B,O
-,I,O
2,I,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
a,O,O
novel,O,O
AP,B,O
-,I,O
2,I,O
-,I,O
like,I,O
transcription,I,O
factor,I,O
is,O,O
responsible,O,O
for,O,O
V,B,O
-,I,O
ATPase,I,B
B,I,I
subunit,I,I
amplification,O,O
during,O,O
monocyte,O,O
differentiation,O,O
.,O,O
c,O,O
-,O,O
Jun,O,O
and,O,O
GST,O,O
-,O,O
pi,O,O
expression,O,O
in,O,O
human,O,O
plasma,O,O
cells,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
these,O,O
two,O,O
proteins,O,O
was,O,O
not,O,O
related,O,O
to,O,O
clinical,O,O
or,O,O
laboratory,O,O
data,O,O
.,O,O
It,O,O
has,O,O
been,O,O
shown,O,O
that,O,O
eosinophil,O,O
stimulation,O,O
by,O,O
these,O,O
cytokines,B,O
is,O,O
associated,O,O
with,O,O
increases,O,O
in,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
several,O,O
cellular,O,O
substrates,O,O
.,O,O
This,O,O
review,O,O
will,O,O
concentrate,O,O
on,O,O
this,O,O
topic,O,O
and,O,O
on,O,O
its,O,O
role,O,O
for,O,O
the,O,O
regulation,O,O
of,O,O
eosinophil,O,B
apoptosis,O,O
.,O,O
Time,O,O
-,O,O
course,O,O
experiments,O,O
showed,O,O
that,O,O
nuclear,O,O
levels,O,O
of,O,O
GATA,B,B
-,I,I
1,I,I
and,O,O
p45,B,B
NF,I,B
-,I,I
E2,I,I
proteins,O,O
increased,O,O
during,O,O
BA,O,O
treatment,O,O
.,O,O
The,O,O
upstream,O,O
regions,O,O
UAS3,B,B
(,O,O
-,B,O
1168,I,O
to,I,O
-,I,O
440,I,O
),O,O
and,O,O
UAS2,B,B
(,O,O
-,B,O
352,I,O
to,I,O
-,I,O
264,I,O
),O,O
both,O,O
functioned,O,O
in,O,O
a,O,O
cell,O,O
lineage,O,O
-,O,O
independent,O,O
manner,O,O
and,O,O
were,O,O
together,O,O
responsible,O,O
for,O,O
the,O,O
bulk,O,O
of,O,O
Wp,O,O
activity,O,O
in,O,O
non,O,B
-,O,I
B,O,I
cells,O,O
;,O,O
mutational,O,O
analysis,O,O
indicated,O,O
the,O,O
importance,O,O
of,O,O
a,O,O
YY1,B,B
binding,I,O
site,I,O
in,O,O
UAS2,B,B
in,O,O
that,O,O
context,O,O
.,O,O
By,O,O
contrast,O,O
",",O,O
UAS1,B,O
(,O,O
-,B,O
140,I,O
to,I,O
-,I,O
87,I,O
),O,O
was,O,O
B,O,O
cell,O,O
specific,O,O
and,O,O
was,O,O
the,O,O
key,O,O
determinant,O,O
of,O,O
the,O,O
promoter,O,O
s,O,O
increased,O,O
activity,O,O
in,O,O
B,O,O
cell,O,O
lines,O,O
.,O,O
When,O,O
mutations,O,O
that,O,O
abolished,O,O
factor,O,O
binding,O,O
in,O,O
bandshift,O,O
assays,O,O
were,O,O
introduced,O,O
into,O,O
a,O,O
Wp,B,O
reporter,I,O
construct,I,O
",",O,O
the,O,O
loss,O,O
of,O,O
any,O,O
one,O,O
of,O,O
the,O,O
three,O,O
UAS1,B,O
binding,I,O
sites,I,O
was,O,O
sufficient,O,O
to,O,O
reduce,O,O
promoter,O,O
activity,O,O
by,O,O
10,O,O
-,O,O
to,O,O
30,O,O
-,O,O
fold,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
Both,O,O
BZLF1,B,B
and,I,O
BRLF1,I,B
immediate,I,O
-,I,O
early,I,O
transcripts,I,O
",",O,O
but,O,O
not,O,O
BMLF1,B,B
transcript,I,O
",",O,O
could,O,O
be,O,O
detected,O,O
in,O,O
individual,O,O
CD4,O,B
+,O,I
and,O,O
CD8,O,B
+,O,I
T,O,O
cells,O,O
infected,O,O
with,O,O
EBV,O,O
.,O,O
T,O,O
-,O,O
lineage,O,O
precursor,O,O
populations,O,O
from,O,O
the,O,O
adult,O,O
mouse,O,O
thymus,O,O
",",O,O
prior,O,O
to,O,O
T,O,O
-,O,O
cell,O,O
receptor,O,O
gene,O,O
rearrangement,O,O
",",O,O
display,O,O
a,O,O
capacity,O,O
to,O,O
produce,O,O
DC,O,B
as,O,O
well,O,O
as,O,O
T,O,O
cells,O,O
in,O,O
the,O,O
thymus,O,O
",",O,O
and,O,O
are,O,O
very,O,O
efficient,O,O
precursors,O,O
of,O,O
DC,O,B
in,O,O
culture,O,O
.,O,O
These,O,O
lymphoid,O,B
/,O,I
DC,O,I
precursors,O,O
have,O,O
little,O,O
capacity,O,O
to,O,O
form,O,O
myeloid,O,O
cells,O,O
",",O,O
indicating,O,O
that,O,O
thymic,O,O
DC,O,O
are,O,O
a,O,O
lymphoid,O,O
-,O,O
related,O,O
rather,O,O
than,O,O
myeloid,O,O
-,O,O
related,O,O
lineage,O,O
.,O,O
Pharmacologic,O,O
blockade,O,O
of,O,O
endogenous,B,O
NFAT,I,O
activity,O,O
by,O,O
FK506,O,O
or,O,O
CsA,O,O
inhibited,O,O
synthesis,O,O
of,O,O
reverse,O,O
transcription,O,O
and,O,O
also,O,O
potently,O,O
blocked,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
.,O,O
The,O,O
first,O,O
step,O,O
in,O,O
the,O,O
nuclear,O,O
import,O,O
process,O,O
is,O,O
recognition,O,O
of,O,O
a,O,O
nuclear,B,O
localization,I,O
sequence,I,O
(,O,O
NLS,B,B
),O,O
within,O,O
the,O,O
karyophilic,B,O
protein,I,O
by,O,O
a,O,O
cytoplasmic,B,O
receptor,I,O
such,O,O
as,O,O
the,O,O
importin,B,B
(,I,O
karyopherin,I,I
),I,O
-,I,O
alpha,I,O
subunit,I,O
.,O,O
NLS,B,B
peptide,O,I
-,O,I
mediated,O,I
disruption,O,O
of,O,O
the,O,O
nuclear,O,O
import,O,O
of,O,O
these,O,O
transcription,B,O
factors,I,O
results,O,O
in,O,O
inhibition,O,O
of,O,O
I,O,O
kappa,O,B
B,O,I
alpha,O,I
and,O,O
IL,O,B
-,O,I
2,O,I
gene,O,I
expression,O,O
",",O,O
processes,O,O
dependent,O,O
on,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
or,O,O
the,O,O
combination,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
AP,B,B
-,I,I
1,I,I
",",O,O
and,O,O
NFAT,B,B
.,O,O
Further,O,O
",",O,O
we,O,O
show,O,O
that,O,O
inhibitory,O,O
NLS,B,B
peptide,O,I
interacts,O,O
in,O,O
vitro,O,O
with,O,O
a,O,O
cytoplasmic,B,O
NLS,I,B
receptor,I,I
complex,I,I
comprised,O,O
of,O,O
the,O,O
Rch1,B,O
/,I,O
importin,I,O
(,I,O
karyopherin,I,O
),I,O
beta,I,O
heterodimer,I,O
expressed,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
.,O,O
Forty,O,O
-,O,O
eight,O,O
hours,O,O
after,O,O
transfection,O,O
",",O,O
EC,O,O
were,O,O
stimulated,O,O
with,O,O
NK,O,O
cells,O,O
or,O,O
NK,O,O
cell,O,O
membrane,O,O
extracts,O,O
for,O,O
7,O,O
hr,O,O
and,O,O
activation,O,O
was,O,O
measured,O,O
by,O,O
a,O,O
luciferase,B,O
assay,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Human,O,O
NK,O,B
cell,O,I
membrane,O,I
-,O,I
bound,O,I
LT,O,I
signals,O,O
across,O,O
species,O,O
via,O,O
TNFRI,B,O
",",O,O
leading,O,O
to,O,O
NF,B,B
-,I,I
kappaB,I,I
nuclear,O,I
translocation,O,I
and,O,O
transcription,O,O
of,O,O
E,B,B
-,I,I
selectin,I,I
and,O,O
IL,B,B
-,I,I
8,I,I
",",O,O
which,O,O
results,O,O
in,O,O
EC,O,O
activation,O,O
.,O,O
The,O,O
discrepancy,O,O
in,O,O
the,O,O
degree,O,O
of,O,O
inhibition,O,O
by,O,O
membrane,O,O
extracts,O,O
and,O,O
NK,O,B
cells,O,I
with,O,O
mutant,B,O
TNFRI,I,O
suggests,O,O
that,O,O
additional,O,O
pathways,O,O
are,O,O
utilized,O,O
by,O,O
NK,O,B
cells,O,I
to,O,O
activate,O,O
EC,O,O
Ras,B,O
-,O,O
dependent,O,O
",",O,O
Ca2,O,O
+,O,O
-,O,O
stimulated,O,O
activation,O,O
of,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
by,O,O
a,O,O
constitutively,O,O
active,O,O
Cbl,B,O
mutant,I,O
in,O,O
T,O,O
cells,O,O
.,O,O
Blood,O,O
monocytes,O,O
spontaneously,O,O
activate,O,O
endothelial,O,B
cells,O,I
in,O,O
culture,O,O
",",O,O
leading,O,O
to,O,O
adhesion,O,O
of,O,O
monocytic,O,B
cells,O,I
onto,O,O
the,O,O
endothelial,O,B
surface,O,I
and,O,O
overproduction,O,O
of,O,O
endothelial,O,B
proteins,O,I
such,O,O
as,O,O
von,B,B
Willebrand,I,I
factor,I,I
(,O,O
vWf,B,O
),O,O
and,O,O
plasminogen,B,B
activator,I,I
inhibitor,I,I
type,I,I
1,I,I
(,O,O
PAI,B,O
-,I,O
1,I,O
),O,O
.,O,O
Addition,O,O
of,O,O
untreated,O,O
THP,O,O
-,O,O
1,O,O
cells,O,O
had,O,O
little,O,O
effect,O,O
on,O,O
HUVEC,O,O
adhesiveness,O,O
.,O,O
Under,O,O
these,O,O
conditions,O,O
HUVEC,B,B
adhesion,I,I
molecules,I,I
",",O,O
E,B,B
-,I,I
selectin,I,I
",",O,O
VCAM,B,B
-,I,I
1,I,I
and,O,O
ICAM,B,B
-,I,I
1,I,I
",",O,O
were,O,O
increased,O,O
at,O,O
3,O,O
h,O,O
with,O,O
only,O,O
ICAM,B,B
-,I,I
1,I,I
remaining,O,O
overexpressed,O,O
at,O,O
24,O,O
h,O,O
.,O,O
Quantitative,O,O
reverse,B,O
transcriptase,I,O
-,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
RT,O,O
-,O,O
PCR,O,O
),O,O
showed,O,O
an,O,O
increase,O,O
in,O,O
steady,O,O
-,O,O
state,O,O
TNF,B,B
-,I,I
alpha,I,I
mRNA,I,I
after,O,O
3,O,O
to,O,O
4,O,O
hours,O,O
of,O,O
cross,O,O
-,O,O
linking,O,O
.,O,O
CD2,B,B
cross,O,O
-,O,O
linking,O,O
concurrently,O,O
increased,O,O
phosphorylation,O,O
of,O,O
CREB,B,B
detected,O,O
by,O,O
immunoblot,O,O
assay,O,O
eightfold,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
specific,O,O
modulation,O,O
of,O,O
the,O,O
CREB,B,B
/,I,I
ATF,I,I
-,I,I
1,I,I
family,I,O
of,O,O
transcription,B,O
factors,I,O
by,O,O
the,O,O
CD2,B,B
signalling,O,O
pathway,O,O
and,O,O
suggest,O,O
CD2,B,B
receptor,O,O
modulation,O,O
of,O,O
CRE,B,B
-,O,I
mediated,O,I
transcription,O,I
following,O,O
ligand,O,O
engagement,O,O
(,O,O
e,O,O
.,O,O
g,O,O
.,O,O
cell,O,O
-,O,O
to,O,O
-,O,O
cell,O,O
contact,O,O
.,O,O
In,O,O
the,O,O
present,O,O
report,O,O
we,O,O
show,O,O
that,O,O
in,O,O
various,O,O
transiently,O,O
or,O,O
stably,O,O
transfected,O,O
cell,O,O
lines,O,O
",",O,O
X,O,O
-,O,O
ray,O,O
irradiation,O,O
up,O,O
-,O,O
regulates,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
transcription,O,O
through,O,O
the,O,O
kappaB,B,O
regulatory,I,O
elements,I,O
.,O,O
In,O,O
addition,O,O
",",O,O
X,O,O
-,O,O
ray,O,O
activation,O,O
of,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
in,O,O
transiently,O,O
or,O,O
stably,O,O
transfected,O,O
cell,O,O
lines,O,O
is,O,O
inhibited,O,O
by,O,O
a,O,O
potent,O,O
antioxidant,O,O
drug,O,O
",",O,O
pyrrolidine,O,O
dithiocarbamate,O,O
and,O,O
by,O,O
another,O,O
drug,O,O
",",O,O
known,O,O
for,O,O
its,O,O
role,O,O
in,O,O
the,O,O
trapping,O,O
of,O,O
growth,B,O
factors,I,O
",",O,O
suramin,O,O
.,O,O
The,O,O
importance,O,O
of,O,O
these,O,O
observations,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
patients,O,O
with,O,O
AIDS,O,O
-,O,O
related,O,O
cancers,O,O
treated,O,O
by,O,O
radiotherapy,O,O
remains,O,O
to,O,O
be,O,O
established,O,O
.,O,O
Restoration,O,O
of,O,O
the,O,O
CCAAT,B,O
box,I,O
at,O,O
-,B,O
70,I,O
bp,I,O
",",O,O
or,O,O
insertion,O,O
of,O,O
an,O,O
EKLF,B,O
binding,I,O
site,I,O
at,O,O
-,B,O
85,I,O
bp,I,O
or,O,O
-,B,O
95,I,O
bp,I,O
in,O,O
the,O,O
promoter,B,O
significantly,O,O
increased,O,O
delta,O,B
globin,O,I
gene,O,I
expression,O,O
in,O,O
hAEC,O,O
.,O,O
Constitutive,O,O
association,O,O
of,O,O
JAK1,B,B
and,O,O
STAT5,B,B
in,O,O
pro,O,B
-,O,I
B,O,I
cells,O,O
is,O,O
dissolved,O,O
by,O,O
interleukin,B,B
-,I,I
4,I,I
-,O,I
induced,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
both,O,O
proteins,O,O
.,O,O
Nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
was,O,O
found,O,O
to,O,O
be,O,O
activated,O,O
in,O,O
ventilated,O,O
macrophages,O,O
.,O,O
To,O,O
determine,O,O
the,O,O
mechanisms,O,O
responsible,O,O
for,O,O
these,O,O
differences,O,O
",",O,O
we,O,O
turned,O,O
to,O,O
human,O,O
U937,O,O
promonocytic,O,O
cells,O,O
.,O,O
Based,O,O
on,O,O
the,O,O
high,O,O
specificity,O,O
of,O,O
this,O,O
compound,O,O
for,O,O
PKC,B,B
",",O,O
we,O,O
conclude,O,O
that,O,O
PKC,B,O
is,O,O
necessary,O,O
for,O,O
FN,B,O
-,O,O
induced,O,O
IL,B,B
-,I,I
1beta,I,I
protein,O,O
production,O,O
.,O,O
A,O,O
novel,O,O
member,O,O
of,O,O
the,O,O
tumor,B,O
necrosis,I,O
factor,I,O
(,I,O
TNF,I,O
),I,O
receptor,I,O
family,I,O
",",O,O
designated,O,O
TRAMP,B,O
",",O,O
has,O,O
been,O,O
identified,O,O
.,O,O
Overexpression,O,O
of,O,O
TRAMP,B,O
leads,O,O
to,O,O
two,O,O
major,O,O
responses,O,O
",",O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
and,O,O
apoptosis,O,O
.,O,O
Using,O,O
a,O,O
nuclear,O,O
run,O,O
-,O,O
on,O,O
assay,O,O
",",O,O
IL,B,B
-,I,I
4,I,I
stimulation,O,O
was,O,O
shown,O,O
to,O,O
enhance,O,O
transcription,O,O
by,O,O
two,O,O
-,O,O
to,O,O
threefold,O,O
.,O,O
Conversely,O,O
",",O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
13,I,I
markedly,O,O
and,O,O
significantly,O,O
inhibited,O,O
HIV,O,B
replication,O,O
at,O,O
the,O,O
transcriptional,O,O
level,O,O
in,O,O
monocyte,O,B
-,O,I
derived,O,I
macrophages,O,I
",",O,O
and,O,O
this,O,O
occurred,O,O
whether,O,O
these,O,O
cytokines,B,O
were,O,O
added,O,O
before,O,O
or,O,O
after,O,O
HIV,O,B
infection,O,O
.,O,O
Interleukin,B,B
-,I,I
10,I,I
(,O,O
IL,B,B
-,I,I
10,I,I
),O,O
protects,O,O
animals,O,O
from,O,O
lethal,O,O
endotoxemia,O,O
.,O,O
Evidence,O,O
suggests,O,O
that,O,O
IL,B,B
-,I,I
10,I,I
may,O,O
inhibit,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
nuclear,B,O
NF,B,B
-,I,I
kappaB,I,I
),O,O
through,O,O
an,O,O
unknown,O,O
mechanism,O,O
.,O,O
We,O,O
hypothesized,O,O
that,O,O
IL,B,B
-,I,I
10,I,I
prevents,O,O
human,O,O
monocyte,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
and,O,O
resultant,O,O
TNF,B,B
-,I,I
alpha,I,I
production,O,O
by,O,O
stabilization,O,O
of,O,O
IkappaB,B,O
-,I,O
alpha,I,O
.,O,O
Cells,O,O
were,O,O
stimulated,O,O
with,O,O
endotoxin,B,O
(,O,O
LPS,O,B
",",O,O
100,O,O
ng,O,O
/,O,O
mL,O,O
),O,O
with,O,O
and,O,O
without,O,O
human,O,O
IL,B,B
-,I,I
10,I,I
(,O,O
10,O,O
ng,O,O
/,O,O
mL,O,O
),O,O
.,O,O
IL,B,B
-,I,I
10,I,I
attenuated,O,O
LPS,O,O
-,O,O
stimulated,O,O
TNF,B,B
-,I,I
alpha,I,I
production,O,O
(,O,O
297,O,O
+,O,O
/,O,O
-,O,O
54,O,O
;,O,O
p,O,O
<,O,O
.,O,O
versus,O,O
LPS,O,O
alone,O,O
),O,O
.,O,O
IL,B,B
-,I,I
10,I,I
appears,O,O
to,O,O
prevent,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
by,O,O
preserving,O,O
IkappaB,B,B
-,I,I
alpha,I,I
protein,O,O
levels,O,O
",",O,O
leading,O,O
to,O,O
a,O,O
reduction,O,O
in,O,O
TNF,B,B
-,I,I
alpha,I,I
release,O,O
.,O,O
Down,O,O
-,O,O
regulation,O,O
of,O,O
human,O,O
granzyme,B,B
B,I,I
expression,O,O
by,O,O
glucocorticoids,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
dexamethasone,O,O
is,O,O
able,O,O
to,O,O
abrogate,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
the,O,O
human,B,O
granzyme,I,B
B,I,I
gene,I,O
promoter,I,O
by,O,O
inhibiting,O,O
the,O,O
binding,O,O
of,O,O
nuclear,B,O
factors,I,O
at,O,O
the,O,O
AP,B,O
-,I,O
1,I,O
and,I,O
Ikaros,I,O
sites,I,O
.,O,O
Therefore,O,O
in,O,O
this,O,O
study,O,O
",",O,O
we,O,O
have,O,O
examined,O,O
the,O,O
role,O,O
of,O,O
glucocorticoid,B,O
receptor,I,O
/,I,O
s,I,O
(,O,O
GR,B,O
),O,O
characteristics,O,O
in,O,O
the,O,O
developing,O,O
of,O,O
these,O,O
abnormalities,O,O
in,O,O
patients,O,O
with,O,O
PCOS,O,O
.,O,O
ngal,O,B
gene,O,I
expression,O,I
was,O,O
found,O,O
at,O,O
moderate,O,O
levels,O,O
in,O,O
only,O,O
2,O,O
of,O,O
17,O,O
human,O,O
tissues,O,O
examined,O,O
",",O,O
breast,O,B
and,O,O
lung,O,B
.,O,O
Immuno,O,O
-,O,O
histochemical,O,O
analysis,O,O
confirmed,O,O
the,O,O
presence,O,O
of,O,O
NGAL,B,B
within,O,O
breast,O,B
carcinoma,O,I
cells,O,O
but,O,O
detected,O,O
only,O,O
low,O,O
levels,O,O
of,O,O
this,O,O
protein,O,B
in,O,O
normal,O,O
ductal,O,O
epithelium,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
significant,O,O
correlation,O,O
between,O,O
NGAL,B,B
expression,O,I
in,O,O
breast,O,B
cancer,O,I
was,O,O
found,O,O
with,O,O
several,O,O
other,O,O
markers,O,O
of,O,O
poor,O,O
prognosis,O,O
",",O,O
including,O,O
estrogen,O,B
and,O,O
progesterone,B,B
receptor,I,I
-,O,I
negative,O,I
status,O,O
and,O,O
high,O,O
proliferation,O,O
(,O,O
S,O,B
-,O,I
phase,O,I
fraction,O,I
),O,O
.,O,O
BASH,B,B
",",O,O
a,O,O
novel,B,O
signaling,I,O
molecule,I,O
preferentially,O,O
expressed,O,O
in,O,O
B,O,B
cells,O,I
of,O,O
the,O,O
bursa,O,O
of,O,O
Fabricius,O,O
.,O,O
The,O,O
gene,O,O
encodes,O,O
an,O,O
85,B,O
-,I,O
kDa,I,O
protein,I,B
",",O,O
designated,O,O
BASH,B,B
(,O,O
B,B,O
cell,I,O
adaptor,I,O
containing,I,O
SH2,I,O
domain,I,O
),O,O
",",O,O
that,O,O
contains,O,O
N,B,O
-,I,O
terminal,I,O
acidic,I,O
domains,I,O
with,O,O
SH2,B,O
domain,I,O
-,I,O
binding,I,O
phosphotyrosine,I,O
-,I,O
based,I,O
motifs,I,O
",",O,O
a,O,O
proline,B,O
-,I,O
rich,I,O
domain,I,O
",",O,O
and,O,O
a,O,O
C,B,O
-,I,O
terminal,I,O
SH2,I,O
domain,I,O
.,O,O
These,O,O
studies,O,O
revealed,O,O
that,O,O
the,O,O
major,B,O
protein,I,B
in,O,O
extracts,O,O
of,O,O
PMN,O,O
activated,O,O
by,O,O
G,B,O
-,I,O
CSF,I,O
to,O,O
bind,O,O
the,O,O
high,B,O
-,I,O
affinity,I,O
serum,I,O
-,I,O
inducible,I,O
element,I,O
(,O,O
hSIE,B,O
),O,O
is,O,O
a,O,O
72,B,O
-,I,O
kDa,I,O
protein,I,O
that,O,O
cross,O,O
-,O,O
reacts,O,O
with,O,O
Stat3,B,B
monoclonal,I,O
antibody,I,O
",",O,O
which,O,O
we,O,O
have,O,O
designated,O,O
Stat3gamma,B,O
.,O,O
In,O,O
order,O,O
to,O,O
investigate,O,O
the,O,O
factors,O,O
that,O,O
influence,O,O
the,O,O
induction,O,O
of,O,O
ICAM,B,O
-,I,O
1,I,O
molecules,O,O
",",O,O
Northern,O,O
blot,O,O
analysis,O,O
to,O,O
measure,O,O
the,O,O
expression,O,O
level,O,O
of,O,O
ICAM,B,O
-,I,O
1,I,O
mRNAs,I,O
and,O,O
Southern,O,O
blot,O,O
hybridization,O,O
to,O,O
analyze,O,O
the,O,O
integration,O,O
of,O,O
human,O,O
T,O,O
-,O,O
cell,O,O
-,O,O
leukemia,O,O
virus,O,O
type,O,O
1,O,O
(,O,O
HTLV,O,O
-,O,O
1,O,O
),O,O
provirus,O,O
were,O,O
done,O,O
.,O,O
These,O,O
sequences,O,O
were,O,O
chosen,O,O
for,O,O
study,O,O
because,O,O
mass,O,O
-,O,O
spectrometric,O,O
analysis,O,O
(,O,O
MS,O,O
),O,O
of,O,O
a,O,O
CTL,O,O
active,O,O
HPLC,O,O
peptide,O,O
fraction,O,O
eluted,O,O
from,O,O
immunoaffinity,B,O
precipitated,I,O
HLA,I,B
-,I,I
A2,I,I
molecule,I,O
",",O,O
revealed,O,O
:,O,O
(,O,O
a,O,O
),O,O
the,O,O
presence,O,O
of,O,O
an,O,O
ion,O,O
with,O,O
a,O,O
mass,O,O
-,O,O
to,O,O
-,O,O
charge,O,O
ratio,O,O
(,O,O
m,O,O
/,O,O
z,O,O
),O,O
of,O,O
793,O,O
which,O,O
was,O,O
more,O,O
abundant,O,O
than,O,O
other,O,O
ions,O,O
of,O,O
similar,O,O
masses,O,O
;,O,O
(,O,O
b,O,O
),O,O
the,O,O
tentatively,O,O
reconstituted,O,O
sequence,O,O
of,O,O
the,O,O
ion,O,O
793,O,O
matched,O,O
the,O,O
sequence,O,O
of,O,O
peptide,O,O
G76,O,O
.,O,O
These,O,O
concentrations,O,O
are,O,O
lower,O,O
than,O,O
concentrations,O,O
reported,O,O
to,O,O
activate,O,O
effector,O,O
function,O,O
of,O,O
CTL,O,O
recognizing,O,O
other,O,O
epithelial,B,B
tumor,I,I
Ag,I,I
.,O,O
Furthermore,O,O
",",O,O
analysis,O,O
with,O,O
cloned,O,O
CD8,O,B
+,O,I
T,O,I
cells,O,O
indicated,O,O
that,O,O
G75,O,O
and,O,O
G76,O,O
were,O,O
not,O,O
cross,O,O
-,O,O
reactive,O,O
specificities,O,O
",",O,O
suggesting,O,O
a,O,O
key,O,O
role,O,O
for,O,O
the,O,O
N,B,B
-,I,I
terminal,I,I
residues,I,I
of,O,O
the,O,O
variant,O,O
peptide,O,O
in,O,O
dictating,O,O
specificities,O,O
.,O,O
Since,O,O
the,O,O
AES,B,B
proteins,I,O
are,O,O
part,O,O
of,O,O
a,O,O
set,O,O
of,O,O
transcriptional,O,O
repressors,O,O
encoded,O,O
by,O,O
the,O,O
Enhancer,B,O
of,I,O
split,I,O
[,I,O
E,I,B
(,I,I
spl,I,I
),I,I
],I,O
genes,I,O
",",O,O
and,O,O
since,O,O
these,O,O
repressors,O,O
are,O,O
activated,O,O
to,O,O
suppress,O,O
cell,O,O
differentiation,O,O
in,O,O
response,O,O
to,O,O
Notch,B,O
receptors,I,O
signalling,O,O
",",O,O
the,O,O
AES,O,B
peptides,O,O
may,O,O
represent,O,O
a,O,O
novel,O,O
class,O,O
of,O,O
self,B,O
-,I,O
antigens,I,O
that,O,O
deserve,O,O
further,O,O
consideration,O,O
as,O,O
tumor,B,O
Ag,I,O
in,O,O
epithelial,O,O
cancers,O,O
.,O,O
Our,O,O
data,O,O
show,O,O
that,O,O
IFNs,B,B
and,O,O
IL,B,B
-,I,I
1,I,I
upregulate,O,O
PML,O,B
transcript,O,O
and,O,O
protein,O,O
expression,O,O
in,O,O
a,O,O
time,O,O
and,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
Glucocorticoid,B,B
receptors,I,I
(,O,O
GR,B,O
),O,O
and,O,O
3,O,O
-,O,O
O,O,O
-,O,O
methyl,O,O
-,O,O
D,O,O
glucose,O,O
(,O,O
3,O,O
-,O,O
O,O,O
-,O,O
MG,O,O
),O,O
transport,O,O
were,O,O
determined,O,O
in,O,O
mononuclear,O,B
leukocytes,O,I
(,O,O
MNL,O,O
),O,O
from,O,O
11,O,O
abdominal,O,O
obese,O,O
subjects,O,O
",",O,O
10,O,O
pituitary,O,B
-,O,I
dependent,O,I
Cushing,O,I
s,O,I
syndrome,O,I
(,O,O
Cushing,O,O
s,O,O
disease,O,O
),O,O
and,O,O
10,O,O
healthy,O,O
controls,O,O
.,O,O
Interleukin,B,B
-,I,I
10,I,I
(,O,I
IL,B,I
-,I,I
10,I,I
),O,I
and,O,O
transforming,B,O
growth,I,O
factor,I,O
beta,I,B
(,O,I
TGF,B,I
-,I,I
beta,I,I
),O,I
are,O,O
inhibitory,O,O
for,O,O
B,O,O
and,O,O
T,O,O
cells,O,O
",",O,O
IgE,B,O
production,O,O
",",O,O
and,O,O
mast,O,O
cell,O,O
proliferation,O,O
",",O,O
and,O,O
they,O,O
induce,O,O
apoptosis,O,O
in,O,O
eosinophils,O,O
.,O,O
The,O,O
IL,B,B
-,I,I
10,I,I
gene,O,O
polymorphism,O,O
was,O,O
a,O,O
C,O,O
-,O,O
to,O,O
-,O,O
A,O,O
exchange,O,O
571,B,O
base,I,O
pairs,I,O
upstream,I,O
from,O,O
the,O,O
translation,B,O
start,I,O
site,I,O
and,O,O
was,O,O
present,O,O
between,O,O
consensus,B,O
binding,I,O
sequences,I,O
for,O,O
Sp1,B,O
and,O,O
elevated,O,O
total,O,O
serum,O,O
.,O,O
This,O,O
polymorphism,O,O
was,O,O
associated,O,O
with,O,O
elevated,O,O
total,B,O
serum,I,O
IgE,I,B
in,O,O
subjects,O,O
heterozygotic,O,O
or,O,O
homozygotic,O,O
for,O,O
this,O,O
base,O,O
exchange,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
This,O,O
polymorphism,O,O
represented,O,O
a,O,O
C,O,B
-,O,I
to,O,I
-,O,I
T,O,I
base,O,I
exchange,O,I
which,O,O
induced,O,O
a,O,O
YY1,B,B
consensus,I,I
sequence,I,I
and,O,O
is,O,O
present,O,O
in,O,O
a,O,O
region,O,O
of,O,O
the,O,O
promoter,O,O
associated,O,O
with,O,O
negative,O,O
transcription,O,O
regulation,O,O
.,O,O
However,O,O
",",O,O
it,O,O
was,O,O
only,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
whose,O,O
activation,O,O
by,O,O
Tpl,B,O
-,I,O
2,I,O
was,O,O
fully,O,O
blocked,O,O
by,O,O
the,O,O
dominant,B,O
negative,I,O
mutant,I,O
MEK1S218,I,B
/,I,I
222A,I,I
and,O,O
the,O,O
MEK1,O,B
/,O,I
MEK2,O,I
inhibitor,O,O
PD098059,O,O
.,O,O
Since,O,O
the,O,O
protein,O,B
has,O,O
a,O,O
homeodomain,B,O
and,O,O
can,O,O
activate,O,O
transcription,O,O
",",O,O
it,O,O
probably,O,O
exerts,O,O
at,O,O
least,O,O
some,O,O
of,O,O
its,O,O
effects,O,O
in,O,O
vivo,O,O
by,O,O
regulation,O,O
of,O,O
target,B,O
genes,I,O
.,O,O
We,O,O
investigated,O,O
the,O,O
function,O,O
of,O,O
the,O,O
evolutionary,O,O
conserved,O,O
X2,B,O
box,I,O
in,O,O
the,O,O
promoter,B,O
of,O,O
the,O,O
HLA,B,B
-,I,I
DRA,I,I
gene,I,I
from,O,O
the,O,O
human,B,O
major,I,O
histocompatibility,I,O
complex,I,O
(,O,O
MHC,B,O
),O,O
in,O,O
resting,O,O
and,O,O
activated,O,O
B,O,O
cells,O,O
.,O,O
Thymocytes,O,O
control,O,O
the,O,O
CD4,B,B
gene,I,I
differently,O,O
from,O,O
mature,O,O
T,O,O
lymphocytes,O,O
.,O,O
Glucocorticoids,O,O
are,O,O
physiological,O,O
molecules,O,O
that,O,O
are,O,O
also,O,O
extensively,O,O
used,O,O
in,O,O
clinics,O,O
as,O,O
anti,O,O
-,O,O
inflammatory,O,O
",",O,O
immunosuppressive,O,O
or,O,O
anti,O,O
-,O,O
tumoral,O,O
agents,O,O
.,O,O
The,O,O
action,O,O
of,O,O
adenoviral,B,B
E1A,I,I
oncoprotein,I,I
on,O,O
host,B,O
immune,I,O
-,I,O
response,I,O
genes,I,O
has,O,O
been,O,O
attributed,O,O
to,O,O
interaction,O,O
with,O,O
p300,B,O
/,I,O
CBP,I,O
-,I,O
type,I,O
transcriptional,I,O
coactivators,I,O
in,O,O
competition,O,O
with,O,O
endogenous,B,O
transcription,I,O
factors,I,O
such,O,O
as,O,O
signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
(,I,O
STAT,I,O
),I,O
proteins,I,O
.,O,O
Effect,O,O
of,O,O
environmental,O,O
estrogens,O,O
on,O,O
IL,B,B
-,I,I
1beta,I,I
promoter,I,I
activity,O,O
in,O,O
a,O,O
macrophage,O,B
cell,O,I
line,O,I
.,O,O
17beta,O,B
-,O,I
estradiol,O,I
(,O,O
E2,O,B
),O,O
markedly,O,O
enhanced,O,O
lipopolysaccharide,O,O
-,O,O
(,O,O
LPS,O,O
),O,O
induced,O,O
IL,B,B
-,I,I
1beta,I,I
promoter,I,O
-,O,O
driven,O,O
CAT,B,O
activity,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
Unlike,O,O
the,O,O
mycoestrogens,O,O
",",O,O
none,O,O
of,O,O
the,O,O
compounds,O,O
",",O,O
with,O,O
the,O,O
exception,O,O
of,O,O
genistein,O,O
",",O,O
synergized,O,O
with,O,O
LPS,O,O
to,O,O
enhance,O,O
IL,B,B
-,I,I
1beta,I,I
promoter,I,O
activity,O,O
.,O,O
Naringenin,O,O
",",O,O
a,O,O
plant,O,O
flavonoid,O,O
",",O,O
showed,O,O
little,O,O
or,O,O
no,O,O
ability,O,O
to,O,O
antagonize,O,O
the,O,O
response,O,O
to,O,O
E2,O,B
.,O,O
Isolation,O,O
and,O,O
utilization,O,O
of,O,O
human,O,B
dendritic,O,I
cells,O,I
from,O,O
peripheral,O,O
blood,O,O
to,O,O
assay,O,O
an,O,O
in,O,O
vitro,O,O
primary,O,O
immune,O,O
response,O,O
to,O,O
varicella,O,O
-,O,O
zoster,O,O
virus,O,O
peptides,O,O
.,O,O
Here,O,O
we,O,O
evaluated,O,O
whether,O,O
xenogeneic,O,O
serum,O,O
",",O,O
as,O,O
a,O,O
source,O,O
of,O,O
xenoreactive,B,O
natural,I,O
antibodies,I,O
and,O,O
complement,O,O
",",O,O
induced,O,O
endothelial,O,B
cell,O,I
activation,O,O
with,O,O
consequent,O,O
leukocyte,O,B
adhesion,O,O
under,O,O
flow,O,O
conditions,O,O
.,O,O
Adherent,O,O
cells,O,O
were,O,O
counted,O,O
by,O,O
digital,O,O
image,O,O
analysis,O,O
.,O,O
In,O,O
order,O,O
to,O,O
elucidate,O,O
possible,O,O
mechanisms,O,O
underlying,O,O
endothelial,O,B
cell,O,I
activation,O,O
by,O,O
xenogeneic,O,O
serum,O,O
",",O,O
we,O,O
focussed,O,O
on,O,O
transcription,B,O
factor,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
",",O,O
a,O,O
central,O,O
regulator,O,O
for,O,O
the,O,O
induction,O,O
of,O,O
different,O,O
genes,O,O
",",O,O
including,O,O
adhesive,B,O
molecules,I,O
and,O,O
chemoattractants,B,O
.,O,O
Anaphylatoxins,B,B
C5a,B,I
and,O,O
C3a,B,B
induce,O,O
nuclear,B,O
factor,I,O
kappaB,I,O
activation,O,O
in,O,O
human,O,B
peripheral,O,I
blood,O,I
monocytes,O,I
.,O,O
These,O,O
results,O,O
imply,O,O
a,O,O
potential,O,O
role,O,O
of,O,O
the,O,O
anaphylatoxins,B,B
C5a,B,I
and,O,O
C3a,B,B
in,O,O
regulating,O,O
leukocytes,O,B
gene,O,I
expression,O,I
through,O,O
G,O,B
protein,O,I
-,O,I
coupled,O,I
transcription,O,I
factor,O,I
activation,O,I
.,O,O
Plasma,O,O
TPO,B,B
levels,O,I
are,O,O
regulated,O,O
by,O,O
the,O,O
platelet,O,B
and,O,O
megakaryocyte,O,B
mass,O,I
through,O,O
Mpl,B,B
receptor,I,I
binding,O,I
",",O,O
internalization,O,O
and,O,O
degradation,O,O
.,O,O
The,O,O
Mpl,B,B
receptor,I,I
is,O,O
a,O,O
member,O,O
of,O,O
the,O,O
hematopoietin,B,O
receptor,I,O
superfamily,I,O
lacking,O,O
intrinsic,O,O
kinase,O,O
activity,O,O
.,O,O
Promoter,O,O
analysis,O,O
revealed,O,O
that,O,O
a,O,O
GATA,B,B
site,I,O
in,O,O
a,O,O
cryptic,B,O
promoter,I,O
in,O,O
the,O,O
second,B,O
intron,I,O
was,O,O
essential,O,O
and,O,O
sufficient,O,O
for,O,O
the,O,O
TAL1,O,O
-,O,O
and,O,O
LMO,O,O
-,O,O
dependent,O,O
transcriptional,O,O
activation,O,O
",",O,O
and,O,O
GATA3,B,B
binds,O,O
to,O,O
this,O,O
site,O,O
.,O,O
Glucocorticoids,O,B
are,O,O
important,O,O
for,O,O
maintaining,O,O
cellular,O,O
and,O,O
humoral,O,O
homeostasis,O,O
and,O,O
are,O,O
key,O,O
mediators,O,O
of,O,O
neuroendocrine,O,O
-,O,O
immune,O,O
regulatory,O,O
interactions,O,O
.,O,O
Several,O,O
neuroendocrine,O,O
-,O,O
immune,O,O
interactions,O,O
could,O,O
be,O,O
responsible,O,O
for,O,O
reduced,O,O
GR,B,B
levels,O,O
with,O,O
age,O,O
and,O,O
sport,O,O
activity,O,O
in,O,O
man,O,O
.,O,O
Glycation,O,O
-,O,O
dependent,O,O
",",O,O
reactive,O,O
oxygen,O,O
species,O,O
-,O,O
mediated,O,O
suppression,O,O
of,O,O
the,O,O
insulin,O,B
gene,O,I
promoter,O,I
activity,O,O
in,O,O
HIT,O,O
cells,O,O
.,O,O
In,O,O
non,O,O
-,O,O
rheumatoid,O,O
arthritis,O,O
",",O,O
binding,O,O
of,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
in,O,O
synovial,O,O
T,O,O
cells,O,O
was,O,O
exclusively,O,O
mediated,O,O
by,O,O
p50,B,B
/,I,I
p50,I,I
homodimers,I,I
.,O,O
X,B,B
chromosome,I,I
inactivation,O,I
patterns,O,I
in,O,O
normal,O,O
females,O,O
.,O,O
Since,O,O
one,O,O
of,O,O
the,O,O
two,O,O
X,B,B
chromosomes,I,I
is,O,O
randomly,O,O
inactivated,O,O
at,O,O
an,O,O
early,O,O
stage,O,O
of,O,O
female,O,O
embryonic,O,O
development,O,O
",",O,O
X,B,B
-,I,I
linked,I,I
markers,I,I
have,O,O
been,O,O
used,O,O
to,O,O
study,O,O
the,O,O
origin,O,O
and,O,O
development,O,O
of,O,O
various,O,O
neoplastic,O,O
disorders,O,O
in,O,O
affected,O,O
heterozygous,O,O
women,O,O
;,O,O
clonality,O,O
assays,O,O
have,O,O
provided,O,O
a,O,O
useful,O,O
tool,O,O
to,O,O
the,O,O
understanding,O,O
of,O,O
the,O,O
mechanisms,O,O
underlying,O,O
the,O,O
development,O,O
of,O,O
neoplasia,O,O
.,O,O
Recently,O,O
",",O,O
a,O,O
technique,O,O
of,O,O
clonal,O,O
analysis,O,O
has,O,O
been,O,O
devised,O,O
that,O,O
takes,O,O
advantage,O,O
of,O,O
a,O,O
highly,O,O
polymorphic,O,O
short,B,O
tandem,I,O
repeat,I,O
within,O,O
the,O,O
X,B,B
-,I,I
linked,I,I
human,I,I
androgen,I,I
receptor,I,I
(,I,O
AR,I,O
),I,O
gene,I,O
",",O,O
resulting,O,O
in,O,O
a,O,O
heterozygosity,O,O
rate,O,O
approaching,O,O
90,O,O
%,O,O
.,O,O
The,O,O
rapid,O,O
expansion,O,O
of,O,O
the,O,O
number,O,O
of,O,O
women,O,O
now,O,O
suitable,O,O
for,O,O
X,O,B
inactivation,O,I
analysis,O,O
has,O,O
however,O,O
given,O,O
rise,O,O
to,O,O
new,O,O
controversies,O,O
",",O,O
one,O,O
of,O,O
the,O,O
more,O,O
troublesome,O,O
being,O,O
the,O,O
possibility,O,O
of,O,O
a,O,O
modification,O,O
of,O,O
the,O,O
pattern,O,O
of,O,O
X,B,B
-,I,I
chromosome,I,I
inactivation,O,I
pattern,O,O
in,O,O
blood,O,O
cells,O,O
of,O,O
elderly,O,O
women,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
we,O,O
analyze,O,O
with,O,O
the,O,O
AR,O,O
assay,O,O
a,O,O
group,O,O
of,O,O
166,O,O
healthy,O,O
females,O,O
aged,O,O
between,O,O
8,O,O
and,O,O
94,O,O
years,O,O
",",O,O
with,O,O
no,O,O
history,O,O
of,O,O
genetic,O,O
or,O,O
neoplastic,O,O
familial,O,O
disorders,O,O
.,O,O
We,O,O
show,O,O
here,O,O
that,O,O
IFN,B,B
-,I,I
alpha,I,I
/,I,I
beta,I,I
act,O,O
directly,O,O
on,O,O
human,O,O
T,O,O
cells,O,O
to,O,O
drive,O,O
Th1,O,O
development,O,O
",",O,O
bypassing,O,O
the,O,O
need,O,O
for,O,O
IL,B,B
-,I,I
12,I,I
-,O,I
induced,O,I
signaling,O,I
",",O,O
whereas,O,O
IFN,B,B
-,I,I
alpha,I,I
can,O,O
not,O,O
substitute,O,O
IL,B,O
-,I,O
12,I,O
for,O,O
mouse,O,O
Th1,O,O
development,O,O
.,O,O
Unlike,O,O
IL,B,B
-,I,I
12,I,I
",",O,O
which,O,O
acts,O,O
only,O,O
on,O,O
Th1,O,O
cells,O,O
",",O,O
IFN,B,B
-,I,I
alpha,I,I
/,I,I
beta,I,I
can,O,O
activate,O,O
Stat4,B,O
not,O,O
only,O,O
in,O,O
human,O,O
Th1,O,O
",",O,O
but,O,O
also,O,O
in,O,O
Th2,O,O
cells,O,O
.,O,O
We,O,O
have,O,O
generated,O,O
antibodies,O,O
that,O,O
specifically,O,O
immunoprecipitated,O,O
the,O,O
in,B,O
-,I,O
vitro,I,O
-,I,O
translated,I,O
20,I,O
-,I,O
kDa,I,O
protein,I,O
.,O,O
The,O,O
mRNA,O,O
levels,O,O
for,O,O
fkhrl1,B,O
is,O,O
elevated,O,O
in,O,O
T,O,O
helper,O,O
-,O,O
induced,O,O
lymphocytes,O,O
in,O,O
comparison,O,O
to,O,O
PHA,O,O
-,O,O
stimulated,O,O
T,O,O
lymphocytes,O,O
.,O,O
Further,O,O
characterization,O,O
of,O,O
FKHRL1,B,B
and,O,O
its,O,O
related,O,O
family,O,O
members,O,O
should,O,O
shed,O,O
light,O,O
on,O,O
the,O,O
transcriptional,O,O
mechanisms,O,O
of,O,O
this,O,O
fork,B,O
head,I,O
gene,I,O
subfamily,I,O
and,O,O
their,O,O
role,O,O
in,O,O
T,O,O
helper,O,O
cell,O,O
differentiation,O,O
and,O,O
regulation,O,O
of,O,O
cell,O,O
growth,O,O
.,O,O
Inhibition,O,O
of,O,O
Th1,O,O
development,O,O
mediated,O,O
by,O,O
GATA,B,O
-,I,O
3,I,O
through,O,O
an,O,O
IL,O,B
-,O,I
4,O,I
-,O,I
independent,O,I
mechanism,O,I
.,O,O
These,O,O
motifs,O,O
are,O,O
regulatory,B,O
sequences,I,O
within,O,O
the,O,O
so,O,O
-,O,O
called,O,O
AU,B,O
-,I,O
rich,I,O
elements,I,O
(,O,O
AREs,B,O
),O,O
often,O,O
found,O,O
in,O,O
3,B,O
untranslated,I,O
regions,I,O
of,O,O
genes,O,O
such,O,O
as,O,O
cytokines,B,O
",",O,O
proto,B,O
-,I,O
oncogenes,I,O
",",O,O
and,O,O
transcription,B,O
factors,I,O
.,O,O
Copyright,O,O
1998,O,O
Academic,O,O
Press,O,O
.,O,O
Transcription,O,O
factor,O,O
NF,B,B
-,I,I
kappaB,I,I
regulation,O,O
of,O,O
renal,O,O
fibrosis,O,O
during,O,O
ureteral,O,O
obstruction,O,O
.,O,O
Irrespective,O,O
of,O,O
the,O,O
etiology,O,O
",",O,O
many,O,O
kidney,O,O
diseases,O,O
result,O,O
in,O,O
inflammation,O,O
and,O,O
fibrosis,O,O
of,O,O
the,O,O
tubulointerstitium,O,O
",",O,O
with,O,O
the,O,O
subsequent,O,O
loss,O,O
of,O,O
renal,O,O
function,O,O
.,O,O
The,O,O
nuclear,B,B
factor,I,I
-,I,I
kappa,I,I
B,I,I
(,I,O
NF,I,B
-,I,I
kappaB,I,I
),I,O
family,I,O
of,O,O
transcription,B,O
factors,I,O
regulates,O,O
genes,O,O
involved,O,O
in,O,O
inflammation,O,O
",",O,O
cell,O,O
proliferation,O,O
",",O,O
and,O,O
cell,O,O
differentiation,O,O
.,O,O
Morphological,O,O
studies,O,O
demonstrated,O,O
characteristic,O,O
features,O,O
of,O,O
erythroid,O,B
differentiation,O,O
and,O,O
maturation,O,O
.,O,O
At,O,O
the,O,O
same,O,O
time,O,O
there,O,O
was,O,O
no,O,O
change,O,O
in,O,O
the,O,O
level,O,O
of,O,O
expression,O,O
of,O,O
the,O,O
cell,B,O
surface,I,O
antigenes,I,O
CD33,B,B
",",O,O
CD34,B,B
",",O,O
CD45,B,B
",",O,O
CD71,B,B
and,O,O
glycophorin,B,B
A,I,I
.,O,O
The,O,O
class,B,O
II,I,O
transactivator,I,O
(,O,O
CIITA,B,B
),O,O
is,O,O
essential,O,O
for,O,O
the,O,O
expression,O,O
of,O,O
major,B,O
histocompatibility,I,O
complex,I,O
(,I,O
MHC,I,B
),I,O
class,I,O
II,I,O
antigens,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
luciferase,B,B
expression,O,O
was,O,O
not,O,O
stimulated,O,O
after,O,O
IFN,B,B
-,I,I
gamma,I,I
treatment,O,O
when,O,O
the,O,O
construct,O,O
was,O,O
transfected,O,O
in,O,O
macrophage,O,B
or,O,O
in,O,O
epithelial,O,B
cell,O,I
lines,O,I
.,O,O
These,O,O
studies,O,O
investigate,O,O
the,O,O
relationship,O,O
between,O,O
leukocyte,O,B
populations,O,I
",",O,O
steroid,B,B
hormone,I,I
receptor,I,I
expression,O,O
",",O,O
proliferative,O,O
activity,O,O
",",O,O
bcl,B,B
-,I,I
2,I,I
expression,O,O
and,O,O
apoptosis,O,O
in,O,O
eutopic,O,B
and,O,O
ectopic,O,B
endometrium,O,I
from,O,O
women,O,O
with,O,O
endometriosis,O,O
or,O,O
adenomyosis,O,O
at,O,O
different,O,O
phases,O,O
of,O,O
the,O,O
menstrual,O,O
cycle,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
demonstrate,O,O
through,O,O
the,O,O
use,O,O
of,O,O
intracellular,O,O
staining,O,O
that,O,O
interleukin,B,B
-,I,I
1beta,I,I
(,O,I
IL,B,I
-,I,I
1beta,I,I
),O,I
is,O,O
expressed,O,O
in,O,O
LCLs,O,O
and,O,O
investigate,O,O
the,O,O
influence,O,O
of,O,O
the,O,O
individual,O,O
latent,B,O
proteins,I,O
on,O,O
the,O,O
expression,O,O
of,O,O
IL,B,B
-,I,I
1beta,I,I
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
(,O,O
EMSAs,O,O
),O,O
demonstrated,O,O
that,O,O
the,O,O
-,O,O
300,O,O
region,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
1beta,I,I
promoter,O,O
",",O,O
which,O,O
contains,O,O
a,O,O
nuclear,B,B
factor,I,I
-,I,I
kappaB,I,I
(,I,I
NF,I,I
-,I,I
kappaB,I,I
),I,I
binding,I,O
site,I,O
",",O,O
contained,O,O
a,O,O
functional,B,O
RBP,I,B
binding,I,I
site,I,I
.,O,O
CD27,B,B
/,O,I
CD70,O,I
interaction,O,O
augments,O,O
IgE,B,B
secretion,O,O
by,O,O
promoting,O,O
the,O,O
differentiation,O,O
of,O,O
memory,O,B
B,O,I
cells,O,I
into,O,O
plasma,O,B
cells,O,I
.,O,O
The,O,O
induction,O,O
of,O,O
IgE,B,B
switching,O,O
in,O,O
B,O,B
cells,O,I
requires,O,O
several,O,O
signals,O,O
given,O,O
by,O,O
cytokines,B,O
and,O,O
cell,O,B
contact,O,I
-,O,I
delivered,O,I
signals,O,I
.,O,O
Here,O,O
",",O,O
we,O,O
investigated,O,O
the,O,O
role,O,O
of,O,O
CD27,B,B
/,O,I
CD70,O,I
interaction,O,O
in,O,O
B,O,B
cell,O,I
IgE,B,B
synthesis,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
CD70,O,B
transfectants,O,O
was,O,O
dose,O,O
dependent,O,O
and,O,O
was,O,O
completely,O,O
blocked,O,O
by,O,O
anti,B,O
-,I,O
CD70,I,B
mAb,I,O
.,I,O
CD27,B,B
/,O,I
CD70,O,I
interaction,O,O
enhanced,O,O
B,O,B
cell,O,I
proliferation,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
or,O,O
IL,B,B
-,I,I
4,I,I
plus,O,O
anti,B,O
-,I,O
CD40,I,B
.,O,O
Recent,O,O
studies,O,O
",",O,O
however,O,O
",",O,O
demonstrate,O,O
that,O,O
the,O,O
transcribed,O,O
5,B,B
-,I,I
untranslated,I,I
leader,I,I
region,I,I
(,O,O
5,B,B
-,I,I
UTR,I,I
),O,O
also,O,O
contains,O,O
important,O,O
transcriptional,B,O
elements,I,O
.,O,O
These,O,O
regulatory,B,O
elements,I,O
situated,O,O
downstream,O,O
of,O,O
transcription,O,O
interact,O,O
with,O,O
constitutive,O,O
and,O,O
inducible,O,O
transcription,B,O
factors,I,O
",",O,O
mediate,O,O
transmission,O,O
of,O,O
cellular,O,O
activation,O,O
signals,O,O
",",O,O
and,O,O
are,O,O
important,O,O
for,O,O
efficient,O,O
HIV,O,O
-,O,O
1,O,O
transcription,O,O
and,O,O
replication,O,O
.,O,O
Regulation,O,O
of,O,O
PAK,O,O
activation,O,O
and,O,O
the,O,O
T,O,O
cell,O,O
cytoskeleton,O,O
by,O,O
the,O,O
linker,B,O
protein,I,O
SLP,B,O
-,I,O
76,I,O
.,O,O
In,O,O
turn,O,O
",",O,O
assembly,O,O
of,O,O
this,O,O
complex,O,O
mediates,O,O
the,O,O
enzymatic,O,O
activation,O,O
of,O,O
the,O,O
p21,B,B
-,I,I
activated,I,I
protein,I,I
kinase,I,I
1,I,I
and,O,O
facilitates,O,O
actin,B,B
polymerization,O,I
.,O,O
Copyright,O,O
1998,O,O
Academic,O,O
Press,O,O
.,O,O
LOX,B,B
-,I,I
1,I,I
is,O,O
an,O,O
endothelial,B,B
receptor,I,I
for,O,O
oxidized,B,O
low,I,O
-,I,O
density,I,O
lipoprotein,I,O
that,O,O
plays,O,O
essential,O,O
roles,O,O
in,O,O
atherogenesis,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
we,O,O
cloned,O,O
and,O,O
characterized,O,O
the,O,O
human,B,B
LOX,I,I
-,I,I
1,I,I
gene,I,I
(,O,O
HGMW,B,O
-,I,O
approved,I,O
symbol,I,O
OLR1,I,O
),O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
expression,O,O
pattern,O,O
of,O,O
LOX,B,B
-,I,I
1,I,I
is,O,O
different,O,O
from,O,O
that,O,O
of,O,O
the,O,O
natural,B,B
killer,I,I
cell,I,I
receptors,I,I
;,O,O
LOX,B,B
-,I,I
1,I,I
is,O,O
expressed,O,O
in,O,O
vascular,O,B
-,O,I
rich,O,I
organs,O,I
",",O,O
but,O,O
not,O,O
in,O,O
lymphocytes,O,B
.,O,O
These,O,O
results,O,O
demonstrate,O,O
that,O,O
the,O,O
human,B,O
LOX,I,B
-,I,I
1,I,I
gene,I,I
is,O,O
a,O,O
new,O,O
member,O,O
of,O,O
the,O,O
natural,B,B
killer,I,I
gene,I,I
complex,I,I
with,O,O
a,O,O
unique,O,O
expression,O,O
profile,O,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
describe,O,O
the,O,O
transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
beta,B,B
-,I,I
casein,I,I
gene,I,I
by,O,O
cytokines,B,O
in,O,O
T,O,O
cells,O,O
.,O,O
Coincidentally,O,O
",",O,O
a,O,O
deletion,O,O
of,O,O
this,O,O
region,O,O
enhanced,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
-,O,I
induced,O,I
expression,O,O
of,O,O
beta,B,B
-,I,I
casein,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
Ras,B,B
(,I,O
G12V,I,O
),I,O
complemented,O,O
signaling,O,O
by,O,O
an,O,O
erythropoietin,B,O
receptor,I,O
mutant,I,O
defective,O,O
in,O,O
Ras,B,B
activation,O,O
and,O,O
augmented,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
beta,B,B
-,I,I
casein,I,I
promoter,I,O
by,O,O
the,O,O
mutant,B,O
erythropoietin,I,O
receptor,I,O
signaling,O,O
",",O,O
suggesting,O,O
a,O,O
possible,O,O
role,O,O
of,O,O
Ras,B,B
in,O,O
Stat5,B,O
-,O,O
mediated,O,O
gene,O,O
expression,O,O
.,O,O
GATA,B,B
-,I,I
3,I,I
represses,O,O
gp91phox,B,O
gene,I,O
expression,O,O
in,O,O
eosinophil,O,O
-,O,O
committed,O,O
HL,O,B
-,O,I
60,O,I
-,O,I
C15,O,I
cells,O,O
.,O,O
An,O,O
81,O,O
%,O,O
increment,O,O
in,O,O
promoter,O,O
activity,O,O
was,O,O
obtained,O,O
when,O,O
a,O,O
mutation,O,O
was,O,O
introduced,O,O
in,O,O
the,O,O
GATA,B,B
-,I,I
3,I,I
binding,I,I
site,I,I
of,O,O
the,O,O
bp,B,O
-,I,O
267,I,O
to,I,O
+,I,O
12,I,O
construct,I,O
",",O,O
which,O,O
is,O,O
comparable,O,O
to,O,O
that,O,O
of,O,O
the,O,O
bp,B,O
-,I,O
245,I,O
to,I,O
+,I,O
12,I,O
construct,I,O
.,O,O
Ligation,O,O
of,O,O
CD3,B,B
also,O,O
induces,O,O
the,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
HS1,B,B
",",O,O
a,O,O
75,B,O
-,I,O
kDa,I,O
hematopoietic,I,O
cell,I,O
-,I,O
specific,I,O
intracellular,I,O
signaling,I,O
protein,I,O
of,O,O
unknown,O,O
function,O,O
.,O,O
Costimulation,O,O
through,O,O
CD28,B,B
and,O,O
/,O,O
or,O,O
CD2,B,B
did,O,O
not,O,O
modulate,O,O
the,O,O
CD3,B,B
-,O,O
dependent,O,O
phosphorylation,O,O
of,O,O
HS1,B,B
.,O,O
c,O,O
-,O,O
fos,O,B
and,O,O
c,O,B
-,O,I
jun,O,I
mRNA,O,I
expression,O,O
in,O,O
activated,O,O
cord,O,O
and,O,O
adult,O,O
lymphocytes,O,O
:,O,O
an,O,O
analysis,O,O
by,O,O
Northern,O,O
hybridization,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
Northern,O,O
blot,O,O
analysis,O,O
of,O,O
cord,O,B
and,O,O
adult,O,B
samples,O,O
revealed,O,O
similar,O,O
maximal,O,O
increases,O,O
in,O,O
c,B,B
-,I,I
fos,I,I
(,O,O
99,O,O
+,O,O
/,O,O
-,O,O
15,O,O
and,O,O
126,O,O
+,O,O
/,O,O
-,O,O
11,O,O
%,O,O
",",O,O
p,O,O
0,O,O
.,O,O
),O,O
and,O,O
c,B,B
-,I,I
jun,I,I
(,I,O
123,I,O
+,I,O
/,I,O
-,I,O
9,I,O
185,I,O
+,I,O
/,I,O
-,I,O
38,I,O
%,I,O
",",I,O
p,I,O
0,I,O
.,I,O
),I,O
mRNA,I,O
expression,O,O
",",O,O
respectively,O,O
",",O,O
as,O,O
early,O,O
as,O,O
15,O,O
min,O,O
post,O,O
-,O,O
alphaCD3,B,O
stimulation,O,O
.,O,O
Receptors,O,O
for,O,O
the,O,O
Fc,B,B
portion,I,I
of,O,I
immunoglobulin,B,I
molecules,I,I
(,O,O
FcR,B,B
),O,O
present,O,O
on,O,O
leukocyte,O,B
cell,O,I
membranes,O,I
mediate,O,O
a,O,O
large,O,O
number,O,O
of,O,O
cellular,O,O
responses,O,O
that,O,O
are,O,O
very,O,O
important,O,O
in,O,O
host,O,O
defense,O,O
",",O,O
including,O,O
phagocytosis,O,O
",",O,O
cell,O,O
cytotoxicity,O,O
",",O,O
production,O,O
and,O,O
secretion,O,O
of,O,O
inflammatory,B,O
mediators,I,O
",",O,O
and,O,O
modulation,O,O
of,O,O
the,O,O
immune,O,O
response,O,O
.,O,O
Cross,O,O
-,O,O
linking,O,O
of,O,O
FcR,B,B
",",O,O
on,O,O
the,O,O
THP,O,B
-,O,I
1,O,I
monocytic,O,I
cell,O,I
line,O,I
",",O,O
by,O,O
immune,B,O
complexes,I,O
resulted,O,O
in,O,O
both,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappaB,I,I
and,O,O
interleukin,B,B
1,I,I
production,O,O
.,O,O
BCL,B,B
-,I,I
6,I,I
mutations,O,O
in,O,O
normal,O,O
germinal,O,O
center,O,O
B,O,B
cells,O,I
:,O,O
evidence,O,O
of,O,O
somatic,O,O
hypermutation,O,O
acting,O,O
outside,O,O
Ig,B,B
loci,I,I
.,O,O
Thirty,O,O
percent,O,O
of,O,O
GC,O,B
B,O,I
cells,O,I
",",O,O
but,O,O
not,O,O
naive,O,O
B,O,B
cells,O,I
",",O,O
displayed,O,O
mutations,O,O
in,O,O
the,O,O
742,B,O
bp,I,O
region,I,O
analyzed,O,O
within,O,O
the,O,O
first,O,O
intron,O,O
of,O,O
BCL,B,B
-,I,I
6,I,I
(,O,I
overall,O,O
frequency,O,O
:,O,O
5,O,O
x,O,O
10,O,O
(,O,O
-,O,O
4,O,O
),O,O
/,O,O
bp,O,O
.,O,O
The,O,O
ability,O,O
of,O,O
E2A,B,B
-,I,I
HLF,I,I
to,O,O
prolong,O,O
the,O,O
survival,O,O
of,O,O
interleukin,O,B
-,O,I
3,O,I
(,O,O
IL,O,B
-,O,I
3,O,I
),O,O
-,O,O
dependent,O,O
murine,O,O
pro,O,O
-,O,O
B,O,O
cells,O,O
after,O,O
IL,B,B
-,I,I
3,I,I
withdrawal,O,O
suggests,O,O
that,O,O
it,O,O
disrupts,O,O
signaling,O,O
pathways,O,O
normally,O,O
responsible,O,O
for,O,O
cell,O,O
suicide,O,O
",",O,O
allowing,O,O
the,O,O
cells,O,O
to,O,O
accumulate,O,O
as,O,O
transformed,O,O
lymphoblasts,O,O
.,O,O
Neither,O,O
the,O,O
E12,B,B
nor,O,O
the,O,O
E47,B,B
product,O,O
of,O,O
the,O,O
E2A,B,B
gene,I,O
nor,O,O
the,O,O
wild,B,O
-,I,O
type,I,O
HLF,I,B
protein,I,O
was,O,O
able,O,O
to,O,O
protect,O,O
the,O,O
cells,O,O
from,O,O
apoptosis,O,O
induced,O,O
by,O,O
IL,B,B
-,I,I
3,I,I
deprivation,O,O
.,O,O
Surprisingly,O,O
",",O,O
different,O,O
combinations,O,O
of,O,O
disabling,O,O
mutations,O,O
within,O,O
the,O,O
HLF,B,B
bZIP,I,I
domain,I,I
had,O,O
little,O,O
effect,O,O
on,O,O
the,O,O
antiapoptotic,O,O
property,O,O
of,O,O
the,O,O
chimeric,B,O
protein,I,O
",",O,O
so,O,O
long,O,O
as,O,O
the,O,O
amino,O,O
-,O,O
terminal,O,O
portion,O,O
of,O,O
E2A,B,O
remained,O,O
intact,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
1,O,O
),O,O
lipid,O,O
A,O,O
myristoyl,O,O
fatty,O,O
acid,O,O
",",O,O
although,O,O
it,O,O
is,O,O
important,O,O
for,O,O
the,O,O
induction,O,O
of,O,O
inflammatory,B,O
cytokine,I,O
production,O,O
by,O,O
human,O,O
monocytes,O,O
",",O,O
is,O,O
not,O,O
necessary,O,O
for,O,O
the,O,O
induction,O,O
of,O,O
Mn,B,B
SOD,I,I
",",O,O
2,O,O
),O,O
endotoxin,B,O
-,O,O
mediated,O,O
induction,O,O
of,O,O
Mn,B,B
SOD,I,I
and,O,O
inflammatory,O,O
cytokines,B,O
are,O,O
regulated,O,O
",",O,O
at,O,O
least,O,O
in,O,O
part,O,O
",",O,O
through,O,O
different,O,O
signal,O,O
transduction,O,O
pathways,O,O
",",O,O
and,O,O
3,O,O
),O,O
failure,O,O
of,O,O
the,O,O
mutant,B,O
endotoxin,I,O
to,O,O
induce,O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
production,O,O
is,O,O
",",O,O
at,O,O
least,O,O
in,O,O
part,O,O
",",O,O
due,O,O
to,O,O
its,O,O
inability,O,O
to,O,O
activate,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,O
kinase,I,O
.,O,O
Characterization,O,O
of,O,O
cytokine,B,O
differential,O,O
induction,O,O
of,O,O
STAT,B,B
complexes,I,I
in,O,O
primary,O,O
human,O,O
T,O,B
and,O,O
NK,O,B
cells,O,O
.,O,O
Finally,O,O
",",O,O
we,O,O
observed,O,O
that,O,O
activated,O,O
STAT5a,B,B
and,O,O
STAT5b,B,B
proteins,O,O
form,O,O
distinct,O,O
Fc,O,O
gamma,O,O
RI,O,O
GAS,O,O
binding,O,O
patterns,O,O
in,O,O
T,O,B
and,O,O
NK,O,B
cells,O,O
",",O,O
suggesting,O,O
that,O,O
they,O,O
might,O,O
have,O,O
different,O,O
roles,O,O
in,O,O
gene,O,O
regulation,O,O
.,O,O
A,O,O
regulatory,B,O
element,I,O
in,O,O
the,O,O
CD95,B,B
(,I,I
APO,I,I
-,I,I
1,I,I
/,I,I
Fas,I,I
),I,I
ligand,I,O
promoter,I,O
is,O,O
essential,O,O
for,O,O
responsiveness,O,O
to,O,O
TCR,B,O
-,O,O
mediated,O,O
activation,O,O
.,O,O
The,O,O
DNA,O,B
sequence,O,O
at,O,O
-,B,O
120,I,O
also,O,O
contains,O,O
two,O,O
DNA,B,B
motifs,I,O
homologous,O,O
to,O,O
the,O,O
binding,O,O
site,O,O
for,O,O
NF,B,B
-,I,O
AT,I,I
.,O,O
NF,B,B
-,I,O
AT,I,I
does,O,O
not,O,O
directly,O,O
bind,O,O
to,O,O
this,O,O
element,O,O
.,O,O
Progesterone,O,O
acts,O,O
distally,O,O
to,O,O
the,O,O
initial,O,O
steps,O,O
of,O,O
T,B,O
cell,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
-,O,O
mediated,O,O
signal,O,O
transduction,O,O
",",O,O
since,O,O
it,O,O
blocks,O,O
sustained,O,O
Ca2,O,B
+,O,I
signals,O,O
after,O,O
thapsigargin,O,O
stimulation,O,O
",",O,O
as,O,O
well,O,O
as,O,O
oscillatory,O,O
Ca2,O,B
+,O,I
signals,O,O
",",O,O
but,O,O
not,O,O
the,O,O
Ca2,O,B
+,O,I
transient,O,O
after,O,O
TCR,B,O
stimulation,O,O
.,O,O
Progesterone,O,B
effectively,O,O
blocked,O,O
a,O,O
broad,O,O
spectrum,O,O
of,O,O
K,B,B
+,I,I
channels,I,O
",",O,O
reducing,O,O
both,O,O
Kv1,B,B
.,I,O
3,I,I
and,O,O
charybdotoxin,B,B
-,I,I
resistant,I,I
components,I,O
of,O,O
KV,B,B
current,O,O
and,O,O
KCa,B,B
in,O,O
T,O,O
cells,O,O
",",O,O
as,O,O
well,O,O
as,O,O
blocking,O,O
several,O,O
cloned,B,O
KV,I,B
channels,I,O
expressed,O,O
in,O,O
cell,O,O
lines,O,O
.,O,O
A,O,O
mouse,O,O
carrying,O,O
genetic,O,O
defect,O,O
in,O,O
the,O,O
choice,O,O
between,O,O
T,O,O
and,O,O
B,O,O
lymphocytes,O,O
.,O,O
The,O,O
present,O,O
study,O,O
shows,O,O
that,O,O
",",O,O
instead,O,O
of,O,O
T,O,O
cells,O,O
",",O,O
B,O,O
cells,O,O
are,O,O
generated,O,O
in,O,O
the,O,O
thymus,O,O
of,O,O
a,O,O
line,O,O
",",O,O
tg,O,O
epsilon26,O,O
",",O,O
of,O,O
the,O,O
human,O,O
CD3epsilon,O,O
transgenic,O,O
mice,O,O
.,O,O
The,O,O
accumulation,O,O
of,O,O
mature,O,O
B,O,O
cells,O,O
in,O,O
the,O,O
thymus,O,O
was,O,O
found,O,O
only,O,O
in,O,O
tg,O,O
epsilon26,O,O
mice,O,O
",",O,O
not,O,O
in,O,O
other,O,O
human,O,O
CD3epsilon,O,O
transgenic,O,O
mouse,O,O
lines,O,O
or,O,O
other,O,O
T,O,O
cell,O,O
-,O,O
deficient,O,O
mice,O,O
",",O,O
including,O,O
CD3,O,O
-,O,O
epsilon,O,O
knockout,O,O
mice,O,O
and,O,O
TCR,O,O
-,O,O
beta,O,O
/,O,O
TCR,O,O
-,O,O
delta,O,O
double,O,O
knockout,O,O
mice,O,O
.,O,O
The,O,O
chemokine,B,O
receptor,I,O
",",O,O
BLR1,B,B
",",O,O
is,O,O
a,O,O
major,O,O
regulator,O,O
of,O,O
the,O,O
microenvironmental,O,O
homing,O,O
of,O,O
B,O,O
cells,O,O
in,O,O
lymphoid,O,O
organs,O,O
.,O,O
Activation,O,O
of,O,O
the,O,O
CD4,B,B
promoter,I,I
occurs,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
viral,O,B
DNA,O,I
polymerase,O,I
inhibitor,O,I
phosphonoformic,O,I
acid,O,I
",",O,O
which,O,O
limits,O,O
expression,O,O
to,O,O
the,O,O
immediate,B,O
-,I,O
early,I,O
and,I,O
early,I,O
classes,I,O
of,I,O
viral,I,O
genes,I,O
.,O,O
Both,O,O
Tax,B,O
-,O,O
mediated,O,O
apoptosis,O,O
and,O,O
oxidative,O,O
stress,O,O
can,O,O
be,O,O
potently,O,O
suppressed,O,O
by,O,O
antioxidants,O,O
",",O,O
as,O,O
is,O,O
seen,O,O
with,O,O
the,O,O
administration,O,O
of,O,O
recombinant,B,O
thioredoxin,I,B
(,O,I
adult,B,I
T,I,I
cell,I,I
leukemia,I,I
-,I,I
derived,I,I
factor,I,I
),O,I
or,O,O
pyrrolidine,O,B
dithiocarbamate,O,I
.,O,O
The,O,O
efficacy,O,O
of,O,O
o,O,O
",",O,O
o,O,O
-,O,O
bismyristoyl,O,O
thiamine,O,O
disulfide,O,O
(,O,O
BMT,O,B
),O,O
was,O,O
examined,O,O
in,O,O
detail,O,O
against,O,O
HIV,O,B
-,O,I
1,O,I
laboratory,O,I
isolates,O,I
(,O,O
HTLV,O,B
-,O,I
IIIB,O,I
",",O,O
JRFL,O,B
",",O,O
and,O,O
MN,O,B
),O,O
",",O,O
primary,O,O
isolates,O,O
(,O,O
KMT,O,B
and,O,O
KMO,O,B
),O,O
",",O,O
and,O,O
simian,O,O
immunodeficiency,O,O
virus,O,O
(,O,O
SIVmac251,O,B
),O,O
in,O,O
vitro,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
BMT,O,B
exhibited,O,O
antiviral,O,O
activity,O,O
against,O,O
SIVmac251,O,O
.,O,O
Minimizing,O,O
energy,O,O
studies,O,O
of,O,O
BMT,O,B
structure,O,O
reveal,O,O
that,O,O
a,O,O
trans,O,O
-,O,O
disulfide,O,O
of,O,O
thiamine,O,O
(,O,O
holo,O,O
drug,O,O
),O,O
disulfide,O,O
(,O,O
TDS,O,O
",",O,O
protodrug,O,O
),O,O
is,O,O
allosterically,O,O
transited,O,O
to,O,O
the,O,O
reactive,O,O
twisted,O,O
disulfide,O,O
of,O,O
BMT,O,B
(,O,O
allo,O,O
drug,O,O
),O,O
by,O,O
o,O,O
",",O,O
o,O,O
-,O,O
bismyristoyl,O,O
esterification,O,O
of,O,O
TDS,O,O
.,O,O
Nor,O,O
was,O,O
fragmentation,O,O
observed,O,O
after,O,O
treatment,O,O
with,O,O
RU38486,O,O
",",O,O
indicating,O,O
that,O,O
repression,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
activity,O,O
is,O,O
not,O,O
involved,O,O
.,O,O
Dexamethasone,O,O
treatment,O,O
completely,O,O
blocked,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
13,O,O
-,O,O
acetate,O,O
induction,O,O
of,O,O
nuclear,B,O
factor,I,O
-,I,O
kappaB,I,O
(,O,O
NF,B,B
-,I,I
kappaB,I,I
),O,O
activity,O,O
and,O,O
elicited,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
amount,O,O
of,O,O
immunoreactive,B,O
IkappaB,I,O
alpha,I,O
in,O,O
sensitive,O,O
6TG1,O,O
.,O,O
1,O,O
cells,O,O
but,O,O
not,O,O
in,O,O
resistant,O,O
ICR27TK,O,O
.,O,O
3,O,O
cells,O,O
.,O,O
It,O,O
was,O,O
proposed,O,O
that,O,O
the,O,O
mechanism,O,O
of,O,O
antiviral,O,O
action,O,O
of,O,O
S9a,O,O
was,O,O
on,O,O
the,O,O
host,O,O
cell,O,O
",",O,O
by,O,O
blocking,O,O
TNF,B,B
-,I,I
alpha,I,I
transcription,O,O
via,O,O
a,O,O
Tat,B,O
-,O,O
induced,O,O
tar,O,O
-,O,O
independent,O,O
loop,O,O
",",O,O
which,O,O
decreases,O,O
downstream,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
of,O,O
HIV,B,B
-,I,I
1,I,I
long,I,I
terminal,I,I
repeat,I,I
(,O,I
LTR,B,I
),O,I
.,O,O
S9a,O,O
was,O,O
superior,O,O
to,O,O
the,O,O
first,O,O
generation,O,O
compound,O,O
Canventol,O,O
",",O,O
which,O,O
was,O,O
superior,O,O
to,O,O
the,O,O
natural,O,O
compound,O,O
sarcophytol,O,O
A,O,O
",",O,O
demonstrating,O,O
that,O,O
further,O,O
structure,O,O
-,O,O
based,O,O
enhancement,O,O
of,O,O
potency,O,O
of,O,O
these,O,O
compounds,O,O
is,O,O
feasible,O,O
.,O,O
Intestinal,O,O
epithelial,O,O
cells,O,O
can,O,O
express,O,O
HLA,B,B
class,I,I
II,I,I
antigens,I,I
and,O,O
may,O,O
function,O,O
as,O,O
antigen,O,O
-,O,O
presenting,O,O
cells,O,O
to,O,O
CD4,O,B
(,O,O
+,O,O
),O,O
T,O,O
cells,O,O
within,O,O
the,O,O
intestinal,O,O
mucosa,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
a,O,O
highly,O,O
polarized,O,O
functional,O,O
architecture,O,O
for,O,O
antigen,O,B
processing,O,O
and,O,O
presentation,O,O
by,O,O
intestinal,O,B
epithelial,O,I
cells,O,O
",",O,O
and,O,O
suggest,O,O
that,O,O
the,O,O
functional,O,O
outcome,O,O
of,O,O
antigen,O,B
processing,O,O
by,O,O
the,O,O
intestinal,O,B
epithelium,O,I
is,O,O
both,O,O
dependent,O,O
on,O,O
the,O,O
cellular,O,O
surface,O,O
at,O,O
which,O,O
the,O,O
foreign,O,O
antigen,O,B
is,O,O
internalized,O,O
and,O,O
by,O,O
the,O,O
underlying,O,O
degree,O,O
of,O,O
mucosal,O,O
inflammation,O,O
We,O,O
determined,O,O
whether,O,O
Hsp70,B,B
induction,O,O
by,O,O
TS,O,O
was,O,O
mediated,O,O
by,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
HS,B,B
transcription,I,O
factor,I,O
",",O,O
HSF,B,B
.,O,O
Thus,O,O
",",O,O
we,O,O
also,O,O
determined,O,O
the,O,O
effects,O,O
of,O,O
TS,O,O
on,O,O
NFkappaB,B,B
.,O,O
TS,O,O
activated,O,O
HSF,B,O
",",O,O
which,O,O
was,O,O
associated,O,O
with,O,O
Hsp70,B,B
overexpression,O,O
and,O,O
inhibition,O,O
of,O,O
NFkappaB,B,B
binding,O,O
activity,O,O
and,O,O
TNFalpha,B,B
release,O,O
.,O,O
[,O,O
Molecular,O,O
mechanism,O,O
of,O,O
cytokine,B,O
gene,I,O
expression,O,O
in,O,O
Th1,O,O
and,O,O
Th2,O,O
],O,O
Among,O,O
them,O,O
",",O,O
both,O,O
the,O,O
activation,O,O
of,O,O
PKC,O,O
/,O,O
Ras,O,O
-,O,O
and,O,O
CaM,O,O
/,O,O
CN,O,O
-,O,O
mediated,O,O
pathways,O,O
play,O,O
a,O,O
central,O,O
role,O,O
in,O,O
the,O,O
signal,O,O
transduction,O,O
of,O,O
cytokine,B,O
gene,I,O
expression,O,O
.,O,O
Activation,O,O
of,O,O
T,O,B
cells,O,I
results,O,O
in,O,O
the,O,O
rapid,O,O
calcineurin,B,O
-,O,O
dependent,O,O
translocation,O,O
of,O,O
NFAT,B,B
transcription,B,O
factors,I,O
from,O,O
the,O,O
cytoplasm,O,O
to,O,O
the,O,O
nucleus,O,O
.,O,O
Replication,O,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
-,O,O
1,O,O
(,O,O
HIV,O,B
-,O,I
1,O,I
),O,O
is,O,O
highly,O,O
dependent,O,O
on,O,O
the,O,O
state,O,O
of,O,O
activation,O,O
of,O,O
the,O,O
infected,O,O
cells,O,O
and,O,O
is,O,O
modulated,O,O
by,O,O
interactions,O,O
between,O,O
viral,B,O
and,I,O
host,I,O
cellular,I,O
factors,I,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
secretion,O,O
of,O,O
PGE2,O,B
by,O,O
macrophages,O,O
in,O,O
response,O,O
to,O,O
infection,O,O
or,O,O
inflammatory,O,O
activators,O,O
could,O,O
induce,O,O
signaling,O,O
events,O,O
resulting,O,O
in,O,O
activation,O,O
of,O,O
proviral,O,B
DNA,O,I
present,O,O
into,O,O
T,O,O
cells,O,O
latently,O,O
infected,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
Unexpectedly,O,O
",",O,O
we,O,O
found,O,O
that,O,O
conventional,O,O
procedures,O,O
employed,O,O
to,O,O
prepare,O,O
cellular,O,B
extracts,O,I
cause,O,O
the,O,O
release,O,O
of,O,O
proteolytic,O,O
activities,O,O
that,O,O
are,O,O
normally,O,O
stored,O,O
in,O,O
intracellular,O,B
granules,O,I
",",O,O
resulting,O,O
in,O,O
the,O,O
degradation,O,O
of,O,O
various,O,O
NF,B,B
-,I,I
kappaB,I,I
/,I,I
Rel,I,I
and,O,O
STAT,B,B
proteins,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
the,O,O
procedure,O,O
described,O,O
herein,O,O
could,O,O
prove,O,O
useful,O,O
in,O,O
other,O,O
cell,O,O
types,O,O
that,O,O
express,O,O
high,O,O
levels,O,O
of,O,O
endogenous,B,O
proteases,I,O
.,O,O
The,O,O
capacity,O,O
of,O,O
neonatal,O,O
T,O,O
cells,O,O
to,O,O
secrete,O,O
interleukin,B,B
-,I,I
2,I,I
(,O,I
IL,B,I
-,I,I
2,I,I
),O,I
has,O,O
been,O,O
reported,O,O
to,O,O
be,O,O
variable,O,O
.,O,O
PDBu,O,O
+,O,O
iono,O,O
induced,O,O
equally,O,O
high,O,O
IL,B,B
-,I,I
2,I,I
levels,O,O
in,O,O
both,O,O
groups,O,O
and,O,O
",",O,O
when,O,O
stimulated,O,O
with,O,O
plate,O,O
-,O,O
bound,O,O
anti,B,O
-,I,O
CD3,I,O
monoclonal,I,O
antibody,I,O
(,O,O
mAb,B,O
),O,O
",",O,O
the,O,O
IL,B,B
-,I,I
2,I,I
secretion,O,O
by,O,O
neonatal,O,O
cells,O,O
was,O,O
undetectable,O,O
and,O,O
adult,O,O
cells,O,O
produced,O,O
low,O,O
amounts,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
(,O,I
mean,O,O
331,O,O
+,O,O
/,O,O
-,O,O
86,O,O
pg,O,O
/,O,O
ml,O,O
),O,O
.,O,O
As,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
a,O,O
critical,O,O
transcription,B,O
factor,I,O
in,O,O
the,O,O
control,O,O
of,O,O
IL,B,O
-,I,O
2,I,O
expression,O,O
",",O,O
we,O,O
next,O,O
analysed,O,O
its,O,O
nuclear,O,O
translocation,O,O
in,O,O
neonatal,O,O
and,O,O
adult,O,O
T,O,O
cells,O,O
using,O,O
the,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
and,O,O
",",O,O
because,O,O
induction,O,O
of,O,O
reactive,O,O
oxygen,O,O
intermediates,O,O
(,O,O
ROI,O,O
),O,O
is,O,O
required,O,O
for,O,O
the,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
we,O,O
also,O,O
analysed,O,O
levels,O,O
of,O,O
intracellular,O,O
ROI,O,O
in,O,O
these,O,O
cells,O,O
using,O,O
the,O,O
ROI,O,O
-,O,O
reactive,O,O
fluorochrome,O,O
DCFH,O,O
-,O,O
DA,O,O
and,O,O
flow,O,O
cytometry,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
reduced,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
by,O,O
neonatal,O,B
T,O,O
cells,O,O
is,O,O
specific,O,O
for,O,O
anti,B,O
-,I,O
CD3,I,O
and,O,O
anti,B,O
-,I,O
CD3,I,O
+,O,O
anti,B,O
-,I,O
CD28,I,O
-,O,O
mediated,O,O
stimulation,O,O
and,O,O
that,O,O
these,O,O
activators,O,O
can,O,O
not,O,O
effectively,O,O
activate,O,O
the,O,O
ROI,O,O
-,B,O
NF,I,O
-,I,O
kappa,I,O
B,I,O
signalling,O,O
pathway,O,O
in,O,O
neonatal,O,B
T,O,O
cells,O,O
.,O,O
CL,O,O
-,O,O
cells,O,O
are,O,O
IgM,B,B
+,O,O
IgD,B,I
+,O,O
CD30,B,I
+,O,O
and,O,O
switch,O,O
to,O,O
IgG,B,B
",",O,O
IgA,B,B
",",O,O
and,O,O
IgE,B,B
when,O,O
exposed,O,O
to,O,O
CD40L,B,O
and,O,O
IL,B,B
-,I,I
4,I,I
.,O,O
Switching,O,O
is,O,O
hampered,O,O
by,O,O
CD30,B,B
coengagement,O,O
",",O,O
possibly,O,O
through,O,O
interference,O,O
with,O,O
the,O,O
CD40,B,B
-,O,I
mediated,O,O
NF,B,B
-,I,I
kappaB,I,I
-,O,I
dependent,O,O
transcriptional,O,O
activation,O,O
of,O,O
downstream,B,O
C,I,B
(,I,I
H,I,I
),I,I
genes,I,O
.,O,O
Are,O,O
there,O,O
effects,O,O
of,O,O
CyA,O,O
and,O,O
FK,O,O
506,O,O
all,O,O
attributable,O,O
to,O,O
CN,O,O
inhibition,O,O
",",O,O
and,O,O
how,O,O
much,O,O
of,O,O
them,O,O
are,O,O
mediated,O,O
through,O,O
the,O,O
NFATC,B,B
family,I,I
of,O,I
transcription,B,I
factors,I,O
?,O,O
To,O,O
investigate,O,O
processes,O,O
related,O,O
to,O,O
B,O,O
and,O,O
T,O,O
cell,O,O
activation,O,O
",",O,O
the,O,O
gene,O,O
expression,O,O
of,O,O
stimulated,O,O
and,O,O
nonstimulated,O,O
Ramos,O,O
and,O,O
Jurkat,O,O
cells,O,O
was,O,O
studied,O,O
using,O,O
cDNA,O,O
microarray,O,O
technology,O,O
.,O,O
Simultaneous,O,O
analysis,O,O
of,O,O
close,O,O
to,O,O
600,B,O
genes,I,O
indicated,O,O
highest,O,O
increase,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
certain,O,O
transcription,B,O
",",I,O
differentiation,I,O
and,I,O
proliferation,I,O
factors,I,O
.,O,O
Also,O,O
genes,O,O
encoding,O,O
proteins,O,O
involved,O,O
in,O,O
DNA,O,B
replication,O,I
",",O,O
binding,O,O
",",O,O
transcription,O,O
and,O,O
translation,O,O
were,O,O
induced,O,O
.,O,O
Signal,B,O
transducer,I,O
and,I,O
activator,I,O
of,I,O
transcription,I,O
3,I,O
(,O,O
Stat3,B,B
),O,O
has,O,O
recently,O,O
been,O,O
shown,O,O
to,O,O
exist,O,O
in,O,O
two,O,O
alternatively,O,O
spliced,O,O
isoforms,O,O
",",O,O
a,O,O
short,O,O
form,O,O
",",O,O
Stat3beta,B,O
",",O,O
and,O,O
a,O,O
longer,O,O
form,O,O
",",O,O
Stat3alpha,B,O
",",O,O
displaying,O,O
differences,O,O
in,O,O
transcriptional,O,O
activity,O,O
.,O,O
It,O,O
is,O,O
unknown,O,O
which,O,O
Stat3,B,B
isoform,I,I
(,O,O
s,O,O
),O,O
is,O,O
activated,O,O
in,O,O
response,O,O
to,O,O
interleukin,B,B
(,I,O
IL,I,I
),I,O
-,I,O
2,I,O
and,O,O
IL,B,B
-,I,O
15,I,O
.,O,O
It,O,O
is,O,O
shown,O,O
here,O,O
that,O,O
during,O,O
monocyte,O,B
to,O,O
macrophage,O,B
differentiation,O,O
",",O,O
the,O,O
expression,O,O
of,O,O
LAL,B,B
-,I,O
mRNA,I,O
is,O,O
induced,O,O
.,O,O
Relationship,O,O
between,O,O
IkappaBalpha,B,B
constitutive,O,I
expression,O,I
",",O,O
TNFalpha,B,B
synthesis,O,O
",",O,O
and,O,O
apoptosis,O,O
in,O,O
EBV,O,B
-,O,O
infected,O,O
lymphoblastoid,O,B
cells,O,O
.,O,O
In,O,O
order,O,O
to,O,O
understand,O,O
the,O,O
role,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
EBV,O,O
transformation,O,O
we,O,O
have,O,O
established,O,O
stably,O,O
transfected,O,O
IkappaBalpha,B,O
into,O,O
lymphoblastoid,O,O
cells,O,O
.,O,O
Protein,O,B
latency,O,I
expression,O,I
was,O,O
determined,O,O
by,O,O
immunocytochemistry,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
TNFalpha,B,B
gene,I,O
could,O,O
be,O,O
one,O,O
of,O,O
the,O,O
targets,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
in,O,O
EBV,O,O
infected,O,O
cells,O,O
and,O,O
that,O,O
NF,O,B
-,O,I
kappaB,O,I
protects,O,O
EBV,O,O
-,O,O
infected,O,O
cells,O,O
from,O,O
apoptosis,O,O
induced,O,O
by,O,O
TNFalpha,B,B
",",O,O
which,O,O
may,O,O
favour,O,O
the,O,O
proliferative,O,O
effect,O,O
of,O,O
this,O,O
cytokine,B,O
.,O,O
We,O,O
report,O,O
an,O,O
unusual,O,O
case,O,O
of,O,O
a,O,O
55,O,O
year,O,O
old,O,O
Japanese,O,O
woman,O,O
with,O,O
a,O,O
seminoma,O,B
but,O,O
relatively,O,O
normal,O,O
menses,O,O
.,O,O
A,O,O
typical,O,O
seminoma,O,O
was,O,O
removed,O,O
from,O,O
the,O,O
left,O,O
adnexal,O,O
region,O,O
and,O,O
an,O,O
immature,O,O
testis,O,B
was,O,O
identified,O,O
separately,O,O
as,O,O
an,O,O
associated,O,O
right,O,O
adnexal,O,O
mass,O,O
.,O,O
Repeated,O,O
karyotypic,O,O
studies,O,O
on,O,O
peripheral,O,O
blood,O,O
lymphocyte,O,O
cultures,O,O
showed,O,O
only,O,O
46,O,O
",",O,O
X,O,B
",",O,I
-,O,I
Y,O,I
",",O,I
t,O,I
(,O,I
Y,O,I
;,O,I
15,O,I
),O,I
(,O,I
q12,O,I
;,O,I
p13,O,I
),O,I
.,O,O
Two,O,O
chronically,O,O
HIV,O,B
-,O,I
1,O,I
-,O,I
infected,O,O
cell,O,O
lines,O,O
",",O,O
U1,O,O
(,O,O
monocytic,O,O
),O,O
and,O,O
ACH,O,O
-,O,O
2,O,O
(,O,O
T,O,O
lymphocytic,O,O
),O,O
",",O,O
were,O,O
stimulated,O,O
with,O,O
TNF,B,B
-,I,I
alpha,I,I
or,O,O
PMA,O,B
and,O,O
cultured,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
various,O,O
concentrations,O,O
of,O,O
the,O,O
compound,O,O
.,O,O
Its,O,O
50,O,O
%,O,O
effective,O,O
and,O,O
cytotoxic,O,O
concentrations,O,O
were,O,O
0,O,O
.,O,O
and,O,O
2,O,O
.,O,O
2,O,O
microg,O,O
/,O,O
ml,O,O
in,O,O
PMA,O,B
-,O,I
stimulated,O,O
U1,O,O
cells,O,O
",",O,O
respectively,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
cepharanthine,O,O
is,O,O
a,O,O
highly,O,O
potent,O,O
inhibitor,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
in,O,O
a,O,O
chronically,O,O
infected,O,O
monocytic,O,B
cell,O,I
line,O,I
.,O,O
This,O,O
study,O,O
shows,O,O
that,O,O
expression,O,O
of,O,O
LMP1,B,B
activates,O,O
transcription,O,O
from,O,O
p50,B,O
/,I,O
p65,I,O
-,I,O
and,I,O
c,I,O
-,I,O
Rel,I,O
-,I,O
responsive,I,O
promoters,I,O
",",O,O
and,O,O
that,O,O
this,O,O
activity,O,O
can,O,O
be,O,O
completely,O,O
inhibited,O,O
by,O,O
expression,O,O
of,O,O
a,O,O
dominant,O,O
inhibitory,B,O
IkappaB,I,B
mutant,I,O
.,O,O
Furthermore,O,O
",",O,O
LMP1,B,O
-,O,O
induced,O,O
cell,O,O
size,O,O
increase,O,O
of,O,O
primary,O,O
B,O,O
cells,O,O
was,O,O
unaffected,O,O
by,O,O
IkappaB,B,O
expression,O,O
.,O,O
When,O,O
cultured,O,O
in,O,O
RPMI,O,O
1640,O,O
medium,O,O
containing,O,O
10,O,O
%,O,O
fetal,O,O
bovine,O,O
serum,O,O
",",O,O
most,O,O
YJ,O,O
cells,O,O
were,O,O
myeloblastoid,O,O
with,O,O
a,O,O
small,O,O
number,O,O
of,O,O
the,O,O
cells,O,O
having,O,O
eosinophilic,O,O
granules,O,O
.,O,O
The,O,O
eosinophilic,O,O
characteristics,O,O
of,O,O
YJ,O,O
cells,O,O
were,O,O
confirmed,O,O
by,O,O
histochemical,O,O
staining,O,O
with,O,O
Fast,O,O
-,O,O
Green,O,O
/,O,O
Neutral,O,O
-,O,O
Red,O,O
and,O,O
by,O,O
the,O,O
expression,O,O
of,O,O
mRNAs,B,O
for,O,O
eosinophil,B,O
-,I,O
associated,I,O
granule,I,O
proteins,I,O
",",O,O
eosinophil,B,O
cationic,I,O
protein,I,O
(,O,O
ECP,B,O
),O,O
",",O,O
eosinophil,B,O
-,I,O
derived,I,O
neurotoxin,I,O
(,O,O
EDN,B,O
),O,O
",",O,O
eosinophil,B,O
peroxidase,I,O
(,O,O
EPO,B,O
),O,O
",",O,O
and,O,O
for,O,O
the,O,O
Charcot,B,O
-,I,O
Leyden,I,O
crystal,I,O
(,I,O
CLC,I,O
),I,O
protein,I,O
.,O,O
The,O,O
expression,O,O
of,O,O
genes,O,O
for,O,O
transcription,B,O
factors,I,O
involved,O,O
in,O,O
myeloid,O,O
differentiation,O,O
was,O,O
evaluated,O,O
by,O,O
Northern,O,O
blot,O,O
analysis,O,O
.,O,O
The,O,O
YJ,O,B
cell,O,I
line,O,I
should,O,O
be,O,O
useful,O,O
for,O,O
elucidating,O,O
the,O,O
molecular,O,O
mechanisms,O,O
governing,O,O
lineage,O,O
switching,O,O
from,O,O
the,O,O
eosinophil,O,B
to,O,O
monocytic,O,B
or,O,O
neutrophil,O,B
lineages,O,O
.,O,O
To,O,O
examine,O,O
the,O,O
hypothesis,O,O
that,O,O
interleukin,B,B
-,I,I
6,I,I
(,O,I
IL,B,I
-,I,I
6,I,I
),O,I
contributes,O,O
to,O,O
PMN,O,B
infiltration,O,O
and,O,O
lung,O,O
damage,O,O
in,O,O
HS,O,O
",",O,O
we,O,O
examined,O,O
the,O,O
lungs,O,O
of,O,O
rats,O,O
subjected,O,O
to,O,O
unresuscitated,O,O
and,O,O
resuscitated,O,O
HS,O,O
for,O,O
the,O,O
production,O,O
of,O,O
IL,B,B
-,I,I
6,I,I
and,O,O
activation,O,O
of,O,O
Stat3,B,B
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
of,O,O
protein,O,B
extracts,O,O
from,O,O
shock,O,O
lungs,O,O
exhibited,O,O
an,O,O
increase,O,O
in,O,O
Stat3,B,B
activation,O,O
with,O,O
kinetics,O,O
similar,O,O
to,O,O
IL,B,B
-,I,I
6,I,I
mRNA,I,I
.,O,O
The,O,O
MHC,B,B
class,I,I
II,I,I
transactivator,I,I
(,O,O
CIITA,B,O
),O,O
requires,O,O
conserved,O,O
leucine,B,O
charged,I,O
domains,I,O
for,O,O
interactions,O,O
with,O,O
the,O,O
conserved,O,O
W,B,O
box,I,O
promoter,I,O
element,I,O
.,O,O
The,O,O
ability,O,O
of,O,O
mutants,O,O
to,O,O
activate,O,O
a,O,O
reporter,O,O
gene,O,O
under,O,O
the,O,O
control,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
conserved,O,I
W,B,I
-,I,I
X,I,I
-,I,I
Y,I,I
or,I,O
X,I,O
-,I,O
Y,I,O
regulatory,I,O
elements,I,O
was,O,O
determined,O,O
.,O,O
Two,O,O
mutants,O,O
displayed,O,O
differential,O,O
activity,O,O
between,O,O
the,O,O
two,O,O
promoters,B,O
",",O,O
activating,O,O
transcription,O,O
with,O,O
the,O,O
W,B,B
-,I,I
X,I,I
-,I,I
Y,I,I
but,I,O
not,I,O
the,I,O
X,I,B
-,I,I
Y,I,I
elements,I,O
.,O,O
All,O,O
mutants,O,O
were,O,O
tested,O,O
for,O,O
their,O,O
ability,O,O
to,O,O
interfere,O,O
with,O,O
wild,O,O
-,O,O
type,O,O
CIITA,B,O
activity,O,O
.,O,O
The,O,O
characterization,O,O
of,O,O
CIITA,B,O
mutants,I,O
that,O,O
are,O,O
able,O,O
to,O,O
discriminate,O,O
between,O,O
promoters,O,O
with,O,O
or,O,O
without,O,O
the,O,O
W,B,B
box,I,I
strongly,O,O
suggests,O,O
that,O,O
CIITA,B,O
requires,O,O
such,O,O
interactions,O,O
for,O,O
function,O,O
.,O,O
Recently,O,O
",",O,O
it,O,O
was,O,O
suggested,O,O
that,O,O
activation,O,O
of,O,O
the,O,O
alpha,B,B
isoform,I,I
of,O,O
PPAR,B,O
by,O,O
the,O,O
potent,O,O
proinflammatory,O,O
mediator,O,O
leukotriene,O,O
B4,O,O
(,O,O
LTB4,O,O
),O,O
enhanced,O,O
degradation,O,O
of,O,O
this,O,O
eicosanoid,O,O
",",O,O
offersuggesting,O,O
a,O,O
new,O,O
aspect,O,O
of,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
inflammation,O,O
.,O,O
Thus,O,O
",",O,O
this,O,O
study,O,O
provides,O,O
no,O,O
evidence,O,O
indicating,O,O
a,O,O
regulatory,O,O
function,O,O
of,O,O
PPARalpha,B,O
in,O,O
LTB4,O,O
induced,O,O
adhesive,O,O
interactions,O,O
between,O,O
endothelial,O,B
cells,O,I
and,O,O
neutrophils,O,O
We,O,O
determined,O,O
whether,O,O
the,O,O
interaction,O,O
of,O,O
SS,O,O
RBC,O,O
with,O,O
cultured,O,O
endothelial,O,B
cells,O,I
induced,O,O
cellular,O,O
oxidant,O,O
stress,O,O
that,O,O
would,O,O
culminate,O,O
in,O,O
expression,O,O
of,O,O
cell,B,O
adhesion,I,O
molecules,I,O
(,O,O
CAMs,B,O
),O,O
involved,O,O
in,O,O
the,O,O
adhesion,O,O
and,O,O
diapedesis,O,O
of,O,O
monocytes,O,O
and,O,O
the,O,O
adherence,O,O
of,O,O
SS,O,O
reticulocytes,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
adherence,O,O
/,O,O
contact,O,O
of,O,O
SS,O,O
RBC,O,O
to,O,O
endothelial,O,B
cells,O,I
in,O,O
large,O,O
vessel,O,O
can,O,O
generate,O,O
enhanced,O,O
oxidant,O,O
stress,O,O
leading,O,O
to,O,O
increased,O,O
adhesion,O,O
and,O,O
diapedesis,O,O
of,O,O
monocytes,O,O
",",O,O
as,O,O
well,O,O
as,O,O
heightened,O,O
adherence,O,O
of,O,O
SS,O,O
reticulocytes,O,O
",",O,O
indicating,O,O
that,O,O
injury,O,O
/,O,O
activation,O,O
of,O,O
endothelium,O,B
can,O,O
contribute,O,O
to,O,O
vaso,O,O
-,O,O
occlusion,O,O
in,O,O
SCD,O,O
.,O,O
Relative,O,O
levels,O,O
were,O,O
then,O,O
correlated,O,O
with,O,O
a,O,O
series,O,O
of,O,O
clinical,O,O
variables,O,O
including,O,O
response,O,O
to,O,O
therapy,O,O
",",O,O
performance,O,O
status,O,O
",",O,O
survival,O,O
",",O,O
disease,O,O
sites,O,O
",",O,O
age,O,O
",",O,O
and,O,O
others,O,O
.,O,O
Changes,O,O
in,O,O
these,O,O
signaling,O,O
molecules,O,O
during,O,O
cytokine,B,O
treatment,O,O
were,O,O
also,O,O
investigated,O,O
.,O,O
Correlations,O,O
of,O,O
TCRzeta,B,B
or,O,O
p56,B,B
(,I,O
lck,I,O
),I,O
levels,O,O
with,O,O
response,O,O
or,O,O
disease,O,O
variables,O,O
",",O,O
except,O,O
for,O,O
lower,O,O
TCRzeta,B,B
levels,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
in,O,O
the,O,O
presence,O,O
of,O,O
bone,O,B
metastases,O,I
",",O,O
were,O,O
not,O,O
found,O,O
.,O,O
In,O,O
the,O,O
majority,O,O
of,O,O
patients,O,O
with,O,O
advanced,O,O
RCC,O,O
",",O,O
peripheral,O,O
blood,O,B
T,O,O
cells,O,O
express,O,O
TCRzeta,B,B
and,O,O
p56,B,B
(,I,O
lck,I,I
),I,O
",",O,O
and,O,O
in,O,O
a,O,O
subset,O,O
",",O,O
reduced,O,O
levels,O,O
of,O,O
these,O,O
TCRzeta,B,B
associated,I,I
molecules,I,I
are,O,O
seen,O,O
that,O,O
may,O,O
increase,O,O
during,O,O
cytokine,B,O
-,O,O
based,O,O
therapy,O,O
.,O,O
Identification,O,O
of,O,O
transcription,B,O
factors,I,O
expressed,O,O
during,O,O
ATRA,O,O
-,O,O
induced,O,O
neutrophil,O,O
differentiation,O,O
of,O,O
HL60,O,O
cells,O,O
.,O,O
In,O,O
order,O,O
to,O,O
understand,O,O
this,O,O
block,O,O
the,O,O
cascade,O,O
of,O,O
molecular,O,O
events,O,O
needs,O,O
to,O,O
be,O,O
characterized,O,O
.,O,O
CD38,O,B
+,O,I
cells,O,O
committed,O,O
towards,O,O
this,O,O
lineage,O,O
were,O,O
enriched,O,O
and,O,O
a,O,O
population,O,O
of,O,O
these,O,O
cells,O,O
treated,O,O
with,O,O
dihydroxyvitamin,O,O
D3,O,O
to,O,O
induce,O,O
neutrophil,O,B
maturation,O,O
.,O,O
The,O,O
differential,O,O
expression,O,O
of,O,O
the,O,O
genes,O,O
in,O,O
the,O,O
zinc,B,B
finger,I,I
and,I,O
POU,I,B
families,I,O
will,O,O
lead,O,O
to,O,O
a,O,O
better,O,O
understanding,O,O
of,O,O
the,O,O
cascade,O,O
of,O,O
gene,O,O
expression,O,O
which,O,O
occurs,O,O
following,O,O
ATRA,O,O
-,O,O
induced,O,O
differentiation,O,O
.,O,O
Interleukin,B,B
-,I,I
4,I,I
and,I,O
-,I,O
13,I,O
induce,O,O
upregulation,O,O
of,O,O
the,O,O
murine,O,O
macrophage,O,B
12,B,I
/,I,I
15,I,I
-,I,I
lipoxygenase,I,I
activity,I,O
:,O,O
evidence,O,O
for,O,O
the,O,O
involvement,O,O
of,O,O
transcription,B,O
factor,I,O
STAT6,B,O
.,O,O
Moreover,O,O
",",O,O
a,O,O
strong,O,O
induction,O,O
of,O,O
the,O,O
enzyme,O,O
was,O,O
observed,O,O
in,O,O
red,O,B
cells,O,I
during,O,O
experimental,O,O
anemia,O,O
in,O,O
mice,O,O
.,O,O
The,O,O
cytokine,B,O
-,O,O
dependent,O,O
upregulation,O,O
of,O,O
the,O,O
murine,B,O
macrophage,I,B
12,I,I
-,I,I
lipoxygenase,I,I
and,O,O
its,O,O
induction,O,O
during,O,O
experimental,O,O
anemia,O,O
suggests,O,O
its,O,O
close,O,O
relatedness,O,O
with,O,O
the,O,O
human,B,O
reticulocyte,I,B
-,I,I
type,I,I
15,I,I
-,I,I
lipoxygenase,I,I
despite,O,O
their,O,O
differences,O,O
in,O,O
the,O,O
positional,O,O
specificity,O,O
of,O,O
arachidonic,O,O
acid,O,O
oxygenation,O,O
.,O,O
Interferon,B,B
-,I,I
gamma,I,I
-,I,I
induced,I,O
factor,I,O
binding,O,O
to,O,O
the,O,O
interleukin,B,B
-,I,I
4,I,I
-,I,I
responsive,I,O
element,I,O
of,O,O
CD23b,B,O
promoter,I,O
in,O,O
human,O,B
tonsillar,O,I
mononuclear,O,I
cells,O,I
:,O,O
role,O,O
in,O,O
transient,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
the,O,O
interleukin,B,B
-,I,I
4,I,I
-,I,I
induced,I,O
CD23b,I,O
mRNA,I,O
.,O,O
Activation,O,O
of,O,O
E2F,B,B
-,O,I
mediated,O,I
transcription,O,I
by,O,O
human,B,B
T,I,I
-,I,I
cell,I,I
leukemia,I,I
virus,I,I
type,I,I
I,I,I
Tax,I,I
protein,I,I
in,O,O
a,O,O
p16,O,B
(,O,I
INK4A,O,I
),O,I
-,O,I
negative,O,I
T,O,I
-,O,I
cell,O,I
line,O,I
.,O,O
Consequently,O,O
",",O,O
Tax,B,O
can,O,O
activate,O,O
the,O,O
signaling,O,O
pathway,O,O
that,O,O
lead,O,O
to,O,O
the,O,O
release,O,O
of,O,O
E2F,B,B
that,O,O
in,O,O
turn,O,O
induces,O,O
expression,O,O
of,O,O
factors,O,O
required,O,O
for,O,O
cell,O,O
cycle,O,O
progression,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
Tax,B,O
also,O,O
stimulates,O,O
the,O,O
transcription,O,O
of,O,O
the,O,O
E2F,B,B
-,I,I
1,I,I
gene,I,I
itself,O,O
.,O,O
Inducible,O,O
nitric,O,B
oxide,O,I
:,O,O
an,O,O
autoregulatory,O,O
feedback,O,O
inhibitor,O,O
of,O,O
vascular,O,O
inflammation,O,O
.,O,O
These,O,O
studies,O,O
indicate,O,O
that,O,O
iNO,O,B
attenuates,O,O
iNOS,B,B
expression,O,O
in,O,O
macrophages,O,O
and,O,O
inhibits,O,O
monocyte,O,B
adhesion,O,O
to,O,O
endothelial,O,B
cells,O,I
",",O,O
and,O,O
suggest,O,O
that,O,O
endogenously,O,O
derived,O,O
iNO,O,O
may,O,O
be,O,O
an,O,O
important,O,O
autoregulatory,O,O
inhibitor,O,O
of,O,O
vascular,O,B
inflammation,O,I
These,O,O
results,O,O
corroborate,O,O
previous,O,O
findings,O,O
that,O,O
the,O,O
presence,O,O
of,O,O
ER,B,B
variants,O,O
is,O,O
not,O,O
a,O,O
characteristic,O,O
of,O,O
breast,O,B
cancer,O,I
.,O,O
p21ras,B,B
initiates,O,O
Rac,B,B
-,I,I
1,I,I
but,O,O
not,O,O
phosphatidyl,B,B
inositol,I,I
3,I,I
kinase,I,I
/,I,I
PKB,I,I
",",O,O
mediated,O,O
signaling,O,O
pathways,O,O
in,O,O
T,O,O
lymphocytes,O,O
.,O,O
We,O,O
also,O,O
examined,O,O
the,O,O
possibility,O,O
that,O,O
Akt,B,B
/,I,I
PKB,I,I
is,O,O
regulated,O,O
by,O,O
Ras,O,B
signaling,O,O
pathways,O,O
in,O,O
T,O,O
lymphocytes,O,O
.,O,O
Moreover,O,O
",",O,O
neither,O,O
TCR,B,B
or,O,O
Ras,B,B
activation,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
is,O,O
dependent,O,O
on,O,O
PtdIns,B,B
3,I,I
-,I,I
kinase,I,I
.,O,O
The,O,O
present,O,O
data,O,O
thus,O,O
highlight,O,O
that,O,O
PtdIns,B,B
3,I,I
-,I,I
kinase,I,I
and,O,O
Akt,B,B
/,I,I
PKB,I,I
are,O,O
not,O,O
universal,O,O
Ras,B,O
effector,I,O
molecules,I,O
.,O,O
LNCaP,O,O
cells,O,O
treated,O,O
with,O,O
prostaglandin,O,O
E2,O,O
showed,O,O
neither,O,O
a,O,O
reduction,O,O
in,O,O
proliferation,O,O
nor,O,O
a,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
AR,B,B
and,O,O
PSA,B,B
levels,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
recombinant,O,O
IL,B,B
-,I,I
1beta,I,I
was,O,O
able,O,O
to,O,O
replace,O,O
MCM,O,O
for,O,O
the,O,O
inhibition,O,O
of,O,O
proliferation,O,O
and,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
AR,B,B
and,O,O
PSA,B,B
proteins,O,O
.,O,O
LNCaP,O,O
cells,O,O
were,O,O
shown,O,O
to,O,O
express,O,O
the,O,O
IL,B,B
-,I,I
1beta,I,I
receptor,O,I
type,O,I
1,O,I
",",O,O
which,O,O
transduces,O,O
IL,B,B
-,I,I
1beta,I,I
signal,O,O
.,O,O
Differential,O,O
responsiveness,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
5,I,I
and,I,O
IL,I,B
-,I,I
4,I,I
genes,I,O
to,O,O
transcription,B,O
factor,I,O
GATA,I,B
-,I,I
3,I,I
.,O,O
Here,O,O
",",O,O
we,O,O
show,O,O
that,O,O
ectopic,O,O
expression,O,O
of,O,O
GATA,B,B
-,I,I
3,I,I
is,O,O
sufficient,O,O
to,O,O
drive,O,O
IL,B,B
-,I,I
5,I,I
but,O,O
not,O,O
IL,B,B
-,I,I
4,I,I
gene,O,O
expression,O,O
.,O,O
Mutations,O,O
of,O,O
sites,O,O
that,O,O
suppress,O,O
NF,B,B
-,I,I
AT,I,I
binding,O,O
impair,O,O
the,O,O
induction,O,O
and,O,O
strong,O,O
NF,B,B
-,I,I
ATp,I,I
-,O,I
mediated,O,O
transactivation,O,O
of,O,O
the,O,O
CD25,B,O
promoter,I,O
in,O,O
T,O,O
cells,O,O
.,O,O
Antibodies,B,O
to,O,O
Duffy,B,B
antigens,I,I
are,O,O
responsible,O,O
for,O,O
some,O,O
cases,O,O
of,O,O
transfusion,O,O
incompatibility,O,O
and,O,O
newborn,O,O
hemolytic,O,O
disease,O,O
.,O,O
The,O,O
Duffy,B,B
protein,I,I
is,O,O
a,O,O
receptor,O,O
for,O,O
the,O,O
Plasmodium,B,O
vivax,I,O
erythrocyte,I,O
-,I,O
binding,I,O
protein,I,O
and,O,O
is,O,O
also,O,O
a,O,O
receptor,O,O
for,O,O
various,O,O
chemokines,B,O
(,O,O
thus,O,O
renamed,O,O
Duffy,B,B
Antigen,I,I
Receptor,I,I
for,I,I
Chemokines,I,I
[,O,I
DARC,B,I
],O,I
.,O,O
The,O,O
Fy,O,B
(,O,O
a,O,O
-,O,O
b,O,O
-,O,O
),O,O
phenotype,O,O
is,O,O
the,O,O
predominant,O,O
one,O,O
in,O,O
populations,O,O
of,O,O
black,O,O
people,O,O
and,O,O
also,O,O
occurs,O,O
in,O,O
other,O,O
populations,O,O
",",O,O
including,O,O
some,O,O
non,O,O
-,O,O
Ashkenazi,O,O
Jewish,O,O
groups,O,O
.,O,O
The,O,O
Fy,O,B
(,O,O
a,O,O
-,O,O
b,O,O
-,O,O
),O,O
phenotype,O,O
has,O,O
been,O,O
associated,O,O
with,O,O
a,O,O
mutation,O,O
in,O,O
the,O,O
FY,B,B
*,I,I
B,I,I
promoter,I,O
at,O,O
the,O,O
GATA,B,B
box,I,I
that,O,O
abolishes,O,O
the,O,O
expression,O,O
of,O,O
erythrocyte,B,B
Duffy,I,I
protein,I,I
.,O,O
The,O,O
271C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
substitution,O,O
represents,O,O
a,O,O
considerable,O,O
change,O,O
in,O,O
chemical,O,O
nature,O,O
(,O,O
Arg91,O,O
-,O,O
-,O,O
>,O,O
Cys,O,O
),O,O
",",O,O
one,O,O
which,O,O
may,O,O
affect,O,O
the,O,O
antigenic,O,O
determinants,O,O
of,O,O
DARC,B,O
",",O,O
and,O,O
thus,O,O
be,O,O
of,O,O
clinical,O,O
significance,O,O
.,O,O
The,O,O
functions,O,O
of,O,O
NFAT,B,B
proteins,I,I
are,O,O
directly,O,O
controlled,O,O
by,O,O
the,O,O
calcium,B,B
-,I,I
and,I,I
calmodulin,I,I
-,I,I
dependent,I,I
phosphatase,I,I
calcineurin,B,I
.,O,O
Expression,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
requires,O,O
activation,O,O
of,O,O
T,O,O
cells,O,O
through,O,O
stimulation,O,O
of,O,O
the,O,O
TCR,B,O
and,O,O
costimulation,O,O
through,O,O
accessory,B,O
receptors,I,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
analyzed,O,O
whether,O,O
activities,O,O
of,O,O
these,O,O
phosphatases,O,O
are,O,O
necessary,O,O
for,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
gene,I,I
.,O,O
In,O,O
both,O,O
activated,O,O
peripheral,O,O
blood,O,O
T,O,O
lymphocytes,O,O
and,O,O
activated,O,O
tumorigenic,O,O
T,O,O
cell,O,O
lines,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
gene,O,I
expression,O,O
was,O,O
blocked,O,O
at,O,O
the,O,O
transcriptional,O,O
level,O,O
by,O,O
okadaic,O,O
acid,O,O
.,O,O
The,O,O
transcription,B,O
factors,I,O
active,O,O
at,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
were,O,O
differentially,O,O
influenced,O,O
:,O,O
upon,O,O
down,O,O
-,O,O
modulation,O,O
of,O,O
okadaic,B,O
acid,I,O
-,I,O
sensitive,I,O
phosphatases,I,O
",",O,O
transactivation,O,O
by,O,O
octamer,O,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
and,O,O
NF,B,B
of,I,I
activated,I,I
T,I,I
cells,I,I
proteins,I,I
was,O,O
abrogated,O,O
",",O,O
while,O,O
transactivation,O,O
by,O,O
AP,B,B
-,I,I
1,I,I
proteins,I,I
was,I,O
even,I,O
enhanced,I,O
.,I,O
The,O,O
purpose,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
examine,O,O
the,O,O
effects,O,O
of,O,O
bis,O,O
[,O,O
4,O,O
-,O,O
[,O,O
2,O,O
",",O,O
4,O,O
-,O,O
-,O,O
-,O,O
thiazolidinyl,O,O
),O,O
methyl,O,O
],O,O
phenyl,O,O
],O,O
methane,O,O
(,O,O
YM,O,O
-,O,O
268,O,O
),O,O
",",O,O
a,O,O
thiazolidinedione,O,O
derivative,O,O
",",O,O
on,O,O
glucose,O,O
uptake,O,O
",",O,O
adipocyte,O,O
differentiation,O,O
through,O,O
peroxisome,B,O
proliferator,I,O
-,I,O
activated,I,O
receptor,I,O
gamma,I,O
(,O,O
PPARgamma,B,O
),O,O
",",O,O
and,O,O
phosphatidylinositol,B,O
3,I,O
-,I,O
kinase,I,O
(,O,O
PI,B,O
3,I,O
-,I,O
kinase,I,O
),O,O
activity,O,O
in,O,O
cultured,O,O
cells,O,O
.,O,O
YM268,O,O
and,O,O
pioglitazone,O,O
dose,O,O
-,O,O
dependently,O,O
increased,O,O
the,O,O
2,O,O
-,O,O
deoxyglucose,O,O
uptake,O,O
in,O,O
3T3,O,O
-,O,O
L1,O,O
cells,O,O
.,O,O
The,O,O
nuclear,B,O
receptor,I,O
PPARgamma,B,B
-,O,I
bigger,O,O
than,O,O
fat,O,O
.,O,O
PPARgamma,B,B
has,O,O
also,O,O
been,O,O
implicated,O,O
recently,O,O
in,O,O
the,O,O
biology,O,O
of,O,O
monocytes,O,O
and,O,O
in,O,O
cell,O,O
-,O,O
cycle,O,O
regulation,O,O
and,O,O
cancer,O,O
.,O,O
Although,O,O
common,O,O
members,O,O
of,O,O
the,O,O
apoptotic,O,O
cascade,O,O
are,O,O
shared,O,O
between,O,O
different,O,O
cell,O,O
types,O,O
",",O,O
it,O,O
appears,O,O
that,O,O
cell,B,O
-,I,O
specific,I,O
factors,I,O
can,O,O
influence,O,O
the,O,O
response,O,O
to,O,O
a,O,O
given,O,O
apoptotic,O,O
stimuli,O,O
.,O,O
These,O,O
results,O,O
establish,O,O
an,O,O
independent,O,O
role,O,O
for,O,O
enhanced,O,O
p75TNF,B,B
-,I,I
R,I,I
production,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
inflammatory,O,O
disease,O,O
and,O,O
implicate,O,O
the,O,O
direct,O,O
involvement,O,O
of,O,O
this,O,O
receptor,O,O
in,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
human,O,O
inflammatory,O,O
pathologies,O,O
.,O,O
Molecular,O,O
and,O,O
cellular,O,O
analysis,O,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
-,O,O
induced,O,O
apoptosis,O,O
in,O,O
lymphoblastoid,B,B
T,I,I
-,I,I
cell,I,I
-,I,I
line,I,I
-,I,I
expressing,I,O
wild,I,O
-,I,O
type,I,O
and,I,O
mutated,I,O
CD4,I,B
receptors,I,I
.,O,O
We,O,O
have,O,O
determined,O,O
how,O,O
the,O,O
phosphorylation,O,O
of,O,O
the,O,O
retinoblastoma,B,B
family,I,I
(,O,O
pRb,B,B
",",O,O
",",O,O
and,O,O
p130,B,B
),O,O
is,O,O
governed,O,O
in,O,O
individual,O,O
cell,O,O
cycle,O,O
phases,O,O
of,O,O
Daudi,O,O
B,O,O
-,O,O
cells,O,O
during,O,O
cell,O,O
cycle,O,O
exit,O,O
triggered,O,O
by,O,O
alpha,B,O
-,I,O
interferon,I,O
(,O,O
alpha,B,O
-,I,O
IFN,I,O
),O,O
.,O,O
alpha,B,O
-,I,O
IFN,I,O
causes,O,O
dephosphorylation,O,O
of,O,O
pRb,B,B
and,O,O
loss,O,O
of,O,O
p130,B,B
phosphorylated,I,O
Form,I,O
3,I,O
.,O,O
However,O,O
",",O,O
the,O,O
change,O,O
in,O,O
p130,B,B
phosphorylation,O,I
in,O,O
response,O,O
to,O,O
alpha,B,O
-,I,O
IFN,I,O
occurs,O,O
before,O,O
dephosphorylation,O,O
of,O,O
pRb,B,B
is,O,O
complete,O,O
because,O,O
loss,O,O
of,O,O
p130,B,B
Form,I,I
3,I,I
occurs,O,O
throughout,O,O
the,O,O
cell,O,O
cycle,O,O
prior,O,O
to,O,O
complete,O,O
arrest,O,O
in,O,O
G1,O,O
",",O,O
whereas,O,O
pRb,B,B
is,O,O
dephosphorylated,O,O
only,O,O
in,O,O
G1,O,O
.,O,O
p130,B,B
",",O,O
predominantly,O,O
in,O,O
Form,O,I
1,O,I
",",O,O
and,O,O
hypophosphorylated,B,O
pRb,I,B
bind,O,O
an,O,O
E2F,B,O
DNA,I,O
binding,I,O
site,I,O
;,O,O
p130,B,B
complexes,O,O
E2F,B,O
-,I,O
4,I,O
",",O,O
whereas,O,O
pRb,B,B
binds,O,O
both,O,O
E2F,O,O
-,O,O
4,O,O
and,O,O
E2F,B,O
-,I,O
1,I,O
.,O,O
The,O,O
phosphorylated,O,O
forms,O,O
of,O,O
E2F,B,B
-,I,I
4,I,I
that,O,O
bind,O,O
to,O,O
the,O,O
E2F,B,B
DNA,I,I
site,I,I
are,O,O
different,O,O
from,O,O
hyperphosphorylated,O,O
E2F,B,B
-,I,I
4,I,I
",",O,O
which,O,O
predominates,O,O
in,O,O
primary,O,O
hemopoietic,O,O
cells,O,O
in,O,O
G0,O,O
.,O,O
Macrophages,O,O
and,O,O
granulocytes,O,O
",",O,O
which,O,O
are,O,O
developed,O,O
from,O,O
a,O,O
common,O,O
progenitor,O,O
cell,O,O
",",O,O
are,O,O
the,O,O
cellular,O,O
components,O,O
of,O,O
the,O,O
specific,O,O
and,O,O
non,O,O
-,O,O
specific,O,O
immunoreaction,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
v,B,O
-,I,O
myb,I,O
reduces,O,O
MRP14,B,B
promoter,I,O
activity,O,O
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
of,O,O
L132,O,B
cells,O,O
transfected,O,O
with,O,O
the,O,O
C,B,B
/,I,I
EBP,I,I
alpha,I,I
expression,O,O
vector,O,O
demonstrate,O,O
that,O,O
C,B,B
/,I,I
EBP,I,I
alpha,I,I
is,O,O
sufficient,O,O
to,O,O
enhance,O,O
MRP14,B,B
expression,O,O
in,O,O
the,O,O
context,O,O
of,O,O
the,O,O
whole,O,O
genome,O,O
.,O,O
This,O,O
observation,O,O
prompted,O,O
us,O,O
to,O,O
postulate,O,O
that,O,O
signal,O,O
2,O,O
(,O,O
costimulatory,O,O
signal,O,O
),O,O
alone,O,O
without,O,O
signal,O,O
1,O,O
(,O,O
TCR,B,O
signal,O,O
),O,O
can,O,O
activate,O,O
T,O,O
cells,O,O
.,O,O
This,O,O
pathway,O,O
resulted,O,O
in,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
transcription,B,O
factors,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
NF,B,B
-,I,I
AT,I,I
",",O,O
and,O,O
proteins,O,B
binding,O,O
to,O,O
the,O,O
CD28,B,B
response,O,I
element,O,I
of,O,I
the,O,I
IL,B,I
-,I,I
2,I,I
promoter,I,I
.,O,O
In,O,O
contrast,O,O
to,O,O
the,O,O
differential,O,O
signaling,O,O
of,O,O
BW,B,O
828,I,O
and,O,O
9,B,O
.,I,O
3,I,O
in,O,O
resting,O,O
T,O,O
cells,O,O
",",O,O
the,O,O
two,O,O
mAbs,O,O
exhibited,O,O
a,O,O
similar,O,O
pattern,O,O
of,O,O
early,O,O
signaling,O,O
events,O,O
in,O,O
activated,O,O
T,O,O
cells,O,O
and,O,O
Jurkat,O,O
cells,O,O
(,O,O
p56,B,B
(,I,I
lck,I,I
),I,I
activation,O,I
",",O,O
association,O,O
of,O,O
phosphatidylinositol,B,B
3,I,I
-,I,I
kinase,I,I
with,O,O
CD28,B,B
),O,I
",",O,O
indicating,O,O
that,O,O
the,O,O
signaling,O,O
capacity,O,O
of,O,O
CD28,B,B
changes,O,O
with,O,O
activation,O,O
.,O,O
IL,B,B
-,I,I
12,I,I
is,O,O
a,O,O
75,B,O
-,I,O
kDa,I,O
heterodimeric,I,O
cytokine,I,O
composed,O,O
of,O,O
two,O,O
covalently,O,O
linked,O,O
p35,B,O
and,I,O
p40,I,O
chains,I,O
.,O,O
Th1,O,O
cell,O,O
-,O,O
mediated,O,O
immune,O,O
responses,O,O
have,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
chronic,O,O
inflammatory,O,O
autoimmune,O,O
diseases,O,O
.,O,O
This,O,O
was,O,O
associated,O,O
with,O,O
the,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
IL,B,B
-,I,I
12p40,I,I
mRNA,I,I
expression,O,O
.,O,O
Metabolic,O,O
labeling,O,O
combined,O,O
with,O,O
pulse,O,O
-,O,O
chase,O,O
experiments,O,O
and,O,O
biochemical,O,O
analysis,O,O
showed,O,O
that,O,O
the,O,O
majority,O,O
of,O,O
class,B,O
II,I,O
molecules,I,O
in,O,O
infected,O,O
cells,O,O
became,O,O
resistant,O,O
to,O,O
endoglycosidase,B,O
H,I,O
",",O,O
consistent,O,O
with,O,O
normal,O,O
Golgi,O,O
processing,O,O
.,O,O
However,O,O
",",O,O
results,O,O
of,O,O
intracellular,O,O
staining,O,O
and,O,O
dual,O,O
color,O,O
confocal,O,O
microscopy,O,O
revealed,O,O
a,O,O
significant,O,O
defect,O,O
in,O,O
transport,O,O
of,O,O
newly,O,O
synthesized,O,O
class,B,O
II,I,O
molecules,I,O
through,O,O
the,O,O
endocytic,O,O
compartment,O,O
.,O,O
Thus,O,O
",",O,O
compared,O,O
with,O,O
findings,O,O
in,O,O
control,O,O
cells,O,O
",",O,O
class,B,O
II,I,O
molecules,I,O
in,O,O
infected,O,O
cells,O,O
colocalized,O,O
to,O,O
a,O,O
minimal,O,O
extent,O,O
with,O,O
a,O,O
lysosomal,B,O
-,I,O
associated,I,O
membrane,I,O
protein,I,O
-,I,O
1,I,O
+,O,O
endosomal,O,O
compartment,O,O
.,O,O
Analyzed,O,O
DNA,B,B
sequences,I,O
included,O,O
delta,B,B
and,I,O
beta,I,B
5,I,O
flanking,I,O
regions,I,O
extending,O,O
from,O,O
approximately,O,O
-,B,O
500,I,O
to,I,O
+,I,O
50bp,I,O
(,O,O
promoter,B,O
regions,I,O
),O,O
",",O,O
truncated,O,O
delta,O,B
and,O,O
beta,B,B
5,I,O
flanking,I,O
regions,I,O
extending,O,O
from,O,O
approximately,O,O
-,B,O
250,I,O
to,I,O
+,I,O
50,I,O
bp,I,O
",",O,O
and,O,O
chimeric,B,O
promoter,I,O
constructions,I,O
",",O,O
which,O,O
consisted,O,O
of,O,O
a,O,O
distal,O,O
delta,B,B
or,I,O
beta,I,B
fragment,I,O
fused,O,O
to,O,O
a,O,O
proximal,B,O
beta,I,B
or,I,O
delta,I,B
sequence,I,O
.,O,O
In,O,O
CAT,B,B
reporter,I,I
constructions,I,I
no,O,O
appreciable,O,O
level,O,O
of,O,O
CAT,B,B
activity,O,O
was,O,O
supported,O,O
by,O,O
the,O,O
beta,B,B
globin,I,I
promoter,I,I
",",O,O
and,O,O
only,O,O
low,O,O
level,O,O
activity,O,O
by,O,O
the,O,O
delta,B,B
promoter,I,I
.,O,O
Fusion,O,O
of,O,O
the,O,O
upstream,B,O
portion,I,O
of,O,O
the,O,O
delta,B,B
promoter,I,I
to,O,O
the,O,O
truncated,O,O
beta,B,B
globin,I,I
promoter,I,I
yielded,O,O
a,O,O
modest,O,O
increase,O,O
in,O,O
promoter,O,O
strength,O,O
relative,O,O
to,O,O
the,O,O
truncated,B,O
beta,I,B
gene,I,I
promoter,I,I
",",O,O
indicating,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
positive,B,O
transcriptional,I,O
element,I,O
(,O,O
s,O,O
),O,O
in,O,O
the,O,O
upstream,B,O
delta,I,B
globin,I,I
regulatory,I,I
region,I,I
.,O,O
The,O,O
induction,O,O
of,O,O
IgE,B,B
by,O,O
IL,B,B
-,I,I
4,I,I
and,O,O
IL,B,B
-,I,I
13,I,I
occurs,O,O
through,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
intracellular,B,O
signal,I,O
-,I,O
transducing,I,O
protein,I,O
Stat6,I,O
",",O,O
whereas,O,O
the,O,O
inhibition,O,O
of,O,O
IgE,B,O
class,O,O
switching,O,O
by,O,O
interferon,B,O
-,I,O
y,I,O
(,O,O
IFN,B,B
-,I,I
gamma,I,I
),O,O
occurs,O,O
through,O,O
the,O,O
activation,O,O
of,O,O
Statl,B,O
.,O,O
NFAT,B,B
regulates,O,O
transcription,O,O
of,O,O
a,O,O
number,O,O
of,O,O
cytokine,O,O
and,O,O
other,O,O
immunoregulatory,B,O
genes,I,O
.,O,O
We,O,O
also,O,O
report,O,O
three,O,O
additional,O,O
isoforms,O,O
of,O,O
NFATx,B,B
",",O,O
designated,O,O
NFATx2,B,B
",",O,O
NFATx3,B,B
",",O,O
and,O,O
NFATx4,B,B
.,O,O
This,O,O
transactivation,O,O
sequence,O,O
is,O,O
altered,O,O
by,O,O
tissue,O,O
-,O,O
specific,O,O
alternative,O,O
splicing,O,O
in,O,O
newly,O,O
isolated,O,O
NFATx,B,B
isoforms,I,O
",",O,O
resulting,O,O
in,O,O
lower,O,O
transactivation,O,O
activity,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
.,O,O
5,B,O
HS3,I,O
contains,O,O
six,O,O
G,O,O
-,O,O
rich,O,O
motifs,O,O
that,O,O
are,O,O
essential,O,O
for,O,O
its,O,O
activity,O,O
.,O,O
We,O,O
show,O,O
that,O,O
the,O,O
function,O,O
of,O,O
such,O,O
closely,O,O
related,O,O
proteins,O,O
can,O,O
be,O,O
distinguished,O,O
in,O,O
vivo,O,O
by,O,O
matching,O,O
point,O,O
mutations,O,O
in,O,O
5,B,O
HS3,I,O
with,O,O
amino,O,O
acid,O,O
changes,O,O
in,O,O
the,O,O
zinc,B,B
fingers,I,I
of,O,O
Sp1,B,B
and,O,O
EKLF,B,O
.,O,O
The,O,O
transition,O,O
of,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
(,O,O
EBV,O,O
),O,O
from,O,O
latency,O,O
into,O,O
the,O,O
lytic,O,O
cycle,O,O
is,O,O
associated,O,O
with,O,O
the,O,O
expression,O,O
of,O,O
two,O,O
immediate,B,O
-,I,O
early,I,O
viral,I,O
genes,I,O
",",O,O
BZLF1,B,O
and,O,O
BRLF1,B,O
.,O,O
In,O,O
HH514,O,O
-,O,O
16,O,O
cells,O,O
",",O,O
transfection,O,O
of,O,O
Rta,B,O
leads,O,O
to,O,O
synthesis,O,O
of,O,O
ZEBRA,B,B
",",O,O
viral,O,O
DNA,O,B
replication,O,O
",",O,O
and,O,O
late,O,O
gene,O,O
expression,O,O
.,O,O
Expression,O,O
of,O,O
either,O,O
BZLF1,B,B
or,O,O
BRLF1,B,B
triggers,O,O
expression,O,O
of,O,O
the,O,O
other,O,O
immediate,B,O
-,I,O
early,I,O
factor,I,O
",",O,O
and,O,O
together,O,O
these,O,O
activators,O,O
act,O,O
individually,O,O
or,O,O
in,O,O
synergy,O,O
on,O,O
downstream,B,O
targets,I,O
to,O,O
activate,O,O
the,O,O
viral,O,O
lytic,O,O
cycle,O,O
.,O,O
We,O,O
first,O,O
demonstrate,O,O
",",O,O
in,O,O
human,O,B
and,O,O
mouse,O,B
intraspecies,O,I
hybrids,O,I
",",O,O
the,O,O
coordinate,O,O
suppression,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
",",O,O
Ii,B,B
(,O,I
invariant,B,I
chain,I,I
),O,I
and,O,O
HLA,B,B
-,I,I
DM,I,I
gene,I,I
transcription,O,O
",",O,O
and,O,O
the,O,O
release,O,O
of,O,O
the,O,O
silencing,O,O
by,O,O
the,O,O
addition,O,O
of,O,O
interferon,B,B
gamma,I,I
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
the,O,O
IFN,B,B
-,I,I
gamma,I,I
-,O,I
independent,O,I
component,O,I
of,O,O
the,O,O
target,O,O
cell,O,O
HLA,B,B
-,I,I
DR,I,I
expression,O,O
induced,O,O
by,O,O
lymphocyte,O,O
adhesion,O,O
uses,O,O
a,O,O
signaling,O,O
pathway,O,O
that,O,O
is,O,O
distinct,O,O
from,O,O
the,O,O
IFN,B,B
-,I,I
gamma,I,I
-,O,I
dependent,O,I
mechanism,O,O
and,O,O
also,O,O
suggest,O,O
that,O,O
CIITA,B,O
is,O,O
not,O,O
required,O,O
.,O,O
In,O,O
this,O,O
report,O,O
expression,O,O
profiles,O,O
and,O,O
activation,O,O
of,O,O
PKC,B,B
were,O,O
analyzed,O,O
in,O,O
human,O,O
Raji,O,B
B,O,I
lymphoblastoid,O,I
cells,O,O
.,O,O
Transient,O,O
transfection,O,O
analysis,O,O
with,O,O
target,B,O
plasmids,I,O
containing,O,O
either,O,O
DRA,B,B
promoter,I,I
(,O,O
wild,O,O
-,O,O
type,O,O
or,O,O
mutated,O,O
),O,O
or,O,O
TPA,B,B
response,I,I
elements,I,I
demonstrated,O,O
that,O,O
pretreatment,O,O
with,O,O
the,O,O
selective,O,O
PKC,B,B
inhibitor,O,I
GF,O,I
109203X,O,I
repressed,O,O
TPA,O,O
-,O,O
mediated,O,O
activation,O,O
.,O,O
Together,O,O
",",O,O
these,O,O
results,O,O
show,O,O
that,O,O
activated,O,O
HLA,B,B
-,I,I
DRA,I,I
expression,O,O
in,O,O
response,O,O
to,O,O
TPA,O,O
treatment,O,O
is,O,O
strictly,O,O
dependent,O,O
on,O,O
PKC,B,B
activation,O,O
acting,O,O
on,O,O
the,O,O
X2,B,O
box,I,O
of,O,O
the,O,O
DRA,B,B
promoter,I,O
and,O,O
that,O,O
selective,O,O
inhibition,O,O
of,O,O
PKC,B,B
enzymatic,O,O
activity,O,O
does,O,O
not,O,O
influence,O,O
subcellular,O,O
localization,O,O
of,O,O
expressed,O,O
PKC,B,B
isoenzymes,I,O
.,O,O
Multiple,O,O
cellular,B,O
DNA,I,B
-,I,I
binding,I,I
transcription,I,I
factors,I,I
are,O,O
required,O,O
by,O,O
HIV,O,O
type,O,O
1,O,O
for,O,O
RNA,O,B
synthesis,O,I
.,O,O
These,O,O
synthetic,O,O
ligands,O,O
specifically,O,O
inhibit,O,O
DNA,O,B
-,O,I
binding,O,I
of,O,O
each,O,O
transcription,B,O
factor,I,O
and,O,O
HIV,O,O
type,O,O
1,O,O
transcription,O,O
in,O,O
cell,O,O
-,O,O
free,O,O
assays,O,O
.,O,O
In,O,O
situ,O,O
hybridisation,O,O
revealed,O,O
musculin,B,O
expression,O,O
in,O,O
embryos,O,O
was,O,O
largely,O,O
restricted,O,O
to,O,O
the,O,O
embryonic,O,O
skeletal,O,O
muscle,O,O
lineage,O,O
.,O,O
While,O,O
all,O,O
skeletal,O,B
muscles,O,I
expressed,O,O
the,O,O
gene,O,O
",",O,O
only,O,O
a,O,O
subset,O,O
of,O,O
myocytes,O,B
within,O,O
each,O,O
muscle,O,O
were,O,O
positive,O,O
",",O,O
indicating,O,O
molecular,O,O
heterogeneity,O,O
within,O,O
fetal,O,O
muscle,O,O
.,O,O
All,O,O
Rights,O,O
Reserved,O,O
.,O,O
The,O,O
TT,O,O
-,O,O
selected,O,O
T,O,B
cell,O,I
line,O,I
could,O,O
be,O,O
rendered,O,O
unresponsive,O,O
to,O,O
its,O,O
dominant,O,O
epitope,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
(,O,O
IC50,O,O
0,O,O
.,O,O
microg,O,O
/,O,O
ml,O,O
.,O,O
JNK,B,B
enzymatic,O,I
activity,O,I
was,O,O
blocked,O,O
in,O,O
anergized,O,O
T,O,O
cells,O,O
.,O,O
Copyright,O,O
1998,O,O
Academic,O,O
Press,O,O
.,O,O
Previously,O,O
",",O,O
we,O,O
demonstrated,O,O
that,O,O
granulocyte,B,O
colony,I,O
-,I,O
stimulating,I,O
factor,I,O
(,I,O
G,I,B
-,I,I
CSF,I,I
),I,O
receptor,I,O
mRNA,I,O
was,O,O
undetectable,O,O
and,O,O
granulocyte,O,O
maturation,O,O
blocked,O,O
in,O,O
CCAAT,B,B
enhancer,I,I
binding,I,I
protein,I,I
alpha,I,I
(,O,O
C,B,B
/,I,I
EBPalpha,I,I
),O,O
-,O,O
deficient,O,O
mice,O,O
.,O,O
Although,O,O
bacterial,O,O
lipopolysaccharides,O,O
(,O,O
LPS,O,O
),O,O
and,O,O
several,O,O
other,O,O
microbial,O,O
agonists,O,O
can,O,O
bind,O,O
to,O,O
mCD14,B,B
(,O,O
membrane,B,O
CD14,I,O
),O,O
",",O,O
a,O,O
cell,O,O
-,O,O
surface,O,O
receptor,O,O
found,O,O
principally,O,O
on,O,O
monocytes,O,O
and,O,O
neutrophils,O,O
",",O,O
host,O,O
-,O,O
derived,O,O
mCD14,B,O
ligands,O,O
are,O,O
poorly,O,O
defined,O,O
.,O,O
We,O,O
report,O,O
here,O,O
that,O,O
phosphatidylinositol,O,B
(,O,O
PtdIns,O,O
),O,O
",",O,O
phosphatidylinositol,O,B
-,O,I
4,O,I
-,O,I
phosphate,O,I
",",O,O
and,O,O
other,O,O
phosphatidylinositid,O,O
can,O,O
bind,O,O
to,O,O
mCD14,B,O
.,O,O
Despite,O,O
progress,O,O
in,O,O
understanding,O,O
the,O,O
death,O,O
signals,O,O
transduced,O,O
from,O,O
Fas,B,B
",",O,O
very,O,O
little,O,O
is,O,O
known,O,O
with,O,O
regard,O,O
to,O,O
the,O,O
mechanisms,O,O
by,O,O
which,O,O
Fas,B,B
expression,O,O
is,O,O
regulated,O,O
.,O,O
PKC,B,O
-,O,O
dependent,O,O
Fas,B,B
expression,O,O
was,O,O
also,O,O
observed,O,O
in,O,O
several,O,O
murine,O,O
and,O,O
human,O,O
tumor,O,O
cell,O,O
lines,O,O
.,O,O
Since,O,O
the,O,O
inhibition,O,O
of,O,O
Ca2,O,B
+,O,I
redistribution,O,O
by,O,O
an,O,O
inhibitor,O,O
of,O,O
intracellular,O,O
Ca2,O,B
+,O,I
mobilization,O,O
",",O,O
8,O,O
-,O,O
(,O,O
diethylamino,O,O
),O,O
-,O,O
octyl,O,O
-,O,O
3,O,O
",",O,O
4,O,O
",",O,O
5,O,O
-,O,O
trimethoxybenzoate,O,O
hydrochloride,O,O
",",O,O
inhibited,O,O
TCR,B,O
-,I,O
induced,I,O
FasL,I,B
but,O,O
not,O,O
Fas,B,B
",",O,O
the,O,O
expression,O,O
of,O,O
Fas,B,B
appears,O,O
to,O,O
be,O,O
independent,O,O
of,O,O
Ca2,O,B
+,O,I
mobilization,O,O
.,O,O
Anti,B,O
-,I,O
CD40,I,O
+,O,O
IL,B,B
-,I,I
mediated,O,O
proliferation,O,O
of,O,O
PBMC,O,O
and,O,O
B,O,O
cells,O,O
was,O,O
inhibited,O,O
by,O,O
RA,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
",",O,O
with,O,O
maximal,O,O
inhibition,O,O
of,O,O
62,O,O
%,O,O
+,O,O
/,O,O
-,O,O
5,O,O
%,O,O
in,O,O
PBMC,O,O
and,O,O
55,O,O
%,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
%,O,O
in,O,O
B,O,O
cells,O,O
by,O,O
all,O,O
-,O,O
trans,O,B
RA,O,I
",",O,O
and,O,O
58,O,O
%,O,O
+,O,O
/,O,O
-,O,O
6,O,O
.,O,O
%,O,O
and,O,O
51,O,O
%,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
%,O,O
",",O,O
respectively,O,O
by,O,O
13,O,O
-,O,O
cis,O,B
RA,O,I
.,O,O
IgE,B,O
synthesis,O,O
was,O,O
even,O,O
more,O,O
markedly,O,O
inhibited,O,O
by,O,O
RA,O,O
starting,O,O
at,O,O
concentrations,O,O
of,O,O
>,O,O
10,O,O
(,O,O
-,O,O
14,O,O
),O,O
mol,O,O
/,O,O
L,O,O
for,O,O
B,O,O
cells,O,O
and,O,O
>,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
mol,O,O
/,O,O
L,O,O
for,O,O
PBMC,O,O
.,O,O
Low,O,O
concentrations,O,O
of,O,O
RA,O,B
inhibiting,O,O
IgE,B,B
synthesis,O,O
(,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
mol,O,O
/,O,O
L,O,O
),O,O
affected,O,O
neither,O,O
B,O,B
-,O,I
cell,O,I
proliferation,O,O
nor,O,O
the,O,O
production,O,O
of,O,O
IgA,B,B
",",O,O
IgG,B,B
",",O,O
and,O,O
IgM,B,B
.,O,O
To,O,O
differentiate,O,O
whether,O,O
the,O,O
RA,O,B
effect,O,O
was,O,O
mediated,O,O
by,O,O
RA,B,B
receptors,I,I
alpha,I,I
",",I,O
beta,I,I
",",I,O
and,I,O
gamma,I,I
",",O,O
the,O,O
expression,O,O
of,O,O
the,O,O
retinoic,B,B
acid,I,I
receptors,I,I
(,O,O
RAR,B,O
),O,O
was,O,O
examined,O,O
by,O,O
reverse,B,O
transcriptase,I,O
-,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
RT,O,O
-,O,O
PCR,O,O
),O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
this,O,O
study,O,O
shows,O,O
that,O,O
RA,O,O
inhibits,O,O
IgE,B,B
production,O,O
of,O,O
anti,O,O
-,O,O
CD40,O,O
+,O,O
IL,O,B
-,O,I
4,O,I
-,O,O
stimulated,O,O
B,O,O
cells,O,O
in,O,O
vitro,O,O
.,O,O
Copyright,O,O
1998,O,O
by,O,O
The,O,O
American,O,O
Society,O,O
of,O,O
Hematology,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
mutant,O,O
of,O,O
Tax,B,O
termed,O,O
M22,B,O
",",O,O
which,O,O
does,O,O
not,O,O
induce,O,O
NF,B,O
-,I,O
kappaB,I,O
",",O,O
fails,O,O
to,O,O
activate,O,O
either,O,O
IKKalpha,B,O
or,O,O
IKKbeta,B,O
.,O,O
The,O,O
pathological,O,O
alteration,O,O
of,O,O
this,O,O
cytokine,O,B
pathway,O,I
leading,O,O
to,O,O
NF,B,B
-,I,I
kappaB,I,I
activation,O,O
by,O,O
Tax,B,O
may,O,O
play,O,O
a,O,O
central,O,O
role,O,O
in,O,O
HTLV,O,O
-,O,O
1,O,O
-,O,O
mediated,O,O
transformation,O,O
of,O,O
human,O,B
T,O,I
cells,O,I
",",O,O
clinically,O,O
manifested,O,O
as,O,O
the,O,O
adult,O,O
T,O,B
-,O,I
cell,O,I
leukemia,O,I
Recently,O,O
",",O,O
we,O,O
have,O,O
reported,O,O
that,O,O
the,O,O
tumor,B,O
necrosis,I,B
factor,I,I
and,O,O
interleukin,B,B
1,I,I
signaling,O,O
pathways,O,O
activate,O,O
two,O,O
kinases,O,O
",",O,O
IKK1,B,O
and,O,O
IKK2,B,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
LPS,O,B
induces,O,O
IKK,B,B
activity,O,O
in,O,O
human,O,B
monocytes,O,I
and,O,O
THP,O,B
-,O,I
1,O,I
monocytic,O,I
cells,O,I
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
dominant,O,O
negative,O,O
mutant,O,O
of,O,O
IKK2,B,B
inhibited,O,O
LPS,O,B
induction,O,O
of,O,O
kappaB,B,B
-,O,I
dependent,O,I
transcription,O,I
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
IL,B,B
-,I,I
7,I,I
did,O,O
not,O,O
maintain,O,O
v,B,O
-,I,O
Abl,I,O
-,O,O
mediated,O,O
differentiation,O,O
arrest,O,O
of,O,O
the,O,O
pre,O,O
-,O,O
B,O,O
cells,O,O
",",O,O
as,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
and,O,O
RAG,B,B
gene,I,I
transcription,O,I
was,O,O
unaffected,O,O
by,O,O
IL,B,O
-,I,O
7,I,O
.,O,O
Functional,O,O
analysis,O,O
of,O,O
the,O,O
promoter,O,O
by,O,O
transient,O,O
transfection,O,O
assays,O,O
indicated,O,O
that,O,O
synergistic,O,O
action,O,O
between,O,O
an,O,O
SP,B,B
-,I,I
1,I,I
-,I,I
like,I,I
element,I,I
at,O,O
-,O,O
21,O,O
/,O,O
-,O,O
12,O,O
",",O,O
a,O,O
GATA,B,B
site,I,I
at,O,O
-,O,O
59,O,O
/,O,O
-,O,O
54,O,O
",",O,O
and,O,O
a,O,O
novel,B,O
regulatory,I,O
element,I,O
",",O,O
CPRE,B,B
(,O,I
-,O,I
GGACTACAG,B,I
-,O,I
),O,I
at,O,O
-,O,O
49,O,O
/,O,O
-,O,O
41,O,O
",",O,O
is,O,O
essential,O,O
for,O,O
the,O,O
promoter,O,O
activity,O,O
in,O,O
murine,O,B
erythroleukemia,O,I
(,O,I
MEL,O,I
),O,I
cells,O,O
.,O,O
Administration,O,O
of,O,O
the,O,O
cytokine,B,O
interleukin,I,B
-,I,I
2,I,I
(,O,O
IL,B,B
-,I,I
2,I,I
),O,O
can,O,O
result,O,O
in,O,O
therapeutic,O,O
benefits,O,O
for,O,O
individuals,O,O
with,O,O
renal,O,B
cell,O,I
carcinoma,O,I
and,O,O
melanoma,O,B
.,O,O
Here,O,O
we,O,O
report,O,O
an,O,O
analysis,O,O
of,O,O
the,O,O
transcription,O,O
factor,O,O
families,O,O
AP,O,B
-,O,I
1,O,I
",",O,O
Sp1,O,B
",",O,O
NF,B,B
-,I,I
kappaB,I,I
",",O,O
and,O,O
signal,B,O
transducers,I,O
and,I,O
activators,I,O
of,I,O
transcription,I,O
(,O,O
STAT,B,O
),O,O
in,O,O
cancer,O,O
patients,O,O
lymphocytes,O,O
before,O,O
and,O,O
after,O,O
IL,B,B
-,I,I
2,I,I
immunotherapy,O,O
",",O,O
as,O,O
assessed,O,O
by,O,O
a,O,O
gel,O,O
-,O,O
shift,O,O
assay,O,O
.,O,O
The,O,O
role,O,O
of,O,O
platelets,O,O
for,O,O
monocyte,B,B
chemotactic,I,I
protein,I,I
-,I,I
1,I,I
(,O,O
MCP,B,O
-,I,O
1,I,O
),O,O
secretion,O,O
and,O,O
surface,O,O
expression,O,O
of,O,O
intercellular,O,B
adhesion,O,I
molecule,O,I
-,O,I
1,O,I
(,O,O
ICAM,B,O
-,I,O
1,I,O
),O,O
on,O,O
endothelial,O,B
cells,O,I
has,O,O
been,O,O
assessed,O,O
.,O,O
Nuclear,B,O
receptors,I,O
are,O,O
important,O,O
regulators,O,O
of,O,O
erythroid,O,B
cell,O,I
development,O,O
.,O,O
Here,O,O
we,O,O
investigated,O,O
the,O,O
impact,O,O
of,O,O
retinoid,B,B
X,I,I
receptor,I,I
(,O,O
RXR,B,O
),O,O
",",O,O
retinoic,B,B
acid,I,I
receptor,I,I
(,O,O
RAR,B,O
),O,O
",",O,O
and,O,O
of,O,O
the,O,O
c,B,B
-,I,I
erbA,I,I
/,I,I
thyroid,I,I
hormone,I,I
(,I,O
T3,I,O
),I,O
receptor,I,O
(,O,O
c,B,O
-,I,O
erbA,I,O
/,I,O
TR,I,O
),O,O
on,O,O
growth,O,O
and,O,O
differentiation,O,O
of,O,O
erythroid,O,B
cells,O,I
using,O,O
an,O,O
in,O,O
vitro,O,O
culture,O,O
system,O,O
of,O,O
stem,O,O
cell,O,O
factor,O,O
-,O,O
dependent,O,O
erythroid,O,B
progenitors,O,I
.,O,O
RXR,B,B
",",O,O
RAR,B,B
",",O,O
and,O,O
c,B,O
-,I,O
erbA,I,B
/,I,I
TR,I,I
-,O,O
specific,O,O
ligands,O,O
were,O,O
found,O,O
to,O,O
induce,O,O
erythroid,B,B
-,I,I
specific,I,I
gene,I,O
expression,O,O
and,O,O
to,O,O
accelerate,O,O
erythroid,O,B
differentiation,O,O
in,O,O
culture,O,O
",",O,O
with,O,O
T3,O,O
being,O,O
most,O,O
effective,O,O
.,O,O
Thus,O,O
",",O,O
c,B,O
-,I,O
erbA,I,B
/,I,I
TR,I,I
appears,O,O
to,O,O
act,O,O
as,O,O
a,O,O
binary,O,O
switch,O,O
affecting,O,O
erythroid,O,B
cell,O,I
fate,O,O
:,O,O
unliganded,O,O
c,B,O
-,I,O
erbA,I,B
/,I,I
TR,I,I
supports,O,O
growth,O,O
while,O,O
ligand,O,O
-,O,O
activated,O,O
c,B,O
-,I,O
erbA,I,B
/,I,I
TR,I,I
induces,O,O
differentiation,O,O
.,O,O
In,O,O
marked,O,O
contrast,O,O
",",O,O
expression,O,O
of,O,O
the,O,O
dominant,B,O
interfering,I,O
deltaDNA,I,B
-,I,I
binding,I,I
domain,I,I
RXR,B,O
",",O,O
containing,O,O
a,O,O
deletion,O,O
of,O,O
the,O,O
entire,B,O
DNA,I,B
-,I,I
binding,I,I
domain,I,I
",",O,O
was,O,O
incompatible,O,O
with,O,O
erythroid,O,B
cell,O,I
growth,O,I
in,O,O
vitro,O,O
",",O,O
suggesting,O,O
a,O,O
pivotal,O,O
role,O,O
of,O,O
RXR,B,O
for,O,O
erythroid,O,B
cell,O,I
development,O,I
.,O,O
We,O,O
examined,O,O
signaling,O,O
molecules,O,O
of,O,O
peripheral,O,O
blood,O,O
T,O,O
lymphocytes,O,O
obtained,O,O
from,O,O
women,O,O
with,O,O
breast,O,O
cancer,O,O
.,O,O
This,O,O
observation,O,O
was,O,O
made,O,O
despite,O,O
normal,O,O
cytoplasmic,O,O
levels,O,O
of,O,O
the,O,O
Rel,B,B
-,I,I
A,I,I
protein,I,I
.,O,O
T,O,O
lymphocytes,O,O
from,O,O
6,O,O
of,O,O
the,O,O
14,O,O
patients,O,O
also,O,O
exhibited,O,O
an,O,O
increased,O,O
expression,O,O
of,O,O
the,O,O
dual,O,O
specificity,B,O
phosphatase,I,O
",",O,O
map,B,O
kinase,I,O
phosphatase,I,O
-,I,O
1,I,O
(,O,O
MKP,B,O
-,I,O
1,I,O
),O,O
.,O,O
We,O,O
studied,O,O
the,O,O
number,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
and,O,O
dissociation,O,O
constant,O,O
in,O,O
isolated,O,O
human,O,O
lymphocytes,O,O
as,O,O
well,O,O
as,O,O
blood,O,O
concentrations,O,O
of,O,O
hormones,O,O
produced,O,O
by,O,O
the,O,O
hypothalamic,O,O
-,O,O
hypophyseal,O,O
-,O,O
adrenocortical,O,O
system,O,O
in,O,O
three,O,O
experimental,O,O
series,O,O
:,O,O
at,O,O
normal,O,O
(,O,O
17,O,O
subjects,O,O
),O,O
",",O,O
decreased,O,O
(,O,O
10,O,O
subjects,O,O
",",O,O
a,O,O
360,O,O
-,O,O
d,O,O
head,O,O
-,O,O
down,O,O
bed,O,O
rest,O,O
),O,O
and,O,O
increased,O,O
(,O,O
8,O,O
subjects,O,O
",",O,O
physical,O,O
exercise,O,O
on,O,O
bicycle,O,O
ergometer,O,O
),O,O
levels,O,O
of,O,O
motor,O,O
activity,O,O
.,O,O
The,O,O
small,B,O
GTP,I,B
-,I,I
binding,I,I
protein,I,I
Rho,I,B
potentiates,O,O
AP,B,B
-,I,I
1,I,I
transcription,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
Rho,B,B
on,O,O
AP,B,B
-,I,I
1,I,I
is,O,O
independent,O,O
of,O,O
the,O,O
mitogen,B,O
-,I,O
activated,I,O
protein,I,O
kinase,I,O
pathway,O,O
",",O,O
as,O,O
a,O,O
dominant,B,O
-,I,O
negative,I,O
MEK,I,O
and,O,O
a,O,O
MEK,B,O
inhibitor,O,O
(,O,O
PD98059,O,O
),O,O
did,O,O
not,O,O
affect,O,O
Rho,B,B
-,O,I
induced,O,O
AP,B,B
-,I,I
1,I,I
activity,O,O
.,O,O
These,O,O
cells,O,O
exhibit,O,O
many,O,O
alterations,O,O
in,O,O
function,O,O
compared,O,O
with,O,O
their,O,O
precursor,O,O
cells,O,O
",",O,O
blood,O,B
monocytes,O,I
.,O,O
To,O,O
evaluate,O,O
a,O,O
potential,O,O
mechanism,O,O
for,O,O
these,O,O
differences,O,O
in,O,O
function,O,O
",",O,O
we,O,O
evaluated,O,O
expression,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
(,I,O
PKC,I,O
),I,O
isoforms,I,O
.,O,O
Using,O,O
mRNA,O,O
differential,O,O
display,O,O
we,O,O
demonstrated,O,O
abnormally,O,O
high,O,O
expression,O,O
of,O,O
the,O,O
signal,B,B
transducer,I,I
and,I,O
activator,I,O
of,I,O
transcription,I,O
(,O,O
STAT1alpha,B,O
),O,O
in,O,O
monocytes,O,O
from,O,O
the,O,O
proband,O,O
II,O,O
-,O,O
2,O,O
.,O,O
Analysis,O,O
of,O,O
monocytes,O,O
from,O,O
familial,O,O
hypercholesterolemic,O,O
(,O,O
FH,O,O
),O,O
subjects,O,O
",",O,O
who,O,O
frequently,O,O
develop,O,O
xanthomatosis,O,O
",",O,O
revealed,O,O
a,O,O
significant,O,O
number,O,O
of,O,O
subjects,O,O
with,O,O
elevated,O,O
STAT1alpha,O,B
and,O,O
IP,O,B
-,O,I
10,O,I
expression,O,O
.,O,O
The,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
has,O,O
been,O,O
recognized,O,O
to,O,O
regulate,O,O
a,O,O
number,O,O
of,O,O
genes,O,O
necessary,O,O
for,O,O
normal,O,O
T,O,O
cell,O,O
responses,O,O
including,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
IL,B,B
-,I,I
6,I,I
",",O,O
IL,B,B
-,I,I
8,I,I
",",O,O
and,O,O
several,O,O
T,B,O
cell,I,O
surface,I,O
receptors,I,O
.,O,O
Uncoupling,O,O
of,O,O
nonreceptor,O,O
tyrosine,B,B
kinases,I,I
from,O,O
PLC,B,B
-,I,I
gamma1,I,I
in,O,O
an,O,O
SLP,O,B
-,O,I
76,O,I
-,O,I
deficient,O,O
T,O,O
cell,O,O
.,O,O
SLP,B,B
-,I,I
76,I,I
was,O,O
not,O,O
required,O,O
for,O,O
TCR,B,O
-,O,O
induced,O,O
tyrosine,O,B
phosphorylation,O,I
of,O,O
most,O,O
proteins,O,O
",",O,O
but,O,O
was,O,O
required,O,O
for,O,O
optimal,O,O
tyrosine,O,B
phosphorylation,O,I
and,O,O
activation,O,O
of,O,O
phospholipase,B,O
C,I,I
-,I,I
gamma1,I,I
(,O,O
PLC,B,O
-,I,O
gamma1,I,O
),O,O
",",O,O
as,O,O
well,O,O
as,O,O
Ras,B,B
pathway,O,I
activation,O,O
.,O,O
Thus,O,O
",",O,O
coupling,O,O
of,O,O
TCR,B,O
-,I,O
regulated,I,O
PTKs,I,O
to,O,O
downstream,O,O
signaling,O,O
pathways,O,O
requires,O,O
SLP,B,B
-,I,I
76,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
we,O,O
have,O,O
shown,O,O
that,O,O
Stat1alpha,B,B
",",O,O
but,O,O
not,O,O
Stat3,B,B
",",O,O
is,O,O
involved,O,O
in,O,O
EPO,B,B
-,O,I
induced,O,I
cellular,O,I
proliferation,O,O
.,O,O
Dominant,O,O
negative,O,O
forms,O,O
of,O,O
Stat1alpha,B,B
or,O,O
Stat3,B,B
promoted,O,O
the,O,O
EPO,B,B
-,O,I
induced,O,I
erythroid,O,I
differentiation,O,O
of,O,O
UT,O,O
-,O,O
7,O,O
/,O,O
GM,O,O
cells,O,O
",",O,O
even,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
",",O,O
although,O,O
this,O,O
cytokine,O,O
never,O,O
induced,O,O
erythroid,O,O
differentiation,O,O
of,O,O
the,O,O
parent,O,O
UT,O,O
-,O,O
7,O,O
/,O,O
GM,O,O
cells,O,O
with,O,O
or,O,O
without,O,O
EPO,B,B
.,O,O
Taken,O,O
together,O,O
",",O,O
our,O,O
data,O,O
suggest,O,O
that,O,O
Stat1alpha,B,B
and,O,O
Stat3,B,B
act,O,O
as,O,O
negative,O,O
regulators,O,O
in,O,O
EPO,B,O
-,O,O
induced,O,O
erythroid,O,O
differentiation,O,O
.,O,O
Data,O,O
obtained,O,O
by,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assay,O,O
suggested,O,O
that,O,O
the,O,O
activated,B,O
Stat,I,B
-,I,I
3,I,I
protein,I,O
associates,O,O
with,O,O
the,O,O
human,B,O
serum,I,B
-,I,I
inducible,I,I
element,I,I
(,I,O
hSIE,I,O
),I,O
DNA,I,B
-,I,I
probe,I,I
derived,O,O
from,O,O
the,O,O
interferon,B,B
-,I,I
gamma,I,I
activated,I,O
site,I,O
(,O,O
GAS,B,O
),O,O
in,O,O
the,O,O
c,B,O
-,I,O
fos,I,O
promoter,I,O
",",O,O
a,O,O
common,O,O
DNA,O,B
sequence,O,I
for,O,O
Stat,B,B
protein,I,I
binding,O,I
.,O,O
In,O,O
conclusion,O,O
",",O,O
our,O,O
data,O,O
suggest,O,O
the,O,O
involvement,O,O
of,O,O
the,O,O
Jak,B,O
/,I,O
Stat,I,O
signal,O,O
pathway,O,O
in,O,O
MHC,B,B
-,I,I
I,I,I
-,O,I
induced,O,O
signal,O,O
transduction,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
These,O,O
apparent,O,O
inconsistencies,O,O
reflect,O,O
the,O,O
complexity,O,O
of,O,O
the,O,O
DTCs,O,O
biological,O,O
activities,O,O
and,O,O
are,O,O
probably,O,O
due,O,O
in,O,O
part,O,O
to,O,O
differences,O,O
in,O,O
dose,O,O
",",O,O
route,O,O
of,O,O
exposure,O,O
",",O,O
animal,O,O
species,O,O
used,O,O
and,O,O
/,O,O
or,O,O
specific,O,O
compound,O,O
tested,O,O
.,O,O
The,O,O
studies,O,O
described,O,O
herein,O,O
were,O,O
undertaken,O,O
to,O,O
investigate,O,O
the,O,O
immunotoxicity,O,O
of,O,O
one,O,O
member,O,O
of,O,O
this,O,O
family,O,O
",",O,O
dimethyldithiocarbam,O,O
(,O,O
DMDTC,O,O
),O,O
.,O,O
This,O,O
inhibition,O,O
is,O,O
not,O,O
accompanied,O,O
by,O,O
a,O,O
loss,O,O
in,O,O
viability,O,O
",",O,O
and,O,O
DMDTC,O,O
-,O,O
treated,O,O
T,O,O
cells,O,O
retain,O,O
other,O,O
active,O,O
signaling,O,O
pathways,O,O
throughout,O,O
the,O,O
exposure,O,O
duration,O,O
.,O,O
We,O,O
further,O,O
demonstrate,O,O
that,O,O
0,O,O
.,O,O
1,O,O
-,O,O
0,O,O
.,O,O
5,O,O
microM,O,O
DMDTC,O,O
inhibits,O,O
intracellular,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
and,O,O
decreases,O,O
surface,O,O
expression,O,O
of,O,O
CD25,B,B
(,O,O
the,O,O
alpha,B,O
subunit,I,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
receptor,I,I
),O,O
in,O,O
T,O,O
cells,O,O
stimulated,O,O
with,O,O
phorbol,O,O
ester,O,O
.,O,O
Using,O,O
deletion,B,O
constructs,I,O
",",O,O
we,O,O
have,O,O
defined,O,O
an,O,O
active,B,O
promoter,I,O
region,I,O
of,O,O
1056,O,O
bp,O,O
.,O,O
Ex,O,O
vivo,O,O
activation,O,O
of,O,O
tumor,O,B
-,O,I
draining,O,I
lymph,O,I
node,O,I
T,O,I
cells,O,I
reverses,O,O
defects,O,O
in,O,O
signal,B,O
transduction,I,O
molecules,I,O
.,O,O
To,O,O
determine,O,O
whether,O,O
the,O,O
acquisition,O,O
of,O,O
antitumor,O,O
function,O,O
during,O,O
ex,O,O
vivo,O,O
activation,O,O
is,O,O
associated,O,O
with,O,O
modifications,O,O
in,O,O
signal,O,O
transduction,O,O
capacity,O,O
",",O,O
the,O,O
protein,O,B
tyrosine,B,I
kinases,I,I
p56lck,B,I
and,O,O
p59fyn,B,B
and,O,O
proteins,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappaB,I,I
family,I,I
were,O,O
analyzed,O,O
in,O,O
tumor,O,B
-,O,I
draining,O,I
LN,O,I
T,O,I
cells,O,I
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
cytoplasmic,O,O
levels,O,O
of,O,O
c,B,B
-,I,I
Rel,I,I
and,O,O
Rel,B,B
A,I,I
were,O,O
normal,O,O
in,O,O
freshly,O,O
isolated,O,O
tumor,O,O
-,O,O
draining,O,O
LN,O,O
",",O,O
as,O,O
was,O,O
nuclear,O,O
kappaB,B,B
DNA,O,I
-,O,I
binding,O,I
activity,O,O
induced,O,O
by,O,O
anti,B,O
-,I,O
CD3,I,O
mAb,I,O
or,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
class,B,O
II,I,O
transactivator,I,O
(,O,O
CIITA,B,O
),O,O
is,O,O
a,O,O
bi,B,O
-,I,O
or,I,O
multifunctional,I,O
domain,I,O
protein,I,O
that,O,O
acts,O,O
as,O,O
a,O,O
transcriptional,B,O
activator,I,O
and,O,O
plays,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
genes,I,O
.,O,O
Porcine,B,B
MHC,I,I
class,I,I
II,I,I
antigens,I,I
are,O,O
potent,O,O
stimulators,O,O
of,O,O
direct,O,O
T,O,B
-,O,I
cell,O,I
recognition,O,I
by,O,O
human,O,O
CD4,O,B
+,O,I
T,O,I
cells,O,I
and,O,O
are,O,O
",",O,O
therefore,O,O
",",O,O
likely,O,O
to,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
rejection,O,O
responses,O,O
to,O,O
transgenic,O,O
pig,O,O
donors,O,O
in,O,O
clinical,O,O
xenotransplantation,O,O
.,O,O
Transient,O,O
transfectants,O,O
of,O,O
the,O,O
porcine,O,O
B,O,B
-,O,I
cell,O,I
line,O,I
L23,O,I
with,O,O
the,O,O
mutated,O,O
CIITA,B,B
constructs,I,I
were,O,O
tested,O,O
for,O,O
the,O,O
suppression,O,O
of,O,O
constitutive,O,O
SLA,O,B
-,O,I
DR,O,I
and,O,O
SLA,O,B
-,O,I
DQ,O,I
expression,O,I
.,O,O
Macrophages,O,O
in,O,O
human,O,O
atheroma,O,O
contain,O,O
PPARgamma,B,B
:,O,O
differentiation,B,O
-,I,O
dependent,I,O
peroxisomal,I,O
proliferator,I,O
-,I,O
activated,I,O
receptor,I,O
gamma,I,O
(,O,O
PPARgamma,B,O
),O,O
expression,O,O
and,O,O
reduction,O,O
of,O,O
MMP,B,B
-,I,I
9,I,I
activity,O,O
through,O,O
PPARgamma,B,O
activation,O,O
in,O,O
mononuclear,O,O
phagocytes,O,O
in,O,O
vitro,O,O
.,O,O
Mononuclear,O,O
phagocytes,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
atherosclerosis,O,O
and,O,O
its,O,O
sequela,O,O
plaque,O,O
rupture,O,O
in,O,O
part,O,O
by,O,O
their,O,O
secretion,O,O
of,O,O
matrix,B,O
metalloproteinases,I,O
(,O,O
MMPs,B,O
),O,O
",",O,O
including,O,O
MMP,B,B
-,I,I
9,I,I
.,O,O
The,O,O
role,O,O
of,O,O
PPARgamma,B,B
in,O,O
human,O,B
atherosclerosis,O,I
is,O,O
unexplored,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
PPARgamma,B,B
mRNA,I,I
expression,O,I
in,O,O
U937,O,B
cells,O,I
increased,O,O
during,O,O
phorbol,O,O
12,O,O
-,O,O
myristate,O,O
13,O,O
acetate,O,O
-,O,O
induced,O,O
differentiation,O,O
.,O,O
We,O,O
examined,O,O
signaling,O,O
by,O,O
erythropoietin,B,O
in,O,O
highly,O,O
purified,O,O
human,O,B
colony,O,I
forming,O,I
unit,O,I
-,O,I
erythroid,O,I
cells,O,I
",",O,O
generated,O,O
in,O,O
vitro,O,O
from,O,O
CD34,O,B
(,O,I
+,O,I
),O,I
cells,O,I
.,O,O
We,O,O
found,O,O
that,O,O
erythropoietin,B,B
induces,O,O
tyrosine,O,O
phosphorylation,O,O
of,O,O
Jak2,B,B
",",O,O
STAT5A,B,B
",",O,O
and,O,O
STAT5B,B,B
.,O,O
Tyrosine,O,O
phosphorylation,O,O
of,O,O
Jak2,B,B
reaches,O,O
a,O,O
peak,O,O
around,O,O
10,O,O
minutes,O,O
after,O,O
stimulation,O,O
and,O,O
is,O,O
maximum,O,O
at,O,O
5,O,O
U,O,O
/,O,O
mL,O,O
of,O,O
erythropoietin,B,B
.,O,O
Effects,O,O
of,O,O
oxidative,O,O
stress,O,O
on,O,O
stimulation,O,O
-,O,O
dependent,O,O
signal,O,O
transduction,O,O
",",O,O
leading,O,O
to,O,O
IL,B,B
-,I,I
2,I,I
expression,O,O
",",O,O
were,O,O
studied,O,O
.,O,O
The,O,O
cells,O,O
were,O,O
then,O,O
stimulated,O,O
for,O,O
6,O,O
h,O,O
.,O,O
Eosinophils,O,O
infiltrating,O,O
hamster,O,O
cutaneous,O,O
wounds,O,O
were,O,O
found,O,O
to,O,O
express,O,O
TGFs,B,B
sequentially,O,O
.,O,O
IL,B,B
-,I,I
3,I,I
",",O,O
IL,B,B
-,I,I
4,I,I
",",O,O
and,O,O
IL,B,B
-,I,I
5,I,I
independently,O,O
up,O,O
-,O,O
regulated,O,O
TGF,B,B
-,I,I
beta1,I,I
mRNA,I,O
and,O,O
product,O,O
expression,O,O
by,O,O
eosinophils,O,O
in,O,O
all,O,O
donors,O,O
.,O,O
The,O,O
observation,O,O
that,O,O
IL,B,B
-,I,I
4,I,I
can,O,O
differentially,O,O
regulate,O,O
the,O,O
expression,O,O
of,O,O
TGF,B,B
-,I,I
alpha,I,I
and,O,O
TGF,B,B
-,I,I
beta1,I,I
suggests,O,O
that,O,O
IL,B,B
-,I,I
4,I,I
may,O,O
serve,O,O
as,O,O
a,O,O
physiologic,O,O
molecular,O,O
switch,O,O
of,O,O
TGF,B,B
expression,O,O
by,O,O
the,O,O
infiltrating,O,O
eosinophils,O,O
in,O,O
wound,O,O
healing,O,O
and,O,O
carcinogenesis,O,O
.,O,O
A,O,O
recent,O,O
study,O,O
showed,O,O
a,O,O
MLL,B,B
/,I,I
AF10,I,I
fusion,I,O
in,O,O
all,O,O
cases,O,O
of,O,O
AML,O,O
with,O,O
t,B,O
(,I,O
10,I,O
;,I,O
11,I,O
),I,O
and,O,O
various,O,O
breakpoints,O,O
on,O,O
chromosome,B,O
11,I,O
ranging,O,O
from,O,O
q13,B,O
to,O,O
q23,B,O
.,O,O
We,O,O
recently,O,O
cloned,O,O
CALM,B,O
(,O,O
Clathrin,B,B
Assembly,I,I
Lymphoid,I,I
Myeloid,I,I
leukemia,I,I
gene,I,I
),O,O
",",O,O
the,O,O
fusion,O,O
partner,O,O
of,O,O
AF10,B,O
at,O,O
11q14,B,O
in,O,O
the,O,O
monocytic,O,B
cell,O,I
line,O,I
U937,O,I
.,O,O
MLL,O,B
was,O,O
rearranged,O,O
in,O,O
3,O,O
AML,O,O
with,O,O
myelomonocytic,O,B
differentiation,O,I
(,O,O
2,O,O
AML,O,O
-,O,O
M2,O,O
and,O,O
1,O,O
AML,O,O
-,O,O
M5,O,O
),O,O
",",O,O
including,O,O
1,O,O
secondary,O,O
AML,O,O
.,O,O
For,O,O
the,O,O
7,O,O
AML,O,B
cases,O,O
that,O,O
were,O,O
uniformly,O,O
treated,O,O
according,O,O
to,O,O
the,O,O
AMLCG86,O,O
/,O,O
92,O,O
protocols,O,O
",",O,O
disease,O,O
-,O,O
free,O,O
and,O,O
overall,O,O
survival,O,O
was,O,O
significantly,O,O
worse,O,O
than,O,O
for,O,O
the,O,O
overall,O,O
study,O,O
group,O,O
(,O,O
P,O,O
.,O,O
and,O,O
P,O,O
.,O,O
",",O,O
respectively,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
t,B,O
(,I,O
10,I,O
;,I,O
11,I,O
),I,O
(,I,O
p13,I,O
;,I,O
q14,I,O
),I,O
indicates,O,O
CALM,B,O
and,I,O
MLL,I,O
rearrangements,I,O
in,O,O
morphologically,O,O
distinct,O,O
subsets,O,O
of,O,O
acute,O,O
leukemia,O,O
and,O,O
may,O,O
be,O,O
associated,O,O
with,O,O
a,O,O
poor,O,O
prognosis,O,O
.,O,O
In,O,O
particular,O,O
",",O,O
one,O,O
class,O,O
of,O,O
helix,B,B
-,I,I
loop,I,I
-,I,I
helix,I,I
proteins,I,O
",",O,O
termed,O,O
E,B,B
-,I,I
proteins,I,O
",",O,O
have,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
gene,O,O
expression,O,O
during,O,O
B,O,B
-,O,I
cell,O,I
development,O,O
.,O,O
Dominant,B,O
negative,I,O
mutants,I,O
of,O,O
NIK,B,O
",",O,O
IKKalpha,B,O
",",O,O
or,O,O
IKKbeta,B,O
substantially,O,O
inhibited,O,O
NF,B,O
-,I,O
kappaB,I,O
activation,O,O
by,O,O
LMP1,B,O
or,O,O
by,O,O
each,O,O
of,O,O
its,O,O
effector,B,O
sites,I,O
.,O,O
MyD88,B,B
",",O,O
originally,O,O
isolated,O,O
as,O,O
a,O,O
myeloid,O,B
differentiation,O,I
primary,B,I
response,I,I
gene,I,I
",",O,O
is,O,O
shown,O,O
to,O,O
act,O,O
as,O,O
an,O,O
adaptor,O,O
in,O,O
interleukin,B,B
-,I,I
1,I,I
(,O,O
IL,B,O
-,I,O
1,I,O
),O,O
signaling,O,O
by,O,O
interacting,O,O
with,O,O
both,O,O
the,O,O
IL,B,B
-,I,I
1,I,I
receptor,I,I
complex,I,I
and,O,O
IL,B,B
-,I,I
1,I,I
receptor,I,I
-,I,I
associated,I,I
kinase,I,I
(,O,O
IRAK,B,O
),O,O
.,O,O
In,O,O
vivo,O,O
Th1,O,B
response,O,I
is,O,O
also,O,O
impaired,O,O
.,O,O
Furthermore,O,O
",",O,O
IL,B,B
-,I,I
18,I,I
-,O,I
induced,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappaB,I,I
and,O,O
c,B,B
-,I,I
Jun,I,I
N,I,I
-,I,I
terminal,I,I
kinase,I,I
(,O,O
JNK,B,O
),O,O
is,O,O
blocked,O,O
in,O,O
MyD88,O,B
-,O,O
/,O,O
-,O,O
Th1,O,O
-,O,O
developing,O,O
cells,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
results,O,O
demonstrate,O,O
that,O,O
MyD88,B,B
is,O,O
a,O,O
critical,O,O
component,O,O
in,O,O
the,O,O
signaling,O,O
cascade,O,O
that,O,O
is,O,O
mediated,O,O
by,O,O
IL,B,B
-,I,I
1,I,I
receptor,I,I
as,O,O
well,O,O
as,O,O
IL,B,B
-,I,I
18,I,I
receptor,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
transcriptional,O,O
activity,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
and,O,O
metallothionein,B,B
enhancer,I,I
and,I,O
promoter,I,O
regions,I,O
and,O,O
transcription,B,O
factors,I,O
AP,B,B
-,I,I
1,I,I
",",O,O
NF,B,B
-,I,I
kappaB,I,I
",",O,O
and,O,O
NF,B,B
-,I,I
AT,I,I
were,O,O
analyzed,O,O
by,O,O
chloramphenicol,B,O
acetyltransferase,I,O
(,O,O
CAT,B,O
),O,O
and,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
concentration,O,O
of,O,O
c,B,B
-,I,I
fos,I,I
",",I,O
c,I,B
-,I,I
jun,I,I
",",I,O
c,I,B
-,I,I
myc,I,I
",",I,O
junB,I,B
",",I,O
and,I,O
fra,I,B
-,I,I
1,I,I
mRNAs,I,O
was,O,O
increased,O,O
in,O,O
activated,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
incubated,O,O
with,O,O
ciprofloxacin,O,O
compared,O,O
to,O,O
that,O,O
in,O,O
untreated,O,O
controls,O,O
.,O,O
Simple,O,O
activation,O,O
of,O,O
RXRs,B,O
is,O,O
not,O,O
sufficient,O,O
to,O,O
induce,O,O
apoptosis,O,O
of,O,O
the,O,O
cells,O,O
.,O,O
Thrombopoietin,B,O
supports,O,O
in,O,O
vitro,O,O
erythroid,O,O
differentiation,O,O
via,O,O
its,O,O
specific,O,O
receptor,O,O
c,B,B
-,I,I
Mpl,I,I
in,O,O
a,O,O
human,O,O
leukemia,O,B
cell,O,I
line,O,I
.,O,O
More,O,O
than,O,O
50,O,O
%,O,O
of,O,O
TPO,O,O
-,O,O
treated,O,O
UT,O,O
-,O,O
7,O,O
/,O,O
GMT,O,O
cells,O,O
positively,O,O
stained,O,O
for,O,O
Hb,B,B
.,O,O
Because,O,O
the,O,O
GATA,B,B
-,I,I
1,I,I
gene,I,O
is,O,O
located,O,O
on,O,O
the,O,O
X,B,O
chromosome,I,O
",",O,O
which,O,O
is,O,O
randomly,O,O
inactivated,O,O
in,O,O
every,O,O
cell,O,O
",",O,O
heterozygous,O,O
females,O,O
can,O,O
bear,O,O
either,O,O
an,O,O
active,O,O
wild,O,O
-,O,O
type,O,O
or,O,O
mutant,O,O
(,O,O
referred,O,O
to,O,O
as,O,O
GATA,B,B
-,I,I
1,I,I
.,I,O
),O,O
GATA,B,O
-,I,O
1,I,O
allele,O,O
",",O,O
consequently,O,O
leading,O,O
to,O,O
variable,O,O
anemic,O,O
severity,O,O
.,O,O
We,O,O
also,O,O
observed,O,O
hematopoiesis,O,O
outside,O,O
of,O,O
the,O,O
bone,O,O
marrow,O,O
in,O,O
the,O,O
affected,O,O
mutant,O,O
mice,O,O
.,O,O
The,O,O
GATA,B,B
-,I,I
1,I,I
heterozygous,O,I
mutant,O,I
mouse,O,I
shows,O,O
a,O,O
phenotype,O,O
that,O,O
is,O,O
analogous,O,O
to,O,O
human,O,O
myelodysplastic,O,O
syndrome,O,O
and,O,O
thus,O,O
may,O,O
serve,O,O
as,O,O
a,O,O
useful,O,O
model,O,O
for,O,O
this,O,O
disorder,O,O
.,O,O
Differential,O,O
regulation,O,O
of,O,O
the,O,O
Janus,B,B
kinase,I,I
-,B,I
STAT,I,I
pathway,O,I
and,O,O
biologic,O,O
function,O,O
of,O,O
IL,B,B
-,I,I
13,I,I
in,O,O
primary,O,O
human,O,O
NK,O,B
and,O,O
T,O,B
cells,O,O
:,O,O
a,O,O
comparative,O,O
study,O,O
with,O,O
IL,B,B
-,I,I
4,I,I
.,O,O
We,O,O
observed,O,O
that,O,O
Abs,O,O
directed,O,O
against,O,O
unique,O,O
domains,O,O
of,O,O
STAT6,B,B
have,O,O
differential,O,O
effects,O,O
on,O,O
complexes,O,O
in,O,O
T,O,O
cells,O,O
but,O,O
not,O,O
in,O,O
NK,O,O
cells,O,O
",",O,O
suggesting,O,O
different,O,O
STAT6,B,B
isoforms,I,O
.,O,O
These,O,O
findings,O,O
show,O,O
that,O,O
IL,B,B
-,I,I
13,I,I
and,O,O
IL,B,B
-,I,I
4,I,I
have,O,O
the,O,O
ability,O,O
to,O,O
regulate,O,O
NK,O,O
and,O,O
T,O,O
cell,O,O
activation,O,O
and,O,O
that,O,O
IL,B,B
-,I,I
13,I,I
is,O,O
a,O,O
potent,O,O
regulator,O,O
of,O,O
STAT6,B,B
and,O,O
JAK3,B,B
in,O,O
these,O,O
cell,O,O
types,O,O
.,O,O
NFkappaB,B,B
activity,O,O
is,O,O
independent,O,O
from,O,O
FADD,B,O
",",O,O
caspases,B,O
",",O,O
and,O,O
apoptosis,O,O
induction,O,O
.,O,O
To,O,O
study,O,O
the,O,O
influence,O,O
of,O,O
NFkappaB,B,B
activity,O,O
on,O,O
apoptosis,O,O
mediated,O,O
by,O,O
TRAIL,B,O
",",O,O
CD95,O,O
",",O,O
TNFalpha,B,O
",",O,O
or,O,O
doxorubicin,O,O
",",O,O
NFkappaB,B,B
activation,O,O
was,O,O
inhibited,O,O
using,O,O
the,O,O
proteasome,B,O
inhibitor,O,O
N,O,O
-,O,O
acetyl,O,O
-,O,O
L,O,O
-,O,O
leucinyl,O,O
-,O,O
L,O,O
-,O,O
leucinyl,O,O
-,O,O
L,O,O
-,O,O
norleucinal,O,O
or,O,O
transient,O,O
overexpression,O,O
of,O,O
mutant,B,O
IkappaBalpha,I,O
.,O,O
Sensitivity,O,O
for,O,O
induction,O,O
of,O,O
apoptosis,O,O
was,O,O
markedly,O,O
increased,O,O
by,O,O
these,O,O
treatments,O,O
in,O,O
apoptosis,O,O
sensitive,O,O
cell,O,O
lines,O,O
.,O,O
Loss,O,O
-,O,O
and,O,O
gain,O,O
-,O,O
of,O,O
-,O,O
function,O,O
mutations,O,O
reveal,O,O
an,O,O
important,O,O
role,O,O
of,O,O
BSAP,B,B
(,O,O
Pax,B,O
-,I,O
5,I,O
),O,O
at,O,O
the,O,O
start,O,O
and,O,O
end,O,O
of,O,O
B,O,B
cell,O,I
differentiation,O,I
.,O,O
However,O,O
",",O,O
its,O,O
interactions,O,O
with,O,O
these,O,O
histone,B,O
acetyltransferases,I,O
are,O,O
not,O,O
equivalent,O,O
",",O,O
as,O,O
CBP,B,B
and,O,O
p300,B,B
",",O,O
but,O,O
not,O,O
P,B,B
/,I,I
CAF,I,I
",",O,O
utilize,O,O
EKLF,B,O
as,O,O
a,O,O
substrate,O,O
for,O,O
in,O,O
vitro,O,O
acetylation,O,O
within,O,O
its,O,O
trans,O,O
-,O,O
activation,B,O
region,I,O
.,O,O
We,O,O
conclude,O,O
that,O,O
contact,O,O
with,O,O
fibrinogen,B,B
-,I,I
derived,I,I
proteins,I,I
may,O,O
contribute,O,O
to,O,O
mononuclear,O,B
phagocyte,O,I
activation,O,O
by,O,O
signaling,O,O
through,O,O
CD11b,B,B
/,I,I
CD18,I,I
",",O,O
resulting,O,O
in,O,O
selective,O,O
activation,O,O
of,O,O
transcriptional,B,O
regulatory,I,O
factors,I,O
",",O,O
including,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
identify,O,O
and,O,O
characterize,O,O
estrogen,B,B
receptor,I,I
(,I,I
ER,I,I
),I,I
transcripts,I,O
expressed,O,O
in,O,O
immune,O,B
cells,O,I
of,O,O
patients,O,O
with,O,O
systemic,O,O
lupus,O,O
erythematosus,O,O
(,O,O
SLE,O,O
),O,O
and,O,O
healthy,O,O
donors,O,O
.,O,O
There,O,O
were,O,O
no,O,O
notable,O,O
differences,O,O
in,O,O
the,O,O
ER,B,B
transcripts,I,I
between,O,O
patients,O,O
and,O,O
healthy,O,O
controls,O,O
.,O,O
Variant,O,O
receptor,O,O
transcripts,O,O
lacking,O,O
exon,B,O
5,I,O
or,O,O
exon,B,O
7,I,O
",",O,O
which,O,O
encodes,O,O
the,O,O
hormone,O,B
binding,O,I
domain,O,I
",",O,O
were,O,O
identified,O,O
in,O,O
the,O,O
majority,O,O
of,O,O
the,O,O
cells,O,O
.,O,O
Whether,O,O
the,O,O
detected,O,O
transcripts,O,O
are,O,O
translated,O,O
into,O,O
functional,O,O
receptor,O,O
proteins,O,O
remains,O,O
to,O,O
be,O,O
determined,O,O
.,O,O
A,O,O
nondegradable,O,O
mutant,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
blocked,O,O
both,O,O
FasL,B,B
expression,O,O
and,O,O
apoptosis,O,O
induced,O,O
by,O,O
DNA,O,B
damage,O,I
but,O,O
not,O,O
Fas,B,B
ligation,O,I
.,O,O
These,O,O
stimuli,O,O
also,O,O
induced,O,O
the,O,O
stress,O,O
-,O,O
activated,O,O
kinase,O,O
pathway,O,O
(,O,O
SAPK,B,B
/,B,I
JNK,I,I
),O,O
",",O,O
which,O,O
was,O,O
required,O,O
for,O,O
the,O,O
maximal,O,O
induction,O,O
of,O,O
apoptosis,O,O
.,O,O
Simultaneously,O,O
",",O,O
T,O,O
lymphocyte,O,O
subsets,O,O
and,O,O
NK,O,B
cells,O,O
from,O,O
the,O,O
peripheral,O,O
blood,O,O
(,O,O
PB,O,O
),O,O
and,O,O
bone,O,O
marrow,O,O
(,O,O
BM,O,O
),O,O
were,O,O
investigated,O,O
by,O,O
flow,O,O
cytometric,O,O
analysis,O,O
.,O,O
Four,O,O
of,O,O
the,O,O
eight,O,O
patients,O,O
in,O,O
LT,O,O
and,O,O
7,O,O
of,O,O
the,O,O
15,O,O
patients,O,O
in,O,O
ST,O,O
remission,O,O
were,O,O
MRD,O,O
-,O,O
positive,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
difference,O,O
of,O,O
the,O,O
possible,O,O
T,O,B
/,O,I
NK,O,I
-,O,I
cell,O,I
phenotype,O,O
in,O,O
the,O,O
BM,O,O
may,O,O
strongly,O,O
influence,O,O
clinical,O,O
and,O,O
molecular,O,O
remission,O,O
.,O,O
The,O,O
implication,O,O
of,O,O
protein,B,B
tyrosine,I,I
kinase,I,I
(,I,I
s,I,I
),I,I
",",O,O
protein,B,B
kinase,I,I
A,I,I
and,O,O
/,O,O
or,O,O
protein,B,B
kinase,I,I
C,I,I
was,O,O
highlighted,O,O
by,O,O
the,O,O
abrogation,O,O
of,O,O
the,O,O
ManLAM,O,O
-,O,O
mediated,O,O
activation,O,O
of,O,O
HIV,B,O
-,I,O
1,I,O
LTR,I,O
-,I,O
driven,I,O
gene,I,O
expression,O,O
using,O,O
herbimycin,O,O
A,O,O
and,O,O
H7,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
LTR,B,B
sequence,I,I
changes,O,O
can,O,O
significantly,O,O
affect,O,O
basal,O,O
LTR,B,B
function,O,O
and,O,O
transcription,B,O
factor,I,O
recruitment,O,O
",",O,O
which,O,O
may,O,O
",",O,O
in,O,O
turn,O,O
",",O,O
alter,O,O
the,O,O
course,O,O
of,O,O
viral,O,O
replication,O,O
in,O,O
cells,O,O
of,O,O
CNS,O,O
and,O,O
immune,O,B
system,O,I
origin,O,O
.,O,O
These,O,O
insights,O,O
in,O,O
the,O,O
molecular,O,O
events,O,O
that,O,O
are,O,O
involved,O,O
in,O,O
TCF,B,O
/,I,O
LEF,I,O
function,O,O
in,O,O
these,O,O
organisms,O,O
may,O,O
eventually,O,O
lead,O,O
to,O,O
the,O,O
understanding,O,O
of,O,O
the,O,O
function,O,O
of,O,O
these,O,O
HMG,B,B
box,I,I
proteins,I,I
in,O,O
lymphoid,O,B
development,O,I
Molecular,O,O
genetic,O,O
characterization,O,O
of,O,O
the,O,O
variant,B,O
allele,I,O
can,O,O
serve,O,O
as,O,O
a,O,O
primary,O,O
tool,O,O
for,O,O
diagnosis,O,O
and,O,O
subsequent,O,O
therapy,O,O
",",O,O
and,O,O
can,O,O
provide,O,O
a,O,O
basis,O,O
for,O,O
distinguishing,O,O
heterozygous,O,O
carriers,O,O
in,O,O
familial,O,O
androgen,O,B
resistance,O,I
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
the,O,O
proliferative,O,O
activity,O,O
of,O,O
129,O,O
primary,O,O
breast,O,B
cancers,O,I
was,O,O
investigated,O,O
",",O,O
and,O,O
the,O,O
results,O,O
were,O,O
related,O,O
to,O,O
prognosis,O,O
.,O,O
RESULTS,O,O
.,O,O
Elf,B,O
-,I,O
1,I,O
binds,O,O
exclusively,O,O
to,O,O
the,O,O
underphosphorylated,O,O
form,O,O
of,O,O
Rb,B,B
and,O,O
fails,O,O
to,O,O
bind,O,O
to,O,O
Rb,B,B
mutants,I,O
derived,O,O
from,O,O
patients,O,O
with,O,O
retinoblastoma,O,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
analyzed,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
(,I,O
TcR,I,O
),I,O
delta,I,O
transcripts,I,O
expressed,O,O
by,O,O
CD3,O,O
-,O,O
CD16,O,O
+,O,O
cells,O,O
and,O,O
we,O,O
investigated,O,O
whether,O,O
these,O,O
cells,O,O
expressed,O,O
the,O,O
hGATA,B,O
-,I,O
3,I,O
T,I,O
cell,I,O
transcription,I,O
factor,I,O
and,O,O
the,O,O
recombination,B,O
-,I,O
activating,I,O
gene,I,O
(,I,O
RAG,I,O
),I,O
-,I,O
1,I,O
.,O,O
Sequence,O,O
analysis,O,O
of,O,O
nine,O,O
different,O,O
2,O,B
.,O,I
3,O,I
-,O,I
kb,O,I
cDNA,O,I
clones,O,I
obtained,O,O
from,O,O
NK,O,B
-,O,I
derived,O,I
polyA,O,I
+,O,I
RNA,O,I
confirmed,O,O
that,O,O
they,O,O
corresponded,O,O
to,O,O
an,O,O
unrearranged,O,O
TcR,B,B
delta,I,I
gene,I,I
.,O,O
However,O,O
",",O,O
only,O,O
that,O,O
located,O,O
at,O,O
the,O,O
3,O,B
end,O,I
appeared,O,O
to,O,O
be,O,O
utilized,O,O
in,O,O
the,O,O
2,B,B
.,I,I
3,I,I
-,I,I
kb,I,I
cDNA,I,I
.,O,O
All,O,O
NK,O,B
clones,O,I
and,O,O
cell,O,O
lines,O,O
studied,O,O
were,O,O
found,O,O
to,O,O
express,O,O
hGATA,B,B
-,I,I
3,I,I
-,I,I
specific,I,I
mRNA,I,I
",",O,O
suggesting,O,O
that,O,O
hGATA,B,B
-,I,I
3,I,I
may,O,O
be,O,O
involved,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
the,O,O
unrearranged,O,O
TcR,B,B
delta,I,I
gene,I,I
expression,O,O
in,O,O
NK,O,B
cells,O,O
.,O,O
To,O,O
correlate,O,O
changes,O,O
in,O,O
nuclear,O,B
factor,O,I
binding,O,I
in,O,O
vitro,O,O
with,O,O
transcriptional,O,O
activity,O,O
in,O,O
vivo,O,O
and,O,O
define,O,O
the,O,O
structural,O,O
requirements,O,O
for,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
repression,O,O
",",O,O
we,O,O
used,O,O
transient,O,O
DNA,O,B
transfections,O,O
.,O,O
Jurkat,O,O
cells,O,O
were,O,O
transfected,O,O
with,O,O
plasmids,B,O
containing,O,O
either,O,O
the,O,O
intact,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
or,O,O
its,O,O
AP,B,B
-,I,I
1,I,I
",",I,O
NF,I,B
-,I,I
AT,I,I
",",I,O
and,I,O
NF,I,B
-,I,I
kB,I,I
motifs,I,O
.,O,O
Other,O,O
bacterial,O,O
toxins,O,O
",",O,O
tumor,B,O
necrosis,I,O
factor,I,B
-,I,I
alpha,I,I
(,O,O
TNF,B,B
),O,O
",",O,O
interleukin,B,B
-,I,I
1,I,I
(,O,O
IL,B,B
-,I,I
1,I,I
),O,O
",",O,O
T,B,O
cell,I,O
mitogens,I,O
",",O,O
UV,O,O
light,O,O
",",O,O
gamma,O,O
rays,O,O
and,O,O
oxidative,O,O
stress,O,O
were,O,O
reported,O,O
to,O,O
induce,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
We,O,O
further,O,O
characterize,O,O
which,O,O
AP1,B,B
family,I,I
members,I,I
can,O,O
assume,O,O
this,O,O
role,O,O
.,O,O
Antisera,O,O
to,O,O
Fos,B,B
inhibits,O,O
NF,B,B
-,I,I
AT,I,I
DNA,O,I
binding,O,O
as,O,O
does,O,O
an,O,O
oligonucleotide,O,O
containing,O,O
a,O,O
binding,B,O
site,I,O
for,I,O
AP1,I,B
.,O,O
The,O,O
patients,O,O
plasma,O,O
cortisol,O,B
concentrations,O,O
were,O,O
normal,O,O
or,O,O
slightly,O,O
elevated,O,O
.,O,O
Despite,O,O
a,O,O
wide,O,O
range,O,O
",",O,O
the,O,O
mean,O,O
GR,B,B
count,O,O
and,O,O
affinity,O,O
in,O,O
MNC,O,O
from,O,O
septic,O,O
patients,O,O
did,O,O
not,O,O
differ,O,O
from,O,O
those,O,O
in,O,O
normal,O,O
controls,O,O
",",O,O
suggesting,O,O
that,O,O
glucocorticoids,O,O
could,O,O
still,O,O
be,O,O
effective,O,O
in,O,O
the,O,O
hemodynamic,O,O
compensatory,O,O
phase,O,O
of,O,O
sepsis,O,O
.,O,O
Activation,O,O
of,O,O
the,O,O
HIV,O,B
-,O,I
1,O,I
provirus,O,O
correlated,O,O
with,O,O
the,O,O
activation,O,O
of,O,O
binding,O,O
of,O,O
55,B,B
-,I,I
and,I,O
85,I,B
-,I,I
kDa,I,I
proteins,I,O
to,O,O
the,O,O
kappa,B,B
B,I,I
enhancer,I,O
and,O,O
binding,O,O
of,O,O
the,O,O
50,B,B
-,I,I
kDa,I,I
HLP,I,B
-,I,I
1,I,I
protein,I,O
to,O,O
the,O,O
LBP,B,B
-,I,I
1,I,I
sequences,I,O
of,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
long,I,O
terminal,I,O
repeat,I,O
.,O,O
Surprisingly,O,O
",",O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,O,O
HLP,O,B
-,O,I
1,O,I
binding,O,O
activities,O,O
were,O,O
substantially,O,O
inhibited,O,O
in,O,O
acyclovir,O,O
-,O,O
treated,O,O
cells,O,O
.,O,O
Transcriptional,O,O
activation,O,O
of,O,O
the,O,O
macrophage,B,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
gene,I,I
by,O,O
IL,B,B
-,I,I
2,I,I
is,O,O
associated,O,O
with,O,O
secretion,O,O
of,O,O
bioactive,O,O
macrophage,B,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
protein,I,I
by,O,O
monocytes,O,B
and,O,O
involves,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Transcriptional,O,O
activation,O,O
of,O,O
the,O,O
M,B,B
-,I,I
CSF,I,I
gene,I,I
by,O,O
IL,B,B
-,I,I
2,I,I
is,O,O
preceded,O,O
by,O,O
enhanced,O,O
binding,O,O
activity,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
to,O,O
its,O,O
recognition,O,O
sequence,O,O
in,O,O
the,O,O
5,O,O
regulatory,O,O
enhancer,O,O
region,O,O
of,O,O
the,O,O
M,B,B
-,I,I
CSF,I,I
gene,I,I
.,O,O
We,O,O
localized,O,O
the,O,O
LAM,O,B
-,O,I
",",O,O
lipopolysaccharide,O,B
(,O,O
LPS,O,O
),O,O
-,O,O
",",O,O
and,O,O
TNF,B,B
-,I,O
alpha,I,I
-,B,O
inducible,I,O
promoter,I,O
activity,O,O
to,O,O
a,O,O
-,O,O
131,O,O
/,O,O
+,O,O
15,O,O
(,O,O
positions,O,O
-,O,O
131,O,O
to,O,O
+,O,O
15,O,O
),O,O
DNA,O,B
fragment,O,I
of,O,O
the,O,O
IL,B,O
-,I,O
1,I,O
beta,I,O
gene,I,O
by,O,O
deletion,O,O
analysis,O,O
and,O,O
chloramphenicol,B,B
acetyltransferase,I,I
assay,O,O
.,O,O
Site,O,O
-,O,O
directed,O,O
mutagenesis,O,O
demonstrated,O,O
that,O,O
the,O,O
two,O,O
NF,B,B
-,I,O
IL,I,O
-,I,O
6,I,O
motifs,I,O
could,O,O
be,O,O
independently,O,O
activated,O,O
by,O,O
LAM,O,O
",",O,O
LPS,O,O
",",O,O
or,O,O
TNF,B,O
-,I,O
alpha,I,O
and,O,O
that,O,O
they,O,O
acted,O,O
in,O,O
an,O,O
orientation,O,O
-,O,O
independent,O,O
manner,O,O
.,O,O
Additionally,O,O
",",O,O
Nef,O,B
expressing,O,O
cells,O,O
were,O,O
transiently,O,O
transfected,O,O
with,O,O
a,O,O
plasmid,O,O
in,O,O
which,O,O
HIV,B,B
-,I,I
1,I,I
AP,I,I
-,I,I
1,I,I
DNA,I,I
recognition,I,I
sequences,I,I
were,O,O
cloned,O,O
downstream,O,O
of,O,O
the,O,O
chloramphenicol,B,B
acetyltransferase,I,I
(,O,I
CAT,B,I
),O,I
gene,O,O
.,O,O
The,O,O
in,O,O
vitro,O,O
effect,O,O
of,O,O
17,O,O
beta,O,O
-,O,O
estradiol,O,O
on,O,O
NK,O,O
activity,O,O
was,O,O
studied,O,O
.,O,O
A,O,O
serum,B,O
response,I,O
element,I,O
and,O,O
a,O,O
binding,B,O
site,I,O
for,I,O
NF,I,B
-,I,I
Y,I,I
mediate,O,O
the,O,O
serum,O,O
response,O,O
of,O,O
the,O,O
human,B,O
thrombospondin,I,O
1,I,O
gene,I,O
.,O,O
Two,O,O
transcriptional,O,O
elements,O,O
in,O,O
the,O,O
TSP,B,B
1,I,I
promoter,O,O
",",O,O
a,O,O
distal,O,O
element,O,O
at,O,O
-,O,O
1280,O,O
and,O,O
a,O,O
proximal,O,O
element,O,O
at,O,O
-,O,O
65,O,O
",",O,O
were,O,O
required,O,O
for,O,O
the,O,O
response,O,O
of,O,O
the,O,O
human,O,O
TSP,O,B
1,O,I
gene,O,O
to,O,O
serum,O,O
.,O,O
Cell,O,O
-,O,O
type,O,O
-,O,O
specific,O,O
transactivation,O,O
of,O,O
the,O,O
parathyroid,B,B
hormone,I,I
-,I,I
related,I,I
protein,I,I
gene,I,I
promoter,I,O
by,O,O
the,O,O
human,B,O
T,I,O
-,I,O
cell,I,O
leukemia,I,O
virus,I,O
type,I,O
I,I,O
(,I,O
HTLV,I,O
-,I,O
I,I,O
),I,O
tax,I,O
and,O,O
HTLV,B,O
-,I,O
II,I,O
tax,I,O
proteins,I,O
.,O,O
The,O,O
human,B,O
T,I,B
-,I,I
cell,I,I
leukemia,I,I
virus,I,I
type,I,I
I,I,I
(,I,O
HTLV,I,B
-,I,I
I,I,I
),I,O
and,I,O
HTLV,I,B
-,I,I
II,I,I
Tax,I,I
proteins,I,O
are,O,O
potent,O,O
transactivators,B,O
of,O,O
viral,O,O
and,O,O
cellular,O,O
gene,O,O
expression,O,O
.,O,O
A,O,O
carboxy,B,O
terminal,I,O
Tax,I,O
deletion,I,O
mutant,I,O
was,O,O
deficient,O,O
in,O,O
transactivation,O,O
of,O,O
both,O,O
the,O,O
PTHrP,B,O
and,I,O
IL2R,I,O
alpha,I,O
promoters,I,O
but,O,O
not,O,O
the,O,O
HTLV,B,B
-,I,I
I,I,I
long,I,I
terminal,I,I
repeat,I,I
(,O,O
LTR,B,O
),O,O
.,O,O
Here,O,O
we,O,O
have,O,O
investigated,O,O
the,O,O
transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
gamma,B,B
chain,I,I
gene,O,I
by,O,O
analyzing,O,O
the,O,O
2,B,O
.,I,O
5,I,O
-,I,O
kilobase,I,O
sequence,I,O
upstream,O,O
of,O,O
the,O,O
transcription,O,O
start,O,O
site,O,O
.,O,O
This,O,O
sequence,O,O
contains,O,O
a,O,O
promoter,B,O
specific,O,O
to,O,O
cells,O,O
of,O,O
hematopoietic,O,B
lineage,O,I
.,O,O
However,O,O
",",O,O
the,O,O
tissue,O,O
specificity,O,O
of,O,O
this,O,O
promoter,B,O
is,O,O
only,O,O
partial,O,O
because,O,O
it,O,O
is,O,O
active,O,O
in,O,O
all,O,O
of,O,O
the,O,O
hematopoietic,O,B
cells,O,I
tested,O,O
here,O,O
",",O,O
regardless,O,O
of,O,O
whether,O,O
they,O,O
constitutively,O,O
express,O,O
Fc,O,O
epsilon,O,O
RI,O,O
-,O,O
gamma,B,B
chain,I,I
transcripts,O,I
.,O,O
Regression,O,O
analysis,O,O
of,O,O
our,O,O
data,O,O
revealed,O,O
slight,O,O
trends,O,O
for,O,O
some,O,O
of,O,O
the,O,O
biomarkers,O,O
(,O,O
e,O,O
.,O,O
g,O,O
.,O,O
CD45R0,O,B
+,O,I
),O,O
.,O,O
HIV,O,B
-,O,I
1,O,I
can,O,O
also,O,O
establish,O,O
a,O,O
latent,O,O
or,O,O
persistent,O,O
infection,O,O
in,O,O
some,O,O
T,O,O
cell,O,O
lines,O,O
that,O,O
show,O,O
minimal,O,O
constitutive,O,O
virus,O,O
expression,O,O
.,O,O
On,O,O
the,O,O
basis,O,O
of,O,O
these,O,O
observations,O,O
",",O,O
it,O,O
has,O,O
been,O,O
proposed,O,O
that,O,O
reactivation,O,O
of,O,O
latent,O,O
HIV,O,B
-,O,I
1,O,I
harbored,O,O
in,O,O
chronically,O,O
infected,O,O
T,O,O
lymphocytes,O,O
",",O,O
monocytes,O,O
",",O,O
or,O,O
macrophages,O,O
plays,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
AIDS,O,O
.,O,O
ACH,O,O
-,O,O
2,O,O
can,O,O
be,O,O
converted,O,O
to,O,O
productive,O,O
infection,O,O
by,O,O
stimulation,O,O
of,O,O
the,O,O
cells,O,O
with,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
TPA,O,O
),O,O
",",O,O
mitogen,O,O
or,O,O
cytokines,B,O
(,O,O
TNF,B,B
-,I,I
alpha,I,I
),O,O
",",O,O
or,O,O
infection,O,O
with,O,O
HSV,O,O
.,O,O
Oxidoreductive,O,O
regulation,O,O
of,O,O
nuclear,B,O
factor,I,O
kappa,I,O
B,I,O
.,O,O
The,O,O
promoter,O,O
activity,O,O
from,O,O
HIV,B,B
long,I,I
terminal,I,I
repeat,I,I
was,O,O
greatly,O,O
augmented,O,O
by,O,O
co,O,O
-,O,O
transfecting,O,O
the,O,O
Trx,B,O
-,I,O
expressing,I,O
plasmid,I,O
",",O,O
whose,O,O
effect,O,O
was,O,O
dependent,O,O
on,O,O
the,O,O
NF,B,B
kappa,I,I
B,I,I
-,O,I
binding,O,I
sites,O,I
.,O,O
These,O,O
results,O,O
may,O,O
also,O,O
provide,O,O
a,O,O
clue,O,O
to,O,O
understanding,O,O
of,O,O
the,O,O
molecular,O,O
process,O,O
of,O,O
AIDS,O,O
pathogenesis,O,O
and,O,O
its,O,O
possible,O,O
biochemical,O,O
intervention,O,O
.,O,O
Synergism,O,O
between,O,O
the,O,O
CD3,O,B
antigen,O,I
-,O,I
and,O,O
CD2,O,B
antigen,O,I
-,O,I
derived,O,O
signals,O,O
.,O,O
We,O,O
have,O,O
demonstrated,O,O
earlier,O,O
that,O,O
the,O,O
crosslinkage,O,O
of,O,O
the,O,O
CD3,B,B
/,I,I
TCR,I,I
complex,I,I
with,O,O
the,O,O
CD2,B,B
antigen,I,I
results,O,O
in,O,O
the,O,O
proliferation,O,O
of,O,O
normal,O,O
human,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
human,O,O
erythroleukemia,O,B
cell,O,I
line,O,I
K562,O,O
can,O,O
be,O,O
induced,O,O
to,O,O
differentiate,O,O
along,O,O
the,O,O
erythroid,O,B
and,O,O
megakaryocytic,O,B
lineages,O,I
.,O,O
This,O,O
was,O,O
accompanied,O,O
by,O,O
downregulation,O,O
of,O,O
two,O,O
transcription,B,O
factors,I,O
normally,O,O
expressed,O,O
in,O,O
erythroid,O,B
",",O,O
mast,O,B
and,O,O
megakaryocyte,O,B
lineages,O,I
.,O,O
Northern,O,O
analysis,O,O
demonstrated,O,O
coordinate,O,O
downregulation,O,O
of,O,O
alpha,B,B
globin,I,I
and,O,O
gamma,B,B
globin,I,I
in,O,O
addition,O,O
to,O,O
the,O,O
two,O,O
lineage,O,O
-,O,O
restricted,O,O
transcription,B,O
factors,I,O
",",O,O
SCL,B,B
and,O,O
GATA,B,B
-,I,I
1,I,I
.,O,O
Electron,O,O
microscopy,O,O
revealed,O,O
a,O,O
marked,O,O
increase,O,O
in,O,O
granules,O,O
resembling,O,O
those,O,O
specific,O,O
for,O,O
eosinophils,O,O
.,O,O
Surface,O,O
marker,O,O
analysis,O,O
showed,O,O
that,O,O
HMBA,O,O
-,O,O
induced,O,O
cells,O,O
expressed,O,O
reduced,O,O
levels,O,O
of,O,O
glycophorin,B,B
A,I,I
",",O,O
CD5,B,B
",",O,O
CD7,B,B
and,O,O
CD11b,B,B
.,O,O
Activation,O,O
of,O,O
primary,O,O
human,O,O
T,O,O
-,O,O
lymphocytes,O,O
through,O,O
CD2,B,B
plus,I,O
CD28,I,B
adhesion,I,O
molecules,I,O
induces,O,O
long,O,O
-,O,O
term,O,O
nuclear,O,O
expression,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Long,O,O
-,O,O
lasting,O,O
IL,B,B
-,I,I
2,I,I
receptivity,O,O
is,O,O
associated,O,O
with,O,O
high,O,O
-,O,O
level,O,O
expression,O,O
of,O,O
the,O,O
inducible,O,O
IL,B,B
-,I,I
2,I,I
receptor,I,I
alpha,I,I
chain,I,O
(,I,O
IL,I,O
-,I,O
2R,I,O
alpha,I,O
),I,O
gene,I,O
that,O,O
is,O,O
regulated,O,O
at,O,O
both,O,O
transcriptional,O,O
and,O,O
posttranscriptional,O,O
levels,O,O
.,O,O
Resting,O,O
T,O,O
-,O,O
cell,O,O
nuclear,O,O
extracts,O,O
contained,O,O
KBF1,B,O
/,I,O
p50,I,O
homodimer,I,O
.,O,O
In,O,O
addition,O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
PKC,B,O
blocked,O,O
both,O,O
activated,O,O
ras,B,O
and,O,O
phorbol,O,O
ester,O,O
stimulation,O,O
",",O,O
suggesting,O,O
a,O,O
role,O,O
for,O,O
ras,B,O
upstream,O,O
of,O,O
PKC,B,O
.,O,O
No,O,O
such,O,O
increase,O,O
was,O,O
observed,O,O
in,O,O
control,O,O
U937,O,O
cells,O,O
.,O,O
We,O,O
show,O,O
that,O,O
the,O,O
ability,O,O
to,O,O
detect,O,O
NF,B,B
-,I,I
ATp,I,I
in,O,O
a,O,O
gel,O,O
shift,O,O
assay,O,O
",",O,O
which,O,O
is,O,O
essential,O,O
for,O,O
purification,O,O
and,O,O
biochemical,O,O
studies,O,O
of,O,O
this,O,O
protein,O,O
",",O,O
is,O,O
strikingly,O,O
dependent,O,O
on,O,O
the,O,O
precise,O,O
sequence,O,O
of,O,O
the,O,O
NF,B,B
-,I,I
AT,I,I
oligonucleotide,O,I
used,O,O
as,O,O
the,O,O
labeled,O,O
probe,O,O
.,O,O
One,O,O
of,O,O
these,O,O
activities,O,O
was,O,O
found,O,O
to,O,O
be,O,O
a,O,O
novel,O,O
",",O,O
less,O,O
abundant,O,O
",",O,O
Rb,O,B
-,O,I
E2F,B,I
complex,O,I
.,O,O
The,O,O
most,O,O
prominent,O,O
E2F,B,B
activity,O,I
in,O,O
resting,O,O
T,O,O
cells,O,O
(,O,O
termed,O,O
complex,O,O
X,O,O
),O,O
was,O,O
abundant,O,O
in,O,O
both,O,O
G0,O,O
and,O,O
G1,O,O
but,O,O
disappeared,O,O
as,O,O
cells,O,O
entered,O,O
S,O,O
phase,O,O
",",O,O
suggesting,O,O
a,O,O
possible,O,O
role,O,O
in,O,O
negatively,O,O
regulating,O,O
E2F,B,B
function,O,O
.,O,O
The,O,O
present,O,O
studies,O,O
have,O,O
examined,O,O
the,O,O
effects,O,O
of,O,O
vincristine,O,O
-,O,O
selected,O,O
",",O,O
multidrug,O,O
resistance,O,O
on,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
TPA,O,O
),O,O
-,O,O
induced,O,O
HL,O,B
-,O,I
60,O,I
cell,O,I
differentiation,O,I
.,O,O
Since,O,O
TPA,O,O
activates,O,O
protein,B,B
kinase,I,I
C,I,I
(,O,O
PKC,B,B
),O,O
",",O,O
we,O,O
examined,O,O
translocation,O,O
of,O,O
PKC,B,B
from,O,O
the,O,O
cytosol,O,O
to,O,O
the,O,O
membrane,O,O
fraction,O,O
.,O,O
To,O,O
determine,O,O
whether,O,O
the,O,O
defect,O,O
in,O,O
the,O,O
patient,O,O
s,O,O
T,O,O
lymphocytes,O,O
involved,O,O
a,O,O
trans,B,O
-,I,O
acting,I,O
factor,I,O
common,O,O
to,O,O
the,O,O
affected,O,O
lymphokine,B,O
genes,I,O
",",O,O
we,O,O
examined,O,O
the,O,O
ability,O,O
of,O,O
nuclear,B,O
factors,I,O
from,O,O
the,O,O
patient,O,O
s,O,O
T,O,O
lymphocytes,O,O
to,O,O
bind,O,O
response,O,O
elements,O,O
present,O,O
in,O,O
the,O,O
regulatory,B,O
region,I,O
of,O,O
IL2,B,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
binding,O,O
of,O,O
the,O,O
nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,B
cells,I,I
(,O,O
NF,B,B
-,I,I
AT,I,I
),O,O
to,O,O
its,O,O
response,O,O
element,O,O
in,O,O
the,O,O
IL2,B,O
enhancer,I,O
and,O,O
to,O,O
an,O,O
NF,B,B
-,I,I
AT,I,I
-,I,I
like,I,I
response,I,I
element,I,I
present,O,O
in,O,O
the,O,O
IL4,B,O
enhancer,I,O
was,O,O
abnormal,O,O
.,O,O
They,O,O
do,O,O
not,O,O
directly,O,O
intercept,O,O
intracellular,O,O
signalling,O,O
molecules,O,O
.,O,O
Instead,O,O
",",O,O
they,O,O
form,O,O
tight,O,O
complexes,O,O
with,O,O
two,O,O
different,O,O
classes,O,O
of,O,O
abundant,O,O
cytosolic,B,B
receptors,I,I
called,O,O
immunophilins,B,O
upon,O,O
entering,O,O
the,O,O
cell,O,O
",",O,O
and,O,O
consequently,O,O
inhibit,O,O
their,O,O
peptidyl,B,O
prolyl,I,O
cis,I,O
-,I,O
trans,I,O
isomerase,I,O
activities,O,O
.,O,O
p105,B,B
and,O,O
p98,B,B
precursor,B,I
proteins,I,I
play,O,O
an,O,O
active,O,O
role,O,O
in,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,O,I
mediated,O,I
signal,O,I
transduction,O,I
.,O,O
Association,O,O
with,O,O
the,O,O
precursors,O,O
is,O,O
sufficient,O,O
for,O,O
cytoplasmic,O,O
retention,O,O
of,O,O
either,O,O
p65,B,B
or,O,O
c,B,B
-,I,I
Rel,I,I
",",O,O
both,O,O
of,O,O
which,O,O
are,O,O
otherwise,O,O
nuclear,O,O
.,O,O
The,O,O
eukaryotic,O,O
transcription,B,O
factor,I,O
nuclear,B,O
factor,I,O
-,I,O
kappa,I,O
B,I,O
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
participates,O,O
in,O,O
many,O,O
parts,O,O
of,O,O
the,O,O
genetic,O,O
program,O,O
mediating,O,O
T,O,O
lymphocyte,O,O
activation,O,O
and,O,O
growth,O,O
.,O,O
Transfection,O,O
studies,O,O
indicate,O,O
that,O,O
the,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
gene,I,O
is,O,O
specifically,O,O
induced,O,O
by,O,O
the,O,O
65,B,O
-,I,O
kilodalton,I,O
transactivating,I,O
subunit,I,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Together,O,O
",",O,O
these,O,O
results,O,O
show,O,O
that,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
controls,O,O
the,O,O
expression,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,O,I
by,O,O
means,O,O
of,O,O
an,O,O
inducible,O,O
autoregulatory,O,O
pathway,O,O
.,O,O
A,O,O
cell,B,O
-,I,O
type,I,O
-,I,O
independent,I,O
lipopolysaccharide,I,O
(,I,O
LPS,I,O
),I,O
-,I,O
responsive,I,O
enhancer,I,O
element,I,O
located,O,O
between,O,O
-,B,O
3757,I,O
and,I,O
-,I,O
2729,I,O
bp,I,O
upstream,I,O
from,O,O
the,O,O
transcription,B,O
start,I,O
site,I,O
(,O,O
cap,B,O
site,I,O
),O,O
consisted,O,O
of,O,O
at,O,O
least,O,O
six,O,O
discrete,O,O
subregions,O,O
which,O,O
were,O,O
essential,O,O
to,O,O
the,O,O
maximal,O,O
induction,O,O
by,O,O
LPS,O,O
in,O,O
transfected,O,O
monocytes,O,O
.,O,O
The,O,O
assessment,O,O
of,O,O
synovial,O,B
lymphocyte,O,I
reactivity,O,O
to,O,O
adenovirus,O,B
antigen,O,O
stimulation,O,O
was,O,O
undertaken,O,O
in,O,O
patients,O,O
with,O,O
persistent,O,O
or,O,O
recurrent,O,O
inflammatory,O,O
arthritis,O,O
.,O,O
The,O,O
3H,O,O
-,O,O
thymidine,O,O
uptake,O,O
procedure,O,O
was,O,O
employed,O,O
",",O,O
incorporating,O,O
multiple,O,O
microbiological,B,O
antigens,I,O
.,O,O
Expression,O,O
of,O,O
PILOT,B,B
",",O,O
a,O,O
putative,O,O
transcription,B,O
factor,I,O
",",O,O
requires,O,O
two,O,O
signals,O,O
and,O,O
is,O,O
cyclosporin,O,B
A,O,I
sensitive,O,O
in,O,O
T,O,B
cells,O,I
.,O,O
Few,O,O
known,O,O
genes,B,O
(,O,O
IL,B,B
-,I,I
2,I,I
",",O,O
members,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
8,I,I
family,I,I
",",O,O
interferon,B,B
-,I,I
gamma,I,I
),O,O
are,O,O
induced,O,O
in,O,O
T,O,O
cells,O,O
only,O,O
through,O,O
the,O,O
combined,O,O
effect,O,O
of,O,O
phorbol,O,O
myristic,O,O
acetate,O,O
(,O,O
PMA,O,O
),O,O
and,O,O
a,O,O
Ca,O,B
(,O,I
2,O,I
+,O,I
),O,O
-,O,O
ionophore,O,O
",",O,O
and,O,O
expression,O,O
of,O,O
only,O,O
these,O,O
genes,B,O
can,O,O
be,O,O
fully,O,O
suppressed,O,O
by,O,O
Cyclosporin,O,B
A,O,I
(,O,I
CyA,O,I
),O,O
.,O,O
The,O,O
PILOT,B,B
protein,O,I
has,O,O
a,O,O
calculated,O,O
M,O,O
(,O,O
r,O,O
),O,O
of,O,O
42,O,O
.,O,O
6,O,B
kDa,O,I
and,O,O
contains,O,O
three,O,O
zinc,B,B
fingers,I,I
of,O,I
the,O,I
C2H2,B,I
-,I,I
type,I,I
at,O,O
the,O,O
carboxyl,B,O
-,I,O
terminus,I,O
which,O,O
are,O,O
highly,O,O
homologous,O,O
to,O,O
the,O,O
zinc,B,B
finger,I,I
regions,I,I
of,O,I
the,O,I
transcription,B,I
factors,I,I
EGR1,B,I
",",O,O
EGR2,B,O
",",O,O
and,O,O
pAT,B,O
133,I,O
.,O,O
In,O,O
contrast,O,O
to,O,O
T,O,O
cells,O,O
",",O,O
in,O,O
fibroblasts,O,O
PILOT,B,O
gene,O,O
expression,O,O
requires,O,O
only,O,O
one,O,O
signal,O,O
(,O,O
PMA,O,O
),O,O
and,O,O
is,O,O
not,O,O
affected,O,O
by,O,O
CyA,O,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
a,O,O
pleiotropic,B,O
regulator,I,O
of,O,O
a,O,O
variety,O,O
of,O,O
genes,O,O
implicated,O,O
in,O,O
the,O,O
cellular,O,O
response,O,O
to,O,O
injury,O,O
.,O,O
However,O,O
",",O,O
the,O,O
p65,B,O
antisense,O,O
phosphorothioate,O,O
oligodeoxynucleotide,O,O
had,O,O
no,O,O
significant,O,O
effect,O,O
on,O,O
the,O,O
production,O,O
of,O,O
reactive,O,O
oxygen,O,O
intermediates,O,O
or,O,O
on,O,O
phagocytosis,O,O
by,O,O
these,O,O
cells,O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
antisense,O,O
oligomers,O,O
to,O,O
p65,B,O
can,O,O
be,O,O
used,O,O
to,O,O
define,O,O
the,O,O
role,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
the,O,O
activation,O,O
pathways,O,O
of,O,O
neutrophils,O,O
.,O,O
Overexpression,O,O
of,O,O
p65,B,B
increases,O,O
endogenous,O,O
I,B,B
kappa,I,I
B,I,I
protein,O,I
in,O,O
both,O,O
carcinoma,O,O
and,O,O
lymphoid,O,O
cells,O,O
by,O,O
two,O,O
mechanisms,O,O
:,O,O
protein,O,B
stabilization,O,I
and,O,O
increased,O,O
transcription,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
mRNA,I,I
.,O,O
The,O,O
precise,O,O
molecular,O,O
abnormalities,O,O
that,O,O
cause,O,O
primary,O,O
cortisol,O,O
resistance,O,O
have,O,O
not,O,O
been,O,O
completely,O,O
described,O,O
.,O,O
At,O,O
nucleotide,O,O
2,O,O
",",O,O
317,O,O
we,O,O
identified,O,O
a,O,O
homozygous,O,O
A,O,O
for,O,O
G,O,O
point,O,O
mutation,O,O
that,O,O
predicts,O,O
an,O,O
isoleucine,O,O
(,O,O
ATT,O,O
),O,O
for,O,O
valine,O,O
(,O,O
GTT,O,O
),O,O
substitution,O,O
at,O,O
amino,O,O
acid,O,O
729,O,O
.,O,O
When,O,O
the,O,O
wild,B,B
-,I,I
type,I,I
hGR,I,I
and,O,O
hGR,B,B
-,I,I
Ile,I,I
729,I,I
were,O,O
expressed,O,O
in,O,O
COS,O,B
-,O,I
1,O,I
cells,O,I
and,O,O
assayed,O,O
for,O,O
[,O,O
3H,O,B
],O,I
-,O,I
Dexamethasone,O,I
binding,O,O
",",O,O
the,O,O
dissociation,O,O
constants,O,O
were,O,O
0,O,O
.,O,O
799,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
and,O,O
1,O,O
.,O,O
54,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
nM,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SEM,O,O
),O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
respectively,O,O
.,O,O
Transcriptional,O,O
regulation,O,O
of,O,O
interleukin,B,B
3,I,I
(,O,I
IL3,B,I
),O,I
in,O,O
primary,O,O
human,O,O
T,O,O
lymphocytes,O,O
.,O,O
Dimerization,O,O
of,O,O
NF,B,B
-,I,I
KB2,I,I
with,O,O
RelA,B,B
(,I,O
p65,I,O
),I,O
regulates,O,O
DNA,O,B
binding,O,O
",",O,O
transcriptional,O,O
activation,O,O
",",O,O
and,O,O
inhibition,O,O
by,O,O
an,O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
(,O,O
MAD,B,O
-,I,O
3,I,O
),O,O
.,O,O
We,O,O
have,O,O
previously,O,O
found,O,O
that,O,O
NFKB2,B,B
(,I,O
p49,I,O
/,I,O
p52,I,O
),I,O
acts,O,O
in,O,O
concert,O,O
with,O,O
RelA,B,B
(,I,O
p65,I,O
),I,O
to,O,O
stimulate,O,O
the,O,O
HIV,B,O
enhancer,I,O
in,O,O
Jurkat,O,O
T,O,O
-,O,O
leukemia,O,O
cells,O,O
.,O,O
Transcriptional,O,O
activation,O,O
of,O,O
the,O,O
HIV,O,O
enhancer,O,O
was,O,O
also,O,O
subject,O,O
to,O,O
regulation,O,O
by,O,O
recently,O,O
cloned,O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
(,O,O
MAD,B,O
-,I,O
3,I,O
),O,O
.,O,O
The,O,O
c,B,O
-,I,O
rel,I,B
protooncogene,I,I
product,I,I
represses,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
p65,B,I
-,O,I
mediated,O,O
transcriptional,O,O
activation,O,O
of,O,O
the,O,O
long,O,O
terminal,O,O
repeat,O,O
of,O,O
type,O,O
1,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
.,O,O
This,O,O
intracellular,O,O
signaling,O,O
complex,O,O
potently,O,O
stimulates,O,O
kappa,O,B
B,O,I
-,O,I
directed,O,I
transcription,O,I
from,O,O
either,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
or,O,O
the,O,O
IL,B,B
-,I,I
2R,I,I
alpha,I,I
promoter,I,I
via,O,O
the,O,O
strong,O,O
transactivation,O,O
domain,O,O
present,O,O
in,O,O
p65,B,O
.,O,O
We,O,O
now,O,O
demonstrate,O,O
that,O,O
nuclear,O,O
expression,O,O
of,O,O
human,O,O
c,B,B
-,I,I
Rel,I,I
",",O,O
which,O,O
is,O,O
induced,O,O
by,O,O
either,O,O
phorbol,O,O
ester,O,O
or,O,O
tumor,B,B
necrosis,I,I
factor,I,I
alpha,I,I
with,O,O
delayed,O,O
kinetics,O,O
relative,O,O
to,O,O
p65,B,O
",",O,O
markedly,O,O
represses,O,O
p65,B,O
-,O,O
mediated,O,O
activation,O,O
of,O,O
these,O,O
transcription,O,O
units,O,O
.,O,O
The,O,O
ras,O,O
-,O,O
transformed,O,O
lymphocytes,O,O
displayed,O,O
a,O,O
fully,O,O
functional,O,O
IL,B,B
-,I,I
2r,I,I
",",O,O
as,O,O
assessed,O,O
by,O,O
c,B,O
-,I,O
fos,I,O
induction,O,O
following,O,O
treatment,O,O
with,O,O
IL,B,B
-,I,I
2,I,I
;,O,O
nevertheless,O,O
",",O,O
they,O,O
were,O,O
not,O,O
growth,O,O
stimulated,O,O
by,O,O
this,O,O
lymphokine,B,O
.,O,O
Somewhat,O,O
unexpectedly,O,O
",",O,O
the,O,O
constitutive,O,O
p21ras,B,B
activity,O,O
did,O,O
not,O,O
cause,O,O
an,O,O
increased,O,O
DNA,O,B
binding,O,O
of,O,O
transcription,B,O
factors,I,O
PEA1,B,B
(,O,O
AP1,B,I
),O,O
",",O,O
PEA3,B,B
",",O,O
Oct,B,B
-,I,I
2,I,I
or,O,O
NF,B,B
-,I,I
kB,I,I
Competition,O,O
with,O,O
an,O,O
AP,B,B
-,I,I
1,I,I
motif,I,O
or,O,O
with,O,O
anti,B,O
-,I,O
Jun,I,B
and,O,O
anti,B,O
-,I,O
Fos,I,B
antibodies,I,O
abolished,O,O
binding,O,O
to,O,O
the,O,O
NFAT,B,B
motif,I,O
in,O,O
both,O,O
T,O,B
and,O,O
B,O,B
cells,O,O
",",O,O
indicating,O,O
that,O,O
Jun,O,B
and,O,O
Fos,O,B
are,O,O
critical,O,O
for,O,O
NFAT,B,B
complex,I,O
formation,O,O
in,O,O
both,O,O
cell,O,O
types,O,O
.,O,O
However,O,O
",",O,O
when,O,O
combined,O,O
with,O,O
unstimulated,O,O
B,O,O
or,O,O
T,O,O
cell,O,O
extracts,O,O
",",O,O
full,O,O
-,O,O
length,O,O
",",O,O
but,O,O
not,O,O
truncated,O,O
",",O,O
Jun,O,O
/,O,O
Fos,O,O
heterodimers,O,O
were,O,O
able,O,O
to,O,O
form,O,O
an,O,O
NFAT,B,O
complex,I,O
",",O,O
indicating,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
constitutively,B,O
expressed,I,O
nuclear,I,O
factor,I,O
(,O,O
s,O,O
),O,O
in,O,O
B,O,O
and,O,O
T,O,O
cells,O,O
necessary,O,O
for,O,O
the,O,O
formation,O,O
of,O,O
the,O,O
NFAT,B,O
complex,I,O
in,O,O
both,O,O
cell,O,O
types,O,O
.,O,O
Differential,O,O
autoregulation,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
expression,O,O
in,O,O
human,O,O
T,O,B
-,O,I
and,O,O
B,O,B
-,O,I
cell,O,I
lines,O,O
.,O,O
In,O,O
contrast,O,O
to,O,O
the,O,O
decrease,O,O
in,O,O
GR,B,B
mRNA,I,I
seen,O,O
in,O,O
IM,O,O
-,O,O
9,O,O
cells,O,O
after,O,O
treatment,O,O
with,O,O
1,O,O
microM,O,O
dexamethasone,O,O
for,O,O
16,O,O
-,O,O
18,O,O
h,O,O
",",O,O
treatment,O,O
of,O,O
6TG1,O,O
.,O,O
1,O,O
cells,O,O
resulted,O,O
in,O,O
an,O,O
8,O,O
-,O,O
fold,O,O
increase,O,O
in,O,O
GR,B,B
mRNA,I,I
",",O,O
as,O,O
determined,O,O
by,O,O
Northern,O,O
blot,O,O
and,O,O
RNase,B,O
protection,O,O
analysis,O,O
",",O,O
with,O,O
a,O,O
corresponding,O,O
3,O,O
-,O,O
to,O,O
4,O,O
-,O,O
fold,O,O
increase,O,O
in,O,O
GR,B,B
protein,I,I
.,O,O
Induction,O,O
of,O,O
CD8,B,B
antigen,I,I
and,O,O
suppressor,O,O
activity,O,O
by,O,O
glucocorticoids,O,O
in,O,O
a,O,O
CEM,O,B
human,O,I
leukemic,O,I
cell,O,I
clone,O,I
.,O,O
It,O,O
has,O,O
been,O,O
thought,O,O
that,O,O
the,O,O
virally,O,O
induced,O,O
inhibition,O,O
of,O,O
IFN,B,B
-,O,I
MCP,O,I
is,O,O
secondary,O,O
to,O,O
the,O,O
shutdown,O,O
of,O,O
cellular,O,O
macromolecular,O,O
synthesis,O,O
that,O,O
accompanies,O,O
cytopathic,O,O
virus,O,O
infections,O,O
.,O,O
IFN,B,B
-,O,I
MCP,O,I
was,O,O
not,O,O
inhibited,O,O
by,O,O
infection,O,O
with,O,O
dl343,O,O
",",O,O
despite,O,O
the,O,O
production,O,O
of,O,O
large,O,O
amounts,O,O
of,O,O
both,O,O
early,O,O
(,O,O
E1B,B,O
",",O,O
p55,B,O
),O,O
and,O,O
late,O,O
(,O,O
hexon,B,O
),O,O
Ad,B,O
proteins,I,O
.,O,O
E1A,B,O
s,O,O
inhibition,O,O
of,O,O
IFN,B,B
-,O,I
MCP,O,I
has,O,O
the,O,O
net,O,O
effect,O,O
of,O,O
promoting,O,O
the,O,O
selective,O,O
NK,O,B
cell,O,I
-,O,I
mediated,O,I
clearance,O,O
of,O,O
Ad,O,B
-,O,I
infected,O,I
or,O,O
Ad,O,B
-,O,I
transformed,O,I
human,O,I
cells,O,O
.,O,O
Nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,B
cells,I,I
(,O,O
NF,B,O
-,I,O
AT,I,O
),O,O
is,O,O
a,O,O
transcriptional,B,O
activator,I,O
involved,O,O
in,O,O
the,O,O
induction,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
gene,O,O
expression,O,O
.,O,O
We,O,O
find,O,O
that,O,O
a,O,O
short,O,O
enhancer,O,O
element,O,O
containing,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
binding,I,I
site,I,O
from,O,O
the,O,O
interleukin,B,O
-,I,O
2,I,O
receptor,I,O
alpha,I,O
-,I,O
chain,I,O
gene,I,O
(,O,O
IL,B,O
-,I,O
2R,I,O
alpha,I,O
),O,O
is,O,O
preferentially,O,O
activated,O,O
in,O,O
T,O,B
cells,O,I
.,O,O
Serum,B,O
response,I,O
factor,I,O
(,O,O
SRF,B,B
),O,O
binds,O,O
to,O,O
a,O,O
site,O,O
adjacent,O,O
to,O,O
the,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
site,I,O
in,O,O
the,O,O
IL,B,B
-,I,O
2R,I,I
enhancer,I,O
",",O,O
and,O,O
both,O,O
sites,O,O
together,O,O
have,O,O
strong,O,O
transcriptional,O,O
activity,O,O
specifically,O,O
in,O,O
T,O,O
cells,O,O
.,O,O
Mutual,O,O
regulation,O,O
of,O,O
the,O,O
transcriptional,B,O
activator,I,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
and,O,O
its,O,O
inhibitor,O,O
",",O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
.,O,O
In,O,O
previous,O,O
transfection,O,O
analyses,O,O
using,O,O
the,O,O
chloramphenicol,B,O
acetyltransferase,I,O
reporter,B,O
gene,I,O
system,O,O
",",O,O
we,O,O
determined,O,O
that,O,O
linker,O,O
substitution,O,O
(,O,O
LS,O,O
),O,O
mutations,O,O
between,O,O
-,B,O
201,I,O
and,I,O
-,I,O
130,I,O
(,O,O
relative,O,O
to,O,O
the,O,O
transcription,O,O
start,O,O
site,O,O
),O,O
of,O,O
the,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
long,B,O
terminal,I,O
repeat,I,O
(,O,O
LTR,B,O
),O,O
caused,O,O
moderate,O,O
decreases,O,O
in,O,O
LTR,B,O
transcriptional,O,O
activity,O,O
in,O,O
a,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
(,O,O
S,O,O
.,O,O
Zeichner,O,O
",",O,O
J,O,O
.,O,O
.,O,O
Kim,O,O
",",O,O
and,O,O
J,O,O
.,O,O
Alwine,O,O
",",O,O
J,O,O
.,O,O
65,O,O
:,O,O
2436,O,O
-,O,O
2444,O,O
",",O,O
1991,O,O
.,O,O
If,O,O
GATA,O,B
-,O,I
1,O,I
-,O,I
red,O,I
cells,O,I
were,O,O
available,O,O
",",O,O
the,O,O
analyses,O,O
would,O,O
involve,O,O
the,O,O
actual,O,O
transcription,O,O
of,O,O
or,O,O
chromatin,O,O
structure,O,O
surrounding,O,O
the,O,O
globin,B,O
genes,I,O
.,O,O
G0S24,B,O
is,O,O
a,O,O
member,O,O
of,O,O
a,O,O
set,O,O
of,O,O
genes,O,O
(,O,O
putative,B,O
G0,I,O
/,I,O
G1,I,O
switch,I,O
regulatory,I,O
genes,I,O
),O,O
that,O,O
are,O,O
expressed,O,O
transiently,O,O
within,O,O
1,O,O
-,O,O
2,O,O
hr,O,O
of,O,O
the,O,O
addition,O,O
of,O,O
lectin,B,O
or,O,O
cycloheximide,O,O
to,O,O
human,O,O
blood,O,O
mononuclear,O,O
cells,O,O
.,O,O
Comparison,O,O
of,O,O
the,O,O
derived,O,O
protein,O,B
sequence,O,I
with,O,O
those,O,O
of,O,O
rodent,O,O
homologs,O,O
allows,O,O
classification,O,O
into,O,O
three,O,O
groups,O,O
.,O,O
Groups,O,O
1,O,O
and,O,O
2,O,O
have,O,O
a,O,O
serine,B,B
-,I,I
rich,I,I
region,I,I
and,O,O
an,O,O
`,O,O
`,O,O
arginine,B,B
element,I,I
`,O,O
`,O,O
(,O,O
RRLPIF,B,O
),O,O
at,O,O
the,O,O
carboxyl,B,O
terminus,I,O
.,O,O
All,O,O
groups,O,O
contain,O,O
cysteine,B,B
-,I,I
and,I,I
histidine,I,I
-,I,I
rich,I,I
putative,I,O
zinc,I,O
finger,I,O
domains,I,O
and,O,O
a,O,O
serine,B,B
-,I,I
phenylalanine,I,I
`,I,O
`,I,O
SFS,I,O
domain,I,O
similar,O,O
to,O,O
part,O,O
of,O,O
the,O,O
large,O,O
subunit,O,O
of,O,O
eukaryotic,B,O
RNA,I,B
polymerase,I,I
II,I,I
.,O,O
Comparison,O,O
of,O,O
group,O,O
1,O,O
human,B,O
and,I,O
mouse,I,O
genomic,I,O
sequences,I,O
shows,O,O
high,O,O
conservation,O,O
in,O,O
the,O,O
5,B,O
flank,I,O
and,O,O
exons,B,O
.,O,O
A,O,O
CpG,O,O
island,O,O
suggests,O,O
expression,O,O
in,O,O
the,O,O
germ,O,O
line,O,O
.,O,O
A,O,O
microB,B,O
binding,I,O
protein,I,O
is,O,O
encoded,O,O
by,O,O
the,O,O
PU,B,O
.,I,O
1,I,O
/,I,O
Spi,I,O
-,I,O
1,I,O
proto,I,O
-,I,O
oncogene,I,O
.,O,O
One,O,O
enigmatic,O,O
aspect,O,O
of,O,O
GATA,B,O
factor,I,O
expression,O,O
is,O,O
that,O,O
several,O,O
GATA,B,O
proteins,I,O
",",O,O
which,O,O
ostensibly,O,O
share,O,O
the,O,O
same,O,O
DNA,B,B
-,I,I
binding,I,I
site,I,I
specificity,O,O
",",O,O
are,O,O
coexpressed,O,O
in,O,O
erythroid,O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
GATA,B,B
-,I,I
2,I,I
transcription,I,O
factor,I,O
appears,O,O
to,O,O
play,O,O
a,O,O
role,O,O
in,O,O
regulating,O,O
the,O,O
self,O,O
-,O,O
renewal,O,O
capacity,O,O
of,O,O
early,O,O
erythroid,O,B
progenitor,O,I
cells,O,I
.,O,O
Endothelial,O,B
cells,O,I
(,O,O
EC,O,O
),O,O
act,O,O
as,O,O
APC,O,O
for,O,O
resting,O,O
PBL,O,O
in,O,O
vitro,O,O
",",O,O
and,O,O
may,O,O
have,O,O
important,O,O
roles,O,O
in,O,O
vivo,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
allograft,O,O
rejection,O,O
and,O,O
delayed,O,O
hypersensitivity,O,O
.,O,O
PBL,O,O
constitutively,O,O
express,O,O
c,B,B
-,I,I
jun,I,I
transcripts,I,O
",",O,O
and,O,O
the,O,O
level,O,O
of,O,O
c,B,B
-,I,I
jun,I,I
mRNA,I,O
is,O,O
not,O,O
altered,O,O
by,O,O
PHA,B,O
activation,O,O
in,O,O
the,O,O
absence,O,O
or,O,O
presence,O,O
of,O,O
EC,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
c,B,B
-,I,I
fos,I,I
mRNA,I,O
is,O,O
absent,O,O
from,O,O
resting,O,O
T,O,O
cells,O,O
and,O,O
is,O,O
induced,O,O
on,O,O
PHA,B,O
activation,O,O
.,O,O
Site,O,O
-,O,O
directed,O,O
mutagenesis,O,O
demonstrated,O,O
that,O,O
this,O,O
HS,B,O
-,I,O
40,I,O
enhancer,O,O
-,O,O
zeta,B,O
2,I,O
globin,I,O
promoter,I,O
interaction,O,O
is,O,O
mediated,O,O
by,O,O
the,O,O
two,O,O
GATA,O,O
-,O,O
1,O,O
factor,O,O
binding,O,O
motifs,O,O
located,O,O
at,O,O
-,O,O
230,O,O
and,O,O
-,O,O
104,O,O
",",O,O
respectively,O,O
.,O,O
Site,O,O
-,O,O
directed,O,O
mutagenesis,O,O
further,O,O
demonstrated,O,O
that,O,O
the,O,O
enhancer,B,O
function,O,O
of,O,O
one,O,O
of,O,O
the,O,O
two,O,O
NF,O,B
-,O,I
E2,O,I
/,O,I
AP1,O,I
motifs,O,O
of,O,O
HS,B,O
-,I,O
40,I,O
is,O,O
mediated,O,O
through,O,O
its,O,O
binding,O,O
to,O,O
NF,B,B
-,I,I
E2,I,I
but,O,O
not,O,O
AP1,B,O
transcription,I,O
factor,I,O
.,O,O
We,O,O
report,O,O
the,O,O
characterization,O,O
of,O,O
the,O,O
cis,B,O
-,I,O
and,I,O
trans,I,O
-,I,O
acting,I,O
elements,I,O
involved,O,O
in,O,O
the,O,O
tissue,O,O
-,O,O
specific,O,O
activity,O,O
of,O,O
the,O,O
L,B,O
gene,I,O
erythroid,I,O
promoter,I,O
.,O,O
Within,O,O
this,O,O
region,O,O
",",O,O
we,O,O
define,O,O
a,O,O
minimal,B,O
promoter,I,O
(,O,O
-,O,O
62,O,O
to,O,O
+,O,O
54,O,O
),O,O
that,O,O
displays,O,O
erythroid,O,B
-,O,I
specific,O,I
activity,O,O
and,O,O
contains,O,O
two,O,O
DNA,O,B
binding,O,O
sites,O,O
.,O,O
Mutations,O,O
and,O,O
deletions,O,O
of,O,O
both,O,O
sites,O,O
indicate,O,O
that,O,O
only,O,O
the,O,O
association,O,O
of,O,O
CCACC,B,B
/,I,I
Sp1,I,I
and,O,O
GATA,B,B
binding,I,O
sites,I,O
can,O,O
drive,O,O
efficient,O,O
and,O,O
tissue,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
this,O,O
R,B,O
-,I,O
PK,I,O
minimal,B,O
promoter,I,O
.,O,O
Protease,O,O
treatment,O,O
of,O,O
nuclear,O,O
extracts,O,O
distinguishes,O,O
between,O,O
class,B,O
II,I,O
MHC,I,O
X1,I,B
box,I,I
DNA,I,I
-,I,I
binding,I,I
proteins,I,I
in,O,O
wild,O,O
-,O,O
type,O,O
and,O,O
class,O,O
II,O,O
-,O,O
deficient,O,O
B,O,O
cells,O,O
.,O,O
The,O,O
X,B,B
box,I,I
region,I,I
is,O,O
critical,O,O
for,O,O
directing,O,O
the,O,O
expression,O,O
of,O,O
class,B,O
II,I,O
major,I,O
histocompatibility,I,O
complex,I,O
genes,I,O
in,O,O
B,O,O
lymphocytes,O,O
.,O,O
To,O,O
further,O,O
evaluate,O,O
the,O,O
role,O,O
of,O,O
X,B,B
box,I,I
DNA,I,I
-,I,I
binding,I,I
proteins,I,I
in,O,O
class,B,O
II,I,O
gene,I,O
expression,O,O
",",O,O
the,O,O
role,O,O
of,O,O
the,O,O
X,B,B
box,I,I
region,I,I
was,O,O
examined,O,O
in,O,O
both,O,O
class,O,O
II,O,O
-,O,O
positive,O,O
and,O,O
-,O,O
negative,O,O
lymphoid,O,O
cells,O,O
.,O,O
To,O,O
determine,O,O
whether,O,O
these,O,O
different,O,O
X1,O,B
box,O,I
activities,O,O
represented,O,O
distinct,O,O
DNA,B,B
binding,I,I
proteins,I,O
or,O,O
multimeric,O,O
forms,O,O
of,O,O
the,O,O
same,O,O
factor,O,O
(,O,O
s,O,O
),O,O
",",O,O
protease,B,O
treatment,O,O
of,O,O
the,O,O
crude,O,O
nuclear,O,O
extracts,O,O
followed,O,O
by,O,O
DNA,O,B
-,O,I
binding,O,I
assays,O,O
were,O,O
carried,O,O
out,O,O
and,O,O
demonstrated,O,O
that,O,O
B,O,B
cell,O,I
extracts,O,O
contain,O,O
at,O,O
least,O,O
two,O,O
X1,B,B
-,I,I
specific,I,I
factors,I,O
.,O,O
A,O,O
similar,O,O
comparison,O,O
with,O,O
protease,O,O
-,O,O
treated,O,O
extracts,O,O
prepared,O,O
from,O,O
Jurkat,O,O
cells,O,O
demonstrated,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
band,O,O
1pk,O,O
activity,O,O
despite,O,O
an,O,O
absence,O,O
of,O,O
the,O,O
native,O,O
RFX,B,O
activity,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
protease,O,O
treatment,O,O
and,O,O
analysis,O,O
of,O,O
SJO,O,O
extracts,O,O
showed,O,O
no,O,O
detectable,O,O
levels,O,O
of,O,O
the,O,O
band,O,O
1pk,O,O
activity,O,O
.,O,O
Human,O,O
immunodeficiency,O,O
viruses,O,O
containing,O,O
heterologous,B,O
enhancer,I,O
/,I,O
promoters,I,O
are,O,O
replication,O,O
competent,O,O
and,O,O
exhibit,O,O
different,O,O
lymphocyte,O,O
tropisms,O,O
.,O,O
Viruses,O,O
containing,O,O
the,O,O
human,B,B
cytomegalovirus,I,I
immediate,I,I
-,I,I
early,I,I
enhancer,I,I
exhibited,O,O
infectious,O,O
kinetics,O,O
similar,O,O
to,O,O
that,O,O
of,O,O
wild,O,O
-,O,O
type,O,O
HIV,O,O
in,O,O
activated,O,O
human,O,B
peripheral,O,I
blood,O,I
lymphocytes,O,I
and,O,O
AA2,O,O
cells,O,O
but,O,O
replicated,O,O
less,O,O
efficiently,O,O
in,O,O
H9,O,O
and,O,O
CEM,O,O
cells,O,O
.,O,O
Our,O,O
report,O,O
expands,O,O
current,O,O
knowledge,O,O
of,O,O
the,O,O
radiation,O,O
-,O,O
induced,O,O
signaling,O,O
cascade,O,O
by,O,O
clarifying,O,O
the,O,O
chronological,O,O
sequence,O,O
of,O,O
biochemical,O,O
events,O,O
that,O,O
follow,O,O
irradiation,O,O
.,O,O
To,O,O
test,O,O
this,O,O
hypothesis,O,O
",",O,O
a,O,O
more,O,O
sensitive,O,O
and,O,O
specific,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
PCR,O,O
),O,O
assay,O,O
was,O,O
developed,O,O
to,O,O
detect,O,O
adenovirus,B,B
DNA,I,I
.,O,O
The,O,O
E1A,B,B
and,I,O
hexon,I,B
primers,I,O
amplified,O,O
DNA,O,B
from,O,O
representative,O,O
adenoviral,O,O
serotypes,O,O
in,O,O
all,O,O
six,O,O
adenoviral,O,O
groups,O,O
(,O,O
A,O,O
-,O,O
F,O,O
),O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
examine,O,O
the,O,O
inter,O,O
-,O,O
relationship,O,O
between,O,O
HIV,O,B
-,O,O
1,O,I
infection,O,O
and,O,O
the,O,O
cell,O,O
surface,O,O
receptors,O,O
for,O,O
tumor,B,O
necrosis,I,O
factor,I,O
(,I,O
TNF,I,B
),I,O
-,I,O
alpha,I,O
",",O,O
an,O,O
immunoregulatory,O,O
cytokine,O,O
that,O,O
can,O,O
enhance,O,O
HIV,O,B
-,O,O
1,O,I
replication,O,O
.,O,O
HIV,O,B
-,O,I
1,O,I
activation,O,O
and,O,O
expression,O,O
was,O,O
quantitated,O,O
by,O,O
reverse,B,O
transcriptase,I,O
assay,O,O
.,O,O
RESULTS,O,O
:,O,O
In,O,O
the,O,O
OM,O,O
-,O,O
10,O,O
.,O,O
1,O,O
promyelocytic,O,O
model,O,O
of,O,O
chronic,O,O
infection,O,O
",",O,O
TNF,O,B
-,O,I
alpha,O,I
-,O,I
induced,O,O
HIV,O,B
-,O,I
1,O,I
expression,O,O
also,O,O
resulted,O,O
in,O,O
a,O,O
substantial,O,O
increase,O,O
in,O,O
75,B,O
kd,I,O
TNF,I,O
receptor,I,O
(,O,O
TR75,B,O
),O,O
expression,O,O
although,O,O
55,B,O
kD,I,O
TNF,I,O
receptor,I,O
(,O,O
TR55,B,O
),O,O
levels,O,O
were,O,O
not,O,O
dramatically,O,O
altered,O,O
.,O,O
Enhanced,O,O
TR75,B,B
expression,O,O
on,O,O
OM,O,B
-,O,I
10,O,I
.,O,O
1,O,O
cells,O,O
followed,O,O
the,O,O
same,O,O
TNF,B,B
-,I,I
alpha,I,I
-,O,I
dose,O,I
dependency,O,O
as,O,O
that,O,O
observed,O,O
for,O,O
HIV,O,B
-,O,I
1,O,I
production,O,O
.,O,O
Although,O,O
TR55,B,B
expression,O,O
was,O,O
unaltered,O,O
during,O,O
TNF,B,B
-,I,I
alpha,I,I
-,O,I
induced,O,I
HIV,O,I
activation,O,O
",",O,O
this,O,O
receptor,O,O
was,O,O
still,O,O
involved,O,O
in,O,O
the,O,O
viral,O,O
activation,O,O
process,O,O
.,O,O
Surprisingly,O,O
",",O,O
this,O,O
was,O,O
the,O,O
case,O,O
even,O,O
when,O,O
an,O,O
antagonistic,B,O
anti,I,B
-,I,I
TR55,I,I
antibody,I,O
was,O,O
used,O,O
.,O,O
Anti,B,O
-,I,O
TR55,I,B
antibody,I,I
cross,O,O
-,O,O
linking,O,O
in,O,O
chronically,O,O
infected,O,O
U1,O,B
promonocytic,O,I
cultures,O,O
could,O,O
only,O,O
partially,O,O
substitute,O,O
for,O,O
TNF,O,B
-,O,I
alpha,O,I
-,O,I
induced,O,I
HIV,O,B
-,O,I
1,O,I
expression,O,O
.,O,O
We,O,O
have,O,O
used,O,O
in,O,O
situ,O,O
hybridization,O,O
to,O,O
define,O,O
these,O,O
rearrangements,O,O
at,O,O
the,O,O
molecular,O,O
level,O,O
.,O,O
A,O,O
reporter,B,O
gene,I,O
under,O,O
the,O,O
control,O,O
of,O,O
a,O,O
T,B,B
-,I,I
cell,I,I
antigen,I,I
receptor,I,I
element,I,O
was,O,O
activated,O,O
in,O,O
Jurkat,O,B
cells,O,O
by,O,O
antigen,O,O
receptor,O,O
triggering,O,O
or,O,O
by,O,O
a,O,O
combination,O,O
of,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
",",O,O
which,O,O
activates,O,O
protein,B,B
kinase,I,I
C,I,I
",",O,O
and,O,O
a,O,O
calcium,O,B
ionophore,O,I
.,O,O
Both,O,O
these,O,O
signals,O,O
were,O,O
necessary,O,O
for,O,O
expression,O,O
of,O,O
the,O,O
reporter,B,O
gene,I,O
.,O,O
When,O,O
co,O,O
-,O,O
transfected,O,O
with,O,O
a,O,O
construct,O,O
capable,O,O
of,O,O
overexpressing,O,O
the,O,O
tyrosine,B,B
kinase,I,I
p59fyn,B,I
",",O,O
the,O,O
reporter,B,O
gene,I,O
was,O,O
activated,O,O
by,O,O
PMA,B,B
alone,O,O
.,O,O
Dependence,O,O
for,O,O
the,O,O
proliferative,O,O
response,O,O
to,O,O
erythropoietin,B,B
on,O,O
an,O,O
established,O,O
erythroid,O,O
differentiation,O,O
program,O,O
in,O,O
a,O,O
human,O,B
hematopoietic,O,I
cell,O,I
line,O,I
",",O,O
UT,O,B
-,O,I
7,O,I
.,O,O
UT,B,B
-,I,I
7,I,I
Epo,I,O
and,O,O
UT,O,B
-,O,I
7,O,I
expressed,O,O
similar,O,O
levels,O,O
of,O,O
GATA,B,B
-,I,I
1,I,I
mRNA,I,O
and,O,O
binding,O,O
activity,O,O
.,O,O
This,O,O
difference,O,O
in,O,O
the,O,O
number,O,O
of,O,O
binding,O,O
sites,O,O
could,O,O
be,O,O
due,O,O
to,O,O
differences,O,O
in,O,O
cell,O,O
surface,O,O
(,O,O
UT,O,B
-,O,I
7,O,I
cells,O,O
are,O,O
20,O,O
%,O,O
smaller,O,O
than,O,O
the,O,O
parental,O,O
UT,O,B
-,O,I
7,O,I
cells,O,O
),O,O
or,O,O
in,O,O
receptor,O,O
turnover,O,O
.,O,O
By,O,O
Northern,O,O
analysis,O,O
",",O,O
UT,O,B
-,O,I
7,O,I
cells,O,O
expressed,O,O
detectable,O,O
levels,O,O
of,O,O
beta,B,B
-,I,I
and,I,O
gamma,I,B
-,I,I
globin,I,I
but,O,O
not,O,O
alpha,B,B
-,I,I
globin,I,I
.,O,O
Globin,B,B
chains,I,I
(,O,O
alpha,B,B
",",O,O
beta,B,B
and,O,O
gamma,B,B
),O,O
were,O,O
clearly,O,O
detectable,O,O
by,O,O
affinity,O,O
chromatography,O,O
in,O,O
UT,B,B
-,I,I
7,I,I
Epo,I,I
but,O,O
not,O,O
in,O,O
UT,O,B
-,O,I
7,O,I
cells,O,I
.,O,O
The,O,O
myeloid,B,B
integrin,I,I
CD11b,I,I
is,O,O
expressed,O,O
selectively,O,O
on,O,O
the,O,O
surface,O,O
of,O,O
mature,O,O
macrophages,O,O
",",O,O
monocytes,O,O
",",O,O
neutrophils,O,O
",",O,O
and,O,O
natural,O,B
killer,O,I
cells,O,I
.,O,O
Recent,O,O
isolation,O,O
of,O,O
the,O,O
CD11b,B,B
promoter,I,I
shows,O,O
that,O,O
92,O,O
base,O,O
pairs,O,O
(,O,O
bp,O,O
),O,O
of,O,O
5,B,O
-,I,O
flanking,I,O
DNA,I,B
are,O,O
sufficient,O,O
to,O,O
direct,O,O
myeloid,O,B
-,O,I
specific,O,I
expression,O,I
of,O,O
a,O,O
reporter,B,O
gene,I,O
.,O,O
Transcription,O,O
factor,O,O
jun,O,B
-,O,I
B,O,I
is,O,O
target,O,O
of,O,O
autoreactive,O,O
T,O,O
-,O,O
cells,O,O
in,O,O
IDDM,O,O
.,O,O
Target,O,O
antigens,O,O
defined,O,O
by,O,O
autoantibodies,B,O
in,O,O
IDDM,O,O
include,O,O
insulin,O,B
",",O,O
a,O,O
putative,O,O
glycolipid,O,O
that,O,O
reacts,O,O
with,O,O
islet,B,B
cell,I,I
antibodies,I,I
",",O,O
and,O,O
a,O,O
64,B,O
",",I,O
-,I,O
M,I,O
(,I,O
r,I,O
),I,O
protein,I,O
recently,O,O
identified,O,O
as,O,O
glutamic,B,B
acid,I,I
decarboxylase,I,I
.,O,O
Okadaic,O,O
acid,O,O
increased,O,O
the,O,O
synthesis,O,O
of,O,O
the,O,O
interleukin,B,B
-,I,I
1,I,I
beta,I,I
precursor,O,I
and,O,O
mature,O,O
forms,O,O
and,O,O
their,O,O
secretion,O,O
.,O,O
Expression,O,O
of,O,O
tal,B,B
-,I,I
1,I,I
and,O,O
GATA,B,B
-,I,I
binding,I,I
proteins,I,I
during,O,O
human,O,O
hematopoiesis,O,O
.,O,O
Because,O,O
the,O,O
GATA,B,B
-,I,I
1,I,I
gene,I,O
is,O,O
known,O,O
to,O,O
transactivate,O,O
several,O,O
genes,O,O
specific,O,O
for,O,O
the,O,O
erythroid,O,B
",",O,O
megakaryocytic,O,B
",",O,O
and,O,O
mastocytic,O,B
/,O,I
basophilic,O,I
lineages,O,I
",",O,O
we,O,O
studied,O,O
GATA,B,B
-,I,I
1,I,I
expression,O,O
in,O,O
these,O,O
purified,O,O
hematopoietic,O,O
cells,O,O
.,O,O
The,O,O
lytic,O,O
transition,O,O
of,O,O
Epstein,O,O
-,O,O
Barr,O,O
virus,O,O
is,O,O
imitated,O,O
by,O,O
recombinant,O,O
B,O,B
-,O,I
cells,O,I
.,O,O
We,O,O
developed,O,O
eukaryotic,O,B
vectors,O,I
suitable,O,O
to,O,O
imitate,O,O
the,O,O
processes,O,O
involved,O,O
in,O,O
lytic,O,B
transition,O,I
in,O,I
cell,O,I
culture,O,I
systems,O,O
.,O,O
R7,O,O
-,O,O
57,O,O
reporter,O,O
cells,O,O
",",O,O
on,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
signaled,O,O
induced,O,O
activity,O,O
of,O,O
the,O,O
lytic,B,B
origin,I,I
of,I,I
EBV,I,I
replication,I,I
(,O,I
ori,B,I
Lyt,I,I
),O,I
.,O,O
Different,O,O
modes,O,O
",",O,O
like,O,O
chemical,O,O
induction,O,O
",",O,O
lytic,O,O
superinfection,O,O
with,O,O
EBV,O,O
and,O,O
single,O,O
gene,O,O
trans,O,O
-,O,O
activation,O,O
converted,O,O
the,O,O
recombinant,B,O
ori,I,O
Lyt,I,O
element,I,O
in,O,O
R7,O,O
-,O,O
57,O,O
reporter,O,O
cells,O,O
.,O,O
Costimulation,O,O
of,O,O
cAMP,O,B
and,O,O
protein,B,B
kinase,I,I
C,I,I
pathways,O,O
inhibits,O,O
the,O,O
CD3,B,B
-,O,I
dependent,O,I
T,O,I
cell,O,I
activation,O,O
and,O,O
leads,O,O
to,O,O
a,O,O
persistent,O,O
expression,O,O
of,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
transcription,I,I
factor,I,I
.,O,O
Analysis,O,O
of,O,O
intracellular,O,O
Ca2,O,B
+,O,I
mobilization,O,O
suggested,O,O
that,O,O
the,O,O
CD3,B,B
/,O,I
TcR,B,I
-,O,I
dependent,O,I
signal,O,I
transduction,O,I
was,O,O
impaired,O,O
in,O,O
PMA,O,B
/,O,I
Bt2cAMP,O,I
-,O,I
treated,O,O
cells,O,O
.,O,O
The,O,O
observation,O,O
that,O,O
a,O,O
mutated,B,O
LT,I,B
-,I,I
kappa,I,I
B,I,I
construct,I,O
(,O,O
M1,B,O
-,I,O
CAT,I,O
),O,O
was,O,O
inactive,O,O
in,O,O
C81,O,O
-,O,O
66,O,O
-,O,O
45,O,O
",",O,O
confirmed,O,O
the,O,O
importance,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
LT,B,O
gene,O,O
expression,O,O
.,O,O
In,O,O
JM,O,O
T,O,O
cells,O,O
",",O,O
tax,B,O
induced,O,O
LT,B,B
-,I,I
293,I,I
activity,O,O
by,O,O
two,O,O
-,O,O
to,O,O
four,O,O
-,O,O
fold,O,O
",",O,O
though,O,O
there,O,O
was,O,O
no,O,O
induction,O,O
of,O,O
M1,B,O
-,I,O
CAT,I,O
.,O,O
We,O,O
combined,O,O
two,O,O
techniques,O,O
to,O,O
identify,O,O
the,O,O
productive,O,O
replicative,O,O
form,O,O
of,O,O
Epstein,B,O
-,I,O
Barr,I,O
viral,I,O
DNA,I,B
in,O,O
the,O,O
lytic,O,O
cycle,O,O
-,O,O
induced,O,O
cells,O,O
.,O,O
This,O,O
indicates,O,O
an,O,O
increase,O,O
in,O,O
either,O,O
episomal,B,B
DNA,I,I
or,O,O
concatameric,B,B
linear,I,I
DNA,I,I
.,O,O
This,O,O
paper,O,O
describes,O,O
how,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
monocyte,B,B
-,I,I
macrophage,I,I
Ag,I,I
",",O,O
CD14,B,B
",",O,O
and,O,O
the,O,O
low,O,O
affinity,B,O
Fc,I,B
receptor,I,I
for,O,O
IgE,B,B
",",O,O
CD23,B,B
",",O,O
were,O,O
inversely,O,O
regulated,O,O
during,O,O
VitD3,O,O
-,O,O
and,O,O
RA,O,O
-,O,O
induced,O,O
monocytic,O,B
differentiation,O,I
of,O,O
human,O,O
U,O,B
-,O,O
937,O,O
monoblasts,O,O
.,O,O
The,O,O
results,O,O
suggest,O,O
that,O,O
there,O,O
exists,O,O
a,O,O
functional,O,O
antagonism,O,O
between,O,O
VitD3,O,B
and,O,O
RA,O,B
that,O,O
may,O,O
have,O,O
important,O,O
implications,O,O
for,O,O
the,O,O
regulation,O,O
of,O,O
certain,O,O
immune,O,O
and,O,O
inflammatory,O,O
responses,O,O
through,O,O
their,O,O
inverse,O,O
effects,O,O
on,O,O
CD14,O,B
and,O,O
CD23,O,B
gene,O,O
expression,O,O
.,O,O
Cell,O,O
-,O,O
specific,O,O
bifunctional,O,O
role,O,O
of,O,O
Jun,B,B
oncogene,I,I
family,I,I
members,I,I
on,O,O
glucocorticoid,B,B
receptor,I,I
-,O,I
dependent,O,I
transcription,O,I
.,O,O
Here,O,O
we,O,O
report,O,O
that,O,O
this,O,O
interference,O,O
is,O,O
cell,O,O
specific,O,O
",",O,O
as,O,O
TPA,O,O
augmented,O,O
dexamethasone,O,O
-,O,O
induced,O,O
transcriptional,O,O
activation,O,O
of,O,O
the,O,O
MMTV,B,O
LTR,I,O
in,O,O
several,O,O
T,O,O
cell,O,O
lines,O,O
but,O,O
was,O,O
inhibitory,O,O
in,O,O
NIH,O,O
-,O,O
3T3,O,O
fibroblasts,O,O
.,O,O
Increased,O,O
c,B,O
-,I,O
jun,I,O
",",O,O
jun,B,O
-,I,O
B,I,O
",",O,O
and,O,O
jun,B,O
-,I,O
D,I,O
expression,O,O
above,O,O
basal,O,O
levels,O,O
and,O,O
increased,O,O
transcriptional,O,O
activity,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
/,I,O
TPA,I,O
responsive,I,O
elements,I,O
fused,O,O
to,O,O
chloramphenicol,B,O
acetyl,I,O
-,I,O
transferase,I,O
vectors,I,O
were,O,O
observed,O,O
in,O,O
T,O,O
cells,O,O
treated,O,O
with,O,O
TPA,O,O
alone,O,O
or,O,O
in,O,O
combination,O,O
with,O,O
dexamethasone,O,O
.,O,O
Studies,O,O
with,O,O
5,B,O
deletion,I,O
CD20,I,B
promoter,I,I
-,I,I
CAT,I,I
constructs,I,O
have,O,O
previously,O,O
revealed,O,O
two,O,O
regions,O,O
of,O,O
the,O,O
promoter,B,O
between,O,O
bases,O,O
-,O,O
186,O,O
and,O,O
-,O,O
280,O,O
and,O,O
between,O,O
bases,O,O
-,O,O
280,O,O
and,O,O
-,O,O
454,O,O
which,O,O
contained,O,O
positive,B,O
regulatory,I,O
elements,I,O
.,O,O
Cross,O,O
competition,O,O
experiments,O,O
with,O,O
an,O,O
octamer,O,O
sequence,O,O
from,O,O
the,O,O
Ig,O,B
heavy,O,I
chain,O,I
promoter,O,I
",",O,O
the,O,O
BAT,B,B
box,I,I
",",O,O
and,O,O
a,O,O
TA,O,B
-,O,I
rich,O,I
sequence,O,I
present,O,O
in,O,O
the,O,O
CD21,B,B
promoter,I,I
revealed,O,O
that,O,O
all,O,O
three,O,O
sequences,O,O
bound,O,O
the,O,O
same,O,O
nuclear,B,B
proteins,I,I
suggesting,O,O
that,O,O
the,O,O
BAT,B,B
box,I,I
binding,I,I
proteins,I,I
were,O,O
Oct,B,B
-,I,I
1,I,I
and,O,O
Oct,B,B
-,I,I
2,I,I
.,O,O
Despite,O,O
this,O,O
lower,O,O
affinity,O,O
",",O,O
a,O,O
trimer,O,O
of,O,O
the,O,O
BAT,B,B
box,I,I
sequence,I,I
was,O,O
as,O,O
efficiently,O,O
transactivated,O,O
by,O,O
an,O,O
Oct,B,B
-,I,I
2,I,I
expression,I,I
vector,I,I
as,O,O
was,O,O
a,O,O
trimer,O,O
of,O,O
the,O,O
octamer,B,B
sequence,I,I
in,O,O
HeLa,O,O
cells,O,O
.,O,O
Control,O,O
peptides,O,O
corresponding,O,O
to,O,O
the,O,O
normal,O,O
pml,B,O
and,O,O
RAR,B,B
alpha,I,I
proteins,I,I
were,O,O
not,O,O
recognized,O,O
.,O,O
One,O,O
cDNA,B,O
clone,I,O
of,O,O
a,O,O
primary,O,O
response,O,O
gene,O,O
",",O,O
expressed,O,O
upon,O,O
macrophage,O,B
differentiation,O,I
",",O,O
encoded,O,O
for,O,O
Egr,B,B
-,I,I
1,I,I
",",O,O
a,O,O
zinc,B,B
finger,I,I
transcription,I,I
factor,I,I
.,O,O
HL,O,B
-,O,I
60,O,I
cells,O,O
constitutively,O,O
expressing,O,O
an,O,O
Egr,B,B
-,I,I
1,I,I
transgene,I,O
(,O,O
HL,B,B
-,I,I
60Egr,I,I
-,I,I
1,I,I
),O,O
could,O,O
be,O,O
induced,O,O
for,O,O
macrophage,O,O
",",O,O
but,O,O
not,O,O
granulocyte,O,O
",",O,O
differentiation,O,O
.,O,O
These,O,O
observations,O,O
indicate,O,O
that,O,O
expression,O,O
of,O,O
Egr,B,B
-,I,I
1,I,I
is,O,O
essential,O,O
for,O,O
and,O,O
restricts,O,O
differentiation,O,O
of,O,O
myeloblasts,O,O
along,O,O
the,O,O
macrophage,O,O
lineage,O,O
.,O,O
Electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
revealed,O,O
three,O,O
specific,O,O
protein,B,B
-,I,I
DNA,I,I
complexes,I,I
formed,O,O
with,O,O
sequences,O,O
of,O,O
the,O,O
EBNA2,B,O
responsive,I,O
element,I,O
.,O,O
Thus,O,O
",",O,O
these,O,O
experiments,O,O
demonstrate,O,O
that,O,O
EBNA2,B,O
interacts,O,O
with,O,O
an,O,O
EBNA2,B,O
responsive,I,O
cis,I,O
-,I,O
element,I,O
of,O,O
the,O,O
TP1,B,O
promoter,I,O
Agents,O,O
which,O,O
increased,O,O
cAMP,O,O
levels,O,O
",",O,O
including,O,O
cholera,O,O
toxin,O,O
",",O,O
pertussis,O,O
toxin,O,O
",",O,O
dibutyryl,O,O
cAMP,O,O
",",O,O
and,O,O
isoproterenol,O,O
mimicked,O,O
the,O,O
actions,O,O
of,O,O
MM,B,O
-,I,O
LDL,I,O
.,O,O
One,O,O
member,O,O
of,O,O
this,O,O
multigene,O,O
family,O,O
",",O,O
GATA,B,B
-,I,I
3,I,I
",",O,O
is,O,O
most,O,O
abundantly,O,O
expressed,O,O
in,O,O
T,O,B
lymphocytes,O,I
",",O,O
a,O,O
cellular,O,O
target,O,O
for,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
(,O,O
HIV,O,B
-,O,I
1,O,I
),O,O
infection,O,O
and,O,O
replication,O,O
.,O,O
Cotransfection,O,O
of,O,O
an,O,O
hGATA,B,O
-,I,O
3,I,O
expression,I,O
plasmid,I,O
with,O,O
a,O,O
reporter,B,O
plasmid,I,O
whose,O,O
transcription,O,O
is,O,O
directed,O,O
by,O,O
the,O,O
HIV,B,O
-,I,O
1,I,O
LTR,I,O
resulted,O,O
in,O,O
6,O,O
-,O,O
to,O,O
10,O,O
-,O,O
fold,O,O
stimulation,O,O
of,O,O
LTR,B,O
-,O,O
mediated,O,O
transcription,O,O
",",O,O
whereas,O,O
site,O,O
specific,O,O
mutation,O,O
of,O,O
these,O,O
GATA,B,B
sites,I,I
resulted,O,O
in,O,O
virtual,O,O
abrogation,O,O
of,O,O
the,O,O
activation,O,O
by,O,O
hGATA,B,O
-,I,O
3,I,O
.,O,O
Conversely,O,O
",",O,O
several,O,O
cytokines,B,O
modulate,O,O
the,O,O
levels,O,O
of,O,O
HIV,O,B
expression,O,O
in,O,O
infected,O,O
cells,O,O
of,O,O
both,O,O
T,O,O
lymphocytic,O,O
and,O,O
mononuclear,O,O
phagocytic,O,O
lineage,O,O
.,O,O
Cloning,O,O
and,O,O
functional,O,O
characterization,O,O
of,O,O
early,B,O
B,I,B
-,I,I
cell,I,I
factor,I,I
",",O,O
a,O,O
regulator,O,O
of,O,O
lymphocyte,O,O
-,O,O
specific,O,O
gene,O,O
expression,O,O
.,O,O
Early,B,O
B,I,B
-,I,I
cell,I,I
factor,I,I
(,O,O
EBF,B,O
),O,O
was,O,O
identified,O,O
previously,O,O
as,O,O
a,O,O
tissue,O,O
-,O,O
specific,O,O
and,O,O
differentiation,O,O
stage,O,O
-,O,O
specific,O,O
DNA,B,B
-,I,I
binding,I,I
protein,I,I
that,O,O
participates,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
the,O,O
pre,B,O
-,I,O
B,I,B
and,I,O
B,I,B
lymphocyte,I,O
-,I,O
specific,I,O
mb,I,O
-,I,O
1,I,O
gene,I,O
.,O,O
Partial,O,O
amino,O,O
acid,O,O
sequences,O,O
obtained,O,O
from,O,O
purified,O,O
EBF,B,B
were,O,O
used,O,O
to,O,O
isolate,O,O
cDNA,B,B
clones,I,O
",",O,O
which,O,O
by,O,O
multiple,O,O
criteria,O,O
encode,O,O
EBF,B,B
.,O,O
DNA,O,B
-,O,I
binding,O,I
assays,O,O
with,O,O
cotranslated,O,O
wild,O,O
-,O,O
type,O,O
and,O,O
truncated,O,O
forms,O,O
of,O,O
EBF,B,B
indicated,O,O
that,O,O
the,O,O
protein,O,O
interacts,O,O
with,O,O
its,O,O
site,O,O
as,O,O
a,O,O
homodimer,B,O
.,O,O
Deletions,O,O
delineated,O,O
a,O,O
carboxy,B,O
-,I,O
terminal,I,O
dimerization,I,O
region,I,O
containing,O,O
two,O,O
repeats,O,O
of,O,O
15,O,O
amino,O,O
acids,O,O
that,O,O
show,O,O
similarity,O,O
with,O,O
the,O,O
dimerization,B,O
domains,I,O
of,O,O
basic,B,B
-,I,I
helix,I,I
-,I,I
loop,I,I
-,I,I
helix,I,I
proteins,I,I
.,O,O
A,O,O
73,B,O
kDa,I,O
protein,I,B
was,O,O
identified,O,O
by,O,O
this,O,O
analysis,O,O
:,O,O
this,O,O
protein,O,O
is,O,O
highly,O,O
enriched,O,O
in,O,O
cell,O,O
lines,O,O
of,O,O
B,O,O
lymphoid,O,O
origin,O,O
as,O,O
compared,O,O
to,O,O
pancreatic,O,O
beta,O,O
-,O,O
cells,O,O
and,O,O
fibroblast,O,O
cells,O,O
.,O,O
The,O,O
detection,O,O
of,O,O
this,O,O
protein,O,O
selectively,O,O
in,O,O
extracts,O,O
of,O,O
lymphoid,O,O
cells,O,O
correlates,O,O
with,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
E,B,O
box,I,O
-,O,O
binding,O,O
activity,O,O
LEF1,B,O
/,I,O
BCF1,I,O
in,O,O
these,O,O
cells,O,O
;,O,O
this,O,O
binding,O,O
activity,O,O
was,O,O
previously,O,O
shown,O,O
to,O,O
be,O,O
efficiently,O,O
recognized,O,O
by,O,O
antiserum,O,O
directed,O,O
against,O,O
E2A,B,O
gene,I,O
products,I,O
.,O,O
Pregnancy,O,O
-,O,O
induced,O,O
hypertension,O,O
(,O,O
PIH,O,O
),O,O
is,O,O
a,O,O
frequent,O,O
cause,O,O
of,O,O
maternal,O,O
and,O,O
neonatal,O,O
morbidity,O,O
and,O,O
mortality,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
we,O,O
focused,O,O
on,O,O
the,O,O
pathophysiology,O,O
of,O,O
PIH,O,O
",",O,O
mainly,O,O
on,O,O
the,O,O
role,O,O
of,O,O
mineralocorticoids,O,O
",",O,O
reversed,O,O
blood,O,O
pressure,O,O
patterns,O,O
",",O,O
and,O,O
the,O,O
resulting,O,O
necessity,O,O
of,O,O
continuous,O,O
monitoring,O,O
of,O,O
the,O,O
preeclamptic,O,O
mother,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
evaluated,O,O
the,O,O
mineralocorticoid,B,B
receptor,I,I
(,O,O
MR,B,O
),O,O
count,O,O
in,O,O
mononuclear,O,B
leukocytes,O,I
in,O,O
the,O,O
2,O,O
groups,O,O
.,O,O
Induction,O,O
by,O,O
hemin,O,O
increases,O,O
",",O,O
while,O,O
induction,O,O
with,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
TPA,O,O
),O,O
represses,O,O
",",O,O
erythroid,B,B
-,I,I
specific,I,I
gene,I,I
expression,O,O
in,O,O
the,O,O
human,O,B
cell,O,I
line,O,I
K562,O,I
.,O,O
Hemin,O,O
induction,O,O
appears,O,O
to,O,O
nonspecifically,O,O
increase,O,O
the,O,O
expression,O,O
of,O,O
transiently,O,O
transfected,O,O
genes,O,O
in,O,O
K562,O,O
cells,O,O
.,O,O
The,O,O
divergent,O,O
effects,O,O
of,O,O
hemin,O,B
and,O,O
TPA,O,O
on,O,O
gene,O,O
expression,O,O
in,O,O
K562,O,O
cells,O,O
are,O,O
mediated,O,O
",",O,O
in,O,O
part,O,O
",",O,O
by,O,O
their,O,O
contrasting,O,O
effects,O,O
on,O,O
the,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
E2,I,I
.,O,O
We,O,O
studied,O,O
the,O,O
effect,O,O
of,O,O
interleukin,B,B
-,I,I
4,I,I
(,O,O
IL,B,O
-,I,O
4,I,O
),O,O
on,O,O
the,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
induction,O,O
of,O,O
two,O,O
immediate,O,O
early,O,O
genes,O,O
c,B,O
-,I,O
fos,I,O
and,O,O
c,B,O
-,I,O
jun,I,O
.,O,O
The,O,O
inhibition,O,O
of,O,O
c,B,B
-,I,I
fos,I,I
and,O,O
c,O,B
-,O,I
jun,O,I
expression,O,O
by,O,O
IL,B,B
-,I,I
4,I,I
in,O,O
LPS,O,O
-,O,O
treated,O,O
cells,O,O
was,O,O
shown,O,O
to,O,O
be,O,O
due,O,O
to,O,O
a,O,O
lower,O,O
transcription,O,O
rate,O,O
of,O,O
the,O,O
c,B,B
-,I,I
fos,I,I
and,I,O
c,I,B
-,I,I
jun,I,I
genes,I,O
.,O,O
These,O,O
involve,O,O
activation,O,O
of,O,O
the,O,O
sodium,B,O
/,I,O
proton,I,O
exchanger,I,O
of,O,O
the,O,O
cell,O,O
membrane,O,O
at,O,O
very,O,O
low,O,O
",",O,O
physiological,O,O
concentrations,O,O
of,O,O
aldosterone,O,O
with,O,O
an,O,O
acute,O,O
onset,O,O
within,O,O
1,O,O
-,O,O
2,O,O
min,O,O
.,O,O
The,O,O
unique,O,O
characteristics,O,O
of,O,O
this,O,O
new,O,O
pathway,O,O
for,O,O
steroid,O,B
action,O,O
include,O,O
its,O,O
rapid,O,O
time,O,O
course,O,O
",",O,O
10,O,O
",",O,O
-,O,O
fold,O,O
selectivity,O,O
for,O,O
aldosterone,O,B
over,O,O
cortisol,O,B
and,O,O
the,O,O
ineffectiveness,O,O
of,O,O
spironolactones,O,O
",",O,O
classical,O,O
mineralocorticoid,O,O
antagonists,O,O
",",O,O
as,O,O
antagonists,O,O
of,O,O
the,O,O
response,O,O
.,O,O
Human,B,O
immunodeficiency,I,O
virus,I,O
type,I,O
1,I,O
Nef,I,B
protein,I,O
inhibits,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
induction,O,O
in,O,O
human,O,O
T,O,O
cells,O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
defective,O,O
recruitment,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
may,O,O
underlie,O,O
Nef,B,O
s,O,O
negative,O,O
transcriptional,O,O
effects,O,O
on,O,O
the,O,O
HIV,B,O
-,I,O
1,I,O
and,I,O
interleukin,I,O
2,I,O
promoters,I,O
.,O,O
The,O,O
expression,O,O
of,O,O
c,B,O
-,I,O
fos,I,O
",",I,O
c,I,O
-,I,O
jun,I,O
and,I,O
jun,I,O
B,I,O
proto,I,O
-,I,O
oncogenes,I,O
was,O,O
studied,O,O
in,O,O
phytohemagglutinin,O,O
(,O,O
PHA,O,O
),O,O
activated,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
(,O,O
PBL,O,O
),O,O
from,O,O
young,O,O
and,O,O
aged,O,O
humans,O,O
.,O,O
In,O,O
PHA,O,O
-,O,O
activated,O,O
PBL,O,O
",",O,O
no,O,O
age,O,O
-,O,O
related,O,O
differences,O,O
were,O,O
observed,O,O
in,O,O
c,O,O
-,O,O
fos,O,B
or,O,O
jun,O,B
B,O,I
mRNA,O,I
expression,O,O
.,O,O
Because,O,O
previous,O,O
work,O,O
has,O,O
demonstrated,O,O
that,O,O
T,O,O
cells,O,O
from,O,O
elderly,O,O
individuals,O,O
may,O,O
display,O,O
normal,O,O
proliferative,O,O
responses,O,O
when,O,O
activated,O,O
via,O,O
the,O,O
anti,B,O
-,I,O
CD2,I,O
pathway,O,O
",",O,O
c,O,O
-,O,O
jun,O,B
and,O,O
jun,O,B
B,O,I
mRNA,O,I
expression,O,O
was,O,O
also,O,O
studied,O,O
in,O,O
anti,O,O
-,O,O
CD2,O,O
-,O,O
activated,O,O
purified,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
CD19,B,B
protein,I,I
is,O,O
expressed,O,O
on,O,O
the,O,O
surface,O,O
of,O,O
all,O,O
B,O,B
-,O,I
lymphoid,O,I
cells,O,I
with,O,O
the,O,O
exception,O,O
of,O,O
terminally,O,O
differentiated,O,O
plasma,O,B
cells,O,I
and,O,O
has,O,O
been,O,O
implicated,O,O
as,O,O
a,O,O
signal,O,O
-,O,O
transducing,O,O
receptor,O,O
in,O,O
the,O,O
control,O,O
of,O,O
proliferation,O,O
and,O,O
differentiation,O,O
.,O,O
This,O,O
high,B,O
-,I,O
affinity,I,O
site,I,O
has,O,O
been,O,O
conserved,O,O
in,O,O
the,O,O
promoters,B,O
of,O,O
both,O,O
human,B,B
and,I,O
mouse,I,B
CD19,I,I
genes,I,I
and,O,O
was,O,O
furthermore,O,O
shown,O,O
to,O,O
confer,O,O
B,O,B
-,O,I
cell,O,I
specificity,O,I
to,O,O
a,O,O
beta,O,O
-,O,O
globin,O,O
reporter,O,O
gene,O,O
in,O,O
transient,O,O
transfection,O,O
experiments,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
BSAP,B,B
was,O,O
found,O,O
to,O,O
be,O,O
the,O,O
only,O,O
abundant,O,O
DNA,O,B
-,O,I
binding,O,I
activity,O,I
of,O,O
B,O,O
-,O,O
cell,O,O
nuclear,O,O
extracts,O,O
that,O,O
interacts,O,O
with,O,O
the,O,O
CD19,B,O
promoter,I,O
.,O,O
Compared,O,O
to,O,O
benign,O,O
tumor,O,O
or,O,O
mammary,O,B
reduction,O,I
test,O,I
material,O,I
the,O,O
eicosanoid,O,O
profile,O,O
of,O,O
tissue,O,O
obtained,O,O
from,O,O
malignant,O,O
mammary,O,B
tumors,O,I
showed,O,O
important,O,O
differences,O,O
.,O,O
The,O,O
implications,O,O
",",O,O
in,O,O
particular,O,O
",",O,O
in,O,O
relation,O,O
to,O,O
future,O,O
prognosis,O,O
of,O,O
the,O,O
patient,O,O
",",O,O
remain,O,O
obscure,O,O
.,O,O
To,O,O
examine,O,O
the,O,O
role,O,O
of,O,O
mineralocorticoids,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
pregnancy,O,O
-,O,O
induced,O,O
hypertension,O,O
(,O,O
PIH,O,O
),O,O
",",O,O
we,O,O
studied,O,O
plasma,O,O
aldosterone,O,B
and,O,O
18,O,B
-,O,I
hydroxycorticosteron,O,I
levels,O,O
in,O,O
25,O,O
women,O,O
with,O,O
PIH,O,O
and,O,O
25,O,O
normal,O,O
pregnant,O,O
women,O,O
",",O,O
as,O,O
controls,O,O
.,O,O
Plasma,O,O
18,O,O
-,O,O
hydroxycorticosteron,O,O
was,O,O
also,O,O
significantly,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
lower,O,O
(,O,O
PIH,O,O
",",O,O
1071,O,O
+,O,O
/,O,O
-,O,O
149,O,O
pmol,O,O
/,O,O
L,O,O
;,O,O
controls,O,O
",",O,O
1907,O,O
+,O,O
/,O,O
-,O,O
318,O,O
pmol,O,O
/,O,O
L,O,O
.,O,O
Small,O,O
apolar,O,O
substitutions,O,O
(,O,O
11,O,O
alpha,O,O
-,O,O
methyl,O,O
",",O,O
11,O,O
alpha,O,O
-,O,O
fluoromethyl,O,O
),O,O
did,O,O
not,O,O
markedly,O,O
decrease,O,O
the,O,O
affinity,O,O
for,O,O
the,O,O
vitamin,B,B
D,I,I
receptor,I,I
",",O,O
but,O,O
larger,O,O
(,O,O
11,O,O
alpha,O,O
-,O,O
chloromethyl,O,O
or,O,O
11,O,O
alpha,O,O
-,O,O
or,O,O
11,O,O
beta,O,O
-,O,O
phenyl,O,O
),O,O
or,O,O
more,O,O
polar,O,O
substitutions,O,O
(,O,O
11,O,O
alpha,O,O
-,O,O
hydroxymethyl,O,O
",",O,O
11,O,O
alpha,O,O
-,O,O
(,O,O
2,O,O
-,O,O
hydroxyethyl,O,O
],O,O
decreased,O,O
the,O,O
affinity,O,O
to,O,O
less,O,O
than,O,O
5,O,O
%,O,O
of,O,O
that,O,O
of,O,O
1,O,O
alpha,O,O
",",O,O
25,O,O
-,O,O
OH,O,O
),O,O
2D3,O,O
.,O,O
The,O,O
11,O,O
beta,O,O
-,O,O
methyl,O,O
analog,O,O
had,O,O
a,O,O
greater,O,O
than,O,O
10,O,O
-,O,O
fold,O,O
lower,O,O
activity,O,O
.,O,O
In,O,O
the,O,O
present,O,O
paper,O,O
",",O,O
the,O,O
binding,O,O
of,O,O
a,O,O
[,O,O
125I,O,O
],O,O
labeled,O,O
aldosterone,O,B
derivative,O,I
to,O,O
plasma,O,B
membrane,O,I
rich,O,I
fractions,O,I
of,O,O
HML,O,O
was,O,O
studied,O,O
.,O,O
This,O,O
variation,O,O
was,O,O
the,O,O
result,O,O
of,O,O
a,O,O
duplication,O,O
of,O,O
a,O,O
short,B,O
DNA,I,B
sequence,I,I
(,O,O
CTG,B,B
-,I,I
motif,I,I
),O,O
.,O,O
No,O,O
positive,O,O
effect,O,O
of,O,O
the,O,O
duplicated,O,O
CTG,B,B
-,I,I
motif,I,I
could,O,O
be,O,O
detected,O,O
.,O,O
Based,O,O
on,O,O
these,O,O
results,O,O
we,O,O
estimate,O,O
a,O,O
5,O,O
-,O,O
10,O,O
%,O,O
difference,O,O
in,O,O
virus,O,O
production,O,O
of,O,O
the,O,O
LTR,B,O
variants,I,O
when,O,O
compared,O,O
to,O,O
that,O,O
of,O,O
wild,O,O
-,O,O
type,O,O
.,O,O
The,O,O
helix,B,B
-,I,I
loop,I,I
-,I,I
helix,I,I
(,I,O
HLH,I,O
),I,O
proteins,I,O
are,O,O
a,O,O
family,O,O
of,O,O
transcription,B,O
factors,I,O
that,O,O
include,O,O
proteins,O,O
critical,O,O
to,O,O
differentiation,O,O
and,O,O
development,O,O
in,O,O
species,O,O
ranging,O,O
from,O,O
plants,O,O
to,O,O
mammals,O,O
.,O,O
Glucocorticoid,B,B
receptor,I,I
in,O,O
patients,O,O
with,O,O
lupus,O,B
nephritis,O,I
:,O,O
relationship,O,O
between,O,O
receptor,O,O
levels,O,O
in,O,O
mononuclear,O,B
leukocytes,O,I
and,O,O
effect,O,O
of,O,O
glucocorticoid,O,B
therapy,O,I
.,O,O
We,O,O
investigated,O,O
the,O,O
clinical,O,O
significance,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
determination,O,O
in,O,O
20,O,O
patients,O,O
with,O,O
systemic,O,O
lupus,O,B
erythematosus,O,I
(,O,I
SLE,O,I
),O,I
who,O,O
afterwards,O,O
developed,O,O
nephrotic,O,B
syndrome,O,I
.,O,O
Improvement,O,O
in,O,O
urinary,O,O
protein,O,B
excretion,O,I
and,O,O
in,O,O
disease,O,O
activity,O,O
",",O,O
which,O,O
was,O,O
scored,O,O
according,O,O
to,O,O
the,O,O
SLE,O,O
Disease,O,O
Activity,O,O
Index,O,O
system,O,O
of,O,O
the,O,O
University,O,O
of,O,O
Toronto,O,O
",",O,O
closely,O,O
related,O,O
to,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
concentrations,O,O
in,O,O
MNL,O,O
isolated,O,O
from,O,O
the,O,O
corresponding,O,O
patients,O,O
.,O,O
Possible,O,O
relationship,O,O
between,O,O
the,O,O
changes,O,O
in,O,O
IL,B,B
-,I,I
1,I,I
and,O,O
GR,B,B
in,O,O
aged,O,O
long,O,O
-,O,O
distance,O,O
runner,O,O
and,O,O
its,O,O
physiological,O,O
significance,O,O
are,O,O
discussed,O,O
.,O,O
Mineralocorticoid,O,B
effector,O,I
mechanism,O,I
in,O,O
preeclampsia,O,O
.,O,O
MR,B,B
were,O,O
reduced,O,O
before,O,O
delivery,O,O
(,O,O
96,O,O
+,O,O
/,O,O
-,O,O
27,O,O
receptors,O,O
/,O,O
cell,O,O
),O,O
",",O,O
and,O,O
SPD,O,B
increased,O,O
(,O,O
64,O,O
+,O,O
/,O,O
-,O,O
8,O,O
mV,O,O
),O,O
",",O,O
with,O,O
both,O,O
parameters,O,O
normalizing,O,O
after,O,O
delivery,O,O
(,O,O
MR,B,B
",",O,O
242,O,O
+,O,O
/,O,O
-,O,O
79,O,O
;,O,O
SPD,O,B
",",O,O
14,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
4,O,O
mV,O,O
),O,O
.,O,O
Aldosterone,O,B
levels,O,O
returned,O,O
to,O,O
normal,O,O
nonpregnant,O,O
values,O,O
after,O,O
delivery,O,O
.,O,O
Kinetics,O,O
of,O,O
nuclear,O,O
translocation,O,O
and,O,O
turnover,O,O
of,O,O
the,O,O
vitamin,B,B
D,I,I
receptor,I,I
in,O,O
human,O,O
HL60,O,B
leukemia,O,I
cells,O,I
and,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
-,O,O
-,O,O
coincident,O,O
rise,O,O
of,O,O
DNA,O,B
-,O,I
relaxing,O,I
activity,O,I
in,O,O
nuclear,O,O
extracts,O,O
.,O,O
HL60,O,B
cells,O,I
",",O,O
expressing,O,O
some,O,O
characteristics,O,O
of,O,O
promyelocytes,O,O
",",O,O
can,O,O
be,O,O
induced,O,O
to,O,O
monocytoid,O,O
differentiation,O,O
by,O,O
calcitriol,O,O
.,O,O
Pulse,O,O
exposure,O,O
of,O,O
HL60,O,O
to,O,O
radiolabeled,O,O
hormone,O,B
for,O,O
3,O,O
h,O,O
followed,O,O
by,O,O
culture,O,O
in,O,O
medium,O,O
without,O,O
serum,O,O
and,O,O
calcitriol,O,B
lead,O,O
to,O,O
nuclear,O,O
retention,O,O
of,O,O
approximately,O,O
1600,B,O
radiolabeled,I,O
VDR,I,B
by,O,O
8,O,O
h,O,O
and,O,O
approximately,O,O
1000,O,O
VDR,B,B
by,O,O
24,O,O
h,O,O
.,O,O
No,O,O
specific,O,O
translocation,O,O
into,O,O
the,O,O
nuclear,O,O
compartment,O,O
was,O,O
seen,O,O
when,O,O
isolated,O,O
nuclei,O,O
were,O,O
incubated,O,O
in,O,O
[,O,O
3H,O,O
],O,O
calcitriol,O,B
.,O,O
Radiolabeled,B,O
hormone,I,B
/,I,I
receptor,I,I
complexes,I,O
of,O,O
nuclei,O,O
isolated,O,O
from,O,O
cells,O,O
exposed,O,O
for,O,O
3,O,O
h,O,O
to,O,O
radiolabeled,O,O
hormone,O,B
-,O,I
-,O,I
in,O,O
contrast,O,O
to,O,O
identical,O,O
experiments,O,O
with,O,O
intact,O,O
cells,O,O
-,O,O
-,O,O
did,O,O
not,O,O
disappear,O,O
from,O,O
the,O,O
nuclear,O,O
compartment,O,O
upon,O,O
incubation,O,O
of,O,O
nuclei,O,O
with,O,O
identical,O,O
concentrations,O,O
of,O,O
the,O,O
unlabeled,O,O
compound,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
a,O,O
specific,O,O
nuclear,O,O
translocation,O,O
mechanism,O,O
exists,O,O
for,O,O
calcitriol,O,O
in,O,O
both,O,O
cell,O,O
types,O,O
examined,O,O
",",O,O
most,O,O
likely,O,O
due,O,O
to,O,O
translocation,O,O
of,O,O
receptor,B,O
proteins,I,O
after,O,O
hormone,O,O
binding,O,O
.,O,O
Enhanced,O,O
activity,O,O
of,O,O
topoisomerases,B,O
in,O,O
nuclear,O,O
extracts,O,O
upon,O,O
translocation,O,O
of,O,O
VDR,B,O
might,O,O
reflect,O,O
interaction,O,O
of,O,O
both,O,O
within,O,O
the,O,O
nuclear,O,O
compartment,O,O
",",O,O
thus,O,O
initiating,O,O
DNA,O,B
-,O,I
unwinding,O,I
",",O,O
a,O,O
prerequisite,O,O
of,O,O
transcription,O,O
initiation,O,O
.,O,O
Estrogen,O,B
receptor,O,I
positive,O,I
(,O,O
ER,O,B
+,O,I
:,O,O
MCF,O,B
-,O,I
7,O,I
),O,O
and,O,O
negative,O,O
(,O,O
ER,O,B
-,O,I
:,O,O
MDA,O,B
-,O,I
MB,O,I
-,O,I
231,O,I
),O,O
human,O,O
breast,O,O
cancer,O,O
cell,O,O
lines,O,O
were,O,O
utilized,O,O
to,O,O
evaluate,O,O
the,O,O
effects,O,O
of,O,O
tamoxifen,O,O
(,O,O
TAM,O,O
),O,O
and,O,O
estradiol,O,O
(,O,O
E2,O,O
),O,O
on,O,O
modulation,O,O
of,O,O
breast,O,O
cancer,O,O
target,O,O
susceptibility,O,O
to,O,O
lysis,O,O
by,O,O
lymphokine,O,O
-,O,O
activated,O,O
killer,O,O
(,O,O
LAK,O,O
),O,O
cells,O,O
.,O,O
E2,O,B
-,O,I
stimulated,O,O
ER,O,B
+,O,I
cells,O,O
were,O,O
more,O,O
susceptible,O,O
to,O,O
lysis,O,O
by,O,O
LAK,O,O
cells,O,O
than,O,O
corresponding,O,O
TAM,O,O
-,O,O
treated,O,O
or,O,O
control,O,O
cells,O,O
",",O,O
while,O,O
treatment,O,O
of,O,O
ER,O,B
-,O,I
cells,O,O
with,O,O
either,O,O
E2,O,B
or,O,O
TAM,O,O
alone,O,O
did,O,O
not,O,O
alter,O,O
from,O,O
control,O,O
their,O,O
susceptibility,O,O
to,O,O
this,O,O
immune,O,O
-,O,O
mediated,O,O
lysis,O,O
.,O,O
Regulation,O,O
of,O,O
replicative,O,O
functions,O,O
in,O,O
the,O,O
Epstein,B,O
-,I,O
Barr,I,O
virus,I,O
(,I,O
EBV,I,O
),I,O
genome,I,O
is,O,O
mediated,O,O
through,O,O
activation,O,O
of,O,O
a,O,O
virally,B,O
encoded,I,O
transcription,I,O
factor,I,O
",",O,O
Z,B,O
(,O,O
BZLF1,B,O
),O,O
.,O,O
The,O,O
long,B,O
terminal,I,O
repeat,I,O
(,I,O
LTR,I,O
),I,O
region,I,O
of,O,O
HIV,B,B
proviral,I,I
DNA,I,I
contains,O,O
binding,O,O
sites,O,O
for,O,O
nuclear,B,B
factor,I,I
kappa,I,I
B,I,I
(,O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
),O,O
",",O,O
and,O,O
this,O,O
transcriptional,B,O
activator,I,O
appears,O,O
to,O,O
regulate,O,O
HIV,O,B
activation,O,O
.,O,O
The,O,O
inhibitory,O,O
action,O,O
of,O,O
alpha,O,O
-,O,O
lipoic,O,O
acid,O,O
was,O,O
found,O,O
to,O,O
be,O,O
very,O,O
potent,O,O
as,O,O
only,O,O
4,O,O
mM,O,O
was,O,O
needed,O,O
for,O,O
a,O,O
complete,O,O
inhibition,O,O
",",O,O
whereas,O,O
20,O,O
mM,O,O
was,O,O
required,O,O
for,O,O
N,O,O
-,O,O
acetylcysteine,O,O
.,O,O
REV,B,O
LTRs,I,O
work,O,O
efficiently,O,O
in,O,O
human,O,B
lymphoid,O,I
cells,O,O
",",O,O
and,O,O
are,O,O
viable,O,O
alternatives,O,O
to,O,O
promoters,B,O
commonly,O,O
used,O,O
for,O,O
expression,O,O
of,O,O
cloned,B,O
genes,I,O
.,O,O
Human,O,B
immunodeficiency,O,I
virus,O,I
type,O,I
1,O,I
(,O,O
HIV,O,B
-,O,I
1,O,I
),O,O
and,O,O
HIV,O,B
-,O,I
2,O,I
are,O,O
structurally,O,O
related,O,O
retroviruses,O,O
which,O,O
both,O,O
cause,O,O
AIDS,O,O
in,O,O
humans,O,O
.,O,O
Although,O,O
both,O,O
viruses,O,O
establish,O,O
latency,O,O
in,O,O
quiescent,O,O
human,O,B
-,O,I
peripheral,O,I
-,O,I
blood,O,I
T,O,I
cells,O,O
",",O,O
the,O,O
asymptomatic,O,O
phase,O,O
of,O,O
HIV,O,B
-,O,I
2,O,I
infection,O,O
may,O,O
be,O,O
more,O,O
prolonged,O,O
than,O,O
that,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
The,O,O
latent,O,O
phases,O,O
of,O,O
both,O,O
HIV,O,B
-,O,I
1,O,I
and,O,O
HIV,O,B
-,O,I
2,O,I
infection,O,O
have,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
disrupted,O,O
by,O,O
T,O,B
-,O,I
cell,O,I
activation,O,O
",",O,O
a,O,O
process,O,O
that,O,O
requires,O,O
host,O,O
cell,O,O
transcription,O,O
factors,O,O
.,O,O
Thus,O,O
",",O,O
Elf,B,O
-,I,O
1,I,O
is,O,O
a,O,O
novel,B,O
transcription,I,O
factor,I,O
that,O,O
appears,O,O
to,O,O
be,O,O
required,O,O
for,O,O
the,O,O
T,O,B
-,O,I
cell,O,I
-,O,I
receptor,O,I
-,O,I
mediated,O,I
trans,O,I
activation,O,O
of,O,O
HIV,O,B
-,O,I
2,O,I
gene,O,O
expression,O,O
.,O,O
These,O,O
results,O,O
may,O,O
explain,O,O
differences,O,O
in,O,O
the,O,O
clinical,O,O
spectra,O,O
of,O,O
diseases,O,O
caused,O,O
by,O,O
HIV,O,O
-,O,O
1,O,O
and,O,O
HIV,O,O
-,O,O
2,O,O
and,O,O
may,O,O
also,O,O
have,O,O
implications,O,O
for,O,O
the,O,O
design,O,O
of,O,O
therapeutic,O,O
approaches,O,O
to,O,O
HIV,O,O
-,O,O
2,O,O
infection,O,O
.,O,O
Okadaic,O,O
acid,O,O
is,O,O
a,O,O
potent,O,O
inducer,O,O
of,O,O
AP,B,O
-,I,O
1,I,O
",",O,O
NF,B,O
-,I,O
kappa,I,O
B,I,O
",",O,O
and,O,O
tumor,B,O
necrosis,I,O
factor,I,O
-,I,O
alpha,I,O
in,O,O
human,O,O
B,O,O
lymphocytes,O,O
.,O,O
Treatment,O,O
of,O,O
human,O,O
B,O,B
lymphocytes,O,I
with,O,O
an,O,O
optimal,O,O
concentration,O,O
of,O,O
okadaic,O,O
acid,O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
phosphatases,B,O
1,I,O
and,I,O
2A,I,O
",",O,O
resulted,O,O
in,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
",",O,O
AP,B,B
-,I,I
1,I,I
and,O,O
a,O,O
marked,O,O
increase,O,O
in,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
levels,O,O
.,O,O
Although,O,O
okadaic,O,O
acid,O,O
provides,O,O
a,O,O
potent,O,O
inductive,O,O
signal,O,O
for,O,O
AP,B,B
-,I,I
1,I,I
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
it,O,O
did,O,O
not,O,O
induce,O,O
either,O,O
B,O,B
cell,O,I
proliferation,O,I
or,O,O
immunoglobulin,B,O
secretion,O,O
.,O,O
c,B,O
-,I,O
myc,I,B
mRNA,I,I
expression,O,O
in,O,O
minor,O,O
salivary,O,O
glands,O,O
of,O,O
patients,O,O
with,O,O
Sjogren,O,O
s,O,O
syndrome,O,O
.,O,O
IL,B,B
-,I,I
4,I,I
secreted,O,O
by,O,O
activated,O,O
T,O,O
cells,O,O
is,O,O
a,O,O
pleiotropic,B,O
cytokine,I,O
affecting,O,O
growth,O,O
and,O,O
differentiation,O,O
of,O,O
diverse,O,O
cell,O,O
types,O,O
such,O,O
as,O,O
T,O,O
cells,O,O
",",O,O
B,O,O
cells,O,O
",",O,O
and,O,O
mast,O,B
cells,O,I
.,O,O
A,O,O
novel,B,O
T,I,O
cell,I,O
-,I,O
specific,I,O
negative,I,O
regulatory,I,O
element,I,O
(,O,O
NRE,B,O
),O,O
composed,O,O
of,O,O
two,O,O
protein,O,B
-,O,I
binding,O,I
sites,O,I
were,O,O
mapped,O,O
in,O,O
the,O,O
5,O,O
flanking,O,O
region,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
4,I,I
gene,I,O
:,O,O
-,O,O
311CTCCCTTCT,O,O
-,O,O
303,O,O
(,O,O
NRE,B,O
-,I,O
I,I,O
),O,O
and,O,O
-,O,O
288CTTTTTGCTT,O,O
-,O,O
TGC,O,O
-,O,O
300,O,O
(,O,O
NRE,B,O
-,I,O
II,I,O
),O,O
.,O,O
A,O,O
T,B,O
cell,I,O
-,I,O
specific,I,O
protein,I,B
Neg,B,I
-,I,I
1,I,I
and,O,O
a,O,O
ubiquitous,B,O
protein,I,B
Neg,B,I
-,I,I
2,I,I
binding,O,O
to,O,O
NRE,B,O
-,I,O
I,I,O
and,O,O
NRE,B,O
-,I,O
II,I,O
",",O,O
respectively,O,O
",",O,O
were,O,O
identified,O,O
.,O,O
The,O,O
addition,O,O
of,O,O
antisense,O,B
oligonucleotides,O,I
to,O,O
c,B,O
-,I,O
fos,I,O
significantly,O,O
inhibited,O,O
IL,B,O
6,I,O
-,O,O
induced,O,O
IgM,B,O
production,O,O
by,O,O
SKW,O,O
6,O,O
.,O,O
cells,O,O
(,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
",",O,O
whereas,O,O
control,O,O
oligonucleotides,O,O
had,O,O
no,O,O
inhibitory,O,O
effect,O,O
.,O,O
In,O,O
this,O,O
article,O,O
",",O,O
transcriptional,O,O
regulation,O,O
of,O,O
the,O,O
archetypal,B,O
T,I,B
-,I,I
cell,I,I
-,I,I
specific,I,I
gene,I,I
",",O,O
alpha,B,O
TCR,I,B
",",O,O
is,O,O
discussed,O,O
.,O,O
Sodium,O,O
dodecyl,O,O
sulfate,O,O
-,O,O
polyacrylamide,O,O
gel,O,O
electrophoresis,O,O
showed,O,O
significant,O,O
aldosterone,O,B
binding,O,O
at,O,O
a,O,O
molecular,O,O
weight,O,O
of,O,O
approximately,O,O
50000,O,O
Dalton,O,O
which,O,O
was,O,O
absent,O,O
with,O,O
1,O,O
microM,O,O
cold,O,O
aldosterone,O,O
",",O,O
but,O,O
not,O,O
cortisol,O,B
in,O,O
the,O,O
binding,O,O
media,O,O
.,O,O
We,O,O
used,O,O
phenolic,O,O
",",O,O
lipid,O,O
-,O,O
soluble,O,O
",",O,O
chain,O,O
-,O,O
breaking,O,O
antioxidants,O,O
(,O,O
butylated,O,O
hydroxyanisole,O,O
(,O,O
BHA,O,O
),O,O
",",O,O
nordihydroquairetic,O,O
acid,O,O
",",O,O
or,O,O
alpha,O,O
-,O,O
tocopherol,O,O
(,O,O
vitamin,O,O
E,O,O
),O,O
to,O,O
show,O,O
that,O,O
peroxyl,O,O
radical,O,O
scavenging,O,O
in,O,O
unstimulated,O,O
and,O,O
PMA,O,O
-,O,O
or,O,O
TNF,O,O
-,O,O
stimulated,O,O
cells,O,O
blocks,O,O
the,O,O
functions,O,O
depending,O,O
on,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
.,O,O
Rather,O,O
",",O,O
TNF,B,B
and,O,O
PMA,B,O
can,O,O
exert,O,O
their,O,O
effect,O,O
only,O,O
if,O,O
cells,O,O
are,O,O
in,O,O
an,O,O
appropriate,O,O
redox,O,O
status,O,O
",",O,O
because,O,O
prior,O,O
modification,O,O
toward,O,O
reduction,O,O
with,O,O
BHA,O,O
treatment,O,O
prevents,O,O
this,O,O
activation,O,O
.,O,O
Selection,O,O
of,O,O
optimal,O,O
kappa,O,O
B,O,O
/,O,O
Rel,O,O
DNA,O,B
-,O,I
binding,O,I
motifs,O,I
:,O,O
interaction,O,O
of,O,O
both,O,O
subunits,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
with,O,O
DNA,O,B
is,O,O
required,O,O
for,O,O
transcriptional,O,O
activation,O,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
p50,B,B
and,O,O
p65,B,B
subunits,I,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
transcription,I,O
factor,I,O
complex,I,O
has,O,O
revealed,O,O
that,O,O
both,O,O
proteins,O,O
can,O,O
interact,O,O
with,O,O
related,O,O
DNA,O,B
sequences,O,O
through,O,O
either,O,O
homo,O,O
-,O,O
or,O,O
heterodimer,O,O
formation,O,O
.,O,O
However,O,O
",",O,O
these,O,O
studies,O,O
have,O,O
used,O,O
a,O,O
limited,O,O
number,O,O
of,O,O
known,O,O
kappa,O,O
B,O,O
DNA,O,B
motifs,O,O
",",O,O
and,O,O
the,O,O
question,O,O
of,O,O
the,O,O
optimal,O,O
DNA,O,B
sequences,O,O
preferred,O,O
by,O,O
each,O,O
homodimer,O,O
has,O,O
not,O,O
been,O,O
addressed,O,O
.,O,O
Using,O,O
purified,O,O
recombinant,O,O
p50,B,B
",",O,O
p65,B,B
",",O,O
and,O,O
c,B,B
-,I,I
Rel,I,I
proteins,I,I
",",O,O
optimal,O,O
DNA,O,B
-,O,I
binding,O,I
motifs,O,I
were,O,O
selected,O,O
from,O,O
a,O,O
pool,O,O
of,O,O
random,O,O
oligonucleotides,O,O
.,O,O
Differential,O,O
binding,O,O
affinities,O,O
were,O,O
also,O,O
obtained,O,O
with,O,O
p50,B,B
-,I,I
and,I,O
c,I,B
-,I,I
Rel,I,I
-,I,I
selected,I,I
sequences,I,I
.,O,O
These,O,O
findings,O,O
demonstrate,O,O
that,O,O
interaction,O,O
of,O,O
both,O,O
subunits,O,O
of,O,O
the,O,O
heterodimeric,B,O
NF,I,O
-,I,O
kappa,I,O
B,I,O
complex,I,O
with,O,O
DNA,O,B
is,O,O
required,O,O
for,O,O
DNA,O,B
binding,O,I
and,O,O
transcriptional,O,O
activation,O,O
and,O,O
suggest,O,O
that,O,O
transcriptional,O,O
activation,O,O
mediated,O,O
by,O,O
the,O,O
individual,O,O
rel,B,O
-,I,O
related,I,O
proteins,I,O
will,O,O
differ,O,O
dramatically,O,O
",",O,O
depending,O,O
on,O,O
the,O,O
specific,O,O
kappa,O,O
B,O,O
motifs,O,O
present,O,O
.,O,O
These,O,O
observations,O,O
indicate,O,O
that,O,O
during,O,O
chronic,O,O
HIV,O,O
infection,O,O
of,O,O
U937,O,O
cells,O,O
",",O,O
continuous,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
(,O,O
p50,B,O
/,I,O
p65,I,O
),O,O
translocation,O,O
results,O,O
in,O,O
p105,O,O
promoter,O,O
upregulation,O,O
with,O,O
subsequent,O,O
cytosolic,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
accumulation,O,O
",",O,O
ready,O,O
for,O,O
further,O,O
translocation,O,O
.,O,O
Similarly,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
activates,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
the,O,O
human,O,O
monocytic,O,O
cell,O,O
line,O,O
U,O,O
937,O,O
",",O,O
but,O,O
not,O,O
in,O,O
resting,O,O
human,O,O
T,O,O
-,O,O
cells,O,O
.,O,O
Blockade,O,O
of,O,O
the,O,O
DNA,B,B
-,I,I
binding,I,I
complexes,I,I
with,O,O
an,O,O
anti,B,O
-,I,O
Fos,I,B
mAb,I,O
demonstrated,O,O
a,O,O
direct,O,O
participation,O,O
of,O,O
c,B,O
-,I,O
Fos,I,O
in,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
complexes,I,I
induced,O,O
by,O,O
anti,B,O
-,I,O
AIM,I,O
mAb,I,O
.,O,O
These,O,O
data,O,O
provide,O,O
the,O,O
evidence,O,O
that,O,O
activation,O,O
of,O,O
human,O,O
peripheral,O,O
blood,O,O
T,O,O
cells,O,O
through,O,O
the,O,O
AIM,O,O
activation,O,O
pathway,O,O
regulate,O,O
the,O,O
activity,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
.,O,O
Gangliosides,O,B
suppress,O,O
tumor,B,O
necrosis,I,O
factor,I,O
production,O,O
in,O,O
human,O,O
monocytes,O,O
.,O,O
Both,O,O
normal,O,O
and,O,O
malignant,O,O
cells,O,O
contain,O,O
gangliosides,O,O
as,O,O
important,O,O
cell,O,O
membrane,O,O
constituents,O,O
that,O,O
",",O,O
after,O,O
being,O,O
shed,O,O
",",O,O
may,O,O
influence,O,O
cells,O,O
of,O,O
the,O,O
immune,O,O
system,O,O
.,O,O
Although,O,O
under,O,O
standard,O,O
culture,O,O
conditions,O,O
",",O,O
bovine,O,O
brain,O,O
gangliosides,O,O
(,O,O
100,O,O
micrograms,O,O
/,O,O
ml,O,O
),O,O
suppressed,O,O
LPS,O,O
-,O,O
stimulated,O,O
TNF,B,B
production,O,O
5,O,O
-,O,O
fold,O,O
in,O,O
PBMC,O,O
and,O,O
10,O,O
-,O,O
fold,O,O
in,O,O
Mono,O,O
Mac,O,O
6,O,O
cells,O,O
",",O,O
suppression,O,O
was,O,O
more,O,O
efficient,O,O
under,O,O
serum,O,O
-,O,O
free,O,O
conditions,O,O
.,O,O
The,O,O
suppressive,O,O
activity,O,O
was,O,O
lost,O,O
in,O,O
molecules,O,O
",",O,O
lacking,O,O
the,O,O
sugar,O,O
moiety,O,O
or,O,O
the,O,O
lipid,O,O
moiety,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
phorbol,O,O
ester,O,O
-,O,O
induced,O,O
production,O,O
of,O,O
O2,O,B
-,O,I
was,O,O
similar,O,O
in,O,O
cells,O,O
treated,O,O
with,O,O
and,O,O
without,O,O
gangliosides,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
our,O,O
data,O,O
demonstrate,O,O
that,O,O
TNF,B,B
gene,O,I
expression,O,O
in,O,O
monocytes,O,O
induced,O,O
by,O,O
different,O,O
types,O,O
of,O,O
stimuli,O,O
can,O,O
be,O,O
blocked,O,O
by,O,O
gangliosides,O,O
at,O,O
an,O,O
early,O,O
step,O,O
of,O,O
signal,O,O
transduction,O,O
.,O,O
Immunoglobulin,B,B
molecules,I,I
on,O,O
the,O,O
surface,O,O
of,O,O
a,O,O
B,O,B
lymphocyte,O,I
are,O,O
the,O,O
endogenous,O,O
`,O,O
receptors,O,O
to,O,O
which,O,O
specific,O,O
antigens,O,O
bind,O,O
.,O,O
Because,O,O
of,O,O
the,O,O
efficient,O,O
binding,O,O
of,O,O
TG,B,O
by,O,O
surrogate,B,O
receptors,I,O
on,O,O
non,O,O
-,O,O
T,O,O
cells,O,O
",",O,O
we,O,O
assessed,O,O
the,O,O
ability,O,O
of,O,O
such,O,O
cells,O,O
to,O,O
present,O,O
TG,B,O
to,O,O
T,O,O
cells,O,O
.,O,O
Proliferation,O,O
in,O,O
response,O,O
to,O,O
TG,B,O
was,O,O
observed,O,O
in,O,O
T,O,O
cells,O,O
from,O,O
only,O,O
1,O,O
of,O,O
5,O,O
Hashimoto,O,O
patients,O,O
.,O,O
The,O,O
transcriptional,O,O
activity,O,O
of,O,O
the,O,O
heterodimer,O,O
is,O,O
regulated,O,O
by,O,O
signal,O,O
-,O,O
dependent,O,O
phosphorylation,O,O
and,O,O
dephosphorylation,O,O
events,O,O
.,O,O
A,O,O
PMA,B,O
responsive,I,O
element,I,O
was,O,O
localized,O,O
to,O,O
a,O,O
region,O,O
between,O,O
-,B,O
95,I,O
and,I,O
-,I,O
36,I,O
bp,I,O
relative,O,O
to,O,O
the,O,O
transcription,B,O
start,I,O
site,I,O
.,O,O
Within,O,O
this,O,O
region,O,O
",",O,O
single,O,O
AP,B,O
-,I,O
2,I,O
-,I,O
and,I,O
AP,I,O
-,I,O
1,I,O
-,I,O
like,I,O
consensus,I,O
sequences,I,O
were,O,O
noted,O,O
.,O,O
While,O,O
all,O,O
the,O,O
M10,O,B
-,O,I
expressing,O,I
cell,O,O
lines,O,O
remained,O,O
infectable,O,O
by,O,O
HIV,O,B
-,O,I
1,O,I
",",O,O
these,O,O
same,O,O
cells,O,O
failed,O,O
to,O,O
support,O,O
a,O,O
productive,O,O
replication,O,O
cycle,O,O
when,O,O
infected,O,O
with,O,O
a,O,O
cloned,O,O
isolate,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
Expression,O,O
of,O,O
M10,B,B
did,O,O
not,O,O
affect,O,O
induction,O,O
of,O,O
HIV,O,B
transcription,O,O
mediated,O,O
by,O,O
the,O,O
kappa,B,O
B,I,O
regulatory,I,O
element,I,O
or,O,O
Tat,B,O
.,O,O
The,O,O
inhibition,O,O
of,O,O
HIV,O,B
infection,O,O
in,O,O
cells,O,O
stably,O,O
expressing,O,O
a,O,O
transdominant,B,O
Rev,I,B
protein,I,I
",",O,O
in,O,O
the,O,O
absence,O,O
of,O,O
any,O,O
deleterious,O,O
effect,O,O
on,O,O
T,O,O
cell,O,O
function,O,O
",",O,O
suggests,O,O
that,O,O
such,O,O
a,O,O
strategy,O,O
could,O,O
provide,O,O
a,O,O
therapeutic,O,O
effect,O,O
in,O,O
the,O,O
T,O,O
lymphocytes,O,O
of,O,O
acquired,O,O
immunodeficiency,O,O
syndrome,O,O
patients,O,O
.,O,O
The,O,O
present,O,O
work,O,O
has,O,O
examined,O,O
the,O,O
effects,O,O
of,O,O
okadaic,O,O
acid,O,O
",",O,O
an,O,O
inhibitor,O,O
of,O,O
type,B,O
1,I,O
and,I,O
2A,I,O
protein,I,B
phosphatases,I,I
",",O,O
on,O,O
the,O,O
regulation,O,O
of,O,O
c,B,O
-,I,O
jun,I,O
expression,O,O
during,O,O
monocytic,O,O
differentiation,O,O
of,O,O
U,O,O
-,O,O
937,O,O
leukemia,O,O
cells,O,O
.,O,O
Mitogen,O,O
stimulation,O,O
of,O,O
T,O,O
-,O,O
cells,O,O
increases,O,O
c,B,B
-,I,I
Fos,I,I
and,O,O
c,B,B
-,I,I
Jun,I,I
protein,O,O
levels,O,O
",",O,O
AP,O,O
-,O,O
1,O,O
binding,O,O
and,O,O
AP,O,O
-,O,O
1,O,O
transcriptional,O,O
activity,O,O
.,O,O
Both,O,O
c,B,B
-,I,I
Fos,I,I
and,O,O
c,B,B
-,I,I
Jun,I,I
protein,O,O
levels,O,O
were,O,O
increased,O,O
after,O,O
Con,O,O
A,O,O
and,O,O
PHA,O,O
stimulation,O,O
.,O,O
The,O,O
kinetics,O,O
of,O,O
expression,O,O
of,O,O
the,O,O
two,O,O
genes,O,O
were,O,O
also,O,O
slightly,O,O
different,O,O
",",O,O
with,O,O
c,B,B
-,I,I
fos,I,I
mRNA,I,O
reaching,O,O
a,O,O
peak,O,O
at,O,O
15,O,O
min,O,O
after,O,O
stimulation,O,O
and,O,O
c,B,B
-,I,I
jun,I,I
at,O,O
30,O,O
min,O,O
.,O,O
Nuclear,O,O
transcription,O,O
studies,O,O
in,O,O
vitro,O,O
showed,O,O
that,O,O
LTB4,O,O
increased,O,O
the,O,O
transcription,O,O
of,O,O
the,O,O
c,B,B
-,I,I
fos,I,I
gene,I,I
7,O,O
-,O,O
fold,O,O
and,O,O
the,O,O
c,B,B
-,I,I
jun,I,I
gene,I,I
1,O,O
.,O,O
Modulation,O,O
of,O,O
normal,O,O
erythroid,O,O
differentiation,O,O
by,O,O
the,O,O
endogenous,O,O
thyroid,O,B
hormone,O,I
and,O,O
retinoic,B,B
acid,I,I
receptors,I,I
:,O,O
a,O,O
possible,O,O
target,O,O
for,O,O
v,B,O
-,I,O
erbA,I,O
oncogene,I,O
action,O,O
.,O,O
Thyroid,O,B
hormone,O,I
(,O,O
T3,O,B
),O,O
alone,O,O
caused,O,O
similar,O,O
but,O,O
weaker,O,O
effects,O,O
.,O,O
Two,O,O
types,O,O
of,O,O
helper,O,O
T,O,O
cell,O,O
(,O,O
Th,O,O
),O,O
clones,O,O
(,O,O
Th1,O,O
and,O,O
Th2,O,O
),O,O
are,O,O
defined,O,O
on,O,O
the,O,O
basis,O,O
of,O,O
different,O,O
patterns,O,O
of,O,O
cytokine,B,O
(,O,O
lymphokine,B,O
),O,O
secretion,O,O
.,O,O
Yet,O,O
phorbol,O,O
ester,O,O
alone,O,O
or,O,O
calcium,O,O
ionophore,O,O
alone,O,O
produce,O,O
several,O,O
lymphokines,B,O
.,O,O
GM2,B,O
defines,O,O
a,O,O
binding,B,O
site,I,O
for,O,O
protein,O,B
(,O,O
s,O,O
),O,O
whose,O,O
binding,O,O
is,O,O
inducible,O,O
by,O,O
PMA,O,O
.,O,O
Mutations,O,O
in,O,O
the,O,O
Pit,B,B
-,I,I
1,I,I
gene,I,O
in,O,O
children,O,O
with,O,O
combined,O,O
pituitary,O,B
hormone,O,I
deficiency,O,I
.,O,O
Pit,B,B
-,I,I
1,I,I
is,O,O
a,O,O
pituitary,B,B
-,I,I
specific,I,I
transcription,I,I
factor,I,I
that,O,O
binds,O,O
to,O,O
and,O,O
transactivates,O,O
promoters,B,O
of,O,O
growth,B,B
hormone,I,I
and,I,O
prolactin,I,B
genes,I,I
.,O,O
Activation,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
and,O,O
elevation,O,O
of,O,O
cAMP,O,B
interact,O,O
synergistically,O,O
to,O,O
raise,O,O
c,B,B
-,I,I
Fos,I,I
and,O,O
AP,B,B
-,I,I
1,I,I
activity,O,O
in,O,O
Jurkat,O,B
cells,O,I
.,O,O
We,O,O
have,O,O
earlier,O,O
found,O,O
that,O,O
in,O,O
Jurkat,O,O
cells,O,O
activation,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
(,O,O
PKC,B,O
),O,O
enhances,O,O
the,O,O
cyclic,O,O
adenosine,O,B
monophosphate,O,I
(,O,O
cAMP,O,O
),O,O
accumulation,O,O
induced,O,O
by,O,O
adenosine,O,B
receptor,O,I
stimulation,O,O
or,O,O
activation,O,O
of,O,O
Gs,B,O
.,O,O
The,O,O
former,O,O
two,O,O
substances,O,O
interact,O,O
with,O,O
T,O,O
cells,O,O
via,O,O
the,O,O
glucocorticoid,B,B
and,I,O
beta,I,B
-,I,I
adrenergic,I,I
receptors,I,I
respectively,O,O
.,O,O
When,O,O
occupied,O,O
by,O,O
their,O,O
natural,O,O
ligands,O,O
",",O,O
glucocorticosteroids,O,B
and,O,O
catecholamines,O,B
",",O,O
these,O,O
receptors,O,O
have,O,O
a,O,O
role,O,O
in,O,O
modulating,O,O
T,O,B
-,O,I
cell,O,I
function,O,O
during,O,O
stress,O,O
.,O,O
3,O,O
.,O,O
Synergistic,O,O
suppression,O,O
of,O,O
T,O,B
-,O,I
cell,O,I
proliferation,O,O
was,O,O
observed,O,O
when,O,O
various,O,O
concentrations,O,O
of,O,O
DEX,O,B
and,O,O
PGE2,O,B
",",O,O
but,O,O
not,O,O
DEX,O,B
and,O,O
ISO,O,B
",",O,O
were,O,O
added,O,O
to,O,O
cultures,O,O
.,O,O
In,O,O
vivo,O,O
footprint,O,O
analysis,O,O
of,O,O
the,O,O
HLA,B,B
-,I,I
DRA,I,I
gene,I,I
promoter,I,I
:,O,O
cell,O,O
-,O,O
specific,O,O
interaction,O,O
at,O,O
the,O,O
octamer,B,O
site,I,O
and,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
X,O,B
box,O,I
binding,O,I
by,O,O
interferon,B,O
gamma,I,O
.,O,O
Danazol,O,O
bound,O,O
to,O,O
these,O,O
sites,O,O
in,O,O
high,O,O
concentration,O,O
(,O,O
10,O,O
(,O,O
-,O,O
6,O,O
),O,O
M,O,O
",",O,O
clinical,O,O
serum,O,O
concentration,O,O
during,O,O
danazol,O,O
therapy,O,O
),O,O
and,O,O
decreased,O,O
the,O,O
number,O,O
of,O,O
both,O,O
sites,O,O
.,O,O
Therefore,O,O
",",O,O
we,O,O
describe,O,O
a,O,O
microtitre,O,O
assay,O,O
system,O,O
for,O,O
glucocorticoid,B,B
receptors,I,I
which,O,O
is,O,O
a,O,O
whole,O,O
-,O,O
cell,O,O
competitive,O,O
binding,O,O
radioassay,O,O
using,O,O
[,O,O
3H,O,B
],O,O
-,O,O
dexamethasone,O,O
as,O,O
radioligand,O,O
.,O,O
Thus,O,O
enabled,O,O
to,O,O
perform,O,O
the,O,O
test,O,O
on,O,O
multiple,O,O
blood,O,B
samples,O,I
in,O,O
parallel,O,O
",",O,O
we,O,O
investigated,O,O
cardiac,O,B
infarction,O,I
patients,O,I
over,O,O
a,O,O
12,O,O
-,O,O
day,O,O
period,O,O
to,O,O
test,O,O
if,O,O
glucocorticoid,B,B
receptor,I,I
binding,O,I
is,O,O
altered,O,O
in,O,O
this,O,O
stressful,O,O
disease,O,O
.,O,O
On,O,O
the,O,O
first,O,O
day,O,O
of,O,O
the,O,O
disease,O,O
",",O,O
glucocorticoid,B,B
receptor,I,I
capacity,O,O
was,O,O
significantly,O,O
decreased,O,O
without,O,O
alteration,O,O
of,O,O
the,O,O
receptor,O,O
-,O,O
ligand,O,O
affinity,O,O
",",O,O
whereas,O,O
on,O,O
days,O,O
4,O,O
and,O,O
12,O,O
the,O,O
number,O,O
of,O,O
receptor,O,O
sites,O,O
was,O,O
normal,O,O
again,O,O
.,O,O
CsA,O,O
was,O,O
found,O,O
not,O,O
to,O,O
inhibit,O,O
lck,B,B
gene,O,I
expression,O,O
",",O,O
nor,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
lck,B,B
gene,I,I
product,O,O
.,O,O
The,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
contains,O,O
binding,B,O
sites,I,O
for,O,O
nuclear,B,O
factors,I,O
including,O,O
NFAT,B,B
-,I,I
1,I,I
",",O,O
Oct,B,B
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
and,O,O
AP,B,B
-,I,I
1,I,I
",",O,O
which,O,O
are,O,O
all,O,O
potentially,O,O
sensitive,O,O
to,O,O
activation,O,O
of,O,O
PKC,B,O
.,O,O
Our,O,O
results,O,O
indicate,O,O
that,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
site,I,O
at,O,O
-,B,O
150,I,O
bp,I,O
represents,O,O
a,O,O
major,O,O
",",O,O
if,O,O
not,O,O
the,O,O
only,O,O
",",O,O
site,O,O
of,O,O
PKC,B,O
responsiveness,O,O
in,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,O
.,O,O
Mice,O,O
transgenic,O,O
for,O,O
the,O,O
human,B,B
T,I,I
cell,I,I
leukemia,I,I
virus,I,I
(,I,O
HTLV,I,B
-,I,I
I,I,I
),I,O
Tax,I,O
gene,I,O
develop,O,O
fibroblastic,O,B
tumors,O,I
that,O,O
express,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,I,O
inducible,I,O
early,I,O
genes,I,O
.,O,O
Mice,O,O
treated,O,O
with,O,O
antisense,O,O
to,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
ODNs,O,I
showed,O,O
rapid,O,O
regression,O,O
of,O,O
transplanted,O,O
fibrosarcomas,O,O
.,O,O
Binding,O,O
of,O,O
125I,O,O
-,O,O
labeled,O,O
aldosterone,O,O
to,O,O
plasma,O,O
membranes,O,O
of,O,O
HML,O,O
shares,O,O
important,O,O
features,O,O
with,O,O
these,O,O
functional,O,O
data,O,O
.,O,O
Leukotriene,O,B
B4,O,I
transcriptionally,O,O
activates,O,O
interleukin,B,B
-,I,I
6,I,I
expression,O,O
involving,O,O
NK,B,O
-,I,O
chi,I,O
B,I,O
and,O,O
NF,B,B
-,I,I
IL6,I,I
.,O,O
It,O,O
is,O,O
",",O,O
however,O,O
",",O,O
still,O,O
unclear,O,O
whether,O,O
LTB4,O,O
acts,O,O
in,O,O
this,O,O
regard,O,O
directly,O,O
or,O,O
indirectly,O,O
by,O,O
stimulating,O,O
the,O,O
release,O,O
of,O,O
chemotactic,O,O
and,O,O
inflammatory,B,O
cytokines,I,O
.,O,O
We,O,O
furthermore,O,O
demonstrate,O,O
that,O,O
this,O,O
process,O,O
involves,O,O
activation,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
NF,B,B
-,I,I
chi,I,I
B,I,I
and,O,O
",",O,O
to,O,O
a,O,O
lesser,O,O
extent,O,O
",",O,O
of,O,O
NF,B,B
-,I,I
IL6,I,I
",",O,O
while,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
AP,B,O
-,I,O
1,I,O
",",O,O
shown,O,O
to,O,O
otherwise,O,O
confer,O,O
IL,B,O
-,I,O
6,I,O
inducibility,O,O
",",O,O
appeared,O,O
to,O,O
be,O,O
unaffected,O,O
by,O,O
LTB4,O,O
.,O,O
The,O,O
signaling,O,O
events,O,O
mediating,O,O
this,O,O
effect,O,O
appeared,O,O
to,O,O
involve,O,O
the,O,O
release,O,O
of,O,O
H2O2,O,B
",",O,O
since,O,O
LTB4,O,O
failed,O,O
to,O,O
induce,O,O
NF,B,O
-,I,O
chi,I,O
B,I,O
or,O,O
NF,B,O
-,I,O
IL6,I,O
in,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
scavenger,O,O
of,O,O
H2O2,O,O
",",O,O
N,O,O
-,O,O
acetyl,O,O
-,O,O
L,O,O
-,O,O
cysteine,O,O
.,O,O
The,O,O
insertion,O,O
was,O,O
not,O,O
required,O,O
for,O,O
Fc,B,O
gamma,I,O
RII,I,O
to,O,O
modulate,O,O
surface,B,O
immunoglobulin,I,O
-,O,O
triggered,O,O
B,O,O
-,O,O
cell,O,O
activation,O,O
.,O,O
Age,O,O
-,O,O
related,O,O
changes,O,O
in,O,O
glucocorticoid,B,B
and,I,O
mineralocorticoid,I,B
receptors,I,I
in,O,O
lymphocytes,O,B
of,O,O
healthy,O,O
persons,O,O
and,O,O
patients,O,O
with,O,O
hypertension,O,O
],O,O
Still,O,O
a,O,O
more,O,O
essential,O,O
rise,O,O
in,O,O
the,O,O
number,O,O
of,O,O
receptors,O,O
is,O,O
observed,O,O
in,O,O
mid,O,O
-,O,O
age,O,O
hypertensive,O,O
patients,O,O
than,O,O
in,O,O
elderly,O,O
ones,O,O
.,O,O
Here,O,O
",",O,O
Stuart,O,O
Schreiber,O,O
and,O,O
Gerald,O,O
Crabtree,O,O
review,O,O
recent,O,O
findings,O,O
that,O,O
indicate,O,O
CsA,O,O
and,O,O
FK506,O,O
operate,O,O
as,O,O
prodrugs,O,O
:,O,O
they,O,O
bind,O,O
endogenous,B,O
intracellular,I,O
receptors,I,O
",",O,O
the,O,O
immunophilins,B,O
",",O,O
and,O,O
the,O,O
resulting,O,O
complex,O,O
targets,O,O
the,O,O
protein,B,B
phosphatase,I,I
",",I,O
calcineurin,B,I
",",O,O
to,O,O
exert,O,O
the,O,O
immunosuppressive,O,O
effect,O,O
.,O,O
PLB,O,O
-,O,O
985,O,O
cells,O,O
represent,O,O
a,O,O
bipotential,O,O
myelomonoblastic,O,O
cell,O,O
population,O,O
capable,O,O
of,O,O
either,O,O
granulocytic,O,O
or,O,O
monocytic,O,O
differentiation,O,O
after,O,O
induction,O,O
with,O,O
appropriate,O,O
inducers,O,O
.,O,O
Mutations,O,O
affecting,O,O
the,O,O
5,B,O
guanine,I,O
residues,I,O
of,O,O
the,O,O
kappa,B,B
site,I,O
were,O,O
unable,O,O
to,O,O
compete,O,O
for,O,O
these,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,I,I
related,I,I
proteins,I,I
.,O,O
Inducibility,O,O
of,O,O
endogenous,O,O
IFN,B,B
-,I,I
beta,I,I
and,I,O
IFN,I,B
-,I,I
alpha,I,I
RNA,I,O
was,O,O
also,O,O
increased,O,O
in,O,O
PLB,O,O
-,O,O
IIIB,O,O
cells,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
we,O,O
report,O,O
on,O,O
6,O,O
patients,O,O
(,O,O
2,O,O
males,O,O
and,O,O
4,O,O
females,O,O
),O,O
with,O,O
the,O,O
syndrome,O,O
.,O,O
First,O,O
is,O,O
an,O,O
expansion,O,O
phase,O,O
prior,O,O
to,O,O
TCR,B,O
rearrangement,O,O
",",O,O
which,O,O
appears,O,O
to,O,O
be,O,O
correlated,O,O
with,O,O
programming,O,O
of,O,O
at,O,O
least,O,O
some,O,O
response,O,O
genes,O,O
for,O,O
inducibility,O,O
.,O,O
However,O,O
",",O,O
the,O,O
profound,O,O
T,O,O
cell,O,O
deficit,O,O
of,O,O
nude,O,O
mice,O,O
indicates,O,O
that,O,O
the,O,O
thymus,O,O
is,O,O
by,O,O
far,O,O
the,O,O
most,O,O
potent,O,O
site,O,O
for,O,O
inducing,O,O
the,O,O
expansion,O,O
per,O,O
se,O,O
",",O,O
even,O,O
if,O,O
other,O,O
sites,O,O
can,O,O
induce,O,O
some,O,O
response,O,O
acquisition,O,O
.,O,O
Second,O,O
is,O,O
a,O,O
controlled,O,O
phase,O,O
of,O,O
TCR,B,B
gene,I,I
rearrangement,O,I
.,O,O
It,O,O
seems,O,O
that,O,O
the,O,O
rearrangement,O,O
of,O,O
the,O,O
TCR,B,B
gamma,I,I
loci,I,I
in,O,O
the,O,O
gamma,O,B
delta,O,I
lineage,O,I
may,O,O
not,O,O
always,O,O
take,O,O
place,O,O
at,O,O
a,O,O
developmental,O,O
stage,O,O
strictly,O,O
equivalent,O,O
to,O,O
the,O,O
rearrangement,O,O
of,O,O
TCR,B,B
beta,I,I
in,O,O
the,O,O
alpha,O,B
beta,O,I
lineage,O,I
",",O,O
and,O,O
it,O,O
is,O,O
not,O,O
clear,O,O
just,O,O
how,O,O
early,O,O
the,O,O
two,O,O
lineages,O,O
diverge,O,O
.,O,O
The,O,O
genes,O,O
that,O,O
need,O,O
to,O,O
be,O,O
induced,O,O
for,O,O
this,O,O
response,O,O
are,O,O
not,O,O
yet,O,O
identified,O,O
",",O,O
but,O,O
it,O,O
is,O,O
unquestionably,O,O
a,O,O
form,O,O
of,O,O
activation,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
p50,I,I
alone,O,O
fails,O,O
to,O,O
stimulate,O,O
kappa,O,O
B,O,O
-,O,O
directed,O,O
transcription,O,O
",",O,O
and,O,O
based,O,O
on,O,O
prior,O,O
in,O,O
vitro,O,O
studies,O,O
",",O,O
is,O,O
not,O,O
directly,O,O
regulated,O,O
by,O,O
I,B,B
kappa,I,I
B,I,I
.,O,O
Together,O,O
",",O,O
these,O,O
findings,O,O
suggest,O,O
that,O,O
the,O,O
nuclear,O,O
localization,O,O
signal,O,O
and,O,O
transactivation,B,O
domain,I,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
p65,I,I
constitute,O,O
a,O,O
bipartite,O,O
system,O,O
that,O,O
is,O,O
critically,O,O
involved,O,O
in,O,O
the,O,O
inhibitory,O,O
function,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
/,I,I
MAD,I,I
-,I,I
3,I,I
.,O,O
This,O,O
interaction,O,O
is,O,O
functional,O,O
as,O,O
it,O,O
leads,O,O
to,O,O
retargeting,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
p50,I,I
from,O,O
the,O,O
nucleus,O,O
to,O,O
the,O,O
cytoplasm,O,O
.,O,O
However,O,O
",",O,O
no,O,O
loss,O,O
of,O,O
DNA,O,B
binding,O,I
activity,O,I
is,O,O
observed,O,O
",",O,O
presumably,O,O
reflecting,O,O
the,O,O
unique,O,O
C,B,O
-,I,O
terminal,I,O
domain,I,O
that,O,O
is,O,O
distinct,O,O
from,O,O
that,O,O
present,O,O
in,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
p65,I,I
.,O,O
We,O,O
have,O,O
biochemically,O,O
and,O,O
functionally,O,O
characterized,O,O
a,O,O
new,O,O
transcription,B,O
factor,I,O
",",O,O
NP,B,B
-,I,I
TCII,I,I
",",O,O
which,O,O
is,O,O
present,O,O
in,O,O
nuclei,O,O
from,O,O
unstimulated,O,O
T,O,B
and,O,O
B,O,B
lymphocytes,O,I
but,O,O
is,O,O
not,O,O
found,O,O
in,O,O
nonhematopoietic,O,O
cells,O,O
.,O,O
Mechanism,O,O
of,O,O
action,O,O
of,O,O
steroid,O,B
hormones,O,I
.,O,O
I,O,O
.,O,O
Estrogens,O,O
],O,O
The,O,O
steroid,O,B
hormone,O,I
are,O,O
very,O,O
versatile,O,O
molecules,O,O
:,O,O
although,O,O
they,O,O
are,O,O
related,O,O
among,O,O
them,O,O
by,O,O
their,O,O
chemical,O,O
structure,O,O
",",O,O
they,O,O
have,O,O
very,O,O
diverse,O,O
functions,O,O
and,O,O
including,O,O
antagonic,O,O
.,O,O
Their,O,O
action,O,O
mechanism,O,O
is,O,O
not,O,O
completely,O,O
cleared,O,O
.,O,O
Chloramphenicol,B,O
acetyl,I,O
transferase,I,O
(,O,O
CAT,B,O
),O,O
assays,O,O
using,O,O
the,O,O
HIV,B,O
-,I,O
1,I,O
(,I,O
-,I,O
139,I,O
),I,O
long,I,O
terminal,I,O
repeat,I,O
-,I,O
CAT,I,O
construct,I,O
showed,O,O
no,O,O
PMA,O,O
induction,O,O
of,O,O
CAT,B,O
activity,O,O
in,O,O
these,O,O
subclones,O,O
(,O,O
unlike,O,O
the,O,O
parental,O,O
line,O,O
and,O,O
other,O,O
subclones,O,O
),O,O
.,O,O
Although,O,O
NF,B,B
-,I,I
AT,I,I
has,O,O
not,O,O
been,O,O
cloned,O,O
or,O,O
purified,O,O
",",O,O
there,O,O
is,O,O
evidence,O,O
that,O,O
it,O,O
is,O,O
a,O,O
major,O,O
target,O,O
for,O,O
immunosuppression,O,O
by,O,O
cyclosporin,O,O
A,O,O
(,O,O
CsA,O,O
),O,O
and,O,O
FK506,O,O
(,O,O
refs,O,O
2,O,O
-,O,O
7,O,O
),O,O
.,O,O
Although,O,O
it,O,O
has,O,O
been,O,O
previously,O,O
shown,O,O
that,O,O
the,O,O
IL,B,B
-,I,I
6,I,I
kappa,I,I
B,I,I
motif,I,O
functions,O,O
as,O,O
a,O,O
potent,O,O
IL,B,O
-,I,O
1,I,O
/,I,O
tumor,I,O
necrosis,I,O
factor,I,O
-,I,O
responsive,I,O
element,I,O
in,O,O
nonlymphoid,O,O
cells,O,O
",",O,O
its,O,O
activity,O,O
was,O,O
found,O,O
to,O,O
be,O,O
repressed,O,O
in,O,O
lymphoid,O,O
cells,O,O
such,O,O
as,O,O
a,O,O
Jurkat,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
.,O,O
Cortisol,O,B
resistance,O,O
in,O,O
acquired,O,O
immunodeficiency,O,O
syndrome,O,O
.,O,O
An,O,O
acquired,O,O
form,O,O
of,O,O
peripheral,O,O
resistance,O,O
to,O,O
glucocorticoids,O,B
was,O,O
suspected,O,O
.,O,O
[,O,O
3H,O,O
],O,O
Thymidine,O,O
incorporation,O,O
was,O,O
decreased,O,O
dose,O,O
-,O,O
dependently,O,O
by,O,O
dexamethasone,O,O
in,O,O
controls,O,O
and,O,O
patients,O,O
;,O,O
the,O,O
effect,O,O
was,O,O
significantly,O,O
blunted,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
in,O,O
group,O,O
1,O,O
patients,O,O
",",O,O
which,O,O
suggests,O,O
that,O,O
activation,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
is,O,O
impaired,O,O
as,O,O
a,O,O
result,O,O
of,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
abnormality,O,O
.,O,O
After,O,O
the,O,O
DNA,B,B
fragment,I,I
containing,O,O
the,O,O
CAG,B,O
repeats,I,O
is,O,O
amplified,O,O
by,O,O
the,O,O
polymerase,O,O
chain,O,O
reaction,O,O
",",O,O
a,O,O
primer,O,O
extension,O,O
is,O,O
carried,O,O
out,O,O
;,O,O
the,O,O
extension,O,O
of,O,O
the,O,O
end,B,O
-,I,O
labelled,I,O
reverse,I,O
primer,I,O
adjacent,O,O
to,O,O
3,B,O
end,I,O
of,O,O
CAG,B,O
repeats,I,O
stops,O,O
at,O,O
the,O,O
first,O,O
T,O,B
after,O,O
CAG,B,O
repeats,I,O
with,O,O
the,O,O
incorporation,O,O
of,O,O
dideoxy,O,O
ATP,O,O
in,O,O
the,O,O
reaction,O,O
mixture,O,O
.,O,O
Cells,O,O
of,O,O
monocyte,O,B
lineage,O,I
serve,O,O
as,O,O
effector,O,O
cells,O,O
in,O,O
the,O,O
cellular,O,B
immune,O,I
response,O,I
.,O,O
The,O,O
response,O,O
to,O,O
antigen,O,O
proceeds,O,O
at,O,O
the,O,O
T,O,B
helper,O,I
cell,O,I
level,O,I
through,O,O
two,O,O
independent,O,O
forms,O,O
of,O,O
cellular,O,B
collaboration,O,I
",",O,O
contact,O,O
and,O,O
lymphokine,B,O
.,O,O
It,O,O
is,O,O
evident,O,O
that,O,O
assembly,O,O
of,O,O
the,O,O
surface,B,O
domain,I,O
of,O,O
TF,B,B
with,O,O
VIIa,B,B
to,O,O
form,O,O
the,O,O
binary,O,O
TF,B,B
.,I,O
VIIa,I,B
complex,I,I
induces,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
the,O,O
Kcat,O,O
of,O,O
the,O,O
catalytic,B,O
domain,I,O
of,O,O
VIIa,B,B
for,O,O
small,O,O
peptidyl,O,O
substrates,O,O
and,O,O
more,O,O
profoundly,O,O
for,O,O
protein,B,B
substrate,I,O
.,O,O
It,O,O
is,O,O
also,O,O
evident,O,O
that,O,O
association,O,O
of,O,O
X,B,O
with,O,O
charged,O,O
phospholipid,O,O
surfaces,O,O
enhances,O,O
the,O,O
proteolytic,O,O
activation,O,O
of,O,O
this,O,O
zymogen,B,O
by,O,O
increasing,O,O
recognition,O,O
and,O,O
susceptibility,O,O
of,O,O
the,O,O
sessile,O,O
peptide,O,O
bond,O,O
deduced,O,O
from,O,O
the,O,O
markedly,O,O
decreased,O,O
Km,O,O
and,O,O
increased,O,O
Kcat,O,O
.,O,O
NF,B,B
kappa,I,I
B,I,I
is,O,O
a,O,O
potent,O,O
mediator,O,O
of,O,O
specific,O,O
gene,O,O
expression,O,O
in,O,O
human,O,B
monocytes,O,I
and,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
play,O,O
a,O,O
role,O,O
in,O,O
transcription,O,O
of,O,O
the,O,O
HIV,O,B
-,O,I
1,O,I
genome,O,I
in,O,O
promonocytic,O,B
leukemias,O,I
.,O,O
There,O,O
is,O,O
little,O,O
information,O,O
available,O,O
on,O,O
the,O,O
response,O,O
of,O,O
NF,B,B
kappa,I,I
B,I,I
to,O,O
cytokines,B,O
in,O,O
normal,O,O
human,O,B
monocytes,O,I
.,O,O
In,O,O
THP,O,B
-,O,I
1,O,I
cells,O,I
",",O,O
TPA,O,O
also,O,O
induced,O,O
a,O,O
new,O,O
",",O,O
faster,B,O
-,I,O
migrating,I,O
NF,I,B
kappa,I,I
B,I,I
species,I,I
not,O,O
induced,O,O
in,O,O
monocytes,O,I
.,O,O
The,O,O
endothelium,O,B
plays,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
inflammation,O,O
by,O,O
directing,O,O
circulating,O,O
leukocytes,O,B
into,O,O
extravascular,O,O
tissues,O,O
by,O,O
expressing,O,O
adhesive,B,O
molecules,I,O
for,O,O
leukocytes,O,B
[,O,O
e,O,O
.,O,O
g,O,O
.,O,O
",",O,O
endothelial,B,B
-,I,I
leukocyte,I,I
adhesion,I,I
molecule,I,I
1,I,I
(,O,I
ELAM,B,I
-,I,I
1,I,I
),O,I
and,O,O
intercellular,B,B
adhesion,I,I
molecule,I,I
1,I,I
(,O,I
ICAM,B,I
-,I,I
1,I,I
),O,I
],O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
sodium,O,O
salicylate,O,O
(,O,O
1,O,O
mM,O,O
),O,O
inhibited,O,O
neither,O,O
adhesion,O,O
nor,O,O
expression,O,O
of,O,O
these,O,O
adhesion,B,O
molecules,I,O
.,O,O
These,O,O
studies,O,O
suggest,O,O
that,O,O
antagonism,O,O
by,O,O
dexamethasone,O,B
of,O,O
endotoxin,B,O
-,O,O
induced,O,O
inflammation,O,O
is,O,O
a,O,O
specific,O,O
instance,O,O
of,O,O
the,O,O
general,O,O
biological,O,O
principle,O,O
that,O,O
the,O,O
glucocorticoid,B,B
receptor,I,I
is,O,O
a,O,O
hormone,O,O
-,O,O
dependent,O,O
regulator,O,O
of,O,O
transcription,O,O
.,O,O
Biochemical,O,O
purification,O,O
and,O,O
cDNA,O,B
cloning,O,O
has,O,O
now,O,O
revealed,O,O
that,O,O
BSAP,B,O
belongs,O,O
to,O,O
the,O,O
family,O,O
of,O,O
paired,B,O
domain,I,O
proteins,I,O
.,O,O
BSAP,B,B
is,O,O
encoded,O,O
by,O,O
the,O,O
Pax,B,O
-,I,O
5,I,O
gene,I,O
and,O,O
has,O,O
been,O,O
highly,O,O
conserved,O,O
between,O,O
human,O,O
and,O,O
mouse,O,O
.,O,O
Later,O,O
",",O,O
the,O,O
expression,O,O
of,O,O
the,O,O
BSAP,B,B
gene,I,O
shifts,O,O
to,O,O
the,O,O
fetal,O,O
liver,O,O
where,O,O
it,O,O
correlates,O,O
with,O,O
the,O,O
onset,O,O
of,O,O
B,O,B
lymphopoiesis,O,I
.,O,O
Specific,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
subunits,I,O
act,O,O
in,O,O
concert,O,O
with,O,O
Tat,B,O
to,O,O
stimulate,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
type,O,O
1,O,O
transcription,O,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
a,O,O
protein,B,O
complex,I,O
which,O,O
functions,O,O
in,O,O
concert,O,O
with,O,O
the,O,O
tat,B,O
-,I,O
I,I,O
gene,I,O
product,I,O
to,O,O
stimulate,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
(,O,O
HIV,O,B
),O,O
transcription,O,O
.,O,O
We,O,O
have,O,O
found,O,O
that,O,O
the,O,O
p49,B,B
(,I,O
100,I,O
),I,O
DNA,I,B
binding,I,I
subunit,I,I
",",O,O
together,O,O
with,O,O
p65,B,O
",",O,O
can,O,O
act,O,O
in,O,O
concert,O,O
with,O,O
Tat,B,O
-,I,O
I,I,O
to,O,O
stimulate,O,O
the,O,O
expression,O,O
of,O,O
HIV,B,O
-,I,O
CAT,I,O
plasmid,I,O
.,O,O
Little,O,O
effect,O,O
was,O,O
observed,O,O
with,O,O
50,B,O
-,I,O
kDa,I,O
forms,I,O
of,O,O
p105,B,B
NF,B,I
-,I,I
kappa,I,I
B,I,I
or,O,O
rel,B,O
",",O,O
in,O,O
combination,O,O
with,O,O
p65,B,O
or,O,O
full,B,O
-,I,O
length,I,O
c,I,O
-,I,O
rel,I,O
",",O,O
which,O,O
do,O,O
not,O,O
stimulate,O,O
the,O,O
HIV,B,O
enhancer,I,O
in,O,O
these,O,O
cells,O,O
.,O,O
Stable,O,O
expression,O,O
of,O,O
HB24,B,O
",",O,O
a,O,O
diverged,B,O
human,I,O
homeobox,I,O
gene,I,O
",",O,O
in,O,O
T,O,O
lymphocytes,O,O
induces,O,O
genes,O,O
involved,O,O
in,O,O
T,O,O
cell,O,O
activation,O,O
and,O,O
growth,O,O
.,O,O
In,O,O
the,O,O
studies,O,O
described,O,O
in,O,O
this,O,O
report,O,O
",",O,O
we,O,O
have,O,O
identified,O,O
two,O,O
potential,O,O
Ets,B,B
binding,I,I
sites,I,I
",",O,O
EBS1,O,B
and,O,O
EBS2,B,B
",",O,O
which,O,O
are,O,O
conserved,O,O
in,O,O
both,O,O
the,O,O
human,B,B
and,I,O
murine,I,B
interleukin,I,I
-,I,I
2,I,I
enhancers,I,I
.,O,O
Possible,O,O
mechanisms,O,O
by,O,O
which,O,O
these,O,O
proteins,O,O
may,O,O
regulate,O,O
transcription,O,O
of,O,O
the,O,O
epsilon,B,B
-,I,I
globin,I,I
-,I,I
encoding,I,I
gene,I,I
in,O,O
erythroid,O,B
and,O,O
non,O,B
-,O,I
erythroid,O,I
cells,O,I
are,O,O
discussed,O,O
.,O,O
A,O,O
MEDLINE,O,O
search,O,O
of,O,O
the,O,O
English,O,O
-,O,O
language,O,O
literature,O,O
was,O,O
conducted,O,O
using,O,O
the,O,O
indexing,O,O
terms,O,O
immunology,O,O
",",O,O
calcitriol,O,B
and,O,O
vitamin,O,O
D,O,O
to,O,O
identify,O,O
studies,O,O
indicating,O,O
a,O,O
role,O,O
for,O,O
calcitriol,O,B
as,O,O
a,O,O
primary,O,O
immunomodulator,O,O
.,O,O
This,O,O
protein,O,O
is,O,O
distinct,O,O
from,O,O
other,O,O
members,O,O
of,O,O
the,O,O
steroid,B,B
/,I,I
thyroid,I,I
hormone,I,I
receptor,I,I
family,I,O
including,O,O
the,O,O
COUP,B,O
protein,I,O
which,O,O
has,O,O
a,O,O
closely,O,O
related,O,O
DNA,O,B
binding,O,I
specificity,O,I
.,O,O
A,O,O
Tat,B,B
-,I,I
responsive,I,I
element,I,I
is,O,O
found,O,O
upstream,O,O
within,O,O
the,O,O
viral,B,O
promoter,I,O
that,O,O
in,O,O
glial,O,B
-,O,I
derived,O,I
cell,O,I
lines,O,I
allows,O,O
transactivation,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
TAR,B,B
.,O,O
Further,O,O
",",O,O
we,O,O
observe,O,O
that,O,O
TAR,B,B
-,I,I
deleted,I,I
mutants,I,I
of,O,O
HIV,O,O
-,O,O
1,O,O
demonstrate,O,O
normal,O,O
late,O,O
gene,O,O
expression,O,O
in,O,O
glial,O,B
cells,O,I
as,O,O
evidenced,O,O
by,O,O
syncytia,O,O
formation,O,O
and,O,O
production,O,O
of,O,O
viral,B,O
p24,I,B
antigen,I,I
.,O,O
At,O,O
least,O,O
two,O,O
21,B,B
bp,I,I
repeats,I,I
were,O,O
required,O,O
for,O,O
high,O,O
levels,O,O
of,O,O
AP,B,O
-,I,O
2,I,O
activation,O,O
and,O,O
mutagenesis,O,O
of,O,O
the,O,O
AP,B,O
-,I,O
2,I,O
consensus,I,O
binding,I,O
sequences,I,O
in,O,O
the,O,O
21,B,B
bp,I,I
repeats,I,I
eliminate,O,O
this,O,O
activation,O,O
.,O,O
Activation,O,O
of,O,O
the,O,O
human,B,O
immunodeficiency,I,O
virus,I,O
type,I,O
1,I,O
enhancer,I,O
is,O,O
not,O,O
dependent,O,O
on,O,O
NFAT,B,O
-,I,O
1,I,O
.,O,O
Activation,O,O
by,O,O
the,O,O
T,B,O
-,I,O
cell,I,O
antigen,I,O
receptor,I,O
is,O,O
minimal,O,O
in,O,O
Jurkat,O,O
cells,O,O
and,O,O
is,O,O
mediated,O,O
by,O,O
the,O,O
kappa,B,O
B,I,O
sites,I,O
.,O,O
The,O,O
promoter,O,O
of,O,O
the,O,O
major,B,O
histocompatibility,I,O
class,I,O
II,I,O
gene,I,O
DRA,B,B
contains,O,O
an,O,O
octamer,B,O
element,I,O
(,O,O
ATTTGCAT,O,O
),O,O
that,O,O
is,O,O
required,O,O
for,O,O
efficient,O,O
DRA,B,B
expression,O,O
in,O,O
B,O,O
cells,O,O
.,O,O
In,O,O
vitro,O,O
transcription,O,O
analysis,O,O
using,O,O
protein,O,B
fractions,O,I
enriched,O,O
for,O,O
the,O,O
octamer,O,O
-,O,O
binding,O,O
protein,O,B
OTF,B,I
-,I,I
2,I,I
demonstrate,O,O
a,O,O
positive,O,O
functional,O,O
role,O,O
for,O,O
OTF,B,B
-,I,I
2,I,I
in,O,O
DRA,B,B
gene,I,I
transcription,O,O
.,O,O
Recombinant,B,O
OTF,I,B
-,I,I
2,I,I
protein,I,I
produced,O,O
by,O,O
in,O,O
vitro,O,O
transcription,O,O
/,O,O
translation,O,O
could,O,O
also,O,O
enhance,O,O
DRA,B,O
gene,I,O
transcription,O,O
in,O,O
vitro,O,O
.,O,O
However,O,O
",",O,O
the,O,O
increase,O,O
in,O,O
ISGF3,B,B
activity,O,O
ultimately,O,O
correlates,O,O
with,O,O
the,O,O
accumulation,O,O
of,O,O
ISGF3,B,B
gamma,I,I
induced,O,O
by,O,O
IFN,B,B
-,I,I
alpha,I,I
or,O,O
IFN,B,B
-,I,I
gamma,I,I
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
An,O,O
attempt,O,O
was,O,O
also,O,O
undertaken,O,O
to,O,O
use,O,O
a,O,O
cell,O,O
harvester,O,O
for,O,O
the,O,O
separation,O,O
of,O,O
cells,O,O
from,O,O
unbound,O,O
ligand,O,O
.,O,O
Glucocorticoid,B,B
receptor,I,I
and,O,O
inhibition,O,O
of,O,O
3,O,O
-,O,O
O,O,O
-,O,O
methyl,O,O
-,O,O
D,O,O
-,O,O
glucose,O,O
uptake,O,O
by,O,O
glucocorticoids,O,O
in,O,O
peripheral,O,O
blood,O,O
leukocytes,O,O
from,O,O
normal,O,O
humans,O,O
:,O,O
correlation,O,O
between,O,O
receptor,O,O
level,O,O
and,O,O
hormone,O,O
effect,O,O
in,O,O
vitro,O,O
.,O,O
It,O,O
was,O,O
found,O,O
that,O,O
lipopolysaccharide,O,O
induced,O,O
strongly,O,O
both,O,O
c,B,B
-,I,I
fos,I,I
and,O,O
c,B,B
-,I,I
jun,I,I
expression,O,O
as,O,O
well,O,O
as,O,O
AP1,B,O
formation,O,O
.,O,O
Regulation,O,O
of,O,O
interleukin,B,B
-,I,I
1,I,I
beta,I,I
production,O,O
by,O,O
glucocorticoids,O,B
in,O,O
human,O,O
monocytes,O,O
:,O,O
the,O,O
mechanism,O,O
of,O,O
action,O,O
depends,O,O
on,O,O
the,O,O
activation,O,O
signal,O,O
.,O,O
Nuclear,B,O
transcription,I,O
factors,I,O
that,O,O
bind,O,O
to,O,O
elements,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
.,O,O
However,O,O
",",O,O
the,O,O
signaling,O,O
requirements,O,O
and,O,O
sensitivity,O,O
to,O,O
protein,O,B
synthesis,O,I
inhibitors,O,I
differ,O,O
considerably,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
p65,B,B
gave,O,O
per,O,O
se,O,O
",",O,O
with,O,O
low,O,O
affinity,O,O
",",O,O
a,O,O
protein,B,B
-,I,I
DNA,I,I
complex,I,O
that,O,O
migrated,O,O
more,O,O
slowly,O,O
than,O,O
native,O,O
NF,B,B
-,I,I
GM2,I,I
complex,I,O
.,O,O
Furthermore,O,O
",",O,O
an,O,O
antiserum,O,O
against,O,O
KBF1,B,O
(,O,O
identical,O,O
to,O,O
50,B,O
kDa,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
protein,I,I
),O,O
reacted,O,O
with,O,O
the,O,O
p50,B,O
of,O,O
NF,B,B
-,I,I
GM2,I,I
",",O,O
indicating,O,O
that,O,O
the,O,O
NF,B,B
-,I,I
GM2,I,I
polypeptide,I,O
can,O,O
not,O,O
be,O,O
immunologically,O,O
differentiated,O,O
from,O,O
the,O,O
50,B,O
kDa,I,O
subunit,I,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
This,O,O
suggests,O,O
that,O,O
the,O,O
activation,O,O
mechanism,O,O
of,O,O
the,O,O
GM,B,B
-,I,I
CSF,I,I
gene,I,I
through,O,O
the,O,O
GM2,B,B
/,I,I
GC,I,I
-,I,I
box,I,I
sequence,I,I
is,O,O
different,O,O
from,O,O
that,O,O
of,O,O
genes,O,O
carrying,O,O
the,O,O
kappa,B,B
B,I,I
enhancer,I,I
alone,O,O
.,O,O
Characterization,O,O
of,O,O
an,O,O
immediate,B,O
-,I,O
early,I,O
gene,I,O
induced,O,O
in,O,O
adherent,O,O
monocytes,O,O
that,O,O
encodes,O,O
I,B,B
kappa,I,I
B,I,I
-,O,I
like,O,I
activity,O,I
.,O,O
The,O,O
C,B,B
-,I,I
terminus,I,I
has,O,O
a,O,O
putative,O,O
protein,B,B
kinase,I,I
C,I,I
phosphorylation,I,I
site,I,I
.,O,O
In,O,O
both,O,O
wild,O,O
-,O,O
type,O,O
and,O,O
highly,O,O
dexamethasone,O,B
(,O,O
dex,O,O
),O,O
-,O,O
resistant,O,O
clones,O,O
of,O,O
the,O,O
human,O,B
leukemic,O,I
cell,O,I
line,O,I
CEM,O,I
",",O,O
exposure,O,O
to,O,O
cortivazol,O,O
leads,O,O
to,O,O
cell,O,O
death,O,O
.,O,O
Permissiveness,O,O
to,O,O
replication,O,O
of,O,O
human,O,B
immunodeficiency,O,I
virus,O,I
(,O,O
HIV,O,O
),O,O
differs,O,O
in,O,O
T,O,B
lymphocytes,O,I
and,O,O
macrophages,O,I
.,O,O
A,O,O
DNA,B,B
probe,I,I
that,O,O
spanned,O,O
a,O,O
domain,O,O
conserved,O,O
among,O,O
the,O,O
proto,B,B
-,I,I
oncogene,I,I
c,I,I
-,I,I
rel,I,I
",",O,O
the,O,O
Drosophila,B,B
morphogen,I,I
dorsal,I,I
",",O,O
and,O,O
the,O,O
p50,B,B
DNA,I,I
binding,I,I
subunit,I,I
of,O,I
NF,B,I
-,I,I
kappa,I,I
B,I,I
was,O,O
generated,O,O
from,O,O
Jurkat,B,B
T,I,I
cell,I,I
complementary,I,I
DNA,I,I
with,O,O
the,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
PCR,O,O
),O,O
and,O,O
degenerate,O,O
oligonucleotides,O,O
.,O,O
This,O,O
probe,O,O
was,O,O
used,O,O
to,O,O
identify,O,O
a,O,O
rel,B,B
-,I,I
related,I,I
complementary,I,I
DNA,I,I
that,O,O
hybridized,O,O
to,O,O
a,O,O
2,B,O
.,I,O
6,I,O
-,I,O
kilobase,I,O
messenger,I,O
RNA,I,O
present,O,O
in,O,O
human,O,O
T,O,O
and,O,O
B,O,O
lymphocytes,O,O
.,O,O
In,O,O
vitro,O,O
transcription,O,O
and,O,O
translation,O,O
of,O,O
the,O,O
complementary,B,O
DNA,I,O
resulted,O,O
in,O,O
the,O,O
synthesis,O,O
of,O,O
a,O,O
protein,O,B
with,O,O
an,O,O
apparent,O,O
molecular,O,O
size,O,O
of,O,O
65,B,O
kilodaltons,I,O
(,O,O
kD,O,O
),O,O
.,O,O
This,O,O
protein,B,B
-,I,I
DNA,I,I
complex,I,I
comigrated,O,O
with,O,O
the,O,O
complex,O,O
obtained,O,O
with,O,O
the,O,O
purified,B,O
human,I,O
p65,I,B
NF,I,I
-,I,I
kappa,I,I
B,I,I
subunit,I,O
and,O,O
binding,O,O
was,O,O
inhibited,O,O
by,O,O
I,B,B
kappa,I,I
B,I,I
-,I,I
alpha,I,I
and,O,O
-,O,O
beta,O,B
proteins,O,I
.,O,O
Regulation,O,O
of,O,O
M,B,O
-,I,O
CSF,I,O
expression,O,O
by,O,O
M,B,O
-,I,O
CSF,I,O
:,O,O
role,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
and,O,O
transcription,B,O
factor,I,O
NF,I,B
kappa,I,I
B,I,I
.,O,O
To,O,O
date,O,O
",",O,O
little,O,O
is,O,O
known,O,O
about,O,O
the,O,O
intracellular,O,O
pathway,O,O
of,O,O
M,B,O
-,I,O
CSF,I,O
signal,O,O
transduction,O,O
.,O,O
The,O,O
pAT,B,B
133,I,I
gene,I,I
is,O,O
immediately,O,O
induced,O,O
",",O,O
with,O,O
FOS,B,O
-,O,O
like,O,O
kinetics,O,O
",",O,O
in,O,O
human,O,B
T,O,O
cells,O,O
and,O,O
in,O,O
fibroblasts,O,O
.,O,O
However,O,O
",",O,O
upon,O,O
transition,O,O
from,O,O
a,O,O
proliferating,O,O
(,O,O
G1,O,O
),O,O
to,O,O
a,O,O
resting,O,O
state,O,O
of,O,O
the,O,O
cell,O,O
cycle,O,O
the,O,O
three,O,O
genes,O,O
were,O,O
differently,O,O
regulated,O,O
.,O,O
v,B,O
-,I,O
erbA,I,O
overexpression,O,O
is,O,O
required,O,O
to,O,O
extinguish,O,O
c,B,O
-,I,O
erbA,I,O
function,O,O
in,O,O
erythroid,O,B
cell,O,I
differentiation,O,I
and,O,O
regulation,O,O
of,O,O
the,O,O
erbA,B,O
target,I,O
gene,I,O
CAII,B,O
.,O,O
The,O,O
v,B,O
-,I,O
erbA,I,B
oncoprotein,I,O
represents,O,O
a,O,O
retrovirus,O,O
-,O,O
transduced,O,O
oncogenic,O,O
version,O,O
of,O,O
the,O,O
thyroid,B,B
hormone,I,I
(,I,I
T3,I,I
/,I,I
T4,I,I
),I,I
receptor,I,O
c,B,O
-,I,O
erbA,I,O
(,I,O
type,I,O
alpha,I,O
),I,O
.,O,O
This,O,O
erbA,B,B
-,I,O
binding,I,O
site,I,O
confers,O,O
thyroid,O,B
hormone,O,I
responsiveness,O,O
to,O,O
a,O,O
heterologous,B,O
promoter,I,O
in,O,O
transient,O,O
expression,O,O
experiments,O,O
and,O,O
is,O,O
a,O,O
target,O,O
for,O,O
efficient,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
CAII,B,O
transcription,O,O
by,O,O
the,O,O
v,B,O
-,I,O
erbA,I,B
oncoprotein,I,O
.,O,O
The,O,O
CD2,B,B
T,I,I
lymphocyte,I,I
glycoprotein,I,I
surface,I,I
molecule,I,I
mediates,O,O
both,O,O
cell,O,O
to,O,O
cell,O,O
adhesion,O,O
and,O,O
T,O,B
cell,O,I
activation,O,I
",",O,O
two,O,O
processes,O,O
that,O,O
are,O,O
involved,O,O
in,O,O
the,O,O
spread,O,O
of,O,O
HIV,O,B
infection,O,I
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
show,O,O
that,O,O
micromolar,O,O
concentrations,O,O
of,O,O
H2O2,O,O
can,O,O
induce,O,O
the,O,O
expression,O,O
and,O,O
replication,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
in,O,O
a,O,O
human,O,B
T,O,I
cell,O,I
line,O,I
.,O,O
The,O,O
effect,O,O
is,O,O
mediated,O,O
by,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
transcription,B,O
factor,I,O
which,O,O
is,O,O
potently,O,O
and,O,O
rapidly,O,O
activated,O,O
by,O,O
an,O,O
H2O2,O,O
treatment,O,O
of,O,O
cells,O,O
from,O,O
its,O,O
inactive,B,O
cytoplasmic,I,B
form,I,O
.,O,O
ROI,O,O
appear,O,O
to,O,O
serve,O,O
as,O,O
messengers,O,O
mediating,O,O
directly,O,O
or,O,O
indirectly,O,O
the,O,O
release,O,O
of,O,O
the,O,O
inhibitory,B,O
subunit,I,O
I,B,B
kappa,I,I
B,I,I
from,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Inhibition,O,O
of,O,O
transcription,B,O
factors,I,O
belonging,O,O
to,O,O
the,O,O
rel,B,B
/,I,I
NF,I,I
-,I,I
kappa,I,I
B,I,I
family,I,O
by,O,O
a,O,O
transdominant,B,O
negative,I,O
mutant,I,O
.,O,O
A,O,O
mutant,O,O
of,O,O
KBF1,B,O
/,I,O
p50,I,O
(,O,O
delta,B,O
SP,I,O
),O,O
",",O,O
unable,O,O
to,O,O
bind,O,O
to,O,O
DNA,O,B
but,O,O
able,O,O
to,O,O
form,O,O
homo,O,O
-,O,O
or,O,O
heterodimers,B,O
",",O,O
has,O,O
been,O,O
constructed,O,O
.,O,O
One,O,O
gene,O,O
of,O,O
interest,O,O
is,O,O
the,O,O
glycoprotein,B,B
IIb,I,I
(,I,I
GPIIb,I,I
),I,I
gene,I,O
;,O,O
GPIIb,B,O
",",O,O
the,O,O
alpha,B,O
subunit,I,O
of,O,O
the,O,O
platelet,B,O
cytoadhesin,I,O
GPIIb,I,O
-,I,O
IIIa,I,O
",",O,O
is,O,O
produced,O,O
in,O,O
megakaryocytes,O,B
at,O,O
an,O,O
early,O,O
stage,O,O
of,O,O
the,O,O
differentiation,O,O
",",O,O
whereas,O,O
the,O,O
other,O,O
subunit,O,O
of,O,O
this,O,O
complex,O,O
",",O,O
GPIIIa,B,O
",",O,O
is,O,O
expressed,O,O
in,O,O
other,O,O
cells,O,O
.,O,O
No,O,O
relationship,O,O
could,O,O
be,O,O
established,O,O
between,O,O
glucocorticoid,B,B
receptor,I,I
binding,O,O
and,O,O
antidepressant,O,O
medication,O,O
.,O,O
These,O,O
data,O,O
support,O,O
the,O,O
view,O,O
of,O,O
an,O,O
impaired,O,O
ligand,O,O
-,O,O
induced,O,O
plasticity,O,O
of,O,O
glucocorticoid,B,B
receptor,I,I
regulation,O,O
rather,O,O
than,O,O
the,O,O
hypothesis,O,O
of,O,O
decreased,O,O
glucocorticoid,B,B
receptor,I,I
numbers,O,O
during,O,O
depression,O,O
.,O,O
The,O,O
promoters,B,O
and,O,O
enhancers,B,O
of,O,O
cell,O,B
type,O,I
-,O,I
specific,O,I
genes,O,O
are,O,O
often,O,O
conserved,O,O
in,O,O
evolution,O,O
",",O,O
and,O,O
hence,O,O
one,O,O
might,O,O
expect,O,O
that,O,O
a,O,O
given,O,O
enhancer,B,O
has,O,O
evolved,O,O
to,O,O
work,O,O
best,O,O
with,O,O
its,O,O
own,O,O
promoter,B,O
.,O,O
Towards,O,O
a,O,O
molecular,O,O
understanding,O,O
of,O,O
T,O,B
-,O,I
cell,O,I
differentiation,O,I
.,O,O
Lymphoid,O,B
differentiation,O,I
is,O,O
one,O,O
of,O,O
the,O,O
best,O,O
studied,O,O
examples,O,O
of,O,O
mammalian,O,O
development,O,O
.,O,O
Circadian,O,O
rhythm,O,O
in,O,O
glucocorticoid,B,B
receptor,I,I
(,O,O
GR,B,O
),O,O
was,O,O
studied,O,O
in,O,O
the,O,O
rat,O,B
liver,O,I
and,O,O
human,O,B
peripheral,O,I
leukocytes,O,I
.,O,O
The,O,O
conversion,O,O
of,O,O
the,O,O
TCEd,B,O
to,O,O
a,O,O
perfect,I,O
NF,I,B
-,I,I
kB,I,I
binding,I,O
site,I,O
leads,O,O
to,O,O
a,O,O
tighter,O,O
binding,O,O
of,O,O
NF,B,B
-,I,I
kB,I,I
to,O,O
TCEd,B,O
DNA,I,B
and,O,O
",",O,O
as,O,O
a,O,O
functional,O,O
consequence,O,O
",",O,O
to,O,O
the,O,O
activity,O,O
of,O,O
the,O,O
converted,I,O
TCEd,I,O
motifs,I,O
in,O,O
HeLa,O,B
cells,O,I
.,O,O
A,O,O
region,O,O
upstream,O,O
to,O,O
the,O,O
first,O,O
exon,O,O
",",O,O
and,O,O
highly,O,O
conserved,O,O
between,O,O
mouse,O,O
and,O,O
man,O,O
",",O,O
acts,O,O
as,O,O
an,O,O
erythroid,O,B
specific,O,I
enhancer,O,I
in,O,O
transient,O,O
assays,O,O
",",O,O
if,O,O
linked,O,O
to,O,O
the,O,O
GATA,B,B
-,I,I
1,I,O
or,O,O
to,O,O
the,O,O
SV40,O,B
promoter,O,I
.,O,O
More,O,O
strikingly,O,O
",",O,O
the,O,O
80,B,O
-,I,O
kDa,I,O
protein,I,B
was,O,O
downregulated,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
fashion,O,O
by,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
;,O,O
this,O,O
effect,O,O
was,O,O
independent,O,O
of,O,O
the,O,O
mode,O,O
of,O,O
lymphocyte,O,B
activation,O,I
and,O,O
specific,O,O
for,O,O
the,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
metabolite,O,O
of,O,O
vitamin,O,B
D3,O,I
.,O,O
Prolonged,O,O
corticosteroid,O,B
treatment,O,O
resulted,O,O
in,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
GcR,B,B
",",O,O
while,O,O
the,O,O
mean,O,O
level,O,O
of,O,O
GcR,B,B
in,O,O
Cushing,O,O
s,O,O
disease,O,O
was,O,O
normal,O,O
.,O,O
Furthermore,O,O
",",O,O
GcR,B,B
were,O,O
unaltered,O,O
after,O,O
these,O,O
patients,O,O
received,O,O
ketoconazole,O,O
",",O,O
in,O,O
spite,O,O
of,O,O
a,O,O
marked,O,O
reduction,O,O
in,O,O
morning,O,O
plasma,O,O
cortisol,O,O
and,O,O
urinary,O,O
free,O,O
cortisol,O,O
.,O,O
Human,O,B
T,O,I
-,O,I
cell,O,I
leukemia,O,I
virus,O,I
type,O,I
1,O,I
(,O,I
HTLV,O,I
-,O,I
1,O,I
),O,I
is,O,O
an,O,O
etiological,O,O
agent,O,O
of,O,O
adult,O,O
T,O,B
-,O,I
cell,O,I
leukemia,O,I
(,O,I
ATL,O,I
),O,I
.,O,O
Previously,O,O
",",O,O
transcription,O,O
of,O,O
the,O,O
c,B,B
-,I,I
fos,I,I
gene,I,I
has,O,O
been,O,O
reported,O,O
to,O,O
be,O,O
transactivated,O,O
by,O,O
the,O,O
viral,B,O
transcription,I,O
factor,I,O
",",O,O
Tax1,B,O
.,O,O
Glucocorticoid,B,B
receptor,I,I
characteristics,O,O
in,O,O
monocytes,O,O
of,O,O
patients,O,O
with,O,O
corticosteroid,O,O
-,O,O
resistant,O,O
bronchial,O,O
asthma,O,O
.,O,O
Vitamin,B,B
D,I,I
receptor,I,I
expression,O,O
in,O,O
human,O,O
lymphocytes,O,O
.,O,O
Signal,O,O
requirements,O,O
and,O,O
characterization,O,O
by,O,O
western,O,O
blots,O,O
and,O,O
DNA,O,B
sequencing,O,O
.,O,O
However,O,O
",",O,O
combination,O,O
of,O,O
OKT3,B,O
and,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
produced,O,O
a,O,O
concentration,O,O
of,O,O
binding,O,O
sites,O,O
similar,O,O
to,O,O
the,O,O
PHA,O,O
-,O,O
activated,O,O
cells,O,O
.,O,O
The,O,O
receptor,O,O
from,O,O
OKT3,B,O
and,O,O
OKT3,B,O
+,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
-,O,O
activated,O,O
lymphocytes,O,O
exhibited,O,O
decreased,O,O
binding,O,O
to,O,O
DNA,O,B
-,O,I
cellulose,O,I
compared,O,O
to,O,O
PHA,O,O
-,O,O
activated,O,O
lymphocytes,O,O
.,O,O
In,O,O
lymphocytes,O,B
activated,O,O
either,O,O
by,O,O
PHA,B,O
or,O,O
OKT3,B,O
(,O,O
but,O,O
not,O,O
in,O,O
resting,O,O
cells,O,O
),O,O
",",O,O
a,O,O
50,B,O
-,I,O
kDa,I,O
species,I,O
cross,O,O
-,O,O
reacting,O,O
with,O,O
a,O,O
monoclonal,B,O
antibody,I,O
against,O,O
the,O,O
intestinal,B,B
vitamin,I,I
D,I,I
receptor,I,I
was,O,O
detected,O,O
.,O,O
Finally,O,O
",",O,O
RNA,O,B
from,O,O
activated,O,O
lymphocytes,O,O
was,O,O
amplified,O,O
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
using,O,O
oligonucleotide,O,O
primers,O,O
flanking,O,O
the,O,O
196,B,O
base,I,O
pair,I,O
long,I,O
region,I,O
encoding,O,O
the,O,O
DNA,B,B
-,I,I
binding,I,I
domain,I,I
of,O,O
the,O,O
human,B,B
intestinal,I,I
receptor,I,I
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
expression,O,O
of,O,O
the,O,O
1,B,O
",",I,O
25,I,O
-,I,O
(,I,O
OH,I,O
),I,O
2D3,I,O
receptor,I,O
in,O,O
lymphocytes,O,O
is,O,O
triggered,O,O
by,O,O
distinct,O,O
and,O,O
contingent,O,O
signals,O,O
",",O,O
and,O,O
that,O,O
the,O,O
protein,O,B
and,O,O
the,O,O
mRNA,B,B
encoding,O,O
it,O,O
are,O,O
identical,O,O
to,O,O
the,O,O
classical,B,O
vitamin,I,O
D,I,O
receptor,I,O
.,O,O
The,O,O
kappa,B,O
B,I,O
sequence,I,O
(,O,O
GGGACTTTCC,O,O
),O,O
binds,O,O
a,O,O
factor,O,O
",",O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
that,O,O
is,O,O
constitutively,O,O
found,O,O
in,O,O
its,O,O
functional,O,O
",",O,O
DNA,O,B
binding,O,I
form,O,O
only,O,O
in,O,O
B,O,O
lymphocytes,O,O
.,O,O
However,O,O
",",O,O
these,O,O
genes,O,O
are,O,O
not,O,O
constitutively,O,O
active,O,O
in,O,O
B,O,O
lymphocytes,O,O
",",O,O
suggesting,O,O
that,O,O
other,O,O
regulatory,O,O
mechanisms,O,O
must,O,O
play,O,O
a,O,O
role,O,O
in,O,O
determining,O,O
the,O,O
patterns,O,O
of,O,O
expression,O,O
.,O,O
We,O,O
have,O,O
investigated,O,O
the,O,O
constitutive,O,O
and,O,O
inducible,O,O
transcriptional,O,O
activity,O,O
mediated,O,O
by,O,O
five,O,O
kappa,B,B
-,I,I
related,I,I
sequence,I,I
elements,I,I
in,O,O
two,O,O
different,O,O
cell,O,O
types,O,O
.,O,O
However,O,O
",",O,O
in,O,O
either,O,O
EL,O,O
-,O,O
4,O,O
(,O,O
T,O,O
),O,O
cells,O,O
or,O,O
S194,O,O
cells,O,O
",",O,O
both,O,O
lower,O,O
-,O,O
affinity,O,O
sites,O,O
can,O,O
be,O,O
significantly,O,O
induced,O,O
by,O,O
the,O,O
tax,B,O
gene,I,O
product,I,O
of,O,O
human,O,O
T,O,O
-,O,O
cell,O,O
leukemia,O,O
virus,O,O
type,O,O
I,O,O
",",O,O
showing,O,O
that,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activity,O,O
can,O,O
be,O,O
modulated,O,O
even,O,O
in,O,O
a,O,O
B,O,O
-,O,O
cell,O,O
line,O,O
that,O,O
constitutively,O,O
expresses,O,O
this,O,O
factor,O,O
.,O,O
Previously,O,O
",",O,O
a,O,O
nuclear,B,O
factor,I,O
",",O,O
IRF,B,B
-,I,I
1,I,I
(,O,I
interferon,B,I
regulatory,I,I
factor,I,I
1,I,I
),O,I
",",O,O
which,O,O
binds,O,O
to,O,O
type,B,O
I,I,O
IFN,I,B
and,O,O
some,O,O
IFN,B,B
-,I,I
inducible,I,I
gene,I,I
promoters,I,I
",",O,O
was,O,O
identified,O,O
and,O,O
cloned,O,O
.,O,O
A,O,O
dimerization,B,O
cofactor,I,O
of,O,O
HNF,B,B
-,I,I
1,I,I
alpha,I,I
(,O,O
DCoH,B,O
),O,O
was,O,O
identified,O,O
that,O,O
displayed,O,O
a,O,O
restricted,O,O
tissue,O,O
distribution,O,O
and,O,O
did,O,O
not,O,O
bind,O,O
to,O,O
DNA,O,B
",",O,O
but,O,O
",",O,O
rather,O,O
",",O,O
selectively,O,O
stabilized,O,O
HNF,B,B
-,I,I
1,I,I
alpha,I,I
dimers,I,O
.,O,O
Previous,O,O
studies,O,O
have,O,O
shown,O,O
that,O,O
treatment,O,O
of,O,O
human,O,O
myeloid,O,O
leukemia,O,O
cells,O,O
with,O,O
12,O,O
-,O,O
O,O,O
-,O,O
tetradecanoylphorbol,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
(,O,O
TPA,O,O
),O,O
is,O,O
associated,O,O
with,O,O
induction,O,O
of,O,O
monocytic,O,O
differentiation,O,O
and,O,O
expression,O,O
of,O,O
the,O,O
c,B,O
-,I,O
jun,I,O
and,I,O
c,I,O
-,I,O
fos,I,O
early,I,O
response,I,O
genes,I,O
.,O,O
Although,O,O
absent,O,O
in,O,O
nonexpressing,O,O
erythroleukemia,O,O
cell,O,O
lines,O,O
",",O,O
the,O,O
DNase,B,B
I,I,I
site,I,I
is,O,O
present,O,O
in,O,O
uninduced,O,O
myelomonocytic,O,O
cell,O,O
lines,O,O
and,O,O
is,O,O
not,O,O
changed,O,O
after,O,O
PMA,O,O
induction,O,O
.,O,O
The,O,O
nuclear,O,O
extracts,O,O
from,O,O
resting,O,O
and,O,O
induced,O,O
ML,O,O
-,O,O
1,O,O
cells,O,O
contain,O,O
proteins,O,O
binding,O,O
specifically,O,O
to,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
",",I,O
AP,I,B
-,I,I
2,I,I
",",I,O
and,I,O
NF,I,B
kappa,I,I
B,I,I
sequence,I,I
located,O,O
within,O,O
the,O,O
TNF,B,O
promoter,I,O
.,O,O
Enhancement,O,O
of,O,O
human,O,B
immunodeficiency,O,I
virus,O,I
1,O,O
replication,O,O
in,O,O
monocytes,O,O
by,O,O
1,O,O
",",O,O
25,O,O
-,O,O
dihydroxycholecalcif,O,O
.,O,O
Human,O,B
immunodeficiency,O,I
virus,O,I
(,O,O
HIV,O,O
),O,O
expression,O,O
and,O,O
replication,O,O
are,O,O
under,O,O
tight,O,O
regulatory,O,O
control,O,O
.,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
is,O,O
therefore,O,O
one,O,O
of,O,O
the,O,O
most,O,O
potent,O,O
regulators,O,O
of,O,O
HIV,O,O
-,O,O
1,O,O
replication,O,O
described,O,O
to,O,O
date,O,O
.,O,O
Transforming,B,O
growth,I,O
factor,I,O
-,I,O
beta,I,B
suppresses,O,O
human,B,O
B,I,B
lymphocyte,I,I
Ig,I,I
production,O,O
by,O,O
inhibiting,O,O
synthesis,O,O
and,O,O
the,O,O
switch,O,O
from,O,O
the,O,O
membrane,B,O
form,I,O
to,O,O
the,O,O
secreted,B,O
form,I,O
of,O,O
Ig,B,B
mRNA,I,I
.,O,O
One,O,O
of,O,O
the,O,O
members,O,O
of,O,O
this,O,O
multigene,O,O
family,O,O
",",O,O
cGATA,B,O
-,I,O
3,I,O
",",O,O
is,O,O
most,O,O
abundantly,O,O
expressed,O,O
in,O,O
the,O,O
T,O,B
-,O,I
lymphocyte,O,I
cell,O,I
lineage,O,I
.,O,O
The,O,O
murine,B,O
and,I,O
human,I,O
factors,I,O
are,O,O
abundantly,O,O
expressed,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
human,O,O
and,O,O
murine,O,O
T,O,B
-,O,I
cell,O,I
lines,O,I
and,O,O
can,O,O
activate,O,O
transcription,O,O
through,O,O
a,O,O
tissue,B,O
-,I,O
specific,I,O
GATA,I,O
-,I,O
binding,I,O
site,I,O
identified,O,O
within,O,O
the,O,O
human,B,O
T,I,B
-,I,I
cell,I,I
receptor,I,I
delta,I,I
gene,I,I
enhancer,I,I
.,O,O
The,O,O
expression,O,O
of,O,O
active,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
might,O,O
therefore,O,O
also,O,O
be,O,O
regulated,O,O
by,O,O
the,O,O
extent,O,O
of,O,O
processing,O,O
of,O,O
p105,B,O
.,O,O
Levels,O,O
of,O,O
RNA,O,B
coding,O,O
for,O,O
the,O,O
receptor,B,O
were,O,O
not,O,O
modulated,O,O
by,O,O
exposure,O,O
to,O,O
high,O,O
levels,O,O
of,O,O
ligand,O,O
.,O,O
Expression,O,O
of,O,O
c,B,B
-,I,I
jun,I,I
",",I,O
jun,I,B
B,I,I
and,I,O
jun,I,B
D,I,I
proto,I,I
-,I,I
oncogenes,I,I
in,O,O
human,O,O
peripheral,O,O
-,O,O
blood,O,O
granulocytes,O,O
.,O,O
We,O,O
have,O,O
found,O,O
that,O,O
purified,O,O
human,O,B
peripheral,O,I
-,O,I
blood,O,I
granulocytes,O,I
express,O,O
constitutively,O,O
significant,O,O
levels,O,O
of,O,O
proto,B,O
-,I,O
oncogenes,I,O
c,B,B
-,I,I
jun,I,I
",",I,O
jun,I,B
B,I,I
and,I,O
jun,I,B
D,I,I
mRNA,I,O
.,O,O
The,O,O
29,B,O
-,I,O
kDa,I,O
proteins,I,O
phosphorylated,O,O
in,O,O
thrombin,O,O
-,O,O
activated,O,O
human,O,B
platelets,O,I
are,O,O
forms,O,O
of,O,O
the,O,O
estrogen,B,B
receptor,I,I
-,I,I
related,I,I
27,I,O
-,I,O
kDa,I,O
heat,I,O
shock,I,O
protein,I,O
.,O,O
We,O,O
have,O,O
isolated,O,O
a,O,O
human,B,B
cDNA,I,I
clone,I,I
encoding,O,O
a,O,O
zinc,B,B
finger,I,I
protein,I,I
(,O,O
NF,B,B
-,I,I
E1,I,I
),O,O
that,O,O
binds,O,O
to,O,O
the,O,O
negative,B,O
-,I,O
acting,I,O
segment,I,O
of,O,O
the,O,O
kappa,B,B
E3,I,I
enhancer,I,O
.,O,O
This,O,O
protein,O,O
also,O,O
binds,O,O
to,O,O
the,O,O
immunoglobulin,B,B
heavy,I,I
-,I,I
chain,I,I
enhancer,I,I
mu,I,I
E1,I,I
site,I,O
.,O,O
NF,B,B
-,I,I
E1,I,I
is,O,O
also,O,O
the,O,O
human,B,O
homologue,I,O
of,O,O
the,O,O
mouse,B,O
delta,I,B
protein,I,I
",",O,O
which,O,O
binds,O,O
to,O,O
ribosomal,B,B
protein,I,I
gene,I,I
promoters,I,I
.,O,O
Cotransfection,O,O
studies,O,O
with,O,O
this,O,O
cDNA,B,B
indicate,O,O
that,O,O
it,O,O
can,O,O
repress,O,O
basal,B,O
promoter,I,O
activity,O,O
.,O,O
The,O,O
apparent,O,O
dual,O,O
function,O,O
of,O,O
this,O,O
protein,O,B
is,O,O
discussed,O,O
.,O,O
An,O,O
upstream,B,O
segment,I,O
contains,O,O
tandem,B,O
dinucleotide,I,O
repeats,I,O
(,B,O
CT,I,B
),I,O
19,I,O
/,I,O
(,I,O
CA,I,B
),I,O
16,I,O
.,O,O
There,O,O
is,O,O
a,O,O
suitably,O,O
located,O,O
TATA,B,O
box,I,O
",",O,O
but,O,O
potential,O,O
sites,O,O
for,O,O
CCAAT,B,B
-,I,I
box,I,I
binding,I,I
factors,I,I
are,O,O
far,O,O
upstream,O,O
",",O,O
embedded,O,O
in,O,O
a,O,O
42,B,O
-,I,O
nucleotide,I,O
repeat,I,O
element,I,O
.,O,O
HIV,B,B
-,I,I
TF1,I,I
had,O,O
a,O,O
molecular,O,O
weight,O,O
of,O,O
39,O,O
",",O,O
.,O,O
A,O,O
potentially,O,O
more,O,O
common,O,O
pharmacogenetic,O,O
syndrome,O,O
.,O,O
The,O,O
activity,O,O
of,O,O
dihydropyrimidine,B,B
dehydrogenase,I,I
(,O,O
DPD,B,O
),O,O
",",O,O
the,O,O
initial,O,O
enzyme,B,O
of,O,O
pyrimidine,O,B
(,O,O
and,O,O
FUra,O,O
),O,O
catabolism,O,O
",",O,O
in,O,O
peripheral,O,O
blood,O,O
mononuclear,O,B
cells,O,I
was,O,O
measured,O,O
in,O,O
each,O,O
subject,O,O
by,O,O
a,O,O
specific,O,O
radiometric,O,O
assay,O,O
using,O,O
FUra,O,O
as,O,O
the,O,O
substrate,O,O
.,O,O
Monitoring,O,O
DPD,B,B
activity,O,O
may,O,O
be,O,O
important,O,O
in,O,O
the,O,O
management,O,O
of,O,O
patients,O,O
experiencing,O,O
severe,O,O
toxicity,O,O
secondary,O,O
to,O,O
FUra,O,O
chemotherapy,O,O
.,O,O
A,O,O
thymus,B,O
-,I,O
specific,I,O
member,I,O
of,O,O
the,O,O
HMG,B,B
protein,I,I
family,I,I
regulates,O,O
the,O,O
human,B,O
T,I,O
cell,I,O
receptor,I,O
C,I,O
alpha,I,O
enhancer,I,O
.,O,O
The,O,O
human,B,O
T,I,O
cell,I,O
-,I,O
specific,I,O
transcription,I,O
factor,I,O
TCF,B,B
-,I,I
1,I,I
alpha,I,I
plays,O,O
a,O,O
key,O,O
role,O,O
in,O,O
the,O,O
tissue,O,O
-,O,O
specific,O,O
activation,O,O
of,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
C,O,O
alpha,O,O
enhancer,O,O
and,O,O
binds,O,O
to,O,O
pyrimidine,B,O
-,I,O
rich,I,O
elements,I,O
(,O,O
5,O,O
-,O,O
PyCTTTG,O,O
-,O,O
3,O,O
),O,O
present,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
other,O,O
T,B,O
cell,I,O
-,I,O
specific,I,O
control,I,O
regions,I,O
.,O,O
TCF,B,B
-,I,I
1,I,I
alpha,I,I
is,O,O
currently,O,O
unique,O,O
among,O,O
the,O,O
newly,O,O
emerging,O,O
family,O,O
of,O,O
DNA,B,B
-,I,I
binding,I,I
regulatory,I,I
proteins,I,I
that,O,O
share,O,O
the,O,O
HMG,B,O
motif,I,O
in,O,O
that,O,O
it,O,O
is,O,O
a,O,O
highly,B,O
tissue,I,B
-,I,I
specific,I,I
RNA,I,B
polymerase,I,I
II,I,I
transcription,B,I
factor,I,I
.,O,O
Ectopic,O,O
expression,O,O
of,O,O
cloned,B,O
Oct2,I,O
cDNA,I,O
was,O,O
shown,O,O
to,O,O
be,O,O
sufficient,O,O
to,O,O
reconstitute,O,O
at,O,O
least,O,O
some,O,O
aspects,O,O
of,O,O
this,O,O
regulation,O,O
in,O,O
non,O,O
-,O,O
lymphoid,O,B
cells,O,I
.,O,O
We,O,O
describe,O,O
the,O,O
isolation,O,O
and,O,O
characterization,O,O
of,O,O
multiple,B,O
cDNAs,I,O
encoding,O,O
mouse,B,O
Oct2,I,B
from,O,O
a,O,O
mature,O,O
B,O,B
-,O,I
cell,O,I
line,O,I
and,O,O
we,O,O
show,O,O
that,O,O
a,O,O
variety,O,O
of,O,O
isoforms,O,O
of,O,O
this,O,O
transcription,B,O
factor,I,O
is,O,O
generated,O,O
from,O,O
a,O,O
single,O,O
gene,O,O
by,O,O
an,O,O
alternative,O,O
splicing,O,O
mechanism,O,O
.,O,O
Different,O,O
amounts,O,O
of,O,O
the,O,O
various,O,O
isoforms,B,O
are,O,O
present,O,O
within,O,O
the,O,O
same,O,O
B,O,B
-,O,I
cell,O,I
regardless,O,O
of,O,O
the,O,O
developmental,O,O
stage,O,O
of,O,O
B,O,B
-,O,I
cell,O,I
differentiation,O,I
and,O,O
at,O,O
least,O,O
some,O,O
of,O,O
the,O,O
isoforms,B,O
are,O,O
conserved,O,O
between,O,O
mouse,O,O
and,O,O
humans,O,O
.,O,O
In,O,O
cotransfection,O,O
experiments,O,O
we,O,O
show,O,O
that,O,O
all,O,O
the,O,O
isoforms,B,O
are,O,O
able,O,O
to,O,O
activate,O,O
an,O,O
octamer,B,O
containing,O,O
promoter,B,O
element,I,O
in,O,O
fibroblasts,O,O
revealing,O,O
an,O,O
unexpected,O,O
functional,O,O
redundancy,O,O
.,O,O
[,O,O
Regulation,O,O
of,O,O
intracellular,O,O
cholesterol,O,B
synthesis,O,I
in,O,O
hypercholesterolemia,O,O
by,O,O
glucocorticoids,O,O
],O,O
The,O,O
rate,O,O
of,O,O
endogenous,O,O
cholesterol,O,B
synthesis,O,I
in,O,O
blood,O,B
lymphocytes,O,I
and,O,O
skin,O,B
fibroblasts,O,I
from,O,O
patients,O,O
with,O,O
type,O,O
IIa,O,O
hyperlipidemia,O,O
was,O,O
found,O,O
to,O,O
be,O,O
increased,O,O
in,O,O
comparison,O,O
with,O,O
healthy,O,O
donors,O,O
.,O,O
The,O,O
decrease,O,O
of,O,O
the,O,O
number,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
in,O,O
patients,O,O
with,O,O
type,O,O
IIa,O,O
hyperlipidemia,O,O
seems,O,O
to,O,O
be,O,O
a,O,O
compensatory,O,O
response,O,O
of,O,O
cells,O,O
culminating,O,O
in,O,O
activation,O,O
of,O,O
endogenous,O,O
cholesterol,O,O
synthesis,O,O
.,O,O
These,O,O
differences,O,O
in,O,O
gene,O,O
expression,O,O
have,O,O
not,O,O
been,O,O
molecularly,O,O
defined,O,O
.,O,O
Thus,O,O
",",O,O
both,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,I,I
binding,I,I
complexes,I,I
are,O,O
needed,O,O
for,O,O
optimal,O,O
viral,O,O
transcription,O,O
.,O,O
Binding,O,O
of,O,O
the,O,O
65,B,B
-,I,I
kDa,I,I
plus,O,O
50,B,B
-,I,I
kDa,I,I
heterodimer,I,O
to,O,O
the,O,O
HIV,B,B
-,I,I
1,I,I
enhancer,I,O
can,O,O
be,O,O
negatively,O,O
regulated,O,O
in,O,O
monocytes,O,O
",",O,O
providing,O,O
one,O,O
mechanism,O,O
restricting,O,O
HIV,B,B
-,I,I
1,I,I
gene,I,I
expression,O,O
.,O,O
An,O,O
age,O,O
-,O,O
related,O,O
decrease,O,O
in,O,O
the,O,O
number,O,O
of,O,O
GR,B,O
was,O,O
suggested,O,O
between,O,O
subjects,O,O
younger,O,O
than,O,O
20,O,O
years,O,O
and,O,O
elderly,O,O
subjects,O,O
;,O,O
there,O,O
was,O,O
no,O,O
apparent,O,O
seasonal,O,O
variation,O,O
in,O,O
GR,B,O
.,O,O
Eight,O,O
patients,O,O
with,O,O
dermatomyositis,O,O
/,O,O
polymyositis,O,O
were,O,O
examined,O,O
to,O,O
determine,O,O
whether,O,O
the,O,O
number,O,O
of,O,O
GR,B,B
in,O,O
MNL,O,O
could,O,O
be,O,O
down,O,O
-,O,O
regulated,O,O
by,O,O
their,O,O
cognate,O,O
ligands,O,O
.,O,O
Formation,O,O
of,O,O
the,O,O
protein,B,B
-,I,I
DNA,I,I
complex,I,I
with,O,O
the,O,O
C26,B,O
subfragment,I,O
was,O,O
positively,O,O
affected,O,O
by,O,O
p40tax,B,O
.,O,O
Human,O,O
tumor,B,O
necrosis,I,O
factor,I,B
alpha,I,I
gene,O,I
regulation,O,O
in,O,O
phorbol,O,O
ester,O,O
stimulated,O,O
T,O,O
and,O,O
B,O,O
cell,O,O
lines,O,O
.,O,O
Moreover,O,O
",",O,O
kappa,B,O
1,I,O
-,I,O
kappa,I,O
3,I,O
can,O,O
each,O,O
be,O,O
deleted,O,O
from,O,O
the,O,O
TNF,B,B
-,I,I
alpha,I,I
promoter,I,O
with,O,O
little,O,O
effect,O,O
on,O,O
the,O,O
gene,O,O
s,O,O
inducibility,O,O
by,O,O
PMA,O,O
.,O,O
We,O,O
have,O,O
generated,O,O
a,O,O
monoclonal,B,O
antibody,I,O
",",O,O
BZ1,B,O
",",O,O
to,O,O
BZLF1,B,O
which,O,O
reacts,O,O
in,O,O
immunohistology,O,O
",",O,O
immunoblotting,O,O
",",O,O
and,O,O
immunoprecipitation,O,O
and,O,O
which,O,O
recognizes,O,O
both,O,O
the,O,O
active,B,O
",",I,O
dimeric,I,O
form,I,O
and,O,O
the,O,O
inactive,B,O
",",I,O
monomeric,I,O
form,I,O
of,O,O
the,O,O
protein,O,O
.,O,O
The,O,O
hormone,B,B
receptors,I,I
of,O,O
the,O,O
primary,O,O
tumor,O,O
were,O,O
known,O,O
in,O,O
15,O,O
(,O,O
ER,B,B
),O,O
and,O,O
14,O,O
(,O,O
PR,B,B
),O,O
patients,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
each,O,O
cohort,O,O
there,O,O
was,O,O
only,O,O
one,O,O
case,O,O
with,O,O
a,O,O
negative,O,O
reaction,O,O
of,O,O
the,O,O
primary,O,O
tumor,O,O
and,O,O
a,O,O
positive,O,O
reaction,O,O
with,O,O
the,O,O
isolated,O,O
tumor,O,O
cells,O,O
from,O,O
the,O,O
pleural,O,O
effusions,O,O
.,O,O
NF,B,B
-,I,I
kB,I,I
is,O,O
a,O,O
eukaryotic,B,O
transcription,I,O
regulatory,I,O
factor,I,O
.,O,O
Regulatory,O,O
effect,O,O
of,O,O
insulin,B,B
on,O,O
glucocorticoid,B,B
receptor,I,I
in,O,O
human,O,B
peripheral,O,I
leukocytes,O,I
],O,O
After,O,O
3,O,O
h,O,O
incubation,O,O
the,O,O
specific,O,O
binding,O,O
power,O,O
with,O,O
[,O,O
3H,O,B
],O,O
Dex,O,I
was,O,O
decreased,O,O
by,O,O
23,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
10,O,O
.,O,O
0,O,O
",",O,O
32,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
13,O,O
.,O,O
2,O,O
%,O,O
(,O,O
P,O,O
greater,O,O
than,O,O
0,O,O
.,O,O
",",O,O
P,O,O
greater,O,O
than,O,O
0,O,O
.,O,O
and,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
as,O,O
compared,O,O
with,O,O
the,O,O
control,O,O
value,O,O
of,O,O
100,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
insulin,B,O
),O,O
respectively,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
20,O,O
mU,O,O
/,O,O
L,O,O
(,O,O
physiological,O,O
testing,O,O
concentration,O,O
),O,O
",",O,O
200,O,O
mU,O,O
/,O,O
L,O,O
(,O,O
physiological,O,O
upper,O,O
limit,O,O
),O,O
and,O,O
2,O,O
",",O,O
mU,O,O
/,O,O
L,O,O
(,O,O
pharmacological,O,O
concentration,O,O
),O,O
insulin,B,B
in,O,O
the,O,O
incubation,O,O
medium,O,O
.,O,O
Serum,O,O
Ig,O,B
levels,O,I
were,O,O
followed,O,O
up,O,O
to,O,O
two,O,O
years,O,O
after,O,O
or,O,O
during,O,O
the,O,O
therapy,O,O
.,O,O
Low,O,O
levels,O,O
of,O,O
c,B,B
-,I,I
jun,I,I
transcripts,I,I
were,O,O
detectable,O,O
in,O,O
resting,O,O
human,O,B
peripheral,O,I
blood,O,I
monocytes,O,I
.,O,O
Moreover,O,O
",",O,O
M,B,B
-,I,I
CSF,I,I
-,O,I
induced,O,O
expression,O,O
of,O,O
the,O,O
fos,B,B
-,I,I
related,I,I
gene,I,I
",",O,O
fra,B,B
-,I,I
1,I,I
",",O,O
was,O,O
delayed,O,O
compared,O,O
to,O,O
that,O,O
for,O,O
both,O,O
c,B,B
-,I,I
fos,I,I
and,O,O
fos,B,B
-,I,I
B,I,I
.,O,O
Glucocorticosteroids,O,B
remain,O,O
the,O,O
major,O,O
treatment,O,O
modality,O,O
for,O,O
systemic,O,O
lupus,O,B
erythematosus,O,I
(,O,O
SLE,O,O
),O,O
",",O,O
but,O,O
their,O,O
mechanism,O,O
of,O,O
action,O,O
is,O,O
unclear,O,O
.,O,O
Over,O,O
the,O,O
past,O,O
decade,O,O
it,O,O
has,O,O
become,O,O
clear,O,O
that,O,O
glucocorticosteroid,B,B
receptors,I,I
play,O,O
a,O,O
significant,O,O
role,O,O
in,O,O
the,O,O
mechanism,O,O
of,O,O
glucocorticosteroid,O,B
action,O,O
.,O,O
Glucocorticosteroid,B,B
receptors,I,I
on,O,O
leukocytes,O,O
of,O,O
patients,O,O
with,O,O
SLE,O,O
were,O,O
significantly,O,O
higher,O,O
than,O,O
in,O,O
healthy,O,O
controls,O,O
(,O,O
4419,O,O
+,O,O
/,O,O
-,O,O
306,O,O
vs,O,O
3369,O,O
+,O,O
/,O,O
-,O,O
196,O,O
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
HIV1,O,O
infection,O,O
of,O,O
human,O,B
monocytes,O,I
and,O,O
macrophages,O,I
promotes,O,O
induction,O,O
or,O,O
translocation,O,O
of,O,O
NF,B,B
-,I,I
KB,I,I
-,I,I
related,I,I
factors,I,I
.,O,O
The,O,O
insertion,O,O
of,O,O
multiple,O,O
copies,O,O
of,O,O
the,O,O
binding,B,O
site,I,O
for,O,O
the,O,O
former,O,O
or,O,O
latter,O,O
factor,O,O
into,O,O
a,O,O
heterologous,B,O
promoter,I,O
reduced,O,O
the,O,O
promoter,O,O
activity,O,O
to,O,O
one,O,O
-,O,O
tenth,O,O
or,O,O
one,O,O
-,O,O
third,O,O
",",O,O
respectively,O,O
.,O,O
Other,O,O
cellular,O,O
parameters,O,O
",",O,O
such,O,O
as,O,O
glycosidase,O,O
activities,O,O
",",O,O
cytokine,B,O
release,O,O
",",O,O
and,O,O
filament,O,O
expression,O,O
",",O,O
returned,O,O
to,O,O
levels,O,O
similar,O,O
to,O,O
that,O,O
observed,O,O
in,O,O
uninduced,O,O
cells,O,O
.,O,O
Levels,O,O
of,O,O
c,B,O
-,I,O
fos,I,B
and,I,O
c,I,B
-,I,I
jun,I,I
transcripts,I,O
remained,O,O
elevated,O,O
during,O,O
periods,O,O
of,O,O
PKC,B,O
activation,O,O
and,O,O
also,O,O
returned,O,O
to,O,O
levels,O,O
observed,O,O
in,O,O
control,O,O
cells,O,O
by,O,O
30,O,O
-,O,O
36,O,O
days,O,O
",",O,O
when,O,O
the,O,O
cells,O,O
entered,O,O
retrodifferentiation,O,O
.,O,O
DNA,O,B
binding,O,O
by,O,O
all,O,O
four,O,O
of,O,O
these,O,O
Rel,B,O
-,I,O
related,I,O
factors,I,O
is,O,O
blocked,O,O
by,O,O
selective,O,O
chemical,O,O
modification,O,O
of,O,O
lysine,O,B
and,O,O
arginine,O,B
residues,O,O
",",O,O
suggesting,O,O
that,O,O
both,O,O
of,O,O
these,O,O
basic,O,O
amino,O,O
acids,O,O
are,O,O
required,O,O
for,O,O
binding,O,O
to,O,O
the,O,O
kappa,B,O
B,I,O
element,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
mild,O,O
oxidation,O,O
with,O,O
glucose,B,O
oxidase,I,O
selectively,O,O
inhibits,O,O
p75,B,B
and,O,O
p85,B,B
binding,O,O
while,O,O
not,O,O
blocking,O,O
p50,B,B
and,O,O
p55,B,B
interactions,O,O
.,O,O
Changes,O,O
in,O,O
leucocytic,O,O
estrogen,B,B
receptor,I,I
levels,O,O
in,O,O
patients,O,O
with,O,O
climacteric,O,O
syndrome,O,O
and,O,O
therapeutic,O,O
effect,O,O
of,O,O
liuwei,O,O
dihuang,O,O
pills,O,O
],O,O
The,O,O
numbers,O,O
of,O,O
estrogen,B,B
receptor,I,I
(,O,O
ER,B,O
),O,O
in,O,O
human,O,O
peripheral,O,O
leucocytes,O,O
in,O,O
22,O,O
women,O,O
with,O,O
climacteric,O,O
syndrome,O,O
were,O,O
measured,O,O
by,O,O
radioligand,O,O
method,O,O
.,O,O
This,O,O
may,O,O
be,O,O
the,O,O
basis,O,O
of,O,O
the,O,O
therapeutic,O,O
effect,O,O
on,O,O
the,O,O
disease,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
cell,B,O
-,I,O
free,I,O
synthesized,I,O
hGR,I,B
was,O,O
capable,O,O
of,O,O
specific,O,O
binding,O,O
to,O,O
glucocorticoid,B,O
response,I,O
element,I,O
(,I,O
GRE,I,O
),I,O
-,I,O
containing,I,O
DNA,I,B
fragments,I,O
.,O,O
DNA,O,B
binding,O,O
by,O,O
in,B,O
vitro,I,O
synthesized,I,O
GR,I,B
was,O,O
blocked,O,O
by,O,O
the,O,O
addition,O,O
of,O,O
sodium,O,O
molybdate,O,O
to,O,O
the,O,O
receptor,O,O
preparations,O,O
before,O,O
steroid,O,O
addition,O,O
and,O,O
thermal,O,O
activation,O,O
.,O,O
Addition,O,O
of,O,O
KCl,O,O
resulted,O,O
in,O,O
less,O,O
DNA,O,B
binding,O,O
either,O,O
due,O,O
to,O,O
blockage,O,O
of,O,O
DNA,O,B
-,O,I
receptor,B,I
complex,I,I
formation,O,O
or,O,O
disruption,O,O
of,O,O
the,O,O
complexes,O,O
.,O,O
Oligonucleotides,O,O
containing,O,O
the,O,O
consensus,B,O
GRE,I,B
were,O,O
the,O,O
most,O,O
efficient,O,O
competitors,O,O
",",O,O
and,O,O
fragments,O,O
containing,O,O
regulatory,B,O
sequences,I,O
from,O,O
glucocorticoid,B,B
-,I,I
repressible,I,I
genes,I,I
were,O,O
somewhat,O,O
competitive,O,O
",",O,O
whereas,O,O
single,O,O
stranded,O,O
oligonucleotides,O,O
were,O,O
unable,O,O
to,O,O
compete,O,O
for,O,O
mouse,B,O
mammary,I,O
tumor,I,O
virus,I,O
-,I,O
long,I,O
terminal,I,O
repeat,I,O
DNA,O,B
binding,O,O
",",O,O
except,O,O
when,O,O
competitor,O,O
was,O,O
present,O,O
at,O,O
extremely,O,O
high,O,O
concentrations,O,O
.,O,O
Expression,O,O
of,O,O
1,B,O
",",I,O
25,I,B
(,I,I
OH,I,I
),I,I
2D3,I,I
receptors,I,I
on,O,O
alveolar,O,O
lymphocytes,O,O
from,O,O
patients,O,O
with,O,O
pulmonary,O,O
granulomatous,O,O
diseases,O,O
.,O,O
1,B,O
",",I,O
25,I,B
(,I,I
OH,I,I
),I,I
2D3,I,I
receptors,I,I
were,O,O
expressed,O,O
to,O,O
a,O,O
greater,O,O
extent,O,O
on,O,O
CD8,O,B
+,O,I
T,O,I
-,O,I
lymphocytes,O,I
than,O,O
on,O,O
CD4,O,B
+,O,I
T,O,I
-,O,I
lymphocytes,O,I
in,O,O
sarcoidosis,O,O
",",O,O
whereas,O,O
a,O,O
greater,O,O
proportion,O,O
of,O,O
CD4,O,B
+,O,I
than,O,O
of,O,O
CD8,O,B
+,O,I
T,O,I
-,O,I
lymphocytes,O,I
from,O,O
patients,O,O
with,O,O
tuberculosis,O,O
were,O,O
receptor,O,O
-,O,O
positive,O,O
.,O,O
Role,O,O
for,O,O
the,O,O
Epstein,B,B
-,I,I
Barr,I,I
virus,I,I
nuclear,I,I
antigen,I,I
2,I,I
in,O,O
viral,B,O
promoter,I,O
switching,O,O
during,O,O
initial,O,O
stages,O,O
of,O,O
infection,O,O
.,O,O
These,O,O
studies,O,O
have,O,O
been,O,O
extended,O,O
to,O,O
show,O,O
that,O,O
(,O,O
i,O,O
),O,O
a,O,O
mutant,O,O
EBV,O,B
strain,O,I
lacking,O,O
the,O,O
gene,O,O
encoding,O,O
EBNA,B,B
2,I,I
fails,O,O
to,O,O
switch,O,O
from,O,O
Wp,O,O
to,O,O
Cp,B,O
usage,O,O
in,O,O
primary,O,O
B,O,B
lymphocytes,O,I
",",O,O
although,O,O
the,O,O
virus,O,O
contains,O,O
a,O,O
functional,O,O
Cp,B,O
;,O,O
(,O,O
ii,O,O
),O,O
a,O,O
region,O,O
from,O,O
-,B,O
429,I,O
to,I,O
-,I,O
245,I,O
base,I,O
pairs,I,O
upstream,O,O
of,O,O
Cp,B,O
is,O,O
essential,O,O
for,O,O
Cp,B,O
activity,O,O
in,O,O
B,O,B
lymphocytes,O,I
",",O,O
but,O,O
only,O,O
in,O,O
the,O,O
context,O,O
of,O,O
upstream,B,O
and,I,O
downstream,I,O
sequences,I,O
;,O,O
(,O,O
iii,O,O
),O,O
this,O,O
region,O,O
contains,O,O
an,O,O
EBNA,B,B
2,I,I
-,I,I
dependent,I,I
enhancer,I,I
;,O,O
and,O,O
(,O,O
iv,O,O
),O,O
DNase,B,O
I,I,O
protection,O,O
employing,O,O
nuclear,O,O
extracts,O,O
from,O,O
B,O,B
and,O,O
T,O,B
lymphocytes,O,I
revealed,O,O
a,O,O
B,B,B
-,I,I
cell,I,I
-,I,I
specific,I,I
footprint,I,I
in,O,O
the,O,O
region,O,O
of,O,O
the,O,O
EBNA,B,B
2,I,I
-,I,I
dependent,I,I
enhancer,I,I
.,O,O
Immune,O,O
response,O,O
of,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
to,O,O
HBx,B,B
-,I,I
antigen,I,I
of,O,I
hepatitis,O,I
B,O,I
virus,O,I
.,O,O
Five,O,O
T,O,O
-,O,O
cell,O,O
clones,O,O
specific,O,O
for,O,O
a,O,O
T,B,O
-,I,O
cell,I,O
epitope,I,O
located,O,O
at,O,O
the,O,O
carboxyterminal,B,O
region,I,O
of,O,O
HBxAg,B,O
were,O,O
established,O,O
and,O,O
found,O,O
to,O,O
belong,O,O
to,O,O
the,O,O
CD2,O,B
/,O,I
CD4,O,I
-,O,I
positive,O,I
",",O,O
CD8,O,B
-,O,I
negative,O,I
subtype,O,I
.,O,O
[,O,O
Changes,O,O
in,O,O
leucocytic,B,O
estrogen,I,B
receptor,I,I
levels,O,I
in,O,O
patients,O,O
with,O,O
gynecomastia,O,O
],O,O
The,O,O
NF,B,B
kappa,I,I
B,I,I
independent,I,I
cis,I,I
-,I,I
acting,I,I
sequences,I,I
in,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
responsive,O,I
to,O,O
T,O,O
-,O,O
cell,O,O
activation,O,O
.,O,O
The,O,O
rate,O,O
of,O,O
transcription,O,O
initiation,O,O
directed,O,O
by,O,O
the,O,O
long,B,O
terminal,I,O
repeat,I,O
(,O,O
LTR,O,B
),O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
increases,O,O
in,O,O
response,O,O
to,O,O
mitogenic,O,O
stimuli,O,O
of,O,O
T,O,O
cells,O,O
.,O,O
The,O,O
rate,O,O
of,O,O
LTR,B,B
-,O,I
directed,O,I
gene,O,I
expression,O,I
increased,O,O
in,O,O
response,O,O
to,O,O
treatment,O,O
with,O,O
either,O,O
a,O,O
phorbol,O,O
ester,O,O
or,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
if,O,O
either,O,O
the,O,O
NFAT,B,B
-,I,I
1,I,I
or,O,O
NF,B,B
kappa,I,I
B,I,I
binding,I,I
sites,I,I
were,O,O
deleted,O,O
",",O,O
but,O,O
failed,O,O
to,O,O
respond,O,O
to,O,O
these,O,O
mitogenic,O,O
stimuli,O,O
if,O,O
both,O,O
sequences,O,O
were,O,O
absent,O,O
.,O,O
Activation,O,O
of,O,O
proenkephalin,O,B
transcription,O,O
by,O,O
JunD,B,B
is,O,O
dependent,O,O
upon,O,O
a,O,O
previously,O,O
characterized,O,O
cAMP,B,B
-,I,I
",",I,O
phorbol,I,B
ester,I,I
-,I,I
",",I,O
and,I,O
Ca,I,B
(,I,I
2,I,I
+,I,I
),I,I
inducible,I,I
enhancer,I,I
",",O,O
and,O,O
JunD,B,B
is,O,O
shown,O,O
to,O,O
bind,O,O
the,O,O
enhancer,B,O
as,O,O
a,O,O
homodimer,B,O
.,O,O
Plasma,O,O
cortisol,O,B
concentration,O,O
and,O,O
blood,O,O
leukocyte,O,B
content,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
(,O,I
GCR,B,I
),O,I
were,O,O
assayed,O,O
in,O,O
20,O,O
patients,O,O
with,O,O
deficiency,O,O
syndromes,O,O
",",O,O
10,O,O
cold,O,O
in,O,O
property,O,O
(,O,O
deficiency,O,O
-,O,O
cold,O,O
),O,O
",",O,O
the,O,O
other,O,O
10,O,O
hot,O,O
in,O,O
property,O,O
(,O,O
deficiency,O,O
-,O,O
heat,O,O
),O,O
",",O,O
and,O,O
also,O,O
in,O,O
10,O,O
healthy,O,O
individuals,O,O
as,O,O
normal,O,O
control,O,O
for,O,O
the,O,O
purpose,O,O
of,O,O
investigating,O,O
the,O,O
nature,O,O
of,O,O
cold,O,O
and,O,O
heat,O,O
syndromes,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
ability,O,O
of,O,O
these,O,O
complexes,O,O
to,O,O
regulate,O,O
gene,O,O
expression,O,O
is,O,O
demonstrated,O,O
by,O,O
increased,O,O
transcription,O,O
from,O,O
an,O,O
AP,B,B
-,I,I
1,I,I
driven,I,I
reporter,I,I
construct,I,I
and,O,O
marked,O,O
increases,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
endogenous,B,O
AP,I,B
-,I,I
1,I,I
regulated,I,I
genes,I,I
.,O,O
This,O,O
tight,O,O
correlation,O,O
between,O,O
c,B,O
-,I,O
jun,I,O
expression,O,O
",",O,O
the,O,O
generation,O,O
of,O,O
AP,B,B
-,I,I
1,I,I
activity,O,I
",",O,O
and,O,O
differentiation,O,O
suggests,O,O
a,O,O
critical,O,O
role,O,O
for,O,O
this,O,O
gene,O,O
and,O,O
transcriptional,B,O
complex,I,O
during,O,O
this,O,O
process,O,O
.,O,O
Cyclosporin,O,B
A,O,I
and,O,O
FK506,O,B
inhibit,O,O
T,O,B
-,O,I
and,O,O
B,O,B
-,O,I
cell,O,I
activation,O,O
and,O,O
other,O,O
processes,O,O
essential,O,O
to,O,O
an,O,O
effective,O,O
immune,O,O
response,O,O
.,O,O
A,O,O
transcription,B,O
factor,I,O
",",O,O
NF,B,B
-,I,I
AT,I,I
",",O,O
which,O,O
is,O,O
essential,O,O
for,O,O
early,O,O
T,O,B
-,O,I
cell,O,I
gene,O,O
activation,O,O
",",O,O
seems,O,O
to,O,O
be,O,O
a,O,O
specific,O,O
target,O,O
of,O,O
cyclosporin,O,O
A,O,O
and,O,O
FK506,O,O
action,O,O
because,O,O
transcription,O,O
directed,O,O
by,O,O
this,O,O
protein,O,O
is,O,O
blocked,O,O
in,O,O
T,O,B
cells,O,O
treated,O,O
with,O,O
these,O,O
drugs,O,O
",",O,O
with,O,O
little,O,O
or,O,O
no,O,O
effect,O,O
on,O,O
other,O,O
transcription,B,O
factors,I,O
such,O,O
as,O,O
AP,B,B
-,I,I
1,I,I
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Glucocorticoid,B,B
receptors,I,I
in,O,O
lymphocytes,O,O
in,O,O
anorexia,O,O
nervosa,O,O
.,O,O
CONCLUSIONS,O,O
Hypercortisolaemia,O,O
does,O,O
not,O,O
down,O,O
-,O,O
regulate,O,O
the,O,O
lymphocyte,O,B
glucocorticoid,B,I
receptors,I,I
in,O,O
anorexia,O,O
nervosa,O,O
and,O,O
a,O,O
post,O,O
-,O,O
receptor,O,B
defect,O,I
might,O,O
be,O,O
involved,O,O
in,O,O
peripheral,O,O
tissue,O,O
resistance,O,O
to,O,O
the,O,O
effects,O,O
of,O,O
glucocorticoid,O,B
hormones,O,I
in,O,O
undernutrition,O,O
.,O,O
The,O,O
induction,O,O
of,O,O
AP1,B,B
by,O,O
okadaic,O,O
acid,O,O
suggests,O,O
that,O,O
protein,B,B
phosphatases,I,I
1,I,I
and,I,I
2A,I,I
(,O,O
PP1,B,B
and,O,O
PP2A,B,B
),O,O
may,O,O
be,O,O
involved,O,O
in,O,O
T,O,O
cell,O,O
activation,O,O
as,O,O
important,O,O
negative,O,O
regulators,O,O
of,O,O
the,O,O
transcription,B,O
factor,I,O
AP1,B,B
.,O,O
CD3,B,B
-,O,I
epsilon,O,I
gene,O,O
expression,O,O
is,O,O
confined,O,O
to,O,O
the,O,O
T,O,O
cell,O,O
lineage,O,O
.,O,O
TCF,B,B
-,I,I
1,I,I
belonged,O,O
to,O,O
a,O,O
novel,O,O
family,O,O
of,O,O
genes,O,O
that,O,O
contain,O,O
the,O,O
so,O,O
-,O,O
called,O,O
high,O,O
mobility,B,O
group,I,O
1,I,O
(,I,O
HMG,I,B
),I,O
box,I,O
.,O,O
Two,O,O
splice,O,O
alternatives,O,O
were,O,O
identified,O,O
that,O,O
were,O,O
not,O,O
previously,O,O
observed,O,O
in,O,O
human,B,O
TCF,I,O
-,I,O
1,I,O
.,O,O
Third,O,O
",",O,O
TCF,B,O
-,I,O
1,I,O
bound,O,O
specifically,O,O
to,O,O
a,O,O
functional,O,O
T,B,O
cell,I,O
-,I,O
specific,I,O
element,I,O
in,O,O
the,O,O
T,B,O
cell,I,O
receptor,I,O
alpha,I,O
(,I,O
TCR,I,O
-,I,O
alpha,I,O
),I,O
enhancer,I,O
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
of,O,O
polyadenylated,B,O
RNA,I,B
purified,O,O
from,O,O
activated,O,O
human,O,O
B,O,O
cells,O,O
revealed,O,O
a,O,O
single,B,O
mRNA,I,B
transcript,I,I
of,O,O
approximately,O,O
2,O,O
.,O,O
3,O,O
kb,O,O
.,O,O
There,O,O
is,O,O
a,O,O
single,O,O
methionine,B,B
codon,I,I
-,I,I
initiated,I,I
open,I,I
reading,I,I
frame,I,I
of,O,I
1,O,I
",",O,I
458,O,I
nt,O,I
in,O,I
frame,O,I
with,O,I
a,O,I
homeobox,B,B
and,O,O
a,O,O
CAX,B,B
repeat,I,I
",",O,I
and,O,O
the,O,O
open,B,O
reading,I,O
frame,I,O
is,O,O
predicted,O,O
to,O,O
encode,O,O
a,O,O
protein,O,B
of,O,I
51,O,I
",",O,I
659,O,I
daltons,O,I
.,O,O
Characterization,O,O
of,O,O
HB24,B,O
expression,O,O
in,O,O
lymphoid,O,B
and,O,O
select,O,O
developing,O,O
tissues,O,O
was,O,O
performed,O,O
by,O,O
in,O,O
situ,O,O
hybridization,O,O
.,O,O
Platelet,B,B
-,I,I
activating,I,I
factor,I,I
induces,O,O
phospholipid,O,O
turnover,O,O
",",O,O
calcium,O,O
flux,O,O
",",O,O
arachidonic,O,B
acid,O,I
liberation,O,O
",",O,O
eicosanoid,O,O
generation,O,O
",",O,O
and,O,O
oncogene,B,O
expression,O,O
in,O,O
a,O,O
human,O,O
B,O,O
cell,O,O
line,O,O
.,O,O
Tandem,O,O
copies,O,O
of,O,O
this,O,O
67,B,O
-,I,O
bp,I,O
MnlI,I,O
-,I,O
AluI,I,O
fragment,I,O
",",O,O
when,O,O
fused,O,O
to,O,O
the,O,O
chloramphenicol,B,O
acetyltransferase,I,O
gene,I,O
driven,O,O
by,O,O
the,O,O
conalbumin,B,O
promoter,I,O
",",O,O
stimulated,O,O
transcription,O,O
in,O,O
B,O,O
cells,O,O
but,O,O
not,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
or,O,O
HeLa,O,O
cells,O,O
.,O,O
Footprinting,O,O
analysis,O,O
revealed,O,O
that,O,O
the,O,O
identical,O,O
sequence,O,O
CCGAAACTGAAAAGG,O,O
",",O,O
designated,O,O
E6,B,O
",",O,O
was,O,O
protected,O,O
by,O,O
nuclear,O,B
extracts,O,I
from,O,O
B,O,O
cells,O,O
",",O,O
T,O,O
cells,O,O
",",O,O
or,O,O
HeLa,O,O
cells,O,O
.,O,O
Gel,O,O
mobility,O,O
shift,O,O
assays,O,O
using,O,O
a,O,O
synthetic,B,O
E6,I,O
motif,I,O
detected,O,O
a,O,O
B,B,B
-,I,I
cell,I,I
-,I,I
specific,I,I
complex,I,I
in,O,O
addition,O,O
to,O,O
a,O,O
ubiquitous,O,O
band,O,O
found,O,O
also,O,O
in,O,O
T,O,O
cells,O,O
and,O,O
HeLa,O,O
cells,O,O
.,O,O
In,O,O
agreement,O,O
with,O,O
the,O,O
results,O,O
of,O,O
gel,O,O
retardation,O,O
assays,O,O
",",O,O
tandem,O,O
copies,O,O
of,O,O
the,O,O
E6,B,B
motif,I,I
stimulated,O,O
transcription,O,O
in,O,O
ARH77,O,O
and,O,O
Raji,O,O
cells,O,O
but,O,O
not,O,O
in,O,O
Jurkat,O,O
or,O,O
HeLa,O,O
cells,O,O
.,O,O
Interestingly,O,O
",",O,O
the,O,O
MnlI,B,O
-,I,O
AluI,I,O
fragment,I,O
could,O,O
suppress,O,O
the,O,O
basal,O,O
-,O,O
level,O,O
activity,O,O
of,O,O
the,O,O
conalbumin,B,O
promoter,I,O
in,O,O
both,O,O
Jurkat,O,O
and,O,O
HeLa,O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
novel,O,O
enhancer,O,O
element,O,O
identified,O,O
in,O,O
this,O,O
study,O,O
is,O,O
probably,O,O
a,O,O
target,O,O
site,O,O
for,O,O
both,O,O
positive,B,O
and,I,O
negative,I,O
factors,I,O
.,O,O
Charybdotoxin,O,O
-,O,O
sensitive,O,O
",",O,O
Ca,O,O
(,O,O
2,O,O
+,O,O
),O,O
-,O,O
dependent,O,O
membrane,O,O
potential,O,O
changes,O,O
are,O,O
not,O,O
involved,O,O
in,O,O
human,O,O
T,O,O
or,O,O
B,O,O
cell,O,O
activation,O,O
and,O,O
proliferation,O,O
.,O,O
The,O,O
involvement,O,O
of,O,O
ion,O,O
channels,O,O
in,O,O
B,O,O
and,O,O
T,O,O
lymphocyte,O,O
activation,O,O
is,O,O
supported,O,O
by,O,O
many,O,O
reports,O,O
of,O,O
changes,O,O
in,O,O
ion,O,O
fluxes,O,O
and,O,O
membrane,O,O
potential,O,O
after,O,O
mitogen,B,O
binding,O,O
.,O,O
However,O,O
",",O,O
blockade,O,O
of,O,O
the,O,O
Ca,B,O
(,I,O
2,I,O
+,I,O
),I,O
-,I,O
activated,I,O
K,I,O
+,I,O
channel,I,O
is,O,O
not,O,O
associated,O,O
with,O,O
changes,O,O
in,O,O
cell,O,O
-,O,O
cycle,O,O
gene,O,O
activation,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
production,O,O
",",O,O
IL,B,B
-,I,I
2R,I,I
expression,O,O
or,O,O
B,O,O
and,O,O
T,O,O
cell,O,O
mitogenesis,O,O
.,O,O
From,O,O
information,O,O
available,O,O
in,O,O
the,O,O
literature,O,O
on,O,O
the,O,O
substrate,O,O
specificity,O,O
of,O,O
the,O,O
three,O,O
enzymes,B,O
",",O,O
it,O,O
is,O,O
clear,O,O
that,O,O
a,O,O
cysteine,O,O
is,O,O
not,O,O
accepted,O,O
in,O,O
any,O,O
of,O,O
the,O,O
S2,B,O
",",I,O
S1,I,O
",",I,O
S1,I,O
",",I,O
and,I,O
S2,I,O
subsites,I,O
of,O,O
cathepsin,B,B
B,I,I
and,I,O
L,I,O
",",O,O
and,O,O
not,O,O
in,O,O
the,O,O
S1,B,O
and,O,O
S1,B,O
subsites,O,O
of,O,O
cathepsin,B,B
D,I,I
.,O,O
Starting,O,O
with,O,O
a,O,O
replication,O,O
-,O,O
incompetent,O,O
molecular,O,O
clone,O,O
of,O,O
human,O,O
immunodeficiency,O,O
virus,O,B
type,O,I
1,O,I
",",O,O
lacking,O,O
all,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,I,O
Sp1,I,B
binding,I,O
sites,I,O
present,O,O
in,O,O
the,O,O
native,B,O
long,I,O
terminal,I,O
repeat,I,O
(,O,O
LTR,B,O
),O,O
",",O,O
proviruses,O,O
containing,O,O
reconstructed,B,O
LTRs,I,O
with,O,O
individual,O,O
or,O,O
combinations,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
and,I,O
Sp1,I,B
elements,I,O
were,O,O
generated,O,O
and,O,O
evaluated,O,O
for,O,O
their,O,O
capacity,O,O
to,O,O
produce,O,O
virus,O,O
progeny,O,O
following,O,O
transfection,O,O
-,O,O
cocultivation,O,O
.,O,O
The,O,O
human,B,O
interferon,I,B
beta,I,I
(,I,O
IFN,I,B
-,I,I
beta,I,I
),I,O
regulatory,I,O
element,I,O
consists,O,O
of,O,O
multiple,O,O
enhanson,B,O
domains,I,O
which,O,O
are,O,O
targets,O,O
for,O,O
transcription,B,O
factors,I,O
involved,O,O
in,O,O
inducible,O,O
expression,O,O
of,O,O
the,O,O
promoter,B,O
.,O,O
A,O,O
2,O,O
-,O,O
4,O,O
-,O,O
fold,O,O
increase,O,O
in,O,O
IFN,B,B
-,I,I
beta,I,I
promoter,I,I
transcription,O,I
was,O,O
observed,O,O
in,O,O
Sendai,O,O
virus,O,O
induced,O,O
extracts,O,O
",",O,O
and,O,O
deletion,O,O
of,O,O
PRDI,B,O
and,O,O
PRDII,B,O
elements,I,O
decreased,O,O
this,O,O
induced,O,O
level,O,O
of,O,O
transcription,O,O
.,O,O
When,O,O
purified,O,O
PRDII,B,B
and,I,O
tetrahexamer,I,O
binding,I,O
proteins,I,O
were,O,O
added,O,O
to,O,O
the,O,O
induced,O,O
extract,O,O
",",O,O
a,O,O
4,O,O
-,O,O
fold,O,O
increase,O,O
in,O,O
transcription,O,O
was,O,O
observed,O,O
.,O,O
Human,B,O
and,I,O
mouse,I,O
Rhom,I,B
-,I,I
2,I,I
are,O,O
highly,O,O
conserved,O,O
and,O,O
",",O,O
like,O,O
rhombotin,B,O
",",O,O
encode,O,O
two,O,O
tandem,B,O
cysteine,I,B
-,I,I
rich,I,I
LIM,I,I
domains,I,I
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
by,O,O
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
in,O,O
the,O,O
Jurkat,O,O
T,O,O
cell,O,O
line,O,O
is,O,O
independent,O,O
of,O,O
protein,B,O
kinase,I,O
A,I,O
",",O,O
protein,B,O
kinase,I,O
C,I,O
",",O,O
and,O,O
Ca,B,B
(,I,I
2,I,I
+,I,I
),I,I
-,I,I
regulated,I,I
kinases,I,I
.,O,O
Furthermore,O,O
",",O,O
while,O,O
PMA,O,O
activation,O,O
was,O,O
inhibited,O,O
by,O,O
the,O,O
PKC,B,O
inhibitor,O,O
staurosporin,O,O
",",O,O
the,O,O
TNF,B,B
alpha,I,I
effect,O,O
was,O,O
unchanged,O,O
.,O,O
Here,O,O
we,O,O
investigated,O,O
the,O,O
transcriptional,O,O
basis,O,O
for,O,O
these,O,O
changes,O,O
.,O,O
Mutations,O,O
at,O,O
the,O,O
B2,B,O
site,O,O
abolish,O,O
this,O,O
transcriptional,O,O
activation,O,O
.,O,O
The,O,O
purified,O,O
homodimer,B,O
(,O,O
two,O,O
p50s,B,O
),O,O
of,O,O
the,O,O
DNA,B,B
-,I,I
binding,I,I
subunit,I,I
of,O,I
NF,B,I
-,I,I
kappa,I,I
B,I,I
binds,O,O
the,O,O
B2,B,O
site,O,O
of,O,O
proenkephalin,O,O
relatively,O,O
better,O,O
than,O,O
does,O,O
the,O,O
heterotetramer,B,O
(,O,O
two,O,O
p65s,B,O
plus,O,O
two,O,O
p50s,B,O
),O,O
form,O,O
of,O,O
the,O,O
factor,O,O
.,O,O
However,O,O
",",O,O
as,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
is,O,O
ubiquitous,O,O
and,O,O
the,O,O
transcriptional,O,O
activation,O,O
through,O,O
the,O,O
B2,B,O
site,O,O
is,O,O
T,O,O
cell,O,O
specific,O,O
",",O,O
yet,O,O
another,O,O
T,B,O
-,I,O
cell,I,O
-,I,O
specific,I,O
factor,I,O
which,O,O
synergizes,O,O
with,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
should,O,O
be,O,O
considered,O,O
.,O,O
In,O,O
nuclear,O,O
extracts,O,O
from,O,O
monocytes,O,O
or,O,O
macrophages,O,O
",",O,O
induction,O,O
of,O,O
NF,B,B
-,I,I
KB,I,I
occurred,O,O
only,O,O
if,O,O
the,O,O
cells,O,O
were,O,O
previously,O,O
infected,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
in,O,O
monocytic,O,B
cell,O,I
lineage,O,I
",",O,O
HIV,O,B
-,O,I
1,O,I
could,O,O
mimic,O,O
some,O,O
differentiation,O,O
/,O,O
activation,O,O
stimuli,O,O
allowing,O,O
nuclear,O,O
NF,B,B
-,I,I
KB,I,I
expression,O,O
.,O,O
Disruption,O,O
of,O,O
the,O,O
human,B,O
SCL,I,B
locus,I,I
by,O,O
`,O,O
`,O,O
illegitimate,O,O
V,O,O
-,O,O
(,O,O
D,O,O
),O,O
-,O,O
J,O,O
recombinase,O,O
activity,O,O
.,O,O
The,O,O
fusion,B,O
cDNA,I,O
results,O,O
from,O,O
an,O,O
interstitial,O,O
deletion,O,O
between,O,O
a,O,O
previously,O,O
unknown,B,O
locus,I,O
",",O,O
SIL,B,B
(,O,O
SCL,B,I
interrupting,I,I
locus,I,I
),O,O
",",O,O
and,O,O
the,O,O
5,B,O
untranslated,I,O
region,I,O
of,O,O
SCL,B,B
.,O,O
Thus,O,O
",",O,O
in,O,O
lymphocytes,O,O
",",O,O
growth,B,O
-,I,O
affecting,I,O
genes,I,O
other,O,O
than,O,O
immune,B,O
receptors,I,O
risk,O,O
rearrangements,O,O
.,O,O
This,O,O
was,O,O
compared,O,O
with,O,O
the,O,O
TREp,B,O
binding,O,O
of,O,O
reticulocyte,B,O
lysate,I,O
-,I,O
synthesized,I,O
TRs,I,O
.,O,O
Incubation,O,O
of,O,O
each,O,O
of,O,O
the,O,O
TRs,B,O
with,O,O
NE,O,O
from,O,O
COS,O,O
-,O,O
7,O,O
cells,O,O
",",O,O
which,O,O
do,O,O
not,O,O
possess,O,O
sufficient,O,O
endogenous,O,O
TRs,B,O
to,O,O
mediate,O,O
T3,O,O
-,O,O
responses,O,O
",",O,O
resulted,O,O
in,O,O
formation,O,O
of,O,O
a,O,O
new,O,O
",",O,O
more,O,O
greatly,B,O
shifted,I,O
complex,I,O
.,O,O
Cell,O,B
-,O,I
specific,O,I
differences,O,I
in,O,O
activation,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
regulatory,I,I
elements,I,I
of,O,O
human,B,O
immunodeficiency,I,O
virus,I,O
and,I,O
beta,I,O
interferon,I,O
promoters,I,O
by,O,O
tumor,B,B
necrosis,I,I
factor,I,I
.,O,O
Tumor,B,B
necrosis,I,I
factor,I,I
alpha,I,I
(,I,O
TNF,I,B
-,I,I
alpha,I,I
),I,O
mRNA,I,O
production,O,O
was,O,O
analyzed,O,O
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
amplification,O,O
in,O,O
monocytic,O,B
U937,O,O
cells,O,O
and,O,O
in,O,O
a,O,O
chronically,O,O
HIV,O,B
infected,O,I
U937,O,O
cell,O,O
line,O,O
(,O,O
U9,O,O
-,O,O
IIIB,O,O
),O,O
.,O,O
Functional,O,O
analysis,O,O
of,O,O
cis,B,O
-,I,O
linked,I,O
regulatory,I,O
sequences,I,O
in,O,O
the,O,O
HLA,B,B
DRA,I,I
promoter,I,I
by,O,O
transcription,O,O
in,O,O
vitro,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
LPS,O,B
on,O,O
HIV,O,B
-,O,I
1,O,I
replication,O,O
occurs,O,O
at,O,O
picogram,O,O
per,O,O
milliliter,O,O
concentrations,O,O
and,O,O
may,O,O
be,O,O
clinically,O,O
significant,O,O
in,O,O
understanding,O,O
the,O,O
variability,O,O
of,O,O
the,O,O
natural,O,O
history,O,O
of,O,O
HIV,O,B
-,O,I
1,O,I
infection,O,O
.,O,O
Inhibitory,O,O
drug,O,O
interactions,O,O
affecting,O,O
the,O,O
metabolism,O,O
of,O,O
methylprednisolone,O,B
(,O,O
MP,O,O
),O,O
may,O,O
produce,O,O
either,O,O
steroid,O,O
sparing,O,O
or,O,O
adverse,O,O
effects,O,O
partly,O,O
by,O,O
increasing,O,O
the,O,O
exposure,O,O
time,O,O
to,O,O
the,O,O
steroid,O,O
.,O,O
This,O,O
phenomenon,O,O
can,O,O
be,O,O
mimicked,O,O
by,O,O
administering,O,O
MP,O,O
in,O,O
divided,O,O
doses,O,O
.,O,O
To,O,O
compare,O,O
extra,O,O
-,O,O
renal,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
production,O,O
in,O,O
different,O,O
types,O,O
of,O,O
granulomatous,O,O
disease,O,O
",",O,O
and,O,O
to,O,O
identify,O,O
the,O,O
cell,O,O
types,O,O
responsible,O,O
",",O,O
we,O,O
have,O,O
evaluated,O,O
the,O,O
conversion,O,O
of,O,O
25,O,O
(,O,O
OH,O,O
),O,O
D3,O,O
in,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
by,O,O
uncultured,O,O
cells,O,O
recovered,O,O
by,O,O
bronchoalveolar,O,O
lavage,O,O
and,O,O
blood,O,O
mononuclear,O,O
cells,O,O
from,O,O
normocalcemic,O,O
patients,O,O
with,O,O
sarcoidosis,O,O
and,O,O
tuberculosis,O,O
.,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,B
),O,O
2D3,O,O
was,O,O
produced,O,O
both,O,O
by,O,O
lavage,O,B
cells,O,I
(,O,O
12,O,O
/,O,O
12,O,O
tuberculosis,O,O
patients,O,O
",",O,O
2,O,O
/,O,O
6,O,O
sarcoidosis,O,O
patients,O,O
),O,O
and,O,O
blood,O,B
mononuclear,O,I
cells,O,I
(,O,O
3,O,O
/,O,O
5,O,O
tuberculosis,O,O
patients,O,O
",",O,O
0,O,O
/,O,O
3,O,O
sarcoidosis,O,O
patients,O,O
),O,O
from,O,O
patients,O,O
but,O,O
not,O,O
controls,O,O
",",O,O
but,O,O
significantly,O,O
greater,O,O
amounts,O,O
were,O,O
produced,O,O
by,O,O
lavage,O,B
cells,O,I
from,O,O
tuberculosis,O,O
patients,O,O
than,O,O
those,O,O
of,O,O
sarcoidosis,O,O
patients,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,B
),O,O
2D3,O,I
production,O,O
by,O,O
lavage,O,O
cells,O,O
from,O,O
tuberculosis,O,O
patients,O,O
correlated,O,O
with,O,O
the,O,O
number,O,O
of,O,O
CD8,O,B
+,O,I
T,O,I
lymphocytes,O,I
present,O,O
but,O,O
not,O,O
other,O,O
cell,O,O
types,O,O
.,O,O
Because,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,B
),O,O
2D3,O,I
can,O,O
improve,O,O
the,O,O
capacity,O,O
of,O,O
macrophages,O,O
to,O,O
kill,O,O
mycobacteria,O,O
",",O,O
our,O,O
results,O,O
support,O,O
the,O,O
conclusion,O,O
that,O,O
macrophage,O,O
-,O,O
lymphocyte,O,O
interactions,O,O
",",O,O
mediated,O,O
at,O,O
least,O,O
in,O,O
part,O,O
by,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,B
),O,O
2D3,O,I
",",O,O
may,O,O
be,O,O
an,O,O
important,O,O
component,O,O
of,O,O
a,O,O
successful,O,O
antituberculous,O,O
immune,O,O
response,O,O
.,O,O
A,O,O
closely,O,O
related,O,O
(,O,O
if,O,O
not,O,O
identical,O,O
),O,O
protein,O,B
is,O,O
found,O,O
in,O,O
both,O,O
a,O,O
human,O,B
megakaryocytic,O,B
cell,O,I
line,O,I
and,O,O
purified,O,O
human,O,B
megakaryocytes,O,I
;,O,O
it,O,O
binds,O,O
to,O,O
promoter,B,O
regions,I,O
of,O,O
two,O,O
megakaryocytic,B,B
-,I,I
specific,I,I
genes,I,I
.,O,O
Furthermore,O,O
",",O,O
point,O,O
mutations,O,O
that,O,O
abolish,O,O
binding,O,O
of,O,O
NF,B,B
-,I,I
E1,I,I
result,O,O
in,O,O
a,O,O
70,O,O
%,O,O
decrease,O,O
in,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
a,O,O
megakaryocytic,B,B
-,I,I
specific,I,I
promoter,I,I
.,O,O
Transcriptional,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
c,B,O
-,I,O
myc,I,O
expression,O,O
by,O,O
protein,O,B
synthesis,O,I
-,O,I
dependent,O,I
and,O,O
-,O,O
independent,O,O
pathways,O,O
in,O,O
a,O,O
human,O,O
T,O,O
lymphoblastic,O,O
tumor,O,O
cell,O,O
line,O,O
.,O,O
We,O,O
studied,O,O
49,O,O
cases,O,O
of,O,O
B,O,O
-,O,O
cell,O,O
chronic,O,O
lymphocytic,O,O
leukemia,O,O
(,O,O
CLL,O,O
),O,O
using,O,O
immunostaining,O,O
of,O,O
cytospin,O,O
preparations,O,O
.,O,O
In,O,O
30,O,O
of,O,O
these,O,O
cases,O,O
ER,B,B
enzyme,O,I
immunoassay,O,I
(,O,O
ER,B,O
-,O,O
EIA,O,O
),O,O
was,O,O
also,O,O
performed,O,O
.,O,O
Type,B,O
-,I,O
II,I,O
estrogen,I,B
-,I,I
binding,I,I
sites,I,I
(,O,O
type,B,O
-,I,O
II,I,O
EBS,I,O
),O,O
have,O,O
been,O,O
demonstrated,O,O
in,O,O
the,O,O
human,O,B
lymphoblastoid,O,I
cell,O,I
line,O,I
IM,O,O
-,O,O
9,O,O
using,O,O
a,O,O
whole,O,O
-,O,O
cell,O,O
assay,O,O
with,O,O
(,O,O
6,O,O
",",O,O
7,O,O
-,O,O
3H,O,O
),O,O
estradiol,O,O
(,O,O
3H,O,O
-,O,O
E2,O,O
),O,O
as,O,O
tracer,O,O
.,O,O
The,O,O
relative,O,O
binding,O,O
affinity,O,O
of,O,O
quercetin,O,O
",",O,O
rutin,O,O
",",O,O
DES,O,B
and,O,O
TAM,O,B
for,O,O
type,B,O
-,I,O
II,I,O
EBS,I,O
correlated,O,O
well,O,O
with,O,O
their,O,O
potency,O,O
as,O,O
cell,O,O
growth,O,O
inhibitors,O,O
.,O,O
Moreover,O,O
",",O,O
hesperidin,O,O
",",O,O
a,O,O
flavonoid,O,O
which,O,O
does,O,O
not,O,O
bind,O,O
to,O,O
type,B,O
-,I,O
II,I,O
EBS,I,O
",",O,O
was,O,O
ineffective,O,O
in,O,O
inhibiting,O,O
cell,O,O
growth,O,O
.,O,O
[,O,O
Glucocorticoid,B,B
receptors,I,I
in,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
of,O,O
patients,O,O
with,O,O
bronchial,O,O
asthma,O,O
],O,O
Quantitation,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
(,O,O
GCR,B,O
),O,O
and,O,O
the,O,O
study,O,O
of,O,O
their,O,O
affinity,O,O
for,O,O
glucocorticosteroids,O,O
(,O,O
GCS,O,O
),O,O
were,O,O
made,O,O
in,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
of,O,O
bronchial,O,O
asthma,O,O
(,O,O
BA,O,O
),O,O
patients,O,O
in,O,O
consideration,O,O
of,O,O
GCR,B,O
treatment,O,O
and,O,O
serum,O,O
levels,O,O
of,O,O
endogenous,O,O
cortisol,O,O
.,O,O
Two,O,O
glucocorticoid,B,B
binding,I,I
sites,I,I
on,O,O
the,O,O
human,B,O
glucocorticoid,I,B
receptor,I,I
.,O,O
Cortivazol,O,O
(,O,O
CVZ,O,O
),O,O
is,O,O
a,O,O
unique,O,O
",",O,O
high,O,O
potency,O,O
synthetic,O,O
glucocorticoid,O,B
",",O,O
which,O,O
has,O,O
a,O,O
phenylpyrazol,O,O
fused,O,O
to,O,O
the,O,O
A,O,O
-,O,O
ring,O,O
of,O,O
the,O,O
steroid,O,B
nucleus,O,I
and,O,O
displays,O,O
binding,O,O
consistent,O,O
with,O,O
two,O,O
or,O,O
more,O,O
sites,O,O
in,O,O
the,O,O
cytosol,O,O
from,O,O
CEM,O,O
C7,O,O
cells,O,O
(,O,O
a,O,O
human,O,O
acute,O,O
lymphoblastic,O,O
T,O,O
-,O,O
cell,O,O
line,O,O
),O,O
.,O,O
We,O,O
have,O,O
carried,O,O
out,O,O
experiments,O,O
to,O,O
define,O,O
the,O,O
nature,O,O
of,O,O
the,O,O
higher,B,O
affinity,I,O
CVZ,I,O
binding,I,O
site,I,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
CVZ,O,O
is,O,O
recognizing,O,O
two,O,O
glucocorticoid,B,B
binding,I,I
sites,I,O
on,O,O
the,O,O
human,O,O
GR,B,O
or,O,O
a,O,O
protein,O,O
very,O,O
similar,O,O
to,O,O
it,O,O
.,O,O
Retroviral,O,O
mediated,O,O
transfer,O,O
and,O,O
expression,O,O
of,O,O
exogenous,B,O
genes,I,O
in,O,O
primary,O,O
lymphoid,O,B
cells,O,I
:,O,O
assaying,O,O
for,O,O
a,O,O
viral,O,O
transactivator,B,O
activity,O,O
in,O,O
normal,O,O
and,O,O
malignant,O,O
cells,O,O
.,O,O
Incidence,O,O
of,O,O
HLA,B,B
antigens,I,I
was,O,O
determined,O,O
in,O,O
94,O,O
of,O,O
them,O,O
.,O,O
Several,O,O
mutants,O,O
derived,O,O
from,O,O
transformed,O,O
human,O,B
B,O,I
cell,O,I
lines,O,I
are,O,O
defective,O,O
in,O,O
expressing,O,O
major,B,O
histocompatibility,I,O
complex,I,O
(,I,O
MHC,I,O
),I,O
class,I,O
II,I,O
genes,I,O
.,O,O
There,O,O
was,O,O
evidence,O,O
for,O,O
an,O,O
autosomal,O,O
recessive,O,O
form,O,O
of,O,O
inheritance,O,O
in,O,O
four,O,O
families,O,O
",",O,O
while,O,O
the,O,O
other,O,O
four,O,O
families,O,O
appeared,O,O
to,O,O
have,O,O
an,O,O
autosomal,O,O
dominant,O,O
mode,O,O
of,O,O
transmission,O,O
.,O,O
These,O,O
parents,O,O
were,O,O
entirely,O,O
asymptomatic,O,O
.,O,O
ER,B,B
content,O,O
in,O,O
lymphocytes,O,B
of,O,O
each,O,O
sample,O,O
was,O,O
expressed,O,O
by,O,O
both,O,O
fmol,O,O
/,O,O
mg,O,O
of,O,O
lymphocyte,B,O
cytosolic,I,O
protein,I,B
and,O,O
fmol,O,O
/,O,O
micrograms,O,O
of,O,O
lymphocyte,B,O
DNA,I,B
.,O,O
The,O,O
results,O,O
showed,O,O
that,O,O
there,O,O
was,O,O
no,O,O
significant,O,O
difference,O,O
between,O,O
the,O,O
ER,B,B
content,O,O
of,O,O
lymphocytes,O,B
from,O,O
the,O,O
controls,O,O
and,O,O
that,O,O
from,O,O
patients,O,O
with,O,O
SLE,O,O
.,O,O
We,O,O
used,O,O
mouse,O,B
embryonic,O,I
stem,O,I
(,O,O
ES,O,B
),O,O
cells,O,O
to,O,O
study,O,O
globin,B,B
gene,I,I
expression,O,O
and,O,O
switching,O,O
in,O,O
vitro,O,O
.,O,O
We,O,O
show,O,O
that,O,O
ES,O,B
-,O,O
derived,O,O
embryoid,O,B
bodies,O,I
express,O,O
the,O,O
full,O,O
complement,O,O
of,O,O
mouse,B,B
embryonic,I,I
globin,I,I
genes,I,I
in,O,O
the,O,O
correct,O,O
temporal,O,O
order,O,O
and,O,O
that,O,O
on,O,O
further,O,O
differentiation,O,O
",",O,O
a,O,O
switch,O,O
occurs,O,O
to,O,O
the,O,O
fetal,B,B
/,I,I
adult,I,I
genes,I,I
.,O,O
When,O,O
the,O,O
human,B,B
epsilon,I,B
-,I,I
or,I,O
beta,I,B
-,I,I
globin,I,I
genes,I,I
driven,O,O
by,O,O
the,O,O
dominant,B,O
control,I,O
region,I,O
(,O,O
DCR,B,O
),O,O
are,O,O
introduced,O,O
into,O,O
this,O,O
system,O,O
",",O,O
the,O,O
human,B,B
epsilon,I,B
-,I,I
globin,I,I
gene,I,I
",",O,O
in,O,O
contrast,O,O
to,O,O
the,O,O
beta,B,B
-,I,I
globin,I,I
gene,I,I
",",O,O
is,O,O
not,O,O
deregulated,O,O
by,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
DCR,B,O
and,O,O
is,O,O
expressed,O,O
strictly,O,O
as,O,O
an,O,O
embryonic,B,O
gene,I,O
.,O,O
These,O,O
effects,O,O
of,O,O
aldosterone,O,O
were,O,O
blocked,O,O
by,O,O
the,O,O
aldosterone,O,O
antagonist,O,O
canrenone,O,O
(,O,O
140,O,O
nmol,O,O
/,O,O
l,O,O
),O,O
.,O,O
Seventeen,O,O
cases,O,O
revealed,O,O
distinct,O,O
immunostaining,O,O
against,O,O
at,O,O
least,O,O
1,O,O
of,O,O
the,O,O
5,O,O
steroid,O,B
hormones,O,I
.,O,O
ZRE,B,O
-,I,O
B,I,O
is,O,O
therefore,O,O
not,O,O
part,O,O
of,O,O
the,O,O
R,B,O
-,I,O
inducible,I,O
enhancer,I,O
.,O,O
However,O,O
",",O,O
one,O,O
palindrome,B,O
",",O,O
either,O,O
alone,O,O
or,O,O
duplicated,O,O
",",O,O
or,O,O
the,O,O
overlapping,B,O
palindromes,I,O
did,O,O
not,O,O
respond,O,O
to,O,O
R,O,O
.,O,O
The,O,O
clinical,O,O
implications,O,O
of,O,O
nuclear,O,O
T3R,B,O
alterations,O,O
of,O,O
circulating,O,O
lymphocytes,O,O
in,O,O
hyperthyroidism,O,O
",",O,O
hypothyroidism,O,O
and,O,O
nonthyroidal,O,O
diseases,O,O
were,O,O
investigated,O,O
.,O,O
The,O,O
results,O,O
showed,O,O
that,O,O
in,O,O
hyper,O,B
-,O,I
and,O,I
hypothyroid,O,I
patients,O,O
the,O,O
nuclear,O,O
affinity,O,O
(,O,O
Ka,O,O
),O,O
for,O,O
T3,O,B
was,O,O
similar,O,O
to,O,O
that,O,O
of,O,O
normal,O,O
subjects,O,O
.,O,O
In,O,O
a,O,O
fourth,O,O
cell,O,O
line,O,O
",",O,O
A1,O,O
-,O,O
VDR,O,O
",",O,O
the,O,O
receptor,O,O
for,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,B
),O,I
2D3,O,I
had,O,O
a,O,O
low,O,O
binding,O,O
capacity,O,O
and,O,O
25,B,O
(,I,O
OH,I,B
),I,I
D3,I,I
-,I,I
24,I,I
-,I,I
hydroxylase,I,I
activity,O,O
was,O,O
not,O,O
detectable,O,O
.,O,O
Binding,O,O
and,O,O
elution,O,O
properties,O,O
to,O,O
DNA,O,B
-,O,I
cellulose,O,I
",",O,O
however,O,O
",",O,O
differed,O,O
from,O,O
normal,O,O
in,O,O
both,O,O
Ro,O,O
-,O,O
VDR,O,O
and,O,O
A1,O,O
-,O,O
VDR,O,O
cells,O,O
where,O,O
elution,O,O
from,O,O
DNA,O,B
-,O,I
cellulose,O,I
occurred,O,O
at,O,O
a,O,O
lower,O,O
salt,O,O
concentration,O,O
than,O,O
is,O,O
typical,O,O
of,O,O
the,O,O
1,B,O
",",I,O
25,I,O
(,I,O
OH,I,B
),I,I
2D3,I,I
receptor,I,O
.,O,O
We,O,O
studied,O,O
the,O,O
effects,O,O
of,O,O
TPA,O,O
on,O,O
the,O,O
regulation,O,O
of,O,O
c,B,O
-,I,O
jun,I,B
gene,O,I
expression,O,O
in,O,O
HL,O,O
-,O,O
60,O,O
cells,O,O
during,O,O
monocytic,O,O
differentiation,O,O
.,O,O
[,O,O
Hormonal,O,O
interactions,O,O
and,O,O
glucocorticoid,B,B
receptors,I,I
in,O,O
patients,O,O
with,O,O
the,O,O
nephrotic,O,O
syndrome,O,O
],O,O
These,O,O
studies,O,O
detected,O,O
two,O,O
novel,B,O
domains,I,O
referred,O,O
to,O,O
as,O,O
L1,B,O
and,O,O
L2,B,O
with,O,O
a,O,O
variety,O,O
of,O,O
lymphoid,O,O
but,O,O
not,O,O
HeLa,O,O
extracts,O,O
.,O,O
Characterization,O,O
of,O,O
defensin,B,B
resistance,O,O
phenotypes,O,O
associated,O,O
with,O,O
mutations,O,O
in,O,O
the,O,O
phoP,B,O
virulence,I,O
regulon,I,O
of,O,O
Salmonella,O,O
typhimurium,O,O
.,O,O
The,O,O
defensin,B,B
sensitivities,O,O
of,O,O
Salmonella,O,O
typhimurium,O,O
strains,O,O
with,O,O
mutations,O,O
in,O,O
the,O,O
phoP,B,O
/,I,O
phoQ,I,O
two,I,O
-,I,O
component,I,O
virulence,I,O
regulon,I,O
were,O,O
tested,O,O
by,O,O
using,O,O
purified,B,O
defensins,I,O
NP,B,B
-,I,I
1,I,I
and,O,O
NP,B,B
-,I,I
2,I,I
.,O,O
The,O,O
predicted,O,O
periplasmic,B,B
domain,I,I
of,O,O
the,O,O
PhoQ,B,B
protein,I,I
contained,O,O
a,O,O
markedly,O,O
anionic,O,O
domain,O,O
that,O,O
could,O,O
interact,O,O
with,O,O
cationic,B,O
proteins,I,O
and,O,O
that,O,O
could,O,O
be,O,O
responsible,O,O
for,O,O
resistance,O,O
to,O,O
defensin,B,O
.,O,O
This,O,O
implied,O,O
that,O,O
a,O,O
pag,B,O
(,I,O
phoP,I,O
-,I,O
activated,I,O
gene,I,O
),I,O
product,I,O
is,O,O
responsible,O,O
for,O,O
defensin,B,O
resistance,O,O
.,O,O
Stimulation,O,O
of,O,O
a,O,O
human,O,B
T,O,I
-,O,I
cell,O,I
clone,O,I
with,O,O
anti,B,O
-,I,O
CD3,I,O
or,O,O
tumor,B,O
necrosis,I,O
factor,I,O
induces,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
translocation,O,O
but,O,O
not,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
1,O,O
enhancer,O,O
-,O,O
dependent,O,O
transcription,O,O
.,O,O
The,O,O
two,O,O
latter,O,O
signals,O,O
were,O,O
nevertheless,O,O
able,O,O
to,O,O
induce,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
translocation,O,O
with,O,O
a,O,O
pattern,O,O
in,O,O
the,O,O
band,O,O
-,O,O
shift,O,O
assay,O,O
indistinguishable,O,O
from,O,O
that,O,O
observed,O,O
using,O,O
phorbol,O,O
ester,O,O
.,O,O
However,O,O
",",O,O
the,O,O
resistance,O,O
to,O,O
vitamin,O,O
D,O,B
treatment,O,O
in,O,O
XLH,O,O
can,O,O
not,O,O
be,O,O
explained,O,O
by,O,O
hypophosphatemia,O,O
alone,O,O
.,O,O
Two,O,O
distinct,O,O
forms,O,O
of,O,O
active,B,O
transcription,I,O
factor,I,O
CREB,I,B
(,O,I
cAMP,B,I
response,I,I
element,I,I
binding,I,I
protein,I,I
),O,I
.,O,O
The,O,O
two,O,O
proteins,O,O
differ,O,O
by,O,O
a,O,O
14,B,O
-,I,O
amino,I,O
acid,I,O
serine,I,B
-,I,I
rich,I,I
insertion,I,I
present,O,O
in,O,O
one,O,O
of,O,O
the,O,O
CREB,B,O
isoforms,I,O
.,O,O
Both,O,O
proteins,O,O
impart,O,O
cAMP,O,O
-,O,O
regulated,O,O
transcriptional,O,O
activity,O,O
to,O,O
a,O,O
heterologous,B,O
DNA,I,B
-,I,I
binding,I,I
domain,I,I
",",O,O
showing,O,O
that,O,O
cAMP,O,O
directly,O,O
modulates,O,O
the,O,O
transcriptional,O,O
stimulatory,O,O
activity,O,O
of,O,O
CREB,B,O
.,O,O
Competition,O,O
experiments,O,O
did,O,O
not,O,O
reveal,O,O
any,O,O
high,B,O
-,I,O
affinity,I,O
binding,I,O
site,I,O
for,O,O
BSAP,B,O
in,O,O
known,O,O
regulatory,B,O
regions,I,O
of,O,O
immunoglobulin,B,O
and,I,O
class,I,O
II,I,O
major,I,O
histocompatibility,I,O
(,I,O
MHC,I,O
),I,O
genes,I,O
",",O,O
suggesting,O,O
that,O,O
BSAP,B,O
is,O,O
a,O,O
regulator,O,O
of,O,O
a,O,O
different,O,O
set,O,O
of,O,O
B,B,O
-,I,O
lymphoid,I,O
-,I,O
specific,I,O
genes,I,O
.,O,O
The,O,O
expression,O,O
of,O,O
the,O,O
antibody,B,B
-,I,I
encoding,I,I
genes,I,I
",",O,O
the,O,O
immunoglobulin,B,B
(,I,I
Ig,I,I
),I,I
genes,I,I
",",O,O
is,O,O
also,O,O
restricted,O,O
to,O,O
B,O,B
cells,O,I
.,O,O
It,O,O
appears,O,O
that,O,O
the,O,O
B,O,B
cell,O,I
-,O,I
specific,O,I
expression,O,I
of,O,O
Ig,B,B
genes,I,I
is,O,O
mediated,O,O
at,O,O
least,O,O
in,O,O
part,O,O
by,O,O
cell,O,B
type,B,I
-,I,I
specific,I,I
Oct,I,B
factors,I,I
",",O,O
and,O,O
that,O,O
there,O,O
are,O,O
both,O,O
quantitative,O,O
and,O,O
qualitative,O,O
differences,O,O
between,O,O
Oct,B,B
-,I,I
1,I,I
and,O,O
Oct,B,B
-,I,I
2,I,I
factors,I,I
.,O,O
Recently,O,O
",",O,O
a,O,O
number,O,O
of,O,O
other,O,O
octamer,B,B
factor,I,I
variants,I,O
were,O,O
identified,O,O
.,O,O
Many,O,O
of,O,O
these,O,O
may,O,O
be,O,O
created,O,O
by,O,O
alternative,O,O
splicing,O,O
of,O,O
a,O,O
primary,B,O
transcript,I,O
of,O,O
one,O,O
Oct,O,B
factor,O,I
gene,O,I
and,O,O
may,O,O
serve,O,O
a,O,O
specific,O,O
function,O,O
in,O,O
the,O,O
fine,O,O
tuning,O,O
of,O,O
gene,O,O
expression,O,O
.,O,O
We,O,O
find,O,O
that,O,O
the,O,O
factor,O,O
that,O,O
binds,O,O
to,O,O
the,O,O
E3,B,O
enhancer,I,O
motif,I,O
",",O,O
CATGTGGC,O,O
",",O,O
is,O,O
a,O,O
ubiquitous,B,O
transcription,I,O
factor,I,O
.,O,O
However,O,O
",",O,O
despite,O,O
its,O,O
ability,O,O
to,O,O
activate,O,O
transcription,O,O
of,O,O
a,O,O
transfected,B,O
reporter,I,O
gene,I,O
",",O,O
the,O,O
factor,O,O
is,O,O
apparently,O,O
unable,O,O
to,O,O
bind,O,O
to,O,O
the,O,O
endogenous,B,O
Ig,I,B
heavy,I,I
chain,I,I
enhancer,I,I
in,O,O
non,O,B
-,O,I
lymphoid,O,I
cells,O,I
:,O,O
In,O,O
previous,O,O
experiments,O,O
by,O,O
others,O,O
",",O,O
the,O,O
characteristic,O,O
in,O,O
vivo,O,O
footprint,O,O
of,O,O
this,O,O
factor,O,O
",",O,O
designated,O,O
NF,B,B
-,I,I
muE3,I,I
",",O,O
was,O,O
detected,O,O
in,O,O
B,O,B
cells,O,I
but,O,O
not,O,O
in,O,O
non,O,B
-,O,I
B,O,I
cells,O,I
.,O,O
Endocrine,O,O
status,O,O
changes,O,O
in,O,O
children,O,O
with,O,O
bronchial,O,B
asthma,O,I
],O,O
A,O,O
study,O,O
was,O,O
made,O,O
of,O,O
adrenocortical,O,B
function,O,I
by,O,O
measuring,O,O
blood,O,O
plasma,O,O
cortisol,O,B
concentration,O,I
and,O,O
amount,O,O
of,O,O
glucocorticoid,B,B
receptors,I,I
in,O,O
lymphocytes,O,B
as,O,O
well,O,O
as,O,O
thyroid,O,B
function,O,I
by,O,O
measuring,O,O
blood,O,O
plasma,O,O
triidothyronine,O,B
and,O,O
thyroxine,O,B
concentration,O,I
in,O,O
58,O,O
bronchial,O,B
asthma,O,I
children,O,O
aged,O,O
1,O,O
to,O,O
14,O,O
years,O,O
.,O,O
The,O,O
authors,O,O
revealed,O,O
alterations,O,O
in,O,O
the,O,O
functional,O,O
activity,O,O
of,O,O
the,O,O
indicated,O,O
endocrine,O,B
glands,O,I
depending,O,O
on,O,O
the,O,O
intensity,O,O
of,O,O
bronchial,O,O
patency,O,O
disorders,O,O
and,O,O
the,O,O
nature,O,O
of,O,O
the,O,O
therapeutic,O,O
measures,O,O
carried,O,O
out,O,O
.,O,O
TAR,B,O
independent,O,O
activation,O,O
of,O,O
the,O,O
human,O,B
immunodeficiency,O,I
virus,O,I
in,O,O
phorbol,O,O
ester,O,O
stimulated,O,O
T,O,O
lymphocytes,O,O
.,O,O
Multiple,B,O
regulatory,I,O
elements,I,O
in,O,O
the,O,O
human,B,B
immunodeficiency,I,I
virus,I,I
long,I,I
terminal,I,I
repeat,I,I
(,O,O
HIV,B,B
LTR,I,I
),O,O
are,O,O
required,O,O
for,O,O
activation,O,O
of,O,O
HIV,O,B
gene,O,I
expression,O,O
.,O,O
Results,O,O
in,O,O
all,O,O
cell,O,B
lines,O,I
indicated,O,O
that,O,O
mutations,O,O
of,O,O
the,O,O
SP1,B,B
",",O,O
TATA,B,B
and,O,O
the,O,O
TAR,O,B
loop,O,I
and,O,O
stem,O,I
secondary,O,I
structure,O,I
resulted,O,O
in,O,O
marked,O,O
decreases,O,O
in,O,O
gene,O,I
expression,O,O
while,O,O
mutations,O,O
of,O,O
the,O,O
enhancer,B,B
motif,I,I
or,O,O
TAR,B,B
primary,I,I
sequence,I,I
resulted,O,O
in,O,O
only,O,O
slight,O,O
decreases,O,O
.,O,O
The,O,O
clinical,O,O
course,O,O
and,O,O
the,O,O
laboratory,O,O
data,O,O
suggest,O,O
that,O,O
the,O,O
tachycardia,O,O
crises,O,O
are,O,O
the,O,O
consequence,O,O
of,O,O
a,O,O
hypersensitivity,O,O
of,O,O
the,O,O
heart,O,O
to,O,O
thyroid,O,B
hormones,O,I
",",O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
number,O,O
of,O,O
T3,B,B
nuclear,I,I
receptor,I,I
sites,O,O
in,O,O
lymphocytes,O,O
.,O,O
Induction,O,O
of,O,O
immediate,B,O
early,I,O
response,I,O
genes,I,O
by,O,O
macrophage,B,B
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
in,O,O
normal,O,O
human,O,O
monocytes,O,O
.,O,O
The,O,O
c,B,O
-,I,O
jun,I,B
gene,I,I
expression,O,O
was,O,O
very,O,O
transient,O,O
and,O,O
was,O,O
not,O,O
detectable,O,O
by,O,O
60,O,O
min,O,O
after,O,O
M,B,O
-,I,O
CSF,I,O
addition,O,O
.,O,O
The,O,O
protein,O,B
synthesis,O,I
inhibitor,O,I
cycloheximide,O,O
did,O,O
not,O,O
block,O,O
the,O,O
induction,O,O
of,O,O
any,O,O
of,O,O
these,O,O
genes,O,O
",",O,O
and,O,O
in,O,O
fact,O,O
",",O,O
super,O,O
-,O,O
induced,O,O
the,O,O
expression,O,O
of,O,O
c,B,O
-,I,O
jun,I,B
and,O,O
hck,B,B
.,O,O
These,O,O
genes,O,O
may,O,O
then,O,O
play,O,O
a,O,O
role,O,O
in,O,O
altering,O,O
the,O,O
physiologic,O,O
status,O,O
of,O,O
the,O,O
cells,O,O
in,O,O
response,O,O
to,O,O
CSF,B,O
.,O,O
Inducible,O,O
nuclear,B,O
factor,I,O
binding,O,O
to,O,O
the,O,O
kappa,B,O
B,I,O
elements,I,O
of,O,O
the,O,O
human,B,O
immunodeficiency,I,O
virus,I,O
enhancer,I,O
in,O,O
T,O,O
cells,O,O
can,O,O
be,O,O
blocked,O,O
by,O,O
cyclosporin,O,O
A,O,O
in,O,O
a,O,O
signal,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
We,O,O
have,O,O
purified,O,O
a,O,O
new,O,O
T,B,O
-,I,O
cell,I,O
-,I,O
specific,I,O
factor,I,O
",",O,O
TCF,B,O
-,I,O
1,I,O
alpha,I,O
",",O,O
that,O,O
is,O,O
implicated,O,O
in,O,O
the,O,O
activation,O,O
of,O,O
genes,O,O
encoding,O,O
a,O,O
major,O,O
component,O,O
of,O,O
the,O,O
human,B,O
T,I,O
-,I,O
cell,I,O
receptor,I,O
(,O,O
TCR,B,O
),O,O
.,O,O
Curiously,O,O
",",O,O
the,O,O
TCF,B,B
-,I,I
1,I,I
alpha,I,I
binding,O,O
element,O,O
was,O,O
inactive,O,O
in,O,O
vivo,O,O
when,O,O
removed,O,O
from,O,O
its,O,O
neighboring,O,O
elements,O,O
on,O,O
the,O,O
TCR,B,B
alpha,I,I
enhancer,I,O
and,O,O
positioned,O,O
in,O,O
one,O,O
or,O,O
more,O,O
copies,O,O
upstream,O,O
of,O,O
a,O,O
heterologous,B,O
promoter,I,O
.,O,O
A,O,O
powerful,O,O
enhancer,O,O
has,O,O
been,O,O
mapped,O,O
to,O,O
an,O,O
18,B,B
-,I,I
bp,I,I
DNA,I,I
segment,I,O
located,O,O
11,O,O
kb,O,O
5,O,O
to,O,O
the,O,O
human,B,O
epsilon,I,B
-,I,I
globin,I,I
gene,I,I
within,O,O
the,O,O
dominant,B,O
control,I,O
or,O,O
locus,B,O
-,I,O
activating,I,O
region,I,O
.,O,O
DNA,O,B
-,O,I
protein,O,I
binding,O,I
assays,O,I
with,O,O
nuclear,O,O
extracts,O,O
from,O,O
induced,O,O
cells,O,O
demonstrate,O,O
a,O,O
high,B,O
molecular,I,O
weight,I,O
complex,I,O
on,O,O
the,O,O
enhancer,B,O
.,O,O
The,O,O
tissue,O,O
-,O,O
specific,O,O
expression,O,O
of,O,O
the,O,O
MOPC,B,O
141,I,O
immunoglobulin,I,B
heavy,I,I
-,I,I
chain,I,I
gene,I,I
was,O,O
studied,O,O
by,O,O
using,O,O
in,O,O
vitro,O,O
transcription,O,O
.,O,O
Purified,O,O
OTF1,B,O
from,O,O
HeLa,O,O
cells,O,O
and,O,O
OTF1,B,O
and,O,O
OTF2,B,O
from,O,O
B,O,O
cells,O,O
bound,O,O
to,O,O
identical,O,O
sequences,O,O
within,O,O
the,O,O
heavy,B,I
-,I,I
chain,I,I
promoter,I,I
.,O,O
In,O,O
addition,O,O
to,O,O
these,O,O
elements,O,O
",",O,O
we,O,O
identified,O,O
a,O,O
second,O,O
regulatory,B,O
element,I,O
",",O,O
the,O,O
N,B,B
element,I,I
with,O,O
the,O,O
sequence,O,O
5,O,O
-,O,O
GGAACCTCCCCC,O,O
-,O,O
3,O,O
.,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
as,O,O
inducible,O,O
transcriptional,B,O
activator,I,O
of,O,O
the,O,O
granulocyte,B,O
-,I,O
macrophage,I,O
colony,I,O
-,I,O
stimulating,I,O
factor,I,O
gene,I,O
.,O,O
The,O,O
same,O,O
agents,O,O
induce,O,O
transcription,O,O
from,O,O
the,O,O
interleukin,B,B
-,I,I
2,I,I
receptor,I,I
alpha,I,I
-,I,I
chain,I,I
and,I,O
interleukin,I,B
-,I,I
2,I,I
genes,I,O
",",O,O
depending,O,O
on,O,O
promoter,B,O
elements,I,O
that,O,O
bind,O,O
the,O,O
inducible,B,O
transcription,I,O
factor,I,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
(,O,O
or,O,O
an,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,I,I
like,I,I
factor,I,I
),O,O
.,O,O
Two,O,O
kappa,B,B
B,I,I
-,I,I
like,I,I
motifs,I,I
at,O,O
positions,B,O
-,I,O
98,I,O
to,I,O
-,I,O
108,I,O
of,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
promoter,I,O
were,O,O
also,O,O
recognized,O,O
but,O,O
with,O,O
much,O,O
lower,O,O
affinities,O,O
.,O,O
Effects,O,O
of,O,O
mitogenic,O,O
agents,O,O
upon,O,O
glucocorticoid,O,O
action,O,O
in,O,O
human,O,O
tonsillar,O,O
T,O,O
-,O,O
lymphocytes,O,O
.,O,O
PMA,O,O
enhanced,O,O
slightly,O,O
the,O,O
stimulatory,O,O
effect,O,O
of,O,O
PHA,B,O
.,O,O
Accordingly,O,O
",",O,O
the,O,O
same,O,O
set,O,O
of,O,O
words,O,O
and,O,O
phrases,O,O
(,O,O
oligopeptides,O,O
),O,O
appear,O,O
in,O,O
totally,O,O
unrelated,O,O
proteins,O,O
.,O,O
Two,O,O
distinct,O,O
signal,O,O
transmission,O,O
pathways,O,O
in,O,O
T,O,O
lymphocytes,O,O
are,O,O
inhibited,O,O
by,O,O
complexes,O,O
formed,O,O
between,O,O
an,O,O
immunophilin,B,O
and,O,O
either,O,O
FK506,O,O
or,O,O
rapamycin,O,O
.,O,O
After,O,O
in,O,O
vitro,O,O
adherence,O,O
",",O,O
human,O,O
monocytes,O,O
had,O,O
a,O,O
biphasic,O,O
increase,O,O
in,O,O
PDGF,B,B
(,I,O
B,I,I
),I,O
mRNA,I,O
with,O,O
peaks,O,O
at,O,O
6,O,O
h,O,O
and,O,O
13,O,O
d,O,O
.,O,O
Modulation,O,O
of,O,O
these,O,O
events,O,O
at,O,O
the,O,O
time,O,O
of,O,O
adherence,O,O
offers,O,O
a,O,O
mechanism,O,O
by,O,O
which,O,O
differential,O,O
priming,O,O
of,O,O
the,O,O
cells,O,O
may,O,O
be,O,O
accomplished,O,O
.,O,O
Unexpectedly,O,O
",",O,O
stimulation,O,O
of,O,O
cloned,O,O
stably,O,O
transfected,O,O
Jurkat,O,O
T,O,O
cells,O,O
leads,O,O
to,O,O
a,O,O
bimodal,O,O
pattern,O,O
of,O,O
beta,O,B
-,O,I
gal,O,I
expression,O,O
in,O,O
which,O,O
some,O,O
cells,O,O
express,O,O
no,O,O
beta,B,B
-,I,I
gal,I,I
and,O,O
others,O,O
express,O,O
high,O,O
levels,O,O
.,O,O
Further,O,O
results,O,O
",",O,O
in,O,O
which,O,O
beta,B,B
-,I,I
gal,I,I
activity,O,O
is,O,O
correlated,O,O
with,O,O
NF,B,B
-,I,I
AT,I,I
-,O,I
binding,O,I
activity,O,O
",",O,O
indicate,O,O
that,O,O
the,O,O
concentration,O,O
of,O,O
NF,B,B
-,I,I
AT,I,I
must,O,O
exceed,O,O
a,O,O
critical,O,O
threshold,O,O
before,O,O
transcription,O,O
initiates,O,O
.,O,O
Similar,O,O
constructs,O,O
controlled,O,O
by,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
or,O,O
the,O,O
entire,O,O
interleukin,B,O
-,I,O
2,I,O
enhancer,I,O
show,O,O
bimodal,O,O
expression,O,O
patterns,O,O
during,O,O
induction,O,O
",",O,O
suggesting,O,O
that,O,O
thresholds,O,O
set,O,O
by,O,O
the,O,O
concentration,O,O
of,O,O
transcription,B,O
factors,I,O
may,O,O
be,O,O
a,O,O
common,O,O
property,O,O
of,O,O
inducible,B,O
genes,I,O
.,O,O
In,O,O
lymphoid,O,B
cells,O,I
",",O,O
Z,B,O
or,O,O
R,B,O
alone,O,O
produced,O,O
only,O,O
small,O,O
increases,O,O
in,O,O
EA,B,O
-,I,O
D,I,O
promoter,I,O
activity,O,O
",",O,O
whereas,O,O
both,O,O
transactivators,B,O
together,O,O
produced,O,O
a,O,O
large,O,O
stimulatory,O,O
effect,O,O
.,O,O
In,O,O
lymphoid,O,B
cells,O,I
",",O,O
only,O,O
the,O,O
upstream,B,O
sequences,I,O
are,O,O
required,O,O
for,O,O
transactivation,O,O
by,O,O
the,O,O
Z,B,O
/,I,O
R,I,O
combination,O,O
",",O,O
and,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
site,I,I
is,O,O
dispensable,O,O
.,O,O
The,O,O
DNA,O,B
isolated,O,O
contained,O,O
an,O,O
open,O,O
reading,O,O
frame,O,O
encoding,O,O
108,O,O
amino,O,B
acid,O,I
residues,O,I
.,O,O
This,O,O
effect,O,O
was,O,O
comparable,O,O
to,O,O
or,O,O
even,O,O
stronger,O,O
than,O,O
the,O,O
effect,O,O
of,O,O
a,O,O
mutation,O,O
in,O,O
the,O,O
OCTA,B,O
site,I,O
.,O,O
DNase,O,B
footprinting,O,I
analysis,O,I
corroborated,O,O
the,O,O
functional,O,O
data,O,O
showing,O,O
that,O,O
a,O,O
lymphoid,B,B
-,I,I
specific,I,I
protein,I,I
binds,O,O
to,O,O
the,O,O
microB,B,B
DNA,I,I
motif,I,I
.,O,O
This,O,O
inducer,O,O
can,O,O
act,O,O
in,O,O
concert,O,O
with,O,O
the,O,O
HIV,B,B
-,I,I
2,I,I
tat,I,I
gene,I,I
and,O,O
T,O,O
-,O,O
cell,O,O
activation,O,O
in,O,O
enhancing,O,O
gene,O,O
expression,O,O
in,O,O
human,O,B
CD4,O,I
+,O,I
lymphocytes,O,I
.,O,O
Both,O,O
HIV,O,B
-,O,I
2,O,I
and,O,O
CMV,B,B
transactivators,I,I
enhance,O,O
HIV,O,B
-,O,I
2,O,I
gene,O,I
expression,O,I
by,O,O
transcriptional,O,O
activation,O,O
involving,O,O
transcript,O,O
initiation,O,O
as,O,O
well,O,O
as,O,O
elongation,O,O
",",O,O
with,O,O
CMV,B,B
transactivator,I,I
affecting,O,O
elongation,O,O
more,O,O
than,O,O
the,O,O
initiation,O,O
.,O,O
Inflammatory,O,O
infiltrates,O,O
were,O,O
analysed,O,O
in,O,O
tissue,O,O
sections,O,O
of,O,O
76,O,O
breast,O,O
carcinomas,O,O
by,O,O
counting,O,O
the,O,O
percentage,O,O
of,O,O
macrophages,O,O
",",O,O
IgA,O,B
+,O,I
and,O,O
IgG,O,B
+,O,I
plasma,O,O
cells,O,O
",",O,O
T,O,B
cells,O,I
with,O,O
their,O,O
subpopulations,O,O
",",O,O
and,O,O
natural,O,O
killer,O,O
cells,O,O
",",O,O
and,O,O
by,O,O
measuring,O,O
postcapillary,O,O
venules,O,O
(,O,O
PCVs,O,O
",",O,O
found,O,O
in,O,O
12,O,O
cases,O,O
),O,O
within,O,O
the,O,O
infiltrates,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
a,O,O
direct,O,O
correlation,O,O
exists,O,O
between,O,O
the,O,O
diameter,O,O
of,O,O
the,O,O
PCVs,O,O
and,O,O
both,O,O
the,O,O
percentage,O,O
of,O,O
the,O,O
OKT8,O,B
+,O,I
T,O,I
cells,O,I
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
and,O,O
the,O,O
Leu,O,B
-,O,I
7,O,I
+,O,I
natural,O,I
killer,O,I
cells,O,I
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
present,O,O
evidence,O,O
for,O,O
reactivity,O,O
of,O,O
pregnancy,O,O
lymphocytes,O,O
",",O,O
but,O,O
not,O,O
nonpregnancy,O,O
lymphocytes,O,O
",",O,O
with,O,O
the,O,O
progesterone,B,B
receptor,I,I
-,I,I
specific,I,I
monoclonal,I,I
antibody,I,I
mPRI,B,I
.,O,O
Depletion,O,O
of,O,O
CD8,O,B
+,O,I
cells,O,O
was,O,O
accompanied,O,O
by,O,O
62,O,O
+,O,O
/,O,O
-,O,O
18,O,O
%,O,O
loss,O,O
of,O,O
progesterone,O,B
receptor,O,I
-,O,I
bearing,O,I
cells,O,O
",",O,O
while,O,O
depletion,O,O
of,O,O
CD4,O,B
+,O,I
cells,O,O
resulted,O,O
in,O,O
a,O,O
twofold,O,O
increase,O,O
in,O,O
the,O,O
number,O,O
of,O,O
positively,O,O
staining,O,O
lymphocytes,O,O
.,O,O
Interaction,O,O
of,O,O
fibronectin,B,B
with,O,O
VLA,B,B
-,I,I
5,I,I
receptor,I,I
on,O,O
CD4,O,B
cells,O,O
induces,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
transcription,I,I
factor,I,I
.,O,O
Int,B,B
-,I,I
2,I,I
was,O,O
amplified,O,O
in,O,O
13,O,O
.,O,O
1,O,O
%,O,O
and,O,O
c,B,B
-,I,I
myc,I,I
was,O,O
amplified,O,O
in,O,O
10,O,O
.,O,O
3,O,O
%,O,O
.,O,O
A,O,O
somewhat,O,O
surprising,O,O
finding,O,O
however,O,O
was,O,O
a,O,O
very,O,O
strong,O,O
association,O,O
between,O,O
oncogene,B,O
amplification,O,O
and,O,O
dense,O,O
lymphocyte,O,B
infiltration,O,I
of,O,O
the,O,O
tumor,O,O
(,O,O
P,O,O
.,O,O
.,O,O
This,O,O
correlation,O,O
is,O,O
even,O,O
stronger,O,O
when,O,O
only,O,O
high,O,O
levels,O,O
of,O,O
amplification,O,O
are,O,O
considered,O,O
",",O,O
either,O,O
for,O,O
each,O,O
oncogene,O,O
separately,O,O
(,O,O
P,O,O
.,O,O
),O,O
or,O,O
in,O,O
combination,O,O
(,O,O
P,O,O
.,O,O
),O,O
.,O,O
Suppression,O,O
of,O,O
signals,O,O
required,O,O
for,O,O
activation,O,O
of,O,O
transcription,B,O
factor,I,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
in,O,O
cells,O,O
constitutively,O,O
expressing,O,O
the,O,O
HTLV,B,B
-,I,I
I,I,I
Tax,I,I
protein,I,O
.,O,O
Transcription,B,O
factor,I,O
IID,I,O
(,O,O
TFIID,B,O
),O,O
binds,O,O
to,O,O
the,O,O
TATA,B,O
box,I,O
promoter,I,O
element,I,O
and,O,O
regulates,O,O
the,O,O
expression,O,O
of,O,O
most,O,O
eukaryotic,B,O
genes,I,O
transcribed,O,O
by,O,O
RNA,B,B
polymerase,I,I
II,I,I
.,O,O
Complementary,B,O
DNA,I,B
(,O,O
cDNA,B,O
),O,O
encoding,O,O
a,O,O
human,B,O
TFIID,I,B
protein,I,O
has,O,O
been,O,O
cloned,O,O
.,O,O
Premenopausal,O,O
patients,O,O
with,O,O
neither,O,O
risk,O,O
factor,O,O
had,O,O
a,O,O
very,O,O
low,O,O
failure,O,O
rate,O,O
(,O,O
2,O,O
.,O,O
6,O,O
%,O,O
at,O,O
5,O,O
years,O,O
),O,O
",",O,O
regardless,O,O
of,O,O
age,O,O
.,O,O
Second,O,O
",",O,O
TRE,B,O
-,I,O
DNA,I,B
binding,I,O
proteins,I,O
sedimented,O,O
through,O,O
a,O,O
glycerol,O,O
density,O,O
gradient,O,O
at,O,O
rates,O,O
corresponding,O,O
to,O,O
proteins,O,O
of,O,O
native,O,O
molecular,O,O
weights,O,O
of,O,O
35,O,O
to,O,O
50,O,O
kD,O,O
and,O,O
110,O,O
kD,O,O
.,O,O
Third,O,O
",",O,O
only,O,O
the,O,O
50,B,B
kD,I,I
protein,I,I
was,O,O
retained,O,O
on,O,O
a,O,O
biotinylated,O,O
DNA,O,B
-,O,I
streptavidin,O,I
matrix,O,O
when,O,O
the,O,O
DNA,O,B
fragment,O,I
contained,O,O
the,O,O
TRE,B,O
-,I,O
DNA,I,B
.,O,O
Fourth,O,O
",",O,O
extensive,O,O
purification,O,O
by,O,O
several,O,O
cycles,O,O
of,O,O
TRE,B,O
-,O,O
DNA,O,B
affinity,O,I
chromatography,O,I
resulted,O,O
in,O,O
the,O,O
32,B,B
",",I,O
36,I,B
to,I,O
42,I,B
and,I,O
110,I,B
kD,I,I
proteins,I,I
and,O,O
to,O,O
less,O,O
extent,O,O
the,O,O
50,B,B
kD,I,I
factor,I,I
.,O,O
Two,O,O
abundant,O,O
proteins,O,B
of,O,O
75,O,O
and,O,O
80,O,O
kD,O,O
were,O,O
competed,O,O
out,O,O
by,O,O
poly,O,O
[,O,O
d,O,O
(,O,O
I,O,O
-,O,O
C,O,O
),O,O
],O,O
in,O,O
all,O,O
reactions,O,O
.,O,O
The,O,O
cAMP,B,O
-,I,O
response,I,O
element,I,O
CRE,B,B
",",O,O
TGACGTCA,O,O
",",O,O
present,O,O
in,O,O
the,O,O
21,B,O
base,I,O
-,I,O
pair,I,O
sequence,I,O
",",O,O
appears,O,O
to,O,O
be,O,O
essential,O,O
for,O,O
specific,O,O
protein,O,B
-,O,O
TRE,B,O
-,O,O
DNA,O,B
interactions,O,O
because,O,O
mutation,O,O
of,O,O
the,O,O
two,O,O
G,O,O
s,O,O
destroys,O,O
this,O,O
complex,O,O
.,O,O
Activity,O,O
of,O,O
the,O,O
immunoglobulin,B,B
heavy,I,I
and,I,I
kappa,I,I
light,I,I
chain,I,I
gene,I,I
enhancers,I,I
depends,O,O
on,O,O
a,O,O
complex,O,O
interplay,O,O
of,O,O
ubiquitous,B,O
and,I,O
developmentally,I,O
regulated,I,O
proteins,I,O
.,O,O
Elevated,O,O
glucocorticoid,B,B
receptor,I,I
concentrations,O,I
before,O,O
and,O,O
after,O,O
glucocorticoid,O,B
therapy,O,I
in,O,O
peripheral,O,O
mononuclear,O,B
leukocytes,O,I
of,O,O
patients,O,O
with,O,O
atopic,O,O
dermatitis,O,O
.,O,O
Patients,O,O
with,O,O
AD,O,O
(,O,O
n,O,O
15,O,O
),O,O
exhibited,O,O
significantly,O,O
more,O,O
glucocorticoid,B,B
receptors,I,I
(,O,O
GR,B,O
),O,O
per,O,O
cell,O,O
than,O,O
the,O,O
control,O,O
group,O,O
(,O,O
n,O,O
22,O,O
),O,O
",",O,O
while,O,O
the,O,O
GR,B,B
affinity,O,I
did,O,O
not,O,O
differ,O,O
.,O,O
Methylprednisolone,O,O
treatment,O,O
resulted,O,O
in,O,O
a,O,O
significant,O,O
reduction,O,O
of,O,O
the,O,O
GR,B,B
sites,O,I
per,O,I
cell,O,I
in,O,O
the,O,O
steroid,O,O
-,O,O
treated,O,O
control,O,O
group,O,O
(,O,O
n,O,O
10,O,O
),O,O
in,O,O
contrast,O,O
to,O,O
the,O,O
patients,O,O
.,O,O
The,O,O
internal,O,O
methionine,O,O
codons,O,O
of,O,O
human,B,B
T,I,I
-,I,I
cell,I,I
leukemia,I,I
virus,I,I
type,I,I
II,I,I
rex,I,I
gene,I,I
are,O,O
not,O,O
required,O,O
for,O,O
p24rex,B,O
production,O,O
or,O,O
virus,O,O
replication,O,O
and,O,O
transformation,O,O
.,O,O
Human,O,B
T,O,I
-,O,I
cell,O,I
leukemia,O,I
virus,O,I
types,O,I
I,O,I
(,O,I
HTLV,O,I
-,O,I
I,O,I
),O,I
and,O,O
II,O,O
(,O,O
HTLV,O,O
-,O,O
II,O,O
),O,O
have,O,O
two,O,O
nonstructural,B,O
trans,I,O
-,I,O
acting,I,O
regulatory,I,O
genes,I,O
",",O,O
tax,B,O
and,O,O
rex,B,O
",",O,O
located,O,O
in,O,O
the,O,O
3,B,O
region,I,O
of,O,O
the,O,O
viral,B,O
genome,I,O
.,O,O
Rex,B,B
acts,O,O
posttranscriptionall,O,O
to,O,O
facilitate,O,O
accumulation,O,O
of,O,O
full,O,O
-,O,O
length,O,O
gag,B,B
/,I,I
pol,I,I
and,O,O
singly,O,O
spliced,O,O
env,B,B
mRNA,I,I
in,O,O
the,O,O
cytoplasm,O,O
of,O,O
HTLV,O,B
-,O,I
infected,O,I
cells,O,I
.,O,O
By,O,O
using,O,O
an,O,O
infectious,O,O
molecular,O,O
clone,O,O
of,O,O
HTLV,O,B
-,O,I
II,O,I
",",O,O
we,O,O
investigated,O,O
the,O,O
importance,O,O
of,O,O
the,O,O
internal,O,O
ATGs,O,B
of,O,O
the,O,O
rex,B,B
gene,I,I
on,O,O
Rex,B,B
protein,O,I
production,O,O
and,O,O
function,O,O
.,O,O
The,O,O
octamer,I,B
sequence,I,O
",",O,O
ATGCAAAT,O,O
or,O,O
its,O,O
complement,O,O
ATTTGCAT,O,O
",",O,O
is,O,O
a,O,O
key,O,O
element,O,O
for,O,O
the,O,O
transcriptional,O,O
regulation,O,O
of,O,O
immunoglobulin,B,O
genes,I,O
in,O,O
B,O,O
-,O,O
lymphocytes,O,O
as,O,O
well,O,O
as,O,O
a,O,O
number,O,O
of,O,O
housekeeping,B,O
genes,I,O
in,O,O
all,O,O
cell,O,O
types,O,O
.,O,O
In,O,O
lymphocytes,O,O
",",O,O
the,O,O
octamer,B,B
-,I,I
binding,I,I
protein,I,I
Oct,B,I
-,I,I
2A,I,I
and,O,O
variants,O,O
thereof,O,O
are,O,O
thought,O,O
to,O,O
contribute,O,O
to,O,O
the,O,O
B,B,O
-,I,O
cell,I,O
specific,I,O
gene,I,O
expression,O,O
",",O,O
while,O,O
the,O,O
ubiquitous,O,O
protein,O,O
Oct,O,B
-,O,I
1,O,I
seems,O,O
to,O,O
control,O,O
general,O,O
octamer,B,O
site,I,O
-,O,O
dependent,O,O
transcription,O,O
.,O,O
Therefore,O,O
",",O,O
the,O,O
phosphorylation,O,O
of,O,O
Rex,B,B
is,O,O
required,O,O
for,O,O
the,O,O
viral,O,O
RNA,O,B
partition,O,O
of,O,O
HTLV,O,O
-,O,O
I,O,O
.,O,O
Cell,O,O
proliferation,O,O
of,O,O
CEM,O,O
-,O,O
C7,O,O
cells,O,O
cultured,O,O
in,O,O
both,O,O
serum,O,O
-,O,O
free,O,O
media,O,O
has,O,O
been,O,O
sustained,O,O
for,O,O
3,O,O
mo,O,O
.,O,O
All,O,O
immunoglobulin,B,O
genes,I,O
contain,O,O
a,O,O
conserved,O,O
octanucleotide,B,O
promoter,I,O
element,I,O
",",O,O
ATGCAAAT,O,O
",",O,O
which,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
required,O,O
for,O,O
their,O,O
normal,O,O
B,O,B
-,O,I
cell,O,I
-,O,I
specific,O,I
transcription,O,O
.,O,O
Proteins,O,B
that,O,O
bind,O,O
this,O,O
octamer,O,O
have,O,O
been,O,O
purified,O,O
",",O,O
and,O,O
cDNAs,B,O
encoding,O,O
octamer,B,O
-,I,O
binding,I,O
proteins,I,O
have,O,O
been,O,O
cloned,O,O
.,O,O
Addition,O,O
of,O,O
a,O,O
highly,O,O
enriched,O,O
preparation,O,O
of,O,O
OTF,B,O
-,I,O
1,I,O
made,O,O
from,O,O
one,O,O
of,O,O
these,O,O
pre,O,O
-,O,O
B,O,O
cells,O,O
or,O,O
from,O,O
HeLa,O,O
cells,O,O
specifically,O,O
stimulated,O,O
in,O,O
vitro,O,O
transcription,O,O
of,O,O
an,O,O
immunoglobulin,B,O
gene,I,O
.,O,O
In,O,O
vitro,O,O
binding,O,O
of,O,O
aldosterone,O,B
to,O,O
mineralocorticoid,B,B
receptors,I,I
on,O,O
human,O,B
mononuclear,O,I
leukocytes,O,I
(,O,O
HML,O,O
),O,O
and,O,O
its,O,O
effects,O,O
on,O,O
the,O,O
intracellular,O,O
sodium,O,B
and,O,O
potassium,O,B
concentrations,O,O
of,O,O
HML,O,O
have,O,O
already,O,O
been,O,O
described,O,O
.,O,O
In,O,O
only,O,O
four,O,O
patients,O,O
sodium,O,B
in,O,O
HML,O,O
without,O,O
incubation,O,O
was,O,O
elevated,O,O
compared,O,O
with,O,O
the,O,O
range,O,O
for,O,O
normal,O,O
persons,O,O
.,O,O
A,O,O
decrease,O,O
of,O,O
intracellular,O,O
sodium,O,B
or,O,O
potassium,O,B
occurred,O,O
during,O,O
incubation,O,O
without,O,O
aldosterone,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
number,O,O
of,O,O
mineralocorticoid,B,B
receptors,I,I
/,O,O
cell,O,O
were,O,O
within,O,O
or,O,O
close,O,O
to,O,O
the,O,O
normal,O,O
range,O,O
(,O,O
n,O,O
9,O,O
),O,O
.,O,O
It,O,O
is,O,O
proposed,O,O
that,O,O
the,O,O
character,O,O
of,O,O
their,O,O
expression,O,O
under,O,O
the,O,O
influence,O,O
of,O,O
vitamin,O,O
D,O,O
may,O,O
be,O,O
used,O,O
with,O,O
differential,O,O
diagnostic,O,O
purposes,O,O
in,O,O
view,O,O
.,O,O
Regulation,O,O
of,O,O
gene,O,O
expression,O,O
with,O,O
double,O,O
-,O,O
stranded,O,O
phosphorothioate,O,O
oligonucleotides,O,O
.,O,O
We,O,O
now,O,O
demonstrate,O,O
the,O,O
following,O,O
.,O,O
Thus,O,O
",",O,O
EBNA,B,B
-,I,I
2,I,I
transactivation,O,O
of,O,O
LMP1,B,O
amplifies,O,O
the,O,O
biological,O,O
impact,O,O
of,O,O
EBNA,B,B
-,I,I
2,I,I
and,O,O
underscores,O,O
its,O,O
central,O,O
role,O,O
in,O,O
EBV,O,O
-,O,O
induced,O,O
growth,O,O
transformation,O,O
.,O,O
Heat,O,O
shock,O,O
caused,O,O
an,O,O
increase,O,O
in,O,O
c,O,O
-,O,O
fos,O,O
and,O,O
c,O,O
-,O,O
jun,O,O
mRNA,O,O
levels,O,O
and,O,O
a,O,O
decrease,O,O
in,O,O
c,B,O
-,I,O
myc,I,O
mRNA,I,O
levels,O,O
in,O,O
pre,O,O
-,O,O
B,O,O
(,O,O
Hyon,O,O
),O,O
and,O,O
T,O,O
(,O,O
DND,O,O
-,O,O
41,O,O
),O,O
cell,O,O
lines,O,O
as,O,O
well,O,O
as,O,O
in,O,O
freshly,O,O
isolated,O,O
normal,O,O
human,O,O
thymocytes,O,O
.,O,O
Mapping,O,O
of,O,O
B,B,B
-,I,I
cell,I,I
epitopes,I,I
of,O,I
the,O,I
human,B,I
hepatitis,I,I
B,I,I
virus,I,I
X,I,I
protein,I,I
.,O,O
Anti,O,O
-,O,O
HBx,B,B
antibody,O,I
titers,O,I
as,O,O
revealed,O,O
by,O,O
peptide,O,O
ELISAs,O,O
were,O,O
highest,O,O
and,O,O
most,O,O
frequent,O,O
in,O,O
patients,O,O
with,O,O
chronic,O,O
hepatitis,O,O
and,O,O
usually,O,O
low,O,O
in,O,O
acutely,O,O
infected,O,O
patients,O,O
and,O,O
asymptomatic,O,O
carriers,O,O
.,O,O
Random,O,O
migration,O,O
(,O,O
RM,O,O
),O,O
and,O,O
chemotactic,O,O
migration,O,O
(,O,O
ChtM,O,O
),O,O
of,O,O
human,O,O
leukocytes,O,O
to,O,O
yeast,O,O
activated,O,O
serum,O,O
were,O,O
studied,O,O
with,O,O
the,O,O
modified,O,O
Boyden,O,O
chamber,O,O
method,O,O
.,O,O
The,O,O
difference,O,O
between,O,O
the,O,O
peak,O,O
(,O,O
0,O,O
:,O,O
),O,O
and,O,O
trough,O,O
values,O,O
(,O,O
8,O,O
:,O,O
),O,O
of,O,O
RM,O,O
and,O,O
ChtM,O,O
was,O,O
significant,O,O
statistically,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
ChtM,O,O
was,O,O
inhibited,O,O
by,O,O
hydrocortisone,O,O
(,O,O
F,O,O
),O,O
of,O,O
physiological,O,O
concentration,O,O
(,O,O
10,O,O
(,O,O
-,O,O
9,O,O
),O,O
-,O,O
10,O,O
(,O,O
-,O,O
7,O,O
),O,O
mol,O,O
/,O,O
L,O,O
),O,O
which,O,O
was,O,O
dose,O,O
-,O,O
dependent,O,O
and,O,O
completely,O,O
antagonized,O,O
by,O,O
the,O,O
competitive,O,O
antagonist,O,O
",",O,O
RU38486,O,O
.,O,O
The,O,O
inhibitory,O,O
effect,O,O
was,O,O
much,O,O
more,O,O
evident,O,O
with,O,O
higher,O,O
dose,O,O
(,O,O
more,O,O
than,O,O
10,O,O
(,O,O
-,O,O
5,O,O
),O,O
mol,O,O
/,O,O
L,O,O
),O,O
and,O,O
it,O,O
was,O,O
also,O,O
reversed,O,O
by,O,O
RU38486,O,O
",",O,O
but,O,O
only,O,O
partially,O,O
.,O,O
Lt,B,O
-,I,O
4,I,O
reacted,O,O
with,O,O
all,O,O
HTLV,O,B
-,O,I
I,O,I
-,O,I
bearing,O,I
cell,O,I
lines,O,I
tested,O,O
and,O,O
five,O,O
out,O,O
of,O,O
eight,O,O
simian,O,O
cell,O,O
lines,O,O
bearing,O,O
STLV,O,O
-,O,O
I,O,O
",",O,O
but,O,O
not,O,O
with,O,O
an,O,O
HTLV,O,B
-,O,I
II,O,I
-,O,I
bearing,O,I
cell,O,I
line,O,I
.,O,O
In,O,O
the,O,O
STLV,O,B
-,O,I
I,O,I
-,O,I
bearing,O,O
T,O,O
cell,O,O
lines,O,O
",",O,O
tax1,B,O
-,I,O
related,I,O
antigen,I,O
molecules,I,O
detected,O,O
by,O,O
Lt,B,O
-,I,O
4,I,O
were,O,O
heterogeneous,O,O
",",O,O
having,O,O
molecular,O,O
weights,O,O
in,O,O
the,O,O
range,O,O
of,O,O
36,O,O
-,O,O
41,O,O
kd,O,O
.,O,O
The,O,O
transcription,O,O
of,O,O
the,O,O
human,O,B
immunodeficiency,O,I
virus,O,I
type,O,I
1,O,I
(,O,O
HIV,O,O
-,O,O
1,O,O
),O,O
is,O,O
under,O,O
the,O,O
control,O,O
of,O,O
cellular,B,O
proteins,I,O
that,O,O
bind,O,O
to,O,O
the,O,O
viral,B,O
long,I,B
terminal,I,I
repeat,I,I
(,O,I
LTR,B,I
),O,O
.,O,O
The,O,O
corresponding,O,O
region,O,O
in,O,O
the,O,O
second,O,O
AIDS,O,O
retrovirus,O,O
",",O,O
HIV,O,B
-,O,I
2,O,I
",",O,O
contains,O,O
a,O,O
conserved,O,O
and,O,O
a,O,O
divergent,O,O
NF,B,B
kappa,I,I
B,I,I
binding,I,I
site,I,I
.,O,O
Instead,O,O
of,O,O
NF,B,B
kappa,I,I
B,I,I
",",O,O
the,O,O
activator,B,O
protein,I,O
3,I,O
binds,O,O
to,O,O
the,O,O
divergent,O,O
site,O,O
in,O,O
HIV,O,B
-,O,I
2,O,I
.,O,O
Expression,O,O
cloning,O,O
of,O,O
c,B,O
-,I,O
Jun,I,O
.,O,O
Whereas,O,O
c,B,O
-,I,O
Fos,I,O
/,I,O
c,I,O
-,I,O
Jun,I,O
heterodimers,I,O
do,O,O
not,O,O
exist,O,O
in,O,O
B,O,O
cells,O,O
",",O,O
they,O,O
form,O,O
and,O,O
bind,O,O
to,O,O
the,O,O
X2,B,O
-,I,O
box,I,O
in,O,O
class,O,O
II,O,O
nonexpressing,O,O
cells,O,O
.,O,O
11,O,O
beta,O,O
",",O,O
19,O,O
-,O,O
epoxy,O,O
-,O,O
4,O,O
",",O,O
21,O,O
-,O,O
dihydroxypregn,O,O
-,O,O
4,O,O
-,O,O
ene,O,O
-,O,O
3,O,O
",",O,O
20,O,O
-,O,O
dione,O,O
(,O,O
2,O,O
),O,O
was,O,O
hydrogenated,O,O
with,O,O
Pd,O,O
-,O,O
C,O,O
to,O,O
yield,O,O
a,O,O
mixture,O,O
of,O,O
all,O,O
four,O,O
dihydro,O,O
derivatives,O,O
5,O,O
",",O,O
accompanied,O,O
by,O,O
4,O,O
",",O,O
21,O,O
-,O,O
diacetoxy,O,O
-,O,O
11,O,O
beta,O,O
",",O,O
19,O,O
-,O,O
epoxy,O,O
-,O,O
3,O,O
-,O,O
hydroxypregnan,O,O
-,O,O
20,O,O
-,O,O
one,O,O
(,O,O
6,O,O
),O,O
and,O,O
21,O,O
-,O,O
acetoxy,O,O
-,O,O
11,O,O
beta,O,O
",",O,O
19,O,O
-,O,O
epoxy,O,O
-,O,O
4,O,O
-,O,O
hydroxypregnane,O,O
-,O,O
3,O,O
",",O,O
20,O,O
-,O,O
dione,O,O
(,O,O
7,O,O
),O,O
Treatment,O,O
of,O,O
10,O,O
with,O,O
warm,O,O
HCl,O,O
furnished,O,O
19,O,O
-,O,O
chloro,O,O
-,O,O
4,O,O
",",O,O
21,O,O
-,O,O
dihydroxypregna,O,O
-,O,O
4,O,O
",",O,O
9,O,O
(,O,O
11,O,O
),O,O
-,O,O
diene,O,O
-,O,O
3,O,O
",",O,O
20,O,O
-,O,O
dione,O,O
(,O,O
13,O,O
),O,O
.,O,O
When,O,O
tested,O,O
in,O,O
a,O,O
radioreceptor,O,O
assay,O,O
in,O,O
human,O,O
mononuclear,O,O
leukocytes,O,O
the,O,O
synthesized,O,O
compounds,O,O
showed,O,O
only,O,O
low,O,O
relative,O,O
binding,O,O
affinities,O,O
(,O,O
RBA,O,O
),O,O
to,O,O
type,B,O
1,I,O
receptor,I,O
",",O,O
the,O,O
highest,O,O
being,O,O
0,O,O
.,O,O
72,O,O
%,O,O
for,O,O
13,O,O
(,O,O
aldosterone,O,O
100,O,O
%,O,O
),O,O
.,O,O
We,O,O
have,O,O
developed,O,O
a,O,O
system,O,O
to,O,O
monitor,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
NFAT,B,B
-,I,O
1,I,O
at,O,O
the,O,O
single,O,O
cell,O,O
level,O,O
in,O,O
whole,O,O
animals,O,O
.,O,O
This,O,O
report,O,O
represents,O,O
the,O,O
first,O,O
demonstration,O,O
that,O,O
a,O,O
multimerized,O,O
short,O,O
binding,O,O
motif,O,O
can,O,O
function,O,O
appropriately,O,O
in,O,O
transgenic,O,O
mice,O,O
.,O,O
This,O,O
similarity,O,O
in,O,O
expression,O,O
and,O,O
the,O,O
fact,O,O
that,O,O
NFAT,B,B
-,I,O
1,I,O
has,O,O
been,O,O
shown,O,O
to,O,O
bind,O,O
functional,B,O
sequences,I,O
in,O,O
HIV,B,B
-,I,O
LTR,I,I
suggest,O,O
a,O,O
role,O,O
for,O,O
NFAT,B,B
-,I,O
1,I,O
in,O,O
dermal,O,O
activation,O,O
of,O,O
the,O,O
HIV,B,B
-,I,O
LTR,I,I
.,O,O
A,O,O
novel,O,O
T,B,B
-,I,I
cell,I,I
protein,I,I
recognized,O,O
the,O,O
palindromic,B,O
sequence,I,O
within,O,O
site,B,O
B,I,O
and,O,O
also,O,O
bound,O,O
estrogen,B,B
-,I,I
or,I,O
thyroid,I,B
hormone,I,I
-,I,I
response,I,I
elements,I,I
with,O,O
lower,O,O
affinity,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
a,O,O
competitive,O,O
progesterone,O,O
antagonist,O,O
(,O,O
RU486,O,O
),O,O
and,O,O
a,O,O
specific,O,O
glucocorticoid,B,B
receptor,I,I
blocker,O,I
(,O,O
RU43044,O,O
),O,O
were,O,O
tested,O,O
on,O,O
the,O,O
release,O,O
of,O,O
a,O,O
blocking,B,O
factor,I,O
by,O,O
progesterone,O,O
-,O,O
treated,O,O
pregnancy,O,O
lymphocytes,O,O
.,O,O
It,O,O
has,O,O
previously,O,O
been,O,O
shown,O,O
that,O,O
9S,B,O
",",O,O
untransformed,B,O
progestin,I,B
",",I,O
estrogen,I,B
",",I,O
androgen,I,B
",",I,O
and,I,O
glucocorticoid,I,B
receptor,I,I
complexes,I,I
in,O,O
rabbit,O,O
uterine,O,B
and,O,O
liver,O,B
cytosols,O,I
contain,O,O
a,O,O
59,B,O
-,I,O
kDa,I,O
protein,I,B
[,O,O
Tai,O,O
",",O,O
P,O,O
.,O,O
K,O,O
.,O,O
",",O,O
Maeda,O,O
",",O,O
Y,O,O
.,O,O
",",O,O
Nakao,O,O
",",O,O
K,O,O
.,O,O
",",O,O
Wakim,O,O
",",O,O
N,O,O
.,O,O
G,O,O
.,O,O
",",O,O
Duhring,O,O
",",O,O
J,O,O
.,O,O
L,O,O
.,O,O
",",O,O
&,O,O
Faber,O,O
",",O,O
L,O,O
.,O,O
E,O,O
.,O,O
(,O,O
1986,O,O
),O,O
Biochemistry,O,O
25,O,O
",",O,O
5269,O,O
-,O,O
5275,O,O
],O,O
.,O,O
Sequence,O,O
-,O,O
specific,O,O
DNA,O,B
binding,O,O
of,O,O
the,O,O
proto,B,O
-,I,O
oncoprotein,I,O
ets,B,O
-,I,O
1,I,O
defines,O,O
a,O,O
transcriptional,B,O
activator,I,O
sequence,I,O
within,O,O
the,O,O
long,B,O
terminal,I,O
repeat,I,O
of,O,O
the,O,O
Moloney,O,O
murine,O,O
sarcoma,O,O
virus,O,O
.,O,O
A,O,O
mutant,B,O
LTR,I,O
containing,O,O
four,O,O
base,O,O
pair,O,O
substitutions,O,O
in,O,O
the,O,O
ets,B,O
-,I,O
1,I,O
binding,I,O
site,I,O
was,O,O
constructed,O,O
and,O,O
was,O,O
shown,O,O
to,O,O
have,O,O
reduced,O,O
binding,O,O
in,O,O
vitro,O,O
.,O,O
We,O,O
propose,O,O
that,O,O
ets,B,B
-,I,I
1,I,I
functions,O,O
as,O,O
a,O,O
transcriptional,O,O
activator,O,O
of,O,O
mammalian,O,O
type,O,O
-,O,O
C,O,O
retroviruses,O,O
and,O,O
speculate,O,O
that,O,O
ets,B,B
-,I,I
related,I,I
genes,I,I
constitute,O,O
a,O,O
new,O,O
group,O,O
of,O,O
eukaryotic,B,O
DNA,I,B
-,I,I
binding,I,I
proteins,I,I
.,O,O
We,O,O
have,O,O
previously,O,O
reported,O,O
that,O,O
human,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
(,O,O
PBMC,O,O
),O,O
contain,O,O
type,O,O
II,B,O
estrogen,I,B
binding,I,I
sites,I,I
(,O,O
type,B,O
II,I,O
EBS,I,O
),O,O
.,O,O
In,O,O
postmenopausal,O,O
women,O,O
the,O,O
mean,O,O
type,B,B
II,I,I
EBS,I,I
levels,O,O
were,O,O
similar,O,O
to,O,O
those,O,O
observed,O,O
in,O,O
the,O,O
follicular,O,O
phase,O,O
of,O,O
the,O,O
cycle,O,O
.,O,O
Tamoxifen,O,O
was,O,O
also,O,O
found,O,O
to,O,O
compete,O,O
with,O,O
17,O,O
beta,O,O
-,O,O
estradiol,O,O
for,O,O
type,B,B
II,I,I
EBS,I,I
in,O,O
PBMC,O,O
",",O,O
although,O,O
to,O,O
a,O,O
lesser,O,O
extent,O,O
than,O,O
diethylstilbestrol,O,O
.,O,O
These,O,O
results,O,O
do,O,O
not,O,O
lend,O,O
support,O,O
to,O,O
previous,O,O
reports,O,O
suggesting,O,O
that,O,O
GC,O,O
resistance,O,O
in,O,O
MDD,O,O
results,O,O
from,O,O
a,O,O
GC,O,O
receptor,O,O
-,O,O
binding,O,O
abnormality,O,O
",",O,O
and,O,O
they,O,O
emphasize,O,O
the,O,O
importance,O,O
of,O,O
considering,O,O
receptor,O,O
studies,O,O
in,O,O
the,O,O
context,O,O
of,O,O
GC,O,O
-,O,O
mediated,O,O
cell,O,O
processes,O,O
in,O,O
order,O,O
to,O,O
identify,O,O
the,O,O
exact,O,O
cellular,O,O
defect,O,O
(,O,O
s,O,O
),O,O
leading,O,O
to,O,O
GC,O,O
resistance,O,O
.,O,O
Proteins,O,B
exist,O,O
in,O,O
leukocytes,O,O
able,O,O
to,O,O
modify,O,O
GTP,B,B
-,I,I
binding,I,I
protein,I,I
function,O,O
in,O,O
this,O,O
manner,O,O
",",O,O
and,O,O
their,O,O
activity,O,O
may,O,O
be,O,O
regulated,O,O
by,O,O
signals,O,O
generated,O,O
on,O,O
phagocyte,O,O
stimulation,O,O
.,O,O
Proteins,O,B
of,O,O
the,O,O
Ras,B,B
superfamily,I,I
are,O,O
likely,O,O
to,O,O
be,O,O
involved,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
normal,O,O
phagocyte,O,O
functions,O,O
through,O,O
their,O,O
ability,O,O
to,O,O
modulate,O,O
the,O,O
assembly,O,O
of,O,O
actin,B,B
filaments,I,I
",",O,O
direct,O,O
vesicle,O,B
trafficking,O,I
and,O,O
fusion,O,O
",",O,O
and,O,O
so,O,O
forth,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
1,O,O
",",O,O
25,O,O
-,O,O
dihydroxyvitamin,O,B
D3,O,I
[,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2,O,O
),O,O
D3,O,O
],O,O
",",O,O
a,O,O
steroid,O,B
hormone,O,I
with,O,O
immunomodulating,O,O
properties,O,O
",",O,O
on,O,O
nuclear,B,O
factor,I,O
kappa,I,O
B,I,O
(,O,O
NF,B,B
-,I,O
kappa,I,O
B,I,O
),O,O
proteins,O,O
was,O,O
examined,O,O
in,O,O
in,O,O
vitro,O,O
activated,O,O
normal,O,B
human,O,I
lymphocytes,O,I
by,O,O
Western,O,O
blot,O,O
analysis,O,O
.,O,O
Over,O,O
a,O,O
72,O,O
-,O,O
hr,O,O
period,O,O
of,O,O
activation,O,O
",",O,O
the,O,O
expression,O,O
of,O,O
the,O,O
50,B,O
-,I,O
kDa,I,O
NF,I,B
-,I,O
kappa,I,O
B,I,O
",",O,O
p50,B,O
",",O,O
and,O,O
its,O,O
precursor,O,O
",",O,O
p105,B,O
",",O,O
was,O,O
increased,O,O
progressively,O,O
.,O,O
When,O,O
cells,O,O
were,O,O
activated,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
",",O,O
the,O,O
levels,O,O
of,O,O
the,O,O
mature,O,O
protein,O,B
as,O,O
well,O,O
as,O,O
its,O,O
precursor,O,O
were,O,O
decreased,O,O
.,O,O
Further,O,O
",",O,O
1,O,O
",",O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
inhibited,O,O
the,O,O
transcriptional,O,O
activity,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
Jurkat,O,O
cells,O,O
transiently,O,O
transfected,O,O
with,O,O
a,O,O
construct,B,O
containing,O,O
four,O,O
tandem,B,O
repeats,I,O
of,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
binding,I,I
sequence,I,I
of,O,O
the,O,O
immunoglobulin,B,O
kappa,I,O
light,I,O
chain,I,O
gene,I,O
linked,O,O
to,O,O
the,O,O
chloramphenicol,B,O
acetyltransferase,I,O
reporter,I,O
gene,I,O
.,O,O
These,O,O
observations,O,O
demonstrate,O,O
directly,O,O
that,O,O
there,O,O
is,O,O
de,O,O
novo,O,O
synthesis,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
during,O,O
human,O,O
lymphocyte,O,O
activation,O,O
and,O,O
suggest,O,O
that,O,O
this,O,O
process,O,O
is,O,O
hormonally,O,O
regulated,O,O
.,O,O
We,O,O
previously,O,O
identified,O,O
the,O,O
DNA,B,B
consensus,I,I
binding,I,I
site,I,I
recognized,O,O
by,O,O
the,O,O
two,O,O
DNA,B,B
binding,I,I
domains,I,I
.,O,O
The,O,O
expression,O,O
vector,O,O
was,O,O
cotransfected,O,O
with,O,O
the,O,O
chloramphenicol,B,O
acetyl,I,O
transferase,I,O
(,I,O
CAT,I,O
),I,O
reporter,I,O
gene,I,O
regulated,O,O
by,O,O
the,O,O
thymidine,B,O
kinase,I,O
promoter,I,O
containing,O,O
GAL4,B,O
DNA,I,B
binding,I,I
sites,I,I
into,O,O
NIH,O,O
3T3,O,O
",",O,O
293,O,O
",",O,O
K562,O,O
",",O,O
and,O,O
Jurkat,O,O
cell,O,O
lines,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
MZF,B,B
-,I,I
1,I,I
activates,O,O
CAT,B,B
reporter,I,I
gene,I,I
expression,O,O
in,O,O
the,O,O
hematopoietic,O,B
cell,O,I
lines,O,I
K562,O,O
and,O,O
Jurkat,O,O
.,O,O
The,O,O
MZF,B,B
-,I,I
1,I,I
binding,I,O
sites,I,O
are,O,O
present,O,O
in,O,O
the,O,O
promoters,B,O
of,O,O
several,O,O
genes,B,O
expressed,O,O
during,O,O
myeloid,O,B
differentiation,O,I
",",O,O
including,O,O
the,O,O
CD34,B,B
promoter,I,I
.,O,O
This,O,O
induction,O,O
was,O,O
not,O,O
inhibited,O,O
by,O,O
treatment,O,O
of,O,O
the,O,O
cells,O,O
with,O,O
a,O,O
protein,O,B
synthesis,O,I
inhibitor,O,I
",",O,O
cycloheximide,O,O
.,O,O
The,O,O
role,O,O
of,O,O
BSAP,B,B
(,O,O
Pax,B,I
in,O,O
B,O,B
-,O,I
cell,O,I
development,O,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
biochemical,O,O
and,O,O
cell,O,O
biological,O,O
properties,O,O
of,O,O
these,O,O
HSFs,B,O
reveals,O,O
that,O,O
HSF3,B,O
has,O,O
properties,O,O
in,O,O
common,O,O
with,O,O
both,O,O
HSF1,B,O
and,O,O
HSF2,B,O
and,O,O
yet,O,O
has,O,O
features,O,O
which,O,O
are,O,O
distinct,O,O
from,O,O
both,O,O
.,O,O
HSF3,B,O
is,O,O
constitutively,O,O
expressed,O,O
in,O,O
the,O,O
erythroblast,O,B
cell,O,I
line,O,I
HD6,O,O
",",O,O
the,O,O
lymphoblast,O,B
cell,O,I
line,O,I
MSB,O,O
",",O,O
and,O,O
embryo,O,B
fibroblasts,O,I
",",O,O
and,O,O
yet,O,O
its,O,O
DNA,O,B
-,O,I
binding,O,I
activity,O,I
is,O,O
induced,O,O
only,O,O
upon,O,O
exposure,O,O
of,O,O
HD6,O,O
cells,O,O
to,O,O
heat,O,O
shock,O,O
.,O,O
Nuclear,B,O
factor,I,O
of,I,O
activated,I,O
T,I,O
cells,I,O
(,O,O
NFAT,B,B
),O,O
regulates,O,O
transcription,O,O
of,O,O
a,O,O
number,O,O
of,O,O
cytokine,B,O
genes,I,O
",",O,O
and,O,O
NFAT,B,B
DNA,O,I
binding,O,I
activity,O,I
is,O,O
stimulated,O,O
following,O,O
T,O,O
cell,O,O
activation,O,O
.,O,O
Treatment,O,O
of,O,O
immunoprecipitated,O,O
NFATp,B,B
from,O,O
untreated,O,O
HT,O,O
-,O,O
2,O,O
cells,O,O
with,O,O
calcineurin,B,O
resulted,O,O
in,O,O
the,O,O
dephosphorylation,O,O
of,O,O
NFATp,B,B
",",O,O
demonstrating,O,O
that,O,O
NFATp,B,B
is,O,O
an,O,O
in,O,O
vitro,O,O
substrate,O,O
for,O,O
calcineurin,B,O
.,O,O
Both,O,O
of,O,O
these,O,O
events,O,O
were,O,O
blocked,O,O
by,O,O
preincubation,O,O
of,O,O
the,O,O
cells,O,O
with,O,O
FK506,O,O
",",O,O
a,O,O
calcineurin,B,B
inhibitor,O,O
",",O,O
consistent,O,O
with,O,O
the,O,O
hypothesis,O,O
that,O,O
NFATp,B,B
is,O,O
a,O,O
calcineurin,B,O
substrate,O,O
in,O,O
cells,O,O
.,O,O
Activation,O,O
and,O,O
expression,O,O
of,O,O
the,O,O
nuclear,B,O
factors,I,O
of,O,O
activated,O,O
T,O,O
cells,O,O
",",O,O
NFATp,B,B
and,O,O
NFATc,B,B
",",O,O
in,O,O
human,O,O
natural,O,O
killer,O,O
cells,O,O
:,O,O
regulation,O,O
upon,O,O
CD16,B,O
ligand,O,O
binding,O,O
.,O,O
The,O,O
results,O,O
of,O,O
supershift,O,O
assays,O,O
using,O,O
NFATp,B,B
-,I,O
and,I,O
NFATc,I,B
-,I,O
specific,I,O
antibodies,I,O
indicate,O,O
that,O,O
NK,O,B
cell,O,I
activation,O,O
early,O,O
after,O,O
CD16,B,O
ligand,O,O
binding,O,O
involves,O,O
primarily,O,O
",",O,O
if,O,O
not,O,O
exclusively,O,O
",",O,O
NFATp,B,B
",",O,O
and,O,O
Western,O,O
blot,O,O
analysis,O,O
shows,O,O
that,O,O
this,O,O
has,O,O
the,O,O
same,O,O
electrophoretic,O,O
mobility,O,O
(,O,O
approximately,O,O
120,O,O
kD,O,O
),O,O
as,O,O
that,O,O
of,O,O
T,O,B
lymphocytes,O,I
.,O,O
Since,O,O
many,O,O
cytokines,B,O
that,O,O
activate,O,O
Jak,B,O
kinases,I,O
also,O,O
lead,O,O
to,O,O
the,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
activation,O,O
of,O,O
members,O,O
of,O,O
the,O,O
Stat,B,B
family,I,I
of,O,I
transcription,B,I
factors,I,I
",",O,O
the,O,O
ability,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
to,O,O
trigger,O,O
Stat,O,B
phosphorylation,O,O
was,O,O
examined,O,O
.,O,O
Exposure,O,O
of,O,O
activated,O,O
human,O,B
T,O,I
lymphocytes,O,I
or,O,O
of,O,O
a,O,O
natural,O,B
killer,O,I
cell,O,I
line,O,I
(,O,O
NKL,O,B
),O,O
to,O,O
IL,B,B
-,I,I
2,I,I
leads,O,O
to,O,O
the,O,O
phosphorylation,O,O
of,O,O
Stat1,B,B
alpha,I,I
",",O,O
Stat1,O,B
beta,O,I
",",O,O
and,O,O
Stat3,B,B
",",O,O
as,O,O
well,O,O
as,O,O
of,O,O
two,O,O
Stat,B,B
-,I,I
related,I,I
proteins,I,I
",",O,O
p94,B,B
and,O,O
p95,B,B
.,O,O
These,O,O
Stat,B,B
proteins,I,I
were,O,O
found,O,O
to,O,O
translocate,O,O
to,O,O
the,O,O
nucleus,O,O
and,O,O
to,O,O
bind,O,O
to,O,O
a,O,O
specific,B,O
DNA,I,B
sequence,I,O
.,O,O
Results,O,O
indicated,O,O
that,O,O
(,O,O
i,O,O
),O,O
constitutive,O,O
c,B,O
-,I,O
fos,I,O
transcript,I,O
levels,O,O
are,O,O
significantly,O,O
higher,O,O
in,O,O
patients,O,O
subsequently,O,O
responding,O,O
to,O,O
IFN,B,B
-,I,I
alpha,I,I
therapy,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
positively,O,O
correlated,O,O
with,O,O
the,O,O
proportion,O,O
of,O,O
lymphocytes,O,O
(,O,O
r,O,O
0,O,O
.,O,O
6895,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
negatively,O,O
with,O,O
the,O,O
proportion,O,O
of,O,O
immature,O,O
cells,O,O
(,O,O
r,O,O
-,O,O
0,O,O
.,O,O
568,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
contained,O,O
in,O,O
the,O,O
pbmc,O,O
preparations,O,O
tested,O,O
",",O,O
(,O,O
ii,O,O
),O,O
constitutive,B,O
mRNA,I,O
levels,O,O
of,O,O
the,O,O
hybrid,B,O
bcr,I,O
/,I,O
abl,I,O
",",O,O
c,B,O
-,I,O
myc,I,O
and,O,O
p53,B,O
are,O,O
positively,O,O
correlated,O,O
with,O,O
each,O,O
other,O,O
",",O,O
but,O,O
failed,O,O
to,O,O
relate,O,O
to,O,O
disease,O,O
parameters,O,O
",",O,O
and,O,O
(,O,O
iii,O,O
),O,O
acute,O,O
and,O,O
chronic,O,O
in,O,O
vivo,O,O
exposure,O,O
to,O,O
IFN,B,B
-,I,I
alpha,I,I
is,O,O
accompanied,O,O
by,O,O
upregulation,O,O
of,O,O
c,B,O
-,I,O
fos,I,O
and,O,O
downregulation,O,O
of,O,O
c,B,O
-,I,O
myc,I,O
mRNA,I,O
levels,O,O
in,O,O
responder,O,O
patients,O,O
.,O,O
In,O,O
parallel,O,O
experiments,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
-,O,I
driven,O,O
proliferation,O,O
was,O,O
inhibited,O,O
significantly,O,O
.,O,O
Yet,O,O
",",O,O
IL,B,B
-,I,I
2,I,I
-,O,I
driven,O,O
proliferation,O,O
remained,O,O
profoundly,O,O
inhibited,O,O
",",O,O
suggesting,O,O
that,O,O
signaling,O,O
events,O,O
other,O,O
than,O,O
Jak3,B,O
/,B,O
Stat,I,O
activation,O,O
had,O,O
also,O,O
been,O,O
changed,O,O
following,O,O
SE,B,O
stimulation,O,O
.,O,O
In,O,O
contrast,O,O
to,O,O
hematopoietic,O,B
cells,O,I
",",O,O
I,O,O
kappa,O,O
B,O,O
alpha,O,O
-,O,O
/,O,O
-,O,O
embryonic,O,B
fibroblasts,O,I
show,O,O
minimal,O,O
constitutive,B,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
",",O,O
as,O,O
well,O,O
as,O,O
normal,O,O
signal,O,O
-,O,O
dependent,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,O
that,O,O
is,O,O
concomitant,O,O
with,O,O
I,B,O
kappa,I,O
B,I,O
beta,I,O
degradation,O,O
.,O,O
Moreover,O,O
",",O,O
the,O,O
induction,O,O
of,O,O
both,O,O
Jak,B,B
1,I,I
and,I,O
3,I,I
",",O,O
and,O,O
STAT,B,B
5,I,I
activity,O,O
strongly,O,O
correlated,O,O
with,O,O
the,O,O
growth,O,O
-,O,O
promoting,O,O
effects,O,O
of,O,O
IL,B,B
-,I,I
7,I,I
",",O,O
suggesting,O,O
that,O,O
this,O,O
signal,O,O
transduction,O,O
mechanism,O,O
may,O,O
play,O,O
a,O,O
key,O,O
role,O,O
in,O,O
IL,B,B
-,I,I
7,I,I
-,O,I
induced,O,I
proliferation,O,O
.,O,O
Cytokine,B,O
-,O,O
modulating,O,O
activity,O,O
of,O,O
tepoxalin,O,O
",",O,O
a,O,O
new,O,O
potential,O,O
antirheumatic,O,O
.,O,O
In,O,O
human,O,O
peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
(,O,O
PBMC,O,O
),O,O
stimulated,O,O
with,O,O
OKT3,O,O
/,O,O
PMA,O,O
",",O,O
tepoxalin,O,O
inhibited,O,O
lymphocyte,O,O
proliferation,O,O
with,O,O
an,O,O
IC50,O,O
of,O,O
6,O,O
microM,O,O
.,O,O
Cytotoxicity,O,O
was,O,O
not,O,O
demonstrated,O,O
at,O,O
these,O,O
concentrations,O,O
.,O,O
Tepoxalin,O,O
also,O,O
inhibits,O,O
the,O,O
activation,O,O
of,O,O
NF,B,B
kappa,I,I
B,I,I
",",O,O
a,O,O
transcription,B,O
factor,I,O
which,O,O
acts,O,O
on,O,O
several,O,O
cytokine,B,O
genes,I,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
expression,O,O
of,O,O
human,B,O
I,I,B
kappa,I,I
B,I,I
alpha,I,I
protein,I,O
in,O,O
stable,O,O
transfectants,O,O
of,O,O
mouse,O,O
70Z,O,O
/,O,O
3,O,O
cells,O,O
shows,O,O
that,O,O
",",O,O
as,O,O
for,O,O
the,O,O
endogenous,O,O
murine,O,O
protein,O,O
",",O,O
exogenous,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
is,O,O
degraded,O,O
in,O,O
response,O,O
to,O,O
inducers,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activity,O,O
",",O,O
such,O,O
as,O,O
phorbol,O,O
myristate,O,O
acetate,O,O
or,O,O
lipopolysaccharide,O,O
.,O,O
By,O,O
expressing,O,O
mutant,O,O
forms,O,O
of,O,O
the,O,O
human,O,O
protein,O,B
in,O,O
this,O,O
cell,O,B
line,O,I
",",O,O
we,O,O
have,O,O
been,O,O
able,O,O
to,O,O
delineate,O,O
the,O,O
sequences,O,O
responsible,O,O
for,O,O
both,O,O
the,O,O
ligand,O,O
-,O,O
induced,O,O
phosphorylation,O,O
and,O,O
the,O,O
degradation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
.,O,O
Interestingly,O,O
",",O,O
microtubule,B,O
disruption,O,O
also,O,O
decreased,O,O
monocyte,O,B
1,O,I
",",O,O
25,O,I
(,O,I
OH,O,I
),O,I
2D3,O,I
synthesis,O,O
",",O,O
not,O,O
by,O,O
decreasing,O,O
the,O,O
Vmax,O,O
of,O,O
monocyte,B,O
mitochondrial,I,O
1,I,O
alpha,I,O
-,I,O
hydroxylase,I,O
but,O,O
through,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
Km,O,O
for,O,O
25,O,O
(,O,O
OH,O,O
),O,O
2D3,O,O
.,O,O
We,O,O
examined,O,O
25,O,O
(,O,O
OH,O,B
),O,I
D3,O,I
transport,O,O
.,O,O
Finally,O,O
",",O,O
by,O,O
studying,O,O
a,O,O
further,O,O
series,O,O
of,O,O
patients,O,O
",",O,O
we,O,O
could,O,O
confirm,O,O
that,O,O
the,O,O
decrease,O,O
in,O,O
Rap1,B,B
protein,I,I
expression,O,O
in,O,O
heart,O,O
failure,O,O
",",O,O
whatever,O,O
its,O,O
extent,O,O
",",O,O
was,O,O
variable,O,O
",",O,O
and,O,O
could,O,O
strictly,O,O
correlate,O,O
the,O,O
expression,O,O
of,O,O
Rap1,B,B
protein,I,I
with,O,O
the,O,O
stimulatory,O,O
effect,O,O
of,O,O
C,B,O
.,I,O
Sub,I,O
.,I,O
on,O,O
Ca2,O,B
+,O,I
transport,O,O
.,O,O
An,O,O
IRF,B,B
-,I,I
1,I,I
-,O,I
dependent,O,O
pathway,O,O
of,O,O
DNA,O,B
damage,O,I
-,O,I
induced,O,I
apoptosis,O,O
in,O,O
mitogen,O,O
-,O,O
activated,O,O
T,O,O
lymphocytes,O,O
.,O,O
Here,O,O
we,O,O
show,O,O
DNA,O,B
damage,O,I
-,O,I
induced,O,I
apoptosis,O,O
in,O,O
these,O,O
T,O,O
lymphocytes,O,O
is,O,O
dependent,O,O
on,O,O
the,O,O
antioncogenic,B,O
transcription,I,O
factor,I,O
interferon,I,O
regulatory,I,O
factor,I,O
(,B,O
IRF,I,O
),I,O
-,I,O
1,I,O
.,O,O
Activation,O,O
through,O,O
the,O,O
Ca2,O,B
+,O,I
/,O,I
calcineurin,B,I
pathway,O,O
is,O,O
essential,O,O
to,O,O
the,O,O
transcription,O,O
of,O,O
many,O,O
cytokine,B,O
genes,I,O
.,O,O
Results,O,O
from,O,O
site,O,O
-,O,O
directed,O,O
mutations,O,O
and,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
assays,O,O
strongly,O,O
suggest,O,O
that,O,O
this,O,O
sequence,O,O
mediates,O,O
the,O,O
ionomycin,O,O
-,O,O
induced,O,O
activation,O,O
of,O,O
the,O,O
TCRG,B,B
enhancer,I,O
.,O,O
Our,O,O
studies,O,O
provide,O,O
an,O,O
explanation,O,O
for,O,O
a,O,O
previous,O,O
observation,O,O
that,O,O
TCRG,B,B
mRNA,I,O
levels,O,O
",",O,O
but,O,O
not,O,O
mRNA,O,O
levels,O,O
for,O,O
T,B,O
cell,I,O
receptor,I,O
alpha,I,O
and,I,O
-,I,O
beta,I,O
",",O,O
are,O,O
increased,O,O
by,O,O
ionomycin,O,O
treatment,O,O
.,O,O
Coexpression,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
/,I,I
Rel,I,I
and,O,O
Sp1,B,B
transcription,B,I
factors,I,I
in,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
1,O,O
-,O,O
induced,O,O
",",O,O
dendritic,O,O
cell,O,O
-,O,O
T,O,O
-,O,O
cell,O,O
syncytia,O,O
.,O,O
These,O,O
syncytia,O,O
lack,O,O
activated,O,O
cells,O,O
as,O,O
determined,O,O
by,O,O
an,O,O
absence,O,O
of,O,O
staining,O,O
for,O,O
Ki,O,O
-,O,O
67,O,O
cell,O,O
cycle,O,O
antigen,O,O
.,O,O
We,O,O
have,O,O
used,O,O
immunolabeling,O,O
",",O,O
Western,O,O
blot,O,O
analysis,O,O
",",O,O
and,O,O
electrophoretic,O,O
mobility,O,O
shift,O,O
and,O,O
supershift,O,O
assays,O,O
.,O,O
T,O,B
cells,O,O
lack,O,O
active,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
but,O,O
express,O,O
Sp1,B,B
as,O,O
expected,O,O
.,O,O
Therefore,O,O
",",O,O
HIV,O,O
-,O,O
1,O,O
-,O,O
induced,O,O
cell,O,O
fusion,O,O
brings,O,O
together,O,O
factors,O,O
that,O,O
upregulate,O,O
virus,O,O
transcription,O,O
.,O,O
Deoxycholate,O,O
treatment,O,O
of,O,O
the,O,O
cytoplasmic,O,B
extract,O,I
prepared,O,O
from,O,O
cells,O,O
stimulated,O,O
by,O,O
TNF,B,B
-,I,I
alpha,I,I
in,O,O
the,O,O
presence,O,O
of,O,O
Cu2,O,O
+,O,O
resulted,O,O
in,O,O
the,O,O
release,O,O
of,O,O
NF,B,B
kappa,I,I
B,I,I
from,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
",",O,O
indicating,O,O
that,O,O
Cu2,O,O
+,O,O
interferes,O,O
with,O,O
the,O,O
dissociation,O,O
of,O,O
the,O,O
NF,B,B
kappa,I,I
B,I,I
-,I,I
I,I,I
kappa,I,I
B,I,I
complex,I,I
.,O,O
Neither,O,O
phosphorylation,O,O
nor,O,O
degradation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
was,O,O
observed,O,O
upon,O,O
TNF,B,B
-,I,I
alpha,I,I
stimulation,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
Cu2,O,O
+,O,O
.,O,O
Cloning,O,O
a,O,O
cDNA,B,O
from,O,O
human,O,O
NK,O,O
/,O,O
T,O,O
cells,O,O
which,O,O
codes,O,O
for,O,O
a,O,O
protein,O,O
with,O,O
high,O,O
proline,O,O
content,O,O
.,O,O
The,O,O
present,O,O
study,O,O
verified,O,O
the,O,O
ability,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
to,O,O
cause,O,O
tyrosine,O,O
phosphorylation,O,O
and,O,O
activation,O,O
of,O,O
JAK1,B,B
and,O,O
JAK3,B,B
",",O,O
but,O,O
demonstrated,O,O
that,O,O
IL,B,B
-,I,I
2,I,I
stimulated,O,O
JAK3,B,B
to,O,O
a,O,O
significantly,O,O
larger,O,O
extent,O,O
than,O,O
JAK1,B,B
in,O,O
human,O,O
T,O,O
lymphocytes,O,O
and,O,O
the,O,O
YT,O,O
cell,O,O
line,O,O
.,O,O
Nonetheless,O,O
",",O,O
a,O,O
membrane,B,O
-,I,O
proximal,I,O
region,I,O
of,O,O
human,O,O
IL,B,B
-,I,I
2R,I,I
beta,I,I
(,O,O
Asn240,B,O
-,I,O
Leu335,I,O
),O,O
was,O,O
critical,O,O
for,O,O
JAK3,B,O
activation,O,O
",",O,O
and,O,O
the,O,O
amount,O,O
of,O,O
JAK3,B,O
present,O,O
in,O,O
activated,O,O
IL,B,B
-,I,I
2,I,I
receptor,I,I
complexes,I,I
increased,O,O
with,O,O
time,O,O
",",O,O
suggesting,O,O
that,O,O
stabilization,O,O
of,O,O
JAK3,B,O
binding,O,O
to,O,O
the,O,O
receptor,B,O
complex,I,O
relies,O,O
on,O,O
both,O,O
IL,B,B
-,I,I
2R,I,I
beta,I,I
and,O,O
IL,B,B
-,I,I
2R,I,I
gamma,I,I
.,O,O
DHEA,O,B
binding,O,I
sites,O,I
were,O,O
examined,O,O
using,O,O
a,O,O
whole,O,O
-,O,O
cell,O,O
binding,O,O
assay,O,O
in,O,O
a,O,O
human,O,O
T,O,B
lymphoid,O,I
cell,O,I
line,O,I
",",O,O
PEER,O,O
",",O,O
revealing,O,O
that,O,O
a,O,O
single,O,O
class,O,O
of,O,O
high,O,O
-,O,O
affinity,O,O
binding,O,O
sites,O,O
for,O,O
DHEA,O,B
(,O,O
dissociation,O,O
constant,O,O
7,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
53,O,O
nmol,O,O
/,O,O
L,O,O
",",O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SE,O,O
",",O,O
n,O,O
4,O,O
),O,O
was,O,O
greatly,O,O
increased,O,O
when,O,O
treated,O,O
with,O,O
DHEA,O,B
",",O,O
phorbol,O,O
-,O,O
12,O,O
-,O,O
myristate,O,O
-,O,O
13,O,O
-,O,O
acetate,O,O
",",O,O
and,O,O
the,O,O
Ca2,O,B
+,O,I
ionophore,O,I
A23187,O,I
.,O,O
In,O,O
most,O,O
cases,O,O
",",O,O
the,O,O
transcriptional,B,O
factor,I,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
is,O,O
a,O,O
heterodimer,B,O
consisting,O,O
of,O,O
two,O,O
subunits,O,O
",",O,O
p50,B,O
and,O,O
p65,B,O
",",O,O
which,O,O
are,O,O
encoded,O,O
by,O,O
two,O,O
distinct,O,O
genes,O,O
of,O,O
the,O,O
Rel,B,O
family,I,O
.,O,O
It,O,O
has,O,O
been,O,O
suggested,O,O
that,O,O
the,O,O
ubiquitin,B,B
-,B,I
proteasome,I,I
system,O,I
is,O,O
involved,O,O
in,O,O
the,O,O
process,O,O
;,O,O
however,O,O
",",O,O
the,O,O
specific,O,O
enzymes,B,O
involved,O,O
and,O,O
the,O,O
mechanism,O,O
of,O,O
limited,O,O
proteolysis,O,O
",",O,O
in,O,O
which,O,O
half,O,O
of,O,O
the,O,O
molecule,O,O
is,O,O
spared,O,O
",",O,O
have,O,O
been,O,O
obscure,O,O
.,O,O
This,O,O
novel,O,O
enzyme,O,O
is,O,O
distinct,O,O
from,O,O
E6,B,B
-,I,I
AP,I,I
",",O,O
the,O,O
p53,B,B
-,I,I
conjugating,I,I
ligase,I,I
",",O,O
and,O,O
from,O,O
E3,B,B
alpha,I,I
",",O,O
the,O,O
`,B,O
`,I,O
N,I,B
-,I,I
end,I,I
rule,I,I
ligase,I,I
.,O,O
Cycles,O,O
remained,O,O
ovulatory,O,O
.,O,O
Before,O,O
treatment,O,O
",",O,O
the,O,O
number,O,O
of,O,O
androgen,B,B
receptors,I,I
was,O,O
higher,O,O
in,O,O
the,O,O
luteal,O,O
than,O,O
in,O,O
the,O,O
follicular,O,O
phase,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Flutamide,O,O
is,O,O
effective,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
hirsutism,O,O
but,O,O
requires,O,O
constant,O,O
surveillance,O,O
of,O,O
liver,O,O
function,O,O
.,O,O
An,O,O
increased,O,O
growth,O,O
rate,O,O
of,O,O
these,O,O
Jurkat,O,O
-,O,O
tat,O,O
cell,O,O
lines,O,O
as,O,O
compared,O,O
with,O,O
control,O,O
cell,O,O
lines,O,O
was,O,O
observed,O,O
.,O,O
To,O,O
identify,O,O
osteoblast,B,O
-,I,O
specific,I,O
cis,I,O
-,I,O
acting,I,O
elements,I,O
and,O,O
trans,B,O
-,I,O
acting,I,O
factors,I,O
",",O,O
we,O,O
initiated,O,O
an,O,O
analysis,O,O
of,O,O
the,O,O
promoter,B,O
of,O,O
a,O,O
mouse,B,O
osteocalcin,I,B
gene,I,I
",",O,O
an,O,O
osteoblast,B,O
-,I,O
specific,I,O
gene,I,O
.,O,O
By,O,O
DNA,O,B
cotransfection,O,I
experiments,O,O
",",O,O
we,O,O
also,O,O
demonstrate,O,O
that,O,O
AML,B,O
-,I,O
1B,I,O
can,O,O
increase,O,O
the,O,O
activity,O,O
of,O,O
a,O,O
short,O,O
osteocalcin,B,B
promoter,I,I
through,O,O
its,O,O
binding,O,O
to,O,O
OSE2,O,O
.,O,O
A,O,O
variety,O,O
of,O,O
other,O,O
cells,O,O
",",O,O
including,O,O
transformed,O,O
erythroid,O,B
precursors,O,I
",",O,O
do,O,O
not,O,O
have,O,O
IBR,B,B
but,O,O
a,O,O
factor,O,O
referred,O,O
to,O,O
as,O,O
IBF,B,B
(,O,O
68,O,O
to,O,O
70,O,O
kDa,O,O
),O,O
that,O,O
recognizes,O,O
the,O,O
same,O,O
IBR,B,B
sites,O,O
.,O,O
IBR,B,B
is,O,O
a,O,O
503,B,O
-,I,O
amino,I,O
-,I,O
acid,I,O
-,I,O
long,I,O
acidic,I,O
protein,I,O
which,O,O
is,O,O
99,O,O
.,O,O
0,O,O
%,O,O
identical,O,O
to,O,O
the,O,O
recently,O,O
reported,O,O
human,B,O
NRF,I,B
-,I,I
1,I,I
/,I,I
alpha,I,I
-,I,I
Pal,I,I
factor,I,I
and,O,O
highly,O,O
related,O,O
to,O,O
the,O,O
invertebrate,O,O
transcription,B,O
factors,I,O
P3A2,B,O
and,O,O
erected,B,O
wing,I,O
gene,I,O
product,I,O
(,O,O
EWG,B,O
),O,O
.,O,O
We,O,O
present,O,O
evidence,O,O
that,O,O
IBR,B,B
and,O,O
IBF,B,B
are,O,O
most,O,O
likely,O,O
identical,O,O
proteins,O,O
",",O,O
differing,O,O
in,O,O
their,O,O
degree,O,O
of,O,O
glycosylation,O,O
.,O,O
Mutation,O,O
of,O,O
Jak3,B,B
in,O,O
a,O,O
patient,O,O
with,O,O
SCID,O,O
:,O,O
essential,O,O
role,O,O
of,O,O
Jak3,B,B
in,O,O
lymphoid,O,B
development,O,O
.,O,O
A,O,O
girl,O,O
with,O,O
immunological,O,O
features,O,O
indistinguishable,O,O
from,O,O
those,O,O
of,O,O
XSCID,O,O
was,O,O
therefore,O,O
selected,O,O
for,O,O
analysis,O,O
.,O,O
The,O,O
lack,O,O
of,O,O
Jak3,B,B
expression,O,O
correlated,O,O
with,O,O
impaired,O,O
B,O,B
cell,O,I
signaling,O,O
",",O,O
as,O,O
demonstrated,O,O
by,O,O
the,O,O
inability,O,O
of,O,O
IL,B,B
-,I,I
4,I,I
to,O,O
activate,O,O
Stat6,B,B
in,O,O
the,O,O
EBV,O,O
-,O,O
transformed,O,O
cell,O,O
line,O,O
from,O,O
the,O,O
patient,O,O
.,O,O
These,O,O
observations,O,O
indicate,O,O
that,O,O
the,O,O
functions,O,O
of,O,O
gamma,B,B
c,I,I
are,O,O
dependent,O,O
on,O,O
Jak3,B,B
and,O,O
that,O,O
Jak3,B,B
is,O,O
essential,O,O
for,O,O
lymphoid,O,B
development,O,O
and,O,O
signaling,O,O
.,O,O
L,B,B
-,I,I
selectin,I,I
is,O,O
an,O,O
adhesion,O,O
molecule,O,O
of,O,O
the,O,O
selectin,O,O
family,O,O
that,O,O
mediates,O,O
the,O,O
initial,O,O
step,O,O
of,O,O
leukocyte,O,O
adhesion,O,O
to,O,O
vascular,O,O
endothelium,O,O
.,O,O
Upon,O,O
cellular,O,O
activation,O,O
",",O,O
expression,O,O
of,O,O
the,O,O
L,B,B
-,I,I
selectin,I,I
gene,I,O
is,O,O
downregulated,O,O
at,O,O
both,O,O
the,O,O
protein,O,B
and,O,O
mRNA,O,B
levels,O,O
.,O,O
The,O,O
induction,O,O
of,O,O
Tax,B,O
expression,O,O
in,O,O
JPX9,O,O
cells,O,O
resulted,O,O
in,O,O
about,O,O
a,O,O
twofold,O,O
increase,O,O
in,O,O
the,O,O
mRNA,B,B
expression,O,O
levels,O,O
compared,O,O
with,O,O
the,O,O
basal,O,O
level,O,O
.,O,O
These,O,O
results,O,O
indicated,O,O
that,O,O
ATL,O,O
cells,O,O
constitutively,O,O
overexpress,O,O
the,O,O
L,B,B
-,I,I
selectin,I,I
gene,I,O
that,O,O
can,O,O
be,O,O
transactivated,O,O
by,O,O
HTLV,O,O
-,O,O
1,O,O
Tax,B,O
.,O,O
Human,O,O
herpesvirus,O,O
6,O,O
",",O,O
a,O,O
predominantly,O,O
T,O,O
lymphotropic,O,O
virus,O,O
",",O,O
has,O,O
been,O,O
recently,O,O
shown,O,O
to,O,O
infect,O,O
some,O,O
EBV,O,B
-,O,I
positive,O,I
B,O,I
cell,O,I
lines,O,I
",",O,O
and,O,O
to,O,O
induce,O,O
in,O,O
them,O,O
the,O,O
activation,O,O
of,O,O
the,O,O
EBV,O,B
lytic,O,I
cycle,O,I
.,O,O
Here,O,O
we,O,O
have,O,O
confirmed,O,O
and,O,O
extended,O,O
such,O,O
observations,O,O
",",O,O
showing,O,O
that,O,O
(,O,O
1,O,O
),O,O
this,O,O
phenomenon,O,O
is,O,O
restricted,O,O
to,O,O
the,O,O
variant,O,O
A,O,O
of,O,O
HHV,O,O
-,O,O
6,O,O
:,O,O
in,O,O
fact,O,O
two,O,O
isolates,O,O
belonging,O,O
to,O,O
the,O,O
HHV,O,O
-,O,O
6,O,O
variant,O,O
B,O,O
(,O,O
BA92,O,O
and,O,O
Z29,O,O
),O,O
were,O,O
neither,O,O
able,O,O
to,O,O
infect,O,O
any,O,O
B,O,O
cell,O,B
line,O,I
",",O,O
independently,O,O
of,O,O
the,O,O
EBV,O,O
status,O,O
",",O,O
nor,O,O
to,O,O
induce,O,O
the,O,O
EBV,O,O
genome,O,O
expression,O,O
.,O,O
Evidence,O,O
for,O,O
normal,O,O
vitamin,B,B
D,I,I
receptor,I,I
messenger,I,I
ribonucleic,I,I
acid,I,I
and,O,O
genotype,O,O
in,O,O
absorptive,O,O
hypercalciuria,O,O
.,O,O
There,O,O
was,O,O
no,O,O
difference,O,O
between,O,O
the,O,O
distribution,O,O
of,O,O
the,O,O
VDR,B,B
alleles,O,I
in,O,O
the,O,O
patient,O,O
population,O,O
when,O,O
compared,O,O
with,O,O
the,O,O
normal,O,O
population,O,O
.,O,O
Sequence,O,O
analysis,O,O
of,O,O
the,O,O
5,B,O
-,I,O
flanking,I,O
region,I,O
of,O,O
the,O,O
CD69,B,O
gene,I,O
revealed,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
potential,O,O
TATA,B,O
element,I,O
30,B,O
base,I,O
pairs,I,O
upstream,I,O
of,O,O
the,O,O
major,O,O
transcription,B,O
initiation,I,O
site,I,O
and,O,O
several,O,O
putative,O,O
binding,O,O
sequences,O,O
for,O,O
inducible,O,O
transcription,B,O
factors,I,O
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
Egr,B,O
-,I,O
1,I,O
",",O,O
AP,B,O
-,I,O
1,I,O
),O,O
",",O,O
which,O,O
might,O,O
mediate,O,O
the,O,O
inducible,O,O
expression,O,O
of,O,O
this,O,O
gene,O,O
.,O,O
The,O,O
exon,B,B
-,I,I
intron,I,I
structure,I,O
of,O,O
the,O,O
5,B,O
portion,I,O
of,O,O
the,O,O
thromboxane,B,B
receptor,I,I
gene,I,I
was,O,O
determined,O,O
initially,O,O
by,O,O
comparing,O,O
the,O,O
nucleotide,B,O
sequence,I,O
of,O,O
the,O,O
5,B,O
flanking,I,O
genomic,I,O
clone,I,O
with,O,O
that,O,O
of,O,O
a,O,O
novel,B,O
human,I,O
uterine,I,B
thromboxane,I,I
receptor,I,I
cDNA,I,I
that,O,O
extended,O,O
the,O,O
mRNA,B,O
141,B,O
bp,I,O
further,I,O
upstream,I,O
than,O,O
the,O,O
previously,B,O
identified,I,O
human,I,O
placental,I,B
cDNA,I,I
.,O,O
Promoter,O,O
function,O,O
of,O,O
the,O,O
5,B,O
flanking,I,O
region,I,O
of,O,O
the,O,O
thromboxane,B,B
receptor,I,I
gene,I,I
was,O,O
evaluated,O,O
by,O,O
transfection,O,O
of,O,O
thromboxane,B,B
receptor,I,I
gene,I,I
promoter,I,I
/,I,O
chloramphenicol,I,B
acetyltransferase,I,I
(,I,O
CAT,I,O
),I,O
chimera,I,O
plasmids,I,O
into,O,O
platelet,O,B
-,O,I
like,O,I
K562,O,I
cells,O,I
.,O,O
These,O,O
studies,O,O
are,O,O
the,O,O
first,O,O
to,O,O
determine,O,O
the,O,O
structure,O,O
and,O,O
organization,O,O
of,O,O
the,O,O
5,O,O
end,O,O
of,O,O
the,O,O
thromboxane,B,B
receptor,I,I
gene,I,I
and,O,O
demonstrate,O,O
that,O,O
thromboxane,B,B
receptor,I,I
gene,I,I
expression,O,O
can,O,O
be,O,O
regulated,O,O
by,O,O
activation,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
via,O,O
induction,O,O
of,O,O
an,O,O
AP,B,O
-,I,O
2,I,O
-,I,O
like,I,O
nuclear,I,O
factor,I,O
binding,O,O
to,O,O
upstream,B,O
promoter,I,O
elements,I,O
.,O,O
Proteins,O,B
in,O,O
the,O,O
first,O,O
group,O,O
contain,O,O
multiple,O,O
HMG,B,B
boxes,I,I
",",O,O
are,O,O
non,O,O
-,O,O
sequence,O,O
-,O,O
specific,O,O
",",O,O
and,O,O
recognize,O,O
structural,O,O
features,O,O
as,O,O
found,O,O
in,O,O
cruciform,B,O
DNA,I,B
and,O,O
cross,B,O
-,I,O
over,I,O
DNA,I,B
.,O,O
The,O,O
abundant,O,O
chromosomal,B,O
protein,I,O
HMG,B,B
-,I,I
1,I,I
belongs,O,O
to,O,O
this,O,O
subgroup,O,O
.,O,O
As,O,O
in,O,O
HMG1B,B,B
",",O,O
the,O,O
overall,O,O
structure,O,O
of,O,O
the,O,O
Sox,B,B
-,I,I
4,I,I
HMG,B,B
box,I,I
is,O,O
L,O,O
-,O,O
shaped,O,O
and,O,O
is,O,O
maintained,O,O
by,O,O
a,O,O
cluster,O,O
of,O,O
conserved,O,O
",",O,O
mainly,O,O
aromatic,O,O
residues,O,O
.,O,O
Nuclear,B,O
factor,I,O
kappa,I,B
B,I,I
(,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
),O,O
is,O,O
stored,O,O
in,O,O
the,O,O
cytoplasm,O,O
as,O,O
an,O,O
inactive,O,O
form,O,O
through,O,O
interaction,O,O
with,O,O
I,B,B
kappa,I,I
B,I,I
.,O,O
We,O,O
have,O,O
recently,O,O
reported,O,O
the,O,O
establishment,O,O
of,O,O
a,O,O
lipopolysaccharide,O,O
(,O,O
LPS,O,O
),O,O
-,O,O
dependent,O,O
cell,O,O
-,O,O
free,O,O
activation,O,O
system,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
in,O,O
association,O,O
with,O,O
the,O,O
induction,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
phosphorylation,O,O
.,O,O
This,O,O
death,O,O
-,O,O
promoting,O,O
activity,O,O
of,O,O
Bik,B,B
can,O,O
be,O,O
suppressed,O,O
by,O,O
coexpression,O,O
of,O,O
Bcl,B,B
-,I,I
2,I,I
",",O,O
Bcl,B,B
-,I,I
XL,I,I
",",O,O
EBV,B,B
-,I,I
BHRF1,I,I
and,O,O
E1B,B,B
-,I,I
19,I,I
kDa,I,I
proteins,O,I
suggesting,O,O
that,O,O
Bik,B,B
may,O,O
be,O,O
a,O,O
common,O,O
target,O,O
for,O,O
both,O,O
cellular,B,O
and,I,O
viral,I,O
anti,I,O
-,I,O
apoptotic,I,O
proteins,I,O
.,O,O
TCF,B,O
-,I,O
1,I,O
mRNA,I,O
was,O,O
originally,O,O
found,O,O
to,O,O
be,O,O
expressed,O,O
in,O,O
a,O,O
T,O,O
cell,O,O
-,O,O
specific,O,O
fashion,O,O
within,O,O
a,O,O
set,O,O
of,O,O
human,O,O
and,O,O
mouse,O,O
cell,O,O
lines,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
expression,O,O
reportedly,O,O
occurs,O,O
in,O,O
multiple,O,O
nonlymphoid,O,O
tissues,O,O
during,O,O
murine,O,O
embryogenesis,O,O
.,O,O
Immunohistochemistry,O,O
on,O,O
a,O,O
panel,O,O
of,O,O
human,O,O
tissues,O,O
revealed,O,O
that,O,O
the,O,O
TCF,B,B
-,I,I
1,I,I
protein,I,I
was,O,O
found,O,O
exclusively,O,O
in,O,O
thymocytes,O,O
and,O,O
in,O,O
CD3,O,B
+,O,I
T,O,I
cells,O,I
in,O,O
peripheral,O,O
lymphoid,O,O
tissues,O,O
.,O,O
Signalling,O,O
via,O,O
CD28,B,B
of,O,O
human,O,O
naive,O,O
neonatal,O,O
T,O,O
lymphocytes,O,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
role,O,O
of,O,O
CD28,B,B
in,O,O
modulating,O,O
the,O,O
naive,O,O
neonatal,O,B
T,O,I
cell,O,I
response,O,O
to,O,O
anti,B,O
-,I,O
CD2,I,O
-,O,O
mediated,O,O
activation,O,O
.,O,O
Costimulation,O,O
with,O,O
anti,B,O
-,I,O
CD28,I,B
MoAb,I,I
greatly,O,O
enhanced,O,O
the,O,O
proliferative,O,O
response,O,O
of,O,O
neonatal,O,B
T,O,I
cells,O,I
to,O,O
levels,O,O
equivalent,O,O
to,O,O
those,O,O
of,O,O
adult,O,B
T,O,I
cells,O,I
",",O,O
whereas,O,O
adult,O,B
T,O,I
cells,O,I
showed,O,O
only,O,O
slight,O,O
increases,O,O
.,O,O
Although,O,O
IL,B,B
-,I,I
2,I,I
secretion,O,O
was,O,O
increased,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
anti,B,O
-,I,O
CD28,I,O
MoAb,I,O
",",O,O
neonatal,O,O
T,O,O
cell,O,O
IL,B,B
-,I,I
2,I,I
production,O,O
remained,O,O
lower,O,O
than,O,O
in,O,O
adults,O,O
.,O,O
TCL1,O,O
oncogene,O,O
activation,O,O
in,O,O
preleukemic,O,O
T,O,O
cells,O,O
from,O,O
a,O,O
case,O,O
of,O,O
ataxia,O,O
-,O,O
telangiectasia,O,O
.,O,O
We,O,O
have,O,O
analyzed,O,O
the,O,O
expression,O,O
of,O,O
TCL1,B,O
mRNA,I,O
and,O,O
protein,B,O
in,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
(,O,O
PBLs,O,O
),O,O
from,O,O
four,O,O
AT,O,O
cases,O,O
and,O,O
from,O,O
healthy,O,O
controls,O,O
.,O,O
We,O,O
found,O,O
that,O,O
the,O,O
TCL1,B,B
gene,I,I
was,O,O
overexpressed,O,O
in,O,O
the,O,O
PBLs,O,O
of,O,O
an,O,O
AT,O,O
patient,O,O
with,O,O
a,O,O
large,O,O
clonal,O,O
T,O,B
-,O,I
cell,O,I
population,O,O
exhibiting,O,O
the,O,O
t,O,O
(,O,O
14,O,O
;,O,O
14,O,O
),O,O
translocation,O,O
but,O,O
not,O,O
in,O,O
the,O,O
lymphocytes,O,O
of,O,O
the,O,O
other,O,O
cases,O,O
.,O,O
Fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
of,O,O
the,O,O
TCL1,B,B
genomic,I,I
locus,I,I
to,O,O
lymphocyte,O,O
metaphases,O,O
from,O,O
the,O,O
AT,O,O
patient,O,O
with,O,O
the,O,O
T,O,B
-,O,I
cell,O,I
clonal,O,I
expansion,O,I
showed,O,O
that,O,O
the,O,O
breakpoint,O,O
of,O,O
the,O,O
t,O,O
(,O,O
14,O,O
;,O,O
14,O,O
),O,O
translocation,O,O
lies,O,O
within,O,O
the,O,O
TCL1,B,B
locus,I,I
and,O,O
is,O,O
accompanied,O,O
by,O,O
an,O,O
inverted,O,O
duplication,O,O
of,O,O
the,O,O
distal,B,O
part,I,O
of,O,O
chromosome,B,O
14,I,O
.,O,O
Deregulation,O,O
of,O,O
TCL1,B,B
is,O,O
the,O,O
first,O,O
event,O,O
in,O,O
the,O,O
initiation,O,O
of,O,O
malignancy,O,O
in,O,O
these,O,O
types,O,O
of,O,O
leukemias,O,O
and,O,O
represents,O,O
a,O,O
potential,O,O
tool,O,O
for,O,O
clinical,O,O
evaluation,O,O
.,O,O
Inhibition,O,O
of,O,O
endogenous,B,O
C,I,B
/,I,I
EBP,I,I
proteins,I,I
",",O,O
using,O,O
either,O,O
an,O,O
excess,O,O
of,O,O
C,B,B
/,I,I
EBP,I,I
binding,I,I
sites,I,I
or,O,O
a,O,O
trans,B,O
-,I,O
dominant,I,O
negative,I,O
inhibitor,I,O
",",O,O
demonstrated,O,O
that,O,O
C,B,B
/,I,I
EBP,I,I
proteins,I,I
are,O,O
required,O,O
for,O,O
basal,O,O
and,O,O
activated,O,O
levels,O,O
of,O,O
HIV,B,B
-,I,I
1,I,I
LTR,I,I
transcription,O,O
in,O,O
the,O,O
promonocytic,O,B
cell,O,I
line,O,I
U937,O,O
.,O,O
Northern,O,O
(,O,O
RNA,O,B
),O,O
blots,O,O
and,O,O
binding,O,O
assays,O,O
showed,O,O
that,O,O
NF,B,B
-,I,I
IL6,I,I
is,O,O
the,O,O
only,O,O
known,O,O
C,B,B
/,I,I
EBP,I,I
family,I,O
member,I,O
which,O,O
is,O,O
increased,O,O
when,O,O
U937,O,O
cells,O,O
are,O,O
activated,O,O
.,O,O
However,O,O
",",O,O
transcription,O,O
from,O,O
crippled,B,O
HIV,I,B
-,I,I
1,I,I
LTRs,I,I
lacking,O,O
C,B,B
/,I,I
EBP,I,I
sites,I,I
can,O,O
still,O,O
be,O,O
induced,O,O
following,O,O
activation,O,O
of,O,O
U937,O,O
cells,O,O
.,O,O
Since,O,O
expression,O,O
of,O,O
the,O,O
viruses,O,O
is,O,O
in,O,O
large,O,O
part,O,O
regulated,O,O
by,O,O
the,O,O
sequence,B,O
elements,I,O
in,O,O
their,O,O
long,B,O
terminal,I,O
repeats,I,O
(,O,O
LTRs,B,O
),O,O
",",O,O
this,O,O
study,O,O
was,O,O
directed,O,O
to,O,O
an,O,O
analysis,O,O
of,O,O
the,O,O
regulatory,B,O
elements,I,O
in,O,O
the,O,O
HIV,B,B
-,I,I
2,I,I
LTR,I,I
.,O,O
The,O,O
HIV,B,B
-,I,I
2,I,I
LTR,I,I
was,O,O
found,O,O
to,O,O
contain,O,O
two,O,O
enhancers,B,O
.,O,O
We,O,O
report,O,O
here,O,O
that,O,O
both,O,O
NF,B,B
-,I,I
M,I,I
-,I,I
dependent,I,I
promoter,I,I
constructs,I,I
and,O,O
resident,O,O
genes,O,O
could,O,O
be,O,O
activated,O,O
by,O,O
addition,O,O
of,O,O
beta,O,O
-,O,O
estradiol,O,O
to,O,O
the,O,O
NF,O,B
-,O,I
M,O,I
-,O,I
estrogen,O,I
receptor,O,I
expressing,O,I
progenitors,O,I
.,O,O
In,O,O
addition,O,O
to,O,O
the,O,O
onset,O,O
of,O,O
differentiation,O,O
",",O,O
cell,O,O
death,O,O
was,O,O
induced,O,O
with,O,O
typical,O,O
apoptotic,O,O
features,O,O
.,O,O
A,O,O
comparison,O,O
with,O,O
the,O,O
Stat,B,O
proteins,I,O
induced,O,O
by,O,O
interferon,B,B
-,I,I
gamma,I,I
",",O,O
PRL,B,O
",",O,O
and,O,O
IL,B,B
-,I,I
6,I,I
in,O,O
T47D,O,O
mammary,O,O
tumor,O,O
cells,O,O
was,O,O
made,O,O
.,O,O
Activation,O,O
of,O,O
a,O,O
second,O,O
protein,O,O
related,O,O
to,O,O
Stat1,B,O
was,O,O
also,O,O
observed,O,O
.,O,O
Granulocyte,B,B
-,I,I
macrophage,I,I
colony,I,I
-,I,I
stimulating,I,I
factor,I,I
(,O,O
GM,B,B
-,I,I
CSF,I,I
),O,O
is,O,O
one,O,O
such,O,O
cytokine,B,O
whose,O,O
increased,O,O
expression,O,O
results,O,O
partly,O,O
from,O,O
increases,O,O
in,O,O
transcription,O,O
.,O,O
A,O,O
number,O,O
of,O,O
the,O,O
ETS,B,B
family,I,I
of,O,I
transcription,B,I
factors,I,I
are,O,O
expressed,O,O
in,O,O
T,O,O
cells,O,O
",",O,O
including,O,O
ETS1,B,B
and,O,O
ELF1,B,B
.,O,O
Other,O,O
unidentified,O,O
ETS,B,B
-,I,I
like,I,I
factors,I,I
present,O,O
in,O,O
Jurkat,O,O
cells,O,O
are,O,O
also,O,O
capable,O,O
of,O,O
binding,O,O
GM5,B,O
.,O,O
No,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
hTR,B,B
beta,I,I
1,I,I
was,O,O
seen,O,O
in,O,O
hypothyroid,O,O
relative,O,O
to,O,O
euthyroid,O,O
patients,O,O
.,O,O
Using,O,O
varying,O,O
conditions,O,O
",",O,O
three,O,O
distinct,O,O
complexes,O,O
were,O,O
shown,O,O
to,O,O
interact,O,O
specifically,O,O
with,O,O
the,O,O
NIP,B,O
region,I,O
",",O,O
although,O,O
only,O,O
one,O,O
correlates,O,O
with,O,O
repressor,O,O
activity,O,O
.,O,O
DNA,O,B
binding,O,I
specificity,O,I
of,O,I
complex,O,I
3,O,I
overlaps,O,O
with,O,O
that,O,O
of,O,O
upstream,B,O
stimulatory,I,O
factor,I,O
but,O,O
is,O,O
clearly,O,O
distinct,O,O
.,O,O
Functional,O,O
specificity,O,O
for,O,O
repression,O,O
matches,O,O
the,O,O
DNA,O,B
binding,O,I
specificity,O,I
of,O,I
complex,B,I
3,I,I
;,O,O
both,O,O
repressor,O,O
activity,O,O
and,O,O
complex,B,O
3,I,O
binding,O,O
require,O,O
the,O,O
consensus,B,O
sequence,I,O
CTCACNTNC,O,O
.,O,O
The,O,O
hematopoietic,B,O
transcription,I,O
factor,I,O
PU,B,O
.,I,O
1,I,O
is,O,O
downregulated,O,O
in,O,O
human,O,O
multiple,O,O
myeloma,O,B
cell,O,I
lines,O,I
.,O,O
PU,B,B
.,I,O
1,I,O
is,O,O
a,O,O
hematopoietic,B,O
transcription,I,O
factor,I,O
belonging,O,O
to,O,O
the,O,O
Ets,B,O
-,I,O
family,I,O
.,O,O
It,O,O
binds,O,O
the,O,O
so,O,O
-,O,O
called,O,O
Pu,B,B
box,I,I
",",O,O
an,O,O
important,O,O
tissue,B,O
-,I,O
specific,I,O
regulatory,I,O
DNA,I,B
element,I,I
present,O,O
in,O,O
a,O,O
number,O,O
of,O,O
genes,O,O
expressed,O,O
in,O,O
these,O,O
cell,O,O
lineages,O,O
.,O,O
We,O,O
have,O,O
analyzed,O,O
the,O,O
expression,O,O
and,O,O
activity,O,O
of,O,O
PU,B,B
.,I,O
during,O,O
human,O,O
B,O,B
-,O,I
cell,O,I
development,O,O
using,O,O
a,O,O
panel,O,O
of,O,O
B,O,B
-,O,I
cell,O,I
lines,O,I
representing,O,O
different,O,O
stages,O,O
of,O,O
maturation,O,O
",",O,O
from,O,O
early,O,O
precursors,O,O
to,O,O
differentiated,O,O
plasma,O,B
cells,O,I
.,O,O
The,O,O
effects,O,O
of,O,O
CsA,O,O
on,O,O
endothelial,O,B
cells,O,I
were,O,O
also,O,O
detected,O,O
at,O,O
the,O,O
chromatin,B,O
structure,O,O
level,O,O
",",O,O
as,O,O
DNasel,B,O
hypersensitive,I,O
sites,I,O
within,O,O
both,O,O
the,O,O
GM,B,O
-,I,O
CSF,I,O
enhancer,O,O
and,O,O
the,O,O
E,B,O
-,I,O
selectin,I,O
promoter,I,O
were,O,O
suppressed,O,O
by,O,O
CsA,O,O
.,O,O
Protein,O,B
phosphorylation,O,O
has,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
these,O,O
two,O,O
factors,O,O
:,O,O
(,O,O
1,O,O
),O,O
it,O,O
induces,O,O
the,O,O
transactivating,O,O
capacity,O,O
of,O,O
the,O,O
AP,B,B
-,I,I
1,I,I
protein,I,I
c,B,I
-,I,I
Jun,I,I
;,O,O
and,O,O
(,O,O
2,O,O
),O,O
it,O,O
is,O,O
involved,O,O
in,O,O
the,O,O
release,O,O
of,O,O
the,O,O
cytoplasmic,B,O
inhibitor,I,O
",",O,O
I,B,B
kappa,I,I
B,I,I
",",O,O
from,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
",",O,O
allowing,O,O
translocation,O,O
of,O,O
the,O,O
latter,O,O
into,O,O
the,O,O
nucleus,O,O
.,O,O
We,O,O
have,O,O
recently,O,O
shown,O,O
that,O,O
both,O,O
phosphorylation,O,O
processes,O,O
require,O,O
T,O,B
-,O,I
cell,O,I
costimulation,O,I
.,O,O
According,O,O
to,O,O
our,O,O
results,O,O
",",O,O
however,O,O
",",O,O
the,O,O
kinases,O,O
responsible,O,O
for,O,O
the,O,O
two,O,O
processes,O,O
are,O,O
distinct,O,O
entities,O,O
.,O,O
We,O,O
",",O,O
therefore,O,O
",",O,O
propose,O,O
the,O,O
activation,O,O
scheme,O,O
presented,O,O
in,O,O
FIGURE,O,O
3,O,O
for,O,O
T,O,B
-,O,I
cell,O,I
costimulation,O,I
.,O,O
Integration,O,O
of,O,O
the,O,O
signals,O,O
generated,O,O
by,O,O
TCR,B,O
and,O,O
CD28,B,O
engagement,O,O
occurs,O,O
along,O,O
this,O,O
pathway,O,O
",",O,O
which,O,O
then,O,O
bifurcates,O,O
to,O,O
induce,O,O
I,B,B
kappa,I,I
B,I,I
phosphorylation,O,I
and,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activation,O,I
on,O,O
the,O,O
one,O,O
hand,O,O
",",O,O
and,O,O
JNK,B,B
activation,O,I
and,O,O
c,B,B
-,I,I
Jun,I,I
phosphorylation,O,I
on,O,O
the,O,O
other,O,O
.,O,O
We,O,O
are,O,O
currently,O,O
engaged,O,O
in,O,O
defining,O,O
where,O,O
the,O,O
two,O,O
signals,O,O
integrate,O,O
along,O,O
the,O,O
AP,B,O
-,I,O
1,I,O
/,O,O
NF,B,B
-,I,O
kappa,I,I
B,I,I
pathway,O,O
.,O,O
Enhancement,O,O
of,O,O
HIV,O,O
-,O,O
1,O,O
replication,O,O
is,O,O
related,O,O
in,O,O
part,O,O
to,O,O
increased,O,O
DNA,O,B
-,O,I
binding,O,I
activity,O,O
of,O,O
cellular,B,O
transcription,I,O
factors,I,O
such,O,O
as,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
.,O,O
Increased,O,O
intracellular,O,O
stores,O,O
of,O,O
latent,B,O
NF,I,B
-,I,I
kappa,I,I
B,I,I
may,O,O
also,O,O
result,O,O
in,O,O
rapid,O,O
inducibility,O,O
of,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,O,O
dependent,O,O
cytokine,B,O
gene,O,O
expression,O,O
.,O,O
Elevated,O,O
levels,O,O
of,O,O
several,O,O
inflammatory,B,O
cytokines,I,O
have,O,O
been,O,O
detected,O,O
in,O,O
the,O,O
sera,O,O
of,O,O
HIV,O,O
-,O,O
1,O,O
-,O,O
infected,O,O
individuals,O,O
.,O,O
We,O,O
measured,O,O
steroid,O,B
mediated,O,I
lysis,O,I
",",O,O
receptor,O,B
number,O,I
and,O,O
induction,O,O
of,O,O
glutamine,B,O
synthetase,I,O
in,O,O
the,O,O
transfected,O,O
cells,O,O
.,O,O
The,O,O
DNA,B,B
binding,I,I
region,I,I
specifying,O,I
high,O,I
affinity,O,I
for,O,I
GRE,B,I
sites,I,I
is,O,O
required,O,O
.,O,O
Our,O,O
data,O,O
support,O,O
the,O,O
view,O,O
that,O,O
steroid,O,B
-,O,I
mediated,O,I
cell,O,I
death,O,I
occurs,O,O
by,O,O
a,O,O
process,O,O
requiring,O,O
direct,O,O
interaction,O,O
of,O,O
steroid,B,B
-,I,I
receptor,I,I
complexes,I,I
with,O,O
the,O,O
genome,O,O
.,O,O
Full,O,O
-,O,O
length,O,O
cDNAs,B,O
and,O,O
genomic,B,O
clones,I,O
were,O,O
isolated,O,O
",",O,O
and,O,O
the,O,O
gene,O,O
structure,O,O
was,O,O
determined,O,O
.,O,O
Comparison,O,O
of,O,O
the,O,O
deduced,O,O
amino,O,O
acids,O,O
shows,O,O
88,O,O
%,O,O
sequence,O,O
identity,O,O
between,O,O
mouse,B,O
and,I,O
human,I,O
BOB,I,B
.,I,O
1,I,O
/,I,O
OBF,I,B
.,I,O
1,I,O
.,O,O
The,O,O
NH2,B,B
-,I,I
terminal,I,I
126,I,I
amino,I,I
acids,I,I
of,O,O
BOB,B,B
.,I,O
1,I,O
/,I,O
OBF,I,O
.,I,O
1,I,O
are,O,O
both,O,O
essential,O,O
and,O,O
sufficient,O,O
for,O,O
interaction,O,O
with,O,O
the,O,O
POU,B,O
domains,I,O
of,O,O
either,O,O
Oct1,B,B
or,O,O
Oct2,B,B
.,O,O
As,O,O
this,O,O
phosphorylation,O,O
was,O,O
independent,O,O
of,O,O
protein,B,O
kinase,I,O
C,I,O
activity,O,O
",",O,O
we,O,O
tested,O,O
whether,O,O
a,O,O
calcium,B,B
/,I,I
calmodulin,I,I
-,I,I
dependent,I,I
protein,I,I
kinase,I,I
(,O,I
CaM,B,I
kinase,I,I
),O,I
might,O,O
phosphorylate,O,O
the,O,O
Ets,B,B
-,I,I
1,I,I
protein,I,I
after,O,O
elevation,O,O
of,O,O
intracellular,O,O
free,O,O
calcium,O,B
concentrations,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
identified,O,O
a,O,O
repression,O,O
domain,O,O
at,O,O
the,O,O
N,O,B
-,O,I
terminus,O,I
of,O,O
Oct,B,O
-,I,O
2a,I,O
.,O,O
Whereas,O,O
the,O,O
mechanism,O,O
of,O,O
nonopsonic,O,O
phagocytosis,O,O
of,O,O
Pseudomonas,O,O
aeruginosa,O,O
has,O,O
been,O,O
described,O,O
",",O,O
the,O,O
bacterial,O,O
ligands,O,O
required,O,O
are,O,O
poorly,O,O
understood,O,O
.,O,O
GP,B,O
Ib,I,O
alpha,I,O
promoter,I,O
activity,O,O
was,O,O
evaluated,O,O
by,O,O
transfection,O,O
of,O,O
human,O,B
erythroleukemia,O,I
cells,O,I
with,O,O
reporter,O,O
plasmids,O,O
coding,O,O
for,O,O
the,O,O
enzyme,B,O
",",O,O
luciferase,B,O
.,O,O
The,O,O
results,O,O
define,O,O
essential,O,O
cis,B,O
-,I,O
acting,I,O
elements,I,O
responsible,O,O
for,O,O
the,O,O
expression,O,O
of,O,O
GP,B,B
Ib,I,I
alpha,I,I
and,O,O
provide,O,O
insights,O,O
into,O,O
molecular,O,O
events,O,O
coinciding,O,O
with,O,O
the,O,O
release,O,O
of,O,O
normal,O,O
platelets,O,O
into,O,O
the,O,O
bloodstream,O,O
.,O,O
CD30,B,B
is,O,O
a,O,O
recently,O,O
described,O,O
member,O,O
of,O,O
the,O,O
tumor,B,B
necrosis,I,I
factor,I,I
/,I,I
nerve,I,I
growth,I,I
factor,I,I
receptor,I,I
superfamily,I,I
.,O,O
In,O,O
all,O,O
cell,O,O
lines,O,O
investigated,O,O
",",O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
complexes,I,O
induced,O,O
following,O,O
CD30,B,O
engagement,O,O
were,O,O
shown,O,O
to,O,O
contain,O,O
p50,B,B
NF,I,I
-,I,I
kappa,I,I
B1,I,I
",",O,O
p65,B,B
RelA,I,I
",",O,O
and,O,O
possibly,O,O
other,O,O
transcription,B,O
factors,I,O
.,O,O
Estrogen,B,B
and,O,O
progesterone,B,B
receptors,I,O
in,O,O
vernal,O,O
keratoconjunctivitis,O,O
.,O,O
RESULTS,O,O
:,O,O
Both,O,O
the,O,O
epithelium,O,O
and,O,O
subepithelium,O,O
of,O,O
the,O,O
tarsal,O,O
and,O,O
bulbar,O,O
conjunctiva,O,O
of,O,O
patients,O,O
with,O,O
VKC,O,O
",",O,O
but,O,O
not,O,O
those,O,O
of,O,O
four,O,O
nonatopic,O,O
control,O,O
subjects,O,O
",",O,O
showed,O,O
intense,O,O
positive,O,O
staining,O,O
for,O,O
estrogen,O,B
and,O,O
progesterone,B,B
receptors,I,O
.,O,O
The,O,O
expression,O,O
of,O,O
MHC,B,B
class,I,I
II,I,I
genes,I,I
in,O,O
mouse,O,O
T,O,B
cells,O,I
can,O,O
be,O,O
reconstituted,O,O
upon,O,O
transfection,O,O
with,O,O
the,O,O
human,B,O
CIITA,I,O
cDNA,I,O
.,O,O
Because,O,O
HLA,B,B
class,I,I
II,I,I
molecules,I,I
present,O,O
antigen,O,O
to,O,O
T,B,B
cell,I,I
receptors,I,I
(,O,O
TCRs,B,O
),O,O
",",O,O
we,O,O
have,O,O
searched,O,O
for,O,O
a,O,O
TCR,B,B
gene,I,I
associated,O,O
with,O,O
the,O,O
production,O,O
of,O,O
anti,B,O
-,I,O
Ro,I,O
(,I,O
SSA,I,O
),I,O
antibodies,I,O
.,O,O
This,O,O
RFLP,B,O
pair,I,O
occurs,O,O
in,O,O
76,O,O
%,O,O
of,O,O
patients,O,O
with,O,O
Ro,B,O
(,I,O
SSA,I,O
),I,O
precipitins,O,O
",",O,O
84,O,O
%,O,O
of,O,O
anti,O,O
-,O,O
Ro,B,O
(,I,O
SSA,I,O
),I,O
-,O,O
positive,O,O
patients,O,O
lacking,O,O
La,B,O
(,I,O
SSB,I,O
),I,O
precipitins,B,O
",",O,O
but,O,O
only,O,O
41,O,O
%,O,O
of,O,O
the,O,O
patients,O,O
lacking,O,O
both,O,O
precipitins,B,O
(,O,O
P,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
majority,O,O
of,O,O
patients,O,O
who,O,O
have,O,O
these,O,O
RFLPs,B,O
and,O,O
HLA,B,B
class,I,I
II,I,I
antigens,I,I
previously,O,O
associated,O,O
with,O,O
the,O,O
anti,O,O
-,O,O
Ro,B,B
(,I,I
SSA,I,I
),I,I
response,O,O
make,O,O
this,O,O
antibody,O,O
",",O,O
suggesting,O,O
that,O,O
interactions,O,O
between,O,O
products,O,O
of,O,O
these,O,O
loci,B,O
occur,I,O
in,O,O
response,O,O
to,O,O
Ro,B,B
(,I,I
SSA,I,I
),I,I
.,O,O
However,O,O
",",O,O
while,O,O
IL2,B,B
expression,O,O
requires,O,O
the,O,O
contribution,O,O
of,O,O
Ca,O,B
(,O,I
2,O,I
+,O,I
),O,I
-,O,I
and,O,O
protein,B,B
kinase,I,I
C,I,I
-,O,I
dependent,O,I
signals,O,O
",",O,O
we,O,O
report,O,O
that,O,O
activation,O,O
of,O,O
human,B,O
IL4,I,B
transcription,O,O
through,O,O
the,O,O
Ca,O,B
(,O,I
2,O,I
+,O,I
),O,I
-,O,I
dependent,O,I
pathway,O,O
is,O,O
diminished,O,O
by,O,O
protein,B,B
kinase,I,I
C,I,I
stimulation,O,O
in,O,O
Jurkat,O,O
T,O,O
cells,O,O
.,O,O
Human,B,O
IL4,I,B
promoter,I,I
-,O,I
mediated,O,I
transcription,O,I
is,O,O
downregulated,O,O
in,O,O
Jurkat,O,B
cells,O,I
stimulated,O,O
with,O,O
the,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
-,I,I
activating,I,I
cytokine,I,I
tumor,B,O
necrosis,I,O
factor,I,O
alpha,I,O
and,O,O
suppressed,O,O
in,O,O
RelA,O,B
-,O,I
overexpressing,O,I
cells,O,O
.,O,O
Many,O,O
cytokines,B,O
activate,O,O
signal,B,O
transducer,I,O
and,I,O
activation,I,O
of,I,O
transcription,I,O
(,I,O
STAT,I,O
),I,O
transcription,I,O
factors,I,O
",",O,O
which,O,O
",",O,O
in,O,O
turn,O,O
",",O,O
activate,O,O
transcription,O,O
of,O,O
inflammatory,O,O
effector,O,O
genes,O,O
.,O,O
The,O,O
present,O,O
study,O,O
demonstrates,O,O
that,O,O
triggering,O,O
of,O,O
complement,B,B
receptors,I,I
CR1,B,I
(,O,O
CD35,B,O
),O,O
and,O,O
CR3,B,B
(,O,O
CD11b,B,O
/,I,O
CD18,I,O
),O,O
enhances,O,O
viral,O,O
replication,O,O
in,O,O
HIV,O,B
-,O,I
infected,O,I
human,O,I
monocytic,O,I
cells,O,I
.,O,O
Monocytic,O,O
cell,O,O
lines,O,O
and,O,O
normal,O,O
peripheral,O,O
blood,O,O
monocytes,O,O
were,O,O
infected,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
in,O,O
vitro,O,O
and,O,O
cultured,O,O
in,O,O
the,O,O
presence,O,O
or,O,O
absence,O,O
of,O,O
F,B,O
(,I,O
ab,I,O
),I,O
2,I,O
fragments,I,O
of,O,O
monoclonal,B,O
anti,I,O
-,I,O
CR1,I,O
or,O,O
anti,B,O
-,I,O
CR3,I,O
Abs,I,O
or,O,O
with,O,O
C3,B,B
fragments,I,I
.,O,O
In,O,O
contrast,O,O
",",O,O
in,O,O
cells,O,O
infected,O,O
with,O,O
L,O,O
.,O,O
donovani,O,O
",",O,O
tyrosine,O,B
phosphorylation,O,O
of,O,O
Jak1,B,B
",",O,O
Jak2,B,B
",",O,O
and,O,O
Stat1,B,B
was,O,O
markedly,O,O
impaired,O,O
.,O,O
Unresponsiveness,O,O
to,O,O
gamma,B,B
interferon,I,I
for,O,O
activation,O,O
of,O,O
this,O,O
pathway,O,O
may,O,O
explain,O,O
impaired,O,O
transcriptional,O,O
responses,O,O
in,O,O
leishmania,O,O
-,O,O
infected,O,O
cells,O,O
.,O,O
Mutually,O,O
exclusive,O,O
interaction,O,O
of,O,O
a,O,O
novel,O,O
matrix,B,O
attachment,I,O
region,I,O
binding,I,O
protein,I,O
and,O,O
the,O,O
NF,B,O
-,I,O
muNR,I,O
enhancer,I,O
repressor,I,O
.,O,O
Implications,O,O
for,O,O
regulation,O,O
of,O,O
immunoglobulin,B,B
heavy,I,I
chain,I,I
expression,O,O
.,O,O
To,O,O
understand,O,O
the,O,O
role,O,O
of,O,O
MARs,B,O
in,O,O
IgH,B,B
enhancer,I,I
regulation,O,O
",",O,O
we,O,O
have,O,O
identified,O,O
a,O,O
novel,O,O
MAR,B,B
-,I,I
binding,I,I
protein,I,I
",",O,O
MAR,B,B
-,I,I
BP1,I,I
",",O,O
from,O,O
soluble,O,O
nuclear,O,O
matrix,O,O
preparations,O,O
based,O,O
on,O,O
its,O,O
ability,O,O
to,O,O
bind,O,O
to,O,O
the,O,O
MARs,B,O
associated,O,O
with,O,O
the,O,O
IgH,B,B
enhancer,I,I
.,O,O
Purified,O,O
MAR,B,B
-,I,I
BP1,I,I
migrates,O,O
as,O,O
a,O,O
33,B,O
-,I,O
kDa,I,O
protein,I,O
",",O,O
and,O,O
it,O,O
can,O,O
be,O,O
found,O,O
in,O,O
nuclear,O,O
matrix,O,O
preparations,O,O
from,O,O
a,O,O
number,O,O
of,O,O
different,O,O
types,O,O
of,O,O
lymphoid,O,B
cell,O,I
lines,O,I
.,O,O
The,O,O
GM,B,B
-,I,I
CSF,I,I
receptor,I,I
alpha,I,I
promoter,I,O
contains,O,O
an,O,O
important,O,O
functional,O,O
site,O,O
between,O,O
positions,O,O
-,O,O
53,O,O
and,O,O
-,O,O
41,O,O
as,O,O
identified,O,O
by,O,O
deletion,O,O
analysis,O,O
of,O,O
reporter,B,O
constructs,I,O
.,O,O
C,B,B
/,I,I
EBP,I,I
alpha,I,I
is,O,O
the,O,O
major,O,O
CCAAT,B,B
/,I,I
enhancer,I,I
-,I,I
binding,I,I
protein,I,I
(,O,O
C,B,O
/,I,O
EBP,I,O
),O,O
form,O,O
binding,O,O
to,O,O
this,O,O
site,O,O
in,O,O
nuclear,O,O
extracts,O,O
of,O,O
U937,O,O
cells,O,O
.,O,O
Tyrosine,O,O
phosphorylation,O,O
of,O,O
this,O,O
protein,O,O
could,O,O
also,O,O
be,O,O
induced,O,O
in,O,O
Balb,O,O
/,O,O
c3T3,O,O
cells,O,O
using,O,O
a,O,O
supernatant,O,O
from,O,O
the,O,O
B,O,O
line,O,O
",",O,O
which,O,O
was,O,O
associated,O,O
with,O,O
induction,O,O
of,O,O
cell,O,O
proliferation,O,O
.,O,O
Regulation,O,O
of,O,O
c,B,O
-,I,O
jun,I,B
mRNA,I,I
expression,O,O
by,O,O
hydroxyurea,O,O
in,O,O
human,O,O
K562,O,O
cells,O,O
during,O,O
erythroid,O,O
differentiation,O,O
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
Biochim,O,O
Biophys,O,O
Acta,O,O
1995,O,O
Dec,O,O
27,O,O
;,O,O
1264,O,O
(,O,O
3,O,O
),O,O
:,O,O
409,O,O
],O,O
In,O,O
addition,O,O
",",O,O
HU,O,O
stimulates,O,O
the,O,O
synthesis,O,O
of,O,O
fetal,B,O
hemoglobin,I,O
in,O,O
sickle,O,O
cell,O,O
anemia,O,O
patients,O,O
.,O,O
HU,O,O
induced,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
stimulation,O,O
of,O,O
c,B,O
-,I,O
jun,I,B
synthesis,O,O
.,O,O
Glucocorticoid,O,B
effects,O,O
were,O,O
assessed,O,O
in,O,O
vivo,O,O
by,O,O
depletion,O,O
of,O,O
endogenous,O,O
glucocorticoids,O,O
after,O,O
oral,O,O
administration,O,O
of,O,O
1,O,O
.,O,O
5,O,O
g,O,O
metyrapone,O,O
(,O,O
MET,O,O
),O,O
and,O,O
subsequent,O,O
glucocorticoid,O,O
replacement,O,O
",",O,O
and,O,O
in,O,O
vitro,O,O
by,O,O
incubation,O,O
of,O,O
the,O,O
cells,O,O
with,O,O
different,O,O
doses,O,O
of,O,O
dexamethasone,O,B
(,O,O
DEX,O,O
),O,O
.,O,O
In,O,O
comparison,O,O
",",O,O
isolated,O,O
nuclei,O,O
of,O,O
human,O,O
lymphocytes,O,O
in,O,O
which,O,O
no,O,O
need,O,O
for,O,O
the,O,O
expression,O,O
of,O,O
this,O,O
gene,O,O
exists,O,O
",",O,O
show,O,O
barely,O,O
hybridization,O,O
signals,O,O
.,O,O
Because,O,O
NF,B,B
-,I,I
kappa,I,I
B,I,I
activates,O,O
many,O,O
immunoregulatory,B,O
genes,I,O
in,O,O
response,O,O
to,O,O
pro,O,O
-,O,O
inflammatory,O,O
stimuli,O,O
",",O,O
the,O,O
inhibition,O,O
of,O,O
its,O,O
activity,O,O
can,O,O
be,O,O
a,O,O
major,O,O
component,O,O
of,O,O
the,O,O
anti,O,O
-,O,O
inflammatory,O,O
activity,O,O
of,O,O
glucocorticoids,O,O
.,O,O
Transcriptional,O,O
repression,O,O
of,O,O
the,O,O
interleukin,B,B
-,I,I
2,I,I
gene,I,I
by,O,O
vitamin,O,O
D3,O,O
:,O,O
direct,O,O
inhibition,O,O
of,O,O
NFATp,B,B
/,I,I
AP,I,I
-,I,I
1,I,I
complex,I,I
formation,O,O
by,O,O
a,O,O
nuclear,B,O
hormone,I,O
receptor,I,O
.,O,O
We,O,O
therefore,O,O
examined,O,O
vitamin,O,B
D3,O,I
-,O,I
mediated,O,O
repression,O,O
of,O,O
activated,O,O
IL,B,B
-,I,I
2,I,I
expression,O,O
by,O,O
cotransfecting,O,O
Jurkat,O,O
cells,O,O
with,O,O
IL,B,B
-,I,I
2,I,I
promoter,I,I
/,I,I
reporter,I,I
constructs,I,O
and,O,O
a,O,O
VDR,B,B
overexpression,I,O
vector,I,O
and,O,O
by,O,O
DNA,O,B
binding,O,O
.,O,O
The,O,O
5,B,O
flanking,I,O
DNA,I,B
also,O,O
contains,O,O
a,O,O
cluster,O,O
of,O,O
three,O,O
binding,B,O
sites,I,O
for,O,O
the,O,O
GATA,B,B
family,I,I
of,O,I
transcription,B,I
factors,I,I
.,O,O
This,O,O
effect,O,O
is,O,O
thought,O,O
to,O,O
be,O,O
largely,O,O
mediated,O,O
through,O,O
inactivation,O,O
of,O,O
the,O,O
phosphatase,O,O
calcineurin,B,O
",",O,O
which,O,O
in,O,O
turn,O,O
inhibits,O,O
translocation,O,O
of,O,O
an,O,O
NFAT,B,O
component,O,O
to,O,O
the,O,O
nucleus,O,O
.,O,O
These,O,O
data,O,O
point,O,O
to,O,O
a,O,O
new,O,O
mechanism,O,O
for,O,O
CsA,O,O
-,O,O
sensitive,O,O
regulation,O,O
of,O,O
NFATp,B,O
in,O,O
which,O,O
dephosphorylation,O,O
is,O,O
critical,O,O
for,O,O
DNA,O,B
binding,O,O
.,O,O
Cysteamine,O,O
treatment,O,O
inhibited,O,O
both,O,O
expression,O,O
of,O,O
the,O,O
IL,B,B
-,I,I
2,I,I
mRNA,I,I
and,O,O
secretion,O,O
of,O,O
IL,B,B
-,I,I
2,I,I
into,O,O
the,O,O
culture,O,O
medium,O,O
.,O,O
The,O,O
mean,O,O
dissociation,O,O
constant,O,O
(,O,O
Kd,O,O
),O,O
was,O,O
similar,O,O
in,O,O
both,O,O
sexes,O,O
(,O,O
1,O,O
.,O,O
35,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
70,O,O
x,O,O
10,O,O
(,O,O
-,O,O
10,O,O
),O,O
M,O,O
in,O,O
males,O,O
",",O,O
1,O,O
.,O,O
13,O,O
),O,O
",",O,O
but,O,O
the,O,O
concentration,O,O
of,O,O
binding,O,O
sites,O,O
(,O,O
Nmax,O,O
),O,O
was,O,O
significantly,O,O
lower,O,O
in,O,O
females,O,O
(,O,O
2,O,O
.,O,O
32,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
92,O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
PBMC,O,O
vs,O,O
4,O,O
.,O,O
43,O,O
+,O,O
/,O,O
-,O,O
1,O,O
38,O,O
fmol,O,O
/,O,O
10,O,O
(,O,O
7,O,O
),O,O
PBMC,O,O
in,O,O
males,O,O
;,O,O
p,O,O
0,O,O
.,O,O
.,O,O
Neither,O,O
Kd,O,O
nor,O,O
Nmax,O,O
were,O,O
significantly,O,O
correlated,O,O
with,O,O
age,O,O
.,O,O
We,O,O
examined,O,O
by,O,O
northern,O,O
hybridization,O,O
the,O,O
expression,O,O
of,O,O
Id2,B,O
and,I,O
Id3,I,O
mRNA,I,O
in,O,O
human,O,B
leukemia,O,I
/,O,I
lymphoma,O,I
lines,O,O
and,O,O
patient,O,O
samples,O,O
",",O,O
as,O,O
well,O,O
as,O,O
resting,O,O
and,O,O
activated,O,O
normal,O,B
human,O,I
lymphocytes,O,I
from,O,O
peripheral,O,O
blood,O,O
(,O,O
PBL,O,O
),O,O
.,O,O
The,O,O
Id2,B,B
mRNA,I,I
was,O,O
abundantly,O,O
expressed,O,O
in,O,O
5,O,O
/,O,O
12,O,O
T,O,B
-,O,I
cell,O,I
and,O,O
3,O,O
/,O,O
4,O,O
B,O,B
-,O,I
cell,O,I
lines,O,I
",",O,O
and,O,O
Id3,B,B
mRNA,I,I
was,O,O
detected,O,O
in,O,O
4,O,O
/,O,O
12,O,O
T,O,B
-,O,I
cell,O,I
and,O,O
3,O,O
/,O,O
4,O,O
B,O,B
-,O,I
cell,O,I
lines,O,I
.,O,O
In,O,O
addition,O,O
",",O,O
resting,O,O
PBL,O,O
constitutively,O,O
expressed,O,O
prominent,O,O
levels,O,O
of,O,O
Id2,B,B
mRNA,I,I
",",O,O
but,O,O
not,O,O
Id3,B,B
mRNA,I,I
.,O,O
Salicylates,O,O
inhibit,O,O
lipopolysaccharide,O,O
-,O,O
induced,O,O
transcriptional,O,O
activation,O,O
of,O,O
the,O,O
tissue,O,O
factor,O,O
gene,O,O
in,O,O
human,O,O
monocytic,O,O
cells,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
a,O,O
family,O,O
of,O,O
anti,O,O
-,O,O
inflammatory,O,O
agents,O,O
",",O,O
known,O,O
as,O,O
the,O,O
salicylates,O,O
",",O,O
inhibited,O,O
LPS,O,O
induction,O,O
of,O,O
TF,O,O
activity,O,O
and,O,O
TF,B,O
gene,I,O
transcription,O,O
in,O,O
human,O,B
monocytes,O,I
and,O,O
monocytic,O,B
THP,O,I
-,O,I
1,O,I
cells,O,O
at,O,O
clinically,O,O
relevant,O,O
doses,O,O
.,O,O
Furthermore,O,O
",",O,O
sodium,O,B
salicylate,O,I
blocked,O,O
the,O,O
LPS,O,O
-,O,O
induced,O,O
proteolytic,O,O
degradation,O,O
of,O,O
I,B,B
kappa,I,I
B,I,I
alpha,I,I
",",O,O
which,O,O
prevented,O,O
the,O,O
nuclear,O,O
translocation,O,O
of,O,O
c,B,O
-,I,O
Rel,I,O
/,I,O
p65,I,O
heterodimers,I,O
.,O,O
In,O,O
contrast,O,O
",",O,O
two,O,O
other,O,O
nonsteroidal,O,O
anti,O,O
-,O,O
inflammatory,O,O
drugs,O,O
",",O,O
ibuprofen,O,O
and,O,O
indomethacin,O,O
",",O,O
did,O,O
not,O,O
inhibit,O,O
LPS,O,O
induction,O,O
of,O,O
the,O,O
TF,B,B
gene,I,I
.,O,O
Critical,O,O
role,O,O
for,O,O
IL,B,B
-,I,I
6,I,I
.,O,O
The,O,O
T,O,O
cell,O,O
activation,O,O
is,O,O
initiated,O,O
by,O,O
interaction,O,O
of,O,O
specific,O,O
Ags,B,O
with,O,O
TCR,B,O
",",O,O
followed,O,O
by,O,O
activation,O,O
of,O,O
intracellular,O,O
biochemical,O,O
events,O,O
leading,O,O
to,O,O
activation,O,O
of,O,O
several,O,O
genes,O,O
.,O,O
As,O,O
neutralizing,B,O
anti,I,O
-,I,O
IL,I,B
-,I,I
6,I,I
Abs,I,O
effectively,O,O
down,O,O
-,O,O
regulated,O,O
the,O,O
early,O,O
induction,O,O
of,O,O
STAT,B,B
proteins,I,I
and,O,O
as,O,O
exogenously,O,O
added,O,O
IL,B,B
-,I,I
6,I,I
rapidly,O,O
activated,O,O
DNA,O,B
binding,O,O
similar,O,O
to,O,O
TCR,B,O
-,O,O
mediated,O,O
bindings,O,O
",",O,O
it,O,O
can,O,O
be,O,O
concluded,O,O
that,O,O
IL,B,B
-,I,I
6,I,I
is,O,O
the,O,O
factor,O,O
responsible,O,O
for,O,O
the,O,O
activation,O,O
of,O,O
STAT,B,B
proteins,I,I
in,O,O
a,O,O
primary,O,O
T,O,O
cell,O,O
response,O,O
.,O,O
Our,O,O
data,O,O
suggest,O,O
an,O,O
involvement,O,O
of,O,O
BLR2,B,B
in,O,O
the,O,O
regulation,O,O
of,O,O
migration,O,O
in,O,O
activated,O,O
lymphocytes,O,O
and,O,O
in,O,O
viral,O,O
pathogenesis,O,O
.,O,O
A,O,O
central,O,O
role,O,O
for,O,O
a,O,O
single,B,O
c,I,O
-,I,O
Myb,I,O
binding,I,O
site,I,O
in,O,O
a,O,O
thymic,B,O
locus,I,O
control,I,O
region,I,O
.,O,O
We,O,O
now,O,O
show,O,O
that,O,O
the,O,O
core,O,O
contains,O,O
a,O,O
single,O,O
critical,O,O
c,B,O
-,I,O
Myb,I,O
binding,I,O
site,I,O
.,O,O
c,B,O
-,I,O
Myb,I,O
protein,I,O
was,O,O
strongly,O,O
evident,O,O
in,O,O
T,O,O
lymphoblasts,O,O
in,O,O
which,O,O
the,O,O
enhancer,B,O
was,O,O
active,O,O
and,O,O
was,O,O
localized,O,O
within,O,O
discrete,O,O
nuclear,O,O
structures,O,O
.,O,O
Lymphoid,B,B
enhancer,I,I
-,I,I
binding,I,I
factor,I,I
1,I,I
(,O,O
LEF,B,B
-,I,I
1,I,I
),O,O
is,O,O
a,O,O
regulatory,B,O
high,I,O
mobility,I,O
group,I,O
(,I,O
HMG,I,B
),I,O
protein,I,O
that,O,O
activates,O,O
the,O,O
T,B,B
cell,I,I
receptor,I,I
alpha,I,I
(,I,O
TCR,I,B
alpha,I,I
),I,O
enhancer,I,O
in,O,O
a,O,O
context,O,O
-,O,O
restricted,O,O
manner,O,O
in,O,O
T,O,B
cells,O,I
.,O,O
We,O,O
conclude,O,O
that,O,O
transcription,O,O
activation,O,O
by,O,O
LEF,B,B
-,I,I
1,I,I
in,O,O
vitro,O,O
is,O,O
a,O,O
chromatin,B,O
-,O,O
dependent,O,O
process,O,O
that,O,O
requires,O,O
a,O,O
functional,O,O
trans,B,O
-,I,O
activation,I,O
domain,I,O
in,O,O
addition,O,O
to,O,O
the,O,O
HMG,B,B
domain,I,O
.,O,O
HIV,B,B
-,I,I
1,I,I
envelope,I,I
glycoproteins,I,I
induce,O,O
activation,O,O
of,O,O
activated,O,B
protein,B,I
-,I,I
1,I,I
in,O,O
CD4,O,B
+,O,I
T,O,I
cells,O,I
[,O,O
published,O,O
erratum,O,O
appears,O,O
in,O,O
J,O,O
Biol,O,O
Chem,O,O
1995,O,O
Dec,O,O
1,O,O
;,O,O
270,O,O
(,O,O
48,O,O
),O,O
:,O,O
29038,O,O
],O,O
Immunoprecipitation,O,O
of,O,O
the,O,O
gp,B,O
160,I,O
-,O,O
induced,O,O
nuclear,O,O
extracts,O,O
with,O,O
polyclonal,B,O
antibodies,I,O
to,O,O
Fos,B,B
and,O,O
Jun,B,B
proteins,I,I
indicates,O,O
that,O,O
AP,B,B
-,I,I
1,I,I
complex,I,I
is,O,O
comprised,O,O
of,O,O
members,O,O
of,O,O
these,O,O
family,O,O
of,O,O
proteins,O,O
.,O,O
This,O,O
stimulation,O,O
can,O,O
also,O,O
be,O,O
abolished,O,O
by,O,O
inhibitors,O,O
of,O,O
protein,B,B
kinase,I,I
C,I,I
",",O,O
but,O,O
it,O,O
is,O,O
unaffected,O,O
by,O,O
calcium,O,B
channel,O,I
blocker,O,I
or,O,O
cyclosporine,O,B
A,O,I
.,O,O
